PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Jiang, JS; Daniels, BV; Fu, D				Jiang, JS; Daniels, BV; Fu, D			Crystal structure of AqpZ tetramer reveals two distinct Arg-189 conformations associated with water permeation through the narrowest constriction of the water-conducting channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AQUAPORIN-0; SELECTIVITY; DYNAMICS; PROTEIN; FAMILY; GLPF	AqpZ is a homotetramer of four water-conducting channels that facilitate rapid water movements across the plasma membrane of Escherichia coli. Here we report a 3.2 angstrom crystal structure of the tetrameric AqpZ (tAqpZ). All channel- lining residues in the four monomeric channels are found orientated in nearly identical positions with one marked exception at the narrowest channel constriction, where the side chain of a highly conserved Arg-189 adopts two distinct conformational orientations. In one of the four monomers, the guanidino group of Arg-189 points toward the periplasmic vestibule, opening up the constriction to accommodate the binding of a water molecule through a tridentate H-bond. In the other three monomers, the Arg-189 guanidino group bends over to form an H-bond with carbonyl oxygen of the Thr-183, thus occluding the channel. Therefore, the tAqpZ structure reveals two distinct Arg-189 confirmations associated with water permeation through the channel constrictions. Alternation between the two Arg-189 conformations disrupts continuous flow of water, thus regulating the open probability of the water pore. Further, the difference in Arg-189 displacements is correlated with a strong electron density found between the first transmembrane helices of two open channels, suggesting that the observed Arg-189 conformations are stabilized by asymmetrical subunit interactions in tAqpZ.	Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	United States Department of Energy (DOE); Brookhaven National Laboratory	Fu, D (corresponding author), Brookhaven Natl Lab, Dept Biol, Bldg 463, Upton, NY 11973 USA.	dax@bnl.gov		Jiang, Jiansheng/0000-0003-0964-5481; Fu, Dax/0000-0002-2663-1316	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065137] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM65137] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON CR, 1973, J PHYSIOL-LONDON, V235, P655, DOI 10.1113/jphysiol.1973.sp010410; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chandy G, 1997, J MEMBRANE BIOL, V159, P29, DOI 10.1007/s002329900266; Daniels BV, 2004, ACTA CRYSTALLOGR D, V60, P561, DOI 10.1107/S090744490302972X; de Groot BL, 2001, SCIENCE, V294, P2353, DOI 10.1126/science.1062459; Fu DX, 2000, SCIENCE, V290, P481, DOI 10.1126/science.290.5491.481; Gonen T, 2004, NATURE, V429, P193, DOI 10.1038/nature02503; Harries WEC, 2004, P NATL ACAD SCI USA, V101, P14045, DOI 10.1073/pnas.0405274101; KATZ B, 1972, J PHYSIOL-LONDON, V224, P665, DOI 10.1113/jphysiol.1972.sp009918; LAUGER P, 1982, BIOPHYS CHEM, V16, P209, DOI 10.1016/0301-4622(82)87004-X; LAUGER P, 1980, J MEMBRANE BIOL, V57, P163, DOI 10.1007/BF01869585; Murata K, 2000, NATURE, V407, P599, DOI 10.1038/35036519; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Savage DF, 2003, PLOS BIOL, V1, P334, DOI 10.1371/journal.pbio.0000072; Sui HX, 2001, NATURE, V414, P872, DOI 10.1038/414872a; Tajkhorshid E, 2002, SCIENCE, V296, P525, DOI 10.1126/science.1067778; TONG L, 1990, ACTA CRYSTALLOGR A, V46, P783, DOI 10.1107/S0108767390005530; Wang Y, 2005, STRUCTURE, V13, P1107, DOI 10.1016/j.str.2005.05.005; WISTOW GJ, 1991, TRENDS BIOCHEM SCI, V16, P170, DOI 10.1016/0968-0004(91)90065-4	22	85	86	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					454	460		10.1074/jbc.M508926200	http://dx.doi.org/10.1074/jbc.M508926200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16239219	hybrid			2022-12-25	WOS:000234307200056
J	Yeh, ES; Lew, BO; Means, AR				Yeh, ES; Lew, BO; Means, AR			The loss of PIN1 deregulates cyclin E and sensitizes mouse embryo fibroblasts to genomic instability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLYL ISOMERASE PIN1; C-MYC OVEREXPRESSION; SQUAMOUS-CELL CARCINOMA; UBIQUITIN-PROTEASOME PATHWAY; BREAST-CANCER; CHROMOSOMAL INSTABILITY; DECREASED APOPTOSIS; TUMOR SUPPRESSION; P53 MUTATIONS; BETA-CATENIN	During the G(0)/G(1)-S phase transition, the timely synthesis and degradation of key regulatory proteins is required for normal cell cycle progression. Two of these proteins, c-Myc and cyclin E, are recognized by the Cdc4 E3 ligase of the Skp1/Cul1/Rbx1 (SCF) complex. SCFCdc4 binds to a similar phosphodegron sequence in c-Myc and cyclin E proteins resulting in ubiquitylation and degradation of both proteins via the 26 S proteosome. Since the prolyl isomerase Pin1 binds the c-Myc phosphodegron and participates in regulation of c-Myc turnover, we hypothesized that Pin1 would bind to and regulate cyclin E turnover in a similar manner. Here we show that Pin1 regulates the turnover of cyclin E in mouse embryo fibroblasts. Pin1 binds to the cyclin E-Cdk2 complex in a manner that depends on Ser(384) of cyclin E, which is phosphorylated by Cdk2. The absence of Pin1 results in an increased steady-state level of cyclin E and stalling of the cells in the G(1)/S phase of the cell cycle. The cellular changes that result from the loss of Pin1 predispose Pin1 null mouse embryo fibroblasts to undergo more rapid genomic instability when immortalized by conditional inactivation of p53 and sensitizes these cells to more aggressive Ras-dependent transformation and tumorigenesis.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Means, AR (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Box 3813, Durham, NC 27710 USA.	means001@mc.duke.edu		Teng, Brian/0000-0002-3721-6732	NATIONAL CANCER INSTITUTE [R01CA082845, T32CA059365] Funding Source: NIH RePORTER; NCI NIH HHS [CA082845, T32 CA-059365] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akli S, 2004, CANCER RES, V64, P3198, DOI 10.1158/0008-5472.CAN-03-3672; Akli S, 2004, BREAST CANCER RES, V6, P188, DOI 10.1186/bcr905; Alessi F, 1998, EXP CELL RES, V245, P8, DOI 10.1006/excr.1998.4216; Allen JD, 1997, ONCOGENE, V15, P1133, DOI 10.1038/sj.onc.1201288; Atchison FW, 2003, DEVELOPMENT, V130, P3579, DOI 10.1242/dev.00584; Ayala G, 2003, CANCER RES, V63, P6244; Bao L, 2004, AM J PATHOL, V164, P1727, DOI 10.1016/S0002-9440(10)63731-5; Bedrosian I, 2004, ONCOGENE, V23, P2648, DOI 10.1038/sj.onc.1207408; Boehm JS, 2005, MOL CELL BIOL, V25, P6464, DOI 10.1128/MCB.25.15.6464-6474.2005; Bowman T, 1996, GENE DEV, V10, P826, DOI 10.1101/gad.10.7.826; Brychtova S, 2004, NEOPLASMA, V51, P84; CHEN J, 1995, NAT MED, V1, P638, DOI 10.1038/nm0795-638; Chrzan P, 2001, CLIN BIOCHEM, V34, P557, DOI 10.1016/S0009-9120(01)00260-0; Chung TKH, 2000, GYNECOL OBSTET INVES, V49, P47, DOI 10.1159/000010212; CIFONE MA, 1980, P NATL ACAD SCI-BIOL, V77, P1039, DOI 10.1073/pnas.77.2.1039; Clurman B, 1997, NATURE, V389, P122, DOI 10.1038/38116; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Crenshaw DG, 1998, EMBO J, V17, P1315, DOI 10.1093/emboj/17.5.1315; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; De Miglio MR, 1999, MOL CARCINOGEN, V25, P21, DOI 10.1002/(SICI)1098-2744(199905)25:1<21::AID-MC3>3.0.CO;2-S; Dougherty MK, 2005, MOL CELL, V17, P215, DOI 10.1016/j.molcel.2004.11.055; Ekholm-Reed S, 2004, J CELL BIOL, V165, P789, DOI 10.1083/jcb.200404092; Fan CS, 2000, HUM PATHOL, V31, P169, DOI 10.1016/S0046-8177(00)80216-6; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Fest T, 2002, ONCOGENE, V21, P2981, DOI 10.1038/sj/onc/1205274; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Fujimori F, 1999, BIOCHEM BIOPH RES CO, V265, P658, DOI 10.1006/bbrc.1999.1736; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Greco C, 2001, ANTICANCER RES, V21, P3185; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Hemann MT, 2005, NATURE, V436, P807, DOI 10.1038/nature03845; Hubalek MM, 2004, ONCOGENE, V23, P4187, DOI 10.1038/sj.onc.1207560; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; Hwang HC, 2005, ONCOGENE, V24, P2776, DOI 10.1038/sj.onc.1208613; Ioachim E, 2004, J EXP CLIN CANC RES, V23, P277; Joseph JD, 2004, J BIOL CHEM, V279, P32373, DOI 10.1074/jbc.M405415200; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kawamura K, 2004, CANCER RES, V64, P4800, DOI 10.1158/0008-5472.CAN-03-3908; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Latil A, 2000, INT J CANCER, V89, P172; Li Q, 1999, MOL CELL BIOL, V19, P5339; Liou YC, 2002, P NATL ACAD SCI USA, V99, P1335, DOI 10.1073/pnas.032404099; Lu KP, 2003, CANCER CELL, V4, P175, DOI 10.1016/S1535-6108(03)00218-6; Lu KP, 2004, TRENDS BIOCHEM SCI, V29, P200, DOI 10.1016/j.tibs.2004.02.002; LUCCHINI F, 1992, CANCER LETT, V64, P203, DOI 10.1016/0304-3835(92)90044-V; Mai S, 1996, ONCOGENE, V12, P277; Mai S, 1996, CHROMOSOME RES, V4, P365, DOI 10.1007/BF02257272; Mai Sabine, 2003, Journal of Environmental Pathology Toxicology and Oncology, V22, P179; Mai Sabine, 1999, Neoplasia (New York), V1, P241, DOI 10.1038/sj.neo.7900030; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Mazelin L, 2004, NATURE, V431, P80, DOI 10.1038/nature02788; McCormack SJ, 1998, ONCOGENE, V16, P2755, DOI 10.1038/sj.onc.1201804; McGowan Clare H, 2003, Prog Cell Cycle Res, V5, P1; Miyashita H, 2003, ONCOL REP, V10, P1045; Miyashita H, 2003, ONCOL REP, V10, P455; Mushinski JF, 1999, CURR TOP MICROBIOL, V246, P183; Nakashima M, 2004, J PATHOL, V202, P446, DOI 10.1002/path.1534; Nakayama KI, 2005, SEMIN CELL DEV BIOL, V16, P323, DOI 10.1016/j.semcdb.2005.02.010; Oberst A, 2005, BIOCHEM BIOPH RES CO, V331, P707, DOI 10.1016/j.bbrc.2005.03.158; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Ozdek A, 2004, OTOLARYNG HEAD NECK, V131, P77, DOI 10.1016/j.otohns.2004.02.015; PULVERER BJ, 1994, ONCOGENE, V9, P59; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Reilly KM, 2004, P NATL ACAD SCI USA, V101, P13008, DOI 10.1073/pnas.0401236101; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Rodrigo JP, 1996, ARCH OTOLARYNGOL, V122, P504; Ryo A, 2003, J CELL SCI, V116, P773, DOI 10.1242/jcs.00276; Ryo A, 2002, MOL CELL BIOL, V22, P5281, DOI 10.1128/MCB.22.15.5281-5295.2002; Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Sheen JH, 2002, MOL CELL BIOL, V22, P1819, DOI 10.1128/MCB.22.6.1819-1833.2002; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; TAINSKY MA, 1995, CANCER METAST REV, V14, P43, DOI 10.1007/BF00690210; Taylor C, 1998, CANCER DETECT PREV, V22, P350, DOI 10.1046/j.1525-1500.1998.CDOA36.x; Welcker M, 2004, CURR BIOL, V14, P1852, DOI 10.1016/j.cub.2004.09.083; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Welcker M, 2003, MOL CELL, V12, P381, DOI 10.1016/S1097-2765(03)00287-9; Willmarth NE, 2004, BREAST CANCER RES, V6, pR531, DOI 10.1186/bcr900; WIMMEL A, 1994, ONCOGENE, V9, P995; Winkler KE, 2000, SCIENCE, V287, P1644, DOI 10.1126/science.287.5458.1644; Wulf G, 2004, EMBO J, V23, P3397, DOI 10.1038/sj.emboj.7600323; Wulf G, 2003, BREAST CANCER RES, V5, P76, DOI 10.1186/bcr572; Wulf GM, 2002, J BIOL CHEM, V277, P47976, DOI 10.1074/jbc.C200538200; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yamada S, 2004, INT J CANCER, V111, P17, DOI 10.1002/ijc.20234; Yamamoto S, 1997, CARCINOGENESIS, V18, P1877, DOI 10.1093/carcin/18.10.1877; Ye X, 2004, J BIOL CHEM, V279, P50110, DOI 10.1074/jbc.M409226200; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Yin XY, 1999, ONCOGENE, V18, P1177, DOI 10.1038/sj.onc.1202410; You H, 2002, J CELL BIOCHEM, V84, P211, DOI 10.1002/jcb.10037	96	70	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					241	251		10.1074/jbc.M505770200	http://dx.doi.org/10.1074/jbc.M505770200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16223725	hybrid			2022-12-25	WOS:000234307200032
J	Nanashima, N; Asano, J; Hayakari, M; Nakamura, T; Nakano, H; Yamada, T; Shimizu, T; Akita, M; Fan, Y; Tsuchida, S				Nanashima, N; Asano, J; Hayakari, M; Nakamura, T; Nakano, H; Yamada, T; Shimizu, T; Akita, M; Fan, Y; Tsuchida, S			Nuclear localization of STAT5A modified with O-linked N-acetylglucosamine and early involution in the mammary gland of Hirosaki hairless rat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-RELATED PROTEIN; SERINE PHOSPHORYLATION; PARATHYROID-HORMONE; TRANSGENIC MICE; DNA-BINDING; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; NULL MUTATION; BETA-CASEIN; GENE	Hirosaki hairless rat (HHR) is a mutant strain spontaneously derived from Sprague-Dawley rats (SDR), and its inheritance is autosomal recessive. In addition to hair loss, female HHRs show involution of the mammary gland at an early stage of lactation. In the present study we investigated the mammary gland development in HHR. Morphological examinations revealed that HHR mammary glands are underdeveloped in virgins and exhibit distended alveoli on day 1 of lactation (L1), followed by involution. Milk secretion was observed on L1 in HHR. Whey acidic protein and other proteins were increased in milk of HHR and heterozygous rats on SDS-polyacrylamide gel electrophoresis. Terminal deoxynucleotide transferase-mediated dUTP nick-end labeling assay revealed apoptosis induction in HHRs at an early stage of lactation. By Western blotting, signal transducer and activator of transcription ( STAT) 5A levels in cytoplasmic and nuclear fractions of the mammary glands were not different between HHR and SDR on L1 and L7. Nuclear localization of STAT5A in HHR and SDR was confirmed by immunohistochemistry. Tyr-phosphorylated STAT5A was not detected in HHR but was detected in SDR nuclear fractions. Several proteins modified with O-linked N-acetylglucosamine (O-GlcNAc) were detected in HHR nuclear extract on L1, although not in SDR or heterozygous rats by Western blotting. When HHR nuclear extract was applied to wheat germ agglutinin-agarose, a part of STAT5A was recovered in bound fractions. STAT5A of SDR or heterozygous rat nuclei were not bound to the lectin. Electrophoretic mobility shift assay revealed that STAT5A modified with O-GlcNAc is bound to the STAT5-responsive element. These results indicate that the mammary glands of HHR showed terminal differentiation for a short period, followed immediately by involution. In HHR, STAT5A is modified with O-GlcNAc but is not Tyr-phosphorylated. This type of glycosylation is suggested to be involved in the transient activation of STAT5A in HHR.	Hirosaki Univ, Sch Med, Dept Biochem 2, Hirosaki, Aomori 0368562, Japan; Hirosaki Univ, Sch Hlth Sci, Dept Med Technol, Hirosaki, Aomori 0368564, Japan; Hirosaki Univ, Sch Med, Dept Dermatol, Hirosaki, Aomori 0368562, Japan	Hirosaki University; Hirosaki University; Hirosaki University	Tsuchida, S (corresponding author), Hirosaki Univ, Sch Med, Dept Biochem 2, 5 Zaifu Cho, Hirosaki, Aomori 0368562, Japan.	tsuchida@cc.hirosaki-u.ac.jp	Shimizu, Takeshi/ABE-6503-2020; Nanashima, Naoki/F-1302-2013; Tsuchida, Shigeki/L-3382-2013	Nanashima, Naoki/0000-0002-4729-3432; Tsuchida, Shigeki/0000-0002-4404-5599				Ariyoshi K, 2000, J BIOL CHEM, V275, P24407, DOI 10.1074/jbc.M909771199; Bole-Feysot C, 1998, ENDOCR REV, V19, P225, DOI 10.1210/edrv.19.3.0334; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTLE W. E., 1955, JOUR HEREDITY, V46, P9; CHOU TY, 1995, P NATL ACAD SCI USA, V92, P4417, DOI 10.1073/pnas.92.10.4417; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Dunbar ME, 1999, DEVELOPMENT, V126, P3485; Emery FE, 1935, AM J PHYSIOL, V111, P392, DOI 10.1152/ajplegacy.1935.111.2.392; Gewinner C, 2004, J BIOL CHEM, V279, P3563, DOI 10.1074/jbc.M306449200; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GRONER B, 1994, MOL CELL ENDOCRINOL, V100, P109, DOI 10.1016/0303-7207(94)90288-7; GRONER B, 1995, CURR OPIN GENET DEV, V5, P587, DOI 10.1016/0959-437X(95)80027-1; HALTIWANGER RS, 1992, BIOCHEM SOC T, V20, P264, DOI 10.1042/bst0200264; Hanada K, 1988, J Dermatol, V15, P257; Howard A, 1940, J HERED, V31, P467, DOI 10.1093/oxfordjournals.jhered.a104815; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; INAZU M, 1984, LAB ANIM SCI, V34, P577; ISHIKAWA T, 1988, EUR J BIOCHEM, V176, P551, DOI 10.1111/j.1432-1033.1988.tb14313.x; Jia YZ, 2005, J BIOL CHEM, V280, P10766, DOI 10.1074/jbc.M413331200; KAZANSKY AV, 1995, MOL ENDOCRINOL, V9, P1598, DOI 10.1210/me.9.11.1598; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; LI S, 1995, MOL CELL BIOL, V15, P2063; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Medina L, 1998, GLYCOBIOLOGY, V8, P383, DOI 10.1093/glycob/8.4.383; Miyoshi K, 2001, J CELL BIOL, V155, P531, DOI 10.1083/jcb.200107065; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; OHNO T, 1978, EXP ANIM, V27, P205; Qi C, 2004, J BIOL CHEM, V279, P33696, DOI 10.1074/jbc.M401266200; ROBERTS E., 1940, JOUR INVEST DERMAL, V3, P1; RUSSO J, 1977, J NATL CANCER I, V59, P435, DOI 10.1093/jnci/59.2.435; SCHMITT-NEY M, 1992, P NATL ACAD SCI USA, V89, P3130, DOI 10.1073/pnas.89.7.3130; Shafi R, 2000, P NATL ACAD SCI USA, V97, P5735, DOI 10.1073/pnas.100471497; Shaw P, 1996, ONCOGENE, V12, P921; Toleman C, 2004, J BIOL CHEM, V279, P53665, DOI 10.1074/jbc.M410406200; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Waddell BJ, 2000, BIOL REPROD, V63, P1913, DOI 10.1095/biolreprod63.6.1913; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wheeler TT, 2001, MOL CELL ENDOCRINOL, V176, P39, DOI 10.1016/S0303-7207(01)00481-6; WYSOLMERSKI JJ, 1995, DEVELOPMENT, V121, P3539; WYSOLMERSKI JJ, 1994, P NATL ACAD SCI USA, V91, P1133, DOI 10.1073/pnas.91.3.1133; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Yamashita H, 1998, J BIOL CHEM, V273, P30218, DOI 10.1074/jbc.273.46.30218; Yamashita H, 2001, MOL CELL ENDOCRINOL, V183, P151, DOI 10.1016/S0303-7207(01)00546-9; Zachara NE, 2002, CHEM REV, V102, P431, DOI 10.1021/cr000406u	49	10	10	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					43010	43016		10.1074/jbc.M509481200	http://dx.doi.org/10.1074/jbc.M509481200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16227201	hybrid			2022-12-25	WOS:000234200800065
J	Rampal, R; Li, ASY; Moloney, DJ; Georgiou, SA; Luther, KB; Nita-Lazar, A; Haltiwanger, RS				Rampal, R; Li, ASY; Moloney, DJ; Georgiou, SA; Luther, KB; Nita-Lazar, A; Haltiwanger, RS			Lunatic fringe, Manic fringe, and Radical fringe recognize similar specificity determinants in O-fucosylated epidermal growth factor-like repeats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA WING DEVELOPMENT; HAMSTER OVARY CELLS; LINKED FUCOSE; NOTCH PATHWAY; GLYCOSYLATION; TRANSFERASE; GLYCOSYLTRANSFERASE; MODULATION; EXPRESSION; BOUNDARY	Notch signaling is a component of a wide variety of developmental processes in many organisms. Notch activity can be modulated by O-fucosylation ( mediated by protein O-fucosyltransferase-1) and Fringe, a beta 1,3-N-acetylglucosaminyltransferase that modifies O-fucose in the context of epidermal growth factor-like (EGF) repeats. Fringe was initially described in Drosophila, and three mammalian homologues have been identified, Manic fringe, Lunatic fringe, and Radical fringe. Here for the first time we have demonstrated that, similar to Manic and Lunatic, Radical fringe is also a fucose-specific beta 1,3-N-acetylglucosaminyltransferase. The fact that three Fringe homologues exist in mammals raises the question of whether and how these enzymes differ. Although Notch contains numerous EGF repeats that are predicted to be modified by O-fucose, previous studies in our laboratory have demonstrated that not all O-fucosylated EGF repeats of Notch are further modified by Fringe, suggesting that the Fringe enzymes can differentiate between them. In this work, we have sought to identify specificity determinants for the recognition of an individual O-fucosylated EGF repeat by the Fringe enzymes. We have also sought to determine differences in the biochemical behavior of the Fringes with regard to their in vitro enzymatic activities. Using both in vivo and in vitro experiments, we have found two amino acids that appear to be important for the recognition of an O-fucosylated EGF repeat by all three mammalian Fringes. These amino acids provide an initial step toward defining sequences that will allow us to predict which O-fucosylated EGF repeats are modified by the Fringes.	SUNY Stony Brook, Inst Cell & Dev Biol, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Haltiwanger, RS (corresponding author), SUNY Stony Brook, Inst Cell & Dev Biol, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.	rhaltiwanger@ms.cc.sunysb.edu	Nita-Lazar, Aleksandra/N-3740-2018	Nita-Lazar, Aleksandra/0000-0002-8523-605X; Luther, Kelvin/0000-0001-9438-9675	NIGMS NIH HHS [T32 GM008444, R01 GM061126, GM 61126] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008444, R01GM061126] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arboleda-Velasquez JF, 2005, HUM MOL GENET, V14, P1631, DOI 10.1093/hmg/ddi171; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; Chen JH, 2001, P NATL ACAD SCI USA, V98, P13716, DOI 10.1073/pnas.241398098; Dale JK, 2003, NATURE, V421, P275, DOI 10.1038/nature01244; Fleming RJ, 1997, DEVELOPMENT, V124, P2973; Grammont M, 2001, DEVELOPMENT, V128, P2243; Haines N, 2003, NAT REV MOL CELL BIO, V4, P786, DOI 10.1038/nrm1228; Haltiwanger RS, 2002, BBA-GEN SUBJECTS, V1573, P328, DOI 10.1016/S0304-4165(02)00400-2; HARDY MR, 1994, METHOD ENZYMOL, V230, P208; HARRIS RJ, 1993, GLYCOBIOLOGY, V3, P219, DOI 10.1093/glycob/3.3.219; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; Johnston SH, 1997, DEVELOPMENT, V124, P2245; Klein T, 1998, DEVELOPMENT, V125, P2951; Li GT, 2005, J BIOL CHEM, V280, P1864, DOI 10.1074/jbc.M410969200; Luo Y, 2005, J BIOL CHEM, V280, P11289, DOI 10.1074/jbc.M414574200; Moloney DJ, 1997, J BIOL CHEM, V272, P19046, DOI 10.1074/jbc.272.30.19046; Moloney DJ, 2000, J BIOL CHEM, V275, P9604, DOI 10.1074/jbc.275.13.9604; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Moran JL, 1999, MAMM GENOME, V10, P535, DOI 10.1007/s003359901039; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Qiu XH, 2004, DEV DYNAM, V231, P621, DOI 10.1002/dvdy.20155; Rampal R, 2005, J BIOL CHEM, V280, P32133, DOI 10.1074/jbc.M506104200; RodriguezEsteban C, 1997, NATURE, V386, P360, DOI 10.1038/386360a0; Shao L, 2003, J BIOL CHEM, V278, P7775, DOI 10.1074/jbc.M212221200; Shao L, 2002, GLYCOBIOLOGY, V12, P763, DOI 10.1093/glycob/cwf085; Shimizu K, 2001, J BIOL CHEM, V276, P25753, DOI 10.1074/jbc.M103473200; STANLEY P, 1977, SOMAT CELL GENET, V3, P391, DOI 10.1007/BF01542968; Sturla L, 2003, J BIOL CHEM, V278, P26727, DOI 10.1074/jbc.M304068200; Unligil UM, 2000, CURR OPIN STRUC BIOL, V10, P510, DOI 10.1016/S0959-440X(00)00124-X; Wang Y, 1998, J BIOL CHEM, V273, P8112, DOI 10.1074/jbc.273.14.8112; Wang Y, 2001, J BIOL CHEM, V276, P40338, DOI 10.1074/jbc.M107849200; Wang Y, 1996, GLYCOBIOLOGY, V6, P837, DOI 10.1093/glycob/6.8.837; Yang LT, 2005, MOL BIOL CELL, V16, P927, DOI 10.1091/mbc.e04-07-0614; Zhang N, 2002, GENESIS, V33, P21, DOI 10.1002/gene.10081; Zhang NA, 1998, NATURE, V394, P374, DOI 10.1038/28625	36	84	85	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42454	42463		10.1074/jbc.M509552200	http://dx.doi.org/10.1074/jbc.M509552200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16221665	hybrid			2022-12-25	WOS:000233992700076
J	Jin, JY; Cai, Y; Yao, T; Gottschalk, AJ; Florens, L; Swanson, SK; Gutierrez, JL; Coleman, MK; Workman, JL; Mushegian, A; Washburn, MP; Conaway, RC; Conaway, JW				Jin, JY; Cai, Y; Yao, T; Gottschalk, AJ; Florens, L; Swanson, SK; Gutierrez, JL; Coleman, MK; Workman, JL; Mushegian, A; Washburn, MP; Conaway, RC; Conaway, JW			A mammalian chromatin remodeling complex with similarities to the yeast INO80 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IDENTIFICATION TECHNOLOGY; HISTONE ACETYLTRANSFERASE COMPLEX; INOSITOL POLYPHOSPHATES; NUCLEOLAR PROTEIN; MOLECULAR-CLONING; BINDING PROTEIN; NUCLEOSOME; TRANSCRIPTION; GROWTH; REPAIR	The mammalian Tip49a and Tip49b proteins belong to an evolutionarily conserved family of AAA(+) ATPases. In Saccharomyces cerevisiae, orthologs of Tip49a and Tip49b, called Rvb1 and Rvb2, respectively, are subunits of two distinct ATP-dependent chromatin remodeling complexes, SWR1 and INO80. We recently demonstrated that the mammalian Tip49a and Tip49b proteins are integral subunits of a chromatin remodeling complex bearing striking similarities to the S. cerevisiae SWR1 complex (Cai, Y., Jin, J., Florens, L., Swanson, S. K., Kusch, T., Li, B., Workman, J. L., Washburn, M. P., Conaway, R. C., and Conaway, J. W. ( 2005) J. Biol. Chem. 280, 13665-13670). In this report, we identify a new mammalian Tip49a- and Tip49b- containing ATP-dependent chromatin remodeling complex, which includes orthologs of 8 of the 15 subunits of the S. cerevisiae INO80 chromatin remodeling complex as well as at least five additional subunits unique to the human INO80 (hINO80) complex. Finally, we demonstrate that, similar to the yeast INO80 complex, the hINO80 complex exhibits DNA- and nucleosome-activated ATPase activity and catalyzes ATP-dependent nucleosome sliding.	Stowers Inst Med Res, Kansas City, MO 64110 USA; Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Microbiol, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Mol Genet, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Immunol, Kansas City, KS 66160 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	Stowers Institute for Medical Research; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Conaway, JW (corresponding author), Stowers Inst Med Res, Kansas City, MO 64110 USA.	jlc@stowers-institute.org	Mushegian, Arcady/ABF-5387-2021	Mushegian, Arcady/0000-0002-6809-9225; Washburn, Michael/0000-0001-7568-2585; Gutierrez, Jose/0000-0002-0957-2297; Conaway, Joan/0000-0002-2786-0663; Florens, Laurence/0000-0002-9310-6650	NIGMS NIH HHS [R37GM47867, R37GM41628] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041628, R37GM047867] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS BS, 1991, NEW BIOL, V3, P1063; Bakshi R, 2004, BIOCHEM BIOPH RES CO, V320, P197, DOI 10.1016/j.bbrc.2004.05.147; Brambillasca F, 1999, LEUKEMIA, V13, P369, DOI 10.1038/sj.leu.2401338; Cai Y, 2005, J BIOL CHEM, V280, P13665, DOI 10.1074/jbc.M500001200; Cai Y, 2003, J BIOL CHEM, V278, P42733, DOI 10.1074/jbc.C300389200; Caruthers JM, 2002, CURR OPIN STRUC BIOL, V12, P123, DOI 10.1016/S0959-440X(02)00298-1; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doyon Y, 2004, CURR OPIN GENET DEV, V14, P147, DOI 10.1016/j.gde.2004.02.009; Doyon Y, 2004, MOL CELL BIOL, V24, P1884, DOI 10.1128/MCB.24.5.1884-1896.2004; DUBANDGOULET I, 1992, J MOL BIOL, V224, P981, DOI 10.1016/0022-2836(92)90464-U; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Fritsch O, 2004, MOL CELL, V16, P479, DOI 10.1016/j.molcel.2004.09.034; HORIKAWA I, 1995, EXP CELL RES, V220, P11, DOI 10.1006/excr.1995.1286; HORIKAWA I, 1995, BIOCHEM BIOPH RES CO, V208, P999, DOI 10.1006/bbrc.1995.1433; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Irie Y, 2000, J BIOL CHEM, V275, P2647, DOI 10.1074/jbc.275.4.2647; Juan LJ, 1997, J BIOL CHEM, V272, P3635, DOI 10.1074/jbc.272.6.3635; KOBOR MS, 2004, PLOS BIOL; Krogan NJ, 2004, P NATL ACAD SCI USA, V101, P13513, DOI 10.1073/pnas.0405753101; Kuroda TS, 2004, GENE, V340, P83, DOI 10.1016/j.gene.2004.05.025; Kusch T, 2004, SCIENCE, V306, P2084, DOI 10.1126/science.1103455; Luger K, 1999, METH MOL B, V119, P1; McDonald WH, 2002, INT J MASS SPECTROM, V219, P245, DOI 10.1016/S1387-3806(02)00563-8; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; Mizuguchi G, 2004, SCIENCE, V303, P343, DOI 10.1126/science.1090701; Morrison AJ, 2004, CELL, V119, P767, DOI 10.1016/j.cell.2004.11.037; Neuwald AF, 1999, GENOME RES, V9, P27; Ohdate H, 2003, J BIOL CHEM, V278, P14647, DOI 10.1074/jbc.M213220200; Owen-Hughes T, 1999, METH MOL B, V119, P319; Ren Y, 1998, EUR J BIOCHEM, V253, P734, DOI 10.1046/j.1432-1327.1998.2530734.x; Sadygov RG, 2002, J PROTEOME RES, V1, P211, DOI 10.1021/pr015514r; SAMBROOK J., 1989, MOL CLONING LAB MANU, pB23; Shen XT, 2000, NATURE, V406, P541, DOI 10.1038/35020123; Shen XT, 2003, MOL CELL, V12, P147, DOI 10.1016/S1097-2765(03)00264-8; Shen XT, 2003, SCIENCE, V299, P112, DOI 10.1126/science.1078068; Steger DJ, 2003, SCIENCE, V299, P114, DOI 10.1126/science.1078062; van Attikum H, 2004, CELL, V119, P777, DOI 10.1016/j.cell.2004.11.033; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Wolters DA, 2001, ANAL CHEM, V73, P5683, DOI 10.1021/ac010617e	39	175	189	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41207	41212		10.1074/jbc.M509128200	http://dx.doi.org/10.1074/jbc.M509128200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16230350	hybrid			2022-12-25	WOS:000233866900013
J	Maoz, T; Koren, R; Ben-Ari, I; Kleinberger, T				Maoz, T; Koren, R; Ben-Ari, I; Kleinberger, T			YND1 interacts with CDC55 and is a novel mediator of E4orf4-induced toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS E4ORF4 PROTEIN; SITE-DIRECTED MUTAGENESIS; SACCHAROMYCES-CEREVISIAE; PHOSPHATASE 2A; BUDDING YEAST; P53-INDEPENDENT APOPTOSIS; TRANSFORMED-CELLS; B-ALPHA; DEATH; SUBUNIT	Adenovirus E4orf4 (early region 4 open reading frame 4) protein induces protein phosphatase 2A-dependent non-classical apoptosis in mammalian cells and irreversible growth arrest in Saccharomyces cerevisiae. Oncogenic transformation sensitizes cells to E4orf4-induced cell death. To uncover additional components of the E4orf4 network required for induction of its unique mode of apoptosis, we used yeast genetics to select gene deletions conferring resistance to E4orf4. Deletion of YND1, encoding a yeast Golgi apyrase, conferred partial resistance to E4orf4. However, Ynd1p apyrase activity was not required for E4orf4-induced toxicity. Ynd1p and Cdc55p, the yeast protein phosphatase 2A-B subunit, contributed additively to E4orf4-induced toxicity. Furthermore, concomitant overexpression of one and deletion of the other was detrimental to yeast growth, demonstrating a functional interaction between the two proteins. YND1 and CDC55 also interacted genetically with CDC20 and CDH1/HCT1, encoding activating subunits of the anaphase-promoting complex/cyclosome. In addition to their functional interaction, Ynd1p and Cdc55p interacted physically, and this interaction was disrupted by E4orf4, which remained associated with both proteins. The results suggested that Ynd1p and Cdc55p share a common downstream target whose balanced modulation by the two E4orf4 partners is crucial to viability. Disruption of this balance by E4orf4 may lead to cell death. NTPDase-4/Lalp70/ UDPase, the closest mammalian homologue of Ynd1p, associated with E4orf4 in mammalian cells, suggesting that the results in yeast are relevant to the mammalian system.	Technion Israel Inst Technol, Gonda Ctr Mol Microbiol, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Rappaport Family Inst Res Med Sci, Fac Med, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Kleinberger, T (corresponding author), Technion Israel Inst Technol, Gonda Ctr Mol Microbiol, IL-31096 Haifa, Israel.	tamark@tx.technion.ac.il						Afifi R, 2001, J VIROL, V75, P4444, DOI 10.1128/JVI.75.9.4444-4447.2001; Baccarini M, 2005, FEBS LETT, V579, P3271, DOI 10.1016/j.febslet.2005.03.024; Biederbick A, 1999, J CELL SCI, V112, P2473; Biederbick A, 2000, J BIOL CHEM, V275, P19018, DOI 10.1074/jbc.M001245200; Bondesson M, 1996, J VIROL, V70, P3844, DOI 10.1128/JVI.70.6.3844-3851.1996; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; Dombroski D, 2005, J IMMUNOL, V174, P1385, DOI 10.4049/jimmunol.174.3.1385; Drosopoulos JHF, 2000, BIOCHEMISTRY-US, V39, P6936, DOI 10.1021/bi992581e; Funakoshi M, 2000, MOL GEN GENET, V264, P29, DOI 10.1007/s004380000300; Gao XD, 1999, J BIOL CHEM, V274, P21450, DOI 10.1074/jbc.274.30.21450; Gingras MC, 2002, MOL CELL BIOL, V22, P41, DOI 10.1128/MCB.22.1.41-56.2002; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HARDWICK KG, 1995, J CELL BIOL, V131, P709, DOI 10.1083/jcb.131.3.709; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; Kanopka A, 1998, NATURE, V393, P185, DOI 10.1038/30277; KLEINBERGER T, 1993, J VIROL, V67, P7556, DOI 10.1128/JVI.67.12.7556-7560.1993; Koren R, 2004, J BIOL CHEM, V279, P48598, DOI 10.1074/jbc.M409359200; Kornitzer D, 2001, J CELL BIOL, V154, P331, DOI 10.1083/jcb.200104104; Lavoie JN, 1998, J CELL BIOL, V140, P637, DOI 10.1083/jcb.140.3.637; Lavoie JN, 2000, J CELL BIOL, V150, P1037, DOI 10.1083/jcb.150.5.1037; Lew DJ, 2003, ANNU REV GENET, V37, P251, DOI 10.1146/annurev.genet.37.042203.120656; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Livne A, 2001, J VIROL, V75, P789, DOI 10.1128/JVI.75.2.789-798.2001; Mannervik M, 1999, VIROLOGY, V256, P313, DOI 10.1006/viro.1999.9663; Marcellus RC, 1998, J VIROL, V72, P7144, DOI 10.1128/JVI.72.9.7144-7153.1998; Marcellus RC, 2000, J VIROL, V74, P7869, DOI 10.1128/JVI.74.17.7869-7877.2000; Matsuyama S, 1999, CURR OPIN MICROBIOL, V2, P618, DOI 10.1016/S1369-5274(99)00031-4; Minshull J, 1996, CURR BIOL, V6, P1609, DOI 10.1016/S0960-9822(02)70784-7; MULLER U, 1992, J VIROL, V66, P5867; Nickels JT, 1996, GENE DEV, V10, P382, DOI 10.1101/gad.10.4.382; Prinz S, 1998, CURR BIOL, V8, P750, DOI 10.1016/S0960-9822(98)70298-2; Putzke AP, 2005, DEVELOPMENT, V132, P3185, DOI 10.1242/dev.01900; Robert A, 2002, J CELL BIOL, V158, P519, DOI 10.1083/jcb.200201106; Roopchand DE, 2001, ONCOGENE, V20, P5279, DOI 10.1038/sj.onc.1204693; Ross KE, 2003, GENETICS, V165, P489; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; Sherman F., 1986, METHODS YEAST GENETI, P163; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Shtrichman R, 2000, ONCOGENE, V19, P3757, DOI 10.1038/sj.onc.1203705; Shtrichman R, 1999, P NATL ACAD SCI USA, V96, P10080, DOI 10.1073/pnas.96.18.10080; Shtrichman R, 1998, J VIROL, V72, P2975, DOI 10.1128/JVI.72.4.2975-2982.1998; Sontag E, 2001, CELL SIGNAL, V13, P7, DOI 10.1016/S0898-6568(00)00123-6; Sutterlin C, 2005, MOL BIOL CELL, V16, P3211, DOI 10.1091/mbc.E04-12-1065; Wang TF, 1998, J BIOL CHEM, V273, P11392, DOI 10.1074/jbc.273.18.11392; Wang YC, 1997, MOL CELL BIOL, V17, P620, DOI 10.1128/MCB.17.2.620; Yang F, 2001, BIOCHEMISTRY-US, V40, P3943, DOI 10.1021/bi002711f; Ying BL, 2003, VIROLOGY, V313, P224, DOI 10.1016/S0042-6822(03)00287-3; Zhao Y, 1997, J BIOL CHEM, V272, P8256, DOI 10.1074/jbc.272.13.8256; Zhong XT, 1999, J BIOL CHEM, V274, P32704, DOI 10.1074/jbc.274.46.32704; Zimmermann H, 2001, DRUG DEVELOP RES, V52, P44, DOI 10.1002/ddr.1097	51	19	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41270	41277		10.1074/jbc.M507281200	http://dx.doi.org/10.1074/jbc.M507281200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16227198	hybrid			2022-12-25	WOS:000233866900021
J	Recklies, AD; Ling, H; White, C; Bernier, SM				Recklies, AD; Ling, H; White, C; Bernier, SM			Inflammatory cytokines induce production of CHI3L1 by articular chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CARTILAGE GLYCOPROTEIN-39; NF-KAPPA-B; CRYSTAL-STRUCTURE; RHEUMATOID-ARTHRITIS; POTENTIAL MARKER; GENETIC-MARKERS; SYNOVIAL-CELLS; SERUM YKL-40; GP-39; EXPRESSION	Elevated levels of CHI3L1 (<(chi)underbar > tinase-(3) under bar-(l) under bar ike protein (1) under bar) are associated with disorders exhibiting increased connective tissue turnover, such as rheumatoid arthritis, osteoarthritis, scleroderma, and cirrhosis of the liver. This secreted protein is not synthesized in young healthy cartilage, but is produced in cartilage from old donors or patients with osteoarthritis. The molecular processes governing the induction of CHI3L1 are currently unknown. To elucidate the molecular events involved in CHI3L1 synthesis, we investigated two models of articular chondrocytes: neonatal rat chondrocytes, which do not express CHI3L1, and human chondrocytes, which express CHI3L1 constitutively. In neonatal rat chondrocytes, the inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 potently induced steady-state levels of CHI3L1 mRNA and protein secretion. Treatment of chondrocytes with TNF-alpha for as little as 1 h was sufficient for sustained induction up to 72 h afterward. Using inhibitors selective for the major signaling pathways implicated in mediating the effects of TNF-alpha and interleukin-1, only inhibition of NF-kappa B activation was effective in curtailing cytokine-induced expression, including after removal of the cytokine, indicating that induction and continued production of CHI3L1 are controlled mainly by this transcription factor. Inhibition of NF-kappa B signaling also abolished constitutive expression by human chondrocytes. Thus, induction and continued secretion of CHI3L1 in chondrocytes require sustained activation of NF-kappa B. Selective induction of CHI3L1 by cytokines acting through NF-kappa B coupled with the known restriction of the catabolic responses by CHI3L1 in response to these inflammatory cytokines represents a key regulatory feedback process in controlling connective tissue turnover.	Shriners Hosp Children, Joint Dis Lab, Montreal, PQ H3G 1A6, Canada; McGill Univ, Dept Surg, Montreal, PQ H3G 1A6, Canada; Univ Western Ontario, Dept Anat & Cell Biol, Canadian Inst Hlth, Res Grp Skeletal Dev & Remodeling, London, ON N6A 5C1, Canada	McGill University; McGill University; Western University (University of Western Ontario)	Recklies, AD (corresponding author), Shriners Hosp Children, Joint Dis Lab, 1529 Cedar Ave, Montreal, PQ H3G 1A6, Canada.	arecklies@shriners.mcgill.ca						Algarte M, 1999, J VIROL, V73, P2694; BELLOWS CG, 1986, CALCIFIED TISSUE INT, V38, P143, DOI 10.1007/BF02556874; Boot RG, 1999, ARTERIOSCL THROM VAS, V19, P687, DOI 10.1161/01.ATV.19.3.687; Connor JR, 2000, OSTEOARTHR CARTILAGE, V8, P87, DOI 10.1053/joca.1999.0276; De Ceuninck F, 2001, BIOCHEM BIOPH RES CO, V285, P926, DOI 10.1006/bbrc.2001.5253; De Ceuninck F, 1998, J CELL BIOCHEM, V69, P414, DOI 10.1002/(SICI)1097-4644(19980615)69:4<414::AID-JCB3>3.0.CO;2-Q; Delhalle S, 2004, ANN NY ACAD SCI, V1030, P1, DOI 10.1196/annals.1329.002; Feldmann M, 2001, ANNU REV IMMUNOL, V19, P163, DOI 10.1146/annurev.immunol.19.1.163; Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661; Fusetti F, 2003, J BIOL CHEM, V278, P37753, DOI 10.1074/jbc.M303137200; Gruber J, 2004, ARTHRITIS RHEUM-US, V50, P2539, DOI 10.1002/art.20369; HAKALA BE, 1993, J BIOL CHEM, V268, P25803; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; Hinz M, 2002, J EXP MED, V196, P605, DOI 10.1084/jem.20020062; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Houston DR, 2003, J BIOL CHEM, V278, P30206, DOI 10.1074/jbc.M303371200; Johansen JS, 1999, RHEUMATOLOGY, V38, P618, DOI 10.1093/rheumatology/38.7.618; JOHANSEN JS, 1995, EUR J CANCER, V31A, P1437, DOI 10.1016/0959-8049(95)00196-P; Johansen JS, 1997, SCAND J GASTROENTERO, V32, P582, DOI 10.3109/00365529709025104; JOHANSEN JS, 1993, BRIT J RHEUMATOL, V32, P949; Johansen JS, 2001, ARTHRITIS RHEUM-US, V44, P826; Krappmann D, 1997, IMMUNOBIOLOGY, V198, P3, DOI 10.1016/S0171-2985(97)80022-8; Krause SW, 1996, J LEUKOCYTE BIOL, V60, P540, DOI 10.1002/jlb.60.4.540; LA MG, 2003, J RHEUMATOL, V30, P2147; Ling H, 2004, BIOCHEM J, V380, P651, DOI 10.1042/BJ20040099; Malinda KM, 1999, EXP CELL RES, V250, P168, DOI 10.1006/excr.1999.4511; MORRISON BW, 1994, ONCOGENE, V9, P3417; Murphy G, 2002, ARTHRITIS RES THER, V4, DOI 10.1186/ar572; Nishikawa KC, 2003, EXP CELL RES, V287, P79, DOI 10.1016/S0014-4827(03)00069-7; NYIRKOS P, 1990, BIOCHEM J, V269, P265, DOI 10.1042/bj2690265; O'Sullivan BJ, 2002, J IMMUNOL, V168, P5491, DOI 10.4049/jimmunol.168.11.5491; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Punzi L, 2003, ANN RHEUM DIS, V62, P1224, DOI 10.1136/ard.2002.004408; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Recklies AD, 2002, BIOCHEM J, V365, P119, DOI 10.1042/BJ20020075; Rehli M, 2003, J BIOL CHEM, V278, P44058, DOI 10.1074/jbc.M306792200; Rehli M, 1997, GENOMICS, V43, P221, DOI 10.1006/geno.1997.4778; Sakai T, 2001, J BONE MINER RES, V16, P1272, DOI 10.1359/jbmr.2001.16.7.1272; Seguin CA, 2003, J CELL PHYSIOL, V197, P357, DOI 10.1002/jcp.10371; Sun YJ, 2001, J BIOL CHEM, V276, P17507, DOI 10.1074/jbc.M010416200; Tsai ML, 2004, J STRUCT BIOL, V148, P290, DOI 10.1016/j.jsb.2004.07.002; Volck B, 1999, SCAND J RHEUMATOL, V28, P171; Wingender E, 2001, NUCLEIC ACIDS RES, V29, P281, DOI 10.1093/nar/29.1.281	43	128	132	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41213	41221		10.1074/jbc.M510146200	http://dx.doi.org/10.1074/jbc.M510146200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16234240	hybrid			2022-12-25	WOS:000233866900014
J	Xu, XM; Mix, H; Carlson, BA; Grabowski, PJ; Gladyshev, VN; Berry, MJ; Hatfield, DL				Xu, XM; Mix, H; Carlson, BA; Grabowski, PJ; Gladyshev, VN; Berry, MJ; Hatfield, DL			Evidence for direct roles of two additional factors, SECp43 and soluble liver antigen, in the selenoprotein synthesis machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELENOCYSTEINE TRANSFER RNA<SER>SEC; MAMMALIAN-CELLS; TRANSFER-RNA; INTERFERING RNAS; PROTEIN; EUKARYOTES; COMPONENT; SELENIUM; AUTOANTIBODIES; IDENTIFICATION	Selenocysteine (Sec) is inserted into selenoproteins co-translationally with the help of various cis- and trans-acting factors. The specific mechanisms of Sec biosynthesis and insertion into protein in eukaryotic cells, however, are not known. Two proteins, SECp43 and the soluble liver antigen (SLA), were previously reported to interact with tRNA([Ser]Sec), but their functions remained elusive. Herein, we report that knockdown of SECp43 in NIH3T3 or TCMK-1 cells using RNA interference technology resulted in a reduction in the level of methylation at the 2'-hydroxylribosyl moiety in the wobble position (Um34) of Sec tRNA([Ser]Sec), and consequently reduced glutathione peroxidase 1 expression. Double knockdown of SECp43 and SLA resulted in decreased selenoprotein expression. SECp43 formed a complex with Sec tRNA([Ser]Sec) and SLA, and the targeted removal of one of these proteins affected the binding of the other to Sec tRNA([Ser]Sec). SECp43 was located primarily in the nucleus, whereas SLA was found in the cytoplasm. Co-transfection of both proteins resulted in the nuclear translocation of SLA suggesting that SECp43 may also promote shuttling of SLA and Sec tRNA([Ser]Sec) between different cellular compartments. Taken together, these data establish the role of SECp43 and SLA in selenoprotein biosynthesis through interaction with tRNA([Ser]Sec) in a multiprotein complex. The data also reveal a role of SECp43 in regulation of selenoprotein expression by affecting the synthesis of Um34 on tRNA([Ser]Sec) and the intracellular location of SLA.	NCI, Mol Biol Selenium Sect, Lab Canc Prevent, Ctr Canc Res,NIH, Bethesda, MD 20892 USA; Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA; Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA; Univ Hawaii Manoa, Dept Cell & Mol Biol, John A Burns Sch Med, Honolulu, HI 96822 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Nebraska System; University of Nebraska Lincoln; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Hawaii System; University of Hawaii Manoa	Hatfield, DL (corresponding author), NCI, Mol Biol Selenium Sect, Lab Canc Prevent, Ctr Canc Res,NIH, Bldg 37,Rm 6032A, Bethesda, MD 20892 USA.	hatfield@dc37a.nci.nih.gov	Gladyshev, Vadim N/A-9894-2013; Gladyshev, Vadim N/J-6187-2013	Gladyshev, Vadim/0000-0002-0372-7016	Intramural NIH HHS Funding Source: Medline; NIGMS NIH HHS [GM061603] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC005317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061603] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bock A, 2001, SELENIUM: ITS MOLECULAR BIOLOGY AND ROLE IN HUMAN HEALTH, P7; Carlson BA, 2005, TOP CURR GENET, V12, P431, DOI 10.1007/b106652; Carlson BA, 2005, J BIOL CHEM, V280, P5542, DOI 10.1074/jbc.M411725200; Chavatte L, 2005, NAT STRUCT MOL BIOL, V12, P408, DOI 10.1038/nsmb922; Copeland PR, 2000, EMBO J, V19, P306, DOI 10.1093/emboj/19.2.306; Copeland PR, 1999, J BIOL CHEM, V274, P25447, DOI 10.1074/jbc.274.36.25447; Costa M, 2000, CLIN EXP IMMUNOL, V121, P364, DOI 10.1046/j.1365-2249.2000.01280.x; DIAMOND AM, 1993, J BIOL CHEM, V268, P14215; Ding F, 1999, RNA, V5, P1561, DOI 10.1017/S1355838299991598; DRISCOLL DM, 2003, ANNU REV BIOCHEM, V14, P11; Fagegaltier D, 2000, EMBO J, V19, P4796, DOI 10.1093/emboj/19.17.4796; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; GELPI C, 1992, P NATL ACAD SCI USA, V89, P9739, DOI 10.1073/pnas.89.20.9739; Grundner-Culemann E, 1999, RNA, V5, P625, DOI 10.1017/S1355838299981542; Guimaraes MJ, 1996, P NATL ACAD SCI USA, V93, P15086, DOI 10.1073/pnas.93.26.15086; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; HATFIELD D, 1979, BIOCHIM BIOPHYS ACTA, V564, P414, DOI 10.1016/0005-2787(79)90032-7; HATFIELD D, 1991, NUCLEIC ACIDS RES, V19, P939, DOI 10.1093/nar/19.4.939; Hatfield DL, 2002, MOL CELL BIOL, V22, P3565, DOI 10.1128/MCB.22.11.3565-3576.2002; KELMERS AD, 1971, ANAL BIOCHEM, V44, P486, DOI 10.1016/0003-2697(71)90236-3; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; Kumaraswamy E, 2003, MOL CELL BIOL, V23, P1477, DOI 10.1128/MCB.23.5.1477-1488.2003; LOW SC, 1995, J BIOL CHEM, V270, P21659, DOI 10.1074/jbc.270.37.21659; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; Moustafa ME, 2001, MOL CELL BIOL, V21, P3840, DOI 10.1128/MCB.21.11.3840-3852.2001; Scherr M, 2003, CURR MED CHEM, V10, P245, DOI 10.2174/0929867033368493; Tujebajeva RM, 2000, EMBO REP, V1, P158, DOI 10.1093/embo-reports/kvd033; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499	28	70	76	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41568	41575		10.1074/jbc.M506696200	http://dx.doi.org/10.1074/jbc.M506696200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16230358	Green Submitted, hybrid			2022-12-25	WOS:000233866900057
J	Chen, SG; Ji, M; Paris, M; Hullinger, RL; Andrisani, OM				Chen, SG; Ji, M; Paris, M; Hullinger, RL; Andrisani, OM			The cAMP pathway regulates both transcription and activity of the paired homeobox transcription factor Phox2a required for development of neural crest-derived and central nervous system-derived catecholaminergic neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROTRANSMITTER BIOSYNTHETIC GENES; DEVELOPING SYMPATHETIC NEURONS; CHICK-EMBRYO; CYCLIC-AMP; SYMPATHOADRENAL LINEAGE; HOMEODOMAIN PROTEIN; PHOSPHORYLATION STATUS; PHENOTYPIC MARKERS; ADRENERGIC CELLS; IN-VIVO	Pluripotent neural crest (NC) cells differentiate to diverse lineages, including the neuronal, sympathoadrenal lineage. In primary NC cultures, bone morphogenetic protein 2 ( BMP2) requires moderate activation of cAMP signaling for induction of the sympathoadrenal lineage. However, the mechanism by which cAMP signaling synergizes with BMP2 to induce the sympathodrenal lineage is unknown. Herein, we demonstrate that moderate activation of cAMP signaling induces both transcription and activity of proneural transcription factor Phox2a. In NC cultures inhibition of cAMP-response element-binding protein (CREB)-mediated transcription by expression of dominant-negative CREB suppresses Phox2a transcription and sympathoadrenal lineage development. Interestingly, the constitutively active CREBDIEDML, despite inducing Phox2a transcription, is insufficient for sympathoadrenal lineage development, requiring activation of the cAMP pathway. Because CREBDIEDML mediates cAMP-dependent transcription without requiring activation by the cAMP-dependent protein kinase A ( PKA), these results identify PKA activation as necessary in sympathoadrenal lineage development. Treatment of NC cultures with the PKA inhibitor H89 or 1-10 nM okadaic acid (OA), a serine/threonine PP2A-like phosphatase inhibitor, suppresses sympathoadrenal lineage development. Likewise, OA treatment of the CNS-derived catecholaminergic CAD cell line inhibits cAMP-mediated neuronal differentiation. Specifically, OA inhibits cAMP-mediated Phox2a dephosphorylation, cAMP-dependent Phox2a DNA binding in vitro, and cAMP- and Phox2a-dependent dopamine-beta-hydroxylaseluciferase reporter expression. Together, these results support cAMP- dependent Phox2a dephosphorylation is required for its activation. We conclude that moderate activation of cAMP signaling has dual inputs in catecholaminergic, sympathoadrenal lineage development; that is, regulation of both Phox2a transcription and activity. These results provide the first mechanistic understanding of how moderate activation of the cAMP pathway in synergy with BMP2 promotes sympathoadrenal lineage development.	Purdue Univ, Dept Basic Med Sci, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Andrisani, OM (corresponding author), Purdue Univ, Dept Basic Med Sci, 625 Harrison St, W Lafayette, IN 47907 USA.	andrisao@purdue.edu	Chen, Sigeng/G-1678-2014; Ji, Ming/C-2795-2011	Andrisani, Ourania/0000-0002-6230-0303	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059367] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK059367] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi M, 2002, J BIOL CHEM, V277, P22915, DOI 10.1074/jbc.M201695200; Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; ANDERSON DJ, 1991, J NEUROSCI, V11, P3507; Andrisani OM, 1999, CRIT REV EUKAR GENE, V9, P19, DOI 10.1615/CritRevEukaryotGeneExpr.v9.i1.20; ANDRISANI OM, 1988, MOL CELL BIOL, V8, P1947, DOI 10.1128/MCB.8.5.1947; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; BENJANIRUT C, 2005, 64 ANN M SOC DEV BIO; Berry M, 2000, EMBO J, V19, P2946, DOI 10.1093/emboj/19.12.2946; Bilodeau ML, 2005, MOL CELL NEUROSCI, V29, P394, DOI 10.1016/j.mcn.2005.03.006; Bilodeau ML, 2001, IN VITRO CELL DEV-AN, V37, P185; Bilodeau ML, 2000, MOL CELL BIOL, V20, P3004, DOI 10.1128/MCB.20.9.3004-3014.2000; Brunet JF, 2002, CURR OPIN GENET DEV, V12, P435, DOI 10.1016/S0959-437X(02)00322-2; Cardinaux JR, 2000, MOL CELL BIOL, V20, P1546, DOI 10.1128/MCB.20.5.1546-1552.2000; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COHEN AM, 1972, J EXP ZOOL, V179, P167, DOI 10.1002/jez.1401790204; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; ERNSBERGER U, 1995, MECH DEVELOP, V52, P125, DOI 10.1016/0925-4773(95)00396-I; FEKETE DM, 1993, MOL CELL BIOL, V13, P2604, DOI 10.1128/MCB.13.4.2604; Firulli BA, 2003, MOL CELL, V12, P1225, DOI 10.1016/S1097-2765(03)00425-8; FURNESS JB, 1977, HISTOCHEMISTRY, V52, P159, DOI 10.1007/BF00492292; Goodman RH, 2000, GENE DEV, V14, P1553; GROVES AK, 1995, DEVELOPMENT, V121, P887; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HAMBURGER V, 1992, DEV DYNAM, V195, P231, DOI 10.1002/dvdy.1001950404; Hirsch MR, 1998, DEVELOPMENT, V125, P599; Hollenbeck PJ, 2003, METHOD CELL BIOL, V71, P369, DOI 10.1016/S0091-679X(03)01018-5; Huber K, 2002, DEVELOPMENT, V129, P4729; Hunter E, 1979, Methods Enzymol, V58, P379; Impey S, 2004, CELL, V119, P1041, DOI 10.1016/j.cell.2004.10.032; Ji M, 2005, MOL CELL BIOL, V25, P5134, DOI 10.1128/MCB.25.12.5134-5145.2005; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; LaBonne C, 1998, J NEUROBIOL, V36, P175, DOI 10.1002/(SICI)1097-4695(199808)36:2<175::AID-NEU6>3.0.CO;2-Z; Le Douarin N M, 1977, Soc Gen Physiol Ser, V32, P11; Le Douarin NM, 2004, DEVELOPMENT, V131, P4637, DOI 10.1242/dev.01350; Lee S, 2002, J BIOL CHEM, V277, P8730, DOI 10.1074/jbc.M108025200; Lo LC, 1997, CURR BIOL, V7, P440, DOI 10.1016/S0960-9822(06)00191-6; Lo LC, 1999, NEURON, V22, P693, DOI 10.1016/S0896-6273(00)80729-1; Lonze BE, 2002, NEURON, V34, P371, DOI 10.1016/S0896-6273(02)00686-4; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Moore KB, 2002, NEURON, V34, P183, DOI 10.1016/S0896-6273(02)00666-9; Morgan BA, 1996, METHOD CELL BIOL, V51, P185, DOI 10.1016/S0091-679X(08)60629-9; Morin X, 1997, NEURON, V18, P411, DOI 10.1016/S0896-6273(00)81242-8; Pattyn A, 1999, NATURE, V399, P366, DOI 10.1038/20700; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Qi YP, 1997, J NEUROSCI, V17, P1217; Reissmann E, 1996, DEVELOPMENT, V122, P2079; Schneider C, 1999, NEURON, V24, P861, DOI 10.1016/S0896-6273(00)81033-8; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; Sommer L, 1995, NEURON, V15, P1245, DOI 10.1016/0896-6273(95)90005-5; Stanke M, 1999, DEVELOPMENT, V126, P4087; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; STERN CD, 1991, DEVELOPMENT, V113, P207; SURI C, 1993, J NEUROSCI, V13, P1280; Swanson DJ, 1997, J BIOL CHEM, V272, P27382, DOI 10.1074/jbc.272.43.27382; TEILLET MA, 1983, DEV BIOL, V98, P192, DOI 10.1016/0012-1606(83)90349-4; Varley JE, 1998, DEV BIOL, V196, P107, DOI 10.1006/dbio.1998.8853; VARLEY JE, 1995, DEV DYNAM, V203, P434, DOI 10.1002/aja.1002030406; Varley JE, 1996, EXP NEUROL, V140, P84, DOI 10.1006/exnr.1996.0118; Zellmer E, 1995, J NEUROSCI, V15, P8109; Zeng G, 1998, BIOTECHNIQUES, V25, P206, DOI 10.2144/98252bm05	62	17	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					41025	41036		10.1074/jbc.M503537200	http://dx.doi.org/10.1074/jbc.M503537200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16204240	hybrid			2022-12-25	WOS:000233666600077
J	Lerner, EC; Trible, RP; Schiavone, AP; Hochrein, JM; Engen, JR; Smithgall, TE				Lerner, EC; Trible, RP; Schiavone, AP; Hochrein, JM; Engen, JR; Smithgall, TE			Activation of the Src family kinase Hck without SH3-linker release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; C-SRC; CRYSTAL-STRUCTURE; SH3 DOMAIN; REGULATORY INTERACTIONS; HYDROGEN-EXCHANGE; NEF PROTEIN; BINDING; SPECIFICITY; COMPLEX	Src family protein-tyrosine kinases are regulated by intramolecular binding of the SH2 domain to the C-terminal tail and association of the SH3 domain with the SH2 kinase-linker. The presence of two regulatory interactions raises the question of whether disruption of both is required for kinase activation. To address this question, we engineered a high affinity linker (HAL) mutant of the Src family member Hck in which an optimal SH3 ligand was substituted for the natural linker. Surface plasmon resonance analysis demonstrated tight intramolecular binding of the modified HAL sequence to SH3. Hck-HAL was then combined with a tail tyrosine mutation (Y501F) and expressed in Rat-2 fibroblasts. Surprisingly, Hck-HAL-Y501F showed strong transforming and kinase activities, demonstrating that intramolecular SH3-linker release is not required for SH2-based kinase activation. In Saccharomyces cerevisiae, which lacks the negative regulatory tail kinase Csk, wild-type Hck was more strongly activated in the presence of an SH3-binding protein ( human immunodeficiency virus-1 Nef), indicating persistence of native SH3-linker interaction in an active Hck conformation. Taken together, these data support the existence of multiple active conformations of Src family kinases that may generate unique downstream signals.	Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of New Mexico	Smithgall, TE (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, E1240 Biomed Sci Tower, Pittsburgh, PA 15261 USA.	tsmithga@pitt.edu		Engen, John R./0000-0002-6918-9476	NATIONAL CANCER INSTITUTE [R24CA088339, R01CA081398] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016480] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI057083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070590] Funding Source: NIH RePORTER; NCI NIH HHS [CA88339, CA81398] Funding Source: Medline; NCRR NIH HHS [RR16480] Funding Source: Medline; NIAID NIH HHS [AI57083] Funding Source: Medline; NIGMS NIH HHS [GM70590] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boggon TJ, 2004, ONCOGENE, V23, P7918, DOI 10.1038/sj.onc.1208081; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; Briggs SD, 1999, J BIOL CHEM, V274, P26579, DOI 10.1074/jbc.274.37.26579; Cowan-Jacob SW, 2005, STRUCTURE, V13, P861, DOI 10.1016/j.str.2005.03.012; Dueber JE, 2003, SCIENCE, V301, P1904, DOI 10.1126/science.1085945; Engen JR, 1999, J MOL BIOL, V287, P645, DOI 10.1006/jmbi.1999.2619; Engen JR, 1999, BIOCHEMISTRY-US, V38, P8926, DOI 10.1021/bi982611y; Engen JR, 1997, BIOCHEMISTRY-US, V36, P14384, DOI 10.1021/bi971635m; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; LaFevre-Bernt M, 1998, J BIOL CHEM, V273, P32129, DOI 10.1074/jbc.273.48.32129; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; Lerner EC, 2002, NAT STRUCT BIOL, V9, P365, DOI 10.1038/nsb782; Lim WA, 2002, CURR OPIN STRUC BIOL, V12, P61, DOI 10.1016/S0959-440X(02)00290-7; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Miller WT, 2003, ACCOUNTS CHEM RES, V36, P393, DOI 10.1021/ar020116v; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Nagar B, 2002, CANCER RES, V62, P4236; Parsons SJ, 2004, ONCOGENE, V23, P7906, DOI 10.1038/sj.onc.1208160; RICKLES RJ, 1995, P NATL ACAD SCI USA, V92, P10909, DOI 10.1073/pnas.92.24.10909; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Young MA, 2001, CELL, V105, P115, DOI 10.1016/S0092-8674(01)00301-4; Zarrinpar Ali, 2003, Sci STKE, V2003, pRE8, DOI 10.1126/stke.2003.179.re8	33	37	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40832	40837		10.1074/jbc.M508782200	http://dx.doi.org/10.1074/jbc.M508782200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16210316	hybrid			2022-12-25	WOS:000233666600054
J	Struffi, P; Arnosti, DN				Struffi, P; Arnosti, DN			Functional interaction between the Drosophila Knirps short range transcriptional repressor and RPD3 histone deacetylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RPD3 HISTONE DEACETYLASE; TARGETED RECRUITMENT; FAMILY PROTEINS; COMPLEX; CTBP; YEAST; COREPRESSOR; ACETYLATION; OLIGOMERIZATION; SEGMENTATION	Knirps and other short range transcriptional repressors play critical roles in patterning the early Drosophila embryo. These repressors are known to bind the C-terminal binding protein corepressor, but their mechanism of action is poorly understood. We purified functional recombinant Knirps protein from transgenic embryos to identify possible cofactors that contribute to the activity of this protein. The protein migrates in a complex of similar to 450 kDa and was found to copurify with the Rpd3 histone deacetylase protein during a double affinity purification procedure. Association of Rpd3 with Knirps was dependent on the presence of the C-terminal binding protein-dependent repression domain of Knirps. Previous studies of an rpd3 mutant had not shown defects in the pattern of expression of even-skipped, a target of the Knirps repressor. However, in embryos doubly heterozygous for knirps and rpd3, a marked increase in the frequency of defects in the Knirps-regulated posterior domain of even-skipped expression was found, indicating that Rpd3 contributes to Knirps repression activity in vivo. This finding implicates deacetylation in the mechanism of short range repression in Drosophila.	Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA; Michigan State Univ, Genet Program, E Lansing, MI 48824 USA	Michigan State University; Michigan State University	Arnosti, DN (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.	arnosti@msu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056976] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56976, R01 GM056976] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aggarwal BD, 2004, NATURE, V430, P372, DOI 10.1038/nature02694; Aparicio JG, 2004, MOL CELL BIOL, V24, P4769, DOI 10.1128/MCB.24.11.4769-4780.2004; Arnosti DN, 1996, EMBO J, V15, P3659, DOI 10.1002/j.1460-2075.1996.tb00735.x; Arnosti DN, 2004, HANDB EXP PHARMACOL, V166, P33; Balasubramanian P, 2003, FEBS LETT, V537, P157, DOI 10.1016/S0014-5793(03)00119-4; Barolo S, 1997, EMBO J, V16, P2883, DOI 10.1093/emboj/16.10.2883; Chang YL, 2001, P NATL ACAD SCI USA, V98, P9730, DOI 10.1073/pnas.171325498; Chen GQ, 2000, GENE, V249, P1, DOI 10.1016/S0378-1119(00)00161-X; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; Chinnadurai G, 2003, BIOESSAYS, V25, P9, DOI 10.1002/bies.10212; Clyde DE, 2003, NATURE, V426, P849, DOI 10.1038/nature02189; Deckert J, 2002, MOL CELL BIOL, V22, P6458, DOI 10.1128/MCB.22.18.6458-6470.2002; Deckert J, 2001, MOL CELL BIOL, V21, P2726, DOI 10.1128/MCB.21.8.2726-2735.2001; Dorland S, 2000, GENETICS, V154, P573; Fujioka M, 1999, DEVELOPMENT, V126, P2527; Gaston K, 2003, CELL MOL LIFE SCI, V60, P721, DOI 10.1007/s00018-003-2260-3; Hewitt GF, 1999, DEVELOPMENT, V126, P1201; Humphrey EL, 2004, CHEM BIOL, V11, P295, DOI 10.1016/j.chembiol.2004.03.001; Kadosh D, 1998, MOL CELL BIOL, V18, P5121, DOI 10.1128/MCB.18.9.5121; Kadosh D, 1998, GENE DEV, V12, P797, DOI 10.1101/gad.12.6.797; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kasten MM, 1997, MOL CELL BIOL, V17, P4852, DOI 10.1128/MCB.17.8.4852; Keller SA, 2000, MOL CELL BIOL, V20, P7247, DOI 10.1128/MCB.20.19.7247-7258.2000; Kumar V, 2002, MOL CELL, V10, P857, DOI 10.1016/S1097-2765(02)00650-0; Kurdistani SK, 2002, NAT GENET, V31, P248, DOI 10.1038/ng907; Lechner T, 2000, J BIOL CHEM, V275, P40961, DOI 10.1074/jbc.M005730200; Lewis PW, 2004, GENE DEV, V18, P2929, DOI 10.1101/gad.1255204; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mannervik M, 1999, P NATL ACAD SCI USA, V96, P6797, DOI 10.1073/pnas.96.12.6797; Mottus R, 2000, GENETICS, V154, P657; Nardini M, 2003, EMBO J, V22, P3122, DOI 10.1093/emboj/cdg283; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Nibu Y, 1998, EMBO J, V17, P7009, DOI 10.1093/emboj/17.23.7009; Pile LA, 2000, EMBO J, V19, P6131, DOI 10.1093/emboj/19.22.6131; Pile LA, 2003, J BIOL CHEM, V278, P37840, DOI 10.1074/jbc.M305996200; Pile LA, 2002, MOL CELL BIOL, V22, P4965, DOI 10.1128/MCB.22.14.4965-4976.2002; Robyr D, 2002, CELL, V109, P437, DOI 10.1016/S0092-8674(02)00746-8; Rosenberg MI, 2002, CELL, V109, P447, DOI 10.1016/S0092-8674(02)00732-8; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Ryu JR, 2003, NUCLEIC ACIDS RES, V31, P4654, DOI 10.1093/nar/gkg491; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; SOELLER WC, 1988, GENE DEV, V2, P68, DOI 10.1101/gad.2.1.68; Sommer A, 1997, CURR BIOL, V7, P357, DOI 10.1016/S0960-9822(06)00183-7; Song HY, 2004, MOL CELL BIOL, V24, P4341, DOI 10.1128/MCB.24.10.4341-4350.2004; Struffi P, 2004, DEVELOPMENT, V131, P2419, DOI 10.1242/dev.01075; Strunk B, 2001, DEV BIOL, V239, P229, DOI 10.1006/dbio.2001.0454; Sutrias-Grau M, 2004, MOL CELL BIOL, V24, P5953, DOI 10.1128/MCB.24.13.5953-5966.2004; Thiel G, 2004, EUR J BIOCHEM, V271, P2855, DOI 10.1111/j.1432-1033.2004.04174.x; Tie F, 2003, MOL CELL BIOL, V23, P3352, DOI 10.1128/MCB.23.9.3352-3362.2003; Vogelauer M, 2002, MOL CELL, V10, P1223, DOI 10.1016/S1097-2765(02)00702-5; Wheeler JC, 2002, NAT GENET, V32, P206, DOI 10.1038/ng942; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Zhang QH, 2002, SCIENCE, V295, P1895; Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1	56	15	15	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40757	40765		10.1074/jbc.M506819200	http://dx.doi.org/10.1074/jbc.M506819200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16186109	Green Accepted, hybrid			2022-12-25	WOS:000233666600045
J	Chen, J; Zhou, YG; Mueller-Steiner, S; Chen, LF; Kwon, H; Yi, SL; Mucke, L; Li, G				Chen, J; Zhou, YG; Mueller-Steiner, S; Chen, LF; Kwon, H; Yi, SL; Mucke, L; Li, G			SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappa B signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; ALZHEIMERS-DISEASE; NEURODEGENERATIVE DISEASES; NEURONAL APOPTOSIS; EXCITOTOXIC INJURY; LENTIVIRAL VECTORS; CELL-SURVIVAL; CATHEPSIN-B; TRANSCRIPTION; ALPHA	Accumulating evidence suggests that neurodegeneration induced by pathogenic proteins depends on contributions from surrounding glia. Here we demonstrate that NF-kappa B signaling in microglia is critically involved in neuronal death induced by amyloid-beta( A beta) peptides, which are widely presumed to cause Alzheimer disease. Constitutive inhibition of NF-kappa B signaling in microglia by expression of the nondegradable I kappa B alpha superrepressor blocked neurotoxicity, indicating a pivotal role for microglial NF-kappa B signaling in mediating A beta toxicity. Stimulation of microglia with A beta increased acetylation of RelA/p65 at lysine 310, which regulates the NF-kappa B pathway. Overexpression of SIRT1 deacetylase and the addition of the SIRT1 agonist resveratrol markedly reduced NF-kappa B signaling stimulated by A beta and had strong neuroprotective effects. Our results support a glial loop hypothesis by demonstrating a critical role for microglial NF-kappa B signaling in A beta-dependent neurodegeneration. They also implicate SIRT1 in this pathway and highlight the therapeutic potential of resveratrol and other sirtuin-activating compounds in Alzheimer disease.	Univ Calif San Francisco, Gladstone Inst Neurol Dis, San Francisco, CA 94158 USA; Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94158 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco	Li, G (corresponding author), Univ Calif San Francisco, Gladstone Inst Neurol Dis, 1650 Owens St, San Francisco, CA 94158 USA.	lgan@gladstone.ucsf.edu			NINDS NIH HHS [NS43945] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aisen PS, 2003, JAMA-J AM MED ASSOC, V289, P2819, DOI 10.1001/jama.289.21.2819; Akama KT, 1998, P NATL ACAD SCI USA, V95, P5795, DOI 10.1073/pnas.95.10.5795; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Arancio O, 2004, EMBO J, V23, P4096, DOI 10.1038/sj.emboj.7600415; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bales KR, 2000, NEUROBIOL AGING, V21, P427, DOI 10.1016/S0197-4580(00)00143-3; Bhakar AL, 2002, J NEUROSCI, V22, P8466; Bien S, 2004, MOL PHARMACOL, V65, P1092, DOI 10.1124/mol.65.5.1092; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; CHEN LF, 2005, IN PRESS MOL CELL BI; Combs CK, 2001, J NEUROSCI, V21, P1179; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Forman MS, 2004, NAT MED, V10, P1055, DOI 10.1038/nm1113; Fridmacher V, 2003, J NEUROSCI, V23, P9403; Gan L, 2004, J BIOL CHEM, V279, P5565, DOI 10.1074/jbc.M306183200; Giulian D, 1996, J NEUROSCI, V16, P6021; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Hewett JA, 1999, J NEUROSCI RES, V56, P189, DOI 10.1002/(SICI)1097-4547(19990415)56:2<189::AID-JNR8>3.3.CO;2-2; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Kaltschmidt B, 1997, P NATL ACAD SCI USA, V94, P2642, DOI 10.1073/pnas.94.6.2642; Kaltschmidt B, 1999, P NATL ACAD SCI USA, V96, P9409, DOI 10.1073/pnas.96.16.9409; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; Li R, 2004, J NEUROSCI, V24, P1760, DOI 10.1523/JNEUROSCI.4580-03.2004; Li XQ, 1998, J BIOL CHEM, V273, P34970, DOI 10.1074/jbc.273.52.34970; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Mattson MP, 2001, J CLIN INVEST, V107, P247, DOI 10.1172/JCI11916; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; Meffert MK, 2003, NAT NEUROSCI, V6, P1072, DOI 10.1038/nn1110; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Parker JA, 2005, NAT GENET, V37, P349, DOI 10.1038/ng1534; RICH JB, 1995, NEUROLOGY, V45, P51, DOI 10.1212/WNL.45.1.51; Roher AE, 1996, J BIOL CHEM, V271, P20631, DOI 10.1074/jbc.271.34.20631; Sawada T, 2000, IMMUNOPHARMACOLOGY, V49, P285, DOI 10.1016/S0162-3109(00)00242-3; Siao CJ, 2003, J NEUROSCI, V23, P3234; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Sun SC, 1996, MOL CELL BIOL, V16, P1058; van Gool WA, 2003, J NEUROL, V250, P788, DOI 10.1007/s00415-003-1146-5; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Veld BAI, 1998, NEUROBIOL AGING, V19, P607, DOI 10.1016/S0197-4580(98)00096-7; Walker Lary C, 2002, Curr Opin Investig Drugs, V3, P782; Wang QW, 2004, J NEUROSCI, V24, P6049, DOI 10.1523/JNEUROSCI.0233-04.2004; Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Yu ZF, 1999, J NEUROSCI, V19, P8856, DOI 10.1523/JNEUROSCI.19-20-08856.1999; Zandi PP, 2001, NEUROBIOL AGING, V22, P811, DOI 10.1016/S0197-4580(01)00297-4	52	614	651	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40364	40374		10.1074/jbc.M509329200	http://dx.doi.org/10.1074/jbc.M509329200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16183991	hybrid			2022-12-25	WOS:000233461300079
J	Feeney, B; Clark, AC				Feeney, B; Clark, AC			Reassembly of active caspase-3 is facilitated by the propeptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED APOPTOSIS; ACTIVATION; PROCASPASE-3; PROTEASE; CELLS; PH; REQUIREMENT; HOMEOSTASIS; POTASSIUM; STABILITY	Changes in ionic homeostasis are early events leading up to the commitment to apoptosis. Although the direct effects of cations on caspase-3 activity have been examined, comparable studies on procaspase-3 are lacking. In addition, the effects of salts on caspase structure have not been examined. We have studied the effects of cations on the activities and conformations of caspase-3 and an uncleavable mutant of procaspase-3 that is enzymatically active. The results show that caspase-3 is more sensitive to changes in pH and ion concentrations than is the zymogen. This is due to the loss of both an intact intersubunit linker and the prodomain. The results show that, although the caspase-3 subunits reassemble to the heterotetramer, the activity return is low after the protein is incubated at or below pH 4.5 and then returned to pH 7.5. The data further show that the irreversible step in assembly results from heterotetramer rather than heterodimer dissociation and demonstrate that the active site does not form properly following reassembly. However, active-site formation is fully reversible when reassembly occurs in the presence of the prodomain, and this effect is specific for the propeptide of caspase-3. The data show that the prodomain facilitates both dimerization and active-site formation in addition to stabilizing the native structure. Overall, the results show that the prodomain acts as an intramolecular chaperone during assembly of the ( pro) caspase subunits and increases the efficiency of formation of the native conformation.	N Carolina State Univ, Dept Mol & Struct Biochem, Raleigh, NC 27695 USA	University of North Carolina; North Carolina State University	Clark, AC (corresponding author), N Carolina State Univ, Dept Mol & Struct Biochem, 128 Polk Hall, Raleigh, NC 27695 USA.	clay_clark@ncsu.edu			NIGMS NIH HHS [GM065970, R01 GM065970-04, R01 GM065970] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065970] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bian XP, 1997, AM J PHYSIOL-CELL PH, V272, pC1241, DOI 10.1152/ajpcell.1997.272.4.C1241; Bortner CD, 1998, BIOCHEM PHARMACOL, V56, P1549, DOI 10.1016/S0006-2952(98)00225-1; Bose K, 2005, PROTEIN SCI, V14, P24; Bose K, 2003, BIOCHEMISTRY-US, V42, P12298, DOI 10.1021/bi034998x; Bose K, 2001, BIOCHEMISTRY-US, V40, P14236, DOI 10.1021/bi0110387; Chai JJ, 2001, CELL, V107, P399, DOI 10.1016/S0092-8674(01)00544-X; Chaudhary PM, 1999, J BIOL CHEM, V274, P19211, DOI 10.1074/jbc.274.27.19211; Cowling V, 2002, CELL DEATH DIFFER, V9, P1046, DOI 10.1038/sj.cdd.4401065; Datta R, 1996, BLOOD, V88, P1936, DOI 10.1182/blood.V88.6.1936.bloodjournal8861936; DECKWERTH TL, 1993, ANN NY ACAD SCI, V679, P121, DOI 10.1111/j.1749-6632.1993.tb18293.x; Denault JB, 2003, J BIOL CHEM, V278, P34042, DOI 10.1074/jbc.M305110200; Denault JB, 2002, CHEM REV, V102, P4489, DOI 10.1021/cr010183n; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Fearnhead HO, 1997, GENE DEV, V11, P1266, DOI 10.1101/gad.11.10.1266; Feeney B, 2004, BIOCHEM J, V384, P515, DOI 10.1042/BJ20040693; Hughes FM, 1999, ADV ENZYME REGUL, V39, P157, DOI 10.1016/S0065-2571(98)00010-7; IKEMURA H, 1987, J BIOL CHEM, V262, P7859; Meergans T, 2000, BIOCHEM J, V349, P135, DOI 10.1042/0264-6021:3490135; Mittl PRE, 1997, J BIOL CHEM, V272, P6539, DOI 10.1074/jbc.272.10.6539; PATTISON SE, 1986, FASEB J, V45, P2805; Perry DK, 1997, J BIOL CHEM, V272, P18530, DOI 10.1074/jbc.272.30.18530; Pop C, 2003, BIOCHEMISTRY-US, V42, P12311, DOI 10.1021/bi034999p; Pop C, 2001, BIOCHEMISTRY-US, V40, P14224, DOI 10.1021/bi011037e; Riedl SJ, 2001, P NATL ACAD SCI USA, V98, P14790, DOI 10.1073/pnas.221580098; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Roy S, 2001, P NATL ACAD SCI USA, V98, P6132, DOI 10.1073/pnas.111085198; ROYER CA, 1993, PROTEIN SCI, V2, P1844, DOI 10.1002/pro.5560021106; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Segal MS, 2001, AM J PHYSIOL-CELL PH, V281, pC1196, DOI 10.1152/ajpcell.2001.281.4.C1196; Shinde U, 2000, SEMIN CELL DEV BIOL, V11, P35, DOI 10.1006/scdb.1999.0349; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; Suzuki H, 2002, AM J PHYSIOL-GASTR L, V283, pG986, DOI 10.1152/ajpgi.00482.2001; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Yu SP, 2001, CURR OPIN CELL BIOL, V13, P405, DOI 10.1016/S0955-0674(00)00228-3; Yu SP, 2003, PROG NEUROBIOL, V70, P363, DOI 10.1016/S0301-0082(03)00090-X	37	30	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					39772	39785		10.1074/jbc.M505834200	http://dx.doi.org/10.1074/jbc.M505834200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16203739	Green Accepted, hybrid			2022-12-25	WOS:000233461300014
J	Iino, R; Murakami, T; Iizuka, S; Kato-Yamada, Y; Suzuki, T; Yoshida, M				Iino, R; Murakami, T; Iizuka, S; Kato-Yamada, Y; Suzuki, T; Yoshida, M			Real-time monitoring of conformational dynamics of the epsilon subunit in F-1-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP SYNTHASE; ESCHERICHIA-COLI; THERMOPHILIC F-1-ATPASE; ROTATION; ACTIVATION; RESOLUTION; CATALYSIS; COMPLEX; MOTOR	It has been proposed that C-terminal two alpha-helices of the epsilon subunit of F-1-ATPase can undergo conformational transition between retracted folded-hairpin form and extended form. Here, using F-1 from thermophilic Bacillus PS3, we monitored this transition in real time by fluorescence resonance energy transfer ( FRET) between a donor dye and an acceptor dye attached to N terminus of the gamma subunit and C terminus of the epsilon subunit, respectively. High FRET ( extended form) of F1 turned to low FRET ( retracted form) by ATP, which then reverted as ATP was hydrolyzed to ADP. 5'-Adenyl-beta, gamma-imidodiphosphate, ADP + AlF4-, ADP + NaN3, and GTP also caused the retracted form, indicating that ATP binding to the catalytic beta subunits induces the transition. The ATP-induced transition from high FRET to low FRET occurred in a similar time scale to the ATP-induced activation of ATPase from inhibition by the epsilon subunit, although detailed kinetics were not the same. The transition became faster as temperature increased, but the extrapolated rate at 65 degrees C ( physiological temperature of Bacillus PS3) was still too slow to assign the transition as an obligate step in the catalytic turnover. Furthermore, binding affinity of ATP to the isolated epsilon subunit was weakened as temperature increased, and the dissociation constant extrapolated to 65 degrees C reached to 0.67mM, a consistent value to assume that the epsilon subunit acts as a sensor of ATP concentration in the cell.	ERATO, ATP Syst Project, Japan Sci & Technol Agcy, Yokohama, Kanagawa 2260026, Japan; Tokyo Inst Technol, Chem Resources Lab, Yokohama, Kanagawa 2268503, Japan; St Paul Univ, Coll Sci, Dept Life Sci, Tokyo 1718501, Japan; St Paul Univ, Coll Sci, Frontier Project Lifes Adaptat Strategies Environ, Tokyo 1718501, Japan	Japan Science & Technology Agency (JST); Tokyo Institute of Technology; Rikkyo University; Rikkyo University	Yoshida, M (corresponding author), ERATO, ATP Syst Project, Japan Sci & Technol Agcy, Nagatsuta 5800-3, Yokohama, Kanagawa 2260026, Japan.	myoshida@res.titech.ac.jp	Iino, Ryota/B-7746-2011	Iino, Ryota/0000-0003-0110-5704				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Braig K, 2000, STRUCTURE, V8, P567, DOI 10.1016/S0969-2126(00)00145-3; Cipriano DJ, 2002, J BIOL CHEM, V277, P16782, DOI 10.1074/jbc.M201349200; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; Hausrath AC, 2001, J BIOL CHEM, V276, P47227, DOI 10.1074/jbc.M107536200; Hirono-Hara Y, 2001, P NATL ACAD SCI USA, V98, P13649, DOI 10.1073/pnas.241365698; Kato Y, 1997, J BIOL CHEM, V272, P24906, DOI 10.1074/jbc.272.40.24906; Kato-Yamada Y, 2003, J BIOL CHEM, V278, P36013, DOI 10.1074/jbc.M306140200; Kato-Yamada Y, 2000, J BIOL CHEM, V275, P35746, DOI 10.1074/jbc.M006575200; Matsui T, 1997, J BIOL CHEM, V272, P8215, DOI 10.1074/jbc.272.13.8215; MUNEYUKI E, 1993, BIOCHIM BIOPHYS ACTA, V1144, P62, DOI 10.1016/0005-2728(93)90031-A; Noji H, 2001, J BIOL CHEM, V276, P25480, DOI 10.1074/jbc.M102200200; PAIK SR, 1994, BIOCHEMISTRY-US, V33, P126, DOI 10.1021/bi00167a016; Rodgers AJW, 2000, NAT STRUCT BIOL, V7, P1051; Shimabukuro K, 2003, P NATL ACAD SCI USA, V100, P14731, DOI 10.1073/pnas.2434983100; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; Suzuki T, 2003, J BIOL CHEM, V278, P46840, DOI 10.1074/jbc.M307165200; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P6560, DOI 10.1073/pnas.111128098; Uhlin U, 1997, STRUCTURE, V5, P1219, DOI 10.1016/S0969-2126(97)00272-4; Wilkens S, 1998, J BIOL CHEM, V273, P26645, DOI 10.1074/jbc.273.41.26645; Yasuda R, 2001, NATURE, V410, P898, DOI 10.1038/35073513; Yasuda R, 2003, P NATL ACAD SCI USA, V100, P9314, DOI 10.1073/pnas.1637860100; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509; YOSHIDA M, 1975, J BIOL CHEM, V250, P7910; Zimmermann B, 2005, EMBO J, V24, P2053, DOI 10.1038/sj.emboj.7600682	27	60	63	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40130	40134		10.1074/jbc.M506160200	http://dx.doi.org/10.1074/jbc.M506160200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16203732	hybrid			2022-12-25	WOS:000233461300052
J	Iizuka, R; Yoshida, T; Ishii, N; Zako, T; Takahashi, K; Maki, K; Inobe, T; Kuwajima, K; Yohda, M				Iizuka, R; Yoshida, T; Ishii, N; Zako, T; Takahashi, K; Maki, K; Inobe, T; Kuwajima, K; Yohda, M			Characterization of archaeal group II chaperonin-ADP-metal fluoride complexes - Implications that group II chaperonins operate as a "two-stroke engine"	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOCOCCUS STRAIN KS-1; X-RAY-SCATTERING; CYTOPLASMIC CHAPERONIN; GROEL-GROES; FUNCTIONAL-CHARACTERIZATION; CONFORMATIONAL-CHANGE; GAMMA-PHOSPHATE; ATP; PROTEIN; MECHANISM	Group II chaperonins, found in Archaea and in the eukaryotic cytosol, act independently of a cofactor corresponding to GroES of group I chaperonins. Instead, the helical protrusion at the tip of the apical domain forms a built-in lid of the central cavity. Although many studies on the lid's conformation have been carried out, the conformation in each step of the ATPase cycle remains obscure. To clarify this issue, we examined the effects of ADP-aluminum fluoride (AlFx) and ADP-beryllium fluoride (BeFx) complexes on alpha-chaperonin from the hyperthermophilic archaeum, Thermococcus sp. strain KS-1. Biochemical assays, electron microscopic observations, and small angle x-ray scattering measurements demonstrate that alpha-chaperonin incubated with ADP and BeFx exists in an asymmetric conformation; one ring is open, and the other is closed. The result indicates that alpha-chaperonin also shares the inherent functional asymmetry of bacterial and eukaryotic cytosolic chaperonins. Most interestingly, addition of ADP and BeFx induced alpha-chaperonin to encapsulate unfolded proteins in the closed ring but did not trigger their folding. Moreover, alpha-chaperonin incubated with ATP and AlFx or BeFx adopted a symmetric closed conformation, and its functional turnover was inhibited. These forms are supposed to be intermediates during the reaction cycle of group II chaperonins.	Tokyo Univ Agr & Technol, Dept Biotechnol & Life Sci, Koganei, Tokyo 1848588, Japan; Japan Agcy Marien Earth Sci & Technol, Res Program Marine Biol & Ecol, Extrembiosphere Res Ctr, Yokosuka, Kanagawa 2370061, Japan; Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Tsukuba, Ibaraki 3058566, Japan; RIKEN, Bioengn Lab, Wako, Saitama 3510198, Japan; Univ Tokyo, Grad Sch Sci, Dept Phys, Bunkyo Ku, Tokyo 1130033, Japan	Tokyo University of Agriculture & Technology; Japan Agency for Marine-Earth Science & Technology (JAMSTEC); National Institute of Advanced Industrial Science & Technology (AIST); RIKEN; University of Tokyo	Yohda, M (corresponding author), Tokyo Univ Agr & Technol, Dept Biotechnol & Life Sci, 2-24-16 Naka Cho, Koganei, Tokyo 1848588, Japan.	yohda@cc.tuat.ac.jp	Zako, Tamotsu/C-3004-2012; Yohda, Masafumi/A-5149-2013; Ishii, Noriyuki/E-5661-2011	Yohda, Masafumi/0000-0001-8307-9671; Ishii, Noriyuki/0000-0002-4120-6203; Iizuka, Ryo/0000-0002-9328-5628; Inobe, Tomonao/0000-0002-5864-6889				Arai M, 2002, J MOL BIOL, V321, P121, DOI 10.1016/S0022-2836(02)00566-1; Arai M, 2003, PROTEIN SCI, V12, P672, DOI 10.1110/ps.0233603; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Chaudhry C, 2003, EMBO J, V22, P4877, DOI 10.1093/emboj/cdg477; de Macario EC, 2003, BIOCHEM BIOPH RES CO, V301, P811, DOI 10.1016/S0006-291X(03)00047-0; Ditzel L, 1998, CELL, V93, P125, DOI 10.1016/S0092-8674(00)81152-6; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; FRANK J, 1981, ULTRAMICROSCOPY, V6, P343, DOI 10.1016/S0304-3991(81)80236-7; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; Gutsche I, 1999, J MOL BIOL, V293, P295, DOI 10.1006/jmbi.1999.3008; Gutsche I, 2001, J STRUCT BIOL, V135, P139, DOI 10.1006/jsbi.2001.4373; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Iizuka R, 2004, J BIOL CHEM, V279, P18834, DOI 10.1074/jbc.M400839200; Iizuka R, 2003, J BIOL CHEM, V278, P44959, DOI 10.1074/jbc.M305484200; Iizuka R, 2001, BIOCHEM BIOPH RES CO, V289, P1118, DOI 10.1006/bbrc.2001.6139; Inobe T, 2003, J MOL BIOL, V329, P121, DOI 10.1016/S0022-2836(03)00409-1; Klunker D, 2003, J BIOL CHEM, V278, P33256, DOI 10.1074/jbc.M302018200; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; Llorca O, 1999, NAT STRUCT BIOL, V6, P639; Llorca O, 2001, EMBO J, V20, P4065, DOI 10.1093/emboj/20.15.4065; Lorimer G, 1997, NATURE, V388, P720, DOI 10.1038/41892; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MELKI R, 1994, MOL CELL BIOL, V14, P2895, DOI 10.1128/MCB.14.5.2895; Melki R, 1997, BIOCHEMISTRY-US, V36, P5817, DOI 10.1021/bi962830o; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; Meyer AS, 2003, CELL, V113, P369, DOI 10.1016/S0092-8674(03)00307-6; Miyazaki T, 2002, J BIOL CHEM, V277, P50621, DOI 10.1074/jbc.M209183200; Motojima F, 2003, J BIOL CHEM, V278, P26648, DOI 10.1074/jbc.M300806200; Murai N, 1996, J BIOL CHEM, V271, P28229, DOI 10.1074/jbc.271.45.28229; Rye HS, 1999, CELL, V97, P325, DOI 10.1016/S0092-8674(00)80742-4; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; Sakikawa C, 1999, J BIOL CHEM, V274, P21251, DOI 10.1074/jbc.274.30.21251; SEMENYUK AV, 1991, J APPL CRYSTALLOGR, V24, P537, DOI 10.1107/S002188989100081X; Shomura Y, 2004, J MOL BIOL, V335, P1265, DOI 10.1016/j.jmb.2003.11.028; Taguchi H, 2004, J BIOL CHEM, V279, P45737, DOI 10.1074/jbc.M406795200; Ueno T, 2004, MOL CELL, V14, P423, DOI 10.1016/S1097-2765(04)00261-8; Yoshida T, 2000, J MOL BIOL, V299, P1399, DOI 10.1006/jmbi.2000.3847; Yoshida T, 2002, J MOL BIOL, V315, P73, DOI 10.1006/jmbi.2001.5220; Yoshida T, 1997, J MOL BIOL, V273, P635, DOI 10.1006/jmbi.1997.1337	42	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40375	40383		10.1074/jbc.M506785200	http://dx.doi.org/10.1074/jbc.M506785200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16183634	hybrid			2022-12-25	WOS:000233461300080
J	Gallagher, PG; Liem, RI; Wong, E; Weiss, MJ; Bodine, DM				Gallagher, PG; Liem, RI; Wong, E; Weiss, MJ; Bodine, DM			GATA-1 and Oct-1 are required for expression of the human alpha-hemoglobin-stabilizing protein gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-LEVEL EXPRESSION; ERYTHROID PROMOTER; POU DOMAIN; ERYTHROPOIESIS; ACTIVATION; INSIGHTS; AHSP	alpha-Hemoglobin-stabilizing protein (AHSP) is an erythroid protein that binds and stabilizes alpha-hemoglobin during normal erythropoiesis and in pathological states of alpha-hemoglobin excess. AHSP has been proposed as a candidate gene in some Heinz body hemolytic anemias and as a modifier gene in the beta-thalassemia syndromes. To gain additional insight into the molecular mechanisms controlling the erythroid-specific expression of the AHSP gene and provide the necessary tools for further genetic studies of these disorders, we have initiated identification and characterization of the regulatory elements controlling the human AHSP gene. We mapped the 5'-end of the AHSP erythroid cDNA and cloned the 5'-flanking genomic DNA containing the putative AHSP gene promoter. In vitro studies using transfection of promoter/reporter plasmids in human tissue culture cell lines, DNase I footprinting analyses and gel mobility shift assays, identified an AHSP gene erythroid promoter with functionally important binding sites for GATA-1- and Oct-1-related proteins. In transgenic mice, a reporter gene directed by a minimal human AHSP promoter was expressed in bone marrow, spleen, and reticulocytes, but not in nonerythroid tissues. In vivo studies using chromatin immunoprecipitation assays demonstrated hyperacetylation of the promoter region and occupancy by GATA-1. The AHSP promoter is an excellent candidate region for mutations associated with decreased AHSP gene expression.	Yale Univ, Dept Pediat, Sch Med, New Haven, CT 06520 USA; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Univ Penn, Philadelphia, PA 19104 USA; NHGRI, Hematopoiesis Sect, NIH, Bethesda, MD 20892 USA	Yale University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Gallagher, PG (corresponding author), Yale Univ, Dept Pediat, Sch Med, 333 Cedar St,POB 208064, New Haven, CT 06520 USA.	patrick.gallagher@yale.edu	Weiss, Mitchell J/W-9814-2018; Weiss, Mitchell J/A-1245-2013	Weiss, Mitchell J/0000-0003-2460-3036; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065448] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK061692, R01DK061692, R01DK062039] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL65448] Funding Source: Medline; NIDDK NIH HHS [DK/HL62039, R01 DK061692, DK061692] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andersen B, 2001, ENDOCR REV, V22, P2, DOI 10.1210/er.22.1.2; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Baudin-Creuza V, 2004, J BIOL CHEM, V279, P36530, DOI 10.1074/jbc.M405389200; Boulanger L, 2002, J BIOL CHEM, V277, P41563, DOI 10.1074/jbc.M208184200; Cappellini MD, 2004, BLOOD, V104, p29B, DOI 10.1182/blood.V104.11.3770.3770; Crossley M, 1996, MOL CELL BIOL, V16, P1695; dos Santos CO, 2004, EXP HEMATOL, V32, P157, DOI 10.1016/j.exphem.2003.11.002; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; Feng L, 2004, CELL, V119, P629, DOI 10.1016/j.cell.2004.11.025; GALANELLO R, 2004, BLOOD S, V104, pA516; Gallagher PG, 1999, J BIOL CHEM, V274, P6062, DOI 10.1074/jbc.274.10.6062; Gallagher PG, 2001, J BIOL CHEM, V276, P41683, DOI 10.1074/jbc.M105844200; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; HOGAN B, 1986, MANIPULATING MOUSE E; Im H, 2003, J BIOL CHEM, V278, P18346, DOI 10.1074/jbc.M300890200; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; Johnson KD, 2002, METHODS, V26, P27, DOI 10.1016/S1046-2023(02)00005-1; Kihm AJ, 2002, NATURE, V417, P758, DOI 10.1038/nature00803; Kong Y, 2004, J CLIN INVEST, V114, P1457, DOI 10.1172/JCI200421982; Lai MI, 2005, BLOOD CELL MOL DIS, V34, P99; Luzzatto L, 2002, NATURE, V417, P703, DOI 10.1038/417703a; MASON P, 1993, GENE TRANSCRIPTION P, P47; Miele G, 2001, NAT MED, V7, P361, DOI 10.1038/85515; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; SHEPHERD NS, 1994, P NATL ACAD SCI USA, V91, P2629, DOI 10.1073/pnas.91.7.2629; Thein SL, 2004, BRIT J HAEMATOL, V124, P264, DOI 10.1046/j.1365-2141.2003.04769.x; Viprakasit V, 2004, BLOOD, V103, P3296, DOI 10.1182/blood-2003-11-3957; Wang VEH, 2004, MOL CELL BIOL, V24, P1022, DOI 10.1128/MCB.24.3.1022-1032.2004; Wong EY, 2004, J BIOL CHEM, V279, P55024, DOI 10.1074/jbc.M408886200; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638	30	31	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39016	39023		10.1074/jbc.M506062200	http://dx.doi.org/10.1074/jbc.M506062200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16186125	hybrid			2022-12-25	WOS:000233362200015
J	Kawai-Yamada, M; Saito, Y; Jin, LH; Ogawa, T; Kim, KM; Yu, LH; Tone, Y; Hirata, A; Umeda, M; Uchimiya, H				Kawai-Yamada, M; Saito, Y; Jin, LH; Ogawa, T; Kim, KM; Yu, LH; Tone, Y; Hirata, A; Umeda, M; Uchimiya, H			A novel Arabidopsis gene causes Bax-like lethality in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CELL-DEATH; PROAPOPTOTIC PROTEIN BAX; INDUCED APOPTOSIS; PLANT HOMOLOG; YEAST; INHIBITOR-1; SUPPRESSES; OVEREXPRESSION; FAMILY; MITOCHONDRIA	Overexpression of the mammalian proapoptotic protein Bax induces cell death in plant and yeast cells. The Bax inihibitor-1 (BI-1) gene rescues yeast and plant from Bax-mediated lethality. Using the Arabidopsis BI-1 (AtBI-1) gene controlled by the GAL1 promoter as a cell death suppressor in yeast, Cdf1 ((c) under bar ell growth (d) under bar efect (f) under bar actor-(1) under bar) was isolated from Arabidopsis cDNA library. Overexpression of Cdf1 caused cell death in yeast, whereas such an effect was suppressed by co-expression of AtBI-1. The Cdf1 protein fused with a green fluorescent protein was localized in the mitochondria and resulted in the loss of mitochondrial membrane potential in yeast. The Bax-resistant mutant BRM1 demonstrated tolerance against Cdf1-mediated lethality, whereas the Delta atp4 strain was sensitive to Cdf1. Our results suggest that Cdf1 and Bax cause mitochondria-mediated yeast lethality through partially overlapped pathways.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Natl Inst Genet, Ctr Informat Biol, Lab DNA Data Anal, Shizuoka 4118540, Japan; Kyungpook Natl Univ, Inst Genet Engn, Taejon 702701, South Korea; Univ Tokyo, Grad Sch Frontier Sci, Dept Integrate Biosci, Kashiwa, Chiba 2778562, Japan; Iwate Biotechnol Res Ctr, Kitakami, Iwate 0240003, Japan	University of Tokyo; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Kyungpook National University; University of Tokyo; Iwate Biotechnology Research Center	Kawai-Yamada, M (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	mkawai@iam.u-tokyo.ac.jp	Kawai-Yamada, Maki/B-2739-2012; Uchimiya, Hirofumi/B-3813-2012	Kawai-Yamada, Maki/0000-0002-8732-052X; 				Abramovitch RB, 2003, EMBO J, V22, P60, DOI 10.1093/emboj/cdg006; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Aravind L, 1999, CURR OPIN GENET DEV, V9, P688, DOI 10.1016/S0959-437X(99)00028-3; Baek D, 2004, PLANT MOL BIOL, V56, P15, DOI 10.1007/s11103-004-3096-4; Bolduc N, 2003, PLANTA, V216, P377, DOI 10.1007/s00425-002-0879-1; Chae HJ, 2004, MOL CELL, V15, P355, DOI 10.1016/j.molcel.2004.06.038; Chae HJ, 2003, GENE, V323, P101, DOI 10.1016/j.gene.2003.09.011; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Dickman MB, 2001, P NATL ACAD SCI USA, V98, P6957, DOI 10.1073/pnas.091108998; Dimitrova I, 2004, FEBS LETT, V566, P100, DOI 10.1016/j.febslet.2004.04.012; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Harris MH, 2000, MOL CELL BIOL, V20, P3590, DOI 10.1128/MCB.20.10.3590-3596.2000; Huckelhoven R, 2003, P NATL ACAD SCI USA, V100, P5555, DOI 10.1073/pnas.0931464100; Ink B, 1997, MOL CELL BIOL, V17, P2468, DOI 10.1128/MCB.17.5.2468; Jin C, 2002, NAT REV MOL CELL BIO, V3, P453, DOI 10.1038/nrm832; Jurgensmeier JM, 1997, MOL BIOL CELL, V8, P325; Kampranis SC, 2000, J BIOL CHEM, V275, P29207, DOI 10.1074/jbc.M002359200; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Kawai M, 1999, FEBS LETT, V464, P143, DOI 10.1016/S0014-5793(99)01695-6; Kawai M, 2000, ANN BOT-LONDON, V86, P405, DOI 10.1006/anbo.2000.1199; Kawai-Yamada M, 2004, PLANT CELL, V16, P21, DOI 10.1105/tpc.014613; Kawai-Yamada M, 2001, P NATL ACAD SCI USA, V98, P12295, DOI 10.1073/pnas.211423998; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lacomme C, 1999, P NATL ACAD SCI USA, V96, P7956, DOI 10.1073/pnas.96.14.7956; Levine A, 2001, J BIOL CHEM, V276, P46284, DOI 10.1074/jbc.M107375200; Ligr M, 1998, FEBS LETT, V438, P61, DOI 10.1016/S0014-5793(98)01227-7; Madeo F, 2002, MOL CELL, V9, P911, DOI 10.1016/S1097-2765(02)00501-4; Madeo F, 1999, J CELL BIOL, V145, P757, DOI 10.1083/jcb.145.4.757; Matsumura H, 2003, PLANT J, V33, P425, DOI 10.1046/j.1365-313X.2003.01639.x; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; Maxwell DP, 1999, P NATL ACAD SCI USA, V96, P8271, DOI 10.1073/pnas.96.14.8271; Mitsuhara I, 1999, CURR BIOL, V9, P775, DOI 10.1016/S0960-9822(99)80341-8; Moon H, 2002, BIOCHEM BIOPH RES CO, V290, P457, DOI 10.1006/bbrc.2001.6208; Pan L, 2001, FEBS LETT, V508, P375, DOI 10.1016/S0014-5793(01)03098-8; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Pennell RI, 1997, PLANT CELL, V9, P1157, DOI 10.1105/tpc.9.7.1157; Possel H, 1997, FEBS LETT, V416, P175, DOI 10.1016/S0014-5793(97)01197-6; Priault M, 1999, FEBS LETT, V443, P225, DOI 10.1016/S0014-5793(98)01661-5; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Sanchez P, 2000, PLANT J, V21, P393, DOI 10.1046/j.1365-313x.2000.00690.x; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Umeda M, 1998, P NATL ACAD SCI USA, V95, P5021, DOI 10.1073/pnas.95.9.5021; Vieira Helena L. A., 2002, Oncogene, V21, P1963, DOI 10.1038/sj.onc.1205270; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Yoshinaga K, 2005, ANN BOT-LONDON, V96, P337, DOI 10.1093/aob/mci181; YOSHINAGA K, 2005, IN PRESS PLANT CELL; Zha HB, 1996, MOL CELL BIOL, V16, P6494	50	40	46	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39468	39473		10.1074/jbc.M509632200	http://dx.doi.org/10.1074/jbc.M509632200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16192270	hybrid			2022-12-25	WOS:000233362200068
J	Kim, SM; Kumagai, A; Lee, J; Dunphy, WG				Kim, SM; Kumagai, A; Lee, J; Dunphy, WG			Phosphorylation of Chk1 by ATM- and Rad3-related (ATR) in Xenopus egg extracts requires binding of ATRIP to ATR but not the stable DNA-binding or coiled-coil domains of ATRIP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN-A; SACCHAROMYCES-CEREVISIAE; CHECKPOINT CONTROL; DAMAGE CHECKPOINT; PREMATURE MITOSIS; POMBE RAD26; ACTIVATION; COMPLEX; KINASE; PATHWAY	ATR, a critical regulator of DNA replication and damage checkpoint responses, possesses a binding partner called ATRIP. We have studied the functional properties of Xenopus ATR and ATRIP in incubations with purified components and in frog egg extracts. In purified systems, ATRIP associates with DNA in both RPA-dependent and RPA-independent manners, depending on the composition of the template. However, in egg extracts, only the RPA-dependent mode of binding to DNA can be detected. ATRIP adopts an oligomeric state in egg extracts that depends upon binding to ATR. In addition, ATR and ATRIP are mutually dependent on one another for stable binding to DNA in egg extracts. The ATR-dependent oligomerization of ATRIP does not require an intact coiled-coil domain in ATRIP and does not change in the presence of check-point inducing DNA templates. Egg extracts containing a mutant of ATRIP that cannot bind to ATR are defective in the phosphorylation of Chk1. However, extracts containing mutants of ATRIP lacking stable DNA-binding and coiled-coil domains show no reduction in the phosphorylation of Chk1 in response to defined DNA templates. Furthermore, activation of Chk1 does not depend upon RPA under these conditions. These results suggest that ATRIP must associate with ATR in order for ATR to carry out the phosphorylation of Chk1 effectively. However, this function of ATRIP does not involve its ability to mediate the stable binding of ATR to defined checkpoint-inducing DNA templates in egg extracts, does not require an intact coiled-coil domain, and does not depend on RPA.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Dunphy, WG (corresponding author), CALTECH, Div Biol 216 76, Pasadena, CA 91125 USA.	dunphy@cco.caltech.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043974, R01GM070891, R01GM043974] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM043974, GM070891] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Ball HL, 2005, MOL BIOL CELL, V16, P2372, DOI 10.1091/mbc.e04-11-1006; Ball HL, 2005, J BIOL CHEM, V280, P31390, DOI 10.1074/jbc.M504961200; Bomgarden RD, 2004, J BIOL CHEM, V279, P13346, DOI 10.1074/jbc.M311098200; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; De Souza CPC, 1999, MOL BIOL CELL, V10, P3661, DOI 10.1091/mbc.10.11.3661; Dodson GE, 2004, J BIOL CHEM, V279, P34010, DOI 10.1074/jbc.C400242200; Edwards RJ, 1999, NAT CELL BIOL, V1, P393, DOI 10.1038/15623; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Itakura E, 2004, FEBS LETT, V577, P289, DOI 10.1016/j.febslet.2004.10.026; Kim HS, 2001, MOL CELL BIOL, V21, P3725, DOI 10.1128/MCB.21.11.3725-3737.2001; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Kumagai A, 2004, J BIOL CHEM, V279, P49599, DOI 10.1074/jbc.M408353200; KUMAGAI A, 1995, MOL BIOL CELL, V6, P199, DOI 10.1091/mbc.6.2.199; Kumagai A, 1998, J CELL BIOL, V142, P1559, DOI 10.1083/jcb.142.6.1559; Lao Y, 1999, BIOCHEMISTRY-US, V38, P3974, DOI 10.1021/bi982371m; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Liu QH, 2000, GENE DEV, V14, P1448; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Michael WM, 2000, SCIENCE, V289, P2133, DOI 10.1126/science.289.5487.2133; Nakamura TM, 2004, MOL CELL BIOL, V24, P6215, DOI 10.1128/MCB.24.14.6215-6230.2004; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Osborn AJ, 2002, TRENDS CELL BIOL, V12, P509, DOI 10.1016/S0962-8924(02)02380-2; Paciotti V, 2000, GENE DEV, V14, P2046; Rouse J, 2000, EMBO J, V19, P5801, DOI 10.1093/emboj/19.21.5801; Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4; Uchiyama M, 1997, MOL CELL BIOL, V17, P3103, DOI 10.1128/MCB.17.6.3103; Umezu K, 1998, GENETICS, V148, P989; Unsal-Kacmaz K, 2004, MOL CELL BIOL, V24, P1292, DOI 10.1128/MCB.24.3.1292-1300.2003; Vidanes GM, 2005, CELL, V121, P973, DOI 10.1016/j.cell.2005.06.013; Wakayama T, 2001, MOL CELL BIOL, V21, P755, DOI 10.1128/MCB.21.3.755-764.2001; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	43	50	50	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38355	38364		10.1074/jbc.M508673200	http://dx.doi.org/10.1074/jbc.M508673200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16186122	hybrid, Green Accepted			2022-12-25	WOS:000233239800031
J	Basha, R; Murali, M; Siddiqi, HK; Ghosal, K; Siddiqi, OK; Lashuel, HA; Ge, YW; Lahiri, DK; Zawia, NH				Basha, R; Murali, M; Siddiqi, HK; Ghosal, K; Siddiqi, OK; Lashuel, HA; Ge, YW; Lahiri, DK; Zawia, NH			Lead (Pb) exposure and its effect on APP proteolysis and A beta aggregation	FASEB JOURNAL			English	Article						beta-amyloid; development; environmental factors; gene regulation; metals; secretases	AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; TRANSCRIPTIONAL REGULATION; TRANSGENIC MICE; ZINC; SECRETASE; IRON; BRAIN; EXPRESSION; ALUMINUM	Alzheimer's disease ( AD) is a progressive neurodegenerative disorder with clinical manifestations appearing in old age, however, the initial stages of this disease may begin early in life. AD is characterized by the presence of excessive deposits of aggregated beta-amyloid ( A beta) peptides, which are derived from the beta-amyloid precursor protein ( APP) following processing by beta-secretase and gamma-secretase. Recently, we have reported that developmental exposure of rats to Pb resulted in latent elevation of APP mRNA, APP, and A beta in old age. Here we examined whether latent up-regulation in APP expression and A beta levels is exacerbated by concurrent disturbances in APP processing or A beta aggregation. Among the environmental metals tested, only A beta solutions containing Pb promoted the formation of A beta aggregates at nanomolar concentrations. The lifetime profiles of alpha-, beta-, and gamma-secretases remained constant in adult and aging animals, and developmental exposure to Pb did not alter them. Furthermore, the addition of various concentrations of Pb ( 0.1 to 50 mu M) to cerebral cortical extracts derived from control animals also did not affect the proteolytic activities of these enzymes. Therefore, we propose that amyloidogenesis is promoted by a latent response to developmental reprogramming of the expression of the APP gene by early exposure to Pb, as well as enhancement of A beta aggregation in old age. In rodents, these events occur without Pb-induced disturbances to the enzymatic processing of APP. The aforementioned results provide further evidence for the developmental basis of amyloidogenesis and late-life disturbances in AD-associated proteins by environmental agents.	Univ Rhode Isl, Neurotoxicol & Epigenom Lab, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA; EPFL, Swiss Fed Inst Technol, Lab Neurobiol & Funct Neuroproteom, Integrat Biosci Inst, Lausanne, Switzerland; Indiana Univ, Sch Med, Dept Psychiat, Mol Neurogenet Lab,Inst Psychiat Res, Indianapolis, IN 46204 USA	University of Rhode Island; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Indiana University System; Indiana University-Purdue University Indianapolis	Zawia, NH (corresponding author), Univ Rhode Isl, Neurotoxicol & Epigenom Lab, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA.	nzawia@uri.edu	Lashuel, Hilal/M-3500-2017; Lahiri, Debomoy/AAZ-3322-2020; Siddiqi, Hasan/AAL-5217-2020	Basha, Riyaz/0000-0002-4071-0993; Siddiqi, Omar/0000-0001-7813-1623	NIA NIH HHS [AG18884, AG18379] Funding Source: Medline; NIEHS NIH HHS [ES08104, ES013022] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES008104, R21ES013022] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018379, R01AG018884] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817; Atwood CS, 1999, MET IONS BIOL SYST, V36, P309; Basha MR, 2003, INT J DEV NEUROSCI, V21, P1, DOI 10.1016/S0736-5748(02)00137-5; Basha MR, 2005, J NEUROSCI, V25, P823, DOI 10.1523/JNEUROSCI.4335-04.2005; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; Bush AI, 2003, TRENDS NEUROSCI, V26, P207, DOI 10.1016/S0166-2236(03)00067-5; Campbell A, 2000, CELL MOL BIOL, V46, P721; Christensen MA, 2004, MOL CELL BIOL, V24, P865, DOI 10.1128/MCB.24.2.865-874.2004; CONNOR JR, 1992, J NEUROSCI RES, V31, P75, DOI 10.1002/jnr.490310111; Cuajungco MP, 1997, BRAIN RES REV, V23, P219, DOI 10.1016/S0165-0173(97)00002-7; DUNCAN MW, 1992, J NEUROSCI, V12, P1523, DOI 10.1523/jneurosci.12-04-01523.1992; Ge YW, 2004, FASEB J, V18, P1037, DOI 10.1096/fj.03-1379fje; GHOSAL KJ, 2002, TOXICOLOGIST, V66, P103; GIBBONS DL, 1995, J BIOL CHEM, V270, P7335, DOI 10.1074/jbc.270.13.7335; GOOD PF, 1992, ANN NEUROL, V31, P286, DOI 10.1002/ana.410310310; Goyer RA, 1996, CASARETT DOULLS TOXI, V5, P691; Guilarte TR, 2000, MOL BRAIN RES, V76, P299, DOI 10.1016/S0169-328X(00)00010-3; Haniu M, 2000, J BIOL CHEM, V275, P21099, DOI 10.1074/jbc.M002095200; HARDY J, 1991, TRENDS PHARMACOL SCI, V12, P383, DOI 10.1016/0165-6147(91)90609-V; HERSHEY CO, 1983, NEUROLOGY, V33, P1350, DOI 10.1212/WNL.33.10.1350; Huang XD, 1997, J BIOL CHEM, V272, P26464, DOI 10.1074/jbc.272.42.26464; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; JOACHIM CL, 1992, ALZ DIS ASSOC DIS, V6, P7, DOI 10.1097/00002093-199205000-00003; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lee JY, 1999, J NEUROSCI, V19, DOI 10.1523/jneurosci.19-11-j0002.1999; Lee JY, 2002, P NATL ACAD SCI USA, V99, P7705, DOI 10.1073/pnas.092034699; Lopez-Toledano MA, 2004, J NEUROSCI, V24, P5439, DOI 10.1523/JNEUROSCI.0974-04.2004; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; MANTYH PW, 1993, J NEUROCHEM, V61, P1171, DOI 10.1111/j.1471-4159.1993.tb03639.x; Maynard CJ, 2002, J BIOL CHEM, V277, P44670, DOI 10.1074/jbc.M204379200; Pallitto MM, 2001, BIOPHYS J, V81, P1805, DOI 10.1016/S0006-3495(01)75831-6; Price DL, 1998, SCIENCE, V282, P1079, DOI 10.1126/science.282.5391.1079; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; SILBERGELD EK, 1992, FASEB J, V6, P3201, DOI 10.1096/fasebj.6.13.1397842; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Smith MA, 1998, J NEUROCHEM, V70, P2212, DOI 10.1046/j.1471-4159.1998.70052212.x; TAKASHIMA S, 1990, BRAIN DEV-JPN, V12, P367, DOI 10.1016/S0387-7604(12)80066-0; WEISS B, 1991, NEUROTOXICOLOGY, V12, P379; Weisskopf MG, 2004, ENVIRON HEALTH PERSP, V112, P620, DOI 10.1289/ehp.6687; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yang YX, 2003, EXP NEUROL, V184, P489, DOI 10.1016/S0014-4886(03)00272-3; Zawia NH, 1998, DEV BRAIN RES, V107, P291, DOI 10.1016/S0165-3806(98)00023-6	43	70	73	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2083	+		10.1096/fj.05-4375fje	http://dx.doi.org/10.1096/fj.05-4375fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16230335	Green Submitted			2022-12-25	WOS:000232991100016
J	Shukla, S; Mishra, A; Fu, PF; MacLennan, GT; Resnick, MI; Gupta, S				Shukla, S; Mishra, A; Fu, PF; MacLennan, GT; Resnick, MI; Gupta, S			Up-regulation of insulin-like growth factor binding protein-3 by apigenin leads to growth inhibition and apoptosis of 22Rv1 xenograft in athymic nude mice	FASEB JOURNAL			English	Article						insulin-like growth factor-I; insulin-like growth factor receptor-1; insulin receptor substrate-1	NECROSIS-FACTOR-ALPHA; PROSTATE-CANCER CELLS; I IGF-I; INCREASED EXPRESSION; DIETARY FLAVONOIDS; KAPPA-B; BREAST; INDUCTION; RISK; CHEMOPREVENTION	Epidemiological studies suggest that increased intake of fruits and vegetables may be associated with a reduced risk of prostate cancer. Apigenin (4', 5, 7,-trihydroxyflavone), a common dietary flavonoid abundantly present in fruits and vegetables, has shown remarkable anti-proliferative effects against various malignant cell lines. However, the mechanisms underlying these effects remain to be elucidated. We investigated the in vivo growth inhibitory effects of apigenin on androgen-sensitive human prostate carcinoma 22Rv1 tumor xenograft subcutaneously implanted in athymic male nude mice. Apigenin was administered to mice by gavage at doses of 20 and 50 mu g/mouse/day in 0.2 ml of a vehicle containing 0.5% methyl cellulose and 0.025% Tween 20 in two different protocols. In the first protocol, apigenin was administered for 2 wk before inoculation of tumor and was continued for 8 wk, resulting in significant inhibition of tumor volume by 44 and 59% ( P < 0.002 and 0.0001), and wet weight of tumor by 41 and 53% ( P < 0.05), respectively. In the second protocol, administration of apigenin began 2 wk after tumor inoculation and continued for 8 wk; tumor volume and wet weights of tumor were reduced by 39 and 53% ( P < 0.01 and 0.002) and 31 and 42% ( P < 0.05), respectively. The tumor inhibitory effect of apigenin was more pronounced in the first protocol of extended treatment, which was associated with increased accumulation of human IGFBP-3 in mouse serum along with significant increase in IGFBP-3 mRNA and protein expression in tumor xenograft. Apigenin intake by these mice also resulted in simultaneous decrease in serum IGF-I levels and induction of apoptosis in tumor xenograft. Importantly, tumor growth inhibition, induction of apoptosis, and accumulation of IGFBP-3 correlated with increasing serum and tumor apigenin levels. In both studies, animals did not exhibit any signs of toxicity or reduced food consumption. In cell culture studies, apigenin treatment resulted in cell growth inhibition and induction of apoptosis, which correlated with increased accumulation of IGFBP- 3 in culture medium and cell lysate. These effects were associated with significant reduction in IGF-I secretion; inhibition of IGF-I-induced cell cycle progression and insulin receptor substrate- 1 (IRS-1) tyrosine phosphorylation, along with an increase in sub-G1 peak by apigenin. Further, treatment of cells with IGFBP-3 antisense oligonucleotide reversed these effects and attenuated apigenin-mediated inhibition of IRS-1 phosphorylation conferring inhibitory effects of apigenin on IGF-signaling. This study presents the first evidence that the in vitro and in vivo growth inhibitory effects of apigenin involve modulation of IGF-axis signaling in prostate cancer.	Case Western Reserve Univ, Dept Urol, James & Eilleen Dicke Res Lab, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ireland Canc Ctr, Cleveland, OH 44106 USA; Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA USA	Case Western Reserve University; University Hospitals of Cleveland; Case Western Reserve University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Gupta, S (corresponding author), Case Western Reserve Univ, Dept Urol, James & Eilleen Dicke Res Lab, 10900 Euclid Ave, Cleveland, OH 44106 USA.	sanjay.gupta@case.edu	Fu, Pingfu/O-5415-2019; MISHRA, ANIL/S-7983-2017	Fu, Pingfu/0000-0002-2334-5218; MISHRA, ANIL/0000-0003-4266-4684; MacLennan, Gregory T./0000-0003-0089-449X; Gupta, Sanjay/0000-0002-9492-3249	NCI NIH HHS [R01 CA108512, R03 CA099049, P30 CA43703, R03 CA094248] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA099049, R03CA094248, R01CA108512, P30CA043703] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adhami VM, 2004, CANCER RES, V64, P8715, DOI 10.1158/0008-5472.CAN-04-2840; Baxter RC, 2000, AM J PHYSIOL-ENDOC M, V278, pE967, DOI 10.1152/ajpendo.2000.278.6.E967; Birt DF, 1997, ANTICANCER RES, V17, P85; Brusselmans K, 2005, J BIOL CHEM, V280, P5636, DOI 10.1074/jbc.M408177200; Butt AJ, 2001, APOPTOSIS, V6, P199, DOI 10.1023/A:1011388710719; Caltagirone S, 2000, INT J CANCER, V87, P595, DOI 10.1002/1097-0215(20000815)87:4&lt;595::AID-IJC21&gt;3.0.CO;2-5; Chen J, 2003, J PHARMACOL EXP THER, V304, P1228, DOI 10.1124/jpet.102.046409; Cohen JH, 2000, JNCI-J NATL CANCER I, V92, P61, DOI 10.1093/jnci/92.1.61; Colston KW, 1998, J MOL ENDOCRINOL, V20, P157, DOI 10.1677/jme.0.0200157; Denis L, 1999, EUR UROL, V35, P377, DOI 10.1159/000019912; Devi GR, 2002, PROSTATE, V51, P141, DOI 10.1002/pros.10068; DiGiovanni J, 2000, P NATL ACAD SCI USA, V97, P3455, DOI 10.1073/pnas.97.7.3455; Djavan B, 2001, WORLD J UROL, V19, P225, DOI 10.1007/s003450100220; Engelmann C, 2002, PHYTOMEDICINE, V9, P489, DOI 10.1078/09447110260573100; Fang J, 2005, FASEB J, V19, P342, DOI 10.1096/fj.04-2175com; Franklin SL, 2003, J CLIN ENDOCR METAB, V88, P900, DOI 10.1210/jc.2002-020472; Gradolatto A, 2005, DRUG METAB DISPOS, V33, P49, DOI 10.1124/dmd.104.000893; Grimberg A, 2002, INT J ONCOL, V21, P327; Grimberg A, 2000, J CELL PHYSIOL, V183, P1, DOI 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J; Grzmil M, 2004, J PATHOL, V202, P50, DOI 10.1002/path.1492; Gucev ZS, 1996, CANCER RES, V56, P1545; Gupta S, 2002, ONCOGENE, V21, P3727, DOI 10.1038/sj.onc.1205474; Gupta S, 2001, BIOCHEM BIOPH RES CO, V287, P914, DOI 10.1006/bbrc.2001.5672; Hessenauer A, 2003, INT J ONCOL, V22, P1263; Hollman PCH, 1999, FOOD CHEM TOXICOL, V37, P937, DOI 10.1016/S0278-6915(99)00079-4; Hong J, 2002, J BIOL CHEM, V277, P10489, DOI 10.1074/jbc.M109604200; Huynh H, 1996, J BIOL CHEM, V271, P1016, DOI 10.1074/jbc.271.2.1016; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Kim MH, 2003, J CELL BIOCHEM, V89, P529, DOI 10.1002/jcb.10543; Knowles LM, 2000, NUTR CANCER, V38, P116, DOI 10.1207/S15327914NC381_16; Kobayashi T, 2002, CANCER LETT, V176, P17, DOI 10.1016/S0304-3835(01)00738-8; Lee HY, 2002, CANCER RES, V62, P3530; Li L, 2003, CANCER CAUSE CONTROL, V14, P721, DOI 10.1023/A:1026383824791; Li SL, 1998, CELL TISSUE RES, V291, P469, DOI 10.1007/s004410051016; Liang YC, 1999, CARCINOGENESIS, V20, P1945, DOI 10.1093/carcin/20.10.1945; Mohan S, 2002, J ENDOCRINOL, V175, P19, DOI 10.1677/joe.0.1750019; Nickerson T, 1997, BIOCHEM BIOPH RES CO, V237, P690, DOI 10.1006/bbrc.1997.7089; Nickerson T, 2001, CANCER RES, V61, P6276; Pollak M, 1998, CANCER METAST REV, V17, P383, DOI 10.1023/A:1006154108619; Rajah R, 2002, CELL GROWTH DIFFER, V13, P163; Ross JA, 2002, ANNU REV NUTR, V22, P19, DOI 10.1146/annurev.nutr.22.111401.144957; Rozen F, 1998, INT J ONCOL, V13, P865; Shukla S, 2004, NEOPLASIA, V6, P390, DOI 10.1593/neo.04112; Shukla S, 2004, CLIN CANCER RES, V10, P3169, DOI 10.1158/1078-0432.CCR-03-0586; Singh RP, 2002, CANCER RES, V62, P3063; Sporn MB, 2002, NAT REV CANCER, V2, P537, DOI 10.1038/nrc844; Stattin P, 2000, J NATL CANCER I, V92, P1910, DOI 10.1093/jnci/92.23.1910; Tsao AS, 2004, CA-CANCER J CLIN, V54, P150, DOI 10.3322/canjclin.54.3.150; WANG W, MOL CARCINOG, V28, P102; Wang Y, 1999, BIOFACTORS, V9, P3, DOI 10.1002/biof.5520090102; Way TD, 2004, J BIOL CHEM, V279, P4479, DOI 10.1074/jbc.M305529200; Wolk A, 1998, J NATL CANCER I, V90, P911, DOI 10.1093/jnci/90.12.911; Yin F, 1999, THYROID, V9, P369, DOI 10.1089/thy.1999.9.369; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472; Zi XL, 2000, CANCER RES, V60, P5617	55	70	72	1	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2042	+		10.1096/fj.05-3740fje	http://dx.doi.org/10.1096/fj.05-3740fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16230333				2022-12-25	WOS:000232991100017
J	Cheng, GF; Cohen, L; Ndegwa, D; Davis, RE				Cheng, GF; Cohen, L; Ndegwa, D; Davis, RE			The flatworm spliced leader 3 '-terminal AUG as a translation initiator methionine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAENORHABDITIS-ELEGANS OPERONS; PARASITE SCHISTOSOMA-MANSONI; CELL-FREE SYSTEM; MESSENGER-RNAS; C-ELEGANS; TRIMETHYLGUANOSINE CAP; TRANS; SEQUENCES; GENE; TRANSCRIPTION	Spliced leader (SL) RNA trans-splicing contributes the 5' termini to mRNAs in a variety of eukaryotes. In contrast with some trans-splicing metazoan groups (e.g. nematodes), flatworm spliced leaders are variable in both sequence and length in different flatworm taxa. However, an absolutely conserved and unique feature of all flatworm spliced leaders is the presence of a 3'-terminal AUG. We previously suggested that the Schistosoma mansoni spliced leader AUG might contribute a required translation initiator methionine to recipient mRNAs. Here we identified and examined trans-spliced cDNAs from a large set of newly available schistosome cDNAs. 28% of the trans-spliced cDNAs have the SL AUG in-frame with the major open reading frame of the mRNA. We identified over 40 cDNAs (40% of the SL AUG in-frame clones) that require the SL AUG as an initiator methionine to synthesize phylogenetically conserved N-terminal residues characteristic of orthologous proteins. RNA transfection experiments using several schistosome stages demonstrated that the flatworm SL AUG can serve as a translation initiator methionine in vivo. We also present in vivo translation studies of the schistosome initiator methionine context and the effect of the spliced leader AUG added upstream and out-of-frame with the main open reading of recipient mRNAs. Overall, our data have provided evidence that another function of flatworm spliced leader trans-splicing is to provide some recipient mRNAs with an initiator methionine for translation initiation.	Univ Colorado, Sch Med, Dept Biochem & Mol Genet, Aurora, CO 80045 USA; Univ Colorado, Sch Med, Dept Biochem & Mol Genet, Aurora, CO 80045 USA; Univ Colorado, Sch Med, Dept Pediat, Aurora, CO 80045 USA; CUNY Coll Staten Isl, Grad Ctr, Dept Biol, Staten Isl, NY 10314 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; City University of New York (CUNY) System; College of Staten Island (CUNY)	Davis, RE (corresponding author), Univ Colorado, Sch Med, Dept Biochem & Mol Genet, Mail Stop 8101,POB 6511,E 12801 E 17th aVE, Aurora, CO 80045 USA.	Richard.Davis@uchsc.edu			NIAID NIH HHS [R01 AI049558, AI49558] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049558] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bixler LM, 2001, J PARASITOL, V87, P1167, DOI 10.2307/3285253; Blumenthal T, 2003, NAT REV GENET, V4, P110, DOI 10.1038/nrg995; Blumenthal T, 2002, NATURE, V417, P851, DOI 10.1038/nature00831; BOOTHROYD JC, 1982, GENE, V20, P279; Brehm K, 2000, J BIOL CHEM, V275, P38311, DOI 10.1074/jbc.M006091200; Brehm K, 2002, MOL BIOCHEM PARASIT, V122, P105, DOI 10.1016/S0166-6851(02)00074-9; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; Cohen LS, 2004, RNA, V10, P1609, DOI 10.1261/rna.7690504; Davis RE, 1997, MOL BIOCHEM PARASIT, V89, P25, DOI 10.1016/S0166-6851(97)00097-2; DAVIS RE, 1995, J BIOL CHEM, V270, P21813, DOI 10.1074/jbc.270.37.21813; Davis RE, 1997, MOL BIOCHEM PARASIT, V87, P29, DOI 10.1016/S0166-6851(97)00040-6; Davis RE, 1996, PARASITOL TODAY, V12, P33, DOI 10.1016/0169-4758(96)80643-0; DAVIS RE, 1994, J BIOL CHEM, V269, P20026; Davis RE, 1999, P NATL ACAD SCI USA, V96, P8687, DOI 10.1073/pnas.96.15.8687; Enjolras N, 1999, THROMB HAEMOSTASIS, V82, P1264; Fernandez C, 2002, MOL BIOCHEM PARASIT, V122, P171, DOI 10.1016/S0166-6851(02)00098-1; Ganot P, 2004, MOL CELL BIOL, V24, P7795, DOI 10.1128/MCB.24.17.7795-7805.2004; HANNON GJ, 1990, EMBO J, V9, P1915, DOI 10.1002/j.1460-2075.1990.tb08318.x; Hastings KEM, 2005, TRENDS GENET, V21, P240, DOI 10.1016/j.tig.2005.02.005; Hu W, 2003, NAT GENET, V35, P139, DOI 10.1038/ng1236; HUANG XY, 1989, P NATL ACAD SCI USA, V86, P8640, DOI 10.1073/pnas.86.22.8640; JOHNSON PJ, 1987, CELL, V51, P273, DOI 10.1016/0092-8674(87)90154-1; Jones LJ, 1998, ANAL BIOCHEM, V265, P368, DOI 10.1006/abio.1998.2914; KAWANAKA M, 1983, J PARASITOL, V69, P991, DOI 10.2307/3281071; Kozak M, 2002, GENE, V299, P1, DOI 10.1016/S0378-1119(02)01056-9; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; Lall S, 2004, J BIOL CHEM, V279, P45573, DOI 10.1074/jbc.M407475200; LEWIS FA, 1986, J PARASITOL, V72, P813, DOI 10.2307/3281829; Lewis VB, 1998, HIST POLIT THOUGHT, V19, P1; Liang XH, 2003, EUKARYOT CELL, V2, P830, DOI 10.1128/EC.2.5.830-840.2003; LIOU RF, 1990, MOL CELL BIOL, V10, P1764, DOI 10.1128/MCB.10.4.1764; Mankad RV, 1998, BIOL BULL, V195, P251, DOI 10.2307/1543135; MARONEY PA, 1990, P NATL ACAD SCI USA, V87, P709, DOI 10.1073/pnas.87.2.709; MUHICH ML, 1988, MOL CELL BIOL, V8, P3837, DOI 10.1128/MCB.8.9.3837; Nilsen TW, 2001, TRENDS GENET, V17, P678, DOI 10.1016/S0168-9525(01)02499-4; Peri S, 2001, TRENDS GENET, V17, P685, DOI 10.1016/S0168-9525(01)02493-3; Pesole G, 1999, FEBS LETT, V464, P60, DOI 10.1016/S0014-5793(99)01675-0; Pouchkina-Stantcheva NN, 2005, MOL BIOL EVOL, V22, P1482, DOI 10.1093/molbev/msi139; RAJKOVIC A, 1990, P NATL ACAD SCI USA, V87, P8879, DOI 10.1073/pnas.87.22.8879; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; Stover NA, 2001, P NATL ACAD SCI USA, V98, P5693, DOI 10.1073/pnas.101049998; TESSIER LH, 1991, EMBO J, V10, P2621, DOI 10.1002/j.1460-2075.1991.tb07804.x; THOMAS JD, 1988, CELL, V54, P533, DOI 10.1016/0092-8674(88)90075-X; Vandenberghe AE, 2001, GENE DEV, V15, P294, DOI 10.1101/gad.865401; VANDERPLOEG LHT, 1982, NUCLEIC ACIDS RES, V10, P3591, DOI 10.1093/nar/10.12.3591; VANDOREN K, 1990, MOL CELL BIOL, V10, P1769, DOI 10.1128/MCB.10.4.1769; Verjovski-Almeida S, 2003, NAT GENET, V35, P148, DOI 10.1038/ng1237; Wang XC, 2002, INT J BIOCHEM CELL B, V34, P983, DOI 10.1016/S1357-2725(02)00019-5; Wang XQ, 2004, NUCLEIC ACIDS RES, V32, P1382, DOI 10.1093/nar/gkh305; Zayas RM, 2005, MOL BIOL EVOL, V22, P2048, DOI 10.1093/molbev/msi200; ZORIO DAR, 1994, NATURE, V372, P270, DOI 10.1038/372270a0	53	22	23	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					733	743		10.1074/jbc.M506963200	http://dx.doi.org/10.1074/jbc.M506963200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16230357	hybrid			2022-12-25	WOS:000234447200009
J	Olofsson, A; Sauer-Eriksson, AE; Ohman, A				Olofsson, A; Sauer-Eriksson, AE; Ohman, A			The solvent protection of Alzheimer amyloid-beta-(1-42) fibrils as determined by solution NMR spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-AMYLOID FIBRILS; NUCLEAR-MAGNETIC-RESONANCE; X-RAY-DIFFRACTION; SOLID-STATE NMR; CORE STRUCTURE; H/D-EXCHANGE; HYDROGEN-EXCHANGE; PROTEIN-PRECURSOR; COMPUTER-PROGRAM; DISEASE	Alzheimer disease is a neurodegenerative disorder that is tightly linked to the self- assembly and amyloid formation of the 39 - 43residue- long amyloid-beta(A beta) peptide. Considerable evidence suggests a correlation between Alzheimer disease development and the longer variants of the peptide, A beta-(1-42/43). Currently, a molecular understanding for this behavior is lacking. In the present study, we have investigated the hydrogen/deuterium exchange of A beta-(1-42) fibrils under physiological conditions, using solution NMR spectroscopy. The obtained residue-specific and quantitative map of the solvent protection within the A beta-(1-42) fibril shows that there are two protected core regions, Glu(11)-Gly(25) and Lys(28)-Ala(42), and that the residues in between, Ser(26) and Asn(27), as well as those in the N terminus, Asp(1)- Tyr(10), are solvent- accessible. This result reveals considerable discrepancies when compared with a previous investigation on A beta- (1-40) fibrils and suggests that the additional residues in A beta-(1-42), Ile(41) and Ala(42), significantly increase the solvent protection and stability of the C-terminal region Lys(28)Ala(42). Consequently, our findings provide a molecular explanation for the increased amyloidogenicity and toxicity of A beta-(1-42) compared with shorter A beta variants found in vivo.	Umea Univ, Dept Biochem, SE-90187 Umea, Sweden; Umea Univ, Umea Ctr Mol Pathogenesis, SE-90187 Umea, Sweden	Umea University; Umea University	Ohman, A (corresponding author), Umea Univ, Dept Biochem, SE-90187 Umea, Sweden.	anders.ohman@chem.umu.se		Sauer-Eriksson, Elisabeth/0000-0003-0124-0199				Antzutkin ON, 2003, BIOPHYS J, V84, P3326, DOI 10.1016/S0006-3495(03)70057-5; Antzutkin ON, 2002, BIOCHEMISTRY-US, V41, P15436, DOI 10.1021/bi0204185; Balbach JJ, 2002, BIOPHYS J, V83, P1205, DOI 10.1016/S0006-3495(02)75244-2; Benzinger TLS, 1998, P NATL ACAD SCI USA, V95, P13407, DOI 10.1073/pnas.95.23.13407; Bitan G, 2001, J BIOL CHEM, V276, P35176, DOI 10.1074/jbc.M102223200; Blake C, 1996, STRUCTURE, V4, P989, DOI 10.1016/S0969-2126(96)00104-9; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Carulla N, 2005, NATURE, V436, P554, DOI 10.1038/nature03986; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Crescenzi O, 2002, EUR J BIOCHEM, V269, P5642, DOI 10.1046/j.1432-1033.2002.03271.x; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Eckman CB, 1997, HUM MOL GENET, V6, P2087, DOI 10.1093/hmg/6.12.2087; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Helgstrand M, 2000, J BIOMOL NMR, V18, P329, DOI 10.1023/A:1026729404698; Hoshino M, 2002, NAT STRUCT BIOL, V9, P332, DOI 10.1038/nsb792; Ippel JH, 2002, P NATL ACAD SCI USA, V99, P8648, DOI 10.1073/pnas.132098999; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kheterpal I, 2001, BIOCHEMISTRY-US, V40, P11757, DOI 10.1021/bi010805z; Kheterpal I, 2003, BIOCHEMISTRY-US, V42, P14092, DOI 10.1021/bi0357816; Kheterpal I, 2000, P NATL ACAD SCI USA, V97, P13597, DOI 10.1073/pnas.250288897; KIRSCHNER DA, 1986, P NATL ACAD SCI USA, V83, P503, DOI 10.1073/pnas.83.2.503; Klein WL, 2002, NEUROCHEM INT, V41, P345, DOI 10.1016/S0197-0186(02)00050-5; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lemere CA, 1996, NEUROBIOL DIS, V3, P16, DOI 10.1006/nbdi.1996.0003; Li LP, 1999, BIOPHYS J, V76, P2871, DOI 10.1016/S0006-3495(99)77442-4; Makin OS, 2005, P NATL ACAD SCI USA, V102, P315, DOI 10.1073/pnas.0406847102; Malinchik SB, 1998, BIOPHYS J, V74, P537, DOI 10.1016/S0006-3495(98)77812-9; McGowan E, 2005, NEURON, V47, P191, DOI 10.1016/j.neuron.2005.06.030; Morgan C, 2004, PROG NEUROBIOL, V74, P323, DOI 10.1016/j.pneurobio.2004.10.004; Nelson R, 2005, NATURE, V435, P773, DOI 10.1038/nature03680; Olofsson A, 2004, J BIOL CHEM, V279, P5699, DOI 10.1074/jbc.M310605200; Perutz MF, 2002, P NATL ACAD SCI USA, V99, P5591, DOI 10.1073/pnas.042681399; Petkova AT, 2005, SCIENCE, V307, P262, DOI 10.1126/science.1105850; Petkova AT, 2002, P NATL ACAD SCI USA, V99, P16742, DOI 10.1073/pnas.262663499; Ritter C, 2005, NATURE, V435, P844, DOI 10.1038/nature03793; Roher AE, 1996, J BIOL CHEM, V271, P20631, DOI 10.1074/jbc.271.34.20631; Sunde M, 1997, J MOL BIOL, V273, P729, DOI 10.1006/jmbi.1997.1348; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Whittemore NA, 2005, BIOCHEMISTRY-US, V44, P4434, DOI 10.1021/bi048292u; Williams AD, 2004, J MOL BIOL, V335, P833, DOI 10.1016/j.jmb.2003.11.008; Wogulis M, 2005, J NEUROSCI, V25, P1071, DOI 10.1523/JNEUROSCI.2381-04.2005; Yamaguchi KI, 2004, J MOL BIOL, V338, P559, DOI 10.1016/j.jmb.2004.02.067	44	110	116	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					477	483		10.1074/jbc.M508962200	http://dx.doi.org/10.1074/jbc.M508962200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16215229	hybrid			2022-12-25	WOS:000234307200059
J	Fraering, PC; Ye, WJ; LaVoie, MJ; Ostaszewski, BL; Selkoe, DJ; Wolfe, MS				Fraering, PC; Ye, WJ; LaVoie, MJ; Ostaszewski, BL; Selkoe, DJ; Wolfe, MS			gamma-Secretase substrate selectivity can be modulated directly via interaction with a nucleotide-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABL TYROSINE KINASE; CHRONIC MYELOGENOUS LEUKEMIA; AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; BCR-ABL; C-ABL; INHIBITORS; COMPLEX; PRESENILIN-1; NOTCH	gamma-Secretase is an unusual protease with an intramembrane catalytic site that cleaves many type I membrane proteins, including the amyloid beta-protein (A beta) precursor (APP) and the Notch receptor. Genetic and biochemical studies have identified four membrane proteins as components of gamma-secretase: heterodimeric presenilin composed of its N- and C-terminal fragments, nicastrin, Aph-1, and Pen-2. Here we demonstrated that certain compounds, including protein kinase inhibitors and their derivatives, act directly on purified gamma-secretase to selectively block cleavage of APP- but not Notch-based substrates. Moreover, ATP activated the generation of the APP intracellular domain and A beta, but not the generation of the Notch intracellular domain by the purified protease complex, and was a direct competitor of the APP- selective inhibitors, as were other nucleotides. In accord, purified gamma-secretase bound specifically to an ATP-linked resin. Finally, a photoactivable ATP analog specifically labeled presenilin 1-C-terminal fragments in purified gamma-secretase preparations; the labeling was blocked by ATP itself and APP- selective gamma-secretase inhibitors. We concluded that a nucleotide binding site exists within gamma-secretase, and certain compounds that bind to this site can specifically modulate the generation of A beta while sparing Notch. Drugs targeting the gamma-secretase nucleotide-binding site represent an attractive strategy for safely treating Alzheimer disease.	Harvard Univ, Inst Med, Ctr Neurol Dis, Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Selkoe, DJ (corresponding author), Harvard Univ, Inst Med, Ctr Neurol Dis, Brigham & Womens Hosp, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	dselkoe@rics.bwh.harvard.edu; mwolfe@rics.bwh.harvard.edu		LaVoie, Matthew/0000-0002-2583-1578; Fraering, Patrick/0000-0002-5841-5327	NIA NIH HHS [AG17574, AG15379, P01 AG015379, R01 AG017574] Funding Source: Medline; NINDS NIH HHS [NS41355, R01 NS041355] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041355] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG015379, R01AG017574] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Brown GR, 2000, BIOORG MED CHEM LETT, V10, P575, DOI 10.1016/S0960-894X(00)00051-2; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; Cowan-Jacob SW, 2004, MINI-REV MED CHEM, V4, P285, DOI 10.2174/1389557043487321; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Etcheberrigaray R, 2004, P NATL ACAD SCI USA, V101, P11141, DOI 10.1073/pnas.0403921101; Fraering PC, 2004, BIOCHEMISTRY-US, V43, P9774, DOI 10.1021/bi0494976; Fraering PC, 2004, BIOCHEMISTRY-US, V43, P323, DOI 10.1021/bi035748j; Hantschel O, 2003, CELL, V112, P845, DOI 10.1016/S0092-8674(03)00191-0; Harrison T, 2004, CURR OPIN DRUG DISC, V7, P709; Kimberly WT, 2003, BIOCHEMISTRY-US, V42, P137, DOI 10.1021/bi026888g; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; Kornilova AY, 2005, P NATL ACAD SCI USA, V102, P3230, DOI 10.1073/pnas.0407640102; LaVoie MJ, 2003, J BIOL CHEM, V278, P37213, DOI 10.1074/jbc.M303941200; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Marjaux E, 2004, NEURON, V42, P189, DOI 10.1016/S0896-6273(04)00218-1; Mauro MJ, 2002, J CLIN ONCOL, V20, P325, DOI 10.1200/JCO.20.1.325; Milano J, 2004, TOXICOL SCI, V82, P341, DOI 10.1093/toxsci/kfh254; Moasser MM, 1999, CANCER RES, V59, P6145; Morin MJ, 2000, ONCOGENE, V19, P6574, DOI 10.1038/sj.onc.1204102; Nagar B, 2002, CANCER RES, V62, P4236; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; Netzer WJ, 2003, P NATL ACAD SCI USA, V100, P12444, DOI 10.1073/pnas.1534745100; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Searfoss GH, 2003, J BIOL CHEM, V278, P46107, DOI 10.1074/jbc.M307757200; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Strife A, 2003, MOL CANCER RES, V1, P176; Vassar R, 2000, NEURON, V27, P419, DOI 10.1016/S0896-6273(00)00051-9; Walker ES, 2005, J NEUROCHEM, V92, P294, DOI 10.1111/j.1471-4159.2004.02858.x; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Wisniewski D, 2002, CANCER RES, V62, P4244; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wong GT, 2004, J BIOL CHEM, V279, P12876, DOI 10.1074/jbc.M311652200; Xia WM, 1998, BIOCHEMISTRY-US, V37, P16465, DOI 10.1021/bi9816195; YOSHIDA M, 1995, FEBS LETT, V359, P1, DOI 10.1016/0014-5793(94)01438-7	38	96	107	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					41987	41996		10.1074/jbc.M501368200	http://dx.doi.org/10.1074/jbc.M501368200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16236717	hybrid, Green Accepted, Green Submitted			2022-12-25	WOS:000233992700024
J	Hossain, MM; Crish, JF; Eckert, RL; Lin, JJC; Jin, JP				Hossain, MM; Crish, JF; Eckert, RL; Lin, JJC; Jin, JP			h2-calponin is regulated by mechanical tension and modifies the function of actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SMOOTH-MUSCLE CALPONIN; IN-VITRO; EXTRACELLULAR-MATRIX; HUMAN INVOLUCRIN; CROSS-LINKING; TROPOMYOSIN ISOFORMS; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; MOLECULAR-CLONING	Calponin is an extensively studied actin-binding protein, but its function is not well understood. Among three isoforms of calponin, h2-calponin is found in both smooth muscle and non-muscle cells. The present study demonstrates that epidermal keratinocytes and fibroblast cells express significant amounts of h2-calponin. The expression of h2-calponin is cell anchorage-dependent. The levels of h2-calponin decrease when cells are rounded up and remain low when cells are prevented from adherence to a culture dish. h2-calponin expression resumes after the floating cells are allowed to form a monolayer in plastic dish. Cell cultures on polyacrylamide gels of different stiffness demonstrated that h2-calponin expression is affected by the mechanical properties of the culture matrix. When cells are cultured on soft gel that applies less traction force to the cell and, therefore, lower mechanical tension in the cytoskeleton, the level of h2-calponin is significantly lower than that in cells cultured on hard gel or rigid plastic dish. Force-expression of h2-calponin enhanced the resistance of the actin filaments to cytochalasin B treatment. Keratinocyte differentiation is accompanied by a mechanical tension-related up-regulation of h2-calponin. Lowering the tension of actin cytoskeleton by inhibiting non-muscle myosin II ATPase decreased h2-calponin expression. In contrast to the mechanical tension regulation of endogenous h2-calponin, the expression of h2-calponin using a cytomegalovirus promotor was independent of the stiffness of culture matrix. The results suggest that h2-calponin represents a novel manifestation of mechanical tension responsive gene regulation that may modify cytoskeleton function.	Northwestern Univ, Feinberg Sch Med, Sect Mol Cardiol, Evanston, IL 60201 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Univ Iowa, Dept Biol Sci, Iowa City, IA 52242 USA	Northwestern University; Feinberg School of Medicine; Case Western Reserve University; University of Iowa	Jin, JP (corresponding author), Northwestern Univ, Feinberg Sch Med, Sect Mol Cardiol, Evanston, IL 60201 USA.	jpjin@northwestern.edu	Jin, Jian-Ping/AAD-1149-2020	Jin, JP/0000-0001-9932-1063	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R21HD044824, P01HD018577] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA134274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048816, R01AR046494, R01AR045357, P30AR039750] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA134274] Funding Source: Medline; NIAMS NIH HHS [R01 AR048816, R01 AR046494, R01 AR045357, P30 AR039750, AR045357, AR039750-130037, AR046494, AR048816] Funding Source: Medline; NICHD NIH HHS [HD018577, P01 HD018577, R21 HD044824, HD044824] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Beningo KA, 2002, J CELL SCI, V115, P849; BROSCHAT KO, 1990, J BIOL CHEM, V265, P21323; BROSCHAT KO, 1989, BIOCHEMISTRY-US, V28, P8501, DOI 10.1021/bi00447a035; BURGESS LPA, 1990, ARCH OTOLARYNGOL, V116, P798; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; Danninger C, 2000, J CELL SCI, V113, P3725; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; Deroanne CF, 2001, CARDIOVASC RES, V49, P647, DOI 10.1016/S0008-6363(00)00233-9; Deucher A, 2002, J BIOL CHEM, V277, P17032, DOI 10.1074/jbc.M109076200; Eckert RL, 2004, J INVEST DERMATOL, V123, P13, DOI 10.1111/j.0022-202X.2004.22723.x; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; Efimova T, 2004, MOL CELL BIOL, V24, P8167, DOI 10.1128/MCB.24.18.8167-8183.2004; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Engler A, 2004, BIOPHYS J, V86, P617, DOI 10.1016/S0006-3495(04)74140-5; Ferhat L, 1996, EUR J NEUROSCI, V8, P1501, DOI 10.1111/j.1460-9568.1996.tb01612.x; Ferhat L, 2001, J CELL SCI, V114, P3899; Filipe J. A. C., 2002, Autonomic & Autacoid Pharmacology, V22, P155, DOI 10.1046/j.1474-8673.2002.00255.x; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Fukui Y, 1997, J DERMATOL SCI, V14, P29, DOI 10.1016/S0923-1811(96)00545-2; Furukawa KS, 2001, CELL TRANSPLANT, V10, P441; GIRARD PR, 1995, J CELL PHYSIOL, V163, P179, DOI 10.1002/jcp.1041630121; Griffin MA, 2004, J CELL SCI, V117, P5855, DOI 10.1242/jcs.01496; HAN EKH, 1993, J CELL BIOL, V122, P461, DOI 10.1083/jcb.122.2.461; HARRIS A, 1973, EXP CELL RES, V77, P285, DOI 10.1016/0014-4827(73)90579-X; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; Hossain MM, 2003, AM J PHYSIOL-CELL PH, V284, pC156, DOI 10.1152/ajpcell.00233.2002; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; INGBER DE, 1993, J CELL SCI, V104, P613; Jiang Z, 1997, FEBS LETT, V413, P441, DOI 10.1016/S0014-5793(97)00944-7; Jin JP, 1996, BIOCHEM CELL BIOL, V74, P187, DOI 10.1139/o96-019; Jin JP, 2003, PROTEIN EXPRES PURIF, V31, P231, DOI 10.1016/S1046-5928(03)00185-2; Jin JP, 2003, J BIOL CHEM, V278, P26159, DOI 10.1074/jbc.M303469200; Kovacs M, 2004, J BIOL CHEM, V279, P35557, DOI 10.1074/jbc.M405319200; LaCelle PT, 1998, SKIN PHARMACOL APPL, V11, P214, DOI 10.1159/000029830; Lin J J, 1997, Int Rev Cytol, V170, P1, DOI 10.1016/S0074-7696(08)61619-8; LIN JJC, 1988, J CELL BIOL, V107, P563, DOI 10.1083/jcb.107.2.563; Lo CM, 2000, BIOPHYS J, V79, P144, DOI 10.1016/S0006-3495(00)76279-5; Masuda H, 1996, J BIOCHEM-TOKYO, V120, P415; Matthew JD, 2000, J PHYSIOL-LONDON, V529, P811, DOI 10.1111/j.1469-7793.2000.00811.x; MENON GK, 1992, CELL TISSUE RES, V270, P503, DOI 10.1007/BF00645052; Morgan KG, 2001, J APPL PHYSIOL, V91, P953, DOI 10.1152/jappl.2001.91.2.953; NAKAMURA F, 1993, J BIOL CHEM, V268, P6194; Nigam R, 1998, J MUSCLE RES CELL M, V19, P695, DOI 10.1023/A:1005389300151; NOVY RE, 1993, CELL MOTIL CYTOSKEL, V26, P248, DOI 10.1002/cm.970260308; Pelham RJ, 1998, BIOL BULL, V194, P348, DOI 10.2307/1543109; Pelham RJ, 1997, P NATL ACAD SCI USA, V94, P13661, DOI 10.1073/pnas.94.25.13661; Pickett BP, 1996, ARCH OTOLARYNGOL, V122, P565; Ponti A, 2004, SCIENCE, V305, P1782, DOI 10.1126/science.1100533; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; Robinson NA, 1996, J INVEST DERMATOL, V107, P101, DOI 10.1111/1523-1747.ep12298323; Sakihara C, 1996, BIOCHEM BIOPH RES CO, V222, P195, DOI 10.1006/bbrc.1996.0721; SASAKI Y, 1989, J BIOCHEM-TOKYO, V106, P1009, DOI 10.1093/oxfordjournals.jbchem.a122956; Shyy JY, 2002, CIRC RES, V91, P769, DOI 10.1161/01.RES.0000038487.19924.18; Small JV, 1998, ACTA PHYSIOL SCAND, V164, P341; Smillie L, 1996, BIOCH SMOOTH MUSCLE, P63; Straight AF, 2003, SCIENCE, V299, P1743, DOI 10.1126/science.1081412; STRASSER P, 1993, FEBS LETT, V330, P13, DOI 10.1016/0014-5793(93)80909-E; TAKAHASHI K, 1986, BIOCHEM BIOPH RES CO, V141, P20, DOI 10.1016/S0006-291X(86)80328-X; TAKAHASHI K, 1991, J BIOL CHEM, V266, P13284; Takahashi K, 2000, BIOCHEM BIOPH RES CO, V279, P150, DOI 10.1006/bbrc.2000.3909; TAKEUCHI K, 1991, J BIOCHEM, V109, P311; Wang J, 1998, BIOCHEMISTRY-US, V37, P14519, DOI 10.1021/bi9812322; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; WARREN KS, 1995, J CELL BIOL, V129, P697, DOI 10.1083/jcb.129.3.697; WARREN KS, 1994, J CELL BIOL, V125, P359, DOI 10.1083/jcb.125.2.359; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; Winder SJ, 1998, ACTA PHYSIOL SCAND, V164, P415, DOI 10.1111/j.1365-201X.1998.tb10697.x; Yeung T, 2005, CELL MOTIL CYTOSKEL, V60, P24, DOI 10.1002/cm.20041	71	48	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42442	42453		10.1074/jbc.M509952200	http://dx.doi.org/10.1074/jbc.M509952200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16236705	Green Accepted, hybrid			2022-12-25	WOS:000233992700075
J	Robert, J; Auzan, C; Ventura, MA; Clauser, E				Robert, J; Auzan, C; Ventura, MA; Clauser, E			Mechanisms of cell-surface rerouting of an endoplasmic reticulum-retained mutant of the vasopressin V1b/V3 receptor by a pharmacological chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEPHROGENIC DIABETES-INSIPIDUS; RESONANCE ENERGY-TRANSFER; DELTA-OPIOID RECEPTOR; FUNCTIONAL EXPRESSION; SECRETORY PATHWAY; MOLECULAR-CLONING; HORMONE RECEPTOR; QUALITY-CONTROL; WILD-TYPE; RESCUE	Cell-surface expression and biological functions of several intra cellular retained G protein-coupled receptors are restored by membrane permeable ligands called pharmacological chaperones. We have previously demonstrated that a mutation of the hydrophobic motif (FNX2LLX3L350)-F-341 in the C terminus of the human pituitary vasopressin V3 receptor ( MUT V3R) led to it being retained in the endoplasmic reticulum ( ER). Here, we establish the precise role of this motif and investigate whether SSR149415, a non-peptide V3R antagonist, behaves as a pharmacological chaperone for the ER-retained MUT V3R. The absence of the mutated receptor in the plasma membrane is linked to its prolonged association with the molecular chaperone calnexin in the ER and to its intensive degradation by the ubiquitin-proteasomal machinery. However, this is not because of a lack of oligomerization, as demonstrated by the presence of MUT V3R homodimers in the ER. Treatment with SSR149415 restores expression of the mutated receptor on the cell surface and its correct maturation, resulting into the functional recovery of its signaling properties. SSR149415 acts by stabilizing a native-like conformation of the V3R, reducing its association with calnexin and, thus, favoring a secretory pathway rather than the proteasomal degradation pathway. In conclusion, the FN(X)(2)LL(X)(3)L sequence is an important motif for the V3R conformation, and the misfolding resulting from its mutation alters the receptor export but can be reverted by SSR149415.	Inst Cochin Genet Mol, Dept Endocrinol, F-75014 Paris, France; CNRS, UMR 8104, F-75014 Paris, France; INSERM U567, F-75014 Paris, France; Univ Paris 05, Fac Med Rene Descartes, UMR S 8104, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite	Clauser, E (corresponding author), Inst Cochin Genet Mol, Dept Endocrinol, 24 Faubourd St Jacques, F-75014 Paris, France.	clauser@cochin.inserm.fr						Aguilera G, 2000, REGUL PEPTIDES, V96, P23, DOI 10.1016/S0167-0115(00)00196-8; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; Birnbaumer M, 2000, TRENDS ENDOCRIN MET, V11, P406, DOI 10.1016/S1043-2760(00)00304-0; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Chaipatikul V, 2003, MOL PHARMACOL, V64, P32, DOI 10.1124/mol.64.1.32; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; Cornea A, 2001, J BIOL CHEM, V276, P2153, DOI 10.1074/jbc.M007850200; DEKEYZER Y, 1994, FEBS LETT, V356, P215, DOI 10.1016/0014-5793(94)01268-7; Derick S, 2004, MOL ENDOCRINOL, V18, P2777, DOI 10.1210/me.2004-0124; Egashira N, 2005, NEUROPSYCHOPHARMACOL, V30, P1996, DOI 10.1038/sj.npp.1300784; Fan J, 2005, MOL ENDOCRINOL, V19, P2579, DOI 10.1210/me.2004-0301; Ferreira PA, 1996, NATURE, V383, P637, DOI 10.1038/383637a0; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Janovick JA, 2003, J PHARMACOL EXP THER, V305, P608, DOI 10.1124/jpet.102.048454; Jard S, 1998, ADV EXP MED BIOL, V449, P1; Kleizen B, 2004, CURR OPIN CELL BIOL, V16, P343, DOI 10.1016/j.ceb.2004.06.012; Krause G, 2000, MOL PHARMACOL, V57, P232; Morello JP, 2000, TRENDS PHARMACOL SCI, V21, P466, DOI 10.1016/S0165-6147(00)01575-3; Morello JP, 2001, ANNU REV PHYSIOL, V63, P607, DOI 10.1146/annurev.physiol.63.1.607; Morello JP, 2001, BIOCHEMISTRY-US, V40, P6766, DOI 10.1021/bi002699r; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; Noorwez SM, 2003, J BIOL CHEM, V278, P14442, DOI 10.1074/jbc.M300087200; Oksche A, 1998, J MOL MED, V76, P326, DOI 10.1007/s001090050224; Petaja-Repo UE, 2002, EMBO J, V21, P1628, DOI 10.1093/emboj/21.7.1628; Petaja-Repo UE, 2000, J BIOL CHEM, V275, P13727, DOI 10.1074/jbc.275.18.13727; Petaja-Repo UE, 2001, J BIOL CHEM, V276, P4416, DOI 10.1074/jbc.M007151200; Robert J, 2005, J BIOL CHEM, V280, P2300, DOI 10.1074/jbc.M410655200; Rozell TG, 1998, ENDOCRINOLOGY, V139, P1588, DOI 10.1210/en.139.4.1588; Saito H, 2004, CELL, V119, P679, DOI 10.1016/j.cell.2004.11.021; Salahpour A, 2004, J BIOL CHEM, V279, P33390, DOI 10.1074/jbc.M403363200; Serradeil-Le Gal C, 2002, J PHARMACOL EXP THER, V300, P1122; Siffroi-Fernandez S, 2002, EUR J BIOCHEM, V269, P4930, DOI 10.1046/j.1432-1033.2002.03192.x; SUGIMOTO T, 1994, J BIOL CHEM, V269, P27088; Terrillon S, 2004, EMBO REP, V5, P30, DOI 10.1038/sj.embor.7400052; Terrillon S, 2003, MOL ENDOCRINOL, V17, P677, DOI 10.1210/me.2002-0222; Thibonnier M, 2002, PROG BRAIN RES, V139, P179; TORRENS Y, 1989, CR ACAD SCI III-VIE, V309, P295; Trombetta ES, 2003, ANNU REV CELL DEV BI, V19, P649, DOI 10.1146/annurev.cellbio.19.110701.153949; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Ulloa-Aguirre A, 2004, TRAFFIC, V5, P821, DOI 10.1111/j.1600-0854.2004.00232.x; Welch WJ, 2000, J CLIN INVEST, V105, P853, DOI 10.1172/JCI9158; Wersinger SR, 2002, MOL PSYCHIATR, V7, P975, DOI 10.1038/sj.mp.4001195; Wuller S, 2004, J BIOL CHEM, V279, P47254, DOI 10.1074/jbc.M408154200; Wurch T, 2001, FEBS LETT, V507, P109, DOI 10.1016/S0014-5793(01)02969-6	45	54	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42198	42206		10.1074/jbc.M510180200	http://dx.doi.org/10.1074/jbc.M510180200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16210325	hybrid			2022-12-25	WOS:000233992700048
J	Schweitzer, JK; Burke, EE; Goodson, HV; D'Souza-Schorey, C				Schweitzer, JK; Burke, EE; Goodson, HV; D'Souza-Schorey, C			Endocytosis resumes during late mitosis and is required for cytokinesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLEAVAGE FURROW; MEMBRANE TRAFFICKING; MEDIATED ENDOCYTOSIS; PLASMA-MEMBRANE; CLATHRIN; ARF6; PROTEIN; CELLS; COMPLEX; GTPASE	Recent work has underscored the importance of membrane trafficking events during cytokinesis. For example, targeted membrane secretion occurs at the cleavage furrow in animal cells, and proteins that regulate endocytosis also influence the process of cytokinesis. Nonetheless, the prevailing dogma is that endosomal membrane trafficking ceases during mitosis and resumes after cell division is complete. In this study, we have characterized endocytic membrane trafficking events that occur during mammalian cell cytokinesis. We have found that, although endocytosis ceases during the early stages of mitosis, it resumes during late mitosis in a temporally and spatially regulated pattern as cells progress from anaphase to cytokinesis. Using fixed and live cell imaging, we have found that, during cleavage furrow ingression, vesicles are internalized from the polar region and subsequently trafficked to the midbody area during later stages of cytokinesis. In addition, we have demonstrated that cytokinesis is inhibited when clathrin-mediated endocytosis is blocked using a series of dominant negative mutants. In contrast to previous thought, we conclude that endocytosis resumes during the later stages of mitosis, before cytokinesis is completed. Furthermore, based on our findings, we propose that the proper regulation of endosomal membrane traffic is necessary for the successful completion of cytokinesis.	Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA; Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; Univ Notre Dame, Walther Canc Ctr, Notre Dame, IN 46556 USA	University of Notre Dame; University of Notre Dame; University of Notre Dame; Walther Cancer Institute	D'Souza-Schorey, C (corresponding author), Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA.	D'Souza-Schorey.1@nd.edu	Goodson, Holly/AAE-6079-2022	Goodson, Holly/0000-0001-7942-8349				Albertson R, 2005, TRENDS CELL BIOL, V15, P92, DOI 10.1016/j.tcb.2004.12.008; Benmerah A, 1999, J CELL SCI, V112, P1303; Benmerah A, 2000, J BIOL CHEM, V275, P3288, DOI 10.1074/jbc.275.5.3288; Bergeland T, 2001, CURR BIOL, V11, P644, DOI 10.1016/S0960-9822(01)00177-4; BERLIN RD, 1980, J CELL BIOL, V85, P660, DOI 10.1083/jcb.85.3.660; Boshans RL, 2000, MOL CELL BIOL, V20, P3685, DOI 10.1128/MCB.20.10.3685-3694.2000; Burgess RW, 1997, J CELL BIOL, V138, P861, DOI 10.1083/jcb.138.4.861; Chen H, 1999, J BIOL CHEM, V274, P3257, DOI 10.1074/jbc.274.6.3257; D'Souza-Schorey C, 1998, J CELL BIOL, V140, P603, DOI 10.1083/jcb.140.3.603; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; Danilchik MV, 2003, J CELL SCI, V116, P273, DOI 10.1242/jcs.00217; Danilchik MV, 1998, DEV BIOL, V194, P47, DOI 10.1006/dbio.1997.8815; Dunster K, 2002, EUR J CELL BIOL, V81, P117, DOI 10.1078/0171-9335-00232; Feng B, 2002, EXP CELL RES, V279, P14, DOI 10.1006/excr.2002.5579; Finger FP, 2002, CELL, V108, P727, DOI 10.1016/S0092-8674(02)00668-2; Franco M, 1999, EMBO J, V18, P1480, DOI 10.1093/emboj/18.6.1480; Gerald NJ, 2001, CELL MOTIL CYTOSKEL, V48, P213, DOI 10.1002/1097-0169(200103)48:3<213::AID-CM1010>3.0.CO;2-V; Glotzer M, 2001, ANNU REV CELL DEV BI, V17, P351, DOI 10.1146/annurev.cellbio.17.1.351; Krauss M, 2003, J CELL BIOL, V162, P113, DOI 10.1083/jcb.200301006; Low SH, 2003, DEV CELL, V4, P753, DOI 10.1016/S1534-5807(03)00122-9; Motley A, 2003, J CELL BIOL, V162, P909, DOI 10.1083/jcb.200305145; O'Halloran TJ, 2000, TRAFFIC, V1, P921, DOI 10.1034/j.1600-0854.2000.011201.x; Palacios F, 2002, NAT CELL BIOL, V4, P929, DOI 10.1038/ncb881; Palacios F, 2001, EMBO J, V20, P4973, DOI 10.1093/emboj/20.17.4973; Paleotti O, 2005, J BIOL CHEM, V280, P21661, DOI 10.1074/jbc.m503099200; Paterson AD, 2003, J BIOL CHEM, V278, P21050, DOI 10.1074/jbc.M300082200; Peters PJ, 2001, TRAFFIC, V2, P885, DOI 10.1034/j.1600-0854.2001.21204.x; Prigent M, 2003, J CELL BIOL, V163, P1111, DOI 10.1083/jcb.200305029; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; Riggs B, 2003, J CELL BIOL, V163, P143, DOI 10.1083/jcb.200305115; Royle SJ, 2005, NATURE, V434, P1152, DOI 10.1038/nature03502; SAGER PR, 1984, CELL, V39, P275, DOI 10.1016/0092-8674(84)90005-9; Schweitzer JK, 2004, EXP CELL RES, V295, P1, DOI 10.1016/j.yexcr.2003.12.023; Schweitzer JK, 2002, J BIOL CHEM, V277, P27210, DOI 10.1074/jbc.M201569200; SCHWEITZER JK, 2005, IN PRESS EXP CELL RE; Shuster CB, 2002, P NATL ACAD SCI USA, V99, P3633, DOI 10.1073/pnas.052342699; Skop AR, 2004, SCIENCE, V305, P61, DOI 10.1126/science.1097931; Straight AF, 2000, CURR BIOL, V10, pR760, DOI 10.1016/S0960-9822(00)00746-6; Strickland LI, 2004, TRENDS CELL BIOL, V14, P115, DOI 10.1016/j.tcb.2004.01.006; Tanabe K, 2005, MOL BIOL CELL, V16, P1617, DOI 10.1091/mbc.E04-08-0683; Thompson HM, 2002, CURR BIOL, V12, P2111, DOI 10.1016/S0960-9822(02)01390-8; Tomas A, 2004, J CELL BIOL, V165, P813, DOI 10.1083/jcb.200311054; WARREN G, 1984, EMBO J, V3, P2217, DOI 10.1002/j.1460-2075.1984.tb02119.x; Wilson GM, 2005, MOL BIOL CELL, V16, P849, DOI 10.1091/mbc.e04-10-0927; Xu H, 2002, SEMIN CELL DEV BIOL, V13, P77, DOI 10.1016/S1084-9521(02)00012-5; Xu H, 2002, DEV BIOL, V251, P294, DOI 10.1006/dbio.2002.0830; Zhao XH, 2001, J CELL SCI, V114, P353	48	93	93	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41628	41635		10.1074/jbc.M504497200	http://dx.doi.org/10.1074/jbc.M504497200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16207714	hybrid			2022-12-25	WOS:000233866900063
J	Obinata, H; Hattori, T; Nakane, S; Tatei, K; Izumi, T				Obinata, H; Hattori, T; Nakane, S; Tatei, K; Izumi, T			Identification of 9-hydroxyoctadecadienoic acid and other oxidized free fatty acids as ligands of the G protein-coupled receptor G2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; ARACHIDONIC-ACID; LINOLEIC-ACID; LYSOPHOSPHATIDYLCHOLINE; EXPRESSION; OXIDATION; ENZYMES; CELLS; CYTOCHROME-P450; HYDROPEROXY	G2A is a G protein-coupled receptor that is predominantly expressed in lymphoid tissues and macrophages. G2A can be induced by diverse stimuli to cause cell cycle arrest in the G(2)/M phase in pro-B and T cells. G2A is also expressed in macrophages within atherosclerotic lesions, suggesting G2A involvement in atherosclerosis. Recently, G2A was discovered to possess proton-sensing ability. In this paper, we report another function of G2A, that is, as a receptor for 9-hydroxyoctadecadienoic acid (9-HODE) and other oxidized free fatty acids. G2A, expressed in CHO-K1 or HEK293 cells, showed 9-HODE-induced intracellular calcium mobilization, inositol phosphate accumulation, inhibition of cAMP accumulation, [S-35] guanosine 5'-3-O-(thio)triphosphate binding, and MAP kinase activation. Furthermore, G2A was activated by various oxidized derivatives of linoleic and arachidonic acids, but it was weakly activated by cholesteryl-9-HODE. Oxidized phosphatidylcholine (1-palmitoyl-2-linoleoyl) when hydrolyzed with phospholipase A(2) also evoked intracellular calcium mobilization in G2A-expressing cells. These results indicate that G2A is activated by oxidized free fatty acids produced by oxidation and subsequent hydrolysis of phosphatidylcholine or cholesteryl linoleate. Thus, G2A might have a biological role in diverse pathological conditions including atherosclerosis.	Gunma Univ, Grad Sch Med, Dept Mol Biochem, Maebashi, Gumma 3718511, Japan	Gunma University	Izumi, T (corresponding author), Gunma Univ, Grad Sch Med, Dept Mol Biochem, Maebashi, Gumma 3718511, Japan.	takizumi@med.gunma-u.ac.jp						Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Capdevila JH, 2000, J LIPID RES, V41, P163; Choi JW, 1996, CELL IMMUNOL, V168, P78, DOI 10.1006/cimm.1996.0051; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; FOLCIK VA, 1994, J LIPID RES, V35, P1570; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Hanasaki K, 2002, J BIOL CHEM, V277, P29116, DOI 10.1074/jbc.M202867200; HARLAND WA, 1971, ATHEROSCLEROSIS, V13, P239, DOI 10.1016/0021-9150(71)90026-8; HECKER M, 1987, EUR J BIOCHEM, V169, P113, DOI 10.1111/j.1432-1033.1987.tb13587.x; HEIBER M, 1995, DNA CELL BIOL, V14, P25, DOI 10.1089/dna.1995.14.25; Ishii S, 2005, J BIOL CHEM, V280, P9083, DOI 10.1074/jbc.M407832200; Jira W, 1997, CHEM PHYS LIPIDS, V87, P81, DOI 10.1016/S0009-3084(97)00030-3; Jira W, 1998, CHEM PHYS LIPIDS, V91, P1, DOI 10.1016/S0009-3084(97)00095-9; Jisaka M, 1997, J BIOL CHEM, V272, P24410, DOI 10.1074/jbc.272.39.24410; Kabarowski JHS, 2000, P NATL ACAD SCI USA, V97, P12109, DOI 10.1073/pnas.97.22.12109; Kabarowski JHS, 2001, SCIENCE, V293, P702, DOI 10.1126/science.1061781; KU G, 1992, J BIOL CHEM, V267, P14183; Kudo I, 2002, PROSTAG OTH LIPID M, V68-9, P3, DOI 10.1016/S0090-6980(02)00020-5; Le LQ, 2001, IMMUNITY, V14, P561, DOI 10.1016/S1074-7613(01)00145-5; LENZ ML, 1990, J LIPID RES, V31, P1043; Lin P, 2003, J BIOL CHEM, V278, P14379, DOI 10.1074/jbc.M209101200; Ludwig MG, 2003, NATURE, V425, P93, DOI 10.1038/nature01905; MAHADEVAN MS, 1995, GENOMICS, V30, P84, DOI 10.1006/geno.1995.0013; Mates JM, 1999, CLIN BIOCHEM, V32, P595, DOI 10.1016/S0009-9120(99)00075-2; Moller P, 1996, CHEM-BIOL INTERACT, V102, P17, DOI 10.1016/0009-2797(96)03729-5; Murakami N, 2004, J BIOL CHEM, V279, P42484, DOI 10.1074/jbc.M406561200; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Radu CG, 2005, P NATL ACAD SCI USA, V102, P1632, DOI 10.1073/pnas.0409415102; Radu CG, 2004, P NATL ACAD SCI USA, V101, P245, DOI 10.1073/pnas.2536801100; Rikitake Y, 2002, ARTERIOSCL THROM VAS, V22, P2049, DOI 10.1161/01.ATV.0000040598.18570.54; SHIMIZU T, 1984, P NATL ACAD SCI-BIOL, V81, P689, DOI 10.1073/pnas.81.3.689; Thuresson ED, 2000, J BIOL CHEM, V275, P8501, DOI 10.1074/jbc.275.12.8501; Wang H, 2004, MOL PHARMACOL, V65, P1148, DOI 10.1124/mol.65.5.1148; Wang JQ, 2004, J BIOL CHEM, V279, P45626, DOI 10.1074/jbc.M406966200; Wang L, 2005, MOL BIOL CELL, V16, P2234, DOI 10.1091/mbc.E04-12-1044; Weng ZG, 1998, P NATL ACAD SCI USA, V95, P12334, DOI 10.1073/pnas.95.21.12334; Witte Owen N, 2005, Science, V307, P206; Xu Y, 1996, GENOMICS, V35, P397, DOI 10.1006/geno.1996.0377; Yang LV, 2005, BLOOD, V105, P1127, DOI 10.1182/blood-2004-05-1916; Yoshida Y, 2003, BIOCHEM BIOPH RES CO, V305, P747, DOI 10.1016/S0006-291X(03)00813-1	41	123	127	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40676	40683		10.1074/jbc.M507787200	http://dx.doi.org/10.1074/jbc.M507787200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16236715	hybrid			2022-12-25	WOS:000233666600037
J	Beullens, M; Vancauwenbergh, S; Morrice, N; Derua, R; Ceulemans, H; Waelkens, E; Bollen, M				Beullens, M; Vancauwenbergh, S; Morrice, N; Derua, R; Ceulemans, H; Waelkens, E; Bollen, M			Substrate specificity and activity regulation of protein kinase MELK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBA DOMAINS; PHOSPHORYLATION; EXPRESSION; SUBFAMILY; ZPR9; LKB1	Maternal embryonic leucine zipper kinase ( MELK) is a protein Ser/Thr kinase that has been implicated in stem cell renewal, cell cycle progression, and pre-mRNA splicing, but its substrates and regulation are not yet known. We show here that MELK has a rather broad substrate specificity and does not appear to require a specific sequence surrounding its ( auto) phosphorylation sites. We have mapped no less than 16 autophosphorylation sites including serines, threonines, and a tyrosine residue and show that the phosphorylation of Thr(167) and Ser(171) is required for the activation of MELK. The expression of MELK activity also requires reducing agents such as dithiothreitol or reduced glutathione. Furthermore, we show that MELK is a Ca2+-binding protein and is inhibited by physiological Ca2+ concentrations. The smallest MELK fragment that was still catalytically active comprises the N-terminal catalytic domain and the flanking ubiquitin-associated domain. A C-terminal fragment of MELK functions as an autoinhibitory domain. Our data show that the activity of MELK is regulated in a complex manner and offer new perspectives for the further elucidation of its biological function.	Katholieke Univ Leuven, Afd Biochem, Fac Geneeskunde, B-3000 Louvain, Belgium; Univ Dundee, Sch Life Sci, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland	KU Leuven; University of Dundee	Beullens, M (corresponding author), Katholieke Univ Leuven, Afd Biochem, Fac Geneeskunde, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.	Monique.Beullens@med.kuleuven.be	Vancauwenbergh, Sadia/H-9704-2015	Vancauwenbergh, Sadia/0000-0002-5201-8101; Ceulemans, Hugo/0000-0002-7059-4399				Barford D, 2004, CURR OPIN STRUC BIOL, V14, P679, DOI 10.1016/j.sbi.2004.09.012; Bertolaet BL, 2001, J MOL BIOL, V313, P955, DOI 10.1006/jmbi.2001.5105; BEULLENS M, 1993, J BIOL CHEM, V268, P13172; Buchberger A, 2002, TRENDS CELL BIOL, V12, P216, DOI 10.1016/S0962-8924(02)02269-9; Ceulemans H, 2004, PHYSIOL REV, V84, P1, DOI 10.1152/physrev.00013.2003; Cross JV, 2004, BIOCHEM J, V381, P675, DOI 10.1042/BJ20040591; Davezac N, 2002, ONCOGENE, V21, P7630, DOI 10.1038/sj.onc.1205870; Davies GC, 2004, ONCOGENE, V23, P7104, DOI 10.1038/sj.onc.1207952; Easterday MC, 2003, DEV BIOL, V264, P309, DOI 10.1016/j.ydbio.2003.09.003; Elbert M, 2005, MOL BIOL CELL, V16, P532, DOI 10.1091/mbc.E04-07-0549; Geschwind DH, 2001, NEURON, V29, P325, DOI 10.1016/S0896-6273(01)00209-4; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hartmann-Petersen R, 2003, INT J BIOCHEM CELL B, V35, P629, DOI 10.1016/S1357-2725(02)00393-X; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Heyer BS, 1997, MOL REPROD DEV, V47, P148, DOI 10.1002/(SICI)1098-2795(199706)47:2&lt;148::AID-MRD4&gt;3.0.CO;2-M; Heyer BS, 1999, DEV DYNAM, V215, P344; Humphries KM, 2002, J BIOL CHEM, V277, P43505, DOI 10.1074/jbc.M207088200; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Johnson LN, 1998, FEBS LETT, V430, P1, DOI 10.1016/S0014-5793(98)00606-1; LEVEBVRE DL, 2001, BOCH J, V355, P297; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; McLachlin DT, 2001, CURR OPIN CHEM BIOL, V5, P591, DOI 10.1016/S1367-5931(00)00250-7; Mueller TD, 2004, J BIOL CHEM, V279, P11926, DOI 10.1074/jbc.M312865200; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Seong HA, 2002, BIOCHEM J, V361, P597, DOI 10.1042/0264-6021:3610597; Seong HA, 2003, J BIOL CHEM, V278, P9655, DOI 10.1074/jbc.M207478200; Sienaert I, 1997, J BIOL CHEM, V272, P25899, DOI 10.1074/jbc.272.41.25899; Suzuki A, 2003, J BIOL CHEM, V278, P48, DOI 10.1074/jbc.M206025200; Tassan JP, 2004, BIOL CELL, V96, P193, DOI 10.1016/j.biolcel.2003.10.009; Vulsteke V, 2004, J BIOL CHEM, V279, P8642, DOI 10.1074/jbc.M311466200; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Zeller M, 2004, ANAL BIOANAL CHEM, V378, P898, DOI 10.1007/s00216-003-2391-2	33	79	87	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40003	40011		10.1074/jbc.M507274200	http://dx.doi.org/10.1074/jbc.M507274200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16216881	hybrid			2022-12-25	WOS:000233461300038
J	Steenbergen, R; Nanowski, TS; Beigneux, A; Kulinski, A; Young, SG; Vance, JE				Steenbergen, R; Nanowski, TS; Beigneux, A; Kulinski, A; Young, SG; Vance, JE			Disruption of the phosphatidylserine decarboxylase gene in mice causes embryonic lethality and mitochondrial defects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; YEAST SACCHAROMYCES-CEREVISIAE; OVARY CELL MUTANT; ESCHERICHIA-COLI; BARTH-SYNDROME; PHOSPHATIDYLETHANOLAMINE BIOSYNTHESIS; PHOSPHOLIPID-SYNTHESIS; NULL ALLELE; MEMBRANE; LIVER	Most of the phosphatidylethanolamine ( PE) in mammalian cells is synthesized by two pathways, the CDP-ethanolamine pathway and the phosphatidylserine ( PS) decarboxylation pathway, the final steps of which operate at spatially distinct sites, the endoplasmic reticulum and mitochondria, respectively. We investigated the importance of the mitochondrial pathway for PE synthesis in mice by generating mice lacking PS decarboxylase activity. Disruption of Pisd in mice resulted in lethality between days 8 and 10 of embryonic development. Electron microscopy of Pisd(-/-) embryos revealed large numbers of aberrantly shaped mitochondria. In addition, fluorescence confocal microscopy of Pisd(-/-) embryonic fibroblasts showed fragmented mitochondria. PS decarboxylase activity and mRNA levels in Pisd(+/-) tissues were approximately one-half of those in wild-type mice. However, heterozygous mice appeared normal, exhibited normal vitality, and the phospholipid composition of livers, testes, brains, and of mitochondria isolated from livers, was the same as in wild-type littermates. The amount and activity of a key enzyme of the CDP-ethanolamine pathway for PE synthesis, CTP: phosphoethanolamine cytidylyltransferase, were increased by 35 - 40 and 100%, respectively, in tissues of Pisd(+/-) mice, as judged by immunoblotting; PE synthesis from [ H-3] ethanolamine was correspondingly increased in hepatocytes. We conclude that the CDP-ethanolamine pathway in mice cannot substitute for a lack of PS decarboxylase during development. Moreover, elimination of PE production in mitochondria causes fragmented, misshapen mitochondria, an abnormality that likely contributes to the embryonic lethality.	Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Med, Edmonton, AB T6G 2S2, Canada; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Cardiol, Los Angeles, CA 90095 USA	University of Alberta; University of Alberta; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Vance, JE (corresponding author), Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, 332 HMRC, Edmonton, AB T6G 2S2, Canada.	jean.vance@ualberta.ca		Young, Stephen/0000-0001-7270-3176	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL066621, U01HL066600, R01HL094732] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL094732-02, U01 HL066600, R01 HL094732, HL66621, R01 HL094732-01S1, U01 HL066621, HL66600, R01 HL094732-01, R01 HL094732-03] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARDAIL D, 1991, J BIOL CHEM, V266, P7978; BEREITERHAHN J, 1994, MICROSC RES TECHNIQ, V27, P198, DOI 10.1002/jemt.1070270303; Bergo MO, 2002, J BIOL CHEM, V277, P47701, DOI 10.1074/jbc.M207734200; Birner R, 2001, MOL BIOL CELL, V12, P997, DOI 10.1091/mbc.12.4.997; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bogdanov M, 1998, EMBO J, V17, P5255, DOI 10.1093/emboj/17.18.5255; Bogdanov M, 1996, J BIOL CHEM, V271, P11615, DOI 10.1074/jbc.271.20.11615; BORKENHAGEN LF, 1961, J BIOL CHEM, V236, P28; Burgermeister M, 2004, BBA-MOL CELL BIOL L, V1686, P161, DOI 10.1016/j.bbalip.2004.09.007; Chen HC, 2004, CURR TOP DEV BIOL, V59, P119, DOI 10.1016/S0070-2153(04)59005-1; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; Cherezov V, 2003, J MEMBRANE BIOL, V195, P165, DOI 10.1007/s00232-003-0617-z; Chow C W, 2000, Hum Reprod, V15 Suppl 2, P68; Cullis P, 1983, CONCEPTS MEMBRANE ST, P39; DECHAVIGNY A, 1991, J BIOL CHEM, V266, P5323; Dobrosotskaya IY, 2002, SCIENCE, V296, P879, DOI 10.1126/science.1071124; Emoto K, 1996, P NATL ACAD SCI USA, V93, P12867, DOI 10.1073/pnas.93.23.12867; Emoto K, 1999, P NATL ACAD SCI USA, V96, P12400, DOI 10.1073/pnas.96.22.12400; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Henneberry AL, 2002, MOL BIOL CELL, V13, P3148, DOI 10.1091/mbc.01-11-0540; KACHAR B, 1986, BIOPHYS J, V50, P779, DOI 10.1016/S0006-3495(86)83518-4; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; King M P, 1996, Methods Enzymol, V264, P304, DOI 10.1016/S0076-6879(96)64029-4; Koshkin V, 2000, BIOCHEM J, V347, P687, DOI 10.1042/0264-6021:3470687; KUGE O, 1986, J BIOL CHEM, V261, P5790; KUGE O, 1991, J BIOL CHEM, V266, P6370; LI QX, 1988, J BIOL CHEM, V263, P11516; Ma LN, 2004, J BIOL CHEM, V279, P44394, DOI 10.1074/jbc.M405479200; MILLER MA, 1986, J BIOL CHEM, V261, P9753; Mitchell KJ, 2001, NAT GENET, V28, P241, DOI 10.1038/90074; PERCY AK, 1983, ARCH BIOCHEM BIOPHYS, V223, P484, DOI 10.1016/0003-9861(83)90613-6; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; RIETVELD AG, 1993, J BIOL CHEM, V268, P12427; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Rontein D, 2003, PLANT PHYSIOL, V132, P1678, DOI 10.1104/pp.103.023242; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; Schlame M, 2002, ANN NEUROL, V51, P634, DOI 10.1002/ana.10176; Shaw JM, 2002, TRENDS CELL BIOL, V12, P178, DOI 10.1016/S0962-8924(01)02246-2; SHIAO YJ, 1995, J BIOL CHEM, V270, P11190, DOI 10.1074/jbc.270.19.11190; SNELL EE, 1977, TRENDS BIOCHEM SCI, V2, P131, DOI 10.1016/0968-0004(77)90441-8; Stone SJ, 1999, BIOCHEM J, V342, P57, DOI 10.1042/0264-6021:3420057; Storey MK, 2001, J BIOL CHEM, V276, P48539, DOI 10.1074/jbc.M109043200; Storey MK, 2001, BBA-MOL CELL BIOL L, V1532, P234, DOI 10.1016/S1388-1981(01)00129-9; SUNDLER R, 1975, J BIOL CHEM, V250, P8585; SUNDLER R, 1975, J BIOL CHEM, V250, P3359; SUNDLER R, 1975, BIOCHEM J, V146, P309, DOI 10.1042/bj1460309; TIJBURG LBM, 1987, BIOCHIM BIOPHYS ACTA, V922, P184, DOI 10.1016/0005-2760(87)90153-6; TIJBURG LBM, 1992, METHOD ENZYMOL, V209, P258; TIJBURG LBM, 1989, BIOCHEM BIOPH RES CO, V160, P1275, DOI 10.1016/S0006-291X(89)80141-X; TROTTER PJ, 1995, J BIOL CHEM, V270, P6071, DOI 10.1074/jbc.270.11.6071; TROTTER PJ, 1995, J BIOL CHEM, V270, P6062, DOI 10.1074/jbc.270.11.6062; TROTTER PJ, 1993, J BIOL CHEM, V268, P21416; Vance JE, 1998, TRENDS BIOCHEM SCI, V23, P423, DOI 10.1016/S0968-0004(98)01297-3; VANCE JE, 1988, J BIOL CHEM, V263, P5898; VANCE JE, 1991, J BIOL CHEM, V266, P8241; VANCE JE, 1990, J BIOL CHEM, V265, P7248; VERKLEIJ AJ, 1984, CIBA F SYMP, V103, P45; VOELKER DR, 1984, P NATL ACAD SCI-BIOL, V81, P2669, DOI 10.1073/pnas.81.9.2669; Voelker DR, 1997, BBA-LIPID LIPID MET, V1348, P236, DOI 10.1016/S0005-2760(97)00101-X; VOELKER DR, 1985, J BIOL CHEM, V260, P4671; Xu Y, 2005, LAB INVEST, V85, P823, DOI 10.1038/labinvest.3700274; ZBOROWSKI J, 1983, FEBS LETT, V157, P179, DOI 10.1016/0014-5793(83)81141-7; ZELINSKI TA, 1982, CAN J BIOCHEM CELL B, V60, P817, DOI 10.1139/o82-102	63	175	176	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40032	40040		10.1074/jbc.M506510200	http://dx.doi.org/10.1074/jbc.M506510200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16192276	Green Accepted, hybrid			2022-12-25	WOS:000233461300041
J	Sagun, KC; Carcamo, JM; Golde, DW				Sagun, KC; Carcamo, JM; Golde, DW			Vitamin C enters mitochondria via facilitative glucose transporter 1 (Glut1) and confers mitochondrial protection against oxidative injury	FASEB JOURNAL			English	Article						ROS; oxidative stress; DNA damage; antioxidants; cellular redox	MYELOID-LEUKEMIA CELLS; ASCORBIC-ACID; DEHYDROASCORBIC ACID; PERMEABILITY TRANSITION; GLUTATHIONE-PEROXIDASE; PROTEIN TRANSLOCATION; TARGETING SEQUENCES; LIVER-MITOCHONDRIA; MAMMALIAN-CELLS; DNA GLYCOSYLASE	Reactive oxygen species (ROS)-induced mitochondrial abnormalities may have important consequences in the pathogenesis of degenerative diseases and cancer. Vitamin C is an important antioxidant known to quench ROS, but its mitochondrial transport and functions are poorly understood. We found that the oxidized form of vitamin C, dehydroascorbic acid (DHA), enters mitochondria via facilitative glucose transporter 1 (Glut1) and accumulates mitochondrially as ascorbic acid (mtAA). The stereo-selective mitochondrial uptake of D-glucose, with its ability to inhibit mitochondrial DHA uptake, indicated the presence of mitochondrial Glut. Computational analysis of N-termini of human Glut isoforms indicated that Glut1 had the highest probability of mitochondrial localization, which was experimentally verified via mitochondrial expression of Glut1-EGFP. In vitro mitochondrial import of Glut1, immunoblot analysis of mitochondrial proteins, and cellular immunolocalization studies indicated that Glut1 localizes to mitochondria. Loading mitochondria with AA quenched mitochondrial ROS and inhibited oxidative mitochondrial DNA damage. mtAA inhibited oxidative stress resulting from rotenone-induced disruption of the mitochondrial respiratory chain and prevented mitochondrial membrane depolarization in response to a protonophore, CCCP. Our results show that analogous to the cellular uptake, vitamin C enters mitochondria in its oxidized form via Glut1 and protects mitochondria from oxidative injury. Since mitochondria contribute significantly to intracellular ROS, protection of the mitochondrial genome and membrane may have pharmacological implications against a variety of ROS-mediated disorders.	Mem Sloan Kettering Canc Ctr, Dept Clin Labs, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol & Chem, New York, NY 10021 USA; Cornell Univ, Dept Pharmacol, Weill Med Coll, New York, NY USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University	Carcamo, JM (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Clin Labs, Box 451,1275 York Ave, New York, NY 10021 USA.	jcarcamo@enzobio.com			NCI NIH HHS [CA 30388] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA030388, R01CA030388] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarraberes FA, 2001, BBA-BIOMEMBRANES, V1513, P1, DOI 10.1016/S0304-4157(01)00005-3; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BIRNBAUM MJ, 1987, SCIENCE, V235, P1495, DOI 10.1126/science.3029870; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Cline GW, 1998, AM J PHYSIOL-ENDOC M, V274, pE381, DOI 10.1152/ajpendo.1998.274.2.E381; Croteau DL, 1997, J BIOL CHEM, V272, P25409, DOI 10.1074/jbc.272.41.25409; Daruwala R, 1999, FEBS LETT, V460, P480, DOI 10.1016/S0014-5793(99)01393-9; de Souza-Pinto NC, 2001, CANCER RES, V61, P5378; DENQ RY, 1989, FREE RADICAL BIO MED, V6, P123, DOI 10.1016/0891-5849(89)90109-3; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Enzmann H, 1999, MUTAT RES-FUND MOL M, V425, P213, DOI 10.1016/S0027-5107(99)00044-5; Esworthy RS, 1997, ARCH BIOCHEM BIOPHYS, V340, P59, DOI 10.1006/abbi.1997.9901; Frankel EN, 1996, J AGR FOOD CHEM, V44, P131, DOI 10.1021/jf950374p; Frei B, 1999, P SOC EXP BIOL MED, V222, P196, DOI 10.1046/j.1525-1373.1999.d01-136.x; FREI B, 1991, AM J CLIN NUTR, V54, pS1113, DOI 10.1093/ajcn/54.6.1113s; Genova ML, 2004, ANN NY ACAD SCI, V1011, P86, DOI 10.1196/annals.1293.010; GIULIVI C, 1995, ARCH BIOCHEM BIOPHYS, V316, P909, DOI 10.1006/abbi.1995.1122; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GRIFFITH OW, 1985, P NATL ACAD SCI USA, V82, P4668, DOI 10.1073/pnas.82.14.4668; Gruss-Fischer T, 2002, BIOCHEM PHARMACOL, V63, P1325, DOI 10.1016/S0006-2952(02)00863-8; Guaiquil VH, 1997, J BIOL CHEM, V272, P9915; Guaiquil VH, 2001, J BIOL CHEM, V276, P40955, DOI 10.1074/jbc.M106878200; HAYAKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P979, DOI 10.1016/0006-291X(92)92300-M; Henry TR, 1996, ARCH TOXICOL, V70, P482, DOI 10.1007/s002040050302; HO YS, 1988, FEBS LETT, V229, P256, DOI 10.1016/0014-5793(88)81136-0; INGEBRETSEN OC, 1982, BIOCHIM BIOPHYS ACTA, V684, P21, DOI 10.1016/0005-2736(82)90044-X; Lemasters JJ, 1999, J BIOENERG BIOMEMBR, V31, P305, DOI 10.1023/A:1005419617371; Li NY, 2003, J BIOL CHEM, V278, P8516, DOI 10.1074/jbc.M210432200; Li X, 2002, ARCH BIOCHEM BIOPHYS, V403, P103, DOI 10.1016/S0003-9861(02)00205-9; Li X, 2001, ARCH BIOCHEM BIOPHYS, V387, P143, DOI 10.1006/abbi.2000.2245; Lim MLR, 2001, FEBS LETT, V503, P69, DOI 10.1016/S0014-5793(01)02693-X; Liu Q, 2004, P NATL ACAD SCI USA, V101, P4302, DOI 10.1073/pnas.0400265101; Lutsenko EA, 2002, J BIOL CHEM, V277, P16895, DOI 10.1074/jbc.M201151200; Manel N, 2003, CELL, V115, P449, DOI 10.1016/S0092-8674(03)00881-X; MICHAELS ML, 1991, NUCLEIC ACIDS RES, V19, P3629, DOI 10.1093/nar/19.13.3629; Minamikawa T, 1999, EXP CELL RES, V246, P26, DOI 10.1006/excr.1998.4290; MYER YP, 1980, J BIOL CHEM, V255, P9666; Orth M, 2001, AM J MED GENET, V106, P27, DOI 10.1002/ajmg.1425; PACKER JE, 1979, NATURE, V278, P737, DOI 10.1038/278737a0; PADH H, 1991, NUTR REV, V49, P65, DOI 10.1111/j.1753-4887.1991.tb07407.x; Perez-Cruz I, 2003, BLOOD, V102, P336, DOI 10.1182/blood-2002-11-3559; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; PHUNG CD, 1994, ARCH BIOCHEM BIOPHYS, V315, P479, DOI 10.1006/abbi.1994.1528; Ramanathan K, 2003, J NUTR BIOCHEM, V14, P416, DOI 10.1016/S0955-2863(03)00076-7; REBOUCHE CJ, 1991, AM J CLIN NUTR, V54, pS1147, DOI 10.1093/ajcn/54.6.1147s; Rodriguez-Manzaneque MT, 2002, MOL BIOL CELL, V13, P1109, DOI 10.1091/mbc.01-10-0517; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SIES H, 1978, EUR J BIOCHEM, V84, P377, DOI 10.1111/j.1432-1033.1978.tb12178.x; Small I, 2004, PROTEOMICS, V4, P1581, DOI 10.1002/pmic.200300776; Sureda FX, 1997, CYTOMETRY, V28, P74, DOI 10.1002/(SICI)1097-0320(19970501)28:1<74::AID-CYTO9>3.0.CO;2-H; Szarka A, 2004, ARCH BIOCHEM BIOPHYS, V428, P73, DOI 10.1016/j.abb.2004.05.011; Tan XZ, 1999, CARCINOGENESIS, V20, P2287, DOI 10.1093/carcin/20.12.2287; TOMKINSON AE, 1988, J BIOL CHEM, V263, P12532; Tsukaguchi H, 1999, NATURE, V399, P70, DOI 10.1038/19986; VATASSERY GT, 1995, NEUROCHEM INT, V26, P527, DOI 10.1016/0197-0186(94)00147-M; Vatassery GT, 2004, J NEUROSCI RES, V75, P845, DOI 10.1002/jnr.20027; VERA JC, 1994, BLOOD, V84, P1628; VERA JC, 1993, NATURE, V364, P79, DOI 10.1038/364079a0; Weber A, 2000, PLANT CELL, V12, P787, DOI 10.1105/tpc.12.5.787; WELLS WW, 1990, J BIOL CHEM, V265, P15361; Witenberg B, 1999, BIOCHEM PHARMACOL, V57, P823, DOI 10.1016/S0006-2952(98)00351-7; Xu DP, 1996, J BIOENERG BIOMEMBR, V28, P77; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173	67	169	173	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					1657	1667		10.1096/fj.05-4107com	http://dx.doi.org/10.1096/fj.05-4107com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16195374				2022-12-25	WOS:000232991100043
J	Singleton, PA; Dudek, SM; Chiang, ET; Garcia, JGN				Singleton, PA; Dudek, SM; Chiang, ET; Garcia, JGN			Regulation of sphingosine 1-phosphate-induced endothelial cytoskeletal rearrangement and barrier enhancement by S1P(1) receptor, PI3 kinase, Tiam1/Rac1, and alpha-actinin	FASEB JOURNAL			English	Article						cytoskeleton; S1P; S1P(1)/Edg1 receptor; Tiam1; PI3 kinase; alpha actinin	MYOSIN LIGHT-CHAIN; PROTEIN-COUPLED RECEPTOR; LIPID RAFTS; CD44 INTERACTION; ACTIVATION; CAVEOLAE; RHO; PHOSPHORYLATION; ADHESION; RAC	Endothelial cell (EC) barrier dysfunction results in increased vascular permeability observed in inflammation, tumor angiogenesis, and atherosclerosis. The platelet-derived phospholipid sphingosine-1-phosphate (S1P) decreases EC permeability in vitro and in vivo and thus has obvious therapeutic potential. We examined S1P-mediated human pulmonary artery EC signaling and barrier regulation in caveolin-enriched microdomains (CEM). Immunoblotting from S1P-treated EC revealed S1P-mediated rapid recruitment ( 1 mu M, 5 min) to CEMs of the S1P receptors S1P(1) and S1P(3), p110 PI3 kinase alpha and beta catalytic subunits, the Rac1 GEF, Tiam1, and alpha-actinin isoforms 1 and 4. Immunoprecipitated p110 PI3 kinase catalytic subunits from S1P-treated EC exhibited PIP3 production in CEMs. Immunoprecipitation of S1P receptors from CEM fractions revealed complexes containing Tiam1 and S1P1. PI3 kinase inhibition (LY294002) attenuated S1P-induced Tiam1 association with S1P1, Tiaml/Rac1 activation, alpha-actinin-1/4 recruitment, and EC barrier enhancement. Silencing of either S1P1 or Tiam1 expression resulted in the loss of S1P-mediated Rac1 activation and alpha-actinin-1/4 recruitment to CEM. Finally, silencing S1P1, Tiam1, or both alpha-actinin isoforms 1/4 inhibits S1P-induced cortical F-actin rearrangement and S1P-mediated barrier enhancement. Taken together, these results suggest that S1P-induced recruitment of S1P1 to CEM fractions promotes PI3 kinase-mediated Tiam1/Rac1 activation required for alpha-actinin-1/4-regulated cortical actin rearrangement and EC barrier enhancement.	Johns Hopkins Univ, Div Pulm & Crit Care Med, Ctr Translat Resp Med, Sch Med, Baltimore, MD 21224 USA	Johns Hopkins University	Garcia, JGN (corresponding author), Johns Hopkins Univ, Div Pulm & Crit Care Med, Ctr Translat Resp Med, Sch Med, Baltimore, MD 21224 USA.	drgarcia@jhmi.edu	Garcia, Joe GN/E-8862-2010					Bourguignon LYW, 2003, J BIOL CHEM, V278, P29420, DOI 10.1074/jbc.M301885200; Bourguignon LYW, 2000, J BIOL CHEM, V275, P1829, DOI 10.1074/jbc.275.3.1829; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Cascone I, 2003, J BIOL CHEM, V278, P50702, DOI 10.1074/jbc.M307234200; DeMali KA, 2003, J CELL SCI, V116, P2389, DOI 10.1242/jcs.00605; Djordjevic S, 2002, TRENDS BIOCHEM SCI, V27, P426, DOI 10.1016/S0968-0004(02)02136-9; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; Dudek SM, 2004, J BIOL CHEM, V279, P24692, DOI 10.1074/jbc.M313969200; Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439; Fleming IN, 1997, J BIOL CHEM, V272, P33105, DOI 10.1074/jbc.272.52.33105; Fleming IN, 1999, J BIOL CHEM, V274, P12753, DOI 10.1074/jbc.274.18.12753; FLEMING IN, 2001, BIOCHEM J, V382, P857; Foukas LC, 2003, ARCH BIOCHEM BIOPHYS, V414, P13, DOI 10.1016/S0003-9861(03)00177-2; FRELEY TS, 2005, IN PRESS J BIOL CHEM; Fukata M, 2003, CURR OPIN CELL BIOL, V15, P590, DOI 10.1016/S0955-0674(03)00097-8; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; Garcia JGN, 1999, AM J PHYSIOL-LUNG C, V276, pL989, DOI 10.1152/ajplung.1999.276.6.L989; Glebov OO, 2004, NAT CELL BIOL, V6, P238, DOI 10.1038/ncb1103; Gratton JP, 2004, CIRC RES, V94, P1408, DOI 10.1161/01.RES.0000129178.56294.17; HANADA, 2004, BIOCHIM BIOPHYS ACTA, V1697, P3; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Harris TJC, 2002, BIOESSAYS, V24, P996, DOI 10.1002/bies.10172; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Igarashi J, 2000, J BIOL CHEM, V275, P32363, DOI 10.1074/jbc.M003075200; Jacobson JR, 2004, AM J RESP CELL MOL, V30, P662, DOI 10.1165/rcmb.2003-0267OC; Jamora C, 2002, NAT CELL BIOL, V4, pE101, DOI 10.1038/ncb0402-e101; Kawamura S, 2003, J BIOL CHEM, V278, P31111, DOI 10.1074/jbc.M300725200; Kos CH, 2003, J CLIN INVEST, V111, P1683, DOI 10.1172/JCI200317988; Lee MJ, 2001, MOL CELL, V8, P693, DOI 10.1016/S1097-2765(01)00324-0; Liu F, 2002, FASEB J, V16, P950, DOI 10.1096/fj.01-0870com; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Malliri A, 2004, J BIOL CHEM, V279, P30092, DOI 10.1074/jbc.M401192200; Martin TFJ, 2001, CURR OPIN CELL BIOL, V13, P493, DOI 10.1016/S0955-0674(00)00241-6; Mathew R, 2004, CIRCULATION, V110, P1499, DOI 10.1161/01.CIR.0000141576.39579.23; McVerry BJ, 2004, J CELL BIOCHEM, V92, P1075, DOI 10.1002/jcb.20088; Mertens AE, 2003, FEBS LETT, V546, P11, DOI 10.1016/S0014-5793(03)00435-6; Minshall RD, 2003, AM J PHYSIOL-LUNG C, V285, pL1179, DOI 10.1152/ajplung.00242.2003; O'Connell KMS, 2004, TRENDS CARDIOVAS MED, V14, P37, DOI 10.1016/j.tcm.2003.10.002; Okamoto H, 1999, BIOCHEM BIOPH RES CO, V260, P203, DOI 10.1006/bbrc.1999.0886; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; Otey CA, 2004, CELL MOTIL CYTOSKEL, V58, P104, DOI 10.1002/cm.20007; PAVALKO FM, 1991, BIOCHEM SOC T, V19, P1065, DOI 10.1042/bst0191065; Pierce SK, 2004, NAT CELL BIOL, V6, P180, DOI 10.1038/ncb0304-180; Pyne S, 2000, PHARMACOL THERAPEUT, V88, P115, DOI 10.1016/S0163-7258(00)00084-X; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Schaphorst KL, 2003, AM J PHYSIOL-LUNG C, V285, pL258, DOI 10.1152/ajplung.00311.2002; Schubert W, 2002, J BIOL CHEM, V277, P40091, DOI 10.1074/jbc.M205948200; Shikata Y, 2003, FASEB J, V17, P2240, DOI 10.1096/fj.03-0198com; Shikata Y, 2003, J APPL PHYSIOL, V94, P1193, DOI 10.1152/japplphysiol.00690.2002; Silvius JR, 2003, BBA-BIOMEMBRANES, V1610, P174, DOI 10.1016/S0005-2736(03)00016-6; Singleton PA, 2004, EXP CELL RES, V295, P102, DOI 10.1016/j.yexcr.2003.12.025; Spiegel S, 2002, LEUKEMIA, V16, P1596, DOI 10.1038/sj.leu.2402611; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; van Leeuwen FN, 2003, J BIOL CHEM, V278, P400, DOI 10.1074/jbc.M210151200; Waeber C, 2004, DRUG NEWS PERSPECT, V17, P365, DOI 10.1358/dnp.2004.17.6.829028; WOSCHOLSKI R, 1994, J BIOL CHEM, V269, P25067; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517	60	220	229	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					1646	1656		10.1096/fj.05-3928com	http://dx.doi.org/10.1096/fj.05-3928com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16195373				2022-12-25	WOS:000232991100042
J	Liu, F; Lei, W; O'Rourke, JP; Ness, SA				Liu, F; Lei, W; O'Rourke, JP; Ness, SA			Oncogenic mutations cause dramatic, qualitative changes in the transcriptional activity of c-Myb	ONCOGENE			English	Article						Myb oncogene; leukemia; hematopoiesis; differentiation; transformation	DNA-BINDING DOMAIN; V-MYB; GENE-EXPRESSION; DIFFERENTIATION; TRANSFORMATION; SPECIFICITY; PROMOTER; TARGET; TRANSACTIVATION; PRODUCT	The v-Myb oncoprotein encoded by Avian Myeloblastosis Virus is highly oncogenic, induces leukemias in chickens and mice and transforms immature hematopoietic cells in vitro. The v-Myb protein is a mutated and truncated version of c-Myb, a DNA-binding transcription factor expressed in many cell types that is essential for normal hematopoiesis. Previous studies suggested that two types of differences, DNA binding domain mutations and the deletion of a C-terminal negative regulatory domain were important for increasing the transforming activity of v-Myb. Here, we combined structure-function studies of the v-Myb and c-Myb proteins with unbiased microarray-based transcription assays to compare the transcriptional specificities of the two proteins. In human cells, the v-Myb and c-Myb proteins displayed strikingly different activities and regulated overlapping, but largely distinct sets of target genes. Each type of mutation that distinguished v-Myb from c-Myb, including the N- and C-terminal deletions, DNA binding domain changes and mutations in the transcriptional activation domain, affected different sets of target genes and contributed to the different activities of c-Myb and v-Myb. The results suggest that v-Myb is not just a de-repressed version of c-Myb. Instead, it is a distinct transcriptional regulator with a unique set of activities.	Univ New Mexico, HSC, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA	University of New Mexico	Ness, SA (corresponding author), Univ New Mexico, HSC, Dept Mol Genet & Microbiol, MSC08 4660, Albuquerque, NM 87131 USA.	ness@unm.edu	Ness, Scott/AAV-4009-2020	Ness, Scott/0000-0001-6965-8909	NATIONAL CANCER INSTITUTE [R01CA058443, P30CA118100] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA58443, P30 CA118100, R01 CA058443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Butz NV, 2004, GENE, V342, P67, DOI 10.1016/j.gene.2004.07.024; Chayka O, 2005, MOL CELL BIOL, V25, P499, DOI 10.1128/MCB.25.1.499-511.2005; Chen XY, 2004, MOL CELL BIOL, V24, P10416, DOI 10.1128/MCB.24.23.10416-10424.2004; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; DINI PW, 1995, J VIROL, V69, P2515, DOI 10.1128/JVI.69.4.2515-2524.1995; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; Epstein JA, 1998, MOL CELL BIOL, V18, P4118, DOI 10.1128/MCB.18.7.4118; Frykberg L, 1988, Oncogene Res, V3, P313; Fu SL, 1996, J VIROL, V70, P5600, DOI 10.1128/JVI.70.8.5600-5610.1996; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; GRASSER FA, 1992, ONCOGENE, V7, P1005; Hodges LC, 2003, MOL CANCER RES, V1, P300; Hou DX, 1997, FEBS LETT, V413, P60, DOI 10.1016/S0014-5793(97)00879-X; INOUE T, 1994, J BIOL CHEM, V269, P32451; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; Kouskouti A, 2004, MOL CELL, V14, P175, DOI 10.1016/S1097-2765(04)00182-0; KowenzLeutz E, 1997, CELL, V91, P185, DOI 10.1016/S0092-8674(00)80401-8; Lang G, 2005, ONCOGENE, V24, P1375, DOI 10.1038/sj.onc.1208301; Lei WL, 2005, BLOOD, V105, P3855, DOI 10.1182/blood-2004-08-3342; Lei WL, 2004, J BIOL CHEM, V279, P29519, DOI 10.1074/jbc.M403133200; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; Leverson JD, 1998, MOL CELL, V1, P203, DOI 10.1016/S1097-2765(00)80021-0; Lipsick JS, 1996, ONCOGENE, V13, P223; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Muller C, 1999, BLOOD, V94, P4255, DOI 10.1182/blood.V94.12.4255.424k32_4255_4262; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1994, CURR OPIN GENET DEV, V4, P718, DOI 10.1016/0959-437X(94)90139-T; Ness SA, 2003, BLOOD CELL MOL DIS, V31, P192, DOI 10.1016/S1079-9796(03)00151-7; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NESS SA, 1996, BIOCHIM BIOPHYS ACTA, V1288, P123; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; PLAZA S, 1995, ONCOGENE, V10, P329; Rushton JJ, 2003, ONCOGENE, V22, P308, DOI 10.1038/sj.onc.1206131; Rushton JJ, 2001, BLOOD CELL MOL DIS, V27, P459, DOI 10.1006/bcmd.2001.0405; SunHoffman L, 1996, ONCOGENE, V13, P1037; SZCZYLIK C, 1993, J EXP MED, V178, P997, DOI 10.1084/jem.178.3.997; Takahashi H, 2005, DEV GROWTH DIFFER, V47, P173; TANNO B, 2002, J BIOL CHEM, V24, P24; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TRAVALI S, 1991, ONCOGENE, V6, P887; Weston K M, 1990, Semin Cancer Biol, V1, P371; Winn LM, 2003, CELL CYCLE, V2, P258, DOI 10.4161/cc.2.3.383	43	37	37	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					795	805		10.1038/sj.onc.1209105	http://dx.doi.org/10.1038/sj.onc.1209105			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16205643				2022-12-25	WOS:000235068800014
J	Piantadosi, CA; Suliman, HB				Piantadosi, CA; Suliman, HB			Mitochondrial transcription factor A induction by redox activation of nuclear respiratory factor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE B; TUMOR-SUPPRESSOR; GENE-EXPRESSION; COPY NUMBER; DNA; BIOGENESIS; MAINTENANCE; PTEN; INACTIVATION; POLYMERASE	The nuclear expression of mitochondrial transcription factor A (Tfam), which is required for mitochondrial DNA ( mtDNA) transcription and replication, must be linked to cellular energy needs. Because respiration generates reactive oxygen species as a side-product, we tested the idea that reactive oxygen species regulate Tfam expression through phosphorylation of nuclear respiratory factor (NRF-1) and binding to the Tfam promoter. In mitochondria-rich rat hepatoma cells that overexpress NRF-1, basal and oxidant-induced increases were found in Tfam expression and mtDNA content. Specific binding of NRF-1 to Tfam promoter was demonstrated by electrophoretic mobility shift assay and chromatin immunoprecipitation. NRF-1-Tfam binding was augmented under pro-oxidant conditions. NRF-1 gene silencing produced 1:1 knockdown of Tfam expression and decreased mtDNA content. To evaluate oxidation-reduction (redox) regulation of NRF-1 in Tfam expression, blockade of upstream phosphatidylinositol 3-kinase was used to demonstrate loss of oxidant stimulation of NRF-1 phosphorylation and Tfam expression. The oxidant response was also abrogated by specific inhibition of Akt/protein kinase B. Examination of the NRF-1 amino acid sequence revealed an Akt phosphorylation consensus at which site-directed mutagenesis abolished NRF-1 phosphorylation by Akt. Finally, Akt phosphorylation and NRF-1 translocation predictably lacked oxidant regulation in a cancer line having no PTEN tumor suppressor (HCC1937 cells). This study discloses novel redox regulation of NRF-1 phosphorylation and nuclear translocation by phosphatidylinositol 3,4,5-triphosphate kinase/Akt signaling in controlling Tfam induction by an anti-oxidant pro-survival network.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	Duke University	Piantadosi, CA (corresponding author), Duke Univ, Med Ctr, Dept Med, Rm 0590,CRII Bldg,Box 3315, Durham, NC 27710 USA.	piant001@mc.duke.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL042444] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL 42444] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alam TI, 2003, NUCLEIC ACIDS RES, V31, P1640, DOI 10.1093/nar/gkg251; Bae I, 2004, CANCER RES, V64, P7893, DOI 10.1158/0008-5472.CAN-04-1119; BERRIDGE MV, 1993, ARCH BIOCHEM BIOPHYS, V303, P474, DOI 10.1006/abbi.1993.1311; Choi YS, 2002, BBA-GENE STRUCT EXPR, V1574, P200, DOI 10.1016/S0167-4781(01)00361-X; Connor KM, 2005, J BIOL CHEM, V280, P16916, DOI 10.1074/jbc.M410690200; Davis AF, 1996, NUCLEIC ACIDS RES, V24, P2753, DOI 10.1093/nar/24.14.2753; Deora AA, 1998, J BIOL CHEM, V273, P29923, DOI 10.1074/jbc.273.45.29923; DIFFLEY JFX, 1992, J BIOL CHEM, V267, P3368; Dong XC, 2002, J BIOL CHEM, V277, P43309, DOI 10.1074/jbc.M206958200; EFIOK BJS, 1994, J BIOL CHEM, V269, P18921; Efiok BJS, 2000, BBA-MOL CELL RES, V1495, P51, DOI 10.1016/S0167-4889(99)00138-X; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; FISHER RP, 1985, J BIOL CHEM, V260, P1330; FISHER RP, 1992, J BIOL CHEM, V267, P3358; FitzGerald PC, 2004, GENOME RES, V14, P1562, DOI 10.1101/gr.1953904; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399; GOPALAKRISHNAN L, 1995, J BIOL CHEM, V270, P18019, DOI 10.1074/jbc.270.30.18019; Gugneja S, 1997, J BIOL CHEM, V272, P18732, DOI 10.1074/jbc.272.30.18732; Herzig RP, 2000, J BIOL CHEM, V275, P13134, DOI 10.1074/jbc.275.17.13134; Inagaki H, 2000, DNA SEQUENCE, V11, P131, DOI 10.3109/10425170009033980; Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; LARSSON NG, 1994, BIOCHEM BIOPH RES CO, V200, P1374, DOI 10.1006/bbrc.1994.1603; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Leslie NR, 2003, EMBO J, V22, P5501, DOI 10.1093/emboj/cdg513; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Matsushima Y, 2003, J BIOL CHEM, V278, P31149, DOI 10.1074/jbc.M303842200; Miranda S, 1999, BIOCHEM BIOPH RES CO, V258, P44, DOI 10.1006/bbrc.1999.0580; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; PARISI MA, 1993, MOL CELL BIOL, V13, P1951, DOI 10.1128/MCB.13.3.1951; PARISI MA, 1991, SCIENCE, V252, P965, DOI 10.1126/science.2035027; Rantanen A, 2001, MAMM GENOME, V12, P787, DOI 10.1007/s00335-001-2052-8; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; Scarpulla RC, 2002, BBA-GENE STRUCT EXPR, V1576, P1, DOI 10.1016/S0167-4781(02)00343-3; Scarpulla RC, 1997, J BIOENERG BIOMEMBR, V29, P109, DOI 10.1023/A:1022681828846; Scully R, 2004, J MAMMARY GLAND BIOL, V9, P237, DOI 10.1023/B:JOMG.0000048771.93906.3e; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; Silva JP, 2000, NAT GENET, V26, P336, DOI 10.1038/81649; Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Suliman HB, 2003, J BIOL CHEM, V278, P41510, DOI 10.1074/jbc.M304719200; Takamatsu C, 2002, EMBO REP, V3, P451, DOI 10.1093/embo-reports/kvf099; Tomlinson GE, 1998, CANCER RES, V58, P3237; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X	48	177	182	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					324	333		10.1074/jbc.M508805200	http://dx.doi.org/10.1074/jbc.M508805200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16230352	hybrid			2022-12-25	WOS:000234307200041
J	Frieden, M; Arnaudeau, S; Castelbou, C; Demaurex, N				Frieden, M; Arnaudeau, S; Castelbou, C; Demaurex, N			Subplasmalemmal mitochondria modulate the activity of plasma membrane Ca2+-ATPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; CA2+ ENTRY; CALCIUM; APOPTOSIS; CELLS; MACHINERY; FISSION; HFIS1	Mitochondria are dynamic organelles that modulate cellular Ca2+ signals by interacting with Ca2+ transporters on the plasma membrane or the endoplasmic reticulum ( ER). To study how mitochondria dynamics affects cell Ca2+ homeostasis, we overexpressed two mitochondrial fission proteins, hFis1 and Drp1, and measured Ca2+ changes within the cytosol and the ER in HeLa cells. Both proteins fragmented mitochondria, decreased their total volume by 25 - 40%, and reduced the fraction of subplasmalemmal mitochondria by 4-fold. The cytosolic Ca2+ signals elicited by histamine were unaltered in cells lacking subplasmalemmal mitochondria as long as Ca2+ was present in the medium, but the signals were significantly blunted when Ca2+ was removed. Upon Ca2+ withdrawal, the free ER Ca2+ concentration decreased rapidly, and hFis1 cells were unable to respond to repetitive histamine stimulations. The loss of stored Ca2+ was due to an increased activity of plasma membrane Ca2+-ATPase (PMCA) pumps and was associated with an increased influx of Ca2+ and Mn2+ across store-operated Ca2+ channels. The increased Ca2+ influx compensated for the loss of stored Ca2+, and brief Ca2+ additions between successive agonist stimulations fully corrected subsequent histamine responses. We propose that the lack of subplasmalemmal mitochondria disrupts the transfer of Ca2+ from plasmamembrane channels to the ER and that the resulting increase in subplasmalemmal [ Ca2+] up-regulates the activity of PMCA. The increased Ca2+ extrusion promotes ER depletion and the subsequent activation of store-operated Ca2+ channels. Cells thus adapt to the lack of subplasmalemmal mitochondria by relying on external rather than on internal Ca2+ for signaling.	Univ Geneva, Sch Med, Dept Cell Physiol & Metab, CH-1211 Geneva 4, Switzerland	University of Geneva	Demaurex, N (corresponding author), Univ Geneva, Sch Med, Dept Cell Physiol & Metab, 1 Michel Servet, CH-1211 Geneva 4, Switzerland.	Nicolas.Demaurex@medecine.unige.ch		Frieden, Maud/0000-0001-7135-0874; Demaurex, Nicolas/0000-0002-9933-6772				Arnaudeau S, 2001, J BIOL CHEM, V276, P29430, DOI 10.1074/jbc.M103274200; Bautista DM, 2002, J PHYSIOL-LONDON, V541, P877, DOI 10.1113/jphysiol.2001.016154; Bossy-Wetzel E, 2003, CURR OPIN CELL BIOL, V15, P706, DOI 10.1016/j.ceb.2003.10.015; Brini M, 2000, EMBO J, V19, P4926, DOI 10.1093/emboj/19.18.4926; Brini M, 2003, J BIOL CHEM, V278, P24500, DOI 10.1074/jbc.M300784200; Demaurex N, 2003, SCIENCE, V300, P65, DOI 10.1126/science.1083628; DEMAUREX N, 1994, BIOCHEM J, V297, P595, DOI 10.1042/bj2970595; Filippin L, 2003, J BIOL CHEM, V278, P39224, DOI 10.1074/jbc.M302301200; Frieden M, 2004, J BIOL CHEM, V279, P22704, DOI 10.1074/jbc.M312366200; Griparic L, 2001, TRAFFIC, V2, P235, DOI 10.1034/j.1600-0854.2001.1r008.x; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; James DI, 2003, J BIOL CHEM, V278, P36373, DOI 10.1074/jbc.M303758200; Legros F, 2002, MOL BIOL CELL, V13, P4343, DOI 10.1091/mbc.E02-06-0330; Malli R, 2005, J BIOL CHEM, V280, P12114, DOI 10.1074/jbc.M409353200; Malli R, 2003, J BIOL CHEM, V278, P10807, DOI 10.1074/jbc.M212971200; Malli R, 2003, J BIOL CHEM, V278, P44769, DOI 10.1074/jbc.M302511200; Nagai T, 2004, P NATL ACAD SCI USA, V101, P10554, DOI 10.1073/pnas.0400417101; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Skulachev VP, 2001, TRENDS BIOCHEM SCI, V26, P23, DOI 10.1016/S0968-0004(00)01735-7; Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351; Szabadkai G, 2004, MOL CELL, V16, P59, DOI 10.1016/j.molcel.2004.09.026; Szabadkai G, 2004, FEBS LETT, V567, P111, DOI 10.1016/j.febslet.2004.04.059; Varadi A, 2004, CELL CALCIUM, V36, P499, DOI 10.1016/j.ceca.2004.05.003; Yaffe MP, 1999, SCIENCE, V283, P1493, DOI 10.1126/science.283.5407.1493	26	57	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					43198	43208		10.1074/jbc.M510279200	http://dx.doi.org/10.1074/jbc.M510279200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16216868	Green Published, hybrid			2022-12-25	WOS:000234200800086
J	Vagin, O; Turdikulova, S; Sachs, G				Vagin, O; Turdikulova, S; Sachs, G			Recombinant addition of N-glycosylation sites to the basolateral Na,K-ATPase beta(1) subunit results in its clustering in caveolae and apical sorting in HGT-1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H,K-ATPASE BETA-SUBUNIT; TRANS-GOLGI NETWORK; PLASMA-MEMBRANE; LIPID RAFTS; PROTEIN TRAFFICKING; EXOCYTIC PATHWAY; EPITHELIAL-CELLS; ALPHA-SUBUNIT; MECHANISMS; EXPRESSION	In most polarized cells, the Na, K-ATPase is localized on the basolateral plasma membrane. However, an unusual location of the Na, K-ATPase was detected in polarized HGT-1 cells (a human gastric adenocarcinoma cell line). The Na, K-ATPase alpha(1) subunit was detected along with the beta(2) subunit predominantly on the apical membrane, whereas the Na, K-ATPase alpha(1) subunit was not found in HGT-1 cells. However, when expressed in the same cell line, a yellow fluorescent protein-linked Na, K-ATPase alpha(1) subunit was localized exclusively to the basolateral surface and resulted in partial redistribution of the endogenous alpha(1) subunit to the basolateral membrane. The human beta(2) subunit has eight N-glycosylation sites, whereas the beta(1) isoform has only three. Accordingly, up to five additional N-glycosylation sites homologous to the ones present in the beta(2) subunit were successively introduced in the alpha(1) subunit by site-directed mutagenesis. The mutated beta(1) subunits were detected on both apical and basolateral membranes. The fraction of a mutant beta(1) subunit present on the apical membrane increased in proportion to the number of glycosylation sites inserted and reached 80% of the total surface amount for the beta(1) mutant with five additional sites. Clustered distribution and co-localization with caveolin-1 was detected by confocal microscopy for the endogenous beta(2) subunit and the beta(1) mutant with additional glycosylation sites but not for the wild type beta(1) subunit. Hence, the N-glycans linked to the beta(2) subunit of the Na, K-ATPase contain apical sorting information, and the high abundance of the beta(2) subunit isoform, which is rich in N-glycans, along with the absence of the beta(1) subunit, is responsible for the unusual apical location of the Na, K-ATPase in HGT-1 cells.	Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90073 USA; Greater Los Angeles Hlth Care Syst, Dept Vet Affairs, Los Angeles, CA 90073 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Vagin, O (corresponding author), VAGLAHS, W LA,Bldg 113,Rm 324,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.	olgav@ucla.edu	Turdikulova, Shahlo/R-7669-2016	Turdikulova, Shahlo/0000-0003-0764-2332	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK058333, R01DK058333, R01DK046917, R21DK053462] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46917, DK53462, DK58333] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Asano S, 2000, J BIOL CHEM, V275, P8324, DOI 10.1074/jbc.275.12.8324; Blanco G, 1998, AM J PHYSIOL-RENAL, V275, pF633, DOI 10.1152/ajprenal.1998.275.5.F633; Campo C, 2005, REV PHYSIOL BIOCH P, V153, P47, DOI 10.1007/s10254-004-0037-1; Caplan MJ, 1997, AM J PHYSIOL-GASTR L, V272, pG1304, DOI 10.1152/ajpgi.1997.272.6.G1304; Devarajan P, 1997, P NATL ACAD SCI USA, V94, P10711, DOI 10.1073/pnas.94.20.10711; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; Fullekrug J, 2004, ANN NY ACAD SCI, V1014, P164, DOI 10.1196/annals.1294.017; Geering K, 2001, J BIOENERG BIOMEMBR, V33, P425, DOI 10.1023/A:1010623724749; GOTTARDI CJ, 1993, J CELL BIOL, V121, P283, DOI 10.1083/jcb.121.2.283; GOTTARDI CJ, 1995, AM J PHYSIOL-RENAL, V268, pF285, DOI 10.1152/ajprenal.1995.268.2.F285; Gut A, 1998, EMBO J, V17, P1919, DOI 10.1093/emboj/17.7.1919; Hara-Kuge S, 1999, GLYCOBIOLOGY, V9, P833, DOI 10.1093/glycob/9.8.833; Hara-Kuge S, 2004, GLYCOBIOLOGY, V14, P739, DOI 10.1093/glycob/cwh082; Hara-Kuge S, 2002, J BIOL CHEM, V277, P16332, DOI 10.1074/jbc.M112188200; Helms JB, 2004, TRAFFIC, V5, P247, DOI 10.1111/j.1600-0854.2004.0181.x; Ikonen E, 1998, SEMIN CELL DEV BIOL, V9, P503, DOI 10.1006/scdb.1998.0258; KOOB R, 1988, EUR J CELL BIOL, V45, P230; Kroepfl JF, 2001, J NEUROCHEM, V77, P1301, DOI 10.1046/j.1471-4159.2001.00343.x; LABOISSE CL, 1982, CANCER RES, V42, P1541; MAYS RW, 1995, J CELL BIOL, V130, P1105, DOI 10.1083/jcb.130.5.1105; Mobasheri A, 2001, HISTOL HISTOPATHOL, V16, P141, DOI 10.14670/HH-16.141; MORROW JS, 1989, J CELL BIOL, V108, P455, DOI 10.1083/jcb.108.2.455; Mostov K, 2003, NAT CELL BIOL, V5, P287, DOI 10.1038/ncb0403-287; Muth TR, 2003, ANNU REV CELL DEV BI, V19, P333, DOI 10.1146/annurev.cellbio.19.110701.161425; Muth TR, 1998, AM J PHYSIOL-CELL PH, V274, pC688, DOI 10.1152/ajpcell.1998.274.3.C688; Nelson WJ, 2004, NAT CELL BIOL, V6, P282, DOI 10.1038/ncb0404-282; Nelson WJ, 2001, TRENDS CELL BIOL, V11, P483, DOI 10.1016/S0962-8924(01)02145-6; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Petrescu AJ, 2004, GLYCOBIOLOGY, V14, P103, DOI 10.1093/glycob/cwh008; Rodriguez-Boulan E, 2005, NAT REV MOL CELL BIO, V6, P233, DOI 10.1038/nrm1593; Rodriguez-Boulan E, 2004, CURR OPIN CELL BIOL, V16, P436, DOI 10.1016/j.ceb.2004.06.013; Rodriguez-Boulan E, 1999, TRENDS CELL BIOL, V9, P291, DOI 10.1016/S0962-8924(99)01595-0; Rudd PM, 1999, J MOL BIOL, V293, P351, DOI 10.1006/jmbi.1999.3104; Ruiz A, 1996, GENE, V176, P237, DOI 10.1016/0378-1119(96)00258-2; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; Scheiffele P, 1998, J CELL BIOL, V140, P795, DOI 10.1083/jcb.140.4.795; Schuck S, 2004, J CELL SCI, V117, P5955, DOI 10.1242/jcs.01596; Simons K, 2004, ANNU REV BIOPH BIOM, V33, P269, DOI 10.1146/annurev.biophys.32.110601.141803; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMOLKA A, 1983, AM J PHYSIOL, V245, pG589, DOI 10.1152/ajpgi.1983.245.4.G589; Traub LM, 1997, CURR OPIN CELL BIOL, V9, P527, DOI 10.1016/S0955-0674(97)80029-4; Vagin O, 2005, J BIOL CHEM, V280, P14741, DOI 10.1074/jbc.M412657200; Vagin O, 2004, J BIOL CHEM, V279, P39026, DOI 10.1074/jbc.M405453200; Vagin O, 2003, AM J PHYSIOL-CELL PH, V285, pC968, DOI 10.1152/ajpcell.00068.2003; Wilson PD, 2000, AM J PATHOL, V156, P253, DOI 10.1016/S0002-9440(10)64726-8; Wilson PD, 2004, NEW ENGL J MED, V350, P151, DOI 10.1056/NEJMra022161; Yeaman C, 1999, PHYSIOL REV, V79, P73, DOI 10.1152/physrev.1999.79.1.73	48	47	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					43159	43167		10.1074/jbc.M508262200	http://dx.doi.org/10.1074/jbc.M508262200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16230337	hybrid			2022-12-25	WOS:000234200800082
J	Zhao, H; Sun, CJ; Stewart, RJ; Waite, JH				Zhao, H; Sun, CJ; Stewart, RJ; Waite, JH			Cement proteins of the tube-building polychaete Phragmatopoma californica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENTIN PHOSPHOPROTEIN; DOPA; 5-S-CYSTEINYL-3,4-DIHYDROXYPHENYLALANINE; 3,4-DIHYDROXYPHENYLALANINE; SEQUENCE; ANNELIDA; MODEL	The mineralized tube of the sandcastle worm Phragmatopoma californica is made from exogenous mineral particles ( sand, shell, etc.) glued together with a cement secreted from the "building organ" on the thorax of the worm. The glue is a cross-linked mixture of three highly polar proteins. The complete sequences of Pc-1 ( 18 kDa) and Pc-2 ( 21 kDa) were deduced from cDNAs derived from previously reported peptide sequences (Waite, J. H., Jensen, R., and Morse, D. E. (1992) Biochemistry 31, 5733-5738). Both proteins are basic (pI similar to 10) and exhibit Gly-rich peptide repeats. The consensus repeats in Pc-1 and -2 are VGGYGYGGKK (15 times), and HPAVXHKALGGYG ( eight times), respectively, in which X denotes an intervening nonrepeated sequence and Y is modified to 3,4-dihydroxyphenyl-L- alanine ( Dopa). The third protein, Pc-3, was deduced from the cement to be about 80 mol% phosphoserine/ serine, and the cDNA was obtained by exploiting the presence of poly-serine repeats. Pc-3 consists of a family of at least seven variants with 60-90 mol % serine most of which is phosphorylated in the cement. Pc-1, -2, and -3 contain cysteine some of which reacts to form 5-S-cysteinyl-Dopa cross-links during the setting process.	Univ Calif Santa Barbara, Inst Marine Sci, Mol Cell & Dev Biol Dept, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Biochem & Chem, Santa Barbara, CA 93106 USA; Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; Utah System of Higher Education; University of Utah	Waite, JH (corresponding author), Univ Calif Santa Barbara, Inst Marine Sci, Mol Cell & Dev Biol Dept, Santa Barbara, CA 93106 USA.	waite@lifesci.ucsb.edu			NIDCR NIH HHS [DE015415] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE015415] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AGRUP G, 1976, COMMUN DEPT ANAT U L, V5, P885; BOFFARDI BP, 1993, MATER PERFORMANCE, V32, P50; Bungenberg de Jong H. G., 1949, COLLOID SCI, P433; Burzio LA, 2000, BBA-PROTEIN STRUCT M, V1479, P315, DOI 10.1016/S0167-4838(00)00010-8; Burzio LA, 2000, BIOCHEMISTRY-US, V39, P11147, DOI 10.1021/bi0002434; BYRNE BM, 1984, BIOCHEMISTRY-US, V23, P4275, DOI 10.1021/bi00314a003; Chisholm JRM, 2001, NATURE, V409, P152, DOI 10.1038/35051660; Dalsin JL, 2005, LANGMUIR, V21, P640, DOI 10.1021/la048626g; DRYHURST G, 1982, BIOL ELECTROCHEMISTR, V1, P138; FISHER LW, 1998, CURRENT ADV SKELETOG, P467; George A, 1996, J BIOL CHEM, V271, P32869, DOI 10.1074/jbc.271.51.32869; GRUET Y, 1987, CAN J ZOOL, V65, P837, DOI 10.1139/z87-133; HAWKINS CJ, 1986, ANAL BIOCHEM, V159, P187, DOI 10.1016/0003-2697(86)90326-X; ITO S, 1981, J MED CHEM, V24, P673, DOI 10.1021/jm00138a006; ITO S, 1984, BIOCHEM J, V222, P407, DOI 10.1042/bj2220407; JENSEN RA, 1988, J COMP PHYSIOL B, V158, P317, DOI 10.1007/BF00695330; JOHNSON RG, 1988, PHYSIOL REV, V68, P232, DOI 10.1152/physrev.1988.68.1.232; KUBOKI Y, 1979, J DENT RES, V58, P1926, DOI 10.1177/00220345790580092001; McDowell LM, 1999, J BIOL CHEM, V274, P20293, DOI 10.1074/jbc.274.29.20293; OHNO H, 1983, MAKROMOL CHEM, V184, P1017; PAPOV VV, 1995, J BIOL CHEM, V270, P20183, DOI 10.1074/jbc.270.34.20183; Ritchie HH, 1996, J BIOL CHEM, V271, P21695, DOI 10.1074/jbc.271.36.21695; Salzberg H.K., 1977, HDB ADHESION, V2nd, P158; Schonhorn H., 1981, ADHESION CELLULOSIC, P91, DOI [10.1007/978-1-4684-8983-5_5, DOI 10.1007/978-1-4684-8983-5_5]; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SISSON RF, 1986, NATL GEOGR, V169, P252; Stewart RJ, 2004, J EXP BIOL, V207, P4727, DOI 10.1242/jeb.01330; Takasaki S, 1997, J AGR FOOD CHEM, V45, P3472, DOI 10.1021/jf9701594; Veis A, 1970, BIOL MACROMOL, V3, P211; VOVELLE J, 1990, CAH BIOL MAR, V31, P333; Vovelle J., 1965, Archives de Zoologie Experimentale et Generale, V106, P1; WAITE JH, 1991, ANAL BIOCHEM, V192, P429, DOI 10.1016/0003-2697(91)90560-G; WAITE JH, 1995, METHOD ENZYMOL, V258, P1; Waite JH, 2002, INTEGR COMP BIOL, V42, P1172, DOI 10.1093/icb/42.6.1172; WAITE JH, 1992, BIOCHEMISTRY-US, V31, P5733, DOI 10.1021/bi00140a007; Warren KC, 1998, J HISTOCHEM CYTOCHEM, V46, P149, DOI 10.1177/002215549804600203	36	211	221	4	92	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42938	42944		10.1074/jbc.M508457200	http://dx.doi.org/10.1074/jbc.M508457200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16227622	hybrid			2022-12-25	WOS:000234200800056
J	Lu, HS; Dalgard, CL; Mohyeldin, A; McFate, T; Tait, AS; Verma, A				Lu, HS; Dalgard, CL; Mohyeldin, A; McFate, T; Tait, AS; Verma, A			Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTOR; ANTIOXIDANT DEFENSE; FACTOR 1-ALPHA; CANCER; ALPHA; PYRUVATE; ACTIVATION; EXPRESSION; ASCORBATE; PROTEIN	Continuous hydroxylation of the HIF-1 transcription factor alpha subunit by oxygen and 2-oxoglutarate-dependent dioxygenases promotes decay of this protein and thus prevents the transcriptional activation of many genes involved in energy metabolism, angiogenesis, cell survival, and matrix modification. Hypoxia blocks HIF-1 alpha hydroxylation and thus activates HIF-1 alpha-mediated gene expression. Several nonhypoxic stimuli can also activate HIF-1, although the mechanisms involved are not well known. Here we show that the glucose metabolites pyruvate and oxaloacetate inactivate HIF-1 alpha decay in a manner selectively reversible by ascorbate, cysteine, histidine, and ferrous iron but not by 2-oxoglutarate or oxygen. Pyruvate and oxaloacetate bind to the 2-oxoglutarate site of HIF-1 alpha prolyl hydroxylases, but their effects on HIF-1 are not mimicked by other Krebs cycle intermediates, including succinate and fumarate. We show that inactivation of HIF-1 hydroxylation by glucose-derived 2-oxoacids underlies the prominent basal HIF-1 activity commonly seen in many highly glycolytic cancer cells. Since HIF-1 itself promotes glycolytic metabolism, enhancement of HIF-1 by glucose metabolites may constitute a novel feed-forward signaling mechanism involved in malignant progression.	Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA	Uniformed Services University of the Health Sciences - USA	Verma, A (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Neurol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	averma@usuhs.mil		Verma, Ajay/0000-0001-7715-0443; Dalgard, Clifton/0000-0003-2025-8239	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037814] Funding Source: NIH RePORTER; NINDS NIH HHS [NS37814] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDRAE U, 1985, TOXICOL LETT, V28, P93, DOI 10.1016/0378-4274(85)90015-3; Anzellotti D, 2000, ARCH BIOCHEM BIOPHYS, V382, P161, DOI 10.1006/abbi.2000.2002; ASHCROFT SJH, 1979, BIOCHEM J, V184, P697, DOI 10.1042/bj1840697; BelAiba RS, 2004, BIOL CHEM, V385, P249, DOI 10.1515/BC.2004.019; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; CAMERON E, 1976, P NATL ACAD SCI USA, V73, P3685, DOI 10.1073/pnas.73.10.3685; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Cohen NA, 2004, LARYNGOSCOPE, V114, P418, DOI 10.1097/00005537-200403000-00006; Constantin-Teodosiu D, 1999, AM J PHYSIOL-ENDOC M, V276, pE472, DOI 10.1152/ajpendo.1999.276.3.E472; D'Angelo G, 2003, J BIOL CHEM, V278, P15406, DOI 10.1074/jbc.M211293200; Dalgard CL, 2004, BIOCHEM J, V380, P419, DOI 10.1042/BJ20031647; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Epsztejn S, 1997, ANAL BIOCHEM, V248, P31, DOI 10.1006/abio.1997.2126; Gerald D, 2004, CELL, V118, P781, DOI 10.1016/j.cell.2004.08.025; Hanauske-Abel HM, 2003, CURR MED CHEM, V10, P1005, DOI 10.2174/0929867033457601; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Hirsila M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Isaacs JS, 2005, CANCER CELL, V8, P143, DOI 10.1016/j.ccr.2005.06.017; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kaule G, 1998, MATRIX BIOL, V17, P205, DOI 10.1016/S0945-053X(98)90059-2; Knowles HJ, 2003, CANCER RES, V63, P1764; KOCH CJ, 1995, BRIT J CANCER, V72, P869, DOI 10.1038/bjc.1995.426; Koukourakis MI, 2005, NEOPLASIA, V7, P1, DOI 10.1593/neo.04373; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Li DX, 2004, J BIOL CHEM, V279, P55051, DOI 10.1074/jbc.M410287200; Lu HS, 2002, J BIOL CHEM, V277, P23111, DOI 10.1074/jbc.M202487200; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; MAJAMAA K, 1985, BIOCHEM J, V229, P127, DOI 10.1042/bj2290127; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Metzen E, 2003, MOL BIOL CELL, V14, P3470, DOI 10.1091/mbc.e02-12-0791; MISKO TP, 1993, ANAL BIOCHEM, V214, P11, DOI 10.1006/abio.1993.1449; Moeller BJ, 2004, CANCER CELL, V5, P429, DOI 10.1016/S1535-6108(04)00115-1; MYLLYLA R, 1978, BIOCHEM BIOPH RES CO, V83, P441, DOI 10.1016/0006-291X(78)91010-0; ODONNELLTORMEY J, 1987, J EXP MED, V165, P500, DOI 10.1084/jem.165.2.500; Padayatty SJ, 2004, ANN INTERN MED, V140, P533, DOI 10.7326/0003-4819-140-7-200404060-00010; Pollard PJ, 2005, HUM MOL GENET, V14, P2231, DOI 10.1093/hmg/ddi227; Rapisarda A, 2002, CANCER RES, V62, P4316; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shoichet SA, 2002, HUM MOL GENET, V11, P815, DOI 10.1093/hmg/11.7.815; Tuckerman JR, 2004, FEBS LETT, V576, P145, DOI 10.1016/j.febslet.2004.09.005; Walenta S, 2004, SEMIN RADIAT ONCOL, V14, P267, DOI 10.1016/j.semradonc.2004.04.004; Walenta S, 2004, CURR MED CHEM, V11, P2195, DOI 10.2174/0929867043364711; WARBURG O, 1930, METABOLISM TUMORS; WINKLER P, 1984, BIOCHIM BIOPHYS ACTA, V796, P226, DOI 10.1016/0005-2760(84)90121-8; Zhong H, 2001, BIOCHEM BIOPH RES CO, V284, P352, DOI 10.1006/bbrc.2001.4981	50	294	314	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					41928	41939		10.1074/jbc.M508718200	http://dx.doi.org/10.1074/jbc.M508718200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16223732	hybrid			2022-12-25	WOS:000233992700019
J	Robinson, CJ; Harmer, NJ; Goodger, SJ; Blundell, TL; Gallagher, JT				Robinson, CJ; Harmer, NJ; Goodger, SJ; Blundell, TL; Gallagher, JT			Cooperative dimerization of fibroblast growth factor 1 (FGF1) upon a single heparin saccharide may drive the formation of 2 : 2 : 1 FGF1 center dot FGFR2c center dot heparin ternary complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; HEPARIN/HEPARAN SULFATE; FACTOR RECEPTOR-1; CRYSTAL-STRUCTURE; BINDING; SPECIFICITY; LIGAND; DOMAIN; MODEL; GLYCOSYLATION	The related glycosaminoglycans heparin and heparan sulfate are essential for the activity of the fibroblast growth factor (FGF) family as they form an integral part of the signaling complex at the cell surface. Using size-exclusion chromatography we have studied the capacities of a variety of heparin oligosaccharides to bind FGF1 and FGFR2c both separately and together in ternary complexes. In the absence of heparin, FGF1 had no detectable affinity for FGFR2c. However, 2:2:1 complexes formed spontaneously in solution between FGF1, FGFR2c, and heparin octasaccharide (dp8). The dp8 sample was the shortest chain length that bound FGFR2c, that dimerized FGF1, and that promoted a strong mitogenic response to FGF1 through FGFR2c. Heparin hexasaccharide and various selectively desulfated heparin dp12s failed to bind FGFR2c and could only interact with FGF1 monomerically. These saccharides formed 1:1:1 complexes with FGF1 and FGFR2c, which had no tendency to self-associate, suggesting that binding of two FGF1 molecules to the same saccharide chain is a prerequisite for subsequent FGFR2c dimerization. We found that FGF1 dimerization upon heparin was favored over monomeric interactions even when a large excess of saccharide was present. A cooperative mechanism of FGF1 dimerization could explain how 2:2:1 signaling complexes form at the cell surface, an environment rich in heparan sulfate.	Univ Manchester, Canc Res UK, Manchester M20 4BX, Lancs, England; Univ Manchester, Dept Med Oncol, Christie Hosp NHS Trust, Manchester M20 4BX, Lancs, England; Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England	Cancer Research UK; University of Manchester; Christie NHS Foundation Trust; Christie Hospital; University of Manchester; University of Cambridge	Robinson, CJ (corresponding author), Univ Manchester, Canc Res UK, Wilmslow Rd, Manchester M20 4BX, Lancs, England.	Christopher.Robinson@manchester.ac.uk		Robinson, Christopher/0000-0001-6146-566X				Allen BL, 2003, J CELL BIOL, V163, P637, DOI 10.1083/jcb.200307053; BERGONZONI L, 1992, EUR J BIOCHEM, V210, P823, DOI 10.1111/j.1432-1033.1992.tb17485.x; Casu B, 2001, ADV CARBOHYD CHEM BI, V57, P159, DOI 10.1016/S0065-2318(01)57017-1; COPELAND RA, 1991, ARCH BIOCHEM BIOPHYS, V289, P53, DOI 10.1016/0003-9861(91)90441-K; Coumoul Xavier, 2003, Birth Defects Research, V69, P286, DOI 10.1002/bdrc.10025; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; Harmer NJ, 2004, J MOL BIOL, V339, P821, DOI 10.1016/j.jmb.2004.04.031; Ibrahimi OA, 2005, MOL CELL BIOL, V25, P671, DOI 10.1128/MCB.25.2.671-684.2005; Ibrahimi OA, 2004, BIOCHEMISTRY-US, V43, P4724, DOI 10.1021/bi0352320; Jeffers Michael, 2002, Expert Opin Ther Targets, V6, P469, DOI 10.1517/14728222.6.4.469; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; Kjellen L, 2003, BIOCHEM SOC T, V31, P340, DOI 10.1042/BST0310340; KLINT P, 1999, FRONT BIOSCI, V4, P165; Kreuger J, 1999, GLYCOBIOLOGY, V9, P723, DOI 10.1093/glycob/9.7.723; Loo BM, 2001, J BIOL CHEM, V276, P16868, DOI 10.1074/jbc.M011226200; Lyon M, 2004, J BIOL CHEM, V279, P43560, DOI 10.1074/jbc.M408510200; Lyon M, 2000, J BIOL CHEM, V275, P4599, DOI 10.1074/jbc.275.7.4599; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; Mulloy B, 2000, GLYCOBIOLOGY, V10, P1147, DOI 10.1093/glycob/10.11.1147; Murphy KJ, 2004, J BIOL CHEM, V279, P27239, DOI 10.1074/jbc.M401774200; Olsen SK, 2004, P NATL ACAD SCI USA, V101, P935, DOI 10.1073/pnas.0307287101; Ornitz DM, 2001, GENOME BIOL, V2; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; Ostrovsky O, 2002, J BIOL CHEM, V277, P2444, DOI 10.1074/jbc.M108540200; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Pellegrini L, 2001, CURR OPIN STRUC BIOL, V11, P629, DOI 10.1016/S0959-440X(00)00258-X; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; Powell AK, 2004, GLYCOBIOLOGY, V14, p17R, DOI 10.1093/glycob/cwh051; Powell AK, 2002, J BIOL CHEM, V277, P28554, DOI 10.1074/jbc.M111754200; PRESTRELSKI SJ, 1992, ARCH BIOCHEM BIOPHYS, V293, P314, DOI 10.1016/0003-9861(92)90401-H; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; Rabenstein DL, 2002, NAT PROD REP, V19, P312, DOI 10.1039/b100916h; Raman R, 2003, P NATL ACAD SCI USA, V100, P2357, DOI 10.1073/pnas.0437842100; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Sher I, 2003, FEBS LETT, V552, P150, DOI 10.1016/S0014-5793(03)00909-8; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Tuominen H, 2001, PROTEIN EXPRES PURIF, V21, P275, DOI 10.1006/prep.2000.1375; TURNBULL JE, 1991, BIOCHEM J, V273, P553, DOI 10.1042/bj2730553; Winterpacht A, 2000, PHYSIOL GENOMICS, V2, P9, DOI 10.1152/physiolgenomics.2000.2.1.9; Wu ZLL, 2003, J BIOL CHEM, V278, P17121, DOI 10.1074/jbc.M212590200; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x; Yeh BK, 2003, P NATL ACAD SCI USA, V100, P2266, DOI 10.1073/pnas.0436500100; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	48	64	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42274	42282		10.1074/jbc.M505720200	http://dx.doi.org/10.1074/jbc.M505720200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16219767	hybrid			2022-12-25	WOS:000233992700056
J	Staerk, J; Kallin, A; Demoulin, JB; Vainchenker, W; Constantinescu, SN				Staerk, J; Kallin, A; Demoulin, JB; Vainchenker, W; Constantinescu, SN			JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation - Cross-talk with IGF1 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; PROTEIN-TYROSINE KINASE; INTERFERON-ALPHA/BETA; REQUIRES PHOSPHORYLATION; THROMBOPOIETIN RECEPTOR; DOMAIN; CELLS; AUTOPHOSPHORYLATION; EXPRESSION; MECHANISM	The majority of polycythemia vera (PV) patients harbor a unique somatic mutation (V617F) in the pseudokinase domain of JAK2, which leads to constitutive signaling. Here we show that the homologous mutations in JAK1 (V658F) and in Tyk2 (V678F) lead to constitutive activation of these kinases. Their expression induces autonomous growth of cytokine-dependent cells and constitutive activation of STAT5, STAT3, mitogen-activated protein kinase, and Akt signaling in Ba/F3 cells. The mutant JAKs exhibit constitutive signaling also when expressed in fibrosarcoma cells deficient in JAK proteins. Expression of the JAK2 V617F mutant renders Ba/F3 cells hypersensitive to insulin-like growth factor 1 (IGF1), which is a hallmark of PV erythroid progenitors. Upon selection of Ba/F3 cells for autonomous growth induced by the JAK2 V617F mutant, cells respond to IGF1 by activating STAT5, STAT3, Erk1/2, and Akt on top of the constitutive activation characteristic of autonomous cells. The synergic effect on proliferation and STAT activation appears specific to the JAK2 V617F mutant. Our results show that the homologous V617F mutation induces activation of JAK1 and Tyk2, suggesting a common mechanism of activation for the JAK1, JAK2, and Tyk2 mutants. JAK3 is not activated by the homologous mutation M592F, despite the presence of the conserved GVC preceding sequence. We suggest that mutations in the JAK1 and Tyk2 genes may be identified as initial molecular defects in human cancers and autoimmune diseases.	Ludwig Inst Canc Res, B-1200 Brussels, Belgium; Catholic Univ Louvain, Christian Duve Inst Cellular Pathol, B-1200 Brussels, Belgium; Catholic Univ Louvain, MEXP Unit, B-1200 Brussels, Belgium; Inst Gustave Roussy, INSERM, U362, F-94805 Villejuif, France	Ludwig Institute for Cancer Research; Universite Catholique Louvain; Universite Catholique Louvain; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy	Constantinescu, SN (corresponding author), Ludwig Inst Canc Res, B-1200 Brussels, Belgium.	stefan.constantinescu@bru.licr.org	Demoulin, Jean-Baptiste/E-5847-2010; Constantinescu, Stefan N/E-5277-2012	Staerk, Judith/0000-0001-8698-6998; Vainchenker, William/0000-0003-4705-202X; Constantinescu, Stefan N./0000-0002-8599-2699; Demoulin, Jean-Baptiste/0000-0002-8016-6689				Argetsinger LS, 2004, MOL CELL BIOL, V24, P4955, DOI 10.1128/MCB.24.11.4955-4967.2004; Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Callus BA, 1998, BLOOD, V91, P3182, DOI 10.1182/blood.V91.9.3182.3182_3182_3192; Chang MS, 1996, DNA CELL BIOL, V15, P827, DOI 10.1089/dna.1996.15.827; Chen M, 2000, MOL CELL BIOL, V20, P947, DOI 10.1128/MCB.20.3.947-956.2000; CORREA PN, 1994, BLOOD, V83, P99; Damen JE, 1998, BLOOD, V92, P425, DOI 10.1182/blood.V92.2.425.414k08_425_433; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DELACHAPELLE A, 1993, P NATL ACAD SCI USA, V90, P4495, DOI 10.1073/pnas.90.10.4495; Dumoutier L, 2000, P NATL ACAD SCI USA, V97, P10144, DOI 10.1073/pnas.170291697; Eyckerman S, 1999, EUR CYTOKINE NETW, V10, P549; Feener EP, 2004, MOL CELL BIOL, V24, P4968, DOI 10.1128/MCB.24.11.4968-4978.2004; Feng J, 1997, MOL CELL BIOL, V17, P2497, DOI 10.1128/MCB.17.5.2497; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; Gauzzi MC, 1996, J BIOL CHEM, V271, P20494, DOI 10.1074/jbc.271.34.20494; Gual P, 1998, ENDOCRINOLOGY, V139, P884, DOI 10.1210/en.139.3.884; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Kurzer JH, 2004, MOL CELL BIOL, V24, P4557, DOI 10.1128/MCB.24.10.4557-4570.2004; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Lindauer K, 2001, PROTEIN ENG, V14, P27, DOI 10.1093/protein/14.1.27; Liu XD, 2000, ANAL BIOCHEM, V280, P20, DOI 10.1006/abio.2000.4478; Luo H, 1997, MOL CELL BIOL, V17, P1562, DOI 10.1128/MCB.17.3.1562; MIRZA AM, 1995, BLOOD, V86, P877; Mirza AM, 1997, BLOOD, V89, P1862, DOI 10.1182/blood.V89.6.1862; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Moliterno AR, 1999, BLOOD, V94, P2555, DOI 10.1182/blood.V94.8.2555.420k14_2555_2561; Moliterno AR, 1998, NEW ENGL J MED, V338, P572, DOI 10.1056/NEJM199802263380903; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; Saharinen P, 2000, MOL CELL BIOL, V20, P3387, DOI 10.1128/MCB.20.10.3387-3395.2000; Seubert N, 2003, MOL CELL, V12, P1239, DOI 10.1016/S1097-2765(03)00389-7; SOTIROPOULOS A, 1995, FEBS LETT, V369, P169, DOI 10.1016/0014-5793(95)00734-Q; VAINCHENKER W, 2003, IN PRESS HEMATOLOGY; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VELAZQUEZ L, 1995, J BIOL CHEM, V270, P3327, DOI 10.1074/jbc.270.7.3327; Yamaoka K, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-12-253; Yeh TC, 2000, P NATL ACAD SCI USA, V97, P8991, DOI 10.1073/pnas.160130297; Zhao RX, 2005, J BIOL CHEM, V280, P22788, DOI 10.1074/jbc.C500138200; Zhao ZJ, 2005, SEMIN HEMATOL, V42, P221, DOI 10.1053/j.seminhematol.2005.05.019; Zong CS, 2000, J BIOL CHEM, V275, P15099, DOI 10.1074/jbc.M000089200	41	129	183	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					41893	41899		10.1074/jbc.C500358200	http://dx.doi.org/10.1074/jbc.C500358200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16239216	hybrid			2022-12-25	WOS:000233992700015
J	Schneeweis, LA; Willard, D; Milla, ME				Schneeweis, LA; Willard, D; Milla, ME			Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-kappa B ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR RECEPTOR; OSTEOCLASTOGENESIS-INHIBITORY FACTOR; BONE-RESORPTION; EXTRACELLULAR DOMAIN; POSTMENOPAUSAL WOMEN; ESCHERICHIA-COLI; FACTOR-ALPHA; T-CELLS; DIFFERENTIATION; OSTEOPOROSIS	The receptor activator of NF-kappa B ( RANK) belongs to the neuregulin/ tumor necrosis factor (TNF) receptor superfamily and is activated by RANK ligand (RANK-L), a homotrimeric, TNF-like cytokine. RANK is present on the surface of osteoclast cell precursors, where its interaction with RANK-L induces their terminal differentiation into osteoclasts, thus increasing bone breakdown. The secreted, soluble receptor osteoprotegerin (OPG) interrupts this activation by binding directly to RANK-L. Therefore, osteoclast maturation (and bone homeostasis) is regulated in vivo by OPG levels of expression. We have studied the assembly state and affinity of OPG for RANK-L by sedimentation analyses and surface plasmon resonance (Biacore). Full- length, homodimeric OPG binds to RANK-L with a K-D of 10 nM. OPG is also a member of the TNF receptor superfamily and contains four disulfide-rich ligand-binding domains, yet lacks a transmembrane region separating the ligand-binding region from the two death domains, as observed for other receptor family members. We showed that dimerization of OPG results from noncovalent interactions mediated by the death domains and to a lesser extent by a C-terminal heparin-binding region. In contrast, a C-terminal intermolecular disulfide bond does not contribute to the formation or stability of OPG dimers. A truncate of osteoprotegerin, containing the ligand-binding domains but lacking the dimerization domains, bound RANK-L with a K-D of similar to 3 mu M, indicating that monomer oligomerization for the OPG provides an increase of 3 orders of magnitude in the affinity for RANK-L. Therefore, OPG dimer formation is required for the mechanism of inhibition of the RANK-L/RANK receptor interaction.	Univ Penn, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Johnson Res Fdn, Philadelphia, PA 19104 USA; GlaxoSmithKline Res & Dev, Dept Gene Express & Prot Biochem, Res Triangle Pk, NC 27709 USA	University of Pennsylvania; University of Pennsylvania; GlaxoSmithKline	Schneeweis, LA (corresponding author), 242 Anat Chem Bldg,3620 Hamilton Walk, Philadelphia, PA 19104 USA.	schneewe@mail.med.upenn.edu; marcos.milla@roche.com			NIDDK NIH HHS [DK067831] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK067831] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aubin JE, 2000, OSTEOPOROSIS INT, V11, P905, DOI 10.1007/s001980070028; Bekker PJ, 2001, J BONE MINER RES, V16, P348, DOI 10.1359/jbmr.2001.16.2.348; Carolino J, 1998, AM FAM PHYSICIAN, V57, P1293; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997; Furuya D, 2001, CLIN CHEM, V47, P1475; Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Idriss HT, 2000, MICROSC RES TECHNIQ, V50, P184, DOI 10.1002/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H; Ito S, 2002, J BIOL CHEM, V277, P6631, DOI 10.1074/jbc.M106525200; Katagiri T, 2002, ORAL DIS, V8, P147, DOI 10.1034/j.1601-0825.2002.01829.x; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kimbrell DA, 2001, NAT REV GENET, V2, P256, DOI 10.1038/35066006; Kong YY, 1999, IMMUNOL CELL BIOL, V77, P188, DOI 10.1046/j.1440-1711.1999.00815.x; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; LUCKOW VA, 1993, J VIROL, V67, P4566, DOI 10.1128/JVI.67.8.4566-4579.1993; Merewether LA, 2000, ARCH BIOCHEM BIOPHYS, V375, P101, DOI 10.1006/abbi.1999.1636; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; Philo JS, 2000, ANAL BIOCHEM, V279, P151, DOI 10.1006/abio.2000.4480; Rizzoli R, 2001, J MOL ENDOCRINOL, V26, P79, DOI 10.1677/jme.0.0260079; Romas E, 2002, BONE, V30, P340, DOI 10.1016/S8756-3282(01)00682-2; Schlondorff J, 2001, J BIOL CHEM, V276, P14665, DOI 10.1074/jbc.M010741200; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; South-Paul JE, 2001, AM FAM PHYSICIAN, V63, P897; Stafford WF, 1997, CURR OPIN BIOTECH, V8, P14, DOI 10.1016/S0958-1669(97)80152-8; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753; Tomoyasu A, 1998, BIOCHEM BIOPH RES CO, V245, P382, DOI 10.1006/bbrc.1998.8443; Willard D, 2000, PROTEIN EXPRES PURIF, V20, P48, DOI 10.1006/prep.2000.1278; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Yamaguchi K, 1998, J BIOL CHEM, V273, P5117, DOI 10.1074/jbc.273.9.5117; Yano K, 1999, J BONE MINER RES, V14, P518, DOI 10.1359/jbmr.1999.14.4.518; Yano K, 2001, BIOCHEM BIOPH RES CO, V288, P217, DOI 10.1006/bbrc.2001.5745; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	37	90	92	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41155	41164		10.1074/jbc.M506366200	http://dx.doi.org/10.1074/jbc.M506366200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16215261	hybrid			2022-12-25	WOS:000233866900006
J	Cadman, CJ; Lopper, M; Moon, PB; Keck, JL; McGlynn, P				Cadman, CJ; Lopper, M; Moon, PB; Keck, JL; McGlynn, P			PriB stimulates PriA helicase via an interaction with single-stranded DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STALLED REPLICATION FORKS; ESCHERICHIA-COLI K-12; PHI X174-TYPE PRIMOSOME; CRYSTAL-STRUCTURE; LAGGING-STRAND; HOMOLOGOUS RECOMBINATION; RECG HELICASE; PROTEIN PRIA; RESTART; BINDING	The frequency with which replication forks break down in all organisms requires that specific mechanisms ensure completion of genome duplication. In Escherichia coli a major pathway for reloading of the replicative apparatus at sites of fork breakdown is dependent on PriA helicase. PriA acts in conjunction with PriB and DnaT to effect loading of the replicative helicase DnaB back onto the lagging strand template, either at stalled fork structures or at recombination intermediates. Here we showed that PriB stimulates PriA helicase, acting to increase the apparent processivity of PriA. This stimulation correlates with the ability of PriB to form a ternary complex with PriA and DNA structures containing single-stranded DNA, suggesting that the known single-stranded DNA binding function of PriB facilitates unwinding by PriA helicase. This enhanced apparent processivity of PriA might play an important role in generating single-stranded DNA at stalled replication forks upon which to load DnaB. However, stimulation of PriA by PriB is not DNA structure-specific, demonstrating that targeting of stalled forks and recombination intermediates during replication restart likely resides with PriA alone.	Univ Aberdeen, Inst Med Sci, Sch Med Sci, Foresterhill, Aberdeen AB25 2ZD, Scotland; Univ Wisconsin, Sch Med, Dept Biomol Chem, Madison, WI 53706 USA	University of Aberdeen; University of Wisconsin System; University of Wisconsin Madison	McGlynn, P (corresponding author), Univ Aberdeen, Inst Med Sci, Sch Med Sci, Foresterhill, Aberdeen AB25 2ZD, Scotland.	p.mcglynn@abdn.ac.uk		Keck, James/0000-0002-5961-0220; McGlynn, Peter/0000-0001-8629-4713	MRC [G0000076] Funding Source: UKRI; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM073495] Funding Source: NIH RePORTER; Medical Research Council [G0000076] Funding Source: Medline; NIGMS NIH HHS [GM073495] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN GC, 1993, J BIOL CHEM, V268, P19204; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cadman CJ, 2004, NUCLEIC ACIDS RES, V32, P6378, DOI 10.1093/nar/gkh980; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Davey MJ, 2002, EMBO J, V21, P3148, DOI 10.1093/emboj/cdf308; Delagoutte E, 2003, Q REV BIOPHYS, V36, P1, DOI 10.1017/S0033583502003864; Gregg AV, 2002, MOL CELL, V9, P241, DOI 10.1016/S1097-2765(02)00455-0; Heller RC, 2005, MOL CELL, V17, P733, DOI 10.1016/j.molcel.2005.01.019; Heller RC, 2005, J BIOL CHEM, V280, P34143, DOI 10.1074/jbc.M507224200; Jones JM, 2001, J MOL BIOL, V312, P935, DOI 10.1006/jmbi.2001.4930; Jones JM, 1999, J MOL BIOL, V289, P503, DOI 10.1006/jmbi.1999.2783; Kogoma T, 1997, MICROBIOL MOL BIOL R, V61, P212, DOI 10.1128/.61.2.212-238.1997; Kogoma T, 1996, J BACTERIOL, V178, P1258, DOI 10.1128/jb.178.5.1258-1264.1996; Kuzminov A, 1999, MICROBIOL MOL BIOL R, V63, P751, DOI 10.1128/MMBR.63.4.751-813.1999; LASKEN RS, 1988, J BIOL CHEM, V263, P5512; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE EH, 1991, P NATL ACAD SCI USA, V88, P3029, DOI 10.1073/pnas.88.8.3029; LEE MS, 1989, J BIOL CHEM, V264, P14531; LEE MS, 1987, P NATL ACAD SCI USA, V84, P8345, DOI 10.1073/pnas.84.23.8345; Liu J, 1996, J BIOL CHEM, V271, P15656, DOI 10.1074/jbc.271.26.15656; Liu JH, 2004, J BIOL CHEM, V279, P50465, DOI 10.1074/jbc.M406773200; Lopper M, 2004, STRUCTURE, V12, P1967, DOI 10.1016/j.str.2004.09.004; Maisnier-Patin S, 2001, MOL MICROBIOL, V42, P1371, DOI 10.1046/j.1365-2958.2001.02718.x; Marians KJ, 1995, METHOD ENZYMOL, V262, P507; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; McGlynn P, 2000, NUCLEIC ACIDS RES, V28, P2324, DOI 10.1093/nar/28.12.2324; McGlynn P, 1997, J MOL BIOL, V270, P212, DOI 10.1006/jmbi.1997.1120; Ng JY, 1996, J BIOL CHEM, V271, P15642, DOI 10.1074/jbc.271.26.15642; Nurse P, 1999, J BIOL CHEM, V274, P25026, DOI 10.1074/jbc.274.35.25026; NURSE P, 1991, J BACTERIOL, V173, P6686, DOI 10.1128/jb.173.21.6686-6693.1991; PARSONS CA, 1990, J BIOL CHEM, V265, P9285; Ponomarev VA, 2003, J MOL MICROB BIOTECH, V5, P225, DOI 10.1159/000071074; Sandler SJ, 2000, GENETICS, V155, P487; Sandler SJ, 2005, GENETICS, V169, P1799, DOI 10.1534/genetics.104.036962; Sandler SJ, 1996, GENETICS, V143, P5; Sandler SJ, 2001, MOL MICROBIOL, V41, P697, DOI 10.1046/j.1365-2958.2001.02547.x; Savvides SN, 2004, PROTEIN SCI, V13, P1942, DOI 10.1110/ps.04661904; Shioi S, 2005, BIOCHEM BIOPH RES CO, V326, P766, DOI 10.1016/j.bbrc.2004.11.104; WAHLE E, 1989, J BIOL CHEM, V264, P2469; Xu LW, 2003, MOL CELL, V11, P817, DOI 10.1016/S1097-2765(03)00061-3; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4; ZAVITZ KH, 1991, J BIOL CHEM, V266, P13988	42	53	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					39693	39700		10.1074/jbc.M508521200	http://dx.doi.org/10.1074/jbc.M508521200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16188886	hybrid			2022-12-25	WOS:000233461300005
J	Forouhar, F; Lee, IN; Vujcic, J; Vujcic, S; Shen, JW; Vorobiev, SM; Xiao, R; Acton, TB; Montelione, GT; Porter, CW; Liang, T				Forouhar, F; Lee, IN; Vujcic, J; Vujcic, S; Shen, JW; Vorobiev, SM; Xiao, R; Acton, TB; Montelione, GT; Porter, CW; Liang, T			Structural and functional evidence for Bacillus subtilis PaiA as a novel N-1-spermidine/spermine acetyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERMIDINE SPERMINE N1-ACETYLTRANSFERASE; SEROTONIN N-ACETYLTRANSFERASE; BIOCHEMICAL-CHARACTERIZATION; GENOMIC IDENTIFICATION; PROTEIN; POLYAMINES; ACETYLATION; SUPERFAMILY; DIFFRACTION; MECHANISM	Bacillus subtilis PaiA has been implicated in the negative control of sporulation as well as production of degradative enzymes. PaiA shares recognizable sequence homology with N-acetyltransferases, including those that can acetylate spermidine/ spermine substrates. We have determined the crystal structure of PaiA in complex with CoA at 1.9 angstrom resolution and found that PaiA is a member of the N-acetyltransferase superfamily of enzymes. Unexpectedly, we observed the binding of an oxidized CoA dimer in the active site of PaiA, and the structural information suggests the substrates of the enzyme could be linear, positively charged compounds. Our biochemical characterization is also consistent with this possibility, since purified PaiA possesses N-1-acetyltransferase activity toward polyamine substrates including spermidine and spermine. Further, conditional overexpression of PaiA in bacteria results in increased acetylation of endogenous spermidine pools. Thus, our structural and biochemical analyses indicate that PaiA is a novel N-acetyltransferase capable of acetylating both spermidine and spermine. In this way, the pai operon may function in regulating intracellular polyamine concentrations and/or binding capabilities. In addition to preventing toxicity due to polyamine excess, this function may also serve to regulate expression of certain bacterial gene products such as those involved in sporulation.	Columbia Univ, Dept Biol Sci, NE Struct Genom Consortium, New York, NY 10027 USA; Roswell Pk Canc Inst, Dept Therapeut & Pharmacol, Buffalo, NY 14263 USA; Rutgers State Univ, Ctr Adv Biotechnol & Med, Dept Biochem & Mol Biol, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, NE Struct Genom Consortium, Piscataway, NJ 08854 USA	Columbia University; Roswell Park Cancer Institute; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center	Liang, T (corresponding author), Columbia Univ, Dept Biol Sci, NE Struct Genom Consortium, New York, NY 10027 USA.	tong@como.bio.columbia.edu		Montelione, Gaetano/0000-0002-9440-3059; Tong, Liang/0000-0002-0563-6468	NCI NIH HHS [CA16056, CA-76428] Funding Source: Medline; NIGMS NIH HHS [P50 GM62413] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076428, P30CA016056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062413] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acton TB, 2005, METHOD ENZYMOL, V394, P210, DOI 10.1016/S0076-6879(05)94008-1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen Y, 2003, BIOCHEM J, V373, P661, DOI 10.1042/BJ20030734; Copeland R. A., 2004, ENZYMES PRACTICAL IN; De Angelis J, 1998, J BIOL CHEM, V273, P3045, DOI 10.1074/jbc.273.5.3045; DeLano W, 2002, PYMOL 0 99; Doublie S, 1996, FEBS LETT, V384, P219, DOI 10.1016/0014-5793(96)00316-X; Dyda F, 2000, ANNU REV BIOPH BIOM, V29, P81, DOI 10.1146/annurev.biophys.29.1.81; FUKUCHI J, 1994, J BIOL CHEM, V269, P22581; FUKUCHI JI, 1995, J BIOL CHEM, V270, P18831, DOI 10.1074/jbc.270.32.18831; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Hickman AB, 1999, CELL, V97, P361, DOI 10.1016/S0092-8674(00)80745-X; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HONJO M, 1990, J BACTERIOL, V172, P1783, DOI 10.1128/jb.172.4.1783-1790.1990; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; Jansson M, 1996, J BIOMOL NMR, V7, P131; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LIBBY PR, 1991, ARCH BIOCHEM BIOPHYS, V284, P238, DOI 10.1016/0003-9861(91)90291-P; Liu BS, 2005, J BIOL CHEM, V280, P16659, DOI 10.1074/jbc.M414008200; Marmorstein R, 2001, J MOL BIOL, V311, P433, DOI 10.1006/jmbi.2001.4859; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Modis Y, 1998, STRUCTURE, V6, P1345, DOI 10.1016/S0969-2126(98)00134-8; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PORTER CW, 1991, CANCER RES, V51, P3715; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; SEILER N, 1987, CAN J PHYSIOL PHARM, V65, P2024, DOI 10.1139/y87-317; SHAPPELL NW, 1993, FEBS LETT, V321, P179, DOI 10.1016/0014-5793(93)80103-2; Sternglanz R, 1999, P NATL ACAD SCI USA, V96, P8807, DOI 10.1073/pnas.96.16.8807; TABOR CW, 1968, BIOCHEM BIOPH RES CO, V30, P339, DOI 10.1016/0006-291X(68)90747-X; TABOR CW, 1985, MICROBIOL REV, V49, P81, DOI 10.1128/MMBR.49.1.81-99.1985; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; Vujcic S, 2000, J BIOL CHEM, V275, P38319, DOI 10.1074/jbc.M003270200; Vujcic S, 2003, BIOCHEM J, V370, P19, DOI 10.1042/BJ20021779; Wang YL, 1998, J BIOL CHEM, V273, P34623, DOI 10.1074/jbc.273.51.34623; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504; Woolridge DP, 1999, BIOCHEM J, V340, P753, DOI 10.1042/0264-6021:3400753; Woolridge DP, 1997, J BIOL CHEM, V272, P8864; Wybenga-Groot LE, 1999, STRUCTURE, V7, P497, DOI 10.1016/S0969-2126(99)80066-5	42	53	76	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40328	40336		10.1074/jbc.M505332200	http://dx.doi.org/10.1074/jbc.M505332200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16210326	hybrid			2022-12-25	WOS:000233461300075
J	Liu, LM; Gudas, LJ				Liu, LM; Gudas, LJ			Disruption of the lecithin: Retinol acyltransferase gene makes mice more susceptible to vitamin a deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; RAT-LIVER MICROSOMES; ACID RECEPTOR-BETA; ALL-TRANS-RETINOL; BINDING-PROTEIN; CANCER CELLS; DIFFERENTIAL EXPRESSION; REDUCED EXPRESSION; DOWN-REGULATION; BREAST-CANCER	Lecithin: retinol acyltransferase (LRAT) catalyzes the esterification of retinol (vitamin A) in the liver and in some extrahepatic tissues, including the lung. We produced an LRAT gene knock-out mouse strain and assessed whether LRAT(-/-) mice were more susceptible to vitamin A deficiency than wild type (WT) mice. After maintenance on a vitamin A-deficient diet for 6 weeks, the serum retinol level was 1.34 +/- 0.32 mu M in WT mice versus 0.13 +/- 0.06 mu M in LRAT (-/-) mice (p < 0.05). In liver, lung, eye, kidney, brain, tongue, adipose tissue, skeletal muscle, and pancreas, the retinol levels ranged from 0.05 pmol/mg (muscle and tongue) to 17.35 +/- 2.66 pmol/mg (liver) in WT mice. In contrast, retinol was not detectable (< 0.007 pmol/mg) in most tissues from LRAT (-/-) mice after maintenance on a vitamin A-deficient diet for 6 weeks. Cyp26A1 mRNA was not detected in hepatic tissue samples from LRAT (-/-) mice but was detected in WT mice fed the vitamin A-deficient diet. These data indicate that LRAT (-/-) mice are much more susceptible to vitamin A deficiency and should be an excellent animal model of vitamin A deficiency. In addition, the retinol levels in serum rapidly increased in the LRAT (-/-) mice upon re-addition of vitamin A to the diet, indicating that serum retinol levels in LRAT (-/-) mice can be conveniently modulated by the quantitative manipulation of dietary retinol.	Cornell Univ, Dept Pharmacol, Weill Med Coll, New York, NY 10021 USA	Cornell University	Gudas, LJ (corresponding author), Cornell Univ, Dept Pharmacol, Weill Med Coll, 1300 York Ave, New York, NY 10021 USA.	ljgudas@med.cornell.edu			NATIONAL CANCER INSTITUTE [T32CA062948, R01CA097543] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE010389] Funding Source: NIH RePORTER; NCI NIH HHS [5R01CA097543, 5T32CA62948, T32 CA062948] Funding Source: Medline; NIDCR NIH HHS [5R01DE10389] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abu-Abed SS, 1998, J BIOL CHEM, V273, P2409, DOI 10.1074/jbc.273.4.2409; Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Aubin J, 1998, DEV DYNAM, V212, P141, DOI 10.1002/(SICI)1097-0177(199805)212:1<141::AID-AJA13>3.0.CO;2-A; Batten ML, 2004, J BIOL CHEM, V279, P10422, DOI 10.1074/jbc.M312410200; BLOMHOFF R, 1991, PHYSIOL REV, V71, P951, DOI 10.1152/physrev.1991.71.4.951; BOERMAN MHEM, 1991, J BIOL CHEM, V266, P22273; Boerman MHEM, 1996, J BIOL CHEM, V271, P5610, DOI 10.1074/jbc.271.10.5610; Boulet AM, 1996, DEV BIOL, V177, P232, DOI 10.1006/dbio.1996.0159; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen AC, 1997, CANCER RES, V57, P4642; CHYTIL F, 1992, AM J PHYSIOL, V262, pL517, DOI 10.1152/ajplung.1992.262.5.L517; DARWICHE N, 1993, CANCER RES, V53, P2287; DE LUCA LM, 1989, CANCER RES, V49, P5400; Dickman ED, 1997, DEVELOPMENT, V124, P3111; Dragnev KH, 2001, ANN NY ACAD SCI, V952, P13, DOI 10.1111/j.1749-6632.2001.tb02724.x; Duester G, 2000, EUR J BIOCHEM, V267, P4315, DOI 10.1046/j.1432-1327.2000.01497.x; Etchamendy N, 2003, BEHAV BRAIN RES, V145, P37, DOI 10.1016/S0166-4328(03)00099-8; Faria TN, 1998, MOL CELL ENDOCRINOL, V143, P155, DOI 10.1016/S0303-7207(98)00127-0; Fujii H, 1997, EMBO J, V16, P4163, DOI 10.1093/emboj/16.14.4163; Ghyselinck NB, 1999, EMBO J, V18, P4903, DOI 10.1093/emboj/18.18.4903; Gottesman ME, 2001, BIOESSAYS, V23, P409, DOI 10.1002/bies.1059; Gudas Lorraine J., 1994, P443; Guo XJ, 2002, CANCER RES, V62, P1654; Guo XJ, 2001, CANCER RES, V61, P2774; Guo XJ, 1998, CANCER RES, V58, P166; Guo XJ, 2000, CARCINOGENESIS, V21, P1925, DOI 10.1093/carcin/21.11.1925; HERR FM, 1992, BIOCHEMISTRY-US, V31, P6748, DOI 10.1021/bi00144a014; Hong Z, 2005, CANCER LETT, V217, P33, DOI 10.1016/j.canlet.2004.07.033; Li R, 2004, EXP CELL RES, V294, P290, DOI 10.1016/j.yexcr.2003.11.014; Lotan Y, 2000, J CLIN ONCOL, V18, P116, DOI 10.1200/JCO.2000.18.1.116; Manley NR, 2001, DEV BIOL, V237, P130, DOI 10.1006/dbio.2001.0365; MATSUURA T, 1993, ARCH BIOCHEM BIOPHYS, V301, P221, DOI 10.1006/abbi.1993.1137; Matsuura T, 1997, J NUTR, V127, P218, DOI 10.1093/jn/127.2.218; Molotkov A, 2002, J BIOL CHEM, V277, P13804, DOI 10.1074/jbc.M112039200; Nagy NE, 1997, J LIPID RES, V38, P645; Napoli JL, 1999, BBA-MOL CELL BIOL L, V1440, P139, DOI 10.1016/S1388-1981(99)00117-1; Napoli JL, 1996, CLIN IMMUNOL IMMUNOP, V80, pS52, DOI 10.1006/clin.1996.0142; Niles RM, 2000, NUTRITION, V16, P1084, DOI 10.1016/S0899-9007(00)00436-6; ONG DE, 1987, J BIOL CHEM, V262, P2729; Pasqualetti M, 2002, GENESIS, V32, P109, DOI 10.1002/gene.10053; Ponnamperuma RM, 1999, AM J CLIN NUTR, V70, P502; Qiu HM, 1999, AM J PATHOL, V155, P1519, DOI 10.1016/S0002-9440(10)65467-3; Quadro L, 2005, ENDOCRINOLOGY, V146, P4479, DOI 10.1210/en.2005-0158; Quadro L, 1999, EMBO J, V18, P4633, DOI 10.1093/emboj/18.17.4633; Quadro L, 2003, MOL ASPECTS MED, V24, P421, DOI 10.1016/S0098-2997(03)00038-4; RANDOLPH RK, 1991, ARCH BIOCHEM BIOPHYS, V288, P500, DOI 10.1016/0003-9861(91)90227-A; Ray WJ, 1997, J BIOL CHEM, V272, P18702, DOI 10.1074/jbc.272.30.18702; ROSS AC, 1982, J BIOL CHEM, V257, P2453; Ross AC, 2004, J NUTR, V134, p269S, DOI 10.1093/jn/134.1.269S; Ross AC, 2003, J NUTR, V133, p291S, DOI 10.1093/jn/133.1.291S; Ruiz A, 1999, J BIOL CHEM, V274, P3834, DOI 10.1074/jbc.274.6.3834; SHENAI JP, 1990, BIOL NEONATE, V57, P126, DOI 10.1159/000243172; Shimada T, 1997, ARCH BIOCHEM BIOPHYS, V344, P220, DOI 10.1006/abbi.1997.0209; Soprano DR, 2004, ANNU REV NUTR, V24, P201, DOI 10.1146/annurev.nutr.24.012003.132407; Srinivas H, 2005, MOL CELL BIOL, V25, P1054, DOI 10.1128/MCB.25.3.1054-1069.2005; STEPHENSEN CB, 1993, J NUTR, V123, P823, DOI 10.1093/jn/123.5.823; Stephensen CB, 2004, J NUTR, V134, P2660, DOI 10.1093/jn/134.10.2660; Sun SY, 2002, CRIT REV ONCOL HEMAT, V41, P41, DOI 10.1016/S1040-8428(01)00144-5; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; White JA, 1997, J BIOL CHEM, V272, P18538, DOI 10.1074/jbc.272.30.18538; Widschwendter M, 2001, J MAMMARY GLAND BIOL, V6, P193, DOI 10.1023/A:1011360724350; XU XC, 1994, CANCER RES, V54, P3580; Yamamoto Y, 2000, FASEB J, V14, P2119, DOI 10.1096/fj.00-0061com; Yen CLE, 2005, J LIPID RES, V46, P1502, DOI 10.1194/jlr.M500036-JLR200; YOST RW, 1988, J BIOL CHEM, V263, P18693; Zhang D, 2001, SCIENCE, V292, P1153, DOI 10.1126/science.1059188; Zolfaghari R, 2002, J NUTR, V132, P1160, DOI 10.1093/jn/132.6.1160	67	139	144	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40226	40234		10.1074/jbc.M509643200	http://dx.doi.org/10.1074/jbc.M509643200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16174770	hybrid			2022-12-25	WOS:000233461300064
J	Thomas, A; Allouche, M; Basyn, F; Brasseur, R; Kerfelec, B				Thomas, A; Allouche, M; Basyn, F; Brasseur, R; Kerfelec, B			Role of the lid hydrophobicity pattern in pancreatic lipase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFACIAL ACTIVATION; MEMBRANE DESTABILIZATION; LIPID-BINDING; BILE-SALTS; COLIPASE; PROTEINS; PEPTIDE; COMPLEX; INSERTION; MUTANTS	Pancreatic lipase is a soluble globular protein that must undergo structural modifications before it can hydrolyze oil droplets coated with bile salts. The binding of colipase and movement of the lipase lid open access to the active site. Mechanisms triggering lid mobility are unclear. The *KNILSQIVDIDGI* fragment of the lid of the human pancreatic lipase is predicted by molecular modeling to be a tilted peptide. Tilted peptides are hydrophobicity motifs involved in membrane fusion and more globally in perturbations of hydrophobic/hydrophilic interfaces. Analysis of this lid fragment predicts no clear consensus of secondary structure that suggests that its structure is not strongly sequence determined and could vary with environment. Point mutations were designed to modify the hydrophobicity profile of the [ 240 - 252] fragment and their consequences on the lipase-mediated catalysis were tested. Two mutants, in which the tilted peptide motif was lost, also have poor activity on bile saltcoated oil droplets and cannot be reactivated by colipase. Conversely, one mutant in which a different tilted peptide is created retains colipase dependence. These results suggest that the tilted hydrophobicity pattern of the [ 240 - 252] fragment is neither important for colipase binding to lipase, nor for interfacial binding but is important to trigger the maximal catalytic efficiency of lipase in the presence of bile salt.	Univ La Mediterranee, Fac Med, INSERM, U476,Inra UMR 1260, F-13385 Marseille, France; Fac Agron, Ctr Biophys Mol Numer, B-5030 Gembloux, Belgium	INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Kerfelec, B (corresponding author), Univ La Mediterranee, Fac Med, INSERM, U476,Inra UMR 1260, 27 Bd Jean Moulin, F-13385 Marseille, France.	Brigitte.Kerfelec@medecine.univ-mrs.fr						[Anonymous], 1972, ENZYMES; Basyn F, 2003, J MOL GRAPH MODEL, V22, P11, DOI 10.1016/S1093-3263(03)00122-0; Benetollo C, 1996, EUR J BIOCHEM, V242, P657, DOI 10.1111/j.1432-1033.1996.0657r.x; Bezzine S, 1999, BIOCHEMISTRY-US, V38, P5499, DOI 10.1021/bi982601x; BORGSTROM B, 1975, J LIPID RES, V16, P411; Brasseur R, 1997, TRENDS BIOCHEM SCI, V22, P167, DOI 10.1016/S0968-0004(97)01047-5; BRASSEUR R, 1991, J BIOL CHEM, V266, P16120; Brasseur R, 2000, MOL MEMBR BIOL, V17, P31, DOI 10.1080/096876800294461; BROCKERHOFF H, 1971, J BIOL CHEM, V246, P5828; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CARRIERE F, 1994, PROTEIN ENG, V7, P563, DOI 10.1093/protein/7.4.563; CARRIERE F, 1994, FEBS LETT, V338, P63, DOI 10.1016/0014-5793(94)80117-7; Chou KC, 1997, PROTEINS, V28, P99, DOI 10.1002/(SICI)1097-0134(199705)28:1<99::AID-PROT10>3.0.CO;2-C; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; De Caro J, 2004, BBA-PROTEINS PROTEOM, V1701, P89, DOI 10.1016/j.bbapap.2004.06.005; Ducarme P, 1998, PROTEINS, V30, P357, DOI 10.1002/(SICI)1097-0134(19980301)30:4<357::AID-PROT3>3.0.CO;2-G; ERLICH HA, 1992, PCR TECHNOLOGY PRINC; Hermoso J, 1997, EMBO J, V16, P5531, DOI 10.1093/emboj/16.18.5531; Hermoso J, 1996, J BIOL CHEM, V271, P18007, DOI 10.1074/jbc.271.30.18007; HORTH M, 1991, EMBO J, V10, P2747, DOI 10.1002/j.1460-2075.1991.tb07823.x; Jaaskelainen S, 1998, PROTEIN SCI, V7, P1359; JENNENS ML, 1994, J BIOL CHEM, V269, P25470; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambert G, 1998, EUR J BIOCHEM, V253, P328, DOI 10.1046/j.1432-1327.1998.2530328.x; Lins L, 2003, PROTEIN SCI, V12, P1406, DOI 10.1110/ps.0304803; Lins L, 2001, PROTEINS, V44, P435, DOI 10.1002/prot.1109; Nini L, 2001, BBA-MOL CELL BIOL L, V1534, P34, DOI 10.1016/S1388-1981(01)00172-X; Perez-Mendez O, 1998, EUR J BIOCHEM, V256, P570, DOI 10.1046/j.1432-1327.1998.2560570.x; Peters GH, 1997, PROTEIN ENG, V10, P137, DOI 10.1093/protein/10.2.137; Rahman M, 1997, J MOL MODEL, V3, P203, DOI 10.1007/s008940050032; Ramos P, 2003, BIOCHEMISTRY-US, V42, P12488, DOI 10.1021/bi034900e; Roussel A, 1998, J BIOL CHEM, V273, P32121, DOI 10.1074/jbc.273.48.32121; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STURLEY SL, 1994, J BIOL CHEM, V269, P21670; Sugar IP, 2001, BIOPHYS J, V81, P3387, DOI 10.1016/S0006-3495(01)75971-1; Talmud P, 1996, PROTEIN ENG, V9, P317, DOI 10.1093/protein/9.4.317; Thomas A, 2001, PROTEINS, V43, P28, DOI 10.1002/1097-0134(20010401)43:1<28::AID-PROT1014>3.3.CO;2-D; VANDERMEERS A, 1974, BIOCHIM BIOPHYS ACTA, V370, P257, DOI 10.1016/0005-2744(74)90050-3; VANTILBEURGH H, 1993, NATURE, V362, P814, DOI 10.1038/362814a0; VANTILBEURGH H, 1993, J MOL BIOL, V229, P552, DOI 10.1006/jmbi.1993.1054; Verger R, 1997, TRENDS BIOTECHNOL, V15, P32, DOI 10.1016/S0167-7799(96)10064-0; VONECHE V, 1992, P NATL ACAD SCI USA, V89, P3810, DOI 10.1073/pnas.89.9.3810; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; Yang YQ, 2000, J LIPID RES, V41, P48	44	30	31	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40074	40083		10.1074/jbc.M502123200	http://dx.doi.org/10.1074/jbc.M502123200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16179352	hybrid			2022-12-25	WOS:000233461300046
J	Henn, A; De La Cruz, EM				Henn, A; De La Cruz, EM			Vertebrate myosin VIIb is a high duty ratio motor adapted for generating and maintaining tension	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-FREE ACTIN; USHER 1B SYNDROME; KINETIC MECHANISM; FLUORESCENT-PROBE; ATPASE ACTIVITY; ACTOMYOSIN; BINDING; ADP; RELEASE; MUSCLE	Kinetic adaptation of muscle and non-muscle myosins plays a central role in defining the unique cellular functions of these molecular motor enzymes. The unconventional vertebrate class VII myosin, myosin VIIb, is highly expressed in polarized cells and localizes to highly ordered actin filament bundles such as those found in the microvilli of the intestinal brush border and kidney. We have cloned mouse myosin VIIb from a cDNA library, expressed and purified the catalytic motor domain, and characterized its actin-activated ATPase cycle using quantitative equilibrium and kinetic methods. The myosin VIIb steady-state ATPase activity is slow (similar to 1 s (-1)), activated by very low actin filament concentrations ( K-ATPase similar to 0.7 mu M), and limited by ADP release from actomyosin. The slow ADP dissociation rate constant generates a long lifetime of the strong binding actomyosin (.) ADP states. ADP and actin binding is uncoupled, which enables myosin VIIb to remain strongly bound to actin and ADP at very low actin concentrations. In the presence of 2 mM ATP and 2 mu M actin, the duty ratio of myosin VIIb is similar to 0.8. The enzymatic properties of actomyosin VIIb are suited for generating and maintaining tension and favor a role for myosin VIIb in anchoring membrane surface receptors to the actin cytoskeleton. Given the high conservation of vertebrate class VII myosins, deafness phenotypes arising from disruption of normal myosin VIIa function are likely to reflect a loss of tension in the stereocilia of inner ear hair cells.	Yale Univ, Dept Biochem & Mol Biophys, New Haven, CT 06520 USA	Yale University	De La Cruz, EM (corresponding author), Yale Univ, Dept Biochem & Mol Biophys, POB 208114,260 Whitney Ave, New Haven, CT 06520 USA.	enrique.delacruz@yale.edu	Henn, Arnon/O-1896-2019	Henn, Arnon/0000-0001-6360-7211				Altman D, 2004, CELL, V116, P737, DOI 10.1016/S0092-8674(04)00211-9; Baker JE, 2004, P NATL ACAD SCI USA, V101, P5542, DOI 10.1073/pnas.0307247101; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; Boeda B, 2002, EMBO J, V21, P6689, DOI 10.1093/emboj/cdf689; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; Chen ZY, 2001, GENOMICS, V72, P285, DOI 10.1006/geno.2000.6456; Cremo CR, 1998, BIOCHEMISTRY-US, V37, P1969, DOI 10.1021/bi9722406; De la Cruz EM, 2000, BIOCHEMISTRY-US, V39, P14196, DOI 10.1021/bi001701b; De la Cruz EM, 2000, BIOPHYS J, V79, P1524, DOI 10.1016/S0006-3495(00)76403-4; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; De La Cruz EM, 2004, CURR OPIN CELL BIOL, V16, P61, DOI 10.1016/j.ceb.2003.11.011; DE LA CRUZ EM, 1995, BIOCHEMISTRY-US, V34, P5452, DOI 10.1021/bi00016a016; De la Cruz EM, 2000, J MOL BIOL, V295, P517, DOI 10.1006/jmbi.1999.3390; De la Cruz EM, 2001, J BIOL CHEM, V276, P32373, DOI 10.1074/jbc.M104136200; Ernest S, 2000, HUM MOL GENET, V9, P2189, DOI 10.1093/hmg/9.14.2189; Etournay R, 2005, J CELL SCI, V118, P2891, DOI 10.1242/jcs.02424; GEEVES MA, 1992, PHILOS T ROY SOC B, V336, P63, DOI 10.1098/rstb.1992.0045; Geeves MA, 2005, CELL MOL LIFE SCI, V62, P1462, DOI 10.1007/s00018-005-5015-5; GIBSON F, 1995, NATURE, V374, P62, DOI 10.1038/374062a0; Hannemann DE, 2005, BIOCHEMISTRY-US, V44, P8826, DOI 10.1021/bi0473509; Inoue A, 2003, J BIOL CHEM, V278, P5478, DOI 10.1074/jbc.M210489200; Joel PB, 2003, BIOCHEMISTRY-US, V42, P9160, DOI 10.1021/bi034415j; Joel PB, 2001, J BIOL CHEM, V276, P2998, DOI 10.1074/jbc.M006930200; Liu XR, 1997, CELL MOTIL CYTOSKEL, V37, P240, DOI 10.1002/(SICI)1097-0169(1997)37:3<240::AID-CM6>3.3.CO;2-2; Nyitrai M, 2004, PHILOS T R SOC B, V359, P1867, DOI 10.1098/rstb.2004.1560; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; Petit C, 2001, ANNU REV GENOM HUM G, V2, P271, DOI 10.1146/annurev.genom.2.1.271; Robblee JP, 2004, J BIOL CHEM, V279, P38608, DOI 10.1074/jbc.M403504200; Rock RS, 2001, P NATL ACAD SCI USA, V98, P13655, DOI 10.1073/pnas.191512398; Rosenfeld SS, 2003, J BIOL CHEM, V278, P27449, DOI 10.1074/jbc.M302555200; ROTH K, 1991, MAGNET RESON MED, V22, P505, DOI 10.1002/mrm.1910220258; Sakamoto T, 2000, BIOCHEM BIOPH RES CO, V272, P586, DOI 10.1006/bbrc.2000.2819; Tamagawa Y, 2002, ADV OTO-RHINO-LARYNG, V61, P79; Tuxworth RI, 2001, CURR BIOL, V11, P318, DOI 10.1016/S0960-9822(01)00097-5; Uemura S, 2004, NAT STRUCT MOL BIOL, V11, P877, DOI 10.1038/nsmb806; Wang F, 2003, J BIOL CHEM, V278, P27439, DOI 10.1074/jbc.M302510200; Weil D, 1996, P NATL ACAD SCI USA, V93, P3232, DOI 10.1073/pnas.93.8.3232; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; White HD, 1997, BIOCHEMISTRY-US, V36, P11828, DOI 10.1021/bi970540h; Williams DS, 2002, VISION RES, V42, P455, DOI 10.1016/S0042-6989(01)00228-0; Yang Y, 2005, J BIOL CHEM, V280, P32061, DOI 10.1074/jbc.M506765200; Zeng W, 2004, PHILOS T R SOC B, V359, P1843, DOI 10.1098/rstb.2004.1527	42	58	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39665	39676		10.1074/jbc.M507667200	http://dx.doi.org/10.1074/jbc.M507667200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16186105	hybrid			2022-12-25	WOS:000233362200090
J	Kaul, SC; Aida, S; Yaguchi, T; Kaur, K; Wadhwa, R				Kaul, SC; Aida, S; Yaguchi, T; Kaur, K; Wadhwa, R			Activation of wild type p53 function by its mortalin-binding, cytoplasmically localizing carboxyl terminus peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR P53; HSP70 FAMILY; NUCLEAR EXPORT; CANCER-CELLS; PATHWAY; SEQUESTRATION; INACTIVATION; MUTATIONS; APOPTOSIS; MOUSE	The Hsp70 family member mortalin (mot-2/mthsp70/GRP75) binds to a carboxyl terminus region of the tumor suppressor protein p53. By in vivo co-immunoprecipitation of mot-2 with p53 and its deletion mutants, we earlier mapped the mot-2-binding site of p53 to its carboxyl terminus 312-352 amino acid residues. In the present study we attempted to disrupt mot-2-p53 interactions by overexpression of short p53 carboxyl-terminal peptides. We report that p53 carboxyl-terminal peptides ( amino acid residues 312-390, 312-352, 323-390, and 323-352) localize in the cytoplasm, whereas 312-322, 337-390, 337-352, and 352-390 locate mostly in the nucleus. Most interestingly, the cytoplasmically localizing p53 peptides harboring the residues 323-337 activated the endogenous p53 function by displacing it from p53-mortalin complexes and relocating it to the nucleus. Such activation of p53 function was sufficient to cause growth arrest of human osteosarcoma and breast carcinoma cells.	Natl Inst Adv Ind Sci & Technol, Gene Funct Res Ctr, Tsukuba, Ibaraki 3058562, Japan	National Institute of Advanced Industrial Science & Technology (AIST)	Wadhwa, R (corresponding author), Natl Inst Adv Ind Sci & Technol, Gene Funct Res Ctr, 1-1-1 Higashi, Tsukuba, Ibaraki 3058562, Japan.	renu-wadhwa@aist.go.jp	Kaul, Sunil C/L-8671-2018; Wadhwa, Renu/L-8898-2018	Kaul, Sunil C/0000-0002-0046-3916; Wadhwa, Renu/0000-0001-8248-5192				BOSARI S, 1995, AM J PATHOL, V147, P790; Brown JM, 1999, CANCER RES, V59, P1391; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Duncan EL, 2000, BIOGERONTOLOGY, V1, P103, DOI 10.1023/A:1010000132671; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; Hasan MK, 2002, J BIOL CHEM, V277, P37765, DOI 10.1074/jbc.M204177200; Haupt S, 2003, J CELL BIOCHEM, V88, P76, DOI 10.1002/jcb.10311; Hollstein M, 1997, Recent Results Cancer Res, V143, P369; Javelaud D, 2002, J BIOL CHEM, V277, P37949, DOI 10.1074/jbc.M204497200; Kaul SC, 2002, EXP GERONTOL, V37, P1157, DOI 10.1016/S0531-5565(02)00135-3; Kaul SC, 2001, NEOPLASIA, V3, P110, DOI 10.1038/sj.neo.7900139; KAUL SC, 1994, BBA-GEN SUBJECTS, V1201, P389, DOI 10.1016/0304-4165(94)90067-1; Koivusalo R, 2002, CANCER RES, V62, P7364; Lane D, 2004, CARCINOGENESIS, V25, P1077, DOI 10.1093/carcin/bgh186; Lee TKW, 2004, ONCOL REP, V12, P25; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Levine AJ, 1995, ANN NY ACAD SCI, V768, P111, DOI 10.1111/j.1749-6632.1995.tb12115.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MERRICK BA, 1996, BIOCHIM BIOPHYS ACTA, V13, P57; Middeler G, 1997, ONCOGENE, V14, P1407, DOI 10.1038/sj.onc.1200949; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Murphy ME, 2004, CELL CYCLE, V3, P836; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; O'Brate A, 2003, DRUG RESIST UPDATE, V6, P313, DOI 10.1016/j.drup.2003.10.004; Perfettini JL, 2004, NAT CELL BIOL, V6, P386, DOI 10.1038/ncb0504-386; Sembritzki O, 2002, NEURO-ONCOLOGY, V4, P171, DOI 10.1093/neuonc/4.3.171; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sugrue MM, 2001, BIOL SIGNAL RECEPT, V10, P176; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Tweddle DA, 2003, CANCER LETT, V197, P93, DOI 10.1016/S0304-3835(03)00088-0; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vousden KH, 2000, NAT CELL BIOL, V2, pE178, DOI 10.1038/35036427; WADHWA R, 1993, J BIOL CHEM, V268, P6615; Wadhwa R, 1998, J BIOL CHEM, V273, P29586, DOI 10.1074/jbc.273.45.29586; Wadhwa R, 2004, HISTOL HISTOPATHOL, V19, P311, DOI 10.14670/HH-19.311; Wadhwa R, 2002, EXP CELL RES, V274, P246, DOI 10.1006/excr.2002.5468; Wadhwa R, 2000, CANCER RES, V60, P6818; Zhang YP, 2001, CELL GROWTH DIFFER, V12, P175; Zhao LY, 2003, J VIROL, V77, P13171, DOI 10.1128/JVI.77.24.13171-13181.2003	43	103	108	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39373	39379		10.1074/jbc.M500022200	http://dx.doi.org/10.1074/jbc.M500022200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16176931	hybrid			2022-12-25	WOS:000233362200058
J	Rattan, R; Giri, S; Singh, AK; Singh, I				Rattan, R; Giri, S; Singh, AK; Singh, I			5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MTOR SIGNALING PATHWAY; PEUTZ-JEGHERS-SYNDROME; FATTY-ACID OXIDATION; N-TERMINAL KINASE; INDUCED APOPTOSIS; PERMEABLE ACTIVATOR; MAMMALIAN TARGET; RIBONUCLEOSIDE; SURVIVAL; GROWTH	5-Aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside ( AICAR) is widely used as an AMP-kinase activator, which regulates energy homeostasis and response to metabolic stress. Here, we investigated the effect of AICAR, an AMPK activator, on proliferation of various cancer cells and observed that proliferation of all the examined cell lines was significantly inhibited by AICAR treatment due to arrest in S-phase accompanied with increased expression of p21, p27, and p53 proteins and inhibition of PI3K-Akt pathway. Inhibition in in vitro growth of cancer cells was mirrored in vivo with increased expression of p21, p27, and p53 and attenuation of Akt phosphorylation. Anti-proliferative effect of AICAR is mediated through activated AMP-activated protein kinase ( AMPK) as iodotubericidin and dominant-negative AMPK expression vector reversed the AICAR-mediated growth arrest. Moreover, constitutive active AMPK arrested the cells in S-phase by inducing the expression of p21, p27, and p53 proteins and inhibiting Akt phosphorylation, suggesting the involvement of AMPK. AICAR inhibited proliferation in both LKB and LKB knock-out mouse embryo fibroblasts to similar extent and arrested cells at S-phase when transfected with dominant negative expression vector of LKB. Altogether, these results indicate that AICAR can be utilized as a therapeutic drug to inhibit cancer, and AMPK can be a potential target for treatment of various cancers independent of the functional tumor suppressor gene, LKB.	Med Univ S Carolina, Childrens Res Inst, Dept Pediat, Charleston, SC 29425 USA; Ralph Johnson Vet Affairs Med Ctr, Dept Pathol & Lab Med, Charleston, SC 29425 USA	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Singh, I (corresponding author), Med Univ S Carolina, Childrens Res Inst, Dept Pediat, 173 Ashley Ave,5th Floor, Charleston, SC 29425 USA.	singhi@musc.edu	Singh, Ashok/HGF-2506-2022		NINDS NIH HHS [NS-37766, NS-34741, NS-40144, NS-40810, NS-22576] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037766, R01NS040144, R37NS022576, R01NS022576, R01NS040810, R01NS034741] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Blazquez C, 2001, FEBS LETT, V489, P149, DOI 10.1016/S0014-5793(01)02089-0; Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; Culmsee C, 2001, J MOL NEUROSCI, V17, P45, DOI 10.1385/JMN:17:1:45; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Forcet C, 2005, HUM MOL GENET, V14, P1283, DOI 10.1093/hmg/ddi139; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; Giocanti N, 2004, BRIT J CANCER, V91, P2026, DOI 10.1038/sj.bjc.6602242; Giri S, 2004, J IMMUNOL, V173, P5196, DOI 10.4049/jimmunol.173.8.5196; Giri S, 2004, J NEUROSCI, V24, P479, DOI 10.1523/JNEUROSCI.4288-03.2004; Hardie DG, 2003, FEBS LETT, V546, P113, DOI 10.1016/S0014-5793(03)00560-X; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Harrington LS, 2005, TRENDS BIOCHEM SCI, V30, P35, DOI 10.1016/j.tibs.2004.11.003; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Ido Y, 2002, DIABETES, V51, P159, DOI 10.2337/diabetes.51.1.159; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Jung JE, 2004, NEUROSCI LETT, V354, P197, DOI 10.1016/j.neulet.2003.10.012; Kato K, 2002, ONCOGENE, V21, P6082, DOI 10.1038/sj.onc.1205737; Kefas BA, 2003, J MOL ENDOCRINOL, V30, P151, DOI 10.1677/jme.0.0300151; Kelly M, 2004, BIOCHEM BIOPH RES CO, V320, P449, DOI 10.1016/j.bbrc.2004.05.188; Kemp BE, 2003, BIOCHEM SOC T, V31, P162; Kimura N, 2003, GENES CELLS, V8, P65, DOI 10.1046/j.1365-2443.2003.00615.x; Li J, 2003, CARCINOGENESIS, V24, P827, DOI 10.1093/carcin/bgg032; Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007; Luo ZJ, 2005, TRENDS PHARMACOL SCI, V26, P69, DOI 10.1016/j.tips.2004.12.011; Meisse D, 2002, FEBS LETT, V526, P38, DOI 10.1016/S0014-5793(02)03110-1; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Nakanishi C, 2004, ONCOLOGY-BASEL, V67, P476, DOI 10.1159/000082933; Nath N, 2004, J IMMUNOL, V172, P1273, DOI 10.4049/jimmunol.172.2.1273; Nath N, 2005, J IMMUNOL, V175, P566, DOI 10.4049/jimmunol.175.1.566; Nishino Y, 2004, CARDIOVASC RES, V61, P610, DOI 10.1016/j.cardiores.2003.10.022; Parsa AT, 2000, NEUROSURGERY, V47, P993, DOI 10.1097/00006123-200010000-00050; Ruderman NB, 2003, ACTA PHYSIOL SCAND, V178, P435, DOI 10.1046/j.1365-201X.2003.01164.x; Russell RR, 2004, J CLIN INVEST, V114, P495, DOI 10.1172/JCI200419297; Saitoh M, 2004, BIOCHEM PHARMACOL, V67, P2005, DOI 10.1016/j.bcp.2004.01.020; Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x; Stefanelli C, 1998, BIOCHEM BIOPH RES CO, V243, P821, DOI 10.1006/bbrc.1998.8154; SULLIVAN JE, 1994, FEBS LETT, V353, P33, DOI 10.1016/0014-5793(94)01006-4; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Xiang XQ, 2004, BIOCHEM BIOPH RES CO, V321, P161, DOI 10.1016/j.bbrc.2004.06.133; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788	46	314	330	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39582	39593		10.1074/jbc.M507443200	http://dx.doi.org/10.1074/jbc.M507443200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16176927	hybrid			2022-12-25	WOS:000233362200081
J	Muraoka-Cook, RS; Shin, I; Yi, JY; Easterly, E; Barcellos-Hoff, MH; Yingling, JM; Zent, R; Arteaga, CL				Muraoka-Cook, R. S.; Shin, I.; Yi, J. Y.; Easterly, E.; Barcellos-Hoff, M. H.; Yingling, J. M.; Zent, R.; Arteaga, C. L.			Activated type I TGF beta receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression	ONCOGENE			English	Article						TGF beta; mammary cancer; transgenic mice; PI-3 kinase; involution; oncogenes	GROWTH-FACTOR-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1 TRANSGENE; SIGNAL-TRANSDUCTION; GLAND INVOLUTION; C-MYC; PHOSPHATIDYLINOSITOL 3-KINASE; MESENCHYMAL TRANSITION; TGF-BETA-1 EXPRESSION; CANCER-CELLS; MICE	We have examined the effects of transforming growth factor-beta (TGF beta) signaling on mammary epithelial cell survival. Transgenic mice expressing an active mutant of Alk5 in the mammary gland (MMTV-Alk5(T204D)) exhibited reduced apoptosis in terminal endbuds and during postlactational involution. Transgene-expressing mammary cells contained lower Smad2/3 and higher c-myc levels than controls, high ligand-independent phosphatidylinositol-3 kinase (PI3K) and Akt activities, and were insensitive to TGF beta-mediated growth arrest. Treatment with a proteasome inhibitor increased Smad2/3 levels and ligand-independent Smad transcriptional reporter activity, as well as reduced both c-myc protein and basal cell proliferation. Treatment with an Alk5 kinase small-molecule inhibitor upregulated Smad2/3 levels, reduced PI3K activity, P-Akt, and c-myc, and inhibited cell survival. Although Alk5(T204D)-expressing mice did not develop mammary tumors, bigenic MMTV-Alk(T204D) x Neu mice developed cancers that were more metastatic than those occurring in MMTV-Neu transgenics. These data suggest that (1) TGF beta can signal to PI3K/Akt and enhance mammary epithelial cell survival in vivo before cytological or histological evidence of transformation, and (2) TGF beta signaling can provide epithelial cells with a 'gain-of-function' effect that synergizes with oncogene-induced transformation.	Vanderbilt Univ, Sch Med, Div Oncol, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA; Vet Affairs Hosp, Dept Med Res, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Breast Canc Res Program, Nashville, TN 37232 USA; Hanyang Univ, Dept Life Sci, Seoul 133791, South Korea	Vanderbilt University; Vanderbilt University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Eli Lilly; Vanderbilt University; Hanyang University	Arteaga, CL (corresponding author), Vanderbilt Univ, Sch Med, Div Oncol, Dept Canc Biol, 2220 Pierce Ave,777 Preston Res Bldg, Nashville, TN 37232 USA.	carlos.arteaga@vanderbilt.edu	Yin, Ji-Ye/AAE-6794-2020		NCI NIH HHS [P50 CA98131, R01 CA80195, R010 CA62212, P30 CA68485] Funding Source: Medline; NIA NIH HHS [R01 AG022413] Funding Source: Medline; NIDDK NIH HHS [R01 DK069921] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA098131, P30CA068485, R01CA062212, R01CA080195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK069921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG022413] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ackler S, 2002, ONCOGENE, V21, P198, DOI 10.1038/sj.onc.1205052; Adams J, 2004, CANCER CELL, V5, P417, DOI 10.1016/S1535-6108(04)00120-5; ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Bottinger EP, 1997, CANCER RES, V57, P5564; Boulanger CA, 2005, ONCOGENE, V24, P552, DOI 10.1038/sj.onc.1208185; Carpenter CL, 1997, ADV ENZYME REGUL, V37, P377, DOI 10.1016/S0065-2571(96)00005-2; Charng MJ, 1996, J BIOL CHEM, V271, P22941, DOI 10.1074/jbc.271.38.22941; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Conery AR, 2004, NAT CELL BIOL, V6, P366, DOI 10.1038/ncb1117; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; Datto MB, 1999, MOL CELL BIOL, V19, P2495; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Dumon N, 2003, J BIOL CHEM, V278, P3275, DOI 10.1074/jbc.M204623200; Ehrhart EJ, 1997, FASEB J, V11, P991, DOI 10.1096/fasebj.11.12.9337152; Engle SJ, 1999, CANCER RES, V59, P3379; Ewan KB, 2002, AM J PATHOL, V160, P2081, DOI 10.1016/S0002-9440(10)61158-3; Forrester E, 2005, CANCER RES, V65, P2296, DOI 10.1158/0008-5472.CAN-04-3272; Glick AB, 1996, CANCER RES, V56, P3645; Gorska AE, 2003, AM J PATHOL, V163, P1539, DOI 10.1016/S0002-9440(10)63510-9; Gotzmann J, 2002, J CELL SCI, V115, P1189; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Higaki M, 1999, ARTERIOSCL THROM VAS, V19, P2127, DOI 10.1161/01.ATV.19.9.2127; Horowitz JC, 2004, J BIOL CHEM, V279, P1359, DOI 10.1074/jbc.M306248200; Huang Y, 2000, J BIOL CHEM, V275, P18234, DOI 10.1074/jbc.M909431199; Hutchinson J, 2001, MOL CELL BIOL, V21, P2203, DOI 10.1128/MCB.21.6.2203-2212.2001; JHAPPAN C, 1993, EMBO J, V12, P1835, DOI 10.1002/j.1460-2075.1993.tb05832.x; KORDON EC, 1995, DEV BIOL, V168, P47, DOI 10.1006/dbio.1995.1060; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Muraoka RS, 2003, MOL CELL BIOL, V23, P8691, DOI 10.1128/MCB.23.23.8691-8703.2003; Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234; Muraoka RS, 2002, MOL CELL BIOL, V22, P2204, DOI 10.1128/MCB.22.7.2204-2219.2002; Muraoka RS, 2001, J CELL BIOL, V153, P917, DOI 10.1083/jcb.153.5.917; Muraoka-Cook RS, 2004, CANCER RES, V64, P9002, DOI 10.1158/0008-5472.CAN-04-2111; Nguyen AV, 2000, DEVELOPMENT, V127, P3107; Peng SB, 2005, BIOCHEMISTRY-US, V44, P2293, DOI 10.1021/bi048851x; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; PIERCE DF, 1993, GENE DEV, V7, P2308, DOI 10.1101/gad.7.12a.2308; Remy I, 2004, NAT CELL BIOL, V6, P358, DOI 10.1038/ncb1113; Sawyer JS, 2004, BIOORG MED CHEM LETT, V14, P3581, DOI 10.1016/j.bmcl.2004.04.007; Schwertfeger KL, 2001, MOL ENDOCRINOL, V15, P867, DOI 10.1210/me.15.6.867; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shin I, 2001, MOL BIOL CELL, V12, P3328, DOI 10.1091/mbc.12.11.3328; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100; Stambolic V, 2000, CANCER RES, V60, P3605; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Yang YA, 2002, CELL GROWTH DIFFER, V13, P123; Yi JY, 2005, J BIOL CHEM, V280, P10870, DOI 10.1074/jbc.M413223200	58	113	119	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2006	25	24					3408	3423		10.1038/sj.onc.1208964	http://dx.doi.org/10.1038/sj.onc.1208964			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16186809				2022-12-25	WOS:000238448100006
J	Iwase, R; Imada, K; Hayashi, F; Uzumaki, T; Morishita, M; Onai, K; Furukawa, Y; Namba, K; Ishiura, M				Iwase, R; Imada, K; Hayashi, F; Uzumaki, T; Morishita, M; Onai, K; Furukawa, Y; Namba, K; Ishiura, M			Functionally important substructures of circadian clock protein KaiB in a unique tetramer complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNECHOCOCCUS-ELONGATUS; CRYSTAL-STRUCTURE; BINDING; BIOLUMINESCENCE; PROGRAM	KaiB is a component of the circadian clock molecular machinery in cyanobacteria, which are the simplest organisms that exhibit circadian rhythms. Here we report the x-ray crystal structure of KaiB from the thermophilic cyanobacterium Thermosynechococcus elongatus BP-1. The KaiB crystal diffracts at a resolution of 2.6 angstrom and includes four subunits organized as a dimer of dimers, each composed of two non-equivalent subunits. The overall shape of the tetramer is an elongated hexagonal plate, with a single positively charged cleft flanked by two negatively charged ridges whose surfaces includes several terminal chains. Site-directed mutagenesis of Synechococcus KaiB confirmed that alanine substitution of residues Lys-11 or Lys-43 in the cleft, or deletion of C-terminal residues 95 - 108, which forms part of the ridges, strongly weakens in vivo circadian rhythms. Characteristics of KaiB deduced from the x-ray crystal structure were also confirmed by physicochemical measurements of KaiB in solution. These data suggest that the positively charged cleft and flanking negatively charged ridges in KaiB are essential for the biological function of KaiB in the circadian molecular machinery in cyanobacteria.	Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan; Nagoya Univ, Biooriented Technol Res Adv Inst, BRAIN, Nagoya, Aichi 4648602, Japan; Nagoya Univ, Grad Sch Sci, Ctr Gene Res, Nagoya, Aichi 4648602, Japan; Nagoya Univ, Grad Sch Sci, Div Biol Sci, Nagoya, Aichi 4648602, Japan; Japan Sci & Technol Agcy, Dynam NanoMachine Project, Int Cooperat Res Project, Suita, Osaka 5650871, Japan	Osaka University; Nagoya University; Nagoya University; Nagoya University; Japan Science & Technology Agency (JST)	Namba, K (corresponding author), Osaka Univ, Grad Sch Frontier Biosci, 1-3 Yamadaoka, Suita, Osaka 5650871, Japan.	keiichi@fbs.osaka-u.ac.jp; ishiura@gene.nagoya-u.ac.jp	Namba, Keiichi/A-9406-2016	Imada, Katsumi/0000-0003-1342-8885; Onai, Kiyoshi/0000-0001-9062-2548				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Fadouloglou VE, 2004, P NATL ACAD SCI USA, V101, P70, DOI 10.1073/pnas.0304579101; Garces RG, 2004, EMBO J, V23, P1688, DOI 10.1038/sj.emboj.7600190; Hayashi F, 2004, BIOCHEM BIOPH RES CO, V316, P195, DOI 10.1016/j.bbrc.2004.02.034; Hayashi F, 2003, GENES CELLS, V8, P287, DOI 10.1046/j.1365-2443.2003.00633.x; Ishiura M, 1998, SCIENCE, V281, P1519, DOI 10.1126/science.281.5382.1519; Iwasaki H, 2002, P NATL ACAD SCI USA, V99, P15788, DOI 10.1073/pnas.222467299; Iwasaki H, 1999, EMBO J, V18, P1137, DOI 10.1093/emboj/18.5.1137; Iwase R, 2004, ACTA CRYSTALLOGR D, V60, P727, DOI 10.1107/S0907444904002112; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mori T, 2002, P NATL ACAD SCI USA, V99, P17203, DOI 10.1073/pnas.262578499; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nishimura H, 2002, MICROBIOL-SGM, V148, P2903, DOI 10.1099/00221287-148-9-2903; Nishiwaki T, 2000, P NATL ACAD SCI USA, V97, P495, DOI 10.1073/pnas.97.1.495; Okamoto K, 2005, ANAL BIOCHEM, V340, P193, DOI 10.1016/j.ab.2004.11.007; Okamoto K, 2005, ANAL BIOCHEM, V340, P187, DOI 10.1016/j.ab.2004.11.009; Onai K, 2004, MOL GENET GENOMICS, V271, P50, DOI 10.1007/s00438-003-0953-9; Onai M, 2004, J BACTERIOL, V186, P4972, DOI 10.1128/JB.186.15.4972-4977.2004; Pattanayek R, 2004, MOL CELL, V15, P375, DOI 10.1016/j.molcel.2004.07.013; Taniguchi Y, 2001, FEBS LETT, V496, P86, DOI 10.1016/S0014-5793(01)02408-5; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Uzumaki T, 2004, NAT STRUCT MOL BIOL, V11, P623, DOI 10.1038/nsmb781; Vakonakis L, 2004, P NATL ACAD SCI USA, V101, P1479, DOI 10.1073/pnas.0305516101; WEBER K, 1969, J BIOL CHEM, V244, P4406; Williams SB, 2002, P NATL ACAD SCI USA, V99, P15357, DOI 10.1073/pnas.232517099; Ye S, 2004, J BIOL CHEM, V279, P20511, DOI 10.1074/jbc.M400077200	31	54	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					43141	43149		10.1074/jbc.M503360200	http://dx.doi.org/10.1074/jbc.M503360200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16227211	hybrid			2022-12-25	WOS:000234200800080
J	Fieulaine, S; Juillan-Binard, CL; Serero, A; Dardel, F; Giglione, C; Meinnel, T; Ferrer, JL				Fieulaine, S; Juillan-Binard, CL; Serero, A; Dardel, F; Giglione, C; Meinnel, T; Ferrer, JL			The crystal structure of mitochondrial (type 1A) peptide deformylase provides clear guidelines for the design of inhibitors specific for the bacterial forms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL METHIONINE EXCISION; ACTIVE-SITE; POLYPEPTIDE DEFORMYLASE; SUBSTRATE RECOGNITION; ACTINONIN; TARGET; IRON; CRYSTALLIZATION; IDENTIFICATION; UNIVERSALITY	Peptide deformylase (PDF) inhibitors have a strong potential to be used as a new class of antibiotics. However, recent studies have shown that the mitochondria of most eukaryotes, including humans, contain an essential PDF, PDF1A. The crystal structure of the Arabidopsis thaliana PDF1A (AtPDF1A), considered representative of PDF1As in general, has been determined. This structure displays several similarities to that of known bacterial PDFs. AtPDF1A behaves as a dimer, with the C-terminal residues responsible for linking the two subunits. This arrangement is similar to that of Leptospira interrogans PDF, the only other dimeric PDF identified to date. AtPDF1A is the first PDF for which zinc has been identified as the catalytic ion. However, the zinc binding pocket does not differ from the binding pockets of PDFs with iron rather than zinc. The crystal structure of AtPDF1A in complex with a substrate analog revealed that the substrate binding pocket of PDF1A displays strong modifications. The S1' binding pocket is significantly narrower, due to the creation of a floor from residues present in all PDF1As but not in bacterial PDFs. A true S3' pocket is created by the residues of a helical CD-loop, which is very long in PDF1As. Finally, these modified substrate binding pockets modify the position of the substrate in the active site. These differences provide guidelines for the design of bacterial PDF inhibitors that will not target mitochondrial PDFs.	CNRS, Inst Sci Vegetal, UPR2355, F-91198 Gif Sur Yvette, France; UJF, Inst Biol Struct JP Ebel, CEA, CNRS,UMR 5075,Lab Cristallog & Cristallogenese Pr, F-38027 Grenoble, France; Univ Paris 05, CNRS, UMR 8015, Lab Cristallog & RMN Biol,Fac Pharm, F-75006 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite	Meinnel, T (corresponding author), CNRS, Inst Sci Vegetal, UPR2355, Batiment 23,1 Ave Terrasse, F-91198 Gif Sur Yvette, France.	thierry.meinnel@isv.cnrs-gif.fr; jean-luc.ferrer@ibs.fr	Dardel, Frédéric/E-5805-2010; Meinnel, Thierry/B-9813-2016	Dardel, Frédéric/0000-0002-9397-3965; Meinnel, Thierry/0000-0001-5642-8637; Giglione, Carmela/0000-0002-7475-1558				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Becker A, 1998, J BIOL CHEM, V273, P11413, DOI 10.1074/jbc.273.19.11413; Becker A, 1998, NAT STRUCT BIOL, V5, P1053, DOI 10.1038/4162; Boularot Adrien, 2004, Curr Opin Investig Drugs, V5, P809; Boxem M, 2004, FEBS LETT, V576, P245, DOI 10.1016/j.febslet.2004.08.077; Bracchi-Ricard V, 2001, ARCH BIOCHEM BIOPHYS, V396, P162, DOI 10.1006/abbi.2001.2631; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bush K, 2004, CURR OPIN MICROBIOL, V7, P466, DOI 10.1016/j.mib.2004.08.013; Chan MK, 1997, BIOCHEMISTRY-US, V36, P13904, DOI 10.1021/bi9711543; Chen DZ, 2000, BIOCHEMISTRY-US, V39, P1256, DOI 10.1021/bi992245y; Dardel F, 1998, J MOL BIOL, V280, P501, DOI 10.1006/jmbi.1998.1882; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fritsche TR, 2005, ANTIMICROB AGENTS CH, V49, P1468, DOI 10.1128/AAC.49.4.1468-1476.2005; Giglione C, 2004, CELL MOL LIFE SCI, V61, P1455, DOI 10.1007/s00018-004-3466-8; Giglione C, 2003, EMBO J, V22, P13, DOI 10.1093/emboj/cdg007; Giglione C, 2001, TRENDS PLANT SCI, V6, P566, DOI 10.1016/S1360-1385(01)02151-3; Giglione C, 2000, MOL MICROBIOL, V36, P1197, DOI 10.1046/j.1365-2958.2000.01908.x; Giglione C, 2000, EMBO J, V19, P5916, DOI 10.1093/emboj/19.21.5916; GORDON JJ, 1962, NATURE, V195, P701, DOI 10.1038/195701b0; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Groche D, 1998, BIOCHEM BIOPH RES CO, V246, P342, DOI 10.1006/bbrc.1998.8616; Guilloteau JP, 2002, J MOL BIOL, V320, P951, DOI 10.1016/S0022-2836(02)00549-1; Hao B, 1999, BIOCHEMISTRY-US, V38, P4712, DOI 10.1021/bi982594c; Jain RK, 2005, J AM CHEM SOC, V127, P4558, DOI 10.1021/ja0503074; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kumar A, 2002, STRUCTURE, V10, P357, DOI 10.1016/S0969-2126(02)00719-0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lazennec C, 1997, ANAL BIOCHEM, V244, P180, DOI 10.1006/abio.1996.9910; Lee MD, 2004, J CLIN INVEST, V114, P1107, DOI 10.1172/JCI200422269; Li YK, 2002, BIOCHEM BIOPH RES CO, V295, P884, DOI 10.1016/S0006-291X(02)00777-5; Li YK, 2002, ACTA CRYSTALLOGR D, V58, P846, DOI 10.1107/S0907444902003736; Mazel D, 1997, J MOL BIOL, V266, P939, DOI 10.1006/jmbi.1996.0835; MAZEL D, 1994, EMBO J, V13, P914, DOI 10.1002/j.1460-2075.1994.tb06335.x; MEINNEL T, 1995, J MOL BIOL, V254, P175, DOI 10.1006/jmbi.1995.0609; Meinnel T, 1996, J MOL BIOL, V262, P375, DOI 10.1006/jmbi.1996.0521; Meinnel T, 1997, J MOL BIOL, V267, P749, DOI 10.1006/jmbi.1997.0904; Meinnel T, 2000, PARASITOL TODAY, V16, P165, DOI 10.1016/S0169-4758(99)01627-0; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Pei D, 2001, Expert Opin Ther Targets, V5, P23, DOI 10.1517/14728222.5.1.23; Ragusa S, 1999, J MOL BIOL, V289, P1445, DOI 10.1006/jmbi.1999.2832; Ragusa S, 1998, J MOL BIOL, V280, P515, DOI 10.1006/jmbi.1998.1883; Rajagopalan PTR, 2000, BIOCHEMISTRY-US, V39, P779, DOI 10.1021/bi9919899; Rajagopalan PTR, 1997, J AM CHEM SOC, V119, P12418, DOI 10.1021/ja9734096; Rajagopalan PTR, 1998, J BIOL CHEM, V273, P22305, DOI 10.1074/jbc.273.35.22305; Ramanathan-Girish S, 2004, ANTIMICROB AGENTS CH, V48, P4835, DOI 10.1128/AAC.48.12.4835-4842.2004; Robien MA, 2004, PROTEIN SCI, V13, P1155, DOI 10.1110/ps.03456404; Ross S, 2005, PLANT PHYSIOL, V137, P623, DOI 10.1104/pp.104.056861; Roth M, 2002, ACTA CRYSTALLOGR D, V58, P805, DOI 10.1107/S0907444902003943; Roussel A., 1989, TURBO FRODO; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Serero A, 2003, J BIOL CHEM, V278, P52953, DOI 10.1074/jbc.M309770200; Serero A, 2001, J MOL BIOL, V314, P695, DOI 10.1006/jmbi.2001.5175; Solbiati J, 1999, J MOL BIOL, V290, P607, DOI 10.1006/jmbi.1999.2913; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; Yuan ZY, 2001, DRUG DISCOV TODAY, V6, P954, DOI 10.1016/S1359-6446(01)01925-0; Zhou ZC, 2004, J MOL BIOL, V339, P207, DOI 10.1016/j.jmb.2004.03.045	60	36	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42315	42324		10.1074/jbc.M507155200	http://dx.doi.org/10.1074/jbc.M507155200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16192279	hybrid			2022-12-25	WOS:000233992700061
J	Hosono, T; Fukao, T; Ogihara, J; Ito, Y; Shiba, H; Seki, T; Ariga, T				Hosono, T; Fukao, T; Ogihara, J; Ito, Y; Shiba, H; Seki, T; Ariga, T			Diallyl trisulfide suppresses the proliferation and induces apoptosis of human colon cancer cells through oxidative modification of beta-tubulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ORGANOSULFUR COMPOUNDS; BCL-2 PROTEIN; PORCINE BRAIN; PHOSPHORYLATION; DISULFIDE; MICROTUBULES; IDENTIFICATION; BINDING; KINASE	Allyl sulfides are characteristic flavor components obtained from garlic. These sulfides are thought to be responsible for their epidemiologically proven anticancer effect on garlic eaters. This study was aimed at clarifying the molecular basis of this anticancer effect of garlic by using human colon cancer cell lines HCT-15 and DLD-1. The growth of the cells was significantly suppressed by diallyl trisulfide (DATS, HCT-15 IC50 = 11.5 mu M, DLD-1 IC50 = 13.3 mu M); however, neither diallyl monosulfide nor diallyl disulfide showed such an effect. The proportion of HCT-15 and that of DLD-1 cells residing at the G(1) and S phases were decreased by DATS, and their populations at the G(2)/M phase were markedly increased for up to 12 h. The cells with a sub-G(1) DNA content were increased thereafter. Caspase-3 activity was also dramatically increased by DATS. Fluorescence-activated cell sorter analysis performed on the cells arrested at the G(1)/S boundary revealed cell cycle-dependent induction of apoptosis through the transition of the G(2)/M phase to the G(1) phase by DATS. DATS inhibited tubulin polymerization in an in vitro cell-free system. DATS disrupted microtubule network formation of the cells, and microtubule fragments could be seen at the interphase. Peptide mass mapping by liquid chromatography-tandem mass spectrometry analysis for DATS-treated tubulin demonstrated that there was a specific oxidative modification of cysteine residues Cys-12 beta and Cys-354 beta to form S-allylmercaptocysteine with a peptide mass increase of 72.1 Da. The potent antitumor activity of DATS was also demonstrated in nude mice bearing HCT-15 xenografts. This is the first paper describing intracellular target molecules directly modified by garlic components.	Nihon Univ, Grad Sch Bioresource Sci, Dept Appl Life Sci, Kanagawa 2528510, Japan; Nihon Univ, Grad Sch Bioresource Sci, Dept Bioresource Utilizat, Kanagawa 2528510, Japan	Nihon University; Nihon University	Seki, T (corresponding author), Nihon Univ, Grad Sch Bioresource Sci, Dept Appl Life Sci, Kanagawa 2528510, Japan.	tseki@brs.nihon-u.ac.jp						Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Bai RL, 1996, J BIOL CHEM, V271, P12639, DOI 10.1074/jbc.271.21.12639; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Chang HS, 2005, CANCER LETT, V223, P47, DOI 10.1016/j.canlet.2004.10.008; Checchi PM, 2003, TRENDS PHARMACOL SCI, V24, P361, DOI 10.1016/S0165-6147(03)00161-5; Cumming RC, 2004, J BIOL CHEM, V279, P21749, DOI 10.1074/jbc.M312267200; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Fan MY, 2000, J BIOL CHEM, V275, P29980, DOI 10.1074/jbc.M003776200; Filomeni G, 2003, CANCER RES, V63, P5940; Fleischauer AT, 2001, J NUTR, V131, p1032S, DOI 10.1093/jn/131.3.1032S; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; Giustarini D, 2004, J CELL MOL MED, V8, P201, DOI 10.1111/j.1582-4934.2004.tb00275.x; Gupta ML, 2001, CELL MOTIL CYTOSKEL, V49, P67, DOI 10.1002/cm.1021; Gupta S, 2003, MOL CELL BIOCHEM, V253, P41, DOI 10.1023/A:1026045100219; Guyonnet D, 2002, CARCINOGENESIS, V23, P1335, DOI 10.1093/carcin/23.8.1335; Islam MN, 2004, MINI-REV MED CHEM, V4, P1077, DOI 10.2174/1389557043402946; Jordan MA, 1996, CANCER RES, V56, P816; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; Knowles LM, 2000, CARCINOGENESIS, V21, P1129, DOI 10.1093/carcin/21.6.1129; KRAUHS E, 1981, P NATL ACAD SCI-BIOL, V78, P4156, DOI 10.1073/pnas.78.7.4156; Kuo CC, 2004, CANCER RES, V64, P4621, DOI 10.1158/0008-5472.CAN-03-3474; Landino LM, 2004, BIOCHEM BIOPH RES CO, V314, P555, DOI 10.1016/j.bbrc.2003.12.126; LAWSON LD, 1993, PLANTA MED, V55, pA688; Lind C, 2002, ARCH BIOCHEM BIOPHYS, V406, P229, DOI 10.1016/S0003-9861(02)00468-X; Ling YH, 2002, MOL PHARMACOL, V62, P529, DOI 10.1124/mol.62.3.529; Lu HF, 2004, FOOD CHEM TOXICOL, V42, P1543, DOI 10.1016/j.fct.2003.06.001; LUDUENA RF, 1991, PHARMACOL THERAPEUT, V49, P133, DOI 10.1016/0163-7258(91)90027-J; MILLIGAN B, 1962, J CHEM SOC, P4850; Milner JA, 2001, J NUTR, V131, p1027S, DOI 10.1093/jn/131.3.1027S; Mollinedo F, 2003, APOPTOSIS, V8, P413, DOI 10.1023/A:1025513106330; Nakagawa H, 2001, CARCINOGENESIS, V22, P891, DOI 10.1093/carcin/22.6.891; Nogales E, 2000, ANNU REV BIOCHEM, V69, P277, DOI 10.1146/annurev.biochem.69.1.277; PONSTINGL H, 1981, P NATL ACAD SCI-BIOL, V78, P2757, DOI 10.1073/pnas.78.5.2757; Sakamoto K, 1997, NUTR CANCER, V29, P152, DOI 10.1080/01635589709514617; Schaffer EM, 1996, CANCER LETT, V102, P199, DOI 10.1016/0304-3835(96)04160-2; Seki T, 2000, CANCER LETT, V160, P29, DOI 10.1016/S0304-3835(00)00552-8; SPARNINS VL, 1988, CARCINOGENESIS, V9, P131, DOI 10.1093/carcin/9.1.131; Srivastava SK, 1997, CANCER LETT, V118, P61, DOI 10.1016/S0304-3835(97)00237-1; SUMIYOSHI H, 1990, CANCER RES, V50, P5084; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Vantieghem A, 2002, J BIOL CHEM, V277, P37718, DOI 10.1074/jbc.M204348200; Xiao D, 2004, ONCOGENE, V23, P5594, DOI 10.1038/sj.onc.1207747; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469	44	184	192	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41487	41493		10.1074/jbc.M507127200	http://dx.doi.org/10.1074/jbc.M507127200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16219763	hybrid			2022-12-25	WOS:000233866900047
J	Zecchinon, L; Oriol, A; Netzel, U; Svennberg, J; Gerardin-Otthiers, N; Feller, G				Zecchinon, L; Oriol, A; Netzel, U; Svennberg, J; Gerardin-Otthiers, N; Feller, G			Stability domains, substrate-induced conformational changes, and hinge-bending motions in a psychrophilic phosphoglycerate kinase - A microcalorimetric study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL SCANNING CALORIMETRY; 3-PHOSPHOGLYCERATE KINASE; CIRCULAR-DICHROISM; ALTEROMONAS-HALOPLANCTIS; THERMODYNAMIC STABILITY; LOW-TEMPERATURES; COLD ADAPTATION; ALPHA-AMYLASE; PROTEINS; MOLECULE	The cold-active phosphoglycerate kinase from the Antarctic bacterium Pseudomonas sp. TACII18 exhibits two distinct stability domains in the free, open conformation. It is shown that these stability domains do not match the structural N- and C-domains as the heat-stable domain corresponds to about 80 residues of the C-domain, including the nucleotide binding site, whereas the remaining of the protein contributes to the main heat-labile domain. This was demonstrated by spectroscopic and microcalorimetric analyses of the native enzyme, of its mutants, and of the isolated recombinant structural domains. It is proposed that the heat-stable domain provides a compact structure improving the binding affinity of the nucleotide, therefore increasing the catalytic efficiency at low temperatures. Upon substrate binding, the enzyme adopts a uniformly more stable closed conformation. Substrate-induced stability changes suggest that the free energy of ligand binding is converted into an increased conformational stability used to drive the hinge-bending motions and domain closure.	Univ Liege, Biochem Lab, Inst Chem B6A, B-4000 Cointe Ougree, Belgium	University of Liege	Feller, G (corresponding author), Univ Liege, Biochem Lab, Inst Chem B6A, B-4000 Cointe Ougree, Belgium.	gfeller@ulg.ac.be						Bentahir M, 2000, J BIOL CHEM, V275, P11147, DOI 10.1074/jbc.275.15.11147; Bernstein BE, 1998, BIOCHEMISTRY-US, V37, P4429, DOI 10.1021/bi9724117; Bernstein BE, 1997, NATURE, V385, P275, DOI 10.1038/385275a0; BLAKE CCF, 1974, J MOL BIOL, V84, P585, DOI 10.1016/0022-2836(74)90118-1; BRANDTS JF, 1989, BIOCHEMISTRY-US, V28, P8588, DOI 10.1021/bi00447a048; D'Amico S, 2003, J BIOL CHEM, V278, P7891, DOI 10.1074/jbc.M212508200; D'Amico S, 2001, J BIOL CHEM, V276, P25791, DOI 10.1074/jbc.M102741200; DAVIES GJ, 1994, ACTA CRYSTALLOGR D, V50, P202, DOI 10.1107/S0907444993011138; Feller G, 1999, BIOCHEMISTRY-US, V38, P4613, DOI 10.1021/bi982650+; Feller G, 1996, J BIOL CHEM, V271, P23836, DOI 10.1074/jbc.271.39.23836; Feller G, 2003, NAT REV MICROBIOL, V1, P200, DOI 10.1038/nrmicro773; FREIRE E, 1992, BIOCHEMISTRY-US, V31, P250, DOI 10.1021/bi00116a034; GAST K, 1995, FEBS LETT, V358, P247, DOI 10.1016/0014-5793(94)01437-6; Georlette D, 2004, FEMS MICROBIOL REV, V28, P25, DOI 10.1016/j.femsre.2003.07.003; HARLOS K, 1992, PROTEINS, V12, P133, DOI 10.1002/prot.340120207; Hosszu LLP, 1997, BIOCHEMISTRY-US, V36, P333, DOI 10.1021/bi961784p; Jaenicke R, 1999, PROG BIOPHYS MOL BIO, V71, P155, DOI 10.1016/S0079-6107(98)00032-7; LIN LN, 1994, BIOCHEMISTRY-US, V33, P1881, DOI 10.1021/bi00173a035; Mandelman D, 2001, ACTA CRYSTALLOGR D, V57, P1666, DOI 10.1107/S0907444901012069; MATOUSCHEK A, 1994, PROTEIN ENG, V7, P1089, DOI 10.1093/protein/7.9.1089; May A, 1996, PROTEINS, V24, P292; McPhillips TM, 1996, BIOCHEMISTRY-US, V35, P4118, DOI 10.1021/bi952500o; MISSELWITZ R, 1994, INT J BIOL MACROMOL, V16, P187, DOI 10.1016/0141-8130(94)90050-7; MISSIAKAS D, 1990, BIOCHEMISTRY-US, V29, P8683, DOI 10.1021/bi00489a025; NOVOKHATNY VV, 1984, J MOL BIOL, V179, P215, DOI 10.1016/0022-2836(84)90466-2; PRIVALOV PL, 1982, ADV PROTEIN CHEM, V35, P1, DOI 10.1016/S0065-3233(08)60468-4; PRIVALOV PL, 1982, J MOL BIOL, V159, P665, DOI 10.1016/0022-2836(82)90107-3; Reed MAC, 2003, J MOL BIOL, V330, P1189, DOI 10.1016/S0022-2836(03)00625-9; SHERMAN MA, 1995, BIOCHEMISTRY-US, V34, P13934, DOI 10.1021/bi00042a027; Suzuki Y, 2005, FEBS J, V272, P632, DOI 10.1111/j.1742-4658.2004.04468.x; Szilagyi AN, 1998, BIOCHEMISTRY-US, V37, P8551, DOI 10.1021/bi973072k; TATUNASHVILI LV, 1990, J MOL BIOL, V211, P161, DOI 10.1016/0022-2836(90)90018-H; Vogl T, 1997, BIOCHEMISTRY-US, V36, P1657, DOI 10.1021/bi962163z; WATSON HC, 1982, EMBO J, V1, P1635, DOI 10.1002/j.1460-2075.1982.tb01366.x; Xu Y, 2003, J BACTERIOL, V185, P2161, DOI 10.1128/JB.185.7.2161-2168.2003; Zaiss K, 1999, BIOCHEMISTRY-US, V38, P4633, DOI 10.1021/bi982447e	36	9	11	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41307	41314		10.1074/jbc.M506464200	http://dx.doi.org/10.1074/jbc.M506464200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16227206	hybrid, Green Published			2022-12-25	WOS:000233866900025
J	Garuti, R; Jones, C; Li, WP; Michaely, P; Herz, J; Gerard, RD; Cohen, JC; Hobbs, HH				Garuti, R; Jones, C; Li, WP; Michaely, P; Herz, J; Gerard, RD; Cohen, JC; Hobbs, HH			The modular adaptor protein autosomal recessive hypercholesterolemia (ARH) promotes low density lipoprotein receptor clustering into clathrin-coated pits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ULTRATHIN FROZEN-SECTIONS; LDL RECEPTOR; FAMILIAL HYPERCHOLESTEROLEMIA; IN-VITRO; LIVING CELLS; BINDING; ENDOCYTOSIS; AP-2; SEQUENCE; MICE	Autosomal recessive hypercholesterolemia is characterized by a cell type-specific defect in low density lipoprotein receptor ( LDLR) endocytosis. LDLR-mediated uptake of LDL is impaired in the liver, but not in fibroblasts of subjects with this disorder. The disease is caused by mutations in ARH, which encodes a putative adaptor protein that interacts with the cytoplasmic tail of the LDLR, phospholipids, and two components of the clathrin endocytic machinery, clathrin and adaptor protein-2 (AP-2) in vitro. To determine the physiological relevance of these interactions, we examined the effect of mutations in the ARH on LDLR location and function in polarized hepatocytes (WIF-B). The integrity of the FDNPVY sequence in the LDLR cytoplasmic tail was required for ARH-associated LDLR clustering into clathrin-coated pits. The phosphotyrosine binding domain of ARH plus either the clathrin box or the AP-2 binding region were required for both clustering and internalization of the LDLR. Parallel studies performed in vivo with the same recombinant forms of ARH in livers of Arh(-/-) mice confirmed the relevance of the cell culture findings. These results demonstrate that ARH must bind the LDLR tail and either clathrin or AP-2 to promote receptor clustering and internalization of LDL.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hobbs, HH (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Helen.hobbs@utsouthwestern.edu			NHLBI NIH HHS [R37 HL063762, HL20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL063762, P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aoki K, 1999, MOL MED, V5, P224, DOI 10.1007/BF03402119; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; CASSIO D, 1991, J CELL BIOL, V115, P1397, DOI 10.1083/jcb.115.5.1397; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; Dell'Angelica EC, 2001, TRENDS CELL BIOL, V11, P315, DOI 10.1016/S0962-8924(01)02043-8; Eden ER, 2002, J CLIN INVEST, V110, P1695, DOI 10.1172/JCI200216445; EHRLICH KC, 1990, MOL CELL BIOL, V10, P4957, DOI 10.1128/MCB.10.9.4957; Ehrlich M, 2004, CELL, V118, P591, DOI 10.1016/j.cell.2004.08.017; Fallaux FJ, 1998, HUM GENE THER, V9, P1909, DOI 10.1089/hum.1998.9.13-1909; Gaidarov I, 1999, NAT CELL BIOL, V1, P1, DOI 10.1038/8971; Garcia CK, 2001, SCIENCE, V292, P1394, DOI 10.1126/science.1060458; Gerard RD, 1995, ADENOVIRUS VECTORS D, P285; GOLDSTEIN J, 2001, METABOLIC MOL BASES, P2683; Haffner C, 2000, CURR BIOL, V10, P471, DOI 10.1016/S0960-9822(00)00446-2; HARADASHIBA M, 1992, ARTERIOSCLER THROMB, V12, P1071, DOI 10.1161/01.ATV.12.9.1071; He GC, 2002, J BIOL CHEM, V277, P44044, DOI 10.1074/jbc.M208539200; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; IHRKE G, 1993, J CELL BIOL, V123, P1761, DOI 10.1083/jcb.123.6.1761; INNERARITY TL, 1990, J LIPID RES, V31, P1337; Jones C, 2003, J BIOL CHEM, V278, P29024, DOI 10.1074/jbc.M304855200; Koivisto UM, 2001, CELL, V105, P575, DOI 10.1016/S0092-8674(01)00371-3; Michaely P, 2004, J BIOL CHEM, V279, P34023, DOI 10.1074/jbc.M405242200; Mishra SK, 2005, J BIOL CHEM, V280, P19270, DOI 10.1074/jbc.M501029200; Mishra SK, 2002, P NATL ACAD SCI USA, V99, P16099, DOI 10.1073/pnas.252630799; Morris SM, 2001, TRAFFIC, V2, P111, DOI 10.1034/j.1600-0854.2001.020206.x; Norman D, 1999, J CLIN INVEST, V104, P619, DOI 10.1172/JCI6677; PATHAK RK, 1990, J CELL BIOL, V111, P347, DOI 10.1083/jcb.111.2.347; Praefcke GJK, 2004, EMBO J, V23, P4371, DOI 10.1038/sj.emboj.7600445; Rosenthal JA, 1999, J BIOL CHEM, V274, P33959, DOI 10.1074/jbc.274.48.33959; Scott MGH, 2002, J BIOL CHEM, V277, P3552, DOI 10.1074/jbc.M106586200; Stolt PC, 2004, BIOCHEMISTRY-US, V43, P10979, DOI 10.1021/bi049092l; Stolt PC, 2003, STRUCTURE, V11, P569, DOI 10.1016/S0969-2126(03)00068-6; TOKUYASU KT, 1980, HISTOCHEM J, V12, P381, DOI 10.1007/BF01011956; TOKUYASU KT, 1978, J ULTRA MOL STRUCT R, V63, P287, DOI 10.1016/S0022-5320(78)80053-7; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Wilund KR, 2002, HUM MOL GENET, V11, P3019, DOI 10.1093/hmg/11.24.3019; Zuliani G, 1999, ARTERIOSCL THROM VAS, V19, P802, DOI 10.1161/01.ATV.19.3.802; ZULIANI G, 1995, EUR J CLIN INVEST, V25, P322, DOI 10.1111/j.1365-2362.1995.tb01709.x	39	65	68	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40996	41004		10.1074/jbc.M509394200	http://dx.doi.org/10.1074/jbc.M509394200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16179341	hybrid			2022-12-25	WOS:000233666600074
J	Gulshan, K; Rovinsky, SA; Coleman, ST; Moye-Rowley, WS				Gulshan, K; Rovinsky, SA; Coleman, ST; Moye-Rowley, WS			Oxidant-specific folding of Yap1p regulates both transcriptional activation and nuclear localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; YEAST SACCHAROMYCES-CEREVISIAE; OXIDATIVE STRESS; GENE-EXPRESSION; MULTIDRUG-RESISTANCE; MEDIATOR COMPLEX; II HOLOENZYME; PROTEIN; ENCODES; EXPORT	The yeast transcriptional regulator Yap1p is a key determinant in oxidative stress resistance. This protein is found in the cytoplasm under non-stressed conditions but rapidly accumulates in the nucleus following oxidant exposure. There it activates transcription of genes encoding antioxidants that return the redox balance of the cell to an acceptable range. Yap1p localization to the nucleus requires the oxidant-specific formation of disulfide bonds in the N-terminal cysteine-rich domain (N-CRD) and/or the C-terminal cysteine-rich domain (C-CRD). H2O2 exposure triggers the formation of two interdomain disulfide bonds between the N- and C-CRDs. This dually disulfide-bonded structure has been argued to mask the nuclear export signal in the C-CRD that would otherwise prevent Yap1p nuclear accumulation. The C-CRD is required for wild-type H2O2 tolerance but dispensable for resistance to diamide. The Saccharomyces cerevisiae TRX2 gene, encoding a thioredoxin protein, cannot be induced by H2O2 in the presence of various mutant forms of Yap1p lacking the normally functioning C-CRD. In this work, we demonstrate that the proper folding of Yap1p in the presence of H2O2 is required for recruitment of the mediator component Rox3p to the TRX2 promoter in addition to the nuclear accumulation of Yap1p during stress by this oxidant. These data demonstrate that the dually disulfide-bonded Yap1p N- and C-CRDs form a bifunctional protein domain controlling both nuclear localization and transcriptional activation.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa	Moye-Rowley, WS (corresponding author), Univ Iowa, Dept Physiol & Biophys, 6-530 Bowen Sci Bldg,51 Newton Rd, Iowa City, IA 52242 USA.	scott-moye-rowley@uiowa.edu	Moye-Rowley, Scott/AFL-7135-2022	Moye-Rowley, Scott/0000-0002-7163-1120	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057007] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49825, GM57007] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUBLE DT, 1993, GENE DEV, V7, P844, DOI 10.1101/gad.7.5.844; Balciunas D, 1999, P NATL ACAD SCI USA, V96, P376, DOI 10.1073/pnas.96.2.376; CADENAS E, 1989, ANNU REV BIOCHEM, V58, P79, DOI 10.1146/annurev.bi.58.070189.000455; Coleman ST, 1999, MOL CELL BIOL, V19, P8302; Coleman ST, 1997, J BIOL CHEM, V272, P23224, DOI 10.1074/jbc.272.37.23224; Conaway JW, 2005, FEBS LETT, V579, P904, DOI 10.1016/j.febslet.2004.11.031; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; Delaunay A, 2000, EMBO J, V19, P5157, DOI 10.1093/emboj/19.19.5157; Delaunay A, 2002, CELL, V111, P471, DOI 10.1016/S0092-8674(02)01048-6; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; Evangelista CC, 1996, GENETICS, V142, P1083; Gadbois EL, 1997, P NATL ACAD SCI USA, V94, P3145, DOI 10.1073/pnas.94.7.3145; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Goppelt A, 1996, NUCLEIC ACIDS RES, V24, P4450, DOI 10.1093/nar/24.22.4450; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Gustafsson CM, 1997, J BIOL CHEM, V272, P48; Han SJ, 1999, MOL CELL BIOL, V19, P979; Imlay JA, 2003, ANNU REV MICROBIOL, V57, P395, DOI 10.1146/annurev.micro.57.030502.090938; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KANG JJ, 1995, MOL CELL BIOL, V15, P1234; Kuge S, 1998, GENES CELLS, V3, P521, DOI 10.1046/j.1365-2443.1998.00209.x; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; Kuge S, 2001, MOL CELL BIOL, V21, P6139, DOI 10.1128/MCB.21.18.6139-6150.2001; Lee M, 2000, GENETICS, V155, P1535; LEPPERT G, 1990, GENETICS, V125, P13; Li S, 2002, MOL BIOL CELL, V13, P412, DOI 10.1091/mbc.01-09-0434; Linke K, 2003, ANTIOXID REDOX SIGN, V5, P425, DOI 10.1089/152308603768295168; Morgan BA, 1997, EMBO J, V16, P1035, DOI 10.1093/emboj/16.5.1035; Moye-Rowley WS, 2003, PROG NUCLEIC ACID RE, V73, P251, DOI 10.1016/S0079-6603(03)01008-0; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; MULLER EGD, 1991, J BIOL CHEM, V266, P9194; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; OHTAKE Y, 1991, YEAST, V7, P953, DOI 10.1002/yea.320070907; Paget MSB, 2003, ANNU REV GENET, V37, P91, DOI 10.1146/annurev.genet.37.110801.142538; Patikoglou GA, 1999, GENE DEV, V13, P3217, DOI 10.1101/gad.13.24.3217; Prelich G, 1997, MOL CELL BIOL, V17, P2057, DOI 10.1128/MCB.17.4.2057; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rodrigues-Pousada CA, 2004, FEBS LETT, V567, P80, DOI 10.1016/j.febslet.2004.03.119; ROSENBLUMVOS LS, 1991, MOL CELL BIOL, V11, P5639, DOI 10.1128/MCB.11.11.5639; Sherman F, 1979, METHODS YEAST GENETI; STEPHEN DWS, 1995, MOL MICROBIOL, V16, P415, DOI 10.1111/j.1365-2958.1995.tb02407.x; STRUHL K, 1989, ANNU REV BIOCHEM, V58, P1051, DOI 10.1146/annurev.bi.58.070189.005155; Sugiyama K, 2000, J BIOL CHEM, V275, P15535, DOI 10.1074/jbc.275.20.15535; SUZUKI Y, 1988, MOL CELL BIOL, V8, P4991, DOI 10.1128/MCB.8.11.4991; Takeuchi T, 1997, FEBS LETT, V416, P339, DOI 10.1016/S0014-5793(97)01233-7; WEMMIE A, 1994, J BIOL CHEM, V269, P14690; Wemmie JA, 1997, J BIOL CHEM, V272, P7908, DOI 10.1074/jbc.272.12.7908; Wood MJ, 2004, NATURE, V430, P917, DOI 10.1038/nature02790; WU AL, 1993, J BIOL CHEM, V268, P18850; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416; Zhang XT, 2001, J BIOL CHEM, V276, P8812, DOI 10.1074/jbc.M010686200	54	59	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40524	40533		10.1074/jbc.M504716200	http://dx.doi.org/10.1074/jbc.M504716200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16219769	hybrid			2022-12-25	WOS:000233666600019
J	Taneja, SS; Ha, S; Swenson, NK; Huang, HY; Lee, P; Melamed, J; Shapiro, E; Garabedian, MJ; Logan, SK				Taneja, SS; Ha, S; Swenson, NK; Huang, HY; Lee, P; Melamed, J; Shapiro, E; Garabedian, MJ; Logan, SK			Cell-specific regulation of androgen receptor phosphorylation in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER CELLS; TRANSCRIPTIONAL ACTIVITY; BETA-CATENIN; SIGNALING PATHWAY; MESSENGER-RNA; KINASE; IDENTIFICATION; GROWTH; SITES; ACTIVATION	The biological ramifications of phosphorylation of the androgen receptor (AR) are largely unknown. To examine the phosphorylation of AR at serine 213, a putative substrate for Akt, a phosphorylation site-specific antibody was generated. The use of this antibody indicated that AR Ser-213 is phosphorylated in vivo and that phosphorylation is tightly regulated in a cell type-specific manner. Furthermore, Ser-213 phosphorylation took place with rapid kinetics and was inhibited by the phosphatidylinositol 3-kinase inhibitor LY294002. Phosphorylation occurred in response to R1881 and dihydrotestosterone but weakly if at all in response to testosterone. It did not occur in response to AR antagonists or growth factor stimulation in the absence of an AR agonist. Transcription assays using an AR-responsive reporter gene construct showed that activated phosphatidylinositol 3-kinase inhibited transcription mediated by wild type AR but not that of a mutant AR variant (S213A), which could not be phosphorylated at Ser-213. By immunohistochemistry, the AR Ser(P)-213 antigen was detected in prostate epithelial but not stromal cells despite the fact that an antibody recognizing both phosphorylated and non-phosphorylated forms of AR demonstrates that AR is present in both cell types as expected. In fetal tissue the AR-Ser(P)-213 antigen was present in epithelial cells of the urogenital sinus when endogenous androgen levels were high and activated Akt was prevalent, but absent at a later stage of development when endogenous androgen levels were low and Akt activation was minimal. Immunoreactivity was evident in differentiated cells lining the lumen of the urogenital sinus but not in rapidly dividing, Ki67 positive cells within the developing prostate or stromal tissue, suggesting that site-specific phosphorylation of AR Ser-213 by cellular kinases occurs in a non-proliferating cellular milieu.	NYU, Sch Med, Dept Urol, New York, NY 10010 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10010 USA; NYU, Sch Med, Dept Microbiol, New York, NY 10010 USA; NYU, Sch Med, Dept Pathol, New York, NY 10010 USA; NYU, Sch Med, Inst Canc, New York, NY 10010 USA	New York University; New York University; New York University; New York University; New York University	Logan, SK (corresponding author), NYU, Sch Med, Dept Urol, 423 E 23rd St,Rm 18064 S, New York, NY 10010 USA.	logans02@med.nyu.edu	Melamed, Jonathan/AAV-3769-2020	Melamed, Jonathan/0000-0003-2844-7990; Logan, Susan/0000-0002-7904-5927	NIDDK NIH HHS [DK58024] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058024] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Black BE, 2004, MOL ENDOCRINOL, V18, P834, DOI 10.1210/me.2003-0145; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; Cunha G R, 1989, Cancer Treat Res, V46, P159; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; Grimm SL, 2002, MOL ENDOCRINOL, V16, P2675, DOI 10.1210/me.2002-0239; Ismail PM, 2003, STEROIDS, V68, P779, DOI 10.1016/S0039-128X(03)00133-8; JENSTER G, 1994, BIOCHEMISTRY-US, V33, P14064, DOI 10.1021/bi00251a015; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; KRONGRAD A, 1991, MOL CELL ENDOCRINOL, V76, P79, DOI 10.1016/0303-7207(91)90262-Q; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Li PF, 2001, J BIOL CHEM, V276, P20444, DOI 10.1074/jbc.M010226200; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; Nan B, 2003, J MOL ENDOCRINOL, V31, P169, DOI 10.1677/jme.0.0310169; REYES FI, 1974, J CLIN ENDOCR METAB, V38, P612, DOI 10.1210/jcem-38-4-612; Sharma M, 2002, J BIOL CHEM, V277, P30935, DOI 10.1074/jbc.M201919200; Sun M, 2003, J BIOL CHEM, V278, P42992, DOI 10.1074/jbc.M306295200; Truica CI, 2000, CANCER RES, V60, P4709; Wen Y, 2000, CANCER RES, V60, P6841; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P605, DOI 10.1210/me.9.5.605; Zhu ZX, 2001, BIOCHEM BIOPH RES CO, V284, P836, DOI 10.1006/bbrc.2001.5030	26	70	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40916	40924		10.1074/jbc.M508442200	http://dx.doi.org/10.1074/jbc.M508442200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16210317	hybrid			2022-12-25	WOS:000233666600064
J	Madsen, CT; Jakobsen, L; Buriankova, K; Doucet-Populaire, F; Pernodet, JL; Douthwaite, S				Madsen, CT; Jakobsen, L; Buriankova, K; Doucet-Populaire, F; Pernodet, JL; Douthwaite, S			Methyltransferase Erm(37) slips on rRNA to confer atypical resistance in Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRINSIC MACROLIDE RESISTANCE; COMPLETE GENOME SEQUENCE; MALDI MASS-SPECTROMETRY; ANTIBIOTIC-RESISTANCE; IN-VITRO; CLARITHROMYCIN; TELITHROMYCIN; ERYTHROMYCIN; SMEGMATIS; ERMC'	Members of the Mycobacterium tuberculosis complex possess a resistance determinant, erm(37) (also termed ermMT), which is a truncated homologue of the erm genes found in a diverse range of drug-producing and pathogenic bacteria. All erm genes examined thus far encode N-6-monomethyltransferases or N-6, N-6-dimethyltransferases that show absolute specificity for nucleotide A2058 in 23 S rRNA. Monomethylation at A2058 confers resistance to a subset of the macrolide, lincosamide, and streptogramin B (MLSB) group of antibiotics and no resistance to the latest macrolide derivatives, the ketolides. Dimethylation at A2058 confers high resistance to all MLSB and ketolide drugs. The erm(37) phenotype fits into neither category. We show here by tandem mass spectrometry that Erm(37) initially adds a single methyl group to its primary target at A2058 but then proceeds to attach additional methyl groups to the neighboring nucleotides A2057 and A2059. Other methyltransferases, Erm(E) and Erm(O), maintain their specificity for A2058 on mycobacterial rRNA. Erm(E) and Erm(O) have a full-length C-terminal domain, which appears to be important for stabilizing the methyltransferases at their rRNA target, and this domain is truncated in Erm(37). The lax interaction of the M. tuberculosis Erm(37) with its rRNA produces a unique methylation pattern and confers resistance to the ketolide telithromycin.	Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense, Denmark; Univ Paris 11, CNRS, UMR 8621, Inst Genet & Microbiol, F-91405 Orsay, France; Univ Paris 05, UFR Sci Pharmaceut & Biol, F-75006 Paris, France	University of Southern Denmark; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Cite	Douthwaite, S (corresponding author), Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense, Denmark.	srd@bmb.sdu.dk	Doucet-Populaire, Florence/AAK-9129-2020; doucet-Populaire, florence/C-2068-2013; Buriánková, Karolína/I-5838-2014; Pernodet, Jean-Luc/A-4074-2015	Douthwaite, Stephen/0000-0001-5468-8486; Pernodet, Jean-Luc/0000-0002-6129-7093				Andersen TE, 2004, RNA, V10, P907, DOI 10.1261/rna.5259404; Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520; Berisio R, 2003, J BACTERIOL, V185, P4276, DOI 10.1128/JB.185.14.4276-4279.2003; Bosne-David S, 2000, J ANTIMICROB CHEMOTH, V46, P391, DOI 10.1093/jac/46.3.391; Buriankova K, 2004, ANTIMICROB AGENTS CH, V48, P143, DOI 10.1128/AAC.48.1.143-150.2004; Bussiere DE, 1998, BIOCHEMISTRY-US, V37, P7103, DOI 10.1021/bi973113c; Butler D, 2000, NATURE, V406, P670, DOI 10.1038/35021291; Camus JC, 2002, MICROBIOL-SGM, V148, P2967, DOI 10.1099/00221287-148-10-2967; Cannone JJ, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-2; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Dye C, 2002, SCIENCE, V295, P2042, DOI 10.1126/science.1063814; Falzari K, 2005, ANTIMICROB AGENTS CH, V49, P1447, DOI 10.1128/AAC.49.4.1447-1454.2005; Farrow KA, 2002, ANTIMICROB AGENTS CH, V46, P1253, DOI 10.1128/AAC.46.5.1253-1261.2002; FROTHINGHAM R, 1994, J CLIN MICROBIOL, V32, P1639, DOI 10.1128/JCM.32.7.1639-1643.1994; Garnier T, 2003, P NATL ACAD SCI USA, V100, P7877, DOI 10.1073/pnas.1130426100; Hansen JL, 2002, MOL CELL, V10, P117, DOI 10.1016/S1097-2765(02)00570-1; Harms JM, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-4; Kirpekar F, 2001, RAPID COMMUN MASS SP, V15, P8, DOI 10.1002/1097-0231(20010115)15:1<8::AID-RCM185>3.0.CO;2-S; Le Dantec C, 2001, J BACTERIOL, V183, P2157, DOI 10.1128/JB.183.7.2157-2164.2001; Liu MF, 2002, ANTIMICROB AGENTS CH, V46, P1629, DOI 10.1128/AAC.46.6.1629-1633.2002; Madsen CT, 2005, ANTIMICROB AGENTS CH, V49, P3803, DOI 10.1128/AAC.49.9.3803-3809.2005; Madsen CT, 2003, NUCLEIC ACIDS RES, V31, P4738, DOI 10.1093/nar/gkg657; Maravic G, 2003, J MOL BIOL, V332, P99, DOI 10.1016/S0022-2836(03)00863-5; Maravic G, 2003, NUCLEIC ACIDS RES, V31, P4941, DOI 10.1093/nar/gkg666; MCLUCKEY SA, 1992, J AM SOC MASS SPECTR, V3, P60, DOI 10.1016/1044-0305(92)85019-G; Mengel-Jorgensen J, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf135; Morris RP, 2005, P NATL ACAD SCI USA, V102, P12200, DOI 10.1073/pnas.0505446102; Nash KA, 2003, ANTIMICROB AGENTS CH, V47, P3053, DOI 10.1128/AAC.47.10.3053-3060.2003; NOLLER HF, 1984, ANNU REV BIOCHEM, V53, P119, DOI 10.1146/annurev.bi.53.070184.001003; Pfister P, 2005, P NATL ACAD SCI USA, V102, P5180, DOI 10.1073/pnas.0501598102; Rastogi N, 2000, ANTIMICROB AGENTS CH, V44, P2848, DOI 10.1128/AAC.44.10.2848-2852.2000; RASTOGI N, 1992, ANTIMICROB AGENTS CH, V36, P2841, DOI 10.1128/AAC.36.12.2841; Roberts MC, 1999, ANTIMICROB AGENTS CH, V43, P2823, DOI 10.1128/AAC.43.12.2823; Schluckebier G, 1999, J MOL BIOL, V289, P277, DOI 10.1006/jmbi.1999.2788; Schlunzen F, 2001, NATURE, V413, P814, DOI 10.1038/35101544; SKINNER R, 1983, J BIOL CHEM, V258, P2702; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; TRUFFOTPERNOT C, 1995, ANTIMICROB AGENTS CH, V39, P2827, DOI 10.1128/AAC.39.12.2827; Tu D, 2005, CELL, V121, P257, DOI 10.1016/j.cell.2005.02.005; WEISBLUM B, 1995, ANTIMICROB AGENTS CH, V39, P797, DOI 10.1128/AAC.39.4.797; WEISBLUM B, 1995, ANTIMICROB AGENTS CH, V39, P577, DOI 10.1128/AAC.39.3.577; Yu LP, 1997, NAT STRUCT BIOL, V4, P483, DOI 10.1038/nsb0697-483; ZALACAIN M, 1990, EUR J BIOCHEM, V189, P67, DOI 10.1111/j.1432-1033.1990.tb15460.x	43	45	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					38942	38947		10.1074/jbc.M505727200	http://dx.doi.org/10.1074/jbc.M505727200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16174779	hybrid			2022-12-25	WOS:000233362200007
J	Yang, K; Kim, JH; Kim, HJ; Park, IS; Kim, IY; Yang, BS				Yang, K; Kim, JH; Kim, HJ; Park, IS; Kim, IY; Yang, BS			Tyrosine 740 phosphorylation of discoidin domain receptor 2 by Src stimulates intramolecular autophosphorylation and Shc signaling complex formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INSULIN-RECEPTOR; KINASE DOMAIN; CRYSTAL-STRUCTURE; OVARIAN-CANCER; EXPRESSION; ACTIVATION; COLLAGEN; OSTEOARTHRITIS; PROLIFERATION; MECHANISM	DDR2 is a receptor tyrosine kinase whose activating ligands are various collagens. DDR2-mediated cellular signaling has been shown to require Src activity. However, the precise mechanism underlying the Src dependence of DDR2 signaling is unknown. Here, using baculoviral co-expression of the DDR2 cytosolic domain and Src, we show that Src targets three tyrosine residues ( Tyr-736, Tyr-740, and Tyr-741) in the activation loop of DDR2 for phosphorylation. This phosphorylation by Src stimulates DDR2 cis-autophosphorylation of additional tyrosine residues. In vitro Shc binding assays demonstrate that phosphotyrosines resulting from DDR2 autophosphorylation are involved in Shc binding to the DDR2 cytosolic domain. Mutating tyrosine 740 of DDR2 to phenylalanine stimulates autophosphorylation of DDR2 to an extent similar to that resulting from Src phosphorylation of DDR2. In addition, the DDR2 Y740F mutant protein displays collagen-independent, constitutively activated signaling. These findings suggest that tyrosine 740 inhibits DDR2 autophosphorylation. Collectively, our findings are consistent with the following mechanism for Src-dependent DDR2 activation and signaling: 1) ligand binding promotes phosphorylation of Tyr-740 in the DDR2 activation loop by Src; 2) Tyr-740 phosphorylation stimulates intramolecular autophosphorylation of DDR2; 3) DDR2 autophosphorylation generates cytosolic domain phosphotyrosines that promote the formation of DDR2 cytosolic domain-Shc signaling complexes.	Korea Inst Sci & Technol, Ctr Biomed Res, Seoul 136791, South Korea; Korea Univ, Grad Sch Biotechnol, Seoul 136701, South Korea	Korea Institute of Science & Technology (KIST); Korea University	Yang, BS (corresponding author), Korea Inst Sci & Technol, Ctr Biomed Res, 39-1 Hawolgok Dong, Seoul 136791, South Korea.	bsyang@kist.re.kr						Cann AD, 1997, BIOCHEMISTRY-US, V36, P7681, DOI 10.1021/bi970170x; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; Evtimova V, 2003, TUMOR BIOL, V24, P189, DOI 10.1159/000074429; Ferri N, 2004, AM J PATHOL, V164, P1575, DOI 10.1016/S0002-9440(10)63716-9; Heinzelmann-Schwarz VA, 2004, CLIN CANCER RES, V10, P4427, DOI 10.1158/1078-0432.CCR-04-0073; Hou GP, 2002, CIRC RES, V90, P1147, DOI 10.1161/01.RES.0000022166.74073.F8; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Ikeda K, 2002, J BIOL CHEM, V277, P19206, DOI 10.1074/jbc.M201078200; Islam S, 2001, OSTEOARTHR CARTILAGE, V9, P684, DOI 10.1053/joca.2001.0465; Kim DM, 2003, EXP MOL MED, V35, P421, DOI 10.1038/emm.2003.55; KINTAK Y, 1985, J BIOL CHEM, V260, P5838; LAI C, 1994, ONCOGENE, V9, P877; LAVAL S, 1994, CELL GROWTH DIFFER, V5, P1173; Matsuyama W, 2003, J IMMUNOL, V171, P3520, DOI 10.4049/jimmunol.171.7.3520; Matsuyama W, 2003, FASEB J, V17, P1286, DOI 10.1096/fj.02-0320fje; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Olaso E, 2002, J BIOL CHEM, V277, P3606, DOI 10.1074/jbc.M107571200; Olaso E, 2001, J CLIN INVEST, V108, P1369, DOI 10.1172/JCI12373; Ray A, 2003, ARTHRITIS RHEUM, V48, P134, DOI 10.1002/art.10706; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Vogel W, 2000, J BIOL CHEM, V275, P5779, DOI 10.1074/jbc.275.8.5779; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Wang JC, 2002, J AUTOIMMUN, V19, P161, DOI 10.1006/jaut.2002.0606; WEI L, 1995, J BIOL CHEM, V270, P8122, DOI 10.1074/jbc.270.14.8122; WHITE MF, 1994, J BIOL CHEM, V269, P1; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; Xu L, 2005, J BIOL CHEM, V280, P548, DOI 10.1074/jbc.M411036200	31	60	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39058	39066		10.1074/jbc.M506921200	http://dx.doi.org/10.1074/jbc.M506921200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16186108	hybrid			2022-12-25	WOS:000233362200020
J	Tomas-Zapico, C; Caballero, B; Sierra, V; Vega-Naredo, I; Alvarez-Garcia, O; Tolivia, D; Rodriguez-Colunga, MJ; Coto-Montes, A				Tomas-Zapico, C; Caballero, B; Sierra, V; Vega-Naredo, I; Alvarez-Garcia, O; Tolivia, D; Rodriguez-Colunga, MJ; Coto-Montes, A			Survival mechanisms in a physiological oxidative stress model	FASEB JOURNAL			English	Article						autophagy; Syrian hamster; Harderian gland; cathepsins; cytokeratins; apoptosis; invasive process; metastasis	LYSOSOMAL CYSTEINE PROTEASES; DELTA-AMINOLEVULINIC-ACID; HAMSTER HARDERIAN-GLAND; PROGRAMMED CELL-DEATH; CATHEPSIN-H; TROPHOBLASTIC INVASION; PERIPHERAL-BLOOD; GENE-EXPRESSION; APOPTOSIS; PORPHYRINS	The Syrian hamster Harderian gland has as the remarkable feature of an extraordinary rate of porphyrin production, even higher than the liver. The low activity of the last enzyme of the route gives rise to the accumulation of the uncomplex porphyrins in the female glands. Moreover, due to the localization of the Harderian gland, porphyrins exposed to light produce reactive oxygen species and, thus, the gland presents a physiological oxidative stress, with a great number of sings of degeneration, but without compromising the gland integrity. The appearance of abnormal features in this gland was largely described in the past, but the significance is interpreted for the first time in this study. We have found that autophagic processes are the first result of an elevated porphyrin metabolism, as it is observed in both sexes. This mechanism is considered, in this case, as a constant renovation system that allows the normal gland activity to be sustained. Furthermore, there is a second procedure, invasive processes toward connective tissue, which even occasionally reach blood vessels with intravasation of damaged gland components into the bloodstream. This effect is a consequence of a strong oxidative stress environment that is mainly observed in the female gland, resembling to tumoral progression. Both mechanisms, autophagy and invasive processes, have to be implied in the maintenance of the gland integrity.	Univ Oviedo, Dept Morfol & Biol Celular, Fac Med, Oviedo 33006, Spain	University of Oviedo	Coto-Montes, A (corresponding author), Univ Oviedo, Dept Morfol & Biol Celular, Fac Med, C Julian Claveria S-N, Oviedo 33006, Spain.	acoto@uniovi.es	coto-montes, ana/D-2544-2016; Tomas-Zapico, Cristina/M-5399-2019; Sierra, 3479/J-9274-2012; Caballero-Garcia, Beatriz/AAC-2636-2020; Vega-Naredo, Ignacio/A-4245-2009	coto-montes, ana/0000-0002-6609-6258; Tomas-Zapico, Cristina/0000-0001-7823-0410; Caballero-Garcia, Beatriz/0000-0003-0242-9620; Sierra, Veronica/0000-0002-7491-3588; Vega-Naredo, Ignacio/0000-0003-1993-6725				Alberts B., 2002, MOL BIOL CELL, P1313; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Alvero AB, 2004, LAB INVEST, V84, P658, DOI 10.1038/labinvest.3700086; Antolin I, 1996, FASEB J, V10, P882, DOI 10.1096/fasebj.10.8.8666165; Antolin I, 1996, J STRUCT BIOL, V116, P377, DOI 10.1006/jsbi.1996.0055; ANTOLIN I, 1994, ANAT REC, V239, P349, DOI 10.1002/ar.1092390402; Asanuma K, 2003, FASEB J, V17, P1165, DOI 10.1096/fj.02-0580fje; Badminton MN, 2002, INT J CLIN PRACT, V56, P272; BARRETT AJ, 1980, BIOCHEM J, V187, P909, DOI 10.1042/bj1870909; BEAULATON J, 1982, INT REV CYTOL, V79, P215, DOI 10.1016/S0074-7696(08)61675-7; BLANKENSHIP TN, 1993, CELL TISSUE RES, V272, P227, DOI 10.1007/BF00302728; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broker LE, 2004, CANCER RES, V64, P27, DOI 10.1158/0008-5472.CAN-03-3060; BUCANA CD, 1972, Z ZELLFORSCH MIK ANA, V129, P178, DOI 10.1007/BF00306934; BUETTNER GR, 1979, FEBS LETT, V98, P18, DOI 10.1016/0014-5793(79)80141-6; Bursch W, 2000, J CELL SCI, V113, P1189; Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Coto-Montes A, 2001, FREE RADICAL BIO MED, V30, P785, DOI 10.1016/S0891-5849(01)00468-3; Coto-Montes A, 2001, CHEM-BIOL INTERACT, V134, P135, DOI 10.1016/S0009-2797(00)00320-3; COTOMONTES A, 1994, CELL TISSUE RES, V278, P483; del Re EC, 2000, BRIT J CANCER, V82, P1317; DHerde K, 1996, REPROD NUTR DEV, V36, P175, DOI 10.1051/rnd:19960203; Ding SJ, 2004, MOL CELL PROTEOMICS, V3, P73, DOI 10.1074/mcp.M300094-MCP200; EMILIANI C, 1983, PHOTOCHEM PHOTOBIOL, V37, P487, DOI 10.1111/j.1751-1097.1983.tb04505.x; ENDERS AC, 1991, AM J ANAT, V192, P329, DOI 10.1002/aja.1001920403; Friedrich B, 1999, EUR J CANCER, V35, P138, DOI 10.1016/S0959-8049(98)00273-1; Fujita J, 2004, RESP MED, V98, P294, DOI 10.1016/j.rmed.2003.10.010; GABRIJELCIC D, 1992, EUR J CLIN CHEM CLIN, V30, P69; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Gradilone A, 2003, ONCOL REP, V10, P217; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; HARDELAND R, 1995, CELLULAR RHYTHMS IND, P145; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; HOFFMAN RA, 1971, AM J ANAT, V132, P463, DOI 10.1002/aja.1001320405; Isahara K, 1999, NEUROSCIENCE, V91, P233, DOI 10.1016/S0306-4522(98)00566-1; Ishisaka R, 2001, J BIOCHEM-TOKYO, V129, P35, DOI 10.1093/oxfordjournals.jbchem.a002833; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kos J, 1997, CLIN CANCER RES, V3, P1815; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Levy-Strumpf N, 1998, ONCOGENE, V17, P3331, DOI 10.1038/sj.onc.1202588; Libbrecht L, 2003, J PATHOL, V199, P191, DOI 10.1002/path.1257; MOAN J, 1984, PHOTOCHEM PHOTOBIOL, V39, P445; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; NICOLSON GL, 2001, CURR OPIN ONCOL, V3, P75; Ohsawa Y, 1998, ARCH HISTOL CYTOL, V61, P395, DOI 10.1679/aohc.61.395; Ollinger K, 2000, ARCH BIOCHEM BIOPHYS, V373, P346, DOI 10.1006/abbi.1999.1567; PAYNE AP, 1977, J ENDOCRINOL, V75, P73, DOI 10.1677/joe.0.0750073; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Raul U, 2004, INT J CANCER, V111, P662, DOI 10.1002/ijc.20349; RIMINGTON C, 1967, Q J MED, V36, P29; Roberg K, 2002, AM J PATHOL, V161, P89, DOI 10.1016/S0002-9440(10)64160-0; Roberg K, 1999, FREE RADICAL BIO MED, V27, P1228, DOI 10.1016/S0891-5849(99)00146-X; RODRIGUEZCOLUNGA MJ, 1993, CELL TISSUE RES, V274, P189, DOI 10.1007/BF00328000; SCHREURS FJG, 1995, POULTRY SCI, V74, P523, DOI 10.3382/ps.0740523; Sivaparvathi M, 1996, CANCER LETT, V104, P121, DOI 10.1016/0304-3835(96)04242-5; SPIKES JD, 1975, ANN NY ACAD SCI, V244, P496, DOI 10.1111/j.1749-6632.1975.tb41550.x; Stefan C, 1997, CHEM RES TOXICOL, V10, P636, DOI 10.1021/tx970006a; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STRUM JM, 1982, TISSUE CELL, V14, P149, DOI 10.1016/0040-8166(82)90014-3; TAKAHASHI T, 1981, PROTEOLITIC ENZYME C, P567; Tolivia D, 1996, MICROSC RES TECHNIQ, V34, P55, DOI 10.1002/(SICI)1097-0029(19960501)34:1<55::AID-JEMT8>3.3.CO;2-T; Tomas-Zapico C, 2002, FREE RADICAL BIO MED, V32, P1197, DOI 10.1016/S0891-5849(02)00812-2; Tomas-Zapico C, 2002, INT J BIOCHEM CELL B, V34, P544, DOI 10.1016/S1357-2725(01)00149-2; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; Uchiyama Y, 2001, ARCH HISTOL CYTOL, V64, P233, DOI 10.1679/aohc.64.233; Uenishi T, 2003, CANCER SCI, V94, P851, DOI 10.1111/j.1349-7006.2003.tb01366.x; URIA H, 1994, CELL BIOL PROBLEMS C, P89; VERMA V, 1983, GYNECOL OBSTET INVES, V15, P193, DOI 10.1159/000299412; Waghray A, 2002, J BIOL CHEM, V277, P11533, DOI 10.1074/jbc.M109557200; Waghray A, 2001, CANCER RES, V61, P4283; Werman H A, 1989, Emerg Med Clin North Am, V7, P927; Xue LZ, 1999, MOL CELL NEUROSCI, V14, P180, DOI 10.1006/mcne.1999.0780	73	26	26	1	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					2066	+		10.1096/fj.04-3595fje	http://dx.doi.org/10.1096/fj.04-3595fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16186173				2022-12-25	WOS:000232315700004
J	Deep, G; Singh, RP; Agarwal, C; Kroll, DJ; Agarwal, R				Deep, G; Singh, RP; Agarwal, C; Kroll, DJ; Agarwal, R			Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin	ONCOGENE			English	Article						prostate cancer; silibinin; silymarin; cell cycle arrest; cyclin-dependent kinase	DEPENDENT KINASE INHIBITORS; THISTLE SILYBUM-MARIANUM; CARCINOMA DU145 CELLS; DNA-DAMAGE; CHECKPOINT CONTROL; BREAST-CANCER; MILK THISTLE; FLAVONOID ANTIOXIDANT; CDC25B PHOSPHATASE; MAMMALIAN-CELLS	Here, we assessed and compared the anticancer efficacy and associated mechanisms of silymarin and silibinin in human prostate cancer (PCA) PC3 cells; silymarin is comprised of silibinin and its other stereoisomers, including isosilybin A, isosilybin B, silydianin, silychristin and isosilychristin. Silymarin and silibinin (50-100 mu g/ml) inhibited cell proliferation, induced cell death, and caused G1 and G2-M cell cycle arrest in a dose/time-dependent manner. Molecular studies showed that G1 arrest was associated with a decrease in cyclin D1, cyclin D3, cyclin E, cyclin-dependent kinase (CDK)4, CDK6 and CDK2 protein levels, and CDK2 and CDK4 kinase activity, together with an increase in CDK inhibitors (CDKIs) Kip1/p27 and Cip1/p21. Further, both agents caused cytoplasmic sequestration of cyclin D1 and CDK2, contributing to G1 arrest. The G2-M arrest by silibinin and silymarin was associated with decreased levels of cyclin B1, cyclin A, pCdc2 (Tyr15), Cdc2, and an inhibition of Cdc2 kinase activity. Both agents also decreased the levels of Cdc25B and cell division cycle 25C (Cdc25C) phosphatases with an increased phosphorylation of Cdc25C at Ser216 and its translocation from nucleus to the cytoplasm, which was accompanied by an increased binding with 14-3-3 beta. Both agents also increased checkpoint kinase (Chk)2 phosphorylation at Thr68 and Ser19 sites, which is known to phosphorylate Cdc25C at Ser216 site. Chk2-specific small interfering RNA largely attenuated the silymarin and silibinin-induced G2-M arrest. An increase in the phosphorylation of histone 2AX and ataxia telangiectasia mutated was also observed. These findings indicate that silymarin and silibinin modulate G1 phase cyclins-CDKs-CDKIs for G1 arrest, and the Chk2-Cdc25C-Cdc2/cyclin B1 pathway for G2-M arrest, together with an altered subcellular localization of critical cell cycle regulators. Overall, we observed comparable effects for both silymarin and silibinin at equal concentrations by weight, suggesting that silibinin could be a major cell cycle-inhibitory component in silymarin. However, other silibinin stereo-isomers present in silymarin also contribute to its efficacy, and could be of interest for future investigation.	Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Ctr Canc, Denver, CO 80202 USA; Ctr Organ & Med Chem, Nat Prod Lab, Res Triangle Pk, NC USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Agarwal, R (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, 4200 E 9th Ave,Box C238, Denver, CO 80262 USA.	Rajesh.Agarwal@UCHSC.edu	Deep, Gagan/H-1853-2012		NATIONAL CANCER INSTITUTE [R01CA104286, R01CA102514] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA102514, R01 CA104286] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; ADELAIDE J, 1995, BRIT J CANCER, V71, P64, DOI 10.1038/bjc.1995.13; Agarwal C, 2003, ONCOGENE, V22, P8271, DOI 10.1038/sj.onc.1207158; *AM CANC SOC, 2008, CANC FACTS FIG 2008, P1; Arber N, 1996, GASTROENTEROLOGY, V110, P669, DOI 10.1053/gast.1996.v110.pm8608874; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; BARTKOVA J, 1995, CANCER RES, V55, P949; Bhatia N, 1999, CANCER LETT, V147, P77, DOI 10.1016/S0304-3835(99)00276-1; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Buscemi G, 2004, ONCOGENE, V23, P7691, DOI 10.1038/sj.onc.1207986; Caputi M, 1999, AM J RESP CELL MOL, V20, P746, DOI 10.1165/ajrcmb.20.4.3366; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dhanalakshmi S, 2002, ONCOGENE, V21, P1759, DOI 10.1038/sj.onc.1205240; Dong XY, 2003, AM J HUM GENET, V72, P270, DOI 10.1086/346094; Drobnjak M, 2000, CLIN CANCER RES, V6, P1891; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Flora K, 1998, AM J GASTROENTEROL, V93, P139, DOI 10.1111/j.1572-0241.1998.00139.x; Gabrielli BG, 1996, J CELL SCI, V109, P1081; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GILLETT C, 1994, CANCER RES, V54, P1812; GRANA X, 1995, ONCOGENE, V11, P211; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Hou DX, 2004, J BIOMED BIOTECHNOL, P321, DOI 10.1155/S1110724304403040; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; Kawabe T, 2004, MOL CANCER THER, V3, P513; Kim NC, 2003, ORG BIOMOL CHEM, V1, P1684, DOI 10.1039/b300099k; Koivisto P, 1998, AM J PATHOL, V152, P1; Kossatz U, 2004, GENE DEV, V18, P2602, DOI 10.1101/gad.321004; Lammer C, 1998, J CELL SCI, V111, P2445; Langner C, 2004, VIRCHOWS ARCH, V445, P631, DOI 10.1007/s00428-004-1121-2; Li Q, 2004, J CUTAN PATHOL, V31, P633, DOI 10.1111/j.0303-6987.2004.00243.x; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Lyon MA, 2002, NAT REV DRUG DISCOV, V1, P961, DOI 10.1038/nrd963; Mallikarjuna G, 2004, CANCER RES, V64, P6349, DOI 10.1158/0008-5472.CAN-04-1632; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; McDonald ER, 2000, INT J ONCOL, V16, P871; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Neuhouser ML, 2004, NUTR CANCER, V50, P1, DOI 10.1207/s15327914nc5001_1; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; Owa T, 2001, CURR MED CHEM, V8, P1487, DOI 10.2174/0929867013371996; Pares A, 1998, J HEPATOL, V28, P615, DOI 10.1016/S0168-8278(98)80285-7; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; SEKI T, 1992, MOL BIOL CELL, V3, P1373, DOI 10.1091/mbc.3.12.1373; Seppala EH, 2003, BRIT J CANCER, V89, P1966, DOI 10.1038/sj.bjc.6601425; Sharma G, 2003, ANTICANCER RES, V23, P2649; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Singh RP, 2004, CLIN CANCER RES, V10, P8641, DOI 10.1158/1078-0432.CCR-04-1435; Singh RP, 2004, CURR CANCER DRUG TAR, V4, P1, DOI 10.2174/1568009043481605; Singh SV, 2004, J BIOL CHEM, V279, P25813, DOI 10.1074/jbc.M313538200; Sumrejkanchanakij P, 2003, ONCOGENE, V22, P8723, DOI 10.1038/sj.onc.1206870; Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189; Takagaki N, 2005, INT J ONCOL, V26, P185; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Thelen P, 2004, J UROLOGY, V171, P1934, DOI 10.1097/01.ju.0000121329.37206.1b; Turowski P, 2003, MOL BIOL CELL, V14, P2984, DOI 10.1091/mbc.E02-08-0515; Vahteristo P, 2002, AM J HUM GENET, V71, P432, DOI 10.1086/341943; von Zglinicki T, 2005, MECH AGEING DEV, V126, P111, DOI 10.1016/j.mad.2004.09.034; WAGNER H, 1974, ARZNEIMITTEL-FORSCH, V24, P466; Wellington K, 2001, BIODRUGS, V15, P465, DOI 10.2165/00063030-200115070-00005; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yang ES, 2003, J BIOL CHEM, V278, P46862, DOI 10.1074/jbc.M306340200; Ye RQ, 2004, DNA REPAIR, V3, P235, DOI 10.1016/j.dnarep.2003.10.014; Ye RQ, 2001, J BIOL CHEM, V276, P4828, DOI 10.1074/jbc.M004894200; Yih LH, 2000, CANCER RES, V60, P6346; Yim D, 2005, CANCER RES, V65, P1035; Zhang YG, 2002, J BIOL CHEM, V277, P3124, DOI 10.1074/jbc.M110245200; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zheng Xiang-Yi, 2004, Ai Zheng, V23, P215; Zi XL, 1998, CANCER RES, V58, P1920; Zi XL, 1998, CLIN CANCER RES, V4, P1055; Zi ZL, 1999, P NATL ACAD SCI USA, V96, P7490, DOI 10.1073/pnas.96.13.7490	85	132	138	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					1053	1069		10.1038/sj.onc.1209146	http://dx.doi.org/10.1038/sj.onc.1209146			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16205633				2022-12-25	WOS:000235361000010
J	Jayasinghe, L; Miles, G; Bayley, H				Jayasinghe, L; Miles, G; Bayley, H			Role of the amino latch of staphylococcal alpha-hemolysin in pore formation - A co-operative interaction between the N terminus and position 217	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL-DEPENDENT CYTOLYSIN; HEPTAMERIC PORE; BICOMPONENT TOXIN; CRYSTAL-STRUCTURE; FORMING PROTEIN; LEUKOCIDIN PORE; GAMMA-HEMOLYSIN; PREPORE; RESIDUES; AUREUS	Staphylococcal alpha-hemolysin (alpha HL) is a beta barrel pore-forming toxin that is secreted by the bacterium as a water-soluble monomeric protein. Upon binding to susceptible cells, alpha HL assembles via an inactive prepore to form a water-filled homoheptameric transmembrane pore. The N terminus of alpha HL, which in the crystal structure of the fully assembled pore forms a latch between adjacent subunits, has been thought to play a vital role in the prepore to pore conversion. For example, the deletion of two N-terminal residues produced a completely inactive protein that was arrested in assembly at the prepore stage. In the present study, we have re-examined assembly with a comprehensive set of truncation mutants. Surprisingly, we found that after truncation of up to 17 amino acids, the ability of alpha HL to form functional pores was diminished, but still substantial. We then discovered that the mutation Ser(217) -> Asn, which was present in our original set of truncations but not in the new ones, promotes complete inactivation upon truncation of the N terminus. Therefore, the N terminus of alpha HL cannot be critical for the prepore to pore transformation as previously thought. Residue 217 is involved in the assembly process and must interact indirectly with the distant N terminus during the last step in pore formation. In addition, we provide evidence that an intact N terminus prevents the premature oligomerization of alpha HL monomers in solution.	Univ Oxford, Dept Chem, Res Lab, Oxford OX1 3TA, England; Texas A&M Univ Syst, Hlth Sci Ctr, Dept Med Biochem & Genet, College Stn, TX 77843 USA	University of Oxford; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Bayley, H (corresponding author), Univ Oxford, Dept Chem, Res Lab, Mansfield Rd, Oxford OX1 3TA, England.	hagan.bayley@chem.ox.ac.uk		Bayley, Hagan/0000-0003-2499-6116				Alouf J. E, 1999, COMPREHENSIVE SOURCE, V2nd; Bayley H, 2001, NATURE, V413, P226, DOI 10.1038/35093038; Bayley H, 2005, NAT STRUCT MOL BIOL, V12, P385, DOI 10.1038/nsmb0505-385; Bayley H, 2004, MOL MEMBR BIOL, V21, P209, DOI 10.1080/09687680410001716853; BHAKDI S, 1981, P NATL ACAD SCI-BIOL, V78, P5475, DOI 10.1073/pnas.78.9.5475; Braha O, 1997, CHEM BIOL, V4, P497, DOI 10.1016/S1074-5521(97)90321-5; Cheley S, 1997, PROTEIN ENG, V10, P1433, DOI 10.1093/protein/10.12.1433; Cheley S, 1999, PROTEIN SCI, V8, P1257, DOI 10.1110/ps.8.6.1257; Czajkowsky DM, 2004, EMBO J, V23, P3206, DOI 10.1038/sj.emboj.7600350; Czajkowsky DM, 1998, J MOL BIOL, V276, P325, DOI 10.1006/jmbi.1997.1535; Fang Y, 1997, BIOCHEMISTRY-US, V36, P9518, DOI 10.1021/bi970600j; Galdiero S, 2004, PROTEIN SCI, V13, P1503, DOI 10.1110/ps.03561104; Gershenson A, 2000, BIOCHEMISTRY-US, V39, P4658, DOI 10.1021/bi992473s; Giver L, 1998, P NATL ACAD SCI USA, V95, P12809, DOI 10.1073/pnas.95.22.12809; GOUAUX JE, 1994, P NATL ACAD SCI USA, V91, P12828, DOI 10.1073/pnas.91.26.12828; Gu LQ, 1999, NATURE, V398, P686, DOI 10.1038/19491; Guillet V, 2004, J BIOL CHEM, V279, P41028, DOI 10.1074/jbc.M406904200; HILDEBRAND A, 1991, J BIOL CHEM, V266, P17195; Hotze EM, 2002, J BIOL CHEM, V277, P11597, DOI 10.1074/jbc.M111039200; Hotze EM, 2001, J BIOL CHEM, V276, P8261, DOI 10.1074/jbc.M009865200; Howorka S, 1998, BIOTECHNIQUES, V25, P764, DOI 10.2144/98255bm03; Jayasinghe L, 2005, PROTEIN SCI, V14, P2550, DOI 10.1110/ps.051648505; Jones Douglas H., 1995, P591; JURSCH R, 1994, INFECT IMMUN, V62, P2249, DOI 10.1128/IAI.62.6.2249-2256.1994; Kaneko J, 2004, BIOSCI BIOTECH BIOCH, V68, P981, DOI 10.1271/bbb.68.981; KIEFER LL, 1995, J AM CHEM SOC, V117, P6831, DOI 10.1021/ja00131a004; Krasilnikov OV, 2000, MOL MICROBIOL, V37, P1372, DOI 10.1046/j.1365-2958.2000.02080.x; KRISHNASASTRY M, 1994, FEBS LETT, V356, P66, DOI 10.1016/0014-5793(94)01240-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Luchian T, 2003, ANGEW CHEM INT EDIT, V42, P1925, DOI 10.1002/anie.200250666; Luchian T, 2003, ANGEW CHEM INT EDIT, V42, P3766, DOI 10.1002/anie.200351313; MENZIES BE, 1994, INFECT IMMUN, V62, P1843, DOI 10.1128/IAI.62.5.1843-1847.1994; Miles G, 2006, J BIOL CHEM, V281, P2205, DOI 10.1074/jbc.M510842200; Miles G, 2002, PROTEIN SCI, V11, P894, DOI 10.1110/ps.4360102; Miles G, 2001, BIOCHEMISTRY-US, V40, P8514, DOI 10.1021/bi010454o; Miller CJ, 1999, BIOCHEMISTRY-US, V38, P10432, DOI 10.1021/bi990792d; Montoya M, 2003, BBA-BIOMEMBRANES, V1609, P19, DOI 10.1016/S0005-2736(02)00663-6; Nguyen VT, 2004, J BIOCHEM, V136, P563, DOI 10.1093/jb/mvh160; Nguyen VT, 2003, EMBO J, V22, P4968, DOI 10.1093/emboj/cdg498; Nguyen VT, 2002, MOL MICROBIOL, V45, P1485, DOI 10.1046/j.1365-2958.2002.03125.x; Olson R, 1999, NAT STRUCT BIOL, V6, P134; PANCHAL RG, 1995, J BIOL CHEM, V270, P23072, DOI 10.1074/jbc.270.39.23072; Pany S, 2004, BIOCHEM BIOPH RES CO, V322, P29, DOI 10.1016/j.bbrc.2004.07.073; Pedelacq JD, 1999, STRUCTURE, V7, P277, DOI 10.1016/S0969-2126(99)80038-0; Prevost G, 2003, CEL MOL MEC TOX ACT, V5, P3; Prevost G, 2001, CURR TOP MICROBIOL, V257, P53; Russ WP, 2005, NATURE, V437, P579, DOI 10.1038/nature03990; Shepard LA, 2000, BIOCHEMISTRY-US, V39, P10284, DOI 10.1021/bi000436r; Shin SH, 2005, J AM CHEM SOC, V127, P10462, DOI 10.1021/ja052194u; Shin SH, 2002, ANGEW CHEM INT EDIT, V41, P3707, DOI 10.1002/1521-3773(20021004)41:19<3707::AID-ANIE3707>3.0.CO;2-5; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Spiller B, 1999, P NATL ACAD SCI USA, V96, P12305, DOI 10.1073/pnas.96.22.12305; Tilley SJ, 2005, CELL, V121, P247, DOI 10.1016/j.cell.2005.02.033; Valeva A, 1997, BBA-BIOMEMBRANES, V1325, P281, DOI 10.1016/S0005-2736(96)00266-0; Valeva A, 1997, BIOCHEMISTRY-US, V36, P13298, DOI 10.1021/bi971075r; Valeva A, 2001, J BIOL CHEM, V276, P14835, DOI 10.1074/jbc.M100301200; Vandana S, 1997, J BIOL CHEM, V272, P24858, DOI 10.1074/jbc.272.40.24858; Vijayvargia R, 2004, BIOCHEM BIOPH RES CO, V324, P1130, DOI 10.1016/j.bbrc.2004.09.164; Vijayvargia R, 2004, BIOCHEM BIOPH RES CO, V324, P1124, DOI 10.1016/j.bbrc.2004.09.165; WALKER B, 1992, J BIOL CHEM, V267, P21782; WALKER B, 1995, CHEM BIOL, V2, P99, DOI 10.1016/1074-5521(95)90282-1; WALKER B, 1995, PROTEIN ENG, V8, P491, DOI 10.1093/protein/8.5.491	62	43	46	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2195	2204		10.1074/jbc.M510841200	http://dx.doi.org/10.1074/jbc.M510841200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16227199	hybrid			2022-12-25	WOS:000234760400043
J	Deval, E; Friend, V; Thirant, C; Salinas, M; Jodar, M; Lazdunski, M; Lingueglia, E				Deval, E; Friend, V; Thirant, C; Salinas, M; Jodar, M; Lazdunski, M; Lingueglia, E			Regulation of sensory neuron-specific acid-sensing ion channel 3 by the adaptor protein Na+/H+ exchanger regulatory factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DORSAL-ROOT GANGLIA; ION CHANNELS; CAENORHABDITIS-ELEGANS; PDZ-DOMAIN; DIFFERENTIAL REGULATION; GATED CURRENT; NHERF FAMILY; ERM PROTEINS; RECEPTORS; EZRIN	Acid-sensing ion channels (ASICs) are cationic channels activated by extracellular protons. The ASIC3 subunit is largely expressed in the peripheral nervous system, where it contributes to pain perception and to some aspects of mechanosensation. We report here a PDZ-dependent and protein kinase C-modulated association between ASIC3 and the Na+/H+ exchanger regulatory factor-1 (NHERF-1) adaptor protein. We show that NHERF-1 and ASIC3 are co-expressed in dorsal root ganglion neurons. NHERF-1 enhances the ASIC3 peak current in heterologous cells, including F-11 dorsal root ganglion cells, by increasing the amount of channel at the plasma membrane. Perhaps more importantly, we show that the plateau current of ASIC3 can be dramatically increased (10-30-fold) by association with NHERF-1, leading to a significant sustained current at pH 6.6. In the presence of NHERF-1, the ASIC3 subcellular localization is modified, and the channel co-localizes with ezrin, a member of the ezrin-radixin-moesin family of actin binding proteins, providing the first direct link between ASIC3 and the cortical cytoskeleton. Given the importance of the ASIC3 sustained current in nociceptor excitability, it is likely that NHERF-1 participates in channel functions associated with nociception and mechanosensation.	UNSA, CNRS, Inst Pharmacol Mol & Cellulaire, Inst Paul hamel,UMR 6097, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Lazdunski, M (corresponding author), UNSA, CNRS, Inst Pharmacol Mol & Cellulaire, Inst Paul hamel,UMR 6097, 660 Route Lucioles, F-06560 Valbonne, France.	lazdunski@ipmc.cnrs.fr	DEVAL, Emmanuel/N-6280-2016; SALINAS, Miguel/N-6380-2016; LINGUEGLIA, Eric/F-5509-2013; Thirant, Cecile/CAG-6257-2022	DEVAL, Emmanuel/0000-0002-0215-9379; SALINAS, Miguel/0000-0002-7445-123X; LINGUEGLIA, Eric/0000-0003-3902-3405; Thirant, Cecile/0000-0003-3873-5240				Anzai N, 2002, J BIOL CHEM, V277, P16655, DOI 10.1074/jbc.M201087200; BEVAN S, 1991, J PHYSIOL-LONDON, V433, P145, DOI 10.1113/jphysiol.1991.sp018419; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Chen CC, 2002, P NATL ACAD SCI USA, V99, P8992, DOI 10.1073/pnas.122245999; Deval E, 2004, J BIOL CHEM, V279, P19531, DOI 10.1074/jbc.M313078200; Deval E, 2003, NEUROPHARMACOLOGY, V44, P662, DOI 10.1016/S0028-3908(03)00047-9; Donowitz M, 2005, J PHYSIOL-LONDON, V567, P1, DOI 10.1113/jphysiol.2005.089698; Drew LJ, 2004, J PHYSIOL-LONDON, V556, P691, DOI 10.1113/jphysiol.2003.058693; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; Fouassier L, 2000, J BIOL CHEM, V275, P25039, DOI 10.1074/jbc.C000092200; Glazebrook PA, 2005, PFLUG ARCH EUR J PHY, V451, P125, DOI 10.1007/s00424-005-1468-5; Hirbec H, 2003, NEURON, V37, P625, DOI 10.1016/S0896-6273(02)01191-1; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hruska-Hageman AM, 2004, J BIOL CHEM, V279, P46962, DOI 10.1074/jbc.M405874200; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; Ji RR, 1995, J NEUROSCI, V15, P8156; Jones NG, 2004, J NEUROSCI, V24, P10974, DOI 10.1523/JNEUROSCI.2619-04.2004; Krishtal O, 2003, TRENDS NEUROSCI, V26, P477, DOI 10.1016/S0166-2236(03)00210-8; Lau AG, 2001, BIOCHEMISTRY-US, V40, P8572, DOI 10.1021/bi0103516; LINGUEGLIA E, 2006, IN PRESS PEPTIDES; Mamet J, 2002, J NEUROSCI, V22, P10662; Melendez-Vasquez CV, 2001, P NATL ACAD SCI USA, V98, P1235, DOI 10.1073/pnas.98.3.1235; Moriyama T, 2003, J NEUROSCI, V23, P6058, DOI 10.1523/JNEUROSCI.23-14-06058.2003; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; O'Hagan R, 2005, NAT NEUROSCI, V8, P43, DOI 10.1038/nn1362; Page AJ, 2005, GUT, V54, P1408, DOI 10.1136/gut.2005.071084; PLATIKA D, 1985, P NATL ACAD SCI USA, V82, P3499, DOI 10.1073/pnas.82.10.3499; Price MP, 2004, J BIOL CHEM, V279, P53886, DOI 10.1074/jbc.M407708200; Price MP, 2001, NEURON, V32, P1071, DOI 10.1016/S0896-6273(01)00547-5; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; Ramesh V, 2004, NAT REV NEUROSCI, V5, P462, DOI 10.1038/nrn1407; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Reczek D, 1998, J BIOL CHEM, V273, P18452, DOI 10.1074/jbc.273.29.18452; Reeh P W, 2001, Curr Opin Pharmacol, V1, P45, DOI 10.1016/S1471-4892(01)00014-5; Ruan HZ, 2003, HISTOCHEM CELL BIOL, V120, P415, DOI 10.1007/s00418-003-0579-3; Shenolikar S, 2004, PHYSIOLOGY, V19, P362, DOI 10.1152/physiol.00020.2004; Shenolikar S, 2001, FEBS LETT, V489, P233, DOI 10.1016/S0014-5793(01)02109-3; Sluka KA, 2003, PAIN, V106, P229, DOI 10.1016/S0304-3959(03)00269-0; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STEEN KH, 1995, NEUROSCI LETT, V199, P29, DOI 10.1016/0304-3940(95)12002-L; Sutherland SP, 2001, P NATL ACAD SCI USA, V98, P711, DOI 10.1073/pnas.011404498; Suzuki H, 2003, NEURON, V39, P1005, DOI 10.1016/j.neuron.2003.08.015; Ugawa S, 2002, J CLIN INVEST, V110, P1185, DOI 10.1172/JCI200215709; Vellani V, 2004, J PHYSIOL-LONDON, V560, P391, DOI 10.1113/jphysiol.2004.067462; Voilley N, 2001, J NEUROSCI, V21, P8026, DOI 10.1523/JNEUROSCI.21-20-08026.2001; Voilley Nicolas, 2004, Current Drug Targets - Inflammation and Allergy, V3, P71, DOI 10.2174/1568010043483980; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1999, ANN NY ACAD SCI, V868, P67, DOI 10.1111/j.1749-6632.1999.tb11274.x; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; Woo YC, 2004, ANESTHESIOLOGY, V101, P468, DOI 10.1097/00000542-200408000-00029	51	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1796	1807		10.1074/jbc.M509669200	http://dx.doi.org/10.1074/jbc.M509669200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16234233	hybrid			2022-12-25	WOS:000234652000061
J	Zu, K; Bihani, T; Lin, A; Park, YM; Mori, K; Ip, C				Zu, K; Bihani, T; Lin, A; Park, YM; Mori, K; Ip, C			Enhanced selenium effect on growth arrest by BiP/GRP78 knockdown in p53-null human prostate cancer cells	ONCOGENE			English	Article						selenium; unfolded protein response; BiP/GRP78 knockdown; ER stress signalings	ENDOPLASMIC-RETICULUM STRESS; UNFOLDED-PROTEIN RESPONSE; TRANSCRIPTION FACTOR ATF6; ER STRESS; MESSENGER-RNA; DIMERIZATION DOMAIN; INDUCIBLE PROTEIN; MAMMALIAN-CELLS; ACTIVATION; APOPTOSIS	Redox modi. cation of thiol/disulfide interchange in proteins by selenium could lead to protein unfolding. When this occurs in the endoplasmic reticulum ( ER), a process known as unfolded protein response (UPR) is orchestrated for survival through activation of PERK eIF2 alpha (PERK: double-stranded RNA-activated protein kinase-like ER kinase; eIF2 alpha: eucaryotic initiation factor 2 alpha), ATF alpha ( ATF alpha: activating transcription factor 6) and inositol requiring 1 (IRE1)-x-box-binding protein 1 (XBP1) signalings. All three UPR transducer pathways were upregulated very rapidly when PC-3 cells were exposed to selenium. These changes were accompanied by increased expression of UPR target genes, including immunoglobulin heavy chain-binding protein/glucoseregulated protein, 78 kDa and CCAAT/enhancer binding protein-homologous protein/growth arrest- and DNA damage-inducible gene (CHOP/GADD153). Induction of BiP/ GRP78, an ER-resident chaperone, is part of the damage control mechanism, while CHOP/GADD153 is a transcription factor associated with growth arrest and apoptosis in the event of prolonged ER stress. Knocking down BiP/ GRP78 induction by small interference RNA produced a differential response of the three transducers to selenium, suggesting that the signaling intensity of each transducer could be fine-tuned depending on BiP/ GRP78 availability. In the presence of selenium, CHOP/GADD153 expression was raised even higher by BiP/ GRP78 knockdown. Under this condition, the selenium effect on wild-type p53-activated fragment p21 (p21(WAF)), cyclin-dependent kinase (CDK)1 and CDK2 was also magnified in a manner consistent with enhanced cell growth arrest. Additional experiments with CHOP/ GADD153 siRNA knockdown strongly suggested that CHOP/ GADD153 may play a positive role in upregulating the expression of p21(WAF) in a p53-independent manner (PC-3 cells are p53 null). Collectively, the above findings support the idea that UPR could be an important mechanism in mediating the anticancer activity of selenium.	Roswell Pk Canc Inst, Dept Canc Chemoprevent, Buffalo, NY 14263 USA; Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; Roswell Pk Canc Inst, Dept Cell Stress Biol, Buffalo, NY 14263 USA; Kyoto Univ, Grad Sch Sci, Dept Biophys, Kyoto, Japan	Roswell Park Cancer Institute; Roswell Park Cancer Institute; Roswell Park Cancer Institute; Kyoto University	Ip, C (corresponding author), Roswell Pk Canc Inst, Dept Canc Chemoprevent, Elm & Carlton St, Buffalo, NY 14263 USA.	clement.ip@roswellpark.org	Longo, Kenneth A/A-5631-2010; Mori, Kazutoshi/K-6106-2015		NCI NIH HHS [P30 CA016056, P30 CA 16056, R01 CA097963-03, CA 09796] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA097963, P30CA016056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BEDNARD K, 2004, BASIC CLIN PHARMACOL, V94, P124; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Cao SS, 2004, CLIN CANCER RES, V10, P2561, DOI 10.1158/1078-0432.CCR-03-0268; Chen X, 2002, J BIOL CHEM, V277, P13045, DOI 10.1074/jbc.M110636200; Dong Y, 2003, CANCER RES, V63, P52; El-Bayoumy K, 2004, MUTAT RES-FUND MOL M, V551, P181, DOI 10.1016/j.mrfmmm.2004.02.023; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; Friedman AD, 1996, CANCER RES, V56, P3250; Gotoh T, 2002, J BIOL CHEM, V277, P12343, DOI 10.1074/jbc.M107988200; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Hung CC, 2003, J BIOL CHEM, V278, P29317, DOI 10.1074/jbc.M302368200; Ip C, 1998, J NUTR, V128, P1845, DOI 10.1093/jn/128.11.1845; IP C, 1990, CANCER RES, V50, P1206; Ip C, 2000, CANCER RES, V60, P2882; Ip C, 2002, CANCER METAST REV, V21, P281, DOI 10.1023/A:1021263027659; IP C, 1991, CANCER RES, V51, P595; Jessop CE, 2004, BIOCHEM SOC T, V32, P655, DOI 10.1042/BST0320655; Kadowaki H, 2004, J CHEM NEUROANAT, V28, P93, DOI 10.1016/j.jchemneu.2004.05.004; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; KUZNETSOV G, 1994, J BIOL CHEM, V269, P22990; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Lehotsky J, 2003, PHYSIOL RES, V52, P269; Liu CY, 2000, J BIOL CHEM, V275, P24881, DOI 10.1074/jbc.M004454200; Liu CY, 2003, J BIOL CHEM, V278, P17680, DOI 10.1074/jbc.M300418200; Liu CY, 2002, J BIOL CHEM, V277, P18346, DOI 10.1074/jbc.M112454200; Ma K, 2002, J BIOL CHEM, V277, P18728, DOI 10.1074/jbc.M200903200; Ma YJ, 2004, J CHEM NEUROANAT, V28, P51, DOI 10.1016/j.jchemneu.2003.08.007; Okada T, 2003, J BIOL CHEM, V278, P31024, DOI 10.1074/jbc.M300923200; Park Eun-Mi, 2005, Cancer Genomics & Proteomics, V2, P25; SATOH M, 1993, EXP CELL RES, V205, P76, DOI 10.1006/excr.1993.1060; Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Shen XH, 2004, J CHEM NEUROANAT, V28, P79, DOI 10.1016/j.jchemneu.2004.02.006; Tajiri S, 2004, CELL DEATH DIFFER, V11, P403, DOI 10.1038/sj.cdd.4401365; Tirasophon W, 2000, GENE DEV, V14, P2725, DOI 10.1101/gad.839400; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; van Huizen R, 2003, J BIOL CHEM, V278, P15558, DOI 10.1074/jbc.M212074200; Wang Y, 2000, J BIOL CHEM, V275, P27013; Yan W, 2002, P NATL ACAD SCI USA, V99, P15920, DOI 10.1073/pnas.252341799; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zu K, 2003, CANCER RES, V63, P6988	51	87	91	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					546	554		10.1038/sj.onc.1209071	http://dx.doi.org/10.1038/sj.onc.1209071			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16205645	Green Accepted			2022-12-25	WOS:000234897400006
J	Gerega, A; Rockel, B; Peters, J; Tamura, T; Baumeister, W; Zwickl, P				Gerega, A; Rockel, B; Peters, J; Tamura, T; Baumeister, W; Zwickl, P			VAT, the Thermoplasma homolog of mammalian p97/VCP, is an N domain-regulated protein unfoldase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETHYLMALEIMIDE SENSITIVE FACTOR; VALOSIN-CONTAINING PROTEIN; ATP-DEPENDENT PROTEASE; AAA-ATPASE; CONFORMATIONAL-CHANGES; CHAPERONE FUNCTION; CRYSTAL-STRUCTURE; DIVERSE FUNCTIONS; BINDING SITES; COMPLEX	The Thermoplasma VCP-like ATPase from Thermoplasma acidophilum (VAT) ATPase is a member of the two-domain AAA ATPases and homologous to the mammalian p97/VCP and NSF proteins. We show here that the VAT ATPase complex unfolds green fluorescent protein (GFP) labeled with the ssrA-degradation tag. Increasing the Mg2+ concentration derepresses the ATPase activity and concomitantly stimulates the unfolding activity of VAT. Similarly, the VAT Delta N complex, a mutant of VAT deleted for the N domain, displays up to 24-fold enhanced ATP hydrolysis and 250-fold enhanced GFP unfolding activity when compared with wild-type VAT. To determine the individual contribution of the two AAA domains to ATP hydrolysis and GFP unfolding we performed extensive site-directed mutagenesis of the Walker A, Walker B, sensor-1, and pore residues in both AAA domains. Analysis of the VAT mutant proteins, where ATP hydrolysis was confined to a single AAA domain, revealed that the first domain (D1) is sufficient to exert GFP unfolding indistinguishable from wild-type VAT, while the second AAA domain (D2), although active, is significantly less efficient than wild-type VAT. A single conserved aromatic residue in the D1 section of the pore was found to be essential for GFP unfolding. In contrast, two neighboring residues in the D2 section of the pore had to be exchanged simultaneously, to achieve a drastic inhibition of GFP unfolding.	Max Planck Inst Biochem, Dept Mol Struct Biol, D-82152 Martinsried, Germany; Natl Inst Adv Ind Sci & Technol, AIST, Res Inst Genomebased Biofactory, Toyohira Ku, Sapporo, Hokkaido 0628517, Japan; Hokkaido Univ, Grad Sch Agr, Lab Mol Environm Microbiol, Kita Ku, Sapporo, Hokkaido 0608589, Japan	Max Planck Society; National Institute of Advanced Industrial Science & Technology (AIST); Hokkaido University	Zwickl, P (corresponding author), Max Planck Inst Biochem, Dept Mol Struct Biol, Klopferspitz 18, D-82152 Martinsried, Germany.	zwickl@biochem.mpg.de	Tamura, Tomohiro/M-4732-2018	Tamura, Tomohiro/0000-0003-2409-6556				Benaroudj N, 2003, MOL CELL, V11, P69, DOI 10.1016/S1097-2765(02)00775-X; Besche H, 2004, FEBS LETT, V574, P161, DOI 10.1016/j.febslet.2004.08.021; Beuron F, 2003, J MOL BIOL, V327, P619, DOI 10.1016/S0022-2836(03)00178-5; Braun S, 2002, EMBO J, V21, P615, DOI 10.1093/emboj/21.4.615; Brunger AT, 2003, FEBS LETT, V555, P126, DOI 10.1016/S0014-5793(03)01107-4; Cao K, 2003, CELL, V115, P355, DOI 10.1016/S0092-8674(03)00815-8; Coles M, 1999, CURR BIOL, V9, P1158, DOI 10.1016/S0960-9822(00)80017-2; Dalal S, 2004, MOL BIOL CELL, V15, P637, DOI 10.1091/mbc.E03-02-0097; Davies JM, 2005, STRUCTURE, V13, P183, DOI 10.1016/j.str.2004.11.014; DeLaBarre B, 2005, J MOL BIOL, V347, P437, DOI 10.1016/j.jmb.2005.01.060; DeLaBarre B, 2003, NAT STRUCT BIOL, V10, P856, DOI 10.1038/nsb972; Dreveny I, 2004, EMBO J, V23, P1030, DOI 10.1038/sj.emboj.7600139; Gnann A, 2004, MOL BIOL CELL, V15, P4125, DOI 10.1091/mbc.e04-01-0024; Golbik R, 1999, BIOL CHEM, V380, P1049, DOI 10.1515/BC.1999.131; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; Hattendorf DA, 2002, EMBO J, V21, P12, DOI 10.1093/emboj/21.1.12; Higashiyama H, 2002, CELL DEATH DIFFER, V9, P264, DOI 10.1038/sj.cdd.4400955; Huyton T, 2003, J STRUCT BIOL, V144, P337, DOI 10.1016/j.jsb.2003.10.007; Ishikawa T, 2001, P NATL ACAD SCI USA, V98, P4328, DOI 10.1073/pnas.081543698; Karata K, 1999, J BIOL CHEM, V274, P26225, DOI 10.1074/jbc.274.37.26225; Karzai AW, 2000, NAT STRUCT BIOL, V7, P449; Krzewska J, 2001, J MOL BIOL, V314, P901, DOI 10.1006/jmbi.2001.5190; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Li XQ, 1997, J BIOL CHEM, V272, P28545, DOI 10.1074/jbc.272.45.28545; Lum R, 2004, J BIOL CHEM, V279, P29139, DOI 10.1074/jbc.M403777200; Matveeva EA, 2002, BIOCHEMISTRY-US, V41, P530, DOI 10.1021/bi015632s; Maurizi Michael R., 2001, EMBO Reports, V2, P980, DOI 10.1093/embo-reports/kve229; Maurizi MR, 2004, J STRUCT BIOL, V146, P1, DOI 10.1016/j.jsb.2003.12.001; Meyer HH, 1998, FEBS LETT, V437, P255, DOI 10.1016/S0014-5793(98)01232-0; Meyer HH, 2002, EMBO J, V21, P5645, DOI 10.1093/emboj/cdf579; Neuwald AF, 1999, GENOME RES, V9, P27; Ortega J, 2000, MOL CELL, V6, P1515, DOI 10.1016/S1097-2765(00)00148-9; Park EY, 2005, J BIOL CHEM, V280, P22892, DOI 10.1074/jbc.M500035200; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002; Rape M, 2001, CELL, V107, P667, DOI 10.1016/S0092-8674(01)00595-5; Richly H, 2005, CELL, V120, P73, DOI 10.1016/j.cell.2004.11.013; Rockel B, 1999, FEBS LETT, V451, P27, DOI 10.1016/S0014-5793(99)00431-7; Rockel B, 2002, J MOL BIOL, V317, P673, DOI 10.1006/jmbi.2002.5448; Rouiller I, 2002, NAT STRUCT BIOL, V9, P950, DOI 10.1038/nsb872; Schirmer EC, 2001, P NATL ACAD SCI USA, V98, P914, DOI 10.1073/pnas.031568098; Schlee S, 2001, J MOL BIOL, V306, P889, DOI 10.1006/jmbi.2001.4455; Schlieker C, 2004, NAT STRUCT MOL BIOL, V11, P607, DOI 10.1038/nsmb787; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Shorter J, 2005, NAT STRUCT MOL BIOL, V12, P4, DOI 10.1038/nsmb0105-4; Siddiqui SM, 2004, GENE DEV, V18, P369, DOI 10.1101/gad.1170304; Song CC, 2003, J BIOL CHEM, V278, P3648, DOI 10.1074/jbc.M208422200; Song HK, 2000, P NATL ACAD SCI USA, V97, P14103, DOI 10.1073/pnas.250491797; Wang J, 2001, STRUCTURE, V9, P177, DOI 10.1016/S0969-2126(01)00570-6; Wang Q, 2004, J STRUCT BIOL, V146, P44, DOI 10.1016/j.jsb.2003.11.014; Watts GDJ, 2004, NAT GENET, V36, P377, DOI 10.1038/ng1332; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; Weibezahn J, 2004, CELL, V119, P653, DOI 10.1016/j.cell.2004.11.027; Weibezahn J, 2004, MICROB CELL FACT, V3, DOI 10.1186/1475-2859-3-1; Whiteheart SW, 2004, J STRUCT BIOL, V146, P32, DOI 10.1016/j.jsb.2003.09.015; Wojcik C, 2004, J CELL SCI, V117, P281, DOI 10.1242/jcs.00841; Yamada-Inagawa T, 2003, J BIOL CHEM, V278, P50182, DOI 10.1074/jbc.M308327200; Yamanaka K, 2004, J STRUCT BIOL, V146, P242, DOI 10.1016/j.jsb.2003.11.017; Ye YH, 2003, J CELL BIOL, V162, P71, DOI 10.1083/jcb.200302169; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X	61	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42856	42862		10.1074/jbc.M510592200	http://dx.doi.org/10.1074/jbc.M510592200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16236712	hybrid			2022-12-25	WOS:000234200800048
J	Kumar, A; Kumar, A; Michael, P; Brabant, D; Parissenti, AM; Ramana, CV; Xu, XL; Parrillo, JE				Kumar, A; Kumar, A; Michael, P; Brabant, D; Parissenti, AM; Ramana, CV; Xu, XL; Parrillo, JE			Human serum from patients with septic shock activates transcription factors STAT1, IRF1, and NF-kappa B and induces apoptosis in human cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-INDUCED APOPTOSIS; NECROSIS-FACTOR-ALPHA; MYOCARDIAL DEPRESSANT SUBSTANCE; NITRIC-OXIDE; SYNTHASE INDUCTION; SIGNALING PATHWAY; RAT MODEL; SEPSIS; DYSFUNCTION; INHIBITION	Proinflammatory cytokines have been linked to depression of myocardial contractility in vivo in patients with acute septic shock and in vitro models employing isolated myocytes exposed to serum from such patients. The key pathways involved in mediating this septic organ dysfunction (cell adhesion molecule expression, inducible nitric-oxide synthase induction, and apoptosis) are known to be regulated by transcription factors STAT1, IRF1, and NF-kappa B. Utilizing a model that mimics human disease, we have demonstrated activation of the transcription factors STAT1, IRF1, and NF-kappa B in human fetal myocytes exposed to human septic serum. Both reporter and electrophoretic mobility shift assays demonstrated a 5-19-fold increase in activation of transcription factors STAT1, IRF1, and NF-kappa B in response to incubation with human septic serum. The addition of human septic serum to human fetal myocytes induced apoptosis in human fetal myocytes and activation of the mitogen-activated protein kinase c-Jun NH2-terminal kinase and caspase 1 as measured by Western blot. These data suggest that transcription factor activation and early myocyte apoptosis play a mechanistic role in septic myocardial depression and sepsis-induced organ dysfunction.	Laurentian Univ, Dept Chem & Biochem, Biomol Sci Programme, Sudbury, ON P3E 2C6, Canada; Univ Manitoba, Sect Crit Care Med, Winnipeg, MB R3A 1R9, Canada; Yale Univ, Dept Med, West Haven, CT 06516 USA; Univ Chicago, Chicago, IL 60612 USA; Rush Presbyterian St Lukes Med Ctr, Dept Gen Surg, Chicago, IL 60612 USA; Cooper Univ Hosp, Div Cardiovasc Dis & Crit Care Med, Robert Wood Johnson Med Sch, Camden, NJ 08103 USA	Laurentian University; University of Manitoba; Yale University; University of Chicago; Rush University; Cooper University Hospital; Rutgers State University New Brunswick; Rutgers State University Medical Center	Kumar, A (corresponding author), Laurentian Univ, Dept Chem & Biochem, Biomol Sci Programme, 935 Ramsey Lake Rd, Sudbury, ON P3E 2C6, Canada.	akumar@laurentian.ca		chilakamarti, ramana/0000-0002-5153-8252				Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Arstall MA, 1999, CIRC RES, V85, P829, DOI 10.1161/01.RES.85.9.829; Ayala A, 1996, BLOOD, V87, P4261, DOI 10.1182/blood.V87.10.4261.bloodjournal87104261; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bergmann MW, 2001, J MOL CELL CARDIOL, V33, P1223, DOI 10.1006/jmcc.2001.1385; Blanco JCG, 2000, J EXP MED, V191, P2131, DOI 10.1084/jem.191.12.2131; Bohlinger I, 1996, AM J PATHOL, V149, P1381; Bohrer H, 1997, J CLIN INVEST, V100, P972, DOI 10.1172/JCI119648; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; BRIKEN V, 1995, MOL CELL BIOL, V15, P975; Chen HW, 2000, CELL STRESS CHAPERON, V5, P188, DOI 10.1379/1466-1268(2000)005<0188:AOSIAB>2.0.CO;2; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Chung SC, 1998, J SURG RES, V77, P63, DOI 10.1006/jsre.1998.5339; Cobb JP, 1999, SURGERY, V126, P438, DOI 10.1067/msy.1999.98930; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Coopersmith CM, 2002, JAMA-J AM MED ASSOC, V287, P1716, DOI 10.1001/jama.287.13.1716; Coutinho HB, 1997, J CLIN PATHOL, V50, P294, DOI 10.1136/jcp.50.4.294; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Esmon CT, 2001, THROMB HAEMOSTASIS, V86, P51; Fauvel H, 2001, AM J PHYSIOL-HEART C, V280, pH1608, DOI 10.1152/ajpheart.2001.280.4.H1608; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; Hashimoto S, 2000, AM J RESP CRIT CARE, V161, P237, DOI 10.1164/ajrccm.161.1.9810007; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hiramatsu M, 1997, SHOCK, V7, P247, DOI 10.1097/00024382-199704000-00002; Hiscott J, 1999, J INTERF CYTOK RES, V19, P1, DOI 10.1089/107999099314360; Hotchkiss RS, 1999, CRIT CARE MED, V27, P1230, DOI 10.1097/00003246-199907000-00002; Hotchkiss RS, 1997, CRIT CARE MED, V25, P1298, DOI 10.1097/00003246-199708000-00015; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Ing DJ, 1999, CIRC RES, V84, P21; Jeschke MG, 2001, AM J PHYSIOL-GASTR L, V280, pG1314, DOI 10.1152/ajpgi.2001.280.6.G1314; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; Krown KA, 1996, J CLIN INVEST, V98, P2854, DOI 10.1172/JCI119114; Kubota T, 2001, J MOL CELL CARDIOL, V33, P1331, DOI 10.1006/jmcc.2001.1393; Kumar A, 1996, J EXP MED, V183, P949, DOI 10.1084/jem.183.3.949; Kumar A, 1999, AM J PHYSIOL-REG I, V276, pR265, DOI 10.1152/ajpregu.1999.276.1.R265; Kumar A, 2001, J CARDIOTHOR VASC AN, V15, P485, DOI 10.1053/jcan.2001.25003; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; Li GQ, 2004, J BIOL CHEM, V279, P1123, DOI 10.1074/jbc.M305893200; Lightfoot E, 1999, SHOCK, V11, P29, DOI 10.1097/00024382-199901000-00004; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; Liu SF, 1997, J IMMUNOL, V159, P3976; Madorin WS, 2001, CRIT CARE MED, V29, P1774, DOI 10.1097/00003246-200109000-00020; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; Mascareno E, 2001, CIRCULATION, V104, P325, DOI 10.1161/01.CIR.104.3.325; Matsukawa A, 2001, J EXP MED, V193, P679, DOI 10.1084/jem.193.6.679; McDonald TE, 2000, AM J PHYSIOL-HEART C, V279, pH2053; MELLOW E, 1986, CRIT CARE MED, V14, P342, DOI 10.1097/00003246-198604000-00068; Murphy K, 1998, NEW HORIZ-SCI PRACT, V6, P181; Neviere R, 2001, AM J RESP CRIT CARE, V163, P218, DOI 10.1164/ajrccm.163.1.2003109; Oddis CV, 1996, AM J PHYSIOL-HEART C, V270, pH1864, DOI 10.1152/ajpheart.1996.270.5.H1864; PARKER MM, 1984, ANN INTERN MED, V100, P483, DOI 10.7326/0003-4819-100-4-483; Parrillo J E, 1993, N Engl J Med, V328, P1471; PARRILLO JE, 1985, J CLIN INVEST, V76, P1539, DOI 10.1172/JCI112135; Paterson RL, 2000, CRIT CARE MED, V28, P1047, DOI 10.1097/00003246-200004000-00022; Pinsky MR, 2000, AM J RESP CRIT CARE, V161, P1087, DOI 10.1164/ajrccm.161.4.9904033; Raeburn CD, 2001, SURGERY, V130, P319, DOI 10.1067/msy.2001.116410; REILLY JM, 1989, CHEST, V95, P1072, DOI 10.1378/chest.95.5.1072; REVHAUG A, 1988, ARCH SURG-CHICAGO, V123, P162; Sabapathy K, 2004, MOL CELL, V15, P713, DOI 10.1016/j.molcel.2004.08.028; Senftleben U, 2002, CRIT CARE MED, V30, pS18, DOI 10.1097/00003246-200201001-00003; Shames BD, 1998, AM J PHYSIOL-HEART C, V275, pH1084, DOI 10.1152/ajpheart.1998.275.3.H1084; Song GY, 2000, SURGERY, V128, P133, DOI 10.1067/msy.2000.107282; Stephanou A, 2000, J BIOL CHEM, V275, P10002, DOI 10.1074/jbc.275.14.10002; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Tsukada J, 1996, MOL CELL BIOL, V16, P2183; Wang GQ, 2001, BURNS, V27, P250, DOI 10.1016/S0305-4179(00)00105-4; Yu CF, 2004, MOL CELL, V13, P329, DOI 10.1016/S1097-2765(04)00028-0	75	56	60	0	11	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42619	42626		10.1074/jbc.M508416200	http://dx.doi.org/10.1074/jbc.M508416200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16223733	hybrid			2022-12-25	WOS:000234200800019
J	Bohnert, S; Schiavo, G				Bohnert, S; Schiavo, G			Tetanus toxin is transported in a novel neuronal compartment characterized by a specialized pH regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; BOTULINUM NEUROTOXINS; RETROGRADE TRANSPORT; MEMBRANE-PROTEINS; FRAGMENT C; VACUOLAR; MOTOR; ACIDIFICATION; ENDOCYTOSIS; ATPASE	Tetanus toxin binds specifically to motor neurons at the neuromuscular junction. There, it is internalized into vesicular carriers undergoing fast retrograde transport to the spinal cord. Despite the importance of this axonal transport pathway in health and disease, its molecular and biophysical characterization is presently lacking. We sought to fill this gap by determining the pH regulation of this compartment in living motor neurons using a chimera of the tetanus toxin binding fragment (TeNTHC) and a pH-sensitive variant of the green fluorescent protein (ratiometric pHluorin). We have demonstrated that moving retrograde carriers display a narrow range of neutral pH values, which is kept constant during transport. Stationary TeNTHC-positive organelles instead exhibit a wide spectrum of pH values, ranging from acidic to neutral. This distinct pH regulation is due to a differential targeting of the vacuolar (H+) ATPase, which is not present on moving TeNT H-C compartments. Accordingly, inhibition of the vacuolar (H+) ATPase under conditions that completely abolish the intracellular accumulation of acidotrophic dyes does not affect axonal retrograde transport of TeNT H-C. However, a functional vacuolar (H+) ATPase is required for early steps of TeNT H-C trafficking following endocytosis, and it is localized to axonal vesicles containing TeNT H-C. Altogether, these findings indicate that the vacuolar (H+) ATPase plays a specific role in early sorting events directing TeNTHC to axonal carriers but not in their subsequent progression along the retrograde transport route, which escapes acidification and targeting to degradative organelles.	Canc Res UK London Res Inst, Mol Neuropathobiol Lab, Lincolns Inn Fields Lab, London WC2A 3PX, England	Cancer Research UK	Schiavo, G (corresponding author), Canc Res UK London Res Inst, Mol Neuropathobiol Lab, Lincolns Inn Fields Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	Giampietro.Schiavo@cancer.org.uk		Schiavo, Giampietro/0000-0002-4319-8745				Al-Younes HM, 1999, CELL MICROBIOL, V1, P237, DOI 10.1046/j.1462-5822.1999.00024.x; Arce V, 1999, J NEUROSCI RES, V55, P119, DOI 10.1002/(SICI)1097-4547(19990101)55:1<119::AID-JNR13>3.3.CO;2-Y; Ashby MC, 2004, TRENDS NEUROSCI, V27, P257, DOI 10.1016/j.tins.2004.03.010; Awaji T, 2001, BIOCHEM BIOPH RES CO, V289, P457, DOI 10.1006/bbrc.2001.6004; Balbis A, 2004, J BIOL CHEM, V279, P12777, DOI 10.1074/jbc.M311493200; Bozza T, 2004, NEURON, V42, P9, DOI 10.1016/S0896-6273(04)00144-8; Deinhardt K, 2005, BIOCHEM SOC SYMP, V72, P139, DOI 10.1042/bss0720139; Gunawardena S, 2004, J NEUROBIOL, V58, P258, DOI 10.1002/neu.10319; HABERMANN E, 1986, CURR TOP MICROBIOL, V129, P93; Hafezparast M, 2003, SCIENCE, V300, P808, DOI 10.1126/science.1083129; Herreros J, 2000, BIOCHEM J, V347, P199, DOI 10.1042/0264-6021:3470199; Herreros J, 2000, J NEUROCHEM, V74, P1941, DOI 10.1046/j.1471-4159.2000.0741941.x; Howe CL, 2004, J NEUROBIOL, V58, P207, DOI 10.1002/neu.10323; Humeau Y, 2000, BIOCHIMIE, V82, P427, DOI 10.1016/S0300-9084(00)00216-9; Inoue T, 2005, J BIOL CHEM, V280, P27896, DOI 10.1074/jbc.M504890200; Lalli G, 2003, J CELL SCI, V116, P4639, DOI 10.1242/jcs.00727; Lalli G, 1999, J CELL SCI, V112, P2715; Lalli G, 2002, J CELL BIOL, V156, P233, DOI 10.1083/jcb.200106142; LENCER WI, 1995, AM J PHYSIOL-GASTR L, V269, pG548, DOI 10.1152/ajpgi.1995.269.4.G548; Matteoli M, 1996, P NATL ACAD SCI USA, V93, P13310, DOI 10.1073/pnas.93.23.13310; Mattsson JP, 1996, BBA-BIOMEMBRANES, V1280, P98, DOI 10.1016/0005-2736(95)00285-5; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Mitchell SJ, 2004, J NEUROSCI, V24, P4884, DOI 10.1523/JNEUROSCI.0174-04.2004; MONTECUCCO C, 1994, FEBS LETT, V346, P92, DOI 10.1016/0014-5793(94)00449-8; Nelson N, 2003, J BIOENERG BIOMEMBR, V35, P281, DOI 10.1023/A:1025768529677; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; Overly CC, 1996, J NEUROSCI, V16, P6056; PARTON RG, 1987, J NEUROCHEM, V49, P1057; Pelkmans L, 2004, CELL, V118, P767, DOI 10.1016/j.cell.2004.09.003; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Pietiainen V, 2004, MOL BIOL CELL, V15, P4911, DOI 10.1091/mbc.E04-01-0070; Schapiro FB, 1998, AM J PHYSIOL-CELL PH, V274, pC319, DOI 10.1152/ajpcell.1998.274.2.C319; Schiavo G, 2000, PHYSIOL REV, V80, P717, DOI 10.1152/physrev.2000.80.2.717; SCHIAVO G, 1990, J PHYSIOLOGY PARIS, V84, P180; Schoonderwoert VTG, 2000, EUR J BIOCHEM, V267, P5646, DOI 10.1046/j.1432-1327.2000.01648.x; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; STOCKEL K, 1975, BRAIN RES, V99, P1, DOI 10.1016/0006-8993(75)90604-6; STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277; TYCKO B, 1983, J CELL BIOL, V97, P1762, DOI 10.1083/jcb.97.6.1762; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; WARD JM, 1992, PLANT PHYSIOL, V99, P161, DOI 10.1104/pp.99.1.161; Weisz OA, 2003, INT REV CYTOL, V226, P259, DOI 10.1016/S0074-7696(03)01005-2; WILLIAMSON LC, 1994, J NEUROCHEM, V63, P2342; Wu MM, 2001, J BIOL CHEM, V276, P33027, DOI 10.1074/jbc.M103917200; Yuste R, 2000, METHOD ENZYMOL, V327, P522, DOI 10.1016/S0076-6879(00)27300-X	45	71	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42336	42344		10.1074/jbc.M506750200	http://dx.doi.org/10.1074/jbc.M506750200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16236708	hybrid			2022-12-25	WOS:000233992700063
J	Cesareo, E; Parker, LJ; Pedersen, JZ; Nuccetelli, M; Mazzetti, AP; Pastore, A; Federici, G; Caccuri, AM; Ricci, G; Adams, JJ; Parker, MW; Lo Bello, M				Cesareo, E; Parker, LJ; Pedersen, JZ; Nuccetelli, M; Mazzetti, AP; Pastore, A; Federici, G; Caccuri, AM; Ricci, G; Adams, JJ; Parker, MW; Lo Bello, M			Nitrosylation of human glutathione transferase P1-1 with dinitrosyl diglutathionyl iron complex in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN-RESONANCE; NITRIC-OXIDE; CRYSTAL-STRUCTURE; S-TRANSFERASES; PROTEINS; THETA; SITE; SUPERFAMILY; NITROSATION; INHIBITION	`We have recently shown that dinitrosyl diglutathionyl iron complex, a possible in vivo nitric oxide ( NO) donor, binds with extraordinary affinity to one of the active sites of human glutathione transferase ( GST) P1-1 and triggers negative cooperativity in the neighboring subunit of the dimer. This strong interaction has also been observed in the human Mu, Alpha, and Theta GST classes, suggesting a common mechanism by which GSTs may act as intracellular NO carriers or scavengers. We present here the crystal structure of GST P1-1 in complex with the dinitrosyl diglutathionyl iron ligand at high resolution. In this complex the active site Tyr-7 coordinates to the iron atom through its phenolate group by displacing one of the GSH ligands. The crucial importance of this catalytic residue in binding the nitric oxide donor is demonstrated by site-directed mutagenesis of this residue with His, Cys, or Phe residues. The relative binding affinity for the complex is strongly reduced in all three mutants by about 3 orders of magnitude with respect to the wild type. Electron paramagnetic resonance spectroscopy studies on intact Escherichia coli cells expressing the recombinant GST P1-1 enzyme indicate that bacterial cells, in response to NO treatment, are able to form the dinitrosyl diglutathionyl iron complex using intracellular iron and GSH. We hypothesize the complex is stabilized in vivo through binding to GST P1-1.	Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Univ Roma Tor Vergata, Dept Chem Sci & Technol, I-00133 Rome, Italy; Univ Roma Tor Vergata, Dept Internal Med, I-00133 Rome, Italy; St Vincents Inst Med Res, Biota Struct Biol Lab, Fitzroy, Vic 3065, Australia; Childrens Hosp, IRCCS Bambino Gesu, I-00165 Rome, Italy	University of Rome Tor Vergata; University of Rome Tor Vergata; University of Rome Tor Vergata; St. Vincent's Institute of Medical Research; IRCCS Bambino Gesu	Lo Bello, M (corresponding author), Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy.	lobello@uniroma2.it	CACCURI, ANNA MARIA/AFU-2643-2022; Pastore, Anna/J-8409-2014; Parker, Michael W/F-9069-2013	Pastore, Anna/0000-0002-0990-9419; Parker, Michael W/0000-0002-3101-1138; Ricci, Giorgio/0000-0002-7108-2846; CACCURI, ANNA MARIA/0000-0002-3756-4163				Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; BATTISTONI A, 1995, PROTEIN EXPRES PURIF, V6, P579, DOI 10.1006/prep.1995.1076; Becker K, 1998, NAT STRUCT BIOL, V5, P267, DOI 10.1038/nsb0498-267; BOESE M, 1995, J BIOL CHEM, V270, P29244, DOI 10.1074/jbc.270.49.29244; Broillet MC, 1999, CELL MOL LIFE SCI, V55, P1036, DOI 10.1007/s000180050354; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUETLER TM, 1992, J ENVIRON SCI HEAL C, V10, P181; Cairo G, 2000, BIOCHEM J, V352, P241, DOI 10.1042/0264-6021:3520241; Cavero M, 2000, BIOORG MED CHEM LETT, V10, P641, DOI 10.1016/S0960-894X(00)00060-3; Cho SG, 2001, J BIOL CHEM, V276, P12749, DOI 10.1074/jbc.M005561200; D'Autreaux B, 2002, P NATL ACAD SCI USA, V99, P16619, DOI 10.1073/pnas.252591299; De Maria F, 2003, J BIOL CHEM, V278, P42283, DOI 10.1074/jbc.M305568200; DEGROOTE MA, 1995, P NATL ACAD SCI USA, V92, P6399, DOI 10.1073/pnas.92.14.6399; Ding HG, 2000, P NATL ACAD SCI USA, V97, P5146, DOI 10.1073/pnas.97.10.5146; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; Dulhunty A, 2001, J BIOL CHEM, V276, P3319, DOI 10.1074/jbc.M007874200; Eu JP, 2000, BIOCHEMISTRY-US, V39, P1040, DOI 10.1021/bi992046e; Habig W H, 1981, Methods Enzymol, V77, P398; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857; Hogg N, 1996, FEBS LETT, V382, P223, DOI 10.1016/0014-5793(96)00086-5; JI XH, 1994, BIOCHEMISTRY-US, V33, P1043, DOI 10.1021/bi00171a002; Kim YM, 2000, J BIOL CHEM, V275, P10954, DOI 10.1074/jbc.275.15.10954; KOLM RH, 1992, BIOCHEM J, V285, P537, DOI 10.1042/bj2850537; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lo Bello M, 2001, J BIOL CHEM, V276, P42138; LOBELLO M, 1995, J BIOL CHEM, V270, P1249; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MCDONALD CC, 1965, J AM CHEM SOC, V87, P3319, DOI 10.1021/ja01093a007; MEYER DJ, 1995, BIOCHEM J, V311, P739, DOI 10.1042/bj3110739; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; Oakley AJ, 1997, J MOL BIOL, V274, P84, DOI 10.1006/jmbi.1997.1364; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PEDERSEN JZ, 1988, J MAGN RESON, V77, P369, DOI 10.1016/0022-2364(88)90186-2; Polekhina G, 2001, BIOCHEMISTRY-US, V40, P1567, DOI 10.1021/bi002249z; Rossjohn J, 1998, STRUCTURE, V6, P309, DOI 10.1016/S0969-2126(98)00034-3; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P72; SIMONS PC, 1977, ANAL BIOCHEM, V82, P334, DOI 10.1016/0003-2697(77)90169-5; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; Turella P, 2003, J BIOL CHEM, V278, P42294, DOI 10.1074/jbc.M305569200; Watts RN, 2002, EUR J BIOCHEM, V269, P3383, DOI 10.1046/j.1432-1033.2002.02987.x; WILCE MCJ, 1995, EMBO J, V14, P2133, DOI 10.1002/j.1460-2075.1995.tb07207.x; Wilce MCJ, 1994, BIOCHIM BIOPHYS ACTA, V205, P1	45	101	103	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42172	42180		10.1074/jbc.M507916200	http://dx.doi.org/10.1074/jbc.M507916200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16195232	hybrid			2022-12-25	WOS:000233992700045
J	Armalyte, E; Bujnicki, JM; Giedriene, J; Gasiunas, G; Kosinksi, J; Lubys, A				Armalyte, E; Bujnicki, JM; Giedriene, J; Gasiunas, G; Kosinksi, J; Lubys, A			Mva1269I: A monomeric type IIS restriction endonuclease from micrococcus varians with two EcoRI- and FokI-like catalytic domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ACTIVE-SITE; DNA METHYLTRANSFERASES; HOMING ENDONUCLEASES; FOLD-RECOGNITION; CALCIUM-IONS; ENZYMES; CLEAVAGE; PURIFICATION; SEQUENCE	Type II restriction endonuclease Mva1269I recognizes an asymmetric DNA sequence 5'-GAATGCN down arrow -3'/5'-NG down arrow CATTC-3' and cuts top and bottom DNA strands at positions, indicated by the "down arrow" symbol. Most restriction endonucleases require dimerization to cleave both strands of DNA. We found that Mva1269I is a monomer both in solution and upon binding of cognate DNA. Protein fold-recognition analysis revealed that Mva1269I comprises two "PD-(D/E)XK" domains. The N-terminal domain is related to the 5'-GAATTC-3'-specific restriction endonuclease EcoRI, whereas the C-terminal one resembles the nonspecific nuclease domain of restriction endonuclease FokI. Inactivation of the C-terminal catalytic site transformed Mva1269I into a very active bottom strand-nicking enzyme, whereas mutants in the N-terminal domain nicked the top strand, but only at elevated enzyme concentrations. We found that the cleavage of the bottom strand is a prerequisite for the cleavage of the top strand. We suggest that Mva1269I evolved the ability to recognize and to cleave its asymmetrical target by a fusion of an EcoRI-like domain, which incises the bottom strand within the target, and a FokI-like domain that completes the cleavage within the nonspecific region outside the target sequence. Our results have implications for the molecular evolution of restriction endonucleases, as well as for perspectives of engineering new restriction and nicking enzymes with asymmetric target sites.	Inst Biotechnol, LT-02241 Vilnius, Lithuania; Int Inst Mol & Cell Biol, PL-02109 Warsaw, Poland	Vilnius University; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej	Lubys, A (corresponding author), Fermentas UAB, Graiciuno 8, LT-02241 Vilnius, Lithuania.	lubys@fermentas.lt	Gasiunas, Giedrius/S-6812-2019; Kosinski, Jan/V-8540-2019	Gasiunas, Giedrius/0000-0003-2509-9054; Kosinski, Jan/0000-0002-3641-0322	FOGARTY INTERNATIONAL CENTER [R03TW007163] Funding Source: NIH RePORTER; FIC NIH HHS [R03 TW007163-01] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Aravind L, 2000, NUCLEIC ACIDS RES, V28, P3417, DOI 10.1093/nar/28.18.3417; Bath AJ, 2002, J BIOL CHEM, V277, P4024, DOI 10.1074/jbc.M108441200; Bitinaite J, 1998, P NATL ACAD SCI USA, V95, P10570, DOI 10.1073/pnas.95.18.10570; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bujnicki JM, 2003, CURR PROTEIN PEPT SC, V4, P327, DOI 10.2174/1389203033487072; Bujnicki JM, 2001, TRENDS BIOCHEM SCI, V26, P9, DOI 10.1016/S0968-0004(00)01690-X; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Chevalier BS, 2002, MOL CELL, V10, P895, DOI 10.1016/S1097-2765(02)00690-1; Chevalier BS, 2001, NUCLEIC ACIDS RES, V29, P3757, DOI 10.1093/nar/29.18.3757; Chmiel AA, 2005, BMC STRUCT BIOL, V5, DOI 10.1186/1472-6807-5-2; Chmiel AA, 2005, PROTEIN ENG DES SEL, V18, P181, DOI 10.1093/protein/gzi019; Christ F, 1999, EMBO J, V18, P6908, DOI 10.1093/emboj/18.24.6908; CONNOLLY BA, 1984, J BIOL CHEM, V259, P760; Feder M, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-21; Heiter DF, 2005, J MOL BIOL, V348, P631, DOI 10.1016/j.jmb.2005.02.034; Higgins LS, 2001, NUCLEIC ACIDS RES, V29, P2492, DOI 10.1093/nar/29.12.2492; KACZOROWSKI T, 1989, GENE, V80, P209, DOI 10.1016/0378-1119(89)90285-0; Kosinski J, 2003, PROTEINS, V53, P369, DOI 10.1002/prot.10545; Kriukiene E, 2005, BBA-PROTEINS PROTEOM, V1751, P194, DOI 10.1016/j.bbapap.2005.06.006; Kurowski MA, 2003, NUCLEIC ACIDS RES, V31, P3305, DOI 10.1093/nar/gkg557; Lagunavicius A, 1997, BIOCHEMISTRY-US, V36, P11093, DOI 10.1021/bi963126a; MUELLER JE, 1995, EMBO J, V14, P5724, DOI 10.1002/j.1460-2075.1995.tb00259.x; Newman M, 1998, EMBO J, V17, P5466, DOI 10.1093/emboj/17.18.5466; Pawlak SD, 2005, NUCLEIC ACIDS RES, V33, P661, DOI 10.1093/nar/gki213; Pingoud A, 2005, CELL MOL LIFE SCI, V62, P685, DOI 10.1007/s00018-004-4513-1; Pingoud V, 2005, J BIOL CHEM, V280, P4289, DOI 10.1074/jbc.M409020200; Pingoud V, 2002, J BIOL CHEM, V277, P14306, DOI 10.1074/jbc.M111625200; Roberts RJ, 2003, NUCLEIC ACIDS RES, V31, P1805, DOI 10.1093/nar/gkg274; Roberts RJ, 2003, NUCLEIC ACIDS RES, V31, P418, DOI 10.1093/nar/gkg069; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Samuelson JC, 2004, NUCLEIC ACIDS RES, V32, P3661, DOI 10.1093/nar/gkh674; Sapranauskas R, 2000, J BIOL CHEM, V275, P30878, DOI 10.1074/jbc.M003350200; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Sasnauskas G, 2003, P NATL ACAD SCI USA, V100, P6410, DOI 10.1073/pnas.1131003100; SEKTAS M, 1992, NUCLEIC ACIDS RES, V20, P433, DOI 10.1093/nar/20.3.433; Simons KT, 1997, J MOL BIOL, V268, P209, DOI 10.1006/jmbi.1997.0959; Skirgaila R, 1998, J MOL BIOL, V279, P473, DOI 10.1006/jmbi.1998.1803; Soundararajan M, 2002, J BIOL CHEM, V277, P887, DOI 10.1074/jbc.M109100200; Stankevicius K, 1998, NUCLEIC ACIDS RES, V26, P1084, DOI 10.1093/nar/26.4.1084; Thorogood H, 1996, J BIOL CHEM, V271, P8855, DOI 10.1074/jbc.271.15.8855; TIMINSKAS A, 1995, GENE, V157, P3, DOI 10.1016/0378-1119(94)00783-O; TUCHOLSKI J, 1995, GENE, V157, P87, DOI 10.1016/0378-1119(94)00787-S; Vanamee ES, 2001, J MOL BIOL, V309, P69, DOI 10.1006/jmbi.2001.4635; VIPOND IB, 1995, BIOCHEMISTRY-US, V34, P1113, DOI 10.1021/bi00004a002; Wah DA, 1997, NATURE, V388, P97, DOI 10.1038/40446; Wah DA, 1998, P NATL ACAD SCI USA, V95, P10564, DOI 10.1073/pnas.95.18.10564; Xu Qian Steven, 2004, Structure (Cambridge), V12, P1741, DOI 10.1016/j.str.2004.07.014; Xu Y, 2001, P NATL ACAD SCI USA, V98, P12990, DOI 10.1073/pnas.241215698; Zhu ZY, 2004, J MOL BIOL, V337, P573, DOI 10.1016/j.jmb.2004.02.003	49	24	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41584	41594		10.1074/jbc.M506775200	http://dx.doi.org/10.1074/jbc.M506775200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16223716	hybrid			2022-12-25	WOS:000233866900059
J	Barona, T; Byrne, RD; Pettitt, TR; Wakelam, MJO; Larijani, B; Poccia, DL				Barona, T; Byrne, RD; Pettitt, TR; Wakelam, MJO; Larijani, B; Poccia, DL			Diacylglycerol induces fusion of nuclear envelope membrane precursor vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URCHIN SPERM CHROMATIN; CELL-FREE PREPARATIONS; PHOSPHOLIPASE-C; IN-VITRO; PRONUCLEAR FORMATION; LIPOSOME FUSION; PHOSPHATIDYLINOSITOL; DECONDENSATION; HYDROLYSIS; BINDING	Purified membrane vesicles isolated from sea urchin eggs form nuclear envelopes around sperm nuclei following GTP hydrolysis in the presence of cytosol. A low density subfraction of these vesicles (MV1), highly enriched in phosphatidylinositol ( PtdIns), is required for nuclear envelope formation. Membrane fusion of MV1 with a second fraction that contributes most of the nuclear envelope can be initiated without GTP by an exogenous bacterial PtdIns-specific phospholipase C (PI-PLC) which hydrolyzes PtdIns to form diacyl-glycerides and inositol 1-phosphate. This PI-PLC hydrolyzes a subset of sea urchin membrane vesicle PtdIns into diglycerides enriched in long chain, polyunsaturated species as revealed by a novel liquid chromatography-mass spectrometry analysis. Large unilammelar vesicles (LUVs) enriched in PtdIns can substitute for MV1 in PI-PLC induced nuclear envelope formation. Moreover, MV1 prehydrolyzed with PI-PLC and washed to remove inositols leads to spontaneous nuclear envelope formation with MV2 without further PI-PLC treatment. LUVs enriched in diacylglycerol mimic prehydrolyzed MV1. These results indicate that production of membrane-destabilizing diglycerides in membranes enriched in PtdIns may facilitate membrane fusion in a natural membrane system and suggest that MV1, which binds only to two places on the sperm nucleus, may initiate fusion locally.	Amherst Coll, Dept Biol, Amherst, MA 01002 USA; London Res Inst, Cell Biophys Lab, Canc Res UK, London WC2A 3PX, England; Univ Birmingham, CRUK Inst Canc Studies, Birmingham B15 2TT, W Midlands, England; Univ Lusofona, Unidade Invest Biol Desenvolvimento, P-1749024 Lisbon, Portugal	Amherst College; Cancer Research UK; University of Birmingham; Lusofona University	Poccia, DL (corresponding author), Amherst Coll, Dept Biol, Amherst, MA 01002 USA.	dlpoccia@amherst.edu	Larijani, Banafshe/H-3909-2015	Larijani, Banafshe/0000-0003-4735-1169; Wakelam, Michael/0000-0003-4059-9276; Barona, Teresa/0000-0002-4826-1694	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLAN D, 1978, NATURE, V276, P289, DOI 10.1038/276289a0; Basanez G, 1997, BIOPHYS J, V72, P2630, DOI 10.1016/S0006-3495(97)78906-9; BOMAN AL, 1992, J CELL BIOL, V116, P281, DOI 10.1083/jcb.116.2.281; BURKE B, 1986, CELL, V44, P639, DOI 10.1016/0092-8674(86)90273-4; Byrne RD, 2005, BIOCHEM J, V387, P393, DOI 10.1042/BJ20040947; CAMERON LA, 1994, DEV BIOL, V162, P568, DOI 10.1006/dbio.1994.1110; COLLAS P, 1995, DEV BIOL, V169, P123, DOI 10.1006/dbio.1995.1132; Collas P, 1998, METHOD CELL BIOL, V53, P417; Collas P, 1996, J CELL SCI, V109, P1275; COLLAS P, 1995, MOL REPROD DEV, V42, P106, DOI 10.1002/mrd.1080420114; COLLAS P, 1995, EXP CELL RES, V219, P687, DOI 10.1006/excr.1995.1280; Collas P, 1996, J CELL BIOL, V135, P1715, DOI 10.1083/jcb.135.6.1715; Collas P, 2000, Subcell Biochem, V34, P273; DAS S, 1984, BIOCHEM BIOPH RES CO, V124, P491, DOI 10.1016/0006-291X(84)91580-8; Griffith OH, 1999, BBA-MOL CELL BIOL L, V1441, P237, DOI 10.1016/S1388-1981(99)00153-5; KISS Z, 1995, BBA-LIPID LIPID MET, V1259, P105, DOI 10.1016/0005-2760(95)00148-6; Larijani B, 2001, BIOCHEM J, V356, P495, DOI 10.1042/0264-6021:3560495; Larijani B, 2000, LIPIDS, V35, P1289, DOI 10.1007/s11745-000-0645-4; LARIJANI B, 1999, THESIS U MASSACHUSET; LOHKA MJ, 1984, J CELL BIOL, V98, P1222, DOI 10.1083/jcb.98.4.1222; LONGO FJ, 1968, J CELL BIOL, V39, P339, DOI 10.1083/jcb.39.2.339; NIEVA JL, 1989, BIOCHEMISTRY-US, V28, P7364, DOI 10.1021/bi00444a032; POCCIA D, 2002, NUCL ENVELOPE ASSEMB, P111; SCHMIDT P P, 1976, Astarte, V9, P13; Stephens S, 2002, MOL REPROD DEV, V62, P496, DOI 10.1002/mrd.90005; ULITZUR N, 1989, FEBS LETT, V259, P113, DOI 10.1016/0014-5793(89)81507-8; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; VIGERS GPA, 1991, J CELL BIOL, V112, P545, DOI 10.1083/jcb.112.4.545; Villar AV, 2000, BIOCHEMISTRY-US, V39, P14012, DOI 10.1021/bi992515c; Villar AV, 2001, FEBS LETT, V494, P117, DOI 10.1016/S0014-5793(01)02333-X	30	36	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41171	41177		10.1074/jbc.M412863200	http://dx.doi.org/10.1074/jbc.M412863200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16216883	hybrid			2022-12-25	WOS:000233866900008
J	Pedarzani, P; McCutcheon, JE; Rogge, G; Jensen, BS; Christophersen, P; Hougaard, C; Strobaek, D; Stocker, M				Pedarzani, P; McCutcheon, JE; Rogge, G; Jensen, BS; Christophersen, P; Hougaard, C; Strobaek, D; Stocker, M			Specific enhancement of SK channel activity selectively potentiates the afterhyperpolarizing current I-AHP and modulates the firing properties of hippocampal pyramidal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-ACTIVATED K+ CHANNELS; SMALL-CONDUCTANCE; ACTIVATION; EXPRESSION; DETERMINANTS; SECRETION	SK channels are Ca2+-activated K+ channels that underlie after hyperpolarizing (AHP) currents and contribute to the shaping of the firing patterns and regulation of Ca2+ influx in a variety of neurons. The elucidation of SK channel function has recently benefited from the discovery of SK channel enhancers, the prototype of which is 1-EBIO. 1-EBIO exerts profound effects on neuronal excitability but displays a low potency and limited selectivity. This study reports the effects of DCEBIO, an intermediate conductance Ca2+-activated K+ channel modulator, and the effects of the recently identified potent SK channel enhancer NS309 on recombinant SK2 channels, neuronal apamin-sensitive AHP currents, and the excitability of CA1 neurons. NS309 and DCEBIO increased the amplitude and duration of the apamin-sensitive afterhyperpolarizing current without affecting the slow afterhyperpolarizing current in contrast to 1-EBIO. The potentiation by DCEBIO and NS309 was reversed by SK channel blockers. In current clamp experiments, NS309 enhanced the medium afterhyperpolarization ( but not the slow afterhyperpolarization sAHP) and profoundly affected excitability by facilitating spike frequency adaptation in a frequency-independent manner. The potent and specific effect of NS309 on the excitability of CA1 pyramidal neurons makes this compound an ideal tool to assess the role of SK channels as possible targets for the treatment of disorders linked to neuronal hyperexcitability.	UCL, Dept Physiol, London WC1E 6BT, England; NeuroSearch AS, DK-3750 Ballerup, Denmark; UCL, Dept Pharmacol, Mol Pharmacol Lab, London WC1E 6BT, England	University of London; University College London; University of London; University College London	Pedarzani, P (corresponding author), UCL, Dept Physiol, Gower St, London WC1E 6BT, England.	P.Pedarzani@ucl.ac.uk	McCutcheon, James/E-8908-2011; Stocker, Martin/C-1844-2008	McCutcheon, James/0000-0002-6431-694X; 	Medical Research Council [G0100066] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G0100066] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; Bond CT, 2004, J NEUROSCI, V24, P5301, DOI 10.1523/JNEUROSCI.0182-04.2004; Cao YJ, 2001, J PHARMACOL EXP THER, V296, P683; Chiesa N, 1997, J PHYSIOL-LONDON, V501, P313, DOI 10.1111/j.1469-7793.1997.313bn.x; Cingolani LA, 2002, J NEUROSCI, V22, P4456, DOI 10.1523/JNEUROSCI.22-11-04456.2002; Devor DC, 1996, AM J PHYSIOL-LUNG C, V271, pL775, DOI 10.1152/ajplung.1996.271.5.L775; Hallworth NE, 2003, J NEUROSCI, V23, P7525; Jensen BS, 1998, AM J PHYSIOL-CELL PH, V275, pC848, DOI 10.1152/ajpcell.1998.275.3.C848; LANCASTER B, 1986, J NEUROPHYSIOL, V55, P1268, DOI 10.1152/jn.1986.55.6.1268; Lisman JE, 1997, TRENDS NEUROSCI, V20, P38, DOI 10.1016/S0166-2236(96)10070-9; NICOLL RA, 1988, SCIENCE, V241, P545, DOI 10.1126/science.2456612; Pedarzani P, 2001, J BIOL CHEM, V276, P9762, DOI 10.1074/jbc.M010001200; Pedarzani P, 2002, J BIOL CHEM, V277, P46101, DOI 10.1074/JBC.m206465200; PEDARZANI P, 1993, NEURON, V11, P1023, DOI 10.1016/0896-6273(93)90216-E; Roche JP, 2002, BRIT J PHARMACOL, V137, P1173, DOI 10.1038/sj.bjp.0704989; Sah P, 2002, PROG NEUROBIOL, V66, P345, DOI 10.1016/S0301-0082(02)00004-7; Sailer CA, 2002, J NEUROSCI, V22, P9698; Schroder RL, 2001, NEUROPHARMACOLOGY, V40, P888, DOI 10.1016/S0028-3908(01)00029-6; Shah MM, 2002, J PHYSIOL-LONDON, V544, P29, DOI 10.1113/jphysiol.2002.028571; Singh S, 2001, J PHARMACOL EXP THER, V296, P600; Stocker M, 1999, P NATL ACAD SCI USA, V96, P4662, DOI 10.1073/pnas.96.8.4662; Stocker M, 2004, NAT REV NEUROSCI, V5, P758, DOI 10.1038/nrn1516; Stocker M, 2004, TOXICON, V43, P933, DOI 10.1016/j.toxicon.2003.12.009; STORM JF, 1989, J PHYSIOL-LONDON, V409, P171, DOI 10.1113/jphysiol.1989.sp017491; Strobaek D, 2004, BBA-BIOMEMBRANES, V1665, P1, DOI 10.1016/j.bbamem.2004.07.006; Syme CA, 2000, AM J PHYSIOL-CELL PH, V278, pC570, DOI 10.1152/ajpcell.2000.278.3.C570; Villalobos C, 2004, J NEUROSCI, V24, P3537, DOI 10.1523/JNEUROSCI.0380-04.2004; Vogalis F, 2003, EUR J NEUROSCI, V18, P3155, DOI 10.1111/j.1460-9568.2003.03040.x; Wolfart J, 2001, J NEUROSCI, V21, P3443, DOI 10.1523/JNEUROSCI.21-10-03443.2001; WONG RKS, 1979, P NATL ACAD SCI USA, V76, P986, DOI 10.1073/pnas.76.2.986; Zhang L, 1995, J NEUROPHYSIOL, V74, P2225, DOI 10.1152/jn.1995.74.6.2225	31	123	124	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41404	41411		10.1074/jbc.M509610200	http://dx.doi.org/10.1074/jbc.M509610200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16239218	hybrid			2022-12-25	WOS:000233866900037
J	Reh, S; Korn, C; Gimadutdinow, O; Meiss, G				Reh, S; Korn, C; Gimadutdinow, O; Meiss, G			Structural basis for stable DNA complex formation by the caspase-activated DNase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEASE ACTIVITY; POLY(ADP-RIBOSE) BINDS; HOMING ENDONUCLEASES; APOPTOTIC NUCLEASE; CLEAVAGE; MECHANISM; FRAGMENTATION; DFF40; DOMAINS; PROTEIN	We describe a structural model for DNA binding by the caspase-activated DNase (CAD). Results of a mutational analysis and computational modeling suggest that DNA is bound via a positively charged surface with two functionally distinct regions, one being the active site facing the DNA minor groove and the other comprising distal residues close to or directly from helix alpha 4, which binds DNA in the major groove. This bipartite protein-DNA interaction is present once in the CAD/inhibitor of CAD heterodimer and repeated twice in the active CAD dimer.	Univ Giessen, Fac Biol & Chem, Inst Biochem, D-35392 Giessen, Germany; Kazan VI Lenin State Univ, Genet Inst, Kazan 420008, Russia	Justus Liebig University Giessen; Kazan Federal University	Meiss, G (corresponding author), Univ Giessen, Fac Biol & Chem, Inst Biochem, Heinrich Buff Ring 58, D-35392 Giessen, Germany.	gf45@uni-giessen.de						Althaus FR, 1999, MOL CELL BIOCHEM, V193, P5, DOI 10.1023/A:1006975002262; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Flick KE, 1998, NATURE, V394, P96, DOI 10.1038/27952; Franke I, 1999, J BIOL CHEM, V274, P825, DOI 10.1074/jbc.274.2.825; Friedhoff P, 1999, NAT STRUCT BIOL, V6, P112; Galburt EA, 1999, NAT STRUCT BIOL, V6, P1096, DOI 10.1038/70027; Galburt EA, 2002, BIOCHEMISTRY-US, V41, P13851, DOI 10.1021/bi020467h; Gu JJ, 1999, J BIOL CHEM, V274, P20759, DOI 10.1074/jbc.274.30.20759; Hsia KC, 2005, CURR OPIN STRUC BIOL, V15, P126, DOI 10.1016/j.sbi.2005.01.015; Hsia KC, 2004, STRUCTURE, V12, P205, DOI 10.1016/j.str.2004.01.004; Jones S, 2001, NUCLEIC ACIDS RES, V29, P943, DOI 10.1093/nar/29.4.943; Jurica MS, 1999, CELL MOL LIFE SCI, V55, P1304, DOI 10.1007/s000180050372; Kirsch RD, 1998, NUCLEIC ACIDS RES, V26, P1848, DOI 10.1093/nar/26.7.1848; Korn C, 2005, J BIOL CHEM, V280, P6005, DOI 10.1074/jbc.M413035200; Korn C, 2002, NUCLEIC ACIDS RES, V30, P1325, DOI 10.1093/nar/30.6.1325; Kuhlmann UC, 1999, FEBS LETT, V463, P1, DOI 10.1016/S0014-5793(99)01499-4; Li CL, 2003, EMBO J, V22, P4014, DOI 10.1093/emboj/cdg377; Liu XS, 1999, J BIOL CHEM, V274, P13836, DOI 10.1074/jbc.274.20.13836; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; Mate MJ, 2004, J BIOL CHEM, V279, P34763, DOI 10.1074/jbc.M403719200; McCarty JS, 1999, BIOCHEM BIOPH RES CO, V264, P181, DOI 10.1006/bbrc.1999.1498; McCarty JS, 1999, BIOCHEM BIOPH RES CO, V264, P176, DOI 10.1006/bbrc.1999.1497; Meiss G, 2001, NUCLEIC ACIDS RES, V29, P3901, DOI 10.1093/nar/29.19.3901; Nadassy K, 1999, BIOCHEMISTRY-US, V38, P1999, DOI 10.1021/bi982362d; Nagata S, 2005, ANNU REV IMMUNOL, V23, P853, DOI 10.1146/annurev.immunol.23.021704.115811; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Scholz SR, 2003, BIOCHEMISTRY-US, V42, P9288, DOI 10.1021/bi0348765; Shen BW, 2004, J MOL BIOL, V342, P43, DOI 10.1016/j.jmb.2004.07.032; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; SUCK D, 1986, NATURE, V321, P620, DOI 10.1038/321620a0; Suck Dietrich, 1994, Journal of Molecular Recognition, V7, P65, DOI 10.1002/jmr.300070203; Toh SY, 1998, BIOCHEM BIOPH RES CO, V250, P598, DOI 10.1006/bbrc.1998.9369; Walker DC, 2002, NUCLEIC ACIDS RES, V30, P3225, DOI 10.1093/nar/gkf420; West JD, 2005, J BIOL CHEM, V280, P15141, DOI 10.1074/jbc.M413147200; Widlak P, 2005, BIOCHEMISTRY-US, V44, P7871, DOI 10.1021/bi050100n; Widlak P, 2005, J CELL BIOCHEM, V94, P1078, DOI 10.1002/jcb.20409; Widlak P, 2000, J BIOL CHEM, V275, P8226, DOI 10.1074/jbc.275.11.8226; Woo EJ, 2004, MOL CELL, V14, P531, DOI 10.1016/S1097-2765(04)00258-8; Zhang JH, 2000, CELL RES, V10, P205, DOI 10.1038/sj.cr.7290049	41	9	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41707	41715		10.1074/jbc.M509133200	http://dx.doi.org/10.1074/jbc.M509133200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16236713	hybrid			2022-12-25	WOS:000233866900072
J	Westfall, MV; Lee, AM; Robinson, DA				Westfall, MV; Lee, AM; Robinson, DA			Differential contribution of troponin I phosphorylation sites to the endothelin-modulated contractile response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RAT VENTRICULAR MYOCYTES; ACTOMYOSIN MGATPASE ACTIVITY; MYOFILAMENT CA2+ SENSITIVITY; BOVINE CARDIAC TROPONIN; GENE-TRANSFER; HUMAN HEART; CALCIUM SENSITIVITY; ARACHIDONIC-ACID; ATPASE ACTIVITY	Cardiac troponin I is a phosphorylation target for endothelin-activated protein kinase C. Earlier work in cardiac myocytes expressing nonphosphorylatable slow skeletal troponin I provided evidence that protein kinase C-mediated cardiac troponin I phosphorylation accelerates relaxation. However, replacement with the slow skeletal isoform also alters the myofilament pH response and the Ca2+ transient, which could influence endothelin-mediated relaxation. Here, differences in the Ca2+ transient could not explain the divergent relaxation response to endothelin in myocytes expressing cardiac versus slow skeletal troponin I nor could activation of Na+/H+ exchange. Three separate clusters within cardiac troponin I are phosphorylated by protein kinase C, and we set out to determine the contribution of the Thr(144) and Ser(23)/Ser(24) clusters to the endothelin-mediated contractile response. Myocyte replacement with a cardiac troponin I containing a Thr(144) substituted with the Pro residue found in slow skeletal troponin I resulted in prolonged relaxation in response to acute endothelin compared with control myocytes. Ser(23)/Ser(24) also is a target for protein kinase C phosphorylation of purified cardiac troponin I, and although this cluster was not acutely phosphorylated in intact myocytes, significant phosphorylation developed within 1 h after adding endothelin. Replacement of Ser(23)/Ser(24) with Ala indicated that this cluster contributes significantly to relaxation during more prolonged endothelin stimulation. Overall, results with these mutants provide evidence that Thr(144) plays an important role in the acute acceleration of relaxation, whereas Ser(23)/Ser(24) contributes to relaxation during more prolonged activation of protein kinase C by endothelin.	Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Westfall, MV (corresponding author), Univ Michigan, Dept Surg, 1150 W Med Ctr Dr,B562 MSRB 2 0686, Ann Arbor, MI 48109 USA.	wfall@umich.edu		Westfall, Margaret/0000-0001-9491-0125				Alden KJ, 2002, AM J PHYSIOL-CELL PH, V282, pC768, DOI 10.1152/ajpcell.00494.2001; Baudet S, 2001, CARDIOVASC RES, V50, P486, DOI 10.1016/S0008-6363(01)00225-5; Bodor GS, 1997, CIRCULATION, V96, P1495, DOI 10.1161/01.CIR.96.5.1495; Bolck B, 2004, AM J PHYSIOL-HEART C, V287, pH1435, DOI 10.1152/ajpheart.00397.2003; Bowling N, 1999, CIRCULATION, V99, P384, DOI 10.1161/01.CIR.99.3.384; Buenaventura P, 1995, ANN THORAC SURG, V60, pS505, DOI 10.1016/0003-4975(95)00842-X; Burkart EM, 2003, J BIOL CHEM, V278, P11265, DOI 10.1074/jbc.M210712200; CLEMENT O, 1992, BIOCHEM J, V285, P311, DOI 10.1042/bj2850311; Coutu P, 2005, AM J PHYSIOL-HEART C, V288, pH601, DOI 10.1152/ajpheart.00424.2004; Coutu P, 2002, BIOPHYS J, V82, P2565, DOI 10.1016/S0006-3495(02)75599-9; DAMRON DS, 1993, J BIOL CHEM, V268, P27335; DAMRON DS, 1995, CIRC RES, V76, P1011, DOI 10.1161/01.RES.76.6.1011; DeSantiago J, 2002, J MOL CELL CARDIOL, V34, P975, DOI 10.1006/jmcc.2002.2034; Ebihara Y, 1996, J MOL CELL CARDIOL, V28, P265, DOI 10.1006/jmcc.1996.0025; F'entzke RC, 1999, J PHYSIOL-LONDON, V517, P143, DOI 10.1111/j.1469-7793.1999.0143z.x; Finley NL, 2004, J BIOL CHEM, V279, P54833, DOI 10.1074/jbc.M408304200; Goldberg AT, 2000, ANN THORAC SURG, V69, P711, DOI 10.1016/S0003-4975(99)01515-5; GWATHMEY JK, 1990, CIRC RES, V67, P744, DOI 10.1161/01.RES.67.3.744; He HP, 1997, J CLIN INVEST, V100, P380, DOI 10.1172/JCI119544; He JQ, 2000, J PHYSIOL-LONDON, V524, P807, DOI 10.1111/j.1469-7793.2000.00807.x; Kanaya N, 2001, ANESTHESIOLOGY, V94, P1096, DOI 10.1097/00000542-200106000-00026; Kentish JC, 2001, CIRC RES, V88, P1059, DOI 10.1161/hh1001.091640; KRAMER BK, 1991, CIRC RES, V68, P269, DOI 10.1161/01.RES.68.1.269; Li ZX, 2001, BIOPHYS J, V81, P321, DOI 10.1016/S0006-3495(01)75702-5; MAYOUX E, 1994, AM J PHYSIOL, V266, pH2051, DOI 10.1152/ajpheart.1994.266.5.H2051; MAZZEI GJ, 1984, BIOCHEM J, V218, P361, DOI 10.1042/bj2180361; Metzger JM, 2004, CIRC RES, V94, P146, DOI 10.1161/01.RES.0000110083.17024.60; Noguchi T, 2004, CIRCULATION, V110, P982, DOI 10.1161/01.CIR.0000139334.43109.F9; NOLAND TA, 1995, J BIOL CHEM, V270, P25445, DOI 10.1074/jbc.270.43.25445; NOLAND TA, 1993, BIOCHEM BIOPH RES CO, V193, P254, DOI 10.1006/bbrc.1993.1617; NOLAND TA, 1989, J BIOL CHEM, V264, P20778; NOLAND TA, 1991, J BIOL CHEM, V266, P4974; NOLAND TA, 1992, BIOCHEM J, V288, P123, DOI 10.1042/bj2880123; Padua RR, 1998, J MOL CELL CARDIOL, V30, P2695, DOI 10.1006/jmcc.1998.0832; Pi YQ, 2003, J PHYSIOL-LONDON, V552, P845, DOI 10.1113/jphysiol.2003.045260; Pi YQ, 2002, CIRC RES, V90, P649, DOI 10.1161/01.RES.0000014080.82861.5F; Pi YQ, 1997, CIRC RES, V81, P92, DOI 10.1161/01.RES.81.1.92; PUCEAT M, 1990, CIRC RES, V67, P517, DOI 10.1161/01.RES.67.2.517; QIU ZH, 1992, EUR J PHARMACOL, V214, P293; Reiffert S, 1999, EUR J BIOCHEM, V261, P40, DOI 10.1046/j.1432-1327.1999.00261.x; ROBERTSON SP, 1982, J BIOL CHEM, V257, P260; Sakthivel S, 2005, J BIOL CHEM, V280, P703, DOI 10.1074/jbc.M409513200; Slepkov E, 2002, BIOCHEM CELL BIOL, V80, P499, DOI 10.1139/O02-151; Strauss JD, 1996, PFLUG ARCH EUR J PHY, V431, P853, DOI 10.1007/BF02332169; Sumandea MP, 2004, ANN NY ACAD SCI, V1015, P39, DOI 10.1196/annals.1302.004; SUZUKI T, 1990, FEBS LETT, V268, P149, DOI 10.1016/0014-5793(90)80995-U; Takeda S, 2003, NATURE, V424, P35, DOI 10.1038/nature01780; Takimoto E, 2004, CIRC RES, V94, P496, DOI 10.1161/01.RES.0000117307.57798.F5; VANEYK JE, 1993, FEBS LETT, V323, P223, DOI 10.1016/0014-5793(93)81344-Y; Ward DG, 2002, J BIOL CHEM, V277, P41795, DOI 10.1074/jbc.M206744200; WESTFALL M, 2004, METHOD MOL BIOL, V219, P159; Westfall MV, 1997, P NATL ACAD SCI USA, V94, P5444, DOI 10.1073/pnas.94.10.5444; Westfall MV, 1999, J BIOL CHEM, V274, P22508, DOI 10.1074/jbc.274.32.22508; Westfall MV, 2003, J BIOL CHEM, V278, P33694, DOI 10.1074/jbc.M305404200; Westfall MV, 2002, CIRC RES, V91, P525, DOI 10.1161/01.RES.0000034710.46739.C0; Westfall MV, 2001, AM J PHYSIOL-CELL PH, V280, pC324, DOI 10.1152/ajpcell.2001.280.2.C324; Westfall MV, 1997, METHOD CELL BIOL, V52, P307, DOI 10.1016/S0091-679X(08)60385-4; Zolk O, 1999, CIRCULATION, V99, P2118, DOI 10.1161/01.CIR.99.16.2118	58	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41324	41331		10.1074/jbc.M506043200	http://dx.doi.org/10.1074/jbc.M506043200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16236710	hybrid			2022-12-25	WOS:000233866900027
J	Yogosawa, S; Hatakeyama, S; Nakayama, KI; Miyoshi, H; Kohsaka, S; Akazawa, C				Yogosawa, S; Hatakeyama, S; Nakayama, KI; Miyoshi, H; Kohsaka, S; Akazawa, C			Ubiquitylation and degradation of serum-inducible kinase by hVPS18, a RING-H2 type ubiquitin ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-BINDING PROTEIN; POLO-LIKE KINASE; DOMAIN; SNK; REGULATOR; HOMOLOGS; PATHWAY; NOTCH; GENE; NUMB	Serum-inducible kinase (SNK) is a member of polo-like kinases that serve as regulators of multiple events during cell division. Rapid changes in the activity and abundance of SNK were reported after the serum stimulation and after the activation of synaptic transmission in the brain. Yet the detailed mechanisms that control the level of SNK protein have not been fully elucidated. In this report, we show that the RING-H2 domain of hVPS18 (human vacuolar protein sorting 18) has a genuine ubiquitin ligase (E3) activity. Using the yeast two-hybrid screening, we identify SNK as a candidate substrate of hVPS18. The half-life of SNK is increased in HeLa cells that down-regulated hVPS18 by lentivirus-mediated small hairpin RNA interference. Furthermore, the delayed entry into S phase is observed in HeLa cells overexpressing hVPS18. These results suggest that hVPS18 may play an important role in regulation of SNK activity through its ubiquitin ligase.	Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Neurochem, Tokyo 1878502, Japan; Tokyo Univ Pharm & Life Sci, Sch Life Sci, Div Mol Life Sci, Tokyo 1920392, Japan; Hokkaido Univ, Grad Sch Med, Dept Mol Biochem, Sapporo, Hokkaido 0608638, Japan; Kyushu Univ, CREST, Med Inst Bioregulat, Dept Mol & Cellular Biol,Japan Sci & Technol Agcy, Fukuoka 8128582, Japan; RIKEN, BioResource Ctr, Subteam Manipulat Cell Fate, Tsukuba, Ibaraki 3050074, Japan	National Center for Neurology & Psychiatry - Japan; Tokyo University of Pharmacy & Life Sciences; Hokkaido University; Japan Science & Technology Agency (JST); Kyushu University; RIKEN	Kohsaka, S (corresponding author), Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Neurochem, Tokyo 1878502, Japan.	kohsaka@ncnp.go.jp	Hatakeyama, Shigetsugu/C-8333-2012; Miyoshi, Hiroyuki/G-9808-2013	Hatakeyama, Shigetsugu/0000-0002-2150-9979; 				Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Casenghi M, 2003, DEV CELL, V5, P113, DOI 10.1016/S1534-5807(03)00193-X; Cheng KY, 2003, EMBO J, V22, P5757, DOI 10.1093/emboj/cdg558; Cornell M, 1999, GENETICS, V152, P567; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Hakak Y, 1999, CURR BIOL, V9, P1039, DOI 10.1016/S0960-9822(99)80453-9; HAMANAKA R, 1994, CELL GROWTH DIFFER, V5, P249; Harris KF, 1999, P NATL ACAD SCI USA, V96, P13738, DOI 10.1073/pnas.96.24.13738; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Jang YJ, 2002, J BIOL CHEM, V277, P44115, DOI 10.1074/jbc.M202172200; Jang YJ, 2002, P NATL ACAD SCI USA, V99, P1984, DOI 10.1073/pnas.042689299; Katayama K, 2004, FEBS LETT, V560, P178, DOI 10.1016/S0014-5793(04)00100-0; Kauselmann G, 1999, EMBO J, V18, P5528, DOI 10.1093/emboj/18.20.5528; Kim BY, 2001, J BIOL CHEM, V276, P29393, DOI 10.1074/jbc.M101778200; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Ma S, 2003, MOL CELL BIOL, V23, P6936, DOI 10.1128/MCB.23.19.6936-6943.2003; Ma S, 2003, MOL CANCER RES, V1, P376; Moshe Y, 2004, P NATL ACAD SCI USA, V101, P7937, DOI 10.1073/pnas.0402442101; Nie J, 2002, EMBO J, V21, P93, DOI 10.1093/emboj/21.1.93; Pak DTS, 2001, NEURON, V31, P289, DOI 10.1016/S0896-6273(01)00355-5; Pak DTS, 2003, SCIENCE, V302, P1368, DOI 10.1126/science.1082475; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Poupon V, 2003, MOL BIOL CELL, V14, P4015, DOI 10.1091/mbc.E03-01-0040; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; Sato TK, 2000, MOL CELL, V6, P661, DOI 10.1016/S1097-2765(00)00064-2; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; Sevrioukov EA, 1999, MOL CELL, V4, P479, DOI 10.1016/S1097-2765(00)80199-9; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; Susini L, 2001, P NATL ACAD SCI USA, V98, P15067, DOI 10.1073/pnas.261571998; Warnke S, 2004, CURR BIOL, V14, P1200, DOI 10.1016/j.cub.2004.06.059; Yogosawa S, 2003, BIOCHEM BIOPH RES CO, V302, P869, DOI 10.1016/S0006-291X(03)00282-1	34	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41619	41627		10.1074/jbc.M508397200	http://dx.doi.org/10.1074/jbc.M508397200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16203730	hybrid			2022-12-25	WOS:000233866900062
J	Buan, NR; Escalante-Semerena, JC				Buan, NR; Escalante-Semerena, JC			Computer-assisted docking of flavodoxin with the ATP: Co(I)rrinoid adenosyltransferase (CobA) enzyme reveals residues critical for protein-protein interactions but not for catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT METHIONINE SYNTHASE; SALMONELLA-ENTERICA ENCODES; ESCHERICHIA-COLI; CORRINOID ADENOSYLTRANSFERASE; ATP-COB(I)ALAMIN ADENOSYLTRANSFERASE; PSEUDOMONAS-DENITRIFICANS; INITIAL-CHARACTERIZATION; TYPHIMURIUM; COBALAMIN; PURIFICATION	The activity of the housekeeping ATP: co(I)rrinoid adenosyltransferase (CobA) enzyme of Salmonella enterica sv. Typhimurium is required to adenosylate de novo biosynthetic intermediates of adenosylcobalamin and to salvage incomplete and complete corrinoids from the environment of this bacterium. In vitro, reduced flavodoxin (FldA) provides an electron to generate the co(I) rrinoid substrate in the CobA active site. To understand how CobA and FldA interact, a computer model of a CobA (.) FldA complex was generated. This model was used to guide the introduction of mutations into CobA using site-directed mutagenesis and the synthesis of a peptide mimic of FldA. Residues Arg-9 and Arg-165 of CobA were critical for FldA-dependent adenosylation but were catalytically as competent as the wild-type protein when cob(I) alamin was provided as substrate. These results indicate that Arg-9 and Arg-165 are important for CobA (.) FldA docking but not to catalysis. A truncation of the 9-amino acid N-terminal helix of CobA reduced its FldA-dependent cobalamin adenosyltransferase activity by 97.4%. The same protein, however, had a 4-fold higher specific activity than the native enzyme when cob(I)alamin was generated chemically in situ.	Univ Wisconsin, Dept Bacteriol, Madison, WI 53726 USA	University of Wisconsin System; University of Wisconsin Madison	Escalante-Semerena, JC (corresponding author), Univ Wisconsin, Dept Bacteriol, Madison, WI 53726 USA.	escalante@bact.wisc.edu			NIGMS NIH HHS [R01 GM040313, GM40313] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM040313, R01GM040313] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALCH WE, 1976, APPL ENVIRON MICROB, V32, P781, DOI 10.1128/AEM.32.6.781-791.1976; Bauer CB, 2001, BIOCHEMISTRY-US, V40, P361, DOI 10.1021/bi002145o; BERKOWIT.D, 1968, J BACTERIOL, V96, P215, DOI 10.1128/JB.96.1.215-220.1968; BLANCHE F, 1992, J BACTERIOL, V174, P7452, DOI 10.1128/jb.174.22.7452-7454.1992; Brinsmade SR, 2004, J BACTERIOL, V186, P1890, DOI 10.1128/JB.186.6.1890-1892.2004; Buan NR, 2004, J BACTERIOL, V186, P5708, DOI 10.1128/JB.186.17.5708-5714.2004; CHANG GW, 1975, NATURE, V254, P150, DOI 10.1038/254150a0; DEBUSSCHE L, 1991, J BACTERIOL, V173, P6300, DOI 10.1128/jb.173.19.6300-6302.1991; ESCALANTESEMERENA JC, 1990, J BACTERIOL, V172, P273, DOI 10.1128/JB.172.1.273-280.1990; Fonseca MV, 2001, J BIOL CHEM, V276, P32101, DOI 10.1074/jbc.M102510200; Fonseca MV, 2000, J BACTERIOL, V182, P4304, DOI 10.1128/JB.182.15.4304-4309.2000; Fonseca MV, 2002, J BIOL CHEM, V277, P33127, DOI 10.1074/jbc.M203893200; FREY B, 1988, J BACTERIOL, V170, P2078, DOI 10.1128/jb.170.5.2078-2082.1988; Gaudu P, 2000, J BACTERIOL, V182, P1788, DOI 10.1128/JB.182.7.1788-1793.2000; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hall DA, 2001, P NATL ACAD SCI USA, V98, P9521, DOI 10.1073/pnas.171168898; Hall DA, 2000, BIOCHEMISTRY-US, V39, P10711, DOI 10.1021/bi001096c; Hoover DM, 1997, PROTEIN SCI, V6, P2525; Hoover DM, 1997, BIOCHEMISTRY-US, V36, P127, DOI 10.1021/bi961693s; Johnson CLV, 2001, J BACTERIOL, V183, P1577, DOI 10.1128/JB.183.5.1577-1584.2001; Johnson CLV, 2004, J BACTERIOL, V186, P7881, DOI 10.1128/JB.186.23.7881-7887.2004; LEXA D, 1977, J AM CHEM SOC, V99, P2786, DOI 10.1021/ja00450a061; MULLER G, 1991, J AM CHEM SOC, V113, P9893; OTOOLE GA, 1993, J BACTERIOL, V175, P6328, DOI 10.1128/JB.175.19.6328-6336.1993; POL A, 1982, BIOCHEM BIOPH RES CO, V108, P731, DOI 10.1016/0006-291X(82)90890-7; POZNANSKAJA AA, 1979, ARCH BIOCHEM BIOPHYS, V194, P379, DOI 10.1016/0003-9861(79)90630-1; Sheppard DE, 2004, J BACTERIOL, V186, P7635, DOI 10.1128/JB.186.22.7635-7644.2004; Stich TA, 2004, J AM CHEM SOC, V126, P9735, DOI 10.1021/ja0481631; SUH SJ, 1995, J BACTERIOL, V177, P921, DOI 10.1128/jb.177.4.921-925.1995; TABOR S, 1990, CURRENT PROTOCOLS MO, V2, P11; VETTER H, 1971, H-S Z PHYSIOL CHEM, V352, P433, DOI 10.1515/bchm2.1971.352.1.433; VITOLS E, 1966, J BIOL CHEM, V241, P1455; WALKER GA, 1969, ARCH BIOCHEM BIOPHYS, V134, P95, DOI 10.1016/0003-9861(69)90255-0; Warren MJ, 2002, NAT PROD REP, V19, P390, DOI 10.1039/B108967F	34	19	20	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40948	40956		10.1074/jbc.M506713200	http://dx.doi.org/10.1074/jbc.M506713200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16207720	Green Published, hybrid			2022-12-25	WOS:000233666600068
J	Minogue, PJ; Liu, XQ; Ebihara, L; Beyer, EC; Berthoud, VM				Minogue, PJ; Liu, XQ; Ebihara, L; Beyer, EC; Berthoud, VM			An aberrant sequence in a Connexin46 mutant underlies congenital cataracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY SECRETORY PATHWAY; GAP-JUNCTION PROTEIN; ENDOPLASMIC-RETICULUM; TRANSMEMBRANE PROTEINS; PLASMA-MEMBRANE; DEFECTIVE TRAFFICKING; ALTERED TRAFFICKING; FAMILY-MEMBERS; P24 PROTEINS; MUTATIONS	An increasing number of diseases have been mapped to genes coding for ion channel proteins, including the gap junction proteins, connexins. Here, we report on the identification of an amino acid sequence underlying the behavior of a non-functional mutant connexin46 (CX46) associated with congenital cataracts. The mutant protein, CX46fs380, is 31 amino acids longer than CX46 and contains 87 aberrant amino acids in its C terminus. When expressed in mammalian cells, the mutant CX46 was not found at gap junctional plaques, but it showed extensive co-localization with markers for ERGIC and Golgi. The severe reductions in function and formation of gap junctional plaques were transferred to other connexins by creating chimeras containing the last third ( or more) of the aberrant C terminus of the CX46 mutant. This sequence also impaired trafficking of a CD8 chimera. Site-directed mutagenesis of a diphenylalanine restored appositional membrane localization and function. These results suggest a novel mechanism in which a mutation causes disease by generating a motif that leads to retention within the synthetic/secretory pathway.	Univ Chicago, Dept Pediat, Hematol Oncol Sect, Chicago, IL 60637 USA; Rosalind Franklin Univ Med & Sci, Dept Physiol & Biophys, N Chicago, IL 60064 USA	University of Chicago; Rosalind Franklin University Medical & Science	Berthoud, VM (corresponding author), Univ Chicago, Dept Pediat, Hematol Oncol Sect, 5841 S Maryland Ave,MC 4060, Chicago, IL 60637 USA.	vberthou@peds.bsd.uchicago.edu	Beyer, Eric/V-1317-2019	Beyer, Eric/0000-0001-8044-1356	NEI NIH HHS [R01 EY010589, R01 EY008368, EY08368, R01 EY008368-19, EY10589] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008368, R01EY010589, R29EY008368] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Berthoud VM, 2003, EUR J CELL BIOL, V82, P209, DOI 10.1078/0171-9335-00316; Berthoud VM, 1997, EUR J BIOCHEM, V244, P89, DOI 10.1111/j.1432-1033.1997.00089.x; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Deschenes SM, 1997, J NEUROSCI, V17, P9077; Di WL, 2005, J CELL SCI, V118, P1505, DOI 10.1242/jcs.01733; Di WL, 2002, HUM MOL GENET, V11, P2005, DOI 10.1093/hmg/11.17.2005; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; Duvernay MT, 2004, J BIOL CHEM, V279, P30741, DOI 10.1074/jbc.M313881200; Ebihara L, 1996, BIOPHYS J, V71, P742, DOI 10.1016/S0006-3495(96)79273-1; EBIHARA L, 1989, SCIENCE, V243, P1194, DOI 10.1126/science.2466337; Emery G, 2000, J CELL SCI, V113, P2507; Fiedler K, 1997, J BIOL CHEM, V272, P24739, DOI 10.1074/jbc.272.40.24739; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; Gottfried I, 2002, HUM MOL GENET, V11, P1311, DOI 10.1093/hmg/11.11.1311; Hubner CA, 2002, HUM MOL GENET, V11, P2435, DOI 10.1093/hmg/11.20.2435; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; Jenne N, 2002, J BIOL CHEM, V277, P46504, DOI 10.1074/jbc.M206989200; Kalandadze A, 2004, J NEUROSCI, V24, P5183, DOI 10.1523/JNEUROSCI.0839-04.2004; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Mackay D, 1999, AM J HUM GENET, V64, P1357, DOI 10.1086/302383; Marziano NK, 2003, HUM MOL GENET, V12, P805, DOI 10.1093/hmg/ddg076; Matsuyama W, 2001, J HUM GENET, V46, P307, DOI 10.1007/s100380170064; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Nakamura N, 1998, MOL BIOL CELL, V9, P3493, DOI 10.1091/mbc.9.12.3493; Nickel W, 1997, P NATL ACAD SCI USA, V94, P11393, DOI 10.1073/pnas.94.21.11393; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; Pal JD, 2000, AM J PHYSIOL-CELL PH, V279, pC596, DOI 10.1152/ajpcell.2000.279.3.C596; Reddy MA, 2004, SURV OPHTHALMOL, V49, P300, DOI 10.1016/j.survophthal.2004.02.013; Rubenstein RC, 1997, J CLIN INVEST, V100, P2457, DOI 10.1172/JCI119788; Saez JC, 2003, PHYSIOL REV, V83, P1359, DOI 10.1152/physrev.00007.2003; SPRAY DC, 1981, J GEN PHYSIOL, V77, P77, DOI 10.1085/jgp.77.1.77; Thonnissen E, 2002, HUM GENET, V111, P190, DOI 10.1007/s00439-002-0750-2; Vanslyke JK, 2000, MOL BIOL CELL, V11, P1933, DOI 10.1091/mbc.11.6.1933; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	35	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40788	40795		10.1074/jbc.M504765200	http://dx.doi.org/10.1074/jbc.M504765200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16204255	Green Accepted, hybrid			2022-12-25	WOS:000233666600049
J	Miyauchi, Y; Michigami, T; Sakaguchi, N; Sekimoto, T; Yoneda, Y; Pike, JW; Yamagata, M; Ozono, K				Miyauchi, Y; Michigami, T; Sakaguchi, N; Sekimoto, T; Yoneda, Y; Pike, JW; Yamagata, M; Ozono, K			Importin 4 is responsible for ligand-independent nuclear translocation of vitamin D receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVING CELLS; NUCLEOCYTOPLASMIC TRANSPORT; TRANSCRIPTION FACTOR; FLUORESCENT PROTEIN; PORE COMPLEX; LOCALIZATION; BETA; BINDING; RAN; MECHANISMS	Vitamin D receptor (VDR) is localized in nuclei and acts as a ligand-dependent transcription factor. To clarify the molecular mechanisms underlying the nuclear translocation of VDR, we utilized an in vitro nuclear transport assay using digitonin-permeabilized semi-intact cells. In this assay, recombinant whole VDR-(4427) and a truncated mutant VDR-(4-232) lacking the carboxyl terminus of VDR were imported to nuclei even in the absence of ligand. In contrast, VDR-(91-427) lacking the amino-terminal DNA-binding domain was not imported to nuclei in the absence of ligand, and was efficiently imported in its liganded form. These results suggested that there are two distinct mechanisms underlying the nuclear transport of VDR; ligand-dependent and -independent pathways, and that the different regions of VDR are responsible for these processes. Therefore, we performed the yeast two-hybrid screening using VDR-(4-232) as the bait to explore the molecules responsible for ligand-independent nuclear translocation of VDR, and have identified importin 4 as an interacting protein. In the reconstruction experiments where transport factors were applied as recombinant proteins, recombinant importin 4 facilitated nuclear translocation of VDR regardless of its ligand, whereas importin beta failed in transporting VDR even in the presence of ligand. In conclusion, importin 4, not importin beta, is responsible for the ligand-independent nuclear translocation of VDR.	Osaka Med Ctr, Dept Environm Med, Izumi, Osaka 5941101, Japan; Osaka Med Ctr, Res Inst Maternal & Child Hlth, Izumi, Osaka 5941101, Japan; Osaka Univ, Grad Sch Med, Dept Pediat, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Frontier Biosci, Dept Frontier Biosci, Suita, Osaka 5650871, Japan; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	Osaka Medical Center for Cancer & Cardiovascular Diseases; Osaka Medical Center for Cancer & Cardiovascular Diseases; Osaka University; Osaka University; University of Wisconsin System; University of Wisconsin Madison	Michigami, T (corresponding author), Osaka Med Ctr, Dept Environm Med, 840 Murodo Cho, Izumi, Osaka 5941101, Japan.	michigami@mch.pref.Osaka.jp	Michigami, Toshimi/AAU-2326-2021					ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; Barsony J, 1997, J BIOL CHEM, V272, P5774, DOI 10.1074/jbc.272.9.5774; Christakos S, 2003, J CELL BIOCHEM, V88, P695, DOI 10.1002/jcb.10423; Cyert MS, 2001, J BIOL CHEM, V276, P20805, DOI 10.1074/jbc.R100012200; DAVIS LI, 1995, ANNU REV BIOCHEM, V64, P865, DOI 10.1146/annurev.bi.64.070195.004245; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; Hsieh JC, 1998, J CELL BIOCHEM, V70, P94, DOI 10.1002/(SICI)1097-4644(19980701)70:1<94::AID-JCB10>3.3.CO;2-Q; Htun H, 1999, MOL BIOL CELL, V10, P471, DOI 10.1091/mbc.10.2.471; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; Jakel S, 2002, EMBO J, V21, P377, DOI 10.1093/emboj/21.3.377; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; Kuersten S, 2001, TRENDS CELL BIOL, V11, P497, DOI 10.1016/S0962-8924(01)02144-4; Kurisaki A, 2001, MOL BIOL CELL, V12, P1079, DOI 10.1091/mbc.12.4.1079; Lee SJ, 2003, SCIENCE, V302, P1571, DOI 10.1126/science.1088372; LUO ZJ, 1994, EUR J BIOCHEM, V223, P381, DOI 10.1111/j.1432-1033.1994.tb19004.x; Michigami T, 1999, J BIOL CHEM, V274, P33531, DOI 10.1074/jbc.274.47.33531; MILDE P, 1989, J HISTOCHEM CYTOCHEM, V37, P1609, DOI 10.1177/37.11.2553800; Nagoshi E, 1999, MOL BIOL CELL, V10, P2221, DOI 10.1091/mbc.10.7.2221; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; OGAWA H, 1995, P NATL ACAD SCI USA, V92, P11899, DOI 10.1073/pnas.92.25.11899; PFUFER K, 2002, MOL ENDOCRINOL, V16, P1738; Pike J. W., 1997, Vitamin D., P105; Rout MP, 2001, J BIOL CHEM, V276, P16593, DOI 10.1074/jbc.R100015200; Sekimoto T, 2004, EMBO J, V23, P1934, DOI 10.1038/sj.emboj.7600198; Sekimoto T, 1996, J BIOL CHEM, V271, P31017, DOI 10.1074/jbc.271.49.31017; Tachibana T, 1996, FEBS LETT, V397, P177, DOI 10.1016/S0014-5793(96)01180-5; Tanaka M, 2003, ENDOCRINOLOGY, V144, P4070, DOI 10.1210/en.2003-0282; Yokoya F, 1999, MOL BIOL CELL, V10, P1119, DOI 10.1091/mbc.10.4.1119	30	35	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40901	40908		10.1074/jbc.M509347200	http://dx.doi.org/10.1074/jbc.M509347200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16207705	hybrid			2022-12-25	WOS:000233666600062
J	Purohit, V; Balakrishnan, M; Kim, B; Bambara, RA				Purohit, V; Balakrishnan, M; Kim, B; Bambara, RA			Evidence that HIV-1 reverse transcriptase employs the DNA 3 ' end-directed primary/secondary RNase H cleavage mechanism during synthesis and strand transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; STRONG STOP TRANSFER; AMINO-ACID-RESIDUES; IN-VITRO; SECONDARY STRUCTURE; RIBONUCLEASE-H; NUCLEOCAPSID PROTEIN; INVASION MECHANISM; CRYSTAL-STRUCTURE; MUTATIONS	We previously analyzed strand transfers catalyzed by human immunodeficiency virus, type 1 reverse transcriptase (RT) in a hair-pin-containing RNA template system. In this system, RT produces a series of adjacent RNase H cuts before the hairpin base on the first, or donor template that clears a region of the donor, facilitating invasion by the second, or acceptor RNA. Here we analyze characteristics of the prominent cuts before the hairpin base and their role in strand transfers. Analysis of the template cleavage pattern during synthesis suggested that the RT performs DNA 3' end-directed primary and secondary cuts while paused at the hairpin base and that these cuts contribute to creation of the invasion site. RT catalyzed similar cleavages on a substrate representing a paused cDNA-template intermediate. DNA 3' end-directed secondary cuts, which require positioning of the polymerase active site downstream of the primer terminus, had previously not been specifically identified during synthesis. Our findings indicate that during synthesis DNA 3' end-directed primary and secondary cuts occur at pause sites. RT mutants with substitutions at the His539 residue in the RNase H active site were defective in secondary cleavages. Analysis of the template cleavage pattern generated by the His539 mutants during synthesis revealed inefficient cleavage at the invasion site, correlating with defects in strand transfer. Overall, results indicate RT can catalyze pause-associated DNA 3' end-directed primary and secondary cuts during synthesis and these cuts can contribute to strand transfer by creation of an invasion site.	Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Microbiol & Immunol, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Ctr Canc, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester	Bambara, RA (corresponding author), 601 Elmwood Ave,Box 712, Rochester, NY 14642 USA.	robert_bambara@urmc.rochester.edu			NIDA NIH HHS [T32-DA07232] Funding Source: Medline; NIGMS NIH HHS [GM 49573] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [T32DA007232] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Archer RH, 2000, J VIROL, V74, P8390, DOI 10.1128/JVI.74.18.8390-8401.2000; Archer RH, 2001, BIOCHEMISTRY-US, V40, P4087, DOI 10.1021/bi002328a; Chen Y, 2005, J BIOL CHEM, V280, P14443, DOI 10.1074/jbc.M412190200; Chen Y, 2003, J BIOL CHEM, V278, P38368, DOI 10.1074/jbc.M305700200; Chen Y, 2003, J BIOL CHEM, V278, P8006, DOI 10.1074/jbc.M210959200; CIRINO NM, 1993, J BIOL CHEM, V268, P14743; Derebail SS, 2004, J BIOL CHEM, V279, P47446, DOI 10.1074/jbc.M408927200; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P7423; DESTEFANO JJ, 1993, NUCLEIC ACIDS RES, V21, P4330, DOI 10.1093/nar/21.18.4330; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P24295; Driscoll MD, 2000, J VIROL, V74, P8785, DOI 10.1128/JVI.74.19.8785-8792.2000; Driscoll MD, 2001, J VIROL, V75, P672, DOI 10.1128/JVI.75.2.672-686.2001; FURFINE ES, 1991, J BIOL CHEM, V266, P406; Gao HQ, 2000, J MOL BIOL, V300, P403, DOI 10.1006/jmbi.2000.3823; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; Hanson MN, 2005, J MOL BIOL, V353, P772, DOI 10.1016/j.jmb.2005.08.065; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kim JK, 1997, J BIOL CHEM, V272, P16769, DOI 10.1074/jbc.272.27.16769; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Lee R, 1998, BIOCHEMISTRY-US, V37, P900, DOI 10.1021/bi972197m; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Negroni M, 2000, P NATL ACAD SCI USA, V97, P6385, DOI 10.1073/pnas.120520497; NEGRONI M, 1995, P NATL ACAD SCI USA, V92, P6971, DOI 10.1073/pnas.92.15.6971; Nikolenko GN, 2004, J VIROL, V78, P8761, DOI 10.1128/JVI.78.16.8761-8770.2004; Palaniappan C, 1996, J BIOL CHEM, V271, P2063, DOI 10.1074/jbc.271.47.29605; Pandey VN, 1996, BIOCHEMISTRY-US, V35, P2168, DOI 10.1021/bi9516642; Roda RH, 2003, J BIOL CHEM, V278, P31536, DOI 10.1074/jbc.M304608200; Roda RH, 2002, J BIOL CHEM, V277, P46900, DOI 10.1074/jbc.M208638200; Sarafianos SG, 2001, EMBO J, V20, P1449, DOI 10.1093/emboj/20.6.1449; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; SCHATZ O, 1989, FEBS LETT, V257, P311, DOI 10.1016/0014-5793(89)81559-5; Schultz SJ, 2004, J MOL BIOL, V344, P635, DOI 10.1016/j.jmb.2004.09.081; Smith CM, 1999, J VIROL, V73, P6573, DOI 10.1128/JVI.73.8.6573-6581.1999; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12468, DOI 10.1021/bi971218+; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12459, DOI 10.1021/bi971217h; Svarovskaia ES, 2000, J VIROL, V74, P7171, DOI 10.1128/JVI.74.15.7171-7178.2000; TISDALE M, 1991, J GEN VIROL, V72, P59, DOI 10.1099/0022-1317-72-1-59; VOLKMANN S, 1993, J BIOL CHEM, V268, P2674; Wisniewski M, 2000, J BIOL CHEM, V275, P37664, DOI 10.1074/jbc.M007381200; Wisniewski M, 2000, P NATL ACAD SCI USA, V97, P11978, DOI 10.1073/pnas.210392297; Wisniewski M, 2002, J BIOL CHEM, V277, P28400, DOI 10.1074/jbc.M201645200; WOHRL BM, 1991, J MOL BIOL, V220, P801, DOI 10.1016/0022-2836(91)90119-Q; WU WM, 1995, J BIOL CHEM, V270, P325, DOI 10.1074/jbc.270.1.263; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	46	17	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40534	40543		10.1074/jbc.M507839200	http://dx.doi.org/10.1074/jbc.M507839200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16221683	hybrid			2022-12-25	WOS:000233666600020
J	Qian, F; Wei, W; Germino, G; Oberhauser, A				Qian, F; Wei, W; Germino, G; Oberhauser, A			The nanomechanics of polycystin-1 extracellular region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY-DISEASE; PKD1 GENE; MOLECULAR-GENETICS; MUTATION ANALYSIS; SINGLE PROTEIN; STRENGTH; DOMAINS; ACTIVATION; CLEAVAGE; RECEPTOR	Recent evidence suggests that polycystin-1 (PC1) acts as a mechanosensor, receiving signals from the primary cilia, neighboring cells, and extracellular matrix and transduces them into cellular responses that regulate proliferation, adhesion, and differentiation that are essential for the control of renal tubules and kidney morphogenesis. PC1 has an unusually long extracellular region (similar to 3000 amino acids) with amultimodular structure. Proteins with a similar architecture have structural and mechanical roles. Based on the structural similarities between PC1 and other modular proteins that have elastic properties we hypothesized that PC1 functions mechanically by providing a flexible and elastic linkage between cells. Here we directly tested this hypothesis by analyzing the mechanical properties of the entire PC1 extracellular region by using single molecule force spectroscopy. We show that the PC1 extracellular region is highly extensible and that this extensibility is mainly caused by the unfolding of its Ig-like domains. Stretching the native PC1 extracellular region results in a sawtooth pattern with equally spaced force peaks that have a wide range of unfolding forces (50-200 pN). By combining single-molecule force spectroscopy and protein engineering techniques, we demonstrate that the sawtooth pattern in native PC1 extracellular region corresponds to the sequential unfolding of individual Ig-like domains. We found that Ig-like domains refold after mechanical unfolding. Hence, the PC1 extracellular region displays a dynamic extensibility whereby the resting length might be regulated through unfolding/refolding of its Ig-like domains. These force-driven reactions may be important for cell elasticity and the regulation of cell signaling events mediated by PC1.	Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Struct Biol, Galveston, TX 77555 USA; Johns Hopkins Univ, Sch Med, Div Nephrol, Baltimore, MD 21205 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Johns Hopkins University	Oberhauser, A (corresponding author), Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA.	afoberha@utmb.edu		Germino, Gregory/0000-0002-3609-5588	NIDDK NIH HHS [DK48006, DK57325, DK067443, DK062199, R21 DK067443, R37 DK048006, P50 DK057325, R01 DK062199, R21 DK067443-01, R01 DK048006] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK048006, R01DK048006, R21DK067443, P50DK057325, R01DK062199] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bateman A, 1996, EMBO J, V15, P6050, DOI 10.1002/j.1460-2075.1996.tb00993.x; Bertoncini P, 2005, J MOL BIOL, V348, P1127, DOI 10.1016/j.jmb.2005.03.040; Best RB, 2003, J MOL BIOL, V330, P867, DOI 10.1016/S0022-2836(03)00618-1; Bhasin N, 2004, J BIOL CHEM, V279, P45865, DOI 10.1074/jbc.M404103200; Bhunia AK, 2002, CELL, V109, P157, DOI 10.1016/S0092-8674(02)00716-X; Burtey S, 2002, J MED GENET, V39, P422, DOI 10.1136/jmg.39.6.422; Bycroft M, 1999, EMBO J, V18, P297, DOI 10.1093/emboj/18.2.297; Carl P, 2001, P NATL ACAD SCI USA, V98, P1565, DOI 10.1073/pnas.031409698; Carrion-Vazquez M, 1999, P NATL ACAD SCI USA, V96, P3694, DOI 10.1073/pnas.96.7.3694; Chauvet V, 2004, J CLIN INVEST, V114, P1433, DOI 10.1172/JCI200421753; Evans E, 1997, BIOPHYS J, V72, P1541, DOI 10.1016/S0006-3495(97)78802-7; Evans E, 1999, BIOPHYS J, V76, P2439, DOI 10.1016/S0006-3495(99)77399-6; Fisher TE, 1999, TRENDS BIOCHEM SCI, V24, P379, DOI 10.1016/S0968-0004(99)01453-X; FLORIN EL, 1995, BIOSENS BIOELECTRON, V10, P895, DOI 10.1016/0956-5663(95)99227-C; Forman JR, 2005, J MOL BIOL, V349, P861, DOI 10.1016/j.jmb.2005.04.008; GABOW PA, 1990, AM J KIDNEY DIS, V16, P403, DOI 10.1016/S0272-6386(12)80051-5; GLUCKSMANNKUIS MA, 1995, CELL, V81, P289; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; HARRIS PC, 1995, NAT MED, V1, P493, DOI 10.1038/nm0695-493a; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; Ibraghimov-Beskrovnaya O, 2000, HUM MOL GENET, V9, P1641, DOI 10.1093/hmg/9.11.1641; Ko KS, 2001, J BIOL CHEM, V276, P35967, DOI 10.1074/jbc.M104106200; Li HB, 2002, NATURE, V418, P998, DOI 10.1038/nature00938; Malhas AN, 2002, J AM SOC NEPHROL, V13, P19, DOI 10.1681/ASN.V13119; Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849; Marko JF, 1995, MACROMOLECULES, V28, P8759, DOI 10.1021/ma00130a008; Moy GW, 1996, J CELL BIOL, V133, P809, DOI 10.1083/jcb.133.4.809; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Oberhauser AF, 2001, P NATL ACAD SCI USA, V98, P468, DOI 10.1073/pnas.021321798; Oberhauser AF, 1998, NATURE, V393, P181, DOI 10.1038/30270; Oberschall A, 2002, CONTEMP SOCIOL, V31, P447, DOI 10.2307/3089104; Phakdeekitcharoen B, 2001, J AM SOC NEPHROL, V12, P955, DOI 10.1681/ASN.V125955; Praetorius HA, 2005, AM J PHYSIOL-RENAL, V288, pF133, DOI 10.1152/ajprenal.00238.2004; Qian F, 2002, P NATL ACAD SCI USA, V99, P16981, DOI 10.1073/pnas.252484899; Rief M, 1997, SCIENCE, V276, P1109, DOI 10.1126/science.276.5315.1109; Rossetti S, 2001, AM J HUM GENET, V68, P46, DOI 10.1086/316939; Sandford R, 1997, HUM MOL GENET, V6, P1483, DOI 10.1093/hmg/6.9.1483; Schlierf M, 2004, P NATL ACAD SCI USA, V101, P7299, DOI 10.1073/pnas.0400033101; Streets AJ, 2003, J AM SOC NEPHROL, V14, P1804, DOI 10.1097/01.ASN.0000076075.49819.9B; Sutters M, 2003, J LAB CLIN MED, V141, P91, DOI 10.1067/mlc.2003.13; Torres VE, 1998, CURR OPIN NEPHROL HY, V7, P159, DOI 10.1097/00041552-199803000-00004; Wilson PD, 1999, EXP NEPHROL, V7, P114; Wu GQ, 2000, MOL GENET METAB, V69, P1, DOI 10.1006/mgme.1999.2943; Xu GM, 2001, J BIOL CHEM, V276, P46544, DOI 10.1074/jbc.M107828200	44	55	58	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40723	40730		10.1074/jbc.M509650200	http://dx.doi.org/10.1074/jbc.M509650200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16219758	Green Accepted, hybrid			2022-12-25	WOS:000233666600042
J	Wang, YR; Inoue, T; Forgac, M				Wang, YR; Inoue, T; Forgac, M			Subunit a of the yeast V-ATPase participates in binding of bafilomycin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; MEDIATED CROSS-LINKING; PROTON-TRANSLOCATING ATPASE; IN-VIVO DISSOCIATION; SACCHAROMYCES-CEREVISIAE; MUTATIONAL ANALYSIS; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; CLOSE PROXIMITY; 100-KDA SUBUNIT	Bafilomycin and concanamycin are potent and highly specific inhibitors of the vacuolar (H+)-ATPases (V-ATPases), typically inhibiting at nanomolar concentrations. Previous studies have shown that subunit c of the integral V-0 domain participates in bafilomycin binding, and that this site resembles the oligomycin binding site of the F-ATPase ( Bowman, B. J., and Bowman, E. J. ( 2002) J. Biol. Chem. 277, 3965-3972). Because mutations in F-ATPase subunit a also confer resistance to oligomycin, we investigated whether the a subunit of the V-ATPase might participate in binding bafilomycin. Twenty-eight subunit a mutations were constructed just N-terminal to the critical Arg(735) residue in transmembrane 7 required for proton transport, a region similar to that shown to participate in oligomycin binding by the F-ATPase. The mutants appeared to assemble normally and all but two showed normal growth at pH 7.5, whereas all but three had at least 25% of wild-type levels of proton transport and ATPase activity. Of the functional mutants, three displayed Ki values for bafilomycin significantly different from wild-type (0.22 +/- 0.03 nM). These included E721K ( Ki 0.38 +/- 0.03 nM), L724A ( 0.40 +/- 0.02 nM), and N725F ( 0.54 +/- 0.06 nM). Only the N725F mutation displayed a Ki for concanamycin ( 0.84 +/- 0.04 nM) that was slightly higher than wild-type ( 0.60 +/- 0.07 nM). These results suggest that subunit a of V-ATPase participates along with subunit c in binding bafilomycin.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	Tufts University	Forgac, M (corresponding author), 136 Harrison Ave, Boston, MA 02111 USA.	michael.forgac@tufts.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034478, R01GM034478] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34928] Funding Source: Medline; NIGMS NIH HHS [GM34478, R37 GM034478, R01 GM034478] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrami L, 2004, J CELL BIOL, V166, P645, DOI 10.1083/jcb.200312072; Arata Y, 2002, BIOCHEMISTRY-US, V41, P11301, DOI 10.1021/bi0262449; Bowman BJ, 2002, J BIOL CHEM, V277, P3965, DOI 10.1074/jbc.M109756200; Bowman EJ, 2004, J BIOL CHEM, V279, P33131, DOI 10.1074/jbc.M404638200; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BREEN GAM, 1986, J BIOL CHEM, V261, P1680; Brown D, 2000, J EXP BIOL, V203, P137; Cain BD, 2000, J BIOENERG BIOMEMBR, V32, P365, DOI 10.1023/A:1005575919638; Cross RL, 2004, FEBS LETT, V576, P1, DOI 10.1016/j.febslet.2004.08.065; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; Fillingame RH, 2002, BBA-BIOENERGETICS, V1555, P29, DOI 10.1016/S0005-2728(02)00250-5; FORGAC M, 1983, P NATL ACAD SCI-BIOL, V80, P1300, DOI 10.1073/pnas.80.5.1300; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Girvin ME, 1998, BIOCHEMISTRY-US, V37, P8817, DOI 10.1021/bi980511m; Graham LA, 2003, J BIOENERG BIOMEMBR, V35, P301, DOI 10.1023/A:1025772730586; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; Hirata T, 2003, J BIOL CHEM, V278, P23714, DOI 10.1074/jbc.M302756200; Huss M, 2002, J BIOL CHEM, V277, P40544, DOI 10.1074/jbc.M207345200; Imamizu H, 2003, P NATL ACAD SCI USA, V100, P5461, DOI 10.1073/pnas.0835746100; Inoue T, 2005, J BIOL CHEM, V280, P27896, DOI 10.1074/jbc.M504890200; Inoue T, 2003, J BIOENERG BIOMEMBR, V35, P291, DOI 10.1023/A:1025720713747; Iwata M, 2004, P NATL ACAD SCI USA, V101, P59, DOI 10.1073/pnas.0305165101; Jiang WP, 1998, P NATL ACAD SCI USA, V95, P6607, DOI 10.1073/pnas.95.12.6607; JOHN UP, 1986, FEBS LETT, V207, P79, DOI 10.1016/0014-5793(86)80016-3; Kane PM, 2003, J BIOENERG BIOMEMBR, V35, P313, DOI 10.1023/A:1025724814656; KANE PM, 1992, J BIOL CHEM, V267, P447; Kawasaki-Nishi S, 2003, J BIOL CHEM, V278, P41908, DOI 10.1074/jbc.M308026200; Kawasaki-Nishi S, 2001, J BIOL CHEM, V276, P47411, DOI 10.1074/jbc.M108310200; Kawasaki-Nishi S, 2001, P NATL ACAD SCI USA, V98, P12397, DOI 10.1073/pnas.221291798; Kluge C, 2003, J BIOENERG BIOMEMBR, V35, P377, DOI 10.1023/A:1025737117382; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landolt-Marticorena C, 2000, J BIOL CHEM, V275, P15449, DOI 10.1074/jbc.M000207200; Leng XH, 1996, J BIOL CHEM, V271, P22487, DOI 10.1074/jbc.271.37.22487; Leng XH, 1998, J BIOL CHEM, V273, P6717, DOI 10.1074/jbc.273.12.6717; Leng XH, 1999, J BIOL CHEM, V274, P14655, DOI 10.1074/jbc.274.21.14655; Liu JZ, 1996, BIOCHEMISTRY-US, V35, P10938, DOI 10.1021/bi9608065; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MacLeod KJ, 1998, J BIOL CHEM, V273, P150, DOI 10.1074/jbc.273.1.150; Manfred G, 1999, J BIOL CHEM, V274, P9386, DOI 10.1074/jbc.274.14.9386; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; Nelson N, 2003, J BIOENERG BIOMEMBR, V35, P281, DOI 10.1023/A:1025768529677; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; Rastogi VK, 1999, NATURE, V402, P263, DOI 10.1038/46224; Sennoune SR, 2004, AM J PHYSIOL-CELL PH, V286, pC1443, DOI 10.1152/ajpcell.00407.2003; Shao E, 2004, J BIOL CHEM, V279, P48663, DOI 10.1074/jbc.M408278200; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sun-Wada GH, 2003, J BIOENERG BIOMEMBR, V35, P347, DOI 10.1023/A:1025780932403; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Vik SB, 2000, BBA-BIOENERGETICS, V1458, P457, DOI 10.1016/S0005-2728(00)00094-3; Wagner CA, 2004, PHYSIOL REV, V84, P1263, DOI 10.1152/physrev.00045.2003; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; Wang YR, 2004, J BIOL CHEM, V279, P44628, DOI 10.1074/jbc.M407345200; Weber J, 2003, FEBS LETT, V545, P61, DOI 10.1016/S0014-5793(03)00394-6; Wieczorek H, 2003, J BIOENERG BIOMEMBR, V35, P359, DOI 10.1023/A:1025733016473; Wilkens S, 2004, J BIOL CHEM, V279, P41942, DOI 10.1074/jbc.M407821200; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509; Zhang D, 2003, J BIOL CHEM, V278, P12319, DOI 10.1074/jbc.M212413200; ZHANG JM, 1994, J BIOL CHEM, V269, P23518	61	63	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40481	40488		10.1074/jbc.M509106200	http://dx.doi.org/10.1074/jbc.M509106200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16216877	hybrid			2022-12-25	WOS:000233666600013
J	Aktas, B; Pozgajova, M; Bergmeier, W; Sunnarborg, S; Offermanns, S; Lee, D; Wagner, DD; Nieswandt, B				Aktas, B; Pozgajova, M; Bergmeier, W; Sunnarborg, S; Offermanns, S; Lee, D; Wagner, DD; Nieswandt, B			Aspirin induces platelet receptor shedding via ADAM17 (TACE)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ALPHA-CONVERTING ENZYME; GLYCOPROTEIN-VI; DOWN-REGULATION; L-SELECTIN; IN-VITRO; ACETYLSALICYLIC-ACID; BLEEDING-TIME; INHIBITORS; CYCLOOXYGENASE	Aspirin is effective in the therapy of cardiovascular diseases, because it causes acetylation of cyclooxygenase 1 ( COX-1) leading to irreversible inhibition of platelets. Additional mechanisms can be suspected, because patients treated with other platelet COX inhibitors such as indomethacin do not display an increased bleeding tendency as observed for aspirin-treated patients. Recently, aspirin and other anti-inflammatory drugs were shown to induce shedding of L-selectin in neutrophils in a metalloproteinase-dependent manner. Therefore, we investigated the effects of aspirin on the von Willebrand Factor receptor complex glycoprotein ( GP) Ib-V-IX, whose lack or dysfunction causes bleeding in patients. As quantified by fluorescence-activated cell sorting analysis in whole blood, aspirin, but not its metabolite salicylic acid, induced dose-dependent shedding of human and murine GPIb alpha and GPV from the platelet surface, whereas other glycoproteins remained unaffected by this treatment. Biotinylated fragments of GPV were detected by immunoprecipitation in the supernatant of washed mouse platelets, and the expression level of GPIb alpha was decreased in these platelets as measured by Western blot analysis. Although shedding occurred normally in COX-1-deficient murine platelets, shedding was completely blocked by a broad-range metalloproteinase inhibitor and, more importantly, in mouse platelets expressing an inactive form of ADAM17. Shed fragments of GPIb alpha and GPV were elevated in the plasma of aspirin-injected mice compared with animals injected with control buffer. These data demonstrate that aspirin at high concentrations induces shedding of GPIb alpha and GPV by an ADAM17-dependent mechanism and that this process can occur in vivo.	Rudolf Virchow Ctr Expt Biomed, D-97078 Wurzburg, Germany; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Heidelberg Univ, Inst Pharmacol, D-69120 Heidelberg, Germany	University of Wurzburg; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Ruprecht Karls University Heidelberg	Nieswandt, B (corresponding author), Rudolf Virchow Ctr Expt Biomed, Verbacherstr 9, D-97078 Wurzburg, Germany.	bernhard.nieswandt@virchow.uni-wuerzburg.de	Pozgajova, Miroslava/AAG-2513-2019; Pozgajova, Miroslava/AAG-1841-2019; Offermanns, Stefan/L-3313-2017	Pozgajova, Miroslava/0000-0003-3713-0717; Offermanns, Stefan/0000-0001-8676-6805				Alberio L, 2002, THROMB HAEMOSTASIS, V88, P510; ALEVRIADOU BR, 1993, BLOOD, V81, P1263; Andre P, 2003, CIRCULATION, V108, P2697, DOI 10.1161/01.CIR.0000093279.36628.12; Andre P, 2003, J CLIN INVEST, V112, P398, DOI 10.1172/JCI200317864; Awtry EH, 2000, CIRCULATION, V101, P1206, DOI 10.1161/01.CIR.101.10.1206; Berger G, 1998, BLOOD, V92, P4446, DOI 10.1182/blood.V92.11.4446; Bergmeier W, 2000, BLOOD, V95, P886, DOI 10.1182/blood.V95.3.886.003k45_886_893; Bergmeier W, 2004, CIRC RES, V95, P677, DOI 10.1161/01.RES.0000143899.73453.11; Bergmeier W, 2004, THROMB HAEMOSTASIS, V91, P951, DOI 10.1160/TH03-12-0795; Bergmeier W, 2003, BLOOD, V102, P4229, DOI 10.1182/blood-2003-04-1305; Bergmeier W, 2002, CYTOMETRY, V48, P80, DOI 10.1002/cyto.10114; Brown SB, 2000, J BIOL CHEM, V275, P5987, DOI 10.1074/jbc.275.8.5987; BUCHANAN MR, 1982, THROMB RES, V25, P263, DOI 10.1016/0049-3848(82)90127-X; Colciaghi F, 2002, MOL MED, V8, P67, DOI 10.1007/BF03402076; Contin C, 2003, J BIOL CHEM, V278, P32801, DOI 10.1074/jbc.M209993200; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; EBLE JN, 1971, NATURE, V231, P181, DOI 10.1038/231181a0; FIORE LD, 1990, AM J CLIN PATHOL, V94, P292, DOI 10.1093/ajcp/94.3.292; FitzGerald GA, 2003, LANCET, V361, P542, DOI 10.1016/S0140-6736(03)12560-3; Gardiner EE, 2004, BLOOD, V104, P3611, DOI 10.1182/blood-2004-04-1549; GASPARI F, 1987, J CLIN INVEST, V79, P1788, DOI 10.1172/JCI113020; Gomez-Gaviro MV, 2002, J BIOL CHEM, V277, P38212, DOI 10.1074/jbc.M205142200; Gomez-Gaviro MV, 2000, BLOOD, V96, P3592, DOI 10.1182/blood.V96.10.3592.h8003592_3592_3600; HIGGS GA, 1987, P NATL ACAD SCI USA, V84, P1417, DOI 10.1073/pnas.84.5.1417; HOOGENDIJK EMG, 1980, LANCET, V1, P93; JAKUBOWSKI JA, 1983, THROMB HAEMOSTASIS, V50, P189; JORGENSEN TG, 1976, SCAND J CLIN LAB INV, V36, P771, DOI 10.3109/00365517609081936; Jurasz P, 2002, CIRC RES, V90, P1041, DOI 10.1161/01.RES.0000021398.28936.1D; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; Lopez JA, 1998, BLOOD, V91, P4397, DOI 10.1182/blood.V91.12.4397.412k42_4397_4418; Mahmud T, 1996, ARTHRITIS RHEUM, V39, P1998, DOI 10.1002/art.1780391208; Matala E, 2001, J IMMUNOL, V167, P1617, DOI 10.4049/jimmunol.167.3.1617; Mingatto FE, 1996, ARCH BIOCHEM BIOPHYS, V334, P303, DOI 10.1006/abbi.1996.0459; Nieswandt B, 2001, EMBO J, V20, P2120, DOI 10.1093/emboj/20.9.2120; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Rabie T, 2005, J BIOL CHEM, V280, P14462, DOI 10.1074/jbc.M500041200; RAINSFORD KD, 1983, BIOCHEM PHARMACOL, V32, P1301, DOI 10.1016/0006-2952(83)90286-1; ROTH GJ, 1975, P NATL ACAD SCI USA, V72, P3073, DOI 10.1073/pnas.72.8.3073; Ruggeri ZM, 2002, NAT MED, V8, P1227, DOI 10.1038/nm1102-1227; Sakakibara M, 2002, ARTERIOSCL THROM VAS, V22, P1360, DOI 10.1161/01.ATV.0000027102.53875.47; Valentin JP, 1997, J PHARMACOL EXP THER, V280, P761; Vane JR, 2003, THROMB RES, V110, P255, DOI 10.1016/S0049-3848(03)00379-7	42	51	57	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					39716	39722		10.1074/jbc.M507762200	http://dx.doi.org/10.1074/jbc.M507762200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16179345	Green Published, hybrid			2022-12-25	WOS:000233461300008
J	Baum, W; Kirkin, V; Fernandez, SBM; Pick, R; Lettau, M; Janssen, O; Zornig, M				Baum, W; Kirkin, V; Fernandez, SBM; Pick, R; Lettau, M; Janssen, O; Zornig, M			Binding of the intracellular Fas ligand (FasL) domain to the adaptor protein PSTPIP results in a cytoplasmic localization of FasL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSKELETAL-ASSOCIATED PROTEIN; ALDRICH-SYNDROME PROTEIN; T-CELL HYBRIDOMAS; CD95 LIGAND; TYROSINE-PHOSPHATASE; SECRETORY LYSOSOMES; SIGNALING COMPLEX; DOWN-REGULATION; DEATH FACTOR; PTP-PEST	The tumor necrosis factor family member Fas ligand ( FasL) induces apoptosis in Fas receptor-expressing target cells and is an important cytotoxic effector molecule used by CTL- and NK-cells. In these hematopoietic cells, newly synthesized FasL is stored in specialized secretory lysosomes and only delivered to the cell surface upon activation and target cell recognition. FasL contains an 80-amino acid-long cytoplasmic tail, which includes a proline-rich domain as a bona fide Src homology 3 domain-binding site. This proline-rich domain has been implicated in FasL sorting to secretory lysosomes, and it may also be important for reverse signaling via FasL, which has been described to influence T-cell activation. Here we report the identification of the Src homology 3 domain-containing adaptor protein PSTPIP as a FasL-interacting partner, which binds to the proline-rich domain. PSTPIP co-expression leads to an increased intracellular localization of Fas ligand, thereby regulating extracellular availability and cytotoxic activity of the molecule. In addition, we demonstrate recruitment of the tyrosine phosphatase PTP-PEST by PSTPIP into FasL.PSTPIP.PTP-PEST complexes which may contribute to FasL reverse signaling.	Georg Speyer Haus, D-60596 Frankfurt, Germany; Inst Immunol, D-24105 Kiel, Germany		Zornig, M (corresponding author), Georg Speyer Haus, Paul Ehrlich Str 42-44, D-60596 Frankfurt, Germany.	zoernig@em.uni-frankfurt.de	Janssen, Ottmar/E-9735-2010; Janssen, Ottmar/N-8769-2019; Lettau, Marcus/H-7595-2019	Janssen, Ottmar/0000-0002-9612-8900; Janssen, Ottmar/0000-0002-9612-8900; Lettau, Marcus/0000-0002-3824-9923; Kirkin, Vladimir/0000-0002-8049-3663				Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Badour K, 2003, IMMUNITY, V18, P141, DOI 10.1016/S1074-7613(02)00516-2; Bai YL, 2001, EXP MOL PATHOL, V71, P115, DOI 10.1006/exmp.2001.2388; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Blott EJ, 2001, J CELL SCI, V114, P2405; Blott EJ, 2002, NAT REV MOL CELL BIO, V3, P122, DOI 10.1038/nrm732; Bodour K, 2004, J EXP MED, V199, P99, DOI 10.1084/jem.20030976; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Cong F, 2000, MOL CELL, V6, P1413, DOI 10.1016/S1097-2765(00)00138-6; Cote JF, 2002, J BIOL CHEM, V277, P2973, DOI 10.1074/jbc.M106428200; Desbarats J, 1998, NAT MED, V4, P1377, DOI 10.1038/3965; Dowbenko D, 1998, J BIOL CHEM, V273, P989, DOI 10.1074/jbc.273.2.989; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Ghadimi MP, 2002, FEBS LETT, V519, P50, DOI 10.1016/S0014-5793(02)02709-6; Hallermalm K, 2004, CANCER RES, V64, P6775, DOI 10.1158/0008-5472.CAN-04-0508; HANE M, 1995, FEBS LETT, V373, P265, DOI 10.1016/0014-5793(95)01051-F; Holler N, 2003, MOL CELL BIOL, V23, P1428, DOI 10.1128/MCB.23.4.1428-1440.2003; Janssen O, 2003, CELL DEATH DIFFER, V10, P1215, DOI 10.1038/sj.cdd.4401305; Jodo S, 2001, J BIOL CHEM, V276, P39938, DOI 10.1074/jbc.M107005200; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; Kamioka Y, 2004, J BIOL CHEM, V279, P40091, DOI 10.1074/jbc.M404899200; Knox PG, 2003, J IMMUNOL, V170, P677, DOI 10.4049/jimmunol.170.2.677; Li J, 1998, EMBO J, V17, P7320, DOI 10.1093/emboj/17.24.7320; Linkermann A, 2003, BIOCHEM PHARMACOL, V66, P1417, DOI 10.1016/S0006-2952(03)00492-1; Martinez-Lorenzo MJ, 2004, EXP CELL RES, V295, P315, DOI 10.1016/j.yexcr.2003.12.024; Martinez-Lorenzo MJ, 1999, J IMMUNOL, V163, P1274; Merrifield CJ, 2004, TRENDS CELL BIOL, V14, P352, DOI 10.1016/j.tcb.2004.05.008; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1994, ADV IMMUNOL, V57, P129, DOI 10.1016/S0065-2776(08)60672-0; Newell MK, 1999, APOPTOSIS, V4, P311, DOI 10.1023/A:1009670802382; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Spencer S, 1997, J CELL BIOL, V138, P845, DOI 10.1083/jcb.138.4.845; Suzuki I, 2000, J IMMUNOL, V165, P5537, DOI 10.4049/jimmunol.165.10.5537; Suzuki I, 1998, J EXP MED, V187, P123, DOI 10.1084/jem.187.1.123; TAKAHASHI T, 1994, INT IMMUNOL, V6, P1567, DOI 10.1093/intimm/6.10.1567; Tanaka M, 1998, NAT MED, V4, P31, DOI 10.1038/nm0198-031; Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007; Ulisse S, 2000, CELL DEATH DIFFER, V7, P916, DOI 10.1038/sj.cdd.4400716; Watts AD, 1999, EMBO J, V18, P2119, DOI 10.1093/emboj/18.8.2119; Wise CA, 2002, HUM MOL GENET, V11, P961, DOI 10.1093/hmg/11.8.961; Wu Y, 1998, J BIOL CHEM, V273, P5765, DOI 10.1074/jbc.273.10.5765; YANG YL, 1995, J EXP MED, V181, P1673, DOI 10.1084/jem.181.5.1673	42	44	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40012	40024		10.1074/jbc.M502222200	http://dx.doi.org/10.1074/jbc.M502222200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16204241	hybrid			2022-12-25	WOS:000233461300039
J	Billiet, L; Furman, C; Larigauderie, G; Copin, C; Brand, K; Fruchart, JC; Rouis, M				Billiet, L; Furman, C; Larigauderie, G; Copin, C; Brand, K; Fruchart, JC; Rouis, M			Extracellular human thioredoxin-1 inhibits lipopolysaccharide-induced interleukin-1 beta expression in human monocyte-derived macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; REDOX REGULATION; TRANSCRIPTIONAL ACTIVITY; TRUNCATED THIOREDOXIN; PLASMA THIOREDOXIN; REPERFUSION INJURY; DIRECT ASSOCIATION; SERUM THIOREDOXIN; OXIDATIVE STRESS	Oxidative stress plays an important role in atherosclerotic vascular disease, and several recent studies were focused on thioredoxin-1 (Trx-1) and its potential protective role against oxidative stress. Since human monocyte-derived macrophages ( HMDM) are important cells in several inflammatory diseases including atherosclerosis, we conducted this study to evaluate the impact of extracellular recombinant human Trx-1 (rhTrx-1) on gene expression in lipopolysaccharide-activated HMDM. Our results showed that rhTrx-1 was capable of reducing interleukin (IL)-1 beta mRNA and protein synthesis in a dose-dependent manner. This effect was partly mediated through a reduction of NF-kappa B activation as analyzed by transient transfection and gel shift assays. In addition, we showed that the attenuation of NF-kappa B activity was the result of the reduction of both p50 and p65 subunit mRNA and protein synthesis on one hand and of the induction of I-kappa Ba mRNA and protein expression on the other hand. Moreover, inhibition of endogenous Trx-1 mRNA was also observed, suggesting a contribution to the diminution of NF-kappa B activity since endogenous Trx-1, in contrast to the exogenous Trx-1, activates the NF-kappa B system. Finally, H2O2x-oxidized rhTrx-1 reduced IL-1 beta mRNA synthesis in lipopolysaccharide-activated HMDM. This result highly suggested that the rhTrx- 1 used in this study could be oxidized in the culture medium and, in turn, reduced IL-1 beta mRNA and protein synthesis. Taken together, these data indicated a potential new mechanism through which extracellular rhTrx-1 exerts an anti-inflammatory function in HMDM.	Inst Pasteur, INSERM, Dept Atherosclerosis, U545, F-59019 Lille, France; Univ Lille 2, F-59019 Lille, France; Tech Univ Munich, Klinikum Rechts Isar, Inst Clin Chem & Pathobiochem, D-81675 Munich, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Universite de Lille - ISITE; Universite de Lille; Technical University of Munich	Rouis, M (corresponding author), Inst Pasteur, INSERM, Dept Atherosclerosis, U545, 1 Rue Prof Calmette, F-59019 Lille, France.	mustapha.rouis@pasteur-lille.fr	Rouis, Mustapha/E-4993-2016	Guilhem, Larigauderie/0000-0003-1859-8832; Rouis, Mustapha/0000-0003-4197-6555; Furman, Christophe/0000-0003-4799-288X				Aota M, 1996, J CARDIOVASC PHARM, V27, P727, DOI 10.1097/00005344-199605000-00016; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; AURON PE, 1994, EUR CYTOKINE NETW, V5, P573; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; Bertini R, 1999, J EXP MED, V189, P1783, DOI 10.1084/jem.189.11.1783; Chang CK, 2004, ANN THORAC SURG, V77, P1222, DOI 10.1016/j.athoracsur.2003.09.128; Dinarello C A, 1998, Int Rev Immunol, V16, P457, DOI 10.3109/08830189809043005; DINARELLO CA, 1991, BLOOD, V77, P1627; Dobrovolskaia MA, 2002, MICROBES INFECT, V4, P903, DOI 10.1016/S1286-4579(02)01613-1; FONG LG, 1991, J LIPID RES, V32, P1899; Furman C, 2004, FREE RADICAL BIO MED, V37, P71, DOI 10.1016/j.freeradbiomed.2004.04.016; Gasdaska JR, 1996, BIOCHEM PHARMACOL, V52, P1741, DOI 10.1016/S0006-2952(96)00595-3; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; GRAY JG, 1993, MOL CELL BIOL, V13, P6678, DOI 10.1128/MCB.13.11.6678; Gromer S, 2004, MED RES REV, V24, P40, DOI 10.1002/med.10051; Harper R, 2001, AM J RESP CELL MOL, V25, P178, DOI 10.1165/ajrcmb.25.2.4471; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HUBER HE, 1987, J BIOL CHEM, V262, P16224; Kelk P, 2005, INFECT IMMUN, V73, P453, DOI 10.1128/IAI.73.1.453-458.2005; Kondo N, 2004, J IMMUNOL, V172, P442, DOI 10.4049/jimmunol.172.1.442; KU G, 1992, J BIOL CHEM, V267, P14183; LANE A, 1991, BIOCHIM BIOPHYS ACTA, V1097, P161, DOI 10.1016/0925-4439(91)90029-9; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Lillig CH, 1999, J BIOL CHEM, V274, P7695, DOI 10.1074/jbc.274.12.7695; Lim S, 2004, BIOCHEM PHARMACOL, V68, P719, DOI 10.1016/j.bcp.2004.05.005; Liu WR, 2004, CIRCULATION, V110, P1276, DOI 10.1161/01.CIR.0000141803.41217.B6; Makino Y, 1996, J CLIN INVEST, V98, P2469, DOI 10.1172/JCI119065; Makino Y, 1999, J BIOL CHEM, V274, P3182, DOI 10.1074/jbc.274.5.3182; Miwa K, 2005, CIRC J, V69, P291, DOI 10.1253/circj.69.291; MOYER CF, 1991, AM J PATHOL, V138, P951; Muegge K, 1990, Cytokine, V2, P1, DOI 10.1016/1043-4666(90)90036-S; MUNRO JM, 1988, LAB INVEST, V58, P249; Nakamura H, 1996, INT IMMUNOL, V8, P603, DOI 10.1093/intimm/8.4.603; Nakamura H, 2001, P NATL ACAD SCI USA, V98, P15143, DOI 10.1073/pnas.191498798; Nakamura H, 2001, P NATL ACAD SCI USA, V98, P2688, DOI 10.1073/pnas.041624998; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Netea MG, 1997, CYTOKINE, V9, P284, DOI 10.1006/cyto.1996.0165; Okubo K, 1997, J THORAC CARDIOV SUR, V113, P1, DOI 10.1016/S0022-5223(97)70393-3; Park PJ, 2004, J BIOTECHNOL, V112, P225, DOI 10.1016/j.jbiotec.2004.05.006; Pekkari K, 2001, BLOOD, V97, P3184, DOI 10.1182/blood.V97.10.3184; Pekkari K, 2000, J BIOL CHEM, V275, P37474, DOI 10.1074/jbc.M001012200; ROSEN A, 1995, INT IMMUNOL, V7, P625, DOI 10.1093/intimm/7.4.625; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Schilling D, 2001, CYTOKINE, V16, P51, DOI 10.1006/cyto.2001.0948; Shioji K, 2002, CIRCULATION, V106, P1403, DOI 10.1161/01.CIR.0000027817.55925.B4; SHIRAKAWA F, 1993, MOL CELL BIOL, V13, P1332, DOI 10.1128/MCB.13.3.1332; SILBERSTEIN DS, 1993, J BIOL CHEM, V268, P9138; Sumida Y, 2000, J HEPATOL, V33, P616, DOI 10.1034/j.1600-0641.2000.033004616.x; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; Takagi Y, 1999, P NATL ACAD SCI USA, V96, P4131, DOI 10.1073/pnas.96.7.4131; WAKASUGI N, 1990, P NATL ACAD SCI USA, V87, P8282, DOI 10.1073/pnas.87.21.8282; Wang HC, 2000, J BIOL CHEM, V275, P8600, DOI 10.1074/jbc.275.12.8600; Watson WH, 2003, J BIOL CHEM, V278, P33408, DOI 10.1074/jbc.M211107200; WOLLMAN EE, 1988, J BIOL CHEM, V263, P15506; Yamawaki H, 2003, CIRC RES, V93, P1029, DOI 10.1161/01.RES.0000102869.39150.23; YOKOMISE H, 1994, RESPIRATION, V61, P99; Yoshida S, 1999, J IMMUNOL, V163, P351	61	54	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40310	40318		10.1074/jbc.M503644200	http://dx.doi.org/10.1074/jbc.M503644200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16207716	hybrid			2022-12-25	WOS:000233461300073
J	Lu, ZJ; Jiang, YP; Ballou, LM; Cohen, IS; Lin, RZ				Lu, ZJ; Jiang, YP; Ballou, LM; Cohen, IS; Lin, RZ			G alpha(q) inhibits cardiac L-type Ca2+ channels through phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; G-PROTEIN MODULATION; CA2+ CHANNELS; CALCIUM-CHANNELS; ALPHA(1A)-ADRENERGIC RECEPTOR; PHOSPHOINOSITIDE 3-KINASE; KINASE; 3,4,5-TRISPHOSPHATE; STIMULATION; ACTIVATION	Cardiac myocyte contractility is initiated by Ca2+ entry through the voltage-dependent L-type Ca2+ channel (LTCC). To study the effect of G alpha(q) on the cardiac LTCC, we utilized two transgenic mouse lines that selectively express inducible G alpha(q)-estrogen receptor hormone-binding domain fusion proteins (G alpha(q)Q209L-hbER or G alpha(q) Q209L-AA-hbER) in cardiac myocytes. Both of these proteins inhibit phosphatidylinositol ( PI) 3-kinase ( PI3K) signaling, but G alpha(q)Q209L-AA-hbER cannot activate the canonical G alpha(q) effector phospholipase C beta( PLC beta). L-type Ca2+ current (I-Ca,I-L) density measured by whole-cell patch clamping was reduced by more than 50% in myocytes from both G alpha(q) animals as compared with wild-type cells, suggesting that inhibition of the LTCC by G alpha q does not require PLC beta. To investigate the role of PI3K in this inhibitory effect, I-Ca,I- L was measured in the presence of various phosphoinositides infused through the patch pipette. Infusion of PI 3,4,5-trisphosphate (PI( 3,4,5) P-3) into wild-type myocytes did not affect I-Ca,I-L but it fully restored ICa, L density in both G alpha(q) transgenic myocytes to wild-type levels. By contrast, PI 4,5- bisphosphate ( PI(4,5)P-2) or PI 3,5-bisphosphate had no effect. Infusion with p110 beta/p85 alpha or p110 gamma PI3K in the presence of PI(4,5) P-2 also restored ICa, L density to wildtype levels. Last, infusion of either PTEN, a PI(3,4,5) P3 phosphatase, or the pleckstrin homology domain of Grp1, which sequesters PI( 3,4,5) P3, reduced the peak ICa, L density in wild-type myocytes by similar to 30%. Taken together, these results strongly suggest that the inhibitory effect of G alpha q on the cardiac LTCC is mediated by inhibition of PI3K.	SUNY Stony Brook, Dept Med, Div Hematol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; SUNY Stony Brook, Inst Mol Cardiol, Stony Brook, NY 11794 USA; Dept Vet Affairs Med Ctr, Northport, NY 11768 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Lin, RZ (corresponding author), SUNY Stony Brook, Dept Med, Div Hematol, Stony Brook, NY 11794 USA.	richard.lin@sunysb.edu	Lu, zhongjul/AAT-5531-2021; Lin, Richard/J-1754-2014	Lin, Richard/0000-0002-3473-7276	NHLBI NIH HHS [HL70161, HL67101, HL28958] Funding Source: Medline; NIDDK NIH HHS [DK62722] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070161, R01HL067101, P01HL028958] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062722] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ballou LM, 2003, J BIOL CHEM, V278, P23472, DOI 10.1074/jbc.M212232200; Ballou LM, 2001, J BIOL CHEM, V276, P40910, DOI 10.1074/jbc.M103480200; Ballou LM, 2000, J BIOL CHEM, V275, P4803, DOI 10.1074/jbc.275.7.4803; Bannister RA, 2002, BIOPHYS J, V83, P3256, DOI 10.1016/S0006-3495(02)75327-7; Blair LAC, 1997, NEURON, V19, P421, DOI 10.1016/S0896-6273(00)80950-2; Dolphin AC, 2003, PHARMACOL REV, V55, P607, DOI 10.1124/pr.55.4.3; Fan GF, 2003, J BIOL CHEM, V278, P52432, DOI 10.1074/jbc.M310982200; Gray A, 1999, BIOCHEM J, V344, P929, DOI 10.1042/0264-6021:3440929; Kerchner KR, 2004, J BIOL CHEM, V279, P44554, DOI 10.1074/jbc.M406071200; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; Le Blanc C, 2004, CIRC RES, V95, P300, DOI 10.1161/01.RES.0000138017.76125.8b; Macrez N, 1997, J BIOL CHEM, V272, P23180, DOI 10.1074/jbc.272.37.23180; Macrez N, 2001, CIRC RES, V89, P692, DOI 10.1161/hh2001.097864; Maier U, 2000, J BIOL CHEM, V275, P13746, DOI 10.1074/jbc.275.18.13746; Oudit GY, 2004, J MOL CELL CARDIOL, V37, P449, DOI 10.1016/j.yjmcc.2004.05.015; Quignard JF, 2001, J BIOL CHEM, V276, P32545, DOI 10.1074/jbc.M102582200; Shapiro MS, 1999, P NATL ACAD SCI USA, V96, P10899, DOI 10.1073/pnas.96.19.10899; Striessnig J, 1999, CELL PHYSIOL BIOCHEM, V9, P242, DOI 10.1159/000016320; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Venkatakrishnan G, 1996, J BIOL CHEM, V271, P5066; Viard P, 2004, NAT NEUROSCI, V7, P939, DOI 10.1038/nn1300	21	29	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40347	40354		10.1074/jbc.M508441200	http://dx.doi.org/10.1074/jbc.M508441200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16186103	hybrid			2022-12-25	WOS:000233461300077
J	Shell, SA; Hesse, C; Morris, SM; Milcarek, C				Shell, SA; Hesse, C; Morris, SM; Milcarek, C			Elevated levels of the 64-kDa cleavage stimulatory factor (CstF-64) in lipopolysaccharide-stimulated macrophages influence gene expression and induce alternative poly(A) site selection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; MESSENGER-RNA; 3'-UNTRANSLATED REGION; POSTTRANSCRIPTIONAL CONTROL; POLYADENYLATION SIGNALS; PROCESSING EFFICIENCY; 3-UNTRANSLATED REGION; ELEMENTS PRESENT; MAMMALIAN-CELLS; DENDRITIC CELLS	Lipopolysaccharide (LPS) activation of murine RAW 264.7 macrophages influences the expression of multiple genes through transcriptional and post-transcriptional mechanisms. Weobserved a 5-fold increase in CstF-64 expression following LPS treatment of RAW macrophages. The increase in CstF-64 protein was specific in that several other factors involved in 3'-end processing were not affected by LPS stimulation. Activation of RAW macrophages with LPS caused an increase in proximal poly(A) site selection within a reporter mini-gene containing two linked poly(A) sites that occurred concomitant with the increase in CstF-64 expression. Furthermore, forced overexpression of the CstF-64 protein also induced alternative poly(A) site selection on the reporter minigene. Microarray analysis performed on CstF-64 overexpressing RAW macrophages revealed that elevated levels of CstF-64 altered the expression of 51 genes, 14 of which showed similar changes in gene expression with LPS stimulation. Sequence analysis of the 3'-untranslated regions of these 51 genes revealed that over 45% possess multiple putative poly(A) sites. Two of these 51 genes demonstrated alternative polyadenylation under both LPS-stimulating and CstF-64-overexpressing conditions. We concluded that the physiologically increased levels of CstF-64 observed in LPS-stimulated RAW macrophages contribute to the changes in expression and alternative polyadenylation of a number of genes, thus identifying another level of gene regulation that occurs in macrophages activated with LPS.	Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA 15221 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15221 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Milcarek, C (corresponding author), Univ Pittsburgh, Sch Med, Dept Immunol, 200 Lothrop St,Biomed Sci Tower E1054, Pittsburgh, PA 15221 USA.	milcarek@pitt.edu	Morris, Sidney M/I-3440-2015		NATIONAL CANCER INSTITUTE [T32CA082084, R01CA086433] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057384] Funding Source: NIH RePORTER; NCI NIH HHS [CA86433, T32 CA82084, R01 CA086433] Funding Source: Medline; NIGMS NIH HHS [GM57384, R01 GM057384] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arhin GK, 2002, NUCLEIC ACIDS RES, V30, P1842, DOI 10.1093/nar/30.8.1842; Beaudoing E, 2000, GENOME RES, V10, P1001, DOI 10.1101/gr.10.7.1001; Bodnar KA, 2001, INFECT IMMUN, V69, P800, DOI 10.1128/IAI.69.2.800-809.2001; Burke B, 2003, AM J PATHOL, V163, P1233, DOI 10.1016/S0002-9440(10)63483-9; Caputi M, 2001, J BIOL CHEM, V276, P43850, DOI 10.1074/jbc.M102861200; CHEN F, 1995, NUCLEIC ACIDS RES, V23, P2614, DOI 10.1093/nar/23.14.2614; Chennathukuzhi VM, 2001, MOL REPROD DEV, V58, P460, DOI 10.1002/1098-2795(20010401)58:4&lt;460::AID-MRD15&gt;3.0.CO;2-F; Chuvpilo S, 1999, IMMUNITY, V10, P261, DOI 10.1016/S1074-7613(00)80026-6; Cok SJ, 2004, J BIOL CHEM, V279, P8196, DOI 10.1074/jbc.M308475200; Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200; Crawford EK, 1997, J BIOL CHEM, V272, P21120, DOI 10.1074/jbc.272.34.21120; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Doherty JK, 1999, GYNECOL ONCOL, V74, P408, DOI 10.1006/gyno.1999.5467; EdwaldsGilbert G, 1997, NUCLEIC ACIDS RES, V25, P2547, DOI 10.1093/nar/25.13.2547; Foss DL, 1998, ANIM BIOTECHNOL, V9, P67, DOI 10.1080/10495399809525893; Goethe R, 1998, J IMMUNOL, V160, P4970; Grolleau A, 2003, J IMMUNOL, V171, P2879, DOI 10.4049/jimmunol.171.6.2879; Hauksdottir H, 2003, MOL ENDOCRINOL, V17, P373, DOI 10.1210/me.2002-0340; Jackson DA, 2000, FASEB J, V14, P242, DOI 10.1096/fasebj.14.2.242; Kepka-Lenhart D, 2000, AM J PHYSIOL-REG I, V279, pR2237; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Lazarov ME, 1999, BBA-GENE STRUCT EXPR, V1446, P253, DOI 10.1016/S0167-4781(99)00098-6; Legendre M, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-7; Martincic K, 1998, P NATL ACAD SCI USA, V95, P11095, DOI 10.1073/pnas.95.19.11095; Matis SA, 1996, NUCLEIC ACIDS RES, V24, P4684, DOI 10.1093/nar/24.23.4684; Mbella EGM, 2000, MOL CELL BIOL, V20, P4572, DOI 10.1128/MCB.20.13.4572-4579.2000; MULLIGAN RC, 1980, SCIENCE, V209, P1422, DOI 10.1126/science.6251549; MURTHY KGK, 1992, J BIOL CHEM, V267, P14804; Natalizio BJ, 2002, J BIOL CHEM, V277, P42733, DOI 10.1074/jbc.M208070200; NAVALGUND LG, 1980, J BIOL CHEM, V255, P7386; Newton R, 1997, BIOCHEM BIOPH RES CO, V234, P85, DOI 10.1006/bbrc.1997.6586; O'Neill LAJ, 2002, TRENDS IMMUNOL, V23, P296, DOI 10.1016/S1471-4906(02)02222-6; QUINTANS J, 1974, J IMMUNOL, V113, P1373; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TAKAGAKI Y, 1992, P NATL ACAD SCI USA, V89, P1403, DOI 10.1073/pnas.89.4.1403; Takagaki Y, 1996, CELL, V87, P941, DOI 10.1016/S0092-8674(00)82000-0; Ubeda M, 1999, MOL CELL BIOL, V19, P7589; Underhill DM, 2002, CURR OPIN IMMUNOL, V14, P103, DOI 10.1016/S0952-7915(01)00304-1; Vadiveloo PK, 1996, ONCOGENE, V13, P599; VAIRO G, 1992, J CELL PHYSIOL, V151, P630, DOI 10.1002/jcp.1041510324; Veraldi KL, 2001, MOL CELL BIOL, V21, P1228, DOI 10.1128/MCB.21.4.1228-1238.2001; Wahab NA, 1998, BIOCHEM J, V336, P405, DOI 10.1042/bj3360405; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Yoshio TD, 1997, MOL CELL BIOL, V17, P3907, DOI 10.1128/MCB.17.7.3907; Zhang T, 2002, BIOCHEM SOC T, V30, P952, DOI 10.1042/BST0300952	46	73	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					39950	39961		10.1074/jbc.M508848200	http://dx.doi.org/10.1074/jbc.M508848200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16207706	hybrid			2022-12-25	WOS:000233461300034
J	Soboloff, J; Spassova, M; Xu, W; He, LP; Cuesta, N; Gill, DL				Soboloff, J; Spassova, M; Xu, W; He, LP; Cuesta, N; Gill, DL			Role of endogenous TRPC6 channels in Ca2+ signal generation in A7r5 smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL TRISPHOSPHATE RECEPTOR; ENTRY; ACTIVATION; EXPRESSION; DIACYLGLYCEROL; KINASE; MECHANISM; LINE; PH	The ubiquitously expressed canonical transient receptor potential ( TRPC) ion channels are considered important in Ca2+ signal generation, but their mechanisms of activation and roles remain elusive. Whereas most studies have examined overexpressed TRPC channels, we used molecular, biochemical, and electrophysiological approaches to assess the expression and function of endogenous TRPC channels in A7r5 smooth muscle cells. Real time PCR and Western analyses reveal TRPC6 as the only member of the diacyl-glycerol-responsive TRPC3/6/7 subfamily of channels expressed at significant levels in A7r5 cells. TRPC1, TRPC4, and TRPC5 were also abundant. An outwardly rectifying, nonselective cation current was activated by phospholipase C-coupled vasopressin receptor activation or by the diacylglycerol analogue, oleoyl-2-acetyl-sn-glycerol ( OAG). Introduction of TRPC6 small interfering RNA sequences into A7r5 cells by electroporation led to 90% reduction of TRPC6 transcript and 80% reduction of TRPC6 protein without any detectable compensatory changes in the expression of other TRPC channels. The OAG-activated nonselective cation current was similarly reduced by TRPC6 RNA interference. Intracellular Ca2+ measurements using fura-2 revealed that thapsigargin-induced store-operated Ca2+ entry was unaffected by TRPC6 knockdown, whereas vasopressin-induced Ca2+ entry was suppressed by more than 50%. In contrast, OAG-induced Ca2+ transients were unaffected by TRPC6 knockdown. Nevertheless, OAG-induced Ca2+ entry bore the hallmarks of TRPC6 function; it was inhibited by protein kinase C and blocked by the Src-kinase inhibitor, 4-amino-5( 4-chlorophenyl)-7-(t-butyl) pyrazolo[ 3,4-d] pyrimidine ( PP2). Importantly, OAG-induced Ca2+ entry was blocked by the potent L-type Ca2+ channel inhibitor, nimodipine. Thus, TRPC6 activation probably results primarily in Na* ion entry and depolarization, leading to activation of L-type channels as the mediators of Ca2+ entry. Calculations reveal that even 90% reduction of TRPC6 channels would allow depolarization sufficient to activate L-type channels. This tight coupling between TRPC6 and L-type channels is probably important in mediating smooth muscle cell membrane potential and muscle contraction.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Gill, DL (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, 108 N Greene St, Baltimore, MD 21201 USA.	dgill@umaryland.edu	Cuesta, Natalia/C-1358-2012; Soboloff, Jonathan/I-6995-2012; Cuesta, Natalia/J-7761-2015; Cuesta, Natalia/Y-1802-2019	Soboloff, Jonathan/0000-0001-5192-1297; Cuesta, Natalia/0000-0003-0809-2934; Cuesta, Natalia/0000-0003-0809-2934	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055426] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058173] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55426] Funding Source: Medline; NIAID NIH HHS [AI058173] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albert AP, 2003, J PHYSIOL-LONDON, V552, P789, DOI 10.1113/jphysiol.2003.052977; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; BYRON KL, 1993, J BIOL CHEM, V268, P6945; Chu X, 2002, J BIOL CHEM, V277, P34375, DOI 10.1074/jbc.M205541200; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Dietrich A, 2005, MOL CELL BIOL, V25, P6980, DOI 10.1128/MCB.25.16.6980-6989.2005; Dietrich A, 2005, N-S ARCH PHARMACOL, V371, P257, DOI 10.1007/s00210-005-1052-8; Freichel M, 2004, BIOCHEM BIOPH RES CO, V322, P1352, DOI 10.1016/j.bbrc.2004.08.041; GILL DL, 2004, SCI STKE, pPE39, DOI DOI 10.1126/ST5E.2432004PE39; Gollasch M, 1998, FASEB J, V12, P593, DOI 10.1096/fasebj.12.7.593; GUDERMANN T, 2004, SCI STKE, pPE35; Gudermann Thomas, 2004, Novartis Found Symp, V258, P103; He LP, 2005, J BIOL CHEM, V280, P10997, DOI 10.1074/jbc.M411797200; Hisatsune C, 2004, J BIOL CHEM, V279, P18887, DOI 10.1074/jbc.M311274200; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Inoue R, 2001, CIRC RES, V88, P325, DOI 10.1161/01.RES.88.3.325; Jung S, 2002, AM J PHYSIOL-CELL PH, V282, pC347, DOI 10.1152/ajpcell.00283.2001; Jungnickel MK, 2001, NAT CELL BIOL, V3, P499, DOI 10.1038/35074570; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li HS, 1999, NEURON, V24, P261, DOI 10.1016/S0896-6273(00)80838-7; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lucas P, 2003, NEURON, V40, P551, DOI 10.1016/S0896-6273(03)00675-5; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Ma HT, 2002, J BIOL CHEM, V277, P6915, DOI 10.1074/jbc.M107755200; Moneer Z, 2005, BIOCHEM J, V389, P821, DOI 10.1042/BJ20050145; Montell C, 1999, ANNU REV CELL DEV BI, V15, P231, DOI 10.1146/annurev.cellbio.15.1.231; Montell Craig, 2005, Sci STKE, V2005, pre3, DOI 10.1126/stke.2722005re3; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Patterson RL, 2002, CELL, V111, P529, DOI 10.1016/S0092-8674(02)01045-0; Poteser M, 2003, CIRC RES, V92, P888, DOI 10.1161/01.RES.0000069216.80612.66; Quest AFG, 1997, ADV EXP MED BIOL, V400, P297; Reading SA, 2005, AM J PHYSIOL-HEART C, V288, pH2055, DOI 10.1152/ajpheart.00861.2004; SCHNITZLER MY, 2005, NAUNYNSCHMIEDEBER S1, V369, pR62; Schuhmann K, 1997, J GEN PHYSIOL, V110, P503, DOI 10.1085/jgp.110.5.503; Seth M, 2004, P NATL ACAD SCI USA, V101, P16683, DOI 10.1073/pnas.0407537101; Spassova MA, 2004, BBA-MOL CELL RES, V1742, P9, DOI 10.1016/j.bbamcr.2004.09.001; Strubing C, 2003, J BIOL CHEM, V278, P39014, DOI 10.1074/jbc.M306705200; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TOWBIN H, 1984, J IMMUNOL METHODS, V72, P313, DOI 10.1016/0022-1759(84)90001-2; van Rossum DB, 2005, NATURE, V434, P99, DOI 10.1038/nature03340; van Rossum DB, 2004, P NATL ACAD SCI USA, V101, P2323, DOI 10.1073/pnas.0308565100; VANRENTERGHEM C, 1988, P NATL ACAD SCI USA, V85, P9365; Vazquez G, 2004, J BIOL CHEM, V279, P40521, DOI 10.1074/jbc.M405280200; Venkatachalam K, 2003, J BIOL CHEM, V278, P29031, DOI 10.1074/jbc.M302751200; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; Venkatachalam K, 2001, J BIOL CHEM, V276, P33980, DOI 10.1074/jbc.C100321200; VENTATACHALAM K, 2004, NOV FOUND S, V28, P172; Welsh DG, 2002, CIRC RES, V90, P248, DOI 10.1161/hh0302.105662; Yu Y, 2003, AM J PHYSIOL-CELL PH, V284, pC316, DOI 10.1152/ajpcell.00125.2002	50	131	139	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					39786	39794		10.1074/jbc.M506064200	http://dx.doi.org/10.1074/jbc.M506064200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16204251	hybrid			2022-12-25	WOS:000233461300015
J	Volz, J; Osta, MA; Kafatos, FC; Muller, HM				Volz, J; Osta, MA; Kafatos, FC; Muller, HM			The roles of two clip domain serine proteases in innate immune responses of the malaria vector Anopheles gambiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-PHENOL-OXIDASE; PREPHENOLOXIDASE-ACTIVATING ENZYME; HOLOTRICHIA-DIOMPHALIA LARVAE; QUANTITATIVE TRAIT LOCI; COMPLEMENT-LIKE PROTEIN; MANDUCA-SEXTA SERPIN-4; BOMBYX-MORI; HORSESHOE-CRAB; CDNA CLONING; PROPHENOLOXIDASE	The malaria vector Anopheles gambiae is capable of multiple immune responses against Plasmodium ookinetes. Accumulating evidence in several insect species suggests the involvement of serine protease cascades in the initiation and coordination of immune responses. We report molecular and reverse genetic characterization of two mosquito clip domain serine proteases, CLIPB14 and CLIPB15, which share structural similarity to proteases involved in prophenoloxidase activation in other insects. Both CLIPs are expressed in mosquito hemocytes and are transcriptionally induced by bacterial and Plasmodium challenges. Functional studies applying RNA interference revealed that both CLIPs are involved in the killing of Plasmodium ookinetes in Anopheles. Studies on parasite melanization demonstrated an additional role for CLIPB14 in the prophenoloxidase cascade. We further report that both CLIPs participate in defense toward Gram-negative bacteria. Our findings strongly suggest that clip domain serine proteases serve multiple functions and play distinctive roles in several immune pathways of A. gambiae.	European Mol Biol Lab, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Kafatos, FC (corresponding author), Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia.	f.kafatos@imperial.ac.uk		Muller, Hans-Michael/0000-0002-2384-7285	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI044220] Funding Source: NIH RePORTER; NIAID NIH HHS [AI044220-07] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSSON K, 1989, INSECT BIOCHEM, V19, P629, DOI 10.1016/0020-1790(89)90097-8; ASHIDA M, 1980, INSECT BIOCHEM, V10, P37, DOI 10.1016/0020-1790(80)90036-0; Blandin S, 2004, CELL, V116, P661, DOI 10.1016/S0092-8674(04)00173-4; Blandin S, 2002, EMBO REP, V3, P852, DOI 10.1093/embo-reports/kvf180; Cerenius L, 2004, IMMUNOL REV, V198, P116, DOI 10.1111/j.0105-2896.2004.00116.x; Christophides GK, 2004, IMMUNOL REV, V198, P127, DOI 10.1111/j.0105-2896.2004.0127.x; Christophides GK, 2002, SCIENCE, V298, P159, DOI 10.1126/science.1077136; COLLINS FH, 1986, SCIENCE, V234, P607, DOI 10.1126/science.3532325; Danielli A, 2003, J BIOL CHEM, V278, P4184, DOI 10.1074/jbc.M208187200; Dimopoulos G, 2000, P NATL ACAD SCI USA, V97, P6619, DOI 10.1073/pnas.97.12.6619; DOHKE K, 1973, ARCH BIOCHEM BIOPHYS, V157, P203, DOI 10.1016/0003-9861(73)90406-2; DOHKE K, 1973, ARCH BIOCHEM BIOPHYS, V157, P210, DOI 10.1016/0003-9861(73)90407-4; Franke-Fayard B, 2004, MOL BIOCHEM PARASIT, V137, P23, DOI 10.1016/j.molbiopara.2004.04.007; Iwanaga S, 2002, CURR OPIN IMMUNOL, V14, P87, DOI 10.1016/S0952-7915(01)00302-8; Jiang HB, 2003, INSECT BIOCHEM MOLEC, V33, P1049, DOI 10.1016/S0965-1748(03)00123-1; Jiang HB, 2003, J BIOL CHEM, V278, P3552, DOI 10.1074/jbc.M205743200; Jiang HB, 2000, INSECT BIOCHEM MOLEC, V30, P95, DOI 10.1016/S0965-1748(99)00113-7; Jiang HB, 1998, P NATL ACAD SCI USA, V95, P12220, DOI 10.1073/pnas.95.21.12220; Kanost Michael R, 2004, Immunol Rev, V198, P97, DOI 10.1111/j.0105-2896.2004.0121.x; Kumar S, 2003, P NATL ACAD SCI USA, V100, P14139, DOI 10.1073/pnas.2036262100; Lee SY, 1998, EUR J BIOCHEM, V254, P50, DOI 10.1046/j.1432-1327.1998.2540050.x; Lee SY, 1998, EUR J BIOCHEM, V257, P615, DOI 10.1046/j.1432-1327.1998.2570615.x; Levashina EA, 2001, CELL, V104, P709, DOI 10.1016/S0092-8674(01)00267-7; Ligoxygakis P, 2002, SCIENCE, V297, P114, DOI 10.1126/science.1072391; Muller HM, 1999, J BIOL CHEM, V274, P11727, DOI 10.1074/jbc.274.17.11727; MUTA T, 1990, J BIOL CHEM, V265, P22426; Osta MA, 2004, SCIENCE, V303, P2030, DOI 10.1126/science.1091789; Richman AM, 1997, EMBO J, V16, P6114, DOI 10.1093/emboj/16.20.6114; Royet J, 2005, CURR OPIN IMMUNOL, V17, P11, DOI 10.1016/j.coi.2004.12.002; Satoh D, 1999, J BIOL CHEM, V274, P7441, DOI 10.1074/jbc.274.11.7441; Schrodel A, 2005, J BIOTECHNOL, V120, P2, DOI 10.1016/j.jbiotec.2005.04.028; Tong YR, 2005, J BIOL CHEM, V280, P14932, DOI 10.1074/jbc.M500532200; Tong YR, 2005, J BIOL CHEM, V280, P14923, DOI 10.1074/jbc.M500531200; Wang RG, 2001, EUR J BIOCHEM, V268, P895, DOI 10.1046/j.1432-1327.2001.01945.x; Zheng LB, 2003, BMC GENET, V4, DOI 10.1186/1471-2156-4-16; Zheng LB, 1997, SCIENCE, V276, P425, DOI 10.1126/science.276.5311.425	36	97	101	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40161	40168		10.1074/jbc.M506191200	http://dx.doi.org/10.1074/jbc.M506191200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16188883	hybrid			2022-12-25	WOS:000233461300056
J	Wall, SJ; Werner, E; Werb, Z; DeClerck, YA				Wall, SJ; Werner, E; Werb, Z; DeClerck, YA			Discoidin domain receptor 2 mediates tumor cell cycle arrest induced by fibrillar collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISCOIDIN DOMAIN RECEPTOR; SMOOTH-MUSCLE-CELLS; EXTRACELLULAR-MATRIX; TRANSCRIPTIONAL ACTIVATION; PROTEIN-KINASE; GROWTH-FACTOR; PROLIFERATION; INTEGRIN; MIGRATION; BINDING	During malignant invasion tumor cells establish contact with extracellular matrix proteins, including fibrillar collagen. In addition to providing a physical barrier against invasion, fibrillar collagen also restricts cell proliferation. It has been assumed that the growth regulatory activity of fibrillar collagen is the result of an indirect restrictive effect on cell spreading and cytoskeletal organization. Here we provide evidence for a direct inhibitory effect of fibrillar collagen on proliferation of human melanoma and fibrosarcoma cells that involves activation of the tyrosine kinase discoidin domain receptor 2 and is independent of effects on cell spreading. Cells plated in the presence of fibrillar collagen were growth arrested in the G(0)/G(1) phase of the cell cycle. However treatment with the tyrosine kinase inhibitor genistein, down-regulation of discoidin domain receptor 2, or collagen deglycosylation that prevents discoidin domain receptor 2 activation allowed cells to enter the cell cycle in the presence of fibrillar collagen without a requirement for spreading and actin organization. Our data provide evidence for a novel direct mechanism by which cell contact with fibrillar collagen restricts proliferation.	Childrens Hosp Los Angeles, Saban Res Inst, Los Angeles, CA 90027 USA; Univ So Calif, Div Hematol Oncol, Los Angeles, CA 90089 USA; Univ So Calif, Dept Pediat, Los Angeles, CA 90089 USA; Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Emory Univ, Dept Cell Biol, Atlanta, GA 30322 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA	Children's Hospital Los Angeles; University of Southern California; University of Southern California; University of Southern California; Emory University; University of California System; University of California San Francisco	DeClerck, YA (corresponding author), Childrens Hosp Los Angeles, Saban Res Inst, 4650 Sunset Blvd,Mailstop 54, Los Angeles, CA 90027 USA.	declerck@usc.edu		DeClerck, Yves/0000-0002-3688-0113; Werner, Erica/0000-0002-8183-1601	NCI NIH HHS [R01 CA057621-07, R01 CA098469, P50 CA058207, P50 CA058207-12, R01 CA042919, R01 CA42919, R01 CA57621, R01 CA98469, R01 CA057621, P50 CA58207] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098469, R01CA042919, P50CA058207, R01CA057621] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bacakova L, 1997, EXP MOL PATHOL, V64, P185, DOI 10.1006/exmp.1997.2219; BARONVANEVERCOOREN A, 1982, J CELL BIOL, V93, P211, DOI 10.1083/jcb.93.1.211; Boudreau J, 1999, BIOCHEM J, V339, P481, DOI 10.1042/0264-6021:3390481; Ferri N, 2004, AM J PATHOL, V164, P1575, DOI 10.1016/S0002-9440(10)63716-9; Fishman DD, 1998, INT J ONCOL, V12, P181; FORNARO M, 1995, J BIOL CHEM, V270, P24666, DOI 10.1074/jbc.270.42.24666; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Heino J, 2000, MATRIX BIOL, V19, P319, DOI 10.1016/S0945-053X(00)00076-7; Henriet P, 2000, P NATL ACAD SCI USA, V97, P10026, DOI 10.1073/pnas.170290997; Herz DB, 2003, J UROLOGY, V170, P2072, DOI 10.1097/01.ju.0000091810.33953.13; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Ikeda K, 2002, J BIOL CHEM, V277, P19206, DOI 10.1074/jbc.M201078200; INOUE M, 1993, INVEST OPHTH VIS SCI, V34, P2313; Kanno N, 2002, HEPATOLOGY, V35, P1329, DOI 10.1053/jhep.2002.33330; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; Leitinger B, 2004, J MOL BIOL, V344, P993, DOI 10.1016/j.jmb.2004.09.089; Leitinger B, 2003, J BIOL CHEM, V278, P16761, DOI 10.1074/jbc.M301370200; LIOTTA LA, 1986, CANCER RES, V46, P1; Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962-8924(98)01362-2; LUTTY G, 1991, CURR EYE RES, V10, P61, DOI 10.3109/02713689109007611; Mettouchi A, 2001, MOL CELL, V8, P115, DOI 10.1016/S1097-2765(01)00285-4; Misiano P, 2003, EUR J PHARMACOL, V468, P159, DOI 10.1016/S0014-2999(03)01673-X; MONTGOMERY AMP, 1994, CANCER RES, V54, P5467; Motamed K, 2002, J CELL BIOCHEM, V84, P759, DOI 10.1002/jcb.10095; OCALAN M, 1988, DEV BIOL, V125, P158, DOI 10.1016/0012-1606(88)90068-1; Olaso E, 2002, J BIOL CHEM, V277, P3606, DOI 10.1074/jbc.M107571200; Olaso E, 2001, J CLIN INVEST, V108, P1369, DOI 10.1172/JCI12373; PARTRIDGE M, 1989, BRIT J CANCER, V60, P542, DOI 10.1038/bjc.1989.310; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; ROBERTS JM, 1990, EXP EYE RES, V50, P165, DOI 10.1016/0014-4835(90)90227-L; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; SPECTOR I, 1983, SCIENCE, V219, P493, DOI 10.1126/science.6681676; Vitale M, 1997, ENDOCRINOLOGY, V138, P1642, DOI 10.1210/en.138.4.1642; Vogel W, 2000, J BIOL CHEM, V275, P5779, DOI 10.1074/jbc.275.8.5779; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Wang YK, 2003, J BIOL CHEM, V278, P21886, DOI 10.1074/jbc.M300092200; WU H, 1990, P NATL ACAD SCI USA, V87, P5888, DOI 10.1073/pnas.87.15.5888; Yamada KM, 2003, NATURE, V424, P889, DOI 10.1038/424889a; Zhao J, 2001, MOL BIOL CELL, V12, P4066, DOI 10.1091/mbc.12.12.4066; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	42	60	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40187	40194		10.1074/jbc.M508226200	http://dx.doi.org/10.1074/jbc.M508226200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16186104	Green Accepted, hybrid			2022-12-25	WOS:000233461300059
J	Yasmin, R; Williams, RM; Xu, M; Noy, N				Yasmin, R; Williams, RM; Xu, M; Noy, N			Nuclear import of the retinoid X receptor, the vitamin D receptor, and their mutual heterodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; LOCALIZATION SIGNAL; HORMONE-RECEPTORS; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; GLUCOCORTICOID-RECEPTOR; INTRANUCLEAR MOBILITY; 9-CIS-RETINOIC ACID; DNA INTERACTIONS; ALPHA	The nuclear receptor retinoid X receptor (RXR) can regulate transcription through homotetramers, homodimers, and heterodimers with other nuclear receptors such as the vitamin D receptor (VDR). The mechanisms that underlie the nuclear import of RXR, VDR, and RXR-VDR heterodimers were investigated. We show that RXR and VDR translocate into the nucleus by distinct pathways. RXR strongly bound to importin beta and was predominantly nuclear in the absence of ligand. Importin binding and nuclear localization of RXR were modestly enhanced by its ligand, 9-cis-retinoic acid. On the other hand, VDR selectively associated with importin alpha. Importin association and correspondingly nuclear import of VDR were markedly augmented by 1,25(OH) D-2(3). RXR-VDR dimerization inhibited the ability of RXR to bind importin beta and to mobilize into the nucleus using its own nuclear localization signal. In contrast, VDR recruited RXR-VDR heterodimers to importin alpha and mediated nuclear import of the heterodimers in response to 1,25(OH)(2)D-3. Hence nuclear import of RXR-VDR heterodimers is mediated preferentially by VDR and is controlled by the VDR ligand. The observations reveal a novel mechanism by which an RXR heterodimerization partner dominates the activity of the heterodimers.	Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA; Cornell Univ, Dept Appl & Engn Phys, Ithaca, NY 14853 USA; Cornell Univ, Dept Biomed Sci, Ithaca, NY 14853 USA	Cornell University; Cornell University; Cornell University	Noy, N (corresponding author), Cornell Univ, Div Nutr Sci, 222 Savage Hall, Ithaca, NY 14853 USA.	nn14@cornell.edu		Williams, Rebecca/0000-0002-1391-5846	NATIONAL CANCER INSTITUTE [R01CA068150] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB001976] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA68150] Funding Source: Medline; NIBIB NIH HHS [9 P41 EB001976-16] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Arbour NC, 1998, ANAL BIOCHEM, V255, P148, DOI 10.1006/abio.1997.2439; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brelivet Y, 2004, EMBO REP, V5, P423, DOI 10.1038/sj.embor.7400119; Chook YM, 2001, CURR OPIN STRUC BIOL, V11, P703, DOI 10.1016/S0959-440X(01)00264-0; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Dong D, 1998, BIOCHEMISTRY-US, V37, P10691, DOI 10.1021/bi980561r; Dong S, 2004, MOL CELL BIOL, V24, P4465, DOI 10.1128/MCB.24.10.4465-4475.2004; Fanara P, 2000, J BIOL CHEM, V275, P21218, DOI 10.1074/jbc.M002217200; Fontes MRM, 2003, J BIOL CHEM, V278, P27981, DOI 10.1074/jbc.M303275200; Freedman ND, 2004, MOL BIOL CELL, V15, P2276, DOI 10.1091/mbc.E03-11-0839; Harreman MT, 2003, J BIOL CHEM, V278, P21361, DOI 10.1074/jbc.M301114200; Harreman MT, 2003, J BIOL CHEM, V278, P5854, DOI 10.1074/jbc.M210951200; Hsieh JC, 1998, J CELL BIOCHEM, V70, P94, DOI 10.1002/(SICI)1097-4644(19980701)70:1<94::AID-JCB10>3.3.CO;2-Q; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kersten S, 1998, J MOL BIOL, V284, P21, DOI 10.1006/jmbi.1998.2168; KERSTEN S, 1995, BIOCHEMISTRY-US, V34, P13717, DOI 10.1021/bi00042a001; KERSTEN S, 1995, P NATL ACAD SCI USA, V92, P8645, DOI 10.1073/pnas.92.19.8645; Kersten S, 1997, J BIOL CHEM, V272, P29759, DOI 10.1074/jbc.272.47.29759; Laudet V, 2002, NUCL RECEPTORS FACTS; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Maruvada P, 2003, J BIOL CHEM, V278, P12425, DOI 10.1074/jbc.M202752200; Michigami T, 1999, J BIOL CHEM, V274, P33531, DOI 10.1074/jbc.274.47.33531; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; Nicoll JB, 2003, MOL CELL ENDOCRINOL, V205, P65, DOI 10.1016/S0303-7207(03)00199-0; Palacios I, 1997, EMBO J, V16, P6783, DOI 10.1093/emboj/16.22.6783; Palmeri D, 1999, MOL CELL BIOL, V19, P1218; Perlmann T, 1996, MOL ENDOCRINOL, V10, P958, DOI 10.1210/me.10.8.958; Prufer K, 2002, MOL ENDOCRINOL, V16, P1738, DOI 10.1210/me.2001-0345; Prufer K, 2000, J BIOL CHEM, V275, P41114, DOI 10.1074/jbc.M003791200; Rochel N, 2000, MOL CELL, V5, P173, DOI 10.1016/S1097-2765(00)80413-X; Savory JGA, 1999, MOL CELL BIOL, V19, P1025; Shaffer PL, 2004, J STEROID BIOCHEM, V89-90, P215, DOI 10.1016/j.jsbmb.2004.03.084; Shaffer PL, 2002, EMBO J, V21, P2242, DOI 10.1093/emboj/21.9.2242; Thompson PD, 1998, J BIOL CHEM, V273, P8483, DOI 10.1074/jbc.273.14.8483; Williams RM, 2000, J CELL SCI, V113, P3839; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P206; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yasmin R, 2004, J MOL BIOL, V343, P327, DOI 10.1016/j.jmb.2004.08.070; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; Zhao Q, 2000, J MOL BIOL, V296, P509, DOI 10.1006/jmbi.1999.3457	43	67	71	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40152	40160		10.1074/jbc.M507708200	http://dx.doi.org/10.1074/jbc.M507708200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16204233	hybrid			2022-12-25	WOS:000233461300055
J	Ohtake, S; Kimata, K; Habuchi, O				Ohtake, S; Kimata, K; Habuchi, O			Recognition of sulfation pattern of chondroitin sulfate by uronosyl 2-O-sulfotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLGALACTOSAMINE 4-SULFATE 6-O-SULFOTRANSFERASE; URONIC-ACID RESIDUES; SEROSAL MAST-CELLS; MOUSE BONE-MARROW; SECRETORY GRANULES; NEURITE OUTGROWTH; SQUID CARTILAGE; HEPARIN PROTEOGLYCANS; MOLECULAR-CLONING; GLYCOSAMINOGLYCAN	We have shown previously that a highly sulfated sequence, GalNAc( 4,6-SO4)-GlcA(2SO(4))-GalNAc(6SO(4)), is present at the nonreducing terminal of chondroitin sulfate (CS), and this structure was synthesized from a unique sequence, GalNAc(4SO(4))-GlcA(2SO(4))GalNAc( 6SO(4)), by sulfation with N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase. Uronosyl 2-O-sulfotrasferase (2OST), which transfers sulfate from 3'-phosphoadenosine 5'-phosphosulfate ( PAPS) to position 2 of the GlcA residue of CS, is expected to be involved in synthesis of these structures; however, the specificity of 2OST concerning recognition of the sulfation pattern of the acceptor has largely remained unclear. In the present study, we examined the specificity of 2OST in terms of recognition of the sulfation pattern around the targeting GlcA residue. The recombinant 2OST could sulfate CS-A, CS-C, and desulfated dermatan sulfate. When [S-35] glycosaminoglycans formed from CS-A after the reaction with the recombinant 2OST and [S-35] PAPS were subjected to limited digestion with chondroitinase ACII, a radioactive tetrasaccharide (Tetra A) was obtained as a sole intermediate product. The sequence of Tetra A was found to be Delta HexA-GalNAc(4SO(4))GlcA(2SO(4))-GalNAc(6SO(4)) by enzymatic and chemical reactions. These observations indicate that 2OST transfers sulfate preferentially to the GlcA residue located in a unique sequence, -GalNAc(4SO(4))-GlcA-GalNAc(6SO(4))-. When oligosaccharides with different sulfation patterns were used as the acceptor, GalNAc(4SO(4))-GlcA-GalNAc(6SO(4)) and GlcA-GalNAc(4SO(4))GlcA-GalNAc( 6SO(4)) were the best acceptors for 2OST among trisaccharides and tetrasaccharides, respectively. These results suggest that 2OST may be involved in the synthesis of the highly sulfated structure found in CS-A.	Aichi Univ Educ, Dept Chem, Kariya, Aichi 4488542, Japan; Aichi Med Univ, Inst Mol Sci Med, Nagakute, Aichi 4801195, Japan	Aichi University Education; Aichi Medical University	Habuchi, O (corresponding author), Aichi Univ Educ, Dept Chem, Igaya Cho, Kariya, Aichi 4488542, Japan.	ohabuchi@auecc.aichi-edu.ac.jp						BOURIN MC, 1990, J BIOL CHEM, V265, P15424; Clement AM, 1999, NEUROSCI LETT, V269, P125, DOI 10.1016/S0304-3940(99)00432-2; Clement AM, 1998, J BIOL CHEM, V273, P28444, DOI 10.1074/jbc.273.43.28444; DAVIDSON S, 1990, J BIOL CHEM, V265, P12324; Deepa SS, 2002, J BIOL CHEM, V277, P43707, DOI 10.1074/jbc.M207105200; DELFERT DM, 1985, ANAL BIOCHEM, V148, P303, DOI 10.1016/0003-2697(85)90233-7; ELIAKIM R, 1986, P NATL ACAD SCI USA, V83, P461, DOI 10.1073/pnas.83.2.461; Habuchi H, 2004, GLYCOCONJUGATE J, V21, P47, DOI 10.1023/B:GLYC.0000043747.87325.5e; HABUCHI O, 1980, BIOCHIM BIOPHYS ACTA, V616, P208, DOI 10.1016/0005-2744(80)90139-4; HABUCHI O, 1977, J BIOL CHEM, V252, P4570; HABUCHI O, 1993, J BIOL CHEM, V268, P21968; Habuchi O, 2002, ANAL BIOCHEM, V310, P129, DOI 10.1016/S0003-2697(02)00277-4; Hayashi K, 2001, GLYCOCONJUGATE J, V18, P401, DOI 10.1023/A:1014864131288; Hirose J, 2001, J BIOL CHEM, V276, P5228, DOI 10.1074/jbc.M007542200; Ito Y, 2000, J BIOL CHEM, V275, P34728, DOI 10.1074/jbc.M909633199; KATZ HR, 1986, J BIOL CHEM, V261, P3393; Kawashima H, 2000, J BIOL CHEM, V275, P35448, DOI 10.1074/jbc.M003387200; Kobayashi M, 1999, J BIOL CHEM, V274, P10474, DOI 10.1074/jbc.274.15.10474; Kobayashi M, 1997, J BIOL CHEM, V272, P13980, DOI 10.1074/jbc.272.21.13980; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUDWIGS U, 1987, BIOCHEM J, V245, P795, DOI 10.1042/bj2450795; Maeda N, 2003, J BIOL CHEM, V278, P35805, DOI 10.1074/jbc.M305530200; Merry CLR, 2001, J BIOL CHEM, V276, P35429, DOI 10.1074/jbc.M100379200; MIDURA RJ, 1995, J BIOL CHEM, V270, P8009, DOI 10.1074/jbc.270.14.8009; Nadanaka S, 1997, GLYCOBIOLOGY, V7, P253, DOI 10.1093/glycob/7.2.253; Nadanaka S, 1998, J BIOL CHEM, V273, P3296, DOI 10.1074/jbc.273.6.3296; NAGASAWA K, 1979, J BIOCHEM-TOKYO, V86, P1323, DOI 10.1093/oxfordjournals.jbchem.a132648; Ohtake S, 2003, J BIOL CHEM, V278, P38443, DOI 10.1074/jbc.M306132200; Ohtake S, 2001, J BIOL CHEM, V276, P43894, DOI 10.1074/jbc.M104922200; OTSU K, 1985, BIOCHEM J, V227, P37, DOI 10.1042/bj2270037; Plaas AHK, 1998, J BIOL CHEM, V273, P12642, DOI 10.1074/jbc.273.20.12642; Plaas AHK, 1997, J BIOL CHEM, V272, P20603, DOI 10.1074/jbc.272.33.20603; RAZIN E, 1982, J BIOL CHEM, V257, P7229; SHAKLEE PN, 1985, J BIOL CHEM, V260, P6064; STEVENS RL, 1983, J BIOL CHEM, V258, P5977; STEVENS RL, 1988, P NATL ACAD SCI USA, V85, P2284, DOI 10.1073/pnas.85.7.2284; Sugahara K, 1996, EUR J BIOCHEM, V239, P871, DOI 10.1111/j.1432-1033.1996.0871u.x; Sugahara K, 1996, EUR J BIOCHEM, V239, P865, DOI 10.1111/j.1432-1033.1996.0865u.x; Thiele H, 2004, P NATL ACAD SCI USA, V101, P10155, DOI 10.1073/pnas.0400334101; Tully SE, 2004, J AM CHEM SOC, V126, P7736, DOI 10.1021/ja0484045; Uchimura K, 2002, J BIOL CHEM, V277, P1443, DOI 10.1074/jbc.M104719200; Yamada T, 2004, BIOCHEM J, V384, P567, DOI 10.1042/BJ20040965; Yamauchi S, 1999, J BIOL CHEM, V274, P2456, DOI 10.1074/jbc.274.4.2456; Zou P, 2003, GLYCOBIOLOGY, V13, P35, DOI 10.1093/glycob/cwg001	44	27	27	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39115	39123		10.1074/jbc.M508816200	http://dx.doi.org/10.1074/jbc.M508816200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16192264	hybrid			2022-12-25	WOS:000233362200026
J	Sarbassov, DD; Sabatini, DM				Sarbassov, DD; Sabatini, DM			Redox regulation of the nutrient-sensitive raptor-mTOR pathway and complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY-CHROMATOGRAPHY; PHENYLARSINE OXIDE; MAMMALIAN PROTEIN; BINDING PARTNER; S6 KINASE; RAPAMYCIN; TARGET; PHOSPHORYLATION; TOR; P70	The raptor-mTOR protein complex is a key component of a nutrient-sensitive signaling pathway that regulates cell size by controlling the accumulation of cellular mass. How nutrients regulate signaling through the raptor- mTOR complex is not well known. Here we show that a redox-sensitive mechanism regulates the phosphorylation of the raptor- mTOR effector S6K1, the interaction between raptor and mTOR, and the kinase activity of the raptor-mTOR complex. In cells treated with the oxidizing agents diamide or phenylarsine oxide, S6K1 phosphorylation increased and became insensitive to nutrient deprivation. Conversely, the reducing reagent BAL (British anti-Lewisite, also known as 2,3-dimercapto-1-propanol) inhibits S6K1 phosphorylation and stabilizes the interaction of mTOR and raptor to mimic the state of the complex under nutrient-deprived conditions. Our findings suggest that a redox-based signaling mechanism may participate in regulating the nutrient-sensitive raptor- mTOR complex and pathway.	Whitehead Inst Biomed Res, Dept Biol, Cambridge, MA 02142 USA; MIT, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Sabatini, DM (corresponding author), Whitehead Inst Biomed Res, Dept Biol, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	sabatini@wi.mit.edu	Sarbassov, Dos/AAS-4950-2020	/0000-0002-1446-7256; Sarbassov, Dos/0000-0002-6848-1133	NATIONAL CANCER INSTITUTE [R01CA103866] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI047389, R01AI047389] Funding Source: NIH RePORTER; NCI NIH HHS [CA103866] Funding Source: Medline; NIAID NIH HHS [AI47389] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Bogumil R, 2002, METHOD ENZYMOL, V348, P271, DOI 10.1016/S0076-6879(02)48645-4; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Dames SA, 2005, J BIOL CHEM, V280, P20558, DOI 10.1074/jbc.M501116200; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; FROST SC, 1990, BIOCHEM J, V269, P589, DOI 10.1042/bj2690589; Grammer TC, 1996, J BIOL CHEM, V271, P23650, DOI 10.1074/jbc.271.39.23650; Graves LM, 1997, J BIOL CHEM, V272, P1920, DOI 10.1074/jbc.272.3.1920; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; HOFFMAN RD, 1992, J BIOL CHEM, V267, P14005; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; KOSOWER EM, 1995, METHOD ENZYMOL, V251, P133, DOI 10.1016/0076-6879(95)51117-2; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Morice M, 2002, NEW ENGL J MED, V346, P1773, DOI 10.1056/NEJMoa012843; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Saunders RN, 2001, KIDNEY INT, V59, P3, DOI 10.1046/j.1523-1755.2001.00460.x; Sousa JE, 2001, CIRCULATION, V104, P2007, DOI 10.1161/hc4201.098056; Vogt PK, 2001, TRENDS MOL MED, V7, P482, DOI 10.1016/S1471-4914(01)02161-X	30	194	195	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39505	39509		10.1074/jbc.M506096200	http://dx.doi.org/10.1074/jbc.M506096200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16183647	hybrid			2022-12-25	WOS:000233362200072
J	Zhang, Z; Okawa, H; Wang, YY; Liman, ER				Zhang, Z; Okawa, H; Wang, YY; Liman, ER			Phosphatidylinositol 4,5-bisphosphate rescues TRPM4 channels from desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-ACTIVATED CATION CHANNEL; RECEPTOR-MEDIATED INHIBITION; PLECKSTRIN HOMOLOGY DOMAINS; CAPSAICIN RECEPTOR; PIP2; CALCIUM; ACTIVATION; PHOSPHOINOSITIDES; MEMBRANE; RECOVERY	TRPM4 is a Ca2+-activated nonselective cation channel that regulates membrane potential in response to intracellular Ca2+ signaling. In lymphocytes it plays an essential role in shaping the pattern of intracellular Ca2+ oscillations that lead to cytokine secretion. To better understand its role in this and other physiological processes, we investigated mechanisms by which TRPM4 is regulated. TRPM4 was expressed in ChoK1 cells, and currents were measured in excised patches. Under these conditions, TRPM4 currents were activated by micromolar concentrations of cytoplasmic Ca2+ and progressively desensitized. Here we show that desensitization can be explained by a loss of phosphatidylinositol 4,5-bisphosphate (PI(4,5)P-2) from the channels. Poly-L-lysine, a PI(4,5)P-2 scavenger, caused rapid desensitization, whereas MgATP, at concentrations that activate lipid kinases, promoted recovery of TRPM4 currents. Application of exogenous PI(4,5)P-2 to the intracellular surface of the patch restored the properties of TRPM4 currents. Our results suggest that PI(4,5)P-2 acts to uncouple channel opening from changes in the transmembrane potential, allowing current activation at physiological voltages. These data argue that hydrolysis of PI(4,5)P-2 underlies desensitization of TRPM4 and support the idea that PI(4,5)P-2 is a general regulator for the gating of TRPM ion channels.	Univ So Calif, Dept Biol Sci, Neurobiol Sect, Div Neurobiol, Los Angeles, CA 90089 USA; Univ So Calif, Program Neurosci, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Liman, ER (corresponding author), Univ So Calif, Dept Biol Sci, Neurobiol Sect, Div Neurobiol, 3641 Watt Way, Los Angeles, CA 90089 USA.	Liman@usc.edu	Wang, Yuanyuan/H-3651-2012; Liman, Emily/AAC-7383-2021	liman, emily/0000-0003-4765-5496	NIDCD NIH HHS [K02-DC05000, R01-DC04564] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [K02DC005000, R01DC004564] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Balla T, 2001, CURR PHARM DESIGN, V7, P475, DOI 10.2174/1381612013397906; Balla T, 1998, BBA-MOL CELL BIOL L, V1436, P69, DOI 10.1016/S0005-2760(98)00134-9; BERS DM, 1994, METHOD CELL BIOL, V40, P3; Chuang HH, 2001, NATURE, V411, P957, DOI 10.1038/35082088; Chyb S, 1999, NATURE, V397, P255, DOI 10.1038/16703; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Earley S, 2004, CIRC RES, V95, P922, DOI 10.1161/01.RES.0000147311.54833.03; Hardie RC, 2001, NEURON, V30, P149, DOI 10.1016/S0896-6273(01)00269-0; HARTENECK C, 2005, NAUNYNSCHMIEDEBERGS; Hilgemann D W, 2001, Sci STKE, V2001, pre19, DOI 10.1126/stke.2001.111.re19; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; Hofmann T, 2003, CURR BIOL, V13, P1153, DOI 10.1016/S0960-9822(03)00431-7; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Launay P, 2004, SCIENCE, V306, P1374, DOI 10.1126/science.1098845; Launay P, 2002, CELL, V109, P397, DOI 10.1016/S0092-8674(02)00719-5; Lemmon MA, 2001, BIOCHEM SOC T, V29, P377, DOI 10.1042/BST0290377; Liman ER, 2003, J PHYSIOL-LONDON, V548, P777, DOI 10.1113/jphysiol.2002.037119; Liu BY, 2005, J NEUROSCI, V25, P4835, DOI 10.1523/JNEUROSCI.1296-05.2005; Liu BY, 2005, J NEUROSCI, V25, P1674, DOI 10.1523/JNEUROSCI.3632-04.2005; Liu D, 2003, P NATL ACAD SCI USA, V100, P15160, DOI 10.1073/pnas.2334159100; Liu D, 2005, J BIOL CHEM, V280, P20691, DOI 10.1074/jbc.M414072200; Lupu VD, 1998, J BIOL CHEM, V273, P14067, DOI 10.1074/jbc.273.23.14067; MacKinnon R, 2004, SCIENCE, V306, P1304, DOI 10.1126/science.1105528; McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; Nilius B, 2005, J BIOL CHEM, V280, P6423, DOI 10.1074/jbc.M411089200; Nilius B, 2004, J PHYSIOL-LONDON, V560, P753, DOI 10.1113/jphysiol.2004.070839; Nilius B, 2004, PFLUG ARCH EUR J PHY, V448, P70, DOI 10.1007/s00424-003-1221-x; Nilius B, 2003, J BIOL CHEM, V278, P30813, DOI 10.1074/jbc.M305127200; PARTRIDGE LD, 1988, TRENDS NEUROSCI, V11, P69, DOI 10.1016/0166-2236(88)90167-1; Peier AM, 2002, CELL, V108, P705, DOI 10.1016/S0092-8674(02)00652-9; Perez CA, 2002, NAT NEUROSCI, V5, P1169, DOI 10.1038/nn952; Prawitt D, 2003, P NATL ACAD SCI USA, V100, P15166, DOI 10.1073/pnas.2334624100; Prescott ED, 2003, SCIENCE, V300, P1284, DOI 10.1126/science.1083646; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Rohacs T, 2003, P NATL ACAD SCI USA, V100, P745, DOI 10.1073/pnas.0236364100; Rohacs T, 2005, NAT NEUROSCI, V8, P626, DOI 10.1038/nn1451; Runnels LW, 2002, NAT CELL BIOL, V4, P329, DOI 10.1038/ncb781; STURGESS NC, 1987, PFLUG ARCH EUR J PHY, V409, P607, DOI 10.1007/BF00584661; Suh BC, 2002, NEURON, V35, P507, DOI 10.1016/S0896-6273(02)00790-0; SUH BC, 2005, CURR OPIN NEUROBIOL; Ullrich ND, 2005, CELL CALCIUM, V37, P267, DOI 10.1016/j.ceca.2004.11.001; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Winks JS, 2005, J NEUROSCI, V25, P3400, DOI 10.1523/JNEUROSCI.3231-04.2005; Xie LH, 1999, J PHYSIOL-LONDON, V514, P655, DOI 10.1111/j.1469-7793.1999.655ad.x; YELLEN G, 1982, NATURE, V296, P357, DOI 10.1038/296357a0; Yuan JP, 2003, CELL, V114, P777, DOI 10.1016/S0092-8674(03)00716-5; Zhang HL, 2003, NEURON, V37, P963, DOI 10.1016/S0896-6273(03)00125-9; Zhang YF, 2003, CELL, V112, P293, DOI 10.1016/S0092-8674(03)00071-0	53	137	146	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39185	39192		10.1074/jbc.M506965200	http://dx.doi.org/10.1074/jbc.M506965200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16186107	hybrid			2022-12-25	WOS:000233362200034
J	Du, ZH; Lee, JK; Tjhen, R; Li, S; Pan, H; Stroud, RM; James, TL				Du, ZH; Lee, JK; Tjhen, R; Li, S; Pan, H; Stroud, RM; James, TL			Crystal structure of the first KH domain of human poly(C)-binding protein-2 in complex with a C-rich strand of human telomeric DNA at 1.7 angstrom	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; POLY(RC) BINDING-PROTEIN; 3' UNTRANSLATED REGION; POLIOVIRUS RNA; KH DOMAIN; ERYTHROID-DIFFERENTIATION; 3'-UNTRANSLATED REGION; HNRNP-K; IDENTIFICATION; TRANSLATION	Recognition of poly( C) DNA and RNA sequences in mammalian cells is achieved by a subfamily of the KH ( hnRNP K homology) domain-containing proteins known as poly(C)-binding proteins (PCBPs). To reveal the molecular basis of poly( C) sequence recognition, we have determined the crystal structure, at 1.7-angstrom resolution, of PCBP2 KH1 in complex with a 7-nucleotide DNA sequence (5'-AACCCTA-3') corresponding to one repeat of the human C-rich strand telomeric DNA. The protein-DNA interaction is mediated by the combination of several stabilizing forces including hydrogen bonding, electrostatic interactions, van der Waals contacts, and shape complementarities. Specific recognition of the three cytosine residues is realized by a dense network of hydrogen bonds involving the side chains of two conserved lysines and one glutamic acid. The co-crystal structure also reveals a protein-protein dimerization interface of PCBP2 KH1 located on the opposite side of the protein from the DNA binding groove. Numerous stabilizing protein-protein interactions, including hydrophobic contacts, stacking of aromatic side chains, and a large number of hydrogen bonds, indicate that the protein-protein interaction interface is most likely genuine. Interaction of PCBP2 KH1 with the C-rich strand of human telomeric DNA suggests that PCBPs may participate in mechanisms involved in the regulation of telomere/telomerase functions.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	James, TL (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, 600 16th St,Genentech Hall, San Francisco, CA 94143 USA.	james@picasso.ucsf.edu	LI, SHANG/HII-4989-2022	LI, SHANG/0000-0002-6226-3362	NIAID NIH HHS [AI46967] Funding Source: Medline; NIGMS NIH HHS [GM51232] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046967] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051232] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Backe PH, 2005, STRUCTURE, V13, P1055, DOI 10.1016/j.str.2005.04.008; Bandiera A, 2003, ARCH BIOCHEM BIOPHYS, V409, P305, DOI 10.1016/S0003-9861(02)00413-7; Blackburn EH, 2005, FEBS LETT, V579, P859, DOI 10.1016/j.febslet.2004.11.036; Blyn LB, 1997, J VIROL, V71, P6243, DOI 10.1128/JVI.71.8.6243-6246.1997; Blyn LB, 1996, P NATL ACAD SCI USA, V93, P11115, DOI 10.1073/pnas.93.20.11115; Braddock DT, 2002, NATURE, V415, P1051, DOI 10.1038/4151051a; Braddock DT, 2002, EMBO J, V21, P3476, DOI 10.1093/emboj/cdf352; BRUNGER AT, 1996, XPLOR VERSION 3 843; Chkheidze AN, 1999, MOL CELL BIOL, V19, P4572; Czyzyk-Krzeska MF, 1999, BLOOD, V93, P2111, DOI 10.1182/blood.V93.6.2111.406k24_2111_2120; DEBOULLE K, 1993, NAT GENET, V3, P31, DOI 10.1038/ng0193-31; Du ZH, 2004, J BIOL CHEM, V279, P48126, DOI 10.1074/jbc.M405371200; Gamarnik AV, 1998, GENE DEV, V12, P2293, DOI 10.1101/gad.12.15.2293; Gamarnik AV, 2000, J VIROL, V74, P2219, DOI 10.1128/JVI.74.5.2219-2226.2000; Gamarnik AV, 1997, RNA, V3, P882; GERBER PR, 1995, J COMPUT AID MOL DES, V9, P251, DOI 10.1007/BF00124456; Lacroix L, 2000, NUCLEIC ACIDS RES, V28, P1564, DOI 10.1093/nar/28.7.1564; Lewis HA, 2000, CELL, V100, P323, DOI 10.1016/S0092-8674(00)80668-6; Lewis HA, 1999, STRUCTURE, V7, P191, DOI 10.1016/S0969-2126(99)80025-2; Lindquist JN, 2000, NUCLEIC ACIDS RES, V28, P4306, DOI 10.1093/nar/28.21.4306; Liu AZ, 2000, J BIOMOL NMR, V16, P127, DOI 10.1023/A:1008305022907; Makeyev AV, 2002, RNA, V8, P265, DOI 10.1017/S1355838202024627; Ostareck DH, 2001, CELL, V104, P281, DOI 10.1016/S0092-8674(01)00212-4; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; OSTARECKLEDERER A, 1994, EMBO J, V13, P1476, DOI 10.1002/j.1460-2075.1994.tb06402.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parsley TB, 1997, RNA, V3, P1124; Paulding WR, 1999, J BIOL CHEM, V274, P2532, DOI 10.1074/jbc.274.4.2532; Ramos A, 2002, BIOCHEMISTRY-US, V41, P4193, DOI 10.1021/bi011994o; Stefanovic B, 1997, MOL CELL BIOL, V17, P5201, DOI 10.1128/MCB.17.9.5201; Tomonaga T, 1996, P NATL ACAD SCI USA, V93, P5830, DOI 10.1073/pnas.93.12.5830; Waggoner SA, 2003, EXP BIOL MED, V228, P387, DOI 10.1177/153537020322800409; Waggoner SA, 2003, MOL CELL BIOL, V23, P7055, DOI 10.1128/MCB.23.19.7055-7067.2003; WEISS IM, 1995, MOL CELL BIOL, V15, P2457	34	47	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38823	38830		10.1074/jbc.M508183200	http://dx.doi.org/10.1074/jbc.M508183200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16186123	hybrid			2022-12-25	WOS:000233239800084
J	Zhang, Y; Higashide, W; Dai, SP; Sherman, DM; Zhou, DG				Zhang, Y; Higashide, W; Dai, SP; Sherman, DM; Zhou, DG			Recognition and ubiquitination of Salmonella type III effector SopA by a ubiquitin E3 ligase, HsRMA1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTERICA SEROVAR TYPHIMURIUM; LYSOSOMAL MEMBRANE-GLYCOPROTEINS; HUMAN-PAPILLOMAVIRUS TYPE-16; PATHOGENICITY ISLAND 2; RING FINGER PROTEIN; SECRETION SYSTEM; CONTAINING VACUOLES; ESCHERICHIA-COLI; BINDING-PROTEIN; E6 ONCOPROTEIN	Salmonella translocate bacterial effectors into host cells to confer bacterial entry and survival. It is not known how the host cells cope with the influx of these effectors. We report here that the Salmonella effector, SopA, interacts with host HsRMA1, a ubiquitin E3 ligase with a previously unknown function. SopA is ubiquitinated and degraded by the HsRMA1-mediated ubiquitination pathway. A sopA mutant escapes out of the Salmonella-containing vacuoles less frequently to the cytosol than wild type Salmonella in HeLa cells in a HsRMA1-dependent manner. Our data suggest that efficient bacterial escape into the cytosol of epithelial cells requires HsRMA1-mediated SopA ubiquitination and contributes to Salmonella-induced enteropathogenicity.	Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Zhou, DG (corresponding author), Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA.	zhoud@purdue.edu	Dai, Shipan/B-3969-2011		NIAID NIH HHS [AI49978] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049978] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Beuzon CR, 2002, MICROBIOL-SGM, V148, P2705, DOI 10.1099/00221287-148-9-2705; Beuzon CR, 2000, EMBO J, V19, P3235, DOI 10.1093/emboj/19.13.3235; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Brumell JH, 2002, TRAFFIC, V3, P407, DOI 10.1034/j.1600-0854.2002.30604.x; Brumell JH, 2002, INFECT IMMUN, V70, P3264, DOI 10.1128/IAI.70.6.3264-3270.2002; Chang JH, 2005, MOL MICROBIOL, V55, P1379, DOI 10.1111/j.1365-2958.2004.04480.x; Dai SP, 2004, J BACTERIOL, V186, P5078, DOI 10.1128/jb.186.15.5078-5086.2004; Dai SP, 2004, CELL MICROBIOL, V6, P459, DOI 10.1111/j.1462-5822.2004.00375.x; Didier C, 2003, MOL CELL BIOL, V23, P5331, DOI 10.1128/MCB.23.15.5331-5345.2003; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; GALAN JE, 1989, P NATL ACAD SCI USA, V86, P6383, DOI 10.1073/pnas.86.16.6383; GARCIADELPORTILLO F, 1995, J CELL BIOL, V129, P81, DOI 10.1083/jcb.129.1.81; Giberson RT, 2003, ULTRASTRUCT PATHOL, V27, P187, DOI 10.1080/01913120309937; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Guy RL, 2000, MOL MICROBIOL, V37, P1417, DOI 10.1046/j.1365-2958.2000.02092.x; Hansen-Wester I, 2002, INFECT IMMUN, V70, P1403, DOI 10.1128/IAI.70.3.1403-1409.2002; Hapfelmeier S, 2004, INFECT IMMUN, V72, P795, DOI 10.1128/IAI.72.2.795-809.2004; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; Hardt WD, 1998, P NATL ACAD SCI USA, V95, P2574, DOI 10.1073/pnas.95.5.2574; Hayward RD, 1999, EMBO J, V18, P4926, DOI 10.1093/emboj/18.18.4926; Hensel M, 1997, MOL MICROBIOL, V24, P155, DOI 10.1046/j.1365-2958.1997.3271699.x; Hensel M, 1998, MOL MICROBIOL, V30, P163, DOI 10.1046/j.1365-2958.1998.01047.x; HOISETH SK, 1981, NATURE, V291, P238, DOI 10.1038/291238a0; Hong KH, 1998, J BACTERIOL, V180, P1793, DOI 10.1128/JB.180.7.1793-1802.1998; HOUGH R, 1987, J BIOL CHEM, V262, P8303; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KANIGA K, 1991, GENE, V109, P137, DOI 10.1016/0378-1119(91)90599-7; Kubori T, 2003, CELL, V115, P333, DOI 10.1016/S0092-8674(03)00849-3; Kyushiki H, 1997, CYTOGENET CELL GENET, V79, P114, DOI 10.1159/000134695; Lessard IAD, 1998, CHEM BIOL, V5, P489, DOI 10.1016/S1074-5521(98)90005-9; Marcus SL, 2002, CELL MICROBIOL, V4, P435, DOI 10.1046/j.1462-5822.2002.00202.x; Matsuda N, 2001, J CELL SCI, V114, P1949; Matsuda N, 1998, PLANT CELL PHYSIOL, V39, P545, DOI 10.1093/oxfordjournals.pcp.a029403; Meresse S, 1999, EMBO J, V18, P4394, DOI 10.1093/emboj/18.16.4394; Perrin AJ, 2004, CURR BIOL, V14, P806, DOI 10.1016/j.cub.2004.04.033; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Reggiori F, 2002, NAT CELL BIOL, V4, P117, DOI 10.1038/ncb743; SALMINEN A, 1989, J CELL BIOL, V109, P1023, DOI 10.1083/jcb.109.3.1023; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; Shea JE, 1999, INFECT IMMUN, V67, P213, DOI 10.1128/IAI.67.1.213-219.1999; Steele-Mortimer O, 1999, CELL MICROBIOL, V1, P33, DOI 10.1046/j.1462-5822.1999.00003.x; Stein MA, 1996, MOL MICROBIOL, V20, P151, DOI 10.1111/j.1365-2958.1996.tb02497.x; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; Uchiya K, 1999, EMBO J, V18, P3924, DOI 10.1093/emboj/18.14.3924; Vazquez-Torres A, 2000, SCIENCE, V287, P1655, DOI 10.1126/science.287.5458.1655; Wood MW, 2000, CELL MICROBIOL, V2, P293, DOI 10.1046/j.1462-5822.2000.00054.x; Zhang SP, 2002, INFECT IMMUN, V70, P3843, DOI 10.1128/IAI.70.7.3843-3855.2002; Zhou D, 1999, SCIENCE, V283, P2092, DOI 10.1126/science.283.5410.2092; Zhou DG, 2001, MOL MICROBIOL, V39, P248, DOI 10.1046/j.1365-2958.2001.02230.x	53	49	52	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38682	38688		10.1074/jbc.M506309200	http://dx.doi.org/10.1074/jbc.M506309200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16176924	hybrid			2022-12-25	WOS:000233239800070
J	Park, CS				Park, CS			Role of compensatory mammary growth in epigenetic control of gene expression	FASEB JOURNAL			English	Article						compensatory growth; mammary development; lactation potential; metabolic imprinting; epigenetics	MILK PROTEIN GENE; CELL-PROLIFERATION; DAIRY HEIFERS; LACTATION; RATS; GLAND; MECHANISMS; NUTRITION; DIFFERENTIATION; RESTRICTION	To better understand the role of nutrition in regulating mammary gland development and lactation, we designed a novel stair-step compensatory nutrition regimen that is a unique combination of dietary energy restriction and realimentation (refeeding) phases; the basic concept of this regimen is to exploit the biological nature of the compensatory growth phenomenon in concert with one or more hormone-sensitive allometric phases of mammary development (i. e., peripuberty through gestation). Nutritionally induced compensatory growth during different developmental stages before first parturition positively affects mammary development and life-long lactation performance. This permanent enhancement of mammary gland growth and lactation potential strongly suggests a possible mechanistic link between nutritionally induced compensatory growth, epigenetic control of mammary gene expression, and metabolic imprinting. We hypothesize that compensatory-directed metabolic imprinting once set during late pregnancy prior to the first parturition persistently maintains and exerts its adaptive response on mammogenesis and galactopoiesis (i. e., maintenance and/or enhancement of milk secretion). The ability to influence heritable genes regulating milk synthesis may be used to improve the quality and quantity of milk ( e. g., infant health, the secretion of certain immunoglobulins or growth factors) as well as the longevity of lactation.	N Dakota State Univ, Dept Anim & Range Sci, Fargo, ND 58105 USA	North Dakota State University Fargo	Park, CS (corresponding author), N Dakota State Univ, Dept Anim & Range Sci, Hultz Hall, Fargo, ND 58105 USA.	c.park@ndsu.edu						ASHWORTH A, 1986, NUTR REV, V44, P157, DOI 10.1111/j.1753-4887.1986.tb07613.x; Choi YJ, 1998, J NUTR BIOCHEM, V9, P380, DOI 10.1016/S0955-2863(98)00027-8; Choi YJ, 1997, J DAIRY SCI, V80, P519, DOI 10.3168/jds.S0022-0302(97)75965-4; CRENSHAW J D, 1989, Journal of Animal Science, V67, P107; Dijkstra J, 1997, J DAIRY SCI, V80, P2340, DOI 10.3168/jds.S0022-0302(97)76185-X; ENCINIAS AM, 2001, J ANIM S1, V79, P296; FILHO JDC, 2000, RES COMMUN MOL PATH, V108, P213; Ford JA, 2001, J DAIRY SCI, V84, P1669, DOI 10.3168/jds.S0022-0302(01)74602-4; Forsyth IA, 1996, J DAIRY SCI, V79, P1085, DOI 10.3168/jds.S0022-0302(96)76462-7; Ginger MR, 2001, MOL ENDOCRINOL, V15, P1993, DOI 10.1210/me.15.11.1993; Hales CN, 2003, DIABETOLOGIA, V46, P1013, DOI 10.1007/s00125-003-1131-7; HOLLIDAY R, 1975, SCIENCE, V187, P226, DOI 10.1126/science.1111098; Hursting SD, 2003, ANNU REV MED, V54, P131, DOI 10.1146/annurev.med.54.101601.152156; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Kim HH, 2004, J NUTR, V134, P756, DOI 10.1093/jn/134.4.756; Kim SH, 1998, BRIT J NUTR, V79, P177, DOI 10.1079/BJN19980029; Kleinberg DL, 2000, J MAMMARY GLAND BIOL, V5, P7, DOI 10.1023/A:1009507030633; Laubach M. S., 2003, Journal of Dairy Science, V86, P166; Lin CH, 1998, J NUTR, V128, P1636, DOI 10.1093/jn/128.10.1636; Lucas A, 1996, BRIT J NUTR, V76, P605, DOI 10.1079/BJN19960066; Moon YS, 2002, ASIAN AUSTRAL J ANIM, V15, P1364, DOI 10.5713/ajas.2002.1364; Moon YS, 1999, J NUTR, V129, P1156, DOI 10.1093/jn/129.6.1156; NEWSHOLME EA, 1980, NEW ENGL J MED, V302, P400, DOI 10.1056/NEJM198002143020711; Park CS, 1998, J DAIRY SCI, V81, P243, DOI 10.3168/jds.S0022-0302(98)75572-9; PARK CS, 1989, GROWTH DEVELOP AGING, V53, P159; PARK CS, 1987, J ANIM SCI, V64, P1751, DOI 10.2527/jas1987.6461751x; PARK CS, 1988, FASEB J, V2, P2619, DOI 10.1096/fasebj.2.10.2454864; PARK CS, 2002, RECENT DEV RUMINANT, V4, P581; PERI I, 1993, J DAIRY SCI, V76, P742, DOI 10.3168/jds.S0022-0302(93)77398-1; Razin Aharon, 1999, Results and Problems in Cell Differentiation, V25, P189; REEVES PG, 1993, J NUTR, V123, P1936; Riggs A. D., 1996, TORRENTS SPRING, P1; RUSSELL DH, 1972, BIOCHEM J, V130, P71, DOI 10.1042/bj1300071; Sivaraman L, 1998, CARCINOGENESIS, V19, P1573, DOI 10.1093/carcin/19.9.1573; Thordarson G., 1987, The mammary gland. Development, regulation, and function., P459; WALKER NI, 1989, AM J ANAT, V185, P19, DOI 10.1002/aja.1001850104; Waterland RA, 1999, AM J CLIN NUTR, V69, P179; WILSON PN, 1960, BIOL REV, V35, P324, DOI 10.1111/j.1469-185X.1960.tb01327.x	38	31	31	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					1586	1591		10.1096/fj.05-3816hyp	http://dx.doi.org/10.1096/fj.05-3816hyp			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16195367				2022-12-25	WOS:000232991100036
J	Cumming, RC; Schubert, D				Cumming, RC; Schubert, D			Amyloid-beta induces disulfide bonding and aggregation of GAPDH in Alzheimer's disease	FASEB JOURNAL			English	Article						protein oxidation; apoptosis; neurodegeneration; protein insolubility	GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE-ACTIVITY; PROTEIN A-BETA; OXIDATIVE STRESS; NUCLEAR TRANSLOCATION; HUNTINGTONS-DISEASE; CELL-DEATH; RAT-BRAIN; APOPTOSIS; FILAMENTS; NERVE	GAPDH is a redox-sensitive glycolytic enzyme that also promotes apoptosis when translocated to the nucleus and associates with aggregate- prone proteins involved in neurodegenerative disorders. Recent evidence indicates that polymorphic variation within GAPDH genes is associated with an elevated risk of developing Alzheimer's disease ( AD). We previously demonstrated that GAPDH readily undergoes disulfide bonding following oxidant exposure, although the consequence of disulfide bonding on GAPDH activity or function is unknown. Here we show that increased GAPDH disulfide bonding is observed in detergent-insoluble extracts from AD patient and transgenic AD mouse brain tissue compared with age-matched controls. Exposure of primary rat cortical neurons to the pro-oxidant amyloid beta peptide promotes nuclear accumulation of a disulfide-linked form of GAPDH, which becomes detergent-insoluble. Disulfide bonding leads to a reduction in GAPDH enzymatic activity and correlates with the appearance of punctate aggregate- like GAPDH staining within the cytoplasm of both oxidant-treated HT22 cells and amyloid beta-treated primary cortical neurons. Our findings suggest that disulfide bonding of GAPDH and subsequent protein aggregate formation may have relevance to the pathophysiology of AD.	Salk Inst Biol Studies, Cellular Neurobiol Lab, La Jolla, CA 92037 USA	Salk Institute	Schubert, D (corresponding author), Salk Inst Biol Studies, Cellular Neurobiol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	schubert@salk.edu	Cumming, Robert/G-2185-2010					BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Bhattacharya K, 2001, BIOCHEM BIOPH RES CO, V285, P20, DOI 10.1006/bbrc.2001.5116; Borchelt DR, 1997, NEURON, V19, P939, DOI 10.1016/S0896-6273(00)80974-5; BRODIE AE, 1990, ARCH BIOCHEM BIOPHYS, V276, P212, DOI 10.1016/0003-9861(90)90028-W; BURKE JR, 1996, NAT MED, V347, P350; Butterfield DA, 2004, BRAIN PATHOL, V14, P426; Carlile GW, 2000, MOL PHARMACOL, V57, P2; CHUANG DM, 2004, ANN REV PHARM TOXICO; Cumming RC, 2004, J BIOL CHEM, V279, P21749, DOI 10.1074/jbc.M312267200; Dastoor Z, 2001, J CELL SCI, V114, P1643; DAVIS JB, 1994, BRAIN RES, V652, P169, DOI 10.1016/0006-8993(94)90334-4; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Forman HJ, 2004, AM J PHYSIOL-CELL PH, V287, pC246, DOI 10.1152/ajpcell.00516.2003; Furukawa Y, 2004, EMBO J, V23, P2872, DOI 10.1038/sj.emboj.7600276; Giasson BI, 2002, FREE RADICAL BIO MED, V32, P1264, DOI 10.1016/S0891-5849(02)00804-3; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; Ischiropoulos H, 2003, J CLIN INVEST, V111, P163, DOI 10.1172/JCI200317638; Koshy B, 1996, HUM MOL GENET, V5, P1311, DOI 10.1093/hmg/5.9.1311; KOSOWER NS, 1995, METHOD ENZYMOL, V251, P123, DOI 10.1016/0076-6879(95)51116-4; Lee S, 2003, NAT STRUCT BIOL, V10, P725, DOI 10.1038/nsb961; Li Y, 2004, P NATL ACAD SCI USA, V101, P15688, DOI 10.1073/pnas.0403535101; Li YH, 1997, NEURON, V19, P453, DOI 10.1016/S0896-6273(00)80953-8; Lind C, 1998, BIOCHEM BIOPH RES CO, V247, P481, DOI 10.1006/bbrc.1998.8695; Lindersson E, 2004, J BIOL CHEM, V279, P12924, DOI 10.1074/jbc.M306390200; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; Mazzola JL, 2003, J NEUROSCI RES, V71, P279, DOI 10.1002/jnr.10484; Mazzola JL, 2001, J NEUROCHEM, V76, P442, DOI 10.1046/j.1471-4159.2001.00033.x; Mohr S, 1999, J BIOL CHEM, V274, P9427, DOI 10.1074/jbc.274.14.9427; Oyama R, 2000, BBA-PROTEIN STRUCT M, V1479, P91, DOI 10.1016/S0167-4838(00)00057-1; Ramsby ML, 1999, METH MOL B, V112, P53; Rhee S G, 2000, Sci STKE, V2000, ppe1; RYZLAK MT, 1988, BIOCHIM BIOPHYS ACTA, V954, P309, DOI 10.1016/0167-4838(88)90086-6; SABRI MI, 1971, J NEUROCHEM, V18, P1509, DOI 10.1111/j.1471-4159.1971.tb00013.x; Sawa A, 1997, P NATL ACAD SCI USA, V94, P11669, DOI 10.1073/pnas.94.21.11669; SCHULZE H, 1993, J NEUROCHEM, V60, P1915, DOI 10.1111/j.1471-4159.1993.tb13420.x; SCHWEERS O, 1995, P NATL ACAD SCI USA, V92, P8463, DOI 10.1073/pnas.92.18.8463; Senatorov VV, 2003, MOL CELL NEUROSCI, V22, P285, DOI 10.1016/S1044-7431(02)00013-1; Sirover MA, 1999, BBA-PROTEIN STRUCT M, V1432, P159, DOI 10.1016/S0167-4838(99)00119-3; SITIA R, 2004, SCI STKE, pPE27; Soucek T, 2003, NEURON, V39, P43, DOI 10.1016/S0896-6273(03)00367-2; SUNAGA K, 1995, NEUROSCI LETT, V200, P133, DOI 10.1016/0304-3940(95)12098-O; Tamaoka A, 1996, NEUROBIOL AGING, V17, P405, DOI 10.1016/0197-4580(96)00031-0; Tatton NA, 2000, EXP NEUROL, V166, P29, DOI 10.1006/exnr.2000.7489; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; Tsuchiya K, 2005, EUR J NEUROSCI, V21, P317, DOI 10.1111/j.1460-9568.2005.03870.x; Tsuchiya K, 2004, LIFE SCI, V74, P3245, DOI 10.1016/j.lfs.2003.11.029; Wang Q, 2005, FASEB J, V19, P869, DOI 10.1096/fj.04-3210fje; Weber H, 2004, MOL MICROBIOL, V52, P133, DOI 10.1111/j.1365-2958.2004.03971.x; Welker E, 2001, P NATL ACAD SCI USA, V98, P4334, DOI 10.1073/pnas.071066598; Worthington V., 1993, WORTHINGTON ENZYME M	51	117	121	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					2060	+		10.1096/fj.05-4195fje	http://dx.doi.org/10.1096/fj.05-4195fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16186172				2022-12-25	WOS:000232315700006
J	Abu-Amero, KK; Alzahrani, AS; Zou, M; Shi, Y				Abu-Amero, KK; Alzahrani, AS; Zou, M; Shi, Y			Association of mitochondrial DNA transversion mutations with familial medullary thyroid carcinoma/multiple endocrine neoplasia type 2 syndrome	ONCOGENE			English	Article						mitochondria; mutation; medullary thyroid neoplasm; RET oncogene; multiple endocrine neoplasia	OXIDATIVE STRESS; CLINICAL-FEATURES; SOMATIC MUTATIONS; HIGH-FREQUENCY; RET; CANCER; REPAIR; TUMORS; GENE; ACTIVATION	Medullary thyroid carcinoma (MTC) is a malignant tumour of the calcitonin-secreting parafollicular C cells of the thyroid, and occurs sporadically or as a component of the multiple endocrine neoplasia (MEN) type 2/familial medullary thyroid carcinoma (FMTC) syndromes. In the present study, we investigated the frequency of mtDNA mutations in 26 MTC tumour specimens (13 sporadic and 13 familial MTC) and their matched normal tissues by sequencing the entire coding regions of mitochondrial genome. Nonsynonymous mutations were detected in 20 MTC samples (76.9%): nine out of 13 sporadic MTC (69.2%) and 11 out of 13 (84.6%) familial MTC/MEN2. Both transition and transversion types of mutations were found in the samples. Interestingly, 76.2% (16/21) of transversion mutations were found in FMTC/MEN2 patients, whereas 66.7% (12/18) of transition mutations were in sporadic MTC. Synonymous mutations were found in 12 MTC samples. In total, we identified 27 transversion mutations (21 nonsynonymous and six synonymous) in MTC. Of them, 22 (81.5%) were from FMTC/MEN2, and five (18.5%) were from sporadic MTC. The association of transversion mutation with familial MTC/MEN2 was statistically significant (P = 0.0015, binomial test). Majority of the mutations were involved in the genes located in the complex I of the mitochondrial genome, and were often resulting in a change of a moderately or highly conserved amino acid of their corresponding protein. Mitochondrial respiratory function was also compromised in a TT cell line, which carries mtDNA mutation at nt 4917 and 11 720, and in peripheral lymphocytes of MTC patients with mtDNA mutations. These data suggest that mtDNA mutation may be involved in MTC tumourigenesis and progression. Given that mtDNA mutation spectra are different between sporadic and familial MTC, different mechanisms of oxidative DNA damage may occur in the disease process.	King Faisal Specialist Hosp & Res Ctr, Dept Genet MBC03, Riyadh 11211, Saudi Arabia; King Faisal Specialist Hosp & Res Ctr, Dept Med, Riyadh 11211, Saudi Arabia	King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center	Shi, Y (corresponding author), King Faisal Specialist Hosp & Res Ctr, Dept Genet MBC03, POB 3354, Riyadh 11211, Saudi Arabia.	yufei@kfshrc.edu.sa	Alzahrani, Ali S/L-3664-2017; Shi, Yufei/ABG-5228-2020; Abu-Amero, Khaled/A-5579-2010	Alzahrani, Ali S/0000-0003-4294-3624; Shi, Yufei/0000-0002-6999-0191; 				Abu-Amero KK, 2005, ONCOGENE, V24, P1455, DOI 10.1038/sj.onc.1208292; ABUAMERO KK, 2005, ARCH PATHOL LABMED, V129, P62; Astuti D, 2001, LANCET, V357, P1181, DOI 10.1016/S0140-6736(00)04378-6; Benn DE, 2003, ONCOGENE, V22, P1358, DOI 10.1038/sj.onc.1206300; Bogenhagen DF, 2001, PROG NUCLEIC ACID RE, V68, P257; BOURGERON T, 1994, J CLIN INVEST, V93, P2514, DOI 10.1172/JCI117261; Chinnery PF, 2003, J NEUROL NEUROSUR PS, V74, P1188, DOI 10.1136/jnnp.74.9.1188; Coller HA, 2001, NAT GENET, V28, P147, DOI 10.1038/88859; Cooke MS, 2003, FASEB J, V17, P1195, DOI 10.1096/fj.02-0752rev; De Vita G, 2000, CANCER RES, V60, P3727; Elisei R, 2004, J CLIN ENDOCR METAB, V89, P3579, DOI 10.1210/jc.2003-031898; Elson JL, 2001, AM J HUM GENET, V68, P802, DOI 10.1086/318801; Eng C, 2003, NAT REV CANCER, V3, P193, DOI 10.1038/nrc1013; FARID NR, 1995, ENDOCRIN METAB CLIN, V24, P865, DOI 10.1016/S0889-8529(18)30024-0; Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017; Girelli ME, 1998, THYROID, V8, P517, DOI 10.1089/thy.1998.8.517; Hansford JR, 2000, J MED GENET, V37, P817, DOI 10.1136/jmg.37.11.817; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hartman P, 2004, MECH AGEING DEV, V125, P417, DOI 10.1016/j.mad.2004.02.007; Hundahl SA, 1998, CANCER-AM CANCER SOC, V83, P2638, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1; Ishii T, 2005, CANCER RES, V65, P203; Jones JB, 2001, CANCER RES, V61, P1299; Kang D, 2003, CLIN CHEM LAB MED, V41, P1281, DOI 10.1515/CCLM.2003.195; Kato M, 2000, MOL BIOL CELL, V11, P93, DOI 10.1091/mbc.11.1.93; Kino K, 2005, MUTAT RES-FUND MOL M, V571, P33, DOI 10.1016/j.mrfmmm.2004.10.010; Kino K, 2001, CHEM BIOL, V8, P369, DOI 10.1016/S1074-5521(01)00019-9; Kiuru M, 2004, CURR MOL MED, V4, P869, DOI 10.2174/1566524043359638; Klaunig JE, 2004, ANNU REV PHARMACOL, V44, P239, DOI 10.1146/annurev.pharmtox.44.101802.121851; Kurokawa K, 2003, J INTERN MED, V253, P627, DOI 10.1046/j.1365-2796.2003.01167.x; LeDoux SP, 2001, PROG NUCLEIC ACID RE, V68, P273; Ludwig L, 2001, CANCER RES, V61, P4526; Mandavilli BS, 2002, MUTAT RES-FUND MOL M, V509, P127, DOI 10.1016/S0027-5107(02)00220-8; Marsh DJ, 1997, HORM RES, V47, P168, DOI 10.1159/000185461; Massoll N, 2004, CLIN LAB MED, V24, P49, DOI 10.1016/j.cll.2004.01.006; Maximo V, 2002, AM J PATHOL, V160, P1857, DOI 10.1016/S0002-9440(10)61132-7; MAZZAFERRI EL, 1993, NEW ENGL J MED, V328, P553; Myers SM, 2004, CANCER RES, V64, P4453, DOI 10.1158/0008-5472.CAN-03-3605; Neeley WL, 2004, J BIOL CHEM, V279, P43568, DOI 10.1074/jbc.M407117200; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; Punales MK, 2003, J CLIN ENDOCR METAB, V88, P2644, DOI 10.1210/jc.2002-021422; Ramensky V, 2002, NUCLEIC ACIDS RES, V30, P3894, DOI 10.1093/nar/gkf493; Rieder MJ, 1998, NUCLEIC ACIDS RES, V26, P967, DOI 10.1093/nar/26.4.967; Santoro M, 2004, ENDOCRINOLOGY, V145, P5448, DOI 10.1210/en.2004-0922; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; Shi Y, 1999, BRIT J CANCER, V79, P1234, DOI 10.1038/sj.bjc.6690198; SHI YF, 1991, CANCER RES, V51, P2690; Shidara Y, 2005, CANCER RES, V65, P1655, DOI 10.1158/0008-5472.CAN-04-2012; Simonnet H, 2002, CARCINOGENESIS, V23, P759, DOI 10.1093/carcin/23.5.759; Slupphaug G, 2003, MUTAT RES-FUND MOL M, V531, P231, DOI 10.1016/j.mrfmmm.2003.06.002; Stevnsner T, 2002, EXP GERONTOL, V37, P1189, DOI 10.1016/S0531-5565(02)00142-0; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Yeh JJ, 2000, ONCOGENE, V19, P2060, DOI 10.1038/sj.onc.1203537; Zhang HX, 2004, ACTA PHARMACOL SIN, V25, P385	54	27	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					677	684		10.1038/sj.onc.1209094	http://dx.doi.org/10.1038/sj.onc.1209094			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16205644				2022-12-25	WOS:000235068800003
J	Hu, B; Tack, DC; Liu, T; Wu, Z; Ullenbruch, MR; Phan, SH				Hu, B; Tack, DC; Liu, T; Wu, Z; Ullenbruch, MR; Phan, SH			Role of Smad3 in the regulation of rat telomerase reverse transcriptase byTGF beta	ONCOGENE			English	Article						telomerase; Smad3; c-myc; TGF beta	CATALYTIC SUBUNIT HTERT; CANCER-CELLS; IN-VITRO; C-MYC; HEPATOCELLULAR CARCINOMAS; PROMOTER REGION; GENE-EXPRESSION; DIRECT BINDING; RNA COMPONENT; ACTIVATION	Telomerase is induced in certain pathological conditions such as cancer and tissue injury and repair. This induction in fibroblasts from injured lung is repressed by trans forming growth factor beta(TGF beta) via yet unknown mechanisms. In this study, the role of Smad3 in the inhibition of telomerase reverse transcriptase ( TERT) gene transcription by TGF beta was investigated. The rat TERT (rTERT) gene promoter was cloned by PCR amplification and fused with a luciferase reporter gene. This construct was used to analyse regulation of promoter activity in. broblasts isolated from bleomycin-injured lung with induced telomerase activity. The results showed that TGFb inhibited rTERT transcription while stimulating Smad3 expression. Interestingly, TGFb also inhibited the expression of c-myc. Cotransfection with a Smad3 expressing plasmid further repressed rTERT transcription and c-myc expression, while cotransfection with the corresponding antisense Smad3 construct had the opposite effect. Mutation of an E-box in the rTERT promoter suppressed its activity, which could be further reduced by TGF beta treatment. In contrast, mutation at a Smad binding element enhanced promoter activity whose inhibition was impaired by TGF beta treatment. Thus TGFb inhibition of rTERT gene expression was directly mediated by Smad3 via the Smad binding element, while c-myc appears to primarily regulate its constitutive or induced expression.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Phan, SH (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 1150 W Med Ctr Dr,MSI 4204, Ann Arbor, MI 48109 USA.	shphan@umich.edu	Hu, Biao/G-6084-2010; Phan, Sem H/A-7033-2009	Phan, Sem H/0000-0002-3711-2159	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052285, R01HL077297] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL77297, HL52285] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLSOPP RC, 1995, EXP CELL RES, V220, P194, DOI 10.1006/excr.1995.1306; Avilion AA, 1996, CANCER RES, V56, P645; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dessain SK, 2000, CANCER RES, V60, P537; Devereux TR, 1999, CANCER RES, V59, P6087; Djojosubroto MW, 2003, MOL CELLS, V15, P164; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Frederick JP, 2004, MOL CELL BIOL, V24, P2546, DOI 10.1128/MCB.24.6.2546-2559.2004; Fujimoto K, 2000, NUCLEIC ACIDS RES, V28, P2557, DOI 10.1093/nar/28.13.2557; Fuxe J, 2000, CELL GROWTH DIFFER, V11, P373; Gilley D, 2005, INT J BIOCHEM CELL B, V37, P1000, DOI 10.1016/j.biocel.2004.09.003; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; GREIDER C W, 1992, Current Biology, V2, P62, DOI 10.1016/0960-9822(92)90190-L; Greider CW, 1998, P NATL ACAD SCI USA, V95, P90, DOI 10.1073/pnas.95.1.90; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Groneberg DA, 2004, EXP LUNG RES, V30, P223, DOI 10.1080/01902140490276320; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Horikawa I, 1999, CANCER RES, V59, P826; Hu B, 2004, J IMMUNOL, V173, P4661, DOI 10.4049/jimmunol.173.7.4661; Hu B, 2003, AM J RESP CELL MOL, V29, P397, DOI 10.1165/rcmb.2003-0063OC; Kanaya T, 2000, CLIN CANCER RES, V6, P1239; Kang SS, 1999, J BIOL CHEM, V274, P13085, DOI 10.1074/jbc.274.19.13085; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Li H, 1999, ONCOGENE, V18, P6785, DOI 10.1038/sj.onc.1203061; Li H, 1998, J BIOL CHEM, V273, P33436, DOI 10.1074/jbc.273.50.33436; Liu JP, 1999, FASEB J, V13, P2091, DOI 10.1096/fasebj.13.15.2091; Liu KB, 1999, P NATL ACAD SCI USA, V96, P5147, DOI 10.1073/pnas.96.9.5147; Liu TJ, 2002, AM J RESP CELL MOL, V26, P534, DOI 10.1165/ajrcmb.26.5.4668; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; Muniyappa K, 1998, CRIT REV BIOCHEM MOL, V33, P297, DOI 10.1080/10409239891204242; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Nozaki Y, 2000, AM J RESP CELL MOL, V23, P460, DOI 10.1165/ajrcmb.23.4.3958; Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439; Oh S, 1999, J BIOL CHEM, V274, P37473, DOI 10.1074/jbc.274.52.37473; PAYS E, 1985, ANN INST PASTEUR IMM, VC136, P25, DOI 10.1016/S0769-2625(85)80037-4; PHAN SH, 1985, J CLIN INVEST, V76, P241, DOI 10.1172/JCI111953; Satyanarayana A, 2004, HEPATOLOGY, V40, P276, DOI 10.1002/hep.20308; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; TAHARA H, 1995, CANCER RES, V55, P2734; Takakura M, 1999, CANCER RES, V59, P551; Taylor RS, 1996, J INVEST DERMATOL, V106, P759, DOI 10.1111/1523-1747.ep12345811; Tsujiuchi T, 1998, CANCER LETT, V122, P115, DOI 10.1016/S0304-3835(97)00378-9; Vaziri H, 1996, EXP GERONTOL, V31, P295, DOI 10.1016/0531-5565(95)02025-X; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wick M, 1999, GENE, V232, P97, DOI 10.1016/S0378-1119(99)00108-0; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198; Yang H, 2001, CELL GROWTH DIFFER, V12, P119; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhao Hong, 2003, Yan Ke Xue Bao, V19, P60	57	37	41	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					1030	1041		10.1038/sj.onc.1209140	http://dx.doi.org/10.1038/sj.onc.1209140			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16205635				2022-12-25	WOS:000235361000008
J	Majid, SM; Liss, AS; You, M; Bose, HR				Majid, SM; Liss, AS; You, M; Bose, HR			The suppression of SH3BGRL is important for v-Rel-mediated transformation	ONCOGENE			English	Article						v-rel; NF-kappa B; SH3BGRL; SH3BGR; transformation	NF-KAPPA-B; HUMAN PROSTATE-CANCER; C-REL; RETICULOENDOTHELIOSIS VIRUS; DNA-BINDING; BREAST-CANCER; ANDROGEN-INDEPENDENCE; MOLECULAR ALTERATIONS; TRANSCRIPTION FACTORS; SELECTIVE ACTIVATION	The v-rel oncogene is the most efficient transforming member of the Rel/NF-kappa B family of transcription factors. v-Rel induces avian and mammalian lymphoid cell tumors and transforms chicken embryo fibroblasts in culture by the aberrant regulation of genes under the control of Rel/NF-kappa B proteins. Here we report that the expression of SH3BGRL, a member of the SH3BGR (SH3 domain-binding glutamicacid-rich) family of proteins, is down-regulated in v-Rel-expressing fibroblasts, lymphoid cells, and splenic tumor cells. Chromatin immunoprecipitation experiments demonstrated that v-Rel binds to the sh3bgrl promoter in transformed cells. Coexpression of SH3BGRL with v-Rel in primary splenic lymphocytes reduced the number of colonies formed by 76%. Mutations in the predicted SH3-binding domain of SH3BGRL abolished the suppressive effect on v-Rel transformation and resulted in colony numbers comparable to those formed by v-Rel alone. However, mutations in the predicted EVH1-binding domain of SH3BGRL only had a modest effect on suppression of v-Rel transformation. This study provides the first example of a gene that is down-regulated in v-Rel-expressing cells that also plays a role in v-Rel transformation.	Univ Texas, Inst Mol & Cellular Biol, Sect Mol Genet & Microbiol, Austin, TX 78712 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA	University of Texas System; University of Texas Austin; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Bose, HR (corresponding author), Univ Texas, Inst Mol & Cellular Biol, Sect Mol Genet & Microbiol, 1 Univ Stn A5000, Austin, TX 78712 USA.	bose@mail.utexas.edu	Liss, Andrew/L-9696-2019		NCI NIH HHS [CA33192] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033192] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA Y, 1974, BIKEN J, V17, P105; BABA TW, 1985, VIROLOGY, V144, P139, DOI 10.1016/0042-6822(85)90312-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Ball LJ, 2002, FEBS LETT, V513, P45, DOI 10.1016/S0014-5793(01)03291-4; BARTH CF, 1990, J VIROL, V64, P6054, DOI 10.1128/JVI.64.12.6054-6062.1990; Barzik M, 2001, J MOL BIOL, V309, P155, DOI 10.1006/jmbi.2001.4640; Berleth ES, 2000, INT J IMMUNOPHARMACO, V22, P1137, DOI 10.1016/S0192-0561(00)00071-0; Berleth ES, 1999, CANCER RES, V59, P5497; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; Cao YX, 2003, J MAMMARY GLAND BIOL, V8, P215, DOI 10.1023/A:1025905008934; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; Cesareni G, 2002, FEBS LETT, V513, P38, DOI 10.1016/S0014-5793(01)03307-5; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen F, 2001, AM J PATHOL, V159, P387, DOI 10.1016/S0002-9440(10)61708-7; CHENG Q, 1994, J BIOL CHEM, V269, P13551; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Deindl E, 2001, BIOTECHNIQUES, V31, P1250, DOI 10.2144/01316bm04; Denk A, 2000, CYTOKINE GROWTH F R, V11, P303, DOI 10.1016/S1359-6101(00)00009-5; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4387, DOI 10.1128/MCB.6.12.4387; DYER RB, 1995, BIOTECHNIQUES, V19, P192; Egeo A, 1998, BIOCHEM BIOPH RES CO, V247, P302, DOI 10.1006/bbrc.1998.8763; FRANKLIN RB, 1977, VIROLOGY, V83, P313, DOI 10.1016/0042-6822(77)90176-3; Fujii M, 1996, ONCOGENE, V12, P2193; Gasparian AV, 2002, J CELL SCI, V115, P141; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; GILMORE TD, 1995, FRONTIERS MOL BIOL E, P104; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Henn AD, 2001, FASEB J, V15, P1315, DOI 10.1096/fj.00-0543fje; HRDLICKOVA R, 1995, J VIROL, V69, P403; HRDLICKOVA R, 1995, J VIROL, V69, P3369; HRDLICKOVA R, 1994, J VIROL, V68, P308; Hrdlickova R, 2001, MOL CELL BIOL, V21, P6369; KABRUN N, 1991, P NATL ACAD SCI USA, V88, P1783, DOI 10.1073/pnas.88.5.1783; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; Kralova J, 1998, MOL CELL BIOL, V18, P2997, DOI 10.1128/MCB.18.5.2997; Kralova J, 2002, J VIROL, V76, P11960, DOI 10.1128/JVI.76.23.11960-11970.2002; Kralova J, 1996, ONCOGENE, V12, P2595; Lee RM, 1999, GENE DEV, V13, P718, DOI 10.1101/gad.13.6.718; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Liss AS, 2002, J VIROL, V76, P4928, DOI 10.1128/JVI.76.10.4928-4939.2002; Madrid Lee V, 2003, Methods Mol Biol, V223, P523; Mayer BJ, 2001, J CELL SCI, V114, P1253; Mazzocco M, 2002, GENE, V291, P233, DOI 10.1016/S0378-1119(02)00602-9; Mazzocco M, 2001, BIOCHEM BIOPH RES CO, V285, P540, DOI 10.1006/bbrc.2001.5169; Mecham BH, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh071; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; MOORE PA, 1993, MOL CELL BIOL, V13, P1666, DOI 10.1128/MCB.13.3.1666; MOSCOVICI C, 1998, EXPRESSION DIFFERNTI, P435; Nehyba J, 2002, MOL CELL BIOL, V22, P3942, DOI 10.1128/MCB.22.11.3942-3957.2002; Nelson DM, 1998, HUM GENE THER, V9, P2401, DOI 10.1089/hum.1998.9.16-2401; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Petrenko O, 1997, ONCOGENE, V15, P1671, DOI 10.1038/sj.onc.1201334; PETSKO G, 2002, CURRENT PROTOCOLS BI; RAO A, 1990, CANCER RES, V50, P4764; Romieu-Mourez R, 2003, MOL CELL BIOL, V23, P5738, DOI 10.1128/MCB.23.16.5738-5754.2003; Sachdev S, 1998, MOL CELL BIOL, V18, P5445, DOI 10.1128/MCB.18.9.5445; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SARKAR S, 1993, ONCOGENE, V8, P2245; Scartezzini P, 1997, HUM GENET, V99, P387, DOI 10.1007/s004390050377; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHATZLE JD, 1995, J VIROL, V69, P5383, DOI 10.1128/JVI.69.9.5383-5390.1995; SCHWARTZ RC, 1988, VIROLOGY, V165, P182, DOI 10.1016/0042-6822(88)90671-X; Shi XB, 2004, PROSTATE, V60, P257, DOI 10.1002/pros.20039; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; Suh J, 2004, J CELL BIOCHEM, V91, P100, DOI 10.1002/jcb.10729; Suh JH, 2002, PROSTATE, V52, P183, DOI 10.1002/pros.10082; Thalmann GN, 2000, PROSTATE, V44, P91; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; WHITE DW, 1995, ONCOGENE, V10, P857; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; You MJ, 1998, METHODS, V16, P373, DOI 10.1006/meth.1998.0692; Zhang GQ, 1996, ONCOGENE, V12, P1153; ZHANG GQ, 1995, MOL CELL BIOL, V15, P1806; Zhou JR, 2004, INT J CANCER, V110, P800, DOI 10.1002/ijc.20206; Zong WX, 1997, ONCOGENE, V15, P971, DOI 10.1038/sj.onc.1201266	82	32	32	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					756	768		10.1038/sj.onc.1209107	http://dx.doi.org/10.1038/sj.onc.1209107			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16186799				2022-12-25	WOS:000235068800011
J	Mei, J; Webb, S; Zhang, B; Shu, HB				Mei, J; Webb, S; Zhang, B; Shu, HB			The p53-inducible apoptotic protein AMID is not required for normal development and tumor suppression	ONCOGENE			English	Article						AMID; p53; apoptosis; knockout; tumor suppression	PROGRAMMED CELL-DEATH; CYTOCHROME-C; FACTOR AIF; P53; MITOCHONDRIA; PATHWAYS; GENE; LETHALITY; HOMOLOG; GROWTH	AMID is an apoptosis-inducing factor (AIF)-homologous and mitochondria-associated protein that has been implicated in caspase-independent apoptosis. Transcription of human AMID gene is upregulated by p53 and downregulated in tumors in comparison to their matched normal tissues, suggesting the possibility that AMID is involved in the downstream effects of p53. To investigate the physiological functions of AMID, we generated AMID-deficient mice by gene targeting. AMID-deficient mice are viable and fertile, develop normally and lack obvious phenotypic changes compared to wild-type mice up to 1 year old. AMID(-/-) mice up to 1 year old have no spontaneous tumors and show similar fibrosarcoma incidence after MCA inoculation compared to wild-type mice. AMID(-/-) embryonic fibroblasts exhibit normal proliferation but slightly increased resistance to genotoxin-induced growth arrest. These findings suggest that AMID is not required for normal development and p53-mediated tumor suppression.	Wuhan Univ, Coll Life Sci, Wuhan 430072, Peoples R China; Natl Jewish Med & Res Ctr, Denver, CO USA	Wuhan University; National Jewish Health	Shu, HB (corresponding author), Wuhan Univ, Coll Life Sci, Wuhan 430072, Peoples R China.	shuh@whu.edu.cn			NATIONAL CANCER INSTITUTE [R01CA108771] Funding Source: NIH RePORTER; NCI NIH HHS [CA 108771] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amarante-Mendes GP, 1998, CELL DEATH DIFFER, V5, P298, DOI 10.1038/sj.cdd.4400354; Bidere N, 2001, APOPTOSIS, V6, P371, DOI 10.1023/A:1011390103783; Cande C, 2002, BIOCHIMIE, V84, P215, DOI 10.1016/S0300-9084(02)01374-3; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Daugas E, 2000, FEBS LETT, V476, P118, DOI 10.1016/S0014-5793(00)01731-2; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Ohiro Y, 2002, FEBS LETT, V524, P163, DOI 10.1016/S0014-5793(02)03049-1; Prives C, 1999, J PATHOL, V187, P112; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang XD, 2001, GENE DEV, V15, P2922; Wu M, 2004, ONCOGENE, V23, P6815, DOI 10.1038/sj.onc.1207909; Wu M, 2002, J BIOL CHEM, V277, P25617, DOI 10.1074/jbc.M202285200; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zhang PM, 2002, NAT GENET, V30, P31, DOI 10.1038/ng797	28	19	21	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					849	856		10.1038/sj.onc.1209121	http://dx.doi.org/10.1038/sj.onc.1209121			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16186796				2022-12-25	WOS:000235212700004
J	Heeley, DH; Belknap, B; White, HD				Heeley, DH; Belknap, B; White, HD			Maximal activation of skeletal muscle thin filaments requires both rigor myosin S1 and calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTOMYOSIN SUBFRAGMENT-1 ATPASE; TROPONIN-TROPOMYOSIN; FLUORESCENT-PROBE; BINDING; ACTIN; KINETICS; MODEL; PHOSPHATE; NUCLEOTIDES; HYDROLYSIS	The regulation by calcium and rigor-bound myosin-S1 of the rate of acceleration of 2'-deoxy-3'-O-(N-methylanthraniloyl)ADP (mdADP) release from myosin-mdADP-P-i by skeletal muscle thin filaments (reconstituted from actin-tropomyosin-troponin) was measured using double mixing stopped-flow fluorescence with the nucleotide substrate 2'-deoxy-3'-O-(N-methylanthraniloyl). The predominant mechanism of regulation is the acceleration of product dissociation by a factor of similar to 200 by thin filaments in the fully activated conformation (bound calcium and rigor S1) relative to the inhibited conformation (no bound calcium or rigor S1). In contrast, only 2-3-fold regulation is due to a change in actin affinity such as would be expected by "steric blocking" of the myosin binding site of the thin filament by tropomyosin. The binding of one ligand (either calcium or rigor-S1) produces partial activation of the rate of product dissociation, but the binding of both is required to maximally accelerate product dissociation to a rate similar to that obtained with F-actin in the absence of regulatory proteins. The data support an allosteric regulation model in which the binding of either calcium or rigor S1 alone to the thin filament shifts the equilibrium in favor of the active conformation, but full activation requires binding of both ligands.	Mem Univ Newfoundland, Dept Biochem, St John, NF A1B 3X9, Canada; Eastern Virginia Med Sch, Dept Physiol Sci, Norfolk, VA 23507 USA	Memorial University Newfoundland; Eastern Virginia Medical School	White, HD (corresponding author), Mem Univ Newfoundland, Dept Biochem, St John, NF A1B 3X9, Canada.	Howard_White@hotmail.com			NHLBI NIH HHS [HL41776] Funding Source: Medline; NIBIB NIH HHS [EB00209] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041776] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000209] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		BREMEL RD, 1972, NATURE-NEW BIOL, V238, P97, DOI 10.1038/newbio238097a0; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; CHALOVICH JM, 1982, J BIOL CHEM, V257, P2432; Chen YD, 2001, BIOPHYS J, V80, P2338, DOI 10.1016/S0006-3495(01)76204-2; CREMO CR, 1990, BIOCHEMISTRY-US, V29, P3309, DOI 10.1021/bi00465a023; Ferguson RE, 2003, MOL CELL, V11, P865, DOI 10.1016/S1097-2765(03)00096-0; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GEEVES MA, 1994, BIOPHYS J, V67, P273, DOI 10.1016/S0006-3495(94)80478-3; Heeley DH, 2002, P NATL ACAD SCI USA, V99, P16731, DOI 10.1073/pnas.252236399; HILL TL, 1980, P NATL ACAD SCI-BIOL, V77, P3186, DOI 10.1073/pnas.77.6.3186; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Huxley H. E., 1972, COLD SPRING HARB SYM, V37, P361; Kovacs M, 2002, J BIOL CHEM, V277, P28459, DOI 10.1074/jbc.M202180200; LIONNE C, 1995, BIOPHYS J, V68, pS217; Maytum R, 1999, BIOCHEMISTRY-US, V38, P1102, DOI 10.1021/bi981603e; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; Pirani A, 2005, J MOL BIOL, V346, P761, DOI 10.1016/j.jmb.2004.12.013; Regnier M, 1998, BIOPHYS J, V74, P3044, DOI 10.1016/S0006-3495(98)78012-9; ROSENFELD SS, 1985, J BIOL CHEM, V260, P252; ROSENFELD SS, 1987, J BIOL CHEM, V262, P9984; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; Steffen W, 2004, P NATL ACAD SCI USA, V101, P12904, DOI 10.1073/pnas.0400227101; Takeda S, 2003, NATURE, V424, P35, DOI 10.1038/nature01780; Vinogradova MV, 2005, P NATL ACAD SCI USA, V102, P5038, DOI 10.1073/pnas.0408882102; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WHITE HD, 1985, J BIOL CHEM, V260, P982; White HD, 1997, BIOCHEMISTRY-US, V36, P11828, DOI 10.1021/bi970540h; WHITE HD, 1982, METHOD ENZYMOL, V85, P698; WILLIAMS DL, 1988, BIOCHEMISTRY-US, V27, P6987, DOI 10.1021/bi00418a048; WOODWARD SKA, 1991, BIOCHEMISTRY-US, V30, P422, DOI 10.1021/bi00216a017; Xu S, 2003, BIOCHEMISTRY-US, V42, P390, DOI 10.1021/bi026085t; [No title captured]	32	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					668	676		10.1074/jbc.M505549200	http://dx.doi.org/10.1074/jbc.M505549200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16186114	hybrid			2022-12-25	WOS:000234307200079
J	Royal, DC; Bianchi, L; Royal, MA; Lizzio, M; Mukherjee, G; Nunez, YO; Driscoll, M				Royal, DC; Bianchi, L; Royal, MA; Lizzio, M; Mukherjee, G; Nunez, YO; Driscoll, M			Temperature-sensitive mutant of the Caenorhabditis elegans neurotoxic MEC-4(d) DEG/ENaC channel identifies a site required for trafficking or surface maintenance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL NA+ CHANNEL; TOUCH RECEPTOR NEURONS; LUNG LIQUID CLEARANCE; C-ELEGANS; SODIUM-CHANNEL; ION CHANNELS; BETA-SUBUNIT; CELL-DEATH; MECHANOSENSORY NEURONS; LIDDLES-SYNDROME	DEG/ENaC channel subunits are two transmembrane domain proteins that assemble into heteromeric complexes to perform diverse biological functions that include sensory perception, electrolyte balance, and synaptic plasticity. Hyperactivation of neuronally expressed DEG/ENaCs that conduct both Na+ and Ca2+, however, can potently induce necrotic neuronal death in vivo. For example, Caenorhabditis elegans DEG/ENaC MEC-4 comprises the core subunit of a touch-transducing ion channel critical for mechanosensation that when hyperactivated by a mec-4(d) mutation induces necrosis of the sensory neurons in which it is expressed. Thus, studies of the MEC-4 channel have provided insight into both normal channel biology and neurotoxicity mechanisms. Here we report on intragenic mec-4 mutations identified in a screen for suppressors of mec-4(d)-induced necrosis, with a focus on detailed characterization of allele bz2 that has the distinctive phenotype of inducing dramatic neuronal swelling without being fully penetrant for toxicity. The bz2 mutation encodes substitution A745T, which is situated in the intracellular C-terminal domain of MEC-4. We show that this substitution renders both MEC-4 and MEC-4(d) activity strongly temperature sensitive. In addition, we show that both in Xenopus oocytes and in vivo, substitution A745T disrupts channel trafficking or maintenance of the MEC-4 subunit at the cell surface. This is the first demonstration of a C-terminal domain that affects trafficking of a neuronally expressed DEG/ENaC. Moreover, this study reveals that neuronal swelling occurs prior to commitment to necrotic death and defines a powerful new tool for inducible necrosis initiation.	Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	Driscoll, M (corresponding author), Nelson Biol Labs, A232,604 Allison Rd, Piscataway, NJ 08854 USA.	driscoll@biology.rutgers.edu	Lopez, Yury O. Nunez/B-9382-2019	Lopez, Yury O. Nunez/0000-0003-0382-9124; Lizzio Jr, Michael A/0000-0002-1842-9206	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS049511, R01NS037955, R01NS034435] Funding Source: NIH RePORTER; NINDS NIH HHS [NS034435, NS049511, NS37955] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ainsley JA, 2003, CURR BIOL, V13, P1557, DOI 10.1016/S0960-9822(03)00596-7; Askwith CC, 2001, P NATL ACAD SCI USA, V98, P6459, DOI 10.1073/pnas.111155398; Barker PM, 1998, J CLIN INVEST, V102, P1634, DOI 10.1172/JCI3971; Bianchi L, 2004, NAT NEUROSCI, V7, P1337, DOI 10.1038/nn1347; Bianchi L, 2000, AM J PHYSIOL-HEART C, V279, pH3003, DOI 10.1152/ajpheart.2000.279.6.H3003; BIANCHI L, 2004, TRANSDUCTION CHANNEL, P1; BRENNER S, 1974, GENETICS, V77, P71; CHALFIE M, 1985, J NEUROSCI, V5, P956; CHALFIE M, 1981, DEV BIOL, V82, P358, DOI 10.1016/0012-1606(81)90459-0; CHALFIE M, 1989, SCIENCE, V243, P1027, DOI 10.1126/science.2646709; Chelur DS, 2002, NATURE, V420, P669, DOI 10.1038/nature01205; Chen CC, 2002, P NATL ACAD SCI USA, V99, P8992, DOI 10.1073/pnas.122245999; Chung SB, 2000, NAT CELL BIOL, V2, P931, DOI 10.1038/35046585; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; DRISCOLL M, 1995, METHOD CELL BIOL, V46, P323; Drummond HA, 2000, BRAIN RES, V884, P1, DOI 10.1016/S0006-8993(00)02831-6; Emtage L, 2004, NEURON, V44, P795, DOI 10.1016/j.neuron.2004.11.010; Ficker E, 2000, AM J PHYSIOL-HEART C, V279, pH1748, DOI 10.1152/ajpheart.2000.279.4.H1748; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Goodman MB, 2002, NATURE, V415, P1039, DOI 10.1038/4151039a; Goulet CC, 1998, J BIOL CHEM, V273, P30012, DOI 10.1074/jbc.273.45.30012; Hall DH, 1997, J NEUROSCI, V17, P1033; HERMAN RK, 1987, GENETICS, V116, P377; Hong K, 2000, J NEUROSCI, V20, P2575; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; HUANG MX, 1995, NATURE, V378, P292, DOI 10.1038/378292a0; Hummler E, 1996, NAT GENET, V12, P325, DOI 10.1038/ng0396-325; Kellenberger S, 2003, MOL PHARMACOL, V64, P848, DOI 10.1124/mol.64.4.848; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kellenberger S, 2001, J GEN PHYSIOL, V118, P679, DOI 10.1085/jgp.118.6.679; Kellenberger S, 1999, P NATL ACAD SCI USA, V96, P4170, DOI 10.1073/pnas.96.7.4170; Kellenberger S, 1999, J GEN PHYSIOL, V114, P13, DOI 10.1085/jgp.114.1.13; Kretz O, 1999, J HISTOCHEM CYTOCHEM, V47, P51, DOI 10.1177/002215549904700106; Krishtal O, 2003, TRENDS NEUROSCI, V26, P477, DOI 10.1016/S0166-2236(03)00210-8; Kuruma A, 1999, AM J PHYSIOL-CELL PH, V276, pC161, DOI 10.1152/ajpcell.1999.276.1.C161; Lai CC, 1996, J CELL BIOL, V133, P1071, DOI 10.1083/jcb.133.5.1071; Lin HP, 2005, P NATL ACAD SCI USA, V102, P12831, DOI 10.1073/pnas.0506420102; Liu L, 2003, NEURON, V39, P133, DOI 10.1016/S0896-6273(03)00394-5; Liu L, 2003, P NATL ACAD SCI USA, V100, P2128, DOI 10.1073/pnas.252785099; McDonald FJ, 1999, P NATL ACAD SCI USA, V96, P1727, DOI 10.1073/pnas.96.4.1727; Mello C, 1995, METHOD CELL BIOL, V48, P451; MITANI S, 1993, DEVELOPMENT, V119, P773; O'Hagan R, 2005, NAT NEUROSCI, V8, P43, DOI 10.1038/nn1362; Peng BG, 2004, J NEUROSCI, V24, P10167, DOI 10.1523/JNEUROSCI.3196-04.2004; Price MP, 2000, NATURE, V407, P1007, DOI 10.1038/35039512; Price MP, 2001, NEURON, V32, P1071, DOI 10.1016/S0896-6273(01)00547-5; ROSENBLUTH RE, 1985, GENETICS, V109, P493; Schild L, 1997, J GEN PHYSIOL, V109, P15, DOI 10.1085/jgp.109.1.15; Shim J, 2004, MOL BIOL CELL, V15, P4818, DOI 10.1091/mbc.E04-02-0108; SHREFFLER W, 1995, GENETICS, V139, P1261; Sluka KA, 2003, PAIN, V106, P229, DOI 10.1016/S0304-3959(03)00269-0; Snyder PM, 2002, ENDOCR REV, V23, P258, DOI 10.1210/er.23.2.258; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Suzuki H, 2003, NEURON, V39, P1005, DOI 10.1016/j.neuron.2003.08.015; Tavernarakis N, 1997, NEURON, V18, P107, DOI 10.1016/S0896-6273(01)80050-7; Wemmie JA, 2002, NEURON, V34, P463, DOI 10.1016/S0896-6273(02)00661-X; Wemmie JA, 2003, J NEUROSCI, V23, P5496; Xiong ZG, 2004, CELL, V118, P687, DOI 10.1016/j.cell.2004.08.026; Xu KL, 2001, NEURON, V31, P957, DOI 10.1016/S0896-6273(01)00432-9; Zhang SF, 2004, CURR BIOL, V14, P1888, DOI 10.1016/j.cub.2004.10.030	61	17	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					41976	41986		10.1074/jbc.M510732200	http://dx.doi.org/10.1074/jbc.M510732200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16239217	hybrid			2022-12-25	WOS:000233992700023
J	Santos, A; Alvarez, MD; San Mauro, M; Abrusci, C; Marquina, D				Santos, A; Alvarez, MD; San Mauro, M; Abrusci, C; Marquina, D			The transcriptional response of Saccharomyces cerevisiae to Pichia membranifaciens killer toxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; ACTIVATED PROTEIN-KINASE; OSMOTIC-STRESS RESPONSE; GLYCEROL HOG PATHWAY; GENE-EXPRESSION; YEAST-CELLS; ENVIRONMENTAL-CHANGES; HIGH SALINITY; OLIVE BRINES; CTT1 GENE	The transcriptional response of Saccharomyces cerevisiae to Pichia membranifaciens killer toxin (PMKT) was investigated. We explored the global gene expression responses of the yeast S. cerevisiae to PMKT using DNA microarrays, real time quantitative PCR, and Northern blot. We identified 146 genes whose expression was significantly altered in response to PMKT in a non-random functional distribution. The majority of induced genes, most of them related to the high osmolarity glycerol (HOG) pathway, were core environmental stress response genes, showing that the coordinated transcriptional response to PMKT is related to changes in ionic homeostasis. Hog1p was observed to be phosphorylated in response to PMKT implicating the HOG signaling pathway. Individually deleted mutants of both up- (99) and down-regulated genes (47) were studied for altered sensitivity; it was observed that the deletion of up- regulated genes generated hypersensitivity (82%) to PMKT. Deletion of down-regulated genes generated wild-type (36%), resistant (47%), and hypersensitive (17%) phenotypes. This is the first study that shows the existence of a transcriptional response to the poisoning effects of a killer toxin.	Univ Complutense Madrid, Dept Microbiol, Fac Biol, E-28040 Madrid, Spain; Univ Complutense Madrid, Dept Biochem & Mol Biol, Fac Med, E-28040 Madrid, Spain	Complutense University of Madrid; Complutense University of Madrid	Marquina, D (corresponding author), Univ Complutense Madrid, Dept Microbiol, Fac Biol, E-28040 Madrid, Spain.	dommarq@bio.ucm.es	Abrusci, Concepcion/AAI-8645-2020; DE LA SEN, ANTONIO SANTOS/L-3118-2014; MARQUINA, DOMINGO/M-2920-2014	Abrusci, Concepcion/0000-0002-4928-5014; DE LA SEN, ANTONIO SANTOS/0000-0002-1253-585X; MARQUINA, DOMINGO/0000-0002-2528-0040; Alvarez, Mar/0000-0002-6086-6557				Ahmed A, 1999, CELL, V99, P283, DOI 10.1016/S0092-8674(00)81659-1; ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; Alexandre H, 2001, FEBS LETT, V498, P98, DOI 10.1016/S0014-5793(01)02503-0; Ansell R, 1997, EMBO J, V16, P2179, DOI 10.1093/emboj/16.9.2179; BELAZZI T, 1991, EMBO J, V10, P585, DOI 10.1002/j.1460-2075.1991.tb07985.x; BEVAN EA, 1973, NATURE, V245, P81, DOI 10.1038/245081b0; BLOMBERG A, 1995, J BACTERIOL, V177, P3563, DOI 10.1128/jb.177.12.3563-3572.1995; BLOMBERG A, 1992, ADV MICROB PHYSIOL, V33, P145, DOI 10.1016/S0065-2911(08)60217-9; Breinig F, 2002, CELL, V108, P395, DOI 10.1016/S0092-8674(02)00634-7; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; Chen WB, 2000, APPL ENVIRON MICROB, V66, P5348, DOI 10.1128/AEM.66.12.5348-5352.2000; DAVENPORT KR, 1995, J BIOL CHEM, V270, P30157; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dihazi H, 2004, J BIOL CHEM, V279, P23961, DOI 10.1074/jbc.M312974200; Eriksson P, 2000, J BIOL CHEM, V275, P29368, DOI 10.1074/jbc.M001663200; ERIKSSON P, 1995, MOL MICROBIOL, V17, P95, DOI 10.1111/j.1365-2958.1995.mmi_17010095.x; ESTRUCH F, 1993, MOL CELL BIOL, V13, P3872, DOI 10.1128/MCB.13.7.3872; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; GABER RF, 1988, MOL CELL BIOL, V8, P2848, DOI 10.1128/MCB.8.7.2848; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; HARO R, 1991, FEBS LETT, V291, P189, DOI 10.1016/0014-5793(91)81280-L; Hasegawa PM, 2000, ANNU REV PLANT PHYS, V51, P463, DOI 10.1146/annurev.arplant.51.1.463; Heath VL, 2004, EUKARYOT CELL, V3, P695, DOI 10.1128/EC.3.3.695-704.2004; Hohmann S, 2002, MICROBIOL MOL BIOL R, V66, P300, DOI 10.1128/MMBR.66.2.300-372.2002; Inoue Y, 1998, J BIOL CHEM, V273, P2977, DOI 10.1074/jbc.273.5.2977; Jelinsky SA, 1999, P NATL ACAD SCI USA, V96, P1486, DOI 10.1073/pnas.96.4.1486; KAGAN BL, 1983, NATURE, V302, P709, DOI 10.1038/302709a0; Kapteyn JC, 2001, MOL MICROBIOL, V39, P469, DOI 10.1046/j.1365-2958.2001.02242.x; KURZWEILOVA H, 1994, ARCH MICROBIOL, V162, P211, DOI 10.1007/s002030050127; Llorente P, 1997, APPL ENVIRON MICROB, V63, P1165, DOI 10.1128/AEM.63.3.1165-1167.1997; Lucau-Danila A, 2005, MOL CELL BIOL, V25, P1860, DOI 10.1128/MCB.25.5.1860-1868.2005; Lyne R, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-27; Madhani HD, 1998, TRENDS GENET, V14, P151, DOI 10.1016/S0168-9525(98)01425-5; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; Makower M, 1963, P 11 INT C GEN, VI, P202; MARQUINA D, 1992, LETT APPL MICROBIOL, V14, P279, DOI 10.1111/j.1472-765X.1992.tb00705.x; MARTINAC B, 1990, P NATL ACAD SCI USA, V87, P6228, DOI 10.1073/pnas.87.16.6228; Matsumoto TK, 2002, J BIOL CHEM, V277, P33075, DOI 10.1074/jbc.M205037200; Mendoza I, 1996, J BIOL CHEM, V271, P23061, DOI 10.1074/jbc.271.38.23061; Murguia JR, 1996, J BIOL CHEM, V271, P29029, DOI 10.1074/jbc.271.46.29029; Nelissen B, 1997, FEMS MICROBIOL REV, V21, P113, DOI 10.1111/j.1574-6976.1997.tb00347.x; Nevitt T, 2004, BIOCHEM J, V379, P367, DOI 10.1042/BJ20031127; Nwaka S, 1998, PROG NUCLEIC ACID RE, V58, P197; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; Page N, 2003, GENETICS, V163, P875; Pahlman AK, 2001, J BIOL CHEM, V276, P3555, DOI 10.1074/jbc.M007164200; Pardo JM, 1998, P NATL ACAD SCI USA, V95, P9681, DOI 10.1073/pnas.95.16.9681; REED RH, 1987, APPL ENVIRON MICROB, V53, P2119, DOI 10.1128/AEM.53.9.2119-2123.1987; Rep M, 2000, J BIOL CHEM, V275, P8290, DOI 10.1074/jbc.275.12.8290; Rep M, 1999, MOL CELL BIOL, V19, P5474; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; Santos A, 2004, MICROBIOL-SGM, V150, P2527, DOI 10.1099/mic.0.27071-0; Santos A, 2004, YEAST, V21, P151, DOI 10.1002/yea.1069; Santos A, 2002, LETT APPL MICROBIOL, V34, P95, DOI 10.1046/j.1472-765x.2002.01053.x; Santos A, 2000, APPL ENVIRON MICROB, V66, P1809, DOI 10.1128/AEM.66.5.1809-1813.2000; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; SETH A, 1992, J BIOL CHEM, V267, P24796; Siderius M, 1997, MICROBIOL-SGM, V143, P3241, DOI 10.1099/00221287-143-10-3241; Siderius M, 2000, MOL MICROBIOL, V36, P1381, DOI 10.1046/j.1365-2958.2000.01955.x; Siniossoglou S, 2000, J BIOL CHEM, V275, P19352, DOI 10.1074/jbc.M001314200; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Tamas MJ, 2000, FEBS LETT, V472, P159, DOI 10.1016/S0014-5793(00)01445-9; Yale J, 2001, J BIOL CHEM, V276, P15996, DOI 10.1074/jbc.M008209200; Zahringer H, 1997, FEBS LETT, V412, P615, DOI 10.1016/S0014-5793(97)00868-5; Zhang L, 2002, J ANTIMICROB CHEMOTH, V49, P905, DOI 10.1093/jac/dkf001	68	18	21	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					41881	41892		10.1074/jbc.M507014200	http://dx.doi.org/10.1074/jbc.M507014200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16204237	hybrid			2022-12-25	WOS:000233992700014
J	Buchholz, DR; Paul, BD; Shi, YB				Buchholz, DR; Paul, BD; Shi, YB			Gene-specific changes in promoter occupancy by thyroid hormone receptor during frog metamorphosis - Implications for developmental gene regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COREPRESSOR COMPLEX; XENOPUS-LAEVIS; TRANSCRIPTIONAL REGULATION; AMPHIBIAN METAMORPHOSIS; RETINOIC ACID; IN-VIVO; EXPRESSION; RECRUITMENT; BETA; REPRESSION	In all vertebrates, thyroid hormones (TH) affect postembryonic development. The role of the TH receptor (TR) in mediating the TH signal is complex as evidenced by divergent phenotypes in mice lacking TH compared with TR knock-out mice. We have proposed a dual function model for TR during development based on studies of frog metamorphosis. Here we examined an important assumption of this dual function model by using the chromatin immunoprecipitation assay, namely constitutive TR binding to promoters in vivo. We examined two target genes with TH-response elements (TRE) in their promoters, TR beta itself and TH/bZIP (TH-responsive basic leucine zipper transcription factor). By using an antibody that recognizes both TR alpha and TR beta, we found that TR binding to the TR beta promoter is indeed constitutive. Most surprisingly, TR binding to the TH/bZIP promoter increases dramatically after TH treatment of premetamorphic tadpoles and during metamorphosis. By using an antibody specific to TR beta, TR beta binding increases at both promoters in response to TH. In vitro biochemical studies showed that TRs bind TH/bZIP TRE with 4-fold lower affinity than to TR beta TRE. Our data show that only high affinity TR beta TRE is occupied by limiting levels of TR during premetamorphosis and that lower affinity TH/bZIP TRE becomes occupied only when overall the TR expression is higher during metamorphosis. These data provide the first in vivo evidence to suggest that one mechanism for tissue- and gene-specific regulation of TR target gene expression is through tissue and developmental stage-dependent regulation of TR levels, likely a critical mechanism for coordinating development in different organs during postembryonic development.	NICHD, Sect Mol Morphogenesis, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Shi, YB (corresponding author), NICHD, Sect Mol Morphogenesis, Lab Gene Regulat & Dev, NIH, Bldg 18 T,Rm 106, Bethesda, MD 20892 USA.	Shi@helix.nih.gov		Shi, Yun-Bo/0000-0002-6330-0639	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001901] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001901] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Brown DD, 1997, P NATL ACAD SCI USA, V94, P13011, DOI 10.1073/pnas.94.24.13011; Buchholz DR, 2004, GENE EXPR PATTERNS, V4, P321, DOI 10.1016/j.modgep.2003.10.005; Buchholz DR, 2003, MOL CELL BIOL, V23, P6750, DOI 10.1128/MCB.23.19.6750-6758.2003; Buchholz DR, 2004, MOL CELL BIOL, V24, P9026, DOI 10.1128/MCB.24.20.9026-9037.2004; BUCHHOLZ DR, 2006, IN PRESS GEN COMP EN; DODD MHI, 1976, PHYSIOLOGY AMPHIBIA, V3, P467; DUSSAULT JH, 1987, ANNU REV PHYSIOL, V49, P321, DOI 10.1146/annurev.ph.49.030187.001541; ELICEIRI BP, 1994, J BIOL CHEM, V269, P24459; Faber J., 1994, NORMAL TABLE XENOPUS, P2; Flamant F, 2003, TRENDS ENDOCRIN MET, V14, P85, DOI 10.1016/S1043-2760(02)00043-7; FORREST D, 1990, EMBO J, V9, P1519, DOI 10.1002/j.1460-2075.1990.tb08270.x; Furlow JD, 1999, MOL ENDOCRINOL, V13, P2076, DOI 10.1210/me.13.12.2076; Furlow JD, 2002, ENDOCRINOLOGY, V143, P3295, DOI 10.1210/en.2002-220126; Guenther MG, 2000, GENE DEV, V14, P1048; Havis E, 2003, EMBO REP, V4, P883, DOI 10.1038/sj.embor.embor908; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; Ito M, 2001, TRENDS ENDOCRIN MET, V12, P127, DOI 10.1016/S1043-2760(00)00355-6; Jones PL, 2003, CURR TOP MICROBIOL, V274, P237; LELOUP J, 1977, CR ACAD SCI D NAT, V284, P2261; McKenna NJ, 2002, ENDOCRINOLOGY, V143, P2461, DOI 10.1210/endo.143.7.8892; Paul BD, 2005, J BIOL CHEM, V280, P27165, DOI 10.1074/jbc.M503999200; Paul BD, 2005, MOL CELL BIOL, V25, P5712, DOI 10.1128/MCB.25.13.5712-5724.2005; Privalsky ML, 2004, ANNU REV PHYSIOL, V66, P315, DOI 10.1146/annurev.physiol.66.032802.155556; Rachez C, 2001, CURR OPIN CELL BIOL, V13, P274, DOI 10.1016/S0955-0674(00)00209-X; RANJAN M, 1994, J BIOL CHEM, V269, P24699; Sachs LM, 2000, P NATL ACAD SCI USA, V97, P13138, DOI 10.1073/pnas.260141297; Sachs LM, 2002, MOL CELL BIOL, V22, P8527, DOI 10.1128/MCB.22.24.8527-8538.2002; Sachs LM, 2000, COMP BIOCHEM PHYS B, V126, P199, DOI 10.1016/S0305-0491(00)00198-X; Shi Y.-B., 1999, AMPHIBIAN METAMORPHO; Shi YB, 2001, PROG NUCLEIC ACID RE, V65, P53; SHI YB, 1992, J BIOL CHEM, V267, P733; Shi YB, 1996, BIOESSAYS, V18, P391, DOI 10.1002/bies.950180509; SHI YB, 1993, J BIOL CHEM, V268, P20312; Tomita A, 2004, MOL CELL BIOL, V24, P3337, DOI 10.1128/MCB.24.8.3337-3346.2004; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WANG Z, 1993, J BIOL CHEM, V268, P16270; WONG JM, 1995, J BIOL CHEM, V270, P18479, DOI 10.1074/jbc.270.31.18479; YAOITA Y, 1990, GENE DEV, V4, P1917, DOI 10.1101/gad.4.11.1917; Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097; YEN PM, 1992, J BIOL CHEM, V267, P23248; Yoon HG, 2003, EMBO J, V22, P1336, DOI 10.1093/emboj/cdg120; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439; Zhang JS, 2002, MOL CELL, V9, P611, DOI 10.1016/S1097-2765(02)00468-9	43	46	46	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41222	41228		10.1074/jbc.M509593200	http://dx.doi.org/10.1074/jbc.M509593200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16236718	hybrid			2022-12-25	WOS:000233866900015
J	Debreczeni, JE; Farkas, L; Harmat, V; Hetenyi, C; Hajdu, I; Zavodszky, P; Kohama, K; Nyitray, L				Debreczeni, JE; Farkas, L; Harmat, V; Hetenyi, C; Hajdu, I; Zavodszky, P; Kohama, K; Nyitray, L			Structural evidence for non-canonical binding of Ca2+ to a canonical EF-hand of a conventional myosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCALLOP MYOSIN; 3-DIMENSIONAL STRUCTURE; CONFORMATIONAL STATES; CALMODULIN-BINDING; CALCIUM REGULATION; REGULATORY DOMAIN; CRYSTAL-STRUCTURE; HEAVY-MEROMYOSIN; ATPASE ACTIVITY; LIGHT-CHAIN	We have previously identified a single inhibitory Ca2+-binding site in the first EF-hand of the essential light chain of Physarum conventional myosin. As a general rule, conformation of the EF-hand-containing domains in the calmodulin family is "closed" in the absence and "open" in the presence of bound cations; a notable exception is the unusual Ca2+-bound closed domain in the essential light chain of the Ca2+-activated scallop muscle myosin. Here we have reported the 1.8 angstrom resolution structure of the regulatory domain (RD) of Physarum myosin II in which Ca2+ is bound to a canonical EF- hand that is also in a closed state. The 12th position of the EF- hand loop, which normally provides a bidentate ligand for Ca2+ in the open state, is too far in the structure to participate in coordination of the ion. The structure includes a second Ca2+ that only mediates crystal contacts. To reveal the mechanism behind the regulatory effect of Ca2+, we compared conformational flexibilities of the liganded and unliganded RD. Our working hypothesis, i.e. the modulatory effect of Ca2+ on conformational flexibility of RD, is in line with the observed suppression of hydrogen-deuterium exchange rate in the Ca2+-bound form, as well as with results of molecular dynamics calculations. Based on this evidence, we concluded that Ca2+-induced change in structural dynamics of RD is a major factor in Ca2+-mediated regulation of Physarum myosin II activity.	Eotvos Lorand Univ, Dept Biochem, H-1117 Budapest, Hungary; Eotvos Lorand Univ, Hungarian Acad Sci, Prot Modelling Grp, H-1117 Budapest, Hungary; Gunma Univ, Dept Pharmacol, Maebashi, Gumma 3718510, Japan; Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, H-1117 Budapest, Hungary	Eotvos Lorand University; Eotvos Lorand University; Hungarian Academy of Sciences; Gunma University; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences	Nyitray, L (corresponding author), Eotvos Lorand Univ, Dept Biochem, Pazmany Peters 1-C, H-1117 Budapest, Hungary.	nyitray@cerberus.elte.hu	Zavodszky, Peter/C-1214-2008; Nyitray, László/AAE-5910-2020; Harmat, Veronika/B-8033-2016; Hetenyi, Csaba/G-5249-2010; Hajdu, Istvan/B-8345-2008	Nyitray, László/0000-0003-4717-5994; Harmat, Veronika/0000-0002-1866-9904; Hetenyi, Csaba/0000-0002-8013-971X; 				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; AHMED FR, 1993, J MOL BIOL, V230, P1216, DOI 10.1006/jmbi.1993.1237; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; Berendsen HJC, 2000, CURR OPIN STRUC BIOL, V10, P165, DOI 10.1016/S0959-440X(00)00061-0; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; Farkas L, 2003, J BIOL CHEM, V278, P27399, DOI 10.1074/jbc.M304220200; FARKAS L, 2001, J MUSCLE RES CELL M, V22, pA591; Gourinath S, 2003, STRUCTURE, V11, P1621, DOI 10.1016/j.str.2003.10.013; Grabarek Z, 2005, J MOL BIOL, V346, P1351, DOI 10.1016/j.jmb.2005.01.004; Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H; Homma K, 2000, J BIOL CHEM, V275, P34766, DOI 10.1074/jbc.M003132200; Homma K, 2001, J BIOL CHEM, V276, P34348, DOI 10.1074/jbc.M104785200; Houdusse A, 2000, P NATL ACAD SCI USA, V97, P11238, DOI 10.1073/pnas.200376897; Houdusse A, 1996, STRUCTURE, V4, P1475, DOI 10.1016/S0969-2126(96)00154-2; Houdusse A, 2000, BIOPHYS J, V78, p272A; Houdusse A, 1996, STRUCTURE, V4, P21, DOI 10.1016/S0969-2126(96)00006-8; Jung HS, 2004, BIOPHYS J, V86, p403A; KOHAMA K, 1986, J BIOCHEM-TOKYO, V99, P1433, DOI 10.1093/oxfordjournals.jbchem.a135613; KOHAMA K, 1991, J BIOCHEM-TOKYO, V110, P508, DOI 10.1093/oxfordjournals.jbchem.a123611; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krementsov DN, 2004, J CELL BIOL, V164, P877, DOI 10.1083/jcb.200310065; Li XD, 2004, BIOCHEM BIOPH RES CO, V315, P538, DOI 10.1016/j.bbrc.2004.01.084; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Malnasi-Csizmadia A, 1999, EUR J BIOCHEM, V261, P452, DOI 10.1046/j.1432-1327.1999.00290.x; Martin SR, 2004, FEBS LETT, V567, P166, DOI 10.1016/j.febslet.2004.04.053; Martin SR, 2002, PROTEIN SCI, V11, P2909, DOI 10.1110/ps.0210402; Mazon H, 2004, PROTEIN SCI, V13, P476, DOI 10.1110/ps.03380604; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nakamura A, 1999, INT REV CYTOL, V191, P53, DOI 10.1016/S0074-7696(08)60157-6; Nelson MR, 1998, PROTEIN SCI, V7, P270; Nyitrai M, 2003, BIOCHEM J, V370, P839, DOI 10.1042/BJ20021519; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SELLERS JR, 1999, MYOSINS, V2, P1323; SHELDRICK GM, 2001, AB INITIO PHASING IN, VF, P333; Shen TY, 2002, ACCOUNTS CHEM RES, V35, P332, DOI 10.1021/ar010025i; Stafford WF, 2001, J MOL BIOL, V307, P137, DOI 10.1006/jmbi.2000.4490; Szent-Gyorgyi AG, 1999, MOL CELL BIOCHEM, V190, P55, DOI 10.1023/A:1006975705724; Terrak M, 2003, EMBO J, V22, P362, DOI 10.1093/emboj/cdg058; Trybus KM, 1999, J BIOL CHEM, V274, P27448, DOI 10.1074/jbc.274.39.27448; TRYBUS KM, 1991, CELL MOTIL CYTOSKEL, V18, P81, DOI 10.1002/cm.970180202; van Gunsteren W, 1996, BIOMOLECULAR SIMULAT; Vetter SW, 2003, EUR J BIOCHEM, V270, P404, DOI 10.1046/j.1432-1033.2003.03414.x; Wang F, 2004, J BIOL CHEM, V279, P2333, DOI 10.1074/jbc.C300488200; Wendt T, 2001, P NATL ACAD SCI USA, V98, P4361, DOI 10.1073/pnas.071051098; Wilson MA, 2000, J MOL BIOL, V301, P1237, DOI 10.1006/jmbi.2000.4029; WOLENSKI JS, 1995, TRENDS CELL BIOL, V5, P310, DOI 10.1016/S0962-8924(00)89053-4; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0; Yap KL, 1999, PROTEINS, V37, P499, DOI 10.1002/(SICI)1097-0134(19991115)37:3<499::AID-PROT17>3.0.CO;2-Y; Yokota E, 1999, PLANT PHYSIOL, V119, P231, DOI 10.1104/pp.119.1.231; Yoshimura M, 2001, J BIOL CHEM, V276, P39600, DOI 10.1074/jbc.M105080200; ZAVODSZKY P, 1975, EUR J BIOCHEM, V56, P67, DOI 10.1111/j.1432-1033.1975.tb02207.x; Zavodszky P, 1998, P NATL ACAD SCI USA, V95, P7406, DOI 10.1073/pnas.95.13.7406; Zhu T, 1998, J BIOL CHEM, V273, P20481, DOI 10.1074/jbc.273.32.20481	63	18	19	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41458	41464		10.1074/jbc.M506315200	http://dx.doi.org/10.1074/jbc.M506315200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16227209	hybrid			2022-12-25	WOS:000233866900043
J	Li, XF; Minden, A				Li, XF; Minden, A			PAK4 functions in tumor necrosis factor (TNF) alpha-induced survival pathways by facilitating TRADD binding to the TNF receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANCHORAGE-INDEPENDENT GROWTH; SERINE/THREONINE KINASE PAK4; PROGRAMMED CELL-DEATH; FACTOR-KAPPA-B; INDUCED APOPTOSIS; ACTIN CYTOSKELETON; INDUCED ACTIVATION; JNK ACTIVATION; PROTECTS CELLS; P38 MAPK	PAK4 is a member of the group B family of p21-activated kinases. Its expression is elevated in many cancer cell lines, and activated PAK4 is highly transforming, suggesting that it plays an important role in tumorigenesis. Although most previous work was carried out with overexpressed PAK4, here we used RNA interference to knock down endogenous PAK4 in cancer cells. By studying PAK4 knockdown HeLa cells, we demonstrated that endogenous PAK4 is required for anchorage-independent growth. Because cell survival is a key part of tumorigenesis and anchorage-independent growth, we studied whether PAK4 has a role in protecting cells from cell death. To address this, we studied the role for PAK4 downstream to the tumor necrosis factor (TNF) alpha receptor. Although overexpressed PAK4 was previously shown to abrogate proapoptotic pathways, here we demonstrate that endogenous PAK4 is required for the full activation of prosurvival pathways induced by TNF alpha. Our results indicate that PAK4 is required for optimal binding of the scaffold protein TRADD to the activated TNF alpha receptor through both kinase-dependent and kinase-independent mechanisms. Consequently, activation of several prosurvival pathways, including the NF kappa B and ERK pathways, is reduced in the absence of PAK4. Interestingly, constitutive activation of the NF kappa B and ERK pathways could compensate for the lack of PAK4, indicating that these pathways function downstream to PAK4. The role for PAK4 in regulating prosurvival pathways is a completely new function for this protein, and the connection between PAK4 and cell survival under stress helps explain its role in tumorigenesis and development.	Columbia Univ, Sherman Fairchild Ctr, Dept Biol Sci MC 2460, New York, NY 10027 USA	Columbia University	Minden, A (corresponding author), Columbia Univ, Sherman Fairchild Ctr, Dept Biol Sci MC 2460, Rm 813, New York, NY 10027 USA.	agm24@columbia.edu			NCI NIH HHS [R01CA076342] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076342] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; BEG AA, 1996, SCIENCE, V274, P784; Bost F, 1999, MOL CELL BIOL, V19, P1938; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Callow MG, 2002, J BIOL CHEM, V277, P550, DOI 10.1074/jbc.M105732200; Chan WH, 1998, J PROTEIN CHEM, V17, P485, DOI 10.1023/A:1022578820147; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Cotteret S, 2003, MOL CELL BIOL, V23, P5526, DOI 10.1128/MCB.23.16.5526-5539.2003; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Eby JJ, 1998, CURR BIOL, V8, P967, DOI 10.1016/S0960-9822(98)00398-4; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; Funakoshi-Tago M, 2003, J BIOL CHEM, V278, P29359, DOI 10.1074/jbc.M213115200; Gnesutta N, 2003, MOL CELL BIOL, V23, P7838, DOI 10.1128/MCB.23.21.7838-7848.2003; Gnesutta N, 2001, J BIOL CHEM, V276, P14414, DOI 10.1074/jbc.M011046200; Grethe S, 2004, EXP CELL RES, V298, P632, DOI 10.1016/j.yexcr.2004.05.007; Ivanov VN, 2003, ONCOGENE, V22, P3152, DOI 10.1038/sj.onc.1206456; Jakobi R, 2001, J BIOL CHEM, V276, P16624, DOI 10.1074/jbc.M007753200; Li Peng, 2004, Cell, VS116, pS57, DOI 10.1016/S0092-8674(04)00031-5; Li XF, 2003, MOL CELL BIOL, V23, P7134, DOI 10.1128/MCB.23.20.7134-7142.2003; Lin AN, 2002, AGING CELL, V1, P112, DOI 10.1046/j.1474-9728.2002.00014.x; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Liu J, 2005, CELL RES, V15, P36, DOI 10.1038/sj.cr.7290262; Liu ZG, 2003, MOL CELL, V12, P795, DOI 10.1016/S1097-2765(03)00399-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; Park JG, 2002, J BIOCHEM MOL BIOL, V35, P267; Porras A, 2004, MOL BIOL CELL, V15, P922, DOI 10.1091/mbc.E03-08-0592; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Qu J, 2003, MOL CELL BIOL, V23, P7122, DOI 10.1128/MCB.23.20.7122-7133.2003; Qu J, 2001, MOL CELL BIOL, V21, P3523, DOI 10.1128/MCB.21.10.3523-3533.2001; Schneider-Brachert W, 2004, IMMUNITY, V21, P415, DOI 10.1016/j.immuni.2004.08.017; Schultz DR, 2003, SEMIN ARTHRITIS RHEU, V32, P345, DOI 10.1053/sarh.2003.50005; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Tang FM, 2002, MOL CELL BIOL, V22, P8571, DOI 10.1128/MCB.22.24.8571-8579.2002; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; Varfolomeev EE, 2004, CELL, V116, P491, DOI 10.1016/S0092-8674(04)00166-7; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yu CF, 2004, MOL CELL, V13, P329, DOI 10.1016/S1097-2765(04)00028-0; Zheng Y, 2003, J EXP MED, V197, P861, DOI 10.1084/jem.20021610	46	22	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41192	41200		10.1074/jbc.M506884200	http://dx.doi.org/10.1074/jbc.M506884200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16227624	hybrid			2022-12-25	WOS:000233866900011
J	Spiegelberg, BD; Hamm, HE				Spiegelberg, BD; Hamm, HE			G beta gamma binds histone deacetylase 5 (HDAC5) and inhibits its transcriptional co-repression activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEIN; MYOCYTE ENHANCER FACTOR-2; MUSCLE DIFFERENTIATION; COUPLED RECEPTORS; REPEAT PROTEINS; NUCLEAR EXPORT; ACETYLATION; ACTIVATION; KINASE; INTERACTS	In a yeast two-hybrid screen designed to identify novel effectors of theG beta gamma subunit of heterotrimeric G proteins, we found thatG beta gamma binds to histone deacetylase 5 (HDAC5), an enzyme involved in a pathway not previously recognized to be directly impacted by G proteins. Formation of the G beta(1)gamma(2)-HDAC5 complex in mammalian cells can be blocked by overexpression of G alpha(0), and this inhibition is relieved by activation of alpha(2A)-adrenergic receptor, suggesting that the interaction occurs in a signal-dependent manner. The C-terminal domain of HDAC5 binds directly to G beta gamma through multiple motifs, and overexpression of this domain mimics the C terminus of G protein-coupled receptor kinase 2, a known G beta gamma scavenger, in its ability to inhibit the G beta gamma/HDAC5 interaction. The C terminus of HDAC4 shares significant similarity with that of HDAC5, and accordingly, HDAC4 is also able to form complexes with G beta(1)gamma(2) in cultured cells, suggesting that the C-terminal domain of class II HDACs is a general G beta gamma binding motif. Activation of aG(i/o)-coupled receptor results in a time-dependent activation of MEF2C, an HDAC5-regulated transcription factor, whereas inhibition of the interaction with a G beta gamma scavenger inhibits MEF2C activity, suggesting a reduced potency of HDAC5-mediated inhibition. Taken together, these data imply that HDAC5 and possibly other class II HDACs can be added to the growing list of G beta gamma effectors.	Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA	Vanderbilt University	Hamm, HE (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, 2200 Pierce Ave,RRB 442, Nashville, TN 37232 USA.	heidi.hamm@vanderbilt.edu	Hamm, Heidi E/G-2374-2014		NATIONAL EYE INSTITUTE [R01EY010291] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH065215] Funding Source: NIH RePORTER; NEI NIH HHS [EY010291] Funding Source: Medline; NIMH NIH HHS [T32 MH65215-02] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Antos CL, 2003, J BIOL CHEM, V278, P28930, DOI 10.1074/jbc.M303113200; Bannister AJ, 2000, CURR BIOL, V10, P467, DOI 10.1016/S0960-9822(00)00445-0; Berger I, 2003, J BIOL CHEM, V278, P17625, DOI 10.1074/jbc.M301646200; Blackmer T, 2001, SCIENCE, V292, P293, DOI 10.1126/science.1058803; Bookout AL, 2003, J BIOL CHEM, V278, P37569, DOI 10.1074/jbc.M306276200; Chen SH, 2004, J MOL CELL CARDIOL, V37, P399, DOI 10.1016/j.yjmcc.2004.04.019; Chen SH, 2004, J BIOL CHEM, V279, P17861, DOI 10.1074/jbc.M313727200; Cheung WL, 2000, CURR OPIN CELL BIOL, V12, P326, DOI 10.1016/S0955-0674(00)00096-X; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Daaka Y, 2002, BBA-MOL CELL BIOL L, V1582, P265, DOI 10.1016/S1388-1981(02)00180-4; DAAKA Y, 2004, SCI STKE, pRE2; Dell EJ, 2002, J BIOL CHEM, V277, P49888, DOI 10.1074/jbc.M202755200; Gong XQ, 2002, J BIOL CHEM, V277, P12310, DOI 10.1074/jbc.M110228200; Gray Richard J, 2002, Cancer Control, V9, P16; Grozinger CM, 2002, CHEM BIOL, V9, P3, DOI 10.1016/S1074-5521(02)00092-3; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Kino T, 2005, J CELL BIOL, V169, P885, DOI 10.1083/jcb.200409150; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Lee HJ, 2001, J BIOL CHEM, V276, P16597, DOI 10.1074/jbc.C000909200; Legube G, 2003, EMBO REP, V4, P944, DOI 10.1038/sj.embor.embor941; Lomonte P, 2004, J VIROL, V78, P6744, DOI 10.1128/JVI.78.13.6744-6757.2004; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; McCahill A, 2002, MOL PHARMACOL, V62, P1261, DOI 10.1124/mol.62.6.1261; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McKinsey TA, 2001, MOL CELL BIOL, V21, P6312, DOI 10.1128/MCB.21.18.6312-6321.2001; McKinsey TA, 2000, P NATL ACAD SCI USA, V97, P14400, DOI 10.1073/pnas.260501497; N'Diaye EN, 2003, J CELL BIOL, V163, P1157, DOI 10.1083/jcb.200307155; Park JG, 1999, EMBO J, V18, P4004, DOI 10.1093/emboj/18.14.4004; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Rahman A, 2002, CIRC RES, V91, P398, DOI 10.1161/01.RES.0000033520.95242.A2; Reusch HP, 2001, J BIOL CHEM, V276, P19540, DOI 10.1074/jbc.M101963200; Schwindinger WF, 2001, ONCOGENE, V20, P1653, DOI 10.1038/sj.onc.1204181; Sheridan AM, 2001, MOL CELL BIOL, V21, P4470, DOI 10.1128/MCB.21.14.4470-4481.2001; Thelen M, 2001, NAT IMMUNOL, V2, P129, DOI 10.1038/84224; Thompson PR, 2004, NAT STRUCT MOL BIOL, V11, P308, DOI 10.1038/nsmb740; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; Wetzker R, 2003, NAT REV MOL CELL BIO, V4, P651, DOI 10.1038/nrm1173; YAMAZAKI A, 1988, METHOD ENZYMOL, V159, P702; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9; Zhang CL, 2002, MOL CELL BIOL, V22, P7302, DOI 10.1128/MCB.22.20.7302-7312.2002	48	47	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41769	41776		10.1074/jbc.M504066200	http://dx.doi.org/10.1074/jbc.M504066200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16221676	hybrid			2022-12-25	WOS:000233866900079
J	Mitsutake, S; Igarashi, Y				Mitsutake, S; Igarashi, Y			Calmodulin is involved in the Ca2+-dependent activation of ceramide kinase as a calcium sensor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; MOLECULAR-CLONING; TYROSINE PHOSPHORYLATION; SPHINGOSINE 1-PHOSPHATE; ALKALINE CERAMIDASE; NEUTRAL CERAMIDASE; EXPRESSION CLONING; PLASMA-MEMBRANE; LIPID KINASE; RAPID METHOD	We recently demonstrated that the activation of ceramide kinase (CERK) and the formation of its product, ceramide 1-phosphate (C1P), are necessary for the degranulation pathway in mast cells and that the kinase activity of this enzyme is completely dependent on the intracellular concentration of Ca2+ (Mitsutake, S., Kim, T.-J., Inagaki, Y., Kato, M., Yamashita, T., and Igarashi, Y. ( 2004) J. Biol. Chem. 279, 17570-17577). Despite the demonstrated importance of Ca2+ as a regulator of CERK activity, there are no apparent binding domains in the enzyme and the regulatory mechanism has not been well understood. In the present study, we found that calmodulin (CaM) is involved in the Ca2+ dependent activation of CERK. The CaM antagonist W-7 decreased both CERK activity and intracellular C1P formation. Additionally, exogenously added CaM enhanced CERK activity even at low concentrations of Ca2+. The CERK protein was co-immunoprecipitated with an anti-CaM antibody, indicating formation of intracellular CaM (.) CERK complexes. An in vitro CaM binding assay also demonstrated Ca2+-dependent binding of CaM to CERK. These results strongly suggest that CaM acts as a Ca2+ sensor for CERK. Furthermore, a CaM binding assay using various mutants of CERK revealed that the binding site of CERK is located within amino acids 422-435. This region appears to include a type 1-8-14B CaM binding motif and is predicted to form an amphipathic helical wheel, which is utilized in CaM recognition. The expression of a deletion mutant of CERK that contained the CaM binding domain but lost CERK activity inhibited the Ca2+-dependent C1P formation. These results suggest that this domain could saturate the CaM and hence block Ca2+- dependent activation of CERK. Finally, we reveal that in mast cell degranulation CERK acts downstream of CaM, similar to CaM-dependent protein kinase II, which had been assumed to be the main target of CaM in mast cells.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biomembrane & Biofunct Chem, Kita Ku, Sapporo, Hokkaido 0600812, Japan	Hokkaido University	Igarashi, Y (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biomembrane & Biofunct Chem, Kita Ku, Kita 12,Nishi 6, Sapporo, Hokkaido 0600812, Japan.	yigarash@pharm.hokudai.ac.jp	Mitsutake, Susumu/A-4082-2012					BAJJALIEH SM, 1989, J BIOL CHEM, V264, P14354; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOUDKER O, 1993, J BIOL CHEM, V268, P22150; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; Funaba M, 2003, CELL BIOL INT, V27, P879, DOI 10.1016/S1065-6995(03)00177-X; Gijsbers S, 1999, FEBS LETT, V453, P269, DOI 10.1016/S0014-5793(99)00735-8; GMEZ MA, 1994, J BIOL CHEM, V269, P8937; HAKOMORI SI, 1993, ADV LIPID RES, V25, P147; HEUMAN RG, 1996, P NATL ACAD SCI USA, V93, P2420; Hinkovska-Galcheva VT, 1998, J BIOL CHEM, V273, P33203, DOI 10.1074/jbc.273.50.33203; Huwiler A, 1998, BIOCHEMISTRY-US, V37, P14556, DOI 10.1021/bi981401i; Ichikawa S, 1996, P NATL ACAD SCI USA, V93, P4638, DOI 10.1073/pnas.93.10.4638; Igarashi Y, 1997, J BIOCHEM-TOKYO, V122, P1080; IMAI Y, 1991, NUCLEIC ACIDS RES, V19, P2785, DOI 10.1093/nar/19.10.2785; Koch J, 1996, J BIOL CHEM, V271, P33110, DOI 10.1074/jbc.271.51.33110; Kohno T, 2003, GENES CELLS, V8, P685, DOI 10.1046/j.1365-2443.2003.00667.x; Kondo T, 2002, CELL DEATH DIFFER, V9, P682, DOI 10.1038/sj.cdd.4401019; Kupperman E, 2000, NATURE, V406, P192, DOI 10.1038/35018092; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mao CG, 2001, J BIOL CHEM, V276, P26577, DOI 10.1074/jbc.M102818200; Mao CG, 2003, J BIOL CHEM, V278, P31184, DOI 10.1074/jbc.M303875200; Min DS, 2000, J NEUROCHEM, V75, P274, DOI 10.1046/j.1471-4159.2000.0750274.x; Mitsutake S, 2004, J BIOL CHEM, V279, P17570, DOI 10.1074/jbc.M312885200; Mitsutake S, 2001, J BIOL CHEM, V276, P26249, DOI 10.1074/jbc.M102233200; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1990, J BIOL CHEM, V265, P3125; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Perry DK, 1998, BBA-MOL CELL BIOL L, V1436, P233, DOI 10.1016/S0005-2760(98)00145-3; Pettus BJ, 2003, J BIOL CHEM, V278, P38206, DOI 10.1074/jbc.M304816200; Pettus BJ, 2004, J BIOL CHEM, V279, P11320, DOI 10.1074/jbc.M309262200; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Rile G, 2003, ACTA HAEMATOL-BASEL, V109, P76, DOI 10.1159/000068491; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Sugiura M, 2002, J BIOL CHEM, V277, P23294, DOI 10.1074/jbc.M201535200; Tani M, 2000, J BIOL CHEM, V275, P11229, DOI 10.1074/jbc.275.15.11229; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Yamaoka S, 2004, J BIOL CHEM, V279, P18688, DOI 10.1074/jbc.M401205200; Yamashita T, 2001, J BIOCHEM-TOKYO, V129, P861, DOI 10.1093/oxfordjournals.jbchem.a002930; Young KW, 2003, CELL CALCIUM, V33, P119, DOI 10.1016/S0143-4160(02)00205-1	41	52	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40436	40441		10.1074/jbc.M501962200	http://dx.doi.org/10.1074/jbc.M501962200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16203736	hybrid			2022-12-25	WOS:000233666600008
J	Yoshida, H; Jono, H; Kai, H; Li, JD				Yoshida, H; Jono, H; Kai, H; Li, JD			The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 and TRAF7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NONTYPABLE HAEMOPHILUS-INFLUENZAE; TOLL-LIKE RECEPTOR-2; MUC5AC MUCIN TRANSCRIPTION; NECROSIS-FACTOR; MAP KINASE; P38 MAPK; ACTIVATION; PATHWAY; ALPHA	Toll-like receptor 2 (TLR2) plays an important role in host defense against bacterial pathogens. Activation of TLR2 signaling not only induces the activation of innate immunity and instructs the development of the acquired immunity but also leads to the detrimental inflammatory responses in inflammatory and infectious diseases. To avoid detrimental inflammatory responses, TLR2 signaling must be tightly regulated. In contrast to the relative known positive regulation of TLR2 signaling, its negative regulation, however, is largely unknown. In addition the distal signaling components that link TLR2 to its downstream signaling pathways have yet to be further defined. In the present study we have provided direct evidence for the negative regulation of TLR2 signaling by the tumor suppressor cylindromatosis ( CYLD). We showed that activation of TLR2 signaling by TLR2 ligands including peptidoglycan ( PGN), MALP-2, and Pam3CSK4 induces activation of IKKs-I kappa B alpha and MKK3/6-p38 pathways not only by TRAF6 but also by TRAF7, a recently identified TRAF family member. The activation of both pathways leads to the transcription of TNF-alpha IL-1 beta, and IL-8 as well as CYLD. CYLD in turn leads to the inhibition of TRAF6 and TRAF7 likely via a deubiquitination-dependent mechanism. The present studies thus unveil a novel autoregulatory feedback mechanism that negatively controls TLR2-IKKs-I kappa B alpha/MKK3/6-p38-NF- kappa B-dependent induction of immune and inflammatory responses via negatively cross-talking with both TRAF6 and TRAF7. These findings provide novel insights into autoregulation and negative regulation of TLR signaling.	Univ So Calif, Gonda Dept Cell & Mol Biol, House Ear Inst, Los Angeles, CA 90057 USA; Univ So Calif, Dept Otolaryngol, Los Angeles, CA USA; Kumamoto Univ, Dept Mol Med, Kumamoto 8620973, Japan	House Research Institute; University of Southern California; University of Southern California; Kumamoto University	Li, JD (corresponding author), Univ So Calif, Gonda Dept Cell & Mol Biol, House Ear Inst, 2100 W 3rd St, Los Angeles, CA 90057 USA.	jdli@hei.org		Li, Jian-Dong/0000-0002-5593-050X	NHLBI NIH HHS [HL070293] Funding Source: Medline; NIDCD NIH HHS [DC005843, DC004562] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070293] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC004562, R01DC005843] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Adams J L, 1999, Curr Opin Drug Discov Devel, V2, P96; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Ben-Neriah Y, 2002, NAT IMMUNOL, V3, P20, DOI 10.1038/ni0102-20; Beutler B, 2004, NATURE, V430, P257, DOI 10.1038/nature02761; Bouwmeester T, 2004, NAT CELL BIOL, V6, P97, DOI 10.1038/ncb1086; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Chen R, 2004, BIOCHEM BIOPH RES CO, V324, P1087, DOI 10.1016/j.bbrc.2004.09.157; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; DUNNE A, 2003, SCI STKE, pRE3, DOI DOI 10.1126/STKE.2003.171.RE3; Dziarski R, 2005, INFECT IMMUN, V73, P5212, DOI 10.1128/IAI.73.8.5212-5216.2005; Habelhah H, 2004, EMBO J, V23, P322, DOI 10.1038/sj.emboj.7600044; Imasato A, 2002, J BIOL CHEM, V277, P47444, DOI 10.1074/jbc.M208140200; Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733; Jono H, 2003, J BIOL CHEM, V278, P27811, DOI 10.1074/jbc.M301773200; Jono H, 2002, J BIOL CHEM, V277, P45547, DOI 10.1074/jbc.M206883200; Jono H, 2004, J BIOL CHEM, V279, P36171, DOI 10.1074/jbc.M406638200; Kopp E, 2003, CURR OPIN IMMUNOL, V15, P396, DOI 10.1016/S0952-7915(03)00080-3; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Latz E, 2002, J BIOL CHEM, V277, P47834, DOI 10.1074/jbc.M207873200; Latz E, 2004, J IMMUNOL, V172, P2431, DOI 10.4049/jimmunol.172.4.2431; Li JD, 2003, J PHARMACOL SCI, V91, P1, DOI 10.1254/jphs.91.1; Liew FY, 2005, NAT REV IMMUNOL, V5, P446, DOI 10.1038/nri1630; Mikami F, 2005, J BIOL CHEM, V280, P36185, DOI 10.1074/jbc.M503941200; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Neish AS, 2000, SCIENCE, V289, P1560, DOI 10.1126/science.289.5484.1560; Regamey A, 2003, J EXP MED, V198, P1959, DOI 10.1084/jem.20031187; Reiley W, 2004, J BIOL CHEM, V279, P55161, DOI 10.1074/jbc.M411049200; Shuto T, 2002, J BIOL CHEM, V277, P17263, DOI 10.1074/jbc.M112190200; Shuto T, 2001, P NATL ACAD SCI USA, V98, P8774, DOI 10.1073/pnas.151236098; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Watanabe T, 2004, P NATL ACAD SCI USA, V101, P3563, DOI 10.1073/pnas.0400557101; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wetzler LM, 2003, VACCINE, V21, pS55, DOI 10.1016/S0264-410X(03)00201-9; Xu LG, 2004, J BIOL CHEM, V279, P17278, DOI 10.1074/jbc.C400063200	35	153	162	2	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					41111	41121		10.1074/jbc.M509526200	http://dx.doi.org/10.1074/jbc.M509526200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16230348	hybrid			2022-12-25	WOS:000233666600085
J	Imai, S; Kai, M; Yasuda, S; Kanoh, H; Sakane, F				Imai, S; Kai, M; Yasuda, S; Kanoh, H; Sakane, F			Identification and characterization of a novel human type II diacylglycerol kinase, DGK kappa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; PHORBOL ESTER RECEPTORS; MOLECULAR-CLONING; PHOSPHATIDIC-ACID; TYROSINE PHOSPHORYLATION; SPLICE VARIANTS; ZINC-FINGER; C ISOTYPES; IN-VITRO; PROTEIN	Diacylglycerol kinase (DGK) plays an important role in signal transduction through modulating the balance between two signaling lipids, diacylglycerol and phosphatidic acid. Here we identified a tenth member of the DGK family designated DGK kappa. The kappa-isozyme (1271 amino acids, calculated molecular mass, 142 kDa) contains a pleckstrin homology domain, two cysteine-rich zinc finger-like structures, and a separated catalytic region as have been found commonly for the type II isozymes previously cloned (DGK delta and DGK eta). The new DGK isozyme has additionally 33 tandem repeats of Glu-Pro-Ala-Pro at the N terminus. Reverse transcriptase-PCR showed that the DGK kappa mRNA is most abundant in the testis, and to a lesser extent in the placenta. DGK kappa, when expressed in HEK293 cells, was persistently localized at the plasma membrane even in the absence of cell stimuli. Deletion analysis revealed that the short C-terminal sequence (amino acid residues 1199-1268) is necessary and sufficient for the plasma membrane localization. Interestingly, DGK kappa, but not other type II DGKs, was specifically tyrosine-phosphorylated at Tyr(78) through the Src family kinase pathway in H2O2-treated cells. Moreover, H2O2 selectively inhibited DGK kappa activity in a Src family kinase-independent manner, suggesting that the isozyme changes the balance of signaling lipids in the plasma membrane in response to oxidative stress. The expression patterns, subcellular distribution, and regulatory mechanisms of DGK kappa are distinct from those of DGK kappa and DGK kappa despite high structural similarity, suggesting unique functions of the individual type II isozymes.	Sapporo Med Univ, Sch Med, Dept Biochem, Chuo Ku, Sapporo, Hokkaido 0608556, Japan	Sapporo Medical University	Sakane, F (corresponding author), Sapporo Med Univ, Sch Med, Dept Biochem, Chuo Ku, S-1,W-17, Sapporo, Hokkaido 0608556, Japan.	sakane@sapmed.ac.jp	Sakane, Fumio/H-2693-2017	Sakane, Fumio/0000-0003-0857-0377; YASUDA, Satoshi/0000-0002-1011-0815				Baldanzi G, 2004, ONCOGENE, V23, P4828, DOI 10.1038/sj.onc.1207633; Bezprozvanny I, 2001, FEBS LETT, V509, P457, DOI 10.1016/S0014-5793(01)03214-8; Bunting M, 1996, J BIOL CHEM, V271, P10230, DOI 10.1074/jbc.271.17.10230; Caricasole A, 2002, J BIOL CHEM, V277, P4790, DOI 10.1074/jbc.M110249200; Cutrupi S, 2000, EMBO J, V19, P4614, DOI 10.1093/emboj/19.17.4614; Davidson L, 2004, J BIOL CHEM, V279, P11906, DOI 10.1074/jbc.M310784200; Ding L, 1998, J BIOL CHEM, V273, P32746, DOI 10.1074/jbc.273.49.32746; Ding L, 1997, P NATL ACAD SCI USA, V94, P5519, DOI 10.1073/pnas.94.11.5519; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GOTO K, 1994, P NATL ACAD SCI USA, V91, P13042, DOI 10.1073/pnas.91.26.13042; Goto K, 1996, P NATL ACAD SCI USA, V93, P11196, DOI 10.1073/pnas.93.20.11196; GOTO K, 1993, P NATL ACAD SCI USA, V90, P7598, DOI 10.1073/pnas.90.16.7598; Hodgkin MN, 1998, TRENDS BIOCHEM SCI, V23, P200, DOI 10.1016/S0968-0004(98)01200-6; Houssa B, 1997, J BIOL CHEM, V272, P10422; Hurley JH, 1997, PROTEIN SCI, V6, P477; Imai S, 2002, J BIOL CHEM, V277, P35323, DOI 10.1074/jbc.M202035200; Ito T, 2004, J BIOL CHEM, V279, P23317, DOI 10.1074/jbc.M312976200; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; KAI M, 1994, J BIOL CHEM, V269, P18492; KANOH H, 1990, TRENDS BIOCHEM SCI, V15, P47, DOI 10.1016/0968-0004(90)90172-8; Kanoh H, 2002, J BIOCHEM, V131, P629, DOI 10.1093/oxfordjournals.jbchem.a003144; Kazanietz MG, 2002, MOL PHARMACOL, V61, P759, DOI 10.1124/mol.61.4.759; Klauck TM, 1996, J BIOL CHEM, V271, P19781, DOI 10.1074/jbc.271.33.19781; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Konishi H, 2001, P NATL ACAD SCI USA, V98, P6587, DOI 10.1073/pnas.111158798; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MASAI I, 1993, P NATL ACAD SCI USA, V90, P11157, DOI 10.1073/pnas.90.23.11157; MORITZ A, 1992, J BIOL CHEM, V267, P7207; Murakami T, 2003, J BIOL CHEM, V278, P34364, DOI 10.1074/jbc.M301542200; NELSON CA, 1971, J BIOL CHEM, V246, P3895; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Ohno S, 2002, J BIOCHEM, V132, P509, DOI 10.1093/oxfordjournals.jbchem.a003249; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Sakane F, 1997, INT J BIOCHEM CELL B, V29, P1139, DOI 10.1016/S1357-2725(97)00037-X; Sakane F, 2002, J BIOL CHEM, V277, P43519, DOI 10.1074/jbc.M206895200; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; Sakane F, 1996, J BIOL CHEM, V271, P8394, DOI 10.1074/jbc.271.14.8394; Sanjuan MA, 2001, J CELL BIOL, V153, P207, DOI 10.1083/jcb.153.1.207; Santos T, 2002, J BIOL CHEM, V277, P30300, DOI 10.1074/jbc.M200999200; SCHAAP D, 1993, BIOCHEM J, V289, P875, DOI 10.1042/bj2890875; SCHAAP D, 1990, FEBS LETT, V275, P151, DOI 10.1016/0014-5793(90)81461-V; Shirai Y, 2000, J BIOL CHEM, V275, P24760, DOI 10.1074/jbc.M003151200; Storz P, 2003, J BIOL CHEM, V278, P17969, DOI 10.1074/jbc.M213224200; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; Tang W, 1996, J BIOL CHEM, V271, P10237, DOI 10.1074/jbc.271.17.10237; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; van Baal J, 2005, J BIOL CHEM, V280, P9870, DOI 10.1074/jbc.M409301200; van Blitterswijk WJ, 2000, CELL SIGNAL, V12, P595, DOI 10.1016/S0898-6568(00)00113-3	50	93	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					39870	39881		10.1074/jbc.M500669200	http://dx.doi.org/10.1074/jbc.M500669200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16210324	hybrid			2022-12-25	WOS:000233461300025
J	Wittschieben, BO; Iwai, S; Wood, RD				Wittschieben, BO; Iwai, S; Wood, RD			DDB1-DDB2 (Xeroderma Pigmentosum Group E) Protein Complex Recognizes a Cyclobutane Pyrimidine Dimer,Mismatches, Apurinic/Apyrimidinic Sites, and Compound Lesions in DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; GLOBAL GENOMIC REPAIR; THYMINE DIMER BYPASS; GROUP-E CELLS; BINDING-PROTEIN; DAMAGED-DNA; UV-IRRADIATION; DODECAMER DUPLEX; MISMATCH REPAIR; IN-VITRO	The DDB protein complex, comprising the subunits DDB1 and DDB2, binds tightly to UV light-irradiated DNA. Mutations in DDB2 are responsible for xeroderma pigmentosum group E, a disorder with defects in nucleotide excision repair of DNA. Both subunits are also components of a complex involved in ubiquitin-mediated proteolysis. Cellular defects in DDB2 disable repair of the major UV radiation photoproduct in DNA, a cyclobutane pyrimidine dimer, but no significant direct binding of DDB to this photoproduct in DNA has ever been demonstrated. Thus, it has been uncertain how DDB could play a specific role in DNA repair of such damage. We investigated DDB function using highly purified proteins. Co-purified DDB1-DDB2 or DDB reconstituted with individual DDB1 and DDB2 subunits binds to damaged DNA as a ternary complex. We found that DDB can indeed recognize a cyclobutane pyrimidine dimer in DNA with an affinity (K(app)(a)) 6-fold higher than that of nondamaged DNA. The DDB1-DDB2 complex also bound with high specificity to a UV radiation-induced (6-4) photoproduct and to an apurinic site in DNA. Unexpectedly, DDB also bound avidly to DNA containing a 2- or 3-bp mismatch (and does not bind well to DNA containing larger mismatches). These data indicate that DDB does not detect lesions per se. It instead recognizes other structural features of damaged DNA, acting as a sensor that probes DNA for a subset of conformational changes. Lesions recognized may include those arising when translesion polymerases such as POLH incorporate bases across from DNA lesions caused by UV radiation.	Univ Pittsburgh, Canc Inst, Hillman Canc Ctr, Pittsburgh, PA 15213 USA; Osaka Univ, Grad Sch Engn Sci, Toyonaka, Osaka 5608531, Japan	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Osaka University	Wood, RD (corresponding author), Univ Pittsburgh, Canc Inst, Hillman Canc Ctr, Res Pavil,Suite 2-6,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	rdwood@pitt.edu	Wood, Richard D/M-6319-2018	Wood, Richard D/0000-0002-9495-6892	NCI NIH HHS [CA101980] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA101980] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; Araujo SJ, 2001, MOL CELL BIOL, V21, P2281, DOI 10.1128/MCB.21.7.2281-2291.2001; Barnes DE, 2004, ANNU REV GENET, V38, P445, DOI 10.1146/annurev.genet.38.072902.092448; Batty D, 2000, J MOL BIOL, V300, P275, DOI 10.1006/jmbi.2000.3857; Bessho T, 1997, J BIOL CHEM, V272, P3833, DOI 10.1074/jbc.272.6.3833; BHATTACHARYYA A, 1989, NUCLEIC ACIDS RES, V17, P6821, DOI 10.1093/nar/17.17.6821; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; DUALAN R, 1995, GENOMICS, V29, P62, DOI 10.1006/geno.1995.1215; Fiumicino S, 2000, INT J CANCER, V85, P590, DOI 10.1002/(SICI)1097-0215(20000215)85:4<590::AID-IJC23>3.0.CO;2-O; Fujiwara Y, 1999, J BIOL CHEM, V274, P20027, DOI 10.1074/jbc.274.28.20027; Gelasco A, 1998, BIOCHEMISTRY-US, V37, P9230, DOI 10.1021/bi973176v; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Hwang BJ, 1998, MOL CELL BIOL, V18, P4391, DOI 10.1128/MCB.18.7.4391; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Itoh T, 1999, J INVEST DERMATOL, V113, P251, DOI 10.1046/j.1523-1747.1999.00652.x; Itoh T, 2000, J INVEST DERMATOL, V114, P1022, DOI 10.1046/j.1523-1747.2000.00952.x; Iwai S, 1996, J AM CHEM SOC, V118, P7642, DOI 10.1021/ja9603158; Karran P, 2003, BIOCHIMIE, V85, P1149, DOI 10.1016/j.biochi.2003.10.007; KEENEY S, 1993, J BIOL CHEM, V268, P21293; KIM JK, 1995, PHOTOCHEM PHOTOBIOL, V62, P44, DOI 10.1111/j.1751-1097.1995.tb05236.x; Lee JH, 2004, NUCLEIC ACIDS RES, V32, P2474, DOI 10.1093/nar/gkh568; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Marathias VM, 1999, NUCLEIC ACIDS RES, V27, P1854, DOI 10.1093/nar/27.8.1854; Marathias VM, 2000, BIOCHEMISTRY-US, V39, P153, DOI 10.1021/bi9916630; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; McAteer K, 1998, J MOL BIOL, V282, P1013, DOI 10.1006/jmbi.1998.2062; McCulloch SD, 2004, NATURE, V428, P97, DOI 10.1038/nature02352; Mizukoshi T, 2001, NUCLEIC ACIDS RES, V29, P4948, DOI 10.1093/nar/29.24.4948; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; MURATA T, 1990, NUCLEIC ACIDS RES, V18, P7279, DOI 10.1093/nar/18.24.7279; Nichols AF, 2000, J BIOL CHEM, V275, P21422, DOI 10.1074/jbc.M000960200; Nichols AF, 1996, J BIOL CHEM, V271, P24317, DOI 10.1074/jbc.271.40.24317; Park H, 2002, P NATL ACAD SCI USA, V99, P15965, DOI 10.1073/pnas.242422699; PAYNE A, 1994, MUTAT RES-FUND MOL M, V310, P89, DOI 10.1016/0027-5107(94)90012-4; Rapic-Otrin V, 2003, HUM MOL GENET, V12, P1507, DOI 10.1093/hmg/ddg174; Rapic-Otrin V, 2002, NUCLEIC ACIDS RES, V30, P2588, DOI 10.1093/nar/30.11.2588; Reardon JT, 2004, CELL CYCLE, V3, P141; REARDON JT, 1993, J BIOL CHEM, V268, P21301; Reardon JT, 2003, GENE DEV, V17, P2539, DOI 10.1101/gad.1131003; TAKAO M, 1993, NUCLEIC ACIDS RES, V21, P4111, DOI 10.1093/nar/21.17.4111; Tang J, 2002, DNA REPAIR, V1, P601, DOI 10.1016/S1568-7864(02)00052-6; Tang JY, 2000, MOL CELL, V5, P737, DOI 10.1016/S1097-2765(00)80252-X; VANASSENDELFT GB, 1993, NUCLEIC ACIDS RES, V21, P3399, DOI 10.1093/nar/21.15.3399; Wakasugi M, 2002, J BIOL CHEM, V277, P1637, DOI 10.1074/jbc.C100610200; Wakasugi M, 2001, J BIOL CHEM, V276, P15434, DOI 10.1074/jbc.M011177200; Wang QE, 2004, CARCINOGENESIS, V25, P1033, DOI 10.1093/carcin/bgh085; Wittschieben BO, 2003, DNA REPAIR, V2, P1065, DOI 10.1016/S1568-7864(03)00113-7	49	116	120	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					39982	39989		10.1074/jbc.M507854200	http://dx.doi.org/10.1074/jbc.M507854200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16223728	hybrid			2022-12-25	WOS:000233461300082
J	Zomber, G; Reuveny, S; Garti, N; Shafferman, A; Elhanany, E				Zomber, G; Reuveny, S; Garti, N; Shafferman, A; Elhanany, E			Effects of spontaneous deamidation on the cytotoxic activity of the Bacillus anthracis protective antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PHENYLALANINE-HYDROXYLASE; LETHAL FACTOR; 3-DIMENSIONAL STRUCTURE; ISOASPARTATE FORMATION; THERMAL INACTIVATION; ASPARAGINE RESIDUES; MONOCLONAL-ANTIBODY; CRYSTAL-STRUCTURE; DEPENDENT PROCESS; MOLECULAR CLOCKS	Protective antigen (PA) is a central virulence factor of Bacillus anthracis and a key component in anthrax vaccines. PA binds to target cell receptors, is cleaved by the furin protease, self-aggregates to heptamers, and finally internalizes as a complex with either lethal or edema factors. Under mild room temperature storage conditions, PA cytotoxicity decreased (t(1/2) approximate to 7 days) concomitant with the generation of new acidic isoforms, probably through deamidation of Asn residues. Ranking all 68 Asn residues in PA based on their predicted deamidation rates revealed five residues with half-lives of < 60 days, and these residues were further analyzed: Asn(10) in the 20-kDa region, Asn(162) at P-6 vicinal to the furin cleavage site, Asn(306) in the pro-pore translocation loop, and both Asn(713) and Asn(719) in the receptor-binding domain. We found that PA underwent spontaneous deamidation at Asn(162) upon storage concomitant with decreased susceptibility to furin. A panel of model synthetic furin substrates was used to demonstrate that Asn(162) deamidation led to a 20-fold decrease in the bimolecular rate constant (k(cat)/K-m) of proteolysis due to the new negatively charged residue at P-6 in the furin recognition sequence. Furthermore, reduced PA cytotoxicity correlated with a decrease in PA cell binding and also with deamidation of Asn(713) and Asn(719). On the other hand, neither deamidation of Asn(10) or Asn(306) nor impairment of heptamerization could be observed upon prolonged PA storage. We suggest that PA inactivation during storage is associated with susceptible deamidation sites, which are intimately involved in both mechanisms of PA cleavage by furin and PA-receptor binding.	Israel Inst Biol Res, Dept Biochem & Mol Genet, IL-74100 Ness Ziona, Israel; Israel Inst Biol Res, Dept Biotechnol, IL-74100 Ness Ziona, Israel; Hebrew Univ Jerusalem, Casali Inst Appl Chem, IL-91905 Jerusalem, Israel	Hebrew University of Jerusalem	Shafferman, A (corresponding author), Israel Inst Biol Res, Dept Biochem & Mol Genet, POB 19, IL-74100 Ness Ziona, Israel.	avigdor@iibr.gov.il						Abrami L, 2003, J CELL BIOL, V160, P321, DOI 10.1083/jcb.200211018; Ascenzi P, 2002, FEBS LETT, V531, P384, DOI 10.1016/S0014-5793(02)03609-8; Barnard JP, 1999, INFECT IMMUN, V67, P562, DOI 10.1128/IAI.67.2.562-567.1999; BELTON FC, 1954, BRIT J EXP PATHOL, V35, P144; Benson EL, 1998, BIOCHEMISTRY-US, V37, P3941, DOI 10.1021/bi972657b; Bergeron E, 2003, BIOCHEM J, V373, P475, DOI 10.1042/BJ20021630; BLAUSTEIN RO, 1989, P NATL ACAD SCI USA, V86, P2209, DOI 10.1073/pnas.86.7.2209; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Brossier F, 1999, INFECT IMMUN, V67, P964, DOI 10.1128/IAI.67.2.964-967.1999; Capasso S, 1999, J PEPT RES, V54, P377, DOI 10.1034/j.1399-3011.1999.00111.x; Chen WS, 1996, J IMMUNOL, V157, P1000; Chirino AJ, 2004, NAT BIOTECHNOL, V22, P1383, DOI 10.1038/nbt1030; Cohen S, 2000, INFECT IMMUN, V68, P4549, DOI 10.1128/IAI.68.8.4549-4558.2000; Deverman BE, 2002, CELL, V111, P51, DOI 10.1016/S0092-8674(02)00972-8; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; Elhanany E, 2001, CHEM RES TOXICOL, V14, P912, DOI 10.1021/tx0100542; Elliott JL, 2000, BIOCHEMISTRY-US, V39, P6706, DOI 10.1021/bi000310u; ESCUYER V, 1991, INFECT IMMUN, V59, P3381, DOI 10.1128/IAI.59.10.3381-3386.1991; Farchaus JW, 1998, APPL ENVIRON MICROB, V64, P982; FRIEDLANDER AM, 1986, J BIOL CHEM, V261, P7123; FRIEDMAN AR, 1991, INT J PEPT PROT RES, V37, P14; GEIGER T, 1987, J BIOL CHEM, V262, P785; HEPNER F, 2005, PROTEOME SCI; HOUGHTEN RA, 1986, INT J PEPT PROT RES, V27, P673; Huang LH, 2005, ANAL CHEM, V77, P1432, DOI 10.1021/ac0494174; IVINS BE, 1994, VACCINE, V12, P872, DOI 10.1016/0264-410X(94)90027-2; JOHNSON BA, 1987, J BIOL CHEM, V262, P5622; Kapphahn RJ, 2003, BIOCHEMISTRY-US, V42, P15310, DOI 10.1021/bi034774e; Kim YH, 2002, BIOCHEMISTRY-US, V41, P14076, DOI 10.1021/bi026288h; KIMPEL MW, 1992, CURR EYE RES, V11, P297, DOI 10.3109/02713689209001783; Krysan DJ, 1999, J BIOL CHEM, V274, P23229, DOI 10.1074/jbc.274.33.23229; Lacy DB, 2004, P NATL ACAD SCI USA, V101, P13147, DOI 10.1073/pnas.0405405101; Lapko VN, 2002, BIOCHEMISTRY-US, V41, P8638, DOI 10.1021/bi015924t; Lazure C, 1998, J BIOL CHEM, V273, P8572, DOI 10.1074/jbc.273.15.8572; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; Marcus H, 2004, INFECT IMMUN, V72, P3471, DOI 10.1128/IAI.72.6.3471-3477.2004; MILNE JC, 1994, J BIOL CHEM, V269, P20607; Moayeri M, 2004, CURR OPIN MICROBIOL, V7, P19, DOI 10.1016/j.mib.2003.12.001; Mogridge J, 2002, P NATL ACAD SCI USA, V99, P7045, DOI 10.1073/pnas.052160199; Mogridge J, 2002, BIOCHEMISTRY-US, V41, P1079, DOI 10.1021/bi015860m; Mogridge J, 2001, J BACTERIOL, V183, P2111, DOI 10.1128/JB.183.6.2111-2116.2001; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Moss CX, 2005, J BIOL CHEM, V280, P18498, DOI 10.1074/jbc.M501241200; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Orlik F, 2005, BIOPHYS J, V88, P1715, DOI 10.1529/biophysj.104.050336; Paradisi F, 2005, BIOCHEMISTRY-US, V44, P3636, DOI 10.1021/bi047679u; PARANANDI MV, 1994, J BIOL CHEM, V269, P243; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; Qin KF, 2000, J BIOL CHEM, V275, P19121, DOI 10.1074/jbc.275.25.19121; Radha C, 1996, J BIOTECHNOL, V50, P235, DOI 10.1016/0168-1656(96)01569-6; Reuveny S, 2001, INFECT IMMUN, V69, P2888, DOI 10.1128/IAI.69.5.2888-2893.2001; Rhie GE, 2003, P NATL ACAD SCI USA, V100, P10925, DOI 10.1073/pnas.1834478100; Robinson NE, 2004, J PEPT RES, V63, P426, DOI 10.1111/j.1399-3011.2004.00151.x; Robinson NE, 2004, MECH AGEING DEV, V125, P259, DOI 10.1016/j.mad.2004.01.001; Robinson NE, 2001, P NATL ACAD SCI USA, V98, P4367, DOI 10.1073/pnas.071066498; Robinson NE, 2001, P NATL ACAD SCI USA, V98, P12409, DOI 10.1073/pnas.221463198; Robinson NE, 2001, P NATL ACAD SCI USA, V98, P944, DOI 10.1073/pnas.98.3.944; Rockwell NC, 2002, CHEM REV, V102, P4525, DOI 10.1021/cr010168i; Santelli E, 2004, NATURE, V430, P905, DOI 10.1038/nature02763; Schneerson R, 2003, P NATL ACAD SCI USA, V100, P8945, DOI 10.1073/pnas.1633512100; Scobie HM, 2005, CURR OPIN MICROBIOL, V8, P106, DOI 10.1016/j.mib.2004.12.005; Scobie HM, 2003, P NATL ACAD SCI USA, V100, P5170, DOI 10.1073/pnas.0431098100; SCOTCHLER JW, 1974, ANAL BIOCHEM, V59, P319, DOI 10.1016/0003-2697(74)90040-2; Singh S, 2004, BIOCHEM BIOPH RES CO, V322, P1029, DOI 10.1016/j.bbrc.2004.08.020; Singh S, 2002, BIOCHEM BIOPH RES CO, V296, P1058, DOI 10.1016/S0006-291X(02)02049-1; Singh Y, 1999, INFECT IMMUN, V67, P1853; Solstad T, 2000, EUR J BIOCHEM, V267, P6302, DOI 10.1046/j.1432-1327.2000.01715.x; Solstad T, 2003, EUR J BIOCHEM, V270, P929, DOI 10.1046/j.1432-1033.2003.03455.x; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Tourasse NJ, 2000, MOL BIOL EVOL, V17, P656, DOI 10.1093/oxfordjournals.molbev.a026344; Varughese M, 1999, INFECT IMMUN, V67, P1860; Vitale G, 1998, BIOCHEM BIOPH RES CO, V248, P706, DOI 10.1006/bbrc.1998.9040; Watanabe A, 1999, J BIOL CHEM, V274, P7368, DOI 10.1074/jbc.274.11.7368; Wei W, 1999, INT J PHARMACEUT, V185, P129, DOI 10.1016/S0378-5173(99)00152-0; Whiting GC, 2004, VACCINE, V22, P4245, DOI 10.1016/j.vaccine.2004.04.036; Zhang W, 2003, J PHARMACEUT BIOMED, V30, P1479, DOI 10.1016/S0731-7085(02)00479-X	77	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					39897	39906		10.1074/jbc.M508569200	http://dx.doi.org/10.1074/jbc.M508569200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16188881	hybrid			2022-12-25	WOS:000233461300028
J	Hu, YM; Rosen, DG; Zhou, Y; Feng, L; Yang, G; Liu, JS; Huang, P				Hu, YM; Rosen, DG; Zhou, Y; Feng, L; Yang, G; Liu, JS; Huang, P			Mitochondrial manganese-superoxide dismutase expression in ovarian cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; ANTIOXIDANT ENZYMES; FREE-RADICALS; HYDROGEN-PEROXIDE; GASTRIC-CANCER; LEUKEMIA-CELLS; PROLIFERATION; INHIBITION; INDUCTION; GENE	Superoxide dismutases ( SODs) are important antioxidant enzymes responsible for the elimination of superoxide radical (O-2(-)). The manganese-containing SOD (Mn-SOD) has been suggested to have tumor suppressor function and is located in the mitochondria where the majority of O-2(-) is generated during respiration. Although increased reactive oxygen species (ROS) in cancer cells has long been recognized, the expression of Mn-SOD in cancer and its role in cancer development remain elusive. The present study used a human tissue microarray to analyze Mn-SOD expression in primary ovarian cancer tissues, benign ovarian lesions, and normal ovary epithelium. Significantly higher levels of Mn-SOD protein expression were detected in the malignant tissues compared with normal tissues (p < 0.05). In experimental systems, suppression of Mn-SOD expression by small interfering RNA caused a 70% increase of superoxide in ovarian cancer cells, leading to stimulation of cell proliferation in vitro and more aggressive tumor growth in vivo. Furthermore, stimulation of mitochondrial O-2(-) production induced an increase of Mn-SOD expression. Our findings suggest that the increase in Mn-SOD expression in ovarian cancer is a cellular response to intrinsic ROS stress and that scavenging of superoxide by SOD may alleviate the ROS stress and thus reduce the simulating effect of ROS on cell growth.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Huang, P (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Box 089,1515 Holcombe Blvd, Houston, TX 77030 USA.	phuang@mdanderson.org			NCI NIH HHS [CA100428, CA109041, CA85563] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100428, R01CA085563, R01CA109041] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMES BN, 1989, MUTAT RES, V214, P41, DOI 10.1016/0027-5107(89)90196-6; Behrend L, 2003, BIOCHEM SOC T, V31, P1441; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; CHANG LY, 1995, LAB INVEST, V73, P29; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; Cobbs CS, 1996, CANCER RES, V56, P3192; CRAPO JD, 1974, AM J PHYSIOL, V226, P1401, DOI 10.1152/ajplegacy.1974.226.6.1401; Cullen JJ, 2003, PANCREAS, V26, P23, DOI 10.1097/00006676-200301000-00005; Devi GS, 2000, CLIN CHIM ACTA, V293, P53, DOI 10.1016/S0009-8981(99)00222-3; DOUGALL WC, 1991, ENDOCRINOLOGY, V129, P2376, DOI 10.1210/endo-129-5-2376; Gopalakrishna R, 2000, FREE RADICAL BIO MED, V28, P1349, DOI 10.1016/S0891-5849(00)00221-5; Halliwell B, 1999, FREE RADICAL BIO MED, P105, DOI DOI 10.1093/ACPR0F:0S0/9780198717478.003.0005; Hileman EO, 2004, CANCER CHEMOTH PHARM, V53, P209, DOI 10.1007/s00280-003-0726-5; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; ISHIKAWA M, 1990, CANCER RES, V50, P2538; Janssen AML, 1999, J CANCER RES CLIN, V125, P327, DOI 10.1007/s004320050282; Janssen AML, 2000, CLIN CANCER RES, V6, P3183; Jung K, 1997, FREE RADICAL BIO MED, V23, P127, DOI 10.1016/S0891-5849(96)00613-2; Kahlos K, 1998, AM J RESP CELL MOL, V18, P570, DOI 10.1165/ajrcmb.18.4.2943; Liu JS, 2004, CANCER RES, V64, P1655, DOI 10.1158/0008-5472.CAN-03-3380; Malafa M, 2000, J SURG RES, V88, P130, DOI 10.1006/jsre.1999.5773; Mallis RJ, 2001, BIOCHEM J, V355, P145, DOI 10.1042/bj3550145; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; MOREL I, 1990, BIOCHEM PHARMACOL, V39, P1647, DOI 10.1016/0006-2952(90)90107-V; MURRELL GAC, 1990, BIOCHEM J, V265, P659, DOI 10.1042/bj2650659; NAKATA T, 1992, CARCINOGENESIS, V13, P1941, DOI 10.1093/carcin/13.10.1941; NICOTERA TM, 1994, CANCER RES, V54, P3884; NISHIURA T, 1992, CANCER LETT, V62, P211, DOI 10.1016/0304-3835(92)90098-G; ONO M, 1992, BIOCHEM BIOPH RES CO, V182, P1100, DOI 10.1016/0006-291X(92)91845-H; Pelicano H, 2004, DRUG RESIST UPDATE, V7, P97, DOI 10.1016/j.drup.2004.01.004; Pelicano H, 2003, J BIOL CHEM, V278, P37832, DOI 10.1074/jbc.M301546200; Policastro L, 2004, MOL CARCINOGEN, V39, P103, DOI 10.1002/mc.20001; PUNNONEN K, 1994, J CANCER RES CLIN, V120, P374, DOI 10.1007/BF01247464; Randerath K, 1996, CHEM RES TOXICOL, V9, P247, DOI 10.1021/tx950085v; Sattler M, 2000, J BIOL CHEM, V275, P24273, DOI 10.1074/jbc.M002094200; SCHADENDORF D, 1995, MELANOMA RES, V5, P351, DOI 10.1097/00008390-199510000-00008; Senthil K, 2004, CLIN CHIM ACTA, V339, P27, DOI 10.1016/j.cccn.2003.08.017; Takada Y, 2002, MOL CANCER RES, V1, P137; TOYOKUNI S, 1995, FEBS LETT, V358, P1, DOI 10.1016/0014-5793(94)01368-B; VanDriel BEM, 1997, FREE RADICAL BIO MED, V23, P435, DOI 10.1016/S0891-5849(97)00102-0; WAN XS, 1994, DNA CELL BIOL, V13, P1127, DOI 10.1089/dna.1994.13.1127; Yang G, 2004, J BIOL CHEM, V279, P4339, DOI 10.1074/jbc.M311153200; YOSHIOKA T, 1994, KIDNEY INT, V46, P405, DOI 10.1038/ki.1994.288; Zhou Y, 2003, BLOOD, V101, P4098, DOI 10.1182/blood-2002-08-2512	44	213	220	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39485	39492		10.1074/jbc.M503296200	http://dx.doi.org/10.1074/jbc.M503296200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16179351	hybrid			2022-12-25	WOS:000233362200070
J	Thebault, S; Lemonnier, L; Bidaux, G; Flourakis, M; Bavencoffe, A; Gordienko, D; Roudbaraki, M; Delcourt, P; Panchin, Y; Shuba, Y; Skryma, R; Prevarskaya, N				Thebault, S; Lemonnier, L; Bidaux, G; Flourakis, M; Bavencoffe, A; Gordienko, D; Roudbaraki, M; Delcourt, P; Panchin, Y; Shuba, Y; Skryma, R; Prevarskaya, N			Novel role of cold/menthol-sensitive transient receptor potential melastatine family member 8 (TRPM8) in the activation of store-operated channels in LNCaP human prostate cancer epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ HOMEOSTASIS; APOPTOTIC RESISTANCE; CAPSAICIN RECEPTOR; CALCIUM-CHANNEL; ION CHANNELS; INVOLVEMENT; DIVERSITY; TRPV3	Recent cloning of a cold/menthol-sensitive TRPM8 channel ( transient receptor potential melastatine family member 8) from rodent sensory neurons has provided the molecular basis for the cold sensation. Surprisingly, the human orthologue of rodent TRPM8 also appears to be strongly expressed in the prostate and in the prostate cancer-derived epithelial cell line, LNCaP. In this study, we show that despite such expression, LNCaP cells respond to cold/ menthol stimulus by membrane current (I-cold/menthol) that shows inward rectification and high Ca2+ selectivity, which are dramatically different properties from "classical" TRPM8-mediated I-cold/menthol. Yet, silencing of endogenous TRPM8 mRNA by either antisense or siRNA strategies suppresses both I-cold/menthol and TRPM8 protein in LNCaP cells. We demonstrate that these puzzling results arise from TRPM8 localization not in the plasma, but in the endoplasmic reticulum ( ER) membrane of LNCaP cells, where it supports cold/menthol/icilin-induced Ca2+ release from the ER with concomitant activation of plasma membrane ( PM) store-operated channels ( SOC). In contrast, GFP-tagged TRPM8 heterologously expressed in HEK-293 cells target the PM. We also demonstrate that TRPM8 expression and the magnitude of SOC current associated with it are androgen-dependent. Our results suggest that the TRPM8 may be an important new ER Ca2+ release channel, potentially involved in a number of Ca2+- and store-dependent processes in prostate cancer epithelial cells, including those that are important for prostate carcinogenesis, such as proliferation and apoptosis.	USTL, EMI 0228, Lab Physiol Cellulaire, INSERM, F-59655 Villeneuve Dascq, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille	Prevarskaya, N (corresponding author), USTL, EMI 0228, Lab Physiol Cellulaire, INSERM, Batiment SN3, F-59655 Villeneuve Dascq, France.	Natacha.Prevarskaya@univ-lille1.fr	Lemonnier, Loic/L-7289-2018; Shuba, Yaroslav/AAT-6758-2021; Thébault, Stéphanie/AAD-8350-2019; Bidaux, Gabriel/F-1294-2016	Lemonnier, Loic/0000-0001-6200-5382; Flourakis, Matthieu/0000-0002-5366-9125; Thebault, Stephanie/0000-0003-3233-282X; Bavencoffe, Alexis Guillaume/0000-0001-5659-5988; Prevarskaya, natacha/0000-0003-0316-197X; Bidaux, Gabriel/0000-0002-6162-3223; Panchin, Yuri/0000-0002-8006-2839; Gordienko, Dmitri (Dmytro)/0000-0002-4118-9976; Morad, Roudbaraki/0000-0001-5751-3323	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bavari S, 2002, J EXP MED, V195, P593, DOI 10.1084/jem.20011500; Bidaux G, 2005, ENDOCR-RELAT CANCER, V12, P367, DOI 10.1677/erc.1.00969; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, CURR OPIN NEUROBIOL, V9, P525, DOI 10.1016/S0959-4388(99)00009-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Gao X, 2003, J BIOL CHEM, V278, P27129, DOI 10.1074/jbc.M302517200; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gunthorpe MJ, 2002, TRENDS PHARMACOL SCI, V23, P183, DOI 10.1016/S0165-6147(02)01999-5; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Liu BY, 2005, J NEUROSCI, V25, P1674, DOI 10.1523/JNEUROSCI.3632-04.2005; MANDERS EMM, 1993, J MICROSC-OXFORD, V169, P375, DOI 10.1111/j.1365-2818.1993.tb03313.x; Mariot P, 2002, J BIOL CHEM, V277, P10824, DOI 10.1074/jbc.M108754200; McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Moran MM, 2004, CURR OPIN NEUROBIOL, V14, P362, DOI 10.1016/j.conb.2004.05.003; Naal RMZG, 2003, TRAFFIC, V4, P190, DOI 10.1034/j.1600-0854.2003.00073.x; Peier AM, 2002, SCIENCE, V296, P2046, DOI 10.1126/science.1073140; Peier AM, 2002, CELL, V108, P705, DOI 10.1016/S0092-8674(02)00652-9; Prescott ED, 2003, SCIENCE, V300, P1284, DOI 10.1126/science.1083646; Prevarskaya N, 2004, BIOCHEM BIOPH RES CO, V322, P1326, DOI 10.1016/j.bbrc.2004.08.037; Skryma R, 1999, RECEPTOR CHANNEL, V6, P241; Skryma R, 2000, J PHYSIOL-LONDON, V527, P71, DOI 10.1111/j.1469-7793.2000.00071.x; Skryma RN, 1997, PROSTATE, V33, P112, DOI 10.1002/(SICI)1097-0045(19971001)33:2<112::AID-PROS5>3.0.CO;2-M; Smith GD, 2002, NATURE, V418, P186, DOI 10.1038/nature00894; Story GM, 2003, CELL, V112, P819, DOI 10.1016/S0092-8674(03)00158-2; Thebault S, 2003, J CLIN INVEST, V111, P1691, DOI 10.1172/JCI200316293; Tsavaler L, 2001, CANCER RES, V61, P3760; Tsuzuki K, 2004, J NEUROSCI, V24, P762, DOI 10.1523/JNEUROSCI.4658-03.2004; Vanden Abeele F, 2004, J BIOL CHEM, V279, P30326, DOI 10.1074/jbc.M400106200; Vanden Abeele F, 2003, CELL CALCIUM, V33, P357, DOI 10.1016/S0143-4160(03)00049-6; Vanden Abeele F, 2002, CANCER CELL, V1, P169; Vanden Abeele F, 2003, J BIOL CHEM, V278, P15381, DOI 10.1074/jbc.M212106200; Vanoverberghe K, 2004, CELL DEATH DIFFER, V11, P321, DOI 10.1038/sj.cdd.4401375; Vanoverberghe K, 2003, CELL CALCIUM, V34, P75, DOI 10.1016/S0143-4160(03)00024-1; Watanabe H, 2003, NATURE, V424, P434, DOI 10.1038/nature01807; Xu HX, 2002, NATURE, V418, P181, DOI 10.1038/nature00882; Zhang L, 2004, CANCER RES, V64, P8365, DOI 10.1158/0008-5472.CAN-04-2146	41	127	133	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39423	39435		10.1074/jbc.M503544200	http://dx.doi.org/10.1074/jbc.M503544200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16174775	Green Published, hybrid, Green Submitted			2022-12-25	WOS:000233362200064
J	Mulder, WJM; Strijkers, GJ; Habets, JW; Bleeker, EJW; van der Schaft, DWJ; Storm, G; Koning, GA; Griffioen, AW; Nicolay, K				Mulder, WJM; Strijkers, GJ; Habets, JW; Bleeker, EJW; van der Schaft, DWJ; Storm, G; Koning, GA; Griffioen, AW; Nicolay, K			MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle	FASEB JOURNAL			English	Article						paramagnetic liposomes; RGD peptide; alpha v beta 3-integrin; angiogenesis; tumor bearing mice	RGD-MODIFIED PROTEINS; ALPHA(V)BETA(3) INTEGRIN; 1.5 TESLA; IN-VIVO; ANGIOGENESIS; LIPOSOMES; CANCER; PEPTIDE; EXPRESSION; VASCULATURE	In oncological research, there is a great need for imaging techniques that specifically identify angiogenic blood vessels in tumors on the basis of differences in the expression level of biomolecular markers. In the angiogenic cascade, different cell surface receptors, including the alpha v beta 3-integrin, are strongly expressed on activated endothelial cells. In the present study, we aimed to image angiogenesis by detecting the expression of alpha v beta 3 in tumor bearing mice with a combination of magnetic resonance imaging (MRI) and fluorescence microscopy. To that end, we prepared MR-detectable and fluorescent liposomes, which carry similar to 700 alpha v beta 3-specific RGD peptides per liposome. RGD competition experiments and RAD-conjugated liposomes were used as controls for specificity. In vivo, both RAD liposomes and RGD liposomes gave rise to signal increase on T-1-weighted MR images. It was established by the use of ex vivo fluorescence microscopy that RGD liposomes and RAD liposomes accumulated in the tumor by different mechanisms. RGD liposomes were specifically associated with activated tumor endothelium, while RAD liposomes were located in the extravascular compartment. This study demonstrates that MR molecular imaging of angiogenesis is feasible by using a targeted contrast agent specific for the alpha v beta 3-integrin, and that the multimodality imaging approach gave insight into the exact mechanism of accumulation in the tumor.	Eindhoven Univ Technol, Dept Biomed Engn, Biomed NMR, NL-5600 MB Eindhoven, Netherlands; Maastricht Univ, Angiogenesis Lab, Res Inst Growth & Dev, Dept Pathol Internal Med, NL-6202 AZ Maastricht, Netherlands; Univ Hosp Maastricht, NL-6202 AZ Maastricht, Netherlands; UIPS, Dept Pharmaceut, NL-3508 TB Utrecht, Netherlands; Delft Univ Technol, Dept Radiat Radioisotopes & Reactors, Fac Sci Appl, NL-2629 JB Delft, Netherlands	Eindhoven University of Technology; Maastricht University; Maastricht University; Maastricht University Medical Centre (MUMC); Utrecht University; Delft University of Technology	Mulder, WJM (corresponding author), Eindhoven Univ Technol, Dept Biomed Engn, Biomed NMR, POB 513, NL-5600 MB Eindhoven, Netherlands.	w.j.m.mulder@tue.nl	Storm, Gerrit/O-8696-2016; Mulder, Willem J.M./B-7232-2009; Nicolay, Klaas/F-4192-2010; Koning, Gerben A/K-2326-2012; Strijkers, Gustav J/H-3158-2011	Mulder, Willem J.M./0000-0001-8665-3878; Koning, Gerben A/0000-0003-3090-2403; Strijkers, Gustav/0000-0001-6700-5058; Nicolay, Klaas/0000-0002-4179-616X				Allen TM, 1997, DRUGS, V54, P8, DOI 10.2165/00003495-199700544-00004; ALLEN TM, 1994, TRENDS PHARMACOL SCI, V15, P215, DOI 10.1016/0165-6147(94)90314-X; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chen XY, 2004, MOL IMAGING, V3, P96, DOI 10.1162/1535350041464892; Chen XY, 2004, BIOCONJUGATE CHEM, V15, P41, DOI 10.1021/bc0300403; Colangelo S, 1998, ARTERIOSCL THROM VAS, V18, P52, DOI 10.1161/01.ATV.18.1.52; Dafni H, 2002, CANCER RES, V62, P6731; Dardzinski BJ, 2001, MAGN RESON IMAGING, V19, P1209, DOI 10.1016/S0730-725X(01)00448-9; de Lussanet QG, 2004, EUR J CANCER, V40, P1262, DOI 10.1016/j.ejca.2004.01.020; Dijkhuizen RM, 2002, STROKE, V33, P2100, DOI 10.1161/01.STR.0000023534.37670.F7; Doubrovin M, 2004, BIOCONJUGATE CHEM, V15, P1376, DOI 10.1021/bc0498572; Drummond DC, 1999, PHARMACOL REV, V51, P691; Dubey PK, 2004, J DRUG TARGET, V12, P257, DOI 10.1080/10611860410001728040; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gillies RJ, 2002, J MAGN RESON IMAGING, V16, P430, DOI 10.1002/jmri.10181; Griffioen AW, 2000, PHARMACOL REV, V52, P237; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Haubner R, 1997, ANGEW CHEM INT EDIT, V36, P1375; Haubner R, 2001, CANCER RES, V61, P1781; Haubner R, 1996, J AM CHEM SOC, V118, P7461, DOI 10.1021/ja9603721; Holig P, 2004, PROTEIN ENG DES SEL, V17, P433, DOI 10.1093/protein/gzh055; Hood JD, 2002, SCIENCE, V296, P2404, DOI 10.1126/science.1070200; Huber MM, 1998, BIOCONJUGATE CHEM, V9, P242, DOI 10.1021/bc970153k; Israely T, 2004, MAGN RESON MED, V52, P741, DOI 10.1002/mrm.20203; Janssen APCA, 2003, INT J PHARMACEUT, V254, P55, DOI 10.1016/S0378-5173(02)00682-8; Janssen ML, 2002, CANCER RES, V62, P6146; Kok RJ, 2002, BIOCONJUGATE CHEM, V13, P128, DOI 10.1021/bc015561+; Koning GA, 2004, APPL RADIAT ISOTOPES, V61, P963, DOI 10.1016/j.apradiso.2004.05.020; Li KCP, 2004, BIOMED MICRODEVICES, V6, P113, DOI 10.1023/B:BMMD.0000031747.05317.81; Li KCP, 2002, J CELL BIOCHEM, P65, DOI 10.1002/jcb.10401; McDonald DM, 2003, NAT MED, V9, P713, DOI 10.1038/nm0603-713; Morawski AM, 2004, MAGN RESON MED, V51, P480, DOI 10.1002/mrm.20010; Moseley M, 2004, STROKE, V35, P2632, DOI 10.1161/01.STR.0000143214.22567.cb; MULDER WJ, 2005, P 13 ISMRM M MIAM FL; MULDER WJ, 2004, P 2U ESMRMB M COP DE; Mulder WJM, 2004, BIOCONJUGATE CHEM, V15, P799, DOI 10.1021/bc049949r; Padhani AR, 2002, J MAGN RESON IMAGING, V16, P407, DOI 10.1002/jmri.10176; Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; Schiffelers RM, 2003, J CONTROL RELEASE, V91, P115, DOI 10.1016/S0168-3659(03)00240-2; Schraa AJ, 2002, INT J CANCER, V102, P469, DOI 10.1002/ijc.10727; Sipkins DA, 1998, NAT MED, V4, P623, DOI 10.1038/nm0598-623; Storm G, 1997, HYBRIDOMA, V16, P119, DOI 10.1089/hyb.1997.16.119; Thumshirn G, 2003, CHEM-EUR J, V9, P2717, DOI 10.1002/chem.200204304; Weissleder R, 2002, NAT REV CANCER, V2, P11, DOI 10.1038/nrc701; Weissleder R, 2001, RADIOLOGY, V219, P316, DOI 10.1148/radiology.219.2.r01ma19316; Winter PM, 2003, CANCER RES, V63, P5838; Zitzmann S, 2002, CANCER RES, V62, P5139	49	232	252	2	46	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2008	+		10.1096/fj.05-4145fje	http://dx.doi.org/10.1096/fj.05-4145fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16204353				2022-12-25	WOS:000232991100028
J	Ceccarelli, DFJ; Song, HK; Poy, F; Schaller, MD; Eck, MJ				Ceccarelli, DFJ; Song, HK; Poy, F; Schaller, MD; Eck, MJ			Crystal structure of the FERM domain of focal adhesion kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL DOMAIN; ERM PROTEINS; NEUROFIBROMATOSIS TYPE-2; CATALYTIC-ACTIVITY; CELL-ADHESION; BINDING-SITE; REGION; SRC; PHOSPHORYLATION; ASSOCIATION	Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that localizes to focal adhesions in adherent cells. Through phosphorylation of proteins assembled at the cytoplasmic tails of integrins, FAK promotes signaling events that modulate cellular growth, survival, and migration. The amino-terminal region of FAK contains a region of sequence homology with band 4.1 and ezrin/radixin/moesin (ERM) proteins termed a FERM domain. FERM domains are found in a variety of signaling and cytoskeletal proteins and are thought to mediate intermolecular interactions with partner proteins and phospholipids at the plasma membrane and intramolecular regulatory interactions. Here we report two crystal structures of an NH2-terminal fragment of avian FAK containing the FERM domain and a portion of the regulatory linker that connects the FERM and kinase domains. The tertiary folds of the three subdomains (F1, F2, and F3) are similar to those of known FERM structures despite low sequence conservation. Differences in the sequence and relative orientation of the F3 subdomain alters the nature of the interdomain interface, and the phosphoinositide binding site found in ERM family FERM domains is not present in FAK. A putative protein interaction site on the F3 lobe is masked by the proximal region of the linker. Additionally, in one structure the adjacent Src SH3 and SH2 binding sites in the linker associate with the surfaces of the F3 and F1 lobes, respectively. These structural features suggest the possibility that protein interactions of the FAK FERM domain can be regulated by binding of Src kinases to the linker segment.	Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea; Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Korea University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Eck, MJ (corresponding author), SM 1036,44 Binney St, Boston, MA 02215 USA.	eck@red.dfci.harvard.edu	Song, Hyun Kyu/D-6763-2016	Song, Hyun Kyu/0000-0001-5684-4059; Ceccarelli, Derek/0000-0002-2674-9234	NATIONAL CANCER INSTITUTE [R01CA080942] Funding Source: NIH RePORTER; NCI NIH HHS [CA080942] Funding Source: Medline; NHLBI NIH HHS [HL48675] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barret C, 2000, J CELL BIOL, V151, P1067, DOI 10.1083/jcb.151.5.1067; Blomberg N, 1999, TRENDS BIOCHEM SCI, V24, P441, DOI 10.1016/S0968-0004(99)01472-3; Bompard G, 2003, J CELL SCI, V116, P2519, DOI 10.1242/jcs.00448; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Chen LM, 2000, J NEUROSCI, V20, P3776, DOI 10.1523/JNEUROSCI.20-10-03776.2000; Chen RY, 2001, NAT CELL BIOL, V3, P439, DOI 10.1038/35074500; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; Cohen LA, 2005, J BIOL CHEM, V280, P8197, DOI 10.1074/jbc.M412021200; Cooper LA, 2003, MOL CELL BIOL, V23, P8030, DOI 10.1128/MCB.23.22.8030-8041.2003; Cowtan KD, 1999, PROG BIOPHYS MOL BIO, V72, P245, DOI 10.1016/S0079-6107(99)00008-5; Dunty JM, 2004, MOL CELL BIOL, V24, P5353, DOI 10.1128/MCB.24.12.5353-5368.2004; Dunty JM, 2002, J BIOL CHEM, V277, P45644, DOI 10.1074/jbc.M201779200; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; Edwards SD, 2001, BIOCHEMISTRY-US, V40, P7061, DOI 10.1021/bi010419h; Garcia-Alvarez B, 2003, MOL CELL, V11, P49, DOI 10.1016/S1097-2765(02)00823-7; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Girault JA, 1999, TRENDS BIOCHEM SCI, V24, P54, DOI 10.1016/S0968-0004(98)01331-0; Haan C, 2001, J BIOL CHEM, V276, P37451, DOI 10.1074/jbc.M106135200; Hamada K, 2000, EMBO J, V19, P4449, DOI 10.1093/emboj/19.17.4449; Hamada K, 2003, EMBO J, V22, P502, DOI 10.1093/emboj/cdg039; Han BG, 2000, NAT STRUCT BIOL, V7, P871; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Hauck CR, 2001, J BIOL CHEM, V276, P17653, DOI 10.1074/jbc.M009329200; Hilkens CMU, 2001, FEBS LETT, V505, P87, DOI 10.1016/S0014-5793(01)02783-1; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Huang LJS, 2001, MOL CELL, V8, P1327, DOI 10.1016/S1097-2765(01)00401-4; Jacamo RO, 2005, BIOCHEM BIOPH RES CO, V334, P1299, DOI 10.1016/j.bbrc.2005.07.034; Kang BS, 2002, ACTA CRYSTALLOGR D, V58, P381, DOI 10.1107/S0907444901021175; KRAGELUND BB, 1993, J MOL BIOL, V230, P1260, DOI 10.1006/jmbi.1993.1240; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEMMON MA, 2005, MODULAR PROTEIN DOMA, P337; Mangeat P, 1999, TRENDS CELL BIOL, V9, P187, DOI 10.1016/S0962-8924(99)01544-5; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; NIGGLI V, 1995, FEBS LETT, V376, P172, DOI 10.1016/0014-5793(95)01270-1; Nowakowski J, 2002, STRUCTURE, V10, P1659, DOI 10.1016/S0969-2126(02)00907-3; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Playford MP, 2004, ONCOGENE, V23, P7928, DOI 10.1038/sj.onc.1208080; Poullet P, 2001, J BIOL CHEM, V276, P37686, DOI 10.1074/jbc.M106175200; Prehoda KE, 1999, CELL, V97, P471, DOI 10.1016/S0092-8674(00)80757-6; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 2004, BBA-MOL CELL RES, V1692, P77, DOI 10.1016/j.bbamcr.2004.04.008; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Shimizu T, 2002, J BIOL CHEM, V277, P10332, DOI 10.1074/jbc.M109979200; Sicheri F, 1997, CURR OPIN STRUC BIOL, V7, P777, DOI 10.1016/S0959-440X(97)80146-7; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Smith WJ, 2003, J BIOL CHEM, V278, P4949, DOI 10.1074/jbc.M210601200; Stewart A, 2002, BIOCHEM BIOPH RES CO, V299, P62, DOI 10.1016/S0006-291X(02)02547-0; Thomas JW, 1998, J BIOL CHEM, V273, P577, DOI 10.1074/jbc.273.1.577; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; Usacheva A, 2002, J IMMUNOL, V169, P1302, DOI 10.4049/jimmunol.169.3.1302; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; Xiong WC, 2003, FRONT BIOSCI, V8, pS676, DOI 10.2741/1116; Zamir E, 2001, J CELL SCI, V114, P3583; Zhou YJ, 2001, MOL CELL, V8, P959, DOI 10.1016/S1097-2765(01)00398-7	63	102	105	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					252	259		10.1074/jbc.M509188200	http://dx.doi.org/10.1074/jbc.M509188200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16221668	hybrid, Green Published			2022-12-25	WOS:000234307200033
J	Chang, NS; Doherty, J; Ensign, A; Schultz, L; Hsu, LJ; Hong, QY				Chang, NS; Doherty, J; Ensign, A; Schultz, L; Hsu, LJ; Hong, QY			WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds and stabilizes serine 46-phosphorylated p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING OXIDOREDUCTASE; WILD-TYPE P53; IN-VIVO; SUPPRESSOR GENE; DOWN-REGULATION; POTENTIAL ROLE; P53-DEPENDENT APOPTOSIS; NUCLEAR TRANSLOCATION; PHYSICALLY INTERACTS; HYAL1 HYALURONIDASE	WW domain-containing oxidoreductase WOX1, also named WWOX or FOR, undergoes Tyr(33) phosphorylation at its first N-terminal WW domain and subsequent nuclear translocation in response to sex steroid hormones and stress stimuli. The activated WOX1 binds tumor suppressor p53, and both proteins may induce apoptosis synergistically. Functional suppression of WOX1 by antisense mRNA or a dominant negative abolishes p53-mediated apoptosis. Here, we determined that UV light, anisomycin, etoposide, and hypoxic stress rapidly induced phosphorylation of p53 at Ser(46) and WOX1 at Tyr(33) (phospho-WOX1) and their binding interactions in several tested cancer cells. Mapping by yeast two-hybrid analysis and co-immunoprecipitation showed that phospho-WOX1 physically interacted with Ser(46)-phosphorylated p53. Knockdown of WOX1 protein expression by small interfering RNA resulted in L929 fibroblast resistance to apoptosis by tumor necrosis factor, staurosporine, UV light, and ectopic p53, indicating an essential role of WOX1 in stress stimuli-induced apoptosis. Notably, UV light could not induce p53 protein expression in these WOX1 knockdown cells, although p53 mRNA levels were not reduced. Suppression of WOX1 by dominant negative WOX1( to block Tyr33 phosphorylation) also abolished UV light-induced p53 protein expression. Time course analysis showed that the stability of ectopic wild type p53, tagged with DsRed, was decreased in WOX1 knockdown cells. Inhibition of MDM2 by nutlin-3 increased the binding of p53 and WOX1 and stability of p53. Together, our data show that WOX1 plays a critical role in conferring cellular sensitivity to apoptotic stress and that Tyr(33) phosphorylation in WOX1 is essential for binding and stabilizing Ser46- phosphorylated p53.	Guthrie Res Inst, Lab Mol Immunol, Sayre, PA 18840 USA		Chang, NS (corresponding author), Guthrie Res Inst, Lab Mol Immunol, 1 Guthrie Sq, Sayre, PA 18840 USA.	chang_nanshan@guthrie.org	Hsu, Li-Jin/G-7822-2011					An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Aqeilan RI, 2005, CANCER RES, V65, P6764, DOI 10.1158/0008-5472.CAN-05-1150; Aqeilan RI, 2004, P NATL ACAD SCI USA, V101, P4401, DOI 10.1073/pnas.0400805101; Aqeilan RI, 2004, CLIN CANCER RES, V10, P3053, DOI 10.1158/1078-0432.CCR-03-0594; Aqeilan RI, 2004, CANCER RES, V64, P8256, DOI 10.1158/0008-5472.CAN-04-2055; Asher G, 2002, P NATL ACAD SCI USA, V99, P3099, DOI 10.1073/pnas.052706799; Bednarek AK, 2000, CANCER RES, V60, P2140; Bell HS, 2005, NEUROPATH APPL NEURO, V31, P191, DOI 10.1111/j.1365-2990.2004.00627.x; Berger M, 2001, J BIOL CHEM, V276, P3785, DOI 10.1074/jbc.M008879200; Bernardi R, 2004, NAT CELL BIOL, V6, P665, DOI 10.1038/ncb1147; Bertrand P, 1997, INT J CANCER, V73, P327, DOI 10.1002/(SICI)1097-0215(19971104)73:3<327::AID-IJC4>3.0.CO;2-1; Bond GL, 2005, CURR CANCER DRUG TAR, V5, P3, DOI 10.2174/1568009053332627; Chang NS, 1998, CANCER LETT, V131, P45, DOI 10.1016/S0304-3835(98)00200-6; Chang NS, 2005, ONCOGENE, V24, P714, DOI 10.1038/sj.onc.1208124; Chang NS, 2003, BIOCHEM PHARMACOL, V66, P1347, DOI 10.1016/S0006-2952(03)00484-2; Chang NS, 2003, J BIOL CHEM, V278, P9195, DOI 10.1074/jbc.M208373200; Chang NS, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-8; Chang NS, 2002, J BIOL CHEM, V277, P10323, DOI 10.1074/jbc.M106607200; Chang NS, 2002, INT J MOL MED, V9, P19; Chang NS, 2001, J BIOL CHEM, V276, P3361, DOI 10.1074/jbc.M007140200; Chen ST, 2005, NEUROSCIENCE, V130, P397, DOI 10.1016/j.neuroscience.2004.07.054; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Driouch K, 2002, ONCOGENE, V21, P1832, DOI 10.1038/sj.onc.1205273; Finnis M, 2005, HUM MOL GENET, V14, P1341, DOI 10.1093/hmg/ddi144; Fotouhi N, 2005, CURR TOP MED CHEM, V5, P159, DOI 10.2174/1568026053507705; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Gourley C, 2005, INT J ONCOL, V26, P1681; Guler G, 2004, CANCER, V100, P1605, DOI 10.1002/cncr.20137; Hu H, 2004, PROTEOMICS, V4, P643, DOI 10.1002/pmic.200300632; Iliopoulos D, 2005, ONCOGENE, V24, P1625, DOI 10.1038/sj.onc.1208398; Ishii H, 2004, INT J HEMATOL, V79, P238, DOI 10.1532/IJH97.03145; Kim H, 2004, J BIOL CHEM, V279, P7812, DOI 10.1074/jbc.M305526200; Klein C, 2004, BRIT J CANCER, V91, P1415, DOI 10.1038/sj.bjc.6602164; Kohn KW, 2005, BIOCHEM BIOPH RES CO, V331, P816, DOI 10.1016/j.bbrc.2005.03.186; Kuroki T, 2004, CLIN CANCER RES, V10, P2459, DOI 10.1158/1078-0432.CCR-03-0096; Lai FJ, 2005, CLIN CANCER RES, V11, P5769, DOI 10.1158/1078-0432.CCR-04-2274; Lohrum MAE, 2000, TRENDS CELL BIOL, V10, P197, DOI 10.1016/S0962-8924(00)01736-0; Lokeshwar VB, 2005, CANCER RES, V65, P7782, DOI 10.1158/0008-5472.CAN-05-1022; Lokeshwar VB, 2001, J BIOL CHEM, V276, P11922, DOI 10.1074/jbc.M008432200; Mayo LD, 2005, J BIOL CHEM, V280, P25953, DOI 10.1074/jbc.M503026200; Nunez MI, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-64; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Paige AJW, 2001, P NATL ACAD SCI USA, V98, P11417, DOI 10.1073/pnas.191175898; Park SW, 2004, BRIT J CANCER, V91, P753, DOI 10.1038/sj.bjc.6602023; Perry ME, 2000, J BIOL CHEM, V275, P5733, DOI 10.1074/jbc.275.8.5733; Pochampally R, 1998, ONCOGENE, V17, P2629, DOI 10.1038/sj.onc.1202206; Reid K, 2000, HUM MOL GENET, V9, P1651; Richards RI, 2001, TRENDS GENET, V17, P339, DOI 10.1016/S0168-9525(01)02303-4; Schultz L, 2004, DNA CELL BIOL, V23, P67, DOI 10.1089/104454904322745943; SHAO ZM, 1995, ONCOGENE, V11, P493; Sze CI, 2004, J BIOL CHEM, V279, P30498, DOI 10.1074/jbc.M401399200; Take Y, 1996, BIOCHEM BIOPH RES CO, V221, P207, DOI 10.1006/bbrc.1996.0575; Thompson T, 2004, J BIOL CHEM, V279, P53015, DOI 10.1074/jbc.M410233200; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vega FM, 2004, MOL CELL BIOL, V24, P10366, DOI 10.1128/MCB.24.23.10366-10380.2004; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Watanabe A, 2003, CANCER RES, V63, P8629; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zheng HW, 2002, NATURE, V419, P849, DOI 10.1038/nature01116; Zhou MX, 2003, ONCOGENE, V22, P8137, DOI 10.1038/sj.onc.1206911; Zhu JH, 2000, J BIOL CHEM, V275, P39927, DOI 10.1074/jbc.M005676200	62	100	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					43100	43108		10.1074/jbc.M505590200	http://dx.doi.org/10.1074/jbc.M505590200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16219768	hybrid			2022-12-25	WOS:000234200800076
J	Hetz, C; Vitte, PA; Bombrun, A; Rostovtseva, TK; Montessuit, S; Hiver, A; Schwarz, MK; Church, DJ; Korsmeyer, SJ; Martinou, JC; Antonsson, B				Hetz, C; Vitte, PA; Bombrun, A; Rostovtseva, TK; Montessuit, S; Hiver, A; Schwarz, MK; Church, DJ; Korsmeyer, SJ; Martinou, JC; Antonsson, B			Bax channel inhibitors prevent mitochondrion-mediated apoptosis and protect neurons in a model of global brain ischemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL CEREBRAL-ISCHEMIA; CYTOCHROME-C RELEASE; CELL-DEATH; PROAPOPTOTIC BAX; FORMING ACTIVITY; ION-CHANNEL; BCL-2; MEMBRANES; VDAC; OLIGOMERIZATION	Ischemic injuries are associated with several pathological conditions, including stroke and myocardial infarction. Several studies have indicated extensive apoptotic cell death in the infarcted area as well as in the penumbra region of the infarcted tissue. Studies with transgenic animals suggest that the mitochondrion-mediated apoptosis pathway is involved in ischemia-related cell death. This pathway is triggered by activation of pro-apoptotic Bcl-2 family members such as Bax. Here, we have identified and synthesized two low molecular weight compounds that block Bax channel activity. The Bax channel inhibitors prevented cytochrome c release from mitochondria, inhibited the decrease in the mitochondrial membrane potential, and protected cells against apoptosis. The Bax channel inhibitors did not affect the conformational activation of Bax or its translocation and insertion into the mitochondrial membrane in cells undergoing apoptosis. Furthermore, the compounds protected neurons in an animal model of global brain ischemia. The protective effect in the animal model correlated with decreased cytochrome c release in the infarcted area. This is the first demonstration that Bax channel activity is required in apoptosis.	Serono Pharmaceut Res Inst, CH-1228 Geneva, Switzerland; NICHD, Lab Phys & Struct Biol, NIH, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Univ Chile, Inst Ciencias Biomed, Santiago, Chile	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Universidad de Chile	Antonsson, B (corresponding author), Serono Pharmaceut Res Inst, 14 Chem Aulx, CH-1228 Geneva, Switzerland.	bruno.antonsson@serono.com	Hetz, Claudio/ABD-7514-2021; Hetz, Claudio/I-1900-2013	Hetz, Claudio/0000-0001-7724-1767; martinou, Jean-claude/0000-0002-9847-2051	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000072] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000072] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Antonawich FJ, 1999, NEUROSCI LETT, V274, P123, DOI 10.1016/S0304-3940(99)00687-4; Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; Carboni S, 2005, J NEUROCHEM, V92, P1054, DOI 10.1111/j.1471-4159.2004.02925.x; Chiesa R, 2005, P NATL ACAD SCI USA, V102, P238, DOI 10.1073/pnas.0406173102; Deshmukh M, 2000, CELL DEATH DIFFER, V7, P250, DOI 10.1038/sj.cdd.4400641; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Fujimura M, 1998, J CEREBR BLOOD F MET, V18, P1239, DOI 10.1097/00004647-199811000-00010; GERHARDT SC, 1988, BEHAV NEUROSCI, V102, P301, DOI 10.1037/0735-7044.102.2.301; Gibson ME, 2001, MOL MED, V7, P644, DOI 10.1007/BF03401871; Gottlieb RA, 1999, ANN NY ACAD SCI, V874, P412, DOI 10.1111/j.1749-6632.1999.tb09255.x; Graham SH, 2001, J CEREBR BLOOD F MET, V21, P99, DOI 10.1097/00004647-200102000-00001; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GREEN DR, 1994, IMPORTANT ADV ONCOL, V37, P52; Gronborg M, 1999, J PHARMACOL EXP THER, V290, P348; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hetz C, 2005, J NEUROSCI, V25, P2793, DOI 10.1523/JNEUROSCI.4090-04.2005; Hetz C, 2002, P NATL ACAD SCI USA, V99, P2696, DOI 10.1073/pnas.052709699; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; Kudla G, 2000, J BIOL CHEM, V275, P22713, DOI 10.1074/jbc.M003807200; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lewis S, 1998, PROTEIN EXPRES PURIF, V13, P120, DOI 10.1006/prep.1997.0871; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; Montessuit S, 1999, PROTEIN EXPRES PURIF, V15, P202, DOI 10.1006/prep.1998.1010; Narula J, 1999, P NATL ACAD SCI USA, V96, P8144, DOI 10.1073/pnas.96.14.8144; PARSONS DF, 1966, ANN NY ACAD SCI, V137, P643, DOI 10.1111/j.1749-6632.1966.tb50188.x; Plesnila N, 2001, P NATL ACAD SCI USA, V98, P15318, DOI 10.1073/pnas.261323298; Rostovtseva TK, 1998, BIOPHYS J, V74, P2365, DOI 10.1016/S0006-3495(98)77945-7; Rostovtseva TK, 2004, J BIOL CHEM, V279, P13575, DOI 10.1074/jbc.M310593200; Roucou X, 2002, BIOCHEM J, V368, P915, DOI 10.1042/BJ20020972; Saikumar P, 1998, ONCOGENE, V17, P3401, DOI 10.1038/sj.onc.1202590; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Schmitz I, 2000, INT J BIOCHEM CELL B, V32, P1123, DOI 10.1016/S1357-2725(00)00048-0; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yao H, 2001, MOL BRAIN RES, V91, P112, DOI 10.1016/S0169-328X(01)00135-8; Yin XM, 2002, J BIOL CHEM, V277, P42074, DOI 10.1074/jbc.M204991200	44	129	140	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42960	42970		10.1074/jbc.M505843200	http://dx.doi.org/10.1074/jbc.M505843200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16219766	hybrid, Green Published			2022-12-25	WOS:000234200800059
J	Dominguez-Cuevas, P; Marin, P; Ramos, JL; Marques, S				Dominguez-Cuevas, P; Marin, P; Ramos, JL; Marques, S			RNA polymerase holoenzymes can share a single transcription start site for the Pm promoter - Critical nucleotides in the -7 to -18 region are needed to select between RNA polymerase with sigma(38) or sigma(32)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							META-CLEAVAGE PATHWAY; ESCHERICHIA-COLI; TOL PLASMID; PSEUDOMONAS-PUTIDA; STATIONARY-PHASE; GROWTH-PHASE; IN-VIVO; GENE-EXPRESSION; XYLS REGULATORS; SEQUENCE	The Pm promoter of the benzoate meta-cleavage pathway is transcribed with E sigma(32) or E sigma(38) according to the growth phase, with an identical transcriptional start site. To investigate sequence determinants in the interaction between either of the two RNA polymerases and Pm, all possible single mutants between positions -7 and -18 were generated, and the activity in the exponential and stationary phases of the resulting mutant promoters was compared. The results precisely delimited a-10 element between positions -7 and -12 (TAGGCT), which defined a promoter sharing nucleotides with both sigma(38) and sigma(32) consensus. The first two and the last positions of this hexamer were crucial for recognition by both polymerases. Position -10 was the only one specifically recognized by E sigma(38), whereas positions -8, -9, and the C-track between positions -14 and -17 were important for specific E sigma(32) recognition. Western blots showed that sigma(32) was only detectable in the exponential phase, and sigma(38) appeared in the early stationary phase. In the rpoH mutant KY1429, sigma(38) was already present in the exponential growth phase both free and bound to the RNA polymerase core, in good correlation with the transcription levels found. Pm seems to be optimized for recognition by sigma(32) as an initial response to the addition of effector to the medium and allows binding of the adaptable sigma(38)-dependent RNA polymerase in the stationary phase. XylS is always required for Pm transcription. Therefore, the mechanism that controls Pm expression involves specific nucleotide sequences, the abundance of free and core-bound sigma(32) and sigma(38) factors during growth, and the presence of the regulator activated by an effector.	CSIC, Estac Expt Zaidin, Dept Biochem & Mol & Cellular Biol Plants, E-18008 Granada, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Experimental del Zaidin (EEZ)	Marques, S (corresponding author), CSIC, Estac Expt Zaidin, Dept Biochem & Mol & Cellular Biol Plants, C Prof Albareda 1,Apartado Correos 419, E-18008 Granada, Spain.	silvia@eez.csic.es	Marqués, Silvia/B-8079-2012; Dominguez-Cuevas, Patricia/D-6608-2017	Marqués, Silvia/0000-0002-6289-3348; Ramos, Juan L./0000-0002-8731-7435; Dominguez-Cuevas, Patricia/0000-0002-9343-091X				ALTUVIA S, 1994, MOL MICROBIOL, V13, P265, DOI 10.1111/j.1365-2958.1994.tb00421.x; ARNQVIST A, 1994, MOL MICROBIOL, V13, P1021, DOI 10.1111/j.1365-2958.1994.tb00493.x; Ausubel F.M., 1998, CURRENT PROTOCOLS MO; Bordes P, 2000, MOL MICROBIOL, V35, P845, DOI 10.1046/j.1365-2958.2000.01758.x; Busby S, 1997, MOL MICROBIOL, V23, P853, DOI 10.1046/j.1365-2958.1997.2771641.x; COWING DW, 1985, P NATL ACAD SCI USA, V82, P2679, DOI 10.1073/pnas.82.9.2679; Dombroski AJ, 1997, J BIOL CHEM, V272, P3487; DOMINGUEZCUEVAS P, 2004, PSEUDOMONAS VIRULENC, V2, P319; Egan SM, 2002, J BACTERIOL, V184, P5529, DOI 10.1128/JB.184.20.5529-5532.2002; EspinosaUrgel M, 1996, MOL MICROBIOL, V21, P657; FRANKLIN FCH, 1981, P NATL ACAD SCI-BIOL, V78, P7458, DOI 10.1073/pnas.78.12.7458; Gaal T, 2001, MOL MICROBIOL, V42, P939, DOI 10.1046/j.1365-2958.2001.02703.x; Gallegos MT, 1996, J BACTERIOL, V178, P2356, DOI 10.1128/jb.178.8.2356-2361.1996; Gallegos MT, 1997, MICROBIOL MOL BIOL R, V61, P393, DOI 10.1128/.61.4.393-410.1997; Gallegos MT, 1996, J BACTERIOL, V178, P6427, DOI 10.1128/jb.178.22.6427-6434.1996; Gonzalez-Perez MM, 2002, FEBS LETT, V519, P117, DOI 10.1016/S0014-5793(02)02730-8; Gonzalez-Perez MM, 1999, J BIOL CHEM, V274, P2286, DOI 10.1074/jbc.274.4.2286; Gross CA, 1998, COLD SPRING HARB SYM, V63, P141, DOI 10.1101/sqb.1998.63.141; GROSS CA, 1996, CELLULAR MOL BIOL, P1382; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Hengge-Aronis R, 2002, CURR OPIN MICROBIOL, V5, P591, DOI 10.1016/S1369-5274(02)00372-7; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; INOUYE S, 1984, GENE, V29, P323; Ishihama A, 2000, ANNU REV MICROBIOL, V54, P499, DOI 10.1146/annurev.micro.54.1.499; Jishage M, 1997, J BACTERIOL, V179, P959, DOI 10.1128/jb.179.3.959-963.1997; Kaldalu N, 1996, MOL MICROBIOL, V20, P569, DOI 10.1046/j.1365-2958.1996.5381060.x; KESSLER B, 1993, J MOL BIOL, V230, P699, DOI 10.1006/jmbi.1993.1189; Lacour S, 2003, J BIOL CHEM, V278, P37160, DOI 10.1074/jbc.M305281200; LANGE R, 1991, MOL MICROBIOL, V5, P49, DOI 10.1111/j.1365-2958.1991.tb01825.x; Lee SJ, 2001, J BIOL CHEM, V276, P30064, DOI 10.1074/jbc.M102886200; LISSER S, 1993, NUCLEIC ACIDS RES, V21, P1507, DOI 10.1093/nar/21.7.1507; Maeda H, 2000, NUCLEIC ACIDS RES, V28, P3497, DOI 10.1093/nar/28.18.3497; Manzanera M, 2001, MICROBIOL-SGM, V147, P1323, DOI 10.1099/00221287-147-5-1323; Marques S, 1999, MOL MICROBIOL, V31, P1105, DOI 10.1046/j.1365-2958.1999.01249.x; Marques S, 1999, ENVIRON MICROBIOL, V1, P103, DOI 10.1046/j.1462-2920.1999.00010.x; Marques S, 1995, MOL MICROBIOL, V18, P851, DOI 10.1111/j.1365-2958.1995.18050851.x; Miller JH., 1972, EXPT MOL GENETICS; Muffler A, 1997, J BACTERIOL, V179, P445; RAMOS JL, 1986, P NATL ACAD SCI USA, V83, P8467, DOI 10.1073/pnas.83.22.8467; RAMOS JL, 1987, MOL MICROBIOL, V1, P293, DOI 10.1111/j.1365-2958.1987.tb01935.x; Ruiz R, 2002, J BIOL CHEM, V277, P7282, DOI 10.1074/jbc.M110226200; Ruiz R, 2001, FEBS LETT, V491, P207, DOI 10.1016/S0014-5793(01)02192-5; Tao L, 2005, METAB ENG, V7, P10, DOI 10.1016/j.ymben.2004.05.006; Tobes R, 2002, NUCLEIC ACIDS RES, V30, P318, DOI 10.1093/nar/30.1.318; Typas A, 2005, MOL MICROBIOL, V55, P250, DOI 10.1111/j.1365-2958.2004.04382.x; Wang Y, 2003, J BACTERIOL, V185, P5800, DOI 10.1128/JB.185.19.5800-5806.2003; Zhou YN, 1998, J BACTERIOL, V180, P1154, DOI 10.1128/JB.180.5.1154-1158.1998; ZHOU YN, 1988, J BACTERIOL, V170, P3640, DOI 10.1128/jb.170.8.3640-3649.1988	48	26	26	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41315	41323		10.1074/jbc.M505415200	http://dx.doi.org/10.1074/jbc.M505415200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16230361	hybrid			2022-12-25	WOS:000233866900026
J	Evans, AM; Mustard, KJW; Wyatt, CN; Peers, C; Dipp, M; Kumar, P; Kinnear, NP; Hardie, DG				Evans, AM; Mustard, KJW; Wyatt, CN; Peers, C; Dipp, M; Kumar, P; Kinnear, NP; Hardie, DG			Does AMP-activated protein kinase couple inhibition of mitochondrial oxidative phosphorylation by hypoxia to calcium signaling in O-2-sensing cells?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; CAROTID-BODY; PULMONARY VASOCONSTRICTION; RESPIRATORY-CHAIN; UPSTREAM KINASE; K+ CURRENTS; RAT; ENERGY; RELEASE; MUSCLE	Specialized O-2-sensing cells exhibit a particularly low threshold to regulation by O-2 supply and function to maintain arterial pO(2) within physiological limits. For example, hypoxic pulmonary vasoconstriction optimizes ventilation-perfusion matching in the lung, whereas carotid body excitation elicits corrective cardio-respiratory reflexes. It is generally accepted that relatively mild hypoxia inhibits mitochondrial oxidative phosphorylation in O-2-sensing cells, thereby mediating, in part, cell activation. However, the mechanism by which this process couples to Ca2+ signaling mechanisms remains elusive, and investigation of previous hypotheses has generated contrary data and failed to unite the field. We propose that a rise in the cellular AMP/ATP ratio activates AMP-activated protein kinase and thereby evokes Ca2+ signals in O-2-sensing cells. Co-immunoprecipitation identified three possible AMP-activated protein kinase subunit isoform combinations in pulmonary arterial myocytes, with alpha 1 beta 2 gamma 1 predominant. Furthermore, their tissue-specific distribution suggested that the AMP-activated protein kinase-alpha 1 catalytic isoform may contribute, via amplification of the metabolic signal, to the pulmonary selectivity required for hypoxic pulmonary vasoconstriction. Immunocytochemistry showed AMP-activated protein kinase-alpha 1 to be located throughout the cytoplasm of pulmonary arterial myocytes. In contrast, it was targeted to the plasma membrane in carotid body glomus cells. Consistent with these observations and the effects of hypoxia, stimulation of AMP-activated protein kinase by phenformin or 5-aminoimidazole-4-carboxamide- riboside elicited discrete Ca2+ signaling mechanisms in each cell type, namely cyclic ADP-ribose-dependent Ca2+ mobilization from the sarcoplasmic reticulum via ryanodine receptors in pulmonary arterial myocytes and transmembrane Ca2+ influx into carotid body glomus cells. Thus, metabolic sensing by AMP-activated protein kinase may mediate chemotransduction by hypoxia.	Univ St Andrews, Div Biomed Sci, Sch Biol, St Andrews KY16 9TS, Fife, Scotland; Univ Dundee, Wellcome Trust Bioctr, Div Mol Physiol, Sch Life Sci, Dundee DD1 5EH, Scotland; Univ Leeds, Inst Cardiovasc Res, Leeds LS2 9JT, W Yorkshire, England; Univ Birmingham, Sch Med, Dept Physiol, Birmingham B15 2TT, W Midlands, England	University of St Andrews; University of Dundee; University of Leeds; University of Birmingham	Evans, AM (corresponding author), Univ St Andrews, Div Biomed Sci, Sch Biol, Bute Bldg, St Andrews KY16 9TS, Fife, Scotland.	ame3@st-and.ac.uk	Hardie, David/Z-1979-2019	Kumar, Prem/0000-0001-7524-6046; Hardie, Grahame/0000-0002-8373-7379; Peers, Chris/0000-0002-8354-346X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARCHER SL, 1986, HERZ, V11, P127; BUCKLER KJ, 1994, J PHYSIOL-LONDON, V476, P423, DOI 10.1113/jphysiol.1994.sp020143; BUESCHER PC, 1991, J APPL PHYSIOL, V70, P1874, DOI 10.1152/jappl.1991.70.4.1874; Cheung PCF, 2000, BIOCHEM J, V346, P659, DOI 10.1042/0264-6021:3460659; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; CORTON JM, 1994, CURR BIOL, V4, P315, DOI 10.1016/S0960-9822(00)00070-1; Dipp M, 2001, CIRC RES, V89, P77, DOI 10.1161/hh1301.093616; Dipp M, 2001, AM J PHYSIOL-LUNG C, V281, pL318, DOI 10.1152/ajplung.2001.281.2.L318; DUCHEN MR, 1992, J PHYSIOL-LONDON, V450, P33, DOI 10.1113/jphysiol.1992.sp019115; Durante PE, 2002, AM J PHYSIOL-ENDOC M, V283, pE178, DOI 10.1152/ajpendo.00404.2001; El-Mir MY, 2000, J BIOL CHEM, V275, P223, DOI 10.1074/jbc.275.1.223; Euler Us V, 1946, ACTA PHYSL SCAND, V12, P301, DOI [10.1111/j.1748-1716.1946.tb00389.x, DOI 10.1111/J.1748-1716.1946.TB00389.X]; Evans AM, 2004, DEV CARDIOVASC MED, V252, P313; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; Gonzalez C, 2002, RESP PHYSIOL NEUROBI, V132, P17, DOI 10.1016/S1569-9048(02)00047-2; Hardie DG, 2003, FEBS LETT, V546, P113, DOI 10.1016/S0014-5793(03)00560-X; Hardie DG, 2001, BIOESSAYS, V23, P1112, DOI 10.1002/bies.10009; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Heymans C, 1930, ARCH INT PHARMACOD T, V39, P400; JIANG C, 1994, P NATL ACAD SCI USA, V91, P7198, DOI 10.1073/pnas.91.15.7198; Kang TM, 2003, LIFE SCI, V72, P1467, DOI 10.1016/S0024-3205(02)02441-4; KATO M, 1966, CIRC RES, V19, P426, DOI 10.1161/01.RES.19.2.426; Killilea DW, 2000, AM J PHYSIOL-LUNG C, V279, pL408, DOI 10.1152/ajplung.2000.279.2.L408; Leach RM, 2001, J PHYSIOL-LONDON, V536, P211, DOI 10.1111/j.1469-7793.2001.00211.x; LEE HC, 1989, J BIOL CHEM, V264, P1608; Lee M, 2003, J BIOL CHEM, V278, P39653, DOI 10.1074/jbc.M306104200; Lopez-Barneo J, 2001, ANNU REV PHYSIOL, V63, P259, DOI 10.1146/annurev.physiol.63.1.259; LOPEZBARNEO J, 1988, SCIENCE, V241, P580, DOI 10.1126/science.2456613; Malvin GM, 2001, AM J PHYSIOL-REG I, V280, pR1308, DOI 10.1152/ajpregu.2001.280.5.R1308; Marsin AS, 2000, CURR BIOL, V10, P1247, DOI 10.1016/S0960-9822(00)00742-9; Olson KR, 2001, AM J PHYSIOL-REG I, V280, pR198, DOI 10.1152/ajpregu.2001.280.1.R198; Ortega-Saenz P, 2003, J PHYSIOL-LONDON, V548, P789, DOI 10.1113/jphysiol.2003.039693; Owen MR, 2000, BIOCHEM J, V348, P607, DOI 10.1042/0264-6021:3480607; PEPPER DR, 1995, J PHYSIOL-LONDON, V485, P531, DOI 10.1113/jphysiol.1995.sp020749; PRABHAKAR NR, 1995, P NATL ACAD SCI USA, V92, P1994, DOI 10.1073/pnas.92.6.1994; Prabhakar NR, 2004, BIOL CHEM, V385, P217, DOI 10.1515/BC.2004.015; Robertson TP, 2001, CARDIOVASC RES, V50, P145, DOI 10.1016/S0008-6363(01)00192-4; ROUNDS S, 1981, CIRC RES, V48, P393, DOI 10.1161/01.RES.48.3.393; Roy C S, 1890, J Physiol, V11, P85; SALVATERRA CG, 1993, AM J PHYSIOL, V264, pL323, DOI 10.1152/ajplung.1993.264.3.L323; Schrauwen P, 2004, INT J OBESITY, V28, P824, DOI 10.1038/sj.ijo.0802629; Scott JW, 2002, J MOL BIOL, V317, P309, DOI 10.1006/jmbi.2001.5316; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Thompson RJ, 1998, J PHYSIOL-LONDON, V512, P421, DOI 10.1111/j.1469-7793.1998.421be.x; Waypa GB, 2001, CIRC RES, V88, P1259, DOI 10.1161/hh1201.091960; Williams SEJ, 2004, SCIENCE, V306, P2093, DOI 10.1126/science.1105010; Wilson HL, 2001, J BIOL CHEM, V276, P11180, DOI 10.1074/jbc.M004849200; Winder WW, 1996, AM J PHYSIOL-ENDOC M, V270, pE299, DOI 10.1152/ajpendo.1996.270.2.E299; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Wyatt CN, 2004, J PHYSIOL-LONDON, V556, P175, DOI 10.1113/jphysiol.2003.058131; WYATT CN, 1995, P NATL ACAD SCI USA, V92, P295, DOI 10.1073/pnas.92.1.295; YOUNGSON C, 1993, NATURE, V365, P153, DOI 10.1038/365153a0; Zhao Y, 1996, EXP LUNG RES, V22, P51, DOI 10.3109/01902149609074017; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505	60	148	153	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41504	41511		10.1074/jbc.M510040200	http://dx.doi.org/10.1074/jbc.M510040200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16199527	hybrid			2022-12-25	WOS:000233866900049
J	Yam, AYW; Albanese, V; Lin, HTJ; Frydman, J				Yam, AYW; Albanese, V; Lin, HTJ; Frydman, J			Hsp110 cooperates with different cytosolic Hsp70 systems in a pathway for de novo folding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETHERED MOLECULAR CHAPERONES; IN-VIVO; SACCHAROMYCES-CEREVISIAE; J-PROTEIN; MULTIGENE FAMILY; TRIGGER FACTOR; NASCENT CHAIN; YEAST; RIBOSOME; COMPLEX	Molecular chaperones such as Hsp70 use ATP binding and hydrolysis to prevent aggregation and ensure the efficient folding of newly translated and stress-denatured polypeptides. Eukaryotic cells contain several cytosolic Hsp70 subfamilies. In yeast, these include the Hsp70s SSB and SSA as well as the Hsp110-like Sse1/2p. The cellular functions and interplay between these different Hsp70 systems remain ill-defined. Here we show that the different cytosolic Hsp70 systems functionally interact with Hsp110 to form a chaperone network that interacts with newly translated polypeptides during their biogenesis. Both SSB and SSA Hsp70s form stable complexes with the Hsp110 Sse1p. Pulse-chase analysis indicates that these Hsp70/Hsp110 teams, SSB/SSE and SSA/SSE, transiently associate with newly synthesized polypeptides with different kinetics. SSB Hsp70s bind cotranslationally to a large fraction of nascent chains, suggesting an early role in the stabilization of nascent chains. SSA Hsp70s bind mostly post-translationally to a more restricted subset of newly translated polypeptides, suggesting a downstream function in the folding pathway. Notably, loss of SSB dramatically enhances the cotranslational association of SSA with nascent chains, suggesting SSA can partially fulfill an SSB-like function. On the other hand, the absence of SSE1 enhances polypeptide binding to both SSB and SSA and impairs cell growth. It, thus, appears that Hsp110 is an important regulator of Hsp70-substrate interactions. Based on our data, we propose that Hsp110 cooperates with the SSB and SSA Hsp70 subfamilies, which act sequentially during de novo folding.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Stanford Univ, BioX Program, Stanford, CA 94305 USA; Univ Calif San Francisco, Mass Spectrometry Facil, San Francisco, CA 94143 USA	Stanford University; Stanford University; University of California System; University of California San Francisco	Frydman, J (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.	jfrydman@stanford.edu	Gimenez, Luis E Diaz/D-9291-2011	, judith/0000-0003-2302-6943; Albanese, Veronique/0000-0002-5947-7415	NCRR NIH HHS [RR01614] Funding Source: Medline; NIGMS NIH HHS [GM56433] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056433] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENAROUDJ N, 1995, BIOCHEMISTRY-US, V34, P15282, DOI 10.1021/bi00046a037; Brachmann CB, 1998, YEAST, V14, P115; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Craig E, 1995, COLD SPRING HARB SYM, V60, P441, DOI 10.1101/SQB.1995.060.01.049; Craig EA, 2003, CURR OPIN MICROBIOL, V6, P157, DOI 10.1016/S1369-5274(03)00030-4; CROMBIE T, 1994, EUR J BIOCHEM, V226, P657, DOI 10.1111/j.1432-1033.1994.tb20093.x; Deuerling E, 1999, NATURE, V400, P693, DOI 10.1038/23301; Easton DP, 2000, CELL STRESS CHAPERON, V5, P276, DOI 10.1379/1466-1268(2000)005<0276:THAGSP>2.0.CO;2; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Gautschi M, 2002, P NATL ACAD SCI USA, V99, P4209, DOI 10.1073/pnas.062048599; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Goeckeler JL, 2002, MOL BIOL CELL, V13, P2760, DOI 10.1091/mbc.02-04-0051; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hatayama T, 1998, BIOCHEM BIOPH RES CO, V248, P395, DOI 10.1006/bbrc.1998.8979; Huang P, 2005, NAT STRUCT MOL BIOL, V12, P497, DOI 10.1038/nsmb942; Hundley H, 2002, P NATL ACAD SCI USA, V99, P4203, DOI 10.1073/pnas.062048399; Hundley HA, 2005, SCIENCE, V308, P1032, DOI 10.1126/science.1109247; Kabani M, 2002, MOL CELL BIOL, V22, P4677, DOI 10.1128/MCB.22.13.4677-4689.2002; Kim S, 1998, P NATL ACAD SCI USA, V95, P12860, DOI 10.1073/pnas.95.22.12860; Labbe S, 1999, METHOD ENZYMOL, V306, P145; Liu XD, 1999, J BIOL CHEM, V274, P26654, DOI 10.1074/jbc.274.38.26654; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Mayer MP, 1998, BIOL CHEM, V379, P261; Melville MW, 2003, MOL CELL BIOL, V23, P3141, DOI 10.1128/MCB.23.9.3141-3151.2003; MUKAI H, 1993, GENE, V132, P57; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; Nollen EAA, 2000, MOL CELL BIOL, V20, P1083, DOI 10.1128/MCB.20.3.1083-1088.2000; Oh HJ, 1999, J BIOL CHEM, V274, P15712, DOI 10.1074/jbc.274.22.15712; Oh HJ, 1997, J BIOL CHEM, V272, P31636, DOI 10.1074/jbc.272.50.31636; Otto H, 2005, P NATL ACAD SCI USA, V102, P10064, DOI 10.1073/pnas.0504400102; Pfund C, 1998, EMBO J, V17, P3981, DOI 10.1093/emboj/17.14.3981; Santos BC, 1998, AM J PHYSIOL-RENAL, V274, pF1054, DOI 10.1152/ajprenal.1998.274.6.F1054; Serio TR, 2000, TRENDS CELL BIOL, V10, P98, DOI 10.1016/S0962-8924(99)01711-0; Shaner L, 2004, J BIOL CHEM, V279, P21992, DOI 10.1074/jbc.M313739200; Shaner L, 2005, J BIOL CHEM, V280, P41262, DOI 10.1074/jbc.M503614200; Siegers K, 2003, EMBO J, V22, P5230, DOI 10.1093/emboj/cdg483; Sondermann H, 2001, SCIENCE, V291, P1553, DOI 10.1126/science.1057268; Steel GJ, 2004, SCIENCE, V303, P98, DOI 10.1126/science.1092287; Teter SA, 1999, CELL, V97, P755, DOI 10.1016/S0092-8674(00)80787-4; Thulasiraman V, 1999, EMBO J, V18, P85, DOI 10.1093/emboj/18.1.85; Trott A, 2005, GENETICS, V170, P1009, DOI 10.1534/genetics.105.043109; Walsh P, 2004, EMBO REP, V5, P567, DOI 10.1038/sj.embor.7400172; Wegele H, 2004, REV PHYSIOL BIOCH P, V151, P1, DOI 10.1007/s10254-003-0021-1; Yamagishi N, 2004, J BIOL CHEM, V279, P41727, DOI 10.1074/jbc.M407947200; Yamagishi N, 2000, BIOCHEM BIOPH RES CO, V272, P850, DOI 10.1006/bbrc.2000.2864; Young JC, 2003, CELL, V112, P41, DOI 10.1016/S0092-8674(02)01250-3	49	69	70	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41252	41261		10.1074/jbc.M503615200	http://dx.doi.org/10.1074/jbc.M503615200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16219770	hybrid			2022-12-25	WOS:000233866900019
J	Qing, GL; Qu, ZX; Xiao, GT				Qing, GL; Qu, ZX; Xiao, GT			Stabilization of basally translated NF-kappa B-inducing kinase (NIK) protein functions as a molecular switch of processing of NF-kappa B2 p100	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IKK-ALPHA; BETA; P100; ACTIVATION; PRECURSOR; SUBUNIT; P50	The non-canonical pathway based on processing of NF-kappa B2 precursor protein p100 to generate p52 plays a critical role in controlling B cell function and lymphoid organogenesis. Activation of this unique pathway by extracellular stimuli requires NF-kappa B-inducing kinase (NIK) and de novo protein synthesis. However, how NIK is regulated is largely unknown. Here, we systematically analyzed NIK expression at different levels in the presence or absence of different NF-kappa B stimuli. We found that NIK mRNA is relatively abundant and undergoes constitutive protein synthesis in resting B cells. However, NIK protein is undetectable. Interestingly, protein expression of NIK is steadily induced by B cell-activating factor or CD40 ligand, two major physiological inducers of p100 processing, but not by mitogen phorbol 12-myristate 13-acetate/ionomycin or cytokine tumor necrosis factor alpha, two well known inducers of the canonical NF-kappa B signaling. Remarkably, both B cell- activating factor and CD40 ligand do not significantly induce expression of NIK at translational or transcriptional level but rather rescue the basally translated NIK protein from undergoing degradation. Furthermore, overexpressed or purified NIK protein triggers p100 processing in the presence of protein synthesis inhibitor. Taken together, these studies define one important mechanism of NIK regulation and the central role of NIK stabilization in the induction of p100 processing. These studies also provide the first evidence explaining why activation of the non- canonical NF-kappa B signaling is delayed and can be inhibited by protein synthesis inhibitor as well as why most classical NF-kappa B stimuli, including mitogens and tumor necrosis factor alpha, fail to induce p100 processing.	Rutgers State Univ, Dept Cell Biol & Neurosci, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	Xiao, GT (corresponding author), Rutgers State Univ, Dept Cell Biol & Neurosci, 604 Allison Rd, Piscataway, NJ 08854 USA.	xiao@biology.rutgers.edu						Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Betts JC, 1996, MOL CELL BIOL, V16, P6363; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; Fong A, 2002, J BIOL CHEM, V277, P22111, DOI 10.1074/jbc.C200151200; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Qing GL, 2005, J BIOL CHEM, V280, P18, DOI 10.1074/jbc.M406619200; Qing GL, 2005, J BIOL CHEM, V280, P9765, DOI 10.1074/jbc.C400502200; Qu XD, 1998, NUCLEIC ACIDS RES, V26, P4068, DOI 10.1093/nar/26.17.4068; Qu ZX, 2004, J BIOL CHEM, V279, P44563, DOI 10.1074/jbc.M403689200; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Xiao GT, 2000, ONCOGENE, V19, P5198, DOI 10.1038/sj.onc.1203894; Xiao GT, 2004, J BIOL CHEM, V279, P30099, DOI 10.1074/jbc.M401428200; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Xiao GT, 2000, J BIOL CHEM, V275, P34060, DOI 10.1074/jbc.M002970200; Xiao GT, 2000, J BIOL CHEM, V275, P21081, DOI 10.1074/jbc.M002552200	26	80	88	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40578	40582		10.1074/jbc.M508776200	http://dx.doi.org/10.1074/jbc.M508776200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16223731	hybrid			2022-12-25	WOS:000233666600025
J	Wang, Q; Song, CC; Irizarry, L; Dai, RM; Zhang, XD; Li, CCH				Wang, Q; Song, CC; Irizarry, L; Dai, RM; Zhang, XD; Li, CCH			Multifunctional roles of the conserved arg residues in the second region of homology of p97/valosin-containing protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VALOSIN-CONTAINING PROTEIN; ATPASE ACTIVITY; AAA-ATPASE; MEMBRANE-FUSION; COMPLEX; HYDROLYSIS; UBIQUITIN; SUBUNIT; PROTEASOME; ARGININE	The 97-kDa molecular chaperone valosin-containing protein (VCP) belongs to a highly conserved AAA family and forms a hexameric structure that is essential for its biological functions. The AAA domain contains highly conserved motifs, the Walker A, Walker B, and the second region of homology (SRH). Although Walker A and B motifs mediate ATP binding and hydrolysis, respectively, the function of the SRH in VCP is not clear. We examined the significance of the SRH in VCP, especially the conserved Arg(359) and Arg(362) in the first AAA domain, D1 and Arg(635) and Arg(638) in the second AAA domain, D2. We show that Arg359 and Arg362 in D1 are critical for maintaining the hexameric structure and the ability to bind the polyubiquitin chains. Although the rest of the tested SRH mutants retain the hexameric structure, all of them exhibit severely reduced ATPase activity. Tryptophan fluorescence analysis showed that all of the tested mutants can bind to ATP or ADP. Thus, the reduced ATPase activity likely results from the hampered communications among protomers during hydrolysis. Moreover, when the ATPase-defective mutant R635A or R638A is mixed with the Walker A mutant of D2, the ATPase activity is partially restored, suggesting that Arg635 and Arg638 can stimulate the ATPase activity of the neighboring protomer. Interestingly, mutation of Arg359 and Arg362 uncouples the inhibitory effect of p47, a VCP co-factor, on the ATPase activity of VCP. Therefore, the Arg residues allow D1 to take on a specific conformation that is required for substrate binding and co-factor communications. Taken together, these results demonstrate that the conserved Arg residues in the SRH of both D1 and D2 play critical roles in communicating the conformational changes required for ATP hydrolysis, and SRH in D1 also contributes to substrate binding and co-factor communications.	NCI, Lab Canc Prevent, NIH, Frederick, MD 21702 USA; NCI, Basic Res Program, Sci Applicat Int Corp, Canc Res Ctr,NIH, Frederick, MD 21702 USA; Univ London Imperial Coll Sci Technol & Med, Ctr Struct Biol, Dept Biol Sci, London SW7 2AZ, England	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); Imperial College London; University of London; Institute of Cancer Research - UK	Wang, Q (corresponding author), NCI, Lab Canc Prevent, NIH, Frederick, MD 21702 USA.	qwang@ncifcrf.gov; licc@ncifcrf.gov			NCI NIH HHS [N01-CO-12400] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; Dai RM, 2001, NAT CELL BIOL, V3, P740, DOI 10.1038/35087056; Dai RM, 1998, J BIOL CHEM, V273, P3562, DOI 10.1074/jbc.273.6.3562; Davey MJ, 2003, J BIOL CHEM, V278, P4491, DOI 10.1074/jbc.M210511200; DeLaBarre B, 2005, J MOL BIOL, V347, P437, DOI 10.1016/j.jmb.2005.01.060; DeLaBarre B, 2003, NAT STRUCT BIOL, V10, P856, DOI 10.1038/nsb972; Dreveny I, 2004, EMBO J, V23, P1030, DOI 10.1038/sj.emboj.7600139; Hishida T, 2004, P NATL ACAD SCI USA, V101, P9573, DOI 10.1073/pnas.0403584101; Johnson A, 2003, J BIOL CHEM, V278, P14406, DOI 10.1074/jbc.M212708200; Karata K, 1999, J BIOL CHEM, V274, P26225, DOI 10.1074/jbc.274.37.26225; Krzywda S, 2002, STRUCTURE, V10, P1073, DOI 10.1016/S0969-2126(02)00806-7; Lupas AN, 2002, CURR OPIN STRUC BIOL, V12, P746, DOI 10.1016/S0959-440X(02)00388-3; Matveeva EA, 2002, BIOCHEMISTRY-US, V41, P530, DOI 10.1021/bi015632s; Maurizi Michael R., 2001, EMBO Reports, V2, P980, DOI 10.1093/embo-reports/kve229; Meyer HH, 2000, EMBO J, V19, P2181, DOI 10.1093/emboj/19.10.2181; Meyer HH, 1998, FEBS LETT, V437, P255, DOI 10.1016/S0014-5793(98)01232-0; Nagahama M, 2003, MOL BIOL CELL, V14, P262, DOI 10.1091/mbc.02-07-0115; Neuwald AF, 1999, GENOME RES, V9, P27; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Ogura T, 2004, J STRUCT BIOL, V146, P106, DOI 10.1016/j.jsb.2003.11.008; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; PETERS JM, 1992, J MOL BIOL, V223, P557, DOI 10.1016/0022-2836(92)90670-F; Rombel I, 1999, J BACTERIOL, V181, P4628, DOI 10.1128/JB.181.15.4628-4638.1999; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Song CC, 2003, J BIOL CHEM, V278, P3648, DOI 10.1074/jbc.M208422200; Song HK, 2000, P NATL ACAD SCI USA, V97, P14103, DOI 10.1073/pnas.250491797; Uchiyama K, 2002, J CELL BIOL, V159, P855, DOI 10.1083/jcb.200208112; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; Wang Q, 2004, J STRUCT BIOL, V146, P44, DOI 10.1016/j.jsb.2003.11.014; Wang Q, 2003, J BIOL CHEM, V278, P32784, DOI 10.1074/jbc.M303869200; Wang Q, 2003, BIOCHEM BIOPH RES CO, V300, P253, DOI 10.1016/S0006-291X(02)02840-1; Woodman PG, 2003, J CELL SCI, V116, P4283, DOI 10.1242/jcs.00817; Ye YH, 2004, NATURE, V429, P841, DOI 10.1038/nature02656; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X; Zwickl P, 1999, NAT CELL BIOL, V1, pE97, DOI 10.1038/12097	35	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40515	40523		10.1074/jbc.M509636200	http://dx.doi.org/10.1074/jbc.M509636200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16216872	hybrid			2022-12-25	WOS:000233666600018
J	Bernard, DG; Quevillon-Cheruel, S; Merchant, S; Guiard, B; Hamel, PP				Bernard, DG; Quevillon-Cheruel, S; Merchant, S; Guiard, B; Hamel, PP			Cyc2p, a membrane-bound flavoprotein involved in the maturation of mitochondrial c-type cytochromes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED SULFHYDRYL OXIDASE; HEME LYASE; SACCHAROMYCES-CEREVISIAE; APOCYTOCHROME-C; INTERMEMBRANE SPACE; ESCHERICHIA-COLI; PROTEIN IMPORT; BORDETELLA-PERTUSSIS; YEAST MITOCHONDRIA; IONIC STABILITY	Mitochondrial apocytochrome c and c(1) are converted to their holoforms in the intermembrane space by attachment of heme to the cysteines of the CXXCH motif through the activity of assembly factors cytochrome c heme lyase and cytochrome c(1) heme lyase (CCHL and CC1HL). The maintenance of apocytochrome sulfhydryls and heme substrates in a reduced state is critical for the ligation of heme. Factors that control the redox chemistry of the heme attachment reaction to apocytochrome c are known in bacteria and plastids but not in mitochondria. We have explored the function of Cyc2p, a candidate redox cytochrome c assembly component in yeast mitochondria. We show that Cyc2p is required for the activity of CCHL toward apocytochrome c and c(1) and becomes essential for the heme attachment to apocytochrome c(1) carrying a CAPCH instead of CAACH heme binding site. A redox function for Cyc2p in the heme lyase reaction is suggested from 1) the presence of a non-covalently bound FAD molecule in the C-terminal domain of Cyc2p, 2) the localization of Cyc2p in the inner membrane with the FAD binding domain exposed to the intermembrane space, and 3) the ability of recombinant Cyc2p to carry the NADPH-dependent reduction of ferricyanide. We postulate that, in vivo, Cyc2p interacts with CCHL and is involved in the reduction of heme prior to its ligation to apocytochrome c by CCHL.	CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Paris 11, Inst Biochim & Biophys Mol & Cellulaire, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of California System; University of California Los Angeles; UDICE-French Research Universities; Universite Paris Saclay	Guiard, B (corresponding author), CNRS, Ctr Genet Mol, Ave Terrasse, F-91198 Gif Sur Yvette, France.	guiard@cgm.cnrs-gif.fr; hamel.16@osu.edu		Bernard, Delphine/0000-0002-9439-5482				Allen JWA, 2003, PHILOS T ROY SOC B, V358, P255, DOI 10.1098/rstb.2002.1192; Allen S, 2005, J MOL BIOL, V353, P937, DOI 10.1016/j.jmb.2005.08.049; Barber MJ, 1996, PROTEIN EXPRES PURIF, V8, P41, DOI 10.1006/prep.1996.0072; BASILE G, 1980, J BIOL CHEM, V255, P7181; Beckett CS, 2000, MOL MICROBIOL, V38, P465, DOI 10.1046/j.1365-2958.2000.02174.x; Bernard DG, 2003, J BIOL CHEM, V278, P49732, DOI 10.1074/jbc.M308881200; Chivers PT, 1996, EMBO J, V15, P2659, DOI 10.1002/j.1460-2075.1996.tb00626.x; CLAISSE ML, 1970, EUR J BIOCHEM, V16, P430, DOI 10.1111/j.1432-1033.1970.tb01098.x; Daltrop O, 2003, J BIOL CHEM, V278, P4404, DOI 10.1074/jbc.M211124200; Deshmukh M, 2000, MOL MICROBIOL, V35, P123, DOI 10.1046/j.1365-2958.2000.01683.x; Dreyfuss BW, 2003, J BIOL CHEM, V278, P2604, DOI 10.1074/jbc.M208652200; DUJARDIN G, 1980, MOL GEN GENET, V179, P469, DOI 10.1007/BF00271736; DUMONT ME, 1991, MOL CELL BIOL, V11, P5487, DOI 10.1128/MCB.11.11.5487; DUMONT ME, 1987, EMBO J, V6, P235, DOI 10.1002/j.1460-2075.1987.tb04744.x; DUMONT ME, 1993, MOL CELL BIOL, V13, P6442, DOI 10.1128/MCB.13.10.6442; DUMONT ME, 1988, J BIOL CHEM, V263, P15928; DUMONT ME, 1996, ADV MOL CEL, V17, P103; Erlendsson LS, 2003, J BIOL CHEM, V278, P17852, DOI 10.1074/jbc.M300103200; Feissner RE, 2005, J BACTERIOL, V187, P3941, DOI 10.1128/JB.187.12.3941-3949.2005; Gerber J, 2001, J BIOL CHEM, V276, P23486, DOI 10.1074/jbc.M100134200; Goldman BS, 2001, RES MICROBIOL, V152, P323, DOI 10.1016/S0923-2508(01)01203-7; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; Hamel P, 1998, GENETICS, V150, P601; Hamel PP, 2003, J BIOL CHEM, V278, P2593, DOI 10.1074/jbc.M208651200; Heazlewood JL, 2004, PLANT CELL, V16, P241, DOI 10.1105/tpc.016055; Kermorgant M, 1997, CURR GENET, V31, P302, DOI 10.1007/s002940050209; Kranz R, 1998, MOL MICROBIOL, V29, P383, DOI 10.1046/j.1365-2958.1998.00869.x; Lee JE, 2000, FEBS LETT, V477, P62, DOI 10.1016/S0014-5793(00)01767-1; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; MATNER RR, 1982, J BIOL CHEM, V257, P9811; MAYER A, 1995, J BIOL CHEM, V270, P12390, DOI 10.1074/jbc.270.21.12390; Mesecke N, 2005, CELL, V121, P1059, DOI 10.1016/j.cell.2005.04.011; MEYER EH, 2005, IN PRESS P NATL ACAD; Mossner E, 1999, J BIOL CHEM, V274, P25254, DOI 10.1074/jbc.274.36.25254; Nakamoto SS, 2000, BIOCHIMIE, V82, P603, DOI 10.1016/S0300-9084(00)00605-2; NICHOLSON DW, 1987, EUR J BIOCHEM, V164, P147, DOI 10.1111/j.1432-1033.1987.tb11006.x; NICHOLSON DW, 1989, P NATL ACAD SCI USA, V86, P4340, DOI 10.1073/pnas.86.12.4340; NICHOLSON DW, 1988, J BIOL CHEM, V263, P19034; NICHOLSON DW, 1989, J BIOL CHEM, V264, P10156; Page MLD, 2004, J BIOL CHEM, V279, P32474, DOI 10.1074/jbc.M404285200; PEARCE DA, 1995, J BIOL CHEM, V270, P20879, DOI 10.1074/jbc.270.36.20879; Pearce DA, 1998, FEBS LETT, V439, P307, DOI 10.1016/S0014-5793(98)01374-X; Quinn GB, 1996, ARCH BIOCHEM BIOPHYS, V327, P151, DOI 10.1006/abbi.1996.0103; Reid E, 2001, BIOCHEM J, V355, P51, DOI 10.1042/0264-6021:3550051; Ren Q, 2002, J BIOL CHEM, V277, P7657, DOI 10.1074/jbc.M110979200; Rissler M, 2005, J MOL BIOL, V353, P485, DOI 10.1016/j.jmb.2005.08.051; Ryan MT, 2001, METHOD CELL BIOL, V65, P189, DOI 10.1016/S0091-679X(01)65012-X; Saint-Georges Y, 2002, J BIOL CHEM, V277, P49397, DOI 10.1074/jbc.M207219200; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sanchez NS, 2001, ARCH BIOCHEM BIOPHYS, V392, P326, DOI 10.1006/abbi.2001.2465; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Sevier CS, 2001, NAT CELL BIOL, V3, P874, DOI 10.1038/ncb1001-874; SHERMAN F, 1965, J MOL BIOL, V13, P21, DOI 10.1016/S0022-2836(65)80077-8; SHERMAN F, 1990, GENETICS, V125, P9; Steiner H, 1996, J BIOL CHEM, V271, P32605, DOI 10.1074/jbc.271.51.32605; STEINER H, 1995, J BIOL CHEM, V270, P22842, DOI 10.1074/jbc.270.39.22842; Stevens JM, 2004, ACCOUNTS CHEM RES, V37, P999, DOI 10.1021/ar030266l; STUART RA, 1990, J BIOL CHEM, V265, P20210; TANIUCHI H, 1983, J BIOL CHEM, V258, P963; ThonyMeyer L, 1997, MICROBIOL MOL BIOL R, V61, P337; Tong JC, 1998, J BIOL CHEM, V273, P25695, DOI 10.1074/jbc.273.40.25695; VELOSO D, 1984, J BIOL CHEM, V259, P6067; VELOSO D, 1981, J BIOL CHEM, V256, P8646; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Xie ZY, 1998, BBA-BIOENERGETICS, V1365, P309, DOI 10.1016/S0005-2728(98)00085-1; ZOLLNER A, 1992, EUR J BIOCHEM, V207, P1093, DOI 10.1111/j.1432-1033.1992.tb17146.x	66	38	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					39852	39859		10.1074/jbc.M508574200	http://dx.doi.org/10.1074/jbc.M508574200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16207709	hybrid			2022-12-25	WOS:000233461300023
J	Hu, ZY; Dai, Y; Prentki, M; Chohnan, S; Lane, MD				Hu, ZY; Dai, Y; Prentki, M; Chohnan, S; Lane, MD			A role for hypothalamic malonyl-CoA in the control of food intake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHASE; ACTIVATED PROTEIN-KINASE; NEUROPEPTIDE-Y; INSULIN-SECRETION; CERULENIN ANALOGS; OBESE MICE; AMP-KINASE; INHIBITOR; C75; PALMITOYLATION	The cellular level of malonyl-CoA, an intermediate in fatty acid biosynthesis, depends on its rate of synthesis catalyzed by acetyl-CoA carboxylase relative to its rate of utilization and degradation catalyzed by fatty acid synthase and malonyl-CoA decarboxylase, respectively. Recent evidence suggests that hypothalamic malonyl-CoA functions in the regulation of feeding behavior by altering the expression of key orexigenic and anorexigenic neuropeptides. Here we report that 5-aminoimidazole-4-carboxamide ribonucleoside ( AICAR), a 5'-AMP kinase activator, rapidly lowers malonyl-CoA both in GT1-7 hypothalamic neurons and in the hypothalami of mice. These effects correlate closely with the phosphorylation of acetyl-CoA carboxylase, an established target of AMP kinase. Intracerebroventricular (i.c.v.)administration of AICAR rapidly lowers hypothalamic [malonyl-CoA] and increases food intake. Expression of an adenoviral cytosolic malonyl-CoA decarboxylase vector ( Ad-cMCD) in hypothalamic GT1-7 cells decreases malonyl-CoA. When delivered by bilateral stereotaxic injection into the ventral hypothalamus ( encompassing the arcuate nucleus) of mice, Ad-cMCD increases food intake and body weight. Ad-MCD delivered into the ventral hypothalamus also reverses the rapid suppression of food intake caused by i.c.v.-administered C75, a fatty acid synthase inhibitor that increases hypothalamic [malonyl-CoA]. Taken together these findings implicate malonyl-CoA in the hypothalamic regulation of feeding behavior.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Ibaraki Univ, Coll Agr, Dept Bioresource Sci, Ami, Ibaraki 3000393, Japan; Univ Montreal, Montreal Diabet Res Ctr, Montreal, PQ H2L 4M1, Canada	Johns Hopkins University; Ibaraki University; Universite de Montreal	Lane, MD (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 512 WBSB,725 N Wolfe St, Baltimore, MD 21205 USA.	dlane@jhmi.edu	Chohnan, Shigeru/AAS-8040-2020; Chohnan, Shigeru/W-1580-2019	Chohnan_, Shigeru/0000-0002-4624-927X				Cha SH, 2005, P NATL ACAD SCI USA, V102, P14557, DOI 10.1073/pnas.0507300102; Cha SH, 2004, BIOCHEM BIOPH RES CO, V317, P301, DOI 10.1016/j.bbrc.2004.03.026; De Vos ML, 2001, BIOCHEM PHARMACOL, V62, P985, DOI 10.1016/S0006-2952(01)00739-0; Dowell P, 2005, ANNU REV BIOCHEM, V74, P515, DOI 10.1146/annurev.biochem.73.011303.074027; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hu ZY, 2003, P NATL ACAD SCI USA, V100, P12624, DOI 10.1073/pnas.1834402100; Kim EK, 2004, J BIOL CHEM, V279, P19970, DOI 10.1074/jbc.M402165200; Kuhajda FP, 2000, P NATL ACAD SCI USA, V97, P3450, DOI 10.1073/pnas.050582897; Kumar MV, 2002, P NATL ACAD SCI USA, V99, P1921, DOI 10.1073/pnas.042683699; Landree LE, 2004, J BIOL CHEM, V279, P3817, DOI 10.1074/jbc.M310991200; Lawrence DS, 1999, J MED CHEM, V42, P4932, DOI 10.1021/jm980591s; Loftus TM, 2000, SCIENCE, V288, P2379, DOI 10.1126/science.288.5475.2379; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Minokoshi Y, 2003, BIOCHEM SOC T, V31, P196, DOI 10.1042/bst0310196; Palmiter RD, 1998, RECENT PROG HORM RES, V53, P163; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; Qian S, 2002, MOL CELL BIOL, V22, P5027, DOI 10.1128/MCB.22.14.5027-5035.2002; Roduit R, 2004, DIABETES, V53, P1007, DOI 10.2337/diabetes.53.4.1007; Ruderman N, 2004, NAT REV DRUG DISCOV, V3, P340, DOI 10.1038/nrd1344; Sacksteder KA, 1999, J BIOL CHEM, V274, P24461, DOI 10.1074/jbc.274.35.24461; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Shimokawa T, 2002, P NATL ACAD SCI USA, V99, P66, DOI 10.1073/pnas.012606199; Takahashi KA, 2004, ENDOCRINOLOGY, V145, P184, DOI 10.1210/en.2003-0337; YEH LA, 1980, J BIOL CHEM, V255, P2308	25	102	106	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					39681	39683		10.1074/jbc.C500398200	http://dx.doi.org/10.1074/jbc.C500398200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16219771	hybrid			2022-12-25	WOS:000233461300003
J	Minard, KI; McAlister-Henn, L				Minard, KI; McAlister-Henn, L			Sources of NADPH in yeast vary with carbon source	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXISOMAL BETA-OXIDATION; SACCHAROMYCES-CEREVISIAE; ISOCITRATE DEHYDROGENASE; FATTY-ACIDS; ACETALDEHYDE DEHYDROGENASE; CYTOSOLIC SOURCES; STRUCTURAL GENE; ALD6 GENE; IDENTIFICATION; EXPRESSION	Production of NADPH in Saccharomyces cerevisiae cells grown on glucose has been attributed to glucose-6-phosphate dehydrogenase (Zwf1p) and a cytosolic aldehyde dehydrogenase (Ald6p) (Grabowska, D., and Chelstowska, A. (2003) J. Biol. Chem. 278, 13984-13988). This was based on compensation by overexpression of Ald6p for phenotypes associated with ZWF1 gene disruption and on the apparent lethality resulting from co-disruption of ZWF1 and ALD6 genes. However, we have found that a zwf1 Delta ald6 Delta mutant can be constructed by mating when tetrads are dissected on plates with a nonfermentable carbon source (lactate), a condition associated with expression of another enzymatic source of NADPH, cytosolic NADP(+)- specific isocitrate dehydrogenase (Idp2p). We demonstrated previously that a zwf1 Delta idp2 Delta mutant loses viability when shifted to medium with oleate or acetate as the carbon source, apparently because of the inadequate supply of NADPH for cellular antioxidant systems. In contrast, the zwf1 Delta ald6 Delta mutant grows as well as the parental strain in similar shifts. In addition, the zwf1 Delta ald6 Delta mutant grows slowly but does not lose viability when shifted to culture medium with glucose as the carbon source, and the mutant resumes growth when the glucose is exhausted from the medium. Measurements of NADP( H) levels revealed that NADPH may not be rapidly utilized in the zwf1 Delta ald6 Delta mutant in glucose medium, perhaps because of a reduction in fatty acid synthesis associated with loss of Ald6p. In contrast, levels of NADP(+) rise dramatically in the zwf1 Delta idp2 Delta mutant in acetate medium, suggesting a decrease in production of NADPH reducing equivalents needed both for biosynthesis and for antioxidant functions.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	McAlister-Henn, L (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	henn@uthscsa.edu			NATIONAL INSTITUTE ON AGING [R01AG017477] Funding Source: NIH RePORTER; NIA NIH HHS [AG017477] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMS A, 1997, METHODS YEAST GENETI, P19; BERTLETT BS, 1997, J BIOL CHEM, V272, P20313, DOI DOI 10.1074/JBC.272.33.20313; Beutler E, 1996, BLOOD REV, V10, P45, DOI 10.1016/S0268-960X(96)90019-3; Boles E, 1998, J BACTERIOL, V180, P2875, DOI 10.1128/JB.180.11.2875-2882.1998; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Butcher RA, 2004, P NATL ACAD SCI USA, V101, P7868, DOI 10.1073/pnas.0402317101; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Grabowska D, 2003, J BIOL CHEM, V278, P13984, DOI 10.1074/jbc.M210076200; HASELBECK RJ, 1993, J BIOL CHEM, V268, P12116; HASELBECK RJ, 1991, J BIOL CHEM, V266, P2339; Henke B, 1998, J BIOL CHEM, V273, P3702, DOI 10.1074/jbc.273.6.3702; Hiltunen JK, 2003, FEMS MICROBIOL REV, V27, P35, DOI 10.1016/S0168-6445(03)00017-2; JACOBSON MK, 1974, BIOCHIM BIOPHYS ACTA, V350, P277, DOI 10.1016/0005-2744(74)90502-6; Kawai S, 2001, FEMS MICROBIOL LETT, V200, P181, DOI 10.1111/j.1574-6968.2001.tb10712.x; Koh HJ, 2004, J BIOL CHEM, V279, P39968, DOI 10.1074/jbc.M402260200; Kunau WH, 1995, PROG LIPID RES, V34, P267, DOI 10.1016/0163-7827(95)00011-9; Lee SM, 2002, FREE RADICAL BIO MED, V32, P1185, DOI 10.1016/S0891-5849(02)00815-8; Lin SJ, 2004, GENE DEV, V18, P12, DOI 10.1101/gad.1164804; Lin SS, 2001, J BIOL CHEM, V276, P36000, DOI 10.1074/jbc.M103509200; LOFTUS TM, 1994, BIOCHEMISTRY-US, V33, P9661, DOI 10.1021/bi00198a035; MCALISTERHENN L, 1987, J BACTERIOL, V169, P5157, DOI 10.1128/jb.169.11.5157-5166.1987; Meaden PG, 1997, YEAST, V13, P1319, DOI 10.1002/(SICI)1097-0061(199711)13:14<1319::AID-YEA183>3.0.CO;2-T; Minard KI, 1998, J BIOL CHEM, V273, P31486, DOI 10.1074/jbc.273.47.31486; Minard KI, 1999, J BIOL CHEM, V274, P3402, DOI 10.1074/jbc.274.6.3402; Minard KL, 2001, FREE RADICAL BIO MED, V31, P832, DOI 10.1016/S0891-5849(01)00666-9; NOGAE I, 1990, GENE, V96, P161, DOI 10.1016/0378-1119(90)90248-P; PASSONNEAU JV, 1993, ENZYMATIC ANAL PRACT, P1; RydstroM J., 1976, ENZYME, V13, P51; Saint-Prix F, 2004, MICROBIOL-SGM, V150, P2209, DOI 10.1099/mic.0.26999-0; Shi F, 2005, FEBS J, V272, P3337, DOI 10.1111/j.1742-4658.2005.04749.x; Sophos NA, 2003, CHEM-BIOL INTERACT, V143, P5, DOI 10.1016/S0009-2797(02)00163-1; Stadtman ER, 2002, FREE RADICAL BIO MED, V33, P597, DOI 10.1016/S0891-5849(02)00904-8; THOMAS D, 1991, EMBO J, V10, P547, DOI 10.1002/j.1460-2075.1991.tb07981.x; van Roermund CWT, 1998, EMBO J, V17, P677, DOI 10.1093/emboj/17.3.677; Vasiliou V, 2000, CHEM-BIOL INTERACT, V129, P1, DOI 10.1016/S0009-2797(00)00211-8; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310	37	91	99	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					39890	39896		10.1074/jbc.M509461200	http://dx.doi.org/10.1074/jbc.M509461200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16179340	hybrid			2022-12-25	WOS:000233461300027
J	Mulcahy, LR; Vaslet, CA; Nillni, EA				Mulcahy, LR; Vaslet, CA; Nillni, EA			Prohormone-convertase 1 processing enhances post-Golgi sorting of prothyrotropin-releasing hormone-derived peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED SECRETORY PATHWAY; TRANSFECTED MAMMALIAN-CELLS; PITUITARY ATT-20 CELLS; DISULFIDE-BONDED LOOP; CARBOXYPEPTIDASE-E; CHROMOGRANIN-B; DIBASIC RESIDUES; RENIN SECRETION; CONVERTASE PC1; PRO-PEPTIDE	Rat prothyrotropin-releasing hormone ( pro-TRH) is endoproteolyzed within the regulated secretory pathway of neuroendocrine cells yielding five TRH peptides and seven to nine other unique peptides. Endoproteolysis is performed by two prohormone convertases, PC1 and PC2. Proteolysis of pro-TRH begins in the trans-Golgi network and forms two intermediates that are then differentially processed as they exit the Golgi and are packaged into immature secretory granules. We hypothesized that this initial endoproteolysis may be necessary for downstream sorting of proTRH-derived peptides as it occurs before Golgi exit and thus entry into the regulated secretory pathway. We now report that when pro-TRH is transiently expressed in GH4C1 cells, a neuroendocrine cell line lacking PC1, under pulse-chase conditions release is constitutive and composed of more immature processing intermediates. This is also observed by radioimmunoassay under steady-state conditions. When a mutant form of pro-TRH, which has the dibasic sites of initial processing mutated to glycines, is expressed in AtT20 cells, a neuroendocrine cell line endogenously expressing PC1, both steady-state and pulse-chase experiments revealed that peptides derived from this mutant precursor are secreted in a constitutive fashion. A constitutively secreted form of PC1 does not target pro-TRH peptides to the constitutive secretory pathway but results in sorting to the regulated secretory pathway. These results indicated that initial processing action of PC1 on pro-TRH in the trans-Golgi network, and not a cargo-receptor relationship, is important for the downstream sorting events that result in storage of pro-TRH-derived peptides in mature secretory granules.	Brown Univ, Rhode Isl Hosp, Sch Med, Dept Med,Div Endocrinol, Providence, RI 02903 USA; Brown Univ, Dept Mol & Cellular Biol & Biochem, Providence, RI 02912 USA; Brown Univ, Dept Pathol & Lab Med, Providence, RI 02912 USA	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Brown University; Brown University	Nillni, EA (corresponding author), Div Endocrinol, 55 Claverick St,Rm 430, Providence, RI 02903 USA.	Eduardo_Nillni@Brown.edu			NIDA NIH HHS [1F31DA016875-01] Funding Source: Medline; NIDDK NIH HHS [R01 DK 1-58148] Funding Source: Medline; NINDS NIH HHS [1R01NS045231] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045231] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [F31DA016875] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ARVAN P, 1991, J BIOL CHEM, V266, P14171; Arvan P, 2004, TRAFFIC, V5, P53, DOI 10.1111/j.1600-0854.2004.00152.x; Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; Blazquez M, 2000, BIOCHEM J, V349, P843, DOI 10.1042/bj3490843; Brakch N, 2002, J NEUROCHEM, V81, P1166, DOI 10.1046/j.1471-4159.2002.00919.x; Brechler V, 1996, J BIOL CHEM, V271, P20636, DOI 10.1074/jbc.271.34.20636; Bundgaard JR, 2004, J BIOL CHEM, V279, P5488, DOI 10.1074/jbc.M310547200; CHANAT E, 1993, EMBO J, V12, P2159, DOI 10.1002/j.1460-2075.1993.tb05864.x; CHIDGEY MAJ, 1990, EUR J BIOCHEM, V190, P139, DOI 10.1111/j.1432-1033.1990.tb15556.x; CHU WN, 1990, MOL ENDOCRINOL, V4, P1905, DOI 10.1210/mend-4-12-1905; Cool DR, 1998, MOL CELL ENDOCRINOL, V139, P7, DOI 10.1016/S0303-7207(98)00081-1; Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7; delaCruz IP, 1996, J BIOL CHEM, V271, P22736, DOI 10.1074/jbc.271.37.22736; Dhanvantari S, 2000, J BIOL CHEM, V275, P29887, DOI 10.1074/jbc.M005364200; Eaton BA, 2000, J NEUROSCI, V20, P7334; Feliciangeli S, 2002, BIOCHEM BIOPH RES CO, V290, P191, DOI 10.1006/bbrc.2001.6137; Feliciangeli S, 2001, J BIOL CHEM, V276, P6140, DOI 10.1074/jbc.M009613200; Feng LJ, 2003, J BIOL CHEM, V278, P31486, DOI 10.1074/jbc.M305690200; FRIEDMAN TC, 1995, ENDOCRINOLOGY, V136, P4462, DOI 10.1210/en.136.10.4462; Glombik MM, 1999, EMBO J, V18, P1059, DOI 10.1093/emboj/18.4.1059; Gorr SU, 1999, AM J PHYSIOL-CELL PH, V277, pC121, DOI 10.1152/ajpcell.1999.277.1.C121; Halban PA, 2003, MOL BIOL CELL, V14, P1195, DOI 10.1091/mbc.E02-05-0299; HARRISON TM, 1989, PROTEINS, V5, P259, DOI 10.1002/prot.340050402; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; Jacob R, 2000, J BIOL CHEM, V275, P6566, DOI 10.1074/jbc.275.9.6566; Jain RK, 2000, J BIOL CHEM, V275, P27032; Jutras I, 1997, J BIOL CHEM, V272, P15184, DOI 10.1074/jbc.272.24.15184; Jutras I, 2000, J BIOL CHEM, V275, P40337, DOI 10.1074/jbc.M004757200; Keeler C, 2004, J MOL NEUROSCI, V22, P43, DOI 10.1385/JMN:22:1-2:43; Kromer A, 1998, J CELL BIOL, V140, P1331, DOI 10.1083/jcb.140.6.1331; Kuliawat R, 2000, MOL BIOL CELL, V11, P1959, DOI 10.1091/mbc.11.6.1959; Lacombe MJ, 2005, J BIOL CHEM, V280, P4803, DOI 10.1074/jbc.M408658200; Lou H, 2005, NEURON, V45, P245, DOI 10.1016/j.neuron.2004.12.037; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Moore H.-P. H., 2002, Archives of Physiology and Biochemistry, V110, P16, DOI 10.1076/apab.110.1.16.903; MOORE HPH, 1986, NATURE, V321, P443, DOI 10.1038/321443a0; NAGAHAMA M, 1990, FEBS LETT, V264, P67, DOI 10.1016/0014-5793(90)80766-C; NAKAYAMA K, 1989, FEBS LETT, V257, P89, DOI 10.1016/0014-5793(89)81793-4; NILLNI EA, 1993, ENDOCRINOLOGY, V132, P1260, DOI 10.1210/en.132.3.1260; NILLNI EA, 1993, ENDOCRINOLOGY, V132, P1271, DOI 10.1210/en.132.3.1271; Nillni EA, 1999, ENDOCR REV, V20, P599, DOI 10.1210/er.20.5.599; NILLNI EA, 1995, J NEUROCHEM, V65, P2462; Nillni EA, 1996, ENDOCRINOLOGY, V137, P5651, DOI 10.1210/en.137.12.5651; Nillni EA, 2001, ENDOCRINOLOGY, V142, P896, DOI 10.1210/en.142.2.896; Normant E, 1998, ENDOCRINOLOGY, V139, P2137, DOI 10.1210/en.139.4.2137; Rovere C, 1999, J BIOL CHEM, V274, P12461, DOI 10.1074/jbc.274.18.12461; ROY P, 1991, MOL CELL ENDOCRINOL, V82, P237, DOI 10.1016/0303-7207(91)90037-S; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schaner P, 1997, J BIOL CHEM, V272, P19958, DOI 10.1074/jbc.272.32.19958; SEVARINO KA, 1989, J BIOL CHEM, V264, P21529; Taupenot L, 2002, J CELL SCI, V115, P4827, DOI 10.1242/jcs.00140; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Varlamov O, 1999, J BIOL CHEM, V274, P14759, DOI 10.1074/jbc.274.21.14759; Yoo SH, 1996, J BIOL CHEM, V271, P1558	54	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					39818	39826		10.1074/jbc.M507193200	http://dx.doi.org/10.1074/jbc.M507193200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16204236	hybrid			2022-12-25	WOS:000233461300019
J	Hut, HMJ; Rembacz, KP; van Waarde, MAWH; Lemstra, W; van Cappellen, WA; Kampinga, HH; Sibon, OCM				Hut, HMJ; Rembacz, KP; van Waarde, MAWH; Lemstra, W; van Cappellen, WA; Kampinga, HH; Sibon, OCM			Dysfunctional BRCA1 is only indirectly linked to multiple centrosomes	ONCOGENE			English	Article						BRCA1; EGFP; BRCA1; BF3; cancer; centrosomes	AMPLIFICATION; INSTABILITY	A remarkable and yet unexplained phenomenon in cancer cells is the presence of multiple centrosomes, organelles required for normal cell division. Previously, it was demonstrated that the tumor suppressor BRCA1 is a component of centrosomes. This observation led to the hypothesis that defective BRCA1 results in malfunctioning centrosomes and faulty centrosomes are a possible cause of cancer. Using EGFP-tagged fusion proteins and BRCA1-/- cells we show that although some BRCA1 antibodies do label centrosomes under certain. xation conditions, BRCA1 is not a centrosomal protein. Therefore, it is unlikely that a mutation in BRCA1 directly alters centrosome structure and function. BRCA1 plays an established role in DNA damage repair and in G(2)/M checkpoint regulation. We present evidence that multiple centrosomes can arise in any cell when G(2)/M checkpoint fails and entrance into mitosis occurs in the presence of DNA damage.	Univ Groningen, Dept Radiat & Stress Cell Biol, UMCG, NL-9713 AV Groningen, Netherlands; Erasmus Univ, Fac Med & Hlth Sci, Dept Reprod & Dev, NL-3000 DR Rotterdam, Netherlands	University of Groningen; Erasmus University Rotterdam	Sibon, OCM (corresponding author), Univ Groningen, Dept Radiat & Stress Cell Biol, UMCG, Ant Deusinglaan 1, NL-9713 AV Groningen, Netherlands.	o.c.m.sibon@med.umcg.nl		Kampinga, Harm/0000-0002-8966-8466; Sibon, Ody/0000-0002-6836-6063				BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Borel F, 2002, P NATL ACAD SCI USA, V99, P9819, DOI 10.1073/pnas.152205299; Deng CX, 2002, ONCOGENE, V21, P6222, DOI 10.1038/sj.onc.1205713; Dodson H, 2004, EMBO J, V23, P3864, DOI 10.1038/sj.emboj.7600393; Doxsey S, 2002, MOL CELL, V10, P439, DOI 10.1016/S1097-2765(02)00654-8; Fisk HA, 2002, CURR OPIN CELL BIOL, V14, P700, DOI 10.1016/S0955-0674(02)00385-X; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Hsu LC, 2001, CANCER RES, V61, P7713; Hut HMJ, 2003, MOL BIOL CELL, V14, P1993, DOI 10.1091/mbc.E02-08-0510; Johannsson OT, 2003, LAB INVEST, V83, P387, DOI 10.1097/01.LAB.0000060030.10652.8C; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Marx J, 2001, SCIENCE, V292, P426, DOI 10.1126/science.292.5516.426; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Rieder CL, 2001, TRENDS CELL BIOL, V11, P413, DOI 10.1016/S0962-8924(01)02085-2; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Sibon OCM, 2000, NAT CELL BIOL, V2, P90, DOI 10.1038/35000041; Takada S, 2003, CELL, V113, P87, DOI 10.1016/S0092-8674(03)00202-2; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Wong C, 2003, NAT CELL BIOL, V5, P539, DOI 10.1038/ncb993; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9	22	14	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2005	24	51					7619	7623		10.1038/sj.onc.1208859	http://dx.doi.org/10.1038/sj.onc.1208859			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	984VQ	16205648				2022-12-25	WOS:000233333800011
J	Koldamova, R; Staufenbiel, M; Lefterov, I				Koldamova, R; Staufenbiel, M; Lefterov, I			Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; BINDING CASSETTE TRANSPORTER-1; ISOFORM-SPECIFIC BINDING; PROTEIN TRANSGENIC MICE; CENTRAL-NERVOUS-SYSTEM; APOLIPOPROTEIN-A-I; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; MOUSE MODEL; TANGIER-DISEASE	ABCA1 (ATP-binding cassette transporter A1) is a major regulator of cholesterol efflux and high density lipoprotein (HDL) metabolism. Mutations in human ABCA1 cause severe HDL deficiencies characterized by the virtual absence of apoA-I and HDL and prevalent atherosclerosis. Recently, it has been reported that the lack of ABCA1 causes a significant reduction of apoE protein level in the brain of ABCA1 knock-out (ABCA1(-/-)) mice. ApoE isoforms strongly affect Alzheimer disease (AD) pathology and risk. To determine further the effect of ABCA1 on amyloid deposition, we used APP23 transgenic mice in which the human familial Swedish AD mutant is expressed only in neurons. We demonstrated that the targeted disruption of ABCA1 increases amyloid deposition in APP23 mice, and the effect is manifested by an increased level of A beta immunoreactivity, as well as thioflavine S-positive plaques in brain parenchyma. We found that the lack of ABCA1 also considerably increased the level of cerebral amyloid angiopathy and exacerbated cerebral amyloid angiopathy-related microhemorrhage in APP23/ ABCA1(-/-) mice. Remarkably, the elevation in parenchymal and vascular amyloid in APP23/ABCA1(-/-) mice was accompanied by a dramatic decrease in the level of soluble brain apoE, although insoluble apoE was not changed. The elevation of insoluble A beta fraction in old APP23/ABCA1(-/-) mice, accompanied by a lack of changes in APP processing and soluble beta-amyloid in young APP23/ABCA1(-/-) animals, supports the conclusion that the ABCA1 deficiency increases amyloid deposition. These results suggest that ABCA1 plays a role in the pathogenesis of parenchymal and cerebrovascular amyloid pathology and thus may be considered a therapeutic target in AD.	Univ Pittsburgh, Grad Sch Publ Hlth, Dept Environm & Occupat Hlth, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA; Novartis Inst BioMed Res, CH-4002 Basel, Switzerland	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Novartis	Koldamova, R (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Environm & Occupat Hlth, Pittsburgh, PA 15260 USA.	radak@pitt.edu; iliyal@pitt.edu	Lefterov, Iliya/B-4767-2008	Lefterov, Iliya/0000-0002-0249-0280; Koldamova, Radosveta/0000-0002-6761-0984	NATIONAL INSTITUTE ON AGING [R03AG023304, R21AG023662] Funding Source: NIH RePORTER; NIA NIH HHS [AG023304, AG023662] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bales KR, 1999, P NATL ACAD SCI USA, V96, P15233, DOI 10.1073/pnas.96.26.15233; Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Bamberger ME, 2003, J NEUROSCI, V23, P2665; Bertram L, 2004, PHARMACOL RES, V50, P385, DOI 10.1016/j.phrs.2003.11.018; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Bornemann KD, 2001, AM J PATHOL, V158, P63, DOI 10.1016/S0002-9440(10)63945-4; Brewer HB, 2004, ARTERIOSCL THROM VAS, V24, P1755, DOI 10.1161/01.ATV.0000142804.27420.5b; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Brown J, 2004, J BIOL CHEM, V279, P34674, DOI 10.1074/jbc.M402324200; Burns MP, 2003, MOL BRAIN RES, V110, P119, DOI 10.1016/S0169-328X(02)00647-2; Bussiere T, 2004, AM J PATHOL, V165, P987, DOI 10.1016/S0002-9440(10)63360-3; Calhoun ME, 1999, P NATL ACAD SCI USA, V96, P14088, DOI 10.1073/pnas.96.24.14088; Calhoun ME, 1998, NATURE, V395, P755, DOI 10.1038/27351; Carson F. L., 1996, HISTOTECHNOLOGY SELF; Clee SM, 2001, CIRCULATION, V103, P1198; Davis J, 2004, J BIOL CHEM, V279, P20296, DOI 10.1074/jbc.M312946200; Deane R, 2004, NEURON, V43, P333, DOI 10.1016/j.neuron.2004.07.017; DeMattos RB, 2004, NEURON, V41, P193, DOI 10.1016/S0896-6273(03)00850-X; Dietschy JM, 2004, J LIPID RES, V45, P1375, DOI 10.1194/jlr.R400004-JLR200; Emery VO, 2005, J NEUROL SCI, V229, P27, DOI 10.1016/j.jns.2004.11.016; Fagan AM, 2004, AM J PATHOL, V165, P1413, DOI 10.1016/S0002-9440(10)63399-8; Fryer JD, 2003, J NEUROSCI, V23, P7889; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Gorelick PB, 2004, STROKE, V35, P2620, DOI 10.1161/01.STR.0000143318.70292.47; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Hasty AH, 2005, J LIPID RES, V46, P1433, DOI 10.1194/jlr.M400418-JLR200; Hirsch-Reinshagen V, 2005, J BIOL CHEM, V280, P43243, DOI 10.1074/jbc.M508781200; Hirsch-Reinshagen V, 2004, J BIOL CHEM, V279, P41197, DOI 10.1074/jbc.M407962200; Holtzman DM, 2000, ANN NEUROL, V47, P739, DOI 10.1002/1531-8249(200006)47:6<739::AID-ANA6>3.0.CO;2-8; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; Honig LS, 2005, NEUROLOGY, V64, P494, DOI 10.1212/01.WNL.0000150886.50187.30; Humphries SE, 2004, LANCET NEUROL, V3, P227, DOI 10.1016/S1474-4422(04)00708-2; Jankowsky JL, 2004, HUM MOL GENET, V13, P159, DOI 10.1093/hmg/ddh019; Katzov H, 2004, HUM MUTAT, V23, P358, DOI 10.1002/humu.20012; Kinchen JM, 2005, NATURE, V434, P93, DOI 10.1038/nature03263; Kivipelto M, 2001, BMJ-BRIT MED J, V322, P1447, DOI 10.1136/bmj.322.7300.1447; Koenigsknecht J, 2004, J NEUROSCI, V24, P9838, DOI 10.1523/JNEUROSCI.2557-04.2004; Koeppen AH, 1995, J NEUROL SCI, V134, P1, DOI 10.1016/0022-510X(95)00202-D; Koistinaho M, 2004, NAT MED, V10, P719, DOI 10.1038/nm1058; Koldamova RP, 2003, J BIOL CHEM, V278, P13244, DOI 10.1074/jbc.M300044200; Koldamova RP, 2001, BIOCHEMISTRY-US, V40, P3553, DOI 10.1021/bi002186k; Koldamova T, 2005, J BIOL CHEM, V280, P4079, DOI 10.1074/jbc.M411420200; Koudinov AR, 1998, CLIN CHIM ACTA, V270, P75, DOI 10.1016/S0009-8981(97)00207-6; Koudinov AR, 2001, NEUROSCI LETT, V314, P115, DOI 10.1016/S0304-3940(01)02263-7; Kuo YM, 2001, MOL MED, V7, P609, DOI 10.1007/BF03401867; LADU MJ, 1994, J BIOL CHEM, V269, P23403; LADU MJ, 1995, J BIOL CHEM, V270, P9039, DOI 10.1074/jbc.270.16.9039; Li YH, 2004, NEUROSCI LETT, V366, P268, DOI 10.1016/j.neulet.2004.05.047; Maezawa I, 2004, J NEUROCHEM, V91, P1312, DOI 10.1111/j.1471-4159.2004.02818.x; Matsuoka Y, 2001, AM J PATHOL, V158, P1345, DOI 10.1016/S0002-9440(10)64085-0; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; Miao JT, 2005, J NEUROSCI, V25, P6271, DOI 10.1523/JNEUROSCI.1306-05.2005; Olichney JM, 1996, NEUROLOGY, V47, P190, DOI 10.1212/WNL.47.1.190; Pappolla MA, 2003, NEUROLOGY, V61, P199, DOI 10.1212/01.WNL.0000070182.02537.84; Reddy ST, 2002, ARTERIOSCL THROM VAS, V22, P1877, DOI 10.1161/01.ATV.0000035700.82829.2A; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Roher AE, 2004, STROKE, V35, P2623, DOI 10.1161/01.STR.0000143317.70478.b3; Ruiz J, 2005, J LIPID RES, V46, P1721, DOI 10.1194/jlr.M500114-JLR200; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Rye KA, 2004, ARTERIOSCL THROM VAS, V24, P421, DOI 10.1161/01.ATV.0000104029.74961.f5; Shibata M, 2000, J CLIN INVEST, V106, P1489, DOI 10.1172/JCI10498; Singaraja RR, 2003, ARTERIOSCL THROM VAS, V23, P1322, DOI 10.1161/01.ATV.0000078520.89539.77; Sturchler-Pierrat C, 2000, ANN NY ACAD SCI, V920, P134; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; Sun Y, 2003, J BIOL CHEM, V278, P27688, DOI 10.1074/jbc.M300760200; Tontonoz P, 2003, MOL ENDOCRINOL, V17, P985, DOI 10.1210/me.2003-0061; Van Dam D, 2005, CNS SPECTRUMS, V10, P207, DOI 10.1017/S1092852900010051; Van Nostrand WE, 1998, J NEUROCHEM, V70, P216; Wahrle SE, 2005, J BIOL CHEM, V280, P43236, DOI 10.1074/jbc.M508780200; Wahrle SE, 2004, J BIOL CHEM, V279, P40987, DOI 10.1074/jbc.M407963200; Wang N, 2003, ARTERIOSCL THROM VAS, V23, P1178, DOI 10.1161/01.ATV.0000075912.83860.26; Winkler DT, 2001, J NEUROSCI, V21, P1619, DOI 10.1523/JNEUROSCI.21-05-01619.2001; Wisniewski HM, 2000, ANN NY ACAD SCI, V903, P6, DOI 10.1111/j.1749-6632.2000.tb06344.x; Wolf H, 2004, ANN NEUROL, V56, P745, DOI 10.1002/ana.20289; Wollmer MA, 2003, NEUROBIOL AGING, V24, P421, DOI 10.1016/S0197-4580(02)00094-5; Yamada M, 2004, J NEUROL SCI, V226, P41, DOI 10.1016/j.jns.2004.09.009; Zlokovic BV, 2005, TRENDS NEUROSCI, V28, P202, DOI 10.1016/j.tins.2005.02.001	77	285	290	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					43224	43235		10.1074/jbc.M504513200	http://dx.doi.org/10.1074/jbc.M504513200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16207713	hybrid			2022-12-25	WOS:000234200800089
J	Masuda, M; Kikuchi, S; Maruyama, T; Sakurai-Yageta, M; Williams, YN; Ghosh, HP; Murakami, Y				Masuda, M; Kikuchi, S; Maruyama, T; Sakurai-Yageta, M; Williams, YN; Ghosh, HP; Murakami, Y			Tumor suppressor in lung cancer (TSLC)1 suppresses epithelial cell scattering and tubulogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE; PROGNOSTIC-SIGNIFICANCE; TSLC1 GENE; RAC; RHO; ADENOCARCINOMA; ASSOCIATION; EXPRESSION; PROTEINS; INVASION	The tumor suppressor in lung cancer 1 ( TSLC1/IGSF4) encodes an immunoglobulin-superfamily cell adhesion molecule whose cytoplasmic domain contains a protein 4.1-binding motif ( protein 4.1-BM) and a PDZ-binding motif ( PDZ-BM). Loss of TSLC1 expression is frequently observed in advanced cancers implying its involvement in tumor invasion and/or metastasis. Using Madin-Darby canine kidney cells expressing a full-length TSLC1 or various cytoplasmic deletion mutants of TSLC1, we examined the role of TSLC1 in epithelial mesenchymal transitions during the hepatocyte growth factor ( HGF)-induced tubulogenesis and cell scattering. In a three-dimensional culture, the full-length TSLC1, which was localized to the lateral membrane of Madin-Darby canine kidney cysts, inhibited HGF-induced tubulogenesis. In contrast, the mutants lacking either the protein 4.1-BM or the PDZ-BM abolished the inhibitory effect on tubulogenesis. In addition, these mutants showed aberrant subcellular localization indicating that lateral localization is correlated with the effect of TSLC1. In a two-dimensional culture, the full-length TSLC1, but not the mutants lacking the protein 4.1-BM or the PDZ-BM, suppressed HGF-induced cell scattering. Furthermore, the cells expressing full-length TSLC1 retained E-cadherin-based cell-cell adhesion even after being treated with HGF. These cells showed prolonged activation of Rac and low activity of Rho, whereas the HGF-treated parental cells induced transient activation of Rac and sustained activation of Rho. Prolonged Rac activation caused by the expression of TSLC1 required its cytoplasmic tail. These findings, taken together, suggest that TSLC1 plays a role in suppressing induction of epithelial mesenchymal transitions by regulating the activation of small Rho GTPases.	Natl Canc Ctr, Res Inst, Tumor Supress & Funct Genom Project, Chuo Ku, Tokyo 1040045, Japan; McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada	National Cancer Center - Japan; McMaster University	Murakami, Y (corresponding author), Natl Canc Ctr, Res Inst, Tumor Supress & Funct Genom Project, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	ymurakam@gan2.res.ncc.go.jp	Sakurai-Yageta, Mika/U-1842-2019	Sakurai-Yageta, Mika/0000-0001-5606-3324				Biederer T, 2002, SCIENCE, V297, P1525, DOI 10.1126/science.1072356; Caron E, 2003, NAT CELL BIOL, V5, P185, DOI 10.1038/ncb0303-185; Fujita E, 2003, EXP CELL RES, V287, P57, DOI 10.1016/S0014-4827(03)00095-8; Fukami T, 2003, INT J CANCER, V107, P53, DOI 10.1002/ijc.11348; Fukuhara H, 2003, ONCOGENE, V22, P6160, DOI 10.1038/sj.onc.1206744; Gomyo H, 1999, GENOMICS, V62, P139, DOI 10.1006/geno.1999.6001; Goto A, 2005, CANCER SCI, V96, P480, DOI 10.1111/j.1349-7006.2005.00075.x; Gotzmann J, 2004, MUTAT RES-REV MUTAT, V566, P9, DOI 10.1016/S1383-5742(03)00033-4; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Ito A, 2003, LAB INVEST, V83, P1175, DOI 10.1097/01.LAB.0000081391.28136.80; Ito A, 2003, BLOOD, V101, P2601, DOI 10.1182/blood-2002-07-2265; Kaibuchi K, 1999, CURR OPIN CELL BIOL, V11, P591, DOI 10.1016/S0955-0674(99)00014-9; Kamei T, 1999, ONCOGENE, V18, P6776, DOI 10.1038/sj.onc.1203114; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; Mao XL, 2003, CANCER RES, V63, P7979; Masuda M, 2002, J BIOL CHEM, V277, P31014, DOI 10.1074/jbc.M203620200; O'Brien LE, 2002, NAT REV MOL CELL BIO, V3, P531, DOI 10.1038/nrm859; Palacios F, 2003, J BIOL CHEM, V278, P17395, DOI 10.1074/jbc.M300998200; Pollack AL, 1997, J CELL BIOL, V137, P1651, DOI 10.1083/jcb.137.7.1651; Shingai T, 2003, J BIOL CHEM, V278, P35421, DOI 10.1074/jbc.M305387200; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Uchino K, 2003, CANCER-AM CANCER SOC, V98, P1002, DOI 10.1002/cncr.11599; Yageta M, 2002, CANCER RES, V62, P5129; Zegers MMP, 2003, TRENDS CELL BIOL, V13, P169, DOI 10.1016/S0962-8924(03)00036-9; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	25	30	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42164	42171		10.1074/jbc.M507136200	http://dx.doi.org/10.1074/jbc.M507136200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16223734	hybrid			2022-12-25	WOS:000233992700044
J	Ippolito, DL; Xu, M; Bruchas, MR; Wickman, K; Chavkin, C				Ippolito, DL; Xu, M; Bruchas, MR; Wickman, K; Chavkin, C			Tyrosine phosphorylation of K(ir)3.1 in spinal cord is induced by acute inflammation, chronic neuropathic pain, and behavioral stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED POTASSIUM CHANNELS; K+ CHANNELS; ACTIVATION; KINASES; BRAIN; P38; INTERNALIZATION; TRAFFICKING; MODULATION; EXPRESSION	Tyrosine phosphorylation is an important means of regulating ion channel function. Our previous gene expression studies using the Xenopus laevis oocyte system suggested that tyrosine phosphorylation of G-protein-gated inwardly rectifying potassium channels (K(ir)3 or GIRK) suppressed basal channel conductance and accelerated channel deactivation. To assess whether similar mechanisms regulate Kir3 function in mammalian cells, we developed and characterized a phosphoselective antibody recognizing K(ir)3.1 phosphorylated at tyrosine 12 in the N-terminal domain and then probed for evidence of Kir3.1 phosphorylation in cultured mammalian cells and spinal cord. The antibody was found to discriminate between the phospho-Tyr(12) of K(ir)3.1 and the native state in transfected cell lines and in primary cultures of mouse atria. Following either mouse hindpaw formalin injection or sciatic nerve ligation, pY12-K(ir)3.1 immunoreactivity was enhanced unilaterally in the superficial layers of the spinal cord dorsal horn, regions previously described as expressing Kir3.1 channels. Mice lacking Kir3.1 following targeted gene disruption did not show specific pY12-Kir3.1 immunoreactivity after sciatic nerve ligation. Further, mice exposed to repeatedly forced swim stress showed bilateral enhancement in pY12-K(ir)3.1 in the dorsal horn. This study provides evidence that Kir3 tyrosine phosphorylation occurred during acute and chronic inflammatory pain and under behavioral stress. The reduction in Kir3 channel activity is predicted to enhance neuronal excitability under physiologically relevant conditions and may mediate a component of the adaptive physiological response.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Washington; University of Washington Seattle; University of Minnesota System; University of Minnesota Twin Cities	Chavkin, C (corresponding author), Univ Washington, Dept Pharmacol, Box 357280,1959 Pacific Ave NE, Seattle, WA 98195 USA.	cchavkin@u.washington.edu	Bruchas, Michael/G-7616-2012; Chavkin, Charles/G-2797-2010	Wickman, Kevin/0000-0002-5179-9540	NIDA NIH HHS [R37 DA011672, P50 DA011806-07, DA11806, P50 DA011806-03, P50 DA011806-02, P50 DA011806, P50 DA011806-05, P50 DA011806-04, R01 DA011672-02, R01 DA011672-01A1, DA11672, R01 DA011672, P50 DA011806-06] Funding Source: Medline; NIGMS NIH HHS [T32 GM07270] Funding Source: Medline; NIMH NIH HHS [MH61933, R01 MH061933] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH061933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA011806, R01DA011672, R37DA011672] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Ahmadian G, 2004, EMBO J, V23, P1040, DOI 10.1038/sj.emboj.7600126; Belcheva MM, 2001, J BIOL CHEM, V276, P33847, DOI 10.1074/jbc.M101535200; Berrino L, 2003, EUR J PAIN, V7, P131, DOI 10.1016/S1090-3801(02)00086-1; Bettahi H, 2002, J BIOL CHEM, V277, P48282, DOI 10.1074/jbc.M209599200; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Celver J, 2004, MOL PHARMACOL, V65, P528, DOI 10.1124/mol.65.3.528; Chan KW, 1996, P NATL ACAD SCI USA, V93, P14193, DOI 10.1073/pnas.93.24.14193; Dascal N, 1997, CELL SIGNAL, V9, P551, DOI 10.1016/S0898-6568(97)00095-8; Doupnik CA, 1997, P NATL ACAD SCI USA, V94, P10461, DOI 10.1073/pnas.94.19.10461; Elvan A, 1998, CIRCULATION, V97, P484; Garraway SM, 2003, EUR J NEUROSCI, V18, P2467, DOI 10.1046/j.1460-9568.2003.02982.x; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; Hsu SC, 1999, J BIOL CHEM, V274, P25769, DOI 10.1074/jbc.274.36.25769; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Ippolito DL, 2002, J BIOL CHEM, V277, P32692, DOI 10.1074/jbc.M204407200; Ji Ru-Rong, 2004, Sci STKE, V2004, preE14; Kofuji P, 2004, NEUROSCIENCE, V129, P1045, DOI 10.1016/j.neurscience.2004.06.008; Li XQ, 2004, J NEUROSCI RES, V78, P533, DOI 10.1002/jnr.20274; Liu YF, 2004, J NEUROCHEM, V89, P1034, DOI 10.1111/j.1471-4159.2004.02391.x; Ma D, 2002, NEURON, V33, P715, DOI 10.1016/S0896-6273(02)00614-1; Marker CL, 2005, J NEUROSCI, V25, P3551, DOI 10.1523/JNEUROSCI.4899-04.2005; Marker CL, 2004, J NEUROSCI, V24, P2806, DOI 10.1523/JNEUROSCI.5251-03.2004; McLaughlin JP, 2003, J BIOL CHEM, V278, P34631, DOI 10.1074/jbc.M304022200; Nishida M, 2002, CELL, V111, P957, DOI 10.1016/S0092-8674(02)01227-8; Paz O., 1991, Journal of Basic and Clinical Physiology and Pharmacology, V2, P287; Peleg S, 2002, NEURON, V33, P87, DOI 10.1016/S0896-6273(01)00567-0; PORSOLT RD, 1977, NATURE, V266, P730, DOI 10.1038/266730a0; Rhee S G, 2000, Sci STKE, V2000, ppe1; Rhee SG, 1999, EXP MOL MED, V31, P53, DOI 10.1038/emm.1999.9; Rogalski SL, 2000, J BIOL CHEM, V275, P25082, DOI 10.1074/jbc.M000183200; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Salter MW, 2004, NAT REV NEUROSCI, V5, P317, DOI 10.1038/nrn1368; SELTZER Z, 1990, PAIN, V43, P205, DOI 10.1016/0304-3959(90)91074-S; Takano T, 2002, ANTIOXID REDOX SIGN, V4, P533, DOI 10.1089/15230860260196335; Taylor BK, 2000, PAIN, V84, P263, DOI 10.1016/S0304-3959(99)00212-2; Tong YH, 2001, J GEN PHYSIOL, V117, P103, DOI 10.1085/jgp.117.2.103; Torrecilla M, 2002, J NEUROSCI, V22, P4328, DOI 10.1523/JNEUROSCI.22-11-04328.2002; Tucker K, 2002, J PHYSIOL-LONDON, V542, P413, DOI 10.1113/jphysiol.2002.017376; Wang XT, 1999, J BIOL CHEM, V274, P29599, DOI 10.1074/jbc.274.42.29599; Wickman K, 1998, NEURON, V20, P103, DOI 10.1016/S0896-6273(00)80438-9; Woolf CJ, 1999, P NATL ACAD SCI USA, V96, P7723, DOI 10.1073/pnas.96.14.7723; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765; Xu M, 2004, J NEUROSCI, V24, P4576, DOI 10.1523/JNEUROSCI.5552-03.2004; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	44	23	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41683	41693		10.1074/jbc.M507069200	http://dx.doi.org/10.1074/jbc.M507069200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16223722	Green Accepted, hybrid			2022-12-25	WOS:000233866900069
J	Noguchi, M; Takata, T; Kimura, Y; Manno, A; Murakami, K; Koike, M; Ohizumi, H; Hori, S; Kakizuka, A				Noguchi, M; Takata, T; Kimura, Y; Manno, A; Murakami, K; Koike, M; Ohizumi, H; Hori, S; Kakizuka, A			ATPase activity of p97/valosin-containing protein is regulated by oxidative modification of the evolutionally conserved cysteine 522 residue in walker a motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; VALOSIN-CONTAINING PROTEIN; MACHADO-JOSEPH-DISEASE; CELL-DEATH; REDOX REGULATION; EXPANDED POLYGLUTAMINE; SIGNALING PATHWAY; S-NITROSYLATION; NITRIC-OXIDE; CYCLE	Valosin-containing protein (p97/VCP) has been proposed as playing crucial roles in a variety of physiological and pathological processes such as cancer and neurodegeneration. We previously showed that VCP(K524A), an ATPase activity-negative VCP mutant, induced vacuolization, accumulation of ubiquitinated proteins, and cell death, phenotypes commonly observed in neurodegenerative disorders. However, any regulatory mechanism of its ATPase activity has not yet been clarified. Here, we show that oxidative stress readily inactivates VCP ATPase activity. With liquid chromatography/tandem mass spectrometry, we found that at least three cysteine residues were modified by oxidative stress. Of them, the 522nd cysteine (Cys-522) was identified as the site responsible for the oxidative inactivation of VCP. VCP(C522T), a single-amino acid substitution mutant from cysteine to threonine, conferred almost complete resistance to the oxidative inactivation. In response to oxidative stress, VCP strengthened the interaction with Npl4 and Ufd1, both of which are essential in endoplasmic reticulum-associated protein degradation. Cys-522 is located in the second ATP binding motif and is highly conserved in multicellular but not unicellular organisms. Cdc48p ( yeast VCP) has threonine in the corresponding amino acid, and it showed resistance to the oxidative inactivation in vitro. Furthermore, a yeast mutant (Delta cdc48 + cdc48[T532C]) was shown to be susceptible to oxidants-induced growth inhibition and cell death. These results clearly demonstrate that VCP ATPase activity is regulated by the oxidative modification of the Cys-522 residue. This regulatory mechanism may play a key role in the conversion of oxidative stress to endoplasmic reticulum stress response in multicellular organisms and also in the pathological process of various neurodegenerative disorders.	Kyoto Univ, Lab Funct Biol, Grad Sch Biostudies & Solut Oriented Res Sci & Te, Kyoto 6068501, Japan; Tokyo Metropolitan Inst Med Sci, Lab Frontier Sci, Tokyo 1138613, Japan	Kyoto University; Tokyo Metropolitan Institute of Medical Science	Kakizuka, A (corresponding author), Kyoto Univ, Lab Funct Biol, Grad Sch Biostudies & Solut Oriented Res Sci & Te, Kyoto 6068501, Japan.	kakizuka@lif.kyoto-u.ac.jp	Kimura, Yoko/E-6845-2013	Kimura, Yoko/0000-0002-3054-9753				Ault JG, 2003, EXP CELL RES, V285, P9, DOI 10.1016/S0014-4827(03)00012-0; Beal MF, 2003, ANN NEUROL, V53, pS39, DOI 10.1002/ana.10479; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Chevalier M, 1998, METHOD ENZYMOL, V290, P384, DOI 10.1016/S0076-6879(98)90033-7; Chiarugi P, 2003, TRENDS BIOCHEM SCI, V28, P509, DOI 10.1016/S0968-0004(03)00174-9; Dai RM, 2001, NAT CELL BIOL, V3, P740, DOI 10.1038/35087056; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Errico A, 2002, HUM MOL GENET, V11, P153, DOI 10.1093/hmg/11.2.153; Fariss MW, 2003, TOXICOLOGY, V189, P129, DOI 10.1016/S0300-483X(03)00158-6; Flattery-O'Brien JA, 1998, J BIOL CHEM, V273, P8564, DOI 10.1074/jbc.273.15.8564; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; Fu XR, 2003, J CELL BIOL, V163, P21, DOI 10.1083/jcb.200307025; Gnann A, 2004, MOL BIOL CELL, V15, P4125, DOI 10.1091/mbc.e04-01-0024; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Halliwell B., 1999, FREE RADICALS BIOL M, P617; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hazan J, 1999, NAT GENET, V23, P296, DOI 10.1038/15472; Higashiyama H, 2002, CELL DEATH DIFFER, V9, P264, DOI 10.1038/sj.cdd.4400955; Hirabayashi M, 2001, CELL DEATH DIFFER, V8, P977, DOI 10.1038/sj.cdd.4400907; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Junn E, 2002, NEUROSCI LETT, V320, P146, DOI 10.1016/S0304-3940(02)00016-2; Kakizuka A, 1998, TRENDS GENET, V14, P396, DOI 10.1016/S0168-9525(98)01559-5; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; Kawahara K, 2001, FEBS LETT, V506, P135, DOI 10.1016/S0014-5793(01)02898-8; Kim SO, 2002, CELL, V109, P383, DOI 10.1016/S0092-8674(02)00723-7; Kimura Y, 2003, IUBMB LIFE, V55, P337, DOI 10.1080/1521654032000114339; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; Kobayashi T, 2003, CYTOGENET GENOME RES, V100, P261, DOI 10.1159/000072862; Kobayashi T, 2002, J BIOL CHEM, V277, P47358, DOI 10.1074/jbc.M207783200; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; Kouroku Y, 2002, HUM MOL GENET, V11, P1505, DOI 10.1093/hmg/11.13.1505; Koutsilieri E., 2002, Journal of Neurology, V249, P1, DOI 10.1007/s00415-002-1201-7; Kuge S, 2001, MOL CELL BIOL, V21, P6139, DOI 10.1128/MCB.21.18.6139-6150.2001; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Matsushita K, 2005, J CELL BIOL, V170, P73, DOI 10.1083/jcb.200502031; Mizuno Y, 2003, NEUROSCI LETT, V343, P77, DOI 10.1016/S0304-3940(03)00280-5; MOIR D, 1982, GENETICS, V100, P547; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Oyadomari S, 2001, P NATL ACAD SCI USA, V98, P10845, DOI 10.1073/pnas.191207498; Pastore A, 2003, J BIOL CHEM, V278, P42588, DOI 10.1074/jbc.M301872200; Perez-Mato I, 1999, J BIOL CHEM, V274, P17075, DOI 10.1074/jbc.274.24.17075; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002; Rutkowski DT, 2003, DEV CELL, V4, P442, DOI 10.1016/S1534-5807(03)00100-X; Salmeen A, 2003, NATURE, V423, P769, DOI 10.1038/nature01680; Sato N, 2001, J BIOL CHEM, V276, P2108, DOI 10.1074/jbc.M006886200; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Song CC, 2003, J BIOL CHEM, V278, P3648, DOI 10.1074/jbc.M208422200; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Ueda S, 1998, J IMMUNOL, V161, P6689; Ward NE, 2000, BIOCHEMISTRY-US, V39, P10319, DOI 10.1021/bi000781g; Watts GDJ, 2004, NAT GENET, V36, P377, DOI 10.1038/ng1332; Wojcik C, 2004, J CELL SCI, V117, P281, DOI 10.1242/jcs.00841; Wyttenbach A, 2002, HUM MOL GENET, V11, P1137, DOI 10.1093/hmg/11.9.1137; Yamamoto S, 2003, J CLIN ONCOL, V21, P2537, DOI 10.1200/JCO.2003.12.102; Yamamoto S, 2003, J CLIN ONCOL, V21, P447, DOI 10.1200/JCO.2003.06.068; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Zaman K, 2001, BIOCHEM BIOPH RES CO, V284, P65, DOI 10.1006/bbrc.2001.4935; ZHANG L, 1994, J CELL BIOL, V127, P1871, DOI 10.1083/jcb.127.6.1871; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X	67	53	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41332	41341		10.1074/jbc.M509700200	http://dx.doi.org/10.1074/jbc.M509700200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16234241	hybrid			2022-12-25	WOS:000233866900028
J	Roh, M; Song, CS; Kim, J; Abdulkadir, SA				Roh, M; Song, CS; Kim, J; Abdulkadir, SA			Chromosomal instability induced by Pim-1 is passage-dependent and associated with dysregulation of cyclin B1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOTIC CHECKPOINT GENES; PUTATIVE ONCOGENE PIM-1; T-CELL LYMPHOMAGENESIS; FINGER PROTEIN GFI-1; C-MYC; CDC25A PHOSPHATASE; N-MYC; KINASE; EXPRESSION; PHOSPHORYLATION	Overexpression of the oncogenic serine/threonine kinase Pim-1 has been shown to induce chromosomal missegregation and polyploidy in prostate epithelial cell lines ( 1). Here we demonstrated that Pim-1-induced polyploidy develops in a passage-dependent manner in culture consistent with a stochastic mode of progression. Induction of chromosomal instability by Pim-1 was not restricted to prostate cells as it was also observed in telomerase-immortalized normal human mammary epithelial cells. Elevated levels of cyclin B1 protein, but not its messenger RNA, were evident in early passage Pim-1 overexpressing cells, suggesting that increased cyclin B1 levels contribute to the development of polyploidy. Furthermore, regulation of cyclin B1 protein and cyclin B1/CDK1 activity after treatment with anti-microtubule agents was impaired. Small interfering RNA targeting cyclin B1 reversed the cytokinesis delay but not the mitotic checkpoint defect in Pim-1 overexpressing cells. These results indicated that chronic Pim-1 overexpression dysregulates cyclin B1 protein expression, which contributes to the development of polyploidy by delaying cytokinesis.	Univ Alabama Birmingham, Sch Med, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Sch Med, Div Hematol & Oncol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Abdulkadir, SA (corresponding author), Vanderbilt Univ, Sch Med, Dept Pathol, 221 Kirkland Hall, Nashville, TN 37232 USA.	sarki.abdulkadir@vanderbilt.edu		Kim, Jongchan/0000-0002-9733-9881				Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Bachmann M, 2005, INT J BIOCHEM CELL B, V37, P726, DOI 10.1016/j.biocel.2004.11.005; Bachmann M, 2004, J BIOL CHEM, V279, P48319, DOI 10.1074/jbc.M404440200; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Bhattacharya N, 2002, CHROMOSOMA, V111, P80, DOI 10.1007/s00412-002-0192-6; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Busino L, 2004, ONCOGENE, V23, P2050, DOI 10.1038/sj.onc.1207394; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chang THT, 1996, J CELL BIOCHEM, V60, P161, DOI 10.1002/(SICI)1097-4644(19960201)60:2<161::AID-JCB1>3.0.CO;2-V; CUYPERS HT, 1984, CELL, V37, P141; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; FRIEDMANN M, 1992, ARCH BIOCHEM BIOPHYS, V298, P594, DOI 10.1016/0003-9861(92)90454-5; Gaidano Gianluca, 1993, Current Opinion in Oncology, V5, P776, DOI 10.1097/00001622-199309000-00002; Gemma A, 2000, GENE CHROMOSOME CANC, V29, P213, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1027>3.0.CO;2-G; Giet R, 2001, J CELL BIOL, V152, P669, DOI 10.1083/jcb.152.4.669; Hanks S, 2004, NAT GENET, V36, P1159, DOI 10.1038/ng1449; Imai Y, 1999, JPN J CANCER RES, V90, P837, DOI 10.1111/j.1349-7006.1999.tb00824.x; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; KAUFMANN WK, 1995, CANCER RES, V55, P7; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Lengauer C, 2004, NAT GENET, V36, P1144, DOI 10.1038/ng1104-1144; McAdams HH, 1999, TRENDS GENET, V15, P65, DOI 10.1016/S0168-9525(98)01659-X; Mochizuki T, 1999, J BIOL CHEM, V274, P18659, DOI 10.1074/jbc.274.26.18659; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; MOROY T, 1991, ONCOGENE, V6, P1941; Murata-Hori M, 2002, MOL BIOL CELL, V13, P1099, DOI 10.1091/mbc.01-09-0467; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Ohshima K, 2000, CANCER LETT, V158, P141, DOI 10.1016/S0304-3835(00)00512-7; Raser JM, 2004, SCIENCE, V304, P1811, DOI 10.1126/science.1098641; RHIM JS, 1994, P NATL ACAD SCI USA, V91, P11874, DOI 10.1073/pnas.91.25.11874; Roh M, 2003, CANCER RES, V63, P8079; Sarafan-Vasseur N, 2002, ONCOGENE, V21, P2051, DOI 10.1038/sj.onc.1205257; Schmidt T, 1998, ONCOGENE, V17, P2661, DOI 10.1038/sj.onc.1202191; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Valdman A, 2004, PROSTATE, V60, P367, DOI 10.1002/pros.20064; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; WALKER DH, 1995, CELL GROWTH DIFFER, V6, P1053; Wang ZP, 2002, BBA-MOL CELL RES, V1593, P45, DOI 10.1016/S0167-4889(02)00347-6; Yin XY, 1999, ONCOGENE, V18, P1177, DOI 10.1038/sj.onc.1202410; Yin XY, 2001, CANCER RES, V61, P6487; Yuan JP, 2004, ONCOGENE, V23, P5843, DOI 10.1038/sj.onc.1207757; Zornig M, 1996, ONCOGENE, V12, P1789	46	29	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40568	40577		10.1074/jbc.M509369200	http://dx.doi.org/10.1074/jbc.M509369200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16221667	hybrid			2022-12-25	WOS:000233666600024
J	Tang, GQ; Bandwar, RP; Patel, SS				Tang, GQ; Bandwar, RP; Patel, SS			Extended upstream A-T sequence increases T7 promoter strength	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 LATE PROMOTERS; RNA-POLYMERASE-PROMOTER; OPEN COMPLEX-FORMATION; INVITRO TRANSCRIPTION PROPERTIES; TATA-BINDING PROTEIN; STRUCTURAL BASIS; POINT MUTATIONS; START SITE; INITIATION; DNA	Bacteriophage T7 promoters contain a consensus sequence from -17 to -6 relative to the transcription start site, -1. In addition, the strong class III promoters are characterized by an extended AT-rich region upstream of -17, which is often interrupted by one or more GC base pairs in the weaker class II promoters. Herein we studied the role of the AT-rich region upstream of -17 in transcription regulation of T7 RNA polymerase. Equilibrium DNA binding studies with promoter fragments of consensus sequence truncated at various positions between -17 and -27 showed that the polymerase-promoter complex is significantly stabilized as the upstream AT-rich sequence is extended to and beyond -22. Similarly, promoters in which the AT-rich region from -17 to -22 is interrupted by several GC base pairs showed weak binding. Kinetic studies indicated that the presence of extended AT-rich sequence slows the dissociation rate constant of the polymerase-promoter complex and slightly stimulates the association rate constant, thereby increasing the stability of the complex. Measurement of the transcription activity revealed that the extended AT-rich region does not affect the kinetics of abortive synthesis up to the formation of 8-nucleotide RNA but causes accumulation of longer abortive products between 9 and 13 nucleotides. The observed effects of the upstream DNA region were AT sequence-specific, and the results suggested a larger role for the extended AT-rich sequence that has been unappreciated previously. We propose that the AT-rich DNA sequence upstream of -17 plays a role in modulating the efficiency of transcription initiation by affecting both the affinity of T7 RNA polymerase for the promoter and the efficiency of promoter clearance.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Patel, SS (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes, Piscataway, NJ 08854 USA.	patelss@umdnj.edu		Bandwar, Rajiv/0000-0002-8081-8958	NIGMS NIH HHS [R01 GM051966, GM51966] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051966, R37GM051966] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baklanov MM, 1996, NUCLEIC ACIDS RES, V24, P3659, DOI 10.1093/nar/24.18.3659; Bandwar RP, 2002, J MOL BIOL, V324, P63, DOI 10.1016/S0022-2836(02)01034-3; Bandwar RP, 2002, BIOCHEMISTRY-US, V41, P3586, DOI 10.1021/bi0158472; Bandwar RP, 2001, J BIOL CHEM, V276, P14075, DOI 10.1074/jbc.M011289200; Bareket-Samish A, 2000, J MOL BIOL, V299, P965, DOI 10.1006/jmbi.2000.3797; CHAPMAN KA, 1982, NUCLEIC ACIDS RES, V10, P6331, DOI 10.1093/nar/10.20.6331; CHAPMAN KA, 1987, NUCLEIC ACIDS RES, V15, P5413, DOI 10.1093/nar/15.13.5413; CHAPMAN KA, 1988, NUCLEIC ACIDS RES, V16, P4511, DOI 10.1093/nar/16.10.4511; Cheetham GMT, 1999, SCIENCE, V286, P2305, DOI 10.1126/science.286.5448.2305; Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999; CRAIG ML, 1995, BIOCHEMISTRY-US, V34, P15624, DOI 10.1021/bi00048a004; DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; Davis CA, 2005, P NATL ACAD SCI USA, V102, P285, DOI 10.1073/pnas.0405779102; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; Forget D, 2004, MOL CELL BIOL, V24, P1122, DOI 10.1128/MCB.24.3.1122-1131.2004; GUNDERSON SI, 1987, BIOCHEMISTRY-US, V26, P1539, DOI 10.1021/bi00380a007; Guo Q, 2005, J BIOL CHEM, V280, P14956, DOI 10.1074/jbc.M500518200; Guo Q, 2005, J BIOL CHEM, V280, P3474, DOI 10.1074/jbc.M412287200; IKEDA RA, 1986, P NATL ACAD SCI USA, V83, P3614, DOI 10.1073/pnas.83.11.3614; IKEDA RA, 1992, NUCLEIC ACIDS RES, V20, P2517, DOI 10.1093/nar/20.10.2517; Imburgio D, 2000, BIOCHEMISTRY-US, V39, P10419, DOI 10.1021/bi000365w; Jia YP, 1996, J BIOL CHEM, V271, P30451, DOI 10.1074/jbc.271.48.30451; JOLLIFFE LK, 1982, NATURE, V299, P653, DOI 10.1038/299653a0; Kelley SO, 1999, SCIENCE, V283, P375, DOI 10.1126/science.283.5400.375; KING GC, 1986, BIOCHEMISTRY-US, V25, P36, DOI 10.1021/bi00349a006; Librizzi MD, 1998, J BIOL CHEM, V273, P4563, DOI 10.1074/jbc.273.8.4563; MARTIN CT, 1987, BIOCHEMISTRY-US, V26, P2690, DOI 10.1021/bi00384a006; MCALLISTER WT, 1980, NUCLEIC ACIDS RES, V8, P4821, DOI 10.1093/nar/8.20.4821; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; PEREZMARTIN J, 1994, MICROBIOL REV, V58, P268; Place C, 1999, BIOCHEMISTRY-US, V38, P4948, DOI 10.1021/bi982689e; Rivetti C, 1999, EMBO J, V18, P4464, DOI 10.1093/emboj/18.16.4464; Sastry SS, 1996, BIOCHEMISTRY-US, V35, P15715, DOI 10.1021/bi960729d; Tahirov TH, 2002, NATURE, V420, P43, DOI 10.1038/nature01129; Ujvari A, 1996, BIOCHEMISTRY-US, V35, P14574, DOI 10.1021/bi961165g; Ujvari A, 1997, J MOL BIOL, V273, P775, DOI 10.1006/jmbi.1997.1350; Wolner BS, 2001, J BIOL CHEM, V276, P6260, DOI 10.1074/jbc.M008273200; Yin YW, 2002, SCIENCE, V298, P1387, DOI 10.1126/science.1077464	39	31	33	3	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40707	40713		10.1074/jbc.M508013200	http://dx.doi.org/10.1074/jbc.M508013200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16215231	hybrid			2022-12-25	WOS:000233666600040
J	Clodfelder-Miller, B; De Sarno, P; Zmijewska, AA; Song, L; Jope, RS				Clodfelder-Miller, B; De Sarno, P; Zmijewska, AA; Song, L; Jope, RS			Physiological and pathological changes in glucose regulate brain akt and glycogen synthase kinase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RESISTANCE; METABOLISM; ROSIGLITAZONE; INHIBITION; ACTIVATION; MEMORY	Insulin regulates the phosphorylation and activities of Akt and glycogen synthase kinase-3 ( GSK3) in peripheral tissues, but in the brain it is less clear how this signaling pathway is regulated in vivo and whether it is affected by diabetes. We found that Akt and GSK3 are sensitive to glucose, because fasting decreased and glucose administration increased by severalfold the phosphorylation of Akt and GSK3 in the cerebral cortex and hippocampus of non-diabetic mice. Brain Akt and GSK3 phosphorylation also increased after streptozotocin administration ( 3 days), which increased blood glucose and depleted blood insulin, indicating regulation by glucose availability even with deficient insulin. Changes in Akt and GSK3 phosphorylation and activities in epididymal fat were opposite to those of brain after streptozotocin treatment. Streptozotocin-induced hyperglycemia and increased brain Akt and GSK3 phosphorylation were reversed by lowering blood glucose with insulin administration. Long term hyperglycemia also increased brain Akt and GSK3 phosphorylation, both 4 weeks after streptozotocin and in db/db insulin-resistant mice. Thus, the Akt-GSK3 signaling pathway is regulated in mouse brain in vivo in response to physiological and pathological changes in insulin and glucose.	Univ Alabama Birmingham, Dept Psychiat, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Psychiat & Behav Neurobiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Jope, RS (corresponding author), Univ Alabama Birmingham, Dept Psychiat, 1720 7th Ave S,SC1057, Birmingham, AL 35294 USA.	jope@uab.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH038752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037768] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021045] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG021045, AG021045] Funding Source: Medline; NIMH NIH HHS [R01 MH038752] Funding Source: Medline; NINDS NIH HHS [R01 NS037768, NS37768] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Attwell D, 2002, TRENDS NEUROSCI, V25, P621, DOI 10.1016/S0166-2236(02)02264-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cline GW, 2002, DIABETES, V51, P2903, DOI 10.2337/diabetes.51.10.2903; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Eldar-Finkelman H, 1999, DIABETES, V48, P1662, DOI 10.2337/diabetes.48.8.1662; Eldar-Finkelman H, 2002, TRENDS MOL MED, V8, P126, DOI 10.1016/S1471-4914(01)02266-3; Gispen WH, 2000, TRENDS NEUROSCI, V23, P542, DOI 10.1016/S0166-2236(00)01656-8; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Henriksen EJ, 2003, AM J PHYSIOL-ENDOC M, V284, pE892, DOI 10.1152/ajpendo.00346.2002; Ho L, 2004, FASEB J, V18, P902, DOI 10.1096/fj.03-0978fje; HOFMAN MA, 1983, Q REV BIOL, V58, P495, DOI 10.1086/413544; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Jope RS, 2003, TRENDS PHARMACOL SCI, V24, P441, DOI 10.1016/S0165-6147(03)00206-2; Kyriaki G, 2003, CELL MOL NEUROBIOL, V23, P1, DOI 10.1023/A:1022598900246; Laughlin SB, 2003, SCIENCE, V301, P1870, DOI 10.1126/science.1089662; Laviola L, 2001, DIABETES, V50, P2709, DOI 10.2337/diabetes.50.12.2709; Lawlor MA, 2001, J CELL SCI, V114, P2903; Li XH, 2004, NEUROPSYCHOPHARMACOL, V29, P1426, DOI 10.1038/sj.npp.1300439; McCall AL, 2004, EUR J PHARMACOL, V490, P147, DOI 10.1016/j.ejphar.2004.02.052; McEwen BS, 2004, EUR J PHARMACOL, V490, P13, DOI 10.1016/j.ejphar.2004.02.041; Messier C, 2004, EUR J PHARMACOL, V490, P33, DOI 10.1016/j.ejphar.2004.02.043; Nikoulina SE, 2000, DIABETES, V49, P263, DOI 10.2337/diabetes.49.2.263; Parkes M, 2000, BEHAV NEUROSCI, V114, P307, DOI 10.1037/0735-7044.114.2.307; Pearce NJ, 2004, METABOLISM, V53, P1322, DOI 10.1016/j.metabol.2004.05.008; Perros P, 1997, HORM METAB RES, V29, P197, DOI 10.1055/s-2007-979022; Planel E, 2004, J NEUROSCI, V24, P2401, DOI 10.1523/JNEUROSCI.5561-03.2004; Plotkin B, 2003, J PHARMACOL EXP THER, V305, P974, DOI 10.1124/jpet.102.047381; Ring DB, 2003, DIABETES, V52, P588, DOI 10.2337/diabetes.52.3.588; Routh VH, 2002, PHYSIOL BEHAV, V76, P403, DOI 10.1016/S0031-9384(02)00761-8; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Schubert M, 2004, P NATL ACAD SCI USA, V101, P3100, DOI 10.1073/pnas.0308724101; Schubert M, 2003, J NEUROSCI, V23, P7084, DOI 10.1523/JNEUROSCI.23-18-07084.2003; Schulingkamp RJ, 2000, NEUROSCI BIOBEHAV R, V24, P855, DOI 10.1016/S0149-7634(00)00040-3; Semiz S, 2002, MOL CELL BIOCHEM, V231, P23, DOI 10.1023/A:1014437019586; Shao J, 2000, J ENDOCRINOL, V167, P107, DOI 10.1677/joe.0.1670107; Smith SA, 2004, J CLIN ENDOCR METAB, V89, P6048, DOI 10.1210/jc.2004-0705; Watcharasit P, 2002, P NATL ACAD SCI USA, V99, P7951, DOI 10.1073/pnas.122062299; White MF, 2003, SCIENCE, V302, P1710, DOI 10.1126/science.1092952; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Yue TL, 2005, DIABETES, V54, P554, DOI 10.2337/diabetes.54.2.554; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	41	98	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					39723	39731		10.1074/jbc.M508824200	http://dx.doi.org/10.1074/jbc.M508824200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16179343	Green Accepted, hybrid			2022-12-25	WOS:000233461300009
J	Fan, GF; Jiang, YP; Lu, ZJ; Martin, DW; Kelly, DJ; Zuckerman, JM; Ballou, LM; Cohen, IS; Lin, RZ				Fan, GF; Jiang, YP; Lu, ZJ; Martin, DW; Kelly, DJ; Zuckerman, JM; Ballou, LM; Cohen, IS; Lin, RZ			A transgenic mouse model of heart failure using inducible G alpha(q)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC SARCOPLASMIC-RETICULUM; PHOSPHOLIPASE-C; MYOCARDIAL HYPERTROPHY; DILATED CARDIOMYOPATHY; CONTRACTILE FAILURE; CALCIUM CURRENTS; FAILING HEARTS; ALPHA-SUBUNIT; SERCA2 GENE; PHOSPHOLAMBAN	Receptors coupled to G alpha(q) play a key role in the development of heart failure. Studies using genetically modified mice suggest that G alpha(q) mediates a hypertrophic response in cardiac myocytes. G alpha(q) signaling in these models is modified during early growth and development, whereas most heart failure in humans occurs after cardiac damage sustained during adulthood. To determine the phenotype of animals that express increased G alpha(q) signaling only as adults, we generated transgenic mice that express a silent G alpha(q) protein (G alpha(q) Q209L- hbER) in cardiac myocytes that can be activated by tamoxifen. Following drug treatment to activate G alpha(q)Q209L- hbER, these mice rapidly develop a dilated cardiomyopathy and heart failure. This phenotype does not appear to involve myocyte hypertrophy but is associated with dephosphorylation of phospholamban ( PLB), decreased sarcoplasmic reticulum Ca2+- ATPase activity, and a decrease in L-type Ca2+ current density. Changes in Ca2+ handling and decreased cardiac contractility are apparent 1 week after (G alpha(q) Q209L-hbER) activation. In contrast, transgenic mice that express an inducible G alpha(q) mutant that cannot activate phospholipase C beta (PLC beta) do not develop heart failure or changes in PLB phosphorylation, but do show decreased L-type Ca2+ current density. These results demonstrate that activation of G alpha(q) in cardiac myocytes of adult mice causes a dilated cardiomyopathy that requires the activation of PLC . However, increased PLC beta signaling is not required for all of the G alpha(q)-induced cardiac abnormalities.	SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; SUNY Stony Brook, Inst Mol Cardiol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Biomed Engn, Stony Brook, NY 11794 USA; Dept Vet Affairs Med Ctr, Northport, NY 11768 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Lin, RZ (corresponding author), SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA.	richard.lin@sunysb.edu	Lu, zhongjul/AAT-5531-2021; Lin, Richard/J-1754-2014	Lin, Richard/0000-0002-3473-7276	NHLBI NIH HHS [HL70161, HL67101, HL28958] Funding Source: Medline; NIDDK NIH HHS [DK62722] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070161, R01HL067101, P01HL028958] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062722] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Ballou LM, 2003, J BIOL CHEM, V278, P23472, DOI 10.1074/jbc.M212232200; Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; Braz JC, 2004, NAT MED, V10, P248, DOI 10.1038/nm1000; Chen XW, 2002, CIRC RES, V91, P517, DOI 10.1161/01.RES.0000033988.13062.7C; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; Dipla K, 1998, CIRCULATION, V97, P2316, DOI 10.1161/01.CIR.97.23.2316; Dorn GW, 2005, J CLIN INVEST, V115, P527, DOI 10.1172/JCI200524178; Fan GF, 2003, J BIOL CHEM, V278, P52432, DOI 10.1074/jbc.M310982200; Haghighi K, 2001, J BIOL CHEM, V276, P24145, DOI 10.1074/jbc.M102403200; Ji Y, 2000, J BIOL CHEM, V275, P38073, DOI 10.1074/jbc.M004804200; Kadambi VJ, 1996, J CLIN INVEST, V97, P533, DOI 10.1172/JCI118446; Knollmann BC, 2000, J PHYSIOL-LONDON, V525, P483, DOI 10.1111/j.1469-7793.2000.t01-1-00483.x; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Lorenz JN, 1997, AM J PHYSIOL-HEART C, V272, pH1137, DOI 10.1152/ajpheart.1997.272.3.H1137; Lu ZJ, 2005, J BIOL CHEM, V280, P40347, DOI 10.1074/jbc.M508441200; MARTIN DW, 1983, BIOCHEMISTRY-US, V22, P2276, DOI 10.1021/bi00278a034; Mende U, 1998, P NATL ACAD SCI USA, V95, P13893, DOI 10.1073/pnas.95.23.13893; MEWES T, 1994, J MOL CELL CARDIOL, V26, P1307, DOI 10.1006/jmcc.1994.1149; Mukherjee R, 1998, J MOL CELL CARDIOL, V30, P1899, DOI 10.1006/jmcc.1998.0755; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; OUADID H, 1995, J CARDIOVASC PHARM, V25, P282, DOI 10.1097/00005344-199502000-00014; Periasamy M, 1999, J BIOL CHEM, V274, P2556, DOI 10.1074/jbc.274.4.2556; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; Schroder F, 1998, CIRCULATION, V98, P969, DOI 10.1161/01.CIR.98.10.969; Schwinger RHG, 1999, J MOL CELL CARDIOL, V31, P479, DOI 10.1006/jmcc.1998.0897; SCHWINGER RHG, 1995, CIRCULATION, V92, P3220, DOI 10.1161/01.CIR.92.11.3220; Sohal DS, 2001, CIRC RES, V89, P20, DOI 10.1161/hh1301.092687; Song QJ, 2003, J CLIN INVEST, V111, P859, DOI 10.1172/JCI200316738; Syed F, 2004, CIRC RES, V95, P1200, DOI 10.1161/01.RES.0000150366.08972.7f; Tang T, 2004, AM J PHYSIOL-HEART C, V287, pH1906, DOI 10.1152/ajpheart.00356.2004; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; Venkatakrishnan G, 1996, J BIOL CHEM, V271, P5066; Wettschureck N, 2001, NAT MED, V7, P1236, DOI 10.1038/nm1101-1236; Xiao GS, 2001, CIRC RES, V89, P1122, DOI 10.1161/hh2401.100742; Zafeiridis A, 1998, CIRCULATION, V98, P656, DOI 10.1161/01.CIR.98.7.656; Zvaritch E, 2000, J BIOL CHEM, V275, P14985, DOI 10.1074/jbc.275.20.14985	37	42	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40337	40346		10.1074/jbc.M506810200	http://dx.doi.org/10.1074/jbc.M506810200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16210321	hybrid			2022-12-25	WOS:000233461300076
J	Gerard, NP; Lu, B; Liu, PX; Craig, S; Fujiwara, Y; Okinaga, S; Gerard, C				Gerard, NP; Lu, B; Liu, PX; Craig, S; Fujiwara, Y; Okinaga, S; Gerard, C			An anti-inflammatory function for the complement anaphylatoxin C5a-binding protein, C5L2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOATTRACTANT RECEPTOR; C3A RECEPTOR; INFLAMMATORY RESPONSES; ARTHUS REACTION; C5A; BINDING	C5L2 is an enigmatic serpentine receptor that is co-expressed with the C5a receptor on many cells including polymorphonuclear neutrophils. The apparent absence of coupling of C5L2 with G proteins suggests that this receptor may modulate the biological activity of C5a, perhaps by acting as a decoy receptor. Alternatively, C5L2 may affect C5a function through formation of a heteromeric complex with the C5aR, or it may utilize a G protein-independent signaling pathway. Here we show that in mice bearing a targeted deletion of C5L2, the biological activity of C5a/C5a(desArg) is enhanced both in vivo and in vitro. The biological role of C5L2 thus appears to be limiting to the pro-inflammatory response to the anaphylatoxin. Accordingly, up-regulation of C5L2 may be of benefit in inflammatory states driven by C5a, including sepsis, asthma, cystic fibrosis, and chronic obstructive lung disease.	Harvard Univ, Childrens Hosp, Sch Med, Dept Pediat,Pulm Div, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Div Hematol & Oncol, Boston, MA 02115 USA; Harvard Univ, Dept Med, Sch Med, Boston, MA 02115 USA; Tohoku Univ, Sch Med, Dept Geriatr & Resp Med, Sendai, Miyagi 9808574, Japan	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Tohoku University	Gerard, C (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Sue Perlmutter Lab, 320 Longwood Ave, Boston, MA 02115 USA.	Craig.Gerard@childrens.harvard.edu			NHLBI NIH HHS [HL36162, HL69511] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036162, R37HL036162, R01HL069511] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Cain SA, 2002, J BIOL CHEM, V277, P7165, DOI 10.1074/jbc.C100714200; Drouin SM, 2002, J IMMUNOL, V169, P5926, DOI 10.4049/jimmunol.169.10.5926; Gao HW, 2005, FASEB J, V19, P1003, DOI 10.1096/fj.04-3424fje; Gao JM, 2003, J BIOL CHEM, V278, P37902, DOI 10.1074/jbc.M306061200; Gavrilyuk V, 2005, J NEUROCHEM, V92, P1140, DOI 10.1111/j.1471-4159.2004.02942.x; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.iy.12.040194.004015; Godau J, 2004, J IMMUNOL, V173, P3437, DOI 10.4049/jimmunol.173.5.3437; Guo RF, 2005, ANNU REV IMMUNOL, V23, P821, DOI 10.1146/annurev.immunol.23.021704.115835; Hopken UE, 1996, NATURE, V383, P86, DOI 10.1038/383086a0; Hopken UE, 1997, J EXP MED, V186, P749, DOI 10.1084/jem.186.5.749; Humbles AA, 2000, NATURE, V406, P998, DOI 10.1038/35023175; Kalant D, 2005, J BIOL CHEM, V280, P23936, DOI 10.1074/jbc.M406921200; Kalant D, 2003, J BIOL CHEM, V278, P11123, DOI 10.1074/jbc.M206169200; Kildsgaard J, 2000, J IMMUNOL, V165, P5406, DOI 10.4049/jimmunol.165.10.5406; Matthews KW, 2004, MOL IMMUNOL, V40, P785, DOI 10.1016/j.molimm.2003.10.002; Ohno M, 2000, MOL IMMUNOL, V37, P407, DOI 10.1016/S0161-5890(00)00067-5; Okinaga S, 2003, BIOCHEMISTRY-US, V42, P9406, DOI 10.1021/bi034489v; Skokowa J, 2005, J IMMUNOL, V174, P3041, DOI 10.4049/jimmunol.174.5.3041; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Ward PA, 2004, NAT REV IMMUNOL, V4, P133, DOI 10.1038/nri1269; WETSEL RA, 1987, BIOCHEMISTRY-US, V26, P737, DOI 10.1021/bi00377a013	21	156	163	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					39677	39680		10.1074/jbc.C500287200	http://dx.doi.org/10.1074/jbc.C500287200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16204243	hybrid			2022-12-25	WOS:000233461300002
J	Herrick-Davis, K; Grinde, E; Harrigan, TJ; Mazurkiewicz, JE				Herrick-Davis, K; Grinde, E; Harrigan, TJ; Mazurkiewicz, JE			Inhibition of serotonin 5-hydroxytryptamine2C receptor function through heterodimerization - Receptor dimers bind two molecules of ligand and one G-protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED RECEPTORS; TRANSMEMBRANE HELICES; SPLICE VARIANT; HOMODIMERIZATION; OLIGOMERIZATION; SUBTYPES; SURFACE; DIMERIZATION; ACTIVATION; EXPRESSION	Although dimerization appears to be a common property of G-protein-coupled receptors (GPCRs), it remains unclear whether a GPCR dimer binds one or two molecules of ligand and whether ligand binding results in activation of one or two G-proteins when measured using functional assays in intact living cells. Previously, we demonstrated that serotonin 5-hydroxytryptamine2C (5-HT2C) receptors form homodimers (Herrick-Davis, K., Grinde, E., and Mazurkiewicz, J. (2004) Biochemistry 43, 13963-13971). In the present study, an inactive 5-HT2C receptor was created and coexpressed with wild-type 5-HT2C receptors to determine whether dimerization regulates receptor function and to determine the ligand/dimer/G-protein stoichiometry in living cells. Mutagenesis of Ser(138) to Arg (S138R) produced a 5-HT2C receptor incapable of binding ligand or stimulating inositol phosphate (IP) signaling. Confocal fluorescence imaging revealed plasma membrane expression of yellow fluorescent protein-tagged S138R receptors. Expression of wild-type 5-HT2C receptors in an S138R-expressing stable cell line had no effect on ligand binding to wild-type 5-HT2C receptors, but inhibited basal and 5-HT-stimulated IP signaling as well as constitutive and 5-HT-stimulated endocytosis of wild-type 5-HT2C receptors. M1 muscarinic receptor activation of IP production was normal in the S138R-expressing cells. Heterodimerization of S138R with wild-type 5-HT2C receptors was visualized in living cells using confocal fluorescence resonance energy transfer (FRET). FRET was dependent on the donor/acceptor ratio and independent of the receptor expression level. Therefore, inactive 5-HT2C receptors inhibit wild-type 5-HT2C receptor function by forming nonfunctional heterodimers expressed on the plasma membrane. These results are consistent with a model in which one GPCR dimer binds two molecules of ligand and one G-protein and indicate that dimerization is essential for 5-HT receptor function.	Albany Med Coll, Ctr Neuropharmacol & Neurosci, Albany, NY 12208 USA	Albany Medical College	Herrick-Davis, K (corresponding author), Albany Med Coll, Ctr Neuropharmacol & Neurosci, MC-136,47 New Scotland Ave, Albany, NY 12208 USA.	daviskh@mail.amc.edu			NCRR NIH HHS [RR017926] Funding Source: Medline; NIMH NIH HHS [MH057019] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR017926] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH057019] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Baneres JL, 2003, J MOL BIOL, V329, P815, DOI 10.1016/S0022-2836(03)00439-X; Bastiaens PIH, 1996, EMBO J, V15, P4246, DOI 10.1002/j.1460-2075.1996.tb00799.x; Carrillo JJ, 2004, MOL PHARMACOL, V66, P1123, DOI 10.1124/mol.104.001586; Chen SH, 2000, EMBO J, V19, P4265, DOI 10.1093/emboj/19.16.4265; Ebersole BJ, 2003, MOL PHARMACOL, V63, P36, DOI 10.1124/mol.63.1.36; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; Fotiadis D, 2004, FEBS LETT, V564, P281, DOI 10.1016/S0014-5793(04)00194-2; George SR, 2002, NAT REV DRUG DISCOV, V1, P808, DOI 10.1038/nrd913; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Gines S, 2000, P NATL ACAD SCI USA, V97, P8606, DOI 10.1073/pnas.150241097; Grosse R, 1997, MOL ENDOCRINOL, V11, P1305, DOI 10.1210/me.11.9.1305; Guo W, 2003, J BIOL CHEM, V278, P4385, DOI 10.1074/jbc.C200679200; Herrick-Davis K, 1999, J NEUROCHEM, V73, P1711, DOI 10.1046/j.1471-4159.1999.731711.x; Herrick-Davis K, 2004, BIOCHEMISTRY-US, V43, P13963, DOI 10.1021/bi048398p; HerrickDavis K, 1997, J NEUROCHEM, V69, P1138; Hoyer D, 2002, PHARMACOL BIOCHEM BE, V71, P533, DOI 10.1016/S0091-3057(01)00746-8; Javitch JA, 2004, MOL PHARMACOL, V66, P1077, DOI 10.1124/mol.104.006320; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Karpa KD, 2000, MOL PHARMACOL, V58, P677, DOI 10.1124/mol.58.4.677; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kenworthy AK, 1998, J CELL BIOL, V142, P69, DOI 10.1083/jcb.142.1.69; Lee SP, 2000, MOL PHARMACOL, V58, P120, DOI 10.1124/mol.58.1.120; Lee SP, 2004, J BIOL CHEM, V279, P35671, DOI 10.1074/jbc.M401923200; Lee SP, 2003, BIOCHEMISTRY-US, V42, P11023, DOI 10.1021/bi0345539; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; Pfeiffer M, 2001, J BIOL CHEM, V276, P14027, DOI 10.1074/jbc.M006084200; Roth BL, 2004, PSYCHOPHARMACOLOGY, V174, P17, DOI 10.1007/s00213-003-1683-8; Salahpour A, 2004, J BIOL CHEM, V279, P33390, DOI 10.1074/jbc.M403363200; Salim K, 2002, J BIOL CHEM, V277, P15482, DOI 10.1074/jbc.M201539200; Shapiro DA, 2002, J BIOL CHEM, V277, P11441, DOI 10.1074/jbc.M111675200; Stanasila L, 2003, J BIOL CHEM, V278, P40239, DOI 10.1074/jbc.M306085200; Terrillon S, 2004, EMBO REP, V5, P30, DOI 10.1038/sj.embor.7400052; Wallrabe H, 2003, BIOPHYS J, V85, P559, DOI 10.1016/S0006-3495(03)74500-7; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Xie XD, 1999, FEBS LETT, V456, P63, DOI 10.1016/S0014-5793(99)00918-7; Zhu XY, 1998, BIOCHEMISTRY-US, V37, P15773, DOI 10.1021/bi981162z	39	110	113	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40144	40151		10.1074/jbc.M507396200	http://dx.doi.org/10.1074/jbc.M507396200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16195233	hybrid			2022-12-25	WOS:000233461300054
J	Moreno-Miralles, I; Pan, L; Keates-Baleeiro, J; Durst-Goodwin, K; Yang, CY; Kim, HG; Thompson, MA; Klug, CA; Cleveland, JL; Hiebert, SW				Moreno-Miralles, I; Pan, L; Keates-Baleeiro, J; Durst-Goodwin, K; Yang, CY; Kim, HG; Thompson, MA; Klug, CA; Cleveland, JL; Hiebert, SW			The inv(16) cooperates with ARF haploinsufficiency to induce acute myeloid leukemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN HEAVY-CHAIN; TUMOR-SUPPRESSOR; FUSION PROTEIN; RUNT DOMAIN; CHIMERIC PROTEIN; STABILIZES P53; GENE; MYC; P19(ARF); TRANSCRIPTION	The inv( 16) is one of the most frequent chromosomal translocations associated with acute myeloid leukemia ( AML) and creates a chimeric fusion protein consisting of most of the runt-related X1 co-factor, core binding factor beta fused to the smooth muscle myosin heavy chain MYH11. Expression of the ARF tumor suppressor is regulated by runt-related X1, suggesting that the inv( 16) fusion protein ( IFP) may repress ARF expression. We established a murine bone marrow transplant model of the inv( 16) in which wild type, Arf(+/-), and Arf(-/-) bone marrow were engineered to express the IFP. IFP expression was sufficient to induce a myelomonocytic AML even when expressed in wild type bone marrow, yet removal of only a single allele of Arf greatly accelerated the disease, indicating that Arf is haploinsufficient for the induction of AML in the presence of the inv( 16).	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37232 USA; Univ Tennessee, St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; Univ Tennessee, Dept Mol Sci, Memphis, TN 38105 USA; Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA; Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Alabama System; University of Alabama Birmingham; Vanderbilt University; Vanderbilt University	Hiebert, SW (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, PRB 512,23rd & Pierce, Nashville, TN 37232 USA.	scott.hiebert@vanderbilt.edu	Hiebert, Scott W/C-9979-2010		NCI NIH HHS [R01-CA87549, R01-CA76379, R01-CA64140, R01-CA77274, CA68485] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064140, P30CA068485, R01CA077274, R01CA076379, R01CA087549] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANG G, 2005, MOL CELL BIOL, V25, P5869; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Castilla LH, 1999, NAT GENET, V23, P144, DOI 10.1038/13776; Castilla LH, 2004, P NATL ACAD SCI USA, V101, P4924, DOI 10.1073/pnas.0400930101; Cong F, 1999, ONCOGENE, V18, P7731, DOI 10.1038/sj.onc.1203290; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Durst KL, 2003, MOL CELL BIOL, V23, P607, DOI 10.1128/MCB.23.2.607-619.2003; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Frank R, 1995, ONCOGENE, V11, P2667; Gartel AL, 2003, EXP CELL RES, V283, P17, DOI 10.1016/S0014-4827(02)00020-4; Growney JD, 2005, BLOOD, V106, P494, DOI 10.1182/blood-2004-08-3280; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kanto S, 2000, LEUKEMIA, V14, P1253, DOI 10.1038/sj.leu.2401821; Kogan SC, 2002, BLOOD, V100, P238, DOI 10.1182/blood.V100.1.238; Kogan SC, 1998, P NATL ACAD SCI USA, V95, P11863, DOI 10.1073/pnas.95.20.11863; LENNY N, 1995, ONCOGENE, V11, P1761; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Liu PP, 1996, GENE CHROMOSOME CANC, V16, P77, DOI 10.1002/(SICI)1098-2264(199606)16:2<77::AID-GCC1>3.0.CO;2-#; Lutterbach B, 1999, P NATL ACAD SCI USA, V96, P12822, DOI 10.1073/pnas.96.22.12822; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; Martins CP, 2002, EMBO J, V21, P3739, DOI 10.1093/emboj/cdf364; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; O'Hagan RC, 2000, GENE DEV, V14, P2185, DOI 10.1101/gad.827200; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Rowley JD, 1999, SEMIN HEMATOL, V36, P59; Rubnitz JE, 1999, LEUKEMIA, V13, P6, DOI 10.1038/sj.leu.2401258; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Tahirov TH, 2001, CELL, V104, P755, DOI 10.1016/S0092-8674(01)00271-9; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Yan JL, 2004, NAT STRUCT MOL BIOL, V11, P901, DOI 10.1038/nsmb819; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245; Yang YD, 2002, CANCER RES, V62, P2232; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	42	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40097	40103		10.1074/jbc.M506855200	http://dx.doi.org/10.1074/jbc.M506855200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16199529	hybrid			2022-12-25	WOS:000233461300048
J	Reihl, P; Stolz, J				Reihl, P; Stolz, J			The monocarboxylate transporter homolog Mch5p catalyzes riboflavin (vitamin B-2) uptake in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; SCHIZOSACCHAROMYCES-POMBE; ENDOPLASMIC-RETICULUM; HEXOSE TRANSPORTER; ASHBYA-GOSSYPII; GENE DISRUPTION; SHUTTLE VECTORS; YEAST; GENOME; EXPRESSION	Riboflavin is a water-soluble vitamin ( vitamin B-2) required for the production of the flavin cofactors FMN and FAD. Mammals are unable to synthesize riboflavin and need a dietary supply of the vitamin. Riboflavin transport proteins operating in the plasma membrane thus have an important role in the absorption of the vitamin. However, their sequences remained elusive, and not a single eukaryotic riboflavin transporter is known to date. Here we used a genetic approach to isolate MCH5, a Saccharomyces cerevisiae gene with homology to mammalian monocarboxylate transporters, and characterize the protein as a plasma membrane transporter for riboflavin. This conclusion is based on the suppression of riboflavin biosynthetic mutants ( rib mutants) by overexpression of MCH5 and by synthetic growth defects caused by deletion of MCH5 in rib mutants. We also show that cellular processes in multiple compartments are affected by deletion of MCH5 and localize the protein to the plasma membrane. Transport experiments in S. cerevisiae and Schizosaccharomyces pombe cells demonstrate that Mch5p is a high affinity transporter ( K-m = 17 mu M) with a pH optimum at pH 7.5. Riboflavin uptake is not inhibited by protonophores, does not require metabolic energy, and operates by a facilitated diffusion mechanism. The expression of MCH5 is regulated by the cellular riboflavin content. This indicates that S. cerevisiae has a mechanism to sense riboflavin and avert riboflavin deficiency by increasing the expression of the plasma membrane transporter MCH5. Moreover, the other members of the MCH gene family appear to have unrelated functions.	Univ Regensburg, Lehrshuhl Zellbiol & Pflanzenphysiol, D-93040 Regensburg, Germany	University of Regensburg	Stolz, J (corresponding author), Univ Regensburg, Lehrshuhl Zellbiol & Pflanzenphysiol, Univ Str 31, D-93040 Regensburg, Germany.	juergen.stolz@biologie.uni-regensburg.de						Bafunno V, 2004, J BIOL CHEM, V279, P95, DOI 10.1074/jbc.M308230200; Bassler K., 2002, VITAMIN LEXIKON; Bender D.A., 2003, NUTR BIOCH VITAMINS; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; BISSON LF, 1983, P NATL ACAD SCI-BIOL, V80, P1730, DOI 10.1073/pnas.80.6.1730; Bomer U, 1997, EMBO J, V16, P2205, DOI 10.1093/emboj/16.9.2205; Boretsky YR, 2005, FEMS YEAST RES, V5, P829, DOI 10.1016/j.femsyr.2005.03.007; Brachmann CB, 1998, YEAST, V14, P115; Casal M, 1999, J BACTERIOL, V181, P2620, DOI 10.1128/JB.181.8.2620-2623.1999; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Christie KR, 2004, NUCLEIC ACIDS RES, V32, pD311, DOI 10.1093/nar/gkh033; Dumitrescu AM, 2004, AM J HUM GENET, V74, P168, DOI 10.1086/380999; Fischer M, 2005, NAT PROD REP, V22, P324, DOI 10.1039/b210142b; Foraker AB, 2003, ADV DRUG DELIVER REV, V55, P1467, DOI 10.1016/j.addr.2003.07.005; FORSBURG SL, 1993, NUCLEIC ACIDS RES, V21, P2955, DOI 10.1093/nar/21.12.2955; Forster C, 2001, APPL MICROBIOL BIOT, V55, P85, DOI 10.1007/s002530000483; Fraaije MW, 2000, TRENDS BIOCHEM SCI, V25, P126, DOI 10.1016/S0968-0004(99)01533-9; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; Friesema ECH, 2003, J BIOL CHEM, V278, P40128, DOI 10.1074/jbc.M300909200; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; HEESEN ST, 1993, EMBO J, V12, P279, DOI 10.1002/j.1460-2075.1993.tb05654.x; Kis K, 2001, J ORG CHEM, V66, P2555, DOI 10.1021/jo001120s; Knauer R, 1999, J BIOL CHEM, V274, P17249, DOI 10.1074/jbc.274.24.17249; Kobayashi M, 1998, J BIOL CHEM, V273, P26394, DOI 10.1074/jbc.273.41.26394; Koser S.A., 1968, VITAMIN REQUIREMENTS; Kruckeberg AL, 1996, ARCH MICROBIOL, V166, P283, DOI 10.1007/s002030050385; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Laage R, 2001, MOL BIOL CELL, V12, P3375, DOI 10.1091/mbc.12.11.3375; LAFRENIERE RG, 1994, HUM MOL GENET, V3, P1133, DOI 10.1093/hmg/3.7.1133; Lesuisse E, 2005, GENETICS, V169, P107, DOI 10.1534/genetics.104.035873; Liang DT, 1999, J CELL SCI, V112, P559; Makuc J, 2001, YEAST, V18, P1131, DOI 10.1002/yea.763; Manthey KC, 2005, J NUTR, V135, P978, DOI 10.1093/jn/135.5.978; Mitchison JM, 1970, METHOD CELL PHYSIOL, V4, P131; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Nelissen B, 1997, FEMS MICROBIOL REV, V21, P113, DOI 10.1111/j.1574-6976.1997.tb00347.x; Opekarova M, 2002, BBA-BIOMEMBRANES, V1564, P9, DOI 10.1016/S0005-2736(02)00455-8; PERL M, 1976, J BIOL CHEM, V251, P3221; Rupp S, 2002, METHOD ENZYMOL, V350, P112, DOI 10.1016/S0076-6879(02)50959-9; SAUER N, 1990, P NATL ACAD SCI USA, V87, P7949, DOI 10.1073/pnas.87.20.7949; SERRANO R, 1983, FEBS LETT, V156, P11, DOI 10.1016/0014-5793(83)80237-3; Sibirny A.A., 1996, NONCONVENTIONAL YEAS, P255; SIBIRNYI A A, 1977, Biokhimiya, V42, P1841; SIBIRNYI A A, 1978, Biokhimiya, V43, P1414; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; Stahmann KP, 2000, APPL MICROBIOL BIOT, V53, P509, DOI 10.1007/s002530051649; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; Stolz J, 1999, J BIOL CHEM, V274, P18747, DOI 10.1074/jbc.274.26.18747; Stolz J, 1999, J BIOL CHEM, V274, P18741, DOI 10.1074/jbc.274.26.18741; Stolz J, 2003, J BIOL CHEM, V278, P18990, DOI 10.1074/jbc.M300949200; Stolz J, 2003, YEAST, V20, P221, DOI 10.1002/yea.959; Stolz J, 2002, J BIOL CHEM, V277, P44801, DOI 10.1074/jbc.M208023200; Tu BP, 2000, SCIENCE, V290, P1571, DOI 10.1126/science.290.5496.1571; Tu BP, 2002, MOL CELL, V10, P983, DOI 10.1016/S1097-2765(02)00696-2; VALLE ABF, 1978, ANAL BIOCHEM, V91, P583, DOI 10.1016/0003-2697(78)90545-6; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724	58	58	61	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					39809	39817		10.1074/jbc.M505002200	http://dx.doi.org/10.1074/jbc.M505002200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16204239	hybrid			2022-12-25	WOS:000233461300018
J	Baxter, BK; Abeliovich, H; Zhang, X; Stirling, AG; Burlingame, AL; Goldfarb, DS				Baxter, BK; Abeliovich, H; Zhang, X; Stirling, AG; Burlingame, AL; Goldfarb, DS			Atg19p ubiquitination and the cytoplasm to vacuole trafficking pathway in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOA4 DEUBIQUITINATING ENZYME; TRANSCRIPTION FACTOR MET4; SACCHAROMYCES-CEREVISIAE; TARGETING PATHWAY; POLYUBIQUITIN CHAINS; PROTEIN-DEGRADATION; H2B UBIQUITYLATION; MEMBRANE-PROTEINS; ENDOCYTIC PATHWAY; TRANSPORTER STE6	The cytoplasm to vacuole (Cvt) trafficking pathway in S. cerevisiae is a constitutive biosynthetic pathway required for the transport of two vacuolar enzymes, aminopeptidase I (Ape1p) and alpha-mannosidase (Ams1p), to the vacuole. Ape1p and Ams1p bind to their receptor, Atg19p, in the cytosol to form a Cvt complex, which then associates with a membrane structure that envelops the complex before fusing with the vacuolar membrane. Ubiquitin-like modifications are required for both Cvt and macroautophagy, but no role for ubiquitin itself has been described. Here, we show that the deubiquitinating enzyme Ubp3p interacts with Atg19p. Moreover, Atg19p is ubiquitinated in vivo, and Atg19p-ubiquitin conjugates accumulate in cells lacking either Ubp3p or its cofactor, Bre5p. Deletion of UBP3 also leads to decreased targeting of Ape1p to the vacuole. Atg19p is ubiquitinated on two lysine residues, Lys(213) and Lys(216), which, when mutated, reduce the interaction of Atg19p with Ape1p. These results suggest that both ubiquitination and deubiquitination of Atg19p are required for its full function.	Univ Rochester, Dept Biol, Rochester, NY 14627 USA; Hebrew Univ Jerusalem, Fac Agr, IL-78100 Rehovot, Israel; Hobart & William Smith Coll, Dept Biol, Geneva, NY 14456 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Mass Spectrometry Facil, San Francisco, CA 94143 USA	University of Rochester; Hebrew University of Jerusalem; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Goldfarb, DS (corresponding author), Univ Rochester, Dept Biol, Rochester, NY 14627 USA.	dasg@mail.rochester.edu			NCRR NIH HHS [RR12961, RR01614] Funding Source: Medline; NIGMS NIH HHS [GM067838] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR012961, P41RR001614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067838] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amerik AY, 1997, EMBO J, V16, P4826; Amerik AY, 2000, MOL BIOL CELL, V11, P3365, DOI 10.1091/mbc.11.10.3365; Auty R, 2004, J BIOL CHEM, V279, P49973, DOI 10.1074/jbc.M409849200; Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; BAKER RT, 1992, J BIOL CHEM, V267, P23364; Baxter BK, 1998, CURR GENET, V33, P412, DOI 10.1007/s002940050354; Brew CT, 2002, GENETICS, V162, P1079; Bryant NJ, 1998, MICROBIOL MOL BIOL R, V62, P230, DOI 10.1128/MMBR.62.1.230-247.1998; Chernova TA, 2003, J BIOL CHEM, V278, P52102, DOI 10.1074/jbc.M310283200; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Cohen M, 2003, J BIOL CHEM, V278, P51989, DOI 10.1074/jbc.C300451200; Cohen M, 2003, NAT CELL BIOL, V5, P661, DOI 10.1038/ncb1003; Damelin M, 2000, MOL CELL, V5, P133, DOI 10.1016/S1097-2765(00)80409-8; Daniel JA, 2004, J BIOL CHEM, V279, P1867, DOI 10.1074/jbc.C300494200; Dupre S, 2001, MOL CELL BIOL, V21, P4482, DOI 10.1128/MCB.21.14.4482-4494.2001; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; Flick K, 2004, NAT CELL BIOL, V6, P634, DOI 10.1038/ncb1143; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Guterman A, 2004, J BIOL CHEM, V279, P1729, DOI 10.1074/jbc.M307050200; Haracska L, 2004, MOL CELL BIOL, V24, P4267, DOI 10.1128/MCB.24.10.4267-4274.2004; Harding TM, 1996, J BIOL CHEM, V271, P17621, DOI 10.1074/jbc.271.30.17621; Henry KW, 2003, GENE DEV, V17, P2648, DOI 10.1101/gad.1144003; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Horak J, 2003, BBA-BIOMEMBRANES, V1614, P139, DOI 10.1016/S0005-2736(03)00195-0; Hutchins MU, 2001, J BIOL CHEM, V276, P20491, DOI 10.1074/jbc.M101150200; James P, 1996, GENETICS, V144, P1425; Kaiser P, 2000, CELL, V102, P303, DOI 10.1016/S0092-8674(00)00036-2; KLIONSKY DJ, 1992, J CELL BIOL, V119, P287, DOI 10.1083/jcb.119.2.287; Losko S, 2001, MOL BIOL CELL, V12, P1047, DOI 10.1091/mbc.12.4.1047; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; Nijman SMB, 2005, MOL CELL, V17, P331, DOI 10.1016/j.molcel.2005.01.008; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Osley MA, 2004, BBA-GENE STRUCT EXPR, V1677, P74, DOI 10.1016/j.bbaexp.2003.10.013; Papa FR, 1999, MOL BIOL CELL, V10, P741, DOI 10.1091/mbc.10.3.741; Papouli E, 2005, MOL CELL, V19, P123, DOI 10.1016/j.molcel.2005.06.001; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Petroski MD, 2003, MOL CELL, V11, P1435, DOI 10.1016/S1097-2765(03)00221-1; Pfander B, 2005, NATURE, V436, P428, DOI 10.1038/nature03665; Pickart CM, 2004, CURR OPIN CHEM BIOL, V8, P610, DOI 10.1016/j.cbpa.2004.09.009; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; Roth AF, 2000, J BIOL CHEM, V275, P8143, DOI 10.1074/jbc.275.11.8143; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schmitz C, 2005, MOL BIOL CELL, V16, P1319, DOI 10.1091/mbc.E04-05-0425; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0; Scott SV, 1996, P NATL ACAD SCI USA, V93, P12304, DOI 10.1073/pnas.93.22.12304; Scott SV, 1997, J CELL BIOL, V138, P37, DOI 10.1083/jcb.138.1.37; Scott SV, 2001, MOL CELL, V7, P1131, DOI 10.1016/S1097-2765(01)00263-5; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shintani T, 2004, J BIOL CHEM, V279, P29889, DOI 10.1074/jbc.M404399200; Shintani T, 2002, DEV CELL, V3, P825, DOI 10.1016/S1534-5807(02)00373-8; SIKORSKI RS, 1989, GENETICS, V122, P19; Stelter P, 2003, NATURE, V425, P188, DOI 10.1038/nature01965; STROMHAUG PE, 2003, AUTOPHAGY; Sun LJ, 2004, CURR OPIN CELL BIOL, V16, P119, DOI 10.1016/j.ceb.2004.02.005; Suzuki K, 2002, DEV CELL, V3, P815, DOI 10.1016/S1534-5807(02)00359-3; Swaminathan S, 1999, MOL BIOL CELL, V10, P2583, DOI 10.1091/mbc.10.8.2583; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; THUMM M, 1994, FEBS LETT, V349, P275, DOI 10.1016/0014-5793(94)00672-5; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; Wang YQ, 2002, J BIOL CHEM, V277, P15766, DOI 10.1074/jbc.M111733200; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Wong BR, 2003, DRUG DISCOV TODAY, V8, P746, DOI 10.1016/S1359-6446(03)02780-6	70	35	38	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39067	39076		10.1074/jbc.M508064200	http://dx.doi.org/10.1074/jbc.M508064200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16186126	hybrid			2022-12-25	WOS:000233362200021
J	Bell, RM; Cave, AC; Johar, S; Hearse, DJ; Shah, AM; Shattock, MJ				Bell, RM; Cave, AC; Johar, S; Hearse, DJ; Shah, AM; Shattock, MJ			Pivotal role of NOX-2-containing NADPH oxidase in early ischemic preconditioning	FASEB JOURNAL			English	Article						reperfusion; gp91(phox); reactive oxygen species (ROS); adenosine; PKC	PROTEIN-KINASE-C; ANGIOTENSIN-II; NITRIC-OXIDE; CARDIAC-HYPERTROPHY; FREE-RADICALS; ACTIVATION; ADENOSINE; P47(PHOX); EPSILON; PHOSPHORYLATION	Reactive oxygen species (ROS)-mediated signaling is implicated in early ischemic preconditioning ( PC). A NOX-2-containing NADPH oxidase is a recognized major source of ROS in cardiac myocytes, whose activity is augmented by preconditioning mimetics, such as angiotensin II. We hypothesized that this oxidase is an essential source of ROS in PC. Hearts from wild-type ( WT) and NOX-2 knockout ( KO) mice were Langendorff perfused and subjected to 35 min ischemia/reperfusion with or without preceding PC or drug treatment. Infarct size was measured by triphenyl tetrazolium chloride staining, and NADPH oxidase activity by lucigenin chemiluminescence. PC significantly attenuated infarct size in WT ( 26 +/- 2% vs. control, 38 +/- 2%, P < 0.05) yet was ineffective in KO hearts ( 33 +/- 3% vs. control, 34 +/- 3%). Concomitantly, PC significantly increased NADPH oxidase activity in WT (+ 41 +/- 13%; P < 0.05), but not in KO ( - 5 +/- 18%, P = NS). The ROS scavenger MPG (N-2-mercaptopropionyl glycine, 300 mu mol/ L) abrogated PC in WT ( 39 +/- 2% vs. control, 33 +/- 1%). CCPA ( 2-chloro N6 cyclopentyl adenosine, 200 nmol/L), a putative ROS-independent PC trigger, significantly attenuated infarct size in WT, MPG-treated WT and KO hearts ( 24 +/- 2, 23 +/- 1, and 20 +/- 3%, respectively, P < 0.05). Furthermore, CCPA did not augment NADPH oxidase activity over control (+ 22 +/- 11%, P = NS). Inhibition of protein kinase C (PKC) with chelerythrine (CHE, 2 mu mol/ L) completely abrogated both PC ( 38 +/- 2% vs. CHE alone, 35 +/- 2%) and associated increases in oxidase activity (+ 3 +/- 10%, P = NS). PKC-dependent activation of a NOX-2-containing NADPH oxidase is pivotally involved in early ischemic PC. However, adenosine receptor activation can trigger a ROS and NOX-2 independent PC pathway.	Kings Coll London, St Thomas Hosp, Rayne Inst, Div Cardiovasc, London SE1 7EH, England; Kings Coll London, Guys Kings & St Thomas Sch Med, Dept Cardiol, Div Cardiovasc, London SE1 7EH, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of London; King's College London	Shattock, MJ (corresponding author), Kings Coll London, St Thomas Hosp, Rayne Inst, Div Cardiovasc, London SE1 7EH, England.	michael.shattock@kcl.ac.uk	Johar, Sofian/AAX-7450-2021	Johar, Sofian/0000-0002-5962-6492; Shattock, Michael/0000-0001-6242-7585; Shah, Ajay/0000-0002-6547-0631				Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Baines CP, 1997, J MOL CELL CARDIOL, V29, P207, DOI 10.1006/jmcc.1996.0265; Bell RM, 2001, CARDIOVASC RES, V52, P274, DOI 10.1016/S0008-6363(01)00394-7; Bendall JK, 2002, CIRCULATION, V105, P293, DOI 10.1161/hc0302.103712; Broussas M, 1999, J LEUKOCYTE BIOL, V66, P495, DOI 10.1002/jlb.66.3.495; Byrne JA, 2003, CIRC RES, V93, P802, DOI 10.1161/01.RES.0000099504.30207.F5; CLARK KJ, 1995, J BIOL CHEM, V270, P7097, DOI 10.1074/jbc.270.13.7097; Cohen MV, 2001, CIRC RES, V89, P273, DOI 10.1161/hh1501.094266; Das DK, 1999, MOL CELL BIOCHEM, V196, P59, DOI 10.1023/A:1006966128795; Di-Capua N, 2003, J NEUROCHEM, V84, P409, DOI 10.1046/j.1471-4159.2003.01563.x; Diaz RJ, 1997, J MOL CELL CARDIOL, V29, P129, DOI 10.1006/jmcc.1996.0258; Dikalov S, 1996, ARCH BIOCHEM BIOPHYS, V326, P207, DOI 10.1006/abbi.1996.0067; Fontayne A, 2002, BIOCHEMISTRY-US, V41, P7743, DOI 10.1021/bi011953s; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Iliodromitis EK, 1998, J MOL CELL CARDIOL, V30, P2201, DOI 10.1006/jmcc.1998.0780; Kawamura S, 1998, AM J PHYSIOL-HEART C, V275, pH2266; Krause KH, 2004, JPN J INFECT DIS, V57, pS28; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Lebuffe G, 2003, AM J PHYSIOL-HEART C, V284, pH299, DOI 10.1152/ajpheart.00706.2002; Li JM, 2002, HYPERTENSION, V40, P477, DOI 10.1161/01.HYP.0000032031.30374.32; Li JM, 2002, CIRC RES, V90, P143, DOI 10.1161/hh0202.103615; Liu HP, 2001, AM J PHYSIOL-HEART C, V281, pH191; LIU YG, 1995, J MOL CELL CARDIOL, V27, P883, DOI 10.1016/0022-2828(95)90038-1; MARTYN KD, 2005, CELL SIGNAL      MAY; Miyamae M, 1998, P NATL ACAD SCI USA, V95, P8262, DOI 10.1073/pnas.95.14.8262; Miyawaki H, 1997, CIRC RES, V80, P790, DOI 10.1161/01.res.80.6.790; Mocanu MM, 2002, J MOL CELL CARDIOL, V34, P661, DOI 10.1006/jmcc.2002.2006; Nakano A, 1997, CORONARY ARTERY DIS, V8, P343, DOI 10.1097/00019501-199706000-00003; Paul K, 1997, CIRC RES, V81, P643; Ping PP, 1999, CIRC RES, V84, P587, DOI 10.1161/01.RES.84.5.587; POLLOCK JD, 1995, NAT GENET, V9, P202, DOI 10.1038/ng0295-202; REIMER KA, 1986, AM J PHYSIOL, V251, pH1306, DOI 10.1152/ajpheart.1986.251.6.H1306; Seshiah PN, 2002, CIRC RES, V91, P406, DOI 10.1161/01.RES.0000033523.08033.16; Tani M, 2001, CARDIOVASC RES, V49, P56, DOI 10.1016/S0008-6363(00)00240-6; Yamamori T, 2004, BIOCHEM BIOPH RES CO, V316, P720, DOI 10.1016/j.bbrc.2004.02.108; YAMAZAKI T, 1995, CIRC RES, V77, P258, DOI 10.1161/01.RES.77.2.258; Yao ZH, 1999, AM J PHYSIOL-HEART C, V277, pH2504; Yue Y, 2002, CARDIOVASC RES, V55, P681, DOI 10.1016/S0008-6363(02)00452-2; Zimmerman MC, 2004, CIRC RES, V95, P532, DOI 10.1161/01.RES.0000139957.22530.b9; Zorov DB, 2000, J EXP MED, V192, P1001, DOI 10.1084/jem.192.7.1001	40	77	79	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2037	+		10.1096/fj.04-2774fje	http://dx.doi.org/10.1096/fj.04-2774fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16236999				2022-12-25	WOS:000232991100012
J	Beitzinger, M; Oswald, C; Beinoraviciute-Kellner, R; Stiewe, T				Beitzinger, M; Oswald, C; Beinoraviciute-Kellner, R; Stiewe, T			Regulation of telomerase activity by the p53 family member p73	ONCOGENE			English	Article						telomerase; hTERT; p53; p73	REVERSE-TRANSCRIPTASE GENE; HUMAN TUMOR-CELLS; WILD-TYPE P53; DOWN-REGULATION; IN-VIVO; NEGATIVE REGULATION; IMMORTAL CELLS; FEEDBACK LOOP; CANCER-CELLS; C-MYC	The terminal ends of eukaryotic chromosomes, termed telomeres, progressively shorten during each round of cell division eventually leading cells into senescence. Tumor cells typically overcome this barrier to unlimited proliferation by activation of the human telomerase reverse transcriptase (hTERT) gene. In contrast, in most human somatic cells hTERT expression is tightly repressed by multiple tumor suppressors. Here, we studied the regulation of hTERT by the p53 family member p73. We show that forced expression of p73 or activation of endogenous p73 by E2F1 results in the downregulation of telomerase activity. Vice versa, siRNA-mediated knockdown of p73 induces hTERT expression. Responsiveness to p73 is conferred by Sp1 binding sites within the hTERT core promoter. In tumor cells, p73 isoforms lacking the transactivation domain (DNp73) are frequently over-expressed and believed to function as oncogenes. We show that DNp73 antagonizes the repressive effect of the proapoptotic p53 family members on hTERT expression and, in addition, induces hTERT expression in telomerase-negative cells by interfering with E2F-RB-mediated repression of the hTERT core promoter. These data provide evidence that the p73 gene functions as an important regulator of telomerase activity with implications for embryonic development, cellular differentiation and tumorigenesis.	Univ Wurzburg, Mol Tumor Biol Grp, Rudolf Virchow Ctr, D-97078 Wurzburg, Germany	University of Wurzburg	Stiewe, T (corresponding author), Univ Wurzburg, Mol Tumor Biol Grp, Rudolf Virchow Ctr, Verbacher Str 9, D-97078 Wurzburg, Germany.	thorsten.stiewe@virchow.uni-wuerzburg.de		Stiewe, Thorsten/0000-0003-0134-7826				Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Crowe DL, 2001, NUCLEIC ACIDS RES, V29, P2789, DOI 10.1093/nar/29.13.2789; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; Fillippovich I, 2001, ONCOGENE, V20, P514, DOI 10.1038/sj.onc.1204118; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Fontemaggi G, 2001, MOL CELL BIOL, V21, P8461, DOI 10.1128/MCB.21.24.8461-8470.2001; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Guilleret I, 2002, CARCINOGENESIS, V23, P2025, DOI 10.1093/carcin/23.12.2025; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kanaya T, 2000, CLIN CANCER RES, V6, P1239; Kartasheva NN, 2002, ONCOGENE, V21, P4715, DOI 10.1038/sj.onc.1205584; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kusumoto M, 1999, CLIN CANCER RES, V5, P2140; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Lin SY, 2003, CELL, V113, P881, DOI 10.1016/S0092-8674(03)00430-6; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Moll UM, 2004, MOL CANCER RES, V2, P371; MURATA Y, 1994, J BIOL CHEM, V269, P20674; Nakamura TM, 1998, CELL, V92, P587, DOI 10.1016/S0092-8674(00)81123-X; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Petrenko O, 2003, MOL CELL BIOL, V23, P5540, DOI 10.1128/MCB.23.16.5540-5555.2003; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Putzer B, 2003, CELL DEATH DIFFER, V10, P612, DOI 10.1038/sj.cdd.4401205; Putzer BM, 2000, GENE THER, V7, P1317, DOI 10.1038/sj.gt.3301235; Sharma HW, 1995, P NATL ACAD SCI USA, V92, P12343, DOI 10.1073/pnas.92.26.12343; Shats I, 2004, J BIOL CHEM, V279, P50976, DOI 10.1074/jbc.M402502200; Slade N, 2004, CELL DEATH DIFFER, V11, P357, DOI 10.1038/sj.cdd.4401335; Stiewe T, 2002, J BIOL CHEM, V277, P14177, DOI 10.1074/jbc.M200480200; Stiewe T, 2002, CELL DEATH DIFFER, V9, P237, DOI 10.1038/sj.cdd.4400995; Stiewe T, 2002, CANCER RES, V62, P3598; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Stiewe T, 2003, J BIOL CHEM, V278, P14230, DOI 10.1074/jbc.M300357200; Suske G, 2000, Methods Mol Biol, V130, P175; Tannapfel A, 1999, J NATL CANCER I, V91, P1154, DOI 10.1093/jnci/91.13.1154; WALDMAN T, 1995, CANCER RES, V55, P5187; Waltermann A, 2003, ONCOGENE, V22, P5686, DOI 10.1038/sj.onc.1206859; Wege H, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng003; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Won J, 2004, P NATL ACAD SCI USA, V101, P11328, DOI 10.1073/pnas.0401801101; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xu D, 1996, LEUKEMIA, V10, P1354; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	56	39	42	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					813	826		10.1038/sj.onc.1209125	http://dx.doi.org/10.1038/sj.onc.1209125			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16205639				2022-12-25	WOS:000235212700001
J	Alfalah, M; Wetzel, G; Fischer, I; Busche, R; Sterchi, EE; Zimmer, KP; Sallmann, HP; Naim, HY				Alfalah, M; Wetzel, G; Fischer, I; Busche, R; Sterchi, EE; Zimmer, KP; Sallmann, HP; Naim, HY			A novel type of detergent-resistant membranes may contribute to an early protein sorting event in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; POLARIZED MDCK CELLS; LACTASE-PHLORHIZIN HYDROLASE; CANINE KIDNEY-CELLS; INFLUENZA-VIRUS HEMAGGLUTININ; DIPEPTIDYL PEPTIDASE-IV; INTRACELLULAR-TRANSPORT; SUCRASE-ISOMALTASE; APICAL MEMBRANE; PLASMA-MEMBRANE	One sorting mechanism of apical and basolateral proteins in epithelial cells is based on their solubility profiles with Triton X-100. Nevertheless, apical proteins themselves are also segregated beyond the trans-Golgi network by virtue of their association or nonassociation with cholesterol/sphingolipid-rich microdomains (Jacob, R., and Naim, H. Y. (2001) Curr. Biol. 11, 1444-1450). Therefore, extractability with Triton X-100 does not constitute an absolute criterion of protein sorting. Here, we investigate the solubility patterns of apical and basolateral proteins with other detergents and demonstrate that the mild detergent Tween 20 is adequate to discriminate between apical and basolateral proteins during early stages in their biosynthesis. Although the mannose-rich forms of the apical proteins sucrase-isomaltase, lactase-phlorizin hydrolase, aminopeptidase N, and dipeptidylpeptidase IV reveal similar solubility profiles comprising soluble and nonsoluble fractions, the basolateral proteins, vesicular stomatitis virus G protein, major histocompatibility complex class I, and CD46 are entirely soluble with this detergent. The insoluble Tween 20 membranes are enriched in phosphatidylinositol and phosphatidylglycerol compatible with their synthesis in the endoplasmic reticulum and the existence of a novel class of detergent-resistant membranes. The association of the mannose-rich biosynthetic forms of the apical proteins, sucrase-isomaltase, lactase-phlorizin hydrolase, aminopeptidase N, and dipeptidylpeptidase IV with the Tween 20-resistant membranes suggests an early polarized sorting mechanism prior to maturation in the Golgi apparatus.	Univ Vet Med Hannover, Dept Physiol Chem, Sch Vet Med, D-30559 Hannover, Germany; Univ Bern, Inst Biochem & Mol Biol, CH-3012 Bern, Switzerland; Univ Munster, Childrens Hosp, D-48149 Munster, Germany	University of Veterinary Medicine Hannover, Foundation; University of Bern; University of Munster	Naim, HY (corresponding author), Univ Vet Med Hannover, Dept Physiol Chem, Sch Vet Med, Bunteweg 17, D-30559 Hannover, Germany.	hassan.naim@tiho-hannover.de	Zimmer, Klaus-Peter/AAY-9261-2020; Al Falah, Dr. Marwan/C-6281-2011; Zimmer, Klaus-Peter/AAY-9351-2020					Alfalah M, 1999, CURR BIOL, V9, P593, DOI 10.1016/S0960-9822(99)80263-2; Alfalah M, 2002, J BIOL CHEM, V277, P10683, DOI 10.1074/jbc.M109357200; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BOULAN ER, 1980, CELL, V20, P45, DOI 10.1016/0092-8674(80)90233-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CAPPS GG, 1994, J BIOL CHEM, V269, P11634; Chuang JZ, 1998, J CELL BIOL, V142, P1245, DOI 10.1083/jcb.142.5.1245; DANIELSEN EM, 1995, BIOCHEMISTRY-US, V34, P1596, DOI 10.1021/bi00005a016; EGAN RW, 1976, J BIOL CHEM, V251, P4442; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; FUHRMANN U, 1984, NATURE, V307, P755, DOI 10.1038/307755a0; GORVEL JP, 1984, BIOL CELL, V52, P249; Graichen R, 1996, J BIOL CHEM, V271, P15854, DOI 10.1074/jbc.271.27.15854; HALLMAN M, 1975, BIOCHIM BIOPHYS ACTA, V409, P172, DOI 10.1016/0005-2760(75)90152-6; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; Heine M, 2005, J BIOL CHEM, V280, P25637, DOI 10.1074/jbc.M502265200; Hoekstra D, 2003, J LIPID RES, V44, P869, DOI 10.1194/jlr.R300003-JLR200; Hooper NM, 1999, MOL MEMBR BIOL, V16, P145, DOI 10.1080/096876899294607; Jacob R, 2000, J BIOL CHEM, V275, P6566, DOI 10.1074/jbc.275.9.6566; Jacob R, 2004, J BIOL CHEM, V279, P3680, DOI 10.1074/jbc.C300503200; Jacob R, 2003, CURR BIOL, V13, P607, DOI 10.1016/S0960-9822(03)00188-X; Jacob R, 1999, J BIOL CHEM, V274, P8061, DOI 10.1074/jbc.274.12.8061; Jacob R, 2001, CURR BIOL, V11, P1444, DOI 10.1016/S0960-9822(01)00446-8; JACOB R, 1994, J BIOL CHEM, V269, P2712; JECKEL D, 1990, FEBS LETT, V261, P155, DOI 10.1016/0014-5793(90)80659-7; Kaether C, 2000, MOL BIOL CELL, V11, P1213, DOI 10.1091/mbc.11.4.1213; KARRENBAUER A, 1990, CELL, V63, P259, DOI 10.1016/0092-8674(90)90159-C; Keller P, 2001, NAT CELL BIOL, V3, P140, DOI 10.1038/35055042; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; KITAGAWA Y, 1994, EXP CELL RES, V213, P449, DOI 10.1006/excr.1994.1222; Kundu A, 1996, J VIROL, V70, P6508, DOI 10.1128/JVI.70.9.6508-6515.1996; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Ledesma MD, 1998, P NATL ACAD SCI USA, V95, P3966, DOI 10.1073/pnas.95.7.3966; Lin SS, 1998, J CELL BIOL, V142, P51, DOI 10.1083/jcb.142.1.51; Lipardi C, 2000, MOL BIOL CELL, V11, P531, DOI 10.1091/mbc.11.2.531; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; Maisner A, 1996, J BIOL CHEM, V271, P18853, DOI 10.1074/jbc.271.31.18853; MAIURI L, 1991, GASTROENTEROLOGY, V100, P359, DOI 10.1016/0016-5085(91)90203-W; Marzolo MP, 1997, P NATL ACAD SCI USA, V94, P1834, DOI 10.1073/pnas.94.5.1834; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; Muniz M, 2000, EMBO J, V19, P10, DOI 10.1093/emboj/19.1.10; NAIM HY, 1988, J BIOL CHEM, V263, P7242; Naim HY, 1999, J BIOL CHEM, V274, P17961, DOI 10.1074/jbc.274.25.17961; NAIM HY, 1991, J BIOL CHEM, V266, P12313; NAIM HY, 1993, J VIROL, V67, P4831, DOI 10.1128/JVI.67.8.4831-4841.1993; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Polishchuk R, 2004, NAT CELL BIOL, V6, P297, DOI 10.1038/ncb1109; Rodriguez-Boulan E, 1999, TRENDS CELL BIOL, V9, P291, DOI 10.1016/S0962-8924(99)01595-0; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Slimane TA, 2003, MOL BIOL CELL, V14, P611, DOI 10.1091/mbc.E02-08-0528; Spodsberg N, 2001, J BIOL CHEM, V276, P46597, DOI 10.1074/jbc.M108187200; Sun AQ, 1998, AM J PHYSIOL-GASTR L, V275, pG1045, DOI 10.1152/ajpgi.1998.275.5.G1045; Tienari PJ, 1996, EMBO J, V15, P5218, DOI 10.1002/j.1460-2075.1996.tb00907.x; Vance JE, 2004, BIOCHEM CELL BIOL, V82, P113, DOI 10.1139/o03-073; VIDUGIRIENE J, 1993, J CELL BIOL, V121, P987, DOI 10.1083/jcb.121.5.987; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929; Zheng XL, 1999, J BIOL CHEM, V274, P1596, DOI 10.1074/jbc.274.3.1596; Zierath JR, 1996, DIABETOLOGIA, V39, P1180, DOI 10.1007/BF02658504; ZUMEYER DH, 1999, ANAN BIOCH, V269, P45; ZURZOLO C, 1994, EMBO J, V13, P42, DOI 10.1002/j.1460-2075.1994.tb06233.x; ZWEIBAUM A, 1984, INT J CANCER, V34, P591, DOI 10.1002/ijc.2910340502	67	51	52	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42636	42643		10.1074/jbc.M505924200	http://dx.doi.org/10.1074/jbc.M505924200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16230359	hybrid			2022-12-25	WOS:000234200800021
J	Chen, ZH; Saito, Y; Yoshida, Y; Sekine, A; Noguchi, N; Niki, E				Chen, ZH; Saito, Y; Yoshida, Y; Sekine, A; Noguchi, N; Niki, E			4-Hydroxynonenal induces adaptive response and enhances PC12 cell tolerance primarily through induction of thioredoxin reductase 1 via activation of Nrf2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEME OXYGENASE-1 EXPRESSION; VASCULAR SMOOTH-MUSCLE; OXIDATIVE DNA-DAMAGE; TRANSCRIPTION FACTOR; GENE-EXPRESSION; UP-REGULATION; CYCLOPENTENONE PROSTAGLANDINS; MOLECULAR-MECHANISM; HYDROGEN-PEROXIDE; REDOX REGULATION	4-Hydroxynonenal (4-HNE) is one of the major end products of lipid peroxidation. It has been widely accepted that 4-HNE can induce oxidative stress, implicating into extensive stress-related diseases. In the present study, however, 4-HNE was found to exert adaptive cytoprotective effect at low concentrations, which was primarily through induction of thioredoxin reductase 1 (TR1) via transcriptional activation of NF-E2-related factor 2 (Nrf2). Pretreatment with 4-HNE at sublethal concentrations significantly protected PC12 cells against the subsequent oxidative cell death induced by H2O2 and 6-hydroxydopamine. The cellular antioxidative glutathione system did not show any considerable changes, whereas the TR1 activity as well as the mRNA level was significantly elevated by the 4-HNE treatment. Cells treated with TR1 small interfering RNA exhibited less resistance to oxidative stress, and the adaptive response was completely abolished. The Nrf2 was transcriptionally activated by 4-HNE. Cells treated with Nrf2-small interfering RNA exerted lower constitutive levels of TR1 and exhibited less resistance to oxidative stress, and the 4-HNE-induced TR1 expression and subsequent adaptive response were again abolished in such cells. Treatment with 4-HNE at the adaptive concentration induced transient activation of extracellular signal-regulated protein kinase 1/2 and Akt/protein kinase B. Pharmacological inhibition of both these kinase pathways effectively attenuated 4-HNE induced TR1 expression and subsequent adaptive protection. The above findings, taken together, suggest that stimulation with 4-HNE at sublethal concentrations induces adaptive response and enhances cell tolerance, primarily through induction of TR1 via transcriptional activation of Nrf2 signaling pathway, thereby protecting cells against the forthcoming oxidative stress.	Natl Inst Adv Ind Sci & Technol, Human Stress Signal Res Ctr, Osaka 5638577, Japan; Univ Tokyo, Adv Sci & Technol Res Ctr, Tokyo 1538904, Japan; Doshisha Univ, Dept Engn Sci, Tataratoya, Kyotanabe 6100394, Japan	National Institute of Advanced Industrial Science & Technology (AIST); University of Tokyo; Doshisha University	Chen, ZH (corresponding author), Natl Inst Adv Ind Sci & Technol, Human Stress Signal Res Ctr, 1-8-31,Midorigaoka, Osaka 5638577, Japan.	zhihua-chen@aist.go.jp	Saito, Yoshiro/H-4597-2019; Yoshida, Yasukazu/H-8510-2016	Saito, Yoshiro/0000-0002-0559-5889; Yoshida, Yasukazu/0000-0001-6034-2502				Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Alam J, 2003, CURR PHARM DESIGN, V9, P2499, DOI 10.2174/1381612033453730; Andersson M, 1996, J BIOL CHEM, V271, P10116, DOI 10.1074/jbc.271.17.10116; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Arner ESJ, 1996, BIOCHEM BIOPH RES CO, V225, P268, DOI 10.1006/bbrc.1996.1165; Awasthi S, 1996, AM J CLIN NUTR, V64, P761, DOI 10.1093/ajcn/64.5.761; Awasthi YC, 2004, FREE RADICAL BIO MED, V37, P607, DOI 10.1016/j.freeradbiomed.2004.05.033; Berggren M, 1996, ANTICANCER RES, V16, P3459; BJORNSTEDT M, 1995, J BIOL CHEM, V270, P11761, DOI 10.1074/jbc.270.20.11761; Blum D, 2001, PROG NEUROBIOL, V65, P135, DOI 10.1016/S0301-0082(01)00003-X; Casso D, 1996, MOL GEN GENET, V252, P518, DOI 10.1007/BF02172398; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Chen CY, 2005, BIOCHEM BIOPH RES CO, V331, P993, DOI 10.1016/j.bbrc.2005.03.237; Chen ZH, 2005, NEUROSCI LETT, V383, P256, DOI 10.1016/j.neulet.2005.04.022; Chen ZH, 2004, CARCINOGENESIS, V25, P2005, DOI 10.1093/carcin/bgh183; Choi BM, 2004, BIOCHEM BIOPH RES CO, V321, P132, DOI 10.1016/j.bbrc.2004.06.120; DEMPLE B, 1983, NATURE, V304, P466, DOI 10.1038/304466a0; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Fang J, 2004, INT J CANCER, V109, P1, DOI 10.1002/ijc.11644; Fang JG, 2005, J BIOL CHEM, V280, P25284, DOI 10.1074/jbc.M414645200; Feng ZH, 2004, P NATL ACAD SCI USA, V101, P8598, DOI 10.1073/pnas.0402794101; Forman HJ, 2004, FREE RADICAL BIO MED, V37, P594, DOI 10.1016/j.freeradbiomed.2004.06.009; Gong PF, 2001, J BIOL CHEM, V276, P27018, DOI 10.1074/jbc.M103658200; Grunblatt E, 2000, J NEUROL, V247, P95; Hammer A, 1997, FREE RADICAL BIO MED, V23, P26, DOI 10.1016/S0891-5849(96)00630-2; Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857; Hintze KJ, 2005, J AGR FOOD CHEM, V53, P5535, DOI 10.1021/jf0580059; Hintze KJ, 2003, J NUTR, V133, P2721, DOI 10.1093/jn/133.9.2721; Ishii T, 2004, CIRC RES, V94, P609, DOI 10.1161/01.RES.0000119171.44657.45; Itoh K, 2004, FREE RADICAL BIO MED, V36, P1208, DOI 10.1016/j.freeradbiomed.2004.02.075; Jarrett SG, 2005, FREE RADICAL BIO MED, V38, P1382, DOI 10.1016/j.freeradbiomed.2005.02.003; Kawamoto Y, 2000, J BIOL CHEM, V275, P11291, DOI 10.1074/jbc.275.15.11291; KIM IK, 1993, FEBS LETT, V321, P209, DOI 10.1016/0014-5793(93)80110-G; Kong ANT, 2001, DRUG METAB REV, V33, P255, DOI 10.1081/DMR-120000652; Labbe RF, 2004, CLIN BIOCHEM, V37, P165, DOI 10.1016/j.clinbiochem.2003.10.006; Leonarduzzi G, 2004, FREE RADICAL BIO MED, V37, P1694, DOI 10.1016/j.freeradbiomed.2004.08.027; Levonen AL, 2004, BIOCHEM J, V378, P373, DOI 10.1042/BJ20031049; Levonen AL, 2001, ARTERIOSCL THROM VAS, V21, P1846, DOI 10.1161/hq1101.098488; Lim SY, 2004, J BIOL CHEM, V279, P46263, DOI 10.1074/jbc.M406555200; Liu XM, 2005, J BIOL CHEM, V280, P872, DOI 10.1074/jbc.M410413200; Martin D, 2004, J BIOL CHEM, V279, P8919, DOI 10.1074/jbc.M309660200; MOCHIZUKI M, 2004, AM J RESP CRIT CARE, V121, P1760; Mustacich D, 2000, BIOCHEM J, V346, P1, DOI 10.1042/0264-6021:3460001; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; Numazawa S, 2003, AM J PHYSIOL-CELL PH, V285, pC334, DOI 10.1152/ajpcell.00043.2003; Park YS, 2005, BIOCHEM BIOPH RES CO, V327, P1058, DOI 10.1016/j.bbrc.2004.12.104; Petersen DR, 2004, FREE RADICAL BIO MED, V37, P937, DOI 10.1016/j.freeradbiomed.2004.06.012; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Rundlof AK, 2004, ANTIOXID REDOX SIGN, V6, P41, DOI 10.1089/152308604771978336; Saito Y, 2003, J BIOL CHEM, V278, P39428, DOI 10.1074/jbc.M305542200; Sakurai A, 2005, J CELL PHYSIOL, V203, P529, DOI 10.1002/jcp.20246; Salinas M, 2003, J BIOL CHEM, V278, P13898, DOI 10.1074/jbc.M209164200; Sayre LM, 1997, J NEUROCHEM, V68, P2092; Sen CK, 2000, CURR TOP CELL REGUL, V36, P1; Seo YJ, 2004, FREE RADICAL BIO MED, V37, P1272, DOI 10.1016/j.freeradbiomed.2004.07.012; Sies H., 1985, OXIDATIVE STRESS, V501, P1, DOI DOI 10.1016/B978-0-12-642760-8.50005-3; Smart DDK, 2004, CANCER RES, V64, P6716, DOI 10.1158/0008-5472.CAN-03-3990; SPITZ DR, 1987, J CELL PHYSIOL, V131, P364, DOI 10.1002/jcp.1041310308; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Sun QA, 1999, J BIOL CHEM, V274, P24522, DOI 10.1074/jbc.274.35.24522; Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189; Uchida K, 2003, PROG LIPID RES, V42, P318, DOI 10.1016/S0163-7827(03)00014-6; UCHIDA K, 1994, BIOCHEMISTRY-US, V33, P12487, DOI 10.1021/bi00207a016; Yu R, 2000, J BIOL CHEM, V275, P39907, DOI 10.1074/jbc.M004037200; Zernecke A, 2003, FASEB J, V17, P1099, DOI 10.1096/fj.02-0485fje	67	169	174	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					41921	41927		10.1074/jbc.M508556200	http://dx.doi.org/10.1074/jbc.M508556200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16219762	hybrid			2022-12-25	WOS:000233992700018
J	Lassot, I; Estrabaud, E; Emiliani, S; Benkirane, M; Benarous, R; Margottin-Goguet, F				Lassot, I; Estrabaud, E; Emiliani, S; Benkirane, M; Benarous, R; Margottin-Goguet, F			p300 modulates ATF4 stability and transcriptional activity independently of its acetyltransferase domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN CBP; UBIQUITIN LIGASE; BETA-TRCP; P300/CBP-ASSOCIATED FACTOR; TARGETED DISRUPTION; CREB-2 ATF-4; DNA-BINDING; ACETYLATION; DEGRADATION; PROMOTER	ATF4 plays a crucial role in the cellular response to stress and multiple stress responses pathways converge to the translational up-regulation of ATF4. ATF4 is a substrate of the SCF beta TrCP ubiquitin ligase that binds to beta TrCP through phosphorylation on a DSGXXXS motif. We show here that ATF4 stability is also modulated by the histone acetyltransferase p300, which induces ATF4 stabilization by inhibiting its ubiquitination. Despite p300 acetylates ATF4, we found that p300-mediated ATF4 stabilization is independent of p300 catalytic activity, using either the inactive form of p300 or the acetylation mutant ATF4-K311R. ATF4 deleted of its p300 binding domain is no more stabilized by p300 nor recruited into nuclear speckles. In consequence of ATF4 stabilization, both p300 and the catalytically inactive enzyme increase ATF4 transcriptional activity.	Univ Paris 05, Inst Cochin, Dept Malad Infect, INSERM U567,CNRS,UMR8104, F-75014 Paris, France; Inst Genet Humaine, CNRS, UPR 1142, F-34396 Montpellier, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Benarous, R (corresponding author), Univ Paris 05, Inst Cochin, Dept Malad Infect, INSERM U567,CNRS,UMR8104, Bat G Roussy,27 Rue Faubourg St Jacques, F-75014 Paris, France.	benarous@cochin.inserm.fr; margottin-goguet@cochin.inserm.fr	Margottin-Goguet, Florence/F-9272-2013; Lassot, Irena/O-3208-2017	Margottin-Goguet, Florence/0000-0002-3124-6690; Lassot, Irena/0000-0001-7059-7963				Bres V, 2003, NAT CELL BIOL, V5, P754, DOI 10.1038/ncb1023; Bres V, 2002, EMBO J, V21, P6811, DOI 10.1093/emboj/cdf669; Bruhat A, 2000, MOL CELL BIOL, V20, P7192, DOI 10.1128/MCB.20.19.7192-7204.2000; Chakraborty S, 2001, J BIOL CHEM, V276, P44936, DOI 10.1074/jbc.M106733200; Chen A, 2003, NEURON, V39, P655, DOI 10.1016/S0896-6273(03)00501-4; Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398; Gachon F, 2002, VIROLOGY, V299, P271, DOI 10.1006/viro.2002.1501; Gachon F, 2001, FEBS LETT, V502, P57, DOI 10.1016/S0014-5793(01)02646-1; Gachon F, 2000, MOL CELL BIOL, V20, P3470, DOI 10.1128/MCB.20.10.3470-3481.2000; Giandomenico V, 2003, MOL CELL BIOL, V23, P2587, DOI 10.1128/MCB.23.7.2587-2599.2003; Gronroos E, 2002, MOL CELL, V10, P483, DOI 10.1016/S1097-2765(02)00639-1; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Heissmeyer V, 2001, MOL CELL BIOL, V21, P1024, DOI 10.1128/MCB.21.4.1024-1035.2001; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Kalkhoven E, 2004, BIOCHEM PHARMACOL, V68, P1145, DOI 10.1016/j.bcp.2004.03.045; Lassot I, 2001, MOL CELL BIOL, V21, P2192, DOI 10.1128/MCB.21.6.2192-2202.2001; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Liang GS, 1997, J BIOL CHEM, V272, P24088, DOI 10.1074/jbc.272.38.24088; Madison DL, 2002, J BIOL CHEM, V277, P38755, DOI 10.1074/jbc.M207512200; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Masuoka HC, 2002, BLOOD, V99, P736, DOI 10.1182/blood.V99.3.736; Miyagishi M, 2000, J BIOL CHEM, V275, P35170, DOI 10.1074/jbc.C000258200; Rutkowski DT, 2003, DEV CELL, V4, P442, DOI 10.1016/S1534-5807(03)00100-X; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Shtutman Michael, 2002, Cancer Research, V62, P5947; Tanaka T, 1998, GENES CELLS, V3, P801, DOI 10.1046/j.1365-2443.1998.00230.x; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; Wolf D, 2002, J BIOL CHEM, V277, P25562, DOI 10.1074/jbc.M201196200; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092-8674(04)00344-7; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yang XL, 2004, J BIOL CHEM, V279, P47109, DOI 10.1074/jbc.M410010200; Zeng SX, 2003, J BIOL CHEM, V278, P7453, DOI 10.1074/jbc.M209030200	38	69	71	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41537	41545		10.1074/jbc.M505294200	http://dx.doi.org/10.1074/jbc.M505294200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16219772	Green Published, hybrid			2022-12-25	WOS:000233866900053
J	Cuerrier, D; Moldoveanu, T; Davies, PL				Cuerrier, D; Moldoveanu, T; Davies, PL			Determination of peptide substrate specificity for mu-calpain by a peptide library-based approach - The importance of promed side interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED NEUTRAL PROTEASE; CRYSTAL-STRUCTURE; CALCIUM; CLEAVAGE; SITE; PROTEOLYSIS; BIOINFORMATICS; IDENTIFICATION; LOCALIZATION; DEGRADATION	Calpains are proteases that catalyze the limited cleavage of target proteins in response to Ca-2(+) signaling. Because of their involvement in pathological conditions such as post-ischemic injury and Alzheimer and Parkinson disease, calpains form a class of pharmacologically significant targets for inhibition. We have determined the sequence preference for the hydrolysis of peptide substrates of the ubiquitous mu-calpain isoform by a peptide library-based approach using the proteolytic core of mu-calpain (mu I-II). The approach, first described by Turk et al. ( Turk, B. E., Huang, L. L., Piro, E. T., and Cantley, L. C. (2001) Nat. Biotechnol. 19, 661 - 667), involved the digestion of an N-terminally acetylated degenerate peptide library in conjunction with Edman sequencing to determine the specificity for residues found at primed positions. The cleavage consensus for these positions was then used to design a second, partially degenerate library, to determine specificity at unprimed positions. We have improved upon the original methodology by using a degenerate peptide dendrimer for determination of specificity at unprimed positions. By using this modified approach, the complete cleavage specificity profile for mu I-II was determined for all positions flanking the cleaved peptide. A previously known preference of calpains for hydrophobic amino acids at unprimed positions was confirmed. In addition, a novel residue specificity for primed positions was revealed to highlight the importance of these sites for substrate recognition. The optimal primed site motif ( MER) was shown to be capable of directing cleavage to a specific peptide bond. Accordingly, we designed a fluorescent resonance energy transfer-based substrate with optimal cleavage motifs on the primed and non-primed sides (PLFAER). The mu-calpain core shows a far greater turnover rate for our substrate than for those based on the cleavage site of alpha-spectrin or the proteolytic sequence consensus compiled from substrate alignments.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Prot Funct Discovery Grp, Kingston, ON K7L 3N6, Canada; McGill Univ, Dept Biochem, Montreal, PQ H2X 4A3, Canada	Queens University - Canada; Queens University - Canada; McGill University	Davies, PL (corresponding author), Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada.	daviesp@post.queensu.ca	Moldoveanu, Tudor/N-8173-2018	Moldoveanu, Tudor/0000-0003-0791-318X				BANIK NL, 1994, J NEUROSCI RES, V37, P489, DOI 10.1002/jnr.490370408; Bano D, 2005, CELL, V120, P275, DOI 10.1016/j.cell.2004.11.049; Barrett AJ, 2004, CURR OPIN DRUG DISC, V7, P334; Carafoli E, 2001, CRIT REV BIOCHEM MOL, V36, P107, DOI 10.1080/20014091074183; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; Dear TN, 2001, GENE, V274, P245, DOI 10.1016/S0378-1119(01)00599-6; DRAPEAU GR, 1980, J BIOL CHEM, V255, P839; FISCHER S, 1986, BIOL CHEM H-S, V367, P1147, DOI 10.1515/bchm3.1986.367.2.1147; Franco SJ, 2004, NAT CELL BIOL, V6, P977, DOI 10.1038/ncb1175; Gil-Parrado S, 2003, J BIOL CHEM, V278, P16336, DOI 10.1074/jbc.M208657200; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; HATANAKA M, 1985, ARCH BIOCHEM BIOPHYS, V242, P557, DOI 10.1016/0003-9861(85)90243-7; Higuchi M, 2005, J BIOL CHEM, V280, P15229, DOI 10.1074/jbc.M500939200; HIRAO T, 1983, J BIOCHEM-TOKYO, V94, P2071, DOI 10.1093/oxfordjournals.jbchem.a134564; Hosfield CM, 1999, EMBO J, V18, P6880, DOI 10.1093/emboj/18.24.6880; Kambe A, 2005, BRAIN RES, V1040, P36, DOI 10.1016/j.brainres.2005.01.080; MATAYOSHI ED, 1990, SCIENCE, V247, P954, DOI 10.1126/science.2106161; MCDERMOTT JR, 1985, LIFE SCI, V37, P725, DOI 10.1016/0024-3205(85)90542-9; Mittoo S, 2003, ANAL BIOCHEM, V319, P234, DOI 10.1016/S0003-2697(03)00324-5; Moldoveanu T, 2004, J MOL BIOL, V343, P1313, DOI 10.1016/j.jmb.2004.09.016; Moldoveanu T, 2004, J BIOL CHEM, V279, P6106, DOI 10.1074/jbc.M310460200; Moldoveanu T, 2002, CELL, V108, P649, DOI 10.1016/S0092-8674(02)00659-1; Richardson PL, 2002, CURR PHARM DESIGN, V8, P2559, DOI 10.2174/1381612023392630; Sadler Kristen, 2002, J Biotechnol, V90, P195; SAKAI K, 1989, BIOCHIM BIOPHYS ACTA, V985, P51, DOI 10.1016/0005-2736(89)90102-8; SAKAI K, 1987, J BIOCHEM-TOKYO, V101, P911, DOI 10.1093/oxfordjournals.jbchem.a121959; SASAKI T, 1984, J BIOL CHEM, V259, P2489; SASAKI T, 1986, J BIOCHEM-TOKYO, V99, P173, DOI 10.1093/oxfordjournals.jbchem.a135457; Sorimachi H, 2001, J BIOCHEM-TOKYO, V129, P653, DOI 10.1093/oxfordjournals.jbchem.a002903; Stabach PR, 1997, BIOCHEMISTRY-US, V36, P57, DOI 10.1021/bi962034i; Strobl S, 2000, P NATL ACAD SCI USA, V97, P588, DOI 10.1073/pnas.97.2.588; Takahashi K, 1990, INTRACELLULAR CALCIU, P55; Tompa P, 2004, J BIOL CHEM, V279, P20775, DOI 10.1074/jbc.M313873200; Turk BE, 2004, METHODS, V32, P398, DOI 10.1016/j.ymeth.2003.10.003; Turk BE, 2003, CURR OPIN CHEM BIOL, V7, P84, DOI 10.1016/S1367-5931(02)00004-2; Turk BE, 2001, NAT BIOTECHNOL, V19, P661, DOI 10.1038/90273; Tyndall JDA, 2005, CHEM REV, V105, P973, DOI 10.1021/cr040669e; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; Wendt A, 2004, BIOL CHEM, V385, P465, DOI 10.1515/BC.2004.054	39	99	103	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40632	40641		10.1074/jbc.M506870200	http://dx.doi.org/10.1074/jbc.M506870200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16216885	hybrid			2022-12-25	WOS:000233666600032
J	Hinnerwisch, J; Reid, BG; Fenton, WA; Horwich, AL				Hinnerwisch, J; Reid, BG; Fenton, WA; Horwich, AL			Roles of the N-domains of the ClpA unfoldase in binding substrate proteins and in stable complex formation with the ClpP protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; MOLECULAR CHAPERONE; HSP100 CHAPERONE; DEGRADATION; ATP; DELIVERY; RECOGNITION; ADAPTER; SSPB; HYDROLYSIS	The hexameric cylindrical Hsp100 chaperone ClpA mediates ATP-dependent unfolding and translocation of recognized substrate proteins into the coaxially associated serine protease ClpP. Each subunit of ClpA is composed of an N-terminal domain of similar to 150 amino acids at the top of the cylinder followed by two AAA+ domains. In earlier studies, deletion of the N-domain was shown to have no effect on the rate of unfolding of substrate proteins bearing a C-terminal ssrA tag, but it did reduce the rate of degradation of these proteins (Lo, J. H., Baker, T. A., and Sauer, R. T. (2001) Protein Sci. 10, 551-559; Singh, S. K., Rozycki, J., Ortega, J., Ishikawa, T., Lo, J., Steven, A. C., and Maurizi, M. R. (2001) J. Biol. Chem. 276, 29420 - 29429). Here we demonstrate, using both fluorescence resonance energy transfer to measure the arrival of substrate at ClpP and competition between wild-type and an inactive mutant form of ClpP, that this effect on degradation is caused by diminished stability of the ClpA-ClpP complex during translocation and proteolysis, effectively disrupting the targeting of unfolded substrates to the protease. We have also examined two larger ssrA-tagged substrates, CFP-GFP-ssrA and luciferase-ssrA, and observed different behaviors. CFP-GFP-ssrA is not efficiently unfolded by the truncated chaperone whereas luciferase-ssrA is, suggesting that the former requires interaction with the N-omains, likely via the body of the protein, to stabilize its binding. Thus, the N- domains play a key allosteric role in complex formation with ClpP and may also have a critical role in recognizing certain tag elements and binding some substrate proteins.	Yale Univ, Sch Med, Dept Genet, New Haven, CT 06519 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06519 USA; Scripps Res Inst, Dept Biol Mol, La Jolla, CA 92037 USA	Yale University; Howard Hughes Medical Institute; Yale University; Scripps Research Institute	Horwich, AL (corresponding author), Yale Univ, Sch Med, Dept Genet, BCMM 145,295 Congress Ave, New Haven, CT 06519 USA.	horwich@csb.yale.edu						Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; Bolon DN, 2004, MOL CELL, V13, P443, DOI 10.1016/S1097-2765(04)00027-9; Conti E, 1996, STRUCTURE, V4, P287, DOI 10.1016/S0969-2126(96)00033-0; Donaldson LW, 2003, J BIOL CHEM, V278, P48991, DOI 10.1074/jbc.M307826200; Dougan DA, 2003, MOL CELL, V12, P373, DOI 10.1016/j.molcel.2003.08.012; Dougan DA, 2002, MOL CELL, V9, P673, DOI 10.1016/S1097-2765(02)00485-9; Flynn JM, 2003, MOL CELL, V11, P671, DOI 10.1016/S1097-2765(03)00060-1; Gonciarz-Swiatek M, 1999, J BIOL CHEM, V274, P13999, DOI 10.1074/jbc.274.20.13999; Guo FS, 2002, J BIOL CHEM, V277, P46743, DOI 10.1074/jbc.M207796200; Guo FS, 2002, J BIOL CHEM, V277, P46753, DOI 10.1074/jbc.M208104200; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hinnerwisch J, 2005, CELL, V121, P1029, DOI 10.1016/j.cell.2005.04.012; Horwich AL, 1999, P NATL ACAD SCI USA, V96, P11033, DOI 10.1073/pnas.96.20.11033; Hoskins JR, 2000, P NATL ACAD SCI USA, V97, P8892, DOI 10.1073/pnas.97.16.8892; Hoskins JR, 2002, P NATL ACAD SCI USA, V99, P11037, DOI 10.1073/pnas.172378899; Hoskins JR, 2002, ADV PROTEIN CHEM, V59, P413; Hoskins JR, 2000, J BIOL CHEM, V275, P35361, DOI 10.1074/jbc.M006288200; Ishikawa T, 2004, J STRUCT BIOL, V146, P180, DOI 10.1016/j.jsb.2003.11.018; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; Kenniston JA, 2003, CELL, V114, P511, DOI 10.1016/S0092-8674(03)00612-3; Kenniston JA, 2004, NAT STRUCT MOL BIOL, V11, P800, DOI 10.1038/nsmb0904-800; Kim DY, 2003, J BIOL CHEM, V278, P50664, DOI 10.1074/jbc.M305882200; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X; Lee S, 2003, CELL, V115, P229, DOI 10.1016/S0092-8674(03)00807-9; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; Levchenko I, 2003, MOL CELL, V12, P365, DOI 10.1016/j.molcel.2003.08.014; Lo JH, 2001, PROTEIN SCI, V10, P551, DOI 10.1110/ps.41401; Matouschek A, 2003, NAT STRUCT BIOL, V10, P674, DOI 10.1038/nsb0903-674; Pickart CM, 2004, NAT REV MOL CELL BIO, V5, P177, DOI 10.1038/nrm1336; Reid BG, 2001, P NATL ACAD SCI USA, V98, P3768, DOI 10.1073/pnas.071043698; Rubin DM, 1998, EMBO J, V17, P4909, DOI 10.1093/emboj/17.17.4909; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SEOL JH, 1995, J BIOL CHEM, V270, P8087, DOI 10.1074/jbc.270.14.8087; Singh SK, 1999, BIOCHEMISTRY-US, V38, P14906, DOI 10.1021/bi991615f; Singh SK, 2001, J BIOL CHEM, V276, P29420, DOI 10.1074/jbc.M103489200; Sousa MC, 2000, CELL, V103, P633, DOI 10.1016/S0092-8674(00)00166-5; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wah DA, 2003, MOL CELL, V12, P355, DOI 10.1016/S1097-2765(03)00272-7; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; Wojtyra UA, 2003, J BIOL CHEM, V278, P48981, DOI 10.1074/jbc.M307825200; WOO KM, 1989, J BIOL CHEM, V264, P2088; Zeth K, 2002, NAT STRUCT BIOL, V9, P906, DOI 10.1038/nsb869; Zhou YN, 2001, GENE DEV, V15, P627, DOI 10.1101/gad.864401; Zwickl P, 2002, ADV PROTEIN CHEM, V59, P187	50	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40838	40844		10.1074/jbc.M507879200	http://dx.doi.org/10.1074/jbc.M507879200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16207718	hybrid			2022-12-25	WOS:000233666600055
J	Cook, RW; Thompson, TB; Kurup, SP; Jardetzky, TS; Wookdruff, TK				Cook, RW; Thompson, TB; Kurup, SP; Jardetzky, TS; Wookdruff, TK			Structural basis for a functional antagonist in the transforming growth factor beta superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; CRYSTAL-STRUCTURE; II RECEPTORS; ACTIVIN-A; INHIBIN; BINDING; COMPLEX; BETAGLYCAN; MEMBRANE; BMP-2	Within the transforming growth factor beta superfamily, the agonist-antagonist relationship between activin and inhibin is unique and critical to integrated reproductive function. Activin acts in the pituitary to stimulate follicle-stimulating hormone, and is antagonized by endocrine acting, gonadally derived inhibin. We have undertaken a mutational analysis of the activin beta A subunit to determine the precise structural aspects that contribute to inhibin antagonism of activin. By substituting specific amino acid residues in the activin beta A subunit with similarly aligned amino acids from the alpha subunit, we have pinpointed the residues required for activin receptor binding and activity, as well as for inhibin antagonism of activin through its receptors. Additionally, we have identified an activin mutant with a higher affinity for the activin type I receptor that provides structural evidence for the evolution of ligand-receptor interactions within the transforming growth factor beta superfamily.	Northwestern Univ, Dept Neurobiol & Physiol, Evanston, IL 60208 USA; Northwestern Univ, Dept Biochem, Evanston, IL 60208 USA; Northwestern Univ, Dept Mol Biol & Cell Biol, Evanston, IL 60208 USA; Northwestern Univ, Dept Microbiol & Immunol, Evanston, IL 60208 USA; Northwestern Univ, Sch Med, Dept Med, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA	Northwestern University; Northwestern University; Northwestern University; Northwestern University; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Wookdruff, TK (corresponding author), Northwestern Univ, Dept Neurobiol & Physiol, OT Hogan 4-150,2205 Tech Dr, Evanston, IL 60208 USA.	tkw@northwestern.edu		Woodruff, Teresa/0000-0002-1197-3399; Thompson, Thomas/0000-0002-7041-5047	NICHD NIH HHS [U54 HD041857, T32HD007068, U54-HD28934] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD028934, U54HD041857] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007068] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Chang H, 2001, MOL CELL ENDOCRINOL, V180, P39, DOI 10.1016/S0303-7207(01)00513-5; CHANNING CP, 1985, P SOC EXP BIOL MED, V178, P339; Chapman SC, 2002, MOL CELL ENDOCRINOL, V196, P79, DOI 10.1016/S0303-7207(02)00227-7; Greenwald J, 2004, MOL CELL, V15, P485, DOI 10.1016/j.molcel.2004.07.011; Harrison CA, 2004, J BIOL CHEM, V279, P28036, DOI 10.1074/jbc.M402782200; Hart PJ, 2002, NAT STRUCT BIOL, V9, P203, DOI 10.1038/nsb766; Innis CA, 2000, PROTEIN ENG, V13, P839, DOI 10.1093/protein/13.12.839; Kirsch T, 2000, NAT STRUCT BIOL, V7, P492; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; Lewis KA, 2000, NATURE, V404, P411, DOI 10.1038/35006129; Muller YA, 1997, STRUCTURE, V5, P1325, DOI 10.1016/S0969-2126(97)00284-0; Nickel J, 2001, J BONE JOINT SURG AM, V83A, pS7; Pangas SA, 2002, J ENDOCRINOL, V172, P199, DOI 10.1677/joe.0.1720199; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shimasaki S, 2004, ENDOCR REV, V25, P72, DOI 10.1210/er.2003-0007; SUN PD, 1995, ANNU REV BIOPH BIOM, V24, P269, DOI 10.1146/annurev.bb.24.060195.001413; Suszko MI, 2003, MOL ENDOCRINOL, V17, P318, DOI 10.1210/me.2002-0081; Thompson TB, 2003, EMBO J, V22, P1555, DOI 10.1093/emboj/cdg156; WOODRUFF TK, 1995, ANNU REV PHYSIOL, V57, P219; Wuytens G, 1999, J BIOL CHEM, V274, P9821, DOI 10.1074/jbc.274.14.9821; XU JM, 1995, J BIOL CHEM, V270, P6308, DOI 10.1074/jbc.270.11.6308	22	15	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40177	40186		10.1074/jbc.M504591200	http://dx.doi.org/10.1074/jbc.M504591200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16186117	hybrid			2022-12-25	WOS:000233461300058
J	Pi, M; Faber, P; Ekema, G; Jackson, PD; Ting, A; Wang, N; Fontilla-Poole, M; Mays, RW; Brunden, KR; Harrington, JJ; Quarles, LD				Pi, M; Faber, P; Ekema, G; Jackson, PD; Ting, A; Wang, N; Fontilla-Poole, M; Mays, RW; Brunden, KR; Harrington, JJ; Quarles, LD			Identification of a novel extracellular cation-sensing G-protein-coupled receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-SENSING RECEPTOR; MOLECULAR-CLONING; 7-TRANSMEMBRANE DOMAIN; MC3T3-E1 OSTEOBLASTS; GABA(B) RECEPTORS; HUMAN CA2+; CALCIUM; BINDING; ACTIVATION; EXPRESSION	The C family G-protein-coupled receptors contain members that sense amino acid and extracellular cations, of which calcium-sensing receptor (CASR) is the prototypic extracellular calcium-sensing receptor. Some cells, such as osteoblasts in bone, retain responsiveness to extracellular calcium in CASR-deficient mice, consistent with the existence of another calcium-sensing receptor. We examined the calcium-sensing properties of GPRC6A, a newly identified member of this family. Alignment of GPRC6A with CASR revealed conservation of both calcium and calcimimetic binding sites. In addition, calcium, magnesium, strontium, aluminum, gadolinium, and the calcimimetic NPS 568 resulted in a dose-dependent stimulation of GPRC6A overexpressed in human embryonic kidney cells 293 cells. Also, osteocalcin, a calcium-binding protein highly expressed in bone, dose-dependently stimulated GPRC6A activity in the presence of calcium but inhibited the calcium-dependent activation of CASR. Coexpression of beta-arrestins 1 and 2, regulators of G-protein signaling RGS2 or RGS4, the RhoA inhibitor C3 toxin, the dominant negative G alpha q-(305-359) minigene, and pretreatment with pertussis toxin inhibited activation of GPRC6A by extracellular cations. Reverse transcription-PCR analyses showed that mouse GPRC6A is widely expressed in mouse tissues, including bone, calvaria, and the osteoblastic cell line MC3T3-E1. These data suggest that in addition to sensing amino acids, GPRC6A is a cation-, calcimimetic, and osteocalcin-sensing receptor and a candidate for mediating extracellular calcium-sensing responses in osteoblasts and possibly other tissues.	Univ Kansas, Med Ctr, Kidney Inst, Dept Internal Med, Kansas City, KS 66160 USA; Athersys Inc, Cleveland, OH 44115 USA	University of Kansas; University of Kansas Medical Center	Quarles, LD (corresponding author), Univ Kansas, Med Ctr, Kidney Inst, Dept Internal Med, 3901 Rainbow Blvd,6018 Wahl Hall E, Kansas City, KS 66160 USA.	dquarles@kumc.edu	Brunden, Kurt/D-1994-2009	Quarles, L. Darryl/0000-0002-5082-7896; Ting, Anthony/0000-0002-5058-9576; Pi, Min/0000-0002-0319-8003	NIAMS NIH HHS [2R01AR037308, R01 AR037308] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR037308] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; AKTORIES K, 1989, TRENDS PHARMACOL SCI, V10, P415, DOI 10.1016/0165-6147(89)90191-0; Bapty BW, 1998, KIDNEY INT, V53, P583, DOI 10.1046/j.1523-1755.1998.00790.x; Brauner-Osborne H, 2000, GENOMICS, V65, P121, DOI 10.1006/geno.2000.6164; BROWN EM, 1991, J BONE MINER RES, V6, P1217; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Calver AR, 2003, MOL BRAIN RES, V110, P305, DOI 10.1016/S0169-328X(02)00662-9; Chattopadhyay N, 2000, CELL SIGNAL, V12, P361, DOI 10.1016/S0898-6568(00)00082-6; Cheng SX, 2002, AM J PHYSIOL-GASTR L, V283, pG240, DOI 10.1152/ajpgi.00500.2001; Choudhary S, 2003, J BONE MINER RES, V18, P1813, DOI 10.1359/jbmr.2003.18.10.1813; Cohen A, 2002, CURR OPIN PHARMACOL, V2, P734, DOI 10.1016/S1471-4892(02)00210-2; Conigrave AD, 2000, P NATL ACAD SCI USA, V97, P4814, DOI 10.1073/pnas.97.9.4814; Conigrave AD, 2004, J BIOL CHEM, V279, P38151, DOI 10.1074/jbc.M406373200; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dvorak MM, 2004, P NATL ACAD SCI USA, V101, P5140, DOI 10.1073/pnas.0306141101; Galvez T, 2000, MOL PHARMACOL, V57, P419, DOI 10.1124/mol.57.3.419; HAUSCHKA PV, 1982, BIOCHEMISTRY-US, V21, P2538, DOI 10.1021/bi00539a038; Hebert RL, 2005, J BIOL CHEM, V280, P35028, DOI 10.1074/jbc.M505852200; Hobson SA, 2003, MOL CELL ENDOCRINOL, V200, P189, DOI 10.1016/S0303-7207(01)00749-3; Hofer AM, 2003, NAT REV MOL CELL BIO, V4, P530, DOI 10.1038/nrm1154; Hu JX, 2005, J BIOL CHEM, V280, P5113, DOI 10.1074/jbc.M413403200; Hu JX, 2002, J BIOL CHEM, V277, P46622, DOI 10.1074/jbc.M207100200; Joshi SA, 1998, FEBS LETT, V441, P67, DOI 10.1016/S0014-5793(98)01527-0; Kameda T, 1998, BIOCHEM BIOPH RES CO, V245, P419, DOI 10.1006/bbrc.1998.8448; Kehrl JH, 2002, INT J BIOCHEM CELL B, V34, P432, DOI 10.1016/S1357-2725(01)00141-8; Kim YH, 2003, BIOCHEM BIOPH RES CO, V304, P729, DOI 10.1016/S0006-291X(03)00661-2; Kohout TA, 2003, MOL PHARMACOL, V63, P9, DOI 10.1124/mol.63.1.9; KUAN GD, 2005, J NEUROCHEM, V93, P383; Kuang DH, 2003, J BIOL CHEM, V278, P42551, DOI 10.1074/jbc.M307120200; Kubo Y, 1998, SCIENCE, V279, P1722, DOI 10.1126/science.279.5357.1722; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; Miedlich SU, 2004, J BIOL CHEM, V279, P7254, DOI 10.1074/jbc.M307191200; Mohler H, 1999, Trends Pharmacol Sci, V20, P87, DOI 10.1016/S0165-6147(99)01323-1; Mun HC, 2004, J BIOL CHEM, V279, P51739, DOI 10.1074/jbc.M406164/200; Nelson G, 2002, NATURE, V416, P199, DOI 10.1038/nature726; Nelson G, 2001, CELL, V106, P381, DOI 10.1016/S0092-8674(01)00451-2; Nemeth EF, 2001, J PHARMACOL EXP THER, V299, P323; Nemeth EF, 1998, P NATL ACAD SCI USA, V95, P4040, DOI 10.1073/pnas.95.7.4040; Nishimoto SK, 2003, J BIOL CHEM, V278, P11843, DOI 10.1074/jbc.M211449200; Petrel C, 2004, J BIOL CHEM, V279, P18990, DOI 10.1074/jbc.M400724200; Pi M, 2005, J CELL BIOCHEM, V95, P1081, DOI 10.1002/jcb.20500; Pi M, 2005, MOL ENDOCRINOL, V19, P1078, DOI 10.1210/me.2004-0450; Pi M, 2004, J BONE MINER RES, V19, P862, DOI 10.1359/JBMR.040114; Pi M, 1999, J BONE MINER RES, V14, P1310, DOI 10.1359/jbmr.1999.14.8.1310; Pi M, 2002, ENDOCRINOLOGY, V143, P3830, DOI 10.1210/en.2002-220240; Pi M, 2000, J BIOL CHEM, V275, P3256, DOI 10.1074/jbc.275.5.3256; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Quarles LD, 2003, J CLIN INVEST, V112, P642, DOI 10.1172/JC1200319687; Quarles LD, 1997, J BONE MINER RES, V12, P393, DOI 10.1359/jbmr.1997.12.3.393; QUARLES LD, 1991, ENDOCRINOLOGY, V128, P3144, DOI 10.1210/endo-128-6-3144; Quinn SJ, 1997, AM J PHYSIOL-CELL PH, V273, pC1315, DOI 10.1152/ajpcell.1997.273.4.C1315; Robbins MJ, 2000, GENOMICS, V67, P8, DOI 10.1006/geno.2000.6226; Saunders R, 1998, NEUROPHARMACOLOGY, V37, P273, DOI 10.1016/S0028-3908(98)00027-6; Shalhoub V, 2003, CRIT REV EUKAR GENE, V13, P89; Spurney RF, 1999, KIDNEY INT, V55, P1750, DOI 10.1046/j.1523-1755.1999.00432.x; Tabata T, 2004, P NATL ACAD SCI USA, V101, P16952, DOI 10.1073/pnas.0405387101; Tu QS, 2003, J CLIN INVEST, V111, P1029, DOI 10.1172/JCI200317054; VanHouten J, 2004, J CLIN INVEST, V113, P598, DOI 10.1172/JCI200418776; Wellendorph P, 2005, MOL PHARMACOL, V67, P589, DOI 10.1124/mol.104.007559; Wellendorph P, 2004, GENE, V335, P37, DOI 10.1016/j.gene.2004.03.003; WEST RE, 1985, J BIOL CHEM, V260, P4428; Wise A, 1999, NEUROPHARMACOLOGY, V38, P1647, DOI 10.1016/S0028-3908(99)00119-7; Yamaguchi T, 1998, J BONE MINER RES, V13, P1530, DOI 10.1359/jbmr.1998.13.10.1530; Yamaguchi T, 2001, AM J PHYSIOL-CELL PH, V280, pC382, DOI 10.1152/ajpcell.2001.280.2.C382; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; Zhang ZX, 2002, J BIOL CHEM, V277, P33727, DOI 10.1074/jbc.M200976200; Zhang ZX, 2002, J BIOL CHEM, V277, P33736, DOI 10.1074/jbc.M200978200	68	238	255	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40201	40209		10.1074/jbc.M505186200	http://dx.doi.org/10.1074/jbc.M505186200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16199532	Green Accepted, hybrid			2022-12-25	WOS:000233461300061
J	Krings, G; Bastia, D				Krings, G; Bastia, D			Sap1p binds to Ter1 at the ribosomal DNA of Schizosaccharomyces pombe and causes polar replication fork arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FISSION YEAST; ESCHERICHIA-COLI; TERMINATOR PROTEIN; SACCHAROMYCES-CEREVISIAE; BLOCK PROTEIN; FOB1 PROTEIN; RNA GENES; S-POMBE; RDNA; TRANSCRIPTION	Eukaryotic DNA replication forks stall at natural replication fork barriers or Ter sites located within the ribosomal DNA ( rDNA) intergenic spacer regions during unperturbed DNA replication. The rDNA intergenic spacer of the fission yeast Schizosaccharomyces pombe contains four polar or orientation-specific fork barriers, Ter1-3 and RFP4. Whereas the transcription terminator Reb1p binds Ter2 and Ter3 to arrest replication, the factor(s) responsible for fork arrest at Ter1 and RFP4 remain unknown. Using linker scanning mutagenesis, we have narrowed down minimal Ter1 to 21 bp. Sequence analysis revealed the presence of a consensus binding motif for the essential switch-activating and genome-stabilizing protein Sap1p within this region. Recombinant Sap1p bound Ter1 with high specificity, and endogenous Ter1 binding activity contained Sap1p and comigrated with the Sap1p-Ter1 complex. Circular permutation analysis suggested that Sap1p bends Ter1 and SAS1 upon binding. Targeted mutational analysis revealed that Ter1 mutations, which prevent Sap1p binding in vitro, are defective for replication fork arrest in vivo, whereas mutations that do not affect Sap1p binding remain competent to arrest replication. The results confirm the hypothesis that the chromatin organizer Sap1p binds site-specifically to genomic regions other than SAS1 and support the notion that Sap1p binds the rDNA fork barrier Ter1 to cause polar replication fork arrest at this site but not at SAS1.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Bastia, D (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave, Charleston, SC 29425 USA.	bastia@musc.edu						ARCANGIOLI B, 1994, MOL CELL BIOL, V14, P2058, DOI 10.1128/MCB.14.3.2058; ARCANGIOLI B, 1991, EMBO J, V10, P3025, DOI 10.1002/j.1460-2075.1991.tb07853.x; ARCANGIOLI B, 1994, NUCLEIC ACIDS RES, V22, P2930, DOI 10.1093/nar/22.15.2930; Bada M, 2000, J MOL BIOL, V300, P563, DOI 10.1006/jmbi.2000.3854; Bastia D., 1996, DNA REPLICATION EUKA, P177; BREWER BJ, 1992, CELL, V71, P267, DOI 10.1016/0092-8674(92)90355-G; Bussiere DE, 1999, MOL MICROBIOL, V31, P1611, DOI 10.1046/j.1365-2958.1999.01287.x; Chan RC, 2003, NATURE, V423, P1002, DOI 10.1038/nature01697; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; D'Amours D, 2004, CELL, V117, P455, DOI 10.1016/S0092-8674(04)00413-1; Dalgaard JZ, 2000, CELL, V102, P745, DOI 10.1016/S0092-8674(00)00063-5; Dalgaard JZ, 2001, GENE DEV, V15, P2060, DOI 10.1101/gad.200801; Dalgaard JZ, 2001, TRENDS GENET, V17, P153, DOI 10.1016/S0168-9525(00)02203-4; Dalgaard LZ, 1999, NATURE, V400, P181, DOI 10.1038/22139; de Lahondes R, 2003, EUKARYOT CELL, V2, P910, DOI 10.1128/EC.2.5.910-921.2003; Defossez PA, 1999, MOL CELL, V3, P447, DOI 10.1016/S1097-2765(00)80472-4; Gerber JK, 1997, CELL, V90, P559, DOI 10.1016/S0092-8674(00)80515-2; GHAZVINI M, 1995, MOL CELL BIOL, V15, P4939; GRANOT D, 1991, CELL MOTIL CYTOSKEL, V20, P47, DOI 10.1002/cm.970200106; GUSTIN KE, 1993, BIOTECHNIQUES, V14, P22; HERNANDEZ P, 1993, EMBO J, V12, P1475, DOI 10.1002/j.1460-2075.1993.tb05791.x; Johzuka K, 2002, GENES CELLS, V7, P99, DOI 10.1046/j.1356-9597.2001.00508.x; Kaykov A, 2004, EMBO J, V23, P930, DOI 10.1038/sj.emboj.7600099; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; Kobayashi T, 2003, MOL CELL BIOL, V23, P9178, DOI 10.1128/MCB.23.24.9178-9188.2003; Kobayashi T, 1998, GENE DEV, V12, P3821, DOI 10.1101/gad.12.24.3821; Kobayashi T, 1996, GENES CELLS, V1, P465, DOI 10.1046/j.1365-2443.1996.d01-256.x; Kralicek AV, 1997, NUCLEIC ACIDS RES, V25, P590, DOI 10.1093/nar/25.3.590; Krings G, 2004, P NATL ACAD SCI USA, V101, P14085, DOI 10.1073/pnas.0406037101; LITTLE RD, 1993, MOL CELL BIOL, V13, P6600, DOI 10.1128/MCB.13.10.6600; Lopez-Estrano C, 1998, J MOL BIOL, V277, P249, DOI 10.1006/jmbi.1997.1607; Manna AC, 1996, CELL, V87, P881, DOI 10.1016/S0092-8674(00)81995-9; Mayer ML, 2004, MOL BIOL CELL, V15, P1736, DOI 10.1091/mbc.E03-08-0619; McGlynn P, 2002, NAT REV MOL CELL BIO, V3, P859, DOI 10.1038/nrm951; Mohanty BK, 2004, J BIOL CHEM, V279, P1932, DOI 10.1074/jbc.M309078200; Mulugu S, 2001, P NATL ACAD SCI USA, V98, P9569, DOI 10.1073/pnas.171065898; Rothstein R, 2000, GENE DEV, V14, P1; SAHOO T, 1995, J BIOL CHEM, V270, P29138, DOI 10.1074/jbc.270.49.29138; Sanchez JA, 1998, EXP CELL RES, V238, P220, DOI 10.1006/excr.1997.3835; Sanchez-Gorostiaga A, 2004, MOL CELL BIOL, V24, P398, DOI 10.1128/MCB.24.1.398-406.2004; SINGH J, 1993, NATURE, V361, P271, DOI 10.1038/361271a0; Takeuchi Y, 2003, GENE DEV, V17, P1497, DOI 10.1101/gad.1085403; Vengrova S, 2004, GENE DEV, V18, P794, DOI 10.1101/gad.289404; WIESENDANGER B, 1994, NUCLEIC ACIDS RES, V22, P5038, DOI 10.1093/nar/22.23.5038; Zhao A, 1997, NUCLEIC ACIDS RES, V25, P904, DOI 10.1093/nar/25.4.904	46	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39135	39142		10.1074/jbc.M508996200	http://dx.doi.org/10.1074/jbc.M508996200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16195226	hybrid			2022-12-25	WOS:000233362200028
J	Mandal, D; Mazumder, A; Das, P; Kundu, M; Basu, J				Mandal, D; Mazumder, A; Das, P; Kundu, M; Basu, J			Fas-, caspase 8-, and caspase 3-dependent signaling regulates the activity of the aminophospholipid translocase and phosphatidylserine externalization in human erythrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELLS; MEMBRANE PHOSPHOLIPID ASYMMETRY; MALARIAL INFECTION; LIPID RAFTS; CYTOPLASMIC DOMAIN; ANCHORED PROTEINS; BETA-THALASSEMIA; PLASMA-MEMBRANE; OUTER LEAFLET; ANNEXIN-V	Apoptosis and erythrocyte senescence share the common feature of exposure of phosphatidylserine ( PS) in the outer leaflet of the cells. Western analysis showed that mature red cells contain Fas, FasL, Fas-associated death domain ( FADD), caspase 8, and caspase 3. Circulating, aged cells showed colocalization of Fas with the raft marker proteins G alpha(s) and CD59; the existence of Fas-associated FasL, FADD and caspase 8; and caspase 8 and caspase 3 activity. Aged red cells had significantly lower aminophospholipid translocase activity and higher levels of PS externalization in comparison with young cells. In support of our contention that caspases play a functional role in the mature red cell, the oxidatively stressed red cell recapitulated apoptotic events, including translocation of Fas into rafts, formation of a Fas-associated complex, and activation of caspases 8 and 3. These events were independent of calpain but dependent on reactive oxygen species ( ROS) as evident from the effects of the ROS scavenger N-acetylcysteine. Caspase activation was associated with loss of aminophospholipid translocase activity and with PS externalization. ROS was not generated by treatment of cells with t-butyl hydroperoxide at 10 degrees C, and Fas did not translocate into rafts. Concomitantly, neither formation of a Fas-associated signaling complex nor caspase activation could be observed, supporting the view that translocation of Fas into rafts was the trigger for the chain of events leading to caspase 3 activation. Our data demonstrate for the first time the novel involvement of Fas/caspase 8/caspase 3-dependent signaling in an enucleated cell leading to PS externalization, a central feature of erythrophagocytosis and erythrocyte biology.	Bose Inst, Dept Chem, Kolkata 700009, W Bengal, India; Natl Int Cholera & Enter Dis, Div Microbiol, Kolkata 700010, W Bengal, India	Department of Science & Technology (India); Bose Institute; Indian Council of Medical Research (ICMR); ICMR - National Institute of Cholera & Enteric Diseases (NICED)	Basu, J (corresponding author), Bose Inst, Dept Chem, 93-1 Acharya Prafulla Chandra Rd, Kolkata 700009, W Bengal, India.	joyoti@vsnl.com	mandal, debabrata/AAF-6690-2019					Banerjee T, 2004, BRIT J HAEMATOL, V124, P391, DOI 10.1046/j.1365-2141.2003.04781.x; BASS DA, 1983, J IMMUNOL, V130, P1910; Berg CP, 2001, CELL DEATH DIFFER, V8, P1197, DOI 10.1038/sj.cdd.4400905; BITBOL M, 1987, BIOCHIM BIOPHYS ACTA, V904, P268, DOI 10.1016/0005-2736(87)90376-2; BLUMENFELD N, 1991, BLOOD, V77, P849; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Bonomini M, 1999, J AM SOC NEPHROL, V10, P1982; BORENSTAINBENYASHAR V, 1993, AM J HEMATOL, V44, P63; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; CALVEZ JY, 1988, BIOCHEMISTRY-US, V27, P5666, DOI 10.1021/bi00415a041; CHAHINE JMEH, 1993, P NATL ACAD SCI USA, V90, P447, DOI 10.1073/pnas.90.2.447; Christian JA, 1998, BLOOD, V92, P2590, DOI 10.1182/blood.V92.7.2590.2590_2590_2591; Comfurius P, 1996, BIOCHEMISTRY-US, V35, P7631, DOI 10.1021/bi9606859; CONNOR J, 1987, BIOCHEMISTRY-US, V26, P5099, DOI 10.1021/bi00390a031; CONNOR J, 1994, J BIOL CHEM, V269, P2399; Corsi D, 1999, EUR J BIOCHEM, V261, P775, DOI 10.1046/j.1432-1327.1999.00336.x; DALEKE DL, 1985, BIOCHEMISTRY-US, V24, P5406, DOI 10.1021/bi00341a019; de Jong K, 2001, BLOOD, V98, P860, DOI 10.1182/blood.V98.3.860; De Maria R, 1999, NATURE, V401, P489, DOI 10.1038/46809; Dekkers DWC, 2000, BIOCHEM J, V350, P531, DOI 10.1042/0264-6021:3500531; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; DEVAUX PF, 1994, CHEM PHYS LIPIDS, V73, P107, DOI 10.1016/0009-3084(94)90177-5; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Gajate C, 2001, BLOOD, V98, P3860, DOI 10.1182/blood.V98.13.3860; Giddings KS, 2003, P NATL ACAD SCI USA, V100, P11315, DOI 10.1073/pnas.2033520100; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Harrison T, 2003, SCIENCE, V301, P1734, DOI 10.1126/science.1089324; Henkler F, 2005, J CELL BIOL, V168, P1087, DOI 10.1083/jcb.200501048; HERMANN A, 1990, BIOCHIM BIOPHYS ACTA, V1027, P41; Hueber AO, 2002, EMBO REP, V3, P190, DOI 10.1093/embo-reports/kvf022; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kamitani T, 1997, J BIOL CHEM, V272, P22307, DOI 10.1074/jbc.272.35.22307; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kuypers FA, 1996, BLOOD, V87, P1179, DOI 10.1182/blood.V87.3.1179.bloodjournal8731179; Kuypers FA, 1998, BLOOD, V91, P3044, DOI 10.1182/blood.V91.8.3044.3044_3044_3051; Lang KS, 2003, CELL DEATH DIFFER, V10, P249, DOI 10.1038/sj.cdd.4401144; Lang PA, 2003, AM J PHYSIOL-CELL PH, V285, pC1553, DOI 10.1152/ajpcell.00186.2003; Mandal D, 2003, J BIOL CHEM, V278, P52551, DOI 10.1074/jbc.M306914200; Mandal D, 2002, FEBS LETT, V513, P184, DOI 10.1016/S0014-5793(02)02294-9; MULLER K, 1994, BIOCHEMISTRY-US, V33, P9968; Muppidi JR, 2004, NAT IMMUNOL, V5, P182, DOI 10.1038/ni1024; Murphy SC, 2004, BLOOD, V103, P1920, DOI 10.1182/blood-2003-09-3165; Nelson KL, 2000, J BIOL CHEM, V275, P19839, DOI 10.1074/jbc.M002785200; OHTANI Y, 1989, EUR J BIOCHEM, V186, P17, DOI 10.1111/j.1432-1033.1989.tb15171.x; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Romero PJ, 1997, BBA-BIOMEMBRANES, V1323, P23, DOI 10.1016/S0005-2736(96)00141-1; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Samuel BU, 2001, J BIOL CHEM, V276, P29319, DOI 10.1074/jbc.M101268200; Scheel-Toellner D, 2002, BIOCHEM BIOPH RES CO, V297, P876, DOI 10.1016/S0006-291X(02)02311-2; SCHROIT AJ, 1994, CURR TOP MEMBR, V40, P47, DOI 10.1016/S0070-2161(08)60976-4; SEIGNEURET M, 1984, P NATL ACAD SCI-BIOL, V81, P3751, DOI 10.1073/pnas.81.12.3751; Shi QL, 2005, J BIOL CHEM, V280, P10888, DOI 10.1074/jbc.M409064200; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Srinivasan PT, 1996, BBA-BIOMEMBRANES, V1285, P65, DOI 10.1016/S0005-2736(96)00146-0; TAIT JF, 1994, J LAB CLIN MED, V123, P741; WILLIAMSON P, 1992, BIOCHEMISTRY-US, V31, P6355, DOI 10.1021/bi00142a027; WILSON MJ, 1993, BIOCHEMISTRY-US, V32, P11302, DOI 10.1021/bi00093a006; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692; YUAN J, 1994, BLOOD, V84, P259; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zhou QS, 1997, J BIOL CHEM, V272, P18240, DOI 10.1074/jbc.272.29.18240	65	156	164	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39460	39467		10.1074/jbc.M506928200	http://dx.doi.org/10.1074/jbc.M506928200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16179347	hybrid			2022-12-25	WOS:000233362200067
J	McCarty, OJT; Larson, MK; Auger, JM; Kalia, N; Atkinson, BT; Pearce, AC; Ruf, S; Henderson, RB; Tybulewicz, VLJ; Machesky, LM; Watson, SP				McCarty, OJT; Larson, MK; Auger, JM; Kalia, N; Atkinson, BT; Pearce, AC; Ruf, S; Henderson, RB; Tybulewicz, VLJ; Machesky, LM; Watson, SP			Rac1 is essential for platelet Lamellipodia formation and aggregate stability under flow	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FILAMENT BARBED ENDS; ARP2/3 COMPLEX; ACTIN CYTOSKELETON; RHO FAMILY; THROMBUS FORMATION; BINDING PROTEIN; ACTIVATION; INTEGRIN; GTPASES; RECEPTOR	The role of Rac family proteins in platelet spreading on matrix proteins under static and flow conditions has been investigated by using Rac-deficient platelets. Murine platelets form filopodia and undergo limited spreading on fibrinogen independent of Rac1 and Rac2. In the presence of thrombin, marked lamellipodia formation is observed on fibrinogen, which is abrogated in the absence of Rac1. However, Rac1 is not required for thrombin-induced aggregation or elevation of F-actin levels. Formation of lamellipodia on collagen and laminin is also Rac1-dependent. Analysis of platelet adhesion dynamics on collagen under flow conditions in vitro revealed that Rac1 is required for platelet aggregate stability at arterial rates of shear, as evidenced by a dramatic increase in platelet embolization. Furthermore, studies employing intravital microscopy demonstrated that Rac1 plays a critical role in the development of stable thrombi at sites of vascular injury in vivo. Thus, our data demonstrated that Rac1 is essential for lamellipodia formation in platelets and indicated that Rac1 is required for aggregate integrity leading to thrombus formation under physiologically relevant levels of shear both in vitro and in vivo.	Univ Birmingham, Ctr Cardiovasc Sci, Inst Biomed Res, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; Natl Inst Med Res, Div Immune Cell Biol, London NW7 1AA, England	University of Birmingham; University of Birmingham; MRC National Institute for Medical Research	McCarty, OJT (corresponding author), Oregon Hlth Sci Univ, Dept Biomed Engn, 20000 NW Walker Rd, Beaverton, OR 97006 USA.	mccartyo@ohsu.edu	Machesky, Laura/Z-4554-2019; Watson, Stephen P/Q-6292-2016	Machesky, Laura/0000-0002-7592-9856; Watson, Stephen P/0000-0002-7846-7423; Tybulewicz, Victor/0000-0003-2439-0798; KALIA, NEENA/0000-0003-2960-7829	MRC [G117/569, G0300102] Funding Source: UKRI; Medical Research Council [G117/569, G0300102] Funding Source: Medline; Wellcome Trust [073107] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Abulencia JP, 2001, ARTERIOSCL THROM VAS, V21, P149, DOI 10.1161/01.ATV.21.1.149; Azim AC, 2000, BLOOD, V95, P959, DOI 10.1182/blood.V95.3.959.003k22_959_964; Barkalow K, 1996, J CELL BIOL, V134, P389, DOI 10.1083/jcb.134.2.389; Barkalow KL, 2003, J CELL BIOL, V161, P557, DOI 10.1083/jcb.200211122; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Best D, 2003, BLOOD, V102, P2811, DOI 10.1182/blood-2003-01-0231; Bialkowska K, 2000, J CELL BIOL, V151, P685, DOI 10.1083/jcb.151.3.685; Bialkowska K, 2003, J BIOL CHEM, V278, P33342, DOI 10.1074/jbc.M301217200; Biyasheva A, 2004, J CELL SCI, V117, P837, DOI 10.1242/jcs.00921; Bolis A, 2003, EUR J NEUROSCI, V18, P2417, DOI 10.1046/j.1460-9568.2003.02938.x; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Celi A, 2003, J THROMB HAEMOST, V1, P60, DOI 10.1046/j.1538-7836.2003.t01-1-00033.x; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; Falati S, 2002, NAT MED, V8, P1175, DOI 10.1038/nm782; Falet H, 2000, BLOOD, V96, P3786, DOI 10.1182/blood.V96.12.3786.h8003786_3786_3792; Falet H, 2002, P NATL ACAD SCI USA, V99, P16782, DOI 10.1073/pnas.222652499; Falet H, 2002, BLOOD, V100, P2113, DOI 10.1182/blood.V100.6.2113.h81802002113_2113_2122; Fox JEB, 1996, J BIOL CHEM, V271, P7004, DOI 10.1074/jbc.271.12.7004; Gratacap MP, 2001, J BIOL CHEM, V276, P47906, DOI 10.1074/jbc.M104442200; Gregg D, 2003, AM J PHYSIOL-CELL PH, V285, pC723, DOI 10.1152/ajpcell.00230.2003; Gu Y, 2003, SCIENCE, V302, P445, DOI 10.1126/science.1088485; Haataja L, 1997, J BIOL CHEM, V272, P20384, DOI 10.1074/jbc.272.33.20384; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; Li Z, 2002, BLOOD, V99, P4466, DOI 10.1182/blood.V99.12.4466; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; McCarty OJT, 2004, J THROMB HAEMOST, V2, P1823, DOI 10.1111/j.1538-7836.2004.00925.x; Miki H, 2000, NATURE, V408, P732, DOI 10.1038/35047107; Nieswandt B, 2003, BLOOD, V102, P449, DOI 10.1182/blood-2002-12-3882; Obergfell A, 2001, J BIOL CHEM, V276, P5916, DOI 10.1074/jbc.M010639200; Oda A, 2005, BLOOD, V105, P3141, DOI 10.1182/blood-2003-04-1319; Pearce AC, 2002, BLOOD, V100, P3561, DOI 10.1182/blood.V100.10.3561; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Small JV, 2002, TRENDS CELL BIOL, V12, P112, DOI 10.1016/S0962-8924(01)02237-1; Soulet C, 2001, FEBS LETT, V507, P253, DOI 10.1016/S0014-5793(01)02984-2; Suzuki-Inoue K, 2001, BLOOD, V98, P3708, DOI 10.1182/blood.V98.13.3708; Walmsley MJ, 2003, SCIENCE, V302, P459, DOI 10.1126/science.1089709; Wonerow P, 2003, J BIOL CHEM, V278, P37520, DOI 10.1074/jbc.M305077200	44	174	175	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39474	39484		10.1074/jbc.M504672200	http://dx.doi.org/10.1074/jbc.M504672200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16195235	hybrid, Green Accepted			2022-12-25	WOS:000233362200069
J	Zwerina, J; Tzima, S; Hayer, S; Redlich, K; Hoffmann, O; Hanslik-Schnabel, B; Smolen, JS; Kollias, G; Schett, G				Zwerina, J; Tzima, S; Hayer, S; Redlich, K; Hoffmann, O; Hanslik-Schnabel, B; Smolen, JS; Kollias, G; Schett, G			Heme oxygenase 1 (HO-1) regulates osteoclastogenesis and bone resorption	FASEB JOURNAL			English	Article						osteoclasts; tumor necrosis factor; inflammatory bone loss	TUMOR-NECROSIS-FACTOR; MEDIATED JOINT DESTRUCTION; RHEUMATOID-ARTHRITIS; GENE-EXPRESSION; DIFFERENTIATION FACTOR; OXIDATIVE STRESS; MINERAL DENSITY; TRANSGENIC MICE; UP-REGULATION; FACTOR-ALPHA	Heme oxygenase 1 (HO-1) plays an important role in vascular disease, transplantation, and inflammation. In animal models of acute and chronic inflammation, induction of HO-1 has antiinflammatory and cytoprotective properties. Since inflammation is an important trigger of osteoclastogenesis, we hypothesized that HO-1 might influence osteoclastogenesis. We investigated the effects of induction of HO-1 on osteoclast formation in vitro and in vivo. Furthermore, we addressed the role of HO-1 in inflammatory bone loss in humans. When HO-1 was induced by hemin in vitro, a significant dose-dependent inhibition of osteoclastogenesis was observed. Up-regulation of HO-1 was mediated by activation of MAPK and primarily prevented differentiation of osteoclast precursors to osteoclasts,whereas it did not affect mature osteoclasts. Anti-osteoclastogenic properties of hemin were based on a down-regulation of c-fms, RANK, TRAF-6, and c-fos. In addition, induction of HO-1 inhibited TNF-triggered osteoclast differentiation in vitro as well as LPS-driven inflammatory bone loss in vivo. Furthermore, HO-1 induction suppressed osteoclastogenesis and bone destruction in a TNF-mediated arthritis. In line, assessment of synovial tissue from rheumatoid arthritis patients revealed that osteoclasts are usually HO-1 negative. Moreover, serum levels of bilirubin, a metabolite of HO-1, were elevated in rheumatoid arthritis patients without bone damage, suggesting HO-1 affects bone loss in humans. In summary, these data indicate that HO-1 negatively regulates osteoclastogenesis, leading to a positive net balance of bone.	Med Univ Vienna, Div Rheumatol, Dept Internal Med 3, A-1090 Vienna, Austria; Alexander Fleming Biomed Sci Res Ctr, Vari, Greece; Univ Vienna, Inst Pharmacol & Toxicol, Vienna, Austria; Med Univ Vienna, Dept Orthoped & Orthoped Surg, A-1090 Vienna, Austria	Medical University of Vienna; Alexander Fleming Biomedical Sciences Research Center; University of Vienna; Medical University of Vienna	Schett, G (corresponding author), Med Univ Vienna, Div Rheumatol, Dept Internal Med 3, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	georg.schett@meduniwien.ac.at	Kollias, George/A-7079-2012	Kollias, George/0000-0003-1867-3150				Alvarez-Maqueda M, 2004, J BIOL CHEM, V279, P21929, DOI 10.1074/jbc.M400492200; Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; CAMHI SL, 1995, AM J RESP CELL MOL, V13, P387, DOI 10.1165/ajrcmb.13.4.7546768; Chen GG, 2004, J CELL BIOCHEM, V92, P1246, DOI 10.1002/jcb.20157; CONTE D, 1989, AM J GASTROENTEROL, V84, P1231; Datta PK, 1999, J AM SOC NEPHROL, V10, P2540; David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082; Devesa I, 2005, LAB INVEST, V85, P34, DOI 10.1038/labinvest.3700205; Djousse L, 2001, AM J CARDIOL, V87, P1196, DOI 10.1016/S0002-9149(01)01494-1; El Maghraoui A, 1999, J RHEUMATOL, V26, P2205; Endler G, 2004, THROMB HAEMOSTASIS, V91, P155, DOI 10.1160/TH03-05-0291; Fondevila C, 2004, HEPATOLOGY, V40, P1333, DOI 10.1002/hep.20480; Goldring SR, 2002, J RHEUMATOL, V29, P44; Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529-0131(200002)43:2<250::AID-ANR3>3.0.CO;2-P; Harpavat M, 2004, J CLIN GASTROENTEROL, V38, P218, DOI 10.1097/00004836-200403000-00005; Haugeberg G, 2000, ARTHRITIS RHEUM, V43, P522, DOI 10.1002/1529-0131(200003)43:3<522::AID-ANR7>3.0.CO;2-Y; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; Kitaura H, 2004, J IMMUNOL, V173, P4838, DOI 10.4049/jimmunol.173.8.4838; Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552; Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176; Lee TS, 2002, NAT MED, V8, P240, DOI 10.1038/nm0302-240; Lin HY, 2003, BIOCHEM PHARMACOL, V66, P1821, DOI 10.1016/S0006-2952(03)00422-2; Liu ZM, 2004, ONCOGENE, V23, P503, DOI 10.1038/sj.onc.1207173; Ohta K, 2003, EXP EYE RES, V77, P665, DOI 10.1016/j.exer.2003.08.014; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002-9440(10)63016-7; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; Redlich K, 2004, AM J PATHOL, V164, P543, DOI 10.1016/S0002-9440(10)63144-6; Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582; Redlich K, 2002, ARTHRITIS RHEUM, V46, P785, DOI 10.1002/art.10097; Schett G, 2003, ARTHRITIS RHEUM, V48, P2042, DOI 10.1002/art.11150; SEITZ M, 1994, BRIT J RHEUMATOL, V33, P613; Shigeyama Y, 2000, ARTHRITIS RHEUM, V43, P2523, DOI 10.1002/1529-0131(200011)43:11<2523::AID-ANR20>3.0.CO;2-Z; Siffledeen JS, 2004, INFLAMM BOWEL DIS, V10, P220, DOI 10.1097/00054725-200405000-00007; Soares MP, 2004, J IMMUNOL, V172, P3553, DOI 10.4049/jimmunol.172.6.3553; Soares MP, 1998, NAT MED, V4, P1073, DOI 10.1038/2063; Takeda Y, 2004, CLIN EXP IMMUNOL, V138, P237, DOI 10.1111/j.1365-2249.2004.02594.x; Takeshita S, 2002, NAT MED, V8, P943, DOI 10.1038/nm752; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Vicente AM, 2003, J PHARMACOL EXP THER, V307, P1030, DOI 10.1124/jpet.103.057992; Wiesel P, 2000, CIRCULATION, V102, P3015, DOI 10.1161/01.cir.102.24.3015; Wu WT, 2004, BIOCHEM J, V379, P587, DOI 10.1042/BJ20031579; Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165; Zwerina J, 2004, ARTHRITIS RHEUM, V50, P277, DOI 10.1002/art.11487	45	108	113	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2011	+		10.1096/fj.05-4278fje	http://dx.doi.org/10.1096/fj.05-4278fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16234431				2022-12-25	WOS:000232991100013
J	Pickering, MT; Kowalik, TF				Pickering, MT; Kowalik, TF			Rb inactivation leads to E2F1-mediated DNA double-strand break accumulation	ONCOGENE			English	Article						Rb inactivation; double-strand breaks; DSBs; E2F1; c-Myc	S-PHASE; C-MYC; DAMAGE CHECKPOINT; HISTONE H2AX; APOPTOSIS; E2F1; PHOSPHORYLATION; INSTABILITY; CELLS; P53	Although it is unclear which cellular factor(s) is responsible for the genetic instability associated with initiating and sustaining cell transformation, it is known that many cancers have mutations that inactivate the Rb-mediated proliferation pathway. We show here that pRb inactivation and the resultant deregulation of one E2F family member, E2F1, leads to DNA double-strand break (DSB) accumulation in normal diploid human cells. These DSBs occur independent of Atm, p53, caspases, reactive oxygen species, and apoptosis. Moreover, E2F1 does not contribute to c-Myc-associated DSBs, indicating that the DSBs associated with these oncoproteins arise through distinct pathways. We also find E2F1-associated DSBs in an Rb mutated cancer cell line in the absence of an exogenous DSB stimulus. These basal, E2F1-associated DSBs are not observed in a p16(ink4a) inactivated cancer cell line that retains functional pRb, unless pRb is depleted. Thus, Rb status is key to regulating both the proliferation promoting functions associated with E2F and for preventing DNA damage accumulation if E2F1 becomes deregulated. Taken together, these data suggest that loss of Rb creates strong selective pressure, via DSB accumulation, for inactivating p53 mutations and that E2F1 contributes to the genetic instability associated with transformation and tumorigenesis.	Univ Massachusetts, Med Ctr, Sch Med, Program Immunol & Virol,Dept Mol Genet & Microbio, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Kowalik, TF (corresponding author), Univ Massachusetts, Med Ctr, Sch Med, Program Immunol & Virol,Dept Mol Genet & Microbio, Room S5-216,55 Lake Ave N, Worcester, MA 01655 USA.	timothy.kowalik@umassmed.edu		Pickering, Mary/0000-0002-0515-7248	NATIONAL CANCER INSTITUTE [R01CA086038] Funding Source: NIH RePORTER; NCI NIH HHS [CA86038] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Berkovich E, 2003, ONCOGENE, V22, P161, DOI 10.1038/sj.onc.1206144; Biroccio A, 2001, MOL PHARMACOL, V60, P174, DOI 10.1124/mol.60.1.174; Bosco EE, 2004, NUCLEIC ACIDS RES, V32, P25, DOI 10.1093/nar/gkg919; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Duensing S, 2002, CANCER RES, V62, P7075; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; Lomazzi M, 2002, NAT GENET, V31, P190, DOI 10.1038/ng891; Matsumura I, 2003, CELL CYCLE, V2, P333, DOI 10.4161/cc.2.4.428; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; OLIVE PL, 1991, CANCER RES, V51, P4671; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Powers JT, 2004, MOL CANCER RES, V2, P203; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rogoff HA, 2004, MOL CELL BIOL, V24, P2968, DOI 10.1128/MCB.24.7.2968-2977.2004; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Tominaga K, 1999, J BIOL CHEM, V274, P31463, DOI 10.1074/jbc.274.44.31463; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666	27	89	89	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					746	755		10.1038/sj.onc.1209103	http://dx.doi.org/10.1038/sj.onc.1209103			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16186801				2022-12-25	WOS:000235068800010
J	Fossen, T; Wray, V; Bruns, K; Rachmat, J; Henklein, P; Tessmer, U; Maczurek, A; Klinger, P; Schubert, U				Fossen, T; Wray, V; Bruns, K; Rachmat, J; Henklein, P; Tessmer, U; Maczurek, A; Klinger, P; Schubert, U			Solution structure of the human immunodeficiency virus type 1 p6 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TSG101 UEV DOMAIN; CELL-CYCLE ARREST; SECONDARY-STRUCTURE; MUTATIONAL ANALYSIS; STRUCTURE PREDICTION; PARTICLE-PRODUCTION; NMR-SPECTROSCOPY; P6(GAG) PROTEIN; EBOLA-VIRUS; GAG PROTEIN	The human immunodeficiency virus type 1 p6 protein represents a docking site for several cellular and viral binding factors and fulfills major roles in the formation of infectious viruses. To date, however, the structure of this 52-amino acid protein, by far the smallest lentiviral protein known, either in its mature form as free p6 or as the C-terminal part of the Pr55 Gag polyprotein has not been unraveled. We have explored the high resolution structure and folding of p6 by CD and NMR spectroscopy. Under membranous solution conditions, p6 can adopt a helix-flexible helix structure; a short helix-1 (amino acids 14-18) is connected to a pronounced helix-2 (amino acids 33-44) by a flexible hinge region. Thus, p6 can be subdivided into two distinct structural and functional domains; helix-2 perfectly defines the region that binds to the virus budding factor AIP-1/ALIX, indicating that this structure is required for interaction with the endosomal sorting complex required for transport. The PTAP motif at the N terminus, comprising the primary late assembly domain, which is crucial for interaction with another cellular budding factor, Tsg101, does not exhibit secondary structure. However, the adjacent helix-1 may play an indirect role in the specific complex formation between p6 and the binding groove in Tsg101. Moreover, binding studies by NMR demonstrate that helix-2, which also comprises the LXXLF motif required for incorporation of the human immunodeficiency virus type 1 accessory protein Vpr into budding virions, specifically interacts with the Vpr binding region, indicating that under the specific solution conditions used for structure analysis, p6 adopted a functional conformation.	Univ Erlangen Nurnberg, Inst Clin & Mol Virol, D-91054 Erlangen, Germany; Gesell Biotechnol Forsch mbH, Dept Biol Struct, D-38124 Braunschweig, Germany; Univ Bergen, Dept Chem, N-5007 Bergen, Norway; Humboldt Univ, Inst Biochem, D-10115 Berlin, Germany; Heinrich Pette Inst, D-20251 Hamburg, Germany	University of Erlangen Nuremberg; Gesellschaft fur Biotechnologische Forschung mbH; University of Bergen; Humboldt University of Berlin; Heinrich Pette Institute	Schubert, U (corresponding author), Univ Erlangen Nurnberg, Inst Clin & Mol Virol, Schlossgarten 4, D-91054 Erlangen, Germany.	ulrich.schubert@viro.med.uni-erlangen.de						Accola MA, 2000, J VIROL, V74, P5395, DOI 10.1128/JVI.74.12.5395-5402.2000; Accola MA, 2000, J VIROL, V74, P6198, DOI 10.1128/JVI.74.13.6198-6202.2000; ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Andersen JL, 2005, CURR HIV RES, V3, P43, DOI 10.2174/1570162052772988; Baldi P, 1999, BIOINFORMATICS, V15, P937, DOI 10.1093/bioinformatics/15.11.937; Blankenfeldt W, 1996, BIOCHEMISTRY-US, V35, P5955, DOI 10.1021/bi9601520; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bruns K, 2003, J BIOL CHEM, V278, P43188, DOI 10.1074/jbc.M305413200; Buck M, 1998, Q REV BIOPHYS, V31, P297, DOI 10.1017/S003358359800345X; Bukrinsky M, 1999, REV MED VIROL, V9, P39, DOI 10.1002/(SICI)1099-1654(199901/03)9:1<39::AID-RMV235>3.0.CO;2-3; CHECROUNE F, 1995, J ACQ IMMUN DEF SYND, V10, P1; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Demirov DG, 2002, J VIROL, V76, P105, DOI 10.1128/JVI.76.1.105-117.2002; DIMARZIO P, 1995, J VIROL, V69, P7909, DOI 10.1128/JVI.69.12.7909-7916.1995; Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589; Emerman M, 1996, CURR BIOL, V6, P1096, DOI 10.1016/S0960-9822(02)00676-0; Freed EO, 2002, J VIROL, V76, P4679, DOI 10.1128/JVI.76.10.4679-4687.2002; FU XY, 1995, J GEN VIROL, V76, P3171, DOI 10.1099/0022-1317-76-12-3171; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; Garnier L, 1999, J VIROL, V73, P2309, DOI 10.1128/JVI.73.3.2309-2320.1999; Garnier L, 1998, J VIROL, V72, P4667, DOI 10.1128/JVI.72.6.4667-4677.1998; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; GOTTLINGER HG, 1991, P NATL ACAD SCI USA, V88, P3195, DOI 10.1073/pnas.88.8.3195; Greene WC, 2002, NAT MED, V8, P673, DOI 10.1038/nm0702-673; Hemonnot B, 2004, J BIOL CHEM, V279, P32426, DOI 10.1074/jbc.M313137200; Henklein P, 2005, J PEPT SCI, V11, P481, DOI 10.1002/psc.641; Henklein P, 2000, J BIOL CHEM, V275, P32016, DOI 10.1074/jbc.M004044200; HUANG MJ, 1995, J VIROL, V69, P6810, DOI 10.1128/JVI.69.11.6810-6818.1995; Jenkins Y, 2001, J VIROL, V75, P10537, DOI 10.1128/JVI.75.21.10537-10542.2001; JOHNSON WC, 1990, PROTEIN-STRUCT FUNCT, V7, P214; Karplus K, 1998, BIOINFORMATICS, V14, P846, DOI 10.1093/bioinformatics/14.10.846; Kino T, 2004, DNA CELL BIOL, V23, P193, DOI 10.1089/104454904773819789; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; Kondo E, 1996, J VIROL, V70, P159, DOI 10.1128/JVI.70.1.159-164.1996; KONDO E, 1995, J VIROL, V69, P2759, DOI 10.1128/JVI.69.5.2759-2764.1995; Krausslich HG, 1996, CURR TOP MICROBIOL, V214, P25; LU YL, 1995, J VIROL, V69, P6873, DOI 10.1128/JVI.69.11.6873-6879.1995; Luban J, 2001, NAT MED, V7, P1278, DOI 10.1038/nm1201-1278; Luidens MK, 1996, BIOPOLYMERS, V39, P367, DOI 10.1002/(SICI)1097-0282(199609)39:3<367::AID-BIP8>3.3.CO;2-C; Martin-Serrano J, 2003, J VIROL, V77, P4794, DOI 10.1128/JVI.77.8.4794-4804.2003; Martin-Serrano J, 2001, NAT MED, V7, P1313, DOI 10.1038/nm1201-1313; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Muller B, 2002, J VIROL, V76, P1015, DOI 10.1128/JVI.76.3.1015-1024.2002; Myers EL, 2002, J VIROL, V76, P11226, DOI 10.1128/JVI.76.22.11226-11235.2002; NEIDIG KP, 1990, J MAGN RESON, V88, P155, DOI 10.1016/0022-2364(90)90119-T; Ott DE, 1999, J VIROL, V73, P19, DOI 10.1128/JVI.73.1.19-28.1999; PAXTON W, 1993, J VIROL, V67, P7229, DOI 10.1128/JVI.67.12.7229-7237.1993; Perez OD, 2001, IMMUNITY, V15, P687, DOI 10.1016/S1074-7613(01)00238-2; Pollastri G, 2002, PROTEINS, V47, P228, DOI 10.1002/prot.10082; Pornillos O, 2002, EMBO J, V21, P2397, DOI 10.1093/emboj/21.10.2397; Pornillos O, 2002, NAT STRUCT BIOL, V9, P812, DOI 10.1038/nsb856; Pornillos O, 2002, TRENDS CELL BIOL, V12, P569, DOI 10.1016/S0962-8924(02)02402-9; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHOMBURG D, 1988, J MOL GRAPHICS, V6, P161, DOI 10.1016/0263-7855(88)80069-9; SCHUBERT U, 1994, J MOL BIOL, V236, P16, DOI 10.1006/jmbi.1994.1114; Strack B, 2003, CELL, V114, P689, DOI 10.1016/S0092-8674(03)00653-6; Stuchell MD, 2004, J BIOL CHEM, V279, P36059, DOI 10.1074/jbc.M405226200; STYS D, 1993, BIOCHIM BIOPHYS ACTA, V1182, P157, DOI 10.1016/0925-4439(93)90137-P; SUGRUE RJ, 1991, VIROLOGY, V180, P617, DOI 10.1016/0042-6822(91)90075-M; Swanstrom R., 1997, P263; Turner BG, 1999, J MOL BIOL, V285, P1, DOI 10.1006/jmbi.1998.2354; VerPlank L, 2001, P NATL ACAD SCI USA, V98, P7724, DOI 10.1073/pnas.131059198; Vogt V. M., 1997, P27; Vogt VM, 2000, P NATL ACAD SCI USA, V97, P12945, DOI 10.1073/pnas.97.24.12945; von Schwedler UK, 2003, CELL, V114, P701, DOI 10.1016/S0092-8674(03)00714-1; Welker R, 2000, J VIROL, V74, P1168, DOI 10.1128/JVI.74.3.1168-1177.2000; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Yu XF, 1998, J VIROL, V72, P3412, DOI 10.1128/JVI.72.4.3412-3417.1998; Zuiderweg ERP, 2002, BIOCHEMISTRY-US, V41, P1, DOI 10.1021/bi011870b	71	47	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42515	42527		10.1074/jbc.M507375200	http://dx.doi.org/10.1074/jbc.M507375200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16234236	hybrid			2022-12-25	WOS:000234200800007
J	Orfeo, T; Butenas, S; Brummel-Ziedins, KE; Mann, KG				Orfeo, T; Butenas, S; Brummel-Ziedins, KE; Mann, KG			The tissue factor requirement in blood coagulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR PATHWAY INHIBITOR; HEPARIN COFACTOR-II; PROTEIN-C PATHWAY; FACTOR-XA; THROMBIN GENERATION; ANTITHROMBIN-III; FACTOR-VIIA; WHOLE-BLOOD; FACTOR-V; EXTRINSIC PATHWAY	Formation of thrombin is triggered when membrane-localized tissue factor (TF) is exposed to blood. In closed models of this process, thrombin formation displays an initiation phase (low rates of thrombin production cause platelet activation and fibrinogen clotting), a propagation phase (> 95% of thrombin production occurs), and a termination phase (prothrombin activation ceases and free thrombin is inactivated). A current controversy centers on whether the TF stimulus requires supplementation from a circulating pool of blood TF to sustain an adequate procoagulant response. We have evaluated the requirement for TF during the progress of the blood coagulation reaction and have extended these analyses to assess the requirement for TF during resupply ("flow replacement"). Elimination of TF activity at various times during the initiation phase indicated: a period of absolute dependence (< 10 s); a transitional period in which the dependence on TF is partial and decreases as the reaction proceeds (10-240 s); and a period in which the progress of the reaction is TF independent (> 240 s). Resupply of reactions late during the termination phase with fresh reactants, but no TF, yielded immediate bursts of thrombin formation similar in magnitude to the original propagation phases. Our data show that independence from the initial TF stimulus is achieved by the onset of the propagation phase and that the ensemble of coagulation products and intermediates that yield this TF independence maintain their prothrombin activating potential for considerable time. These observations support the hypothesis that the transient, localized expression of TF is sufficient to sustain a TF-independent procoagulant response as long as flow persists.	Univ Vermont, Dept Biochem, Burlington, VT 05405 USA	University of Vermont	Mann, KG (corresponding author), Given Bldg,89 Beaumont Ave, Burlington, VT 05405 USA.	Kenneth.Mann@uvm.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046703] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL046703-140001, P01 HL046703, HL46703] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahmad SS, 2002, BIOCHEMISTRY-US, V41, P11269, DOI 10.1021/bi025785v; BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531; Baugh RJ, 1998, J BIOL CHEM, V273, P4378, DOI 10.1074/jbc.273.8.4378; Bedsted T, 2003, BIOCHEMISTRY-US, V42, P8143, DOI 10.1021/bi034363y; Berckmans RJ, 2001, THROMB HAEMOSTASIS, V85, P639; BJOERN S, 1991, J BIOL CHEM, V266, P11051; Bogdanov VY, 2003, NAT MED, V9, P458, DOI 10.1038/nm841; BROZE GJ, 1988, BLOOD, V71, P335; BROZE GJ, 1995, THROMB HAEMOSTASIS, V74, P90; Brummel KE, 2002, BLOOD, V100, P148, DOI 10.1182/blood.V100.1.148; Brummel-Ziedins KE, 2004, J THROMB HAEMOST, V2, P281, DOI 10.1046/j.1538-7933.2003.00576.x; BUSCH C, 1982, J CLIN INVEST, V69, P726, DOI 10.1172/JCI110502; Butenas S, 2005, BLOOD, V105, P2764, DOI 10.1182/blood-2004-09-3567; Butenas S, 2004, J BIOL CHEM, V279, P22875, DOI 10.1074/jbc.M400531200; Butenas S, 2004, NAT MED, V10, P1155, DOI 10.1038/nm1104-1155b; Butenas S, 1997, J BIOL CHEM, V272, P21527, DOI 10.1074/jbc.272.34.21527; Butenas S, 2003, ARTERIOSCL THROM VAS, V23, P123, DOI 10.1161/01.ATV.0000042081.57854.A2; Butenas S, 2002, BLOOD, V99, P923, DOI 10.1182/blood.V99.3.923; Cawthern KM, 1998, BLOOD, V91, P4581, DOI 10.1182/blood.V91.12.4581.412k12_4581_4592; Chuang YJ, 2001, J BIOL CHEM, V276, P14961, DOI 10.1074/jbc.M011550200; Day SM, 2005, BLOOD, V105, P192, DOI 10.1182/blood-2004-06-2225; Diamant M, 2002, CIRCULATION, V106, P2442, DOI 10.1161/01.CIR.0000036596.59665.C6; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; Esmon CT, 2003, CHEST, V124, p26S, DOI 10.1378/chest.124.3_suppl.26S; ESMON CT, 1981, P NATL ACAD SCI-BIOL, V78, P2249, DOI 10.1073/pnas.78.4.2249; ESMON CT, 1989, J BIOL CHEM, V264, P4743; Falati S, 2003, J EXP MED, V197, P1585, DOI 10.1084/jem.20021868; Giesen PLA, 1999, P NATL ACAD SCI USA, V96, P2311, DOI 10.1073/pnas.96.5.2311; GRIFFITH MJ, 1985, J BIOL CHEM, V260, P2218; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; Hockin MF, 2002, J BIOL CHEM, V277, P18322, DOI 10.1074/jbc.M201173200; HOJIMA Y, 1980, THROMB RES, V20, P149, DOI 10.1016/0049-3848(80)90381-3; Huang ZF, 1997, BLOOD, V90, P944, DOI 10.1182/blood.V90.3.944.944_944_951; JESTY J, 1994, BIOCHEMISTRY-US, V33, P12686, DOI 10.1021/bi00208a020; JONES KC, 1994, J BIOL CHEM, V269, P23367; KATZMANN JA, 1981, P NATL ACAD SCI-BIOL, V78, P162, DOI 10.1073/pnas.78.1.162; KOMIYAMA Y, 1990, BIOCHEMISTRY-US, V29, P9418, DOI 10.1021/bi00492a016; LAWSON JH, 1994, J BIOL CHEM, V269, P23357; Lu G, 2004, J BIOL CHEM, V279, P17241, DOI 10.1074/jbc.M312827200; Lundblad R L, 1976, Methods Enzymol, V45, P156; Mann KG, 2003, ARTERIOSCL THROM VAS, V23, P17, DOI 10.1161/01.ATV.0000046238.23903.FC; MILETICH JP, 1978, J BIOL CHEM, V253, P6908; MONCADA S, 1977, LANCET, V1, P18; Morrissey JH, 2001, THROMB HAEMOSTASIS, V86, P66; MUSTARD JF, 1972, BRIT J HAEMATOL, V22, P193, DOI 10.1111/j.1365-2141.1972.tb08800.x; NEMERSON Y, 1988, BLOOD, V71, P1; NOVOTNY WF, 1991, BLOOD, V78, P394; Orfeo T, 2004, J BIOL CHEM, V279, P19580, DOI 10.1074/jbc.M400727200; RADOMSKI MW, 1987, BIOCHEM BIOPH RES CO, V148, P1482, DOI 10.1016/S0006-291X(87)80299-1; Rand MD, 1996, BLOOD, V88, P3432, DOI 10.1182/blood.V88.9.3432.bloodjournal8893432; RUF W, 1991, J BIOL CHEM, V266, P16256; Santucci RA, 2000, THROMB HAEMOSTASIS, V83, P445, DOI 10.1055/s-0037-1613835; Siddiqui FA, 2002, PLATELETS, V13, P247, DOI 10.1080/09537100220146398; So AK, 2003, J THROMB HAEMOST, V1, P2510, DOI 10.1111/j.1538-7836.2003.00462.x; SPICER EK, 1987, P NATL ACAD SCI USA, V84, P5148, DOI 10.1073/pnas.84.15.5148; TAKAHASHI H, 1994, AM J HEMATOL, V46, P333, DOI 10.1002/ajh.2830460414; vantVeer C, 1997, J BIOL CHEM, V272, P4367, DOI 10.1074/jbc.272.7.4367; vantVeer C, 1997, J BIOL CHEM, V272, P7983, DOI 10.1074/jbc.272.12.7983; WUN TC, 1988, J BIOL CHEM, V263, P6001	59	75	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42887	42896		10.1074/jbc.M505506200	http://dx.doi.org/10.1074/jbc.M505506200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16215234	Green Accepted, hybrid			2022-12-25	WOS:000234200800051
J	Ved, R; Saha, S; Westlund, B; Perier, C; Burnam, L; Sluder, A; Hoener, M; Rodrigues, CMP; Alfonso, A; Steer, C; Liu, L; Przedborski, S; Wolozin, B				Ved, R; Saha, S; Westlund, B; Perier, C; Burnam, L; Sluder, A; Hoener, M; Rodrigues, CMP; Alfonso, A; Steer, C; Liu, L; Przedborski, S; Wolozin, B			Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of alpha-synuclein, parkin, and DJ-1 in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAUROURSODEOXYCHOLIC ACID; COMPLEX-I; C-ELEGANS; OXIDATIVE DAMAGE; DROSOPHILA MODEL; CELL-DEATH; DISEASE; PROTEIN; MUTATIONS; NEURODEGENERATION	How genetic and environmental factors interact in Parkinson disease is poorly understood. We have now compared the patterns of vulnerability and rescue of Caenorhabditis elegans with genetic modifications of three different genetic factors implicated in Parkinson disease (PD). We observed that expressing alpha-synuclein, deleting parkin (K08E3.7), or knocking down DJ-1 (B0432.2) or parkin produces similar patterns of pharmacological vulnerability and rescue. C. elegans lines with these genetic changes were more vulnerable than nontransgenic nematodes to mitochondrial complex I inhibitors, including rotenone, fenperoximate, pyridaben, or stigmatellin. In contrast, the genetic manipulations did not increase sensitivity to paraquat, sodium azide, divalent metal ions (Fe(II) or Cu(II)), or etoposide compared with the nontransgenic nematodes. Each of the PD-related lines was also partially rescued by the antioxidant probucol, the mitochondrial complex II activator, D-beta-hydroxybutyrate, or the anti-apoptotic bile acid tauroursodeoxycholic acid. Complete protection in all lines was achieved by combining D-beta-hydroxybutyrate with tauroursodeoxycholic acid but not with probucol. These results show that diverse PD-related genetic modifications disrupt the mitochondrial function in C. elegans, and they raise the possibility that mitochondrial disruption is a pathway shared in common by many types of familial PD.	Boston Univ, Sch Med, Dept Pharmacol, Boston, MA 02118 USA; Cambria Biosci, Woburn, MA 01801 USA; Hoffmann Roche, CH-4070 Basel, Switzerland; Columbia Univ Coll Phys & Surg, Inst Neurol, New York, NY 10032 USA; Univ Lisbon, Fac Pharm, Ctr Patogenese Mol, P-1600083 Lisbon, Portugal; Univ Illinois, Dept Biol Sci, Chicago, IL 60607 USA; Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA	Boston University; Roche Holding; Columbia University; Universidade de Lisboa; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Minnesota System; University of Minnesota Twin Cities	Wolozin, B (corresponding author), Boston Univ, Sch Med, Dept Pharmacol, 715 Albany St,Rm R614, Boston, MA 02118 USA.	bwolozin@bu.edu	Hoener, Marius C/I-6464-2012; Rodrigues, Cecilia MP/M-3572-2013; iMed.ULisboa, CellFun/A-4244-2014; Sluder, Ann/AAS-3102-2020	Hoener, Marius C/0000-0001-6510-6250; Rodrigues, Cecilia MP/0000-0002-4829-754X; 	NIA NIH HHS [AG/NS17485] Funding Source: Medline; NIEHS NIH HHS [R01 ES015567] Funding Source: Medline; NINDS NIH HHS [NS41786, R01 NS041786, R01 NS060872] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES015567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS060872, R01NS041786] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017485] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; BARNHART RL, 1989, J LIPID RES, V30, P1703; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; BRENNER S, 1974, GENETICS, V77, P71; Chun HS, 2001, J NEUROCHEM, V76, P1010, DOI 10.1046/j.1471-4159.2001.00096.x; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Dong MQ, 2000, GENE DEV, V14, P2003; DRAGUNOW M, 1995, NEUROREPORT, V6, P1053, DOI 10.1097/00001756-199505090-00026; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Giasson BI, 2002, NEURON, V34, P521, DOI 10.1016/S0896-6273(02)00682-7; Goldberg MS, 2003, J BIOL CHEM, V278, P43628, DOI 10.1074/jbc.M308947200; Greene JC, 2003, P NATL ACAD SCI USA, V100, P4078, DOI 10.1073/pnas.0737556100; Hoglinger GU, 2003, J NEUROCHEM, V86, P1297, DOI 10.1046/j.1471-4159.2003.01952.x; Kahle PJ, 2002, EMBO REP, V3, P583, DOI 10.1093/embo-reports/kvf109; Kahle PJ, 2001, AM J PATHOL, V159, P2215, DOI 10.1016/S0002-9440(10)63072-6; KASHIWAYA Y, 1994, J BIOL CHEM, V269, P25502; Kashiwaya Y, 2000, P NATL ACAD SCI USA, V97, P5440, DOI 10.1073/pnas.97.10.5440; Kayser EB, 2004, ANESTHESIOLOGY, V101, P365, DOI 10.1097/00000542-200408000-00017; Keene CD, 2002, P NATL ACAD SCI USA, V99, P10671, DOI 10.1073/pnas.162362299; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kraemer BC, 2003, P NATL ACAD SCI USA, V100, P9980, DOI 10.1073/pnas.1533448100; Kramer KA, 2005, CLIN CHEM, V51, P2110, DOI 10.1373/clinchem.2005.050146; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Labrousse AM, 1999, MOL CELL, V4, P815, DOI 10.1016/S1097-2765(00)80391-3; Ladha JS, 2005, CELL DEATH DIFFER, V12, P1417, DOI 10.1038/sj.cdd.4401668; Lakso M, 2003, J NEUROCHEM, V86, P165, DOI 10.1046/j.1471-4159.2003.01809.x; Langston JW, 1998, ANN NEUROL, V44, pS45, DOI 10.1002/ana.410440707; Lee D, 2002, J NEUROCHEM, V82, P1007, DOI 10.1046/j.1471-4159.2002.01024.x; Lee MK, 2002, P NATL ACAD SCI USA, V99, P8968, DOI 10.1073/pnas.132197599; Maraganore DM, 1999, NEUROLOGY, V53, P1858, DOI 10.1212/WNL.53.8.1858; Mitsumoto A, 2001, FREE RADICAL RES, V35, P885, DOI 10.1080/10715760100301381; Mochizuki H, 1996, J NEUROL SCI, V137, P120, DOI 10.1016/0022-510X(95)00336-Z; Nagakubo D, 1997, BIOCHEM BIOPH RES CO, V231, P509, DOI 10.1006/bbrc.1997.6132; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; Ostrerova-Golts N, 2000, J NEUROSCI, V20, P6048, DOI 10.1523/JNEUROSCI.20-16-06048.2000; Palacino JJ, 2004, J BIOL CHEM, V279, P18614, DOI 10.1074/jbc.M401135200; Perez RG, 2002, J NEUROSCI, V22, P3090, DOI 10.1523/JNEUROSCI.22-08-03090.2002; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rodrigues CMP, 1998, J CLIN INVEST, V101, P2790, DOI 10.1172/JCI1325; Rodrigues CMP, 2003, P NATL ACAD SCI USA, V100, P6087, DOI 10.1073/pnas.1031632100; Rodrigues CMP, 2003, BIOCHEMISTRY-US, V42, P3070, DOI 10.1021/bi026979d; Schuler F, 2001, BBA-BIOENERGETICS, V1506, P79, DOI 10.1016/S0005-2728(01)00183-9; Sharon R, 2001, P NATL ACAD SCI USA, V98, P9110, DOI 10.1073/pnas.171300598; Sherer TB, 2003, J NEUROSCI, V23, P10756, DOI 10.1523/jneurosci.23-34-10756.2003; Sherer TB, 2002, J NEUROSCI, V22, P7006; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; SLICE LW, 1990, J BIOL CHEM, V265, P256; Snyder H, 2003, J BIOL CHEM, V278, P11753, DOI 10.1074/jbc.M208641200; Souza JM, 2000, FEBS LETT, V474, P116, DOI 10.1016/S0014-5793(00)01563-5; Tieu K, 2003, J CLIN INVEST, V112, P892, DOI 10.1172/JCI200318797; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284; Vila M, 2001, P NATL ACAD SCI USA, V98, P2837, DOI 10.1073/pnas.051633998; Yang YF, 2003, NEURON, V37, P911, DOI 10.1016/S0896-6273(03)00143-0; Yokota T, 2003, BIOCHEM BIOPH RES CO, V312, P1342, DOI 10.1016/j.bbrc.2003.11.056; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797; Zimprich A, 2004, NEURON, V44, P601, DOI 10.1016/j.neuron.2004.11.005	66	202	214	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42655	42668		10.1074/jbc.M505910200	http://dx.doi.org/10.1074/jbc.M505910200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16239214	Green Accepted, hybrid			2022-12-25	WOS:000234200800023
J	Di Cola, A; Bailey, S; Robinson, C				Di Cola, A; Bailey, S; Robinson, C			The thylakoid Delta pH/Delta Psi are not required for the initial stages of Tat-dependent protein transport in tobacco protoplasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TWIN-ARGININE TRANSLOCASE; SIGNAL PEPTIDE; PATHWAY; EXPORT; CHLOROPLASTS; MEMBRANES; SYSTEM; COMPONENTS; ENERGETICS; GRADIENT	The twin-arginine translocation ( Tat) system transports folded proteins across the chloroplast thylakoid membrane and bacterial plasma/membrane. In vitro import assays have pointed to a key role for the thylakoid Delta pH in the initial assembly of the full translocon from two subcomplexes; more generally, the Delta pH is believed to provide the overall driving force for translocation. Here, we have studied the role of the Delta pH in vivo by analyzing the translocation of Tat substrates in transfected tobacco protoplasts. We show that the complete maturation of the precursor of the 23-kDa lumenal protein (pre-23K) and of a fusion of the 23K presequence linked to green fluorescent protein (pre-GFP) are unaffected by dissipation of the Delta pH. High level expression of Tat substrates in protoplasts has recently been shown to result in "translocation reversal" in that a large proportion of a given substrate is partially translocated across the thylakoid membrane, processed to the mature size, and returned to the stroma. However, the efficiency of translocation of pre-23K is undiminished in the absence of the Delta pH and/or Delta Psi, and the rate and extent of maturation of both pre-23K and pre-GFP by the lumen-facing processing peptidase is similarly unaffected. These data demonstrate that the proton motive force is not required for the functional assembly of the Tat translocon and the initial stages of translocation in higher plant chloroplasts in vivo. We conclude that unknown factors play an influential role in both the mechanism and energetics of this system under in vivo conditions.	Univ Warwick, Dept Sci Biol, Coventry CV4 7AL, W Midlands, England	University of Warwick	Robinson, C (corresponding author), Univ Warwick, Dept Sci Biol, Coventry CV4 7AL, W Midlands, England.	Crobinson@bio.warwick.ac.uk						Alami M, 2003, MOL CELL, V12, P937, DOI 10.1016/S1097-2765(03)00398-8; Alder NN, 2003, CELL, V112, P231, DOI 10.1016/S0092-8674(03)00032-1; Bogsch EG, 1998, J BIOL CHEM, V273, P18003, DOI 10.1074/jbc.273.29.18003; Bolhuis A, 2001, J BIOL CHEM, V276, P20213, DOI 10.1074/jbc.M100682200; CHADDOCK AM, 1995, EMBO J, V14, P2715, DOI 10.1002/j.1460-2075.1995.tb07272.x; Clark SA, 1997, MOL BIOL CELL, V8, P923, DOI 10.1091/mbc.8.5.923; CLINE K, 1992, J BIOL CHEM, V267, P2688; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; Cline K, 2001, J CELL BIOL, V154, P719, DOI 10.1083/jcb.200105149; Di Cola A, 2005, J CELL BIOL, V171, P281, DOI 10.1083/jcb.200502067; Finazzi G, 2003, EMBO J, V22, P807, DOI 10.1093/emboj/cdg081; Foresti O, 2003, PLANT CELL, V15, P2464, DOI 10.1105/tpc.013052; Frigerio L, 1998, J BIOL CHEM, V273, P14194, DOI 10.1074/jbc.273.23.14194; Horton P, 1996, ANNU REV PLANT PHYS, V47, P655, DOI 10.1146/annurev.arplant.47.1.655; Hynds PJ, 1998, J BIOL CHEM, V273, P34868, DOI 10.1074/jbc.273.52.34868; Marques JP, 2004, J EXP BOT, V55, P1697, DOI 10.1093/jxb/erh191; Mori H, 2002, J CELL BIOL, V157, P205, DOI 10.1083/jcb.200202048; Motohashi R, 2001, P NATL ACAD SCI USA, V98, P10499, DOI 10.1073/pnas.181304598; MOULD RM, 1991, J BIOL CHEM, V266, P12189; Oates J, 2005, J MOL BIOL, V346, P295, DOI 10.1016/j.jmb.2004.11.047; Pedrazzini E, 1997, PLANT CELL, V9, P1869, DOI 10.1105/tpc.9.10.1869; Porcelli I, 2002, BIOCHEMISTRY-US, V41, P13690, DOI 10.1021/bi026142i; Robinson C, 2004, BBA-MOL CELL RES, V1694, P135, DOI 10.1016/j.bbamcr.2004.03.010; Santini CL, 1998, EMBO J, V17, P101, DOI 10.1093/emboj/17.1.101; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; Settles AM, 1997, SCIENCE, V278, P1467, DOI 10.1126/science.278.5342.1467; Stanley NR, 2000, J BIOL CHEM, V275, P11591, DOI 10.1074/jbc.275.16.11591; Theg SM, 2005, TRENDS PLANT SCI, V10, P153, DOI 10.1016/j.tplants.2005.02.001; Thomas JD, 2001, MOL MICROBIOL, V39, P47, DOI 10.1046/j.1365-2958.2001.02253.x; VREDENBERG WJ, 1976, PLANT SCI LETT, V7, P101, DOI 10.1016/0304-4211(76)90079-1; Walker MB, 1999, J CELL BIOL, V147, P267, DOI 10.1083/jcb.147.2.267; WALTERS RG, 1991, PHOTOSYNTH RES, V27, P121, DOI 10.1007/BF00033251; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; Yen MR, 2002, ARCH MICROBIOL, V177, P441, DOI 10.1007/s00203-002-0408-4	34	13	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41165	41170		10.1074/jbc.M509215200	http://dx.doi.org/10.1074/jbc.M509215200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16215228	hybrid			2022-12-25	WOS:000233866900007
J	To, R; Hirama, T; Arbabi-Ghahroudi, M; MacKenzie, R; Wang, P; Xu, P; Ni, F; Tanha, J				To, R; Hirama, T; Arbabi-Ghahroudi, M; MacKenzie, R; Wang, P; Xu, P; Ni, F; Tanha, J			Isolation of monomeric human VHS by a phage selection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-DOMAIN; ANTIBODY FRAGMENTS; CRYSTAL-STRUCTURE; MONOCLONAL-ANTIBODIES; CHAIN ANTIBODIES; VARIABLE DOMAIN; GENE LIBRARIES; DISPLAY; BINDING; PROTEIN	Human V-H domains are promising molecules in applications involving antibodies, in particular, immunotherapy because of their human origin. However, they are, in general, prone to aggregation. Therefore, various strategies have been employed to acquire monomeric human V(H)s. We had previously discovered that filamentous phages displaying engineered monomeric VH domains gave rise to significantly larger plaques on bacterial lawns than phages displaying wild type VHs with aggregation tendencies. Using plaque size as the selection criterion and a phage-displayed naive human VH library we identified 15 V(H)s that were monomeric. Additionally, the VHs demonstrated good expression yields, good refolding properties following thermal denaturation, resistance to aggregation during long incubation at 37 C, and to trypsin at 37 C. These 15 VHs should serve as good scaffolds for developing immunotherapeutics, and the selection method employed here should have general utility for isolating proteins with desirable biophysical properties.	Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada	National Research Council Canada; National Research Council Canada	Tanha, J (corresponding author), Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada.	jamshid.tanha@nrc-cnrc.gc.ca						AKERSTROM B, 1994, J IMMUNOL METHODS, V177, P151, DOI 10.1016/0022-1759(94)90152-X; ALTIERI AS, 1995, J AM CHEM SOC, V117, P7566, DOI 10.1021/ja00133a039; Baca M, 1997, J BIOL CHEM, V272, P10678; Bai YW, 2004, EUR J BIOCHEM, V271, P1609, DOI 10.1111/j.1432-1033.2004.04074.x; Bond CJ, 2003, J MOL BIOL, V332, P643, DOI 10.1016/S0022-2836(03)00967-7; BUNDLE DR, 1994, BIOCHEMISTRY-US, V33, P5172, DOI 10.1021/bi00183a022; COOK GP, 1995, IMMUNOL TODAY, V16, P237, DOI 10.1016/0167-5699(95)80166-9; DAVIES J, 1994, FEBS LETT, V339, P285, DOI 10.1016/0014-5793(94)80432-X; DAVIES J, 1995, BIO-TECHNOL, V13, P475, DOI 10.1038/nbt0595-475; De Genest E, 2005, J BIOL CHEM, V280, P14114, DOI 10.1074/jbc.M413011200; de Haard HJ, 1999, J BIOL CHEM, V274, P18218, DOI 10.1074/jbc.274.26.18218; DENG SJ, 1995, P NATL ACAD SCI USA, V92, P4992, DOI 10.1073/pnas.92.11.4992; Desmyter A, 1996, NAT STRUCT BIOL, V3, P803, DOI 10.1038/nsb0996-803; Ewert S, 2002, BIOCHEMISTRY-US, V41, P3628, DOI 10.1021/bi011239a; Forrer P, 1999, CURR OPIN STRUC BIOL, V9, P514, DOI 10.1016/S0959-440X(99)80073-6; Frenken LGJ, 2000, J BIOTECHNOL, V78, P11, DOI 10.1016/S0168-1656(99)00228-X; HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0; Jespers L, 2004, NAT BIOTECHNOL, V22, P1161, DOI 10.1038/nbt1000; Jespers L, 2004, J MOL BIOL, V337, P893, DOI 10.1016/j.jmb.2004.02.013; Jung S, 1999, J MOL BIOL, V294, P163, DOI 10.1006/jmbi.1999.3196; Loset GA, 2005, J IMMUNOL METHODS, V299, P47, DOI 10.1016/j.jim.2005.01.014; Martin F, 1997, PROTEIN ENG, V10, P607, DOI 10.1093/protein/10.5.607; Matsuura T, 2003, FEBS LETT, V539, P24, DOI 10.1016/S0014-5793(03)00178-9; Nguyen VK, 2001, ADV IMMUNOL, V79, P261, DOI 10.1016/S0065-2776(01)79006-2; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Rader C, 1998, P NATL ACAD SCI USA, V95, P8910, DOI 10.1073/pnas.95.15.8910; RANDEN I, 1993, EUR J IMMUNOL, V23, P2682, DOI 10.1002/eji.1830231044; Reilly RM, 2001, NUCL MED COMMUN, V22, P587, DOI 10.1097/00006231-200105000-00019; Reiter Y, 1999, J MOL BIOL, V290, P685, DOI 10.1006/jmbi.1999.2923; ROGUSKA MA, 1994, P NATL ACAD SCI USA, V91, P969, DOI 10.1073/pnas.91.3.969; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; Spinelli S, 1996, NAT STRUCT BIOL, V3, P752, DOI 10.1038/nsb0996-752; Tanha J, 2002, J IMMUNOL METHODS, V263, P97, DOI 10.1016/S0022-1759(02)00027-3; Tanha J, 2001, J BIOL CHEM, V276, P24774, DOI 10.1074/jbc.M100770200; Tanha Jamshid, 2003, Methods Mol Med, V89, P435; Terpe K, 2003, APPL MICROBIOL BIOT, V60, P523, DOI 10.1007/s00253-002-1158-6; van der Linden RHJ, 1999, BBA-PROTEIN STRUCT M, V1431, P37, DOI 10.1016/S0167-4838(99)00030-8; Waldo GS, 2003, CURR OPIN CHEM BIOL, V7, P33, DOI 10.1016/S1367-5931(02)00017-0; WARD ES, 1989, NATURE, V341, P544, DOI 10.1038/341544a0; Zhang JB, 2004, J MOL BIOL, V335, P49, DOI 10.1016/j.jmb.2003.09.034	42	39	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41395	41403		10.1074/jbc.M509900200	http://dx.doi.org/10.1074/jbc.M509900200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16221664	hybrid			2022-12-25	WOS:000233866900036
J	Elvington, SM; Bu, F; Nichols, JW				Elvington, SM; Bu, F; Nichols, JW			Fluorescent, acyl chain-labeled phosphatidylcholine analogs reveal novel transport pathways across the plasma membrane of yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASES; PHOSPHOLIPID TRANSLOCATION; SACCHAROMYCES-CEREVISIAE; LIPID TRANSPORT; ENDOCYTOSIS; PHOSPHATIDYLETHANOLAMINE; INTERNALIZATION; PROTEIN; PDR3	Acyl chain-labeled NBD-phosphatidylcholine (NBD-PC) has been used to identify three gene products (Lem3p, Dnf1p, and Dnf2p) that are required for normal levels of inward-directed phospholipid transport (flip) across the plasma membrane of yeast. Although the head group structure of acyl chain-labeled NBD phospholipids has been shown to influence the mechanism of flip across the plasma membrane, the extent to which the acyl chain region and the associated fluorophore affect flip has not been assessed. Given the identification of these proteins required for NBD-PC flip, it is now possible to determine whether the fluorophore attached to a phospholipid acyl chain influences the mechanism of flip. Thus, flip of phosphatidylcholine molecules with three different Bodipy fluorophores (Bodipy FL, Bodipy 530, and Bodipy 581) was tested and compared with that of NBD-PC in strains carrying deletions in LEM3, DNF1, and DNF2. Deletion of these genes significantly reduced the flip of NBD-PC and Bodipy FL-PC but had no effect on that of Bodipy 581-PC and Bodipy 530-PC. These data, in combination with comparisons of the effect of ATP depletion, collapse of the proton electrochemical gradient across the plasma membrane, and culture density led to the conclusion that at least three different flip pathways exist in yeast that are selective for the structure of the fluorophore attached to the acyl chain of phosphatidylcholine molecules.	Emory Univ, Sch Med, Dept Physiol, Atlanta, GA 30322 USA	Emory University	Nichols, JW (corresponding author), Emory Univ, Sch Med, Dept Physiol, 605G Whitehead Bldg,615 Michael St, Atlanta, GA 30322 USA.	wylie.nichols@emory.edu			NIGMS NIH HHS [GM064770] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064770] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Grant AM, 2001, TRAFFIC, V2, P37, DOI 10.1034/j.1600-0854.2001.020106.x; Hanson PK, 2003, J BIOL CHEM, V278, P36041, DOI 10.1074/jbc.M305263200; Hanson PK, 2002, J CELL SCI, V115, P2725; Hanson PK, 2001, J BIOL CHEM, V276, P9861, DOI 10.1074/jbc.M009065200; Kato U, 2002, J BIOL CHEM, V277, P37855, DOI 10.1074/jbc.M205564200; KEAN LS, 1993, J CELL BIOL, V123, P1403, DOI 10.1083/jcb.123.6.1403; Kean LS, 1997, J CELL BIOL, V138, P255, DOI 10.1083/jcb.138.2.255; KIHARA A, 2004, MOL BIOL CELL; Marks DL, 2005, METHODS, V36, P186, DOI 10.1016/j.ymeth.2004.12.001; Natarajan P, 2004, P NATL ACAD SCI USA, V101, P10614, DOI 10.1073/pnas.0404146101; Nichols JW, 2002, SEMIN CELL DEV BIOL, V13, P179, DOI 10.1016/S1084-9521(02)00046-0; PAGANO RE, 1985, SCIENCE, V229, P1051, DOI 10.1126/science.4035344; Pomorski T, 2004, J CELL SCI, V117, P805, DOI 10.1242/jcs.01055; Pomorski T, 2003, MOL BIOL CELL, V14, P1240, DOI 10.1091/mbc.E02-08-0501; RIEZMAN H, 1986, TRENDS BIOCHEM SCI, V11, P325, DOI 10.1016/0968-0004(86)90290-2; RIEZMAN H, 1985, CELL, V40, P1001, DOI 10.1016/0092-8674(85)90360-5; Saito K, 2004, MOL BIOL CELL, V15, P3418, DOI 10.1091/mbc.E03-11-0829; SERRANO R, 1977, EUR J BIOCHEM, V80, P97, DOI 10.1111/j.1432-1033.1977.tb11861.x; SHERMAN F, 1986, METHODS YEAST GENETI, P181; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; Wang TY, 2000, BIOPHYS J, V79, P919, DOI 10.1016/S0006-3495(00)76347-8	22	22	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40957	40964		10.1074/jbc.M507926200	http://dx.doi.org/10.1074/jbc.M507926200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16204231	hybrid			2022-12-25	WOS:000233666600069
J	Guerra, L; Fanelli, T; Favia, M; Riccardi, SM; Busco, G; Cardone, RA; Carrabino, S; Weinman, EJ; Reshkin, SJ; Conese, M; Casavola, V				Guerra, L; Fanelli, T; Favia, M; Riccardi, SM; Busco, G; Cardone, RA; Carrabino, S; Weinman, EJ; Reshkin, SJ; Conese, M; Casavola, V			Na+/H+ exchanger regulatory factor isoform 1 overexpression modulates cystic fibrosis transmembrane conductance regulator (CFTR) expression and activity in human airway 16HBE14o-cells and rescues Delta F508 CFTR functional expression in cystic fibrosis cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; DOMAIN INTERACTION CONTROLS; PDZ-INTERACTING DOMAIN; EPITHELIAL-CELLS; PLASMA-MEMBRANE; APICAL MEMBRANE; BETA-2-ADRENERGIC RECEPTOR; DEPENDENT REGULATION; BINDING MOTIF; CYCLIC-AMP	There is evidence that cystic fibrosis transmembrane conductance regulator ( CFTR) interacting proteins play critical roles in the proper expression and function of CFTR. The Na+/H+ exchanger regulatory factor isoform 1 (NHERF1) was the first identified CFTR-binding protein. Here we further clarify the role of NHERF1 in the regulation of CFTR activity in two human bronchial epithelial cell lines: the normal, 16HBE14o-, and the homozygous Delta F508 CFTR, CFBE41o-. Confocal analysis in polarized cell monolayers demonstrated that NHERF1 distribution was associated with the apical membrane in 16HBE14o- cells while being primarily cytoplasmic in CFBE41o- cells. Transfection of 16HBE14o- monolayers with vectors encoding for wild-type (wt) NHERF1 increased both apical CFTR expression and apical protein kinase A (PKA)-dependent CFTR-mediated chloride efflux, whereas transfection with NHERF1 mutated in the binding groove of the PDZ domains or truncated for the ERM domain inhibited both the apical CFTR expression and the CFTR-dependent chloride efflux. These data led us to hypothesize an important role for NHERF1 in regulating CFTR localization and stability on the apical membrane of 16HBE14o- cell monolayers. Importantly, wt NHERF1 overexpression in confluent Delta F508 CFBE41o- and Delta F508 CFT1-C2 cell monolayers induced both a significant redistribution of CFTR from the cytoplasm to the apical membrane and a PKA-dependent activation of CFTR-dependent chloride secretion.	Univ Bari, Dept Gen & Environm Physiol, I-70126 Bari, Italy; Univ Maryland, Div Nephrol, Baltimore, MD 21201 USA; Inst Expt Treatment Cystic Fibrosis, I-20132 Milan, Italy; Univ Foggia, Dept Biomed Sci, I-71100 Foggia, Italy	Universita degli Studi di Bari Aldo Moro; University System of Maryland; University of Maryland Baltimore; University of Foggia	Casavola, V (corresponding author), Univ Bari, Dept Gen & Environm Physiol, Via Amendola 165-A, I-70126 Bari, Italy.	casavola@biologia.uniba.it	Favia, Maria/ABD-1405-2020; Reshkin, Stephan/AAI-6680-2020; Busco, Giovanni/F-2711-2018; Conese, Massimo/AAB-7926-2019; Favia, Maria/AAB-5670-2020	Favia, Maria/0000-0001-6039-9365; Reshkin, Stephan/0000-0001-9757-5908; Busco, Giovanni/0000-0001-6859-9468; Conese, Massimo/0000-0003-3465-6641; CASAVOLA, Valeria/0000-0003-4471-4948; GUERRA, Lorenzo/0000-0003-3950-9405				Ahn W, 2001, J BIOL CHEM, V276, P17236, DOI 10.1074/jbc.M011763200; Andersson C, 2003, BIOCHEM BIOPH RES CO, V308, P518, DOI 10.1016/S0006-291X(03)01436-0; Bagorda A, 2002, J BIOL CHEM, V277, P21480, DOI 10.1074/jbc.M112245200; Benharouga M, 2003, J BIOL CHEM, V278, P22079, DOI 10.1074/jbc.M301030200; Bertrand CA, 2003, AM J PHYSIOL-CELL PH, V285, pC1, DOI 10.1152/ajpcell.00554.2002; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bronsveld I, 2001, J CLIN INVEST, V108, P1705; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Chen P, 2001, J GEN PHYSIOL, V118, P135, DOI 10.1085/jgp.118.2.135; Cheng J, 2004, J BIOL CHEM, V279, P1892, DOI 10.1074/jbc.M308640200; Cheng J, 2002, J BIOL CHEM, V277, P3520, DOI 10.1074/jbc.M110177200; COZENS AL, 1994, AM J RESP CELL MOL, V10, P38, DOI 10.1165/ajrcmb.10.1.7507342; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; EGAN ME, 1995, AM J PHYSIOL-CELL PH, V268, pC243, DOI 10.1152/ajpcell.1995.268.1.C243; Gage RM, 2001, J BIOL CHEM, V276, P44712, DOI 10.1074/jbc.M107417200; Haggie PM, 2004, J BIOL CHEM, V279, P5494, DOI 10.1074/jbc.M312445200; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Harris BZ, 2001, J CELL SCI, V114, P3219; Howard M, 2000, AM J PHYSIOL-CELL PH, V279, pC375, DOI 10.1152/ajpcell.2000.279.2.C375; Ingraffea J, 2002, EUR J CELL BIOL, V81, P61, DOI 10.1078/0171-9335-00218; Jilling T, 1996, J BIOL CHEM, V271, P4381; Kalin N, 1999, J CLIN INVEST, V103, P1379, DOI 10.1172/JCI5731; Klussmann E, 1999, J BIOL CHEM, V274, P4934, DOI 10.1074/jbc.274.8.4934; Li JG, 2002, J BIOL CHEM, V277, P27545, DOI 10.1074/jbc.M200058200; Liedtke CM, 2002, J BIOL CHEM, V277, P22925, DOI 10.1074/jbc.M201917200; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; Ma TH, 2002, J CLIN INVEST, V110, P1651, DOI 10.1172/JCI200216112; Milewski MI, 2001, J CELL SCI, V114, P719; Mohler PJ, 1999, J CELL BIOL, V147, P879, DOI 10.1083/jcb.147.4.879; Moyer BD, 1998, J BIOL CHEM, V273, P21759, DOI 10.1074/jbc.273.34.21759; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Moyer BD, 2000, J BIOL CHEM, V275, P27069; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Schultz BD, 1999, PHYSL REV S, V79, P109; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Sun F, 2000, J BIOL CHEM, V275, P14360, DOI 10.1074/jbc.275.19.14360; Sun F, 2000, J BIOL CHEM, V275, P29539, DOI 10.1074/jbc.M004961200; Swiatecka-Urban A, 2002, J BIOL CHEM, V277, P40099, DOI 10.1074/jbc.M206964200; Taddei A, 2004, FEBS LETT, V558, P52, DOI 10.1016/S0014-5793(04)00011-0; Taouil K, 2003, J BIOL CHEM, V278, P17320, DOI 10.1074/jbc.M212227200; Tousson A, 1996, J CELL SCI, V109, P1325; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Weinman EJ, 2000, BIOCHEMISTRY-US, V39, P6123, DOI 10.1021/bi000064m; Weinman EJ, 1997, EXP NEPHROL, V5, P449; Weinman EJ, 2003, BIOCHEMISTRY-US, V42, P12662, DOI 10.1021/bi035244l; Weinman EJ, 2001, J CLIN INVEST, V108, P185, DOI 10.1172/JCI13518; YANKASKAS JR, 1993, AM J PHYSIOL, V264, pC1219, DOI 10.1152/ajpcell.1993.264.5.C1219; Yoo D, 2004, J BIOL CHEM, V279, P6863, DOI 10.1074/jbc.M311599200	52	90	92	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40925	40933		10.1074/jbc.M505103200	http://dx.doi.org/10.1074/jbc.M505103200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16203733	hybrid			2022-12-25	WOS:000233666600065
J	Wieland, JA; Gewirth, AA; Leckband, DE				Wieland, JA; Gewirth, AA; Leckband, DE			Single molecule adhesion measurements reveal two homophilic neural cell adhesion molecule bonds with mechanically distinct properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NCAM; BINDING; FORCE; DOMAINS; PLASTICITY; KINETICS	Neural cell adhesion molecule ( NCAM) is a cell surface adhesion glycoprotein that plays an important role in the development and stability of nervous tissue. The homophilic binding mechanism of NCAM is still a subject of debate on account of findings that appear to support different mechanisms. This paper describes single molecule force measurements with both full-length NCAM and NCAM mutants that lack different immunoglobulin (Ig) domains. By systematically applying an external, time-dependent force to the bond, we obtained parameters that describe the energy landscape of NCAM-NCAM bonds. Histograms of the rupture forces between the full-length NCAM extracellular domains revealed two binding events, one rupturing at higher forces than the other. These bond rupture data show that the two bonds have the same dissociation rates. Despite the energetic and kinetic similarities, the bond strengths differ significantly, and are mechanically distinct. Measurements with NCAM domain deletion mutants mapped the weaker bond to the Ig 1-2 segment, and the stronger bond to the Ig3 domain. Finally, the quantitative agreement between the fragment adhesion and the strengths of both NCAM bonds shows that the domain deletions considered in this study do not alter the intrinsic strengths of either of the two bonds.	Univ Illinois, Dept Chem, Urbana, IL 61801 USA; Univ Illinois, Dept Chem & Biomol Engm, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Gewirth, AA (corresponding author), Univ Illinois, Dept Chem, Urbana, IL 61801 USA.	agewirth@uiuc.edu; leckband@uiuc.edu	Gewirth, Andrew A./A-7183-2009		NIGMS NIH HHS [R01 GM63536] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063536] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atkins AR, 1999, FEBS LETT, V451, P162, DOI 10.1016/S0014-5793(99)00554-2; Atkins AR, 2004, J BIOL CHEM, V279, P49633, DOI 10.1074/jbc.M409159200; Baumgartner W, 2000, ULTRAMICROSCOPY, V82, P85, DOI 10.1016/S0304-3991(99)00154-0; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; Bevington P. R., 2003, DATA REDUCTION ERROR, DOI 10.2307/2284752; Evans E, 1997, BIOPHYS J, V72, P1541, DOI 10.1016/S0006-3495(97)78802-7; Evans E, 2001, ANNU REV BIOPH BIOM, V30, P105, DOI 10.1146/annurev.biophys.30.1.105; Evans E, 1998, FARADAY DISCUSS, V111, P1; Hukkanen EJ, 2005, BIOPHYS J, V89, P3434, DOI 10.1529/biophysj.105.061606; Hummer G, 2003, BIOPHYS J, V85, P5, DOI 10.1016/S0006-3495(03)74449-X; HUTTER JL, 1993, REV SCI INSTRUM, V64, P1868, DOI 10.1063/1.1143970; Jensen PH, 1999, NAT STRUCT BIOL, V6, P486; Johnson CP, 2005, J BIOL CHEM, V280, P137, DOI 10.1074/jbc.M410216200; Johnson CP, 2004, P NATL ACAD SCI USA, V101, P6963, DOI 10.1073/pnas.0307567100; Kang MC, 2002, J PHYS CHEM B, V106, P12211, DOI 10.1021/jp025882y; Kasper C, 2000, NAT STRUCT BIOL, V7, P389; Kiselyov VV, 1997, J BIOL CHEM, V272, P10125; Kiss JZ, 2001, BRAIN RES REV, V36, P175, DOI 10.1016/S0165-0173(01)00093-5; Ranheim TS, 1996, P NATL ACAD SCI USA, V93, P4071, DOI 10.1073/pnas.93.9.4071; RAO Y, 1993, J BIOL CHEM, V268, P20630; RAO Y, 1992, J CELL BIOL, V118, P937, DOI 10.1083/jcb.118.4.937; RAO Y, 1994, J BIOL CHEM, V269, P27540; Ronn LCB, 1998, EXP GERONTOL, V33, P853, DOI 10.1016/S0531-5565(98)00040-0; Soroka V, 2003, STRUCTURE, V11, P1291, DOI 10.1016/j.str.2003.09.006; Thomsen NK, 1996, NAT STRUCT BIOL, V3, P581, DOI 10.1038/nsb0796-581; Walsh FS, 1997, ANNU REV CELL DEV BI, V13, P425, DOI 10.1146/annurev.cellbio.13.1.425; Wieland JA, 2005, J PHYS CHEM B, V109, P5985, DOI 10.1021/jp045461b	27	36	36	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					41037	41046		10.1074/jbc.M503975200	http://dx.doi.org/10.1074/jbc.M503975200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16188877	hybrid			2022-12-25	WOS:000233666600078
J	Ding, F; LaRocque, JJ; Dokholyan, NV				Ding, F; LaRocque, JJ; Dokholyan, NV			Direct observation of protein folding, aggregation, and a prion-like conformational conversion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-DYNAMICS SIMULATION; AMYLOID FORMATION; SH3 DOMAIN; MODEL; MECHANICS; FIBRILS	Protein conformational transition from alpha-helices to beta-sheets precedes aggregation of proteins implicated in many diseases, including Alzheimer and prion diseases. Direct characterization of such transitions is often hindered by the complicated nature of the interaction network among amino acids. A recently engineered small protein-like peptide with a simple amino acid composition features a temperature-driven alpha-helix to beta-sheet conformational change. Here we studied the conformational transition of this peptide by molecular dynamics simulations. We observed a critical temperature, below which the peptide folds into an alpha-helical coiled-coil state and above which the peptide misfolds into beta-rich structures with a high propensity to aggregate. The structures adopted by this peptide during low temperature simulations have a backbone root mean square deviation less than 2 angstrom from the crystal structure. At high temperatures, this peptide adopts an amyloid-like structure, which is mainly composed of coiled anti-parallel beta-sheets with the cross-beta-signature of amyloid fibrils. Most strikingly, we observed conformational conversions in which an alpha-helix is converted into a beta-strand by proximate stable beta-sheets with exposed hydrophobic surfaces and unsaturated hydrogen bonds. Our study suggested a possible generic molecular mechanism of the template-mediated aggregation process, originally proposed by Prusiner (Prusiner, S. B. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 13363 13383) to account for prion infectivity.	Univ N Carolina, Dept Biochem & Biophys, Sch Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Phys & Astron, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill	Dokholyan, NV (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Sch Med, Chapel Hill, NC 27599 USA.	dokh@med.unc.edu	Ding, Feng/G-6029-2011; Dokholyan, Nikolay/D-8081-2018; Dokholyan, Nikolay/B-2238-2009	Ding, Feng/0000-0003-1850-6336; Dokholyan, Nikolay/0000-0002-8225-4025; Dokholyan, Nikolay/0000-0002-8225-4025				BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Ding F, 2005, TRENDS BIOTECHNOL, V23, P450, DOI 10.1016/j.tibtech.2005.07.001; Ding F, 2005, BIOPHYS J, V88, P147, DOI 10.1529/biophysj.104.046375; Ding F, 2003, PROTEINS, V53, P220, DOI 10.1002/prot.10468; Ding F, 2002, J MOL BIOL, V324, P851, DOI 10.1016/S0022-2836(02)01112-9; Dokholyan NV, 1998, FOLD DES, V3, P577, DOI 10.1016/S1359-0278(98)00072-8; Dokholyan NV, 2003, METHOD ENZYMOL, V374, P616, DOI 10.1016/S0076-6879(03)74025-7; Dunbrack RL, 1997, PROTEIN SCI, V6, P1661, DOI 10.1002/pro.5560060807; Fandrich M, 2001, NATURE, V410, P165, DOI 10.1038/35065514; Guijarro JI, 1998, P NATL ACAD SCI USA, V95, P4224, DOI 10.1073/pnas.95.8.4224; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; HERMANS J, 1984, BIOPOLYMERS, V23, P1513, DOI 10.1002/bip.360230807; Kammerer RA, 2004, P NATL ACAD SCI USA, V101, P4435, DOI 10.1073/pnas.0306786101; Kirkitadze MD, 2001, J MOL BIOL, V312, P1103, DOI 10.1006/jmbi.2001.4970; Kollman PA, 2000, ACCOUNTS CHEM RES, V33, P889, DOI 10.1021/ar000033j; Kortemme T, 2003, J MOL BIOL, V326, P1239, DOI 10.1016/S0022-2836(03)00021-4; Lazaridis T, 1999, PROTEINS, V35, P133, DOI 10.1002/(SICI)1097-0134(19990501)35:2<133::AID-PROT1>3.0.CO;2-N; Lipfert J, 2005, J MOL BIOL, V349, P648, DOI 10.1016/j.jmb.2005.03.083; Malolepsza E, 2005, P NATL ACAD SCI USA, V102, P7835, DOI 10.1073/pnas.0409389102; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Peng S, 2004, PHYS REV E, V69, DOI 10.1103/PhysRevE.69.041908; Peng Y., 2003, PHYS REV E, V68; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Sethuraman A, 2005, BIOPHYS J, V88, P1322, DOI 10.1529/biophysj.104.051797; Srinivasan R, 1999, P NATL ACAD SCI USA, V96, P14258, DOI 10.1073/pnas.96.25.14258; Sunde M, 1997, J MOL BIOL, V273, P729, DOI 10.1006/jmbi.1997.1348; Urbanc B, 2004, BIOPHYS J, V87, P2310, DOI 10.1529/biophysj.104.040980; Vorobjev YN, 1997, BIOPHYS J, V72, pMP459; Zhou YQ, 1997, J CHEM PHYS, V107, P10691, DOI 10.1063/1.474186	29	64	69	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40235	40240		10.1074/jbc.M506372200	http://dx.doi.org/10.1074/jbc.M506372200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16204250	Green Published, hybrid			2022-12-25	WOS:000233461300065
J	Azarov, I; Huang, KT; Basu, S; Gladwin, MT; Hogg, N; Kim-Shapiro, DB				Azarov, I; Huang, KT; Basu, S; Gladwin, MT; Hogg, N; Kim-Shapiro, DB			Nitric oxide scavenging by red blood cells as a function of hematocrit and oxygenation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE CONSUMPTION; HEMOGLOBIN; DIFFUSION; BINDING; NO; OXIDATION; BIOAVAILABILITY; MECHANISM; MYOGLOBIN; TRANSPORT	The reaction rate between nitric oxide and intraerythrocytic hemoglobin plays a major role in nitric oxide bioavailability and modulates homeostatic vascular function. It has previously been demonstrated that the encapsulation of hemoglobin in red blood cells restricts its ability to scavenge nitric oxide. This effect has been attributed to either factors intrinsic to the red blood cell such as a physical membrane barrier or factors external to the red blood cell such as the formation of an unstirred layer around the cell. We have performed measurements of the uptake rate of nitric oxide by red blood cells under oxygenated and deoxygenated conditions at different hematocrit percentages. Our studies include stopped-flow measurements where both the unstirred layer and physical barrier potentially participate, as well as competition experiments where the potential contribution of the unstirred layer is limited. We find that deoxygenated erythrocytes scavenge nitric oxide faster than oxygenated cells and that the rate of nitric oxide scavenging for oxygenated red blood cells increases as the hematocrit is raised from 15% to 50%. Our results 1) confirm the critical biological phenomenon that hemoglobin compartmentalization within the erythrocyte reduces reaction rates with nitric oxide, 2) show that extra-erythocytic diffusional barriers mediate most of this effect, and 3) provide novel evidence that an oxygen-dependent intrinsic property of the red blood cell contributes to this barrier activity, albeit to a lesser extent. These observations may have important physiological implications within the microvasculature and for pathophysiological disruption of nitric oxide homeostasis in diseases.	Wake Forest Univ, Dept Phys, Sch Med, Winston Salem, NC 27109 USA; Wake Forest Univ, Dept Biomed Engn, Sch Med, Winston Salem, NC 27109 USA; NHLBI, Vasc Med Branch, Bethesda, MD 20892 USA; NIH, Dept Crit Care Med, Bethesda, MD 20892 USA; Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Free Rad Res Ctr, Milwaukee, WI 53226 USA	Wake Forest University; Wake Forest University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; Medical College of Wisconsin; Medical College of Wisconsin	Kim-Shapiro, DB (corresponding author), Wake Forest Univ, Dept Phys, Sch Med, Winston Salem, NC 27109 USA.	shapiro@wfu.edu	Kim-Shapiro, Daniel/HGA-2682-2022	Azarov, Ivan/0000-0002-9886-3298	NHLBI NIH HHS [K02-HL078706, HL58091, R01 HL058091] Funding Source: Medline; NIGMS NIH HHS [GM55792] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K02HL078706, R37HL058091, R29HL058091, R01HL058091] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055792, R29GM055792] Funding Source: NIH RePORTER; CLINICAL CENTER [Z01CL008050] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); CLINICAL CENTER		BUNN HF, 1969, J EXP MED, V129, P909, DOI 10.1084/jem.129.5.909; Butler AR, 1998, BBA-GEN SUBJECTS, V1425, P168, DOI 10.1016/S0304-4165(98)00065-8; CARLSEN E, 1958, J GEN PHYSIOL, V42, P83, DOI 10.1085/jgp.42.1.83; CASSOLY R, 1975, J MOL BIOL, V91, P301, DOI 10.1016/0022-2836(75)90382-4; COIN JT, 1979, J BIOL CHEM, V254, P1178; Cooper CE, 1999, BBA-BIOENERGETICS, V1411, P290, DOI 10.1016/S0005-2728(99)00021-3; Doherty DH, 1998, NAT BIOTECHNOL, V16, P672, DOI 10.1038/nbt0798-672; Dou Y, 2002, BIOPHYS CHEM, V98, P127, DOI 10.1016/S0301-4622(02)00090-X; DOYLE MP, 1981, J INORG BIOCHEM, V14, P351, DOI 10.1016/S0162-0134(00)80291-3; Dull RO, 2004, J APPL PHYSIOL, V97, P1930, DOI 10.1152/japplphysiol.00102.2004; Eaton W A, 1981, Methods Enzymol, V76, P175; Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g; Fernandez BO, 2003, J AM CHEM SOC, V125, P10510, DOI 10.1021/ja036693b; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; Gladwin MT, 1999, J CLIN INVEST, V104, P937, DOI 10.1172/JCI7637; GOLDSMITH HL, 1989, AM J PHYSIOL, V257, pH1005, DOI 10.1152/ajpheart.1989.257.3.H1005; Gow AJ, 1999, P NATL ACAD SCI USA, V96, P9027, DOI 10.1073/pnas.96.16.9027; Han TH, 2005, BBA-GEN SUBJECTS, V1723, P135, DOI 10.1016/j.bbagen.2005.01.013; Han TH, 2003, P NATL ACAD SCI USA, V100, P12504, DOI 10.1073/pnas.2133409100; Herold S, 2001, BIOCHEMISTRY-US, V40, P3385, DOI 10.1021/bi002407m; HESS JR, 1993, J APPL PHYSIOL, V74, P1769, DOI 10.1152/jappl.1993.74.4.1769; Huang KT, 2001, P NATL ACAD SCI USA, V98, P11771, DOI 10.1073/pnas.201276698; Huang Z, 2002, BIOCHEM BIOPH RES CO, V292, P812, DOI 10.1006/bbrc.2002.6730; Huang Z, 2001, BBA-GEN SUBJECTS, V1568, P252, DOI 10.1016/S0304-4165(01)00227-6; IGNARRO LJ, 1987, CIRC RES, V61, P866, DOI 10.1161/01.RES.61.6.866; KATSUKI S, 1977, J CYCLIC NUCL PROT, V3, P23; Kim-Shapiro DB, 2004, FREE RADICAL BIO MED, V36, P402, DOI 10.1016/j.freeradbiomed.2003.10.030; Lamkin-Kennard KA, 2004, MICROCIRCULATION, V11, P337, DOI 10.1080/10739680490437496; LANCASTER JR, 1994, P NATL ACAD SCI USA, V91, P8137, DOI 10.1073/pnas.91.17.8137; LEE R, 1995, J APPL PHYSIOL, V79, P236, DOI 10.1152/jappl.1995.79.1.236; Liao JC, 1999, P NATL ACAD SCI USA, V96, P8757, DOI 10.1073/pnas.96.15.8757; Liu XP, 1998, J BIOL CHEM, V273, P18709, DOI 10.1074/jbc.273.30.18709; Liu XP, 2002, J BIOL CHEM, V277, P26194, DOI 10.1074/jbc.M201939200; Loscalzo J, 1997, J LAB CLIN MED, V129, P580, DOI 10.1016/S0022-2143(97)90191-8; Matheson B, 2002, J APPL PHYSIOL, V93, P1479, DOI 10.1152/japplphysiol.00191.2002; MURRAY JA, 1995, GASTROENTEROLOGY, V109, P1241, DOI 10.1016/0016-5085(95)90584-7; Olson J S, 1981, Methods Enzymol, V76, P631; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Reiter CD, 2002, NAT MED, V8, P1383, DOI 10.1038/nm799; Rother RP, 2005, JAMA-J AM MED ASSOC, V293, P1653, DOI 10.1001/jama.293.13.1653; Sakai H, 2000, AM J PHYSIOL-HEART C, V279, pH908, DOI 10.1152/ajpheart.2000.279.3.H908; SHARMA VS, 1987, BIOCHEMISTRY-US, V26, P3837, DOI 10.1021/bi00387a015; Sloan EP, 1999, JAMA-J AM MED ASSOC, V282, P1857, DOI 10.1001/jama.282.19.1857; Tsoukias NM, 2002, AM J PHYSIOL-HEART C, V282, pH2265, DOI 10.1152/ajpheart.01080.2001; Ulatowski JA, 1996, CRIT CARE MED, V24, P558, DOI 10.1097/00003246-199604000-00003; Vaughn MW, 1998, AM J PHYSIOL-HEART C, V274, pH1705, DOI 10.1152/ajpheart.1998.274.5.H1705; Vaughn MW, 2000, J BIOL CHEM, V275, P2342, DOI 10.1074/jbc.275.4.2342; Vaughn MW, 2001, NITRIC OXIDE-BIOL CH, V5, P18, DOI 10.1006/niox.2000.0328; VOGEL WM, 1986, AM J PHYSIOL, V251, pH413, DOI 10.1152/ajpheart.1986.251.2.H413	49	134	136	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39024	39032		10.1074/jbc.M509045200	http://dx.doi.org/10.1074/jbc.M509045200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16186121	hybrid			2022-12-25	WOS:000233362200016
J	Ohashi, T; Erickson, HP				Ohashi, T; Erickson, HP			Domain unfolding plays a role in superfibronectin formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; PLASMA FIBRONECTIN; SELF-ASSOCIATION; EXTRACELLULAR-MATRIX; III MODULES; FRAGMENT; BINDING; POLYMERIZATION; STABILITY; MULTIMERS	Superfibronectin (sFN) is a fibronectin (FN) aggregate that is formed by mixing FN with anastellin, a fragment of the first type III domain of FN. However, the mechanism of this aggregation has not been clear. In this study, we found that anastellin co-precipitated with FN in a ratio of similar to 4:1, anastellin: FN monomer. The primary binding site for anastellin was in the segment (III)1-3, which bound three molecules of anastellin and was able to form a precipitate without the rest of the FN molecule. Anastellin binding to (III)3 caused a conformational change in that domain that exposed a cryptic thermolysin-sensitive site. An additional anastellin binds to (III)11, where it enhances thermolysin digestion of (III)11. An engineered disulfide bond in (III)3 inhibited both aggregation and protease digestion, suggesting that the stability of (III)3 is a key factor in sFN formation. We propose a three-step model for sFN formation: 1) FN-III domains spontaneously unfold and refold; 2) anastellin binds to an unfolded domain, preventing its refolding and leaving it with exposed hydrophobic surfaces and beta-sheet edges; and 3) these exposed elements bind to similar exposed elements on other molecules, leading to aggregation. The model is consistent with our observation that the kinetics of aggregation are first order, with a reaction time of 500-700 s. Similar mechanisms may contribute to the assembly of the native FN matrix.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University	Erickson, HP (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Box 3709, Durham, NC 27710 USA.	H.Erickson@cellbio.duke.edu			NATIONAL CANCER INSTITUTE [R01CA047056, R37CA047056] Funding Source: NIH RePORTER; NCI NIH HHS [CA47056] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGUIRRE KM, 1994, J BIOL CHEM, V269, P27863; Akerman ME, 2005, P NATL ACAD SCI USA, V102, P2040, DOI 10.1073/pnas.0409844102; Ambesi A, 2005, CANCER RES, V65, P148; AUKHIL I, 1993, J BIOL CHEM, V268, P2542; Bourdoulous S, 1998, J CELL BIOL, V143, P267, DOI 10.1083/jcb.143.1.267; Briknarova K, 2003, J MOL BIOL, V332, P205, DOI 10.1016/S0022-2836(03)00890-8; BROWN RA, 1994, BIOMATERIALS, V15, P457, DOI 10.1016/0142-9612(94)90225-9; Bultmann H, 1998, J BIOL CHEM, V273, P2601, DOI 10.1074/jbc.273.5.2601; Carrion-Vazquez M, 1999, P NATL ACAD SCI USA, V96, P3694, DOI 10.1073/pnas.96.7.3694; CASTELLANI P, 1986, J CELL BIOL, V103, P1671, DOI 10.1083/jcb.103.5.1671; Clarke J, 1997, J MOL BIOL, V270, P771, DOI 10.1006/jmbi.1997.1147; EJIM OS, 1993, BIOMATERIALS, V14, P743, DOI 10.1016/0142-9612(93)90038-4; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Fong S, 1996, J MOL BIOL, V264, P624, DOI 10.1006/jmbi.1996.0665; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; Hynes RO, 1990, FIBRONECTINS; ICHIHARATANAKA K, 1992, FEBS LETT, V299, P155, DOI 10.1016/0014-5793(92)80236-A; Ingham KC, 1997, J BIOL CHEM, V272, P1718, DOI 10.1074/jbc.272.3.1718; Johnson KJ, 1999, J BIOL CHEM, V274, P15473, DOI 10.1074/jbc.274.22.15473; Klein RM, 2003, J CELL SCI, V116, P4663, DOI 10.1242/jcs.00778; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; Litvinovich SV, 1998, J MOL BIOL, V280, P245, DOI 10.1006/jmbi.1998.1863; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; MCKEOWNLONGO PJ, 1984, J BIOL CHEM, V259, P2210; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; Mercurius KO, 2001, BMC CELL BIOL, V2, part. no., DOI 10.1186/1471-2121-2-18; MORLA A, 1994, NATURE, V367, P193, DOI 10.1038/367193a0; MOSHER DF, 1993, CURR OPIN STRUC BIOL, V3, P214, DOI 10.1016/S0959-440X(05)80155-1; MOSHER DF, 1983, J BIOL CHEM, V258, P6595; Muro AF, 2003, J CELL BIOL, V162, P149, DOI 10.1083/jcb.200212079; Oberhauser AF, 2002, J MOL BIOL, V319, P433, DOI 10.1016/S0022-2836(02)00306-6; Ohashi T, 1999, P NATL ACAD SCI USA, V96, P2153, DOI 10.1073/pnas.96.5.2153; Ohashi T, 2004, J BIOL CHEM, V279, P6534, DOI 10.1074/jbc.M310555200; Ohashi T, 2002, J CELL SCI, V115, P1221; Pankov R, 2000, J CELL BIOL, V148, P1075, DOI 10.1083/jcb.148.5.1075; Peters DMP, 1998, MICROSC MICROANAL, V4, P385, DOI 10.1017/S1431927698980369; Phillips JB, 2004, BIOMATERIALS, V25, P2769, DOI 10.1016/j.biomaterials.2003.09.052; Plaxco KW, 1997, J MOL BIOL, V270, P763, DOI 10.1006/jmbi.1997.1148; Plaxco KW, 1996, P NATL ACAD SCI USA, V93, P10703, DOI 10.1073/pnas.93.20.10703; Sakai T, 2001, NAT MED, V7, P324, DOI 10.1038/85471; Schwarz-Linek U, 2003, NATURE, V423, P177, DOI 10.1038/nature01589; SCHWARZBAUER JE, 1991, J CELL BIOL, V113, P1463, DOI 10.1083/jcb.113.6.1463; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Sechler JL, 2000, J CELL SCI, V113, P1491; Sechler JL, 2001, J CELL BIOL, V154, P1081, DOI 10.1083/jcb.200102034; SEKIGUCHI K, 1981, J BIOL CHEM, V256, P6452; VARTIO T, 1986, J BIOL CHEM, V261, P9433; Wennerberg K, 1996, J CELL BIOL, V132, P227, DOI 10.1083/jcb.132.1.227; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Yi M, 2003, P NATL ACAD SCI USA, V100, P11435, DOI 10.1073/pnas.1635112100; Yi M, 2001, P NATL ACAD SCI USA, V98, P620, DOI 10.1073/pnas.98.2.620	53	53	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39143	39151		10.1074/jbc.M509082200	http://dx.doi.org/10.1074/jbc.M509082200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16195231	hybrid			2022-12-25	WOS:000233362200029
J	Caspersen, C; Wang, N; Yao, J; Sosunov, A; Chen, X; Lustbader, JW; Xu, HW; Stern, D; McKhann, G; Yan, SD				Caspersen, C; Wang, N; Yao, J; Sosunov, A; Chen, X; Lustbader, JW; Xu, HW; Stern, D; McKhann, G; Yan, SD			Mitochondrial A beta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease	FASEB JOURNAL			English	Article						oxidative stress; transgenic mouse model of Alzheimer's disease; respiratory chain enzyme; intracellular A beta; energy metabolism	AMYLOID PRECURSOR PROTEIN; INTRANEURONAL A-BETA-42 ACCUMULATION; CYTOCHROME-C-OXIDASE; OXIDATIVE STRESS; TRANSGENIC MICE; ENDOPLASMIC-RETICULUM; PLAQUE-FORMATION; CELL-DEATH; HIPPOCAMPAL-NEURONS; DOWN-SYNDROME	Although amyloid-beta peptide (A beta) is the neurotoxic species implicated in the pathogenesis of Alzheimer's disease ( AD), mechanisms through which intracellular A beta impairs cellular properties, resulting in neuronal dysfunction, remain to be clarified. Here we demonstrate that intracellular A beta is present in mitochondria from brains of transgenic mice with targeted neuronal overexpression of mutant human amyloid precursor protein and AD patients. A beta progressively accumulates in mitochondria and is associated with diminished enzymatic activity of respiratory chain complexes (III and IV) and a reduction in the rate of oxygen consumption. Importantly, mitochondria-associated A beta, principally A beta 42, was detected as early as 4 months, before extensive extracellular A beta deposits. Our studies delineate a new means through which A beta potentially impairs neuronal energetics, contributing to cellular dysfunction in AD.	Columbia Univ Coll Phys & Surg, Dept Surg, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Neurosurg, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Obstet & Gynecol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY 10032 USA; Univ Cincinnati, Coll Med, Deans Off, Cincinnati, OH 45229 USA; Fujian Med Univ, Dept Neurol, Affiliated Hosp 1, Fuzhou, Peoples R China	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; University System of Ohio; University of Cincinnati; Fujian Medical University	Yan, SD (corresponding author), Columbia Univ Coll Phys & Surg, Dept Surg, 650 W 168th St,Black Bldg,Room 17-07, New York, NY 10032 USA.	sdy1@columbia.edu			NIA NIH HHS [P50 AG08702, AG16736, P01 AG17490] Funding Source: Medline; NINDS NIH HHS [NS 042855] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042855] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG017490, P50AG008702, R01AG016736] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anandatheerthavarada HK, 2003, J CELL BIOL, V161, P41, DOI 10.1083/jcb.200207030; ARISPE N, 1994, ANN NY ACAD SCI, V747, P256; Bahr BA, 1998, J COMP NEUROL, V397, P139; Bosetti F, 2002, NEUROBIOL AGING, V23, P371, DOI 10.1016/S0197-4580(01)00314-1; Brizio C, 2000, EUR J BIOCHEM, V267, P4346, DOI 10.1046/j.1432-1327.2000.01464.x; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Cardoso SM, 2001, FASEB J, V15, P1439, DOI 10.1096/fj.00-0561fje; Casley CS, 2002, J NEUROCHEM, V80, P91, DOI 10.1046/j.0022-3042.2001.00681.x; Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200; Chui DH, 1999, NAT MED, V5, P560, DOI 10.1038/8438; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; Du Y, 2001, NEUROLOGY, V57, P801, DOI 10.1212/WNL.57.5.801; Eckert A, 2001, J NEUROSCI RES, V64, P183, DOI 10.1002/jnr.1064; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; Giovanni A, 2000, J BIOL CHEM, V275, P11553, DOI 10.1074/jbc.275.16.11553; Glabe C, 2001, J MOL NEUROSCI, V17, P137, DOI 10.1385/JMN:17:2:137; Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1; Greenfield JP, 1999, P NATL ACAD SCI USA, V96, P742, DOI 10.1073/pnas.96.2.742; Gyure KA, 2001, ARCH PATHOL LAB MED, V125, P489; Hartmann T, 1999, EUR ARCH PSY CLIN N, V249, P291, DOI 10.1007/s004060050102; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; He XY, 2001, EUR J BIOCHEM, V268, P4899, DOI 10.1046/j.0014-2956.2001.02421.2421.x; Hoffman JM, 2000, J NUCL MED, V41, P1920; Hoshi M, 1997, J BIOL CHEM, V272, P2038, DOI 10.1074/jbc.272.4.2038; HSUAN F, 2005, BIOCHEM BIOPH RES CO, V328, P1; Kienlen-Campard P, 2002, J BIOL CHEM, V277, P15666, DOI 10.1074/jbc.M200887200; Kim HS, 2002, NEUROREPORT, V13, P1989, DOI 10.1097/00001756-200210280-00032; KISH SJ, 1992, J NEUROCHEM, V59, P776, DOI 10.1111/j.1471-4159.1992.tb09439.x; Kobayashi A, 1996, J BIOCHEM-TOKYO, V119, P775, DOI 10.1093/oxfordjournals.jbchem.a021307; KOO EH, 1994, J BIOL CHEM, V269, P17386; KUDO T, 2003, ALZHEIMERS DIS RELAT, P415; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; Lai J C, 1979, Methods Enzymol, V55, P51; Lesnefsky EJ, 2001, AM J PHYSIOL-HEART C, V280, pH2770; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; Lustbader JW, 2004, SCIENCE, V304, P448, DOI 10.1126/science.1091230; Magrane J, 2004, J NEUROSCI, V24, P1700, DOI 10.1523/JNEUROSCI.4330-03.2004; Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6; Marques CA, 2003, J BIOL CHEM, V278, P28294, DOI 10.1074/jbc.M212265200; MARTIN BL, 1995, J BIOL CHEM, V270, P26727, DOI 10.1074/jbc.270.45.26727; Mattson MP, 2002, J NEUROVIROL, V8, P539, DOI 10.1080/13550280290100978; Mattson MP, 1998, BRAIN RES, V807, P167, DOI 10.1016/S0006-8993(98)00763-X; Maurer I, 2000, NEUROBIOL AGING, V21, P455, DOI 10.1016/S0197-4580(00)00112-3; Moncada S, 2002, NAT REV MOL CELL BIO, V3, P214, DOI 10.1038/nrm762; Mori C, 2002, AMYLOID, V9, P88, DOI 10.3109/13506120208995241; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Muller WE, 2001, BIOCHEM SOC T, V29, P617, DOI 10.1042/BST0290617; MUTISYA EM, 1994, J NEUROCHEM, V63, P2179; Nishimura I, 1998, J NEUROSCI, V18, P2387, DOI 10.1523/jneurosci.18-07-02387.1998; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Pappolla MA, 1998, AM J PATHOL, V152, P871; PARKER WD, 1994, NEUROLOGY, V44, P1090, DOI 10.1212/WNL.44.6.1090; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Perry George, 1998, J Alzheimers Dis, V1, P45; Pillot T, 1996, J BIOL CHEM, V271, P28757, DOI 10.1074/jbc.271.46.28757; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Silverman Daniel H.S., 1999, Clin Positron Imaging, V2, P119, DOI 10.1016/S1095-0397(99)00020-5; Silverman Daniel H S, 2002, Mol Imaging Biol, V4, P283, DOI 10.1016/S1536-1632(02)00016-1; Tabner BJ, 2002, FREE RADICAL BIO MED, V32, P1076, DOI 10.1016/S0891-5849(02)00801-8; Takahashi RH, 2002, AM J PATHOL, V161, P1869, DOI 10.1016/S0002-9440(10)64463-X; Takahashi RH, 2004, J NEUROSCI, V24, P3592, DOI 10.1523/JNEUROSCI.5167-03.2004; Tamagno E, 2003, FREE RADICAL BIO MED, V35, P45, DOI 10.1016/S0891-5849(03)00244-2; Tienari PJ, 1997, P NATL ACAD SCI USA, V94, P4125, DOI 10.1073/pnas.94.8.4125; Tieu K, 2003, J CLIN INVEST, V112, P892, DOI 10.1172/JCI200318797; Walsh DM, 2000, BIOCHEMISTRY-US, V39, P10831, DOI 10.1021/bi001048s; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Wilson CA, 1999, J NEUROPATH EXP NEUR, V58, P787, DOI 10.1097/00005072-199908000-00001; Wirths O, 2001, NEUROSCI LETT, V306, P116, DOI 10.1016/S0304-3940(01)01876-6; WOOD SJ, 1995, BIOCHEMISTRY-US, V34, P724, DOI 10.1021/bi00003a003; Wood SJ, 1996, J BIOL CHEM, V271, P4086; Yan SD, 1997, NATURE, V389, P689; Yang AJ, 1998, J NEUROSCI RES, V52, P691, DOI 10.1002/(SICI)1097-4547(19980615)52:6<691::AID-JNR8>3.0.CO;2-3; Zhang Y, 2002, J CELL BIOL, V156, P519, DOI 10.1083/jcb.200110119	75	574	590	2	47	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2040	+		10.1096/fj.05-3735fje	http://dx.doi.org/10.1096/fj.05-3735fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16210396				2022-12-25	WOS:000232991100026
J	Kato, H; Ishida, J; Imagawa, S; Saito, T; Suzuki, N; Matsuoka, T; Sugaya, T; Tanimoto, K; Yokoo, T; Ohneda, O; Sugiyama, F; Yagami, K; Fujita, T; Yamamoto, M; Nangaku, M; Fukamizu, A				Kato, H; Ishida, J; Imagawa, S; Saito, T; Suzuki, N; Matsuoka, T; Sugaya, T; Tanimoto, K; Yokoo, T; Ohneda, O; Sugiyama, F; Yagami, K; Fujita, T; Yamamoto, M; Nangaku, M; Fukamizu, A			Enhanced erythropoiesis mediated by activation of the renin-angiotensin system via angiotensin II type 1a receptor	FASEB JOURNAL			English	Article						RAS; ANG II; erythropoietin	TISSUE-SPECIFIC REGULATION; RENAL-ARTERY STENOSIS; DEFICIENT MICE; ERYTHROID PROGENITORS; CELL TUMOR; EXPRESSION; ANEMIA; GENE; RATS; ERYTHROCYTOSIS	Although clinical and experimental studies have long suggested a role for the renin-angiotensin system (RAS) in the regulation of erythropoiesis, the molecular basis of this role has not been well understood. We report here that transgenic mice carrying both the human renin and human angiotensinogen genes displayed persistent erythrocytosis as well as hypertension. To identify the receptor molecule responsible for this phenotype, we introduced both transgenes into the AT1a receptor null background and found that the hematocrit level in the compound mice was restored to the normal level. Angiotensin II has been shown to influence erythropoiesis by two means, up-regulation of erythropoietin levels and direct stimulation of erythroid progenitor cells. Thus, we conducted bone marrow transplantation experiments and clarified that AT1a receptors on bone marrow-derived cells were dispensable for RAS-dependent erythrocytosis. Plasma erythropoietin levels and kidney erythropoietin mRNA expression in the double transgenic mice were significantly increased compared with those of the wild-type control, while the elevated plasma erythropoietin levels were significantly attenuated in the compound mice. These results provide clear genetic evidence that activated RAS enhances erythropoiesis through the AT1a receptor of kidney cells and that this effect is mediated by the elevation of plasma erythropoietin levels in vivo.	Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Div Hematol, Inst Clin Med, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Lab Anim Resource Ctr, Tsukuba, Ibaraki 3058577, Japan; Univ Tokyo, Sch Med, Div Nephrol & Endocrinol, Bunkyo Ku, Tokyo 1138655, Japan; Jikei Univ, Dept Internal Med, Sch Med, Div Nephrol & Hypertens,Minato Ku, Tokyo, Japan	University of Tsukuba; University of Tsukuba; University of Tsukuba; University of Tsukuba; University of Tokyo; Jikei University	Fukamizu, A (corresponding author), Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan.	akif@tara.tsukuba.ac.jp	Tanimoto, Keiji/B-2600-2014; Suzuki, Norio/F-3456-2010; Suzuki, Norio/AAZ-9458-2021	Suzuki, Norio/0000-0001-6100-3350; Tanimoto, Keiji/0000-0003-1971-6546				Albiston AL, 2001, J BIOL CHEM, V276, P48623, DOI 10.1074/jbc.C100512200; ANAGNOSTOU A, 1976, J LAB CLIN MED, V88, P707; Benohr P, 2004, NEPHRON EXP NEPHROL, V98, pE124, DOI 10.1159/000081556; Chikuma M, 2000, AM J PHYSIOL-ENDOC M, V279, pE1242, DOI 10.1152/ajpendo.2000.279.6.E1242; Coulthard MG, 2002, ARCH DIS CHILD, V86, P307, DOI 10.1136/adc.86.4.307; Crowley SD, 2004, ACTA PHYSIOL SCAND, V181, P561, DOI 10.1111/j.1365-201X.2004.01331.x; de la Grange PB, 2002, STEM CELLS, V20, P269, DOI 10.1634/stemcells.20-3-269; Ebert BL, 1999, BLOOD, V94, P1864; Fandrey J, 2004, AM J PHYSIOL-REG I, V286, pR977, DOI 10.1152/ajpregu.00577.2003; FISHER JW, 1967, J PHARMACOL EXP THER, V157, P618; Freudenthaler SM, 1999, EUR J CLIN INVEST, V29, P816; FRIED W, 1982, J LAB CLIN MED, V99, P520; FUKAMIZU A, 1993, J BIOL CHEM, V268, P11617; GOLDBERG MA, 1987, P NATL ACAD SCI USA, V84, P7972, DOI 10.1073/pnas.84.22.7972; Gossmann J, 2001, KIDNEY INT, V60, P83, DOI 10.1046/j.1523-1755.2001.00773.x; GOULD AB, 1973, LAB INVEST, V28, P719; GOULD AB, 1980, J LAB CLIN MED, V96, P523; Hartley C, 2003, BRIT J HAEMATOL, V122, P623, DOI 10.1046/j.1365-2141.2003.04467.x; Hisada Y, 2001, LAB INVEST, V81, P1243, DOI 10.1038/labinvest.3780338; HUDGSON P, 1967, BMJ-BRIT MED J, V1, P18, DOI 10.1136/bmj.1.5531.18; Lambert JF, 2000, J NEUROSCI METH, V95, P127, DOI 10.1016/S0165-0270(99)00157-0; Mrug M, 2004, SEMIN NEPHROL, V24, P120, DOI 10.1016/j.semnephrol.2003.11.006; Mrug M, 1997, J CLIN INVEST, V100, P2310, DOI 10.1172/JCI119769; Naeshiro I, 1998, EUR J PHARMACOL, V354, P179, DOI 10.1016/S0014-2999(98)00451-8; Nakano Y, 2004, BLOOD, V104, P4300, DOI 10.1182/blood-2004-04-1631; NAKAO K, 1967, BLOOD-J HEMATOL, V29, P754, DOI 10.1182/blood.V29.5.754.754; Nunia V, 2004, J RADIAT RES, V45, P11, DOI 10.1269/jrr.45.11; PESCHLE C, 1973, ENDOCRINOLOGY, V92, P358; REMYNSE LC, 1989, J UROLOGY, V142, P1560, DOI 10.1016/S0022-5347(17)39165-6; Rodgers KE, 2000, STEM CELLS, V18, P287, DOI 10.1634/stemcells.18-4-287; Santos RAS, 2003, P NATL ACAD SCI USA, V100, P8258, DOI 10.1073/pnas.1432869100; Stephen MR, 1998, J CLIN PATHOL, V51, P75, DOI 10.1136/jcp.51.1.75; SUGAYA T, 1995, J BIOL CHEM, V270, P18719, DOI 10.1074/jbc.270.32.18719; TAKASE K, 1995, ARZNEIMITTEL-FORSCH, V45-1, P15; TANIMOTO K, 1994, J BIOL CHEM, V269, P31334; VLAHAKOS DV, 1995, CLIN NEPHROL, V43, P53; Vlahakos DV, 2003, KIDNEY INT, V63, P1187, DOI 10.1046/j.1523-1755.2003.00850.x; Yanai K, 2000, J BIOL CHEM, V275, P5, DOI 10.1074/jbc.275.1.5; Yasuda Y, 1998, J BIOL CHEM, V273, P25381, DOI 10.1074/jbc.273.39.25381	39	89	99	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2023	+		10.1096/fj.05-3820fje	http://dx.doi.org/10.1096/fj.05-3820fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16223784				2022-12-25	WOS:000232991100021
J	Boraston, AB; Healey, M; Klassen, J; Ficko-Blean, E; van Bueren, AL; Law, V				Boraston, AB; Healey, M; Klassen, J; Ficko-Blean, E; van Bueren, AL; Law, V			A structural and functional analysis of alpha-glucan recognition by family 25 and 26 carbohydrate-binding modules reveals a conserved mode of starch recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPERGILLUS-NIGER GLUCOAMYLASE; LIGAND-BINDING; OLIGOSACCHARIDE RECOGNITION; NONCRYSTALLINE CELLULOSE; THERMOTOGA-MARITIMA; CRYSTAL-STRUCTURE; DOMAIN; AMYLASE; THERMODYNAMICS; COEFFICIENTS	Starch-hydrolyzing enzymes lacking alpha-glucan-specific carbohydrate-binding modules (CBMs) typically have lowered activity on granular starch relative to their counterparts with CBMs. Thus, consideration of starch recognition by CBMs is a key factor in understanding granular starch hydrolysis. To this end, we have dissected the modular structure of the maltohexaose-forming amylase from Bacillus halodurans (C-125). This five-module protein comprises an N-terminal family 13 catalytic module followed in order by two modules of unknown function, a family 26 CBM (BhCBM26), and a family 25 CBM(BhCBM25). Here we present a comprehensive structure-function analysis of starch and alpha-glucooligosaccharide recognition by BhCBM25 and BhCBM26 using UV methods, isothermal titration calorimetry, and x-ray crystallography. The results reveal that the two CBMs bind alpha-glucooligosaccharides, particularly those containing alpha-1,6 linkages, with different affinities but have similar abilities to bind granular starch. Notably, these CBMs appear to recognize the same binding sites in granular starch. The enhanced affinity of the tandem CBMs for granular starch is suggested to be the main biological advantage for this enzyme to contain two CBMs. Structural studies of the native and ligand-bound forms of BhCBM25 and BhCBM26 show a structurally conserved mode of ligand recognition but through non-sequence-conserved residues. Comparison of these CBM structures with other starch-specific CBM structures reveals a generally conserved mode of starch recognition.	Univ Victoria, Victoria, BC V8W 3P6, Canada	University of Victoria	Boraston, AB (corresponding author), Univ Victoria, POB 3055 STN CSC, Victoria, BC V8W 3P6, Canada.	boraston@uvic.ca	Klassen, Jonathan/B-5060-2010; Ficko-Blean, Elizabeth/N-1746-2013	Klassen, Jonathan/0000-0003-1745-8838; Boraston, Alisdair/0000-0001-6417-0592				Abe A, 2004, J MOL BIOL, V335, P811, DOI 10.1016/j.jmb.2003.10.078; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bolam DN, 2001, BIOCHEMISTRY-US, V40, P2468, DOI 10.1021/bi002564l; Bolam DN, 1998, BIOCHEM J, V331, P775, DOI 10.1042/bj3310775; Boraston AB, 2003, J BIOL CHEM, V278, P6120, DOI 10.1074/jbc.M209554200; Boraston AB, 2002, J MOL BIOL, V319, P1143, DOI 10.1016/S0022-2836(02)00374-1; Boraston AB, 2002, MOL MICROBIOL, V43, P187, DOI 10.1046/j.1365-2958.2002.02730.x; Boraston AB, 2001, BIOCHEMISTRY-US, V40, P6240, DOI 10.1021/bi0101695; Boraston AB, 2001, BIOCHEMISTRY-US, V40, P14679, DOI 10.1021/bi015760g; Boraston AB, 2004, BIOCHEM J, V382, P769, DOI 10.1042/BJ20040892; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Buleon A, 1998, INT J BIOL MACROMOL, V23, P85, DOI 10.1016/S0141-8130(98)00040-3; Cowtan KD, 1999, PROG BIOPHYS MOL BIO, V72, P245, DOI 10.1016/S0079-6107(99)00008-5; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Evans G, 2002, ACTA CRYSTALLOGR D, V58, P976, DOI 10.1107/S0907444902005486; Giardina T, 2001, J MOL BIOL, V313, P1149, DOI 10.1006/jmbi.2001.5097; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HALL J, 1995, BIOCHEM J, V309, P749, DOI 10.1042/bj3090749; Hashim SO, 2005, ENZYME MICROB TECH, V36, P139, DOI 10.1016/j.enzmictec.2004.07.017; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Jamal S, 2004, J MOL BIOL, V339, P253, DOI 10.1016/j.jmb.2004.03.069; Jamal-Talabani S, 2004, STRUCTURE, V12, P1177, DOI 10.1016/j.str.2004.04.022; Kamitori S, 1999, J MOL BIOL, V287, P907, DOI 10.1006/jmbi.1999.2647; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; MAGLIONE G, 1992, APPL ENVIRON MICROB, V58, P3593, DOI 10.1128/AEM.58.11.3593-3597.1992; MCLEAN BW, 2002, J BIOL CHEM; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Notenboom V, 2001, J MOL BIOL, V314, P797, DOI 10.1006/jmbi.2001.5153; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; SHIROKIZAWA O, 1990, FEMS MICROBIOL LETT, V70, P131, DOI 10.1016/S0378-1097(05)80026-6; SIGURSKJOLD BW, 1994, EUR J BIOCHEM, V225, P133, DOI 10.1111/j.1432-1033.1994.00133.x; Sorimachi K, 1997, STRUCTURE, V5, P647, DOI 10.1016/S0969-2126(97)00220-7; Sorimachi K, 1996, J MOL BIOL, V259, P970, DOI 10.1006/jmbi.1996.0374; Southall SM, 1999, FEBS LETT, V447, P58, DOI 10.1016/S0014-5793(99)00263-X; Sumitani J, 2000, BIOCHEM J, V350, P477, DOI 10.1042/0264-6021:3500477; TOMME P, 1988, EUR J BIOCHEM, V170, P575, DOI 10.1111/j.1432-1033.1988.tb13736.x; Tunnicliffe RB, 2005, J MOL BIOL, V347, P287, DOI 10.1016/j.jmb.2005.01.038; van Bueren AL, 2005, J BIOL CHEM, V280, P530, DOI 10.1074/jbc.M410113200; van Bueren AL, 2004, J MOL BIOL, V340, P869, DOI 10.1016/j.jbm.2004.05.038; van Bueren AL, 2004, BIOCHEMISTRY-US, V43, P15633, DOI 10.1021/bi048215z; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	44	79	80	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					587	598		10.1074/jbc.M509958200	http://dx.doi.org/10.1074/jbc.M509958200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16230347	hybrid			2022-12-25	WOS:000234307200071
J	Miller, CT; Lin, L; Casper, AM; Lim, J; Thomas, DG; Orringer, MB; Chang, AC; Chambers, AF; Giordano, TJ; Glover, TW; Beer, DG				Miller, CT; Lin, L; Casper, AM; Lim, J; Thomas, DG; Orringer, MB; Chang, AC; Chambers, AF; Giordano, TJ; Glover, TW; Beer, DG			Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma	ONCOGENE			English	Article						MET oncogene; esophageal adenocarcinoma; gene amplification; FRA7G	RECEPTOR TYROSINE KINASE; BREAST-CANCER CELLS; LUNG ADENOCARCINOMAS; GENE AMPLIFICATION; ANTITUMOR-ACTIVITY; UNITED-STATES; GROWTH; TUMOR; OVEREXPRESSION; DYSPLASIA	Esophageal adenocarcinoma (EA) is characterized by a poor prognosis making the identification of clinically targetable proteins essential for improving patient outcome. We report the involvement of multiple alterations of the MET pathway in EA development and progression. Microarray analysis of Barrett's metaplasia, dysplasia, and EA revealed overexpression of the MET oncogene in EAs but only those with MET gene amplication. STS-amplication mapping revealed that the boundary of the MET amplicon in these EAs is defined by fragile site FRA7G. We also identified an amplicon at 11p13 that resulted in amplication and overexpression of CD44, a gene involved in MET autophosphorylation upon HGF stimulation. Tissue microarrays with phospho-MET-specific antibodies demonstrated a uniformly high abundance of MET activation in primary EA and cells metastatic to lymph nodes but to a lesser extent in a subset of metaplastic and dysplastic Barrett's samples. Increased expression of multiple genes in the MET pathway associated with invasive growth, for example, many MMPs and osteopontin, also was found in EAs. Treatment of EA-derived cell lines with geldanamycin, an inhibitor for tyrosine kinases including MET receptor kinase, reduced cell migration and induced EA cell apoptosis. The data indicate that upregulation of the MET pathway may contribute to the poor outcome of EA patients and that therapeutic agents targeting this pathway may help improve patient survival.	Univ Michigan, Sch Med, Dept Surg, Sect Gen Thorac Surg, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; London Reg Canc Ctr, Dept Oncol, London, England	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Beer, DG (corresponding author), Univ Michigan, Sch Med, Dept Surg, Sect Gen Thorac Surg, MSRB 2 B560,Box 0686, Ann Arbor, MI 48109 USA.	dgbeer@umich.edu	Chambers, Ann F/L-6285-2015	Chambers, Ann F/0000-0002-9509-5123; Giordano, Thomas/0000-0003-0641-8873; Chang, Andrew/0000-0001-9506-0425; Casper, Anne/0000-0003-4975-5749	NATIONAL CANCER INSTITUTE [R01CA071606, R01CA043222] Funding Source: NIH RePORTER; NCI NIH HHS [CA43222, CA71606] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arlt MF, 2003, CYTOGENET GENOME RES, V100, P92, DOI 10.1159/000072843; Barrett MT, 1999, NAT GENET, V22, P106, DOI 10.1038/8816; Blagosklonny MV, 2002, LEUKEMIA, V16, P455, DOI 10.1038/sj.leu.2402415; BLOUNT PL, 1993, P NATL ACAD SCI USA, V90, P3221, DOI 10.1073/pnas.90.8.3221; Briggs J, 2002, ONCOGENE, V21, P7077, DOI 10.1038/sj.onc.1205857; Cao B, 2001, P NATL ACAD SCI USA, V98, P7443, DOI 10.1073/pnas.131200498; Christensen JG, 2003, CANCER RES, V63, P7345; Ciullo M, 2002, HUM MOL GENET, V11, P2887, DOI 10.1093/hmg/11.23.2887; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; Devesa SS, 1998, CANCER, V83, P2049, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.0.CO;2-2; Eliceiri BP, 2001, CIRC RES, V89, P1104, DOI 10.1161/hh2401.101084; Farrow DC, 1996, CANCER CAUSE CONTROL, V7, P322, DOI 10.1007/BF00052937; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; Fukuda Y, 2000, GENE CHROMOSOME CANC, V29, P315, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1047>3.0.CO;2-E; Gonzalez MV, 1997, J CLIN PATHOL, V50, P212, DOI 10.1136/jcp.50.3.212; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hellman A, 2002, CANCER CELL, V1, P89, DOI 10.1016/S1535-6108(02)00017-X; Huang NN, 1998, J CHIN INST ENG, V21, P159, DOI 10.1080/02533839.1998.9670381; Hughes SJ, 1998, P NATL ACAD SCI USA, V95, P12410, DOI 10.1073/pnas.95.21.12410; Hughes SJ, 1997, CANCER RES, V57, P5571; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Kim SJ, 2003, CLIN CANCER RES, V9, P5161; Kong-Beltran M, 2004, CANCER CELL, V6, P75, DOI 10.1016/j.ccr.2004.06.013; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Lin J, 2004, CLIN CANCER RES, V10, P5708, DOI 10.1158/1078-0432.CCR-04-0468; Lin L, 2000, CANCER RES, V60, P1341; Lin L, 2002, CANCER RES, V62, P5273; Matsuyama A, 2003, P NATL ACAD SCI USA, V100, P14988, DOI 10.1073/pnas.2336256100; Michieli P, 2004, CANCER CELL, V6, P61, DOI 10.1016/j.ccr.2004.05.032; Miller CT, 2003, CLIN CANCER RES, V9, P4819; Miller CT, 2003, CANCER RES, V63, P4136; NALDINI L, 1991, EMBO J, V10, P2857; Orian-Rousseau V, 2002, GENE DEV, V16, P3074, DOI 10.1101/gad.242602; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Recio JA, 2003, CANCER RES, V63, P1576; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; Rosenberg C, 2002, CANCER GENET CYTOGEN, V135, P35, DOI 10.1016/S0165-4608(01)00639-2; Sage EH, 2003, J BIOL CHEM, V278, P37849, DOI 10.1074/jbc.M302946200; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Weber GF, 2002, CANCER RES, V62, P2281; Weber GF, 2001, BBA-REV CANCER, V1552, P61, DOI 10.1016/S0304-419X(01)00037-3; Wong DJ, 1997, CANCER RES, V57, P2619; Zhang YW, 2003, J CELL BIOCHEM, V88, P408, DOI 10.1002/jcb.10358; Zhang YW, 2004, CANCER CELL, V6, P5, DOI 10.1016/j.ccr.2004.07.003	47	126	137	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					409	418		10.1038/sj.onc.1209057	http://dx.doi.org/10.1038/sj.onc.1209057			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16186806				2022-12-25	WOS:000234714100009
J	Bouazoune, K; Brehm, A				Bouazoune, K; Brehm, A			dMi-2 chromatin binding and remodeling activities are regulated by dCK2 phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; HISTONE DEACETYLASE; NURD-COMPLEX; CELL FATE; PROTEIN; SUBUNIT; ISWI; COMPONENTS; INTERACTS; MI-2/NURD	(A) plethora of ATP-dependent chromatin-remodeling enzymes have been identified during the last decade. Many have been shown to play pivotal roles in the organization and expression of eukaryotic genomes. It is clear that their activities need to be tightly regulated to ensure their coordinated action. However, little is known about how ATP-dependent remodelers are regulated at the molecular level. Here, we have investigated the ATP-dependent chromatin remodeling enzyme Mi-2 of Drosophila melanogaster. Radioactive labeling of S2 cells reveals that dMi-2 is a phosphoprotein in vivo. dMi-2 phosphorylation is constitutive, and we identify dCK2 as a major dMi-2 kinase in cell extracts. dCK2 binds to and phosphorylates a dMi-2 N-terminal region. Dephosphorylation of recombinant dMi-2 increases its affinity for the nucleosome substrate, nucleosome-stimulated ATPase, and ATP-dependent nucleosome mobilization activities. Our results reveal a potential mechanism for regulation of the dMi-2 enzyme and point toward CK2 phosphorylation as a common feature of CHD family ATPases.	Univ Munich, Adolf Butenandt Inst, Lehrstuhl Molekularbiol, D-80336 Munich, Germany	University of Munich	Brehm, A (corresponding author), Univ Munich, Adolf Butenandt Inst, Lehrstuhl Molekularbiol, Schillerstr 44, D-80336 Munich, Germany.	abrehm@lmu.de		Bouazoune, Karim/0000-0002-5766-679X				Beausoleil SA, 2004, P NATL ACAD SCI USA, V101, P12130, DOI 10.1073/pnas.0404720101; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BIDWAI AP, 1992, J BIOL CHEM, V267, P18790; Bouazoune K, 2002, EMBO J, V21, P2430, DOI 10.1093/emboj/21.10.2430; Bowen NJ, 2004, BBA-GENE STRUCT EXPR, V1677, P52, DOI 10.1016/j.bbaexp.2003.10.010; Brehm A, 2000, EMBO J, V19, P4332, DOI 10.1093/emboj/19.16.4332; Corona DFV, 2002, EMBO REP, V3, P242, DOI 10.1093/embo-reports/kvf056; Eberharter A, 2004, EMBO J, V23, P4029, DOI 10.1038/sj.emboj.7600382; Eberharter A, 2004, J CELL SCI, V117, P3707, DOI 10.1242/jcs.01175; Eberharter A, 2004, METHOD ENZYMOL, V377, P344; Eberharter A, 2001, EMBO J, V20, P3781, DOI 10.1093/emboj/20.14.3781; Feng Q, 2001, GENE DEV, V15, P827; Ficarro SB, 2002, NAT BIOTECHNOL, V20, P301, DOI 10.1038/nbt0302-301; Fujita N, 2004, CELL, V119, P75, DOI 10.1016/j.cell.2004.09.014; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; Grune T, 2003, MOL CELL, V12, P449, DOI 10.1016/S1097-2765(03)00273-9; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; Hassan AH, 2002, CELL, V111, P369, DOI 10.1016/S0092-8674(02)01005-X; Hong W, 2005, EMBO J, V24, P2367, DOI 10.1038/sj.emboj.7600703; Jeong SY, 2004, PLANTA, V219, P298, DOI 10.1007/s00425-004-1215-8; Jiang CL, 2004, J BIOL CHEM, V279, P52456, DOI 10.1074/jbc.M409149200; Jin SG, 2005, J BIOL CHEM, V280, P12700, DOI 10.1074/jbc.M413492200; Kehle J, 1998, SCIENCE, V282, P1897, DOI 10.1126/science.282.5395.1897; Koipally J, 1999, COLD SPRING HARB SYM, V64, P79, DOI 10.1101/sqb.1999.64.79; Langst G, 1999, CELL, V97, P843, DOI 10.1016/S0092-8674(00)80797-7; LEHNER CF, 1990, EMBO J, V9, P3573, DOI 10.1002/j.1460-2075.1990.tb07568.x; Li JW, 2002, GENE DEV, V16, P687, DOI 10.1101/gad.962502; Li YP, 2005, J BIOL CHEM, V280, P11869, DOI 10.1074/jbc.M413944200; MANAK JR, 1991, MOL CELL BIOL, V11, P3652, DOI 10.1128/MCB.11.7.3652; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; Muchardt C, 1996, EMBO J, V15, P3394, DOI 10.1002/j.1460-2075.1996.tb00705.x; Murawsky CM, 2001, EMBO REP, V2, P1089, DOI 10.1093/embo-reports/kve252; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Pray-Grant MG, 2005, NATURE, V433, P434, DOI 10.1038/nature03242; Rodriguez P, 2005, EMBO J, V24, P2354, DOI 10.1038/sj.emboj.7600702; Shen XT, 2000, NATURE, V406, P541, DOI 10.1038/35020123; Shen XT, 2003, SCIENCE, V299, P112, DOI 10.1126/science.1078068; Sif S, 1998, GENE DEV, V12, P2842, DOI 10.1101/gad.12.18.2842; Solari F, 2000, CURR BIOL, V10, P223, DOI 10.1016/S0960-9822(00)00343-2; Srinivasan S, 2005, DEVELOPMENT, V132, P1623, DOI 10.1242/dev.01713; Steger DJ, 2003, SCIENCE, V299, P114, DOI 10.1126/science.1078062; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Tsai SC, 2002, J BIOL CHEM, V277, P31826, DOI 10.1074/jbc.M204149200; Unhavaithaya Y, 2002, CELL, V111, P991, DOI 10.1016/S0092-8674(02)01202-3; von Zelewsky T, 2000, DEVELOPMENT, V127, P5277; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Wang HB, 2001, NUCLEIC ACIDS RES, V29, P2517, DOI 10.1093/nar/29.12.2517; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yang YH, 2002, GENE DEV, V16, P994, DOI 10.1101/gad.965102; Yoo EJ, 2000, NUCLEIC ACIDS RES, V28, P2004, DOI 10.1093/nar/28.9.2004; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	54	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					41912	41920		10.1074/jbc.M507084200	http://dx.doi.org/10.1074/jbc.M507084200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16223721	hybrid			2022-12-25	WOS:000233992700017
J	Garcia, AL; Han, SK; Janssen, WG; Khaing, ZZ; Ito, T; Glucksman, MJ; Benson, DL; Salton, SRJ				Garcia, AL; Han, SK; Janssen, WG; Khaing, ZZ; Ito, T; Glucksman, MJ; Benson, DL; Salton, SRJ			A prohormone convertase cleavage site within a predicted alpha-helix mediates sorting of the neuronal and endocrine polypeptide VGF into the regulated secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; GREEN FLUORESCENT PROTEIN; DISULFIDE-BONDED LOOP; TRANS-GOLGI NETWORK; CARBOXYPEPTIDASE-E; CHROMOGRANIN-A; CELL-LINES; CPE(FAT)/CPE(FAT) MICE; RECEPTOR/CA2+ CHANNEL; INDEPENDENT PATHWAY	Distinct intracellular pathways are involved in regulated and constitutive protein secretion from neuronal and endocrine cells, yet the peptide signals and molecular mechanisms responsible for targeting and retention of soluble proteins in secretory granules are incompletely understood. By using confocal microscopy and subcellular fractionation, we examined trafficking of the neuronal and endocrine peptide precursor VGF that is stored in large dense core vesicles and undergoes regulated secretion. VGF cofractionated with secretory vesicle membranes but was not detected in detergent-resistant lipid rafts. Deletional analysis using epitope-tagged VGF suggested that the C-terminal 73-amino acid fragment of VGF, containing two predicted alpha-helical loops and four potential prohormone convertase ( PC) cleavage sites, was necessary and sufficient with an N-terminal signal peptide-containing domain, for large dense core vesicle sorting and regulated secretion from PC12 and INS-1 cells. Further transfection analysis identified the sorting sequence as a compact C-terminal alpha-helix and embedded (RRR566)-R-564 PC cleavage site; mutation of the (RRR566)-R-564 PC site in VGF-(1-65): GFP:VGF-(545-617) blocked regulated secretion, whereas disruption of the alpha-helix had no effect. Mutation of the adjacent (HFHH570)-H-567 motif, a charged region that might enhance PC cleavage in acidic environments, also blocked regulated release. Finally, inhibition of PC cleavage in PC12 cells using the membrane-permeable synthetic peptide chloromethyl ketone (decanoyl-RVKR-CMK) blocked regulated secretion of VGF. Our studies define a critical RRR-containing C-terminal domain that targets VGF into the regulated pathway in neuronal PC12 and endocrine INS-1 cells, providing additional support for the proposed role that PCs and their cleavage sites play in regulated peptide secretion.	Mt Sinai Sch Med, Fishberg Dept Neurosci, New York, NY 10029 USA; Mt Sinai Sch Med, Kastor Neurobiol Aging Labs, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Geriatr, New York, NY 10029 USA; Rosalind Franklin Univ Med & Sci, Midw Proteome Ctr, N Chicago, IL 60064 USA; Rosalind Franklin Univ Med & Sci, Dept Biochem & Mol Biol, N Chicago, IL 60064 USA; Chicago Med Sch, N Chicago, IL 60064 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Rosalind Franklin University Medical & Science; Rosalind Franklin University Medical & Science; Chicago Medical School	Salton, SRJ (corresponding author), Mt Sinai Sch Med, Fishberg Dept Neurosci, Box 1065,1 Gustave L Levy Pl, New York, NY 10029 USA.	stephen.salton@mssm.edu		Khaing, Zin/0000-0001-5652-5891; Benson, Deanna/0000-0001-7037-1147; Salton, Stephen/0000-0003-4087-8427	NCRR NIH HHS [S10 RR19325, 1 S10 RR09145-01] Funding Source: Medline; NIDDK NIH HHS [DK57702, DK071308] Funding Source: Medline; NINDS NIH HHS [R01 NS037731-06, NS45305, R01 NS037731-05A1, R01 NS050634, R01 NS037731-07, R01 NS037731, R01 NS037731-08] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR019325, S10RR009145] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK071308, R01DK057702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037731, R01NS045305, R01NS050634] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alder J, 2003, J NEUROSCI, V23, P10800; Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Barbero P, 1998, J BIOL CHEM, V273, P25339, DOI 10.1074/jbc.273.39.25339; BENSON DL, 1994, J NEUROCYTOL, V23, P279, DOI 10.1007/BF01188497; Benson DL, 1996, DEV BRAIN RES, V96, P219, DOI 10.1016/0165-3806(96)00108-3; BenTal N, 1996, BIOPHYS J, V71, P561, DOI 10.1016/S0006-3495(96)79280-9; Bergeron E, 2003, BIOCHEM J, V373, P475, DOI 10.1042/BJ20021630; Bernard N, 2003, J NEUROCHEM, V85, P1592, DOI 10.1046/j.1471-4159.2003.01823.x; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Blazquez M, 2000, BIOCHEM J, V349, P843, DOI 10.1042/bj3490843; Brakch N, 2002, J NEUROCHEM, V81, P1166, DOI 10.1046/j.1471-4159.2002.00919.x; Brechler V, 1996, J BIOL CHEM, V271, P20636, DOI 10.1074/jbc.271.34.20636; Bredt DS, 1998, CELL, V94, P691, DOI 10.1016/S0092-8674(00)81727-4; Bundgaard JR, 2004, J BIOL CHEM, V279, P5488, DOI 10.1074/jbc.M310547200; CHANAT E, 1993, EMBO J, V12, P2159, DOI 10.1002/j.1460-2075.1993.tb05864.x; Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7; Cowley DJ, 2000, J BIOL CHEM, V275, P7743, DOI 10.1074/jbc.275.11.7743; Dannies PS, 1999, ENDOCR REV, V20, P3, DOI 10.1210/er.20.1.3; de Bree FM, 2000, FEBS LETT, V475, P175, DOI 10.1016/S0014-5793(00)01623-9; DeLisle RC, 1996, EUR J CELL BIOL, V71, P62; Dhanvantari S, 2000, J BIOL CHEM, V275, P29887, DOI 10.1074/jbc.M005364200; Dickson TC, 2002, J CELL BIOL, V157, P1105, DOI 10.1083/jcb.200111076; Eagleson KL, 2001, J NEUROSCI, V21, P9315, DOI 10.1523/JNEUROSCI.21-23-09315.2001; El Meskini R, 2001, ENDOCRINOLOGY, V142, P864, DOI 10.1210/endo.142.2.7929; Fasciotto BH, 2002, REGUL PEPTIDES, V103, P53, DOI 10.1016/S0167-0115(01)00328-7; Feliciangeli S, 2002, BIOCHEM BIOPH RES CO, V290, P191, DOI 10.1006/bbrc.2001.6137; Feliciangeli S, 2001, J BIOL CHEM, V276, P6140, DOI 10.1074/jbc.M009613200; GALANOPOULOU AS, 1993, J BIOL CHEM, V268, P6041; Gentile F, 2004, EXP CELL RES, V295, P269, DOI 10.1016/j.yexcr.2004.01.010; Glombik MM, 1999, EMBO J, V18, P1059, DOI 10.1093/emboj/18.4.1059; Gorr SU, 1999, BIOCHEM BIOPH RES CO, V257, P545, DOI 10.1006/bbrc.1999.0504; Gorr SU, 1999, AM J PHYSIOL-CELL PH, V277, pC121, DOI 10.1152/ajpcell.1999.277.1.C121; Gorr SU, 2001, MOL CELL ENDOCRINOL, V172, P1, DOI 10.1016/S0303-7207(00)00342-7; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9; Hahm S, 1999, NEURON, V23, P537, DOI 10.1016/S0896-6273(00)80806-5; Hahm S, 2002, J NEUROSCI, V22, P6929; Irminger JC, 1997, J BIOL CHEM, V272, P27532, DOI 10.1074/jbc.272.44.27532; Jain RK, 2001, BIOCHEM J, V360, P645, DOI 10.1042/0264-6021:3600645; Jutras I, 2000, J BIOL CHEM, V275, P40337, DOI 10.1074/jbc.M004757200; Kromer A, 1998, J CELL BIOL, V140, P1331, DOI 10.1083/jcb.140.6.1331; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVI A, 1985, SCIENCE, V229, P393, DOI 10.1126/science.3839317; LINDBERG I, 1994, MOL CELL NEUROSCI, V5, P614, DOI 10.1006/mcne.1994.1075; Lopez-Perez E, 2001, J NEUROCHEM, V76, P1532, DOI 10.1046/j.1471-4159.2001.00180.x; Lou H, 2005, NEURON, V45, P245, DOI 10.1016/j.neuron.2004.12.037; Molinete M, 2000, DIABETOLOGIA, V43, P1157, DOI 10.1007/s001250051507; Morrow IC, 2002, J BIOL CHEM, V277, P48834, DOI 10.1074/jbc.M209082200; Mouchantaf R, 2001, J BIOL CHEM, V276, P26308, DOI 10.1074/jbc.M102514200; Murray D, 1999, BIOPHYS J, V77, P3176, DOI 10.1016/S0006-3495(99)77148-1; Mzhavia N, 2002, BIOCHEM J, V361, P67, DOI 10.1042/0264-6021:3610067; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Normant E, 1998, ENDOCRINOLOGY, V139, P2137, DOI 10.1210/en.139.4.2137; POSSENTI R, 1989, EMBO J, V8, P2217, DOI 10.1002/j.1460-2075.1989.tb08345.x; Possenti R, 1999, ENDOCRINOLOGY, V140, P3727, DOI 10.1210/en.140.8.3727; Pouli AE, 1998, BIOCHEM J, V331, P669, DOI 10.1042/bj3310669; SALTON SRJ, 1991, MOL CELL BIOL, V11, P2335, DOI 10.1128/MCB.11.5.2335; SALTON SRJ, 1991, J NEUROCHEM, V57, P991, DOI 10.1111/j.1471-4159.1991.tb08248.x; Salton SRJ, 2000, FRONT NEUROENDOCRIN, V21, P199, DOI 10.1006/frne.2000.0199; SALTON SRJ, 1995, FEBS LETT, V360, P106, DOI 10.1016/0014-5793(95)00086-O; Sato T, 1999, J BIOL CHEM, V274, P37280, DOI 10.1074/jbc.274.52.37280; SCHWARZENBRUNNER U, 1990, NEUROSCIENCE, V37, P819, DOI 10.1016/0306-4522(90)90111-G; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Seidah NG, 1998, ANN NY ACAD SCI, V839, P9, DOI 10.1111/j.1749-6632.1998.tb10727.x; Seidah NG, 1996, P NATL ACAD SCI USA, V93, P3388, DOI 10.1073/pnas.93.8.3388; Stark M, 2001, J CHROMATOGR B, V754, P357, DOI 10.1016/S0378-4347(00)00628-9; Thiele C, 1997, CURR BIOL, V7, P496; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Tooze SA, 2001, TRENDS CELL BIOL, V11, P116, DOI 10.1016/S0962-8924(00)01907-3; Trani E, 2002, J NEUROCHEM, V81, P565, DOI 10.1046/j.1471-4159.2002.00842.x; Varlamov O, 1997, ENDOCRINOLOGY, V138, P4883, DOI 10.1210/en.138.11.4883; Varoqui H, 1998, J BIOL CHEM, V273, P9094, DOI 10.1074/jbc.273.15.9094; Yoo SH, 2002, J BIOL CHEM, V277, P16011, DOI 10.1074/jbc.M105594200; Yoo SH, 2001, J BIOL CHEM, V276, P45806, DOI 10.1074/jbc.M107532200; Yoo SH, 2000, TRENDS NEUROSCI, V23, P424, DOI 10.1016/S0166-2236(00)01621-0; Zhang CF, 2003, BIOCHEM J, V369, P453, DOI 10.1042/BJ20020827	77	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41595	41608		10.1074/jbc.M509122200	http://dx.doi.org/10.1074/jbc.M509122200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16221685	hybrid			2022-12-25	WOS:000233866900060
J	Jensen, LT; Culotta, VC				Jensen, LT; Culotta, VC			Activation of CuZn superoxide dismutases from Caenorhabditis elegans does not require the copper chaperone CCS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CU,ZN-SUPEROXIDE DISMUTASE; PROTEIN OXIDATION; GENE; OXYGEN; SOD1; EXPRESSION; METALLOCHAPERONE; MITOCHONDRIA; CLONING; DISEASE	Reactive oxygen species are produced as the direct result of aerobic metabolism and can cause damage to DNA, proteins, and lipids. A principal defense against reactive oxygen species involves the superoxide dismutases (SOD) that act to detoxify superoxide anions. Activation of CuZn-SODs in eukaryotic cells occurs posttranslationally and is generally dependent on the copper chaperone for SOD1 (CCS), which inserts the catalytic copper cofactor and catalyzes the oxidation of a conserved disulfide bond that is essential for activity. In contrast to other eukaryotes, the nematode Caenorhabditis elegans does not contain an obvious CCS homologue, and we have found that the C. elegans intracellular CuZn-SODs (wSOD-1 and wSOD-5) are not dependent on CCS for activation when expressed in Saccharomyces cerevisiae. CCS-independent activation of CuZn-SODs is not unique to C. elegans; however, this is the first organism identified that appears to exclusively use this alternative pathway. As was found for mammalian SOD1, wSOD-1 exhibits a requirement for reduced glutathione in CCS-independent activation. Unexpectedly, wSOD-1 was inactive even in the presence of CCS when glutathione was depleted. Our investigation of the cysteine residues that form the disulfide bond in wSOD-1 suggests that the ability of wSODs to readily form this disulfide bond may be the key to obtaining high levels of activation through the CCS-independent pathway. Overall, these studies demonstrate that the CuZn-SODs of C. elegans have uniquely evolved to acquire copper without the copper chaperone and this may reflect the lifestyle of this organism.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Jensen, LT (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, 615 N Wolfe St,Rm W7032, Baltimore, MD 21205 USA.	ljensen@jhsph.edu		Jensen, Laran/0000-0003-3199-1743	NIGMS NIH HHS [GM50016] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050016, R37GM050016] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abdel-Ghany SE, 2005, FEBS LETT, V579, P2307, DOI 10.1016/j.febslet.2005.03.025; Arnesano F, 2004, J BIOL CHEM, V279, P47998, DOI 10.1074/jbc.M406021200; Bartnikas TB, 2003, J BIOL CHEM, V278, P33602, DOI 10.1074/jbc.M305435200; Beckman JS, 2002, FREE RADICAL BIO MED, V33, P1433, DOI 10.1016/S0891-5849(02)01092-4; Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; BERTINI I, 1994, EUR BIOPHYS J BIOPHY, V23, P167, DOI 10.1007/BF01007608; BLUM J, 1983, ARCH BIOCHEM BIOPHYS, V222, P35, DOI 10.1016/0003-9861(83)90499-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown NM, 2004, P NATL ACAD SCI USA, V101, P5518, DOI 10.1073/pnas.0401175101; Carroll MC, 2004, P NATL ACAD SCI USA, V101, P5964, DOI 10.1073/pnas.0308298101; Casareno RLB, 1998, J BIOL CHEM, V273, P23625, DOI 10.1074/jbc.273.37.23625; CIRIOLO MR, 1990, J BIOL CHEM, V265, P11030; CRAPO JD, 1992, P NATL ACAD SCI USA, V89, P10405, DOI 10.1073/pnas.89.21.10405; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; Doucette PA, 2004, J BIOL CHEM, V279, P54558, DOI 10.1074/jbc.M409744200; Field LS, 2003, J BIOL CHEM, V278, P28052, DOI 10.1074/jbc.M304296200; FLOHE L, 1984, METHOD ENZYMOL, V105, P93; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; FRIDOVICH I, 1983, ANNU REV PHARMACOL, V23, P239, DOI 10.1146/annurev.pa.23.040183.001323; Fujii M, 1998, DNA Res, V5, P25, DOI 10.1093/dnares/5.1.25; Furukawa Y, 2004, EMBO J, V23, P2872, DOI 10.1038/sj.emboj.7600276; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; HALLIWELL B, 1994, LANCET, V344, P721, DOI 10.1016/S0140-6736(94)92211-X; Hiromura M, 2000, BIOCHEM BIOPH RES CO, V275, P394, DOI 10.1006/bbrc.2000.3328; HJALMARSSON K, 1987, P NATL ACAD SCI USA, V84, P6340, DOI 10.1073/pnas.84.18.6340; Hunter T, 1997, J BIOL CHEM, V272, P28652, DOI 10.1074/jbc.272.45.28652; JIN JP, 1995, J BIOL CHEM, V270, P6908; Laliberte J, 2004, J BIOL CHEM, V279, P28744, DOI 10.1074/jbc.M403426200; Lamb AL, 2000, BIOCHEMISTRY-US, V39, P14720, DOI 10.1021/bi002207a; Lapinskas PJ, 1996, MOL MICROBIOL, V21, P519, DOI 10.1111/j.1365-2958.1996.tb02561.x; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; Lin SJ, 1997, J BIOL CHEM, V272, P9215; LIU XF, 1992, J BIOL CHEM, V267, P18298; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Lyons TJ, 1998, J BIOL INORG CHEM, V3, P650, DOI 10.1007/s007750050279; MARKLUND SL, 1982, P NATL ACAD SCI-BIOL, V79, P7634, DOI 10.1073/pnas.79.24.7634; MARRES CAM, 1985, EUR J BIOCHEM, V147, P153, DOI 10.1111/j.1432-1033.1985.tb08731.x; Moore SDP, 2000, CYTOGENET CELL GENET, V88, P35, DOI 10.1159/000015480; Okado-Matsumoto A, 2001, J BIOL CHEM, V276, P38388, DOI 10.1074/jbc.M105395200; Ostergaard H, 2004, J CELL BIOL, V166, P337, DOI 10.1083/jcb.200402120; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rae TD, 2001, J BIOL CHEM, V276, P5166, DOI 10.1074/jbc.M008005200; Schmidt PJ, 2000, J BIOL CHEM, V275, P33771, DOI 10.1074/jbc.M006254200; Schmidt PJ, 1999, J BIOL CHEM, V274, P36952, DOI 10.1074/jbc.274.52.36952; Sherman F., 1978, METHODS YEAST GENETI; Slekar KH, 1996, J BIOL CHEM, V271, P28831, DOI 10.1074/jbc.271.46.28831; Stadtman ER, 2000, ANN NY ACAD SCI, V899, P191; Stadtman ER, 1997, CHEM RES TOXICOL, V10, P485, DOI 10.1021/tx960133r; Sturtz LA, 2001, J BIOL CHEM, V276, P38084; Subramaniam JR, 2002, NAT NEUROSCI, V5, P301, DOI 10.1038/nn823; Suzuki N, 1996, DNA Res, V3, P171, DOI 10.1093/dnares/3.3.171; Trindade LM, 2003, PLANT PHYSIOL, V133, P618, DOI 10.1104/pp.103.025320; Van Voorhies WA, 2000, J EXP BIOL, V203, P2467; Wakabayashi T, 1998, FEBS LETT, V440, P141, DOI 10.1016/S0014-5793(98)01431-8; Wang J, 2003, DEVELOPMENT, V130, P1621, DOI 10.1242/dev.00363; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; Wintz H, 2002, BIOCHEM SOC T, V30, P732, DOI 10.1042/bst0300732; Wong PC, 2000, P NATL ACAD SCI USA, V97, P2886, DOI 10.1073/pnas.040461197; Wood WB, 1988, NEMATODE CAENORHABDI, P587; Zelko IN, 2002, FREE RADICAL BIO MED, V33, P337, DOI 10.1016/S0891-5849(02)00905-X; Zhu HN, 2000, BIOCHEMISTRY-US, V39, P5413, DOI 10.1021/bi992727+	63	79	86	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41373	41379		10.1074/jbc.M509142200	http://dx.doi.org/10.1074/jbc.M509142200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16234242	hybrid			2022-12-25	WOS:000233866900033
J	Tholema, N; Vor der Bruggen, M; Maser, P; Nakamura, T; Schroeder, JI; Kobayashi, H; Uozumi, N; Bakker, EP				Tholema, N; Vor der Bruggen, M; Maser, P; Nakamura, T; Schroeder, JI; Kobayashi, H; Uozumi, N; Bakker, EP			All four putative selectivity filter glycine residues in KtrB are essential for high affinity and selective K+ uptake by the KtrAB system from Vibrio alginolyticus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SUBSTITUTIONS; POTASSIUM UPTAKE; HKT TRANSPORTERS; KDPFABC COMPLEX; ION CONDUCTION; CARRIER TRK2P; KDPA SUBUNIT; CHANNEL; NA+; MUTATIONS	The subunit KtrB of bacterial Na+- dependent K+- translocating KtrAB systems belongs to a superfamily of K+ transporters. These proteins contain four repeated domains, each composed of two transmembrane helices connected by a putative pore loop (p-loop). The four p-loops harbor a conserved glycine residue at a position equivalent to a glycine selectivity filter residue in K+ channels. We investigated whether these glycines also form a selectivity filter in KtrB. The single residues Gly(70), Gly(185), Gly(290), and Gly(402) from p-loops P-A to P-D of Vibrio alginolyticus KtrB were replaced with alanine, serine, or aspartate. The three alanine variants KtrB(A70), KtrB(A185), and KtrB(A290) maintained a substantial activity in KtrAB-mediated K+ uptake in Escherichia coli. This activity was associated with a decrease in the affinity for K+ by 2 orders of magnitude, with little effect on V-max. Minor activities were also observed for three other variants: KtrB(A402), KtrB(S70), and KtrB(D185). With all of these variants, the property of Na+ dependence of K+ transport was preserved. Only the four serine variants mediated Na+ uptake, and these variants differed considerably in their K+/Na+ selectivity. Experiments on cloned ktrB in the pBAD18 vector showed that V. alginolyticus KtrB alone was still active in E. coli. It mediated Na+-independent, slow, high affinity, and mutation-specific K+ uptake as well as K+-independent Na+ uptake. These data demonstrate that KtrB contains a selectivity filter for K+ ions and that all four conserved p-loop glycine residues are part of this filter. They also indicate that the role of KtrA lies in conferring velocity and ion coupling to the Ktr complex.	Univ Osnabruck, Abt Mikrobiol, D-49076 Osnabruck, Germany; Univ Calif San Diego, Div Biol Sci, Cell & Dev Biol Sect, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Genet Mol, La Jolla, CA 92093 USA; Niigata Univ Pharm & Appl Life Sci, Fac Pharm, Niigata 9502081, Japan; Nagoya Univ, Biosci & Biotechnol Ctr, Nagoya, Aichi 4648601, Japan; Chiba Univ, Grad Sch Pharmaceut Sci, Inage Ku, Chiba 263, Japan	University Osnabruck; University of California System; University of California San Diego; University of California System; University of California San Diego; Niigata University; Nagoya University; Chiba University	Bakker, EP (corresponding author), Univ Osnabruck, Abt Mikrobiol, Barabarastr 11, D-49076 Osnabruck, Germany.	Bakker_e@biologie.uni-osnabrueck.de	Uozumi, Nobuyuki/AAG-3252-2019	Maser, Pascal/0000-0003-3122-1941; Schroeder, Julian/0000-0002-3283-5972; Uozumi, Nobuyuki/0000-0003-4268-1126				BAKKER EP, 1981, J BACTERIOL, V147, P820, DOI 10.1128/JB.147.3.820-826.1981; BECKE V, 2003, THESIS U OSNABRUCK G; Berneche S, 2001, NATURE, V414, P73, DOI 10.1038/35102067; Bertrand J, 2004, J BACTERIOL, V186, P5519, DOI 10.1128/JB.186.16.5519-5522.2004; Bihler H, 1999, FEBS LETT, V447, P115, DOI 10.1016/S0014-5793(99)00281-1; BOOTH IR, 1985, MICROBIOL REV, V49, P359, DOI 10.1128/MMBR.49.4.359-378.1985; BUURMAN ET, 1995, J BIOL CHEM, V270, P6678, DOI 10.1074/jbc.270.12.6678; Dorus S, 2001, J BIOL CHEM, V276, P9590, DOI 10.1074/jbc.M009365200; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Durell SR, 2000, BIOPHYS J, V78, P188, DOI 10.1016/S0006-3495(00)76584-2; Durell SR, 1999, BIOPHYS J, V77, P775, DOI 10.1016/S0006-3495(99)76931-6; Durell SR, 1999, BIOPHYS J, V77, P789, DOI 10.1016/S0006-3495(99)76932-8; EPSTEIN W, 1971, J BACTERIOL, V108, P639, DOI 10.1128/JB.108.2.639-644.1971; Fairbairn DJ, 2000, PLANT MOL BIOL, V43, P515, DOI 10.1023/A:1006496402463; Fersht A., 1985, ENZYME STRUCTURE MEC; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Haro R, 2002, BBA-BIOMEMBRANES, V1564, P114, DOI 10.1016/S0005-2736(02)00408-X; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; Holtmann G, 2003, J BACTERIOL, V185, P1289, DOI 10.1128/JB.185.4.1289-1298.2003; Horie T, 2001, PLANT J, V27, P129, DOI 10.1046/j.1365-313x.2001.01077.x; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Kato Y, 2001, P NATL ACAD SCI USA, V98, P6488, DOI 10.1073/pnas.101556598; Kawano M, 1999, FEMS MICROBIOL LETT, V176, P449; Kawano M, 2000, J BACTERIOL, V182, P2507, DOI 10.1128/JB.182.9.2507-2512.2000; Kuo AL, 2003, SCIENCE, V300, P1922, DOI 10.1126/science.1085028; Maser P, 2002, P NATL ACAD SCI USA, V99, P6428, DOI 10.1073/pnas.082123799; Matsuda N, 2004, J BIOL CHEM, V279, P54952, DOI 10.1074/jbc.M407268200; Morais-Cabral JH, 2001, NATURE, V414, P37, DOI 10.1038/35102000; Murata T, 1996, J BIOL CHEM, V271, P10042, DOI 10.1074/jbc.271.17.10042; Nakamura T, 1998, J BACTERIOL, V180, P3491, DOI 10.1128/JB.180.13.3491-3494.1998; Ren DJ, 2001, SCIENCE, V294, P2372, DOI 10.1126/science.1065635; Roosild TP, 2002, CELL, V109, P781, DOI 10.1016/S0092-8674(02)00768-7; Rubio F, 1999, J BIOL CHEM, V274, P6839, DOI 10.1074/jbc.274.11.6839; RUBIO F, 1995, SCIENCE, V270, P1660, DOI 10.1126/science.270.5242.1660; Sakuma T, 1998, BBA-BIOENERGETICS, V1363, P231, DOI 10.1016/S0005-2728(97)00102-3; SCHACHTMAN DP, 1994, NATURE, V370, P655, DOI 10.1038/370655a0; Schrader M, 2000, BIOPHYS J, V79, P802, DOI 10.1016/S0006-3495(00)76337-5; SCHREMPF H, 1995, EMBO J, V14, P5170, DOI 10.1002/j.1460-2075.1995.tb00201.x; STEWART GSAB, 1986, PLASMID, V15, P172, DOI 10.1016/0147-619X(86)90035-1; Stumpe S, 1997, ARCH MICROBIOL, V167, P126, DOI 10.1007/s002030050425; STUMPE S, 1996, HDB BIOL PHYS, V2, P473; Tholema N, 1999, FEBS LETT, V450, P217, DOI 10.1016/S0014-5793(99)00504-9; THOLEMA N, 2002, THESIS U OSNABRUCK G; Uozumi N, 2000, PLANT PHYSIOL, V122, P1249, DOI 10.1104/pp.122.4.1249; van der Laan M, 2002, J BACTERIOL, V184, P5491, DOI 10.1128/JB.184.19.5491-5494.2002; Zeng GF, 2004, J BIOL CHEM, V279, P3003, DOI 10.1074/jbc.M309760200; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	49	67	69	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41146	41154		10.1074/jbc.M507647200	http://dx.doi.org/10.1074/jbc.M507647200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16210320	hybrid			2022-12-25	WOS:000233866900005
J	Chatterji, U; Bobardt, MD; Stanfield, R; Ptak, RG; Pallansch, LA; Ward, PA; Jones, MJ; Stoddart, CA; Scalfaro, P; Dumont, JM; Besseghir, K; Rosenwirth, B; Gallay, PA				Chatterji, U; Bobardt, MD; Stanfield, R; Ptak, RG; Pallansch, LA; Ward, PA; Jones, MJ; Stoddart, CA; Scalfaro, P; Dumont, JM; Besseghir, K; Rosenwirth, B; Gallay, PA			Naturally occurring capsid substitutions render HIV-1 cyclophilin A independent in human cells and TRIM-cyclophilin-resistant in owl monkey cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CYCLOSPORINE-A; POSTENTRY RESTRICTION; SDZ NIM-811; T-CELLS; REPLICATION; GAG; VIRIONS; INFECTIVITY; ANALOG	In this study, we asked if a naturally occurring HIV-1 variant exists that circumvents CypA dependence in human cells. To address this issue, we sought viruses for CypA independence using Debio-025, a cyclosporine A (CsA) analog that disrupts CypA-capsid interaction. Surprisingly, viral variants from the Main group replicate even in the presence of the drug. Sequencing analyses revealed that these viruses encode capsid substitutions within the CypA-binding site (V86P/H87Q/191V/M961). When we introduced these substitutions into viruses that normally rely on CypA for replication, these mutants no longer depended on CypA, suggesting that naturally occurring capsid substitutions obviate the need for CypA. This is the first demonstration that isolates from the Main group naturally develop CypA- independent strategies to replicate in human cells. Surprisingly, we found that these capsid substitutions render HIV-1 capable of infecting Owl monkey (OMK) cells that highly restrict HIV-1. OMK cell resistance to HIV-1 is mediated via TRIM-Cyp, which arose from a retrotransposition of CypA into the TRIM5 alpha gene. Interestingly, saturation experiments suggest that the Pro(86)/Gln(87)/Val(91)/ Ile(96) capsid core is "invisible" to TRIM-Cyp. This study demonstrates that specific capsid substitutions can release HIV-1 from both CypA dependence in human cells and TRIM-Cyp restriction in monkey cells.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; So Res Inst, Dept Infect Dis Res, Frederick, MD 21701 USA; Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94103 USA; Debiopharm, CH-1002 Lausanne, Switzerland; Biomed Primate Res Ctr, Dept Virol, NL-2280 GH Rijswijk, Netherlands	Scripps Research Institute; Scripps Research Institute; University of California System; University of California San Francisco; The J David Gladstone Institutes; Debiopharm	Gallay, PA (corresponding author), Scripps Res Inst, Dept Immunol, IMM-9,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	gallay@scripps.edu	Liu, FL/D-1795-2009; Stanfield, Robyn/AAH-3190-2019		NIAID NIH HHS [AI-046958, N01-AI-25478] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI046958, R01AI046958] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aberham C, 1996, J VIROL, V70, P3536, DOI 10.1128/JVI.70.6.3536-3544.1996; Ackerson B, 1998, J VIROL, V72, P303, DOI 10.1128/JVI.72.1.303-308.1998; BILLICH A, 1995, J VIROL, V69, P2451, DOI 10.1128/JVI.69.4.2451-2461.1995; Bosco DA, 2002, P NATL ACAD SCI USA, V99, P5247, DOI 10.1073/pnas.082100499; Braaten D, 2001, EMBO J, V20, P1300, DOI 10.1093/emboj/20.6.1300; Braaten D, 1996, J VIROL, V70, P3551, DOI 10.1128/JVI.70.6.3551-3560.1996; Braaten D, 1996, J VIROL, V70, P5170, DOI 10.1128/JVI.70.8.5170-5176.1996; Braaten D, 1997, J VIROL, V71, P2107, DOI 10.1128/JVI.71.3.2107-2113.1997; Braaten D, 1996, J VIROL, V70, P4220, DOI 10.1128/JVI.70.7.4220-4227.1996; Dorfman T, 1997, J VIROL, V71, P7110, DOI 10.1128/JVI.71.9.7110-7113.1997; Dorfman T, 1996, J VIROL, V70, P5751, DOI 10.1128/JVI.70.9.5751-5757.1996; Franke EK, 1996, VIROLOGY, V222, P279, DOI 10.1006/viro.1996.0421; FRANKE EK, 1994, NATURE, V372, P359, DOI 10.1038/372359a0; Gamble TR, 1996, CELL, V87, P1285, DOI 10.1016/S0092-8674(00)81823-1; Hatziioannou T, 2005, J VIROL, V79, P176, DOI 10.1128/JVI.79.1.176-183.2005; Ikeda Y, 2004, J VIROL, V78, P11816, DOI 10.1128/JVI.78.21.11816-11822.2004; Kootstra NA, 2003, P NATL ACAD SCI USA, V100, P1298, DOI 10.1073/pnas.0337541100; Liu SK, 2004, NUCLEIC ACIDS RES, V32, P3752, DOI 10.1093/nar/gkh715; Luban J, 1996, CELL, V87, P1157, DOI 10.1016/S0092-8674(00)81811-5; Mlynar E, 1997, J GEN VIROL, V78, P825, DOI 10.1099/0022-1317-78-4-825; Nisole S, 2004, P NATL ACAD SCI USA, V101, P13324, DOI 10.1073/pnas.0404640101; Owens CM, 2004, J VIROL, V78, P5423, DOI 10.1128/JVI.78.10.5423-5437.2004; ROSENWIRTH B, 1994, ANTIMICROB AGENTS CH, V38, P1763, DOI 10.1128/AAC.38.8.1763; Sayah DM, 2004, NATURE, V430, P569, DOI 10.1038/nature02777; Sokolskaja E, 2004, J VIROL, V78, P12800, DOI 10.1128/JVI.78.23.12800-12808.2004; STEINKASSERER A, 1995, J VIROL, V69, P814, DOI 10.1128/JVI.69.2.814-824.1995; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; Towers GJ, 2003, NAT MED, V9, P1138, DOI 10.1038/nm910; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; Wiegers K, 2002, VIROLOGY, V294, P289, DOI 10.1006/viro.2001.1347; Yin L, 1998, J VIROL, V72, P6430, DOI 10.1128/JVI.72.8.6430-6436.1998	31	66	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40293	40300		10.1074/jbc.M506314200	http://dx.doi.org/10.1074/jbc.M506314200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16199531	hybrid			2022-12-25	WOS:000233461300071
J	Liu, GQ; Voyno-Yasenetskaya, TA				Liu, GQ; Voyno-Yasenetskaya, TA			Radixin stimulates Rac1 and Ca2+/calmodulin-dependent kinase, CaMKII - Cross-talk with G alpha(13) signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; NUCLEOTIDE EXCHANGE FACTOR; ERM PROTEINS; CONFORMATIONAL ACTIVATION; GROWTH-FACTOR; P115 RHOGEF; EZRIN; RHOA; RECEPTOR; TRANSFORMATION	The ERM (ezrin, radixin, moesin) proteins function as cross-linkers between cell membrane and cytoskeleton by binding to membrane proteins via their N-terminal domain and to F-actin via their C-terminal domain. Previous studies from our laboratory have shown that the alpha-subunit of heterotrimeric G(13) protein induces conformational activation of radixin via interaction with its N-terminal domain (Vaiskunaite, R., Adarichev, V., Furthmayr, H., Kozasa, T., Gudkov, A., and Voyno-Yasenetskaya, T. A.( 2000) J. Biol. Chem. 275,26206 - 26212). In the present study, we tested whether radixin can regulate G alpha(13)-mediated signaling pathways. We determined the effects of the N-terminal domain ( amino acids 1 - 318) and C-terminal domain ( amino acids 319 - 583) of radixin on serum response element (SRE)-dependent gene transcription initiated by a constitutively activated G alpha(13)Q226L. The N-terminal domain potentiated SRE activation induced by G alpha(13)Q226L; RhoGDI inhibited this effect. Surprisingly, the C-terminal domain also stimulated the SRE-dependent gene transcription. When co-transfected with G alpha(13)Q226L, the C-terminal domain of radixin synergistically stimulated the SRE activation; RhoGDI inhibited this effect. Using in vivo pull-down assays, we have determined that the C-terminal domain of radixin activated Rac1 but not RhoA or Cdc42 proteins. By contrast, G alpha(13)Q226L activated RhoA but not Rac1 or Cdc42. We have also shown that both the C-terminal domain of radixin and G alpha(13)Q226L can stimulate Ca2+/calmodulin-dependent kinase, CaMKII. Activated mutant that mimics the phosphorylated state of radixin (T564E) stimulated Rac1, induced the phosphorylation of CaMKII, and stimulated SRE-dependent gene transcription. Downregulation of endogenous radixin using small interference RNA inhibited SRE-dependent gene transcription and phosphorylation of CaMKII induced by G alpha(13)Q226L. Overall, our results indicated that radixin via its C-terminal domain mediates SRE-dependent gene transcription through activation of Rac1 and CaMKII. In addition, the radixin-CaMKII signaling pathway is involved in G alpha(13)-mediated SRE-dependent gene transcription, suggesting that radixin could be involved in novel signaling pathway regulated by G13 protein.	Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Voyno-Yasenetskaya, TA (corresponding author), Univ Illinois, Dept Pharmacol, MC 868,835 S Wolcott Ave, Chicago, IL 60612 USA.	tvy@uic.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065160, R01GM056159, R55GM056159] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL06078] Funding Source: Medline; NIGMS NIH HHS [GM56159, GM65160] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adarichev VA, 2003, AM J PHYSIOL-CELL PH, V285, pC922, DOI 10.1152/ajpcell.00115.2003; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; Bretscher A, 1997, J CELL SCI, V110, P3011; Buchanan FG, 2000, J BIOL CHEM, V275, P9742, DOI 10.1074/jbc.275.13.9742; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Davis FJ, 2003, J BIOL CHEM, V278, P20047, DOI 10.1074/jbc.M209998200; Fleming IN, 1999, J BIOL CHEM, V274, P12753, DOI 10.1074/jbc.274.18.12753; Fujii T, 2005, J BIOL CHEM, V280, P23041, DOI 10.1074/jbc.M409397200; Fukuhara S, 2000, J BIOL CHEM, V275, P21730, DOI 10.1074/jbc.M002410200; Gautreau A, 1999, P NATL ACAD SCI USA, V96, P7300, DOI 10.1073/pnas.96.13.7300; Gautreau A, 2000, J CELL BIOL, V150, P193, DOI 10.1083/jcb.150.1.193; Hao SL, 2003, EMBO J, V22, P4166, DOI 10.1093/emboj/cdg401; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kurose H, 2003, LIFE SCI, V74, P155, DOI 10.1016/j.lfs.2003.09.003; Lin KD, 2002, J BIOL CHEM, V277, P40789, DOI 10.1074/jbc.M202745200; Linseman DA, 2003, J BIOL CHEM, V278, P41472, DOI 10.1074/jbc.M307245200; Louvet-Vallee S, 2000, BIOL CELL, V92, P305, DOI 10.1016/S0248-4900(00)01078-9; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Miller KG, 2003, TRENDS CELL BIOL, V13, P165, DOI 10.1016/S0962-8924(03)00029-1; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; Niu JX, 2003, CIRC RES, V93, P848, DOI 10.1161/01.RES.0000097607.14733.0C; Niu JX, 2001, CURR BIOL, V11, P1686, DOI 10.1016/S0960-9822(01)00530-9; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; Ponimaskin EG, 2002, J BIOL CHEM, V277, P20812, DOI 10.1074/jbc.M112216200; Postma FR, 2001, CURR BIOL, V11, P121, DOI 10.1016/S0960-9822(01)00030-6; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; Pujuguet P, 2003, MOL BIOL CELL, V14, P2181, DOI 10.1091/mbc.E02-07-0410; Radhika V, 2004, J BIOL CHEM, V279, P49406, DOI 10.1074/jbc.M408836200; Shcherbina A, 1999, FEBS LETT, V443, P31, DOI 10.1016/S0014-5793(98)01674-3; Shi CS, 2000, J BIOL CHEM, V275, P24470, DOI 10.1074/jbc.M908449199; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Suzuki N, 2003, P NATL ACAD SCI USA, V100, P733, DOI 10.1073/pnas.0234057100; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; Urzainqui A, 2002, IMMUNITY, V17, P401, DOI 10.1016/S1074-7613(02)00420-X; Vaiskunaite R, 2000, J BIOL CHEM, V275, P26206, DOI 10.1074/jbc.M001863200; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Yamaguchi Y, 2001, J BIOL CHEM, V276, P18977, DOI 10.1074/jbc.M100254200	45	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39042	39049		10.1074/jbc.M504341200	http://dx.doi.org/10.1074/jbc.M504341200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16186118	hybrid			2022-12-25	WOS:000233362200018
J	Mazzola, S; Forni, M; Albertini, M; Bacci, ML; Zannoni, A; Gentilini, F; Lavitrano, M; Bach, FH; Otterbein, LE; Clement, MG				Mazzola, S; Forni, M; Albertini, M; Bacci, ML; Zannoni, A; Gentilini, F; Lavitrano, M; Bach, FH; Otterbein, LE; Clement, MG			Carbon monoxide pretreatment prevents respiratory derangement and ameliorates hyperacute endotoxic shock in pigs	FASEB JOURNAL			English	Article						LPS; CO; heme oxygenase	GMP-RELATED MESSENGER; HEME OXYGENASE-1; NITRIC-OXIDE; CYCLIC-GMP; LUNG INJURY; IN-VIVO; INHALATION; PULMONARY; INFLAMMATION; EXPRESSION	Endotoxic shock, one of the most prominent causes of mortality in intensive care units, is characterized by pulmonary hypertension, systemic hypotension, heart failure, widespread endothelial activation/ injury, and clotting culminating in disseminated intravascular coagulation and multi-organ system failure. In the last few years, studies in rodents have shown that administration of low concentrations of carbon monoxide ( CO) exerts potent therapeutic effects in a variety of diseases/disorders. In this study, we have administered CO ( one our pretreatment at 250 ppm) in a clinically relevant, well-characterized model of LPS-induced acute lung injury in pigs. Pretreatment only with inhaled CO significantly ameliorated several of the acute pathological changes induced by endotoxic shock. In terms of lung physiology, CO pretreatment corrected the LPS-induced changes in resistance and compliance and improved the derangement in pulmonary gas exchange. In terms of coagulation and inflammation, CO reduced the development of disseminated intravascular coagulation and completely suppressed serum levels of the proinflammatory IL-1 beta in response to LPS, while augmenting the anti-inflammatory cytokine IL-10. Moreover, the effects of CO blunted the deterioration of kidney and liver function, suggesting a beneficial effect in terms of end organ damage associated with endotoxic shock. Lastly, CO pretreatment prevents LPS-induced ICAM expression on lung endothelium and inhibits leukocyte marginalization on lung parenchyma.	Univ Milan, Dipartimento Patol Anim Igiene & Sanita Pubbl Vet, Sez Biochim & Fisiol Vet, Milan, Italy; Univ Bologna, Dipartimento Morfofisiol Vet & Prod Anim, Bologna, Italy; Univ Milan Bicocca, Dipartimento Sci Chirurg & Terapia Intens, Milan, Italy; Univ Bologna, Dipartimento Clin Vet, Bologna, Italy; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Immunobiol Res Ctr, Boston, MA 02115 USA	University of Milan; University of Bologna; University of Milano-Bicocca; University of Bologna; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Mazzola, S (corresponding author), Via Celoria 10, I-20133 Milan, Italy.	silvia.mazzola@unimi.it	Albertini, Mariangela/I-5989-2017; Bacci, Maria Laura/B-8494-2013; Lavitrano, Marialuisa/H-3417-2012; Mazzola, Silvia Michela/J-8137-2012	Albertini, Mariangela/0000-0002-6969-7809; Mazzola, Silvia Michela/0000-0001-8131-4340; Forni, Monica/0000-0003-1310-6202; Bacci, Maria Laura/0000-0001-6702-5868				Akamatsu Y, 2004, FASEB J, V18, P771, DOI 10.1096/fj.03-0921fje; Albertini M, 2000, J CRIT CARE, V15, P73, DOI 10.1053/jcrc.2000.7903; Ameredes BT, 2003, AM J PHYSIOL-LUNG C, V285, pL1270, DOI 10.1152/ajplung.00145.2003; Aukrust Pal, 2004, Am J Cardiovasc Drugs, V4, P169, DOI 10.2165/00129784-200404030-00004; Bouchet D, 2002, TRANSPL IMMUNOL, V9, P235, DOI 10.1016/S0966-3274(02)00037-0; BRIAN JE, 1994, STROKE, V25, P639, DOI 10.1161/01.STR.25.3.639; Cardell LO, 1998, BRIT J PHARMACOL, V124, P1065, DOI 10.1038/sj.bjp.0701878; Cardell LO, 1998, PULM PHARMACOL THER, V11, P309, DOI 10.1006/pupt.1998.0152; Choi AMK, 2002, ANTIOXID REDOX SIGN, V4, P227, DOI 10.1089/152308602753666271; DANGELO E, 1991, J APPL PHYSIOL, V70, P2602, DOI 10.1152/jappl.1991.70.6.2602; Dinarello CA, 2000, CHEST, V118, P503, DOI 10.1378/chest.118.2.503; FURCHGOTT RF, 1991, BLOOD VESSELS, V28, P52; HYRICH KL, 2004, ANN RHEUM DIS; Ishikawa K, 2003, CURR PHARM DESIGN, V9, P2489, DOI 10.2174/1381612033453767; KOCHI T, 1988, J APPL PHYSIOL, V64, P441; Kourembanas S, 2002, ANTIOXID REDOX SIGN, V4, P291, DOI 10.1089/152308602753666343; Lavitrano M, 2004, FASEB J, V18, P1093, DOI 10.1096/fj.03-0996fje; Macdougall IC, 2004, NEPHROL DIAL TRANSPL, V19, P73, DOI 10.1093/ndt/gfh1060; Mayr FB, 2005, AM J RESP CRIT CARE, V171, P354, DOI 10.1164/rccm.200404-446OC; Middelveld RJM, 2003, ACTA PHYSIOL SCAND, V179, P203, DOI 10.1046/j.1365-201X.2003.01141.x; Middelveld RJM, 2002, ACTA PHYSIOL SCAND, V176, P71, DOI 10.1046/j.1365-201X.2002.01007.x; MORITA T, 1995, P NATL ACAD SCI USA, V92, P1475, DOI 10.1073/pnas.92.5.1475; Nakao A, 2003, AM J PATHOL, V163, P1587, DOI 10.1016/S0002-9440(10)63515-8; Otterbein LE, 1999, AM J PHYSIOL-LUNG C, V276, pL688; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Otterbein LE, 2003, NAT MED, V9, P183, DOI 10.1038/nm817; Otterbein LE, 2002, ANTIOXID REDOX SIGN, V4, P309, DOI 10.1089/152308602753666361; Rutgeerts P, 2004, GASTROENTEROLOGY, V126, P1593, DOI 10.1053/j.gastro.2004.02.070; Ryter SW, 2004, BIOESSAYS, V26, P270, DOI 10.1002/bies.20005; Sarady JK, 2002, AM J RESP CELL MOL, V27, P739, DOI 10.1165/rcmb.4816; Sass G, 2003, HEPATOLOGY, V38, P909, DOI 10.1053/jhep.2003.50386; Soares MP, 1998, NAT MED, V4, P1073, DOI 10.1038/2063; Wang R, 1997, BRIT J PHARMACOL, V121, P927, DOI 10.1038/sj.bjp.0701222; Yet SF, 1997, J BIOL CHEM, V272, P4295, DOI 10.1074/jbc.272.7.4295; Zampetaki A, 2003, EXP BIOL MED, V228, P442, DOI 10.1177/15353702-0322805-02; Zuckerbraun BS, 2003, J EXP MED, V198, P1707, DOI 10.1084/jem.20031003	36	76	84	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2045	+		10.1096/fj.05-3782fje	http://dx.doi.org/10.1096/fj.05-3782fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16223783				2022-12-25	WOS:000232991100020
J	Muhlisch, J; Schwering, A; Grotzer, M; Vince, GH; Roggendorf, W; Hagemann, C; Sorensen, N; Rickert, CH; Osada, N; Jurgens, H; Fruhwald, MC				Muhlisch, J; Schwering, A; Grotzer, M; Vince, GH; Roggendorf, W; Hagemann, C; Sorensen, N; Rickert, CH; Osada, N; Jurgens, H; Fruhwald, MC			Epigenetic repression of RASSF1A but not CASP8 in supratentorial PNET (sPNET) and atypical teratoid/rhabdoit tumors (AT/RT) of childhood	ONCOGENE			English	Article						brain tumors; epigenetics; methylation; childhood; sPNET; AT/ RT	COMPARATIVE GENOMIC HYBRIDIZATION; PRIMITIVE NEUROECTODERMAL TUMORS; CENTRAL-NERVOUS-SYSTEM; ABERRANT PROMOTER METHYLATION; MOLECULAR ANALYSIS; PEDIATRIC TUMORS; SUPPRESSOR GENE; EXPRESSION; HYPERMETHYLATION; MEDULLOBLASTOMAS	Supratentorial primitive neuroectodermal tumors (sPNET) and atypical teratoid/rhabdoid tumors (AT/RT) of the CNS represent a biological and clinical enigma, despite advances in both molecular techniques and clinical management for these two rare embryonal brain tumors of childhood. Epigenetic changes hold great potential as possible disease mechanisms and may be manipulated therapeutically. We thus studied aberrant methylation of the genes RASSF1A and CASP8 and its consequence on expression in cell lines and primary tumors using a combination of semiquantitative methylation specific PCR (MSP), bisulfite sequencing and RT-PCR. In all, 17 samples of autopsy-derived normal appearing brain served as controls. Opposed to control tissues 19/24 sPNET and 4/6 AT/RT demonstrated aberrant methylation for the RASSF1A promoter region. Treatment of cell lines using 5-Aza-2'-deoxycytidine (5AZA) alone or in combination with trichostatin A (TSA) succeeded in re-establishing expression of RASSF1A in cell lines derived from a renal rhabdoid, an AT/RT and a medulloblastoma. A 5'-CpG-rich region of CASP8 was methylated in normal tissues and in tumors. However, CASP8 showed inconsistent expression patterns in normal and tumor tissues. Our results indicate that aberrant methylation of the RASSF1A promoter region maybe of importance in the origin and progression of sPNET and AT/RT while the analysed 5'-CpG rich region of the CASP8 gene does not seem to play an important role in these tumors. Further studies of epigenetic changes in these rare tumors are warranted as their biology remains obscure and treatment efforts have been rather unsuccessfull.	Univ Munster, Childrens Hosp, Dept Paediat Haematol & Oncol, D-48149 Munster, Germany; Univ Zurich, Childrens Hosp, Zurich, Switzerland; Univ Hosp Wuerzburg, Dept Neurosurg, Wurzburg, Germany; Univ Hosp Wuerzburg, Inst Neuropathol, Wurzburg, Germany; Univ Hosp Munster, Inst Neuropathol & Pathol, Munster, Germany; Univ Munster, Dept Med Informat & Biomath, Munster, Germany	University of Munster; University Children's Hospital Zurich; University of Zurich; University of Wurzburg; University of Wurzburg; University of Munster; University of Munster	Fruhwald, MC (corresponding author), Univ Munster, Childrens Hosp, Dept Paediat Haematol & Oncol, Albert Schweitzer Str 33, D-48149 Munster, Germany.	fruhwald@uni-muenster.de	Hagemann, Carsten/AAC-8037-2019	Grotzer, Michael/0000-0002-1154-2732; Vince, Giles/0000-0002-0222-8733				Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088; Banelli B, 2002, NAT MED, V8, P1333, DOI 10.1038/nm1202-1333; Bayani J, 2000, J NEUROSURG, V93, P437, DOI 10.3171/jns.2000.93.3.0437; Biegel JA, 2002, CLIN CANCER RES, V8, P3461; BIEGEL JA, 1992, GENE CHROMOSOME CANC, V5, P104, DOI 10.1002/gcc.2870050203; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Fruhwald MC, 2001, GENE CHROMOSOME CANC, V30, P38; Fruhwald MC, 2004, CLIN CANCER RES, V10, P2997, DOI 10.1158/1078-0432.CCR-03-0083; Fruhwald MC, 2002, MOL GENET METAB, V75, P1, DOI 10.1006/mgme.2001.3265; Fruhwald MC, 2001, ONCOGENE, V20, P5033, DOI 10.1038/sj.onc.1204613; Fruhwald MC, 2000, J MED GENET, V37, P501, DOI 10.1136/jmg.37.7.501; Grotzer MA, 2000, J CLIN ONCOL, V18, P1027, DOI 10.1200/JCO.2000.18.5.1027; Harada K, 2002, CANCER RES, V62, P5897; Harada K, 2002, ONCOGENE, V21, P4345, DOI 10.1038/sj.onc.1205446; KELLY WK, 2005, J CLIN ONCOL, V16, P16; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Kortmann RD, 2000, INT J RADIAT ONCOL, V46, P269, DOI 10.1016/S0360-3016(99)00369-7; Lindsey JC, 2004, CARCINOGENESIS, V25, P661, DOI 10.1093/carcin/bgh055; Lusher ME, 2002, CANCER RES, V62, P5906; Melnick AM, 2005, J CLIN ONCOL, V23, P3957, DOI 10.1200/JCO.2005.14.498; Packer RJ, 2002, J PEDIAT HEMATOL ONC, V24, P337, DOI 10.1097/00043426-200206000-00004; Pingoud-Meier C, 2003, CLIN CANCER RES, V9, P6401; Rickert CH, 2004, CHILD NERV SYST, V20, P221, DOI 10.1007/s00381-003-0909-8; Russo C, 1999, CANCER, V86, P331, DOI 10.1002/(SICI)1097-0142(19990715)86:2<331::AID-CNCR18>3.0.CO;2-#; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Scheurlen WG, 1998, J CLIN ONCOL, V16, P2478, DOI 10.1200/JCO.1998.16.7.2478; Sevenet N, 1999, HUM MOL GENET, V8, P2359, DOI 10.1093/hmg/8.13.2359; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Zhang F, 2002, GENE CHROMOSOME CANC, V34, P398, DOI 10.1002/gcc.10078; Zuzak TJ, 2002, EUR J CANCER, V38, P83, DOI 10.1016/S0959-8049(01)00355-0	31	25	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					1111	1117		10.1038/sj.onc.1209137	http://dx.doi.org/10.1038/sj.onc.1209137			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16186793				2022-12-25	WOS:000235361000015
J	Moe, E; Leiros, I; Smalas, AO; McSweeney, S				Moe, E; Leiros, I; Smalas, AO; McSweeney, S			The crystal structure of mismatch-specific uracil-DNA glycosylase (MUG) from Deinococcus radiodurans reveals a novel catalytic residue and broad substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GENOME SEQUENCE; THYMINE; RECOGNITION; FAMILY; UNG; PURIFICATION; ALIGNMENT; EXCISION; CYTOSINE	Deinococcus radiodurans is extremely resistant to the effects of ionizing radiation. The source of the radiation resistance is not known, but an expansion of specific protein families related to stress response and damage control has been observed. DNA repair enzymes are among the expanded protein families in D. radiodurans, and genes encoding five different uracil-DNA glycosylases are identified in the genome. Here we report the three-dimensional structure of the mismatch-specific uracil-DNA glycosylase (MUG) from D. radiodurans (drMUG) to a resolution of 1.75 angstrom. Structural analyses suggest that drMUG possesses a novel catalytic residue, Asp-93. Activity measurements show that drMUG has a modified and broadened substrate specificity compared with Escherichia coli MUG. The importance of Asp-93 for activity was confirmed by structural analysis and abolished activity for the mutant drMUGD93A. Two other microorganisms, Bradyrhizobium japonicum and Rhodopseudomonas palustris, possess genes that encode MUGs with the highest sequence identity to drMUG among all of the bacterial MUGs examined. A phylogenetic analysis indicates that these three MUGs form a new MUG/thymidine-DNA glycosylase subfamily, here called the MUG2 family. We suggest that the novel catalytic residue (Asp-93) has evolved to provided rMUG with broad substrate specificity to increase the DNA repair repertoire of D. radiodurans.	European Synchrotron Radiat Facil, F-38043 Grenoble 9, France; Univ Tromso, Norwegian Struct Biol Ctr, N-9037 Tromso, Norway	European Synchrotron Radiation Facility (ESRF); UiT The Arctic University of Tromso	McSweeney, S (corresponding author), European Synchrotron Radiat Facil, BP 220, F-38043 Grenoble 9, France.	mcsweeney@esrf.fr	Moe, Elin/Q-6131-2019; Smalås, Arne/C-4131-2016; Moe, Elin/J-4367-2013; Leiros, Ingar/AAM-2940-2020	Moe, Elin/0000-0002-7923-1471; Smalås, Arne/0000-0002-4651-9911; Moe, Elin/0000-0002-7923-1471; Leiros, Ingar/0000-0001-9333-4541				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker D, 2002, CHEM RES TOXICOL, V15, P33, DOI 10.1021/tx010113b; Barrett TE, 1999, EMBO J, V18, P6599, DOI 10.1093/emboj/18.23.6599; Barrett TE, 1998, CELL, V92, P117, DOI 10.1016/S0092-8674(00)80904-6; Battista JR, 1997, ANNU REV MICROBIOL, V51, P203, DOI 10.1146/annurev.micro.51.1.203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chung JH, 2003, NUCLEIC ACIDS RES, V31, P2045, DOI 10.1093/nar/gkg319; Daly MJ, 1996, J BACTERIOL, V178, P4461, DOI 10.1128/jb.178.15.4461-4471.1996; Dinner AR, 2001, NATURE, V413, P752, DOI 10.1038/35099587; Gallinari P, 1996, NATURE, V383, P735, DOI 10.1038/383735a0; Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563; Hang B, 2002, BIOCHEMISTRY-US, V41, P2158, DOI 10.1021/bi011542b; Hardeland U, 2000, J BIOL CHEM, V275, P33449, DOI 10.1074/jbc.M005095200; Hardeland U, 2003, NUCLEIC ACIDS RES, V31, P2261, DOI 10.1093/nar/gkg344; Haushalter KA, 1999, CURR BIOL, V9, P174, DOI 10.1016/S0960-9822(99)80087-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaneko T, 2002, DNA RES, V9, P225, DOI 10.1093/dnares/9.6.225; Kavli B, 1996, EMBO J, V15, P3442, DOI 10.1002/j.1460-2075.1996.tb00710.x; Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244; Lanes O, 2000, COMP BIOCHEM PHYS B, V127, P399, DOI 10.1016/S0305-0491(00)00271-6; Larimer FW, 2004, NAT BIOTECHNOL, V22, P55, DOI 10.1038/nbt923; Leiros I, 2005, ACTA CRYSTALLOGR D, V61, P1049, DOI 10.1107/S090744490501382X; LESLIE AGW, 1992, JNT CCP4 ESF EAMCB N, V26, P27; LINDAHL T, 1974, P NATL ACAD SCI USA, V71, P3649, DOI 10.1073/pnas.71.9.3649; Liu PF, 2002, CHEM RES TOXICOL, V15, P1001, DOI 10.1021/tx020030a; Makarova KS, 2001, MICROBIOL MOL BIOL R, V65, P44, DOI 10.1128/MMBR.65.1.44-79.2001; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; NEDDERMANN P, 1993, J BIOL CHEM, V268, P21218; NEDDERMANN P, 1994, P NATL ACAD SCI USA, V91, P1642, DOI 10.1073/pnas.91.5.1642; O'Neill RJ, 2003, J BIOL CHEM, V278, P20526, DOI 10.1074/jbc.M210860200; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Sandigursky M, 2004, DNA REPAIR, V3, P163, DOI 10.1016/j.dnarep.2003.10.011; Sandigursky M, 1999, CURR BIOL, V9, P531, DOI 10.1016/S0960-9822(99)80237-1; Saparbaev M, 1998, P NATL ACAD SCI USA, V95, P8508, DOI 10.1073/pnas.95.15.8508; Saparbaev M, 2002, J BIOL CHEM, V277, P26987, DOI 10.1074/jbc.M111100200; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; White O, 1999, SCIENCE, V286, P1571, DOI 10.1126/science.286.5444.1571; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Yang HJ, 2000, J BACTERIOL, V182, P1272, DOI 10.1128/JB.182.5.1272-1279.2000	42	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					569	577		10.1074/jbc.M508032200	http://dx.doi.org/10.1074/jbc.M508032200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16223719	hybrid			2022-12-25	WOS:000234307200069
J	Baker, BY; Yaworsky, DC; Miller, WL				Baker, BY; Yaworsky, DC; Miller, WL			A pH-dependent molten globule transition is required for activity of the steroidogenic acute regulatory protein, StAR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOID ADRENAL-HYPERPLASIA; BENZODIAZEPINE-RECEPTOR; MITOCHONDRIAL-MEMBRANE; CHOLESTEROL TRANSFER; SYNTHETIC MEMBRANES; HUMAN GENE; DOMAIN; MECHANISM; BINDING; MLN64	The steroidogenic acute regulatory protein (StAR) simulates steroid biosynthesis by increasing the flow of cholesterol from the outer mitochondrial membrane (OMM) to the inner membrane. StAR acts exclusively on the OMM, and only StAR's carboxyl-terminal alpha-helix (C-helix) interacts with membranes. Biophysical studies have shown that StAR becomes a molten globule at acidic pH, but a physiologic role for this structural transition has been controversial. Molecular modeling shows that the C-helix, which forms the floor of the sterol-binding pocket, is stabilized by hydrogen bonding to adjacent loops. Molecular dynamics simulations show that protonation of the C-helix and adjacent loops facilitates opening and closing the sterol-binding pocket. Two disulfide mutants, S100C/S261C (SS) and D106C/A268C (DA), designed to limit the mobility of the C-helix but not disrupt overall conformation, were prepared in bacteria, and their correct folding and positioning of the disulfide bonds was confirmed. The SS mutant lost half, and the DA mutant lost all cholesterol binding capacity and steroidogenic activity with isolated mitochondria in vitro, but full binding and activity was restored to each mutant by disrupting the disulfide bonds with dithiothreitol. These data strongly support the model that StAR activity requires a pH-dependent molten globule transition on the OMM.	Univ Calif San Francisco, Dept Pediat, Metab Res Unit, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, Mass Spectrometry Facil, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Miller, WL (corresponding author), Univ Calif San Francisco, Dept Pediat, Metab Res Unit, Bldg MR 4,Rm 209, San Francisco, CA 94143 USA.	wlmlab@itsa.ucsf.edu	Miller, Walter L/J-3696-2012; Baker, Bo/C-1466-2010		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037922] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37922] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allen JA, 2004, ENDOCRINE, V25, P265, DOI 10.1385/ENDO:25:3:265; Arakane F, 1996, P NATL ACAD SCI USA, V93, P13731, DOI 10.1073/pnas.93.24.13731; Arakane F, 1998, J BIOL CHEM, V273, P16339, DOI 10.1074/jbc.273.26.16339; Artemenko IP, 2001, J BIOL CHEM, V276, P46583, DOI 10.1074/jbc.M107815200; Bose HS, 2000, BIOCHEMISTRY-US, V39, P11722, DOI 10.1021/bi000911l; Bose HS, 1999, P NATL ACAD SCI USA, V96, P7250, DOI 10.1073/pnas.96.13.7250; Bose HS, 2002, NATURE, V417, P87, DOI 10.1038/417087a; Bose HS, 1996, NEW ENGL J MED, V335, P1870, DOI 10.1056/NEJM199612193352503; CEHN X, 2005, J CLIN ENDOCR METAB, V90, P835; Christensen K, 2001, J BIOL CHEM, V276, P17044, DOI 10.1074/jbc.M100903200; CORNELL WD, 1995, J AM CHEM SOC, V117, P5197; Granot Z, 2003, MOL ENDOCRINOL, V17, P2461, DOI 10.1210/me.2003-0074; Hauet T, 2005, MOL ENDOCRINOL, V19, P540, DOI 10.1210/me.2004-0307; Jamin N, 2005, MOL ENDOCRINOL, V19, P588, DOI 10.1210/me.2004-0308; Joseph-Liauzun E, 1998, J BIOL CHEM, V273, P2146, DOI 10.1074/jbc.273.4.2146; Kallen CB, 1998, J BIOL CHEM, V273, P26285, DOI 10.1074/jbc.273.41.26285; King SR, 1999, J STEROID BIOCHEM, V69, P143, DOI 10.1016/S0960-0760(98)00152-6; Li H, 2001, P NATL ACAD SCI USA, V98, P1267, DOI 10.1073/pnas.031461598; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; Mathieu AP, 2002, J MOL ENDOCRINOL, V29, P327, DOI 10.1677/jme.0.0290327; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; Miller WL, 1999, J STEROID BIOCHEM, V69, P131, DOI 10.1016/S0960-0760(98)00153-8; Miller WL, 1997, J MOL ENDOCRINOL, V19, P227, DOI 10.1677/jme.0.0190227; MoogLutz C, 1997, INT J CANCER, V71, P183, DOI 10.1002/(SICI)1097-0215(19970410)71:2<183::AID-IJC10>3.0.CO;2-J; PAPADOPOULOS V, 1993, ENDOCR REV, V14, P222, DOI 10.1210/er.14.2.222; Petrescu AD, 2001, J BIOL CHEM, V276, P36970, DOI 10.1074/jbc.M101939200; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; POVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; Romanowski MJ, 2002, P NATL ACAD SCI USA, V99, P6949, DOI 10.1073/pnas.052140699; Sechi S, 1998, ANAL CHEM, V70, P5150, DOI 10.1021/ac9806005; Soccio RE, 2003, J BIOL CHEM, V278, P22183, DOI 10.1074/jbc.R300003200; Soccio RE, 2002, P NATL ACAD SCI USA, V99, P6943, DOI 10.1073/pnas.052143799; Song MS, 2001, BIOCHEM J, V356, P151, DOI 10.1042/0264-6021:3560151; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; STEVENS VL, 1992, ENDOCRINOLOGY, V130, P1557, DOI 10.1210/en.130.3.1557; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; TEE MK, 1995, HUM MOL GENET, V4, P2299, DOI 10.1093/hmg/4.12.2299; Tsujishita Y, 2000, NAT STRUCT BIOL, V7, P408; Tuckey RC, 2002, J BIOL CHEM, V277, P47123, DOI 10.1074/jbc.M206965200; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; Wang XJ, 1998, ENDOCRINOLOGY, V139, P3903, DOI 10.1210/en.139.9.3903; Watari H, 1997, P NATL ACAD SCI USA, V94, P8462, DOI 10.1073/pnas.94.16.8462; West LA, 2001, ENDOCRINOLOGY, V142, P502, DOI 10.1210/en.142.1.502; Yaworsky DC, 2005, J BIOL CHEM, V280, P2045, DOI 10.1074/jbc.M410937200	45	60	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41753	41760		10.1074/jbc.M510241200	http://dx.doi.org/10.1074/jbc.M510241200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16234239	hybrid			2022-12-25	WOS:000233866900077
J	Curien, G; Ravanel, S; Robert, M; Dumas, R				Curien, G; Ravanel, S; Robert, M; Dumas, R			Identification of six novel allosteric effectors of Arabidopsis thaliana aspartate kinase-homoserine dehydrogenase isoforms - Physiological context sets the specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THREONINE; BIOSYNTHESIS; OVERPRODUCTION; PURIFICATION; METHIONINE; PLANTS; GENE	The Arabidopsis genome contains two genes predicted to code for bifunctional aspartate kinase-homoserine dehydrogenase enzymes (isoforms I and II). These two activities catalyze the first and the third steps toward the synthesis of the essential amino acids threonine, isoleucine, and methionine. We first characterized the kinetic and regulatory properties of the recombinant enzymes, showing that they mainly differ with respect to the inhibition of the homoserine dehydrogenase activity by threonine. A systematic search for other allosteric effectors allowed us to identify an additional inhibitor (leucine) and 5 activators (alanine, cysteine, isoleucine, serine, and valine) equally efficient on aspartate kinase I activity (4-fold activation). The six effectors of aspartate kinase I were all activators of aspartate kinase II activity (13-fold activation) and displayed a similar specificity for the enzyme. No synergy between different effectors could be observed. The activation, which resulted from a decrease in the Km values for the substrates, was detected using low substrates concentrations. Amino acid quantification revealed that alanine and threonine were much more abundant than the other effectors in Arabidopsis leaf chloroplasts. In vitro kinetics in the presence of physiological concentrations of the seven allosteric effectors confirmed that aspartate kinase I and II activities were highly sensitive to changes in alanine and threonine concentrations. Thus, physiological context rather than enzyme structure sets the specificity of the allosteric control. Stimulation by alanine may play the role of a feed forward activation of the aspartate-derived amino acid pathway in plant.	Univ Grenoble 1, Physiol Cellulaire Vegetale Lab, UMR 5168,INRA, CEA,CNRS, F-38054 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); CNRS - National Institute for Biology (INSB); INRAE; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA	Curien, G (corresponding author), Univ Grenoble 1, Physiol Cellulaire Vegetale Lab, UMR 5168,INRA, CEA,CNRS, F-38054 Grenoble, France.	gcurien@cea.fr	Dumas, Renaud/E-1835-2011	Ravanel, Stephane/0000-0001-9475-4222				AARNES H, 1974, PHYTOCHEMISTRY, V13, P2717, DOI 10.1016/0031-9422(74)80229-3; Azevedo RA, 1997, PHYTOCHEMISTRY, V46, P395, DOI 10.1016/S0031-9422(97)00319-1; Block MA, 2002, EUR J BIOCHEM, V269, P240, DOI 10.1046/j.0014-2956.2001.02643.x; Chipman DM, 2001, CURR OPIN STRUC BIOL, V11, P694, DOI 10.1016/S0959-440X(01)00272-X; COSTREJEAN JM, 1977, J BIOL CHEM, V252, P5332; Curien G, 2003, EUR J BIOCHEM, V270, P4615, DOI 10.1046/j.1432-1033.2003.03851.x; GHISLAIN M, 1994, PLANT MOL BIOL, V24, P835, DOI 10.1007/BF00014439; IRELAND R, 1997, PLANT METABOLISM, P483; KRAUSE GH, 1976, INTACT CHLOROPLAST, P174; Kreft O, 2003, PLANT PHYSIOL, V131, P1843, DOI 10.1104/pp.102.015933; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; Paris S, 2002, PROTEIN EXPRES PURIF, V24, P99, DOI 10.1006/prep.2001.1538; Paris S, 2003, J BIOL CHEM, V278, P5361, DOI 10.1074/jbc.M207379200; Paris S, 2002, PROTEIN EXPRES PURIF, V24, P105, DOI 10.1006/prep.2001.1539; ROGNES SE, 1980, NATURE, V287, P357, DOI 10.1038/287357a0; Rognes SE, 2003, PLANT MOL BIOL, V51, P281, DOI 10.1023/A:1021134621488; UMBARGER HE, 1978, ANNU REV BIOCHEM, V47, P533, DOI 10.1146/annurev.bi.47.070178.002533; WINTER H, 1994, PLANTA, V193, P530, DOI 10.1007/BF02411558	18	37	44	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41178	41183		10.1074/jbc.M509324200	http://dx.doi.org/10.1074/jbc.M509324200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16216875	hybrid, Green Published			2022-12-25	WOS:000233866900009
J	Mashima, R; Saeki, K; Aki, D; Minoda, Y; Takaki, H; Sanada, T; Kobayashi, T; Aburatani, H; Yamanashi, Y; Yoshimura, A				Mashima, R; Saeki, K; Aki, D; Minoda, Y; Takaki, H; Sanada, T; Kobayashi, T; Aburatani, H; Yamanashi, Y; Yoshimura, A			FLN29, a novel interferon- and LPS-inducible gene acting as a negative regulator of toll-like receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INTERLEUKIN-1 RECEPTOR; ENDOTOXIN TOLERANCE; ADAPTER; ACTIVATION; PATHWAY; KINASE; IRAK; LIPOPOLYSACCHARIDE; MYD88	Lipopolysaccharide (LPS) activates macrophages through toll-like receptor (TLR) 4. Although the mechanism of the TLR signaling pathway has been well documented, the mechanism of the negative regulation in response to LPS, particularly LPS tolerance, is still poorly understood. In this study we identified and characterized a novel interferon- and LPS-inducible gene, FLN29, which contains a TRAF6-related zinc finger motif and TRAF family member-associated NF-kappa B activator-related sequences. The induction of FLN29 was dependent on STAT1. The forced expression of FLN29 in macrophage-like RAW cells resulted in the suppression of TLR-mediated NF-kappa B and mitogen-activated protein kinase activation, while a reduced expression of FLN29 by small interfering RNA partly cancelled the down-regulation of LPS signaling. Furthermore, we demonstrated that NF-kappa B activation induced by TRAF6 and TAB2 was impaired by co-expression of FLN29, suggesting FLN29 may regulate the downstream of TRAF6. Taken together, FLN29 is a new negative feedback regulator of TLR signaling.	Kyushu Univ, Div Mol & Cellular Immunol, Med Inst Bioregulat, Higashi Ku, Fukuoka 8128582, Japan; Tokyo Med & Dent Univ, Dept Cell Regulat, Bunkyo Ku, Tokyo 1138510, Japan; Univ Tokyo, Div Genome Sci, Adv Sci & Technol Res Ctr, Meguro Ku, Tokyo 1538904, Japan	Kyushu University; Tokyo Medical & Dental University (TMDU); University of Tokyo	Yoshimura, A (corresponding author), Kyushu Univ, Div Mol & Cellular Immunol, Med Inst Bioregulat, Higashi Ku, Fukuoka 8128582, Japan.	yakihiko@bioreg.kyushu-u.ac.jp	Yoshimura, Akihiko/K-5515-2013					Abbas A, 2000, CELLULAR MOL IMMUNOL, P235; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Brint EK, 2004, NAT IMMUNOL, V5, P373, DOI 10.1038/ni1050; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Crespo A, 2002, EUR J IMMUNOL, V32, P710, DOI 10.1002/1521-4141(200203)32:3<710::AID-IMMU710>3.0.CO;2-T; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; GREISMAN SE, 1966, J EXP MED, V124, P983, DOI 10.1084/jem.124.5.983; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Janssens S, 2003, MOL CELL, V11, P293, DOI 10.1016/S1097-2765(03)00053-4; Joo A, 2004, ONCOGENE, V23, P726, DOI 10.1038/sj.onc.1207174; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; Kawai T, 2001, J IMMUNOL, V167, P5887, DOI 10.4049/jimmunol.167.10.5887; Kinjyo I, 2002, IMMUNITY, V17, P583, DOI 10.1016/S1074-7613(02)00446-6; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Li XX, 1999, MOL CELL BIOL, V19, P4643; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Saeki K, 2003, EMBO J, V22, P3015, DOI 10.1093/emboj/cdg293; Sato S, 2003, J IMMUNOL, V171, P4304, DOI 10.4049/jimmunol.171.8.4304; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Suzuki R, 1998, ONCOGENE, V17, P2271, DOI 10.1038/sj.onc.1202143; Wald D, 2003, NAT IMMUNOL, V4, P920, DOI 10.1038/ni968; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888; ZIEGLERHEITBROCK HWL, 1995, IMMUNOBIOLOGY, V193, P217	31	48	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41289	41297		10.1074/jbc.M508221200	http://dx.doi.org/10.1074/jbc.M508221200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16221674	hybrid			2022-12-25	WOS:000233866900023
J	Ford, L; Guiliano, DB; Oksov, Y; Debnath, AK; Liu, J; Williams, SA; Blaxter, ML; Lustigman, S				Ford, L; Guiliano, DB; Oksov, Y; Debnath, AK; Liu, J; Williams, SA; Blaxter, ML; Lustigman, S			Characterization of a novel filarial serine protease inhibitor, Ov-SPI-1, from Onchocerca volvulus, with potential multifunctional roles during development of the parasite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							EARLY LARVAL DEVELOPMENT; COAGULATION-FACTOR XA; CAENORHABDITIS-ELEGANS; BRUGIA-MALAYI; CHYMOTRYPSIN ELASTASE; ASCARIS-LUMBRICOIDES; PROTEINASE-INHIBITOR; CYSTEINE PROTEASE; TRYPSIN-INHIBITORS; MOLECULAR-CLONING	A novel filarial serine protease inhibitor (SPI) from the human parasitic nematode Onchocerca volvulus, Ov-SPI-1, was identified through the analysis of a molting third-stage larvae expressed sequence tag dataset. Subsequent analysis of the expressed sequence tag datasets of O. volvulus and other filariae identified four other members of this family. These proteins are related to the low molecular weight SPIs originally isolated from Ascaris suum where they are believed to protect the parasite from host intestinal proteases. The two Ov-spi transcripts are up-regulated in the molting larvae and adult stages of the development of the parasite. Recombinant Ov-SPI-1 is an active inhibitor of serine proteases, specifically elastase, chymotrypsin, and cathepsin G. Immunolocalization of the Ov-SPI proteins demonstrates that the endogenous proteins are localized to the basal layer of the cuticle of third-stage, molting third-stage, and fourth-stage larvae, the body channels and multivesicular bodies of third-stage larvae and the processed material found between the two cuticles during molting. In O. volvulus adult worms the Ov-SPI proteins are localized to the sperm and to eggshells surrounding the developing embryos. RNA interference targeting the Ov-spi genes resulted in the specific knockdown of the transcript levels of both Ov-spi-1 and Ov-spi-2, a loss of native proteins, and a significant reduction in both molting and viability of third-stage larvae. We suggest the Ov-SPI proteins play a vital role in nematode molting by controlling the activity of an endogenous serine protease(s). The localization data in adults also indicate that these inhibitors may be involved in other processes such as embryogenesis and spermatogenesis.	New York Blood Ctr, Lindsley F Kimball Res Inst, Mol Parasitol Lab, New York, NY 10021 USA; New York Blood Ctr, Lindsley F Kimball Res Inst, Electron Microscopy Lab, New York, NY 10021 USA; New York Blood Ctr, Lindsley F Kimball Res Inst, Dept Mol Modeling & Drug Design, New York, NY 10021 USA; Univ London Imperial Coll Sci Technol & Med, Div Cell & Mol Biol, Mol & Biochem Parasitol Grp, London SW7 2AY, England; Smith Coll, Clark Sci Ctr, Northampton, MA 01063 USA; Univ Edinburgh, Inst Evolutionary Biol, Edinburgh EH9 3JT, Midlothian, Scotland	New York Blood Center; New York Blood Center; New York Blood Center; Imperial College London; Smith College; University of Edinburgh	Lustigman, S (corresponding author), New York Blood Ctr, Lindsley F Kimball Res Inst, Mol Parasitol Lab, 310 E 67th St, New York, NY 10021 USA.	slustigman@nybloodcenter.org	Blaxter, Mark L/B-4113-2010; Blaxter, Mark/O-2535-2019	Blaxter, Mark L/0000-0003-2861-949X; Williams, Steven/0000-0002-4881-7496; Ford, Louise/0000-0001-7919-2866	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abraham D, 2001, INFECT IMMUN, V69, P262, DOI 10.1128/IAI.69.1.262-270.2001; Ali MF, 2002, BBA-PROTEINS PROTEOM, V1601, P55, DOI 10.1016/S1570-9639(02)00432-6; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BABIN DR, 1984, ARCH BIOCHEM BIOPHYS, V232, P143, DOI 10.1016/0003-9861(84)90530-7; Bania J, 1999, EUR J BIOCHEM, V262, P680, DOI 10.1046/j.1432-1327.1999.00406.x; Bank U, 2001, J LEUKOCYTE BIOL, V69, P197; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Blaxter ML, 1998, NATURE, V392, P71, DOI 10.1038/32160; BONTHRON D, 1986, NUCLEIC ACIDS RES, V14, P7125, DOI 10.1093/nar/14.17.7125; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CAPPELLO M, 1995, P NATL ACAD SCI USA, V92, P6152, DOI 10.1073/pnas.92.13.6152; CAUGHEY GH, 1994, AM J RESP CRIT CARE, V150, pS138, DOI 10.1164/ajrccm/150.6_Pt_2.S138; Chu D, 2004, INFECT IMMUN, V72, P2214, DOI 10.1128/IAI.72.4.2214-2221.2004; COLE SCJ, 1993, FEMS MICROBIOL LETT, V113, P189, DOI 10.1016/0378-1097(93)90267-6; COMLEY JCW, 1989, TROP MED PARASITOL, V40, P311; Dainichi T, 2001, INFECT IMMUN, V69, P7380, DOI 10.1128/IAI.69.12.7380-7386.2001; DAVEY KG, 1968, CAN J ZOOLOG, V46, P893, DOI 10.1139/z68-125; Davis MW, 2004, DEVELOPMENT, V131, P6001, DOI 10.1242/dev.01454; Frand AR, 2005, PLOS BIOL, V3, P1719, DOI 10.1371/journal.pbio.0030312; GALLIN MY, 1995, J EXP MED, V182, P41, DOI 10.1084/jem.182.1.41; GAMBLE HR, 1989, MOL BIOCHEM PARASIT, V33, P49, DOI 10.1016/0166-6851(89)90041-8; GOODMAN RB, 1983, ACTA BIOCHIM POL, V30, P233; GOODMAN RB, 1982, ANAL BIOCHEM, V120, P387, DOI 10.1016/0003-2697(82)90362-1; GREENE BM, 1981, J IMMUNOL, V127, P1611; Guiliano DB, 2004, MOL BIOCHEM PARASIT, V136, P227, DOI 10.1016/j.molbiopara.2004.03.015; GutierrezPena EJ, 1996, PARASITOLOGY, V113, P403, DOI 10.1017/S0031182000066543; Haffner A, 1998, EXP PARASITOL, V90, P26, DOI 10.1006/expr.1998.4313; Hall LR, 1999, CLIN MICROBIOL REV, V12, P445, DOI 10.1128/CMR.12.3.445; HARDY DM, 1995, J BIOL CHEM, V270, P26025, DOI 10.1074/jbc.270.44.26025; Harrison LM, 2002, J BIOL CHEM, V277, P6223, DOI 10.1074/jbc.M109908200; Hartmann S, 2003, INT J PARASITOL, V33, P1291, DOI 10.1016/S0020-7519(03)00163-2; Hartmann S, 2002, PARASITE IMMUNOL, V24, P253, DOI 10.1046/j.1365-3024.2002.00459.x; Hashmi S, 2002, J BIOL CHEM, V277, P3477, DOI 10.1074/jbc.M106117200; Hashmi S, 2004, J BIOL CHEM, V279, P6035, DOI 10.1074/jbc.M312346200; HAWLEY JH, 1992, EXP PARASITOL, V75, P112, DOI 10.1016/0014-4894(92)90126-U; HONG XQ, 1993, EXP PARASITOL, V76, P127, DOI 10.1006/expr.1993.1015; HOTEZ P, 1990, INFECT IMMUN, V58, P3883, DOI 10.1128/IAI.58.12.3883-3892.1990; HUANG K, 1994, STRUCTURE, V2, P679, DOI 10.1016/S0969-2126(00)00068-X; Huelsenbeck JP, 2001, SYST BIOL, V50, P351, DOI 10.1080/106351501300317978; Jackson AL, 2004, TRENDS GENET, V20, P521, DOI 10.1016/j.tig.2004.08.006; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Jakobsen RK, 2005, HISTOCHEM CELL BIOL, V123, P51, DOI 10.1007/s00418-004-0734-5; Jin JM, 1999, GENE, V237, P161, DOI 10.1016/S0378-1119(99)00282-6; JOHNSON EH, 1994, TROP MED PARASITOL, V45, P331; JONES G, 1993, INSECT BIOCHEM MOLEC, V23, P825, DOI 10.1016/0965-1748(93)90071-Y; Joseph GT, 1997, MOL BIOCHEM PARASIT, V90, P55, DOI 10.1016/S0166-6851(97)00132-1; Kettle S, 1997, J GEN VIROL, V78, P677, DOI 10.1099/0022-1317-78-3-677; Krem MM, 2002, TRENDS BIOCHEM SCI, V27, P67, DOI 10.1016/S0968-0004(01)02007-2; Kress H, 2004, INSECT BIOCHEM MOLEC, V34, P855, DOI 10.1016/j.ibmb.2004.05.006; LACKEY A, 1989, EXP PARASITOL, V68, P176, DOI 10.1016/0014-4894(89)90095-7; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Letunic I, 2004, NUCLEIC ACIDS RES, V32, pD142, DOI 10.1093/nar/gkh088; Lizotte-Waniewski M, 2000, INFECT IMMUN, V68, P3491, DOI 10.1128/IAI.68.6.3491-3501.2000; Lu CC, 1998, EXP PARASITOL, V89, P257, DOI 10.1006/expr.1998.4284; Lung O, 2002, GENETICS, V160, P211; Lustigman S, 1996, J BIOL CHEM, V271, P30181, DOI 10.1074/jbc.271.47.30181; LUSTIGMAN S, 1995, ANTIMICROB AGENTS CH, V39, P1913, DOI 10.1128/AAC.39.9.1913; LUSTIGMAN S, 1991, MOL BIOCHEM PARASIT, V45, P65, DOI 10.1016/0166-6851(91)90028-5; LUSTIGMAN S, 1993, PARASITOL TODAY, V9, P294, DOI 10.1016/0169-4758(93)90128-3; LUSTIGMAN S, 1992, J BIOL CHEM, V267, P17339; Lustigmana S, 2004, MOL BIOCHEM PARASIT, V138, P165, DOI 10.1016/j.molbiopara.2004.08.003; MACEN JL, 1993, VIROLOGY, V195, P348, DOI 10.1006/viro.1993.1385; MacLennan K, 2005, PARASITOLOGY, V130, P349, DOI 10.1017/S003118200400616X; Maizels RM, 2001, INT J PARASITOL, V31, P889, DOI 10.1016/S0020-7519(01)00213-2; Maizels RM, 2001, PARASITE IMMUNOL, V23, P327, DOI 10.1046/j.1365-3024.2001.00397.x; Manoury B, 2001, CURR BIOL, V11, P447, DOI 10.1016/S0960-9822(01)00118-X; MARTZEN MR, 1986, EXP PARASITOL, V61, P138, DOI 10.1016/0014-4894(86)90145-1; MARTZEN MR, 1985, EXP PARASITOL, V60, P139, DOI 10.1016/0014-4894(85)90016-5; McKerrow JH, 1999, PARASITOL TODAY, V15, P123, DOI 10.1016/S0169-4758(99)01411-8; Mieszczanek J, 2004, MOL BIOCHEM PARASIT, V137, P151, DOI 10.1016/j.molbiopara.2004.05.011; Mignogna G, 1996, PROTEIN SCI, V5, P357; MORRIS SR, 1994, J BIOL CHEM, V269, P27650; Murray J, 2005, MOL BIOCHEM PARASIT, V139, P197, DOI 10.1016/j.molbiopara.2004.11.008; Nagano I, 2003, J PARASITOL, V89, P92, DOI 10.1645/0022-3395(2003)089[0092:MCACOA]2.0.CO;2; Nguyen TT, 1999, MOL BIOCHEM PARASIT, V102, P79, DOI 10.1016/S0166-6851(99)00088-2; NJOO FL, 1993, CLIN EXP IMMUNOL, V94, P330, DOI 10.1111/j.1365-2249.1993.tb03452.x; Owen CA, 1999, J LEUKOCYTE BIOL, V65, P137, DOI 10.1002/jlb.65.2.137; Page Antony P., 2001, P167, DOI 10.1079/9780851994239.0167; Parkinson J, 2004, NAT GENET, V36, P1259, DOI 10.1038/ng1472; Parkinson J, 2004, NUCLEIC ACIDS RES, V32, pD427, DOI 10.1093/nar/gkh018; Parkinson NM, 2004, INSECT BIOCHEM MOLEC, V34, P565, DOI 10.1016/j.ibmb.2004.03.003; PEANASKY RJ, 1984, ARCH BIOCHEM BIOPHYS, V232, P127, DOI 10.1016/0003-9861(84)90528-9; PEANASKY RJ, 1984, ARCH BIOCHEM BIOPHYS, V232, P135, DOI 10.1016/0003-9861(84)90529-0; Pearlman E, 1998, INVEST OPHTH VIS SCI, V39, P1176; PETERS K, 1991, GENETICS, V129, P95; Pfaff AW, 2002, INT J PARASITOL, V32, P171, DOI 10.1016/S0020-7519(01)00350-2; POLANOWSKI A, 1992, COMP BIOCHEM PHYS B, V102, P757, DOI 10.1016/0305-0491(92)90075-3; Poole CB, 2003, J BIOL CHEM, V278, P36183, DOI 10.1074/jbc.M302601200; Rawlings ND, 2004, BIOCHEM J, V378, P705, DOI 10.1042/BJ20031825; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Rayburn LYM, 2003, GENETICS, V163, P227; Rhoads ML, 2000, EXP PARASITOL, V95, P36, DOI 10.1006/expr.2000.4502; RICHER JK, 1992, EXP PARASITOL, V75, P213, DOI 10.1016/0014-4894(92)90181-9; Romaris F, 2002, MOL BIOCHEM PARASIT, V122, P149, DOI 10.1016/S0166-6851(02)00094-4; SAKANARI JA, 1989, P NATL ACAD SCI USA, V86, P4863, DOI 10.1073/pnas.86.13.4863; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SAMUELS RI, 1995, COMP BIOCHEM PHYS B, V110, P661, DOI 10.1016/0305-0491(94)00205-9; SAMUELS RI, 1993, INSECT BIOCHEM MOLEC, V23, P607, DOI 10.1016/0965-1748(93)90034-P; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Schierack P, 2003, INFECT IMMUN, V71, P2422, DOI 10.1128/IAI.71.5.2422-2429.2003; Schonemeyer A, 2001, J IMMUNOL, V167, P3207, DOI 10.4049/jimmunol.167.6.3207; Stanssens P, 1996, P NATL ACAD SCI USA, V93, P2149, DOI 10.1073/pnas.93.5.2149; Steinhoff M, 2005, ENDOCR REV, V26, P1, DOI 10.1210/er.2003-0025; Suzuki M, 2004, BIOL CHEM, V385, P565, DOI 10.1515/BC.2004.069; SWOFFORD DL, 1996, MOL SYSTEMATICS, V2, P407; Thacker C, 2000, BIOESSAYS, V22, P545, DOI 10.1002/(SICI)1521-1878(200006)22:6&lt;545::AID-BIES7&gt;3.0.CO;2-F; THACKER C, 1995, GENE DEV, V9, P956, DOI 10.1101/gad.9.8.956; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Unnasch TR, 2000, INT J PARASITOL, V30, P543, DOI 10.1016/S0020-7519(99)00184-8; YENBUTR P, 1995, INFECT IMMUN, V63, P1745, DOI 10.1128/IAI.63.5.1745-1753.1995; Zang XX, 2000, J IMMUNOL, V165, P5161, DOI 10.4049/jimmunol.165.9.5161; Zang XX, 2001, TRENDS BIOCHEM SCI, V26, P191, DOI 10.1016/S0968-0004(00)01761-8; Zhan B, 2002, MOL BIOCHEM PARASIT, V120, P291, DOI 10.1016/S0166-6851(01)00453-4; Zhu SY, 2002, COMP BIOCHEM PHYS B, V131, P749, DOI 10.1016/S1096-4959(02)00020-9	114	58	76	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40845	40856		10.1074/jbc.M504434200	http://dx.doi.org/10.1074/jbc.M504434200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16186127	Green Published, hybrid			2022-12-25	WOS:000233666600056
J	Hu, JP; de Souza-Pinto, NC; Haraguchi, K; Hogue, BA; Jaruga, P; Greenberg, MM; Dizdaroglu, M; Bohr, VA				Hu, JP; de Souza-Pinto, NC; Haraguchi, K; Hogue, BA; Jaruga, P; Greenberg, MM; Dizdaroglu, M; Bohr, VA			Repair of formamidopyrimidines in DNA involves different glycosylases - Role of the OGG1, NTH1, and NEIL1 enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE DAMAGE; CENTER-DOT; ENDONUCLEASE-VIII; EXCISION; IDENTIFICATION; CHROMATIN; GUANINE; LESIONS; MICE; NTH1	The oxidatively induced DNA lesions 2,6-diamino-4-hydroxy-5-formamidopyrimidine (FapyG) and 4,6-diamino-5-formamidopyrimidine (FapyA) are formed abundantly in DNA of cultured cells or tissues exposed to ionizing radiation or to other free radical-generating systems. In vitro studies indicate that these lesions are miscoding, can block the progression of DNA polymerases, and are substrates for base excision repair. However, no study has yet addressed how these lesions are metabolized in cellular extracts. The synthesis of oligonucleotides containing FapyG and FapyA at defined positions was recently reported. These constructs allowed us to investigate the repair of Fapy lesions in nuclear and mitochondrial extracts from wild type and knock-out mice lacking the two major DNA glycosylases for repair of oxidative DNA damage, OGG1and NTH1. The background level of FapyG/FapyA in DNA from these mice was also determined. Endogenous FapyG levels in liver DNA from wild type mice were significantly higher than 8-hydroxyguanine levels. FapyG and FapyA were efficiently repaired in nuclear and mitochondrial extracts from wild type animals but not in the glycosylase-deficient mice. Our results indicated that OGG1 and NTH1 are the major DNA glycosylases for the removal of FapyG and FapyA, respectively. Tissue-specific analysis suggested that other DNA glycosylases may contribute to FapyA repair when NTH1 is poorly expressed. We identified NEIL1 in liver mitochondria, which could account for the residual incision activity in the absence of OGG1 and NTH1. FapyG and FapyA levels were significantly elevated in DNA from the knock-out mice, underscoring the biological role of OGG1 and NTH1 in the repair of these lesions.	NIA, Lab Mol Gerontol, IRP, NIH, Baltimore, MD 21224 USA; Johns Hopkins Univ, Dept Chem, Baltimore, MD 21218 USA; Natl Inst Stand & Technol, Chem Sci & Technol Lab, Gaithersburg, MD 20899 USA; Univ Maryland Baltimore Cty, Dept Chem & Biochem Engn, Baltimore, MD 21250 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins University; National Institute of Standards & Technology (NIST) - USA; University System of Maryland; University of Maryland Baltimore County	Bohr, VA (corresponding author), NIA, Lab Mol Gerontol, IRP, NIH, Box1,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	vbohr@nih.gov	Bohr, Vilhelm/AAP-5931-2020; Souza-Pinto, Nadja/T-3050-2019; Jaruga, Pawel/M-4378-2015; Souza-Pinto, Nadja C./C-3462-2013	Souza-Pinto, Nadja/0000-0003-4206-964X; Souza-Pinto, Nadja C./0000-0003-4206-964X; Jaruga, Pawel/0000-0001-9192-6084	NCI NIH HHS [CA-074954] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [ZIAAG000727, ZIAAG000733, Z01AG000733, Z01AG000727] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Asagoshi K, 2002, J BIOL CHEM, V277, P14589, DOI 10.1074/jbc.M200316200; Bandaru V, 2002, DNA REPAIR, V1, P517, DOI 10.1016/S1568-7864(02)00036-8; Candeias LP, 2000, CHEM-EUR J, V6, P475, DOI 10.1002/(SICI)1521-3765(20000204)6:3<475::AID-CHEM475>3.0.CO;2-E; Dantzer F, 2002, NUCLEIC ACIDS RES, V30, P2349, DOI 10.1093/nar/30.11.2349; de Souza-Pinto NC, 2001, FREE RADICAL BIO MED, V30, P916, DOI 10.1016/S0891-5849(01)00483-X; de Souza-Pinto NC, 2001, CANCER RES, V61, P5378; Delaney MO, 2002, ANGEW CHEM INT EDIT, V41, P771, DOI 10.1002/1521-3773(20020301)41:5<771::AID-ANIE771>3.0.CO;2-V; Dherin C, 1999, NUCLEIC ACIDS RES, V27, P4001, DOI 10.1093/nar/27.20.4001; DIZDAROGLU M, 1993, CANCER RES, V53, P1269; Dizdaroglu M, 2003, MUTAT RES-FUND MOL M, V531, P109, DOI 10.1016/j.mrfmmm.2003.07.003; DIZDAROGLU M, 1993, FEBS LETT, V315, P1, DOI 10.1016/0014-5793(93)81120-O; Dizdaroglu M, 2001, FREE RADICAL BIO MED, V30, P774, DOI 10.1016/S0891-5849(01)00464-6; DOETSCH PW, 1995, BIOCHEMISTRY-US, V34, P737, DOI 10.1021/bi00003a005; Evans MD, 2004, MUTAT RES-REV MUTAT, V567, P1, DOI 10.1016/j.mrrev.2003.11.001; Graziewicz MA, 2000, FREE RADICAL BIO MED, V28, P75, DOI 10.1016/S0891-5849(99)00208-7; Haraguchi K, 2002, J AM CHEM SOC, V124, P3263, DOI 10.1021/ja012135q; Hazra TK, 2002, J BIOL CHEM, V277, P30417, DOI 10.1074/jbc.C200355200; Hazra TK, 2002, P NATL ACAD SCI USA, V99, P3523, DOI 10.1073/pnas.062053799; Hu JP, 2005, NUCLEIC ACIDS RES, V33, P3271, DOI 10.1093/nar/gki636; Hudson EK, 1998, FREE RADICAL RES, V29, P573, DOI 10.1080/10715769800300611; Jaruga P, 2004, BIOCHEMISTRY-US, V43, P15909, DOI 10.1021/bi048162l; Jaruga P, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh087; Jaruga P, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.6.e16; Jiang YL, 2005, J ORG CHEM, V70, P141, DOI 10.1021/jo048253o; Karahalil B, 2003, J BIOL CHEM, V278, P33701, DOI 10.1074/jbc.M301617200; Kasprzak KS, 1997, CARCINOGENESIS, V18, P271, DOI 10.1093/carcin/18.2.271; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Luna L, 2000, MUTAT RES-DNA REPAIR, V460, P95, DOI 10.1016/S0921-8777(00)00015-X; MORI T, 1993, INT J RADIAT BIOL, V64, P645, DOI 10.1080/09553009314551881; Morland I, 2002, NUCLEIC ACIDS RES, V30, P4926, DOI 10.1093/nar/gkf618; *NIH, NIH PUBL, V8523; Reddy P, 2004, PROTEIN EXPRES PURIF, V34, P126, DOI 10.1016/j.pep.2003.11.019; Rosenquist TA, 2003, DNA REPAIR, V2, P581, DOI 10.1016/S1568-7864(03)00025-9; Souza-Pinto NC, 1999, NUCLEIC ACIDS RES, V27, P1935, DOI 10.1093/nar/27.8.1935; Stierum RH, 1999, J BIOL CHEM, V274, P7128, DOI 10.1074/jbc.274.11.7128; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; Takao M, 2002, J BIOL CHEM, V277, P42205, DOI 10.1074/jbc.M206884200; Tudek B, 2003, J BIOCHEM MOL BIOL, V36, P12; Tudek B, 1999, ACTA BIOCHIM POL, V46, P785, DOI 10.18388/abp.1999_4151; Wang D, 1998, MUTAT RES-FUND MOL M, V400, P99, DOI 10.1016/S0027-5107(98)00066-9; Wiederholt CJ, 2005, NUCLEIC ACIDS RES, V33, P3331, DOI 10.1093/nar/gki655; Wiederholt CJ, 2002, J AM CHEM SOC, V124, P7278, DOI 10.1021/ja026522r; Wilson DM, 2003, FRONT BIOSCI-LANDMRK, V8, pD963, DOI 10.2741/1109	43	164	168	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40544	40551		10.1074/jbc.M508772200	http://dx.doi.org/10.1074/jbc.M508772200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16221681	hybrid			2022-12-25	WOS:000233666600021
J	Kerov, V; Chen, DS; Moussaif, M; Chen, YJ; Chen, CK; Artemyev, NO				Kerov, V; Chen, DS; Moussaif, M; Chen, YJ; Chen, CK; Artemyev, NO			Transducin activation state controls its light-dependent translocation in rod photoreceptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE ACCELERATING PROTEIN; RHODOPSIN PHOSPHORYLATION; MEMBRANE ANCHOR; TRANSGENIC MICE; OUTER SEGMENTS; ALPHA-SUBUNIT; RAT RETINA; PHOTOTRANSDUCTION; MECHANISM; PHOSPHODIESTERASE	Light-dependent redistribution of transducin between the rod outer segments ( OS) and other photoreceptor compartments including the inner segments (IS) and synaptic terminals (ST) is recognized as a critical contributing factor to light and dark adaptation. The mechanisms of light-induced transducin translocation to the IS/ST and its return to the OS during dark adaptation are not well understood. We have probed these mechanisms by examining light-dependent localizations of the transducin-alpha subunit (Gt alpha) in mice lacking the photoreceptor GAP-protein RGS9, or expressing the GTPase-deficient mutant Gt alpha Q200L. An illumination threshold for the Gt alpha movement out of the OS is lower in the RGS9 knockout mice, indicating that the fast inactivation of transducin in the wild-type mice limits its translocation to the IS/ST. Transgenic Gt alpha Q200L mice have significantly diminished levels of proteins involved in cGMP metabolism in rods, most notably the PDE6 catalytic subunits, and severely reduced sensitivity to light. Similarly to the native Gt alpha, the Gt alpha Q200L mutant is localized to the IS/ST compartment in light-adapted transgenic mice. However, the return of Gt alpha Q200L to the OS during dark adaptation is markedly slower than normal. Thus, the light-dependent translocations of transducin are controlled by the GTP-hydrolysis on Gt alpha, and apparently, do not require Gt alpha interaction with RGS9 and PDE6.	Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Virginia Commonwealth Univ, Dept Biochem, Richmond, VA 23298 USA	University of Iowa; Virginia Commonwealth University	Artemyev, NO (corresponding author), Univ Iowa, Coll Med, Dept Physiol & Biophys, 5-532 Bowen Sci Bldg,51 Newton Rd, Iowa City, IA 52242 USA.	nikolai-artemyev@uiowa.edu		Artemyev, Nikolai/0000-0002-5266-6854	NATIONAL EYE INSTITUTE [R01EY013811, R01EY012682, R56EY013811] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY012682, EY12682, EY13811] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Alves ID, 2005, BIOPHYS J, V88, P198, DOI 10.1529/biophj.104.046722; ARSHAVSKY VY, 1991, J BIOL CHEM, V266, P18530; Arshavsky VY, 2002, ANNU REV PHYSIOL, V64, P153, DOI 10.1146/annurev.physiol.64.082701.102229; BRANN MR, 1987, SCIENCE, V235, P585, DOI 10.1126/science.3101175; Calvert PD, 2000, P NATL ACAD SCI USA, V97, P13913, DOI 10.1073/pnas.250478897; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; DETERRE P, 1986, Proteins Structure Function and Genetics, V1, P188, DOI 10.1002/prot.340010210; Dizhoor AM, 1999, METHODS, V19, P521, DOI 10.1006/meth.1999.0894; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Hu G, 2003, J BIOL CHEM, V278, P14550, DOI 10.1074/jbc.M212046200; Hu G, 2002, P NATL ACAD SCI USA, V99, P9755, DOI 10.1073/pnas.152094799; Hurley JB, 1998, VISION RES, V38, P1341, DOI 10.1016/S0042-6989(97)00459-8; Kerov VS, 2005, MOL CELL NEUROSCI, V28, P485, DOI 10.1016/j.mcn.2004.10.010; KLEUSS C, 1994, P NATL ACAD SCI USA, V91, P9828, DOI 10.1073/pnas.91.21.9828; LEM J, 1991, NEURON, V6, P201, DOI 10.1016/0896-6273(91)90356-5; Lishko PV, 2002, J BIOL CHEM, V277, P24376, DOI 10.1074/jbc.M203237200; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; Medina R, 1996, J BIOL CHEM, V271, P24720, DOI 10.1074/jbc.271.40.24720; Mendez A, 2003, J NEUROSCI, V23, P3124; Muradov KG, 2000, J BIOL CHEM, V275, P6969, DOI 10.1074/jbc.275.10.6969; Nair KS, 2005, NEURON, V46, P555, DOI 10.1016/j.neuron.2005.03.023; Nair KS, 2005, INVEST OPHTH VIS SCI, V46, P383, DOI 10.1167/iovs.04-1006; Natochin M, 1997, J BIOL CHEM, V272, P17444, DOI 10.1074/jbc.272.28.17444; Ohguro H, 1996, J BIOL CHEM, V271, P5215; Palczewski K, 2004, BIOCHEM BIOPH RES CO, V322, P1123, DOI 10.1016/j.bbrc.2004.07.122; PHILP NJ, 1987, FEBS LETT, V225, P127, DOI 10.1016/0014-5793(87)81144-4; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; RAPORT CJ, 1994, INVEST OPHTH VIS SCI, V35, P2932; RAPORT CJ, 1989, J BIOL CHEM, V264, P7122; Sokolov M, 2004, J BIOL CHEM, V279, P19149, DOI 10.1074/jbc.M311058200; Sokolov M, 2002, NEURON, V34, P95, DOI 10.1016/S0896-6273(02)00636-0; Strissel KJ, 2005, J BIOL CHEM, V280, P29250, DOI 10.1074/jbc.M501789200; WHELAN JP, 1988, J NEUROSCI RES, V20, P263, DOI 10.1002/jnr.490200216; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILSON PT, 1995, J BIOL CHEM, V270, P9667, DOI 10.1074/jbc.270.16.9667; Zhang HB, 2003, MOL VIS, V9, P231	40	47	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					41069	41076		10.1074/jbc.M508849200	http://dx.doi.org/10.1074/jbc.M508849200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16207703	hybrid			2022-12-25	WOS:000233666600081
J	Kim, KM; Song, JJ; An, JY; Kwon, YT; Lee, YJ				Kim, KM; Song, JJ; An, JY; Kwon, YT; Lee, YJ			Pretreatment of acetylsalicylic acid promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by down-regulating BCL-2 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRAIL-INDUCED APOPTOSIS; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PROTEIN-KINASE-B; CHEMOPREVENTIVE AGENTS; SODIUM-SALICYLATE; DECOY RECEPTORS; FACTOR REQUIRES; CYTOCHROME-C; CANCER-CELLS	Tumor necrosis factor-related apoptosis-inducing ligand ( TRAIL) has been shown to be selective in the induction of apoptosis in cancer cells with minimal toxicity to normal tissues. However, not all cancers are sensitive to TRAIL-mediated apoptosis. Thus, TRAIL-resistant cancer cells must be sensitized first to become responsive to TRAIL. In this study, we observed that pretreatment by acetylsalicylic acid (ASA) augmented TRAIL-induced apoptotic death in human prostate adenocarcinoma LNCaP and human colorectal carcinoma CX-1 cells. Western blot analysis showed that pretreatment of ASA followed by TRAIL treatment activated caspases (8, 9, and 3) and cleaved poly(ADP-ribose) polymerase, the hallmark feature of apoptosis. Most interestingly, at least 12 h of pretreatment with ASA was prerequisite for promoting TRAIL- induced apoptosis and was related to down-regulation of BCL-2. Biochemical analysis revealed that ASA inhibited NF-kappa B activity, which is known to regulate BCL-2 gene expression, by dephosphorylating I kappa B-alpha and inhibiting IKK beta activity but not by affecting the HER-2/ neu phosphatidylinositol 3-kinase-Akt signal pathway. Overexpression of BCL-2 suppressed the promotive effect of ASA on TRAIL-induced apoptosis and changes in mitochondrial membrane potential. Taken together, our studies suggested that ASA-promoted TRAIL cytotoxicity is mediated through down-regulating BCL-2 and by decreasing mitochondrial membrane potential.	Univ Pittsburgh, Hillman Canc Ctr 1 19, Dept Surg & Pharmacol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Pharm, Ctr Pharmacogenet, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lee, YJ (corresponding author), Univ Pittsburgh, Hillman Canc Ctr 1 19, Dept Surg, 5117 Ctr Ave,Rm 1-19, Pittsburgh, PA 15213 USA.	leeyj@msx.upmc.edu		Song, Jae/0000-0001-8183-9550	NCI NIH HHS [CA95191, CA96989] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095191, R01CA096989] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; Bair WB, 2002, CANCER EPIDEM BIOMAR, V11, P1645; Bouralexis S, 2003, BRIT J CANCER, V89, P206, DOI 10.1038/sj.bjc.6601021; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Bui NT, 2001, J CELL BIOL, V152, P753, DOI 10.1083/jcb.152.4.753; Burow ME, 1998, CANCER RES, V58, P4940; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chawla-Sarkar M, 2003, J BIOL CHEM, V278, P39461, DOI 10.1074/jbc.M306111200; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; de Jong S, 2001, CANCER METAST REV, V20, P51, DOI 10.1023/A:1013112624971; DEL PL, 1997, SCIENCE, V278, P687; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Fulda S, 2004, ONCOGENE, V23, P7611, DOI 10.1038/sj.onc.1207970; Gu Q, 2005, CARCINOGENESIS, V26, P541, DOI 10.1093/carcin/bgh345; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hersey P, 2003, CANCER BIOL THER, V2, P541, DOI 10.4161/cbt.2.5.543; Hetman M, 2000, J NEUROSCI, V20, P2567; Hofer S, 2001, MICROBES INFECT, V3, P259, DOI 10.1016/S1286-4579(01)01378-8; Hosomi Y, 2000, LUNG CANCER, V30, P73, DOI 10.1016/S0169-5002(00)00132-X; Kim KY, 2003, CANCER LETT, V189, P157, DOI 10.1016/S0304-3835(02)00519-0; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Kutuk O, 2004, CYTOKINE, V25, P229, DOI 10.1016/j.cyto.2003.11.007; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee YJ, 2001, ONCOGENE, V20, P1476, DOI 10.1038/sj.onc.1204225; Li M, 2000, CANCER EPIDEM BIOMAR, V9, P545; Li Xiao-an, 2003, Zhonghua Gan Zang Bing Za Zhi, V11, P676; MARNETT LJ, 1995, PREV MED, V24, P103, DOI 10.1006/pmed.1995.1017; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; Nagane M, 2000, CANCER RES, V60, P847; Ng CP, 2002, ADV CANCER RES, V85, P145, DOI 10.1016/S0065-230X(02)85005-9; Nyormoi O, 2003, CELL DEATH DIFFER, V10, P558, DOI 10.1038/sj.cdd.4401209; Ozes ON, 1999, NATURE, V401, P82; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Park SY, 2002, BIOCHEM BIOPH RES CO, V291, P233, DOI 10.1006/bbrc.2002.6452; Pique M, 2000, FEBS LETT, V480, P193, DOI 10.1016/S0014-5793(00)01922-0; Qiao L, 1998, BIOCHEM PHARMACOL, V55, P53, DOI 10.1016/S0006-2952(97)00400-0; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; RodriguezViciana P, 1996, PHILOS T ROY SOC B, V351, P225, DOI 10.1098/rstb.1996.0020; Rosenberg L, 1998, CANCER-AM CANCER SOC, V82, P2326, DOI 10.1002/(SICI)1097-0142(19980615)82:12<2326::AID-CNCR5>3.0.CO;2-Q; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Tillman DM, 2003, CANCER RES, V63, P5118; Wajant H, 2002, APOPTOSIS, V7, P449, DOI 10.1023/A:1020039225764; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wargovich MJ, 2000, CARCINOGENESIS, V21, P1149, DOI 10.1093/carcin/21.6.1149; Williams CS, 1997, J CLIN INVEST, V100, P1325, DOI 10.1172/JCI119651; Wong BCY, 1999, BIOMED PHARMACOTHER, V53, P315, DOI 10.1016/S0753-3322(00)88503-0; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zandi E, 1999, MOL CELL BIOL, V19, P4547; Zimmermann KC, 2000, NEOPLASIA, V2, P505, DOI 10.1038/sj.neo.7900120	62	48	54	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					41047	41056		10.1074/jbc.M503713200	http://dx.doi.org/10.1074/jbc.M503713200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16199534	hybrid			2022-12-25	WOS:000233666600079
J	Jung, JH; Traugh, JA				Jung, JH; Traugh, JA			Regulation of the interaction of Pak2 with Cdc42 via autophosphorylation of serine 141	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE GAMMA-PAK; P21-ACTIVATED-KINASE-1 PAK1; ALPHA-PAK; ACTIVATION; PHOSPHORYLATION; LOCALIZATION; MEMBRANE; REVEALS; CELLS; MECHANISM	Pak2, a member of the p21-activated protein kinase ( Pak) family, is activated in response to a variety of stresses and is directly involved in the induction of cytostasis. At the molecular level Pak2 binds Cdc42( GTP), translocating Pak2 to the endoplasmic reticulum where it is autophosphorylated and activated. Pak2 is autophosphorylated at eight sites; Ser-141 and Ser-165 in the regulatory domain and Thr-402 in the activation loop are identified as key sites in activation of the protein kinase. The function of phosphorylation of Ser-141 and Ser-165 on the activation was analyzed with wildtype ( WT) and mutants of Pak2. With S141A, the level of autophosphorylation was reduced to 65% as compared with that of WT and S141D with a concomitant 45% reduction in substrate phosphorylation, indicating that phosphorylation at Ser-141 is required for optimal activity. Autophosphorylation inhibited the interaction between WT Pak2 and Cdc42( GTP). In 293T cells, WT Pak2, S141A, and S141D formed a stable complex with the constitutively active mutant Cdc42 L61, but not with the dominant negative Cdc42 N17. As shown in glutathione S-transferase pull-down assays, S141A bound to Cdc42( GTP) at a 6-fold higher level than that of S141D. In contrast, the S165A and S165D mutants had no effect on autophosphorylation, binding to Cdc42, or activation of Pak2. In summary, autophosphorylation of Ser-141 was required for activation of Pak2 and down-regulated the interaction of Pak2 with Cdc42. A model is proposed suggesting that binding of Cdc42 localizes Pak2 to the endoplasmic reticulum, where autophosphorylation alters association of the two proteins.	Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA	University of California System; University of California Riverside	Traugh, JA (corresponding author), Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.	jolinda.traugh@ucr.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026738] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26738] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGRODIA S, 1995, J BIOL CHEM, V270, P731; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Chong C, 2001, J BIOL CHEM, V276, P17347, DOI 10.1074/jbc.M009316200; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Dharmawardhane S, 1999, J LEUKOCYTE BIOL, V66, P521, DOI 10.1002/jlb.66.3.521; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Gatti A, 1999, J BIOL CHEM, V274, P8022, DOI 10.1074/jbc.274.12.8022; Huang ZD, 2003, J BIOL CHEM, V278, P13101, DOI 10.1074/jbc.M212557200; Jakobi R, 1996, J BIOL CHEM, V271, P6206, DOI 10.1074/jbc.271.11.6206; Jakobi R, 2000, EUR J BIOCHEM, V267, P4414, DOI 10.1046/j.1432-1327.2000.01488.x; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Roig J, 2000, J BIOL CHEM, V275, P16933, DOI 10.1074/jbc.M001627200; Roig J, 2001, VITAM HORM, V62, P167, DOI 10.1016/S0083-6729(01)62004-1; Roig J, 2000, P NATL ACAD SCI USA, V97, P14346, DOI 10.1073/pnas.97.26.14346; Roig J, 1999, J BIOL CHEM, V274, P31119, DOI 10.1074/jbc.274.44.31119; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Sells MA, 2000, J CELL BIOL, V151, P1449, DOI 10.1083/jcb.151.7.1449; TUAZON PT, 1989, J BIOL CHEM, V264, P2773; Tuazon PT, 1998, BIOCHEMISTRY-US, V37, P17024, DOI 10.1021/bi982103o; Tuazon PT, 1997, BIOCHEMISTRY-US, V36, P16059, DOI 10.1021/bi9717845; Walter BN, 1998, J BIOL CHEM, V273, P28733, DOI 10.1074/jbc.273.44.28733; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	28	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40025	40031		10.1074/jbc.M509075200	http://dx.doi.org/10.1074/jbc.M509075200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16204230	hybrid			2022-12-25	WOS:000233461300040
J	Williams, KL; Lich, JD; Duncan, JA; Reed, W; Rallabhandi, P; Moore, C; Kurtz, S; Coffield, VM; Accavitti-Loper, MA; Su, LS; Vogel, SN; Braunstein, M; Ting, JPY				Williams, KL; Lich, JD; Duncan, JA; Reed, W; Rallabhandi, P; Moore, C; Kurtz, S; Coffield, VM; Accavitti-Loper, MA; Su, LS; Vogel, SN; Braunstein, M; Ting, JPY			The CATERPILLER protein Monarch-1 is an antagonist of Toll-like receptor-, tumor necrosis factor alpha-, and Mycobacterium tuberculosis-induced pro-inflammatory signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ENDOTOXIN-TOLERANT CELLS; CUTTING EDGE; AUTOINFLAMMATORY DISORDERS; BACTERIAL PEPTIDOGLYCAN; NEGATIVE REGULATION; HOST RECOGNITION; CIAS1 MUTATIONS; CROHNS-DISEASE; FAMILY	The CATERPILLER (CLR, also NOD and NLR) proteins share structural similarities with the nucleotide binding domain ( NBD)leucine- rich repeat (LRR) superfamily of plant disease-resistance (R) proteins and are emerging as important immune regulators in animals. CLR proteins contain NBD-LRR motifs and are linked to a limited number of distinct N-terminal domains including transactivation, CARD (caspase activation and recruitment), and pyrin domains (PyD). The CLR gene, Monarch-1/Pypaf7, is expressed by resting primary myeloid/monocytic cells, and its expression in these cells is reduced by Toll-like receptor (TLR) agonists tumor necrosis factor (TNF) alpha and Mycobacterium tuberculosis. Monarch-1 reduces NF kappa B activation by TLR-signaling molecules MyD88, IRAK-1 (type I interleukin-1 receptor-associated protein kinase), and TRAF6 (TNF receptor (TNFR)-associated factor) as well as TNFR signaling molecules TRAF2 and RIP1 but not the downstream NF kappa B subunit p65. This indicates that Monarch-1 is a negative regulator of both TLR and TNFR pathways. Reducing Monarch-1 expression with small interference RNA in myeloid/monocytic cells caused a dramatic increase in NF kappa B activation and cytokine expression in response to TLR2/TLR4 agonists, TNF alpha, or M. tuberculosis infection, suggesting that Monarch-1 is a negative regulator of inflammation. Because Monarch-1 is the first CLR protein that interferes with both TLR2 and TLR4 activation, the mechanism of this interference is significant. We find that Monarch-1 associates with IRAK-1 but not MyD88, resulting in the blockage of IRAK-1 hyperphosphorylation. Mutants containing the NBD-LRR or PyD-NBD also blocked IRAK-1 activation. This is the first example of a CLR protein that antagonizes inflammatory responses initiated by TLR agonists via interference with IRAK-1 activation.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Immunol Microbiol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Med, Div Infect Dis, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Environm Med & Lung Biol, Chapel Hill, NC 27599 USA; Univ Maryland, Dept Microbiol & Immunol, Baltimore, MD 21201 USA; Univ Alabama Birmingham, Birmingham, AL 35294 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University System of Maryland; University of Maryland Baltimore; University of Alabama System; University of Alabama Birmingham	Ting, JPY (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, CB7295, Chapel Hill, NC 27599 USA.	panyun@med.unc.edu		Kurtz, Sherry/0000-0002-2281-8984	NIAID NIH HHS [R01 AI077454, AI057175, R01 AI063031, R01 AI080432, AI063031, L30 AI057175] Funding Source: Medline; NIDCR NIH HHS [DE16326, R01 DE016326] Funding Source: Medline; NIDDK NIH HHS [P01 DK038108, DK38108] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI080432, R01AI063031, R01AI077454] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE016326] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038108] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aksentijevich I, 2002, ARTHRITIS RHEUM-US, V46, P3340, DOI 10.1002/art.10688; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Bernot A, 1998, HUM MOL GENET, V7, P1317, DOI 10.1093/hmg/7.8.1317; Beutler B, 2004, NATURE, V430, P257, DOI 10.1038/nature02761; Beutler B, 2001, IMMUNITY, V15, P5, DOI 10.1016/S1074-7613(01)00176-5; Bruey JM, 2004, J BIOL CHEM, V279, P51897, DOI 10.1074/jbc.M406741200; Burns K, 2003, J EXP MED, V197, P263, DOI 10.1084/jem.20021790; Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945; Conti BJ, 2005, J BIOL CHEM, V280, P18375, DOI 10.1074/jbc.M413169200; Cross AS, 2004, VACCINE, V22, P812, DOI 10.1016/j.vaccine.2003.11.025; Dempsey PW, 2003, CYTOKINE GROWTH F R, V14, P193, DOI 10.1016/S1359-6101(03)00021-2; Eliezer D, 2003, STRUCTURE, V11, P1190, DOI 10.1016/j.str.2003.09.008; Fukao T, 2003, TRENDS IMMUNOL, V24, P358, DOI 10.1016/S1471-4906(03)00139-X; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; Harton JA, 2002, J IMMUNOL, V169, P4088, DOI 10.4049/jimmunol.169.8.4088; Heldwein KA, 2002, MICROBES INFECT, V4, P937, DOI 10.1016/S1286-4579(02)01611-8; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Hoffman HM, 2001, NAT GENET, V29, P301, DOI 10.1038/ng756; Hofmann A, 1996, P NATL ACAD SCI USA, V93, P5185, DOI 10.1073/pnas.93.11.5185; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Hull KM, 2003, CURR OPIN RHEUMATOL, V15, P61, DOI 10.1097/00002281-200301000-00011; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Janssens S, 2003, CLIN MICROBIOL REV, V16, P637, DOI 10.1128/CMR.16.4.637-646.2003; Janssens S, 2002, CURR BIOL, V12, P467, DOI 10.1016/S0960-9822(02)00712-1; Kinoshita T, 2005, J BIOL CHEM, V280, P21720, DOI 10.1074/jbc.M410057200; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Kollewe C, 2004, J BIOL CHEM, V279, P5227, DOI 10.1074/jbc.M309251200; Kopp E, 2003, CURR OPIN IMMUNOL, V15, P396, DOI 10.1016/S0952-7915(03)00080-3; Lee LF, 1997, MOL CELL BIOL, V17, P5097, DOI 10.1128/MCB.17.9.5097; Li LW, 2000, J BIOL CHEM, V275, P23340, DOI 10.1074/jbc.M001950200; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Martinon F, 2001, CURR BIOL, V11, pR118, DOI 10.1016/S0960-9822(01)00056-2; McDermott MF, 2002, CURR OPIN ALLERGY CL, V2, P511, DOI 10.1097/00130832-200212000-00006; MCINTIRE FC, 1976, J IMMUNOL, V117, P674; Medvedev AE, 2002, J IMMUNOL, V169, P5209, DOI 10.4049/jimmunol.169.9.5209; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Miceli-Richard C, 2001, NAT GENET, V29, P19, DOI 10.1038/ng720; Neven B, 2004, BLOOD, V103, P2809, DOI 10.1182/blood-2003-07-2531; O'Neill LAJ, 2003, TRENDS IMMUNOL, V24, P287, DOI 10.1016/S1471-4906(03)00115-7; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Pawlowski K, 2001, TRENDS BIOCHEM SCI, V26, P85, DOI 10.1016/S0968-0004(00)01729-1; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; Stewart GR, 2003, NAT REV MICROBIOL, V1, P97, DOI 10.1038/nrmicro749; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Tschopp J, 2003, NAT REV MOL CELL BIO, V4, P95, DOI 10.1038/nrm1019; Vogel Stefanie N, 2003, Mol Interv, V3, P466, DOI 10.1124/mi.3.8.466; Wang L, 2002, J BIOL CHEM, V277, P29874, DOI 10.1074/jbc.M203915200; Williams KL, 2003, J IMMUNOL, V170, P5354, DOI 10.4049/jimmunol.170.11.5354; Yamamoto M, 2004, MOL IMMUNOL, V40, P861, DOI 10.1016/j.molimm.2003.10.006; Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351; Zhang GL, 2002, J BIOL CHEM, V277, P7059, DOI 10.1074/jbc.M109537200	53	163	170	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					39914	39924		10.1074/jbc.M502820200	http://dx.doi.org/10.1074/jbc.M502820200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16203735	Green Published, Green Accepted, hybrid			2022-12-25	WOS:000233461300030
J	Wright, DJ; Smith, SC; Joardar, V; Scherer, S; Jervis, J; Warren, A; Helm, RF; Potts, M				Wright, DJ; Smith, SC; Joardar, V; Scherer, S; Jervis, J; Warren, A; Helm, RF; Potts, M			UV irradiation and desiccation modulate the three-dimensional extracellular matrix of Nostoc commune (cyanobacteria)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WATER-STRESS; SUPEROXIDE-DISMUTASE; SECRETION SYSTEMS; PROTEIN; POLYSACCHARIDE; PIGMENTS; SITES	Cyanobacterium Nostoc commune can tolerate the simultaneous stresses of desiccation, UV irradiation, and oxidation. Acidic WspA, of similar to 33.6 kDa, is secreted to the three-dimensional extracellular matrix and accounts for greater than 70% of the total soluble protein. The wspA gene of N. commune strain DRH1 was cloned and found in a single genomic copy, in a monocistronic operon. Transcription of wspA and sodF ( superoxide dismutase), and synthesis and secretion of WspA, were induced upon desiccation or UV-A/B irradiation of cells. Recombinant WspA binds the UV-A/B absorbing pigment scytonemin through non-covalent interactions. WspA peptide polymorphism, and heterogeneity of multiple wspA sequences within cells of a single colony, account for distinct WspA isoforms. WspA has no similarity to entries in the sequence data-bases and wspA, a possible xenolog, is restricted to a subset of strains in the "form species" N. commune characterized through group I intron phylogeny. We hypothesize that WspA plays a central role in the global stress response of N. commune through modulation of the structure and function of the three-dimensional extracellular matrix, particularly the transport, distribution, and/ or macromolecular architecture of mycosporine and scytonemin UV-A/B absorbing pigment complexes.	Virginia Polytech Inst & State Univ, Dept Biochem, Virginia Tech Ctr Genom, Blacksburg, VA 24061 USA; Tech Univ Munich, Inst Mikrobiol, D-80333 Freising Weihenstephan, Germany	Virginia Polytechnic Institute & State University; Technical University of Munich	Potts, M (corresponding author), Virginia Polytech Inst & State Univ, Dept Biochem, Virginia Tech Ctr Genom, Blacksburg, VA 24061 USA.	geordie@vt.edu	Scherer, Siegfried/I-1320-2013; Helm, Richard/N-6249-2018	Helm, Richard/0000-0001-5317-0925; Scherer, Siegfried/0000-0002-0394-9890; Joardar, Vinita/0000-0001-9018-3151				Andersen C, 2003, REV PHYSIOL BIOCH P, V147, P122, DOI 10.1007/s10254-003-0008-y; BOHM GA, 1995, J BIOL CHEM, V270, P8536, DOI 10.1074/jbc.270.15.8536; Boles BR, 2004, P NATL ACAD SCI USA, V101, P16630, DOI 10.1073/pnas.0407460101; Braunstein M, 2003, MOL MICROBIOL, V48, P453, DOI 10.1046/j.1365-2958.2003.03438.x; Ehling-Schulz M, 2002, MOL MICROBIOL, V46, P827, DOI 10.1046/j.1365-2958.2002.03209.x; Ehling-Schulz M, 1997, J BACTERIOL, V179, P1940, DOI 10.1128/jb.179.6.1940-1945.1997; Helm RF, 2000, J BACTERIOL, V182, P974, DOI 10.1128/JB.182.4.974-982.2000; HILL DR, 1994, J BIOL CHEM, V269, P7726; HILL DR, 1994, PROTOPLASMA, V182, P126, DOI 10.1007/BF01403474; Hill DR, 1997, J APPL PHYCOL, V9, P237, DOI 10.1023/A:1007965229567; Hunsucker SW, 2004, BIOCHEM BIOPH RES CO, V317, P1121, DOI 10.1016/j.bbrc.2004.03.173; Hunsucker SW, 2001, ANAL BIOCHEM, V288, P227, DOI 10.1006/abio.2000.4895; Linding R, 2003, NUCLEIC ACIDS RES, V31, P3701, DOI 10.1093/nar/gkg519; Majander K, 2005, NAT BIOTECHNOL, V23, P475, DOI 10.1038/nbt1077; Mollenhauer D, 1999, EUR J PHYCOL, V34, P349, DOI 10.1017/S0967026299002358; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Omori K, 2003, J BIOSCI BIOENG, V95, P1; Pallen MJ, 2003, CURR OPIN MICROBIOL, V6, P519, DOI 10.1016/j.mib.2003.09.005; POTTS M, 1994, MICROBIOL REV, V58, P755, DOI 10.1128/MMBR.58.4.755-805.1994; POTTS M, 1992, SCIENCE, V256, P1690, DOI 10.1126/science.256.5064.1690; Potts M, 1997, INT J SYST BACTERIOL, V47, P584, DOI 10.1099/00207713-47-2-584; POTTS M, 1985, ARCH MICROBIOL, V141, P51, DOI 10.1007/BF00446739; Potts M., 2000, NOSTOC ECOLOGY CYANO, P465; Ramamurthi KS, 2003, MOL MICROBIOL, V50, P1095, DOI 10.1046/j.1365-2958.2003.03777.x; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Robinson N. E., 2004, MOL CLOCKS DEAMIDATI; SCHERER S, 1989, J BIOL CHEM, V264, P12546; Shaw E, 2003, APPL ENVIRON MICROB, V69, P5679, DOI 10.1128/AEM.69.9.5679-5684.2003; Shirkey B, 2003, NUCLEIC ACIDS RES, V31, P2995, DOI 10.1093/nar/gkg404; Shirkey B, 2000, J BACTERIOL, V182, P189, DOI 10.1128/JB.182.1.189-197.2000; Venter JC, 2004, SCIENCE, V304, P66, DOI 10.1126/science.1093857; Vogel J, 2003, NUCLEIC ACIDS RES, V31, P2890, DOI 10.1093/nar/gkg398; Whitton B.A., 2000, ECOLOGY CYANOBACTERI; Wright D, 2001, INT J SYST EVOL MICR, V51, P1839, DOI 10.1099/00207713-51-5-1839	34	74	86	1	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40271	40281		10.1074/jbc.M505961200	http://dx.doi.org/10.1074/jbc.M505961200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16192267	hybrid			2022-12-25	WOS:000233461300069
J	Gonzalez-Guerrico, AM; Kazanietz, MG				Gonzalez-Guerrico, AM; Kazanietz, MG			Phorbol ester-induced apoptosis in prostate cancer cells via autocrine activation of the extrinsic apoptotic cascade - A key role for protein kinase C delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; LIGAND-MEDIATED APOPTOSIS; TRAIL-INDUCED APOPTOSIS; TNF-ALPHA; SIGNALING PATHWAY; EPITHELIAL-CELLS; DEPENDENT PATHWAY; ACINAR-CELLS; PKC-EPSILON	It is well established that activation of protein kinase C (PKC) by phorbol esters promotes apoptosis in androgen-dependent prostate cancer cells. However, there is limited information regarding the cellular mechanisms involved in this effect. In this report we identified a novel autocrine pro-apoptotic loop triggered by PKC delta activation in prostate cancer cells that is mediated by death receptor ligands. The apoptotic effect of phorbol 12-myristate 13-acetate in LNCaP cells was impaired by inhibition or depletion of tumor necrosis factor alpha-converting enzyme, the enzyme responsible for tumor necrosis factor alpha(TNF alpha) shedding. Moreover, the apoptogenic effect of conditioned medium collected after phorbol 12-myristate 13-acetate treatment could be inhibited by blocking antibodies against TNF alpha and tumor necrosis factor-related apoptosisinducing ligand (TRAIL), but not FasL, as well as by RNA interference depletion of TNF alpha and TRAIL receptors. Moreover, depletion or inhibition of death receptor downstream effectors, including caspase-8, FADD, p38 MAPK, and JNK, significantly reduced the apoptogenic effect of the conditioned medium. PKC delta played a major role in this autocrine loop, both in the secretion of autocrine factors as well as a downstream effector. Taken together, our results demonstrate that activation of PKC delta in prostate cancer cells causes apoptosis via the release of death receptor ligands and the activation of the extrinsic apoptotic cascade.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Kazanietz, MG (corresponding author), 816 Biomed Res Bldg 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	marcelo@spirit.gcrc.upenn.edu			NATIONAL CANCER INSTITUTE [R01CA089202] Funding Source: NIH RePORTER; NCI NIH HHS [CA89202] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Altuwaijri S, 2003, CANCER RES, V63, P7106; Barry OP, 2001, CURR PHARM DESIGN, V7, P1725, DOI 10.2174/1381612013397041; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Cacace AM, 1998, J CELL PHYSIOL, V175, P314, DOI 10.1002/(SICI)1097-4652(199806)175:3<314::AID-JCP9>3.0.CO;2-R; Carson JP, 1999, CANCER RES, V59, P1449; Chang Q, 2003, BRIT J PHARMACOL, V140, P41, DOI 10.1038/sj.bjp.0705398; Chang Q, 2001, AM J PHYSIOL-GASTR L, V280, pG572, DOI 10.1152/ajpgi.2001.280.4.G572; Chopra DP, 2004, CANCER LETT, V203, P145, DOI 10.1016/j.canlet.2003.09.016; Comalada N, 2003, AM J PHYSIOL-CELL PH, V285, pC1235, DOI 10.1152/ajpcell.00228.2003; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; Doedens JR, 2003, BIOCHEM BIOPH RES CO, V308, P331, DOI 10.1016/S0006-291X(03)01381-0; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Engedal N, 2002, ONCOGENE, V21, P1017, DOI 10.1038/sj.onc.1205167; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Garzotto M, 1999, CANCER RES, V59, P5194; Goerke A, 2002, J BIOL CHEM, V277, P32054, DOI 10.1074/jbc.M203734200; Ikezoe T, 2004, BRIT J CANCER, V90, P2017, DOI 10.1038/sj.bjc.6601834; Kilpatrick LE, 2004, AM J PHYSIOL-CELL PH, V287, pC633, DOI 10.1152/ajpcell.00486.2003; Kimura K, 2003, CELL DEATH DIFFER, V10, P240, DOI 10.1038/sj.cdd.4401145; Kimura K, 2002, CELL DEATH DIFFER, V9, P972, DOI 10.1038/sj.cdd.4401049; Kimura K, 2000, J BIOL CHEM, V275, P8610, DOI 10.1074/jbc.275.12.8610; Ling MT, 2003, ONCOGENE, V22, P4498, DOI 10.1038/sj.onc.1206693; Madhusudan S, 2003, BRIT J CANCER, V89, P1418, DOI 10.1038/sj.bjc.6601321; Meinhardt G, 2000, EUR J CELL BIOL, V79, P824, DOI 10.1078/0171-9335-00100; Mukhopadhyay A, 2001, ONCOGENE, V20, P7597, DOI 10.1038/sj.onc.1204997; Munshi A, 2002, CANCER CHEMOTH PHARM, V50, P46, DOI 10.1007/s00280-002-0465-z; Murillo H, 2001, CANCER RES, V61, P7408; Nakanishi H, 2003, GENE THER, V10, P434, DOI 10.1038/sj.gt.3301912; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Powell CT, 1996, CELL GROWTH DIFFER, V7, P419; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Satoh A, 2004, AM J PHYSIOL-GASTR L, V287, pG582, DOI 10.1152/ajpgi.00087.2004; Shankar S, 2004, PROSTATE, V61, P35, DOI 10.1002/pros.20069; Steinberg SF, 2004, BIOCHEM J, V384, P449, DOI 10.1042/BJ20040704; Strair RK, 2002, CLIN CANCER RES, V8, P2512; Tanaka Y, 2003, J BIOL CHEM, V278, P33753, DOI 10.1074/jbc.M303313200; Tillman DM, 2003, CANCER RES, V63, P5118; Varfolomeev EE, 2004, CELL, V116, P491, DOI 10.1016/S0092-8674(04)00166-7; Wheeler DL, 2003, CANCER RES, V63, P6547; Wu DQ, 2002, CANCER RES, V62, P2423; Yang CF, 2003, TRENDS PHARMACOL SCI, V24, P602, DOI 10.1016/j.tips.2003.09.003; Yin LH, 2005, J BIOL CHEM, V280, P5533, DOI 10.1074/jbc.M405266200; Yu R, 2000, CANCER RES, V60, P2384; Yuan XJ, 2002, ONCOGENE, V21, P319, DOI 10.1038/sj/onc/1205054; Zhang XP, 2004, CANCER RES, V64, P7086, DOI 10.1158/0008-5472.CAN-04-1498; Zhao X, 1997, J BIOL CHEM, V272, P22751, DOI 10.1074/jbc.272.36.22751; Zheng X, 2004, CANCER RES, V64, P1811, DOI 10.1158/0008-5472.CAN-03-2848	51	71	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					38982	38991		10.1074/jbc.M506767200	http://dx.doi.org/10.1074/jbc.M506767200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16183650	hybrid			2022-12-25	WOS:000233362200012
J	Katou, S; Karita, E; Yamakawa, H; Seo, S; Mitsuhara, I; Kuchitsu, K; Ohashi, Y				Katou, S; Karita, E; Yamakawa, H; Seo, S; Mitsuhara, I; Kuchitsu, K; Ohashi, Y			Catalytic activation of the plant MAPK phosphatase NtMKP1 by its physiological substrate salicylic acid-induced protein kinase but not by calmodulins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANCE; ARABIDOPSIS; STRESS; IDENTIFICATION; RESPONSES; HOMOLOGS; MUTATION; PATHWAY	MAPK phosphatases (MKPs) are negative regulators of MAPKs. Previously, we identified NtMKP1 as a novel calmodulin (CaM)binding protein (Yamakawa, H., Katou, S., Seo, S., Mitsuhara, I., Kamada, H., and Ohashi, Y. (2004) J. Biol. Chem. 279, 928-936). In this study, we characterized the interaction of NtMKP1 with substrate MAPKs and CaM. NtMKP1 ( produced by in vitro transcription/ translation) inactivated salicylic acid-induced protein kinase ( SIPK) through dephosphorylation of the TEY motif of SIPK. CaM bound but unexpectedly did not activate the phosphatase activity of NtMKP1. NtMKP1 has four characteristic domains, viz. a dual-specificity phosphatase catalytic domain, a gelsolin homology domain, a CaM-binding domain, and C-terminal domain. Deletion analysis revealed that the N-terminal non-catalytic region of NtMKP1 bound SIPK and was essential for inactivating SIPK, whereas the CaM-binding and C-terminal domains were dispensable. Moreover, the phosphatase activity of NtMKP1 was increased strongly by the binding of SIPK, but weakly by another MAPK, wound-induced protein kinase. Swapping and site-directed mutagenesis of SIPK and wound-induced protein kinase revealed that the strong activation of NtMKP1 phosphatase activity by SIPK partially depended on the putative common docking domain of SIPK. On the other hand, conversion of Lys(41) and Arg(43) of NtMKP1 to Ala (K41A/R43A) abolished the interaction with SIPK. Expression of constitutively active MAPK kinase in Nicotiana benthamiana induced activation of SIPK and cell death. Simultaneous expression of either NtMKP1 or NtMKP1 L443R, which was unable to bind CaM, compromised the constitutively active MAPK kinase-induced responses, whereas that of NtMKP1 K41A/R43A did not. These results indicate that the regulation of NtMKP1 activity by SIPK binding, but not by CaM binding, is important for the function of NtMKP1.	Natl Inst Agrobiol Sci, Dept Plant Physiol, Tsukuba, Ibaraki 3058602, Japan; Program Promot Basic Res Act Innovat Biosci, Minato Ku, Tokyo 1050001, Japan; Tokyo Univ Sci, Dept Appl Biol Sci, Noda, Chiba 2788510, Japan	National Institute of Agrobiological Sciences - Japan; Tokyo University of Science	Ohashi, Y (corresponding author), Natl Inst Agrobiol Sci, Dept Plant Physiol, Kannondai 2-1-2, Tsukuba, Ibaraki 3058602, Japan.	yohashi@affrc.go.jp	Kuchitsu, Kazuyuki/G-3024-2013	Kuchitsu, Kazuyuki/0000-0001-8854-0375; Seo, Shigemi/0000-0003-4940-288X				Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chen PL, 2001, J BIOL CHEM, V276, P29440, DOI 10.1074/jbc.M103463200; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Gupta R, 1998, PLANT J, V16, P581, DOI 10.1046/j.1365-313x.1998.00327.x; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; Huang YF, 2000, PLANT PHYSIOL, V122, P1301, DOI 10.1104/pp.122.4.1301; Ichimura K, 2002, TRENDS PLANT SCI, V7, P301, DOI 10.1016/S1360-1385(02)02302-6; Jin HL, 2003, PLANT J, V33, P719, DOI 10.1046/j.1365-313X.2003.01664.x; Kanzaki H, 2003, MOL PLANT PATHOL, V4, P383, DOI [10.1046/j.1364-3703.2003.00186.x, 10.1046/J.1364-3703.2003.00186.X]; Karita E, 2004, PLANT CELL PHYSIOL, V45, P1371, DOI 10.1093/pcp/pch158; Katou Shinpei, 2003, Journal of General Plant Pathology, V69, P161; Kerk D, 2002, PLANT PHYSIOL, V129, P908, DOI 10.1104/pp.004002; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lebrun-Garcia A, 1998, PLANT J, V15, P773, DOI 10.1046/j.1365-313X.1998.00269.x; Li ZG, 2001, J BIOL CHEM, V276, P17354, DOI 10.1074/jbc.M010238200; Marchetti S, 2005, MOL CELL BIOL, V25, P854, DOI 10.1128/MCB.25.2.854-864.2005; Meskiene I, 2003, J BIOL CHEM, V278, P18945, DOI 10.1074/jbc.M300878200; Monroe-Augustus M, 2003, PLANT CELL, V15, P2979, DOI 10.1105/tpc.017046; Naoi K, 2004, PLANT CELL, V16, P1841, DOI 10.1105/tpc.021865; Ohtsubo N, 1999, PLANT CELL PHYSIOL, V40, P808, DOI 10.1093/oxfordjournals.pcp.a029609; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Samuel MA, 2002, PLANT CELL, V14, P2059, DOI 10.1105/tpc.002337; Samuel MA, 2000, PLANT J, V22, P367, DOI 10.1046/j.1365-313x.2000.00741.x; Seo S, 2000, PLANT CELL, V12, P917, DOI 10.1105/tpc.12.6.917; Seo S, 1999, PLANT CELL, V11, P289, DOI 10.1105/tpc.11.2.289; SEO S, 1995, SCIENCE, V270, P1988, DOI 10.1126/science.270.5244.1988; Slack DN, 2001, J BIOL CHEM, V276, P16491, DOI 10.1074/jbc.M010966200; Tanoue T, 2001, J BIOL CHEM, V276, P26629, DOI 10.1074/jbc.M101981200; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Theodosiou A, 2002, GENOME BIOL, V3; Turner WL, 2004, PLANT PHYSIOL, V135, P1243, DOI 10.1104/pp.104.040428; Ulm R, 2002, EMBO J, V21, P6483, DOI 10.1093/emboj/cdf646; Ulm R, 2001, GENE DEV, V15, P699, DOI 10.1101/gad.192601; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Yamakawa H, 2004, J BIOL CHEM, V279, P928, DOI 10.1074/jbc.M310277200; Yamakawa H, 2001, EUR J BIOCHEM, V268, P3916, DOI 10.1046/j.1432-1327.2001.02301.x; Yang KY, 2001, P NATL ACAD SCI USA, V98, P741, DOI 10.1073/pnas.98.2.741; Yang T, 2002, P NATL ACAD SCI USA, V99, P4097, DOI 10.1073/pnas.052564899; Yoo JH, 2004, J BIOL CHEM, V279, P848, DOI 10.1074/jbc.M310709200; Yoshioka H, 2003, PLANT CELL, V15, P706, DOI 10.1105/tpc.008680; Zhang SQ, 2000, RES PRO CEL, V27, P65; Zhang SQ, 1998, P NATL ACAD SCI USA, V95, P7433, DOI 10.1073/pnas.95.13.7433; Zhang SQ, 2001, PLANT CELL, V13, P1877, DOI 10.1105/tpc.13.8.1877; Zhou B, 1999, J BIOL CHEM, V274, P35526, DOI 10.1074/jbc.274.50.35526; Zielinski RE, 1998, ANNU REV PLANT PHYS, V49, P697, DOI 10.1146/annurev.arplant.49.1.697	49	37	41	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39569	39581		10.1074/jbc.M508115200	http://dx.doi.org/10.1074/jbc.M508115200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16183637	hybrid			2022-12-25	WOS:000233362200080
J	Rezgui, SS; Vassilopoulos, SP; Brocard, J; Platel, JC; Bouron, A; Arnoult, C; Oddoux, S; Garcia, L; De Waard, M; Marty, I				Rezgui, SS; Vassilopoulos, SP; Brocard, J; Platel, JC; Bouron, A; Arnoult, C; Oddoux, S; Garcia, L; De Waard, M; Marty, I			Triadin (Trisk 95) overexpression blocks excitation-contraction coupling in rat skeletal myotubes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM MEMBRANE; JUNCTIONAL FOOT PROTEIN; CALCIUM-RELEASE CHANNEL; RYANODINE RECEPTOR; DIHYDROPYRIDINE RECEPTOR; MUSCLE CELLS; BIOCHEMICAL-CHARACTERIZATION; IMPAIRED RELAXATION; MOLECULAR-CLONING; CARDIAC MYOCYTES	To identify the function of triadin in skeletal muscle, adenovirus-mediated overexpression of Trisk 95 or Trisk 51, the two major skeletal muscle isoforms, was induced in rat skeletal muscle primary cultures, and the physiological behavior of the modified cells was analyzed. Overexpression did not modify the expression level of their protein partners ryanodine receptor, dihydropyridine receptor, and the other triadin. Caffeine-induced calcium release was also unaffected by triadin overexpression. Nevertheless, in the absence of extracellular calcium, depolarization-induced calcium release was almost abolished in Trisk 95 overexpressing myotubes (T95 myotubes), and not modified in Trisk 51 overexpressing myotubes (T51 myotubes). This was not because of amodification of dihydropyridine receptors, as depolarization in presence of external calcium still induced a calcium release, and the activation curve of dihydropyridine receptor was unchanged, in both T95 and T51 myotubes. The calcium release complex was also maintained in T95 myotubes as Trisk 95, ryanodine receptor, dihydropyridine receptor, and Trisk 51 were still co-localized. The effect of Trisk 95 overexpression on depolarization-induced calcium release was reversed by a simultaneous infection with an antisense Trisk 95 adenovirus, indicating the specificity of this effect. Thus, the level of Trisk 95 and not Trisk 51 is important on regulating the calcium release complex, and an excess of this protein can lead to an inhibition of the physiological function of the complex.	CEA Grenoble, DRDC, CCFP, INSERM,U607,Lab Canaux Calc Fonct & Pathol, F-38054 Grenoble, France; Univ Grenoble, F-38000 Grenoble, France; Genethon, F-91002 Evry, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA)	Marty, I (corresponding author), CEA Grenoble, DRDC, CCFP, INSERM,U607,Lab Canaux Calc Fonct & Pathol, 17 Rue Martyrs, F-38054 Grenoble, France.	imarty@cea.fr	vassilopoulos, stephane/AAF-3865-2021; Marty, Isabelle/N-7114-2017; vassilopoulos, stéphane/F-6041-2014; De Waard, Michel/G-7406-2014; Marty, Isabelle/ABF-5362-2020; ARNOULT, christophe/E-8312-2013	vassilopoulos, stephane/0000-0003-0172-330X; De Waard, Michel/0000-0002-2782-9615; Marty, Isabelle/0000-0003-3625-913X; Brocard, Julie/0000-0001-9345-5191; ARNOULT, christophe/0000-0002-3753-5901; Bouron, Alexandre/0000-0003-4471-7727; platel, jean-claude/0000-0001-5542-3076; Oddoux, Sarah/0000-0002-2888-8430				ARMSTRONG CM, 1992, PHYSIOL REV, V72, pS5, DOI 10.1152/physrev.1992.72.suppl_4.S5; BEAM KG, 1992, NATURE, V360, P169, DOI 10.1038/360169a0; BRANDT NR, 1990, J MEMBRANE BIOL, V113, P237, DOI 10.1007/BF01870075; BRUM G, 1988, J PHYSIOL-LONDON, V398, P441, DOI 10.1113/jphysiol.1988.sp017052; CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; COGNARD C, 1993, CELL CALCIUM, V14, P333, DOI 10.1016/0143-4160(93)90054-A; CONSTANTIN B, 1995, EXP CELL RES, V217, P497, DOI 10.1006/excr.1995.1115; FLUCHER BE, 1993, J CELL BIOL, V123, P1161, DOI 10.1083/jcb.123.5.1161; FLUCHER BE, 1994, MOL BIOL CELL, V5, P1105, DOI 10.1091/mbc.5.10.1105; Groh S, 1999, J BIOL CHEM, V274, P12278, DOI 10.1074/jbc.274.18.12278; Gschwend MH, 1999, PFLUG ARCH EUR J PHY, V438, P101, DOI 10.1007/s004240050885; Guo W, 1996, J BIOL CHEM, V271, P458, DOI 10.1074/jbc.271.1.458; GUO W, 1995, J BIOL CHEM, V270, P9027, DOI 10.1074/jbc.270.16.9027; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hong CS, 2001, GENE, V278, P193, DOI 10.1016/S0378-1119(01)00718-1; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; Jones LR, 1998, J CLIN INVEST, V101, P1385, DOI 10.1172/JCI1362; KIM KC, 1990, BIOCHEMISTRY-US, V29, P9281, DOI 10.1021/bi00491a025; Kirchhefer U, 2003, CARDIOVASC RES, V59, P369, DOI 10.1016/S0008-6363(03)00432-2; Kirchhefer U, 2001, J BIOL CHEM, V276, P4142, DOI 10.1074/jbc.M006443200; KNUDSON CM, 1993, J BIOL CHEM, V268, P12637; Kobayashi YM, 2000, J BIOL CHEM, V275, P17639, DOI 10.1074/jbc.M002091200; Kobayashi YM, 1999, J BIOL CHEM, V274, P28660, DOI 10.1074/jbc.274.40.28660; LAI FA, 1990, ADV EXP MED BIOL, V269, P73; Lee JM, 2004, J BIOL CHEM, V279, P6994, DOI 10.1074/jbc.M312446200; MARTY I, 1994, P NATL ACAD SCI USA, V91, P2270, DOI 10.1073/pnas.91.6.2270; MARTY I, 1995, BIOCHEM J, V307, P769, DOI 10.1042/bj3070769; Marty I, 2000, J BIOL CHEM, V275, P8206, DOI 10.1074/jbc.275.11.8206; Monnier N, 2003, HUM MOL GENET, V12, P1171, DOI 10.1093/hmg/ddg121; Ohkura M, 1998, BIOCHEMISTRY-US, V37, P12987, DOI 10.1021/bi972803d; Prestle J, 2001, CIRC RES, V88, P188; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; Szappanos H, 2004, J BIOCHEM BIOPH METH, V59, P89, DOI 10.1016/j.jbbm.2003.12.002; Terentyev D, 2005, CIRC RES, V96, P651, DOI 10.1161/01.RES.0000160609.98948.25; Thevenon D, 2003, BIOCHEM BIOPH RES CO, V303, P669, DOI 10.1016/S0006-291X(03)00406-6; Vassilopoulos S, 2005, J BIOL CHEM, V280, P28601, DOI 10.1074/jbc.M501484200; Zhang L, 1997, J BIOL CHEM, V272, P23389, DOI 10.1074/jbc.272.37.23389; Zhang XH, 1999, PFLUG ARCH EUR J PHY, V438, P827, DOI 10.1007/s004240051112	39	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39302	39308		10.1074/jbc.M506566200	http://dx.doi.org/10.1074/jbc.M506566200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16176928	Green Submitted, Green Accepted, hybrid			2022-12-25	WOS:000233362200049
J	Chen, YR; Fu, YN; Lin, CH; Yang, ST; Hu, SF; Chen, YT; Tsai, SF; Huang, SF				Chen, YR; Fu, YN; Lin, CH; Yang, ST; Hu, SF; Chen, YT; Tsai, SF; Huang, SF			Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants	ONCOGENE			English	Article						NSCLC; EGFR; mutation; gefitinib; tyrosine phosphorylation	GROWTH-FACTOR-RECEPTOR; NONSMALL CELL LUNG; TYROSINE KINASE; CANCER; MUTATIONS; ENDOCYTOSIS; INHIBITOR; GENE; RESPONSIVENESS; EXPRESSION	Mutations in the kinase domain of epidermal growth factor receptor ( EGFR) are associated with clinical responsiveness to gefitinib in patients with non-small-cell lung cancers (NSCLC). Recently, we have identified many novel EGFR mutations in NSCLC tissues. In this study, we found that gefitinib could suppress the tyrosine phosphorylation of most EGFR mutants better than the wild-type receptor. However, gefitinib had quite variable growth-suppressive effects on different EGFR mutant-expressing cells. All tested EGFR mutants have high basal phosphorylation at multiple tyrosine residues. Upon EGF stimulation, the mutated EGFRs did not have apparently stronger phosphorylation at tyrosines 845, 992, 1068, and 1173 than the wild-type receptor. However, stronger phosphorylation at tyrosine 1045 was observed in the S768I, L861Q, E709G, and G719S mutants. The E746-A750 deletion mutant was less responsive to EGF than the wild-type and other mutant receptors. The S768I, L861Q, E709G, and G719S mutants were refractory to EGF-induced ubiquitination and had more sustained tyrosine phosphorylation. E709G and G719S also lacked EGF-induced receptor downregulation. Our results indicate that, in addition to sensitivity to gefitinib, EGFR mutations also caused various changes in EGFR's regulatory mechanisms, which may contribute to the constitutive activation of EGFR mutants and oncogenesis in NSCLC.	Natl Hlth Res Inst, Div Mol & Gen Med, Zhunan 350, Taiwan; Natl Yang Ming Univ, Inst Genet & Gen Res Ctr, Taipei 112, Taiwan; Chang Gung Mem Hosp, Dept Pathol, Taipei 10591, Taiwan; Municipal Wan Fang Hosp, Dept Pathol, Taipei, Taiwan; Taipei Med Univ, Sch Med, Dept Pathol, Taipei, Taiwan	National Health Research Institutes - Taiwan; National Yang Ming Chiao Tung University; Chang Gung Memorial Hospital; Taipei Municipal WanFang Hospital; Taipei Medical University	Huang, SF (corresponding author), Natl Hlth Res Inst, Div Mol & Gen Med, 35,Keyan Rd, Zhunan 350, Taiwan.	sfhuang@nhri.org.tw	Chen, Yi-Rong/CAF-2186-2022; Tsai, Shih-Feng/E-3997-2010; Huang, Shiu-Feng Kathy/E-3977-2010; Chen, Yi-Rong/CAH-7991-2022; Chen, Yi-Rong/E-3991-2010	Chen, Yi-Rong/0000-0002-4307-3002; Chen, Yi-Rong/0000-0002-4307-3002; Chen, Yi-Rong/0000-0002-4307-3002				Amann J, 2005, CANCER RES, V65, P226; Brabender J, 2001, CLIN CANCER RES, V7, P1850; Chen YR, 2002, J BIOL CHEM, V277, P39334, DOI 10.1074/jbc.M202070200; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068; Fontanini G, 1998, CLIN CANCER RES, V4, P241; Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Herbst RS, 2003, CLIN CANCER RES, V9, P5813; Herbst RS, 2002, J CLIN ONCOL, V20, P3815, DOI 10.1200/JCO.2002.03.038; Hirsch FR, 2003, J CLIN ONCOL, V21, P3798, DOI 10.1200/JCO.2003.11.069; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; Huang SF, 2004, CLIN CANCER RES, V10, P8195, DOI 10.1158/1078-0432.CCR-04-1245; Jiang XJ, 2003, TRAFFIC, V4, P529, DOI 10.1034/j.1600-0854.2003.t01-1-00109.x; Kosaka T, 2004, CANCER RES, V64, P8919, DOI 10.1158/0008-5472.CAN-04-2818; Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149; Lai WW, 2001, ANN THORAC SURG, V72, P1868, DOI 10.1016/S0003-4975(01)03207-6; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mitsudomi T, 2005, J CLIN ONCOL, V23, P2513, DOI 10.1200/JCO.2005.00.992; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Nakagawa K, 2003, ANN ONCOL, V14, P922, DOI 10.1093/annonc/mdg250; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; RUSCH V, 1993, CANCER RES, V53, P2379; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637	29	107	117	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2006	25	8					1205	1215		10.1038/sj.onc.1209159	http://dx.doi.org/10.1038/sj.onc.1209159			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	015FO	16205628				2022-12-25	WOS:000235537500008
J	Link, CD; Fonte, V; Hiester, B; Yerg, J; Ferguson, J; Csontos, S; Silverman, MA; Stein, GH				Link, CD; Fonte, V; Hiester, B; Yerg, J; Ferguson, J; Csontos, S; Silverman, MA; Stein, GH			Conversion of green fluorescent protein into a toxic, aggregation-prone protein by C-terminal addition of a short peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC CAENORHABDITIS-ELEGANS; UBIQUITIN-PROTEASOME SYSTEM; BETA-AMYLOID PEPTIDE; NEURODEGENERATIVE DISEASES/; MISFOLDING DISEASES; ALPHA-SYNUCLEIN; EXPRESSION; MODEL; DYSFUNCTION; IMPAIRMENT	A non-natural 16-residue "degron" peptide has been reported to convey proteasome-dependent degradation when fused to proteins expressed in yeast (Gilon, T., Chomsky, O., and Kulka, R. ( 2000) Mol. Cell. Biol. 20, 7214-7219) or when fused to green fluorescent protein (GFP) and expressed in mammalian cells (Bence, N. F., Sampat, R. M., and Kopito, R. R. ( 2001) Science 292, 1552-1555). We find that expression of the GFP::degron in Caenorhabditis elegans muscle or neurons results in the formation of stable perinuclear deposits. Similar perinuclear deposition of GFP::degron was also observed upon transfection of primary rat hippocampal neurons or mouse Neuro2A cells. The generality of this observation was supported by transfection of HEK 293 cells with both GFP::degron and DsRed(monomer)::degron constructs. GFP::degron expressed in C. elegans is less soluble than unmodified GFP and induces the small chaperone protein HSP-16, which co-localizes and co-immunoprecipitates with GFP::degron deposits. Induction of GFP::degron in C. elegans muscle leads to rapid paralysis, demonstrating the in vivo toxicity of this aggregating variant. This paralysis is suppressed by co-expression of HSP-16, which dramatically alters the subcellular distribution of GFP::degron. Our results suggest that in C. elegans, and perhaps in mammalian cells, the degron peptide is not a specific proteasome-targeting signal but acts instead by altering GFP secondary or tertiary structure, resulting in an aggregation-prone form recognized by the chaperone system. This altered form of GFP can form toxic aggregates if its expression level exceeds the capacity of chaperone-based degradation pathways. GFP::degron may serve as an instructive "generic" aggregating control protein for studies of disease-associated aggregating proteins, such as huntingtin, alpha-synuclein, and the beta-amyloid peptide.	Univ Colorado, Inst Behav Genet, Boulder, CO 80309 USA; Calif State Polytech Univ Pomona, Pomona, CA 91768 USA	University of Colorado System; University of Colorado Boulder; California State University System; California State Polytechnic University Pomona	Link, CD (corresponding author), Univ Colorado, Inst Behav Genet, UCB 447, Boulder, CO 80309 USA.	linkc@colorado.edu		Hiester, Brian/0000-0002-2416-0637; Silverman, Michael A./0000-0001-6967-4917	NATIONAL INSTITUTE ON AGING [R01AG021037, R01AG012423] Funding Source: NIH RePORTER; NIA NIH HHS [AG21037, AG12423] Funding Source: Medline; NINDS NIH HHS [R15 NS048047A] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Auluck PK, 2005, J BIOL CHEM, V280, P2873, DOI 10.1074/jbc.M412106200; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bennett EJ, 2005, MOL CELL, V17, P351, DOI 10.1016/j.molcel.2004.12.021; Bonini NM, 2002, P NATL ACAD SCI USA, V99, P16407, DOI 10.1073/pnas.152330499; Bucciantini M, 2004, J BIOL CHEM, V279, P31374, DOI 10.1074/jbc.M400348200; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; DAHL R, 1989, J ELECTRON MICR TECH, V13, P165, DOI 10.1002/jemt.1060130305; Dong X, 2004, AM J PHYSIOL-HEART C, V287, pH1417, DOI 10.1152/ajpheart.01233.2003; Drake J, 2003, NEUROBIOL AGING, V24, P415, DOI 10.1016/S0197-4580(02)00225-7; Faber PW, 1999, P NATL ACAD SCI USA, V96, P179, DOI 10.1073/pnas.96.1.179; Fay DS, 1998, J NEUROCHEM, V71, P1616; Fonte V, 2002, P NATL ACAD SCI USA, V99, P9439, DOI 10.1073/pnas.152313999; Garcia-Mata R, 1999, J CELL BIOL, V146, P1239, DOI 10.1083/jcb.146.6.1239; Goslin K., 1998, CULTURING NERVE CELL, P339; HOCKERTZ MK, 1991, FEBS LETT, V280, P375, DOI 10.1016/0014-5793(91)80335-Z; Hope AD, 2003, J NEUROCHEM, V86, P394, DOI 10.1046/j.1471-4159.2003.01844.x; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kraemer BC, 2003, P NATL ACAD SCI USA, V100, P9980, DOI 10.1073/pnas.1533448100; Kranenburg O, 2003, FEBS LETT, V539, P149, DOI 10.1016/S0014-5793(03)00218-7; Lakso M, 2003, J NEUROCHEM, V86, P165, DOI 10.1046/j.1471-4159.2003.01809.x; LINK CD, 1995, P NATL ACAD SCI USA, V92, P9368, DOI 10.1073/pnas.92.20.9368; Link CD, 2001, MECH AGEING DEV, V122, P1639, DOI 10.1016/S0047-6374(01)00291-3; Link CD, 2003, NEUROBIOL AGING, V24, P397, DOI 10.1016/S0197-4580(02)00224-5; Magrane J, 2004, J NEUROSCI, V24, P1700, DOI 10.1523/JNEUROSCI.4330-03.2004; Morley JF, 2002, P NATL ACAD SCI USA, V99, P10417, DOI 10.1073/pnas.152161099; Nollen EAA, 2004, P NATL ACAD SCI USA, V101, P6403, DOI 10.1073/pnas.0307697101; Parker JA, 2001, P NATL ACAD SCI USA, V98, P13318, DOI 10.1073/pnas.231476398; Price DL, 2000, ANN NY ACAD SCI, V920, P179; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; Taylor JP, 2002, SCIENCE, V296, P1991, DOI 10.1126/science.1067122; Tsien RY, 1998, SCIENCE, V280, P1954, DOI 10.1126/science.280.5371.1954; Walsh DM, 2004, PROTEIN PEPTIDE LETT, V11, P213, DOI 10.2174/0929866043407174	33	62	64	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1808	1816		10.1074/jbc.M505581200	http://dx.doi.org/10.1074/jbc.M505581200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16239215	hybrid			2022-12-25	WOS:000234652000062
J	Dorval, KM; Bobechko, BP; Fujieda, H; Chen, SM; Zack, DJ; Bremner, R				Dorval, KM; Bobechko, BP; Fujieda, H; Chen, SM; Zack, DJ; Bremner, R			CHX10 targets a subset of photoreceptor genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINAL PROGENITOR PROLIFERATION; HOMEODOMAIN RECOGNITION HELIX; INNER NUCLEAR LAYER; FACTOR-BINDING SITE; CONE-ROD DYSTROPHY; HOMEOBOX GENE; TRANSCRIPTION FACTOR; CELL-DIFFERENTIATION; UPSTREAM REGION; TRANSGENIC MICE	The homeobox gene CHX10 is required for retinal progenitor cell proliferation early in retinogenesis and subsequently for bipolar neuron differentiation. To clarify the molecular mechanisms employed by CHX10 we sought to identify its target genes. In a yeast one-hybrid assay Chx10 interacted with the Ret1 site of the photoreceptor-specific gene Rhodopsin. Gel shift assays using in vitro translated protein confirmed that CHX10 binds to Ret1, but not to the similar Rhodopsin sites Ret4 and BAT-1. Using retinal nuclear lysates, we observed interactions between Chx10 and additional photoreceptor-specific elements including the PCE-1 (Rod arrestin/S-antigen) and the Cone opsin locus control region (Red/green cone opsin). However, chromatin immunoprecipitation assays revealed that in vivo, Chx10 bound sites upstream of the Rod arrestin and Interphotoreceptor retinoid-binding protein genes but not Rhodopsin or Cone opsin. Thus, in a chromatin context, Chx10 associates with a specific subset of elements that it binds with comparable apparent affinity in vitro. Our data suggest that CHX10 may target these motifs to inhibit rod photoreceptor gene expression in bipolar cells.	Univ Toronto, Univ Hlth Network, Toronto Western Res Inst, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Ophthalmol & Visual Sci, Toronto, ON M5T 2S8, Canada; Univ Toronto, Vis Sci Res Program, Toronto, ON M5T 2S8, Canada; Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD 21287 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Toronto; Washington University (WUSTL); Washington University (WUSTL); Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Bremner, R (corresponding author), Cellular & Mol Div, MC6-424,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	rbremner@uhnres.utoronto.ca	Bremner, Rod/I-6490-2012	Bremner, Rod/0000-0001-9184-7212; Zack, Don/0000-0002-7966-1973	NEI NIH HHS [R01EY009769, R01 EY012543] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012543, R01EY009769] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADLER R, 1990, METHODS NEUROSCIENCE, V2, P134; Bibb LC, 2001, HUM MOL GENET, V10, P1571, DOI 10.1093/hmg/10.15.1571; Blackshaw S, 2001, CELL, V107, P579, DOI 10.1016/S0092-8674(01)00574-8; Bone-Larson C, 2000, J NEUROBIOL, V42, P232, DOI 10.1002/(SICI)1097-4695(20000205)42:2<232::AID-NEU7>3.0.CO;2-4; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Burmeister M, 1996, NAT GENET, V12, P376, DOI 10.1038/ng0496-376; Chakrabarti SK, 2002, J BIOL CHEM, V277, P13286, DOI 10.1074/jbc.M111857200; Chen SM, 1996, J BIOL CHEM, V271, P28549, DOI 10.1074/jbc.271.45.28549; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; Chow L, 1998, MECH DEVELOP, V77, P149, DOI 10.1016/S0925-4773(98)00135-X; DANIELS MP, 1974, J CELL BIOL, V63, P691, DOI 10.1083/jcb.63.2.691; DesJardin LE, 1996, INVEST OPHTH VIS SCI, V37, P154; Dorval KM, 2005, J BIOL CHEM, V280, P10100, DOI 10.1074/jbc.M412676200; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; Dyer MA, 2005, NAT REV CANCER, V5, P91, DOI 10.1038/nrc1545; Freund C, 1996, HUM MOL GENET, V5, P1471, DOI 10.1093/hmg/5.Supplement_1.1471; Freund CL, 1998, NAT GENET, V18, P311, DOI 10.1038/ng0498-311; Freund CL, 1997, CELL, V91, P543, DOI 10.1016/S0092-8674(00)80440-7; Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0; Green ES, 2003, DEVELOPMENT, V130, P539, DOI 10.1242/dev.00275; HANES SD, 1991, SCIENCE, V251, P426, DOI 10.1126/science.1671176; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; Hatakeyama J, 2001, DEVELOPMENT, V128, P1313; Hayashi T, 2000, GENOMICS, V67, P128, DOI 10.1006/geno.2000.6248; Horsford DJ, 2005, DEVELOPMENT, V132, P177, DOI 10.1242/dev.01571; Jean D, 1998, MECH DEVELOP, V76, P3, DOI 10.1016/S0925-4773(98)00117-8; KIKUCHI T, 1993, MOL CELL BIOL, V13, P4400, DOI 10.1128/MCB.13.7.4400; Kimura A, 2000, J BIOL CHEM, V275, P1152, DOI 10.1074/jbc.275.2.1152; LIOU GI, 1991, BIOCHEM BIOPH RES CO, V181, P159, DOI 10.1016/S0006-291X(05)81395-6; LIOU GI, 1990, J BIOL CHEM, V265, P8373; LIOU GI, 1994, DEV BIOL, V161, P345, DOI 10.1006/dbio.1994.1036; LIU ISC, 1994, NEURON, V13, P377, DOI 10.1016/0896-6273(94)90354-9; MORABITO MA, 1991, J BIOL CHEM, V266, P9667; Pattenden SG, 2002, EMBO J, V21, P1978, DOI 10.1093/emboj/21.8.1978; Percin EF, 2000, NAT GENET, V25, P397, DOI 10.1038/78071; Rowan S, 2005, DEV BIOL, V281, P240, DOI 10.1016/j.ydbio.2005.02.023; Rowan S, 2004, DEVELOPMENT, V131, P5139, DOI 10.1242/dev.01300; Swain PK, 1997, NEURON, V19, P1329, DOI 10.1016/S0896-6273(00)80423-7; TREISMAN J, 1989, CELL, V59, P553; WANG YS, 1992, NEURON, V9, P429, DOI 10.1016/0896-6273(92)90181-C; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; YOUNG RW, 1985, ANAT REC, V212, P199, DOI 10.1002/ar.1092120215; Yu X, 1996, J NEUROCHEM, V67, P2494; ZACK DJ, 1991, NEURON, V6, P187, DOI 10.1016/0896-6273(91)90355-4	44	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					744	751		10.1074/jbc.M509470200	http://dx.doi.org/10.1074/jbc.M509470200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16236706	hybrid			2022-12-25	WOS:000234447200010
J	Conseil, GRL; Deeley, RG; Cole, SPC				Conseil, GRL; Deeley, RG; Cole, SPC			Functional importance of three basic residues clustered at the cytosolic interface of transmembrane helix 15 in the multidrug and organic anion transporter MRP1 (ABCC1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANCE PROTEIN-1 MRP1/ABCC1; NUCLEOTIDE-BINDING DOMAINS; AMINO-ACID-RESIDUES; SUBSTRATE-SPECIFICITY; LEUKOTRIENE C-4; PROLINE RESIDUES; MEMBRANE; IDENTIFICATION; MUTATION; REGION	The multidrug resistance protein 1 ( MRP1) mediates drug and organic anion efflux across the plasma membrane. The 17 transmembrane ( TM) helices of MRP1 are linked by extracellular and cytoplasmic ( CL) loops of various lengths and two cytoplasmic nucleotide binding domains. In this study, three basic residues clustered at the predicted TM15/ CL7 interface were investigated for their role in MRP1 expression and activity. Thus, Arg(1138), Lys(1141), and Arg(1142) were replaced with residues of the same or opposite charge, expressed in human embryonic kidney cells, and the properties of the mutant proteins were assessed. Neither Glu nor Lys substitutions of Arg1138 and Arg1142 affected MRP1 expression; however, all four mutants showed a decrease in organic anion transport with a relatively greater decrease in leukotriene C-4 and glutathione transport. These mutations also modulated MRP1 ATPase activity as reflected by a decreased vanadate- induced trapping of 8- azido-[ P-32] ADP. Mutation of Lys(1141) to either Glu orArg reduced MRP1 expression, and routing to the plasma membrane was impaired. However, only the Glu- substituted Lys(1141) mutant showed a decrease in organic anion transport, and this was associated with decreased substrate binding and vanadate- induced trapping of 8- azido- ADP. These studies identified a cluster of basic amino acids likely at the TM15/ CL7 interface as a region important for both MRP1 expression and activity and demonstrated that each of the three residues plays a distinct role in the substrate specificity and catalytic activity of the transporter.	Queens Univ, Inst Canc Res, Div Canc Biol & Genet, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Cole, SPC (corresponding author), Queens Univ, Inst Canc Res, Div Canc Biol & Genet, Kingston, ON K7L 3N6, Canada.	SusanPC.Cole@Queensu.Ca	Deeley, Roger/J-4828-2012; Cole, Susan P.C./I-6389-2017	Cole, Susan P.C./0000-0001-6571-6884				AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Campbell JD, 2004, J BIOL CHEM, V279, P463, DOI 10.1074/jbc.M310711200; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Conrad S, 2002, PHARMACOGENETICS, V12, P321, DOI 10.1097/00008571-200206000-00008; Conseil G, 2005, PHARMACOGENET GENOM, V15, P523, DOI 10.1097/01.fpc.0000167333.38528.ec; Conseil G, 2005, BIOCHEM PHARMACOL, V69, P451, DOI 10.1016/j.bcp.2004.10.014; Davidson AL, 2005, SCIENCE, V308, P963, DOI 10.1126/science.1113414; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; Haimeur A, 2004, MOL PHARMACOL, V65, P1375, DOI 10.1124/mol.65.6.1375; Haimeur A, 2004, CURR DRUG METAB, V5, P21, DOI 10.2174/1389200043489199; Haimeur A, 2002, J BIOL CHEM, V277, P41326, DOI 10.1074/jbc.M206228200; Hipfner DR, 1999, J BIOL CHEM, V274, P15420, DOI 10.1074/jbc.274.22.15420; Hipfner DR, 1996, CANCER RES, V56, P3307; HIPFNER DR, 1994, CANCER RES, V54, P5788; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Ito K, 2003, BBA-BIOMEMBRANES, V1615, P103, DOI 10.1016/S0005-2736(03)00228-1; Ito K, 2001, J BIOL CHEM, V276, P15616, DOI 10.1074/jbc.M011246200; Koike K, 2004, J BIOL CHEM, V279, P12325, DOI 10.1074/jbc.M311435200; Koike K, 2002, J BIOL CHEM, V277, P49495, DOI 10.1074/jbc.M206896200; KONIG J, 2003, ABC PROTEINS BACTERI, P423; Le Saux O, 2000, NAT GENET, V25, P223, DOI 10.1038/76102; Leslie EM, 2003, BIOCHEMISTRY-US, V42, P5214, DOI 10.1021/bi027076n; Leslie EM, 2001, MOL PHARMACOL, V59, P1171, DOI 10.1124/mol.59.5.1171; Letourneau IJ, 2005, TOXICOL LETT, V157, P9, DOI 10.1016/j.toxlet.2004.12.014; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Mor-Cohen R, 2001, J BIOL CHEM, V276, P36923, DOI 10.1074/jbc.M105047200; Payen LF, 2003, J BIOL CHEM, V278, P38537, DOI 10.1074/jbc.M305786200; Perdu J, 2001, HUM MUTAT, V17, DOI 10.1002/1098-1004(2001)17:1<74::AID-HUMU14>3.0.CO;2-F; Qian YM, 2001, J BIOL CHEM, V276, P38636, DOI 10.1074/jbc.M107025200; Ren XQ, 2002, BIOCHEMISTRY-US, V41, P14132, DOI 10.1021/bi026443s; Reyes CL, 2005, SCIENCE, V308, P1028, DOI 10.1126/science.1107733; RIORDAN JR, 1989, SCIENCE, V245, P1066; Situ D, 2004, J BIOL CHEM, V279, P38871, DOI 10.1074/jbc.M403832200; Tabas LB, 2002, ANAL BIOCHEM, V310, P61, DOI 10.1016/S0003-2697(02)00282-8; VONHEIJNE G, 1986, J MOL BIOL, V189, P239, DOI 10.1016/0022-2836(86)90394-3; Westlake CJ, 2003, BIOCHEMISTRY-US, V42, P14099, DOI 10.1021/bi035333y; Zhang DW, 2003, J BIOL CHEM, V278, P46052, DOI 10.1074/jbc.M308403200; Zhang DW, 2002, J BIOL CHEM, V277, P20934, DOI 10.1074/jbc.M201311200; Zhang DW, 2001, J BIOL CHEM, V276, P34966, DOI 10.1074/jbc.M105063200; Zhang DW, 2001, J BIOL CHEM, V276, P13231, DOI 10.1074/jbc.M010008200	43	39	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					43	50		10.1074/jbc.M510143200	http://dx.doi.org/10.1074/jbc.M510143200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16230346	hybrid			2022-12-25	WOS:000234307200009
J	Kobayashi, Y; Ohtsuki, M; Murakami, T; Kobayashi, T; Sutheesophon, K; Kitayama, H; Kano, Y; Kusano, E; Nakagawa, H; Furukawa, Y				Kobayashi, Y; Ohtsuki, M; Murakami, T; Kobayashi, T; Sutheesophon, K; Kitayama, H; Kano, Y; Kusano, E; Nakagawa, H; Furukawa, Y			Histone deacetylase inhibitor FK228 suppresses the Ras-MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma	ONCOGENE			English	Article						melanoma; histone deacetylase inhibitor; Raf; MAP kinase; Rap1; apoptosis	ACTIVATED PROTEIN-KINASE; DEPENDENT ACTIVATION; BRAF MUTATIONS; T-CELL; B-RAF; DEPSIPEPTIDE FR901228; ONCOGENIC MUTATIONS; CYCLIN D1; GENE; EXPRESSION	Histone deacetylase ( HDAC) inhibitors are expected to be effective for refractory cancer because their mechanism of action differs from that of conventional antineoplastic agents. In this study, we examined the effect of the HDAC inhibitor FK228 on malignant melanoma, as well as its molecular mechanisms. FK228 was highly effective against melanoma compared with other commonly used drugs. By comparing the gene expression profiles of melanoma cells and normal melanocytes, we defined a subset of genes specifically upregulated in melanoma cells by FK228, which included Rap1, a small GTP-binding protein of the Ras family. The expression of Rap1 mRNA and protein increased in FK228-treated melanoma cells in both a dose- and a time-dependent manner. A decrease in the phosphorylation of c-Raf, MEK1/2, and ERK1/2 was accompanied by an increase in Rap1 expression in both FK228-treated and Rap1-overexpressing cells. Inhibition of Rap1 upregulation by small interfering RNA ( siRNA) abrogated the induction of apoptosis and suppression of ERK1/2 phosphorylation in FK228-treated melanoma cells. These results indicate that the cytotoxic effects of FK228 are mediated via the upregulation of Rap1. Furthermore, we found that Rap1 was overexpressed and formed a complex with B-Raf in melanoma cell lines with a V599E mutation of B-Raf. The siRNA-mediated abrogation of Rap1 overexpression increased the viability of these cells, suggesting that Rap1 is also an endogenous regulator of Ras-MAP kinase signaling in melanomas.	Jichi Med Sch, Ctr Mol Med, Div Stem Cell Regulat, Minami Kawachi, Tochigi 3290498, Japan; Jichi Med Sch, Dept Dermatol, Minami Kawachi, Tochigi 3290498, Japan; Jichi Med Sch, Div Organ Transplantat, Minami Kawachi, Tochigi 3290498, Japan; Jichi Med Sch, Dept Nephrol, Minami Kawachi, Tochigi 3290498, Japan; Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Sakyo Ku, Kyoto, Japan; Tochigi Canc Ctr, Div Med Oncol, Utsunomiya, Tochigi, Japan; Jikei Univ, Sch Med, Dept Dermatol, Minato Ku, Tokyo, Japan	Jichi Medical University; Jichi Medical University; Jichi Medical University; Jichi Medical University; Kyoto University; Tochigi Prefectural Cancer Center; Jikei University	Furukawa, Y (corresponding author), Jichi Med Sch, Ctr Mol Med, Div Stem Cell Regulat, 3311-1 Yakushiji, Minami Kawachi, Tochigi 3290498, Japan.	furuyu@jichi.ac.jp	Furukawa, Yusuke/Y-1342-2018	Furukawa, Yusuke/0000-0002-7249-6418				Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; BOKOCH GM, 1993, BIOCHEM J, V289, P17, DOI 10.1042/bj2890017; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; BYERS HR, 1991, AM J PATHOL, V139, P423; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; D'Silva NJ, 2003, J CELL PHYSIOL, V196, P532, DOI 10.1002/jcp.10331; Daniotti M, 2004, ONCOGENE, V23, P5968, DOI 10.1038/sj.onc.1207780; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Derjuga A, 2001, J BIOL CHEM, V276, P37815; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Francken AB, 2004, ANN SURG ONCOL, V11, P426, DOI 10.1245/ASO.2004.07.014; Furukawa Y, 2002, J BIOL CHEM, V277, P39760, DOI 10.1074/jbc.M200805200; Furumai R, 2002, CANCER RES, V62, P4916; Gore SD, 2002, CLIN CANCER RES, V8, P963; Helmbach H, 2001, INT J CANCER, V93, P617, DOI 10.1002/ijc.1378; Henderson C, 2003, J BIOL CHEM, V278, P12579, DOI 10.1074/jbc.M213093200; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HOSHIKAWA Y, 1994, EXP CELL RES, V214, P189, DOI 10.1006/excr.1994.1248; Hu CD, 1997, J BIOL CHEM, V272, P11702, DOI 10.1074/jbc.272.18.11702; Hubbard SR, 2004, CELL, V116, P764, DOI 10.1016/S0092-8674(04)00256-9; Ishida D, 2003, CANCER CELL, V4, P55, DOI 10.1016/S1535-6108(03)00163-6; Johnstone RW, 2003, CANCER CELL, V4, P13, DOI 10.1016/S1535-6108(03)00165-X; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; Katagiri K, 2002, MOL CELL BIOL, V22, P1001, DOI 10.1128/MCB.22.4.1001-1015.2002; Kim DH, 2003, J BIOCHEM MOL BIOL, V36, P110; Kim JH, 2001, COMPOS INTERFACE, V7, P443, DOI 10.1163/156855400750262932; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Klisovic DD, 2003, INVEST OPHTH VIS SCI, V44, P2390, DOI 10.1167/iovs.02-1052; Kumar R, 2004, J INVEST DERMATOL, V122, P342, DOI 10.1046/j.0022-202X.2004.22225.x; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Maeda T, 2000, BLOOD, V96, P3847, DOI 10.1182/blood.V96.12.3847.h8003847_3847_3856; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Melnick A, 2002, CURR OPIN HEMATOL, V9, P322, DOI 10.1097/00062752-200207000-00010; Nakajima H, 1998, EXP CELL RES, V241, P126, DOI 10.1006/excr.1998.4027; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; Omholt K, 2003, CLIN CANCER RES, V9, P6483; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Ribeiro-Neto F, 2002, P NATL ACAD SCI USA, V99, P5418, DOI 10.1073/pnas.082122499; Sandor V, 2002, CLIN CANCER RES, V8, P718; Sandor V, 2000, BRIT J CANCER, V83, P817, DOI 10.1054/bjoc.2000.1327; Satyamoorthy K, 2003, CANCER RES, V63, P756; Schmidt A, 2001, MOL CELL BIOL, V21, P438, DOI 10.1128/MCB.21.2.438-448.2001; Skov S, 2003, BLOOD, V101, P1430, DOI 10.1182/blood-2002-07-2073; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Somech R, 2004, CANCER TREAT REV, V30, P461, DOI 10.1016/j.ctrv.2004.04.006; Sutheesophon K, 2005, J CELL PHYSIOL, V203, P387, DOI 10.1002/jcp.20235; SWOPE VB, 1995, EXP CELL RES, V217, P453, DOI 10.1006/excr.1995.1109; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; UEDA H, 1994, J ANTIBIOT, V47, P301; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Yajnik V, 2003, CELL, V112, P673, DOI 10.1016/S0092-8674(03)00155-7; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X	57	47	50	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					512	524		10.1038/sj.onc.1209072	http://dx.doi.org/10.1038/sj.onc.1209072			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16186804				2022-12-25	WOS:000234897400003
J	Guo, YB; Chen, CF; Zheng, Y; Zhang, JC; Tao, XH; Liu, SL; Zheng, DX; Liu, YX				Guo, YB; Chen, CF; Zheng, Y; Zhang, JC; Tao, XH; Liu, SL; Zheng, DX; Liu, YX			A novel anti-human DR5 monoclonal antibody with tumoricidal activity induces caspase-dependent and caspase-independent cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRAIL-MEDIATED APOPTOSIS; CYTOTOXIC LIGAND TRAIL; TERMINAL KINASE; JNK/SAPK ACTIVITY; HUMAN HEPATOCYTES; RECEPTORS 1; TNF FAMILY; T-CELLS; NECROSIS	Like anti-Fas monoclonal antibodies, some monoclonal antibodies against tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors have tumoricidal activity too. In this article we report a novel mouse anti-human DR5 monoclonal antibody, AD5-10, that induces apoptosis of various tumor cell lines in the absence of second cross-linking in vitro and showed strong tumoricidal activity in vivo. AD5-10 does not compete with TRAIL for binding to DR5 and synergizes with TRAIL to induce apoptosis of tumor cells. AD5-10 induces both caspase-dependent and caspase-independent cell death in Jurkat cells, whereas TRAIL induces only caspase-dependent cell death. We show for the first time that DR5 can mediate caspase-independent cell death, and DR5 can mediate distinct cell signals when interacting with different extracellular proteins. Studies on AD5-10 help us to understand more on the functions of DR5 and may provide new ideas for cancer immunotherapy.	Chinese Acad Med Sci, Inst Basic Med Sci, Natl Lab Med Mol Biol, Beijing 100005, Peoples R China; Peking Union Med Coll, Beijing 100005, Peoples R China; Univ Alberta, Dept Biochem, Edmonton, AB T6G 1K7, Canada	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; University of Alberta	Zheng, DX (corresponding author), Chinese Acad Med Sci, Inst Basic Med Sci, Natl Lab Med Mol Biol, 5 Dong Dan Tiao, Beijing 100005, Peoples R China.	zhengdx@tom.com	Guo, Yabin/AAS-9022-2021	Guo, Yabin/0000-0001-8316-8527; Zheng, Dexian/0000-0003-3966-1212				Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; CHINNAIYAN AM, 1995, CELL, V81, P512; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Griffith TS, 1999, J IMMUNOL, V162, P2597; Hao CH, 2004, CANCER RES, V64, P8502, DOI 10.1158/0008-5472.CAN-04-2599; Herr I, 1999, CELL DEATH DIFFER, V6, P130, DOI 10.1038/sj.cdd.4400467; Herr I, 1999, INT J CANCER, V80, P417, DOI 10.1002/(SICI)1097-0215(19990129)80:3<417::AID-IJC14>3.3.CO;2-2; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hymowitz SG, 1999, MOL CELL, V4, P563, DOI 10.1016/S1097-2765(00)80207-5; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Jaattela M, 2003, NAT IMMUNOL, V4, P416, DOI 10.1038/ni0503-416; Jeremias I, 1998, EUR CYTOKINE NETW, V9, P687; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Keane MM, 2000, BREAST CANCER RES TR, V64, P211, DOI 10.1023/A:1006458407515; Kim YS, 2002, HEPATOLOGY, V36, P1498, DOI 10.1053/jhep.2002.36942; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; MacFarlane M, 2000, BIOCHEM J, V348, P93, DOI 10.1042/0264-6021:3480093; Maianski NA, 2003, BLOOD, V101, P1987, DOI 10.1182/blood-2002-02-0522; Mori E, 2004, CELL DEATH DIFFER, V11, P203, DOI 10.1038/sj.cdd.4401331; Muhlenbeck F, 1998, J BIOL CHEM, V273, P33091, DOI 10.1074/jbc.273.49.33091; Nitsch R, 2000, LANCET, V356, P827, DOI 10.1016/S0140-6736(00)02659-3; Ohtsuka T, 2002, J BIOL CHEM, V277, P29294, DOI 10.1074/jbc.M203342200; Ohtsuka T, 2003, ONCOGENE, V22, P2034, DOI 10.1038/sj.onc.1206290; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Seol DW, 2001, CANCER RES, V61, P1138; SHI J, 2003, CHIN J BIOENGINEERIN, V23, P46; Shiiki K, 2000, CELL DEATH DIFFER, V7, P939, DOI 10.1038/sj.cdd.4400727; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Thorburn J, 2005, MOL BIOL CELL, V16, P1189, DOI 10.1091/mbc.E04-10-0906; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Vivo C, 2003, J BIOL CHEM, V278, P25461, DOI 10.1074/jbc.M302161200; Vonarbourg C, 2002, EUR J IMMUNOL, V32, P2376, DOI 10.1002/1521-4141(200208)32:8<2376::AID-IMMU2376>3.0.CO;2-V; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang MJ, 2004, ONCOL REP, V12, P193; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wilson CA, 2002, CELL DEATH DIFFER, V9, P1321, DOI 10.1038/sj.cdd.4401107; Zhang LD, 2004, CANCER BIOL THER, V3, P296, DOI 10.4161/cbt.3.3.696	47	64	85	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					41940	41952		10.1074/jbc.M503621200	http://dx.doi.org/10.1074/jbc.M503621200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16234248	hybrid			2022-12-25	WOS:000233992700020
J	Watanabe, N; Tomita, T; Sato, C; Kitamura, T; Morohashi, Y; Iwatsubo, T				Watanabe, N; Tomita, T; Sato, C; Kitamura, T; Morohashi, Y; Iwatsubo, T			Pen-2 is incorporated into the gamma-secretase complex through binding to transmembrane domain 4 of presenilin 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; C-TERMINUS; MEMBRANE TOPOLOGY; SIGNAL-TRANSDUCTION; BETA-APP; APH-1; STABILIZATION; NICASTRIN; ENDOPROTEOLYSIS; SEQUENCE	gamma-Secretase is a multimeric membrane protein complex comprised of presenilin (PS), nicastrin (Nct), Aph-1, and Pen-2. It is a member of an atypical class of aspartic proteases that hydrolyzes peptide bonds within the membrane. During the biosynthetic process of the gamma-secretase complex, Nct and Aph-1 form a heterodimeric intermediate complex and bind to the C-terminal region of PS, serving as a stabilizing scaffold for the complex. Pen- 2 is then recruited into this trimeric complex and triggers endoproteolysis of PS, conferring gamma-secretase activity. Although the Pen- 2 accumulation depends on PS, the binding partner of Pen- 2 within the gamma-secretase complex remains unknown. We reconstituted PS1 in Psen1/Psen2 deficient cells by expressing a series of PS1 mutants in which one of the N-terminal six transmembrane domains (TMDs) was swapped with those of CD4 (a type I transmembrane protein) or CLAC-P (a type II transmembrane protein). We report that the proximal two-thirds of TMD4 of PS1, including the conserved Trp-Asn-Phe sequence, are required for its interaction with Pen-2. Using a chimeric CD4 molecule harboring PS1 TMD4, we further demonstrate that the PS1 TMD4 bears a direct binding motif to Pen-2. Pen-2 may contribute to the activation of the gamma-secretase complex by directly binding to the TMD4 of PS1.	Univ Tokyo, Dept Neuropathol & Neurosci, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Dept Cellular Therapy, Adv Clin Res Ctr, Inst Med Sci,Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo	Tomita, T (corresponding author), Univ Tokyo, Dept Neuropathol & Neurosci, Grad Sch Pharmaceut Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	taisuke@mol.f.u-tokyo.ac.jp; iwatsubo@mol.f.u-tokyo.ac.jp	Kitamura, Toshio/AAA-2071-2021; Tomita, Taisuke/L-5427-2015	Tomita, Taisuke/0000-0002-0075-5943; Sato, Chihiro/0000-0002-7639-8727				Annaert WG, 2001, NEURON, V32, P579, DOI 10.1016/S0896-6273(01)00512-8; Bergman A, 2004, J BIOL CHEM, V279, P45564, DOI 10.1074/jbc.M407717200; Bergman A, 2004, J BIOL CHEM, V279, P16744, DOI 10.1074/jbc.M313999200; Brunkan AL, 2005, J NEUROCHEM, V94, P1315, DOI 10.1111/j.1471-4159.2005.03278.x; Brunkan AL, 2005, J NEUROCHEM, V92, P1158, DOI 10.1111/j.1471-4159.2004.02945.x; Capell A, 2005, J BIOL CHEM, V280, P6471, DOI 10.1074/jbc.M409106200; Capell A, 2003, J BIOL CHEM, V278, P52519, DOI 10.1074/jbc.C300435200; Chiu J, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh172; Crystal AS, 2003, J BIOL CHEM, V278, P20117, DOI 10.1074/jbc.M213107200; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Farmery MR, 2003, J BIOL CHEM, V278, P24277, DOI 10.1074/jbc.M211992200; Fraering PC, 2004, BIOCHEMISTRY-US, V43, P323, DOI 10.1021/bi035748j; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Hardy J, 2001, NEUROSCI LETT, V306, P203, DOI 10.1016/S0304-3940(01)01910-3; Hasegawa H, 2004, J BIOL CHEM, V279, P46455, DOI 10.1074/jbc.M406289200; Hashimoto T, 2002, EMBO J, V21, P1524, DOI 10.1093/emboj/21.7.1524; Hayashi I, 2004, J BIOL CHEM, V279, P38040, DOI 10.1074/jbc.M405597200; Henricson A, 2005, FEBS J, V272, P2727, DOI 10.1111/j.1742-4658.2005.04691.x; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; Iwata H, 2001, J BIOL CHEM, V276, P21678, DOI 10.1074/jbc.M007989200; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; Kaether C, 2004, EMBO J, V23, P4738, DOI 10.1038/sj.emboj.7600478; Karlstrom H, 2002, J BIOL CHEM, V277, P6763, DOI 10.1074/jbc.C100649200; Kim SH, 2005, J BIOL CHEM, V280, P41953, DOI 10.1074/jbc.M509070200; Kim SH, 2005, J BIOL CHEM, V280, P1992, DOI 10.1074/jbc.M412404200; Kim SH, 2004, J BIOL CHEM, V279, P48615, DOI 10.1074/jbc.C400396200; Kim SH, 2003, J BIOL CHEM, V278, P33992, DOI 10.1074/jbc.M305834200; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; LaVoie MJ, 2003, J BIOL CHEM, V278, P37213, DOI 10.1074/jbc.M303941200; Lee SF, 2004, J BIOL CHEM, V279, P4144, DOI 10.1074/jbc.M309745200; Leem JY, 2002, NEUROBIOL DIS, V11, P64, DOI 10.1006/nbdi.2002.0546; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Lehmann S, 1997, J BIOL CHEM, V272, P12047, DOI 10.1074/jbc.272.18.12047; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; Li T, 2003, J NEUROSCI, V23, P3272; Li XJ, 1996, NEURON, V17, P1015, DOI 10.1016/S0896-6273(00)80231-7; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; MA G, 2002, J NEUROSCI, V25, P192; Moehlmann T, 2002, P NATL ACAD SCI USA, V99, P8025, DOI 10.1073/pnas.112686799; Morais VA, 2003, J BIOL CHEM, V278, P43284, DOI 10.1074/jbc.M305685200; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Morohashi Y, 2002, J BIOL CHEM, V277, P14965, DOI 10.1074/jbc.M200897200; Murphy MP, 2000, J BIOL CHEM, V275, P26277, DOI 10.1074/jbc.M002812200; Nakai T, 1999, J BIOL CHEM, V274, P23647, DOI 10.1074/jbc.274.33.23647; Niimura M, 2005, J BIOL CHEM, V280, P12967, DOI 10.1074/jbc.M409829200; Oh YS, 2005, AM J PHYSIOL-CELL PH, V289, pC576, DOI 10.1152/ajpcell.00636.2004; Prokop S, 2005, J NEUROCHEM, V94, P57, DOI 10.1111/j.1471-4159.2005.03165.x; Prokop S, 2004, J BIOL CHEM, V279, P23255, DOI 10.1074/jbc.M401789200; Ratovitski T, 1997, J BIOL CHEM, V272, P24536, DOI 10.1074/jbc.272.39.24536; Saura CA, 2000, J BIOL CHEM, V275, P17136, DOI 10.1074/jbc.M909624199; Saura CA, 1999, J BIOL CHEM, V274, P13818, DOI 10.1074/jbc.274.20.13818; Schroeter EH, 2003, P NATL ACAD SCI USA, V100, P13075, DOI 10.1073/pnas.1735338100; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; Serneels L, 2005, P NATL ACAD SCI USA, V102, P1719, DOI 10.1073/pnas.0408901102; Shiraishi H, 2004, J NEUROCHEM, V90, P1402, DOI 10.1111/j.1471-4159.2004.02597.x; Shirotani K, 2004, J NEUROCHEM, V89, P1520, DOI 10.1111/j.1471-4159.2004.02447.x; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Steiner H, 1999, BIOCHEMISTRY-US, V38, P14600, DOI 10.1021/bi9914210; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Takahashi Y, 2003, J BIOL CHEM, V278, P18664, DOI 10.1074/jbc.M301619200; Takasugi N, 2002, J BIOL CHEM, V277, P50198, DOI 10.1074/jbc.M205352200; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tomita T, 1999, J NEUROSCI, V19, P10627, DOI 10.1523/JNEUROSCI.19-24-10627.1999; Tomita T, 2004, DRUG NEWS PERSPECT, V17, P321, DOI 10.1358/dnp.2004.17.5.829036; Tomita T, 1998, J BIOL CHEM, V273, P21153, DOI 10.1074/jbc.273.33.21153; Tomita T, 2001, J BIOL CHEM, V276, P33273, DOI 10.1074/jbc.M011152200; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Urano Y, 2005, J LIPID RES, V46, P904, DOI 10.1194/jlr.M400333-JLR200; Urano Y, 2003, BIOCHEM BIOPH RES CO, V308, P191, DOI 10.1016/S0006-291X(03)01355-X; Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200; Wang J, 2004, NEUROBIOL DIS, V15, P654, DOI 10.1016/j.nbd.2003.12.008; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009	81	97	102	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					41967	41975		10.1074/jbc.M509066200	http://dx.doi.org/10.1074/jbc.M509066200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16234244	hybrid			2022-12-25	WOS:000233992700022
J	Capurro, MI; Shi, W; Sandal, S; Filmus, J				Capurro, MI; Shi, W; Sandal, S; Filmus, J			Processing by convertases is not required for glypican-3-induced stimulation of hepatocellular carcinoma growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; WINGLESS MORPHOGEN GRADIENT; CONTROLS CELLULAR-RESPONSES; PROPROTEIN CONVERTASES; DALLY-LIKE; GASTRULATION MOVEMENTS; CONVERGENT EXTENSION; DROSOPHILA; GLYPICANS; HEDGEHOG	Glypicans are a family of heparan sulfate proteoglycans that are bound to the cell surface by a lipid anchor. Six members of this family have been identified in mammals (GPC1-GPC6). Glypicans act as regulators of the activity of various cytokines, including Wnts, Hedgehogs, and bone morphogenetic proteins. It has been reported that processing by a convertase is required for GPC3 activity during convergent extension in zebrafish embryos, for GPC3-induced regulation of Wnt signaling, and for the binding of GPC3 to Wnt5a. In our laboratory, we have recently demonstrated that GPC3 promotes the growth of hepatocellular carcinomas (HCCs) by stimulating canonical Wnt signaling. Because there is increasing evidence indicating that the structural requirements for GPC3 activity are cell type specific, we decided to investigate whether GPC3 needs to be processed by convertases to stimulate cell proliferation and Wnt signaling in HCC cells. We report here that a mutant GPC3 that cannot be processed by convertases is still able to play its stimulatory role in Wnt activity and HCC growth.	Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Cell & Mol Biol, Toronto, ON M4N 3M5, Canada; Univ Toronto, Hlth Sci Ctr, Div Cell & Mol Biol, Sunnybrook & Womens Coll, Toronto, ON M4N 3M5, Canada; Univ Toronto, Hlth Sci Ctr, Dept Med Biophys, Toronto, ON M4N 3M5, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; University Toronto Affiliates; Sunnybrook Health Science Center	Filmus, J (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Cell & Mol Biol, 2075 Bayview Ave,Rm S-220, Toronto, ON M4N 3M5, Canada.	jorge.filmus@swri.ca		Capurro, Mariana/0000-0002-4560-7186				Ai XB, 2003, J CELL BIOL, V162, P341, DOI 10.1083/jcb.200212083; Baeg GH, 2004, DEV BIOL, V276, P89, DOI 10.1016/j.ydbio.2004.08.023; Baeg GH, 2001, DEVELOPMENT, V128, P87; Baeg GH, 2000, CURR OPIN CELL BIOL, V12, P575, DOI 10.1016/S0955-0674(00)00134-4; Blair SS, 2005, CURR BIOL, V15, pR92, DOI 10.1016/j.cub.2005.01.026; Capurro M, 2003, GASTROENTEROLOGY, V125, P89, DOI 10.1016/S0016-5085(03)00689-9; Capurro MI, 2005, CANCER RES, V65, P6245, DOI 10.1158/0008-5472.CAN-04-4244; Cumberledge S, 1997, TRENDS GENET, V13, P421, DOI 10.1016/S0168-9525(97)01275-4; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; De Cat B, 2003, J CELL BIOL, V163, P625, DOI 10.1083/jcb.200302152; Desbordes SC, 2003, DEVELOPMENT, V130, P6245, DOI 10.1242/dev.00874; Duenas-Gonzalez A, 1998, J CELL BIOL, V141, P1407, DOI 10.1083/jcb.141.6.1407; Filmus J, 2001, J CLIN INVEST, V108, P497, DOI 10.1172/JCI13712; FILMUS J, 1995, BIOCHEM J, V311, P561, DOI 10.1042/bj3110561; FILMUS J, 2000, PROTEOGLYCANS, P161; Fujise M, 2003, DEVELOPMENT, V130, P1515, DOI 10.1242/dev.00379; Gonzalez EM, 2003, J BIOL CHEM, V278, P38113, DOI 10.1074/jbc.C300310200; Han C, 2005, DEVELOPMENT, V132, P667, DOI 10.1242/dev.01636; Han C, 2004, DEVELOPMENT, V131, P601, DOI 10.1242/dev.00958; Huang JS, 2004, BIOCHEM BIOPH RES CO, V315, P950, DOI 10.1016/j.bbrc.2004.01.151; Jackson SM, 1997, DEVELOPMENT, V124, P4113; Khatib AM, 2002, AM J PATHOL, V160, P1921, DOI 10.1016/S0002-9440(10)61140-6; Kirkpatrick CA, 2004, DEV CELL, V7, P513, DOI 10.1016/j.devcel.2004.08.004; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kramer KL, 2003, ANNU REV GENET, V37, P461, DOI 10.1146/annurev.genet.37.061103.090226; LANDER AD, 1998, PERSPECT DEV NEUROBI, V1, P1; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Lum L, 2003, SCIENCE, V299, P2039, DOI 10.1126/science.1081403; Ohkawara B, 2003, DEVELOPMENT, V130, P2129, DOI 10.1242/dev.00435; Paine-Saunders S, 2000, DEV BIOL, V225, P179, DOI 10.1006/dbio.2000.9831; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Song HH, 2002, BBA-GEN SUBJECTS, V1573, P241, DOI 10.1016/S0304-4165(02)00390-2; Song HH, 2005, J BIOL CHEM, V280, P2116, DOI 10.1074/jbc.M410090200; Taylor NA, 2003, FASEB J, V17, P1215, DOI 10.1096/fj.02-0831rev; Topczewski J, 2001, DEV CELL, V1, P251, DOI 10.1016/S1534-5807(01)00005-3; Veugelers M, 1999, J BIOL CHEM, V274, P26968, DOI 10.1074/jbc.274.38.26968; Veugelers M, 1998, TRENDS GLYCOSCI GLYC, V10, P145, DOI 10.4052/tigg.10.145; WATANABE K, 1995, J CELL BIOL, V130, P1207, DOI 10.1083/jcb.130.5.1207	38	45	48	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41201	41206		10.1074/jbc.M507004200	http://dx.doi.org/10.1074/jbc.M507004200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16227623	hybrid			2022-12-25	WOS:000233866900012
J	Louvain-Quintard, VB; Bianchini, EP; Calmel-Tareau, C; Tagzirt, M; Le Bonniec, BF				Louvain-Quintard, VB; Bianchini, EP; Calmel-Tareau, C; Tagzirt, M; Le Bonniec, BF			Thrombin-activable factor X re-establishes an intrinsic amplification in tenase-deficient plasmas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT FACTOR VIIA; DOSE FACTOR-VIIA; TISSUE FACTOR; ACTIVATION PEPTIDE; BLOOD-COAGULATION; BOVINE THROMBIN; CRYSTAL-STRUCTURE; GENERATION RATE; HEMOPHILIA-A; PROTEIN-C	Classical hemophilia results from a defect of the intrinsic tenase complex, the main factor X (FX) activator. Binding of factor VIIa to tissue factor triggers coagulation, but little amplification of thrombin production occurs. Handling of hemophilia by injection of the deficient or missing ( thus foreign) factor often causes immunological complications. Several strategies have been designed to bypass intrinsic tenase complex, but none induce true auto-amplification of thrombin production. In an attempt to re-establish a cyclic amplification of prothrombin activation in the absence of tenase, we prepared a chimera of FX having fibrinopeptide A for the activation domain (FXFpA). We reasoned that cascade initiation would produce traces of thrombin that would activate FXFpA ( contrary to its normal homologue). Given that the activation domain of FX is released upon activation, thrombin cleavage would produce authentic FXa that would produce more thrombin, which in turn would activate more chimeras. FXFpA was indeed activable by thrombin, albeit at a relatively low rate (5 x 10(3) M-1 s(-1)). Nevertheless, FXFpA allowed in vitro amplification of thrombin production, and 100 nM efficiently corrected thrombin generation in tenase-deficient plasmas. A decisive advantage of FXFpA could be that the artificial cascade is self-regulating: FXFpA had little influence on the clotting time of normal plasma, yet corrected that of tenase deficiency. Another advantage could be the half-life of FXFpA in blood; FX has a half-life of about 30 h (less than 3 h for FVIIa). It is also reasonable to expect little or no immunogenicity, because FX and fibrinopeptide A both circulate normally in the blood of hemophiliacs.	Univ Paris 05, INSERM, U428, Fac Pharm, F-75270 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Le Bonniec, BF (corresponding author), Univ Paris 05, INSERM, U428, Fac Pharm, 4 Av Observ, F-75270 Paris, France.	lebonnie@infoblogen.fr	Le Bonniec, Bernard/S-5756-2016; Le Bonniec, Bernard/ABA-1366-2020; TAGZIRT, Madjid MT/R-8048-2018	Le Bonniec, Bernard/0000-0002-8432-7363; Le Bonniec, Bernard/0000-0002-8432-7363; TAGZIRT, Madjid MT/0000-0001-7914-0695; BIANCHINI, Elsa/0000-0002-1370-5312; CALMEL, Claire/0000-0001-7215-7910				Baugh RJ, 1996, J BIOL CHEM, V271, P16126, DOI 10.1074/jbc.271.27.16126; BHARADWAJ D, 1995, J BIOL CHEM, V270, P6537, DOI 10.1074/jbc.270.12.6537; Bianchini EP, 2004, J BIOL CHEM, V279, P3671, DOI 10.1074/jbc.M309691200; Bianchini EP, 2002, J BIOL CHEM, V277, P20527, DOI 10.1074/jbc.M201139200; BINNIE CG, 1993, BLOOD, V81, P3186; Bode W, 1997, THROMB HAEMOSTASIS, V78, P501; Bolton-Maggs PHB, 2003, LANCET, V361, P1801, DOI 10.1016/S0140-6736(03)13405-8; Braud S, 2002, BIOCHEMISTRY-US, V41, P8478, DOI 10.1021/bi016069g; Brummel KE, 2002, BLOOD, V100, P148, DOI 10.1182/blood.V100.1.148; Butenas S, 2002, BLOOD, V99, P923, DOI 10.1182/blood.V99.3.923; Camire RM, 2000, BIOCHEMISTRY-US, V39, P14322, DOI 10.1021/bi001074q; Dahlback B, 2000, LANCET, V355, P1627, DOI 10.1016/S0140-6736(00)02225-X; DAVIE EW, 1995, THROMB HAEMOSTASIS, V74, P1; DUFFY EJ, 1992, J BIOL CHEM, V267, P7821; Everse SJ, 1998, BIOCHEMISTRY-US, V37, P8637, DOI 10.1021/bi9804129; GILES AR, 1988, BRIT J HAEMATOL, V69, P491, DOI 10.1111/j.1365-2141.1988.tb02405.x; Hedner U, 1999, THROMB HAEMOSTASIS, V82, P531; Hedner U, 2000, SEMIN THROMB HEMOST, V26, P363, DOI 10.1055/s-2000-8453; Himmelspach M, 2002, THROMB HAEMOSTASIS, V88, P1003, DOI 10.1055/s-0037-1613347; HOFFMAN M, 1994, BLOOD, V83, P38; Hrachovinova I, 2003, NAT MED, V9, P1020, DOI 10.1038/nm899; JESTY J, 1990, J BIOL CHEM, V265, P17539; Krishnaswamy S, 2005, J THROMB HAEMOST, V3, P54, DOI 10.1111/j.1538-7836.2004.01021.x; Kwan E, 2002, BIOTECHNOL BIOENG, V79, P724, DOI 10.1002/bit.10312; Larson PJ, 1998, BIOCHEMISTRY-US, V37, P5029, DOI 10.1021/bi972428p; LAUDANO AP, 1980, BIOCHEMISTRY-US, V19, P1013, DOI 10.1021/bi00546a028; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P6970; LEBONNIEC BF, 1993, J BIOL CHEM, V268, P19055; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; LEWIS SD, 1985, J BIOL CHEM, V260, P192; Lin PH, 1997, THROMB RES, V88, P365, DOI 10.1016/S0049-3848(97)00267-3; LINDLEY CM, 1994, CLIN PHARMACOL THER, V55, P638, DOI 10.1038/clpt.1994.80; Malkowski MG, 1997, BIOCHEM J, V326, P815, DOI 10.1042/bj3260815; Mann KG, 2003, J THROMB HAEMOST, V1, P1504, DOI 10.1046/j.1538-7836.2003.00298.x; Mannucci PM, 2003, J THROMB HAEMOST, V1, P1349, DOI 10.1046/j.1538-7836.2003.00262.x; MARTIN PD, 1992, J BIOL CHEM, V267, P7911; Martin PD, 1996, BIOCHEMISTRY-US, V35, P13030, DOI 10.1021/bi960656y; MERTENS K, 1990, THROMB HAEMOSTASIS, V64, P138; Monroe DM, 1997, BRIT J HAEMATOL, V99, P542, DOI 10.1046/j.1365-2141.1997.4463256.x; Picard V, 1999, J BIOL CHEM, V274, P4586, DOI 10.1074/jbc.274.8.4586; RAO LVM, 1990, BLOOD, V75, P1069; Roberts HR, 2004, BLOOD, V104, P3858, DOI 10.1182/blood-2004-06-2223; ROBERTS HR, 1965, THROMB DIATH HAEMOST, V13, P305, DOI 10.1055/s-0038-1656232; Rudolph AE, 2002, THROMB HAEMOSTASIS, V88, P756; Schenone M, 2004, CURR OPIN HEMATOL, V11, P272, DOI 10.1097/01.moh.0000130308.37353.d4; Schulman S, 2000, SEMIN THROMB HEMOST, V26, P421, DOI 10.1055/s-2000-8462; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; Tomokiyo K, 2003, VOX SANG, V85, P290, DOI 10.1111/j.0042-9007.2003.00365.x; Uprichard J, 2002, BLOOD REV, V16, P97, DOI 10.1054/blre.2002.0191; WOLF DL, 1995, BLOOD, V86, P4153, DOI 10.1182/blood.V86.11.4153.bloodjournal86114153; YU NH, 1992, THROMB HAEMOSTASIS, V67, P264	51	20	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41352	41359		10.1074/jbc.M507846200	http://dx.doi.org/10.1074/jbc.M507846200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16207719	hybrid			2022-12-25	WOS:000233866900030
J	Tanaka, Y; Tachiwana, H; Yoda, K; Masumoto, H; Okazaki, T; Kurumizaka, H; Yokoyama, S				Tanaka, Y; Tachiwana, H; Yoda, K; Masumoto, H; Okazaki, T; Kurumizaka, H; Yokoyama, S			Human centromere protein B induces translational positioning of nucleosomes on alpha-satellite sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNER KINETOCHORE PLATE; CENP-B; CRYSTAL-STRUCTURE; CELL-CYCLE; NULL MICE; ANGSTROM RESOLUTION; BINDING PROTEIN; CORE PARTICLE; HISTONE H3; IN-VITRO	The human centromere proteins A (CENP-A) and B (CENP-B) are the fundamental centromere components of chromosomes. CENP-A is the centromere-specific histone H3 variant, and CENP-B specifically binds a 17-base pair sequence (the CENP-B box), which appears within every other alpha-satellite DNA repeat. In the present study, we demonstrated centromere-specific nucleosome formation in vitro with recombinant proteins, including histones H2A, H2B, H4, CENP-A, and the DNA-binding domain of CENP-B. The CENP-A nucleosome wraps 147 base pairs of the alpha-satellite sequence within its nucleosome core particle, like the canonical H3 nucleosome. Surprisingly, CENP-B binds to nucleosomal DNA when the CENP-B box is wrapped within the nucleosome core particle and induces translational positioning of the nucleosome without affecting its rotational setting. This CENP-B-induced translational positioning only occurs when the CENP-B box sequence is settled in the proper rotational setting with respect to the histone octamer surface. Therefore, CENP-B may be a determinant for translational positioning of the centromere-specific nucleosomes through its binding to the nucleosomal CENP-B box.	Waseda Univ, Grad Sch Sci & Engn, Dept Elect Engn & Biosci, Shinjuku Ku, Tokyo 1698555, Japan; RIKEN, Genom Sci Ctr, Prot Res Grp, Yokohama, Kanagawa 2300045, Japan; Univ Tokyo, Grad Sch Sci, Dept Biochem & Biophys, Bunkyo Ku, Tokyo 1130033, Japan; Nagoya Univ, Biosci Ctr, Chikusa Ku, Nagoya, Aichi 4648601, Japan; NCI, Lab Biosyst & Canc, NIH, Bethesda, MD 20892 USA; Fujita Hlth Univ, Inst Comprehens Med Sci, Toyoake, Aichi 4701192, Japan; RIKEN, Harima Inst, SPring 8, Sayo, Hyogo 6795148, Japan	Waseda University; RIKEN; University of Tokyo; Nagoya University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Fujita Health University; Japan Synchrotron Radiation Research Institute; RIKEN	Kurumizaka, H (corresponding author), Waseda Univ, Grad Sch Sci & Engn, Dept Elect Engn & Biosci, Shinjuku Ku, 3-4-1 Okubo, Tokyo 1698555, Japan.	kurumizaka@waseda.jp; yokoyama@biochem.s.u-tokyo.ac.jp	Yokoyama, Shigeyuki/N-6911-2015; Tachiwana, Hiroaki/AHB-3091-2022	Yokoyama, Shigeyuki/0000-0003-3133-7338; Tachiwana, Hiroaki/0000-0001-9227-7653; Kurumizaka, Hitoshi/0000-0001-7412-3722				Ando S, 2002, MOL CELL BIOL, V22, P2229, DOI 10.1128/MCB.22.7.2229-2241.2002; Black BE, 2004, NATURE, V430, P578, DOI 10.1038/nature02766; Blower MD, 2002, DEV CELL, V2, P319, DOI 10.1016/S1534-5807(02)00135-1; Blower MD, 2001, NAT CELL BIOL, V3, P730, DOI 10.1038/35087045; Buchwitz BJ, 1999, NATURE, V401, P547, DOI 10.1038/44062; Choo KHA, 2000, TRENDS CELL BIOL, V10, P182, DOI 10.1016/S0962-8924(00)01739-6; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; CROTHERS DM, 1991, METHOD ENZYMOL, V208, P118; Davey CA, 2002, J MOL BIOL, V319, P1097, DOI 10.1016/S0022-2836(02)00386-8; EARNSHAW WC, 1985, CHROMOSOMA, V91, P313, DOI 10.1007/BF00328227; EARNSHAW WC, 1987, J CELL BIOL, V104, P817, DOI 10.1083/jcb.104.4.817; FITZGERALD DJ, 1994, J BIOL CHEM, V269, P21303; Fowler KJ, 2000, GENOME RES, V10, P30; Goshima G, 2003, J CELL BIOL, V160, P25, DOI 10.1083/jcb.200210005; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; Henikoff S, 2004, TRENDS GENET, V20, P320, DOI 10.1016/j.tig.2004.05.004; Howman EV, 2000, P NATL ACAD SCI USA, V97, P1148, DOI 10.1073/pnas.97.3.1148; Hudson DF, 1998, J CELL BIOL, V141, P309, DOI 10.1083/jcb.141.2.309; IKENO M, 1994, HUM MOL GENET, V3, P1245, DOI 10.1093/hmg/3.8.1245; Ikeno M, 1998, NAT BIOTECHNOL, V16, P431, DOI 10.1038/nbt0598-431; KIPLING D, 1995, MOL CELL BIOL, V15, P4009; KITAGAWA K, 1995, MOL CELL BIOL, V15, P1602; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Malik HS, 2003, NAT STRUCT BIOL, V10, P882, DOI 10.1038/nsb996; MARTINEZBALBAS A, 1990, BIOCHEMISTRY-US, V29, P2342, DOI 10.1021/bi00461a019; MASUMOTO H, 1989, J CELL BIOL, V109, P1963, DOI 10.1083/jcb.109.5.1963; Masumoto H, 1993, PROPERTIES CENP B IT; Mitchell AR, 1996, J CELL SCI, V109, P2199; MURO Y, 1992, J CELL BIOL, V116, P585, DOI 10.1083/jcb.116.3.585; Ohyama T, 1998, NUCLEIC ACIDS RES, V26, P4811, DOI 10.1093/nar/26.21.4811; Ohzeki J, 2002, J CELL BIOL, V159, P765, DOI 10.1083/jcb.200207112; PALMER DK, 1991, P NATL ACAD SCI USA, V88, P3734, DOI 10.1073/pnas.88.9.3734; Perez-Castro AV, 1998, DEV BIOL, V201, P135, DOI 10.1006/dbio.1998.9005; PLUTA AF, 1995, SCIENCE, V270, P1591, DOI 10.1126/science.270.5242.1591; Politi V, 2002, J CELL SCI, V115, P2317; Poo H, 2002, BIOTECHNOL LETT, V24, P1185, DOI 10.1023/A:1016107230825; Richmond TJ, 2003, NATURE, V423, P145, DOI 10.1038/nature01595; SAITOH H, 1992, CELL, V70, P115, DOI 10.1016/0092-8674(92)90538-N; Shelby RD, 1997, J CELL BIOL, V136, P501, DOI 10.1083/jcb.136.3.501; Smit AFA, 1996, P NATL ACAD SCI USA, V93, P1443, DOI 10.1073/pnas.93.4.1443; STOLER S, 1995, GENE DEV, V9, P573, DOI 10.1101/gad.9.5.573; SUGIMOTO K, 1994, J BIOCHEM-TOKYO, V116, P877, DOI 10.1093/oxfordjournals.jbchem.a124610; Sullivan BA, 2001, NAT REV GENET, V2, P584, DOI 10.1038/35084512; SULLIVAN KF, 1994, J CELL BIOL, V127, P581, DOI 10.1083/jcb.127.3.581; Suzuki N, 2004, J BIOL CHEM, V279, P5934, DOI 10.1074/jbc.M306477200; Takahashi K, 2000, SCIENCE, V288, P2215, DOI 10.1126/science.288.5474.2215; Tanaka Y, 2004, METHODS, V33, P3, DOI 10.1016/j.ymeth.2003.10.024; Tanaka Y, 2001, EMBO J, V20, P6612, DOI 10.1093/emboj/20.23.6612; Tawaramoto MS, 2003, J BIOL CHEM, V278, P51454, DOI 10.1074/jbc.M310388200; TOTH M, 1995, NAT GENET, V11, P71, DOI 10.1038/ng0995-71; Ura K, 1996, EMBO J, V15, P4959, DOI 10.1002/j.1460-2075.1996.tb00876.x; Vafa O, 1997, CURR BIOL, V7, P897, DOI 10.1016/S0960-9822(06)00381-2; Yoda K, 1997, CHROMOSOME RES, V5, P207, DOI 10.1023/A:1018407316908; Yoda K, 1998, GENES CELLS, V3, P533, DOI 10.1046/j.1365-2443.1998.00210.x; YODA K, 1992, J CELL BIOL, V119, P1413, DOI 10.1083/jcb.119.6.1413; Yoda K, 2000, P NATL ACAD SCI USA, V97, P7266, DOI 10.1073/pnas.130189697	57	46	47	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41609	41618		10.1074/jbc.M509666200	http://dx.doi.org/10.1074/jbc.M509666200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16183641	hybrid			2022-12-25	WOS:000233866900061
J	Cramer, J; Restle, T				Cramer, J; Restle, T			Pre-steady-state kinetic characterization of the DinB homologue DNA polymerase of Sulfolobus solfataricus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; I KLENOW FRAGMENT; ERROR-PRONE; Y-FAMILY; CRYSTAL-STRUCTURE; REPLICATION FIDELITY; BETA-CLAMP; MECHANISM; IDENTIFICATION; REVEALS	Equilibrium as well as pre-steady-state measurements were performed to characterize the molecular basis of DNA binding and nucleotide incorporation by the thermostable archaeal DinB homologue (Dbh) DNA polymerase of Sulfolobus solfataricus. Equilibrium titrations show a DNA binding affinity of about 60 nM, which is similar to 10- fold lower compared with other DNA polymerases. Investigations of the binding kinetics applying stopped-flow and pressure jump techniques confirm this weak binding affinity. Furthermore, these measurements suggest that the DNA binding occurs in a single step, diffusion-controlled manner. Single-turnover, single dNTP incorporation studies reveal maximal pre-steady-state burst rates of 0.64, 2.5, 3.7, and 5.6 s(-1) for dTTP, dATP, dGTP, and dCTP ( at 25 degrees C), which is 10-100-fold slower than the corresponding rates of classical DNA polymerases. Another unique feature of the Dbh is the very low nucleotide binding affinity ( K-d similar to 600 mu M), which again is 10-20-fold lower compared with classical DNA polymerases as well as other Y-family polymerases. Surprisingly, the rate-limiting step of nucleotide incorporation ( correct and incorrect) is the chemical step ( phosphoryl transfer) and not a conformational change of the enzyme. Thus, unlike replicative polymerases, an "induced fit" mechanism to select and incorporate nucleotides during DNA polymerization could not be detected for Dbh.	Univ Klinikum Schleswig Holstein, Inst Mol Med, D-23538 Lubeck, Germany; Max Planck Inst Mol Physiol, Phys Biochem Abt, D-44227 Dortmund, Germany	University of Kiel; Schleswig Holstein University Hospital; Max Planck Society	Restle, T (corresponding author), Univ Klinikum Schleswig Holstein, Inst Mol Med, Campus Lubeck,Ratzeburger Allee 160, D-23538 Lubeck, Germany.	restle@imm.uni-luebeck.de						ASTATKE M, 1995, J BIOL CHEM, V270, P1945, DOI 10.1074/jbc.270.4.1945; Bertram JG, 2004, J BIOL CHEM, V279, P33047, DOI 10.1074/jbc.C400265200; Boudsocq F, 2004, J BIOL CHEM, V279, P32932, DOI 10.1074/jbc.M405249200; Bunting KA, 2003, EMBO J, V22, P5883, DOI 10.1093/emboj/cdg568; Cramer J, 2002, J BIOL CHEM, V277, P43593, DOI 10.1074/jbc.M207854200; DAHLBERG ME, 1991, BIOCHEMISTRY-US, V30, P4835, DOI 10.1021/bi00234a002; DIVITA G, 1993, BIOCHEMISTRY-US, V32, P7966, DOI 10.1021/bi00082a018; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; Fiala KA, 2004, BIOCHEMISTRY-US, V43, P2116, DOI 10.1021/bi035746z; Fiala KA, 2004, BIOCHEMISTRY-US, V43, P2106, DOI 10.1021/bi0357457; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; HERSCHLAG D, 1991, BIOCHEMISTRY-US, V30, P4844, DOI 10.1021/bi00234a003; HSIEH JC, 1993, J BIOL CHEM, V268, P24607; Jacob MH, 2002, J MOL BIOL, V318, P837, DOI 10.1016/S0022-2836(02)00165-1; Joyce CM, 2004, BIOCHEMISTRY-US, V43, P14317, DOI 10.1021/bi048422z; Krebs R, 1997, BIOCHEMISTRY-US, V36, P10292, DOI 10.1021/bi970512z; Kulaeva OI, 1996, MUTAT RES-FUND MOL M, V357, P245, DOI 10.1016/0027-5107(96)00164-9; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; Lehmann AR, 2005, FEBS LETT, V579, P873, DOI 10.1016/j.febslet.2004.11.029; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; LOEB LA, 1982, ANNU REV BIOCHEM, V51, P429, DOI 10.1146/annurev.bi.51.070182.002241; MIZRAHI V, 1985, BIOCHEMISTRY-US, V24, P4010, DOI 10.1021/bi00336a031; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; Potapova O, 2002, J BIOL CHEM, V277, P28157, DOI 10.1074/jbc.M202607200; Rattray AJ, 2003, ANNU REV GENET, V37, P31, DOI 10.1146/annurev.genet.37.042203.132748; Silvian LF, 2001, NAT STRUCT BIOL, V8, P984, DOI 10.1038/nsb1101-984; Thrall SH, 1998, BIOCHEMISTRY-US, V37, P13349; Trincao J, 2001, MOL CELL, V8, P417, DOI 10.1016/S1097-2765(01)00306-9; Vidal AE, 2004, J BIOL CHEM, V279, P48360, DOI 10.1074/jbc.M406511200; Washington MT, 2001, CELL, V107, P917, DOI 10.1016/S0092-8674(01)00613-4; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; Yang W, 2005, FEBS LETT, V579, P868, DOI 10.1016/j.febslet.2004.11.047; Yang W, 2003, CURR OPIN STRUC BIOL, V13, P23, DOI 10.1016/S0959-440X(02)00003-9; Zhou BL, 2001, MOL CELL, V8, P427, DOI 10.1016/S1097-2765(01)00310-0; Zillig W, 1998, EXTREMOPHILES, V2, P131, DOI 10.1007/s007920050052	36	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40552	40558		10.1074/jbc.M504481200	http://dx.doi.org/10.1074/jbc.M504481200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16223720	hybrid			2022-12-25	WOS:000233666600022
J	Shen, Q; Christakos, S				Shen, Q; Christakos, S			The vitamin D receptor, Runx2, and the notch signaling pathway cooperate in the transcriptional regulation of osteopontin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED BONE-RESORPTION; CD4 GENE-EXPRESSION; LOOP-HELIX FACTORS; PARATHYROID-HORMONE; OSTEOBLAST DIFFERENTIATION; NEURONAL DIFFERENTIATION; COLLAGENASE-3 PROMOTER; TARGETED DISRUPTION; DROSOPHILA HAIRY; IN-VIVO	Osteopontin (OPN), a glycosylated phosphoprotein that binds calcium, is present in bone extracellular matrix and has been reported to modulate both mineralization and bone resorption. Targeted disruption in mice of the vitamin D receptor (VDR) or Runx2 results in marked inhibition of OPN expression in osteoblasts. In this study, we addressed possible cross-talk between VDR and Runx2 in regulating OPN transcription. 1,25-Dihydroxyvitamin D-3 (1,25(OH)(2)D-3) or Runx2 stimulated OPN transcription (mouse OPN promoter - 777/ - 79) 2 - 3- fold. However, coexpression of Runx2 and VDR in COS- 7 cells and treatment with 1,25(OH)(2)D-3 resulted in an 8-fold induction of OPN transcription, indicating for the first time functional cooperation between Runx2 and VDR in the regulation of OPN transcription. In ROS 17/2.8 and MC3T3- E1 cells that contain endogenous Runx2, AML-1/ETO, which acts as a repressor of Runx2, significantly inhibited 1,25(OH)(2)D-3 induction of OPN transcription, OPN mRNA, and protein expression. Both a Runx2 site (- 136/ - 130) and the vitamin D response element (- 757/ - 743) in the OPN promoter are needed for cooperative activation. Chromatin immunoprecipitation analyses showed that 1,25(OH)(2)D-3 can enhance VDR and Runx2 recruitment on the OPN promoter, further indicating cooperation between these two factors in the regulation of OPN. In osteoblastic cells, Hes-1, a downstream factor of the Notch signaling pathway, was found to enhance basal and 1,25(OH)(2)D-3- induced OPN transcription. This enhancement was inhibited by AML- 1/ ETO, an inhibitor of Runx2. Immunoprecipitation assays indicated that Hes- 1 and Runx2 interact and that 1,25(OH)(2)D-3 can enhance this interaction. Taken together, these findings define novel mechanisms involving the intersection of three pathways, Runx2, 1,25(OH)(2)D-3, and Notch signaling, that play a major role in the regulation of OPN in osteoblastic cells and therefore in the process of bone remodeling.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; Univ Med & Dent New Jersey Grad Sch Biomed Sci, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Christakos, S (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, 185 S Orange Ave, Newark, NJ 07103 USA.	christak@umdnj.edu			NIDDK NIH HHS [R01 DK038961, R01 DK038961-16] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038961] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allen RD, 2001, MOL CELL BIOL, V21, P3071, DOI 10.1128/MCB.21.9.3071-3082.2001; Asou Y, 2001, ENDOCRINOLOGY, V142, P1325, DOI 10.1210/en.142.3.1325; AUBIN JE, 1995, BONE, V17, pS77, DOI 10.1016/8756-3282(95)00183-E; AUSUBEL FM, 2005, CURRENT PROTOCOL MOL; Barletta F, 2002, MOL ENDOCRINOL, V16, P301, DOI 10.1210/me.16.2.301; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chellaiah MA, 2003, MOL BIOL CELL, V14, P173, DOI 10.1091/mbc.E02-06-0354; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; Christakos S, 2003, J CELL BIOCHEM, V88, P695, DOI 10.1002/jcb.10423; CHRISTAKOS S, 2002, PRINCIPLES BONE BIOL, P573; D'Alonzo RC, 2002, J BIOL CHEM, V277, P816, DOI 10.1074/jbc.M107082200; Denhardt DT, 2001, ANNU REV PHARMACOL, V41, P723, DOI 10.1146/annurev.pharmtox.41.1.723; Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097-4652(200009)184:3<341::AID-JCP8>3.0.CO;2-Z; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369; Hess J, 2001, J BIOL CHEM, V276, P20029, DOI 10.1074/jbc.M010601200; Ihara H, 2001, J BIOL CHEM, V276, P13065, DOI 10.1074/jbc.M010938200; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; Javed A, 1999, MOL CELL BIOL, V19, P7491; Javed A, 2001, MOL CELL BIOL, V21, P2891, DOI 10.1128/MCB.21.8.2891-2905.2001; Javed A, 2000, J CELL SCI, V113, P2221; Jimenez G, 1996, EMBO J, V15, P7088, DOI 10.1002/j.1460-2075.1996.tb01100.x; Jogi A, 2002, J BIOL CHEM, V277, P9118, DOI 10.1074/jbc.M107713200; Karsenty G, 2000, SEMIN CELL DEV BIOL, V11, P343, DOI 10.1006/scdb.2000.0188; Kim HK, 1998, MOL CELL BIOL, V18, P7166, DOI 10.1128/MCB.18.12.7166; Kim RH, 1996, BIOCHEM J, V318, P219, DOI 10.1042/bj3180219; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; MALAVAL L, 1994, J CELL PHYSIOL, V158, P555, DOI 10.1002/jcp.1041580322; Matsue M, 1997, BONE, V20, P329, DOI 10.1016/S8756-3282(97)00005-7; McKee MD, 1996, CONNECT TISSUE RES, V35, P197, DOI 10.3109/03008209609029192; McLarren KW, 2000, J BIOL CHEM, V275, P530, DOI 10.1074/jbc.275.1.530; McLarrent FW, 2001, J BIOL CHEM, V276, P1578, DOI 10.1074/jbc.M007629200; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Paredes R, 2004, MOL CELL BIOL, V24, P8847, DOI 10.1128/MCB.24.20.8847-8861.2004; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; POCKWINSE SM, 1992, J CELL BIOCHEM, V49, P310, DOI 10.1002/jcb.240490315; Porte D, 1999, ONCOGENE, V18, P667, DOI 10.1038/sj.onc.1202333; Rachez C, 2000, GENE, V246, P9, DOI 10.1016/S0378-1119(00)00052-4; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; Selvamurugan N, 1998, J BIOL CHEM, V273, P10647, DOI 10.1074/jbc.273.17.10647; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shapses SA, 2003, CALCIFIED TISSUE INT, V73, P86, DOI 10.1007/s00223-002-1090-x; Terai K, 1999, J BONE MINER RES, V14, P839, DOI 10.1359/jbmr.1999.14.6.839; TSAI CC, 1995, DEVELOPMENT, V121, P453; van Driel M, 2004, CURR PHARM DESIGN, V10, P2535; Yamamoto H, 2003, J BIOL CHEM, V278, P31756, DOI 10.1074/jbc.M304737200; Yan B, 2002, J BIOL CHEM, V277, P29760, DOI 10.1074/jbc.M204721200; Yoshitake H, 1999, P NATL ACAD SCI USA, V96, P8156, DOI 10.1073/pnas.96.14.8156; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391	53	133	137	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40589	40598		10.1074/jbc.M504166200	http://dx.doi.org/10.1074/jbc.M504166200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16195230	hybrid			2022-12-25	WOS:000233666600027
J	Stadthagen, G; Kordulakova, J; Griffin, R; Constant, P; Bottova, I; Barilone, N; Gicquel, B; Daffe, M; Jackson, M				Stadthagen, G; Kordulakova, J; Griffin, R; Constant, P; Bottova, I; Barilone, N; Gicquel, B; Daffe, M; Jackson, M			p-Hydroxybenzoic acid synthesis in Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHORISMATE PYRUVATE-LYASE; CELL-WALL; ESCHERICHIA-COLI; PHENOLIC GLYCOLIPID-1; IMMUNE-RESPONSE; GENE-CLUSTER; BOVIS BCG; COMPLEX; BIOSYNTHESIS; EXPRESSION	Glycosylated p-hydroxybenzoic acid methyl esters and structurally related phenolphthiocerol glycolipids are important virulence factors of Mycobacterium tuberculosis. Although both types of molecules are thought to be derived from p-hydroxybenzoic acid, the origin of this putative biosynthetic precursor in mycobacteria remained to be established. We describe the characterization of a transposon mutant of M. tuberculosis deficient in the production of all forms of p-hydroxybenzoic acid derivatives. The transposon was found to be inserted in Rv2949c, a gene located in the vicinity of the polyketide synthase gene pks15/1, involved in the elongation of p-hydroxybenzoate to phenolphthiocerol in phenolic glycolipid producing strains. A recombinant form of the Rv2949c enzyme was produced in the fast-growing non-pathogenic Mycobacterium smegmatis and purified to near homogeneity. The recombinant enzyme catalyzed the removal of the pyruvyl moiety of chorismate to form p-hydroxybenzoate with an apparent Km value for chorismate of 19.7 mu M and a k(cat) value of 0.102 s(-1). Strong inhibition of the reaction by p-hydroxybenzoate but not by pyruvate was observed. These results establish Rv2949c as a chorismate pyruvate-lyase responsible for the direct conversion of chorismate to p-hydroxybenzoate and identify Rv2949c as the sole enzymatic source of p-hydroxybenzoic acid in M. tuberculosis.	Inst Pasteur, Unite Genet Mycobacterienne, F-75015 Paris, France; CNRS, Dept Mecanismes Mol Infect Mycobacteriennes, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France; Natl Inst Med Res, London NW7 1AA, England	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); MRC National Institute for Medical Research	Jackson, M (corresponding author), Inst Pasteur, Unite Genet Mycobacterienne, 25 Rue Dr Roux, F-75015 Paris, France.	mjackson@pasteur.fr	Jackson, Mary/D-5345-2017; Kordulakova, Jana/I-3887-2014; Griffin, Ruth/AAO-2413-2021	Jackson, Mary/0000-0002-9212-0258; Kordulakova, Jana/0000-0003-2834-0165; Griffin, Ruth/0000-0002-0269-059X				Azad AK, 1997, J BIOL CHEM, V272, P16741, DOI 10.1074/jbc.272.27.16741; Azad AK, 1996, P NATL ACAD SCI USA, V93, P4787, DOI 10.1073/pnas.93.10.4787; Brennan PJ, 1988, MICROBIAL LIPIDS, V1, P-298; Camacho LR, 1999, MOL MICROBIOL, V34, P257, DOI 10.1046/j.1365-2958.1999.01593.x; Camacho LR, 2001, J BIOL CHEM, V276, P19845, DOI 10.1074/jbc.M100662200; CHAN J, 1989, P NATL ACAD SCI USA, V86, P2453, DOI 10.1073/pnas.86.7.2453; COLLINS MD, 1981, MICROBIOL REV, V45, P316, DOI 10.1128/MMBR.45.2.316-354.1981; Constant P, 2002, J BIOL CHEM, V277, P38148, DOI 10.1074/jbc.M206538200; Cox JS, 1999, NATURE, V402, P79, DOI 10.1038/47042; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; Daugelat S, 2003, MICROBES INFECT, V5, P1082, DOI 10.1016/S1286-4579(03)00205-3; De Voss JJ, 1999, J BACTERIOL, V181, P4443, DOI 10.1128/JB.181.15.4443-4451.1999; De Voss JJ, 2000, P NATL ACAD SCI USA, V97, P1252, DOI 10.1073/pnas.97.3.1252; Dosselaere F, 2001, CRIT REV MICROBIOL, V27, P75, DOI 10.1080/20014091096710; Fitzmaurice AM, 1998, J BIOL CHEM, V273, P8033, DOI 10.1074/jbc.273.14.8033; GARBE T, 1993, INFECT IMMUN, V61, P260, DOI 10.1128/IAI.61.1.260-267.1993; GASTAMBIDEODIER M, 1973, EUR J BIOCHEM, V33, P81, DOI 10.1111/j.1432-1033.1973.tb02657.x; GRIFFIN R, 2005, KEYST S BRIT COL APR; Hisert KB, 2004, INFECT IMMUN, V72, P5315, DOI 10.1128/IAI.72.9.5315-5321.2004; Holden MJ, 2002, BBA-PROTEIN STRUCT M, V1594, P160, DOI 10.1016/S0167-4838(01)00302-8; Kordulakova J, 2002, J BIOL CHEM, V277, P31335, DOI 10.1074/jbc.M204060200; Ng V, 2000, CELL, V103, P511, DOI 10.1016/S0092-8674(00)00142-2; NICHOLS BP, 1992, J BACTERIOL, V174, P5309, DOI 10.1128/JB.174.16.5309-5316.1992; Onwueme KC, 2004, P NATL ACAD SCI USA, V101, P4608, DOI 10.1073/pnas.0306928101; Perez E, 2004, J BIOL CHEM, V279, P42584, DOI 10.1074/jbc.M406134200; Perez E, 2004, J BIOL CHEM, V279, P42574, DOI 10.1074/jbc.M406246200; Prod'hom G, 1998, FEMS MICROBIOL LETT, V158, P75, DOI 10.1111/j.1574-6968.1998.tb12803.x; PUZO G, 1990, CRIT REV MICROBIOL, V17, P305, DOI 10.3109/10408419009105730; Reed MB, 2004, NATURE, V431, P84, DOI 10.1038/nature02837; Roche PW, 1996, CLIN EXP IMMUNOL, V103, P226, DOI 10.1046/j.1365-2249.1996.d01-613.x; SAUTON MB, 1912, CR HEBD ACAD SCI, V155, P860; SCHLESINGER LS, 1991, J EXP MED, V174, P1031, DOI 10.1084/jem.174.5.1031; SIEBERT M, 1992, FEBS LETT, V307, P347, DOI 10.1016/0014-5793(92)80710-X; SIEBERT M, 1994, MICROBIOL-SGM, V140, P897, DOI 10.1099/00221287-140-4-897; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; Soni MG, 2002, FOOD CHEM TOXICOL, V40, P1335, DOI 10.1016/S0278-6915(02)00107-2; Triccas JA, 1996, INFECT IMMUN, V64, P5171, DOI 10.1128/IAI.64.12.5171-5177.1996; Trivedi OA, 2005, MOL CELL, V17, P631, DOI 10.1016/j.molcel.2005.02.009; Trivedi OA, 2004, NATURE, V428, P441, DOI 10.1038/nature02384	39	59	67	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40699	40706		10.1074/jbc.M508332200	http://dx.doi.org/10.1074/jbc.M508332200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16210318	Green Published, Green Accepted, hybrid			2022-12-25	WOS:000233666600039
J	Tanaka, H; Fujita, N; Tsuruo, T				Tanaka, H; Fujita, N; Tsuruo, T			3-Phosphoinositide-dependent protein kinase-1-mediated I kappa B kinase beta (IKKB) phosphorylation activates NF-kappa B signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; PROTEIN KINASE-1; MICE LACKING; LIVER DEGENERATION; APOPTOSIS; AKT; ALPHA; PDK1; TRANSFORMATION; SUBUNIT	The I kappa B kinase (IKK)/NF-kappa B and phosphatidylinositol 3-OH-kinase/3-phosphoinositide-dependent protein kinase-1 (PDK1)/Akt pathways regulate various cellular functions, especially cell survival. These two pathways are often activated in many tumors and are thought to be associated with tumor progression. However, the cross-talk between them remains unclear. Here we show that PDK1 can activate IKK/NF-kappa B signaling in addition to Akt signaling to promote cell survival. Screening kinases that could modulate NF-kappa B activity revealed that expression of an upstream Akt kinase PDK1 up-regulates NF-kappa B transcriptional activity. We found that PDK1 directly phosphorylates IKK beta at the Ser(181) residue in the activation loop, leading to NF-kappa B nuclear translocation and NF-kappa B-dependent anti-apoptotic gene expression. IKK alpha is not required for PDK1-mediated NF-kappa B activation because NF-kappa B activation was observed in IKK alpha(-/-) mouse embryonic fibroblast (MEF) cells as in wild type MEF cells. Akt, which was previously reported to activate IKK alpha, did not participate in the PDK1-dependent IKK beta or NF-kappa B activation. The siRNA-mediated PDK1 gene silencing attenuated NF-kappa B activity and increased TRAIL-mediated cytotoxicity. Moreover, expression of constitutively active IKK beta overcame the PDK1 siRNA-mediated susceptibility to TRAIL. These results indicate that PDK1 is a critical regulator of cell survival by modulating the IKK/NF-kappa B pathway in addition to the Akt pathway.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 1358550, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	ttsuruo@iam.u-tokyo.ac.jp		Fujita, Naoya/0000-0002-9631-9264				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Arico S, 2002, J BIOL CHEM, V277, P27613, DOI 10.1074/jbc.M201119200; Arsura M, 2000, MOL CELL BIOL, V20, P5381, DOI 10.1128/MCB.20.15.5381-5391.2000; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Boothby MR, 1997, J EXP MED, V185, P1897, DOI 10.1084/jem.185.11.1897; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dixit V, 2002, CELL, V111, P615, DOI 10.1016/S0092-8674(02)01166-2; Fujita N, 2002, J BIOL CHEM, V277, P10346, DOI 10.1074/jbc.M106736200; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hinton HJ, 2004, NAT IMMUNOL, V5, P539, DOI 10.1038/ni1062; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Katome T, 2003, J BIOL CHEM, V278, P28312, DOI 10.1074/jbc.M302094200; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lee KY, 2005, SCIENCE, V308, P114, DOI 10.1126/science.1107107; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Ozes ON, 1999, NATURE, V401, P82; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Sato S, 2004, J BIOL CHEM, V279, P33759, DOI 10.1074/jbc.M402055200; Sato S, 2002, J BIOL CHEM, V277, P39360, DOI 10.1074/jbc.M205141200; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tsuruo T, 2003, CANCER SCI, V94, P15, DOI 10.1111/j.1349-7006.2003.tb01345.x; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Xie ZH, 2003, CANCER RES, V63, P5370; Zeng X, 2002, CANCER RES, V62, P3538	48	73	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40965	40973		10.1074/jbc.M506235200	http://dx.doi.org/10.1074/jbc.M506235200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16207722	hybrid			2022-12-25	WOS:000233666600070
J	Hirano, Y; Segawa, M; Ouchi, FS; Yamakawa, Y; Furukawa, K; Takeyasu, K; Horigome, T				Hirano, Y; Segawa, M; Ouchi, FS; Yamakawa, Y; Furukawa, K; Takeyasu, K; Horigome, T			Dissociation of emerin from barrier-to-autointegration factor is regulated through mitotic phosphorylation of emerin in a Xenopus egg cell-free system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DREIFUSS MUSCULAR-DYSTROPHY; LAMIN-B RECEPTOR; NUCLEAR-MEMBRANE PROTEIN; IN-VITRO; TRANSCRIPTIONAL REPRESSOR; BINDING; CHROMATIN; IDENTIFICATION; MAN1; BAF	Emerin is the gene product of STA whose mutations cause Emery-Dreifuss muscular dystrophy. It is an inner nuclear membrane protein and phosphorylated in a cell cycle-dependent manner. However, the means of phosphorylation of emerin are poorly understood. We investigated the regulation mechanism for the binding of emerin to chromatin, focusing on its cell cycle-dependent phosphorylation in a Xenopus egg cell-free system. It was shown that emerin dissociates from chromatin depending on mitotic phosphorylation of the former, and this plays a critical role in the dissociation of emerin from barrier-to-autointegration factor (BAF). Then, we analyzed the mitotic phosphorylation sites of emerin. Emerin was strongly phosphorylated in an M-phase Xenopus egg cell-free system, and five phosphorylated sites, Ser(49), Ser(66), Thr(67), Ser(120), and Ser(175), were identified on analysis of chymotryptic and tryptic emerin peptides using a phosphopeptide-concentrating system coupled with a Titansphere column, which specifically binds phosphopeptides, and tandem mass spectrometry sequencing. An in vitro binding assay involving an emerin S175A point mutant protein suggested that phosphorylation at Ser(175) regulates the dissociation of emerin from BAF.	Niigata Univ, Grad Sch Sci & Technol, Course Funct Biol, Niigata 9502181, Japan; Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068205, Japan; Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, Tokyo 1628640, Japan; Niigata Univ, Ctr Transdisciplinary Res, Niigata 9502181, Japan	Niigata University; Kyoto University; National Institute of Infectious Diseases (NIID); Niigata University	Horigome, T (corresponding author), Niigata Univ, Grad Sch Sci & Technol, Course Funct Biol, Igarashi 2, Niigata 9502181, Japan.	thori@chem.sc.niigata-u.ac.jp	Shinkai-ouchi, Fumiko/E-3207-2010; Hirano, Yasuhiro/AAN-4617-2021	Shinkai-ouchi, Fumiko/0000-0002-0095-941X; Hirano, Yasuhiro/0000-0001-7339-4053				BIONE S, 1994, NAT GENET, V8, P323, DOI 10.1038/ng1294-323; Clements L, 2000, BIOCHEM BIOPH RES CO, V267, P709, DOI 10.1006/bbrc.1999.2023; Cohen M, 2001, TRENDS BIOCHEM SCI, V26, P41, DOI 10.1016/S0968-0004(00)01727-8; Dreger M, 1999, BIOCHEMISTRY-US, V38, P9426, DOI 10.1021/bi990645f; Ellis JA, 1998, J CELL SCI, V111, P781; Fairley EAL, 1999, J CELL SCI, V112, P2571; FOISNER R, 1993, CELL, V73, P1267, DOI 10.1016/0092-8674(93)90355-T; Furukawa K, 1999, J CELL SCI, V112, P2485; Gajewski A, 2004, J BIOL CHEM, V279, P35813, DOI 10.1074/jbc.M402546200; Gant TM, 1997, ANNU REV CELL DEV BI, V13, P669, DOI 10.1146/annurev.cellbio.13.1.669; Haraguchi T, 2000, J CELL SCI, V113, P779; Haraguchi T, 2004, EUR J BIOCHEM, V271, P1035, DOI 10.1111/j.1432-1033.2004.04007.x; Haraguchi T, 2001, J CELL SCI, V114, P4575; Holaska JM, 2004, PLOS BIOL, V2, P1354, DOI 10.1371/journal.pbio.0020231; Holaska JM, 2003, J BIOL CHEM, V278, P6969, DOI 10.1074/jbc.M208811200; Kawahire S, 1997, J BIOCHEM-TOKYO, V121, P881, DOI 10.1093/oxfordjournals.jbchem.a021669; Kuroda I, 2004, ANAL SCI, V20, P1313, DOI 10.2116/analsci.20.1313; Kuyama H, 2003, RAPID COMMUN MASS SP, V17, P1493, DOI 10.1002/rcm.1078; Lattanzi G, 2003, BIOCHEM BIOPH RES CO, V303, P764, DOI 10.1016/S0006-291X(03)00415-7; Lee KK, 2001, J CELL SCI, V114, P4567; Lin F, 2000, J BIOL CHEM, V275, P4840, DOI 10.1074/jbc.275.7.4840; Liu J, 2003, P NATL ACAD SCI USA, V100, P4598, DOI 10.1073/pnas.0730821100; Mansharamani M, 2005, J BIOL CHEM, V280, P13863, DOI 10.1074/jbc.M413020200; Martins SB, 2003, BIOCHEMISTRY-US, V42, P10456, DOI 10.1021/bi0350699; Mislow JMK, 2002, FEBS LETT, V525, P135, DOI 10.1016/S0014-5793(02)03105-8; Nakagawa T, 2003, J BIOL CHEM, V278, P20395, DOI 10.1074/jbc.M210824200; Nikolakaki E, 1997, J BIOL CHEM, V272, P6208, DOI 10.1074/jbc.272.10.6208; Segura-Totten M, 2002, J CELL BIOL, V158, P475, DOI 10.1083/jcb.200202019; Takano M, 2004, J BIOL CHEM, V279, P13265, DOI 10.1074/jbc.M308854200; Takano M, 2002, EUR J BIOCHEM, V269, P943, DOI 10.1046/j.0014-2956.2001.02730.x; Tsuchiya Y, 1999, EUR J BIOCHEM, V259, P859, DOI 10.1046/j.1432-1327.1999.00112.x; Wang MY, 2005, ELECTROPHORESIS, V26, P2092, DOI 10.1002/elps.200410428; Wilkinson FL, 2003, EUR J BIOCHEM, V270, P2459, DOI 10.1046/j.1432-1033.2003.03617.x; Wolff N, 2001, FEBS LETT, V501, P171, DOI 10.1016/S0014-5793(01)02649-7	34	52	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					39925	39933		10.1074/jbc.M503214200	http://dx.doi.org/10.1074/jbc.M503214200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16204256	hybrid			2022-12-25	WOS:000233461300031
J	Song, J; Zhang, ZM; Hu, WD; Chen, Y				Song, J; Zhang, ZM; Hu, WD; Chen, Y			Small ubiquitin-like modifier (SUMO) recognition of a SUMO binding motif - A reversal of the bound orientation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; SACCHAROMYCES-CEREVISIAE; PROTEIN SUMOYLATION; HOMOLOGY; INSIGHTS; DOMAINS; RANGAP1; SYSTEM; NMR; IDENTIFICATION	Sumoylation has recently been identified as an important mechanism that regulates protein interactions and localization in essential cellular functions, such as gene transcription, subnuclear structure formation, viral infection, and cell cycle progression. A SUMO binding amino acid sequence motif ( SBM), which recognizes the SUMO moiety of modified proteins in sumoylation-dependent cellular functions, has been consistently identified by several recent studies. To understand the mechanism of SUMO recognition by the SBM, we have solved the solution structure of SUMO-1 in complex with a peptide containing the SBM derived from the protein PIASX ( KVDVIDLTIESSSDEEEDPPAKR). Surprisingly, the structure reveals that the bound orientation of the SBM can reverse depending on the sequence context. The structure also reveals a novel mechanism of recognizing target sequences by a ubiquitin-like module. Unlike ubiquitin binding motifs, which all form helices and bind to the main beta-sheet of ubiquitin, the SBM forms an extended structure that binds between the alpha-helix and a beta-strand of SUMO-1. This study provides a clear mechanism of the SBM sequence variations and its recognition of the SUMO moiety in sumoylated proteins.	Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA; Beckman Res Inst, Grad Sch Biol Sci, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope	Chen, Y (corresponding author), Beckman Res Inst, Div Immunol, 1450 E Duarte Rd, Duarte, CA 91010 USA.	ychen@coh.org			NATIONAL CANCER INSTITUTE [R01CA094595] Funding Source: NIH RePORTER; NCI NIH HHS [CA94595] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alam SL, 2004, EMBO J, V23, P1411, DOI 10.1038/sj.emboj.7600114; Ayaydin F, 2004, MOL BIOL CELL, V15, P5208, DOI 10.1091/mbc.E04-07-0589; Baba D, 2005, NATURE, V435, P979, DOI 10.1038/nature03634; Bayer P, 1998, J MOL BIOL, V280, P275, DOI 10.1006/jmbi.1998.1839; Bohren KM, 2004, J BIOL CHEM, V279, P27233, DOI 10.1074/jbc.M402273200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chupreta S, 2005, MOL CELL BIOL, V25, P4272, DOI 10.1128/MCB.25.10.4272-4282.2005; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Dalgarno DC, 1997, BIOPOLYMERS, V43, P383; Denison C, 2005, MOL CELL PROTEOMICS, V4, P246, DOI 10.1074/mcp.M400154-MCP200; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; Engelhardt OG, 2003, EXP CELL RES, V283, P36, DOI 10.1016/S0014-4827(02)00025-3; Gill G, 2004, GENE DEV, V18, P2046, DOI 10.1101/gad.1214604; Guo DH, 2004, NAT GENET, V36, P837, DOI 10.1038/ng1391; Hannich JT, 2005, J BIOL CHEM, V280, P4102, DOI 10.1074/jbc.M413209200; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Jin CW, 2001, INT J BIOL MACROMOL, V28, P227, DOI 10.1016/S0141-8130(00)00169-0; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kang RS, 2003, CELL, V113, P621, DOI 10.1016/S0092-8674(03)00362-3; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lin DH, 2002, J BIOL CHEM, V277, P21740, DOI 10.1074/jbc.M108418200; Lois LM, 2005, EMBO J, V24, P439, DOI 10.1038/sj.emboj.7600552; Macauley MS, 2004, J BIOL CHEM, V279, P49131, DOI 10.1074/jbc.M408705200; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Mishra RK, 2004, J BIOL CHEM, V279, P31445, DOI 10.1074/jbc.M402911200; Mueller TD, 2003, EMBO J, V22, P4634, DOI 10.1093/emboj/cdg467; Panse VG, 2004, J BIOL CHEM, V279, P41346, DOI 10.1074/jbc.M407950200; Pichler A, 2005, NAT STRUCT MOL BIOL, V12, P264, DOI 10.1038/nsmb903; Reverter D, 2005, NATURE, V435, P687, DOI 10.1038/nature03588; Reverter D, 2004, STRUCTURE, V12, P1519, DOI 10.1016/j.str.2004.05.023; Rosendorff A, 2004, J VIROL, V78, P367, DOI 10.1128/JVI.78.1.367-377.2004; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Song J, 2004, P NATL ACAD SCI USA, V101, P14373, DOI 10.1073/pnas.0403498101; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Sundquist WI, 2004, MOL CELL, V13, P783, DOI 10.1016/S1097-2765(04)00129-7; Swanson KA, 2003, EMBO J, V22, P4597, DOI 10.1093/emboj/cdg471; Takahashi H, 2005, J BIOL CHEM, V280, P5611, DOI 10.1074/jbc.M408130200; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Wohlschlegel JA, 2004, J BIOL CHEM, V279, P45662, DOI 10.1074/jbc.M409203200; Yang SH, 2005, EMBO J, V24, P2161, DOI 10.1038/sj.emboj.7600690	46	216	223	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40122	40129		10.1074/jbc.M507059200	http://dx.doi.org/10.1074/jbc.M507059200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16204249	hybrid			2022-12-25	WOS:000233461300051
J	Akool, ES; Doller, A; Muller, R; Gutwein, P; Xin, CY; Huwiler, A; Pfeilschifter, J; Eberhardt, W				Akool, ES; Doller, A; Muller, R; Gutwein, P; Xin, CY; Huwiler, A; Pfeilschifter, J; Eberhardt, W			Nitric oxide induces TIMP-1 expression by activating the transforming growth factor beta-Smad signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ARGININE SUPPLEMENTATION; RAT MESANGIAL CELLS; TGF-BETA; TISSUE INHIBITOR; GENE-EXPRESSION; MATRIX METALLOPROTEINASES; EXPERIMENTAL GLOMERULONEPHRITIS; EXTRACELLULAR-MATRIX; ANTIFIBROTIC ACTIONS; MATRIX-METALLOPROTEINASE-9	Excessive accumulation of the extracellular matrix is a hallmark of many inflammatory and fibrotic diseases, including those of the kidney. This study addresses the question whether NO, in addition to inhibiting the expression of MMP-9, a prominent metalloprotease expressed by mesangial cells, additionally modulates expression of its endogenous inhibitor TIMP-1. We demonstrate that exogenous NO has no modulatory effect on the extracellular TIMP-1 content but strongly amplifies the early increase in cytokine-induced TIMP-1 mRNA and protein levels. We examined whether transforming growth factor beta(TGF beta), a potent profibrotic cytokine, is involved in the regulation of NO-dependent TIMP-1 expression. Experiments utilizing a pan-specific neutralizing TGF beta antibody demonstrate that the NO-induced amplification of TIMP-1 is mediated by extracellular TGF beta. Mechanistically, NO causes a rapid increase in Smad-2 phosphorylation, which is abrogated by the addition of neutralizing TGF beta antisera. Similarly, the NO-dependent increase in Smad-2 phosphorylation is prevented in the presence of an inhibitor of TGF beta-RI kinase, indicating that the NO-dependent activation of Smad-2 occurs via the TGF beta-type I receptor. Furthermore, activation of the Smad signaling cascade by NO is corroborated by the NO-dependent increase in nuclear Smad-4 level and is paralleled by increased DNA binding of Smad2/3 containing complexes to a TIMP-1-specific Smad-binding element ( SBE). Reporter gene assays revealed that NO activates a 0.6-kb TIMP-1 gene promoter fragment as well as a TGF beta-inducible and SBE-driven control promoter. Chromatin immunoprecipitation analysis also demonstrated DNA binding activity of Smad-3 and Smad-4 proteins to the TIMP-1-specific SBE. Finally, by enzyme-linked immunosorbent assay, we demonstrated that NO causes a rapid increase in TGF beta(1) levels in cell supernatants. Together, these experiments demonstrate that NO by induction of the Smad signaling pathway modulates TIMP-1 expression.	Univ Frankfurt Klinikum, Pharmazentrum Frankfurt, ZAFES, D-60590 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital	Eberhardt, W (corresponding author), Univ Frankfurt Klinikum, Pharmazentrum Frankfurt, ZAFES, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	w.eberhardt@em.uni-frankfurt.de	Akool, El-Sayed/ABB-7729-2021	Akool, El-Sayed/0000-0003-4216-5164				Akool ES, 2003, MOL CELL BIOL, V23, P4901, DOI 10.1128/MCB.23.14.4901-4916.2003; Albrecht EWJA, 2003, NITRIC OXIDE-BIOL CH, V8, P53, DOI 10.1016/S1089-8603(02)00132-5; Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Blakytny R, 2004, J CELL PHYSIOL, V199, P67, DOI 10.1002/jcp.10454; Bugno M, 1995, NUCLEIC ACIDS RES, V23, P5041, DOI 10.1093/nar/23.24.5041; CAMPBELL CE, 1991, J BIOL CHEM, V266, P7199; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Eagleton MJ, 2002, J SURG RES, V104, P15, DOI 10.1006/jsre.2002.6396; Eberhardt W, 2000, KIDNEY INT, V57, P59, DOI 10.1046/j.1523-1755.2000.00808.x; Eberhardt W, 1998, J IMMUNOL, V160, P4961; Eberhardt W, 2002, KIDNEY INT, V61, P20, DOI 10.1046/j.1523-1755.2002.00087.x; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; Fukasawa H, 2004, KIDNEY INT, V65, P63, DOI 10.1111/j.1523-1755.2004.00393.x; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Hall MC, 2003, J BIOL CHEM, V278, P10304, DOI 10.1074/jbc.M212334200; Hmadcha A, 1999, J EXP MED, V190, P1595, DOI 10.1084/jem.190.11.1595; Huang XJ, 2000, CLIN EXP METASTAS, V18, P329, DOI 10.1023/A:1010867618014; Ito K, 2004, KIDNEY INT, V66, P1365, DOI 10.1111/j.1523-1755.2004.00899.x; Kampfer H, 2000, EUR CYTOKINE NETW, V11, P626; Lawrence DA, 1996, EUR CYTOKINE NETW, V7, P363; Leask A, 2004, FASEB J, V18, P816, DOI 10.1096/fj.03-1273rev; LECO KJ, 1994, J BIOL CHEM, V269, P9352; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Ling H, 2003, J AM SOC NEPHROL, V14, P377, DOI 10.1097/01.ASN.0000042168.43665.9B; LOTZ M, 1991, J BIOL CHEM, V266, P2017; Marcet-Palacios M, 2003, J PHARMACOL EXP THER, V307, P429, DOI 10.1124/jpet.103.050385; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Munger JS, 1997, KIDNEY INT, V51, P1376, DOI 10.1038/ki.1997.188; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; Peters H, 2000, KIDNEY INT, V57, P992, DOI 10.1046/j.1523-1755.2000.00927.x; Peters H, 1999, KIDNEY INT, V55, P2264, DOI 10.1046/j.1523-1755.1999.00462.x; Peters H, 2003, KIDNEY INT, V64, P509, DOI 10.1046/j.1523-1755.2003.00112.x; PFEILSCHIFTER J, 1991, BIOCHEM BIOPH RES CO, V175, P372, DOI 10.1016/0006-291X(91)91574-V; PFEILSCHIFTER J, 1990, FEBS LETT, V273, P185, DOI 10.1016/0014-5793(90)81080-8; Pfeilschifter J, 2002, KIDNEY INT, V61, P809, DOI 10.1046/j.1523-1755.2002.00225.x; Pfeilschifter J, 2001, PFLUG ARCH EUR J PHY, V442, P479, DOI 10.1007/s004240100586; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Poczatek MH, 2000, AM J PATHOL, V157, P1353, DOI 10.1016/S0002-9440(10)64649-4; ROBERTS AB, 1992, KIDNEY INT, V41, P557, DOI 10.1038/ki.1992.81; Sawyer JS, 2004, BIOORG MED CHEM LETT, V14, P3581, DOI 10.1016/j.bmcl.2004.04.007; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Todorovic V, 2005, INT J BIOCHEM CELL B, V37, P38, DOI 10.1016/j.biocel.2004.03.011; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; Wang SX, 2002, J BIOL CHEM, V277, P9880, DOI 10.1074/jbc.M108360200; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Wong C, 1999, MOL CELL BIOL, V19, P1821; Xin CY, 2004, J BIOL CHEM, V279, P35255, DOI 10.1074/jbc.M312091200; Yingling JM, 2004, NAT REV DRUG DISCOV, V3, P1011, DOI 10.1038/nrd1580; Zaragoza C, 2002, KIDNEY INT, V61, P804, DOI 10.1046/j.1523-1755.2002.00224.x; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Ziyadeh FN, 2000, P NATL ACAD SCI USA, V97, P8015, DOI 10.1073/pnas.120055097	56	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39403	39416		10.1074/jbc.M504140200	http://dx.doi.org/10.1074/jbc.M504140200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16183640	hybrid			2022-12-25	WOS:000233362200062
J	Deitermann, S; Sprie, GS; Koch, HG				Deitermann, S; Sprie, GS; Koch, HG			A dual function for SecA in the assembly of single spanning membrane proteins in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-RECOGNITION PARTICLE; ENDOPLASMIC-RETICULUM MEMBRANE; CYTOPLASMIC MEMBRANE; PREPROTEIN TRANSLOCATION; TARGETING PATHWAYS; STEPWISE MOVEMENT; PLASMA-MEMBRANE; NASCENT CHAINS; INSERTION; INTEGRATION	The assembly of bacterial membrane proteins with large periplasmic loops is an intrinsically complex process because the SecY translocon has to coordinate the signal recognition particle-dependent targeting and integration of transmembrane domains with the SecA-dependent translocation of the periplasmic loop. The current model suggests that the ATP hydrolysis by SecA is required only if periplasmic loops larger than 30 amino acids have to be translocated. In agreement with this model, our data demonstrate that the signal recognition particle-and SecA-dependent multiple spanning membrane protein YidC becomes SecA-independent if the large periplasmic loop connecting transmembrane domains 1 and 2 is reduced to less than 30 amino acids. Strikingly, however, we were unable to render single spanning membrane proteins SecA-independent by reducing the length of their periplasmic loops. For these proteins, the complete assembly was always SecA-dependent even if the periplasmic loop was reduced to 13 amino acids. If, however, the 13-amino acid-long periplasmic loop was fused to a downstream transmembrane domain, SecA was no longer required for complete translocation. Although these data support the current model on the SecA dependence of multiple spanning membrane proteins, they indicate a novel function of SecA for the assembly of single spanning membrane proteins. This could suggest that single and multiple spanning membrane proteins are processed differently by the bacterial SecY translocon.	Univ Freiburg, Fac Med, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany; Univ Freiburg, Fac Biol, D-79104 Freiburg, Germany	University of Freiburg; University of Freiburg	Koch, HG (corresponding author), Univ Freiburg, Fac Med, Inst Biochem & Mol Biol, Hermann Herder Str 7, D-79104 Freiburg, Germany.	Hans-Georg.Koch@biochemie.uni-freiburg.de						AKIYAMA Y, 1990, BIOCHEM BIOPH RES CO, V167, P711, DOI 10.1016/0006-291X(90)92083-C; Alder NN, 2004, J BIOL CHEM, V279, P22787, DOI 10.1074/jbc.R400002200; ANDERSSON H, 1993, EMBO J, V12, P683, DOI 10.1002/j.1460-2075.1993.tb05702.x; Angelini S, 2005, EMBO REP, V6, P476, DOI 10.1038/sj.embor.7400385; Beck K, 2000, EMBO J, V19, P134, DOI 10.1093/emboj/19.1.134; Beck K, 2001, EMBO REP, V2, P709, DOI 10.1093/embo-reports/kve154; Beha D, 2003, J BIOL CHEM, V278, P22161, DOI 10.1074/jbc.M300929200; Behrmann M, 1998, J BIOL CHEM, V273, P13898, DOI 10.1074/jbc.273.22.13898; Cannon KS, 2005, J CELL BIOL, V169, P219, DOI 10.1083/jcb.200412019; Cheng ZL, 2005, J CELL BIOL, V168, P67, DOI 10.1083/jcb.200408188; Dalbey RE, 2004, BBA-MOL CELL RES, V1694, P37, DOI 10.1016/j.bbamcr.2004.03.009; Driessen AJM, 2001, NAT STRUCT BIOL, V8, P492, DOI 10.1038/88549; Duong F, 2003, EMBO J, V22, P4375, DOI 10.1093/emboj/cdg418; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; Froderberg L, 2003, MOL MICROBIOL, V47, P1015, DOI 10.1046/j.1365-2958.2003.03346.x; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; Halic M, 2005, CURR OPIN STRUC BIOL, V15, P116, DOI 10.1016/j.sbi.2005.01.013; Hegde RS, 1996, CELL, V85, P217, DOI 10.1016/S0092-8674(00)81098-3; Heinrich SU, 2003, EMBO J, V22, P3654, DOI 10.1093/emboj/cdg346; Hermansson M, 2001, J MOL BIOL, V313, P1171, DOI 10.1006/jmbi.2001.5108; Hessa T, 2005, NATURE, V433, P377, DOI 10.1038/nature03216; Houben ENG, 2005, J CELL BIOL, V170, P27, DOI 10.1083/jcb.200503035; Houben ENG, 2004, EMBO REP, V5, P970, DOI 10.1038/sj.embor.7400261; Koch HG, 2000, J CELL BIOL, V150, P689, DOI 10.1083/jcb.150.3.689; Koch HG, 2002, J BIOL CHEM, V277, P5715, DOI 10.1074/jbc.C100683200; Koch HG, 1999, MOL BIOL CELL, V10, P2163, DOI 10.1091/mbc.10.7.2163; Koch HG, 2003, REV PHYSIOL BIOCH P, V146, P55, DOI 10.1007/s10254-002-0002-9; KUHN A, 1988, EUR J BIOCHEM, V177, P267, DOI 10.1111/j.1432-1033.1988.tb14372.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANEEWANNAKUL S, 1994, PLASMID, V31, P300, DOI 10.1006/plas.1994.1032; Manting EH, 2000, EMBO J, V19, P852, DOI 10.1093/emboj/19.5.852; Matsumoto G, 1997, EMBO J, V16, P6384, DOI 10.1093/emboj/16.21.6384; McCormick PJ, 2003, MOL CELL, V12, P329, DOI 10.1016/S1097-2765(03)00304-6; Mori H, 2001, TRENDS MICROBIOL, V9, P494, DOI 10.1016/S0966-842X(01)02174-6; MULLER M, 1984, P NATL ACAD SCI-BIOL, V81, P7421, DOI 10.1073/pnas.81.23.7421; Neumann-Haefelin C, 2000, EMBO J, V19, P6419, DOI 10.1093/emboj/19.23.6419; Nishiyama KI, 1996, CELL, V85, P71, DOI 10.1016/S0092-8674(00)81083-1; Ota K, 2000, J BIOL CHEM, V275, P29743, DOI 10.1074/jbc.M002468200; Qi HY, 1999, J BIOL CHEM, V274, P8993, DOI 10.1074/jbc.274.13.8993; Raden D, 2000, J CELL BIOL, V150, P53, DOI 10.1083/jcb.150.1.53; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; Sato K, 1997, J BIOL CHEM, V272, P5880, DOI 10.1074/jbc.272.9.5880; Sauri A, 2005, J BIOL CHEM, V280, P25907, DOI 10.1074/jbc.M412476200; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Scotti PA, 1999, J BIOL CHEM, V274, P29883, DOI 10.1074/jbc.274.42.29883; Serek J, 2004, EMBO J, V23, P294, DOI 10.1038/sj.emboj.7600063; SILHAVY TJ, 1984, EXPT GENE FUSION; Traxler B, 1996, J BIOL CHEM, V271, P12394, DOI 10.1074/jbc.271.21.12394; Uchida K, 1995, J BIOL CHEM, V270, P30862, DOI 10.1074/jbc.270.52.30862; Urbanus ML, 2002, J BIOL CHEM, V277, P12718, DOI 10.1074/jbc.M200311200; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; van der Laan M, 2004, J BIOL CHEM, V279, P1659, DOI 10.1074/jbc.M306527200; van der Wolk JPW, 1997, EMBO J, V16, P7297, DOI 10.1093/emboj/16.24.7297; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319; Yahr TL, 2000, EMBO J, V19, P4393, DOI 10.1093/emboj/19.16.4393; Zito CR, 2003, J BIOL CHEM, V278, P40640, DOI 10.1074/jbc.M308025200	57	43	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39077	39085		10.1074/jbc.M509647200	http://dx.doi.org/10.1074/jbc.M509647200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16186099	hybrid			2022-12-25	WOS:000233362200022
J	Hagiya, A; Naganuma, T; Maki, Y; Ohta, J; Tohkairin, Y; Shimizu, T; Nomura, T; Hachimori, A; Uchiumi, T				Hagiya, A; Naganuma, T; Maki, Y; Ohta, J; Tohkairin, Y; Shimizu, T; Nomura, T; Hachimori, A; Uchiumi, T			A mode of assembly of P0, P1, and P2 proteins at the GTPase-associated center in animal ribosome - In vitro analyses with P0 truncation mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; BINDING-SITES; RNA; COMPLEX; DOMAIN; STALK; ELONGATION; RIBOSOMAL-PROTEIN-L7; STOICHIOMETRY; RECOGNITION	Ribosomal P0, P1, and P2 proteins, together with the conserved domain of 28 S rRNA, constitute a major part of the GTPase-associated center in eukaryotic ribosomes. We investigated the mode of assembly in vitro by using various truncation mutants of silkworm P0. When compared with wild type (WT)-P0, the C-terminal truncation mutants C Delta 65 and C Delta 81 showed markedly reduced binding ability to P1 and P2, which was offset by the addition of an rRNA fragment covering the P0(.)P1-P2 binding site. The mutant C Delta 107 lost the P1/P2 binding activity, whereas it retained the rRNA binding. In contrast, the N-terminal truncation mutants N Delta 21-N Delta 92 completely lost the rRNA binding, although they retained P1/P2 binding capability, implying an essential role of the N terminus of P0 for rRNA binding. The P0 mutants N Delta 6, N Delta 14, and C Delta 18-C Delta 81, together with P1/P2 and eL12, bound to the Escherichia coli core 50 S subunits deficient in L10(.)L7/L12 complex and L11. Analysis of incorporation of P-32- labeled P1/P2 into the 50 S subunits with WT-P0 and C Delta 81 by sedimentation analysis indicated that WT-P0 bound two copies of P1 and P2, but C Delta 81 bound only one copy each. The hybrid ribosome with C Delta 81 that appears to contain one P1-P2 heterodimer retained lower but considerable activities dependent on eukaryotic elongation factors. These results suggested that two P1-P2 dimers bind to close but separate regions on the C-terminal half of P0. The results were further confirmed by binding experiments using chimeric P0 mutants in which the C-terminal 81 or 107 amino acids were replaced with the homologous sequences of the archaebacterial P0.	Niigata Univ, Fac Sci, Dept Biol, Niigata 9502181, Japan; Shinshu Univ, Fac Text Sci & Technol, Inst High Polymer Res, Ueda, Nagano 3868567, Japan	Niigata University; Shinshu University	Uchiumi, T (corresponding author), Niigata Univ, Fac Sci, Dept Biol, Niigata 9502181, Japan.	uchiumi@bio.sc.niigata-u.ac.jp						Agrawal RK, 2001, J MOL BIOL, V311, P777, DOI 10.1006/jmbi.2001.4907; Ballesta JPG, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P115; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; BEAUCLERK AAD, 1984, J BIOL CHEM, V259, P6559; Cundliffe E., 1986, STRUCTURE FUNCTION G, P586; DABBS ER, 1979, J BACTERIOL, V140, P734, DOI 10.1128/JB.140.2.734-737.1979; Diaconu M, 2005, CELL, V121, P991, DOI 10.1016/j.cell.2005.04.015; DIJK J, 1979, NUCLEIC ACIDS RES, V6, P2717, DOI 10.1093/nar/6.8.2717; EGEBJERG J, 1990, J MOL BIOL, V213, P275, DOI 10.1016/S0022-2836(05)80190-1; Gonzalo P, 2001, J BIOL CHEM, V276, P19762, DOI 10.1074/jbc.M101398200; Griaznova O, 2000, BIOCHEMISTRY-US, V39, P4075, DOI 10.1021/bi992621e; Guarinos E, 2001, J BIOL CHEM, V276, P32474, DOI 10.1074/jbc.M103229200; GUDKOV AT, 1978, FEBS LETT, V93, P215, DOI 10.1016/0014-5793(78)81106-5; GUDKOV AT, 1980, FEBS LETT, V109, P34, DOI 10.1016/0014-5793(80)81305-6; Hanson CL, 2004, J BIOL CHEM, V279, P42750, DOI 10.1074/jbc.M405718200; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; Iwasaki K, 1979, Methods Enzymol, V60, P657; Lalioti VS, 2002, MOL MICROBIOL, V46, P719, DOI 10.1046/j.1365-2958.2002.03179.x; LEE CC, 1981, J BIOL CHEM, V256, P41; MAASSEN JA, 1985, EUR J BIOCHEM, V149, P609, DOI 10.1111/j.1432-1033.1985.tb08968.x; MOLLER W, 1983, J MOL BIOL, V163, P553, DOI 10.1016/0022-2836(83)90112-2; Moller W., 1986, STRUCTURE FUNCTION G, P309; Perez-Fernandez J, 2005, BIOCHEMISTRY-US, V44, P5532, DOI 10.1021/bi047332r; PETTERSSON I, 1979, NUCLEIC ACIDS RES, V6, P2637, DOI 10.1093/nar/6.7.2637; PETTERSSON I, 1976, FEBS LETT, V64, P135, DOI 10.1016/0014-5793(76)80267-0; RICH BE, 1987, MOL CELL BIOL, V7, P4065, DOI 10.1128/MCB.7.11.4065; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANTOS C, 1995, J BIOL CHEM, V270, P20608, DOI 10.1074/jbc.270.35.20608; Shimizu T, 2002, NUCLEIC ACIDS RES, V30, P2620, DOI 10.1093/nar/gkf379; SHIMMIN LC, 1989, J MOL EVOL, V29, P448, DOI 10.1007/BF02602915; Tchorzewski M, 2000, INT J BIOCHEM CELL B, V32, P737, DOI 10.1016/S1357-2725(00)00017-0; Tchorzewski M, 2003, BIOCHEMISTRY-US, V42, P3399, DOI 10.1021/bi0206006; Tchorzewski M, 2000, BBA-MOL CELL RES, V1499, P63, DOI 10.1016/S0167-4889(00)00108-7; TOKIMATSU H, 1981, J MOL BIOL, V152, P397, DOI 10.1016/0022-2836(81)90250-3; UCHIUMI T, 1995, J BIOL CHEM, V270, P29889; Uchiumi T, 1999, J BIOL CHEM, V274, P27578, DOI 10.1074/jbc.274.39.27578; UCHIUMI T, 1992, J BIOL CHEM, V267, P19179; UCHIUMI T, 1987, P NATL ACAD SCI USA, V84, P5580, DOI 10.1073/pnas.84.16.5580; Uchiumi T, 2002, J BIOL CHEM, V277, P41401, DOI 10.1074/jbc.M207424200; Uchiumi T, 2002, J BIOL CHEM, V277, P3857, DOI 10.1074/jbc.M107730200; WOOL IG, 1992, TRENDS BIOCHEM SCI, V17, P266, DOI 10.1016/0968-0004(92)90407-Z; Wool IG, 1995, BIOCHEM CELL BIOL, V73, P933, DOI 10.1139/o95-101; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089; ZHONG DG, 1993, BIOTECHNIQUES, V15, P874	44	61	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39193	39199		10.1074/jbc.M506050200	http://dx.doi.org/10.1074/jbc.M506050200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16188884	hybrid			2022-12-25	WOS:000233362200035
J	Lester, RD; Jo, M; Campana, WM; Gonias, SL				Lester, RD; Jo, M; Campana, WM; Gonias, SL			Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK/mitogen-activated protein kinase-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR; RECEPTOR EXPRESSION; ERK; BINDING; MECHANISM; APOPTOSIS; GROWTH; RAS; MEK; EPO	Recent studies indicate that cancer cells express erythropoietin receptor (EpoR). In this study, we have shown that erythropoietin (Epo) activates the mitogen-activated protein kinase, extracellular signal-regulated kinase (ERK), and promotes migration in MCF-7 breast cancer cells. Epo-stimulated MCF-7 cell migration was blocked by the MEK inhibitor PD098059 and by dominant negative MEK-1, indicating an essential role for ERK. When MCF-7 cells were exposed to hypoxia (1.0% O-2) for 3 h, the Epo mRNA level increased 2.4 +/- 0.5-fold, the basal level of ERK activation increased, and cell migration increased 2.0 +/- 0.1-fold. Soluble EpoR and Eponeutralizing antibody significantly inhibited hypoxia-induced MCF-7 cell migration, suggesting a major role for autocrine EpoR cell signaling. MCF-7 cell migration under hypoxic conditions was also inhibited by PD098059. These experiments identify a novel pathway by which exogenously administered Epo, and Epo that is produced locally by cancer cells under hypoxic conditions, may stimulate cancer cell migration.	Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Anesthesiol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Gonias, SL (corresponding author), Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA.	sgonias@ucsd.edu			NCI NIH HHS [R01 CA-94900] Funding Source: Medline; NINDS NIH HHS [R01 NS-41983] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094900] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041983] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Acs G, 2002, CANCER-AM CANCER SOC, V95, P969, DOI 10.1002/cncr.10787; Acs G, 2004, CANCER LETT, V214, P243, DOI 10.1016/j.canlet.2004.04.027; Acs G, 2004, CANCER-AM CANCER SOC, V100, P2376, DOI 10.1002/cncr.20244; Acs G, 2001, CANCER RES, V61, P3561; ANAGNOSTOU A, 1990, P NATL ACAD SCI USA, V87, P5978, DOI 10.1073/pnas.87.15.5978; Arcasoy MO, 2002, LAB INVEST, V82, P911, DOI 10.1097/01.LAB.0000020415.72863.40; Bando H, 2003, BIOMED PHARMACOTHER, V57, P333, DOI 10.1016/S0753-3322(03)00098-2; Blackwell K, 2004, ONCOLOGIST, V9, P41, DOI 10.1634/theoncologist.9-90005-41; Brizel DM, 1996, CANCER RES, V56, P941; Campana WM, 2003, EUR J NEUROSCI, V18, P1497, DOI 10.1046/j.1460-9568.2003.02875.x; Carvalho G, 2005, ONCOGENE, V24, P737, DOI 10.1038/sj.onc.1208205; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; Chen CM, 2001, J BIOL CHEM, V276, P38518, DOI 10.1074/jbc.M105702200; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; Hockel M, 1996, CANCER RES, V56, P4509; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Jo M, 2002, J BIOL CHEM, V277, P12479, DOI 10.1074/jbc.M111147200; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Keshamouni VG, 2002, J BIOL CHEM, V277, P22558, DOI 10.1074/jbc.M202351200; KRANTZ SB, 1991, BLOOD, V77, P419; LAI SY, 2005, ONCOGENE; Lee KH, 2004, EXP MOL MED, V36, P57, DOI 10.1038/emm.2004.8; Leyland-Jones B, 2003, LANCET ONCOL, V4, P459, DOI 10.1016/S1470-2045(03)01163-X; Li XQ, 2005, GLIA, V51, P254, DOI 10.1002/glia.20202; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; MASUDA S, 1994, J BIOL CHEM, V269, P19488; MASUDA S, 1993, J BIOL CHEM, V268, P11208; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; Nguyen DHD, 2000, J BIOL CHEM, V275, P19382, DOI 10.1074/jbc.M909575199; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Ribatti D, 1999, BLOOD, V93, P2627, DOI 10.1182/blood.V93.8.2627.408k21_2627_2636; Ribatti D, 2003, HISTOPATHOLOGY, V42, P246, DOI 10.1046/j.1365-2559.2003.01581.x; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Schmidt EK, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-7; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; TAN CC, 1991, KIDNEY INT, V40, P69, DOI 10.1038/ki.1991.181; Vleugel MM, 2005, J CLIN PATHOL, V58, P172, DOI 10.1136/jcp.2004.019885; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Yasuda Y, 2003, CARCINOGENESIS, V24, P1021, DOI 10.1093/carcin/bgg060	44	109	115	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39273	39277		10.1074/jbc.M509446200	http://dx.doi.org/10.1074/jbc.M509446200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16207704	hybrid			2022-12-25	WOS:000233362200045
J	Tsutsumi, S; Namba, T; Tanaka, KI; Arai, Y; Ishihara, T; Aburaya, M; Mima, S; Hoshino, T; Mizushima, T				Tsutsumi, S; Namba, T; Tanaka, KI; Arai, Y; Ishihara, T; Aburaya, M; Mima, S; Hoshino, T; Mizushima, T			Celecoxib upregulates endoplasmic reticulum chaperones that inhibit celecoxib-induced apoptosis in human gastric cells	ONCOGENE			English	Article						celecoxib; endoplasmic reticulum chaperones; apoptosis; calcium	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; UNFOLDED-PROTEIN RESPONSE; STRESS-RESPONSE; CANCER CELLS; ER STRESS; MUCOSAL CELLS; CYCLOOXYGENASE-2 INHIBITOR; INTRACELLULAR CALCIUM; PROSTAGLANDIN E-2; GENE-EXPRESSION	Nonsteroidal anti-inflammatory drugs (NSAIDs) induce apoptosis in cancer cells and this effect is involved in their antitumor activity. We recently demonstrated that NSAIDs upregulate GRP78, an endoplasmic reticulum ( ER) chaperone, in gastric mucosal cells in primary culture. In the present study, induction of ER chaperones by NSAIDs and the effect of those chaperones on NSAID-induced apoptosis were examined in human gastric carcinoma cells. Celecoxib, an NSAID, upregulated ER chaperones ( GRP78 and its cochaperones ERdj3 and ERdj4) but also C/EBP homologous transcription factor ( CHOP), a transcription factor involved in apoptosis. Celecoxib also upregulated GRP78 in xenograft tumors, accompanying with the suppression of tumor growth in nude mice. Celecoxib caused phosphorylation of eukaryotic translation initiation factor 2 kinase ( PERK) and eukaryotic initiation factor-2 alpha (eIF2a) and production of activating transcription factor (ATF)4 mRNA. Suppression of ATF4 expression by small interfering RNA ( siRNA) partially inhibited the celecoxib-dependent upregulation of GRP78. Celecoxib increased the intracellular Ca2+ concentration, while 1,2-bis(2-aminophenoxy) ethane-N,N,N'N'-tetraacetic acid, an intracellular Ca2+ chelator, inhibited the upregulation of GRP78 and ATF4. These results suggest that the Ca2+- dependent activation of the PERK-eIF2 alpha-ATF4 pathway is involved in the upregulation of ER chaperones by celecoxib. Overexpression of GRP78 partially suppressed the apoptosis and induction of CHOP in the presence of celecoxib and this suppression was stimulated by coexpression of either ERdj3 or ERdj4. On the other hand, suppression of GRP78 expression by siRNA drastically stimulated cellular apoptosis and production of CHOP in the presence of celecoxib. These results show that upregulation of ER chaperones by celecoxib protects cancer cells from celecoxib-induced apoptosis, thus may decrease the potential antitumor activity of celecoxib.	Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, Kumamoto 8620973, Japan	Kumamoto University	Mizushima, T (corresponding author), Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, 5-1,Oehonmachi, Kumamoto 8620973, Japan.	mizu@gpo.kumamoto-u.ac.jp	Tanaka, Ken-ichiro/J-8557-2013					Ben-Chetrit E, 2005, RHEUMATOL INT, V25, P332, DOI 10.1007/s00296-004-0442-4; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Bush KT, 1997, J BIOL CHEM, V272, P9086; da Costa CA, 2002, P NATL ACAD SCI USA, V99, P4043, DOI 10.1073/pnas.062059899; Dong DZ, 2005, CANCER RES, V65, P5785, DOI 10.1158/0008-5472.CAN-05-0754; DRUMMOND IAS, 1987, J BIOL CHEM, V262, P12801; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Elder DJE, 1997, CLIN CANCER RES, V3, P1679; Fan XM, 2001, J GASTROEN HEPATOL, V16, P1098, DOI 10.1046/j.1440-1746.2001.02593.x; Farrow DC, 1998, CANCER EPIDEM BIOMAR, V7, P97; Fernandez PM, 2000, BREAST CANCER RES TR, V59, P15, DOI 10.1023/A:1006332011207; Gotoh T, 2001, CELL DEATH DIFFER, V8, P357, DOI 10.1038/sj.cdd.4400829; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hong M, 2004, J CELL BIOCHEM, V92, P723, DOI 10.1002/jcb.20118; Hoshino T, 2003, J BIOL CHEM, V278, P12752, DOI 10.1074/jbc.M212097200; Hu PJ, 2004, GUT, V53, P195, DOI 10.1136/gut.2003.021477; Huang YC, 2002, MOL PHARMACOL, V62, P1515, DOI 10.1124/mol.62.6.1515; Huo R, 2004, CELL TISSUE RES, V316, P359, DOI 10.1007/s00441-004-0885-7; Husain SS, 2002, AM J GASTROENTEROL, V97, P542; Jamora C, 1996, P NATL ACAD SCI USA, V93, P7690, DOI 10.1073/pnas.93.15.7690; Jiang HY, 2004, MOL CELL BIOL, V24, P1365, DOI 10.1128/MCB.24.3.1365-1377.2004; Johnson AJ, 2002, BIOCHEM J, V366, P831, DOI 10.1042/BJ20020279; KAO JPY, 1989, J BIOL CHEM, V264, P8179; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Kawai S, 1998, EUR J PHARMACOL, V347, P87, DOI 10.1016/S0014-2999(98)00078-8; Kismet K, 2004, CANCER DETECT PREV, V28, P127, DOI 10.1016/j.cdp.2003.12.005; Koki Alane T, 2002, Cancer Control, V9, P28; Koomagi R, 1999, ANTICANCER RES, V19, P4333; Kulp SK, 2004, CANCER RES, V64, P1444, DOI 10.1158/0008-5472.CAN-03-2396; Kurisu J, 2003, GENES CELLS, V8, P189, DOI 10.1046/j.1365-2443.2003.00625.x; Landry SJ, 2003, BIOCHEMISTRY-US, V42, P4926, DOI 10.1021/bi027070y; Leahy KM, 2002, CANCER RES, V62, P625; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Lim JW, 2001, LAB INVEST, V81, P349, DOI 10.1038/labinvest.3780243; Lopez-Parra M, 2005, J HEPATOL, V42, P75, DOI 10.1016/j.jhep.2004.09.011; Luo SZ, 2003, J BIOL CHEM, V278, P37375, DOI 10.1074/jbc.M303619200; Mima S, 2005, CANCER RES, V65, P1868, DOI 10.1158/0008-5472.CAN-04-2770; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; Okada K, 2000, CANCER GENET CYTOGEN, V118, P99, DOI 10.1016/S0165-4608(99)00182-X; Patel MI, 2005, CLIN CANCER RES, V11, P1999, DOI 10.1158/1078-0432.CCR-04-1877; PIAZZA GA, 1995, CANCER RES, V55, P3110; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Riendeau D, 1997, CAN J PHYSIOL PHARM, V75, P1088, DOI 10.1139/cjpp-75-9-1088; Ristimaki A, 1997, CANCER RES, V57, P1276; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Roybal CN, 2004, J BIOL CHEM, V279, P14844, DOI 10.1074/jbc.M312948200; Schroeder CR, 2004, CANCER BIOL THER, V3, P847, DOI 10.4161/cbt.3.9.1037; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Shen Y, 2002, J BIOL CHEM, V277, P15947, DOI 10.1074/jbc.M112214200; SMALLEY WE, 1995, AM J EPIDEMIOL, V141, P539, DOI 10.1093/oxfordjournals.aje.a117469; Song MS, 2001, CANCER RES, V61, P8322; Sorensen HT, 2003, BRIT J CANCER, V88, P1687, DOI 10.1038/sj.bjc.6600945; Tanaka K, 2005, J BIOL CHEM, V280, P31059, DOI 10.1074/jbc.M502956200; Tomisato W, 2004, BIOCHEM BIOPH RES CO, V323, P1032, DOI 10.1016/j.bbrc.2004.08.205; Tomisato W, 2004, BIOCHEM PHARMACOL, V67, P575, DOI 10.1016/j.bcp.2003.09.020; Tomisato W, 2001, AM J PHYSIOL-GASTR L, V281, pG1092, DOI 10.1152/ajpgi.2001.281.4.G1092; Tsutsumi S, 2004, CELL DEATH DIFFER, V11, P1009, DOI 10.1038/sj.cdd.4401436; Tsutsumi S, 2002, BBA-MOL CELL RES, V1589, P168, DOI 10.1016/S0167-4889(02)00171-4; Wang JL, 2004, BIOCHEM PHARMACOL, V67, P1123, DOI 10.1016/j.bcp.2003.11.004; Williams CS, 2000, CANCER RES, V60, P6045; WOODEN SK, 1991, MOL CELL BIOL, V11, P5612, DOI 10.1128/MCB.11.11.5612; Xu WM, 2004, NAT CELL BIOL, V6, P1129, DOI 10.1038/ncb1188; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yu M, 2000, J BIOL CHEM, V275, P24984, DOI 10.1074/jbc.M000739200; Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451; Zweifel BS, 2002, CANCER RES, V62, P6706	68	109	117	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					1018	1029		10.1038/sj.onc.1209139	http://dx.doi.org/10.1038/sj.onc.1209139			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16205636				2022-12-25	WOS:000235361000007
J	Chen, N; Szentirmay, MN; Pawar, SA; Sirito, M; Wang, J; Wang, Z; Zhai, Q; Yang, HX; Peehl, DM; Ware, JL; Sawadogo, M				Chen, N; Szentirmay, MN; Pawar, SA; Sirito, M; Wang, J; Wang, Z; Zhai, Q; Yang, HX; Peehl, DM; Ware, JL; Sawadogo, M			Tumor-suppression function of transcription factor USF2 in prostate carcinogenesis	ONCOGENE			English	Article						USF; transcription factor; tumor-suppressor gene; prostate cancer	HELIX-LOOP-HELIX; EPITHELIAL-CELLS; CANCER CELLS; DNA-BINDING; RECEPTOR; PROMOTER; TUMORIGENICITY; PROLIFERATION; EXPRESSION; NKX3.1	Although the transcription factor USF2 has been implicated in the regulation of cellular growth and proliferation, it is unknown whether alterations in USF2 contribute to tumorigenesis and tumor development. We examined the role of USF2 in prostate tumorigenesis. Western blot analysis revealed markedly decreased USF2 levels in three androgen-independent prostate cancer cell lines, PC-3, DU145, and M12, as compared to nontumorigenic prostate epithelial cells or the androgen-dependent cell line, LNCaP. Ectopic expression of USF2 in PC-3 cells did not affect the cell proliferation rate of PC-3 cells on plastic surfaces. However, it dramatically decreased anchorage-independent growth of PC-3 cells in soft agar (90-98% inhibition) and the invasion capability (80% inhibition) of PC-3 cells in matrix gel assay. Importantly, expression of USF2 in PC-3 cells inhibited the tumorigenicity of PC-3 cells in an in vivo nude mice xenograft model (80-90% inhibition). These results suggest that USF2 has tumor-suppression function. Consistent with its function in tumor suppression, we found that the USF2 protein is present in normal prostate epithelial cells but absent in 18 of 42 (43%) human prostate cancer tissues (P = 0.015). To further examine the functional role of USF2 in vivo, we generated mice with genetic deletion of USF2 gene. We found that USF2-null mice displayed marked prostate hyperplasia at a young age, suggesting that USF2 is involved in the normal growth and differentiation of prostate. Together, these studies demonstrate that USF2 has tumor-suppressor function and plays a role in prostate carcinogenesis.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Methodist Hosp, Dept Pathol, Houston, TX 77030 USA; Stanford Univ, Dept Urol, Stanford, CA 94305 USA; Virginia Commonwealth Univ, Sch Med, Dept Pathol, Richmond, VA USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; The Methodist Hospital System; The Methodist Hospital - Houston; Stanford University; Virginia Commonwealth University	Chen, N (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.	nanchen@mdanderson.org	Pawar, Snehalata/ABD-4557-2020	Pawar, Snehalata/0000-0003-3992-2494	NCI NIH HHS [CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aperlo C, 1996, EUR J BIOCHEM, V241, P249, DOI 10.1111/j.1432-1033.1996.0249t.x; Astbury C, 2001, GENE CHROMOSOME CANC, V31, P143, DOI 10.1002/gcc.1128; BAE VL, 1994, INT J CANCER, V58, P721, DOI 10.1002/ijc.2910580517; Bello D, 1997, CARCINOGENESIS, V18, P1215, DOI 10.1093/carcin/18.6.1215; BENDALL AJ, 1994, NUCLEIC ACIDS RES, V22, P2801, DOI 10.1093/nar/22.14.2801; Bhatia-Gaur R, 1999, GENE DEV, V13, P966, DOI 10.1101/gad.13.8.966; Blain SW, 2003, CANCER CELL, V3, P111, DOI 10.1016/S1535-6108(03)00026-6; Bookstein R, 2001, CONT CANC RES, P61; Bowen C, 2000, CANCER RES, V60, P6111; Choe C, 2005, EXP CELL RES, V302, P1, DOI 10.1016/j.yexcr.2004.08.013; Colella R, 2004, BIOTECH HISTOCHEM, V79, P121, DOI 10.1080/10520290400010572; Davis PL, 1999, ONCOGENE, V18, P6000, DOI 10.1038/sj.onc.1202990; Dehm SM, 2005, EXPERT REV ANTICANC, V5, P63, DOI 10.1586/14737140.5.1.63; GAO X, 1999, ADV ONCOBIOL, V3, P85; Gonzalgo ML, 2003, J UROLOGY, V170, P2444, DOI 10.1097/01.ju.0000085381.20139.b6; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; Isaacs W, 2001, EPIDEMIOL REV, V23, P36, DOI 10.1093/oxfordjournals.epirev.a000794; Ismail PM, 1999, ONCOGENE, V18, P5582, DOI 10.1038/sj.onc.1202932; Jaiswal AS, 2001, J CELL BIOCHEM, V81, P262, DOI 10.1002/1097-4644(20010501)81:2<262::AID-JCB1041>3.0.CO;2-R; Karayi MK, 2004, PROSTATE CANCER P D, V7, P6, DOI 10.1038/sj.pcan.4500697; Kivinen A, 2004, PROSTATE, V59, P190, DOI 10.1002/pros.20015; KOZLOWSKI JM, 1999, HUMAN CELL CULTURE, V2, P305; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; Luo X, 1996, MOL CELL BIOL, V16, P1367; Macleod K, 2000, CURR OPIN GENET DEV, V10, P81, DOI 10.1016/S0959-437X(99)00041-6; Maddison LA, 2004, CANCER RES, V64, P6018, DOI 10.1158/0008-5472.CAN-03-2509; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nupponen NN, 1998, AM J PATHOL, V153, P141, DOI 10.1016/S0002-9440(10)65554-X; Pawar SA, 2004, ONCOGENE, V23, P6125, DOI 10.1038/sj.onc.1207806; Peehl DM, 2002, CULTURE EPITHELIAL C, P171; Plymate SR, 2004, PROSTATE, V61, P276, DOI 10.1002/pros.20099; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; RUDDON RW, 1995, CANC BIOL, P96; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHMID HP, 1992, AM J SURG PATHOL, V16, P184, DOI 10.1097/00000478-199202000-00012; Shappell SB, 2004, CANCER RES, V64, P2270, DOI 10.1158/0008-5472.CAN-03-0946; Sirito M, 1998, P NATL ACAD SCI USA, V95, P3758, DOI 10.1073/pnas.95.7.3758; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; STEINGRIMSSON E, 1995, GENOMICS, V28, P179, DOI 10.1006/geno.1995.1129; Szentirmay MN, 2003, J BIOL CHEM, V278, P37231, DOI 10.1074/jbc.M305791200; Vakar-Lopez F, 2004, J PATHOL, V203, P688, DOI 10.1002/path.1568; Voeller HJ, 1997, CANCER RES, V57, P4455	44	23	23	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					579	587		10.1038/sj.onc.1209079	http://dx.doi.org/10.1038/sj.onc.1209079			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16186802				2022-12-25	WOS:000234897400009
J	de Oca, ROM; Lee, KK; Wilson, KL				de Oca, ROM; Lee, KK; Wilson, KL			Binding of barrier to autointegration factor (BAF) to histone H3 and selected linker histones including H1.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; GLOBULAR DOMAIN; NUCLEAR-ENVELOPE; RETROVIRAL DNA; CHROMATIN STRUCTURES; CRYSTAL-STRUCTURE; LEM-DOMAIN; PROTEIN; EMERIN; NUCLEOSOME	Barrier to autointegration factor (BAF) is an essential conserved double-stranded DNA-binding protein in metazoans. BAF binds directly to LEM domain nuclear proteins ( e. g. LAP2, Emerin, and MAN1), lamin A, homeodomain transcription factors, and human immunodeficiency virus type 1-encoded proteins. BAF influences higher order chromatin structure and is required to assemble nuclei. BAF also facilitates retroviral preintegration complex insertion into target DNA in vitro, through unknown mechanisms. We report that BAF binds directly and selectively to linker histone H1.1 (among three subtypes tested) and core histone H3 with affinities of similar to 700 nM and similar to 100-200 nM, respectively, in vitro and in vivo. Mutations at the bottom and top surfaces of the BAF dimer disrupted or enhanced, respectively, this binding and affected H1 and H3 similarly. Biochemical studies showed that C-terminal residues 108-215 of histone H1.1 and the N-terminal tail plus helix alpha N in the core of histone H3.1 were each necessary and sufficient to bind BAF. Based on its interactions with histones and DNA, we propose BAF might bind nucleosomes in vivo.	Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA	Johns Hopkins University	Wilson, KL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Cell Biol, 725 N Wolfe St, Baltimore, MD 21205 USA.	klwilson@jhmi.edu			NIGMS NIH HHS [R01 GM48646] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048646] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alami R, 2003, P NATL ACAD SCI USA, V100, P5920, DOI 10.1073/pnas.0736105100; ALBIG W, 1993, GENOMICS, V16, P649, DOI 10.1006/geno.1993.1243; Albig W, 1997, GENOMICS, V40, P314, DOI 10.1006/geno.1996.4592; ALLAN J, 1986, J MOL BIOL, V187, P591, DOI 10.1016/0022-2836(86)90337-2; Belikov S, 1998, J BIOMOL STRUCT DYN, V16, P35, DOI 10.1080/07391102.1998.10508224; Bengtsson L, 2004, CURR OPIN CELL BIOL, V16, P73, DOI 10.1016/j.ceb.2003.11.012; Bharath MMS, 2002, BIOCHEMISTRY-US, V41, P7617, DOI 10.1021/bi025773+; Bharath MMS, 2002, PROTEINS, V49, P71, DOI 10.1002/prot.10204; Black BE, 1999, MOL CELL BIOL, V19, P8616; BRADBURY EM, 1975, EUR J BIOCHEM, V52, P605, DOI 10.1111/j.1432-1033.1975.tb04032.x; Burke B, 2002, NAT REV MOL CELL BIO, V3, P575, DOI 10.1038/nrm879; Cai M, 1998, NAT STRUCT BIOL, V5, P903, DOI 10.1038/2345; Cai ML, 2001, EMBO J, V20, P4399, DOI 10.1093/emboj/20.16.4399; Catez F, 2004, MOL CELL BIOL, V24, P4321, DOI 10.1128/MCB.24.10.4321-4328.2004; Chen HM, 1998, P NATL ACAD SCI USA, V95, P15270, DOI 10.1073/pnas.95.26.15270; CLARK DJ, 1988, EUR J BIOCHEM, V178, P225, DOI 10.1111/j.1432-1033.1988.tb14447.x; De S, 2002, GENE, V292, P173, DOI 10.1016/S0378-1119(02)00675-3; Dechat T, 2004, J CELL SCI, V117, P6117, DOI 10.1242/jcs.01529; Forne I, 2003, J BIOL CHEM, V278, P50641, DOI 10.1074/jbc.M308531200; Franke K, 1998, BBA-GENE STRUCT EXPR, V1398, P232, DOI 10.1016/S0167-4781(98)00062-1; Furukawa K, 2003, J CELL SCI, V116, P3811, DOI 10.1242/jcs.00682; Garcia BA, 2004, J PROTEOME RES, V3, P1219, DOI 10.1021/pr0498887; Gelbart ME, 2001, MOL CELL BIOL, V21, P2098, DOI 10.1128/MCB.21.6.2098-2106.2001; Georgel PT, 2003, J BIOL CHEM, V278, P32181, DOI 10.1074/jbc.M305308200; Georgel PT, 2001, P NATL ACAD SCI USA, V98, P8584, DOI 10.1073/pnas.151258798; Goytisolo FA, 1996, EMBO J, V15, P3421, DOI 10.1002/j.1460-2075.1996.tb00708.x; Haraguchi T, 2001, J CELL SCI, V114, P4575; Harris D, 2000, J BIOL CHEM, V275, P39671, DOI 10.1074/jbc.M002626200; Holaska JM, 2003, J BIOL CHEM, V278, P6969, DOI 10.1074/jbc.M208811200; KINKADE JM, 1966, J BIOL CHEM, V241, P5798; Kuzmichev A, 2004, MOL CELL, V14, P183, DOI 10.1016/S1097-2765(04)00185-6; Laguri C, 2001, STRUCTURE, V9, P503, DOI 10.1016/S0969-2126(01)00611-6; Lee KK, 2001, J CELL SCI, V114, P4567; LEE MS, 1994, P NATL ACAD SCI USA, V91, P9823, DOI 10.1073/pnas.91.21.9823; Lee MS, 1998, P NATL ACAD SCI USA, V95, P1528, DOI 10.1073/pnas.95.4.1528; LENNOX RW, 1984, DEV BIOL, V103, P80, DOI 10.1016/0012-1606(84)90009-5; Liu J, 2003, P NATL ACAD SCI USA, V100, P4598, DOI 10.1073/pnas.0730821100; LOSA R, 1984, J MOL BIOL, V175, P529, DOI 10.1016/0022-2836(84)90183-9; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luger K, 1999, METH MOL B, V119, P1; Malik HS, 2003, NAT STRUCT BIOL, V10, P882, DOI 10.1038/nsb996; Mansharamani M, 2005, J BIOL CHEM, V280, P13863, DOI 10.1074/jbc.M413020200; Mansharamani M, 2003, J VIROL, V77, P13084, DOI 10.1128/JVI.77.24.13084-13092.2003; Margalit A, 2005, P NATL ACAD SCI USA, V102, P3290, DOI 10.1073/pnas.0408364102; MORAN F, 1989, BIOPHYS CHEM, V33, P133, DOI 10.1016/0301-4622(89)80016-X; Mounkes LC, 2004, CURR OPIN CELL BIOL, V16, P322, DOI 10.1016/j.ceb.2004.03.009; Ng HH, 2002, GENE DEV, V16, P1518, DOI 10.1101/gad.1001502; Parseghian MH, 2001, J CELL BIOCHEM, V83, P643, DOI 10.1002/jcb.1224; Parseghian MH, 2001, BIOCHEM CELL BIOL, V79, P289; Parseghian MH, 1993, CHROMOSOME RES, V1, P127, DOI 10.1007/BF00710036; Ramakrishnan V, 1997, CRIT REV EUKAR GENE, V7, P215, DOI 10.1615/CritRevEukarGeneExpr.v7.i3.20; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; RASHEED BKA, 1989, J CELL SCI, V94, P61; Reeves R, 2001, GENE, V277, P63, DOI 10.1016/S0378-1119(01)00689-8; Richmond TJ, 2003, NATURE, V423, P145, DOI 10.1038/nature01595; RODRIGUEZ AT, 1991, BIOPHYS CHEM, V39, P145, DOI 10.1016/0301-4622(91)85016-J; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; Segura-Totten M, 2002, J CELL BIOL, V158, P475, DOI 10.1083/jcb.200202019; Segura-Totten M, 2004, TRENDS CELL BIOL, V14, P261, DOI 10.1016/j.tcb.2004.03.004; Shimi T, 2004, J STRUCT BIOL, V147, P31, DOI 10.1016/j.jsb.2003.11.013; Shumaker DK, 2001, EMBO J, V20, P1754, DOI 10.1093/emboj/20.7.1754; Suzuki Y, 2004, EMBO J, V23, P4670, DOI 10.1038/sj.emboj.7600452; Suzuki Y, 2002, J VIROL, V76, P12376, DOI 10.1128/JVI.76.23.12376-12380.2002; Swank RA, 1997, BIOCHEMISTRY-US, V36, P13761, DOI 10.1021/bi9714363; Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092-8674(03)01064-X; Th'ng JPH, 2005, J BIOL CHEM, V280, P27809, DOI 10.1074/jbc.M501627200; THOMA F, 1983, J MOL BIOL, V167, P619, DOI 10.1016/S0022-2836(83)80102-8; Umland TC, 2000, BIOCHEMISTRY-US, V39, P9130, DOI 10.1021/bi000572w; Vermaak D, 2003, CURR OPIN CELL BIOL, V15, P266, DOI 10.1016/S0955-0674(03)00043-7; Vignali M, 1998, NAT STRUCT BIOL, V5, P1025, DOI 10.1038/4133; Vlcek S, 1999, EMBO J, V18, P6370, DOI 10.1093/emboj/18.22.6370; Wang XJ, 2002, J BIOL CHEM, V277, P43288, DOI 10.1074/jbc.M207952200; Wang Yanming, 2004, Novartis Found Symp, V259, P3; Wolff N, 2001, FEBS LETT, V501, P171, DOI 10.1016/S0014-5793(01)02649-7; Wolffe AP, 1997, INT J BIOCHEM CELL B, V29, P1463, DOI 10.1016/S1357-2725(97)00026-5; Zhang LW, 2003, CHROMOSOMA, V112, P77, DOI 10.1007/s00412-003-0244-6; Zheng RL, 2000, P NATL ACAD SCI USA, V97, P8997, DOI 10.1073/pnas.150240197	78	78	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42252	42262		10.1074/jbc.M509917200	http://dx.doi.org/10.1074/jbc.M509917200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16203725	hybrid			2022-12-25	WOS:000233992700054
J	Murthy, S; Tong, H; Hohl, RJ				Murthy, S; Tong, H; Hohl, RJ			Regulation of fatty acid synthesis by farnesyl pyrophosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR LXR; LIVER-X-RECEPTORS; ELEMENT-BINDING PROTEIN-1; GENE-EXPRESSION; SYNTHASE GENE; GERANYLGERANYL PYROPHOSPHATE; TRIACYLGLYCEROL TRANSPORT; RESPONSE PATHWAY; CULTURED-CELLS; CACO-2 CELLS	Fatty acid biosynthesis is transcriptionally regulated by liver X receptor (LXR) and its gene target, sterol regulatory element binding protein-1c (SREBP-1c). LXR activation is induced by oxysterol end products of the mevalonate pathway and is inhibited by the upstream non-sterol isoprenoid, geranylgeranyl pyrophosphate (GGPP). Whether isoprenoids play a role in regulating the transcription of genes involved in fatty acid biosynthesis is unknown. In CaCo-2 colon epithelial cells, depletion of mevalonate and its derivatives, including oxysterol ligandsfor LXR, increased fatty acid synthesis. Addition of mevalonate or its isoprenoid derivative, farnesyl pyrophosphate (FPP), prevented this increase. The effects of FPP were likely due to itself or its degradation products, because none of its downstream derivatives, GGPP, ubiquinone, or cholesterol, were effective. Moreover, the effects of FPP could not be accounted for by protein prenylation, because inhibition of farnesylation did not alter fatty acid synthesis in mevalonate-depleted cells incubated with the isoprenoid. Neither was fatty acid synthesis in these cells altered by inhibition of beta-oxidation. Mevalonate depletion increased fatty acid synthase (FAS) mRNA by transcriptional mechanisms, without increasing gene expression of other enzymes involved in fatty acid biosynthesis or of SREBP-1c. The abundance of mature SREBP- 2 but not SREBP- 1 was increased following mevalonate depletion. FPP prevented the increase in FAS mRNA in mevalonate-depleted cells without altering SREBP- 2 activation. Thus, FPP regulates fatty acid synthesis by a mechanism that is likely independent of the SREBP pathway.	Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Carver Coll Med, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Murthy, S (corresponding author), Univ Iowa, Dept Internal Med, 5219 MERF,375 Newton Rd, Iowa City, IA 52242 USA.	murthys@mail.medicine.uiowa.edu						Adjei AA, 2000, CANCER RES, V60, P1871; ANTONSON P, 1995, BIOCHEM BIOPH RES CO, V215, P106, DOI 10.1006/bbrc.1995.2439; BECK LA, 1990, J CELL BIOL, V110, P1489, DOI 10.1083/jcb.110.5.1489; Brendel C, 2002, MOL ENDOCRINOL, V16, P2065, DOI 10.1210/me.2001-0194; Chen JC, 2004, EXP CELL RES, V301, P305, DOI 10.1016/j.yexcr.2004.05.039; Coleman ML, 2004, NAT REV MOL CELL BIO, V5, P355, DOI 10.1038/nrm1365; DeBose-Boyd RA, 2001, P NATL ACAD SCI USA, V98, P1477, DOI 10.1073/pnas.98.4.1477; Djouadi F, 2003, MOL GENET METAB, V78, P112, DOI 10.1016/S1096-7192(03)00017-9; Field FJ, 2002, BIOCHEM J, V368, P855, DOI 10.1042/BJ20020731; Field FJ, 2001, J BIOL CHEM, V276, P17576, DOI 10.1074/jbc.M010917200; Forman BM, 1997, P NATL ACAD SCI USA, V94, P10588, DOI 10.1073/pnas.94.20.10588; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; Fujioka T, 1997, EUR J PHARMACOL, V328, P235, DOI 10.1016/S0014-2999(97)83050-6; Gan XD, 2001, J BIOL CHEM, V276, P48702, DOI 10.1074/jbc.M109402200; HILLGARTNER F, 1995, PHYSIOL REV, V75, P47, DOI 10.1152/physrev.1995.75.1.47; Hiyoshi H, 2003, J LIPID RES, V44, P128, DOI 10.1194/jlr.M200316-JLR200; Holstein SA, 2002, BIOCHEMISTRY-US, V41, P13698, DOI 10.1021/bi026251x; Hornby JM, 2003, ANTIMICROB AGENTS CH, V47, P2366, DOI 10.1128/AAC.47.7.2366-2369.2003; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; Hu X, 2003, MOL ENDOCRINOL, V17, P1019, DOI 10.1210/me.2002-0399; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Kim MK, 2004, J ORG CHEM, V69, P8186, DOI 10.1021/jo049101w; Kleinbaum DG, 1978, APPL REGRESSION ANAL; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Lu TT, 2001, J BIOL CHEM, V276, P37735, DOI 10.1074/jbc.R100035200; Matsumoto M, 2004, J IMMUNOL, V172, P7377, DOI 10.4049/jimmunol.172.12.7377; Matsusue K, 2004, MOL ENDOCRINOL, V18, P2751, DOI 10.1210/me.2004-0213; Maurer-Stroh S, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-212; Murthy S, 1996, AM J PHYSIOL-GASTR L, V270, pG94, DOI 10.1152/ajpgi.1996.270.1.G94; MURTHY S, 1990, BIOCHIM BIOPHYS ACTA, V1045, P147, DOI 10.1016/0005-2760(90)90144-M; Ownby SE, 2002, LIPIDS, V37, P185, DOI 10.1007/s11745-002-0879-1; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; Repa JJ, 2000, ANNU REV CELL DEV BI, V16, P459, DOI 10.1146/annurev.cellbio.16.1.459; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Roglans N, 2002, LIPIDS, V37, P445, DOI 10.1007/s11745-002-0916-0; Rufo C, 1999, BIOCHEM BIOPH RES CO, V261, P400, DOI 10.1006/bbrc.1999.1034; Rufo C, 2001, J BIOL CHEM, V276, P21969, DOI 10.1074/jbc.M100461200; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sebti SM, 2003, NAT REV CANCER, V3, P945, DOI 10.1038/nrc1234; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Sul HS, 1998, ANNU REV NUTR, V18, P331, DOI 10.1146/annurev.nutr.18.1.331; Takahashi N, 2002, FEBS LETT, V514, P315, DOI 10.1016/S0014-5793(02)02390-6; Tong HX, 2005, ANAL BIOCHEM, V336, P51, DOI 10.1016/j.ab.2004.09.024; Vaidya S, 1998, ARCH BIOCHEM BIOPHYS, V355, P84, DOI 10.1006/abbi.1998.0704; Watanabe M, 2004, J CLIN INVEST, V113, P1408, DOI 10.1172/JCI200421025; WEIS BC, 1994, J BIOL CHEM, V269, P26443; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033	52	31	32	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					41793	41804		10.1074/jbc.M504101200	http://dx.doi.org/10.1074/jbc.M504101200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16221687	hybrid			2022-12-25	WOS:000233992700004
J	Nakahara, M; Furuya, N; Takagaki, K; Sugaya, T; Hirota, K; Fukamizu, A; Kanda, T; Fujii, H; Sato, R				Nakahara, M; Furuya, N; Takagaki, K; Sugaya, T; Hirota, K; Fukamizu, A; Kanda, T; Fujii, H; Sato, R			Ileal bile acid-binding protein, functionally associated with the farnesoid X receptor or the ileal bile acid transporter, regulates bile acid activity in the small intestine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTORS; NEGATIVE FEEDBACK-REGULATION; LOW-DENSITY-LIPOPROTEIN; GENE-EXPRESSION; NUCLEAR RECEPTOR; ELEMENT; IDENTIFICATION; LOCALIZATION; INVOLVEMENT; CASCADE	Bile acids secreted in the small intestine are reabsorbed in the ileum where they activate the nuclear farnesoid X receptor (FXR), which in turn stimulates expression of the ileal bile acid-binding protein (I-BABP). We first hypothesized that I-BABP may negatively regulate the FXR activity by competing for the ligands, bile acids. Reporter assays using stable HEK293 cell lines expressing I-BABP revealed that I-BABP enhances rather than attenuates FXR activity. In these cells I-BABP localizes predominantly in the cytosol and partially in the nucleus, a distribution that does not shift in response to FXR expression. In vitro binding assays reveal that recombinant I-BABP is able to bind S-35-labeled FXR and that chenodeoxycholic acid (CDCA) stimulates this interaction modestly. When FLAG-tagged FXR was expressed in stable cells, the (FXRI)-I-.-BABP complex in the nuclear extracts was more efficiently immunoprecipitable with anti-FLAG antibodies in the presence of CDCA. These results indicate that I-BABP stimulates FXR activity through a mutual interaction augmented by bile acids. When stable cells were transfected with an expression plasmid of the ileal bile acid transporter (IBAT) essential for the reabsorption of conjugated bile acids, the C-14-labeled conjugated bile acid, glycocholic acid, was more efficiently imported via IBAT in the presence than absence of I-BABP, whereas no change was observed in C-14-labeled CDCA uptake, which is independent of IBAT. Immunofluorescent staining analysis revealed that these two proteins co-localize in the vicinity of the plasma membrane in stable cells. Taken together, the current data provide the first evidence that I-BABP is functionally associated with FXR and IBAT in the nucleus and on the membrane, respectively, stimulating FXR transcriptional activity and the conjugated bile acid uptake mediated by IBAT in the ileum.	Univ Tokyo, Dept Appl Biol Chem, Grad Sch Agr & Life Sci, Tokyo 1138657, Japan; BRAIN, Tokyo 1050001, Japan; Univ Tsukuba, Inst Appl Biochem, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Niigata Univ, Dept Signal Transduct Res, Grad Sch Med & Dent, Niigata 9518510, Japan	University of Tokyo; University of Tsukuba; Niigata University	Sato, R (corresponding author), Univ Tokyo, Dept Appl Biol Chem, Grad Sch Agr & Life Sci, Tokyo 1138657, Japan.	aroysato@mail.ecc.u-tokyo.ac.jp	Furuya, Norihiko/K-7299-2015; fukamizu, akiyoshi/J-5350-2012; Takagaki, Kentaroh/A-9829-2009	Furuya, Norihiko/0000-0001-7695-4271; fukamizu, akiyoshi/0000-0002-8786-6020; Takagaki, Kentaroh/0000-0002-1852-529X				Arimura N, 2004, J BIOL CHEM, V279, P10070, DOI 10.1074/jbc.M308522200; Chen F, 2003, J BIOL CHEM, V278, P19909, DOI 10.1074/jbc.M207903200; Dawson PA, 2005, J BIOL CHEM, V280, P6960, DOI 10.1074/jbc.M412752200; Dawson PA, 2003, J BIOL CHEM, V278, P33920, DOI 10.1074/jbc.M306370200; FUJITA M, 1995, EUR J BIOCHEM, V233, P406, DOI 10.1111/j.1432-1033.1995.406_2.x; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; Hirano Y, 2003, J BIOL CHEM, V278, P16809, DOI 10.1074/jbc.M212448200; Hirano Y, 2001, J BIOL CHEM, V276, P36431, DOI 10.1074/jbc.M105200200; Hirokane H, 2004, J BIOL CHEM, V279, P45685, DOI 10.1074/jbc.M404255200; ISEKI S, 1993, MOL CELL BIOCHEM, V123, P113, DOI 10.1007/BF01076482; Jung D, 2004, GUT, V53, P78, DOI 10.1136/gut.53.1.78; Kanda T, 1998, BIOCHEM J, V330, P261, DOI 10.1042/bj3300261; Kerr TA, 2002, DEV CELL, V2, P713, DOI 10.1016/S1534-5807(02)00154-5; Kok T, 2003, J BIOL CHEM, V278, P41930, DOI 10.1074/jbc.M306309200; Kramer W, 1997, EUR J BIOCHEM, V249, P456, DOI 10.1111/j.1432-1033.1997.00456.x; Kramer W, 2001, J BIOL CHEM, V276, P36020, DOI 10.1074/jbc.M104665200; Landrier JF, 2002, MOL CELL BIOCHEM, V239, P149, DOI 10.1023/A:1020557502795; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Misawa K, 2003, J BIOL CHEM, V278, P36176, DOI 10.1074/jbc.M302387200; Nakahara M, 2002, J BIOL CHEM, V277, P37229, DOI 10.1074/jbc.M206749200; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; Savkur RS, 2005, J PHARMACOL EXP THER, V312, P170, DOI 10.1124/jpet.104.072124; Sessler RJ, 2005, MOL CELL, V18, P343, DOI 10.1016/j.molcel.2005.03.026; Tan NS, 2002, MOL CELL BIOL, V22, P5114, DOI 10.1128/MCB.22.14.5114-5127.2002; Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9; Wolfrum C, 2001, P NATL ACAD SCI USA, V98, P2323, DOI 10.1073/pnas.051619898; WONG MH, 1994, J BIOL CHEM, V269, P1340; Zaghini I, 2002, J BIOL CHEM, V277, P1324, DOI 10.1074/jbc.M106375200	30	59	60	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42283	42289		10.1074/jbc.M507454200	http://dx.doi.org/10.1074/jbc.M507454200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16230354	hybrid			2022-12-25	WOS:000233992700057
J	Keetch, CA; Bromley, EHC; McCammon, MG; Wang, N; Christodoulou, J; Robinson, CV				Keetch, CA; Bromley, EHC; McCammon, MG; Wang, N; Christodoulou, J; Robinson, CV			L55P transthyretin accelerates subunit exchange and leads to rapid formation of hybrid tetramers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID FIBRIL FORMATION; PHYSIOLOGICAL CONDITIONS; KINETIC STABILIZATION; PROTEIN; VARIANT; DENATURATION; STABILITY; REVEALS; FORM	Transthyretin is a tetrameric protein associated with the commonest form of systemic amyloid disease. Using isotopically labeled proteins and mass spectrometry, we compared subunit exchange in wild-type transthyretin with that of the variant associated with the most aggressive form of the disease, L55P. Wild-type subunit exchange occurs via both monomers and dimers, whereas exchange via dimers is the dominant mechanism for the L55P variant. Because patients with the L55P mutation are heterozygous, expressing both proteins simultaneously, we also analyzed the subunit exchange reaction between wild-type and L55P tetramers. We found that hybrid tetramers containing two or three L55P subunits dominate in the early stages of the reaction. Surprisingly, we also found that, in the presence of L55P transthyretin, the rate of dissociation of wild-type transthyretin is increased. This implies interactions between the two proteins that accelerate the formation of hybrid tetramers, a result with important implications for transthyretin amyloidosis.	Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England	University of Cambridge	Robinson, CV (corresponding author), Univ Cambridge, Dept Chem, Lensfield Rd, Cambridge CB2 1EW, England.	cvr24@cam.ac.uk		robinson, carol/0000-0001-7829-5505; Christodoulou, John/0000-0002-6710-3843	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BENSON MD, 1996, NATURE ORIGIN AMYLOI; BERNSTEIN R S, 1970, Endocrinology, V86, P383; Blake C, 1996, STRUCTURE, V4, P989, DOI 10.1016/S0969-2126(96)00104-9; Bova MP, 1997, J BIOL CHEM, V272, P29511, DOI 10.1074/jbc.272.47.29511; COLON W, 1992, BIOCHEMISTRY-US, V31, P8654, DOI 10.1021/bi00151a036; Ferreira ST, 2001, FEBS LETT, V498, P129, DOI 10.1016/S0014-5793(01)02491-7; FERSHT A, 2000, STRUCTURE MECH PROTE, P508; Foss TR, 2005, J MOL BIOL, V347, P841, DOI 10.1016/j.jmb.2005.01.050; Gu LX, 2002, J MOL BIOL, V319, P517, DOI 10.1016/S0022-2836(02)00311-X; GUSTAVSSON A, 1991, BIOCHEM BIOPH RES CO, V175, P1159, DOI 10.1016/0006-291X(91)91687-8; Hammarstrom P, 2003, BIOCHEMISTRY-US, V42, P6656, DOI 10.1021/bi027319b; Hammarstrom P, 2003, SCIENCE, V299, P713, DOI 10.1126/science.1079589; Hammarstrom P, 2001, SCIENCE, V293, P2459, DOI 10.1126/science.1062245; Hammarstrom P, 2001, BIOCHEMISTRY-US, V40, P11453, DOI 10.1021/bi010673+; Hornberg A, 2004, BBA-PROTEINS PROTEOM, V1700, P93, DOI 10.1016/j.bbapap.2004.04.004; Hornberg A, 2000, J MOL BIOL, V302, P649, DOI 10.1006/jmbi.2000.4078; Jiang X, 2001, BIOCHEMISTRY-US, V40, P11442, DOI 10.1021/bi011194d; Lashuel HA, 1998, BIOCHEMISTRY-US, V37, P17851, DOI 10.1021/bi981876+; Lashuel HA, 1999, BIOCHEMISTRY-US, V38, P13560, DOI 10.1021/bi991021c; Matsubara K, 2005, BIOCHEMISTRY-US, V44, P3280, DOI 10.1021/bi048838c; MCCUTCHEN SL, 1993, BIOCHEMISTRY-US, V32, P12119, DOI 10.1021/bi00096a024; Miroy GJ, 1996, P NATL ACAD SCI USA, V93, P15051, DOI 10.1073/pnas.93.26.15051; MURAKAMI T, 1992, ANN NEUROL, V31, P340, DOI 10.1002/ana.410310319; Nelson SW, 2001, FEBS LETT, V492, P254, DOI 10.1016/S0014-5793(01)02262-1; Nettleton EJ, 1998, J MOL BIOL, V281, P553, DOI 10.1006/jmbi.1998.1937; Olofsson A, 2001, J BIOL CHEM, V276, P39592, DOI 10.1074/jbc.M103599200; Plante-Bordeneuve V, 1998, NEUROLOGY, V51, P708, DOI 10.1212/WNL.51.3.708; SARAIVA MJM, 1990, SCAND J IMMUNOL, V32, P341, DOI 10.1111/j.1365-3083.1990.tb02928.x; SARAIVA MJM, 1995, HUM MUTAT, V5, P191; Saxl RL, 2001, BIOCHEMISTRY-US, V40, P5275, DOI 10.1021/bi002925x; Schneider F, 2001, PROTEIN SCI, V10, P1606, DOI 10.1110/ps.8901; Sebastiao MP, 1998, J BIOL CHEM, V273, P24715, DOI 10.1074/jbc.273.38.24715; Sekijima Y, 2003, LAB INVEST, V83, P409, DOI 10.1097/01.LAB.0000059937.11023.1F; Sekijima Y, 2005, CELL, V121, P73, DOI 10.1016/j.cell.2005.01.018; Selkoe DJ, 2003, NATURE, V426, P900, DOI 10.1038/nature02264; Serag AA, 2002, NAT STRUCT BIOL, V9, P734, DOI 10.1038/nsb838; Serag AA, 2001, BIOCHEMISTRY-US, V40, P9089, DOI 10.1021/bi010655s; THYLEN C, 1993, EMBO J, V12, P743, DOI 10.1002/j.1460-2075.1993.tb05708.x; Wiseman RL, 2005, BIOCHEMISTRY-US, V44, P9265, DOI 10.1021/bi050352o; Wojtczak A, 2001, ACTA CRYSTALLOGR D, V57, P957, DOI 10.1107/S0907444901006047	40	52	52	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41667	41674		10.1074/jbc.M508753200	http://dx.doi.org/10.1074/jbc.M508753200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16219761	hybrid			2022-12-25	WOS:000233866900067
J	Lo, KY; Chin, WH; Ng, YP; Cheng, AW; Cheung, ZH; Ip, NY				Lo, KY; Chin, WH; Ng, YP; Cheng, AW; Cheung, ZH; Ip, NY			SLAM-associated protein as a potential negative regulator in Trk signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; NEURONAL SURVIVAL; TYROSINE KINASE; FACTOR RECEPTOR; BINDING-SITES; FULL-LENGTH; TRANSDUCTION; SHC; GENE; ROLES	Neurotrophin signaling plays important roles in regulating the survival, differentiation, and maintenance of neurons in the nervous system. Binding of neurotrophins to their cognate receptors Trks induces transactivation and phosphorylation of the receptor at several tyrosine residues. These phosphorylated tyrosine residues then serve as crucial docking sites for adaptor proteins containing a Src homology 2 or phosphotyrosine binding domain, which upon association with the receptor initiates multiple signaling events to mediate the action of neurotrophins. Here we report the identification of a Src homology 2 domain-containing molecule, SLAM-associated protein ( SAP), as an interacting protein of TrkB in a yeast two-hybrid screen. SAP was initially identified as an adaptor molecule in SLAM family receptor signaling for regulating interferon-gamma secretion. In the current study, we found that SAP interacted with TrkA, TrkB, and TrkC receptors in vitro and in vivo. Binding of SAP required Trk receptor activation and phosphorylation at the tyrosine 674 residue, which is located in the activation loop of the kinase domain. Overexpression of SAP with Trk attenuated tyrosine phosphorylation of the receptors and reduced the binding of SH2B and Shc to TrkB. Moreover, overexpression of SAP in PC12 cells suppressed the nerve growth factor-dependent activation of extracellular signal-regulated kinases 1/2 and phospholipase C gamma, in addition to inhibiting neurite outgrowth. In summary, our findings demonstrated that SAP may serve as a negative regulator of Trk receptor activation and downstream signaling.	Hong Kong Univ Sci & Technol, Dept Biochem, Biotechnol Res Inst, Hong Kong, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Mol Neurosci Ctr, Hong Kong, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology	Ip, NY (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Biotechnol Res Inst, Clear Water Bay, Hong Kong, Hong Kong, Peoples R China.	BOIP@UST.HK	Cheung, Zelda Hiu Yee/C-1402-2012	Cheng, Albert/0000-0003-2653-5743; Ip, Nancy Yuk-Yu/0000-0002-2763-8907				Atwal JK, 2000, NEURON, V27, P265, DOI 10.1016/S0896-6273(00)00035-0; Blum R, 2002, NATURE, V419, P687, DOI 10.1038/nature01085; Coffey AJ, 1998, NAT GENET, V20, P129, DOI 10.1038/2424; Cunningham ME, 1997, J BIOL CHEM, V272, P10957; Czar MJ, 2001, P NATL ACAD SCI USA, V98, P7449, DOI 10.1073/pnas.131193098; Du JL, 2004, NATURE, V429, P878, DOI 10.1038/nature02618; Elmariah SB, 2004, J NEUROSCI, V24, P2380, DOI 10.1523/JNEUROSCI.4112-03.2004; Fu AKY, 2001, NAT NEUROSCI, V4, P374, DOI 10.1038/86019; Goldsmith BA, 1997, J NEUROCHEM, V69, P1014; Gonzalez M, 1999, NEURON, V24, P567, DOI 10.1016/S0896-6273(00)81113-7; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Ip NY, 1996, ANNU REV NEUROSCI, V19, P491; Itami C, 2003, P NATL ACAD SCI USA, V100, P13069, DOI 10.1073/pnas.2131948100; Ji YY, 2005, NAT NEUROSCI, V8, P164, DOI 10.1038/nn1381; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Marsh HN, 2003, J CELL BIOL, V163, P999, DOI 10.1083/jcb.200309036; McCarty JH, 1998, ONCOGENE, V16, P1691, DOI 10.1038/sj.onc.1201688; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; Minichiello L, 2002, NEURON, V36, P121, DOI 10.1016/S0896-6273(02)00942-X; Musatov S, 2004, P NATL ACAD SCI USA, V101, P3627, DOI 10.1073/pnas.0308289101; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; Poy F, 1999, MOL CELL, V4, P555, DOI 10.1016/S1097-2765(00)80206-3; Qian XZ, 2001, MOL CELL BIOL, V21, P1613, DOI 10.1128/MCB.21.5.1613-1620.2001; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; Segal RA, 2003, ANNU REV NEUROSCI, V26, P299, DOI 10.1146/annurev.neuro.26.041002.131421; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Sullivan JL, 1999, CURR OPIN IMMUNOL, V11, P431, DOI 10.1016/S0952-7915(99)80072-7; Suzuki S, 2004, J CELL BIOL, V167, P1205, DOI 10.1083/jcb.200404106; Yacoubian TA, 2000, NAT NEUROSCI, V3, P342, DOI 10.1038/73911	35	14	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41744	41752		10.1074/jbc.M506554200	http://dx.doi.org/10.1074/jbc.M506554200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16223723	hybrid			2022-12-25	WOS:000233866900076
J	Shi, GW; Chen, JY; Concepcion, F; Motamedchaboki, K; Marjoram, P; Langen, R; Chen, J				Shi, GW; Chen, JY; Concepcion, F; Motamedchaboki, K; Marjoram, P; Langen, R; Chen, J			Light causes phosphorylation of nonactivated visual pigments in intact mouse rod photoreceptor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOPSIN KINASE; IN-VIVO; DEPENDENT PHOSPHORYLATION; MULTIPLE PHOSPHORYLATION; LATERAL DIFFUSION; ACTIVATION; PROTEIN; DEACTIVATION; MECHANISM; OPSIN	Phosphorylation of G-protein-coupled receptors (GPCRs) is a required step in signal deactivation. Rhodopsin, a prototypical GPCR, exhibits high gain phosphorylation in vitro whereby a hundredfold molar excess of phosphates are incorporated into the rhodopsin pool per molecule of activated rhodopsin. The extent by which high gain phosphorylation occurs in the intact mammalian photoreceptor cell, and the molecular mechanism underlying this reaction in vivo, is not known. Trans-phosphorylation is a mechanism proposed for high gain phosphorylation, whereby rhodopsin kinase, upon phosphorylating the activated receptor, continues to phosphorylate nearby nonactivated rhodopsin. We used two different transgenic mouse models to test whether trans-phosphorylation occurs in the intact photoreceptor cell. The first transgenic model expressed a murine cone pigment, S-opsin, together with the endogenous rhodopsin in the rod cell. We showed that selective stimulation of rhodopsin also led to phosphorylation of S-opsin. The second mouse model expressed the constitutively active human opsin mutant K296E. K296E, in the arrestin-/-background, also led to phosphorylation of endogenous mouse rhodopsin in the dark-adapted retina. Both mouse models provide strong support of transphosphorylation as an underlying mechanism of high gain phosphorylation, and provide evidence that a substantial fraction of nonactivated visual pigments becomes phosphorylated through this mechanism. Because activated, phosphorylated receptors exhibit decreased catalytic activity, our results suggest that dephosphorylation would be an important step in the full recovery of visual sensitivity during dark adaptation. These results may also have implications for other GPCR signaling pathways.	Univ So Calif, Zilkha Neurogenet Inst, Beckman Macular Res Ctr, Doheny Eye Inst, Los Angeles, CA 90033 USA; Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ So Calif, Dept Cell & Neurobiol, Los Angeles, CA 90033 USA; Univ So Calif, Dept Prevent Med, Los Angeles, CA 90033 USA; Univ So Calif, Dept Ophthalmol, Keck Sch Med, Los Angeles, CA 90033 USA	Doheny Eye Institute; University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California	Chen, J (corresponding author), Univ So Calif, Zilkha Neurogenet Inst, Beckman Macular Res Ctr, Doheny Eye Inst, 1501 San Pablo St,ZNI 227, Los Angeles, CA 90033 USA.	jeannie@usc.edu	Marjoram, Paul/A-3066-2008		NATIONAL EYE INSTITUTE [R01EY012155] Funding Source: NIH RePORTER; NEI NIH HHS [EY12155] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADAMUS G, 1993, ARCH BIOCHEM BIOPHYS, V304, P443, DOI 10.1006/abbi.1993.1373; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; ATON BR, 1986, BIOCHEMISTRY-US, V25, P677, DOI 10.1021/bi00351a025; BAYLOR DA, 1984, J PHYSIOL-LONDON, V357, P575, DOI 10.1113/jphysiol.1984.sp015518; BIERNBAUM MS, 1991, VISUAL NEUROSCI, V7, P499, DOI 10.1017/S0952523800009780; BINDER BM, 1990, J BIOL CHEM, V265, P15333; Binder BM, 1996, J BIOL CHEM, V271, P19826, DOI 10.1074/jbc.271.33.19826; BOWNDS D, 1967, NATURE, V216, P1178, DOI 10.1038/2161178a0; BROWN NG, 1992, EUR J BIOCHEM, V208, P659, DOI 10.1111/j.1432-1033.1992.tb17232.x; Burns ME, 2001, ANNU REV NEUROSCI, V24, P779, DOI 10.1146/annurev.neuro.24.1.779; Chen CK, 1999, P NATL ACAD SCI USA, V96, P3718, DOI 10.1073/pnas.96.7.3718; CHEN CK, 1995, J BIOL CHEM, V270, P18060, DOI 10.1074/jbc.270.30.18060; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; COHEN GB, 1992, BIOCHEMISTRY-US, V31, P12592, DOI 10.1021/bi00165a008; CONE RA, 1972, NATURE-NEW BIOL, V236, P39, DOI 10.1038/newbio236039a0; Dean KR, 1996, BIOCHEMISTRY-US, V35, P6164, DOI 10.1021/bi952480q; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; Ianoul A, 2005, NAT CHEM BIOL, V1, P196, DOI 10.1038/nchembio726; JACOBS GH, 1991, NATURE, V353, P655, DOI 10.1038/353655a0; KEEN TJ, 1991, GENOMICS, V11, P199, DOI 10.1016/0888-7543(91)90119-Y; Kennedy MJ, 2001, NEURON, V31, P87, DOI 10.1016/S0896-6273(01)00340-3; LAIRD DW, 1988, INVEST OPHTH VIS SCI, V29, P419; Laitko U, 1998, BIOPHYS J, V74, P803, DOI 10.1016/S0006-3495(98)74005-6; Langen R, 1999, BIOCHEMISTRY-US, V38, P7918, DOI 10.1021/bi990010g; Lem J, 1999, P NATL ACAD SCI USA, V96, P736, DOI 10.1073/pnas.96.2.736; LI TS, 1995, P NATL ACAD SCI USA, V92, P3551, DOI 10.1073/pnas.92.8.3551; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; LIEBMAN PA, 1974, SCIENCE, V185, P457, DOI 10.1126/science.185.4149.457; Lyubarsky AL, 1999, J NEUROSCI, V19, P442, DOI 10.1523/JNEUROSCI.19-01-00442.1999; Mendez A, 2000, NEURON, V28, P153, DOI 10.1016/S0896-6273(00)00093-3; OHGURO H, 1995, J BIOL CHEM, V270, P14259, DOI 10.1074/jbc.270.24.14259; PALCZEWSKI K, 1989, BIOCHEMISTRY-US, V28, P8764, DOI 10.1021/bi00448a013; PALCZEWSKI K, 1988, J BIOL CHEM, V263, P14067; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1988, BIOCHEMISTRY-US, V27, P2306, DOI 10.1021/bi00407a010; POO MM, 1974, NATURE, V247, P438, DOI 10.1038/247438a0; Rieke F, 1998, BIOPHYS J, V75, P1836, DOI 10.1016/S0006-3495(98)77625-8; Rim J, 1997, BIOCHEMISTRY-US, V36, P7064, DOI 10.1021/bi970470e; Shi G, 2004, REC ADV HUM BIOL, V10, P93; Waldhoer M, 2005, P NATL ACAD SCI USA, V102, P9050, DOI 10.1073/pnas.0501112102; Weiss ER, 2001, J NEUROSCI, V21, P9175, DOI 10.1523/JNEUROSCI.21-23-09175.2001; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; Xu J, 1997, NATURE, V389, P505, DOI 10.1038/39068; ZHUKOVSKY EA, 1991, SCIENCE, V251, P558, DOI 10.1126/science.1990431	45	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41184	41191		10.1074/jbc.M506935200	http://dx.doi.org/10.1074/jbc.M506935200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16219764	hybrid			2022-12-25	WOS:000233866900010
J	Xiu, XN; Hanek, AP; Wang, JT; Lester, HA; Dougherty, DA				Xiu, XN; Hanek, AP; Wang, JT; Lester, HA; Dougherty, DA			A unified view of the role of electrostatic interactions in modulating the gating of Cys loop receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; GATED ION-CHANNEL; SIGNATURE DISULFIDE LOOP; AGONIST BINDING; TRANSMEMBRANE SEGMENT; EXTRACELLULAR DOMAIN; CRYSTAL-STRUCTURE; CHARGED RESIDUES; GLYCINE RECEPTOR; GABA(A) RECEPTOR	In the Cys loop superfamily of ligand-gated ion channels, a global conformational change, initiated by agonist binding, results in channel opening and the passage of ions across the cell membrane. The detailed mechanism of channel gating is a subject that has lent itself to both structural and electrophysiological studies. Here we defined a gating interface that incorporates elements from the ligand binding domain and transmembrane domain previously reported as integral to proper channel gating. An overall analysis of charged residues within the gating interface across the entire superfamily showed a conserved charging pattern, although no specific interacting ion pairs were conserved. We utilized a combination of conventional mutagenesis and the high precision methodology of unnatural amino acid incorporation to study extensively the gating interface of the mouse muscle nicotinic acetylcholine receptor. We found that charge reversal, charge neutralization, and charge introduction at the gating interface are often well tolerated. Furthermore, based on our charging pattern of the gating interface, and not any specific pairwise electrostatic interactions, controls the gating process in the Cys loop superfamily.	CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology	Dougherty, DA (corresponding author), CALTECH, Div Chem & Chem Engn, 164-30, Pasadena, CA 91125 USA.	dadougherty@caltech.edu			NINDS NIH HHS [NS-11756, NS-34407] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034407, R01NS011756, R37NS034407] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Absalom NL, 2003, J BIOL CHEM, V278, P50151, DOI 10.1074/jbc.M305357200; Bouzat C, 2004, NATURE, V430, P896, DOI 10.1038/nature02753; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; CamposCaro A, 1996, P NATL ACAD SCI USA, V93, P6118, DOI 10.1073/pnas.93.12.6118; Cashin AL, 2005, J AM CHEM SOC, V127, P350, DOI 10.1021/ja0461771; Castaldo P, 2004, J BIOL CHEM, V279, P25598, DOI 10.1074/jbc.M311021200; Celie PHN, 2004, NEURON, V41, P907, DOI 10.1016/S0896-6273(04)00115-1; Celie PHN, 2005, J BIOL CHEM, V280, P26457, DOI 10.1074/jbc.M414476200; Chakrapani S, 2004, J GEN PHYSIOL, V123, P341, DOI 10.1085/jgp.200309004; Changeux JP, 2001, CURR OPIN NEUROBIOL, V11, P369, DOI 10.1016/S0959-4388(00)00221-X; CHOTHIA C, 1975, J MOL BIOL, V105, P1; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; England PM, 1999, CELL, V96, P89, DOI 10.1016/S0092-8674(00)80962-9; FILATOV GN, 1995, MOL PHARMACOL, V48, P379; Grosman C, 2000, J GEN PHYSIOL, V116, P327, DOI 10.1085/jgp.116.3.327; Grosman C, 2000, NATURE, V403, P773, DOI 10.1038/35001586; Grosman C, 2000, J GEN PHYSIOL, V115, P637, DOI 10.1085/jgp.115.5.637; Karplus PA, 1997, PROTEIN SCI, V6, P1302; Kash TL, 2004, BIOCHEM SOC T, V32, P540, DOI 10.1042/BST0320540; Kash TL, 2004, NEUROSCI LETT, V371, P230, DOI 10.1016/j.neulet.2004.09.002; Kash TL, 2004, J BIOL CHEM, V279, P4887, DOI 10.1074/jbc.M311441200; Kash TL, 2003, NATURE, V421, P272, DOI 10.1038/nature01280; Kearney PC, 1996, NEURON, V17, P1221, DOI 10.1016/S0896-6273(00)80252-4; Kearney PC, 1996, MOL PHARMACOL, V50, P1401; LABARCA C, 1995, NATURE, V376, P514, DOI 10.1038/376514a0; Leite JF, 2003, J CLIN INVEST, V111, P436, DOI 10.1172/JC1200317882; Lester HA, 2004, TRENDS NEUROSCI, V27, P329, DOI 10.1016/j.tins.2004.04.002; Lummis SCR, 2004, BIOCHEM SOC T, V32, P535, DOI 10.1042/BST0320535; Lummis SCR, 2005, NATURE, V438, P248, DOI 10.1038/nature04130; Mitra A, 2004, STRUCTURE, V12, P1909, DOI 10.1016/j.str.2004.08.004; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Nowak MW, 1998, METHOD ENZYMOL, V293, P504; Paterson D, 2000, PROG NEUROBIOL, V61, P75, DOI 10.1016/S0301-0082(99)00045-3; Placzek AN, 2004, MOL PHARMACOL, V66, P169, DOI 10.1124/mol.66.1.169; RADZICKA A, 1988, BIOCHEMISTRY-US, V27, P1664, DOI 10.1021/bi00405a042; Schofield CM, 2004, BIOCHEMISTRY-US, V43, P10058, DOI 10.1021/bi036159g; Schofield CM, 2003, J BIOL CHEM, V278, P34079, DOI 10.1074/jbc.M302416200; Taly A, 2005, BIOPHYS J, V88, P3954, DOI 10.1529/biophysj.104.050229; Tong YH, 2001, J GEN PHYSIOL, V117, P103, DOI 10.1085/jgp.117.2.103; Unwin N, 2005, J MOL BIOL, V346, P967, DOI 10.1016/j.jmb.2004.12.031; Unwin N, 2002, J MOL BIOL, V319, P1165, DOI 10.1016/S0022-2836(02)00381-9; YOSHII K, 1987, J GEN PHYSIOL, V90, P553, DOI 10.1085/jgp.90.4.553; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3	44	120	120	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41655	41666		10.1074/jbc.M508635200	http://dx.doi.org/10.1074/jbc.M508635200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16216879	Green Accepted, hybrid			2022-12-25	WOS:000233866900066
J	Sanz, L; Chen, RQ; Perez, A; Hilario, R; Juarez, P; Marcinkiewicz, C; Monleon, D; Celda, B; Xiong, YL; Perez-Paya, E; Calvete, JJ				Sanz, L; Chen, RQ; Perez, A; Hilario, R; Juarez, P; Marcinkiewicz, C; Monleon, D; Celda, B; Xiong, YL; Perez-Paya, E; Calvete, JJ			cDNA cloning and functional expression of jerdostatin, a novel RTS-disintegrin from Trimeresurus jerdonii and a specific antagonist of the alpha(1)beta(1) integrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE-BOND PATTERN; AMINO-ACID-SEQUENCE; SELECTIVE INHIBITOR; CRYSTAL-STRUCTURE; ECHIS-CARINATUS; CELL-MIGRATION; SNAKE-VENOM; INTEGRINS; PROTEIN; BINDING	Jerdostatin represents a novel RTS-containing short disintegrin cloned by reverse transcriptase-PCR from the venom gland mRNA of the Chinese Jerdons pit viper Trimeresurus jerdonii. The jerdostatins precursor cDNA contained a 333-bp open reading frame encoding a signal peptide, a pre-peptide, and a 43-amino acid disintegrin domain, whose amino acid sequence displayed 80% identity with that of the KTS-disintegrins obtustatin and viperistatin. The jerdostatin cDNA structure represents the first complete open reading frame of a short disintegrin and points to the emergence of jerdostatin from a short-coding gene. The different residues between jerdostatin and obtustatin/viperistatin are segregated within the integrin-recognition loop and the C-terminal tail. Native jerdostatin (r-jerdostatin-R21) and a R21K mutant (r-jerdostatin-K21) were produced in Escherichia coli. In each case, two conformers were isolated. One-dimensional (1)HNMRshowed that conformers 1 and 2 of r-jerdostatin-R21 represent, respectively, well folded and unfolded proteins. The two conformers of the wild-type and the R21K mutant inhibited the adhesion of alpha(1)-K562 cells to collagen IV with IC50 values of 180 and 703 nM, respectively. The IC50 values of conformers 2 of r-jerdostatin-R21 and r-jerdostatin-K21 were, respectively, 5.95 and 12.5 mu M. Neither r-jerdostatin-R21 nor r-jerdostatin-K21 showed inhibitory activity toward other integrins, including alpha(IIb)beta(3), alpha(v)beta(3), alpha(2)beta(1), alpha(5)beta(1), alpha(4)beta(1), alpha(6)beta(1), and alpha(9)beta(1) up to a concentration of 24 mu M. Although the RTS motif appears to be more potent than KTS inhibiting the alpha(1)beta(1) integrin, r-jerdostatin-R21 is less active than the KTS-disintegrins, strongly suggesting that substitutions outside the integrin- binding motif and/or C-terminal proteolytic processing are responsible for the decreased inhibitory activity.	CSIC, Inst Biomed Valencia, Valencia 46010, Spain; Chinese Acad Sci, Kumming Inst Zool, Dept Anim Toxicol, Kunming 650223, Peoples R China; Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, Philadelphia, PA 19122 USA; Univ Valencia, Dept Quim Fis, E-46100 Valencia, Spain; CSIC, Valencia 46013, Spain; Ctr Invest Principe Felipe, Valencia 46013, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV); Chinese Academy of Sciences; Kunming Institute of Zoology; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Valencia; Consejo Superior de Investigaciones Cientificas (CSIC); Prince Felipe Research Center	Calvete, JJ (corresponding author), CSIC, Inst Biomed Valencia, Jaime Roig 11, Valencia 46010, Spain.	jcalvete@ibv.csic.es	Calvete, Juan/P-2555-2019; Monleon, Daniel/A-5078-2010; Monleon, Daniel/GNP-4083-2022; Calvete, Juan J/K-9619-2014	Calvete, Juan/0000-0001-5026-3122; Monleon, Daniel/0000-0002-4803-1573; Monleon, Daniel/0000-0002-4803-1573; Calvete, Juan J/0000-0001-5026-3122; Sanz, Libia/0000-0003-4991-9598	NCI NIH HHS [R01 CA100145-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100145] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUER M, 1993, J PROTEIN CHEM, V12, P759, DOI 10.1007/BF01024934; Bilgrami S, 2004, J MOL BIOL, V341, P829, DOI 10.1016/j.jmb.2004.06.048; Calvete JJ, 2003, BIOCHEM J, V372, P725, DOI 10.1042/BJ20021739; Calvete JJ, 1997, FEBS LETT, V416, P197, DOI 10.1016/S0014-5793(97)01203-9; Calvete JJ, 2000, BIOCHEM J, V345, P573, DOI 10.1042/0264-6021:3450573; Danen EHJ, 2005, CURR PHARM DESIGN, V11, P881, DOI 10.2174/1381612053381756; DeClerck YA, 2004, AM J PATHOL, V164, P1131, DOI 10.1016/S0002-9440(10)63200-2; Dickeson SK, 1999, J BIOL CHEM, V274, P32182, DOI 10.1074/jbc.274.45.32182; Dyson HJ, 1996, ANNU REV PHYS CHEM, V47, P369, DOI 10.1146/annurev.physchem.47.1.369; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hodivala-Dilke KM, 2003, CELL TISSUE RES, V314, P131, DOI 10.1007/s00441-003-0774-5; Horii K, 2004, J MOL BIOL, V341, P519, DOI 10.1016/j.jmb.2004.06.036; Hynes RO, 2002, NAT MED, V8, P918, DOI 10.1038/nm0902-918; Jin H, 2004, BRIT J CANCER, V90, P561, DOI 10.1038/sj.bjc.6601576; Juarez P, 2004, PROTEOMICS, V4, P327, DOI 10.1002/pmic.200300628; Kisiel DG, 2004, FEBS LETT, V577, P478, DOI 10.1016/j.febslet.2004.10.050; Klekotka PA, 2001, AM J PATHOL, V159, P983, DOI 10.1016/S0002-9440(10)61774-9; Liu ML, 1998, J MAGN RESON, V132, P125, DOI 10.1006/jmre.1998.1405; Lobel L, 2002, PROTEIN EXPRES PURIF, V25, P124, DOI 10.1006/prep.2002.1618; Marcinkiewicz C, 2003, CANCER RES, V63, P2020; Marcinkiewicz C, 1999, J BIOL CHEM, V274, P12468, DOI 10.1074/jbc.274.18.12468; Marcinkiewicz C, 1997, BLOOD, V90, P1565, DOI 10.1182/blood.V90.4.1565.1565_1565_1575; Marcinkiewicz C, 2000, BIOCHEMISTRY-US, V39, P9859, DOI 10.1021/bi000428a; Mercurio AM, 2002, AM J PATHOL, V161, P3, DOI 10.1016/S0002-9440(10)64149-1; Mistry A, 2003, CURR OPIN MOL THER, V5, P603; Monleon D, 2005, BIOCHEM J, V387, P57, DOI 10.1042/BJ20041343; Monleon D, 2003, J BIOL CHEM, V278, P45570, DOI 10.1074/jbc.M307030200; Moreno-Murciano MP, 2003, J MOL BIOL, V329, P135, DOI 10.1016/S0022-2836(03)00371-1; Moreno-Murciano MP, 2003, PROTEIN SCI, V12, P366, DOI 10.1110/ps.0230203; Okuda D, 2001, J BIOCHEM-TOKYO, V129, P615, DOI 10.1093/oxfordjournals.jbchem.a002898; Pastor MT, 2002, P NATL ACAD SCI USA, V99, P614, DOI 10.1073/pnas.012583999; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Pozzi A, 2000, P NATL ACAD SCI USA, V97, P2202, DOI 10.1073/pnas.040378497; Rehn M, 2001, P NATL ACAD SCI USA, V98, P1024, DOI 10.1073/pnas.031564998; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Senger DR, 2002, AM J PATHOL, V160, P195, DOI 10.1016/S0002-9440(10)64363-5; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; Springer TA, 2004, ADV PROTEIN CHEM, V68, P29; Tulla M, 2001, J BIOL CHEM, V276, P48206, DOI 10.1074/jbc.M104058200; Wang RH, 1999, BIOCHEMISTRY-US, V38, P7584, DOI 10.1021/bi982132z; White DJ, 2004, INT J BIOCHEM CELL B, V36, P1405, DOI 10.1016/j.biocel.2003.08.016; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yamada D, 1999, FEBS LETT, V451, P299, DOI 10.1016/S0014-5793(99)00604-3; YOKOSAKI Y, 1994, J BIOL CHEM, V269, P26691	44	36	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40714	40722		10.1074/jbc.M509738200	http://dx.doi.org/10.1074/jbc.M509738200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16215260	hybrid			2022-12-25	WOS:000233666600041
J	Yavrom, S; Chen, L; Xiong, SG; Wang, JH; Rippe, RA; Tsukamoto, H				Yavrom, S; Chen, L; Xiong, SG; Wang, JH; Rippe, RA; Tsukamoto, H			Peroxisome proliferator-activated receptor gamma suppresses proximal alpha 1(I) collagen promoter via inhibition of p300-facilitated NF-I binding to DNA in hepatic stellate cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NUCLEAR FACTOR-I; MOUSE ALPHA-2(I); GENE-EXPRESSION; RAT-LIVER; TRANSCRIPTION; MECHANISMS; COL1A1; SP1; FIBROSIS	Depletion of peroxisome proliferator-activated receptor gamma (PPAR gamma) represents one of the key molecular changes that underlie transdifferentiation ( activation) of hepatic stellate cells in the genesis of liver fibrosis ( Miyahara, T., Schrum, L., Rippe, R., Xiong, S., Yee, H. F., Jr., Motomura, K., Anania, F. A., Willson, T. M., and Tsukamoto, H. (2000) J. Biol. Chem. 275, 35715 - 35722; Hazra, S., Xiong, S., Wang, J., Rippe, R. A., Krishna, V., Chatterjee, K., and Tsukamoto, H. ( 2004) J. Biol. Chem. 279, 11392 - 11401). In support of this notion, ectopic expression of PPAR gamma suppresses hepatic stellate cells activation markers, most notably expression of alpha 1( I) procollagen. However, the mechanisms underlying this antifibrotic effect are largely unknown. The present study utilized deletion- reporter gene constructs of proximal 2.2-kb alpha 1( I) procollagen promoter to demonstrate that a region proximal to - 133 bp is where PPAR gamma exerts its inhibitory effect. Within this region, two DNase footprints with Sp1 and reverse CCAAT box sites exist. NF-I, but not CCAAT DNA-binding factor/NF-Y, binds to the proximal CCAAT box in hepatic stellate cells. A mutation of this site almost completely abrogates the promoter activity. NF-I mildly but independently stimulates the promoter activity and synergistically promotes Sp1-induced activity. PPAR gamma inhibits NF-I binding to the most proximal footprint (-97/-85 bp) and inhibits its transactivity. The former effect is mediated by the ability of PPAR gamma to inhibit p300-facilitated NF-I binding to DNA as demonstrated by chromatin immunoprecipitation assay.	Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Dept Vet Affairs Greater Los Angeles Healthcare S, Los Angeles, CA 90073 USA	University of Southern California; University of North Carolina; University of North Carolina Chapel Hill	Tsukamoto, H (corresponding author), Univ So Calif, Keck Sch Med, Dept Pathol, 1333 San Pablo St,MMR-402, Los Angeles, CA 90033 USA.	htsukamo@usc.edu						ARMENDARIZBORUNDA J, 1992, J BIOL CHEM, V267, P14316; Asahina K, 2002, AM J PATHOL, V160, P2191, DOI 10.1016/S0002-9440(10)61167-4; BACHEM MG, 1993, VIRCHOWS ARCH B, V63, P123, DOI 10.1007/BF02899251; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; Friedman SL, 1997, J GASTROENTEROL, V32, P424, DOI 10.1007/BF02934504; Galli A, 2002, GASTROENTEROLOGY, V122, P1924, DOI 10.1053/gast.2002.33666; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HATAMOCHI A, 1986, J BIOL CHEM, V261, P1310; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; Hazra S, 2004, J BIOL CHEM, V279, P11392, DOI 10.1074/jbc.M310284200; Kinnman N, 2001, LAB INVEST, V81, P1709, DOI 10.1038/labinvest.3780384; Kochanek Kenneth D, 2004, Natl Vital Stat Rep, V53, P1; Maher JJ, 1998, AM J PHYSIOL-GASTR L, V275, pG847, DOI 10.1152/ajpgi.1998.275.4.G847; Miura K, 2003, BIOCHEM BIOPH RES CO, V311, P415, DOI 10.1016/j.bbrc.2003.09.225; Miyahara T, 2000, J BIOL CHEM, V275, P35715, DOI 10.1074/jbc.M006577200; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; Norman JT, 2001, J BIOL CHEM, V276, P29880, DOI 10.1074/jbc.M103145200; OIKARINEN J, 1987, J BIOL CHEM, V262, P11064; RIPPE RA, 1989, MOL CELL BIOL, V9, P2224, DOI 10.1128/MCB.9.5.2224; RIPPE RA, 1995, HEPATOLOGY, V22, P241, DOI 10.1016/0270-9139(95)90378-X; Riquet FB, 2001, J BIOL CHEM, V276, P38665, DOI 10.1074/jbc.M009881200; ROJKIND M, 1979, GASTROENTEROLOGY, V76, P710; ROJKIND M, 1995, AM J PATHOL, V146, P1508; Saitta B, 2000, ARTHRITIS RHEUM-US, V43, P2219, DOI 10.1002/1529-0131(200010)43:10<2219::AID-ANR9>3.0.CO;2-N; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sengupta P, 2005, J BIOL CHEM, V280, P21004, DOI 10.1074/jbc.M413191200; She HY, 2005, J BIOL CHEM, V280, P4959, DOI 10.1074/jbc.M410078200; Skrtic S, 1999, J HEPATOL, V30, P115, DOI 10.1016/S0168-8278(99)80015-4; Sugawara A, 2002, J BIOL CHEM, V277, P9676, DOI 10.1074/jbc.M104560200; Sung CK, 2004, AM J PHYSIOL-GASTR L, V286, pG722, DOI 10.1152/ajpgi.00411.2003; SUZUKI K, 1993, INT J LEPROSY, V61, P609; Tsukamoto H, 1996, AM J PHYSIOL-GASTR L, V270, pG581, DOI 10.1152/ajpgi.1996.270.4.G581; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; WEINER FR, 1990, HEPATOLOGY, V11, P111, DOI 10.1002/hep.1840110119	34	54	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40650	40659		10.1074/jbc.M510094200	http://dx.doi.org/10.1074/jbc.M510094200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16216869	Green Published, hybrid			2022-12-25	WOS:000233666600034
J	Zheng, G; Yang, YC				Zheng, G; Yang, YC			Sumoylation and acetylation play opposite roles in the transactivation of PLAG1 and PLAGL2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; SUMO-1 MODIFICATION; BINDING; PROTEIN; CONJUGATION; INVOLVEMENT; HYPOXIA; GENES; IDENTIFICATION; LIPOBLASTOMA	PLAG1 ( pleomorphic adenoma gene 1) and PLAGL2 (PLAG-like 2) are oncogenes involved in various malignancies. Thus the study of their regulatory mechanisms may lead to identification of novel therapeutic targets. In this study, we provide supporting evidence that sumoylation and acetylation regulate functions of PLAG1 and PLAGL2. A conserved transcriptional repression domain exists in both PLAG1 and PLAGL2, whose activity depends on the presence of three sumoylation motifs and an intact sumoylation pathway. In vivo sumoylation assays confirmed that lysines 244, 263, and 353 of PLAG1 and lysines 250, 269, and 356 of PLAGL2 are indeed sumoylation sites. Further study showed that sumoylation inhibits PLAG1-induced IGF-II expression in reporter assays. The repression mediated by sumoylation may be partially explained by its effect on the cellular localization of PLAG1 and PLAGL2, because sumoylation-deficient but not wild-type PLAG1 and PLAGL2 concentrate in the nucleolus. PLAG1 and PLAGL2 are also regulated by acetylation. They are acetylated and activated by p300 and deacetylated and repressed by HDAC7. Interestingly, the sumoylation- deficient mutant of PLAGL2 is acetylated at a lower level than its wildtype counterpart, suggesting that some of the lysine residues may be targets for both modifications. Finally, mutation of three lysine residues in sumoylation motifs significantly impairs the transformation ability of PLAG1 and PLAGL2, suggesting the essential roles of these sites in the oncogenic potential of PLAG proteins. Taken together, the activities of PLAG1 and PLAGL2 are tightly modulated by both sumoylation and acetylation, which have opposite effects on their transactivation. To our knowledge, this is the first demonstration that oncoproteins can be regulated by both sumoylation and acetylation.	Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Ctr Canc, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Yang, YC (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, 2109 Adelbert Rd,W353, Cleveland, OH 44106 USA.	yxy36@case.edu		Zheng, Gang/0000-0003-0276-9430	NCI NIH HHS [CA78433] Funding Source: Medline; NHLBI NIH HHS [HL48819] Funding Source: Medline; NIDDK NIH HHS [DK50570] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078433] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050570] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Astrom AK, 1999, CANCER RES, V59, P918; Astrom AK, 2000, INT J ONCOL, V16, P1107; Bies J, 2002, J BIOL CHEM, V277, P8999, DOI 10.1074/jbc.M110453200; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Castilla LH, 2004, P NATL ACAD SCI USA, V101, P4924, DOI 10.1073/pnas.0400930101; Comerford KM, 2003, P NATL ACAD SCI USA, V100, P986, DOI 10.1073/pnas.0337412100; Freiman RN, 2003, CELL, V112, P11, DOI 10.1016/S0092-8674(02)01278-3; Furukawa T, 2001, ONCOGENE, V20, P4718, DOI 10.1038/sj.onc.1204647; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Gisselsson D, 2001, AM J PATHOL, V159, P955, DOI 10.1016/S0002-9440(10)61771-3; Hardeland U, 2002, EMBO J, V21, P1456, DOI 10.1093/emboj/21.6.1456; Hensen K, 2002, CANCER RES, V62, P1510; Hibbard MK, 2000, CANCER RES, V60, P4869; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Kas K, 1998, J BIOL CHEM, V273, P23026, DOI 10.1074/jbc.273.36.23026; Kas K, 1997, NAT GENET, V15, P170, DOI 10.1038/ng0297-170; Landrette SF, 2005, BLOOD, V105, P2900, DOI 10.1182/blood-2004-09-3630; Liu JD, 2002, MOL CELL, V10, P1511, DOI 10.1016/S1097-2765(02)00783-9; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Malakhova OA, 2003, GENE DEV, V17, P455, DOI 10.1101/gad.1056303; Mao Y, 2000, J BIOL CHEM, V275, P26066, DOI 10.1074/jbc.M001831200; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Nishida T, 2002, J BIOL CHEM, V277, P41311, DOI 10.1074/jbc.M206741200; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Polesskaya A, 2000, J BIOL CHEM, V275, P34359, DOI 10.1074/jbc.M003815200; Rallabhandi P, 2002, J BIOL CHEM, V277, P40020, DOI 10.1074/jbc.M200388200; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Shao RJ, 2004, FEBS LETT, V569, P293, DOI 10.1016/j.febslet.2004.05.079; Shilo Y, 2003, P NATL ACAD SCI USA, V100, P13225, DOI 10.1073/pnas.1735528100; Soutoglou E, 2000, MOL CELL, V5, P745, DOI 10.1016/S1097-2765(00)80253-1; Stelter P, 2003, NATURE, V425, P188, DOI 10.1038/nature01965; VANDYCK F, 2004, J BIOL CHEM; Voz ML, 2000, CANCER RES, V60, P106; Voz ML, 2004, ONCOGENE, V23, P179, DOI 10.1038/sj.onc.1207013; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7; Yang SH, 2003, MOL CELL, V12, P63, DOI 10.1016/S1097-2765(03)00265-X; Yang XJ, 2005, MOL CELL BIOL, V25, P2873, DOI 10.1128/MCB.25.8.2873-2884.2005; Zhang QH, 2000, P NATL ACAD SCI USA, V97, P14323, DOI 10.1073/pnas.011283598; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855; Zheng G, 2004, J BIOL CHEM, V279, P42410, DOI 10.1074/jbc.M407287200	44	28	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40773	40781		10.1074/jbc.M504334200	http://dx.doi.org/10.1074/jbc.M504334200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16207715	hybrid			2022-12-25	WOS:000233666600047
J	Remus, D; Blanchette, M; Rio, DC; Botchan, MR				Remus, D; Blanchette, M; Rio, DC; Botchan, MR			CDK phosphorylation inhibits the DNA-binding and ATP-hydrolysis activities of the Drosophila origin recognition complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; CELL-CYCLE; S-PHASE; REPLICATION ORIGINS; RE-REPLICATION; ENDOREDUPLICATION CYCLES; PROTEIN COMPLEXES; FISSION YEAST; LARGE SUBUNIT; XENOPUS	Faithful propagation of eukaryotic chromosomes usually requires that no DNA segment be replicated more than once during one cell cycle. Cyclin-dependent kinases ( Cdks) are critical for the re-replication controls that inhibit the activities of components of the pre-replication complexes ( pre-RCs) following origin activation. The origin recognition complex ( ORC) initiates the assembly of pre-RCs at origins of replication and Cdk phosphorylation of ORC is important for the prevention of re-initiation. Here we show that Drosophila melanogaster ORC ( DmORC) is phosphorylated in vivo and is a substrate for Cdks in vitro. Cdk phosphorylation of DmORC subunits DmOrc1p and DmOrc2p inhibits the intrinsic ATPase activity of DmORC without affecting ATP binding to DmOrc1p. Moreover, Cdk phosphorylation inhibits the ATP-dependent DNA-binding activity of DmORC in vitro, thus identifying a novel determinant for DmORC-DNA interaction. DmORC is a substrate for both Cdk2(.)cyclin E and Cdk1(.)cyclin B in vitro. Such phosphorylation of DmORC by Cdk2(.)cyclin E, but not by Cdk1(.)cyclin B, requires an "RXL" motif in DmOrc1p. We also identify casein kinase 2 ( CK2) as a kinase activity in embryonic extracts targeting DmORC for modification. CK2 phosphorylation does not affect ATP hydrolysis by DmORC but modulates the ATP-dependent DNA-binding activity of DmORC. These results suggest molecular mechanisms by which Cdks may inhibit ORC function as part of re-replication control and show that DmORC activity may be modulated in response to phosphorylation by multiple kinases.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Biochem & Mol Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Botchan, MR (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Biochem & Mol Biol, 16 Barker Hall 3204, Berkeley, CA 94720 USA.	mbotchan@uclink.berkeley.edu		Remus, Dirk/0000-0002-5155-181X	NCI NIH HHS [2-R37-CA 030490-25] Funding Source: Medline; NIGMS NIH HHS [R01-GM48862] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA030490] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048862] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abdurashidova G, 2003, EMBO J, V22, P4294, DOI 10.1093/emboj/cdg404; Abdurashidova G, 1998, EMBO J, V17, P2961, DOI 10.1093/emboj/17.10.2961; Araki M, 2003, EMBO J, V22, P6115, DOI 10.1093/emboj/cdg573; Archambault V, 2004, MOL CELL, V14, P699, DOI 10.1016/j.molcel.2004.05.025; Asano M, 1999, EMBO J, V18, P2435, DOI 10.1093/emboj/18.9.2435; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Bowers JL, 2004, MOL CELL, V16, P967, DOI 10.1016/j.molcel.2004.11.038; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; Brown NR, 1999, NAT CELL BIOL, V1, P438, DOI 10.1038/15674; Callebaut I, 1999, FEBS LETT, V446, P189, DOI 10.1016/S0014-5793(99)00132-5; Calvi BR, 1998, GENE DEV, V12, P734, DOI 10.1101/gad.12.5.734; Carpenter PB, 1998, J BIOL CHEM, V273, P24891, DOI 10.1074/jbc.273.38.24891; Chesnokov I, 1999, GENE DEV, V13, P1289, DOI 10.1101/gad.13.10.1289; Chesnokov I, 2001, P NATL ACAD SCI USA, V98, P11997, DOI 10.1073/pnas.211342798; Chesnokov IN, 2003, P NATL ACAD SCI USA, V100, P9150, DOI 10.1073/pnas.1633580100; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; DePamphilis ML, 2005, CELL CYCLE, V4, P70, DOI 10.4161/cc.4.1.1333; Diffley JFX, 2004, CURR BIOL, V14, pR778, DOI 10.1016/j.cub.2004.09.019; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; Findeisen M, 1999, EUR J BIOCHEM, V264, P415, DOI 10.1046/j.1432-1327.1999.00613.x; Follette PJ, 1997, CURR OPIN GENET DEV, V7, P17, DOI 10.1016/S0959-437X(97)80104-9; Follette PJ, 1998, CURR BIOL, V8, P235, DOI 10.1016/S0960-9822(98)70089-2; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; Green BM, 2005, MOL BIOL CELL, V16, P421, DOI 10.1091/mbc.e04-09-0833; Hayashi S, 1996, DEVELOPMENT, V122, P1051; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; Hua XH, 1997, J CELL BIOL, V137, P183, DOI 10.1083/jcb.137.1.183; Hua XQH, 1998, J CELL BIOL, V140, P271, DOI 10.1083/jcb.140.2.271; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Itzhaki JE, 1997, NAT GENET, V15, P258, DOI 10.1038/ng0397-258; Klemm RD, 1997, CELL, V88, P493, DOI 10.1016/S0092-8674(00)81889-9; Lewis PW, 2004, GENE DEV, V18, P2929, DOI 10.1101/gad.1255204; Liu JY, 2000, MOL CELL, V6, P637, DOI 10.1016/S1097-2765(00)00062-9; Loog M, 2005, NATURE, V434, P104, DOI 10.1038/nature03329; Lygerou Z, 1999, J CELL SCI, V112, P3703; MacCoss MJ, 2002, P NATL ACAD SCI USA, V99, P7900, DOI 10.1073/pnas.122231399; Mailand N, 2005, CELL, V122, P915, DOI 10.1016/j.cell.2005.08.013; McNairn AJ, 2005, EXP CELL RES, V308, P345, DOI 10.1016/j.yexcr.2005.05.009; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; Melixetian M, 2004, J CELL BIOL, V165, P473, DOI 10.1083/jcb.200403106; Mendez J, 2002, MOL CELL, V9, P481, DOI 10.1016/S1097-2765(02)00467-7; Miller ME, 2001, J CELL SCI, V114, P1811; Miyata Y, 2004, MOL CELL BIOL, V24, P4065, DOI 10.1128/MCB.24.9.4065-4074.2004; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; Neuwald AF, 1999, GENOME RES, V9, P27; Nguyen VQ, 2001, NATURE, V411, P1068, DOI 10.1038/35082600; PAK D, 1996, DROSOPHILA MELANOGAS; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; Pelizon C, 2000, GENE DEV, V14, P2526, DOI 10.1101/gad.176300; Pinna LA, 2002, J CELL SCI, V115, P3873, DOI 10.1242/jcs.00074; Pinto S, 1999, NEURON, V23, P45, DOI 10.1016/S0896-6273(00)80752-7; Remus D, 2004, EMBO J, V23, P897, DOI 10.1038/sj.emboj.7600077; Rohrbough J, 1999, NEURON, V23, P55, DOI 10.1016/S0896-6273(00)80753-9; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Romanowski P, 2000, J BIOL CHEM, V275, P4239, DOI 10.1074/jbc.275.6.4239; Rowles A, 1999, J CELL SCI, V112, P2011; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Sarno S, 2001, FEBS LETT, V496, P44, DOI 10.1016/S0014-5793(01)02404-8; SAUER K, 1995, GENE DEV, V9, P1327, DOI 10.1101/gad.9.11.1327; Sugimoto N, 2004, J BIOL CHEM, V279, P19691, DOI 10.1074/jbc.M313175200; Tabb DL, 2002, J PROTEOME RES, V1, P21, DOI 10.1021/pr015504q; Thomer M, 2004, DEVELOPMENT, V131, P4807, DOI 10.1242/dev.01348; Tugal T, 1998, J BIOL CHEM, V273, P32421, DOI 10.1074/jbc.273.49.32421; Vas A, 2001, MOL CELL BIOL, V21, P5767, DOI 10.1128/MCB.21.17.5767-5777.2001; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Weiss A, 1998, CURR BIOL, V8, P239, DOI 10.1016/S0960-9822(98)70090-9; Wilmes GM, 2004, GENE DEV, V18, P981, DOI 10.1101/gad.1202304; Wuarin J, 2002, CELL, V111, P419, DOI 10.1016/S0092-8674(02)01042-5; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020; Zhu WG, 2004, MOL CELL BIOL, V24, P7140, DOI 10.1128/MCB.24.16.7140-7150.2004	72	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					39740	39751		10.1074/jbc.M508515200	http://dx.doi.org/10.1074/jbc.M508515200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16188887	hybrid			2022-12-25	WOS:000233461300011
J	Hizi, A; Levin, HL				Hizi, A; Levin, HL			The integrase of the long terminal repeat-retrotransposon Tf1 has a chromodomain that modulates integrase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1 REVERSE-TRANSCRIPTASE; SUBSTRATE-SPECIFICITY; HISTONE ACETYLATION; DNA INTEGRATION; TYPE-1; PROTEIN; TRANSPOSITION; MECHANISM; RNA	Chromodomains in a variety of proteins mediate the formation of heterochromatin by interacting directly with histone H3, DNA, or RNA. A diverse family of long terminal repeat (LTR)-retrotransposons possesses chromodomains in their integrases (IN), suggesting that the chromodomains may control integration. The LTR-retrotransposon Tf1 of Schizosaccharomyces pombe is highly active and possesses a chromodomain in the COOH terminus of its IN. To test this chromodomain for a role in integration, recombinant INs with and without the chromodomain were assayed for activity in in vitro reactions. The full-length IN had integration activity with oligonucleotide substrates that modeled both the insertion reaction and a reverse reaction known as disintegration. The INs of retroviruses possess an additional activity termed 3' processing that must remove 2-3 nucleotides from the 3' ends of the viral cDNA before insertion can occur. These additional nucleotides are added during reverse transcription because of the position of the minus strand primer downstream of the LTR. The position of the primer for Tf1 suggests no nucleotides are added 3' of the LTR. It was therefore surprising that Tf1 IN was capable of 3' cleavage. The most unexpected result reported here was that the IN lacking the chromodomain had significantly higher activity and substantially reduced substrate specificity. These results reveal that both the activity and specificity of enzymes can be modulated by their chromodomains.	NICHD, Sect Eukaryot Transposable Elements, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA; Tel Aviv Univ, Sackler Fac Med, Dept Cell & Dev Biol, IL-69978 Tel Aviv, Israel	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Tel Aviv University; Sackler Faculty of Medicine	Levin, HL (corresponding author), 18 Lib Dr,Rm 106, Bethesda, MD 20892 USA.	henry_levin@nih.gov		Levin, Henry/0000-0003-1728-118X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001009] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001009] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Asante-Appiah E, 1997, ANTIVIR RES, V36, P139, DOI 10.1016/S0166-3542(97)00046-6; Atwood A, 1998, J VIROL, V72, P1324, DOI 10.1128/JVI.72.2.1324-1333.1998; Atwood A, 1996, MOL CELL BIOL, V16, P338; Balakrishnan M, 1997, J VIROL, V71, P1025, DOI 10.1128/JVI.71.2.1025-1035.1997; Bannister AJ, 2004, METHOD ENZYMOL, V376, P269; BOEKE JD, 1988, RNA GENETICS, V2, P59; Brehm A, 2004, BIOESSAYS, V26, P133, DOI 10.1002/bies.10392; Brown P. O., 1997, P161; BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428; Chiu TK, 2004, CURR TOP MED CHEM, V4, P965, DOI 10.2174/1568026043388547; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; CRAIG NL, 1995, SCIENCE, V270, P253, DOI 10.1126/science.270.5234.253; Craigie R, 2001, J BIOL CHEM, V276, P23213, DOI 10.1074/jbc.R100027200; Craigie R, 2002, MOBILE DNA, P613; DONZELLA GA, 1993, J VIROL, V67, P7077, DOI 10.1128/JVI.67.12.7077-7087.1993; DOTAN I, 1995, J VIROL, V69, P456, DOI 10.1128/JVI.69.1.456-468.1995; EICHINGER DJ, 1990, GENE DEV, V4, P324, DOI 10.1101/gad.4.3.324; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Golinelli MP, 2002, BIOCHEMISTRY-US, V41, P5894, DOI 10.1021/bi0160415; Gorinsek B, 2004, MOL BIOL EVOL, V21, P781, DOI 10.1093/molbev/msh057; GRANDGENETT D, 1985, J BIOL CHEM, V260, P8243; Hampsey M, 2003, CELL, V113, P429, DOI 10.1016/S0092-8674(03)00360-X; Hindmarsh P, 1999, MICROBIOL MOL BIOL R, V63, P836, DOI 10.1128/MMBR.63.4.836-843.1999; Iizuka M, 2003, CURR OPIN GENET DEV, V13, P154, DOI 10.1016/S0959-437X(03)00020-0; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; KIRCHNER J, 1993, J VIROL, V67, P19, DOI 10.1128/JVI.67.1.19-28.1993; Kirchner J, 1996, J VIROL, V70, P4737, DOI 10.1128/JVI.70.7.4737-4747.1996; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; LEVIN HL, 1995, MOL CELL BIOL, V15, P3310; Levin HL, 1996, MOL CELL BIOL, V16, P5645; Levin HL, 1997, CELL, V88, P5, DOI 10.1016/S0092-8674(00)81851-6; Malik HS, 1999, J VIROL, V73, P5186, DOI 10.1128/JVI.73.6.5186-5190.1999; Miller MD, 1997, J VIROL, V71, P5382, DOI 10.1128/JVI.71.7.5382-5390.1997; MOORE SP, 1995, J VIROL, V69, P4683, DOI 10.1128/JVI.69.8.4683-4692.1995; Mules EH, 1998, J VIROL, V72, P6490, DOI 10.1128/JVI.72.8.6490-6503.1998; Nielsen PR, 2002, NATURE, V416, P103, DOI 10.1038/nature722; Oz I, 2002, BIOCHEM J, V361, P557, DOI 10.1042/0264-6021:3610557; PATEL PH, 1994, P NATL ACAD SCI USA, V91, P549, DOI 10.1073/pnas.91.2.549; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; Robyr D, 2004, METHOD ENZYMOL, V376, P289; Singleton TL, 2002, EUKARYOT CELL, V1, P44, DOI 10.1128/EC.01.1.44-55.2002; Skinner LM, 2001, J BIOL CHEM, V276, P114, DOI 10.1074/jbc.M007032200; TELENITSKY A, 1997, REVERSE TRANSCRIPTIO; Teysset L, 2003, J VIROL, V77, P5451, DOI 10.1128/JVI.77.9.5451-5463.2003; VANDENENT FMI, 1994, J VIROL, V68, P7825, DOI 10.1128/JVI.68.12.7825-7832.1994; VINCENT KA, 1993, J VIROL, V67, P425, DOI 10.1128/JVI.67.1.425-437.1993; VINK C, 1991, J VIROL, V65, P4636, DOI 10.1128/JVI.65.9.4636-4644.1991	47	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39086	39094		10.1074/jbc.M506363200	http://dx.doi.org/10.1074/jbc.M506363200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16188891	hybrid			2022-12-25	WOS:000233362200023
J	Li, XQ; Hansen, PA; Xi, L; Chandraratna, RAS; Burant, CF				Li, XQ; Hansen, PA; Xi, L; Chandraratna, RAS; Burant, CF			Distinct mechanisms of glucose lowering by specific agonists for peroxisomal proliferator activated receptor gamma and retinoic acid X receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED INSULIN-RESISTANCE; NUCLEAR FACTOR-3; FEMALE RATS; MICE; SENSITIVITY; METABOLISM; REXINOIDS; ALPHA; LIVER; HETERODIMERS	Agonists for the nuclear receptor peroxisomal proliferator-activated receptor-gamma (PPAR gamma) and its heterodimeric partner, retinoid X receptor (RXR), are effective agents for the treatment of type 2 diabetes. To gain insight into the antidiabetic action of these compounds, we treated female Zucker diabetic rats (ZFF) with AGN194204, which we show to be a homodimer-specific RXR agonist, or the PPAR gamma agonist, troglitazone. Hyperinsulinemic-euglycemic clamps in ZFF showed that troglitazone and AGN194204 reduced basal endogenous glucose production (EGP) similar to 30% and doubled the insulin suppression of EGP. AGN194204 had no effect on peripheral glucose utilization, whereas troglitazone increased insulin-stimulated glucose utilization by 50%, glucose uptake into skeletal muscle by 85%, and de novo skeletal muscle glycogen synthesis by 300%. Troglitazone increased skeletal muscle Irs-1 and phospho-Akt levels following in vivo insulin treatment, whereas AGN194204 increased hepatic Irs-2 and insulin stimulated phospho-Akt in liver. Gene profiles of AGN194204-treated mouse liver analyzed by Ingenuity Pathway Analysis identified increases in fatty acid synthetic genes, including Srebp-1 and fatty acid synthase, a pathway previously shown to be induced by RXR agonists. A network of down-regulated genes containing Foxa2, Foxa3, and G-protein subunits was identified, and decreases in these mRNA levels were confirmed by quantitative reverse transcription-PCR. Treatment of HepG2 cells with AGN194204 resulted in inhibition of glucagon-stimulated cAMP accumulation suggesting the G-protein down-regulation may provide an additional mechanism for hepatic insulin sensitization by RXR. These studies demonstrate distinct molecular events lead to insulin sensitization by high affinity RXR and PPAR gamma agonists.	Univ Michigan, Dept Internal Med, Div Endocrinol & Metab, Ann Arbor, MI 48109 USA; St Louis Univ, Dept Biochem & Cell Biol, St Louis, MO 63104 USA; Pfizer Global Res & Dev, Ann Arbor, MI 48105 USA; Vitae Pharmaceut, Retinoid Res, Irvine, CA 92612 USA	University of Michigan System; University of Michigan; Saint Louis University; Pfizer	Burant, CF (corresponding author), Univ Michigan, Dept Med, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	burantc@umich.edu	Burant, Charles/GPC-5690-2022	Burant, Charles/0000-0001-9189-5003				A IJ, 2004, EMBO J, V23, P2083; Beard RL, 1996, J MED CHEM, V39, P3556, DOI 10.1021/jm960386h; Bouscarel B, 1998, AM J PHYSIOL-GASTR L, V274, pG1151, DOI 10.1152/ajpgi.1998.274.6.G1151; Burant CF, 1997, J CLIN INVEST, V100, P2900, DOI 10.1172/JCI119839; Corsetti JP, 2000, ATHEROSCLEROSIS, V148, P231, DOI 10.1016/S0021-9150(99)00265-8; Davies PJA, 2001, MOL PHARMACOL, V59, P170, DOI 10.1124/mol.59.2.170; de la Lastra CA, 2004, CURR PHARM DESIGN, V10, P3505; Duvic M, 2001, ARCH DERMATOL, V137, P581; Haffner CD, 2004, J MED CHEM, V47, P2010, DOI 10.1021/jm030565g; Hevener A, 2002, DIABETES, V51, P1907, DOI 10.2337/diabetes.51.6.1907; JAMES DE, 1985, AM J PHYSIOL, V248, pE567, DOI 10.1152/ajpendo.1985.248.5.E567; Jiang GQ, 2003, AM J PHYSIOL-ENDOC M, V284, pE671, DOI 10.1152/ajpendo.00492.2002; Kaestner KH, 2000, TRENDS ENDOCRIN MET, V11, P281, DOI 10.1016/S1043-2760(00)00271-X; Koch SSC, 1999, J MED CHEM, V42, P742, DOI 10.1021/jm980621r; KREY G, 1995, MOL ENDOCRINOL, V9, P219, DOI 10.1210/me.9.2.219; Lenhard JM, 1999, DIABETOLOGIA, V42, P545, DOI 10.1007/s001250051193; Lin BC, 1997, BIOCHEMISTRY-US, V36, P14096, DOI 10.1021/bi9703249; Liu YL, 2000, INT J OBESITY, V24, P997, DOI 10.1038/sj.ijo.0801351; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210; Miyazaki Y, 2004, J CLIN ENDOCR METAB, V89, P4312, DOI 10.1210/jc.2004-0190; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Rigas JR, 2005, ONCOLOGIST, V10, P22, DOI 10.1634/theoncologist.10-1-22; SAAD MJA, 1994, MOL ENDOCRINOL, V8, P545, DOI 10.1210/me.8.5.545; Schulman IG, 1998, MOL CELL BIOL, V18, P3483, DOI 10.1128/MCB.18.6.3483; Shen Q, 2004, J BIOL CHEM, V279, P19721, DOI 10.1074/jbc.M311729200; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; Standeven AM, 2001, BIOCHEM PHARMACOL, V62, P1501, DOI 10.1016/S0006-2952(01)00803-6; Standeven AM, 1997, BIOCHEM PHARMACOL, V54, P517, DOI 10.1016/S0006-2952(97)00209-8; Stumvoll M, 2003, EXPERT OPIN INV DRUG, V12, P1179; SUGIYAMA Y, 1990, ARZNEIMITTEL-FORSCH, V40-1, P436; Tonelli J, 2004, DIABETES, V53, P1621, DOI 10.2337/diabetes.53.6.1621; Vasudevan Abu R, 2004, Diabetes Technol Ther, V6, P850, DOI 10.1089/dia.2004.6.850; Wang JC, 2000, J BIOL CHEM, V275, P14717, DOI 10.1074/jbc.275.19.14717; Wolfrum C, 2004, NATURE, V432, P1027, DOI 10.1038/nature03047; Ye JM, 2004, DIABETOLOGIA, V47, P1306, DOI 10.1007/s00125-004-1436-1; Yeagley D, 1998, J BIOL CHEM, V273, P18743, DOI 10.1074/jbc.273.30.18743	39	56	69	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38317	38327		10.1074/jbc.M505853200	http://dx.doi.org/10.1074/jbc.M505853200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16179348	hybrid			2022-12-25	WOS:000233239800027
J	Sandoval, FJ; Roje, S				Sandoval, FJ; Roje, S			An FMN hydrolase is fused to a riboflavin kinase homolog in plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLAVIN-ADENINE-DINUCLEOTIDE; WEIGHT ACID-PHOSPHATASE; RAT-LIVER; BACILLUS-SUBTILIS; FAD SYNTHETASE; SACCHAROMYCES-CEREVISIAE; SUBSTRATE-SPECIFICITY; PARTIAL-PURIFICATION; CRYSTAL-STRUCTURE; CONFORMATIONAL-CHANGES	Riboflavin kinases catalyze synthesis of FMN from riboflavin and ATP. These enzymes have to date been cloned from bacteria, yeast, and mammals, but not from plants. Bioinformatic approaches suggested that diverse plant species, including many angiosperms, two gymnosperms, a moss ( Physcomitrella patens), and a unicellular green alga ( Chlamydomonas reinhardtii), encode proteins that are homologous to riboflavin kinases of yeast and mammals, but contain an N-terminal domain that belongs to the haloacid dehalogenase superfamily of enzymes. The Arabidopsis homolog of these proteins was cloned by RT-PCR, and was shown to have riboflavin kinase and FMN hydrolase activities by characterizing the recombinant enzyme produced in Escherichia coli. Both activities of the purified recombinant Arabidopsis enzyme (AtFMN/FHy) increased when the enzyme assays contained 0.02% Tween 20. The FMN hydrolase activity of AtFMN/FHy greatly decreased when EDTA replaced Mg2+ in the assays, as expected for a member of the Mg2+-dependent haloacid dehalogenase family. The functional overexpression of the individual domains in E. coli establishes that the riboflavin kinase and FMN hydrolase activities reside, respectively, in the C-terminal (AtFMN) and N-terminal (AtFHy) domains of AtFMN/FHy. Biochemical characterization of AtFMN/FHy, AtFMN, and AtFHy shows that the riboflavin kinase and FMN hydrolase domains of AtFMN/FHy can be physically separated, with little change in their kinetic properties.	Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA	Washington State University	Roje, S (corresponding author), Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA.	sanja@wsu.edu		Roje, Sanja/0000-0002-6302-5382				[Anonymous], 2005, PHYLIP PHYLOGENY INF; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; Bafunno V, 2004, J BIOL CHEM, V279, P95, DOI 10.1074/jbc.M308230200; BALAKRISHNAN CV, 1977, EUR J BIOCHEM, V78, P95, DOI 10.1111/j.1432-1033.1977.tb11717.x; Barile M, 1997, EUR J BIOCHEM, V249, P777, DOI 10.1111/j.1432-1033.1997.00777.x; Bauer S, 2003, J MOL BIOL, V326, P1463, DOI 10.1016/S0022-2836(03)00059-7; BOWERSKOMRO DM, 1989, BIOCHEMISTRY-US, V28, P8439, DOI 10.1021/bi00447a025; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYRD JC, 1985, J BIOL CHEM, V260, P7474; CECCHINI G, 1979, J BIOL CHEM, V254, P7295; Clarebout G, 2001, ANTIMICROB AGENTS CH, V45, P2280, DOI 10.1128/AAC.45.8.2280-2286.2001; Efimov I, 1998, BIOCHEMISTRY-US, V37, P9716, DOI 10.1021/bi972817j; Fischer M, 2004, J BIOL CHEM, V279, P36299, DOI 10.1074/jbc.M404406200; Foraker AB, 2003, ADV DRUG DELIVER REV, V55, P1467, DOI 10.1016/j.addr.2003.07.005; Forster C, 2001, APPL MICROBIOL BIOT, V55, P85, DOI 10.1007/s002530000483; FUCHS KR, 1992, BIOCHEM BIOPH RES CO, V189, P1598, DOI 10.1016/0006-291X(92)90259-N; Garcia NAT, 2004, PLANT PHYSIOL BIOCH, V42, P585, DOI 10.1016/j.plaphy.2004.04.004; GIRI KV, 1957, NATURE, V179, P1134, DOI 10.1038/1791134b0; GIRI KV, 1960, BIOCHEM J, V75, P381, DOI 10.1042/bj0750381; Granjeiro JM, 1997, BIOCHEM MOL BIOL INT, V41, P1201; Herz S, 2000, PHYTOCHEMISTRY, V53, P723, DOI 10.1016/S0031-9422(00)00013-3; Jordan DB, 1999, J BIOL CHEM, V274, P22114, DOI 10.1074/jbc.274.31.22114; Karthikeyan S, 2003, BIOCHEMISTRY-US, V42, P12532, DOI 10.1021/bi035450t; Karthikeyan S, 2003, STRUCTURE, V11, P265, DOI 10.1016/S0969-2126(03)00024-8; KOONIN EV, 1994, J MOL BIOL, V244, P125, DOI 10.1006/jmbi.1994.1711; KORNBERG A, 1950, J BIOL CHEM, V186, P763; KUMAR SA, 1965, ARCH BIOCHEM BIOPHYS, V111, P646, DOI 10.1016/0003-9861(65)90246-8; Lahiri SD, 2004, BIOCHEMISTRY-US, V43, P2812, DOI 10.1021/bi0356810; Lahiri SD, 2002, BIOCHEMISTRY-US, V41, P8351, DOI 10.1021/bi0202373; LEE RSF, 1988, J BIOL CHEM, V263, P14878; Lopez-Millan AF, 2000, PLANT PHYSIOL, V124, P885, DOI 10.1104/pp.124.2.885; Mack M, 1998, J BACTERIOL, V180, P950, DOI 10.1128/JB.180.4.950-955.1998; MANSTEIN DJ, 1986, J BIOL CHEM, V261, P6169; Mayhew S G, 1980, Methods Enzymol, V66, P323; MERRILL AH, 1980, J BIOL CHEM, V255, P1335; Meyer S. L., 1975, DATA ANAL SCI ENG, P39; MITSUDA H, 1970, J VITAMINOL, V16, P52, DOI 10.5925/jnsv1954.16.52; MITSUDA H, 1965, J VITAMINOL, V11, P20, DOI 10.5925/jnsv1954.11.20; MITSUDA H, 1970, J VITAMINOL, V16, P31; NAKANO H, 1991, J BIOL CHEM, V266, P22125; OKA M, 1987, J BIOL CHEM, V262, P7418; Peisach E, 2004, BIOCHEMISTRY-US, V43, P12770, DOI 10.1021/bi0490688; PERL M, 1976, J BIOL CHEM, V251, P3221; RAVINDRANATH SD, 1969, ARCH BIOCHEM BIOPHYS, V133, P54, DOI 10.1016/0003-9861(69)90487-1; SADASIVAM S, 1966, ENZYMOLOGIA, V31, P203; Santos MA, 2000, J BIOL CHEM, V275, P28618, DOI 10.1074/jbc.M004621200; Selengut JD, 2001, BIOCHEMISTRY-US, V40, P12704, DOI 10.1021/bi011405e; SENSABAUGH GF, 1978, AM J HUM GENET, V30, P553; SHIN H, 1988, ARCH BIOCHEM BIOPHYS, V267, P95, DOI 10.1016/0003-9861(88)90012-4; SOBHANADITYA J, 1981, BIOCHEM J, V197, P227, DOI 10.1042/bj1970227; Solovieva IM, 1999, MICROBIOL-SGM, V145, P67, DOI 10.1099/13500872-145-1-67; Stahmann KP, 2000, APPL MICROBIOL BIOT, V53, P509, DOI 10.1007/s002530051649; SUSIN S, 1993, J BIOL CHEM, V268, P20958; TAGA EM, 1982, ARCH BIOCHEM BIOPHYS, V214, P505, DOI 10.1016/0003-9861(82)90054-6; Tzagoloff A, 1996, J BIOL CHEM, V271, P7392, DOI 10.1074/jbc.271.13.7392; Varsanyi M, 2004, J BIOL CHEM, V279, P3370, DOI 10.1074/jbc.M307783200; WU M, 1995, MOL CELL BIOL, V15, P264, DOI 10.1128/MCB.15.1.264; YAMADA Y, 1990, ARCH BIOCHEM BIOPHYS, V278, P125, DOI 10.1016/0003-9861(90)90240-Y; ZHANG ZY, 1990, ARCH BIOCHEM BIOPHYS, V282, P39, DOI 10.1016/0003-9861(90)90084-C	59	42	46	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38337	38345		10.1074/jbc.M500350200	http://dx.doi.org/10.1074/jbc.M500350200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16183635	hybrid			2022-12-25	WOS:000233239800029
J	LaRonde-LeBlanc, N; Wlodawer, A				LaRonde-LeBlanc, N; Wlodawer, A			A family portrait of the RIO kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							PRE-RIBOSOMAL-RNA; PROTEIN-KINASE; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; WINGED-HELIX; FULGIDUS RIO2; GENE; PATTERNS; BACTERIA; SUBUNIT	The RIO family of atypical serine protein kinases has been first characterized only recently. It consists of enzymes that contain a unique domain with a characteristic kinase sequence motif and usually some additional domains. At least two RIO proteins, Rio1 and Rio2, are present in organisms varying from Archaea to humans, with a third Rio3 subfamily present only in multicellular eukaryotes. Yeast Rio1 and Rio2 proteins have been implicated in the processing of 20 S pre-rRNA and are necessary for survival of the cells. Crystal structures of Archaeoglobus fulgidus Rio1 and Rio2 have shown that whereas the overall fold of these enzymes resembles typical protein kinases, some of the structural domains, particularly those involved in peptide substrate binding, are not present. The mode of binding of nucleotides also differs from that found in typical protein kinases. Although it has been shown that both Rio1 and Rio2 have the enzymatic activity of kinases and are capable of autophosphorylation, the biological substrates of RIO proteins and their full biological role still remain to be discovered.	NCI, Prot Struct Sect, MCL, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wlodawer, A (corresponding author), NCI, Prot Struct Sect, MCL, NIH, Bldg 536,Rm 5, Frederick, MD 21702 USA.	wlodawer@ncifcrf.gov	LaRonde-LeBlanc, Nicole A/C-3399-2009	LaRonde-LeBlanc, Nicole A/0000-0002-2778-8358	NATIONAL CANCER INSTITUTE [Z01BC010348, ZIABC010348] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Anaya P, 1998, GENE, V211, P323, DOI 10.1016/S0378-1119(98)00115-2; Angermayr M, 2002, FEBS LETT, V524, P31, DOI 10.1016/S0014-5793(02)02993-9; Angermayr M, 2002, MOL MICROBIOL, V44, P309, DOI 10.1046/j.1365-2958.2002.02881.x; Angermayr M, 1997, J BIOL CHEM, V272, P31630, DOI 10.1074/jbc.272.50.31630; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Cohen MS, 2005, SCIENCE, V308, P1318, DOI 10.1126/science1108367; Gajiwala KS, 2000, NATURE, V403, P916, DOI 10.1038/35002634; Gajiwala KS, 2000, CURR OPIN STRUC BIOL, V10, P110, DOI 10.1016/S0959-440X(99)00057-3; Geerlings TH, 2003, J BIOL CHEM, V278, P22537, DOI 10.1074/jbc.M300759200; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Krupa A, 2002, PROTEIN SCI, V11, P1580, DOI 10.1110/ps.3560102; LaRonde-LeBlanc N, 2005, FEBS J, V272, P3698, DOI 10.1111/j.1742-4658.2005.04796.x; LaRonde-LeBlanc N, 2005, FEBS J, V272, P2800, DOI 10.1111/j.1742-4658.2005.04702.x; LaRonde-LeBlanc N, 2004, STRUCTURE, V12, P1585, DOI 10.1016/j.str.2004.06.016; Leonard CJ, 1998, GENOME RES, V8, P1038, DOI 10.1101/gr.8.10.1038; Line A, 2002, CANCER IMMUNOL IMMUN, V51, P574, DOI 10.1007/s00262-002-0322-2; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Roesch A, 2003, MELANOMA RES, V13, P503, DOI 10.1097/00008390-200310000-00009; Schafer T, 2003, EMBO J, V22, P1370, DOI 10.1093/emboj/cdg121; Skamnaki VT, 1999, BIOCHEMISTRY-US, V38, P14718, DOI 10.1021/bi991454f; Stephens P, 2005, NAT GENET, V37, P590, DOI 10.1038/ng1571; Vanrobays E, 2003, MOL CELL BIOL, V23, P2083, DOI 10.1128/MCB.23.6.2083-2095.2003; Vanrobays E, 2001, EMBO J, V20, P4204, DOI 10.1093/emboj/20.15.4204; Wolberger C, 2000, NAT STRUCT BIOL, V7, P261, DOI 10.1038/74004; XU RM, 1995, EMBO J, V14, P1015, DOI 10.1002/j.1460-2075.1995.tb07082.x; Yoshioka K, 2004, MOL CELLS, V17, P223; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	28	78	80	4	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37297	37300		10.1074/jbc.R500013200	http://dx.doi.org/10.1074/jbc.R500013200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16183636	hybrid			2022-12-25	WOS:000233044500002
J	Sugano, M; Tsuchida, K; Hata, T; Makino, N				Sugano, M; Tsuchida, K; Hata, T; Makino, N			RNA interference targeting SHP-1 attenuates myocardial infarction in rats	FASEB JOURNAL			English	Article						siRNA; apoptosis; gene therapy	PROTEIN-TYROSINE-PHOSPHATASE; GENE-EXPRESSION; MEDIATED APOPTOSIS; ISCHEMIA; MYOCYTES; ISCHEMIA/REPERFUSION; REPERFUSION; INHIBITION; ACTIVATION; DELIVERY	The Src homology domain 2 (SH2)-containing tyrosine phosphatase- 1 (SHP-1) plays a key role in apoptosis and decreases phosphorylation of Akt. Apoptosis of cardiomyocytes is thought to contribute to the increased area of acute myocardial infarction ( AMI), and Akt activation exerts a powerful cardioprotective effect after ischemia. Thus, a therapeutic strategy designed to inhibit expression of SHP-1 would be beneficial in AMI. Here we report that siRNA targeting SHP-1 reduced infarct size in a rat model of AMI. Upon injection into the ischemic left ventricular wall, the vector-based siRNA significantly suppressed the increase in the SHP-1 mRNA and the SHP-1 protein levels. The siRNA vector also significantly reduced the SHP-1 that bound to Fas-R. The SHP-1 siRNA vector increased phospho-Akt and reduced DNA fragmentation and caspase activity compared with the scramble siRNA vector. Finally, the area of myocardial infarction was significantly smaller with the SHP-1 siRNA vector than with the scramble siRNA vector at 2 days after LCA ligation. In conclusion, SHP-1 in the heart increased from the early stage of AMI, and this increase was thought to contribute to the increased area of myocardial infarction. Suppression of SHP-1 with the SHP-1 siRNA vector markedly reduced the infarct size in AMI.	Kyushu Univ, Dept Mol & Cellular Biol, Div Mol & Clin Gerontol, Med Inst Bioregulat, Beppu, Oita 8740838, Japan	Kyushu University	Sugano, M (corresponding author), Kyushu Univ, Dept Mol & Cellular Biol, Div Mol & Clin Gerontol, Med Inst Bioregulat, 4546 Tsurumihara, Beppu, Oita 8740838, Japan.	massy@tsurumi.beppu.kyushu-u.ac.jp						Black SC, 1998, J MOL CELL CARDIOL, V30, P733, DOI 10.1006/jmcc.1998.0660; Bousquet C, 1998, J BIOL CHEM, V273, P7099, DOI 10.1074/jbc.273.12.7099; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bryant D, 1998, CIRCULATION, V97, P1375, DOI 10.1161/01.CIR.97.14.1375; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; Cuevas B, 1999, J BIOL CHEM, V274, P27583, DOI 10.1074/jbc.274.39.27583; Cui TX, 2001, CARDIOVASC RES, V49, P863, DOI 10.1016/S0008-6363(00)00299-6; Daigle I, 2002, NAT MED, V8, P61, DOI 10.1038/nm0102-61; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Guo DQ, 2000, J BIOL CHEM, V275, P11216, DOI 10.1074/jbc.275.15.11216; Haque SJ, 1998, J BIOL CHEM, V273, P33893, DOI 10.1074/jbc.273.51.33893; Kajstura J, 1996, LAB INVEST, V74, P86; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Lee P, 2003, AM J PHYSIOL-HEART C, V284, pH456, DOI 10.1152/ajpheart.00777.2002; Lewis DL, 2002, NAT GENET, V32, P107, DOI 10.1038/ng944; Mangi AA, 2003, NAT MED, V9, P1195, DOI 10.1038/nm912; Matsui T, 2001, CIRCULATION, V104, P330; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Mizuno K, 2002, J IMMUNOL, V169, P778, DOI 10.4049/jimmunol.169.2.778; Nakagami H, 2002, ARTERIOSCL THROM VAS, V22, P238, DOI 10.1161/hq0202.104001; Song W, 2000, CARDIOVASC RES, V45, P595, DOI 10.1016/S0008-6363(99)00395-8; Stephanou A, 2001, J BIOL CHEM, V276, P28340, DOI 10.1074/jbc.M101177200; SU X, 1995, IMMUNITY, V2, P353, DOI 10.1016/1074-7613(95)90143-4; Sugano M, 2002, FASEB J, V16, P1421, DOI 10.1096/fj.01-0894fje; Takeshita S, 1996, LAB INVEST, V74, P1061; TANAKA M, 1994, CIRC RES, V75, P426, DOI 10.1161/01.RES.75.3.426; Thangaraju M, 1999, J BIOL CHEM, V274, P29549, DOI 10.1074/jbc.274.41.29549; Wishcamper CA, 2003, BRAIN RES, V974, P88, DOI 10.1016/S0006-8993(03)02564-2; Yamaoka M, 2000, J MOL CELL CARDIOL, V32, P881, DOI 10.1006/jmcc.2000.1132; Yaoita H, 1998, CIRCULATION, V97, P276, DOI 10.1161/01.CIR.97.3.276; Yoshida H, 2000, HYPERTENSION, V35, P25, DOI 10.1161/01.HYP.35.1.25	34	32	35	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2054	+		10.1096/fj.05-4020fje	http://dx.doi.org/10.1096/fj.05-4020fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16223786				2022-12-25	WOS:000232991100018
J	Chau, JFL; Lee, MK; Law, JWS; Chung, SK; Chung, SSM				Chau, JFL; Lee, MK; Law, JWS; Chung, SK; Chung, SSM			Sodium/myo-inositol cotransporter-1 is essential for the development and function of the peripheral nerves	FASEB JOURNAL			English	Article						SMIT; neuropathy; respiration; neonatal lethality	DIABETIC NEUROPATHY; CONDUCTION-VELOCITY; SYNAPSE FORMATION; XENOPUS-OOCYTES; MYO-INOSITOL; MYOINOSITOL; EXPRESSION; GLUCOSE; CELLS; MICE	Sodium/myo- inositol cotransporter-1 (SMIT-1) is one of the transporters responsible for importing myo-inositol (MI) into the cells. MI is a precursor for a family of signal transduction molecules, phosphatidylinositol, and its derivatives that regulates many cellular functions. SMIT-1 null mice died soon after birth due to respiratory failure, but neonatal lethality was prevented by prenatal maternal MI supplement. Although the lung air sacs were closed, lung development was not significantly affected in the SMIT-1 null mice. The development of the peripheral nerves, including the brachial plexus, facial, vagus, and intercostal nerves, and the phrenic nerve that innervates the diaphragm was severely affected. All of these peripheral nerve abnormalities were corrected by prenatal MI supplement, indicating that MI is essential for the development of peripheral nerve and that neonatal lethality of the SMIT-1 knockout mice is most likely due to abnormal development of the nerves that control breathing. In the adult SMIT-1 deficient mice rescued by MI supplement, MI content in their brain, kidney, skeletal muscle, liver, and sciatic nerve was greatly reduced. The sciatic nerve, in particular, was most dependent on SMIT-1 for the accumulation of MI, and nerve conduction velocity and protein kinase C activity in this tissue were significantly reduced by SMIT-1 deficiency.	Univ Hong Kong, Inst Mol Biol, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong	Chung, SSM (corresponding author), Univ Hong Kong, Inst Mol Biol, 8-F Kadoorie Biol Sci Bldg Pokfulam, Hong Kong, Hong Kong, Peoples R China.	skchung@hkucc.hku.hk; smchung@hkucc.hku.hk						BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; Berry GT, 2003, J BIOL CHEM, V278, P18297, DOI 10.1074/jbc.M213176200; Berry GT, 1999, J PEDIATR-US, V135, P94, DOI 10.1016/S0022-3476(99)70334-3; Chauvin TR, 2004, BIOL REPROD, V70, P744, DOI 10.1095/biolreprod.103.022731; Coady MJ, 2002, J BIOL CHEM, V277, P35219, DOI 10.1074/jbc.M204321200; DYCK PJ, 1988, NEW ENGL J MED, V319, P542, DOI 10.1056/NEJM198809013190904; EAGLE H, 1957, J BIOL CHEM, V226, P191; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; GARCIAPEREZ A, 1991, PHYSIOL REV, V71, P1081, DOI 10.1152/physrev.1991.71.4.1081; GREENE DA, 1988, DIABETES, V37, P688, DOI 10.2337/diabetes.37.6.688; GREENE DA, 1975, J CLIN INVEST, V55, P1326, DOI 10.1172/JCI108052; Guo W, 1997, MOL BRAIN RES, V51, P91, DOI 10.1016/S0169-328X(97)00220-9; HAGER K, 1995, J MEMBRANE BIOL, V143, P103; Hamilton JW, 1944, J NUTR, V27, P213, DOI 10.1093/jn/27.3.213; Handler JS, 1996, KIDNEY INT, V49, P1682, DOI 10.1038/ki.1996.246; HITOMI K, 1994, BBA-BIOMEMBRANES, V1190, P469, DOI 10.1016/0005-2736(94)90110-4; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; KNIPPER M, 1993, NEUROREPORT, V4, P483, DOI 10.1097/00001756-199305000-00005; Lin WC, 2000, P NATL ACAD SCI USA, V97, P1299, DOI 10.1073/pnas.97.3.1299; Matskevitch J, 1998, PFLUG ARCH EUR J PHY, V436, P854, DOI 10.1007/s004240050714; Misgeld T, 2002, NEURON, V36, P635, DOI 10.1016/S0896-6273(02)01020-6; NOAKES PG, 1993, DEV BIOL, V155, P275, DOI 10.1006/dbio.1993.1025; Poppe R, 1997, J NEUROCHEM, V69, P84, DOI 10.1046/j.1471-4159.1997.69010084.x; PRPIC V, 1982, J BIOL CHEM, V257, P1315; Sima AAF, 1997, DIABETES, V46, P301, DOI 10.2337/diabetes.46.2.301; Song ZT, 2003, MOL CELL NEUROSCI, V23, P638, DOI 10.1016/S1044-7431(03)00096-4; Takei K, 1998, SCIENCE, V282, P1705, DOI 10.1126/science.282.5394.1705; Uldry M, 2001, EMBO J, V20, P4467, DOI 10.1093/emboj/20.16.4467; WILLIAMSON JR, 1985, AM J PHYSIOL, V248, pC203, DOI 10.1152/ajpcell.1985.248.3.C203; Wright EM, 2004, PFLUG ARCH EUR J PHY, V447, P510, DOI 10.1007/s00424-003-1063-6	30	49	50	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2005	19	11					1887	+		10.1096/fj.05-4192fje	http://dx.doi.org/10.1096/fj.05-4192fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16174787				2022-12-25	WOS:000232315700008
J	Xu, ZH; Sproul, A; Wang, WY; Kukekov, N; Greene, LA				Xu, ZH; Sproul, A; Wang, WY; Kukekov, N; Greene, LA			Siah1 interacts with the scaffold protein POSH to promote JNK activation and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; C-JUN; MAMMALIAN HOMOLOGS; NEURONAL APOPTOSIS; TUMOR SUPPRESSION; UBIQUITIN LIGASE; CEP-1347 KT7515; MAP KINASES; CELL-DEATH; SINA GENE	Siah proteins are ubiquitin-protein isopeptide ligases (E3) that have been implicated in a variety of cellular actions, including promotion of apoptotic death. Here, we show that Siah1 is a binding partner for POSH (plenty of SH3s), a scaffold component of the apoptotic JNK pathway, and that Siah contributes to death of neurons and other cell types by activating the JNK pathway. Such proapoptotic activity requires the E3 ligase activity of Siah1. Moreover, apoptotic stimuli markedly elevate cellular Siah1 levels by a mechanism reliant on Siah1 protein stabilization. This stabilization requires JNK pathway activation and interaction with POSH and is enhanced by phosphorylation of SIAH1 at tyrosines 100 and 126. Depletion of intracellular Siah proteins via small interference RNA partially protects cells from death evoked by apoptotic stimuli such as trophic factor deprivation and DNA damage. These findings thus reveal a "loop" mechanism in which the JNK pathway promotes SIAH1 stabilization and in which SIAH1 in turn activates the JNK pathway and, ultimately, contributes to cell death.	Columbia Univ, Dept Pathol, New York, NY 10032 USA; Columbia Univ, Ctr Neurobiol & Behav, New York, NY 10032 USA; Columbia Univ, Dept Biol Sci, Coll Phys & Surg, New York, NY 10032 USA; Chinese Acad Sci, Inst Genet & Dev Biol, Key Lab Mol & Dev Biol, Beijing 100080, Peoples R China	Columbia University; Columbia University; Columbia University; Chinese Academy of Sciences; Institute of Genetics & Developmental Biology, CAS	Xu, ZH (corresponding author), Columbia Univ, Dept Pathol, P&S 15-401,630 W 168th St, New York, NY 10032 USA.	zhxu@genetics.ac.cn		Wang, Wenyi/0000-0003-0617-9438; Xu, Zhiheng/0000-0002-4809-2851; Sproul, Andrew/0000-0001-6972-1592				Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; Bazenet CE, 1998, P NATL ACAD SCI USA, V95, P3984, DOI 10.1073/pnas.95.7.3984; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Boehm J, 2001, EMBO J, V20, P4153, DOI 10.1093/emboj/20.15.4153; Bossy-Wetzel E, 2004, NAT MED, V10, pS2, DOI 10.1038/nm1067; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; DELLA NG, 1993, DEVELOPMENT, V117, P1333; Dunn C, 2002, CELL SIGNAL, V14, P585, DOI 10.1016/S0898-6568(01)00275-3; Frew IJ, 2002, MOL CELL BIOL, V22, P8155, DOI 10.1128/MCB.22.23.8155-8164.2002; Ham J, 2000, BIOCHEM PHARMACOL, V60, P1015, DOI 10.1016/S0006-2952(00)00372-5; Hara MR, 2005, NAT CELL BIOL, V7, P665, DOI 10.1038/ncb1268; House CM, 2003, P NATL ACAD SCI USA, V100, P3101, DOI 10.1073/pnas.0534783100; Hu G, 1999, MOL CELL BIOL, V19, P724; Hu G, 1997, GENOMICS, V46, P103, DOI 10.1006/geno.1997.4997; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; Kim CJ, 2004, ONCOGENE, V23, P8591, DOI 10.1038/sj.onc.1208113; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Maroney AC, 1999, J NEUROCHEM, V73, P1901; Maroney AC, 2001, J BIOL CHEM, V276, P25302, DOI 10.1074/jbc.M011601200; Matsuo K, 2003, GENE CHROMOSOME CANC, V36, P283, DOI 10.1002/gcc.10170; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; Merritt SE, 1999, J BIOL CHEM, V274, P10195, DOI 10.1074/jbc.274.15.10195; Nakayama K, 2004, CELL, V117, P941, DOI 10.1016/j.cell.2004.06.001; Nemani M, 1996, P NATL ACAD SCI USA, V93, P9039, DOI 10.1073/pnas.93.17.9039; Polekhina G, 2002, NAT STRUCT BIOL, V9, P68, DOI 10.1038/nsb743; Relaix F, 2000, P NATL ACAD SCI USA, V97, P2105, DOI 10.1073/pnas.040378897; Roperch JP, 1999, P NATL ACAD SCI USA, V96, P8070, DOI 10.1073/pnas.96.14.8070; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; Tiedt R, 2001, EMBO J, V20, P4143, DOI 10.1093/emboj/20.15.4143; Tuynder M, 2002, P NATL ACAD SCI USA, V99, P14976, DOI 10.1073/pnas.222470799; Wheeler TC, 2002, J BIOL CHEM, V277, P10273, DOI 10.1074/jbc.M107857200; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu ZH, 2005, MOL CELL BIOL, V25, P9949, DOI 10.1128/MCB.25.22.9949-9959.2005; Xu ZH, 2003, EMBO J, V22, P252, DOI 10.1093/emboj/cdg021; Xu ZH, 2001, MOL CELL BIOL, V21, P4713, DOI 10.1128/MCB.21.14.4713-4724.2001	40	57	61	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					303	312		10.1074/jbc.M509060200	http://dx.doi.org/10.1074/jbc.M509060200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16230351	hybrid			2022-12-25	WOS:000234307200039
J	Chung, CC; Hernandez-Guzman, FG; Luo, W; Wang, XH; Ferrone, S; Ghosh, D				Chung, CC; Hernandez-Guzman, FG; Luo, W; Wang, XH; Ferrone, S; Ghosh, D			Structural basis of antigen mimicry in a clinically relevant melanoma antigen system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY MK2-23; CHONDROITIN SULFATE PROTEOGLYCAN; MOLECULAR MIMICRY; MALIGNANT-MELANOMA; VIRAL MIMICRY; HMW-MAA; IMMUNOGENICITY; AUTOIMMUNITY; PROTEIN; IMMUNOGLOBULINS	Although mimics of human tumor antigens are effective immunogens to overcome host unresponsiveness to the nominal antigen, the structural basis of this mimicry remains poorly defined. Therefore, in this study we have characterized the structural basis of the human high molecular weight-melanoma-associated antigen (HMW-MAA) mimicry by the mouse anti-idiotypic (anti- id) monoclonal antibody (mAb) MK2-23. Using x-ray crystallography, we have characterized the three-dimensional structure of the anti- id mAb MK2-23 Fab' and shown that its heavy chain complementarity-determining region (CDR3) (H3) and its light chain CDR1 (L1) are closely associated. These moieties are the source of HMW-MAA mimicry, since they display partial amino acid sequence homology along with a similar structural fold with the HMW-MAA core protein. Furthermore, a 15-residue peptide comprising the H3 loop of anti-id mAb MK2-23 demonstrates HMW-MAA-like in vitro and in vivo reactivity. This peptide in conjunction with the structural data will facilitate the characterization of the effect of the degree of antigen mimicry on the induction of a self-antigen-specific immune response by a mimic.	Roswell Pk Canc Inst, Dept Immunol, Buffalo, NY 14263 USA; Roswell Pk Canc Inst, Dept Pharm & Therapeut, Buffalo, NY 14263 USA; Hauptman Woodward Med Res Inst Inc, Buffalo, NY 14203 USA	Roswell Park Cancer Institute; Roswell Park Cancer Institute; Hauptman Woodward Medical Research Institute	Ferrone, S (corresponding author), Roswell Pk Canc Inst, Dept Immunol, Elm & Carlton St, Buffalo, NY 14263 USA.	soldano.ferrone@roswellpark.org; ghosh@hwi.buffalo.edu			NATIONAL CANCER INSTITUTE [R01CA105500, P01CA089480] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA89480, R01 CA105500] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcami A, 2003, NAT REV IMMUNOL, V3, P36, DOI 10.1038/nri980; AlLazikani B, 1997, J MOL BIOL, V273, P927, DOI 10.1006/jmbi.1997.1354; Ang CW, 2004, TRENDS IMMUNOL, V25, P61, DOI 10.1016/j.it.2003.12.004; BAN N, 1994, P NATL ACAD SCI USA, V91, P1604, DOI 10.1073/pnas.91.5.1604; Bernet J, 2003, J BIOSCIENCES, V28, P249, DOI 10.1007/BF02970145; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; Campoli MR, 2004, CRIT REV IMMUNOL, V24, P267, DOI 10.1615/CritRevImmunol.v24.i4.40; CHEN ZJ, 1991, J IMMUNOL, V147, P1082; CHEN ZJ, 1993, CANCER RES, V53, P112; Chikuma S, 2003, IMMUNOL RES, V28, P241, DOI 10.1385/IR:28:3:241; Diers-Fenger M, 2001, GLIA, V34, P213, DOI 10.1002/glia.1055; FIELDS BA, 1995, NATURE, V374, P739, DOI 10.1038/374739a0; GIACOMINI P, 1983, CANCER RES, V43, P3586; KUSAMA M, 1989, J IMMUNOL, V143, P3844; Luo W, 2005, J IMMUNOL, V174, P7104, DOI 10.4049/jimmunol.174.11.7104; Luo Wei, 2005, Cancer Chemother Biol Response Modif, V22, P769; Mamula MJ, 1999, J BIOL CHEM, V274, P22321, DOI 10.1074/jbc.274.32.22321; McClain MT, 2005, NAT MED, V11, P85, DOI 10.1038/nm1167; McGuire KL, 2005, TRENDS IMMUNOL, V26, P367, DOI 10.1016/j.it.2005.05.001; MITTELMAN A, 1992, P NATL ACAD SCI USA, V89, P466, DOI 10.1073/pnas.89.2.466; MITTELMAN A, 1994, CANCER RES, V54, P415; Mittelman A, 1995, CLIN CANCER RES, V1, P705; Morea V, 1998, J MOL BIOL, V275, P269, DOI 10.1006/jmbi.1997.1442; Pluschke G, 1996, P NATL ACAD SCI USA, V93, P9710, DOI 10.1073/pnas.93.18.9710; SCHLINGEMANN RO, 1990, AM J PATHOL, V136, P1393; Staub E, 2002, FEBS LETT, V527, P114, DOI 10.1016/S0014-5793(02)03195-2; TEMPONI M, 1992, CANCER RES, V52, P2497; TEMPONI M, 1989, HYBRIDOMA, V8, P85, DOI 10.1089/hyb.1989.8.85; von Boehmer H, 2005, NAT IMMUNOL, V6, P338, DOI 10.1038/ni1180; Wang X, 2001, Cancer Chemother Biol Response Modif, V19, P309; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8	32	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41546	41552		10.1074/jbc.M504562200	http://dx.doi.org/10.1074/jbc.M504562200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16227204	hybrid			2022-12-25	WOS:000233866900054
J	Gamage, NU; Tsvetanov, S; Duggleby, RG; McManus, ME; Martin, JL				Gamage, NU; Tsvetanov, S; Duggleby, RG; McManus, ME; Martin, JL			The structure of human SULT1A1 crystallized with estradiol - An insight into active site plasticity and substrate inhibition with multi-ring substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC SULFOTRANSFERASES; ESTROGEN SULFOTRANSFERASE; PHENOL SULFOTRANSFERASES; ARYL SULFOTRANSFERASE; BREAST-CANCER; SULFATION; ENZYME; BIOACTIVATION; POLYMORPHISM; SPECIFICITY	Human SULT1A1 belongs to the supergene family of sulfotransferases (SULTs) involved in the sulfonation of xeno- and endobiotics. The enzyme is also one of the SULTs responsible for metabolic activation of mutagenic and carcinogenic compounds and therefore is implicated in various cancer forms. Further, it is not well understood how substrate inhibition takes place with rigid fused multiring substrates such as 17 beta-estradiol (E2) at high substrate concentrations when subcellular fractions or recombinant enzymes are used. To investigate how estradiol binds to SULT1A1, we co-crystallized SULT1A1 with sulfated estradiol and the cofactor product, PAP (3'-phosphoadenosine 5'-phosphate). The crystal structure of SULT1A1 that we present here has PAP and one molecule of E2 bound in a nonproductive mode in the active site. The structure reveals how the SULT1A1 binding site undergoes conformational changes to accept fused ring substrates such as steroids. In agreement with previous reports, the enzyme shows partial substrate inhibition at high concentrations of E2. A model to explain these kinetics is developed based on the formation of an enzyme(.)PAP(.)E2 dead-end complex during catalysis. This model provides a very good quantitative description of the rate versus the [ E2] curve. This dead-end complex is proposed to be that described by the observed structure, where E2 is bound in a nonproductive mode.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Mol & Microbial Sci, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland; University of Queensland	Martin, JL (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	j.martin@imb.uq.edu.au	Martin, Jennifer L./A-6039-2010	Martin, Jennifer L./0000-0002-9225-8863				Banoglu E, 2000, CURR DRUG METAB, V1, P1, DOI 10.2174/1389200003339234; Barnett AC, 2004, J BIOL CHEM, V279, P18799, DOI 10.1074/jbc.M312253200; BEDFORD CT, 1995, BIOORGAN MED CHEM, V3, P167, DOI 10.1016/0968-0896(95)00015-9; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bidwell LM, 1999, J MOL BIOL, V293, P521, DOI 10.1006/jmbi.1999.3153; Blanchard RL, 2004, PHARMACOGENETICS, V14, P199, DOI 10.1097/00008571-200403000-00009; Brix LA, 1999, BIOCHEM J, V337, P337, DOI 10.1042/0264-6021:3370337; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHOU HC, 1995, CANCER RES, V55, P525; DUFFEL MW, 1981, J BIOL CHEM, V256, P1123; Falany CN, 1997, FASEB J, V11, P1; FOLDES A, 1973, BIOCHIM BIOPHYS ACTA, V327, P365, DOI 10.1016/0005-2744(73)90419-1; Gaedigk A, 1998, CHEM-BIOL INTERACT, V109, P43, DOI 10.1016/S0009-2797(97)00119-1; Gamage NU, 2003, J BIOL CHEM, V278, P7655, DOI 10.1074/jbc.M207246200; Glatt H, 1997, FASEB J, V11, P314, DOI 10.1096/fasebj.11.5.9141497; Glatt H, 2000, CHEM-BIOL INTERACT, V129, P141, DOI 10.1016/S0009-2797(00)00202-7; JAKOBY WB, 1990, J BIOL CHEM, V265, P20715; Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P940; Marshall AD, 2000, ARCH BIOCHEM BIOPHYS, V382, P95, DOI 10.1006/abbi.2000.2020; MEISHERI KD, 1993, BIOCHEM PHARMACOL, V45, P271, DOI 10.1016/0006-2952(93)90061-Z; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Pasqualini JR, 2004, BBA-REV CANCER, V1654, P123, DOI 10.1016/j.bbcan.2004.03.001; Pedersen LC, 2002, J BIOL CHEM, V277, P17928, DOI 10.1074/jbc.M111651200; Raftogianis RB, 1999, BIOCHEM PHARMACOL, V58, P605, DOI 10.1016/S0006-2952(99)00145-8; Rehse PH, 2002, BIOCHEM J, V364, P165, DOI 10.1042/bj3640165; REITER C, 1983, N-S ARCH PHARMACOL, V324, P140, DOI 10.1007/BF00497020; Seth P, 2000, CANCER RES, V60, P6859; Varon R, 1997, COMPUT APPL BIOSCI, V13, P159; Wang YF, 2002, LUNG CANCER, V35, P137, DOI 10.1016/S0169-5002(01)00406-8; Yang YS, 1998, CHEM-BIOL INTERACT, V109, P129, DOI 10.1016/S0009-2797(97)00127-0	33	85	88	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41482	41486		10.1074/jbc.M508289200	http://dx.doi.org/10.1074/jbc.M508289200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16221673	hybrid, Green Published			2022-12-25	WOS:000233866900046
J	Siddiq, A; Ayoub, IA; Chavez, JC; Aminova, L; Shah, S; LaManna, JC; Patton, SM; Connor, JR; Cherny, RA; Volitakis, I; Bush, AI; Langsetmo, I; Seeley, T; Gunzler, V; Ratan, RR				Siddiq, A; Ayoub, IA; Chavez, JC; Aminova, L; Shah, S; LaManna, JC; Patton, SM; Connor, JR; Cherny, RA; Volitakis, I; Bush, AI; Langsetmo, I; Seeley, T; Gunzler, V; Ratan, RR			Hypoxia-inducible factor prolyl 4-hydroxylase inhibition - A target for neuroprotection in the central nervous system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBRAL ISCHEMIC ACIDOSIS; PARKINSONS-DISEASE; OXIDATIVE STRESS; ALZHEIMERS-DISEASE; HIF-ALPHA; IN-VITRO; PROLINE HYDROXYLATION; TRANSFERRIN RECEPTOR; FRIEDREICHS-ATAXIA; SUBSTANTIA-NIGRA	Hypoxia-inducible factor (HIF) prolyl 4-hydroxylases are a family of iron- and 2-oxoglutarate-dependent dioxygenases that negatively regulate the stability of several proteins that have established roles in adaptation to hypoxic or oxidative stress. These proteins include the transcriptional activators HIF-1 alpha and HIF-2 alpha. The ability of the inhibitors of HIF prolyl 4-hydroxylases to stabilize proteins involved in adaptation in neurons and to prevent neuronal injury remains unclear. We reported that structurally diverse low molecular weight or peptide inhibitors of the HIF prolyl 4-hydroxylases stabilize HIF-1 alpha and up-regulate HIF-dependent target genes (e.g. enolase, p21(waf1/cip1), vascular endothelial growth factor, or erythropoietin) in embryonic cortical neurons in vitro or in adult rat brains in vivo. We also showed that structurally diverse HIF prolyl 4-hydroxylase inhibitors prevent oxidative death in vitro and ischemic injury in vivo. Taken together these findings identified low molecular weight and peptide HIF prolyl 4-hydroxylase inhibitors as novel neurological therapeutics for stroke as well as other diseases associated with oxidative stress.	Burke Cornell Med Res Inst, White Plains, NY 10605 USA; Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, New York, NY 10021 USA; Case Western Reserve Univ, Dept Anat & Neurol, Cleveland, OH 44106 USA; Penn State Coll Med, George M Leader Family Lab Alzheimer Dis Res, Dept Neurosurg, Hershey, PA 17033 USA; Univ Melbourne, Dept Pathol, Mental Hlth Res Inst Victoria, Parkville, Vic 3052, Australia; Harvard Univ, Sch Med, Massachusetts Gen Hosp,Lab Oxidat Biol, Dept Psychiat,Genet & Aging Res Unit, Charlestown, MA 02129 USA; Fibrogen Inc, San Francisco, CA 94080 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Cornell University; Case Western Reserve University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Melbourne; Harvard University; Massachusetts General Hospital; FibroGen	Ratan, RR (corresponding author), Burke Cornell Med Res Inst, 785 Mamaroneck Ave, White Plains, NY 10605 USA.	rrr2001@cornell.med.edu	LaManna, Joseph/D-3860-2013; LaManna, Joseph C/C-3347-2012; Bush, Ashley I/A-1186-2007; Bush, Ashley/Y-2457-2019	LaManna, Joseph/0000-0002-0159-4512; LaManna, Joseph C/0000-0002-0159-4512; Bush, Ashley I/0000-0001-8259-9069; Bush, Ashley/0000-0001-8259-9069; Volitakis, Irene/0000-0003-0766-817X	NINDS NIH HHS [R01 NS040591, R01 NS039170-02, NS40591, NS46239, F32 NS046239, NS39170] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040591, F32NS046239, R01NS039170] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aarts M, 2002, SCIENCE, V298, P846, DOI 10.1126/science.1072873; AISEN P, 1994, ADV EXP MED BIOL, V356, P31; Ayoub IA, 1999, NEUROSCI LETT, V259, P21, DOI 10.1016/S0304-3940(98)00881-7; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; Bergeron M, 2000, ANN NEUROL, V48, P285, DOI 10.1002/1531-8249(200009)48:3<285::AID-ANA2>3.0.CO;2-8; BETTANY AJE, 1992, J BIOL CHEM, V267, P16531; BOWERN N, 1984, J EXP MED, V160, P1532, DOI 10.1084/jem.160.5.1532; BRALET J, 1992, BIOCHEM PHARMACOL, V43, P979, DOI 10.1016/0006-2952(92)90602-F; Breuer W, 1996, FEBS LETT, V382, P304, DOI 10.1016/0014-5793(96)00190-1; Bruick RK, 2003, GENE DEV, V17, P2614, DOI 10.1101/gad.1145503; Castellani RJ, 2000, ACTA NEUROPATHOL, V100, P111, DOI 10.1007/s004010050001; Connor JR, 2001, PEDIATR NEUROL, V25, P118, DOI 10.1016/S0887-8994(01)00303-4; CONNOR JR, 1992, J NEUROSCI RES, V31, P75, DOI 10.1002/jnr.490310111; Davis S, 1997, STROKE, V28, P198, DOI 10.1161/01.STR.28.1.198; Deibel MA, 1996, J NEUROL SCI, V143, P137, DOI 10.1016/S0022-510X(96)00203-1; DEXTER DT, 1989, J NEUROCHEM, V52, P1830, DOI 10.1111/j.1471-4159.1989.tb07264.x; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; GERLACH M, 1994, J NEUROCHEM, V63, P793, DOI 10.1046/j.1471-4159.1994.63030793.x; GOOD PF, 1992, ANN NEUROL, V31, P286, DOI 10.1002/ana.410310310; Hanson ES, 2003, J BIOL CHEM, V278, P40337, DOI 10.1074/jbc.M302798200; Hirsila M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200; HURN PD, 1995, STROKE, V26, P688, DOI 10.1161/01.STR.26.4.688; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kaur D, 2002, AGING CELL, V1, P17, DOI 10.1046/j.1474-9728.2002.00001.x; Kaur D, 2003, NEURON, V37, P899, DOI 10.1016/S0896-6273(03)00126-0; Kienzl E, 1999, LIFE SCI, V65, P1973, DOI 10.1016/S0024-3205(99)00458-0; Kress GJ, 2002, J NEUROSCI, V22, P5848; Kuznetsova AV, 2003, P NATL ACAD SCI USA, V100, P2706, DOI 10.1073/pnas.0436037100; Liang D, 2004, CURR MOL MED, V4, P207, DOI 10.2174/1566524043479194; Lipscomb DC, 1998, STROKE, V29, P487, DOI 10.1161/01.STR.29.2.487; MAJAMAA K, 1986, J BIOL CHEM, V261, P7819; MazurKolecka B, 1997, BRAIN RES, V760, P255, DOI 10.1016/S0006-8993(97)00327-2; MCLACHLAN DRC, 1993, THER DRUG MONIT, V15, P602; Metzen E, 2003, J CELL SCI, V116, P1319, DOI 10.1242/jcs.00318; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MURPHY TH, 1990, FASEB J, V4, P1624, DOI 10.1096/fasebj.4.6.2180770; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; Prass K, 2002, J CEREBR BLOOD F MET, V22, P520, DOI 10.1097/00004647-200205000-00003; Ratan RR, 2002, METHOD ENZYMOL, V352, P183; Ritchie CW, 2003, ARCH NEUROL-CHICAGO, V60, P1685, DOI 10.1001/archneur.60.12.1685; Schapira AHV, 1999, BBA-BIOENERGETICS, V1410, P159, DOI 10.1016/S0005-2728(98)00164-9; Semenza GL, 2000, ADV EXP MED BIOL, V475, P123; Shi YH, 2005, J PATHOL, V205, P530, DOI 10.1002/path.1734; Smith MA, 2000, BBA-MOL BASIS DIS, V1502, P139, DOI 10.1016/S0925-4439(00)00040-5; SOFIC E, 1988, J NEURAL TRANSM, V74, P199, DOI 10.1007/BF01244786; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Thompson KJ, 2001, BRAIN RES BULL, V55, P155, DOI 10.1016/S0361-9230(01)00510-X; Waldvogel D, 1999, ANN NEUROL, V46, P123, DOI 10.1002/1531-8249(199907)46:1<123::AID-ANA19>3.0.CO;2-H; Wang F, 2002, BIOCHEM BIOPH RES CO, V295, P657, DOI 10.1016/S0006-291X(02)00729-5; Wang XY, 2004, J NEUROCHEM, V91, P900, DOI 10.1111/j.1471-4159.2004.02769.x; Warnecke C, 2003, FASEB J, V17, P1186, DOI 10.1096/fj.02-1062fje; White KC, 2005, PEDIATRICS, V115, P315, DOI 10.1542/peds.2004-1488; Willam C, 2002, P NATL ACAD SCI USA, V99, P10423, DOI 10.1073/pnas.162119399; Winterbourn CC, 1995, TOXICOL LETT, V82-3, P969, DOI 10.1016/0378-4274(95)03532-X; Yu F, 2001, CANCER RES, V61, P4136; Zaman K, 1999, J NEUROSCI, V19, P9821; Zecca L, 2004, P NATL ACAD SCI USA, V101, P9843, DOI 10.1073/pnas.0403495101	59	250	269	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41732	41743		10.1074/jbc.M504963200	http://dx.doi.org/10.1074/jbc.M504963200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16227210	Green Accepted, hybrid			2022-12-25	WOS:000233866900075
J	Meidan, R; Klipper, E; Gilboa, T; Muller, L; Levy, N				Meidan, R; Klipper, E; Gilboa, T; Muller, L; Levy, N			Endothelin-converting enzyme-1, abundance of isoforms a-d and identification of a novel alternatively spliced variant lacking a transmembrane domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; FUNCTIONAL EXPRESSION; CORPUS-LUTEUM; ECE-1; CLONING; PEPTIDE; CELLS; LOCALIZATION; DEGRADATION; INHIBITORS	Endothelin-converting enzyme-1 (ECE-1) cleaves big endothelins, as well as bradykinin and beta-amyloid peptide. Several isoforms of ECE-1 (a-d) have been identified to date; they differ only in their NH2 terminus but share the catalytic domain located in the COOH-terminal end. Using quantitative PCR, we found ECE-1d to be the most abundant type in several endothelial cells (EC) types. In addition to full-length ECE-1 forms we have identified novel, alternatively spliced mRNAs of ECE-1b-d. These splice variants (SVs) lack exon 3', which codes for the transmembrane region and is present in full-length forms. SVs mRNA were highly expressed in EC derived from macro and microvascular beds but much less so in other, non-endothelial cells expressing ECE-1, which suggests that the splicing mechanism is cell-specific. Analyses of ECE-1d and its SV form in stably transfected HEK-293 cells revealed that both proteins were recognized by anti COOH-terminal ECE-1 antibodies, but anti NH2-terminal antibodies only bound ECE-1d. The novel protein, designated ECE-1 sv, has an apparent molecular mass of 75 kDa; by using site-directed mutagenesis its start site was identified in a region common to all ECE-1 forms suggesting that ECE-1 b-d SV mRNAs are translated into the same protein. In agreement with the findings demonstrating common COOH terminus for ECE-1sv and ECE-1d, both exhibited a similar catalytic activity. However, immunofluorescence staining and differential centrifugation revealed a distinct intracellular localization for these two proteins. The presence of ECE-1sv in different cellular compartments than full-length forms of the enzyme may suggest a distinct physiological role for these proteins.	Hebrew Univ Jerusalem, Fac Agr Food & Environm Qual Sci, Dept Anim Sci, IL-76100 Rehovot, Israel; INSERM, Coll France Paris, U 36, F-75005 Paris, France	Hebrew University of Jerusalem; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France	Meidan, R (corresponding author), Hebrew Univ Jerusalem, Fac Agr Food & Environm Qual Sci, Dept Anim Sci, IL-76100 Rehovot, Israel.	rina.meidan@huji.ac.il	muller, laurent/S-1990-2016	muller, laurent/0000-0001-9634-4323				Ahn K, 1998, ARCH BIOCHEM BIOPHYS, V359, P258, DOI 10.1006/abbi.1998.0913; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; Barker S, 2001, MOL PHARMACOL, V59, P163, DOI 10.1124/mol.59.2.163; Boue S, 2003, BIOESSAYS, V25, P1031, DOI 10.1002/bies.10371; Corder R, 2000, J CARDIOVASC PHARM, V36, pS19, DOI 10.1097/00005344-200036001-00008; Eckman EA, 2001, J BIOL CHEM, V276, P24540, DOI 10.1074/jbc.M007579200; Emoto N, 1999, J BIOL CHEM, V274, P1509, DOI 10.1074/jbc.274.3.1509; Funalot B, 2004, MOL PSYCHIATR, V9, P1122, DOI 10.1038/sj.mp.4001584; Funke-Kaiser H, 2003, J HYPERTENS, V21, P2111, DOI 10.1097/00004872-200311000-00021; Grant K, 2003, BRIT J CANCER, V88, P163, DOI 10.1038/sj.bjc.6700750; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; Jeng Arco Y, 2003, Curr Opin Investig Drugs, V4, P1076; Jeng AY, 2002, CAN J PHYSIOL PHARM, V80, P440, DOI 10.1139/y02-025; Johnson GD, 2000, ANAL BIOCHEM, V286, P112, DOI 10.1006/abio.2000.4772; Johnson GD, 1999, J BIOL CHEM, V274, P4053, DOI 10.1074/jbc.274.7.4053; Kedzierski RM, 2001, ANNU REV PHARMACOL, V41, P851, DOI 10.1146/annurev.pharmtox.41.1.851; Kelly JJ, 1999, CLIN EXP PHARMACOL P, V26, P158, DOI 10.1046/j.1440-1681.1999.03011.x; Klipper E, 2004, REPRODUCTION, V128, P463, DOI 10.1530/rep.1.00271; Korth P, 1999, J HISTOCHEM CYTOCHEM, V47, P447, DOI 10.1177/002215549904700403; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; Lareau LF, 2004, CURR OPIN STRUC BIOL, V14, P273, DOI 10.1016/j.sbi.2004.05.002; Lehmann I, 2000, J VASC RES, V37, P408, DOI 10.1159/000025757; Levy N, 2003, BIOL REPROD, V68, P1361, DOI 10.1095/biolreprod.102.009134; Levy N, 2001, ENDOCRINOLOGY, V142, P5254, DOI 10.1210/en.142.12.5254; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Luciani N, 2001, BIOCHEM J, V356, P813, DOI 10.1042/0264-6021:3560813; Maguire JJ, 1997, BRIT J PHARMACOL, V122, P1647, DOI 10.1038/sj.bjp.0701564; Mamluk R, 1998, BIOL REPROD, V58, P849, DOI 10.1095/biolreprod58.3.849; Muller L, 2003, J BIOL CHEM, V278, P545, DOI 10.1074/jbc.M208949200; Muller L, 2000, J CARDIOVASC PHARM, V36, pS15, DOI 10.1097/00005344-200036051-00007; Nelboeck P, 1998, J CARDIOVASC PHARM, V31, pS4, DOI 10.1097/00005344-199800001-00003; Orzechowski HD, 1997, J MOL MED-JMM, V75, P512, DOI 10.1007/s001090050136; Russell FD, 1998, J CARDIOVASC PHARM, V31, P424, DOI 10.1097/00005344-199803000-00014; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SAWAMURA T, 1993, BIOCHIM BIOPHYS ACTA, V1161, P295, DOI 10.1016/0167-4838(93)90228-J; SCHMIDT M, 1994, FEBS LETT, V356, P238, DOI 10.1016/0014-5793(94)01277-6; Schweizer A, 1997, BIOCHEM J, V328, P871, DOI 10.1042/bj3280871; SHIMADA K, 1994, J BIOL CHEM, V269, P18275; Spanel-Borowski K., 1994, Arzneimittel-Forschung, V44, P385; SPANELBOROWSKI K, 1991, CELL TISSUE RES, V266, P37, DOI 10.1007/BF00678709; TAKAHASHI M, 1995, BIOCHEM J, V311, P657, DOI 10.1042/bj3110657; Turner AJ, 1998, TRENDS PHARMACOL SCI, V19, P483, DOI 10.1016/S0165-6147(98)01251-6; Valdenaire O, 1999, EUR J BIOCHEM, V264, P341, DOI 10.1046/j.1432-1327.1999.00602.x; VALDENAIRE O, 1995, J BIOL CHEM, V270, P29794; Valdenaire O, 1999, J CELL SCI, V112, P3115; Valdenaire O, 2000, BIOCHEM SOC T, V28, P426, DOI 10.1042/0300-5127:0280426; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; Yanagisawa H, 1998, DEVELOPMENT, V125, P825; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	50	24	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40867	40874		10.1074/jbc.M505679200	http://dx.doi.org/10.1074/jbc.M505679200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16186113	hybrid			2022-12-25	WOS:000233666600058
J	Oriente, F; Andreozzi, F; Romano, C; Perruolo, G; Perfetti, A; Fiory, F; Miele, C; Beguinot, F; Formisano, P				Oriente, F; Andreozzi, F; Romano, C; Perruolo, G; Perfetti, A; Fiory, F; Miele, C; Beguinot, F; Formisano, P			Protein kinase C-alpha regulates insulin action and degradation by interacting with insulin receptor substrate-1 and 14-3-3 epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR SUBSTRATE-1; TYROSINE KINASE; SKELETAL-MUSCLE; CELL-PROLIFERATION; ACTIVATION; PHOSPHORYLATION; STIMULATION; ISOFORMS; GLUCOSE; MECHANISM	Protein kinase C (PKC)-alpha exerts a regulatory function on insulin action. We showed by overlay blot that PKC alpha directly binds a 180-kDa protein, corresponding to IRS-1, and a 30-kDa molecular species, identified as 14-3-3 epsilon. In intact NIH-3T3 cells overexpressing insulin receptors (3T3-hIR), insulin selectively increased PKC alpha coprecipitation with IRS-1, but not with IRS-2, and with 14-3-3 epsilon, but not with other 14-3-3 isoforms. Overexpression of 14-3-3 epsilon in 3T3-hIR cells significantly reduced IRS-1-bound PKC alpha activity, without altering IRS-1/PKC alpha co-precipitation. 14-3-3 epsilon overexpression also increased insulin-stimulated insulin receptor and IRS-1 tyrosine phosphorylation, followed by increased activation of Raf1, ERK1/2, and Akt/protein kinase B. Insulin-induced glycogen synthase activity and thymidine incorporation were also augmented. Consistently, selective depletion of 14-3-3 epsilon by antisense oligonucleotides caused a 3-fold increase of IRS-1-bound PKC alpha activity and a similarly sized reduction of insulin receptor and IRS-1 tyrosine phosphorylation and signaling. In turn, selective inhibition of PKC alpha expression by antisense oligonucleotides reverted the negative effect of 14-3-3 epsilon depletion on insulin signaling. Moreover, PKC alpha inhibition was accompanied by a > 2-fold decrease of insulin degradation. Similar results were also obtained by overexpressing 14-3-3 epsilon. Thus, in NIH-3T3 cells, insulin induces the formation of multimolecular complexes, including IRS-1, PKC alpha, and 14-3-3 epsilon. The presence of 14-3-3 epsilon in the complex is not necessary for IRS-1/PKC alpha interaction but modulates PKC alpha activity, thereby regulating insulin signaling and degradation.	Univ Naples Federico II, Dept Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Univ Naples Federico II, CNR, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Magna Graecia Univ Catanzaro, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; Magna Graecia University of Catanzaro	Formisano, P (corresponding author), Univ Naples Federico II, Dept Biol & Patol Cellulare & Mol, Via S Pansini 5, I-80131 Naples, Italy.	fpietro@unina.it	giuseppe, perruolo/AAW-3869-2021; Formisano, Pietro/J-4237-2018; ORIENTE, Francesco/J-6652-2018; Andreozzi, Francesco/J-4073-2018	Perruolo, Giuseppe/0000-0003-0479-8729; ORIENTE, Francesco/0000-0003-4375-4526; Formisano, Pietro/0000-0001-7020-6870; Andreozzi, Francesco/0000-0001-9375-1513	Telethon [GGP04041] Funding Source: Medline	Telethon(Fondazione Telethon)		AITKEN A, 1995, MOL CELL BIOCHEM, V149, P41, DOI 10.1007/BF01076562; Andreozzi F, 2003, ONCOGENE, V22, P2942, DOI 10.1038/sj.onc.1206475; Asante-Appiah E, 2003, AM J PHYSIOL-ENDOC M, V284, pE663, DOI 10.1152/ajpendo.00462.2002; Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; Bifulco G, 2002, J BIOL CHEM, V277, P24306, DOI 10.1074/jbc.M202962200; Bossenmaier B, 1997, DIABETOLOGIA, V40, P863, DOI 10.1007/s001250050761; Braiman L, 1999, DIABETES, V48, P1922, DOI 10.2337/diabetes.48.10.1922; Braiman L, 2001, MOL ENDOCRINOL, V15, P565, DOI 10.1210/me.15.4.565; CARPENTIER JL, 1992, P NATL ACAD SCI USA, V89, P162, DOI 10.1073/pnas.89.1.162; Caruso M, 2001, J BIOL CHEM, V276, P45088, DOI 10.1074/jbc.M105451200; Caruso R, 1999, J BIOL CHEM, V274, P28637, DOI 10.1074/jbc.274.40.28637; CHIN JE, 1994, MOL ENDOCRINOL, V8, P51, DOI 10.1210/me.8.1.51; CHIN JE, 1993, J BIOL CHEM, V268, P6338; Craparo A, 1997, J BIOL CHEM, V272, P11663; FARESE RV, 1992, CELL SIGNAL, V4, P133, DOI 10.1016/0898-6568(92)90077-L; Fiory F, 2004, J BIOL CHEM, V279, P11137, DOI 10.1074/jbc.M308751200; Formisano P, 2000, MOL CELL BIOL, V20, P6323, DOI 10.1128/MCB.20.17.6323-6333.2000; Formisano P, 1998, J BIOL CHEM, V273, P13197, DOI 10.1074/jbc.273.21.13197; Formisano P, 2001, J ENDOCRINOL INVEST, V24, P460, DOI 10.1007/BF03351048; Goldstein BJ, 2000, J BIOL CHEM, V275, P4283, DOI 10.1074/jbc.275.6.4283; Greene MW, 2002, BIOCHEMISTRY-US, V41, P7082, DOI 10.1021/bi015992f; Hool LC, 2005, CURR PHARM DESIGN, V11, P549, DOI 10.2174/1381612053381990; Idris I, 2001, DIABETOLOGIA, V44, P659, DOI 10.1007/s001250051675; ISOBE T, 1992, FEBS LETT, V308, P121, DOI 10.1016/0014-5793(92)81257-M; Kagan A, 2002, EMBO J, V21, P1889, DOI 10.1093/emboj/21.8.1889; Kapasi AA, 2001, AM J PHYSIOL-RENAL, V280, pF333, DOI 10.1152/ajprenal.2001.280.2.F333; Katz AB, 1999, J INVEST DERMATOL, V112, P818, DOI 10.1046/j.1523-1747.1999.00572.x; Kellerer M, 1998, DIABETOLOGIA, V41, P833, DOI 10.1007/s001250050995; Koya D, 1998, DIABETES, V47, P859, DOI 10.2337/diabetes.47.6.859; Letiges M, 2002, MOL ENDOCRINOL, V16, P847, DOI 10.1210/me.16.4.847; Liu YF, 2001, J BIOL CHEM, V276, P14459, DOI 10.1074/jbc.M007281200; Mendez R, 1997, MOL CELL BIOL, V17, P5184, DOI 10.1128/MCB.17.9.5184; Miele C, 2003, J BIOL CHEM, V278, P47376, DOI 10.1074/jbc.M301088200; Motley ED, 2003, HYPERTENSION, V41, P775, DOI 10.1161/01.HYP.0000051891.90321.12; Ogihara T, 1997, J BIOL CHEM, V272, P25267, DOI 10.1074/jbc.272.40.25267; Pula G, 2005, J BIOL CHEM, V280, P7194, DOI 10.1074/jbc.M409212200; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Schmitz-Peiffer C, 2000, CELL SIGNAL, V12, P583, DOI 10.1016/S0898-6568(00)00110-8; SEEDORF K, 1995, J BIOL CHEM, V270, P18953, DOI 10.1074/jbc.270.32.18953; Shen S, 2001, DIABETES, V50, P255, DOI 10.2337/diabetes.50.2.255; Sugden PH, 2003, J MOL CELL CARDIOL, V35, P871, DOI 10.1016/S0022-2828(03)00153-6; TANJI M, 1994, J NEUROCHEM, V63, P1908; TOKER A, 1990, EUR J BIOCHEM, V191, P421, DOI 10.1111/j.1432-1033.1990.tb19138.x; van der Hoeven PCJ, 2000, BIOCHEM J, V347, P781, DOI 10.1042/0264-6021:3470781; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; Wilkes JJ, 2003, DIABETES, V52, P1904, DOI 10.2337/diabetes.52.8.1904; Xiang XQ, 2002, MOL ENDOCRINOL, V16, P552, DOI 10.1210/me.16.3.552; Zick Yehiel, 2005, Sci STKE, V2005, ppe4, DOI 10.1126/stke.2682005pe4	50	32	32	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40642	40649		10.1074/jbc.M508570200	http://dx.doi.org/10.1074/jbc.M508570200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16216880	hybrid			2022-12-25	WOS:000233666600033
J	Iwata, A; Riley, BE; Johnston, JA; Kopito, RR				Iwata, A; Riley, BE; Johnston, JA; Kopito, RR			HDAC6 and microtubules are required for autophagic degradation of aggregated Huntingtin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME SYSTEM; INCLUSION-BODY FORMATION; MUTANT HUNTINGTIN; ALPHA-SYNUCLEIN; POLYGLUTAMINE EXPANSIONS; EXPANDED POLYGLUTAMINE; PROTEIN AGGREGATION; CASPASE ACTIVATION; MOUSE MODELS; AGGRESOMES	CNS neurons are endowed with the ability to recover from cytotoxic insults associated with the accumulation of proteinaceous polyglutamine aggregates via a process that appears to involve capture and degradation of aggregates by autophagy. The ubiquitin-proteasome system protects cells against proteotoxicity by degrading soluble monomeric misfolded aggregation- prone proteins but is ineffective against, and impaired by, non-native protein oligomers. Here we show that autophagy is induced in response to impaired ubiquitin proteasome system activity. We show that ATG proteins, molecular determinants of autophagic vacuole formation, and lysosomes are recruited to pericentriolar cytoplasmic inclusion bodies by a process requiring an intact microtubule cytoskeleton and the cytoplasmic deacetylase HDAC6. These data suggest that HDAC6-dependent retrograde transport on microtubules is used by cells to increase the efficiency and selectivity of autophagic degradation.	Stanford Univ, Dept Biol Sci, BIO X Program, Stanford, CA 94305 USA	Stanford University	Kopito, RR (corresponding author), Stanford Univ, Dept Biol Sci, BIO X Program, Stanford, CA 94305 USA.	kopito@stanford.edu	Iwata, Atsushi/A-9598-2013; Iwata, Atsushi/AAH-8924-2019	Iwata, Atsushi/0000-0001-7308-5314; Iwata, Atsushi/0000-0001-7308-5314; Johnston, Jennifer/0000-0002-4867-9230	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS042842, R01NS042842] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-042842] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		APLIN A, 1992, J CELL PHYSIOL, V152, P458, DOI 10.1002/jcp.1041520304; Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bennett EJ, 2005, MOL CELL, V17, P351, DOI 10.1016/j.molcel.2004.12.021; Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Fortun J, 2003, J NEUROSCI, V23, P10672; Gunawardena S, 2003, NEURON, V40, P25, DOI 10.1016/S0896-6273(03)00594-4; Haggarty SJ, 2003, P NATL ACAD SCI USA, V100, P4389, DOI 10.1073/pnas.0430973100; Hashimoto M, 2003, NEUROMOL MED, V4, P21, DOI 10.1385/NMM:4:1-2:21; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hazeki N, 2000, BIOCHEM BIOPH RES CO, V277, P386, DOI 10.1006/bbrc.2000.3682; Horwich AL, 1997, CELL, V89, P499, DOI 10.1016/S0092-8674(00)80232-9; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Hutchins MU, 2001, J BIOL CHEM, V276, P20491, DOI 10.1074/jbc.M101150200; Iwata A, 2005, P NATL ACAD SCI USA, V102, P13135, DOI 10.1073/pnas.0505801102; Jackson GR, 1998, NEURON, V21, P633, DOI 10.1016/S0896-6273(00)80573-5; Jana NR, 2001, HUM MOL GENET, V10, P1049, DOI 10.1093/hmg/10.10.1049; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kamada Y, 2003, CURR TOP MICROBIOL, V279, P73; Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5; Kegel KB, 2000, J NEUROSCI, V20, P7268, DOI 10.1523/jneurosci.20-19-07268.2000; Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Kopito RR, 2000, NAT CELL BIOL, V2, pE207, DOI 10.1038/35041139; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kopito RR, 2003, MOL CELL, V12, P1349, DOI 10.1016/S1097-2765(03)00498-2; KOPITZ J, 1990, J CELL BIOL, V111, P941, DOI 10.1083/jcb.111.3.941; Kovacs JJ, 2005, MOL CELL, V18, P601, DOI 10.1016/j.molcel.2005.04.021; Larsen KE, 2002, HISTOL HISTOPATHOL, V17, P897, DOI 10.14670/HH-17.897; Liu CW, 2005, J BIOL CHEM, V280, P22670, DOI 10.1074/jbc.M501508200; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MATTEONI R, 1987, J CELL BIOL, V105, P1253, DOI 10.1083/jcb.105.3.1253; Menalled LB, 2002, TRENDS PHARMACOL SCI, V23, P32, DOI 10.1016/S0165-6147(00)01884-8; Mortimore G E, 1996, Subcell Biochem, V27, P93; Muchowski PJ, 2002, P NATL ACAD SCI USA, V99, P727, DOI 10.1073/pnas.022628699; Nixon RA, 2000, NEUROCHEM RES, V25, P1161, DOI 10.1023/A:1007675508413; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Park Y, 2005, MOL CELLS, V19, P23; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; Qin ZH, 2003, HUM MOL GENET, V12, P3231, DOI 10.1093/hmg/ddg346; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; Ravikumar B, 2002, HUM MOL GENET, V11, P1107, DOI 10.1093/hmg/11.9.1107; Ravikumar B, 2003, HUM MOL GENET, V12, P985, DOI 10.1093/hmg/ddg109; Rideout HJ, 2004, INT J BIOCHEM CELL B, V36, P2551, DOI 10.1016/j.biocel.2004.05.008; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Sapp E, 1997, ANN NEUROL, V42, P604, DOI 10.1002/ana.410420411; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Seigneurin-Berny D, 2001, MOL CELL BIOL, V21, P8035, DOI 10.1128/MCB.21.23.8035-8044.2001; Snyder H, 2003, J BIOL CHEM, V278, P11753, DOI 10.1074/jbc.M208641200; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Taylor JP, 2002, SCIENCE, V296, P1991, DOI 10.1126/science.1067122; Taylor JP, 2003, HUM MOL GENET, V12, P749, DOI 10.1093/hmg/ddg074; TUTTLE DL, 1995, J CELL SCI, V108, P25; Wang GH, 1999, NEUROREPORT, V10, P2435, DOI 10.1097/00001756-199908200-00001; Wanker EE, 1999, METHOD ENZYMOL, V309, P375; Webb JL, 2004, INT J BIOCHEM CELL B, V36, P2541, DOI 10.1016/j.biocel.2004.02.003; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6; Yoshimori T, 2004, BIOCHEM BIOPH RES CO, V313, P453, DOI 10.1016/j.bbrc.2003.07.023; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217; Zu T, 2004, J NEUROSCI, V24, P8853, DOI 10.1523/JNEUROSCI.2978-04.2004	65	592	613	0	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40282	40292		10.1074/jbc.M508786200	http://dx.doi.org/10.1074/jbc.M508786200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16192271	hybrid			2022-12-25	WOS:000233461300070
J	Guo, XR; Li, Y; Peng, K; Hu, YF; Li, CM; Xia, B; Jin, CW				Guo, XR; Li, Y; Peng, K; Hu, YF; Li, CM; Xia, B; Jin, CW			Solution structures and backbone dynamics of arsenate reductase from Bacillus subtilis - Reversible conformational switch associated with arsenate reduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE RELAXATION; MODEL-FREE APPROACH; STAPHYLOCOCCUS-AUREUS; ROTATIONAL DIFFUSION; CHEMICAL-SHIFT; ARSC PROTEIN; SPECTROSCOPY; RESISTANCE; PI258; C-13	Arsenate reductase encoded by the chromosomal arsC gene in Bacillus subtilis catalyzes the intracellular reduction of arsenate to arsenite, which is then extruded from cells through an efficient and specific transport system. Herein, we present the solution structures and backbone dynamics of both the reduced and oxidized forms of arsenate reductase from B. subtilis. The overall structures of both forms are similar to those of bovine low molecular weight protein-tyrosine phosphatase and arsenate reductase from Staphylococcus aureus. However, several features of the tertiary structure and mobility are notably different between the reduced and oxidized forms of B. subtilis arsenate reductase, particularly in the P-loop region and the segment Cys(82)-Cys(89). The backbone dynamics results demonstrated that the reduced form of arsenate reductase undergoes millisecond conformational changes in the functional P-loop and Cys(82)-Cys(89), which may facilitate the formation of covalent intermediates and subsequent reduction of arsenate. In the oxidized form, Cys(82)-Cys(89) shows motional flexibility on both picosecond-to-nanosecond and possibly millisecond time scales, which may facilitate the reduction of the oxidized enzyme by thioredoxin to regenerate the active enzyme. Overall, the internal dynamics and static structures of the enzyme provide insights into the molecular mechanism of arsenate reduction, especially the reversible conformational switch and changes in internal motions associated with the catalytic reaction.	Peking Univ, Beijing NMR Ctr, Beijing 100871, Peoples R China; Peking Univ, Coll Chem & Mol Engn, Beijing 100871, Peoples R China; Peking Univ, Coll Life Sci, Beijing 100871, Peoples R China	Peking University; Peking University; Peking University	Jin, CW (corresponding author), Peking Univ, Beijing NMR Ctr, 5 Yi He Yuan Rd, Beijing 100871, Peoples R China.	changwen@pku.edu.cn						BAX A, 1990, J MAGN RESON, V87, P620, DOI 10.1016/0022-2364(90)90320-9; Bennett MS, 2001, P NATL ACAD SCI USA, V98, P13577, DOI 10.1073/pnas.241397198; CERVANTES C, 1994, FEMS MICROBIOL REV, V15, P355, DOI 10.1016/0168-6445(94)90069-8; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; de la Torre JG, 2000, J MAGN RESON, V147, P138, DOI 10.1006/jmre.2000.2170; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dosset P, 2000, J BIOMOL NMR, V16, P23, DOI 10.1023/A:1008305808620; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Fushman D, 1997, J MOL BIOL, V266, P173, DOI 10.1006/jmbi.1996.0771; GLADYSHEVA TB, 1994, BIOCHEMISTRY-US, V33, P7288, DOI 10.1021/bi00189a033; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; GRZESIEK S, 1993, J BIOMOL NMR, V3, P185; Guan Z, 2001, ACTA CRYSTALLOGR D, V57, P1718, DOI 10.1107/S0907444901014020; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; JI GY, 1992, P NATL ACAD SCI USA, V89, P9474, DOI 10.1073/pnas.89.20.9474; JI GY, 1994, BIOCHEMISTRY-US, V33, P7294, DOI 10.1021/bi00189a034; Johnson Bruce A, 2004, Methods Mol Biol, V278, P313; KAY LE, 1990, J MAGN RESON, V89, P496, DOI 10.1016/0022-2364(90)90333-5; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; Lah N, 2003, J BIOL CHEM, V278, P24673, DOI 10.1074/jbc.M303194200; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MARKLEY JL, 1971, J CHEM PHYS, V55, P3604, DOI 10.1063/1.1676626; Marley J, 2001, J BIOMOL NMR, V20, P71, DOI 10.1023/A:1011254402785; Messens J, 2004, J MOL BIOL, V339, P527, DOI 10.1016/j.jmb.2004.04.016; Messens J, 2004, ACTA CRYSTALLOGR D, V60, P1180, DOI 10.1107/S0907444904007334; Messens J, 2002, P NATL ACAD SCI USA, V99, P8506, DOI 10.1073/pnas.132142799; Messens J, 2002, J BIOL INORG CHEM, V7, P146, DOI 10.1007/s007750100282; Messens J, 1999, BIOCHEMISTRY-US, V38, P16857, DOI 10.1021/bi9911841; Mukhopadhyay R, 2000, J BIOL CHEM, V275, P21149, DOI 10.1074/jbc.M910401199; Mukhopadhyay R, 2002, ENVIRON HEALTH PERSP, V110, P745, DOI 10.1289/ehp.02110s5745; Mulder FAA, 1999, J MOL BIOL, V292, P111, DOI 10.1006/jmbi.1999.3034; ODEN KL, 1994, MOL MICROBIOL, V12, P301, DOI 10.1111/j.1365-2958.1994.tb01018.x; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Peng K, 2004, J BIOMOL NMR, V29, P459, DOI 10.1023/B:JNMR.0000032555.97201.bb; Rosen BP, 1999, TRENDS MICROBIOL, V7, P207, DOI 10.1016/S0966-842X(99)01494-8; Rosen BP, 2002, FEBS LETT, V529, P86, DOI 10.1016/S0014-5793(02)03186-1; Saltikov CW, 2003, P NATL ACAD SCI USA, V100, P10983, DOI 10.1073/pnas.1834303100; Sato T, 1998, J BACTERIOL, V180, P1655, DOI 10.1128/JB.180.7.1655-1661.1998; Schubert M, 2002, J BIOMOL NMR, V24, P149, DOI 10.1023/A:1020997118364; Silver S, 1996, GENE, V179, P9, DOI 10.1016/S0378-1119(96)00323-X; SILVER S, 1982, P NATL ACAD SCI-BIOL, V79, P6114, DOI 10.1073/pnas.79.20.6114; SMITH AH, 1992, ENVIRON HEALTH PERSP, V97, P259, DOI 10.2307/3431362; SU XD, 1994, NATURE, V370, P575, DOI 10.1038/370575a0; Tjandra N, 1995, J AM CHEM SOC, V117, P12562, DOI 10.1021/ja00155a020; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; Wuthrich K., 1986, NMR PROTEINS NUCL AC, P93; Zegers I, 2001, NAT STRUCT BIOL, V8, P843, DOI 10.1038/nsb1001-843	51	13	15	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39601	39608		10.1074/jbc.M508132200	http://dx.doi.org/10.1074/jbc.M508132200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16192272	hybrid			2022-12-25	WOS:000233362200083
J	Liu, Y; Furuta, K; Teshima, R; Shirata, N; Sugimoto, Y; Ichikawa, A; Tanaka, S				Liu, Y; Furuta, K; Teshima, R; Shirata, N; Sugimoto, Y; Ichikawa, A; Tanaka, S			Critical role of protein kinase C beta II in activation of mast cells by monomeric IgE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTAMINE SYNTHESIS; CYTOKINE PRODUCTION; EXPRESSION; SURVIVAL; RECEPTOR; BINDING; PHOSPHORYLATION; DEGRANULATION; INHIBITION; INDUCTION	Accumulating evidence suggests that IgE-mediated activation of mast cells occurs even in the absence of antigen, which is referred to as "monomeric IgE" responses. Although monomeric IgE was found to induce a wide variety of responses, such as up-regulation of the Fc epsilon RI, survival, cytokine production, histamine synthesis, and adhesion to fibronectin, it remains to be clarified how mast cells are activated in the absence of antigen. It has been controversial whether monomeric IgE responses are mediated by a similar signaling mechanism to antigen stimulation, although recent studies suggest that IgE can induce the Fc epsilon RI aggregation even in the absence of antigen. In this study, we focused on the role of conventional protein kinase C (cPKC), since this response is suppressed by a specific inhibitor for cPKC. Monomeric IgE-induced Ca2+ influx was not observed in a mouse mastocytoma cell line, which lacks the expression of PKC beta II, although Ca2+ influx induced by cross-linking of the Fc epsilon RI was intact. Transfection of PKC beta II cDNA was found to restore the Ca2+ influx induced by monomeric IgE in this cell line. Furthermore, the dominant negative form of PKC beta II (PKC beta II/T500V) significantly suppressed the Ca2+ influx, histamine synthesis, and interleukin-6 production in another mouse mast cell line, which is highly sensitive to monomeric IgE. Expression of PKC beta II/T500V was found not to affect the antigen-induced responses. These results suggest that PKC beta II plays a critical role in monomeric IgE responses, but not in antigen responses.	Kyoto Univ, Dept Physiol Chem, Grad Sch Pharmaceut Sci, Sakyo Ku, Kyoto 6068501, Japan; Natl Inst Hlth Sci, Div Biochem & Immunochem, Tokyo 1588501, Japan; Mukogawa Womens Univ, Sch Pharmaceut Sci, Nishinomiya, Hyogo 6638179, Japan	Kyoto University; National Institute of Health Sciences - Japan; Mukogawa Women's University	Tanaka, S (corresponding author), Kyoto Univ, Dept Physiol Chem, Grad Sch Pharmaceut Sci, Sakyo Ku, Kyoto 6068501, Japan.	satoshit@pharm.kyoto-u.ac.jp	Sugimoto, Yukihiko/AAV-6470-2021; TANAKA, Satoshi/B-1624-2011; Tanaka, Satoshi/H-6800-2019	Sugimoto, Yukihiko/0000-0001-6973-932X; TANAKA, Satoshi/0000-0002-3468-7694; Tanaka, Satoshi/0000-0002-3468-7694				Asai K, 2001, IMMUNITY, V14, P791, DOI 10.1016/S1074-7613(01)00157-1; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; Galli SJ, 2005, NAT IMMUNOL, V6, P135, DOI 10.1038/ni1158; Gonzalez-Espinosa C, 2003, J EXP MED, V197, P1453, DOI 10.1084/jem.20021806; Hsu C, 1996, IMMUNOL LETT, V52, P129, DOI 10.1016/0165-2478(96)02599-0; Kalesnikoff J, 2001, IMMUNITY, V14, P801, DOI 10.1016/S1074-7613(01)00159-5; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; Kawakami Y, 2000, P NATL ACAD SCI USA, V97, P7423, DOI 10.1073/pnas.120175097; Kawakami Y, 2003, P NATL ACAD SCI USA, V100, P9470, DOI 10.1073/pnas.1633695100; Kawakami Y, 2004, J BIOL CHEM, V279, P47720, DOI 10.1074/jbc.M408797200; Kitaura J, 2005, BLOOD, V105, P3222, DOI 10.1182/blood-2004-11-4205; Kitaura J, 2005, J IMMUNOL, V174, P4495, DOI 10.4049/jimmunol.174.8.4495; Kitaura J, 2000, J EXP MED, V192, P729, DOI 10.1084/jem.192.5.729; Kitaura J, 2003, P NATL ACAD SCI USA, V100, P12911, DOI 10.1073/pnas.1735525100; Kohno M, 2005, BLOOD, V105, P2059, DOI 10.1182/blood-2004-07-2639; Lam V, 2003, BLOOD, V102, P1405, DOI 10.1182/blood-2002-10-3176; Liu Y, 2004, J BIOL CHEM, V279, P45556, DOI 10.1074/jbc.M407701200; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; MILLER L, 1990, J BIOL CHEM, V265, P12444; Nechushtan H, 2000, BLOOD, V95, P1752, DOI 10.1182/blood.V95.5.1752.005k18_1752_1757; OKA T, 2003, AM J PHYSIOL, V286, pC256; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; ORR JW, 1994, J BIOL CHEM, V269, P27715; Pandey V, 2004, J IMMUNOL, V172, P4048, DOI 10.4049/jimmunol.172.7.4048; Safina F, 2002, J BIOL CHEM, V277, P14211, DOI 10.1074/jbc.M200702200; Schweitzer-Stenner R, 2005, J IMMUNOL, V174, P4461, DOI 10.4049/jimmunol.174.8.4461; SIRAGANIAN RP, 2002, CURR OPIN IMMUNOL, V14, P728; Stebbins EG, 2001, J BIOL CHEM, V276, P29644, DOI 10.1074/jbc.M101044200; Tanaka S, 2002, J EXP MED, V196, P229, DOI 10.1084/jem.20012037; Tanaka S, 2005, EUR J IMMUNOL, V35, P460, DOI 10.1002/eji.200425622; Todt JC, 2002, J BIOL CHEM, V277, P35906, DOI 10.1074/jbc.M202967200; Yamaguchi M, 1997, J EXP MED, V185, P663, DOI 10.1084/jem.185.4.663	33	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					38976	38981		10.1074/jbc.M506351200	http://dx.doi.org/10.1074/jbc.M506351200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16183638	hybrid			2022-12-25	WOS:000233362200011
J	Jones, BW; Hinkle, PM				Jones, BW; Hinkle, PM			beta-arrestin mediates desensitization and internalization but does not affect dephosphorylation of the thyrotropin-releasing hormone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; DEPENDENT INTERNALIZATION; AGONIST STIMULATION; FLUORESCENT PROTEIN; SIGNAL-TRANSDUCTION; PITUITARY-CELLS; TERMINAL TAIL; PHOSPHORYLATION; KINASE; ENDOCYTOSIS	The G protein-coupled thyrotropin-releasing hormone (TRH) receptor is phosphorylated and binds to beta-arrestin after agonist exposure. To define the importance of receptor phosphorylation and beta-arrestin binding in desensitization, and to determine whether beta-arrestin binding and receptor endocytosis are required for receptor dephosphorylation, we expressed TRH receptors in fibroblasts from mice lacking beta-arrestin-1 and/or beta-arrestin-2. Apparent affinity for [H-3] MeTRH was increased 8-fold in cells expressing beta-arrestins, including a beta-arrestin mutant that did not permit receptor internalization. TRH caused extensive receptor endocytosis in the presence of beta-arrestins, but receptors remained primarily on the plasma membrane without beta-arrestin. beta-Arrestins strongly inhibited inositol 1,4,5-trisphosphate production within 10 s. At 30 min, endogenous beta-arrestins reduced TRH-stimulated inositol phosphate production by 48% (beta-arrestin-1), 71% (beta-arrestin-2), and 84% (beta-arrestins- 1 and -2). In contrast, receptor phosphorylation, detected by the mobility shift of deglycosylated receptor, was unaffected by beta-arrestins. Receptors were fully phosphorylated within 15 s of TRH addition. Receptor dephosphorylation was identical with or without beta-arrestins and almost complete 20 min after TRH withdrawal. Blocking endocytosis with hypertonic sucrose did not alter the rate of receptor phosphorylation or dephosphorylation. Expressing receptors in cells lacking G alpha(q) and G alpha(11) or inhibiting protein kinase C pharmacologically did not prevent receptor phosphorylation or dephosphorylation. Overexpression of dominant negative G protein-coupled receptor kinase-2 (GRK2), however, retarded receptor phosphorylation. Receptor activation caused translocation of endogenous GRK2 to the plasma membrane. The results show conclusively that receptor dephosphorylation can take place on the plasma membrane and that beta-arrestin binding is critical for desensitization and internalization.	Univ Rochester, Med Ctr, Dept Physiol & Pharmacol, Rochester, NY 14642 USA	University of Rochester	Hinkle, PM (corresponding author), Univ Rochester, Med Ctr, Dept Physiol & Pharmacol, Box 711, Rochester, NY 14642 USA.	Patricia_Hinkle@urmc.rochester.edu		Jones, Brian/0000-0002-3277-4735	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019974] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK19974] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON L, 1995, BIOCHEM J, V311, P385, DOI 10.1042/bj3110385; ASHWORTH R, 1995, P NATL ACAD SCI USA, V92, P512, DOI 10.1073/pnas.92.2.512; Cook LB, 2004, ENDOCRINOLOGY, V145, P3095, DOI 10.1210/en.2004-0304; Cook LB, 2003, MOL ENDOCRINOL, V17, P1777, DOI 10.1210/me.2003-0073; Drmota T, 2000, BIOCHEM J, V346, P711, DOI 10.1042/0264-6021:3460711; DRUMMOND AH, 1984, MOL PHARMACOL, V25, P201; FALCKPEDERSEN E, 1994, MOL PHARMACOL, V45, P684; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Gardner B, 2001, MOL PHARMACOL, V59, P310, DOI 10.1124/mol.59.2.310; Gershengorn MC, 1996, PHYSIOL REV, V76, P175, DOI 10.1152/physrev.1996.76.1.175; Groarke DA, 1999, J BIOL CHEM, V274, P23263, DOI 10.1074/jbc.274.33.23263; Groarke DA, 2001, MOL PHARMACOL, V59, P375, DOI 10.1124/mol.59.2.375; Gurevich VV, 2004, TRENDS PHARMACOL SCI, V25, P105, DOI 10.1016/j.tips.2003.12.008; Gurevich VV, 1997, J BIOL CHEM, V272, P28849, DOI 10.1074/jbc.272.46.28849; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; Hanyaloglu AC, 2001, J BIOL CHEM, V276, P18066, DOI 10.1074/jbc.M009275200; Heding A, 2000, ENDOCRINOLOGY, V141, P299, DOI 10.1210/en.141.1.299; HEINFLINK M, 1995, MOL ENDOCRINOL, V9, P1455, DOI 10.1210/me.9.11.1455; IMAI A, 1985, J BIOL CHEM, V260, P536; Key TA, 2003, J BIOL CHEM, V278, P4041, DOI 10.1074/jbc.M204687200; Kim OJ, 2004, J BIOL CHEM, V279, P7999, DOI 10.1074/jbc.M308281200; Kim YM, 2002, J BIOL CHEM, V277, P16340, DOI 10.1074/jbc.M200678200; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Krueger KM, 1997, J BIOL CHEM, V272, P5; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Luttrell LM, 2002, J CELL SCI, V115, P455; Maestri-El Kouhen O, 2000, J BIOL CHEM, V275, P36659, DOI 10.1074/jbc.M006788200; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Paing MM, 2002, J BIOL CHEM, V277, P1292, DOI 10.1074/jbc.M109160200; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; PERLMAN JH, 1991, ENDOCRINOLOGY, V129, P2679, DOI 10.1210/endo-129-5-2679; Petrou C, 1997, J BIOL CHEM, V272, P2326; Pollok-Kopp B, 2003, J BIOL CHEM, V278, P2190, DOI 10.1074/jbc.M209844200; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P1130, DOI 10.1074/jbc.270.3.1130; Rabeler R, 2004, MOL ENDOCRINOL, V18, P1450, DOI 10.1210/me.2004-0017; Scott MGH, 2002, J BIOL CHEM, V277, P3552, DOI 10.1074/jbc.M106586200; SONG GJ, 2005, IN PRESS MOL ENDOCRI; Tran TM, 2004, MOL PHARMACOL, V65, P196, DOI 10.1124/mol.65.1.196; van Koppen CJ, 2004, MOL PHARMACOL, V66, P365, DOI 10.1124/mol.104.003822; Vrecl M, 1998, MOL ENDOCRINOL, V12, P1818, DOI 10.1210/me.12.12.1818; Wang Q, 2004, SCIENCE, V304, P1940, DOI 10.1126/science.1098274; Yu R, 1997, J BIOL CHEM, V272, P28301, DOI 10.1074/jbc.272.45.28301; Yu R, 1998, MOL ENDOCRINOL, V12, P737, DOI 10.1210/me.12.5.737; Yu R, 1999, J BIOL CHEM, V274, P15745, DOI 10.1074/jbc.274.22.15745; Zhu CC, 2002, J BIOL CHEM, V277, P28228, DOI 10.1074/jbc.M204221200	45	25	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38346	38354		10.1074/jbc.M502918200	http://dx.doi.org/10.1074/jbc.M502918200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16183993	hybrid			2022-12-25	WOS:000233239800030
J	Lukong, KE; Larocque, D; Tyner, AL; Richard, S				Lukong, KE; Larocque, D; Tyner, AL; Richard, S			Tyrosine phosphorylation of Sam68 by breast tumor kinase regulates intranuclear localization and cell cycle progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEIN; MAMMARY EPITHELIAL-CELLS; SRC-ASSOCIATED PROTEIN; GSG DOMAIN; MESSENGER-RNA; REV FUNCTION; KH DOMAIN; C-SRC; BRK; EXPRESSION	The breast tumor kinase (BRK) is a growth promoting non-receptor tyrosine kinase overexpressed in the majority of human breast tumors. BRK is known to potentiate the epidermal growth factor (EGF) response in these cells. Although BRK is known to phosphorylate the RNA-binding protein Sam68, the specific tyrosines phosphorylated and the exact role of this phosphorylation remains unknown. Herein, we have generated Sam68 phospho-specific antibodies against C-terminal phosphorylated tyrosine residues within the Sam68 nuclear localization signal. We show that BRK phosphorylates Sam68 on all three tyrosines in the nuclear localization signal. By indirect immunofluorescence we observed that BRK and EGF treatment not only phosphorylates Sam68 but also induces its relocalization. Tyrosine 440 was identified as a principal modulator of Sam68 localization and this site was phosphorylated in response to EGF treatment in human breast tumor cell lines. Moreover, this phosphorylation event was inhibited by BRK small interfering RNA treatment, consistent with Sam68 being a physiological substrate of BRK downstream of the EGF receptor in breast cancer cells. Finally, we observed that Sam68 suppressed BRK-induced cell proliferation, suggesting that Sam68 does indeed contain anti-proliferative properties that may be neutralized in breast cancer cells by phosphorylation.	McGill Univ, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada; McGill Univ, Bloomfield Ctr Res Aging, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada; Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA; Univ Illinois, Dept Med, Chicago, IL 60607 USA	McGill University; Lady Davis Institute; McGill University; McGill University; McGill University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Richard, S (corresponding author), 3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.	stephane.richard@mcgill.ca		Tyner, Angela/0000-0001-7448-8625	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044525] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK044525-13A1, DK4452, R01 DK044525] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Babic I, 2004, ONCOGENE, V23, P3781, DOI 10.1038/sj.onc.1207484; Barker KT, 1997, ONCOGENE, V15, P799, DOI 10.1038/sj.onc.1201241; Barlat I, 1997, J BIOL CHEM, V272, P3129, DOI 10.1074/jbc.272.6.3129; Bedford MT, 2000, J BIOL CHEM, V275, P16030, DOI 10.1074/jbc.M909368199; Chen HY, 2004, MOL CELL BIOL, V24, P10558, DOI 10.1128/MCB.24.24.10558-10572.2004; Chen TP, 1999, MOL BIOL CELL, V10, P3015, DOI 10.1091/mbc.10.9.3015; Chen TP, 2001, J BIOL CHEM, V276, P30803, DOI 10.1074/jbc.M102247200; Cote J, 2003, MOL BIOL CELL, V14, P274, DOI 10.1091/mbc.E02-08-0484; Coyle JH, 2003, MOL CELL BIOL, V23, P92, DOI 10.1128/MCB.23.1.92-103.2003; Derry JJ, 2000, MOL CELL BIOL, V20, P6114, DOI 10.1128/MCB.20.16.6114-6126.2000; Derry JJ, 2003, ONCOGENE, V22, P4212, DOI 10.1038/sj.onc.1206465; Di Fruscio M, 1998, J BIOL CHEM, V273, P30122, DOI 10.1074/jbc.273.46.30122; Fessart D, 2005, MOL ENDOCRINOL, V19, P491, DOI 10.1210/me.2004-0246; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Galarneau A, 2005, NAT STRUCT MOL BIOL, V12, P691, DOI 10.1038/nsmb963; Haegebarth A, 2004, J BIOL CHEM, V279, P54398, DOI 10.1074/jbc.M409579200; Harfmann AM, 1999, MOL BIOL CELL, V10, P3909, DOI 10.1091/mbc.10.11.3909; Harvey AJ, 2003, ONCOGENE, V22, P5006, DOI 10.1038/sj.onc.1206577; Ishidate T, 1997, FEBS LETT, V409, P237, DOI 10.1016/S0014-5793(97)00455-9; Itoh M, 2002, NUCLEIC ACIDS RES, V30, P5452, DOI 10.1093/nar/gkf673; JONES AR, 1995, GENE DEV, V9, P1491, DOI 10.1101/gad.9.12.1491; Kamalati T, 2000, ONCOGENE, V19, P5471, DOI 10.1038/sj.onc.1203931; Kamalati T, 1996, J BIOL CHEM, V271, P30956, DOI 10.1074/jbc.271.48.30956; Kool J, 2001, CELL GROWTH DIFFER, V12, P535; Lang V, 1997, EUR J IMMUNOL, V27, P3360, DOI 10.1002/eji.1830271235; Larocque D, 2005, NAT NEUROSCI, V8, P27, DOI 10.1038/nn1359; Lev DC, 2004, BRIT J CANCER, V91, P795, DOI 10.1038/sj.bjc.6602051; Li JL, 2002, J VIROL, V76, P4526, DOI 10.1128/JVI.76.9.4526-4535.2002; Li QH, 2002, FEBS LETT, V525, P145, DOI 10.1016/S0014-5793(02)03103-4; Lin Q, 1997, J BIOL CHEM, V272, P27274, DOI 10.1074/jbc.272.43.27274; Liu K, 2000, J BIOL CHEM, V275, P40195, DOI 10.1074/jbc.M006194200; Lukong KE, 2003, BBA-REV CANCER, V1653, P73, DOI 10.1016/j.bbcan.2003.09.001; Massie B, 1998, J VIROL, V72, P2289, DOI 10.1128/JVI.72.3.2289-2296.1998; Matter N, 2002, NATURE, V420, P691, DOI 10.1038/nature01153; McBride AE, 1996, P NATL ACAD SCI USA, V93, P2296, DOI 10.1073/pnas.93.6.2296; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; Mitchell PJ, 2000, ONCOGENE, V19, P4273, DOI 10.1038/sj.onc.1203775; Pilotte J, 2001, GENE DEV, V15, P845, DOI 10.1101/gad.860301; Reddy TR, 2000, ONCOGENE, V19, P4071, DOI 10.1038/sj.onc.1203749; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; Serfas MS, 2003, ONCOL RES, V13, P409; Soros VB, 2001, J VIROL, V75, P8203, DOI 10.1128/JVI.75.17.8203-8215.2001; Stoss O, 2001, J BIOL CHEM, V276, P8665, DOI 10.1074/jbc.M006851200; Taylor SJ, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-5; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Vasioukhin V, 1997, P NATL ACAD SCI USA, V94, P14477, DOI 10.1073/pnas.94.26.14477; Venables JP, 1999, HUM MOL GENET, V8, P959, DOI 10.1093/hmg/8.6.959; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; Wu J, 1999, J BIOL CHEM, V274, P29202, DOI 10.1074/jbc.274.41.29202; Zhang P, 2005, J BIOL CHEM, V280, P1982, DOI 10.1074/jbc.M412038200	52	96	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38639	38647		10.1074/jbc.M505802200	http://dx.doi.org/10.1074/jbc.M505802200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16179349	hybrid			2022-12-25	WOS:000233239800065
J	Cesaire, R; Oliere, S; Sharif-Askari, E; Loignon, M; Lezin, A; Olindo, S; Panelatti, G; Kazanji, M; Aloyz, R; Panasci, L; Bell, JC; Hiscott, J				Cesaire, R; Oliere, S; Sharif-Askari, E; Loignon, M; Lezin, A; Olindo, S; Panelatti, G; Kazanji, M; Aloyz, R; Panasci, L; Bell, JC; Hiscott, J			Oncolytic activity of vesicular stomatitis virus in primary adult T-cell leukemia	ONCOGENE			English	Article						ATL; HTLV-1; HAM/TSP; VSV; apoptosis; oncolysis	CHRONIC LYMPHOCYTIC-LEUKEMIA; MATRIX PROTEIN; SIGNALING PATHWAYS; ANTIVIRAL DEFENSE; DNA FRAGMENTATION; INNATE IMMUNITY; IN-VIVO; APOPTOSIS; CANCER; INDUCTION	Treatments for hematological malignancies have improved considerably over the past decade, but the growing therapeutic arsenal has not benefited adult T-cell leukemia (ATL) patients. Oncolytic viruses such as vesicular stomatitis virus (VSV) have recently emerged as a potential treatment of solid tumors and leukemias in vitro and in vivo. In the current study, we investigated the ability of VSV to lyse primary human T-lymphotropic virus type 1 (HTLV-1)- infected T-lymphocytes from patients with ATL. Ex vivo primary ATL cells were permissive for VSV and underwent rapid oncolysis in a time-dependent manner. Importantly, VSV infection showed neither viral replication nor oncolysis in HTLV1- infected, nonleukemic cells from patients with HTLV-1associated myelopathy/ tropical spastic paraparesis (HAM/TSP), and in naive CD4+ T- lymphocytes from normal individuals or in ex vivo cell samples from patients with chronic lymphocytic leukemia (CLL). Interestingly, activation of primary CD4+ T- lymphocytes with antiCD3/ CD28 monoclonal antibody, and specifically with anti-CD3, was sufficient to induce limited viral replication and oncolysis. However, at a similar level of T- cell activation, VSV replication was increased fourfold in ATL cells compared to activated CD4+ T- lymphocytes, emphasizing the concept that VSV targets genetic defects unique to tumor cells to facilitate its replication. In conclusion, our findings provide the first essential information for the development of a VSV-based treatment for ATL.	McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada; CHU Ft France, Lab Virol Immunol, Martinique, France; CHU Ft de France, INSERM, UMR433, Martinique, France; McGill Univ, Dept Microbiol, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 2T5, Canada; CHU Ft de France, Neurol Serv, Martinique, France; CHU Ft de France, Serv Med Interne, Martinique, France; Inst Pasteur, Retrovirus Lab, Cayenne, French Guiana; Univ Ottawa, Ottawa Reg Canc Ctr, Ottawa, ON, Canada	Lady Davis Institute; McGill University; CHU Martinique; CHU Martinique; Institut National de la Sante et de la Recherche Medicale (Inserm); McGill University; McGill University; CHU Martinique; CHU Martinique; University of Ottawa; Ottawa Hospital Research Institute	Hiscott, J (corresponding author), McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Mol Oncol Grp, Room 526,3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.	john.hiscott@mcgill.ca	Aloyz, Raquel S/N-6606-2013	Aloyz, Raquel S/0000-0002-6812-497X				Balachandran S, 2004, CANCER CELL, V5, P51, DOI 10.1016/S1535-6108(03)00330-1; Balachandran S, 2001, J VIROL, V75, P3474, DOI 10.1128/JVI.75.7.3474-3479.2001; Balachandran S, 2000, IUBMB LIFE, V50, P135, DOI 10.1080/15216540050212169; Bazarbachi A, 2004, LANCET ONCOL, V5, P664, DOI 10.1016/S1470-2045(04)01608-0; BELKOWSKI LS, 1987, J VIROL, V61, P653, DOI 10.1128/JVI.61.3.653-660.1987; Bell J. C., 2002, Current Gene Therapy, V2, P243, DOI 10.2174/1566523024605582; Caligaris-Cappio F, 2003, BRIT J HAEMATOL, V123, P380, DOI 10.1046/j.1365-2141.2003.04679.x; Cavrois M, 1996, ONCOGENE, V12, P2419; Chiocca EA, 2002, NAT REV CANCER, V2, P938, DOI 10.1038/nrc948; Desforges M, 2002, VIROLOGY, V295, P63, DOI 10.1006/viro.2001.1329; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Eastman A, 1999, SEMIN ONCOL, V26, P7; Ebert O, 2003, CANCER RES, V63, P3605; Fernandez M, 2002, J VIROL, V76, P895, DOI 10.1128/JVI.76.2.895-904.2002; Franchini G, 2003, ADV CANCER RES, V89, P69, DOI 10.1016/S0065-230X(03)01003-0; Gadaleta P, 2002, VIRUS RES, V86, P87, DOI 10.1016/S0168-1702(02)00049-7; GESSAIN A, 1985, LANCET, V2, P407; Grigera PR, 1996, J VIROL, V70, P8492, DOI 10.1128/JVI.70.12.8492-8501.1996; Gromeier M, 2001, CURR OPIN MOL THER, V3, P503; Hawkins LK, 2002, LANCET ONCOL, V3, P17, DOI 10.1016/S1470-2045(01)00618-0; HINUMA Y, 1982, INT J CANCER, V29, P631, DOI 10.1002/ijc.2910290606; Hobbs JA, 2003, HUM IMMUNOL, V64, P82, DOI 10.1016/S0198-8859(02)00702-4; Hobbs JA, 2001, VIRUS RES, V80, P53, DOI 10.1016/S0168-1702(01)00350-1; Huang TG, 2003, MOL THER, V8, P434, DOI 10.1016/S1525-0016(03)00204-1; Kirn D, 2001, NAT MED, V7, P781, DOI 10.1038/89901; Kopecky SA, 2003, J VIROL, V77, P5524, DOI 10.1128/JVI.77.9.5524-5528.2003; Kopecky SA, 2001, J VIROL, V75, P12169, DOI 10.1128/JVI.75.24.12169-12181.2001; Lichty BD, 2004, HUM GENE THER, V15, P821, DOI 10.1089/1043034041839208; LINGE C, 1995, CANCER RES, V55, P4099; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; Matin SF, 2001, CANCER RES, V61, P2261; Matsuoka M, 2003, ONCOGENE, V22, P5131, DOI 10.1038/sj.onc.1206551; Meinhardt G, 1999, J MOL MED-JMM, V77, P282, DOI 10.1007/s001090050351; Mortreux F, 2003, LEUKEMIA, V17, P26, DOI 10.1038/sj.leu.2402777; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; Nguyen JT, 2003, P NATL ACAD SCI USA, V100, P7533, DOI 10.1073/pnas.1031631100; Norman KL, 2001, CYTOKINE GROWTH F R, V12, P271, DOI 10.1016/S1359-6101(00)00024-1; Obuchi M, 2003, J VIROL, V77, P8843, DOI 10.1128/JVI.77.16.8843-8856.2003; OSAME M, 1986, LANCET, V1, P1031; Satoh M, 2002, ONCOGENE, V21, P2466, DOI 10.1038/sj.onc.1205329; Sharif-Askari E, 2001, EMBO J, V20, P3101, DOI 10.1093/emboj/20.12.3101; SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x; Steele TA, 2000, P SOC EXP BIOL MED, V223, P118, DOI 10.1046/j.1525-1373.2000.22317.x; Stojdl DF, 2003, CANCER CELL, V4, P263, DOI 10.1016/S1535-6108(03)00241-1; Stojdl DF, 2000, NAT MED, V6, P821, DOI 10.1038/77558; Sun WH, 1998, BLOOD, V91, P570, DOI 10.1182/blood.V91.2.570.570_570_576; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; Wolf BB, 1999, J BIOL CHEM, V274, P30651, DOI 10.1074/jbc.274.43.30651; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wu JT, 2001, B MATH BIOL, V63, P731, DOI 10.1006/bulm.2001.0245; Yasunaga JI, 2003, INT J HEMATOL, V78, P312, DOI 10.1007/BF02983555; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475	56	25	28	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					349	358		10.1038/sj.onc.1209055	http://dx.doi.org/10.1038/sj.onc.1209055			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16186807				2022-12-25	WOS:000234714100003
J	Carlisle-Moore, L; Gordon, CR; Machutta, CA; Miller, WT; Tonge, PJ				Carlisle-Moore, L; Gordon, CR; Machutta, CA; Miller, WT; Tonge, PJ			Substrate recognition by the human fatty-acid synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE-DINUCLEOTIDE PHOSPHATE; ACYL-BINDING SITES; ENOYL-REDUCTASE; IN-VITRO; MYCOBACTERIUM-TUBERCULOSIS; REACTION-MECHANISM; ESCHERICHIA-COLI; ELEMENTARY STEPS; ACTIVE-SITE; FOOD-INTAKE	The human fatty-acid synthase (HFAS) is a potential target for anti-tumor drug discovery. As a prelude to the design of compounds that target the enoyl reductase (ER) component of HFAS, the recognition of NADPH and exogenous substrates by the ER active site has been investigated. Previous studies demonstrate that modification of Lys-1699 by pyridoxal 5'-phosphate results in a specific decrease in ER activity. For the overall HFAS reaction, the K1699A and K1699Q mutations reduced k(cat) and k(cat)/K-NADPH by 8- and 600-fold, respectively (where K-NADPH indicates the K-m value for NADPH). Thus, Lys-1699 contributes 4 kcal/mol to stabilization of the rate-limiting transition state following NADPH binding, while also stabilizing the most stable ground state after NADPH binding by 3 kcal/ mol. A similar effect of the mutations on the ER partial reaction was observed, in agreement with the proposal that Lys1699 is located in the ER NADPH-binding site. Most unexpectedly, however, both k(cat) and k(cat)/KNADPH for the beta-ketoacyl reductase (BKR) reaction were also impacted by the Lys-1699 mutations, raising the possibility that the ER and BKR activities share a single active site. However, based on previous data indicating that the two reductase activities utilize distinct cofactor binding sites, mutagenesis of Lys-1699 is hypothesized to modulate BKR activity via allosteric effects between the ER and BKR NADPH sites.	SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; SUNY Stony Brook, Grad Program Mol & Cellular Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Tonge, PJ (corresponding author), SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA.	peter.tonge@sunysb.edu	Tonge, Peter J/A-7443-2009	Tonge, Peter J/0000-0003-1606-3471	NATIONAL CANCER INSTITUTE [R01CA058530] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI044639, R01AI044639] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA058530, R01 CA058530-12] Funding Source: Medline; NIAID NIH HHS [R21 AI044639, AIA44639, R01 AI044639] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON VE, 1984, BIOCHEMISTRY-US, V23, P2088, DOI 10.1021/bi00304a033; CARDON JW, 1983, J BIOL CHEM, V258, P4802; CARDON JW, 1982, BIOCHEMISTRY-US, V21, P2863, DOI 10.1021/bi00541a009; Cha SH, 2004, BIOCHEM BIOPH RES CO, V317, P301, DOI 10.1016/j.bbrc.2004.03.026; CHANG SI, 1989, BIOCHEMISTRY-US, V28, P3781, DOI 10.1021/bi00435a023; Chirala SS, 2001, P NATL ACAD SCI USA, V98, P3104, DOI 10.1073/pnas.051635998; Chirala SS, 2003, P NATL ACAD SCI USA, V100, P6358, DOI 10.1073/pnas.0931394100; COGNET JAH, 1985, BIOCHEMISTRY-US, V24, P290, DOI 10.1021/bi00323a008; COGNET JAH, 1983, BIOCHEMISTRY-US, V22, P6281, DOI 10.1021/bi00295a037; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Jayakumar A, 1996, P NATL ACAD SCI USA, V93, P14509, DOI 10.1073/pnas.93.25.14509; JAYAKUMAR A, 1995, P NATL ACAD SCI USA, V92, P8695, DOI 10.1073/pnas.92.19.8695; Joshi AK, 1998, BIOCHEMISTRY-US, V37, P2515, DOI 10.1021/bi971886v; Joshi AK, 1997, BIOCHEMISTRY-US, V36, P2316, DOI 10.1021/bi9626968; KATIYAR SS, 1982, BIOCHEM BIOPH RES CO, V107, P1219, DOI 10.1016/S0006-291X(82)80127-7; Kuhajda FP, 2000, P NATL ACAD SCI USA, V97, P3450, DOI 10.1073/pnas.050582897; Kuhajda FP, 2000, NUTRITION, V16, P202, DOI 10.1016/S0899-9007(99)00266-X; Li JN, 2001, CANCER RES, V61, P1493; Liu BQ, 2002, CANCER CHEMOTH PHARM, V49, P187, DOI 10.1007/s00280-001-0399-x; Nemoto T, 2001, PATHOBIOLOGY, V69, P297, DOI 10.1159/000064636; Oppermann U, 2003, CHEM-BIOL INTERACT, V143, P247, DOI 10.1016/S0009-2797(02)00164-3; Parikh S, 1999, BIOCHEMISTRY-US, V38, P13623, DOI 10.1021/bi990529c; POULOSE AJ, 1981, J BIOL CHEM, V256, P8379; POULOSE AJ, 1980, ARCH BIOCHEM BIOPHYS, V201, P313, DOI 10.1016/0003-9861(80)90516-0; Powell AJ, 2000, J MOL BIOL, V303, P311, DOI 10.1006/jmbi.2000.4139; QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004; Rangan VS, 2001, BIOCHEMISTRY-US, V40, P10792, DOI 10.1021/bi015535z; Sivaraman S, 2003, BIOCHEMISTRY-US, V42, P4406, DOI 10.1021/bi0300229; STOOPS JK, 1981, J BIOL CHEM, V256, P5128; Takahiro T, 2003, CLIN CANCER RES, V9, P2204; Thupari JN, 2004, AM J PHYSIOL-ENDOC M, V287, pE97, DOI 10.1152/ajpendo.00261.2003; Thupari JN, 2002, P NATL ACAD SCI USA, V99, P9498, DOI 10.1073/pnas.132128899; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; WEISS L, 1986, BIOL CHEM H-S, V367, P905, DOI 10.1515/bchm3.1986.367.2.905; Witkowski A, 1996, BIOCHEMISTRY-US, V35, P10569, DOI 10.1021/bi960910m; Witkowski A, 2004, BIOCHEMISTRY-US, V43, P10458, DOI 10.1021/bi048988n	36	9	9	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42612	42618		10.1074/jbc.M507082200	http://dx.doi.org/10.1074/jbc.M507082200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16215233	hybrid, Green Accepted			2022-12-25	WOS:000234200800018
J	Walter, K; Warnecke, G; Bowater, R; Deppert, W; Ella, K				Walter, K; Warnecke, G; Bowater, R; Deppert, W; Ella, K			Tumor suppressor p53 binds with high affinity to CTG center dot CAG trinucleotide repeats and induces topological alterations in mismatched duplexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE CORRELATION SPECTROSCOPY; C-TERMINAL DOMAIN; DNA-BINDING; GENOMIC INSTABILITY; HOLLIDAY JUNCTIONS; TRIPLET REPEATS; POSTTRANSLATIONAL MODIFICATIONS; P53-MEDIATED APOPTOSIS; NEUROLOGICAL DISEASES; DYNAMIC MUTATIONS	DNA binding is central to the ability of p53 to function as a tumor suppressor. In line with the remarkable functional versatility of p53, which can act on DNA as a transcription, repair, recombination, replication, and chromatin accessibility factor, the modes of p53 interaction with DNA are also versatile. One feature common to all modes of p53-DNA interaction is the extraordinary sensitivity of p53 to the topology of its target DNA. Whereas the strong impact of DNA topology has been demonstrated for p53 binding to sequence-specific sites or to DNA lesions, the possibility that DNA structure-dependent recognition may underlie p53 interaction with other types of DNA has not been addressed until now. We demonstrate for the first time that conformationally flexible CTG center dot CAG trinucleotide repeats comprise a novel class of p53-binding sites targeted by p53 in a DNA structure-dependent mode in vitro and in vivo. Our major finding is that p53 binds to CTG center dot CAG tracts by different modes depending on the conformation of DNA. Although p53 binds preferentially to hairpins formed by either CTG or CAG strands, it can also bind to linear forms of CTG center dot CAG tracts such as canonic B DNA or mismatched duplex. Intriguingly, by binding to a mismatched duplex p53 can induce further topological alterations in DNA, indicating that p53 may act as a DNA topology-modulating factor.	Univ Schleswig Holstein, Neuro Oncol Grp, Dept Neurosurg, D-23538 Lubeck, Germany; Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England	University of Kiel; Schleswig Holstein University Hospital; Heinrich Pette Institute; University of East Anglia	Ella, K (corresponding author), Univ Schleswig Holstein, Neuro Oncol Grp, Dept Neurosurg, Campus Luebeck,Ratzeburger Allee 160, D-23538 Lubeck, Germany.	ella.kim@neurochirurgie.uni-luebeck.de	Bowater, Richard P/A-4227-2010	Bowater, Richard P/0000-0002-2745-7807				Ahn J, 2001, NAT STRUCT BIOL, V8, P730, DOI 10.1038/nsb0901-730; Albertoni M, 2002, ONCOGENE, V21, P4212, DOI 10.1038/sj.onc.1205610; Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Attardi LD, 2005, MUTAT RES-FUND MOL M, V569, P145, DOI 10.1016/j.mrfmmm.2004.04.019; Bacolla A, 2004, J BIOL CHEM, V279, P47411, DOI 10.1074/jbc.R400028200; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Bowater RP, 2001, PROG NUCLEIC ACID RE, V66, P159; Cain C, 2000, J BIOL CHEM, V275, P39944, DOI 10.1074/jbc.M002509200; Chattopadhyay B, 2005, NEUROSCI LETT, V374, P81, DOI 10.1016/j.neulet.2004.10.018; Chi LM, 2005, NUCLEIC ACIDS RES, V33, P1604, DOI 10.1093/nar/gki307; Degtyareva N, 2001, J BIOL CHEM, V276, P8778, DOI 10.1074/jbc.M006795200; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gohler T, 2002, J BIOL CHEM, V277, P41192, DOI 10.1074/jbc.M202344200; Gohler T, 2005, NUCLEIC ACIDS RES, V33, P1087, DOI 10.1093/nar/gki252; Gottifredi V, 2005, SEMIN CELL DEV BIOL, V16, P355, DOI 10.1016/j.semcdb.2005.02.011; Grillo G, 2003, NUCLEIC ACIDS RES, V31, P3608, DOI 10.1093/nar/gkg548; Hou MH, 2002, NUCLEIC ACIDS RES, V30, P4910, DOI 10.1093/nar/gkf619; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Jett SD, 2000, J MOL BIOL, V299, P585, DOI 10.1006/jmbi.2000.3759; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kim E, 1999, ONCOGENE, V18, P7310, DOI 10.1038/sj.onc.1203139; Kim E, 2003, ONCOGENE, V22, P7716, DOI 10.1038/sj.onc.1207155; Kim E, 2003, BIOCHEM CELL BIOL, V81, P141, DOI 10.1139/o03-046; Kim E, 1997, ONCOGENE, V15, P857, DOI 10.1038/sj.onc.1201412; Kovtun IV, 2001, BIOCHEM CELL BIOL, V79, P325, DOI 10.1139/bcb-79-3-325; Lahiri M, 2004, MOL CELL, V15, P287, DOI 10.1016/j.molcel.2004.06.034; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; Li L, 2005, J CELL BIOCHEM, V94, P298, DOI 10.1002/jcb.20355; Liu YG, 2004, CANCER BIOL THER, V3, P1102, DOI 10.4161/cbt.3.11.1189; Lowndes NF, 2000, CURR OPIN GENET DEV, V10, P17, DOI 10.1016/S0959-437X(99)00050-7; Mateu MG, 1998, EMBO J, V17, P2748, DOI 10.1093/emboj/17.10.2748; McKinney K, 2002, MOL CELL BIOL, V22, P6797, DOI 10.1128/MCB.22.19.6797-6808.2002; Milyavsky M, 2001, NUCLEIC ACIDS RES, V29, P5207, DOI 10.1093/nar/29.24.5207; Mitas M, 1997, NUCLEIC ACIDS RES, V25, P2245, DOI 10.1093/nar/25.12.2245; Motoyama N, 2004, CURR OPIN GENET DEV, V14, P11, DOI 10.1016/j.gde.2003.12.003; Nakamura Y, 2004, CANCER SCI, V95, P7, DOI 10.1111/j.1349-7006.2004.tb03163.x; Nie Y, 2000, MOL CELL BIOL, V20, P741, DOI 10.1128/MCB.20.3.741-748.2000; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; Pearson CE, 1997, HUM MOL GENET, V6, P1117, DOI 10.1093/hmg/6.7.1117; Pearson CE, 2002, NUCLEIC ACIDS RES, V30, P4534, DOI 10.1093/nar/gkf572; Pearson CE, 1998, CURR OPIN STRUC BIOL, V8, P321, DOI 10.1016/S0959-440X(98)80065-1; Petruska J, 1996, NUCLEIC ACIDS RES, V24, P1992, DOI 10.1093/nar/24.11.1992; Robles AI, 2001, ACTA ONCOL, V40, P696; Rosche WA, 1996, J BACTERIOL, V178, P5042, DOI 10.1128/jb.178.16.5042-5044.1996; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Saito S, 2003, J BIOL CHEM, V278, P37536, DOI 10.1074/jbc.M305135200; Sinden RR, 2002, J BIOSCIENCES, V27, P53, DOI 10.1007/BF02703683; Stansel RM, 2002, J BIOL CHEM, V277, P11625, DOI 10.1074/jbc.C100764200; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Steffen SE, 2001, ARCH BIOCHEM BIOPHYS, V388, P165, DOI 10.1006/abbi.2001.2286; Stros M, 2004, BIOCHEMISTRY-US, V43, P7215, DOI 10.1021/bi049928k; Subramanian D, 2005, BIOCHEMISTRY-US, V44, P2536, DOI 10.1021/bi048700u; Subramanian D, 2002, NUCLEIC ACIDS RES, V30, P2427, DOI 10.1093/nar/30.11.2427; Suck Dietrich, 1994, Journal of Molecular Recognition, V7, P65, DOI 10.1002/jmr.300070203; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vukojevic V, 2004, BIOCHEM BIOPH RES CO, V316, P1150, DOI 10.1016/j.bbrc.2004.02.167; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; Wells RD, 2005, NUCLEIC ACIDS RES, V33, P3785, DOI 10.1093/nar/gki697; Wells RD, 1997, AM J PSYCHIAT, V154, P887; Wiesmueller Lisa, 2001, Journal of Biomedicine and Biotechnology, V1, P7, DOI 10.1155/S1110724301000043; Wolcke J, 2003, J BIOL CHEM, V278, P32587, DOI 10.1074/jbc.M303615200; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; Zheng MX, 1996, J MOL BIOL, V264, P323, DOI 10.1006/jmbi.1996.0643; Zhou BBS, 2003, CANCER BIOL THER, V2, pS16; Zink D, 2002, ONCOGENE, V21, P4788, DOI 10.1038/sj.onc.1205614	74	22	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42497	42507		10.1074/jbc.M507038200	http://dx.doi.org/10.1074/jbc.M507038200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16230356	hybrid, Green Accepted			2022-12-25	WOS:000234200800005
J	Fortin, PD; MacPherson, I; Neau, DB; Bolin, JT; Eltis, LD				Fortin, PD; MacPherson, I; Neau, DB; Bolin, JT; Eltis, LD			Directed evolution of a ring-cleaving dioxygenase for polychlorinated biphenyl degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSSESS HIGHER SPECIFICITIES; EXTRADIOL DIOXYGENASES; MICROBIAL-DEGRADATION; ENHANCED DEGRADATION; ENZYMES; MUTAGENESIS; NAPHTHALENE; STRAIN; REGION; BPHA	DoxG, an extradiol dioxygenase involved in the aerobic catabolism of naphthalene, possesses a weak ability to cleave 3,4-dihydroxybiphenyls ( 3,4-DHB), critical polychlorinated biphenyl metabolites. A directed evolution strategy combining error-prone PCR, saturation mutagenesis, and DNA shuffling was used to improve the polychlorinated biphenyl-degrading potential of DoxG. Screening was facilitated through analysis of filtered, digital imaging of plated colonies. A simple scheme, which is readily adaptable to other activities, enabled the screening of > 10(5) colonies/h. The best variant, designated DoxG(SMA2), cleaved 3,4-DHB with an apparent specificity constant of 2.0 +/- 0.3 x 10(6) m(-1) s(-1), which is 770 times that of wild-type (WT) DoxG. The specificities of DoxGSMA2 for 1,2-DHN and 2,3-DHB were increased by 6.7-fold and reduced by 2-fold, respectively, compared with the WT enzyme. DoxGSMA2 contained three substituted residues with respect to the WT enzyme: L190M, S191W, and L242S. Structural data indicate that the side chains of residues 190 and 242 occur on opposite walls of the substrate binding pocket and may interact directly with the distal ring of 3,4-DHB or influence contacts between this substrate and other residues. Thus, the introduction of two bulkier residues on one side of the substrate binding pocket and a smaller residue on the other may reshape the binding pocket and alter the catalytically relevant interactions of 3,4- DHB with the enzyme and dioxygen. Kinetic analyses reveal that the substitutions are anti-cooperative.	Univ British Columbia, Dept Microbiol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Biochem, Vancouver, BC V6T 1Z3, Canada; Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA	University of British Columbia; University of British Columbia; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Eltis, LD (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, 1365-2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	leltis@interchange.ubc.ca	Eltis, Lindsay/J-8272-2015	Eltis, Lindsay/0000-0002-6774-8158; Fortin, Pascal/0000-0001-9796-791X	NIGMS NIH HHS [R01-GM52381, T32-GM008296] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008296] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barriault D, 2004, J BIOL CHEM, V279, P47480, DOI 10.1074/jbc.M406805200; Barriault D, 1998, APPL ENVIRON MICROB, V64, P4637; Barriault D, 2002, J BACTERIOL, V184, P3794, DOI 10.1128/JB.184.14.3794-3800.2002; BOPP LH, 1986, J IND MICROBIOL, V1, P23, DOI 10.1007/BF01569413; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; Cho CMH, 2004, APPL ENVIRON MICROB, V70, P4681, DOI 10.1128/AEM.70.8.4681-4685.2004; Cornish-Bowden A., 1995, ANAL ENZYME KINETIC; Dai SD, 2002, NAT STRUCT BIOL, V9, P934, DOI 10.1038/nsb866; DeLano W.L., 2005, PYMOL MOL GRAPHICS S; DELORENZO V, 1993, GENE, V123, P17, DOI 10.1016/0378-1119(93)90533-9; DENOME SA, 1993, J BACTERIOL, V175, P6890, DOI 10.1128/jb.175.21.6890-6901.1993; Fortin PD, 2005, J BACTERIOL, V187, P415, DOI 10.1128/JB.187.2.415-421.2005; Furukawa K, 2004, J BACTERIOL, V186, P5189, DOI 10.1128/JB.186.16.5189-5196.2004; Gibson DT, 2000, CURR OPIN BIOTECH, V11, P236, DOI 10.1016/S0958-1669(00)00090-2; HERRERO M, 1990, J BACTERIOL, V172, P6557, DOI 10.1128/jb.172.11.6557-6567.1990; Kumamaru T, 1998, NAT BIOTECHNOL, V16, P663, DOI 10.1038/nbt0798-663; Li QS, 2000, CHEM-EUR J, V6, P1531, DOI 10.1002/(SICI)1521-3765(20000502)6:9<1531::AID-CHEM1531>3.3.CO;2-4; Mildvan AS, 2004, BIOCHEMISTRY-US, V43, P14517, DOI 10.1021/bi048052e; Miyazaki K, 1999, J MOL EVOL, V49, P716, DOI 10.1007/PL00006593; NEAU DB, 2004, THESIS PURDUE U; Nerdinger S, 1999, CHEM COMMUN, P2259, DOI 10.1039/a907279i; Reetz MT, 2004, P NATL ACAD SCI USA, V101, P5716, DOI 10.1073/pnas.0306866101; Seah SYK, 2001, J BACTERIOL, V183, P1511, DOI 10.1128/JB.183.5.1511-1516.2001; Smith J.A., 2000, CURRENT PROTOCOLS MO; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; Suenaga H, 2001, J BACTERIOL, V183, P5441, DOI 10.1128/JB.183.18.5441-5444.2001; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Taylor SV, 2001, ANGEW CHEM INT EDIT, V40, P3310, DOI 10.1002/1521-3773(20010917)40:18<3310::AID-ANIE3310>3.0.CO;2-P; Vaillancourt FH, 1998, J BIOL CHEM, V273, P34887, DOI 10.1074/jbc.273.52.34887; Vaillancourt FH, 2003, J BACTERIOL, V185, P1253, DOI 10.1128/JB.185.4.1253-1260.2003; Valetti F, 2004, NAT PROD REP, V21, P490, DOI 10.1039/b202342n; Zhang JH, 1997, P NATL ACAD SCI USA, V94, P4504, DOI 10.1073/pnas.94.9.4504	32	21	25	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42307	42314		10.1074/jbc.M510456200	http://dx.doi.org/10.1074/jbc.M510456200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16227200	hybrid			2022-12-25	WOS:000233992700060
J	Zhang, ZR; Song, BL; McCarty, NA				Zhang, ZR; Song, BL; McCarty, NA			State-dependent chemical reactivity of an engineered cysteine reveals conformational changes in the outer vestibule of the cystic fibrosis transmembrane conductance regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING DOMAINS; CHLORIDE CHANNEL; CL-CHANNELS; ATP HYDROLYSIS; CFTR CHANNELS; PORE; PERMEATION; BLOCK; RESIDUES	Cystic fibrosis transmembrane conductance regulator (CFTR) chloride channels are gated by binding and hydrolysis of ATP at the nucleotide-binding domains (NBDs). We used covalent modification of CFTR channels bearing a cysteine engineered at position 334 to investigate changes in pore conformation that might accompany channel gating. In single R334C-CFTR channels studied in excised patches, modification by [2-(trimethylammonium)ethyl] methanethiosulfonate (MTSET+), which increases conductance, occurred only during channel closed states. This suggests that the rate of reaction of the cysteine was greater in closed channels than in open channels. R334C-CFTR channels in outside-out macropatches activated by ATP alone were modified with first order kinetics upon rapid exposure to MTSET+. Modification was much slower when channels were locked open by the addition of nonhydrolyzable nucleotide or when the R334C mutation was coupled to a second mutation, K1250A, which greatly decreases channel closing rate. In contrast, modification was faster in R334C/K464A-CFTR channels, which exhibit prolonged interburst closed states. These data indicate that the reactivity of the engineered cysteine in R334C-CFTR is state-dependent, providing evidence of changes in pore conformation coupled to ATP binding and hydrolysis at the NBDs. The data also show that maneuvers that lock open R334C-CFTR do so by locking channels into the prominent s2 subconductance state, suggesting that the most stable conducting state of the pore reflects the fully occupied, prehydrolytic state of the NBDs.	Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA	University System of Georgia; Georgia Institute of Technology	McCarty, NA (corresponding author), Georgia Inst Technol, Sch Biol, 310 Ferst Dr, Atlanta, GA 30332 USA.	Nael.McCarty@biology.gatech.edu			NIDDK NIH HHS [DK-056481] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK056481, R01DK056481] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; DAWSON DC, 2003, CFTR CHLORIDE CHANNE, P1; Fuller MD, 2005, BIOPHYS J, V89, P3960, DOI 10.1529/biophysj.105.060731; Fuller MD, 2004, AM J PHYSIOL-CELL PH, V287, pC1328, DOI 10.1152/ajpcell.00162.2004; Gadsby DC, 1998, ACTA PHYSIOL SCAND, V163, P247; GUNDERSON KL, 1995, CELL, V82, P231, DOI 10.1016/0092-8674(95)90310-0; Harrington MA, 2002, BIOPHYS J, V82, P1278, DOI 10.1016/S0006-3495(02)75484-2; HAWS C, 1992, AM J PHYSIOL, V263, pL692, DOI 10.1152/ajplung.1992.263.6.L692; HWANG TC, 1994, P NATL ACAD SCI USA, V91, P4698, DOI 10.1073/pnas.91.11.4698; Ishihara H, 1997, AM J PHYSIOL-CELL PH, V273, pC1278, DOI 10.1152/ajpcell.1997.273.4.C1278; Lansdell KA, 1998, J PHYSIOL-LONDON, V512, P751, DOI 10.1111/j.1469-7793.1998.751bd.x; Linsdell P, 1998, J GEN PHYSIOL, V111, P601, DOI 10.1085/jgp.111.4.601; MCCARTY NA, 1993, J GEN PHYSIOL, V102, P1, DOI 10.1085/jgp.102.1.1; McCarty NA, 2000, J EXP BIOL, V203, P1947; MCDONOUGH S, 1994, NEURON, V13, P623, DOI 10.1016/0896-6273(94)90030-2; Powe AC, 2002, J PHYSIOL-LONDON, V539, P333, DOI 10.1113/jphysiol.2001.013162; RIORDAN JR, 1989, SCIENCE, V245, P1066; Smith SS, 2001, J GEN PHYSIOL, V118, P407, DOI 10.1085/jgp.118.4.407; Tao T, 1996, BIOPHYS J, V70, P743, DOI 10.1016/S0006-3495(96)79614-5; Vergani P, 2003, J GEN PHYSIOL, V121, P17, DOI 10.1085/jgp.20028673; Vergani P, 2005, NATURE, V433, P876, DOI 10.1038/nature03313; Wang F, 1998, J GEN PHYSIOL, V111, P477, DOI 10.1085/jgp.111.3.477; XIE JX, 1995, J BIOL CHEM, V270, P28084; Yue HW, 2000, J BIOL CHEM, V275, P10030, DOI 10.1074/jbc.275.14.10030; Zhang ZR, 2005, J BIOL CHEM, V280, P458, DOI 10.1074/jbc.M409626200; Zhang ZR, 2000, J MEMBRANE BIOL, V175, P35, DOI 10.1007/s002320001053	26	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					41997	42003		10.1074/jbc.M510242200	http://dx.doi.org/10.1074/jbc.M510242200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16227620	hybrid			2022-12-25	WOS:000233992700025
J	Luo, M; Jones, SM; Flamand, N; Aronoff, DM; Peters-Golden, M; Brock, TG				Luo, M; Jones, SM; Flamand, N; Aronoff, DM; Peters-Golden, M; Brock, TG			Phosphorylation by protein kinase a inhibits nuclear import of 5-lipoxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID METABOLISM; LEUKOTRIENE SYNTHESIS; HUMAN-MONOCYTES; PHOSPHATASE 2A; EP4 RECEPTOR; LOCALIZATION; PROSTAGLANDINS; EXPRESSION; RELEASE; IDENTIFICATION	The enzyme 5-lipoxygenase initiates the synthesis of leukotrienes from arachidonic acid. Protein kinase A phosphorylates 5-lipoxygenase on Ser(523), and this reduces its activity. We report here that phosphorylation of Ser(523) also shifts the subcellular distribution of 5-lipoxygenase from the nucleus to the cytoplasm. Phosphorylation and redistribution of 5-lipoxygenase could be produced by overexpression of the protein kinase A catalytic subunit alpha, by pharmacological activators of protein kinase A, and by prostaglandin E-2. Mimicking phosphorylation by replacing Ser(523) with glutamic acid caused cytoplasmic localization; replacement of Ser(523) with alanine prevented phosphorylation and redistribution in response to protein kinase A activation. Because Ser(523) is positioned within the nuclear localization sequence-518 of 5-lipoxygenase, the ability of protein kinaseA to phosphorylate and alter the localization of green fluorescent protein fused to the nuclear localization sequence-518 peptide was also tested. Site-directed replacement of Ser(523) with glutamic acid within the peptide impaired nuclear accumulation; overexpression of the protein kinaseA catalytic subunit alpha and pharmacological activation of protein kinase caused phosphorylation of the fusion protein at Ser(523), and the phosphorylated protein was found chiefly in the cytoplasm. Taken together, these results indicate that phosphorylation of Ser(523) inhibits the nuclear import function of a nuclear localization sequence, resulting in the accumulation of 5-lipoxygenase enzyme in the cytoplasm. As cytoplasmic localization can be associated with reduced leukotriene synthetic capacity, phosphorylation of Ser(523) serves to inhibit leukotriene production by both impairing catalytic activity and by placing the enzyme in a site that is unfavorable for action.	Univ Michigan Hlth Syst, Dept Internal Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA; Univ Michigan Hlth Syst, Dept Infect Dis, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Brock, TG (corresponding author), Univ Michigan, Dept Internal Med, 6301 MSRB 3, Ann Arbor, MI 48109 USA.	brocko@umich.edu	Flamand, Nicolas/H-5823-2019	Flamand, Nicolas/0000-0001-5944-7200; Aronoff, David/0000-0003-4587-6121	NHLBI NIH HHS [HL50496, HL078727] Funding Source: Medline; NIAID NIH HHS [R01 AI43955] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL078727, R01HL050496] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aronoff DM, 2004, J IMMUNOL, V173, P559, DOI 10.4049/jimmunol.173.1.559; Brock TG, 1997, J BIOL CHEM, V272, P8276, DOI 10.1074/jbc.272.13.8276; Brock TG, 1999, J IMMUNOL, V162, P1669; Burelout C, 2004, MOL PHARMACOL, V66, P293, DOI 10.1124/mol.66.2.293; Christopoulos A, 2003, J BIOL CHEM, V278, P3293, DOI 10.1074/jbc.C200629200; Coffey MJ, 1996, J IMMUNOL, V157, P393; Covin RB, 1998, AM J PHYSIOL-LUNG C, V275, pL303, DOI 10.1152/ajplung.1998.275.2.L303; Cowburn AS, 1999, J IMMUNOL, V163, P456; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Drazen J M, 1994, Adv Prostaglandin Thromboxane Leukot Res, V22, P251; Dwyer JH, 2004, NEW ENGL J MED, V350, P29, DOI 10.1056/NEJMoa025079; Feschenko MS, 2002, J PHARMACOL EXP THER, V302, P111, DOI 10.1124/jpet.302.1.111; Flamand N, 2002, MOL PHARMACOL, V62, P250, DOI 10.1124/mol.62.2.250; Flamand N, 2000, AM J RESP CRIT CARE, V161, pS88, DOI 10.1164/ajrccm.161.supplement_1.ltta-18; FONTEH AN, 1993, J IMMUNOL, V151, P339; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; GODFREY RW, 1987, J CELL PHYSIOL, V131, P384, DOI 10.1002/jcp.1041310310; HAM EA, 1983, P NATL ACAD SCI-BIOL, V80, P4349, DOI 10.1073/pnas.80.14.4349; Hanaka H, 2002, BIOCHEM J, V361, P505, DOI 10.1042/0264-6021:3610505; Harizi H, 2003, J LEUKOCYTE BIOL, V73, P756, DOI 10.1189/jlb.1002483; Healy AM, 1999, J BIOL CHEM, V274, P29812, DOI 10.1074/jbc.274.42.29812; Hsieh FH, 2001, J EXP MED, V193, P123, DOI 10.1084/jem.193.1.123; Iwasaki K, 2003, ORAL MICROBIOL IMMUN, V18, P150, DOI 10.1034/j.1399-302X.2003.00046.x; Jones SM, 2003, J BIOL CHEM, V278, P10257, DOI 10.1074/jbc.M211021200; Jones SM, 2002, J BIOL CHEM, V277, P38550, DOI 10.1074/jbc.M206070200; Kooman W J, 1970, J Immunol, V105, P1096; Luo M, 2004, J BIOL CHEM, V279, P41512, DOI 10.1074/jbc.M312568200; Luo M, 2003, P NATL ACAD SCI USA, V100, P12165, DOI 10.1073/pnas.2133253100; Luo M, 2004, TRAFFIC, V5, P847, DOI 10.1111/j.1600-0854.2004.00227.x; Pemberton LF, 2005, TRAFFIC, V6, P187, DOI 10.1111/j.1600-0854.2005.00270.x; Peters-Golden M, 2002, AM J RESP CRIT CARE, V165, P229, DOI 10.1164/ajrccm.165.2.2104050; Revan S, 1996, J BIOL CHEM, V271, P17114, DOI 10.1074/jbc.271.29.17114; Schuchner S, 1999, J VIROL, V73, P9266; SKERRETT SJ, 1990, J IMMUNOL, V144, P1052; THORSEN S, 1989, AIDS, V3, P651, DOI 10.1097/00002030-198910000-00006; Treffkorn L, 2004, PROSTAG OTH LIPID M, V74, P113, DOI 10.1016/j.prostaglandins.2004.07.005; Werz O, 2000, P NATL ACAD SCI USA, V97, P5261, DOI 10.1073/pnas.050588997; WIGHTMAN PD, 1990, J BIOL CHEM, V265, P9176; Wilborn J, 1996, J CLIN INVEST, V97, P1827, DOI 10.1172/JCI118612	39	62	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40609	40616		10.1074/jbc.M507045200	http://dx.doi.org/10.1074/jbc.M507045200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16230355	hybrid			2022-12-25	WOS:000233666600029
J	Gao, L; Tse, SW; Conrad, C; Andreadis, A				Gao, L; Tse, SW; Conrad, C; Andreadis, A			Saitohin, which is nested in the tau locus and confers allele-specific susceptibility to several neurodegenerative diseases, interacts with peroxiredoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSELENIUM GLUTATHIONE-PEROXIDASE; PROGRESSIVE SUPRANUCLEAR PALSY; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; PARKINSONS-DISEASE; Q7R POLYMORPHISM; EXPRESSION PATTERNS; 1-CYS PEROXIREDOXIN; GENE POLYMORPHISM; HUMAN BRAIN	Saitohin is a gene unique to humans and their closest relatives, the function of which is not yet known. Saitohin contains a single polymorphism (Q7R), and its Q and R alleles belong to the H1 and H2 tau haplotype, respectively. The Saitohin Q allele confers susceptibility to several neurodegenerative diseases. To get a handle on Saitohin function, we used it as a bait in a yeast two-hybrid screen. By this assay and subsequent co-immunoprecipitation and glutathione S-transferase pull-down assays, we discovered and confirmed that Saitohin interacts with peroxiredoxin 6, a unique member of that family that is bifunctional and the levels of which increase in Pick disease. The strength of the interaction appeared to be allele-specific, giving the first distinction between the two forms of Saitohin.	Univ Massachusetts, Shriver Ctr, Sch Med, Waltham, MA 02452 USA; Massachusetts Gen Hosp, Dept Neurol, Alzheimers Unit, Charlestown, MA 02129 USA; Univ Massachusetts, Med Ctr, Dept Cell Biol, Worcester, MA 01655 USA	University of Massachusetts System; Harvard University; Massachusetts General Hospital; University of Massachusetts System; University of Massachusetts Worcester	Andreadis, A (corresponding author), Univ Massachusetts, Shriver Ctr, Sch Med, 200 Trapelo Rd, Waltham, MA 02452 USA.	athena.andreadis@umassmed.edu			NIA NIH HHS [AG018486] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG018486] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Andreadis A, 2005, BBA-MOL BASIS DIS, V1739, P91, DOI 10.1016/j.bbadis.2004.08.010; Chen JW, 2000, J BIOL CHEM, V275, P28421, DOI 10.1074/jbc.M005073200; Choi HJ, 1998, NAT STRUCT BIOL, V5, P400, DOI 10.1038/nsb0598-400; Clark LN, 2003, NEUROSCI LETT, V347, P17, DOI 10.1016/S0304-3940(03)00635-9; Combarros O, 2003, DEMENT GERIATR COGN, V16, P132, DOI 10.1159/000071000; Conrad C, 2004, J NEUROCHEM, V89, P179, DOI 10.1046/j.1471-4159.2004.02320.x; Conrad C, 2002, P NATL ACAD SCI USA, V99, P7751, DOI 10.1073/pnas.112194599; Cook L, 2002, ANN NEUROL, V52, P690, DOI 10.1002/ana.10362; de Silva R, 2003, NEUROLOGY, V61, P407, DOI 10.1212/01.WNL.0000073140.25533.90; Ezquerra M, 2004, J NEUROL NEUROSUR PS, V75, P155; Farooqui AA, 2004, NEUROCHEM RES, V29, P1961, DOI 10.1007/s11064-004-6871-3; Fatma N, 2001, J BIOL CHEM, V276, P48899, DOI 10.1074/jbc.M100733200; Fisher AB, 1999, J BIOL CHEM, V274, P21326, DOI 10.1074/jbc.274.30.21326; Fujii T, 2001, EUR J BIOCHEM, V268, P218, DOI 10.1046/j.1432-1033.2001.01843.x; Goedert M, 2005, BBA-MOL BASIS DIS, V1739, P240, DOI 10.1016/j.bbadis.2004.08.007; Holzer M, 2004, GENE, V341, P313, DOI 10.1016/j.gene.2004.07.013; Krapfenbauer K, 2003, BRAIN RES, V967, P152, DOI 10.1016/S0006-8993(02)04243-9; Krapfenbauer K, 2002, ELECTROPHORESIS, V23, P2541, DOI 10.1002/1522-2683(200208)23:15<2541::AID-ELPS2541>3.0.CO;2-1; Lee TH, 1999, GENE, V234, P337, DOI 10.1016/S0378-1119(99)00190-0; Levecque C, 2004, J NEUROL NEUROSUR PS, V75, P478, DOI 10.1136/jnnp.2003.015750; Leyens G, 2003, COMP BIOCHEM PHYS B, V136, P943, DOI 10.1016/S1096-4959(03)00290-2; Oliveira SA, 2003, NEUROSCI LETT, V347, P143, DOI 10.1016/S0304-3940(03)00670-0; Phelan SA, 1999, ANTIOXID REDOX SIGN, V1, P571, DOI 10.1089/ars.1999.1.4-571; Power JHT, 2002, AM J PATHOL, V161, P885, DOI 10.1016/S0002-9440(10)64249-6; Salmon M, 2004, FEBS LETT, V557, P26, DOI 10.1016/S0014-5793(03)01437-6; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Seripa D, 2004, NEUROLOGY, V62, P1631, DOI 10.1212/01.WNL.0000125693.59817.31; Sparling NE, 2003, REDOX REP, V8, P87, DOI 10.1179/135100003125001404; Streffer JR, 2003, J NEUROL NEUROSUR PS, V74, P362, DOI 10.1136/jnnp.74.3.362; Tanahashi H, 2004, NEUROREPORT, V15, P175, DOI 10.1097/00001756-200401190-00034; Verpillat P, 2002, ANN NEUROL, V52, P829, DOI 10.1002/ana.10384; Wang JN, 2004, J NEUROCHEM, V88, P1078, DOI 10.1046/j.1471-4159.2003.02232.x; Wang XS, 2003, J BIOL CHEM, V278, P25179, DOI 10.1074/jbc.M302706200; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8	34	24	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39268	39272		10.1074/jbc.M506116200	http://dx.doi.org/10.1074/jbc.M506116200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16186110	hybrid			2022-12-25	WOS:000233362200044
J	Beinfeld, MC; Blum, A; Vishnuvardhan, D; Fanous, S; Marchand, JE				Beinfeld, MC; Blum, A; Vishnuvardhan, D; Fanous, S; Marchand, JE			Cholecystokinin levels in prohormone convertase 2 knock-out mouse brain regions reveal a complex phenotype of region-specific alterations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPRESSION; CAMP RESPONSE ELEMENTS; RAT-BRAIN; PRO-CCK; CHROMOSOMAL LOCALIZATION; GENE-EXPRESSION; CDNA STRUCTURE; CELL-LINE; PROHORMONE; PC1	Prohormone convertase 2 is widely co-localized with cholecystokinin in rodent brain. To examine its role in cholecystokinin processing, cholecystokinin levels were measured in dissected brain regions from prohormone convertase 2 knock-out mice. Cholecystokinin levels were lower in hippocampus, septum, thalamus, mesencephalon, and pons in knock-out mice than wild-type mice. In cerebral cortex, cortex-related structures and olfactory bulb, cholecystokinin levels were higher than wild type. Female mice were more affected by the loss of prohormone convertase 2 than male mice. The decrease in cholecystokinin levels in these brain regions shows that prohormone convertase 2 is important for cholecystokinin processing. Quantitative polymerase chain reaction measurements were performed to examine the relationship between peptide levels and cholecystokinin and enzyme expression. They revealed that cholecystokinin and prohormone convertase 1 mRNA levels in cerebral cortex and olfactory bulb were actually lower in knock-out than wild type, whereas their expression in other brain regions of knock-out mouse brain was the same as wild type. Female mice frequently had higher expression of cholecystokinin and prohormone convertase 1, 2, and 5 mRNA than male mice. The loss of prohormone convertase 2 alters CCK processing in specific brain regions. This loss also appears to trigger compensatory mechanisms in cerebral cortex and olfactory bulb that produce elevated levels of cholecystokinin but do not involve increased expression of cholecystokinin, prohormone convertase 1 or 5 mRNA.	Tufts Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Anat & Cell Biol, Boston, MA 02111 USA	Tufts University; Tufts University	Beinfeld, MC (corresponding author), Tufts Univ, Sch Med, Dept Pharmacol & Expt Therapeut, 136 Harrison Ave, Boston, MA 02111 USA.	Margery.beinfeld@tufts.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031602] Funding Source: NIH RePORTER; NINDS NIH HHS [NS31602] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Beinfeld MC, 1998, PEPTIDES, V19, P1393, DOI 10.1016/S0196-9781(98)00098-9; BEINFELD MC, 1992, NEUROPEPTIDES, V22, P213, DOI 10.1016/0143-4179(92)90048-2; Beinfeld MC, 2003, LIFE SCI, V72, P747, DOI 10.1016/S0024-3205(02)02330-5; BEINFELD MC, 1980, J LIQ CHROMATOGR, V3, P1367, DOI 10.1080/01483918008062782; Beinfeld MC, 1996, REGUL PEPTIDES, V67, P75, DOI 10.1016/S0167-0115(96)00115-2; BEINFELD MC, 1981, BRAIN RES, V212, P51, DOI 10.1016/0006-8993(81)90031-7; Cain BM, 2004, J NEUROCHEM, V89, P307, DOI 10.1046/j.1471-4159.2003.02295.x; Cain BM, 2003, J COMP NEUROL, V467, P307, DOI 10.1002/cne.10924; Cain BM, 2001, PEPTIDES, V22, P1271, DOI 10.1016/S0196-9781(01)00451-X; DONG W, 1995, J NEUROSCI, V15, P1778, DOI 10.1523/JNEUROSCI.15-03-01778.1995; Dong WJ, 1997, J NEUROSCI, V17, P563; Furuta M, 1997, P NATL ACAD SCI USA, V94, P6646, DOI 10.1073/pnas.94.13.6646; HANDELMANN GE, 1983, PEPTIDES, V4, P331, DOI 10.1016/0196-9781(83)90143-2; Hansen TV, 1999, MOL ENDOCRINOL, V13, P466, DOI 10.1210/me.13.3.466; HAUN RS, 1989, ENDOCRINOLOGY, V125, P850, DOI 10.1210/endo-125-2-850; JANSEN E, 1995, J BIOL CHEM, V270, P15391, DOI 10.1074/jbc.270.25.15391; Jansen E, 1997, J BIOL CHEM, V272, P2500; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LUSSON J, 1993, P NATL ACAD SCI USA, V90, P6691, DOI 10.1073/pnas.90.14.6691; Miller R, 2003, NEUROPEPTIDES, V37, P140, DOI 10.1016/S0143-4179(03)00027-1; NAKAGAWA T, 1993, J BIOCHEM-TOKYO, V113, P132, DOI 10.1093/oxfordjournals.jbchem.a124015; Nielsen FC, 1996, DNA CELL BIOL, V15, P53, DOI 10.1089/dna.1996.15.53; Rehfeld JF, 2002, J NEUROCHEM, V83, P1329, DOI 10.1046/j.1471-4159.2002.01244.x; SCHAFER MKH, 1993, J NEUROSCI, V13, P1258; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; Seidah NG, 1996, P NATL ACAD SCI USA, V93, P3388, DOI 10.1073/pnas.93.8.3388; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; Villeneuve P, 1999, NEUROSCIENCE, V92, P641, DOI 10.1016/S0306-4522(98)00763-5; Villeneuve P, 2000, J COMP NEUROL, V424, P461, DOI 10.1002/1096-9861(20000828)424:3<461::AID-CNE5>3.0.CO;2-J; Vishnuvardhan D, 2000, BIOCHEM BIOPH RES CO, V273, P188, DOI 10.1006/bbrc.2000.2915; Winsky-Sommerer P, 2000, J COMP NEUROL, V424, P439, DOI 10.1002/1096-9861(20000828)424:3<439::AID-CNE4>3.0.CO;2-1; YOON JY, 1994, ENDOCRINE, V2, P973; Zhu XR, 2002, P NATL ACAD SCI USA, V99, P10293, DOI 10.1073/pnas.162352599	33	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38410	38415		10.1074/jbc.M500055200	http://dx.doi.org/10.1074/jbc.M500055200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16174778	hybrid			2022-12-25	WOS:000233239800037
J	Yamamoto, M; Clark, JD; Pastor, JV; Gurnani, P; Nandi, A; Kurosu, H; Miyoshi, M; Ogawa, Y; Castrillon, DH; Rosenblatt, KP; Kuro-o, M				Yamamoto, M; Clark, JD; Pastor, JV; Gurnani, P; Nandi, A; Kurosu, H; Miyoshi, M; Ogawa, Y; Castrillon, DH; Rosenblatt, KP; Kuro-o, M			Regulation of oxidative stress by the anti-aging hormone Klotho	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL VARIANT; BONE-DENSITY; LIFE-SPAN; TRANSCRIPTION; GENE; ASSOCIATION; DAF-16; LONG; DROSOPHILA; SURVIVAL	klotho is an aging suppressor gene and extends life span when overexpressed in mice. Klotho protein was recently demonstrated to function as a hormone that inhibits insulin/insulin-like growth factor-1 (IGF-1) signaling. Here we show that Klotho protein increases resistance to oxidative stress at the cellular and organismal level in mammals. Klotho protein activates the FoxO forkhead transcription factors that are negatively regulated by insulin/IGF-1 signaling, thereby inducing expression of manganese superoxide dismutase. This in turn facilitates removal of reactive oxygen species and confers oxidative stress resistance. Thus, Klotho-induced inhibition of insulin/IGF-1 signaling is associated with increased resistance to oxidative stress, which potentially contributes to the anti-aging properties of klotho.	Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Kuro-o, M (corresponding author), Univ Texas, SW Med Ctr, Dept Pathol, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	makoto.kuro-o@utsouthwestern.edu	Ogawa, Yasushi/I-1140-2012; Ogawa, Yasushi/M-8900-2014	Ogawa, Yasushi/0000-0003-3553-9607	NATIONAL INSTITUTE ON AGING [R01AG025326, R01AG019712] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG025326, R01 AG019712-05, R01 AG025326-03, R01AG19712, R01 AG019712, R01AG25326] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Arking DE, 2005, CIRC RES, V96, P412, DOI 10.1161/01.RES.0000157171.04054.30; Arking DE, 2003, AM J HUM GENET, V72, P1154, DOI 10.1086/375035; Arking DE, 2002, P NATL ACAD SCI USA, V99, P856, DOI 10.1073/pnas.022484299; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Daitoku H, 2003, DIABETES, V52, P642, DOI 10.2337/diabetes.52.3.642; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Geho D, 2005, BIOCONJUGATE CHEM, V16, P559, DOI 10.1021/bc0497113; Giannakou ME, 2004, SCIENCE, V305, P361, DOI 10.1126/science.1098219; Henderson ST, 2001, CURR BIOL, V11, P1975, DOI 10.1016/S0960-9822(01)00594-2; Higami Y, 2000, CELL TISSUE RES, V301, P125, DOI 10.1007/s004419900156; Hwangbo DS, 2004, NATURE, V429, P562, DOI 10.1038/nature02549; Kawano KI, 2002, J BONE MINER RES, V17, P1744, DOI 10.1359/jbmr.2002.17.10.1744; Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766; Lin K, 2001, NAT GENET, V28, P139, DOI 10.1038/88850; Ogata N, 2002, BONE, V31, P37, DOI 10.1016/S8756-3282(02)00786-X; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Pap EHW, 1999, FEBS LETT, V453, P278, DOI 10.1016/S0014-5793(99)00696-1; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653; SHIGENAGA MK, 1989, P NATL ACAD SCI USA, V86, P9697, DOI 10.1073/pnas.86.24.9697; Yamada Y, 2005, J MOL MED, V83, P50, DOI 10.1007/s00109-004-0578-4	29	486	539	0	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					38029	38034		10.1074/jbc.M509039200	http://dx.doi.org/10.1074/jbc.M509039200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16186101	hybrid, Green Accepted			2022-12-25	WOS:000233044500086
J	Li, J; Zou, C; Bai, Y; Wazer, DE; Band, V; Gao, Q				Li, J; Zou, C; Bai, Y; Wazer, DE; Band, V; Gao, Q			DSS1 is required for the stability of BRCA2	ONCOGENE			English	Article						DSS1; BRCA2; DNA damage repair; tumor; suppressor gene; protein degradation; breast cancer	BREAST-CANCER SUSCEPTIBILITY; MAMMARY EPITHELIAL-CELLS; DNA-REPAIR; GENE BRCA2; RADIATION HYPERSENSITIVITY; SACCHAROMYCES-CEREVISIAE; CANDIDATE GENE; PROTEIN; RAD51; RECOMBINATION	DSS1 is an evolutionarily conserved acidic protein that binds to BRCA2. However, study of the function of DSS1 in mammalian cells has been hampered because endogenous DSS1 has not been detectable by Western blotting. Here, we developed a modified Western blotting protocol that detects endogenous DSS1 protein, and used it to study the function of DSS1 and its interaction with BRCA2 in mammalian cells. We found that essentially all BRCA2 in human cell lines is associated with DSS1. Importantly, we found that RNAi knockdown of DSS1 in human cell lines led to dramatic loss of BRCA2 protein, mainly due to its increased degradation. Furthermore, the stability of BRCA2 mutant devoid of the DSS1-binding domain is unaffected by the depletion of DSS1. Most notably, like BRCA2 depletion, DSS1 depletion also led to hypersensitivity to DNA damage. These results demonstrated that the stability of BRCA2 protein in mammalian cells depends on the presence of DSS1. Deletion or mutation of DSS1 or suppression of its expression by other mechanisms are therefore potential causative mechanisms for human breast and ovarian cancer. Such mechanisms may be relevant to sporadic as well as familiar breast cancer where BRCA1 and BRCA2 mutations are not present.	Northwestern Univ, Feinberg Sch Med, Div Canc Biol, Dept Med,Evanston Northwestern Healthcare Res Ins, Evanston, IL 60201 USA; Tufts Univ, Sch Med, Dept Radiat Oncol, New England Med Ctr, Boston, MA 02111 USA	Northwestern University; Feinberg School of Medicine; Tufts Medical Center; Tufts University	Gao, Q (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Canc Biol, Dept Med,Evanston Northwestern Healthcare Res Ins, 1001 Univ Pl, Evanston, IL 60201 USA.	Q-GAO@Northwestern.edu			NCI NIH HHS [R01 CA095221-04, R01 CA096986-03, R01 CA095221-03, R01 CA095221-02, R01 CA096986-04, R01 CA095221-01A1, R01 CA096986-01A1, R01 CA096986-02, R01 CA096986-05, R01 CA095221-05] Funding Source: Medline; NIAID NIH HHS [1 R01 CA095221-01AI, 1 R01 CA96986-01AI] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095221, R01CA096986] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; BORING CC, 1991, CA-CANCER J CLIN, V41, P19, DOI 10.3322/canjclin.41.1.19; Brody LC, 1998, MEDICINE, V77, P208, DOI 10.1097/00005792-199805000-00006; Chen CF, 1999, J BIOL CHEM, V274, P32931, DOI 10.1074/jbc.274.46.32931; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Crackower MA, 1996, HUM MOL GENET, V5, P571, DOI 10.1093/hmg/5.5.571; Daniels MJ, 2004, SCIENCE, V306, P876, DOI 10.1126/science.1102574; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; Gudmundsdottir K, 2004, EMBO REP, V5, P989, DOI 10.1038/sj.embor.7400255; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Hughes-Davies L, 2003, CELL, V115, P523, DOI 10.1016/S0092-8674(03)00930-9; Isono E, 2004, J BIOL CHEM, V279, P27168, DOI 10.1074/jbc.M314231200; Jantti J, 1999, P NATL ACAD SCI USA, V96, P909, DOI 10.1073/pnas.96.3.909; Kojic M, 2003, MOL CELL, V12, P1043, DOI 10.1016/S1097-2765(03)00367-8; Kraakman-van der Zwet M, 2002, MOL CELL BIOL, V22, P669, DOI 10.1128/MCB.22.2.669-679.2002; Marston NJ, 1999, MOL CELL BIOL, V19, P4633; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Rahman N, 1998, ANNU REV GENET, V32, P95, DOI 10.1146/annurev.genet.32.1.95; Ratsch SB, 2001, RADIAT RES, V155, P143, DOI 10.1667/0033-7587(2001)155[0143:MGCARF]2.0.CO;2; Sharan SK, 2004, DEVELOPMENT, V131, P131, DOI 10.1242/dev.00888; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shin S, 2003, P NATL ACAD SCI USA, V100, P7201, DOI 10.1073/pnas.1132020100; Sone T, 2004, J BIOL CHEM, V279, P28807, DOI 10.1074/jbc.M403165200; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Tian XX, 2005, CANCER RES, V65, P4747, DOI 10.1158/0008-5472.CAN-05-0018; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Wang SC, 2002, CANCER RES, V62, P1311; Wang SC, 2001, CANCER RES, V61, P2838; Wei SJ, 2003, J BIOL CHEM, V278, P1758, DOI 10.1074/jbc.M206328200; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Xia F, 2001, P NATL ACAD SCI USA, V98, P8644, DOI 10.1073/pnas.151253498; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837	40	95	99	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2006	25	8					1186	1194		10.1038/sj.onc.1209153	http://dx.doi.org/10.1038/sj.onc.1209153			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	015FO	16205630	Bronze			2022-12-25	WOS:000235537500006
J	Sterneck, E; Zhu, S; Ramirez, A; Jorcano, JL; Smart, RC				Sterneck, E; Zhu, S; Ramirez, A; Jorcano, JL; Smart, RC			Conditional ablation of C/EBP beta demonstrates its keratinocyte-specific requirement for cell survival and mouse skin tumorigenesis	ONCOGENE			English	Article						C/EBP; apoptosis; carcinogenesis	CCAAT/ENHANCER-BINDING-PROTEINS; GENE-EXPRESSION; CARCINOMA-CELLS; ONCOGENIC RAS; DIFFERENTIATION; INACTIVATION; APOPTOSIS; ARREST	The CCAAT/enhancer binding protein beta(C/EBP beta) is implicated in the regulation of many different molecular and physiological processes. Mice with a germline deletion of C/EBP beta (C/EBP beta(-/-)) display phenotypes in a multitude of cell types and organ systems, including skin where C/EBP beta(-/-) mice exhibit increased apoptosis in epidermal keratinocytes in response to carcinogen treatment and are completely resistant to carcinogen-induced skin tumorigenesis. To determine the contribution of systemic versus cell autonomous functions of C/EBP beta to specific phenotypes, mice with a conditional 'floxed' C/EBP beta null allele were generated. Epidermal-specific deletion of C/EBP beta was achieved by Cre recombinase expression from a keratin 5 (K5) promoter. Similar to C/EBP beta(-/-) mice, K5-Cre; C/EBP beta(fl)/(fl) mice were completely refractory to 7,12 dimethylbenz[a] anthracene (DMBA)-induced skin tumorigenesis and these mice displayed increased DMBA-induced apoptosis in epidermal keratinocytes compared to wild-type mice. In contrast, mice lacking the related gene, C/ EBP delta, were not resistant to DMBA-induced skin tumorigenesis, indicating a unique role of C/EBP beta in skin tumor development. Our findings demonstrate that C/EBP beta exerts an essential, keratinocyte-intrinsic role in cell survival in response to carcinogen treatment and the elimination of C/EBP beta in keratinocytes is sufficient to confer complete resistance of the skin to chemical carcinogenesis.	N Carolina State Univ, Dept Environm & Mol Toxicol, Cell Signaling & Canc Grp, Raleigh, NC 27695 USA; NCI, Mol Mech Dev Grp, Lab Prot Dynam & Signaling, Frederick, MD USA; CIEMAT, Repair & Tissue Engn Program, Madrid, Spain	University of North Carolina; North Carolina State University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Centro de Investigaciones Energeticas, Medioambientales Tecnologicas	Smart, RC (corresponding author), N Carolina State Univ, Dept Environm & Mol Toxicol, Cell Signaling & Canc Grp, Raleigh, NC 27695 USA.	rcsmart@unity.ncsu.edu	Ramirez, Angel/A-4800-2018	Ramirez, Angel/0000-0001-7745-5108; Sterneck, Esta/0000-0001-7716-8766; Smart, Robert/0000-0002-6767-6756	NATIONAL CANCER INSTITUTE [Z01BC010307, R01CA046637, R29CA046637] Funding Source: NIH RePORTER; NCI NIH HHS [CA46637, R01 CA046637] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOUTWELL RK, 1983, CANCER RES, V43, P2465; Bundy LM, 2003, ONCOGENE, V22, P869, DOI 10.1038/sj.onc.1206216; de Bruin A, 2003, P NATL ACAD SCI USA, V100, P6546, DOI 10.1073/pnas.1031853100; Huang AM, 2004, ONCOGENE, V23, P1549, DOI 10.1038/sj.onc.1207285; Johnson PF, 2005, J CELL SCI, V118, P2545, DOI 10.1242/jcs.02459; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; Klatt P, 2003, CARCINOGENESIS, V24, P817, DOI 10.1093/carcin/bgg057; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Lewandoski M, 2001, NAT REV GENET, V2, P743, DOI 10.1038/35093537; Li WL, 2005, CANCER RES, V65, P2592, DOI 10.1158/0008-5472.CAN-04-1532; Ma WB, 2003, CANCER RES, V63, P5320; MacPherson D, 2003, MOL CELL BIOL, V23, P1044, DOI 10.1128/MCB.23.3.1044-1053.2003; Oh HS, 1998, J INVEST DERMATOL, V110, P939, DOI 10.1046/j.1523-1747.1998.00199.x; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Porter KL, 2002, TOXICOL SCI, V69, P42, DOI 10.1093/toxsci/69.1.42; Ramirez A, 2004, GENESIS, V39, P52, DOI 10.1002/gene.20025; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Rask K, 2000, INT J CANCER, V86, P337, DOI 10.1002/(SICI)1097-0215(20000501)86:3<337::AID-IJC6>3.3.CO;2-V; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; Screpanti I, 1996, J EXP MED, V184, P1561, DOI 10.1084/jem.184.4.1561; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; Shim M, 2005, CANCER RES, V65, P861; Shuman JD, 2004, MOL CELL BIOL, V24, P7380, DOI 10.1128/MCB.24.17.7380-7391.2004; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; Sundfeldt K, 1999, BRIT J CANCER, V79, P1240, DOI 10.1038/sj.bjc.6690199; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; Tessarollo L, 2000, METH MOL B, V158, P47; Wessells J, 2004, MOL CELL BIOL, V24, P3238, DOI 10.1128/MCB.24.8.3238-3250.2004; Zhu SY, 2002, P NATL ACAD SCI USA, V99, P207, DOI 10.1073/pnas.012437299; Zhu SY, 1999, MOL CELL BIOL, V19, P7181	31	59	59	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2006	25	8					1272	1276		10.1038/sj.onc.1209144	http://dx.doi.org/10.1038/sj.onc.1209144			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	015FO	16205634	Green Accepted			2022-12-25	WOS:000235537500014
J	Hirsch-Reinshagen, V; Maia, LF; Burgess, BL; Blain, JF; Naus, KE; McIsaac, SA; Parkinson, PF; Chan, JY; Tansley, GH; Hayden, MR; Poirier, J; Van Nostrand, W; Wellington, CL				Hirsch-Reinshagen, V; Maia, LF; Burgess, BL; Blain, JF; Naus, KE; McIsaac, SA; Parkinson, PF; Chan, JY; Tansley, GH; Hayden, MR; Poirier, J; Van Nostrand, W; Wellington, CL			The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; LIVER-X-RECEPTOR; DENSITY-LIPOPROTEIN DEFICIENCY; BINDING CASSETTE TRANSPORTER-1; HEREDITARY CEREBRAL-HEMORRHAGE; ISOFORM-SPECIFIC BINDING; TRANSGENIC MOUSE MODEL; BETA-PROTEIN-PRECURSOR; APOLIPOPROTEIN-E; A-BETA	ABCA1, a cholesterol transporter expressed in the brain, has been shown recently to be required to maintain normal apoE levels and lipidation in the central nervous system. In addition, ABCA1 has been reported to modulate beta-amyloid (A beta) production in vitro. These observations raise the possibility that ABCA1 may play a role in the pathogenesis of Alzheimer disease. Here we report that the deficiency of ABCA1 does not affect soluble or guanidine-extractable A beta levels in Tg-SwDI/B or amyloid precursor protein/presenilin 1 (APP/PS1) mice, but rather is associated with a dramatic reduction in soluble apoE levels in brain. Although this reduction in apoE was expected to reduce the amyloid burden in vivo, we observed that the parenchymal and vascular amyloid load was increased in Tg-SwDI/B animals and was not diminished in APP/PS1 mice. Furthermore, we observed an increase in the proportion of apoE retained in the insoluble fraction, particularly in the APP/PS1 model. These data suggested that ABCA1-mediated effects on apoE levels and lipidation influenced amyloidogenesis in vivo.	Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V4Z 5H5, Canada; Hosp Geral Santo Antonio, Dept Neurol, P-4099001 Oporto, Portugal; McGill Ctr Studies Aging, Montreal, PQ H4H 1R3, Canada; Univ British Columbia, Ctr Mol Med & Therapeut, Vancouver, BC V4Z 5H5, Canada; SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA	University of British Columbia; McGill University; University of British Columbia; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Wellington, CL (corresponding author), Univ British Columbia, Dept Pathol & Lab Med, 980 W 28th Ave, Vancouver, BC V5Z 4H4, Canada.	cheryl@cmmt.ubc.ca	Hayden, Michael R/D-8581-2011; Maia, Luis F./J-1742-2014	Hayden, Michael R/0000-0001-5159-1419; Maia, Luis F./0000-0002-8140-3471	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036645] Funding Source: NIH RePORTER; NINDS NIH HHS [NS36645] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aleshkov S, 1997, BIOCHEMISTRY-US, V36, P10571, DOI 10.1021/bi9626362; Atwood CS, 2002, PEPTIDES, V23, P1343, DOI 10.1016/S0196-9781(02)00070-0; Bales K R, 2002, Mol Interv, V2, P363, DOI 10.1124/mi.2.6.363; Bales KR, 1999, P NATL ACAD SCI USA, V96, P15233, DOI 10.1073/pnas.96.26.15233; Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Beffert U, 2004, J LIPID RES, V45, P403, DOI 10.1194/jlr.R300017-JLR200; Blennow K, 2003, LANCET NEUROL, V2, P605, DOI 10.1016/S1474-4422(03)00530-1; Bodovitz S, 1996, J BIOL CHEM, V271, P4436; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Burns MP, 2003, MOL BRAIN RES, V110, P119, DOI 10.1016/S0169-328X(02)00647-2; Buxbaum JD, 2001, J ALZHEIMERS DIS, V3, P221; Cheng IH, 2004, NAT MED, V10, P1190, DOI 10.1038/nm1123; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Curtiss LK, 2000, CURR OPIN LIPIDOL, V11, P243, DOI 10.1097/00041433-200006000-00004; Danik M, 1999, CRIT REV NEUROBIOL, V13, P357, DOI 10.1615/CritRevNeurobiol.v13.i4.20; Davis J, 2004, J BIOL CHEM, V279, P20296, DOI 10.1074/jbc.M312946200; DeMattos RB, 2004, NEURON, V41, P193, DOI 10.1016/S0896-6273(03)00850-X; Demeester N, 2000, J LIPID RES, V41, P963; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Fagan AM, 2002, NEUROBIOL DIS, V9, P305, DOI 10.1006/nbdi.2002.0483; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; FREDRICKSON D, 1961, ANN INTERN MED, V55, P1016, DOI 10.7326/0003-4819-55-6-1016; Fukumoto H, 2002, J BIOL CHEM, V277, P48508, DOI 10.1074/jbc.M209085200; Geldmacher DS, 1997, NEUROLOGY, V48, pS2, DOI 10.1212/WNL.48.5_Suppl_6.2S; Grabowski TJ, 2001, ANN NEUROL, V49, P697, DOI 10.1002/ana.1009; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; Hayden MR, 2000, CURR OPIN LIPIDOL, V11, P117, DOI 10.1097/00041433-200004000-00003; Hirsch-Reinshagen V, 2004, J BIOL CHEM, V279, P41197, DOI 10.1074/jbc.M407962200; Holtzman DM, 2000, ANN NEUROL, V47, P739, DOI 10.1002/1531-8249(200006)47:6<739::AID-ANA6>3.0.CO;2-8; Holtzman DM, 1999, J CLIN INVEST, V103, pR15, DOI 10.1172/JCI6179; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; Hong SH, 2002, BBA-MOL BASIS DIS, V1587, P60, DOI 10.1016/S0925-4439(02)00066-2; Ignatius MJ, 1987, PROG BRAIN RES <D>, V71, P177; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; Irizarry MC, 2000, ANN NY ACAD SCI, V920, P171; Jankowsky JL, 2004, HUM MOL GENET, V13, P159, DOI 10.1093/hmg/ddh019; Katzov H, 2004, HUM MUTAT, V23, P358, DOI 10.1002/humu.20012; Koch S, 2001, J LIPID RES, V42, P1143; Koistinaho M, 2004, NAT MED, V10, P719, DOI 10.1038/nm1058; Kojro E, 2001, P NATL ACAD SCI USA, V98, P5815, DOI 10.1073/pnas.081612998; Koldamova R, 2005, J BIOL CHEM, V280, P43224, DOI 10.1074/jbc.M504513200; Koldamova RP, 2003, J BIOL CHEM, V278, P13244, DOI 10.1074/jbc.M300044200; Koldamova T, 2005, J BIOL CHEM, V280, P4079, DOI 10.1074/jbc.M411420200; LaDu MJ, 2000, ANN NY ACAD SCI, V903, P167, DOI 10.1111/j.1749-6632.2000.tb06365.x; LADU MJ, 1994, J BIOL CHEM, V269, P23403; LADU MJ, 1995, J BIOL CHEM, V270, P9039, DOI 10.1074/jbc.270.16.9039; LaDu MJ, 1998, J NEUROCHEM, V70, P2070; Lake S, 1991, Lakartidningen, V88, P1271; Lawn RM, 2001, ARTERIOSCL THROM VAS, V21, P378, DOI 10.1161/01.ATV.21.3.378; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; Li YH, 2004, NEUROSCI LETT, V366, P268, DOI 10.1016/j.neulet.2004.05.047; Liang Y, 2004, J NEUROCHEM, V88, P623, DOI 10.1111/j.1471-4159.2004.02183.x; Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; Mehta PD, 2000, ARCH NEUROL-CHICAGO, V57, P100, DOI 10.1001/archneur.57.1.100; Miao JT, 2005, J NEUROSCI, V25, P6271, DOI 10.1523/JNEUROSCI.1306-05.2005; Miravalle L, 2000, J BIOL CHEM, V275, P27110; Morris JC, 1996, ACTA NEUROL SCAND, V93, P41; Naidu A, 2001, NEUROREPORT, V12, P1265, DOI 10.1097/00001756-200105080-00042; Narita M, 2002, J BIOCHEM, V132, P743, DOI 10.1093/oxfordjournals.jbchem.a003282; Nishimura M, 1999, CLIN GENET, V55, P219, DOI 10.1034/j.1399-0004.1999.550401.x; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; Poirier J, 2000, ANN NY ACAD SCI, V924, P81; Price DL, 1998, ANNU REV GENET, V32, P461, DOI 10.1146/annurev.genet.32.1.461; Puglielli L, 2003, NAT NEUROSCI, V6, P345, DOI 10.1038/nn0403-345; Ruiz J, 2005, J LIPID RES, V46, P1721, DOI 10.1194/jlr.M500114-JLR200; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Schwab C, 2004, EXP NEUROL, V188, P52, DOI 10.1016/j.expneurol.2004.03.016; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Selkoe DJ, 2001, P NATL ACAD SCI USA, V98, P11039, DOI 10.1073/pnas.211352598; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Singaraja RR, 2001, J BIOL CHEM, V276, P33969, DOI 10.1074/jbc.M102503200; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Sun Y, 2003, J BIOL CHEM, V278, P27688, DOI 10.1074/jbc.M300760200; Tanzi RE, 2001, NEURON, V32, P181, DOI 10.1016/S0896-6273(01)00476-7; Tokuda T, 2000, BIOCHEM J, V348, P359, DOI 10.1042/0264-6021:3480359; VAN BROECKHOVEN C, 1990, SCIENCE, V248, P1120, DOI 10.1126/science.1971458; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vaucher E, 2001, J CHEM NEUROANAT, V21, P323, DOI 10.1016/S0891-0618(01)00120-X; Wahrle SE, 2005, J BIOL CHEM, V280, P43236, DOI 10.1074/jbc.M508780200; Wahrle SE, 2004, J BIOL CHEM, V279, P40987, DOI 10.1074/jbc.M407963200; Wellington CL, 2004, CLIN GENET, V66, P1, DOI 10.1111/j.0009-9163.2004.00280.x; Wellington CL, 2002, LAB INVEST, V82, P273, DOI 10.1038/labinvest.3780421; Whitney KD, 2002, MOL ENDOCRINOL, V16, P1378, DOI 10.1210/me.16.6.1378; Wollmer MA, 2003, NEUROBIOL AGING, V24, P421, DOI 10.1016/S0197-4580(02)00094-5; Wyss-Coray T, 2003, NAT MED, V9, P453, DOI 10.1038/nm838; Yang DS, 1997, J NEUROCHEM, V68, P721; Zerbinatti CV, 2005, REV NEUROSCIENCE, V16, P123	93	190	194	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					43243	43256		10.1074/jbc.M508781200	http://dx.doi.org/10.1074/jbc.M508781200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16207707	Green Published, hybrid			2022-12-25	WOS:000234200800091
J	Manolescu, A; Salas-Burgos, AM; Fischbarg, J; Cheeseman, CI				Manolescu, A; Salas-Burgos, AM; Fischbarg, J; Cheeseman, CI			Identification of a hydrophobic residue as a key determinant of fructose transport by the facilitative hexose transporter SLC2A7 (GLUT7)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-SCANNING MUTAGENESIS; GLUCOSE-TRANSPORTER; MECHANISM; ALGORITHM; POSITION; MUTATION; FAMILY; GENE	Until recently, the only facilitated hexose transporter GLUT proteins (SLC2A) known to transport fructose were GLUTs 2 and 5. However, the recently cloned GLUT7 can also transport fructose as well as glucose. Comparison of sequence alignments indicated that GLUTs 2, 5, and 7 all had an isoleucine residue at position "314" ( GLUT7), whereas the non-fructose-transporting isoforms, GLUTs 1, 3, and 4, had a valine at this position. Mutation of Ile-314 to a valine in GLUT7 resulted in a loss of fructose transport, whereas glucose transport remained completely unaffected. Similar results were obtained with GLUTs 2 and 5. Energy minimization modeling of GLUT7 indicated that Ile-314 projects from transmembrane domain 7 (TM7) into the lumen of the aqueous pore, where it could form a hydrophobic interaction with tryptophan 89 from TM2. A valine residue at 314 appeared to produce a narrowing of the vestibule when compared with the isoleucine. It is proposed that this hydrophobic interaction across the pore forms a selectivity filter restricting the access of some hexoses to the substrate binding site(s) within the aqueous channel. The presence of a selectivity filter in the extracellular vestibule of GLUTproteins would allow for subtle changes in substrate specificity without changing the kinetic parameters of the protein.	Univ Alberta, Dept Physiol, Edmonton, AB T6G 2H7, Canada; Columbia Univ, Coll Phys & Surg, Dept Physiol & Biophys, Newark, NJ 07103 USA	University of Alberta; Columbia University	Cheeseman, CI (corresponding author), Univ Alberta, Dept Physiol, Edmonton, AB T6G 2H7, Canada.	chris.cheeseman@ualberta.ca		Salas-Burgos, Alexis/0000-0002-6577-9970	NATIONAL EYE INSTITUTE [R01EY008918] Funding Source: NIH RePORTER; NEI NIH HHS [EY08918] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Alisio A, 2004, J BIOL CHEM, V279, P26540, DOI 10.1074/jbc.M402303200; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BURANT CF, 1992, J BIOL CHEM, V267, P14523; CHEESEMAN CI, 1993, GASTROENTEROLOGY, V105, P1050, DOI 10.1016/0016-5085(93)90948-C; FISCHBARG J, 1993, P NATL ACAD SCI USA, V90, P11658, DOI 10.1073/pnas.90.24.11658; Fiser A, 2003, METHOD ENZYMOL, V374, P461, DOI 10.1016/S0076-6879(03)74020-8; Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H; Hruz PW, 2001, MOL MEMBR BIOL, V18, P183; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Iserovich P, 2002, J BIOL CHEM, V277, P30991, DOI 10.1074/jbc.M202763200; Joost HG, 2002, AM J PHYSIOL-ENDOC M, V282, pE974, DOI 10.1152/ajpendo.00407.2001; JORGENSEN WL, 1988, J AM CHEM SOC, V110, P1657, DOI 10.1021/ja00214a001; KUSARI J, 1991, J CLIN INVEST, V88, P1323, DOI 10.1172/JCI115437; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; MIYAMOTO S, 1992, J COMPUT CHEM, V13, P952, DOI 10.1002/jcc.540130805; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Mueckler M, 2004, J BIOL CHEM, V279, P10494, DOI 10.1074/jbc.M310786200; MUECKLER M, 1994, J BIOL CHEM, V269, P17765; MUECKLER M, 1994, J BIOL CHEM, V269, P20533; Mueckler M, 1997, J BIOL CHEM, V272, P30141, DOI 10.1074/jbc.272.48.30141; Olsowski A, 2000, BIOCHEMISTRY-US, V39, P2469, DOI 10.1021/bi992160x; Salas-Burgos A, 2004, BIOPHYS J, V87, P2990, DOI 10.1529/biophysj.104.047886; Seatter MJ, 1998, BIOCHEMISTRY-US, V37, P1322, DOI 10.1021/bi972322u; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wu XH, 2002, GENOMICS, V80, P553, DOI 10.1006/geno.2002.7010; Yao SYM, 2000, PRACT APPROACH SER, P47; Zuniga FA, 2001, J BIOL CHEM, V276, P44970, DOI 10.1074/jbc.M107350200	28	45	46	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42978	42983		10.1074/jbc.M508678200	http://dx.doi.org/10.1074/jbc.M508678200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16186102	hybrid			2022-12-25	WOS:000234200800061
J	Golczak, M; Imanishi, Y; Kuksa, V; Maeda, T; Kubota, R; Palczewski, K				Golczak, M; Imanishi, Y; Kuksa, V; Maeda, T; Kubota, R; Palczewski, K			Lecithin: Retinol acyltransferase is responsible for amidation of retinylamine, a potent inhibitor of the retinoid cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENT EPITHELIAL-CELLS; MOUSE MODEL; VITAMIN-A; RPE65; MUTATIONS; BINDING; GENE; RHODOPSIN; ISOMEROHYDROLASE; ACCUMULATION	Lecithin: retinol acyltransferase (LRAT) catalyzes the transfer of an acyl group from the sn-1 position of phosphatidylcholine to all-trans-retinol (vitamin A) and plays an essential role in the regeneration of visual chromophore as well as in the metabolism of vitamin A. Here we demonstrate that retinylamine (Ret-NH2), a potent and selective inhibitor of 11-cis-retinal biosynthesis (Golczak, M., Kuksa, V., Maeda, T., Moise, A. R., and Palczewski, K. (2005) Proc. Natl. Acad. Sci. U.S.A. 102, 8162-8167), is a substrate for LRAT. LRAT catalyzes the transfer of the acyl group onto Ret-NH2 leading to the formation of N-retinylpalmitamide, N-retinylstearamide, and N-retinylmyristamide with a ratio of 15:6:2, respectively. The presence of N-retinylamides was detected in vivo in mice supplemented with Ret-NH2. N-Retinylamides are thus the main metabolites of Ret-NH2 in the liver and the eye and can be mobilized by hydrolysis/deamidation back to Ret-NH2. Using two-photon microscopy and the intrinsic fluorescence of N-retinylamides, we showed that newly formed amides colocalize with the retinyl ester storage particles (retinosomes) in the retinal pigment epithelium. These observations provide new information concerning the substrate specificity of LRAT and explain the prolonged effect of Ret-NH2 on the rate of 11-cis-retinal recovery in vivo.	Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Acucela Inc, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Palczewski, K (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, BRB Bldg,10900 Euclid Ave, Cleveland, OH 44106 USA.	kxp65@case.edu	Imanishi, Yoshikazu/E-8178-2010	Imanishi, Yoshikazu/0000-0003-4696-4836	NEI NIH HHS [EY09339] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009339] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Batten ML, 2004, J BIOL CHEM, V279, P10422, DOI 10.1074/jbc.M312410200; CANADA FJ, 1990, BIOCHEMISTRY-US, V29, P9690, DOI 10.1021/bi00493a026; Cremers FPM, 2002, HUM MOL GENET, V11, P1169, DOI 10.1093/hmg/11.10.1169; Edwards AO, 2001, INVEST OPHTH VIS SCI, V42, P2652; Filipek S, 2003, ANNU REV PHYSIOL, V65, P851, DOI 10.1146/annurev.physiol.65.092101.142611; Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899; Gao J, 2005, J INVEST DERMATOL, V124, P1259, DOI 10.1111/j.0022-202X.2005.23761.x; Golczak M, 2005, P NATL ACAD SCI USA, V102, P8162, DOI 10.1073/pnas.0503318102; Gollapalli DR, 2004, P NATL ACAD SCI USA, V101, P10030, DOI 10.1073/pnas.0401936101; Grimm C, 2000, NAT GENET, V25, P63, DOI 10.1038/75614; Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194; HUBBARD R., 1971, Methods in Enzymology, V18C, P615, DOI 10.1016/S0076-6879(71)18045-7; Imanishi Y, 2004, J CELL BIOL, V166, P447, DOI 10.1083/jcb.200405110; Imanishi Y, 2004, J CELL BIOL, V164, P373, DOI 10.1083/jcb.200311079; Janecke AR, 2004, NAT GENET, V36, P850, DOI 10.1038/ng1394; Jin MH, 2005, CELL, V122, P449, DOI 10.1016/j.cell.2005.06.042; Kuksa V, 2003, VISION RES, V43, P2959, DOI 10.1016/S0042-6989(03)00482-6; Linder ME, 2003, BIOCHEMISTRY-US, V42, P4311, DOI 10.1021/bi034159a; MACDONALD PN, 1988, BIOCHEM BIOPH RES CO, V156, P157, DOI 10.1016/S0006-291X(88)80818-0; MACDONALD PN, 1988, J BIOL CHEM, V263, P12478; McBee JK, 2000, BIOCHEMISTRY-US, V39, P11370, DOI 10.1021/bi001061c; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; Moiseyev G, 2005, P NATL ACAD SCI USA, V102, P12413, DOI 10.1073/pnas.0503460102; Morimura H, 1998, P NATL ACAD SCI USA, V95, P3088, DOI 10.1073/pnas.95.6.3088; O'Byrne SM, 2005, J BIOL CHEM, V280, P35647, DOI 10.1074/jbc.M507924200; Perrault I, 1999, MOL GENET METAB, V68, P200, DOI 10.1006/mgme.1999.2906; Perrault I, 2004, AM J HUM GENET, V75, P639, DOI 10.1086/424889; Radu RA, 2003, P NATL ACAD SCI USA, V100, P4742, DOI 10.1073/pnas.0737855100; Redmond TM, 2005, P NATL ACAD SCI USA, V102, P13658, DOI 10.1073/pnas.0504167102; Reeves PJ, 2002, P NATL ACAD SCI USA, V99, P13413, DOI 10.1073/pnas.212519199; ROBESON CD, 1955, J AM CHEM SOC, V77, P4111, DOI 10.1021/ja01620a043; Ruiz A, 1999, J BIOL CHEM, V274, P3834, DOI 10.1074/jbc.274.6.3834; SHI YQ, 1993, BIOCHEMISTRY-US, V32, P1257, DOI 10.1021/bi00056a009; SHI YQ, 1993, BIOCHEMISTRY-US, V32, P3077, DOI 10.1021/bi00063a019; Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981; Stecher H, 1999, J BIOL CHEM, V274, P8577, DOI 10.1074/jbc.274.13.8577; Swarthout JT, 2005, J BIOL CHEM, V280, P31141, DOI 10.1074/jbc.M504113200; Thompson DA, 2001, NAT GENET, V28, P123, DOI 10.1038/88828; Van Hooser JP, 2002, J BIOL CHEM, V277, P19173, DOI 10.1074/jbc.M112384200; Yen CLE, 2005, J LIPID RES, V46, P1502, DOI 10.1194/jlr.M500036-JLR200; Zernant J, 2005, INVEST OPHTH VIS SCI, V46, P3052, DOI 10.1167/iovs.05-0111; Zhang K, 2001, NAT GENET, V27, P89, DOI 10.1038/83817	43	52	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42263	42273		10.1074/jbc.M509351200	http://dx.doi.org/10.1074/jbc.M509351200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16216874	hybrid			2022-12-25	WOS:000233992700055
J	Guiral, M; Tron, P; Aubert, C; Gloter, A; Iobbi-Nivol, C; Giudici-Orticoni, MT				Guiral, M; Tron, P; Aubert, C; Gloter, A; Iobbi-Nivol, C; Giudici-Orticoni, MT			A membrane-bound multienzyme, hydrogen-oxidizing, and sulfur-reducing complex from the hyperthermophilic bacterium Aquifex aeolicus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIMETHYL-SULFOXIDE REDUCTASE; RESPIRATORY-CHAIN SUPERCOMPLEXES; RAY-ABSORPTION SPECTROSCOPY; YELLOWSTONE-NATIONAL-PARK; ESCHERICHIA-COLI; ELEMENTAL SULFUR; OXIDOREDUCTASE COMPLEX; QUINONE OXIDOREDUCTASE; SULFIDE DEHYDROGENASE; HYDROTHERMAL WATERS	Aquifex aeolicus is a hyperthermophilic, chemolithoautotrophic, hydrogen-oxidizing, and microaerophilic bacterium growing at 85 degrees C. We have shown that it can grow on an H-2/S degrees medium and produce H2S from sulfur in the later exponential phase. The complex carrying the sulfur reducing activity (electron transport from H-2 to S degrees) has been purified and characterized. It is a membrane-bound multiprotein complex containing a [NiFe] hydrogenase and a sulfur reductase connected via quinones. The sulfur reductase is encoded by an operon annotated dms (dimethyl sulfoxide reductase) that we have renamed sre and is composed of three subunits. Sequence analysis showed that it belongs to the Me2SO reductase molybdoenzyme family and is similar to the sulfur/polysulfide/thiosulfate/tetrathionate reductases. The study of catalytic properties clearly demonstrated that it can reduce tetrathionate, sulfur, and polysulfide, but cannot reduce Me2SO and thiosulfate, and that NADPH increases the sulfur reducing activity. To date, this is the first characterization of a supercomplex from a bacterium that couples hydrogen oxidation and sulfur reduction. The distinctive feature in A. aeolicus is the cytoplasmic localization of the sulfur reduction, which is in accordance with the presence of sulfur globules in the cytoplasm. Association of this sulfur-reducing complex with a hydrogen-oxygen pathway complex (hydrogenase I, bc(1) complex) in the membrane suggests that subcomplexes involved in respiratory chains in this bacterium are part of supramolecular organization.	CNRS, IBSM, Lab Bioenerget & Ingn Prot, F-13402 Marseille, France; Univ Paris 11, CNRS, UMR 8502, Phys Solides Lab, Orsay, France; Natl Inst Mat Sci, Inst Ctr Young Sci, Tsukuba, Ibaraki 3050044, Japan; CNRS, Inst Microbiol & Struct Biol, Chim Bacterienne Lab, F-13420 Marseille, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Universite Paris Saclay; National Institute for Materials Science; Centre National de la Recherche Scientifique (CNRS)	Giudici-Orticoni, MT (corresponding author), CNRS, IBSM, Lab Bioenerget & Ingn Prot, 31 Chem Joseph Aiguier, F-13402 Marseille, France.	giudici@ibsm.cnrs-mrs.fr	Gloter, Alexandre/ABE-2539-2020; GLOTER, Alexandre/F-7130-2017	Gloter, Alexandre/0000-0002-4813-3799; 				Aguilar CF, 1997, J MOL BIOL, V271, P789, DOI 10.1006/jmbi.1997.1215; Amend JP, 2001, FEMS MICROBIOL REV, V25, P175, DOI 10.1111/j.1574-6976.2001.tb00576.x; [Anonymous], 1995, GLOBAL EARTH PHYS HD; Aubert C, 2001, BIOCHEMISTRY-US, V40, P13690, DOI 10.1021/bi011202q; Aubert C, 2000, BBA-PROTEIN STRUCT M, V1476, P85, DOI 10.1016/S0167-4838(99)00221-6; Baymann F, 2003, PHILOS T ROY SOC B, V358, P267, DOI 10.1098/rstb.2002.1184; Baymann F, 2001, BIOCHEMISTRY-US, V40, P13681, DOI 10.1021/bi011201y; Berks BC, 1995, BBA-BIOENERGETICS, V1232, P97, DOI 10.1016/0005-2728(95)00092-5; Bernadac A, 1998, J BACTERIOL, V180, P4872, DOI 10.1128/JB.180.18.4872-4878.1998; Bertero MG, 2003, NAT STRUCT BIOL, V10, P681, DOI 10.1038/nsb969; Bhuiya MW, 2005, J MOL BIOL, V345, P325, DOI 10.1016/j.jmb.2004.10.063; Blochl E, 1997, EXTREMOPHILES, V1, P14; Brugna-Guiral M, 2003, EXTREMOPHILES, V7, P145, DOI 10.1007/s00792-002-0306-3; CORDRUWISCH R, 1985, J MICROBIOL METH, V4, P33, DOI 10.1016/0167-7012(85)90005-3; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; Dietrich V, 2002, EUR J BIOCHEM, V269, P1086, DOI 10.1046/j.0014-2956.2001.02662.x; Dirmeier R, 1998, EUR J BIOCHEM, V252, P486, DOI 10.1046/j.1432-1327.1998.2520486.x; Ebel C, 2004, J MOL RECOGNIT, V17, P382, DOI 10.1002/jmr.697; Eubel H, 2004, PLANT PHYSIOL BIOCH, V42, P937, DOI 10.1016/j.plaphy.2004.09.010; FAUQUE G, 1979, ARCH MICROBIOL, V121, P261, DOI 10.1007/BF00425065; Geijer P, 2004, BBA-BIOMEMBRANES, V1660, P66, DOI 10.1016/j.bbamem.2003.10.016; Gross R, 2004, J BIOL CHEM, V279, P274, DOI 10.1074/jbc.M310610200; Guiral M, 2005, BIOCHEM SOC T, V33, P22, DOI 10.1042/BST0330022; Hedderich R, 1998, FEMS MICROBIOL REV, V22, P353, DOI 10.1111/j.1574-6976.1998.tb00376.x; Hensel M, 1999, MOL MICROBIOL, V32, P275, DOI 10.1046/j.1365-2958.1999.01345.x; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; Hinsley AP, 2002, MICROBIOL-SGM, V148, P3631, DOI 10.1099/00221287-148-11-3631; HUBER R, 1992, SYST APPL MICROBIOL, V15, P340, DOI 10.1016/S0723-2020(11)80206-7; Ilbert M, 2004, MICROBIOL-SGM, V150, P935, DOI 10.1099/mic.0.26909-0; Ilbert M, 2003, J BIOL CHEM, V278, P28787, DOI 10.1074/jbc.M302730200; JOHNSON JL, 1980, J BIOL CHEM, V255, P1783; Johnson KE, 2001, J BIOL CHEM, V276, P13178, DOI 10.1074/jbc.M010965200; Khangulov SV, 1998, BIOCHEMISTRY-US, V37, P3518, DOI 10.1021/bi972177k; Kletzin A, 2004, J BIOENERG BIOMEMBR, V36, P77, DOI 10.1023/B:JOBB.0000019600.36757.8c; Laska S, 2003, MICROBIOL-SGM, V149, P2357, DOI 10.1099/mic.0.26455-0; MA K, 1993, P NATL ACAD SCI USA, V90, P5341, DOI 10.1073/pnas.90.11.5341; MA K, 1994, J BACTERIOL, V176, P6509, DOI 10.1128/JB.176.21.6509-6517.1994; McDevitt CA, 2002, MOL MICROBIOL, V44, P1575, DOI 10.1046/j.1365-2958.2002.02978.x; Mortz E, 2001, PROTEOMICS, V1, P1359, DOI 10.1002/1615-9861(200111)1:11<1359::AID-PROT1359>3.0.CO;2-Q; Moura JJG, 2004, J BIOL INORG CHEM, V9, P791, DOI 10.1007/s00775-004-0573-9; Nelson KJ, 2004, BIOCHEMISTRY-US, V43, P11226, DOI 10.1021/bi0490845; Nubel T, 2000, ARCH MICROBIOL, V173, P233, DOI 10.1007/s002030000135; OLSEN GJ, 1994, J BACTERIOL, V176, P1, DOI 10.1128/JB.176.1.1-6.1994; Peng GH, 2003, BIOCHEMISTRY-US, V42, P3032, DOI 10.1021/bi026876v; Pereira IAC, 1997, EUR J BIOCHEM, V248, P323, DOI 10.1111/j.1432-1033.1997.00323.x; Pickering IJ, 2001, BIOCHEMISTRY-US, V40, P8138, DOI 10.1021/bi0105532; Prange A, 2004, ARCH MICROBIOL, V182, P165, DOI 10.1007/s00203-004-0683-3; Prange A, 2002, MICROBIOL-SGM, V148, P267, DOI 10.1099/00221287-148-1-267; Rees GN, 2002, INT J SYST EVOL MICR, V52, P671, DOI 10.1099/00207713-52-2-671; Reinartz M, 1998, ARCH MICROBIOL, V170, P59, DOI 10.1007/s002030050615; SAMBASIVARAO D, 1991, J BACTERIOL, V173, P5935, DOI 10.1128/jb.173.19.5935-5943.1991; Schagger H, 2002, BBA-BIOENERGETICS, V1555, P154, DOI 10.1016/S0005-2728(02)00271-2; SCHAUDER R, 1993, ARCH MICROBIOL, V159, P491, DOI 10.1007/BF00249025; Scheide D, 2002, FEBS LETT, V512, P80, DOI 10.1016/S0014-5793(02)02224-X; SCHONHEIT P, 1995, WORLD J MICROB BIOT, V11, P26, DOI 10.1007/BF00339135; Schulz HN, 1999, SCIENCE, V284, P493, DOI 10.1126/science.284.5413.493; Schutz M, 1999, J BACTERIOL, V181, P6516; Schutz M, 2003, BIOCHEMISTRY-US, V42, P10800, DOI 10.1021/bi034452a; SETZKE E, 1994, EUR J BIOCHEM, V220, P139, DOI 10.1111/j.1432-1033.1994.tb18608.x; Stroh A, 2004, J BIOL CHEM, V279, P5000, DOI 10.1074/jbc.M309505200; Sugio T, 1998, BIOSCI BIOTECH BIOCH, V62, P705, DOI 10.1271/bbb.62.705; Suzuki I, 1999, CAN J MICROBIOL, V45, P97, DOI 10.1139/cjm-45-2-97; Tehei M, 2004, EMBO REP, V5, P66, DOI 10.1038/sj.embor.7400049; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRUEPER H G, 1964, Antonie Van Leeuwenhoek, V30, P225; Valdes J, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-51; Wakai S, 2004, BIOSCI BIOTECH BIOCH, V68, P2519, DOI 10.1271/bbb.68.2519; Wu LF, 2000, J MOL MICROB BIOTECH, V2, P179; Xu Y, 1998, GEOCHIM COSMOCHIM AC, V62, P3729, DOI 10.1016/S0016-7037(98)00269-5; Xu Y, 2000, J VOLCANOL GEOTH RES, V97, P407, DOI 10.1016/S0377-0273(99)00173-0; Yeh AP, 2000, J MOL BIOL, V300, P587, DOI 10.1006/jmbi.2000.3871; ZOPHEL A, 1991, EUR J BIOCHEM, V195, P849, DOI 10.1111/j.1432-1033.1991.tb15774.x	72	71	74	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42004	42015		10.1074/jbc.M508034200	http://dx.doi.org/10.1074/jbc.M508034200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16236714	hybrid			2022-12-25	WOS:000233992700026
J	Juarez, MA; Su, FY; Chun, S; Kiel, MJ; Lyons, SE				Juarez, MA; Su, FY; Chun, S; Kiel, MJ; Lyons, SE			Distinct roles for SCL in erythroid specification and maturation in zebrafish	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; PRIMITIVE ERYTHROPOIESIS; GENE DOSAGE; HEMATOPOIESIS; EXPRESSION; MICE; HAPLOINSUFFICIENCY; PROGENITORS; ABSENCE; CLOCHE	The stem cell leukemia (SCL) transcription factor is essential for vertebrate hematopoiesis. Using the powerful zebrafish model for embryonic analysis, we compared the effects of either reducing or ablating Scl using morpholino-modified antisense RNAs. Ablation of Scl resulted in the loss of primitive and definitive hematopoiesis, consistent with its essential role in these processes. Interestingly, in embryos with severely reduced Scl levels, erythroid progenitors expressing gata1 and embryonic globin developed. Erythroid maturation was deficient in these Scl hypomorphs, supporting that Scl was required both for the erythroid specification and for the maturation steps, with maturation requiring higher Scl levels than specification. Although all hematopoietic functions were rescued by wild-type Scl mRNA, an Scl DNA binding mutant rescued primitive and definitive hematopoiesis but did not rescue primitive erythroid maturation. Together, we showed that there is a distinct Scl hypomorphic phenotype and demonstrated that distinct functions are required for the roles of Scl in the specification and differentiation of primitive and definitive hematopoietic lineages. Our results revealed that Scl participates in multiple processes requiring different levels and functions. Further, we identified an Scl hypomorphic phenotype distinct from the null state.	Univ Michigan, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Mol & Cellular Biol Program, Ann Arbor, MI 48109 USA; Univ Michigan, Med Scientist Training Program, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Lyons, SE (corresponding author), Univ Michigan, Dept Internal Med, Div Hematol Oncol, Med Sci Bldg 1,Rm 5315,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	suslyons@umich.edu		Lyons, Susan/0000-0001-5601-1938	NCI NIH HHS [K22-CA095024-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K22CA095024] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Back J, 2004, BLOOD, V103, P3615, DOI 10.1182/blood-2003-11-4089; Bahary N, 1998, STEM CELLS, V16, P89, DOI 10.1002/stem.160089; Barton K, 2000, BIOESSAYS, V22, P214, DOI 10.1002/(SICI)1521-1878(200003)22:3<214::AID-BIES2>3.0.CO;2-I; Bennett CM, 2001, BLOOD, V98, P643, DOI 10.1182/blood.V98.3.643; Brownlie A, 2003, DEV BIOL, V255, P48, DOI 10.1016/S0012-1606(02)00041-6; DETRICH HW, 1995, P NATL ACAD SCI USA, V92, P10713, DOI 10.1073/pnas.92.23.10713; DETRICH HW, 1999, ZEBRAFISH GENETICS G, V60; Donovan GP, 1997, J NEUROSCI, V17, P4562; DOOLEY KA, 2004, DEV BIOL, V15, P522; Emambokus N, 2003, EMBO J, V22, P4478, DOI 10.1093/emboj/cdg434; Gage PJ, 1999, DEVELOPMENT, V126, P4643; Galloway JL, 2003, CURR TOP DEV BIOL, V53, P139, DOI 10.1016/S0070-2153(03)53004-6; Ganly P, 2004, LEUKEMIA LYMPHOMA, V45, P1, DOI 10.1080/1042819031000139611; Gering M, 2003, DEVELOPMENT, V130, P6187, DOI 10.1242/dev.00875; Gering M, 1998, EMBO J, V17, P4029, DOI 10.1093/emboj/17.14.4029; Gottgens B, 2002, GENOME RES, V12, P749, DOI 10.1101/gr.45502; Herbomel P, 1999, DEVELOPMENT, V126, P3735; Keith D, 1999, HUM MOL GENET, V8, P143, DOI 10.1093/hmg/8.1.143; Lacaud G, 2004, BLOOD, V103, P886, DOI 10.1182/blood-2003-06-2149; Lacaud G, 2001, ANN NY ACAD SCI, V938, P96; Liao EC, 1998, GENE DEV, V12, P621, DOI 10.1101/gad.12.5.621; Liao EC, 2000, DEVELOPMENT, V127, P5123; Lieschke GJ, 2002, DEV BIOL, V246, P274, DOI 10.1006/dbio.2002.0657; Lieschke GJ, 2001, BLOOD, V98, P3087, DOI 10.1182/blood.V98.10.3087; Liu F, 2002, MECH DEVELOP, V113, P69, DOI 10.1016/S0925-4773(01)00658-X; Lun K, 1998, DEVELOPMENT, V125, P3049; Lyons SE, 2001, BLOOD, V97, P2611, DOI 10.1182/blood.V97.9.2611; MAY G, 2001, HEMATOPOIESIS DEV AP, P61; Mead PE, 2001, DEVELOPMENT, V128, P2301; Mead PE, 1998, DEVELOPMENT, V125, P2611; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Patterson LJ, 2005, BLOOD, V105, P3502, DOI 10.1182/blood-2004-09-3547; Paw BH, 2001, BLOOD CELL MOL DIS, V27, P62, DOI 10.1006/bcmd.2000.0354; Porcher C, 1999, DEVELOPMENT, V126, P4603; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; Raas-Rothschild A, 2002, AM J MED GENET, V112, P75, DOI 10.1002/ajmg.10652; Ravet E, 2004, BLOOD, V103, P3326, DOI 10.1182/blood-2003-05-1689; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; Robb L, 1996, EMBO J, V15, P4123, DOI 10.1002/j.1460-2075.1996.tb00787.x; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; Sanchez MJ, 2001, DEVELOPMENT, V128, P4815; Scott DA, 2005, AM J MED GENET A, V134A, P430, DOI 10.1002/ajmg.a.30654; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; STAINIER DYR, 1995, DEVELOPMENT, V121, P3141; Sun W, 2004, BLOOD, V104, P3565, DOI 10.1182/blood-2003-12-4349; Talbot WS, 2000, GENE DEV, V14, P755; Thompson MA, 1998, DEV BIOL, V197, P248, DOI 10.1006/dbio.1998.8887; Traver D, 2003, NAT IMMUNOL, V4, P1238, DOI 10.1038/ni1007; Traver D, 2001, BLOOD, V98, P627, DOI 10.1182/blood.V98.3.627; Vivian JL, 1999, DEV BIOL, V208, P44, DOI 10.1006/dbio.1998.9182; Walter MJ, 2005, P NATL ACAD SCI USA, V102, P12513, DOI 10.1073/pnas.0504247102; Westerfield M., 1995, ZEBRAFISH BOOK GUIDE; Willett CE, 2001, DEV DYNAM, V222, P694, DOI 10.1002/dvdy.1223; Yamagata T, 2005, INT J HEMATOL, V82, P1, DOI 10.1532/IJH97.05075	54	18	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41636	41644		10.1074/jbc.M507998200	http://dx.doi.org/10.1074/jbc.M507998200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16210319	hybrid			2022-12-25	WOS:000233866900064
J	Cisse, MA; Sunyach, C; Lefranc-Jullien, S; Postina, R; Vincent, B; Checler, F				Cisse, MA; Sunyach, C; Lefranc-Jullien, S; Postina, R; Vincent, B; Checler, F			The disintegrin ADAM9 indirectly contributes to the physiological processing of cellular prion by modulating ADAM10 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ALPHA-SECRETASE ACTIVITY; INTRACELLULAR MATURATION; ALZHEIMERS; CLEAVAGE; PRP; NEUROTOXICITY; BIOLOGY; HEALTH; FORM	The cellular prion protein (PrPc) is physiologically cleaved in the middle of its 106 - 126 amino acid neurotoxic region at the 110/111 down arrow 112 peptidyl bond, yielding an N-terminal fragment referred to as N1. We recently demonstrated that two disintegrins, namely ADAM10 and ADAM17 ( TACE, tumor necrosis factor alpha converting enzyme) participated in both constitutive and protein kinase C-regulated generation of N1, respectively. These proteolytic events were strikingly reminiscent of those involved in the so-called "alpha-secretase pathway" that leads to the production of secreted sAPP alpha from beta APP. We show here, by transient and stable transfection analyses, that ADAM9 also participates in the constitutive secretion of N1 in HEK293 cells, TSM1 neurons, and mouse fibroblasts. Decreasing endogenous ADAM9 expression by an antisense approach drastically reduces both N1 and sAPP alpha recoveries. However, we establish that ADAM9 was unable to increase N1 and sAPP alpha productions after transient transfection in fibroblasts depleted of ADAM10. Accordingly, ADAM9 is unable to cleave a fluorimetric substrate of membrane-bound alpha-secretase activity in ADAM10(-/-) fibroblasts. However, we establish that co-expression of ADAM9 and ADAM10 in ADAM10-deficient fibroblasts leads to enhanced membrane-bound and released fluorimetric substrate hydrolyzing activity when compared with that observed after ADAM10 cDNA transfection alone in ADAM10(-/-) cells. Interestingly, we demonstrate that shedded ADAM10 displays the ability to cleave endogenous PrPc in fibroblasts. Altogether, these data provide evidence that ADAM9 is an important regulator of the physiological processing of PrPc and beta APP but that this enzyme acts indirectly, likely by contributing to the shedding of ADAM10. ADAM9 could therefore represent, besides ADAM10, another potential therapeutic target to enhance the breakdown of the 106 - 126 and A beta toxic domains of the prion and beta APP proteins.	CNRS, Inst Pharmacol Mol & Cellulaire, UMR 6097, F-06560 Valbonne, France; Johannes Gutenberg Univ Mainz, Inst Biochem, D-55128 Mainz, Germany	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Johannes Gutenberg University of Mainz	Vincent, B (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, UMR 6097, F-06560 Valbonne, France.	vincentb@ipmc.cnrs.fr; checler@ipmc.cnrs.fr	CISSE, Moustapha/AAM-1022-2021; Checler, Frederic/C-1241-2009	Checler, Frederic/0000-0003-2098-1750; CISSE, Moustapha/0000-0003-3890-9183; Vincent, Bruno/0000-0003-3876-2118				Aguzzi A, 2001, NAT REV MOL CELL BIO, V2, P118, DOI 10.1038/35052063; Ancolio K, 1999, P NATL ACAD SCI USA, V96, P4119, DOI 10.1073/pnas.96.7.4119; Anders A, 2001, FASEB J, V15, P1837, DOI 10.1096/fj.01-0007fje; Asai M, 2003, BIOCHEM BIOPH RES CO, V301, P231, DOI 10.1016/S0006-291X(02)02999-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brandner S, 1996, P NATL ACAD SCI USA, V93, P13148, DOI 10.1073/pnas.93.23.13148; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; Brown DR, 1999, J NEUROCHEM, V73, P1105, DOI 10.1046/j.1471-4159.1999.0731105.x; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Checler F, 2002, TRENDS NEUROSCI, V25, P616, DOI 10.1016/S0166-2236(02)02263-4; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; Chun J, 1996, MOL CELL NEUROSCI, V7, P304, DOI 10.1006/mcne.1996.0023; Collinge J, 1999, LANCET, V354, P317, DOI 10.1016/S0140-6736(99)05128-4; Demart S, 1999, BIOCHEM BIOPH RES CO, V265, P652, DOI 10.1006/bbrc.1999.1730; Duffy MJ, 2003, THROMB HAEMOSTASIS, V89, P622; Endres K, 2003, EUR J BIOCHEM, V270, P2386, DOI 10.1046/j.1432-1033.2003.03606.x; Flechsig E, 2004, CURR MOL MED, V4, P337, DOI 10.2174/1566524043360645; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; Glatzel M, 2001, BRAIN RES REV, V36, P241, DOI 10.1016/S0165-0173(01)00100-X; Hartmann D, 2002, HUM MOL GENET, V11, P2615, DOI 10.1093/hmg/11.21.2615; Hotoda N, 2002, BIOCHEM BIOPH RES CO, V293, P800, DOI 10.1016/S0006-291X(02)00302-9; Jobling MF, 1999, J NEUROCHEM, V73, P1557, DOI 10.1046/j.1471-4159.1999.0731557.x; Koike H, 1999, BIOCHEM J, V343, P371, DOI 10.1042/0264-6021:3430371; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; Mallucci GR, 2002, EMBO J, V21, P202, DOI 10.1093/emboj/21.3.202; MARTINS VR, 2002, NEUROCHEM INT, V1223, P1; Postina R, 2004, J CLIN INVEST, V113, P1456, DOI 10.1172/JCI200420864; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Suh YH, 2002, PHARMACOL REV, V54, P469, DOI 10.1124/pr.54.3.469; Tousseyn TA, 2004, NEUROBIOL AGING, V25, pS524, DOI 10.1016/S0197-4580(04)81730-5; Vincent B, 2000, J BIOL CHEM, V275, P35612, DOI 10.1074/jbc.M004628200; Vincent B, 2001, J BIOL CHEM, V276, P37743; Weissmann C, 2002, ACTA NEUROBIOL EXP, V62, P153	36	110	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40624	40631		10.1074/jbc.M506069200	http://dx.doi.org/10.1074/jbc.M506069200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16236709	hybrid			2022-12-25	WOS:000233666600031
J	Domitrovich, AM; Felmlee, DJ; Siddiqui, A				Domitrovich, AM; Felmlee, DJ; Siddiqui, A			Hepatitis C virus nonstructural proteins inhibit apolipoprotein B100 secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; UBIQUITIN-PROTEASOME PATHWAY; B-CONTAINING LIPOPROTEINS; CORE PROTEIN; INTRACELLULAR DEGRADATION; OXIDATIVE STRESS; STEATOSIS; INFECTION; REPLICATION; EXPRESSION	Host genes involved in lipid metabolism are differentially regulated during the early stages of hepatitis C virus ( HCV) infection. The majority of lipids synthesized in the liver are exported to other tissues in the form of lipoproteins. The formation of these lipoproteins is dependent upon the association of triglycerides with apolipoprotein B100. Using the HCV subgenomic replicon expression system, we show that secretion of apoB100 is significantly reduced. Inhibition of apoB100 degradation by ALLN did not improve secretion. Triglyceride levels as well as microsomal triglyceride transfer protein mRNA and activity levels were reduced in replicon-expressing cells, indicating potential reasons for the observed decrease. Further evidence is presented for the interaction between the HCV nonstructural protein 5A and apoB100. These results provide further insight into the alteration of lipid metabolism by HCV.	Univ Calif San Diego, Moores Canc Ctr, Dept Med, La Jolla, CA 92093 USA; Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Program Mol Biol, Aurora, CO 80045 USA	University of California System; University of California San Diego; University of Colorado System; University of Colorado Anschutz Medical Campus	Siddiqui, A (corresponding author), Univ Calif San Diego, Moores Canc Ctr, Dept Med, La Jolla, CA 92093 USA.	asiddiqui@ucsd.edu		Felmlee, Daniel/0000-0001-8350-122X	NIDDK NIH HHS [DK061566] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061566] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADELI K, 1994, J BIOL CHEM, V269, P9166; Adeli K, 1997, J BIOL CHEM, V272, P5031, DOI 10.1074/jbc.272.8.5031; Adeli K, 2001, TRENDS CARDIOVAS MED, V11, P170, DOI 10.1016/S1050-1738(01)00084-6; Adeli K, 1997, J BIOL CHEM, V272, P22489, DOI 10.1074/jbc.272.36.22489; Andre P, 2005, SEMIN LIVER DIS, V25, P93, DOI 10.1055/s-2005-864785; Bakillah A, 1998, BIOCHEMISTRY-US, V37, P3727, DOI 10.1021/bi972629t; Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; Bartenschlager R, 2000, J GEN VIROL, V81, P1631, DOI 10.1099/0022-1317-81-7-1631; Bigger CB, 2004, J VIROL, V78, P13779, DOI 10.1128/JVI.78.24.13779-13792.2004; Cavallo D, 1999, J BIOL CHEM, V274, P23135, DOI 10.1074/jbc.274.33.23135; Davidson NO, 2000, ANNU REV NUTR, V20, P169, DOI 10.1146/annurev.nutr.20.1.169; Davis RA, 1999, BBA-MOL CELL BIOL L, V1440, P1, DOI 10.1016/S1388-1981(99)00083-9; DiBisceglie AM, 1997, HEPATOLOGY, V26, pS34, DOI 10.1002/hep.510260706; Dubuisson J, 2002, TRENDS CELL BIOL, V12, P517, DOI 10.1016/S0962-8924(02)02383-8; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fujie H, 1999, J MED VIROL, V59, P141, DOI 10.1002/(SICI)1096-9071(199910)59:2&lt;141::AID-JMV3&gt;3.0.CO;2-5; Giannini C, 2003, CELL DEATH DIFFER, V10, pS27, DOI 10.1038/sj.cdd.4401121; Gong GZ, 2001, P NATL ACAD SCI USA, V98, P9599, DOI 10.1073/pnas.171311298; Gordon DA, 2000, BBA-MOL CELL BIOL L, V1486, P72, DOI 10.1016/S1388-1981(00)00049-4; Gordon DA, 1997, CURR OPIN LIPIDOL, V8, P131, DOI 10.1097/00041433-199706000-00002; Guo JT, 2001, J VIROL, V75, P8516, DOI 10.1128/JVI.75.18.8516-8523.2001; Higashi Y, 2003, J BIOL CHEM, V278, P21450, DOI 10.1074/jbc.M301376200; Hussain MM, 1998, J BIOL CHEM, V273, P25612, DOI 10.1074/jbc.273.40.25612; JAMIL H, 1995, J BIOL CHEM, V270, P6549, DOI 10.1074/jbc.270.12.6549; Jamil H, 1998, J LIPID RES, V39, P1448; Kang S, 2003, J BIOL CHEM, V278, P30478, DOI 10.1074/jbc.M304201200; Kolykhalov AA, 2000, J VIROL, V74, P2046, DOI 10.1128/JVI.74.4.2046-2051.2000; Kumar D, 2002, HEPATOLOGY, V36, P1266, DOI 10.1053/jhep.2002.36370; Liao W, 1999, BIOCHEMISTRY-US, V38, P7532, DOI 10.1021/bi9904196; Lindenbach BD, 2005, SCIENCE, V309, P623, DOI 10.1126/science.1114016; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Mihm S, 1997, HEPATOLOGY, V25, P735, DOI 10.1002/hep.510250340; Moriya K, 2003, HEPATOL RES, V25, P371, DOI 10.1016/S1386-6346(02)00309-1; Moriya K, 1997, J GEN VIROL, V78, P1527, DOI 10.1099/0022-1317-78-7-1527; Negro F, 2002, HEPATOLOGY, V36, P1050, DOI 10.1053/jhep.2002.37118; Olofsson SO, 1999, CURR OPIN LIPIDOL, V10, P341, DOI 10.1097/00041433-199908000-00008; Patel SB, 1996, J BIOL CHEM, V271, P18686, DOI 10.1074/jbc.271.31.18686; PAWLOTSKY JM, 1995, J INFECT DIS, V171, P1607, DOI 10.1093/infdis/171.6.1607; Perlemuter G, 2002, FASEB J, V16, P185, DOI 10.1096/fj.01-0396com; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; Raabe M, 1998, P NATL ACAD SCI USA, V95, P8686, DOI 10.1073/pnas.95.15.8686; Rubbia-Brandt L, 2000, J HEPATOL, V33, P106, DOI 10.1016/S0168-8278(00)80166-X; Rustaeus S, 1999, J NUTR, V129, p463S, DOI 10.1093/jn/129.2.463S; Sabile A, 1999, HEPATOLOGY, V30, P1064, DOI 10.1002/hep.510300429; Serfaty L, 2001, J HEPATOL, V34, P428, DOI 10.1016/S0168-8278(00)00036-2; Shelness GS, 2001, CURR OPIN LIPIDOL, V12, P151, DOI 10.1097/00041433-200104000-00008; Shi ST, 2002, VIROLOGY, V292, P198, DOI 10.1006/viro.2001.1225; Su AI, 2002, P NATL ACAD SCI USA, V99, P15669, DOI 10.1073/pnas.202608199; Tardif KD, 2005, TRENDS MICROBIOL, V13, P159, DOI 10.1016/j.tim.2005.02.004; Tardif KD, 2004, J BIOL CHEM, V279, P17158, DOI 10.1074/jbc.M312144200; Tietge UJF, 1999, J LIPID RES, V40, P2134; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268; Waris G, 2005, J VIROL, V79, P9725, DOI 10.1128/JVI.79.15.9725-9734.2005; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277; Wu XJ, 1997, J BIOL CHEM, V272, P11575; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; Zhong J, 2005, P NATL ACAD SCI USA, V102, P9294, DOI 10.1073/pnas.0503596102	59	57	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					39802	39808		10.1074/jbc.M510391200	http://dx.doi.org/10.1074/jbc.M510391200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16203724	hybrid			2022-12-25	WOS:000233461300017
J	Girard, M; Poupon, V; Blondeau, F; McPherson, PS				Girard, M; Poupon, V; Blondeau, F; McPherson, PS			The DnaJ-domain protein RME-8 functions in endosomal trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-COATED VESICLES; ENDOCYTOSIS; AUXILIN; BINDING; TRANSPORT; HSC70; GOLGI; IDENTIFICATION; INVOLVEMENT; MUTANTS	Through a proteomic analysis of clathrin-coated vesicles from rat liver we identified the mammalian homolog of receptor-mediated endocytosis 8 ( RME-8), a DnaJ domain-containing protein originally identified in a screen for endocytic defects in Caenorhabditis elegans. Mammalian RME-8 has a broad tissue distribution, and affinity selection assays reveal the ubiquitous chaperone Hsc70, which regulates protein conformation at diverse membrane sites as the major binding partner for its DnaJ domain. RME-8 is tightly associated with microsomal membranes and co-localizes with markers of the endosomal system. Small interfering RNA-mediated knock down of RME-8 has no influence on transferrin endocytosis but causes a reduction in epidermal growth factor internalization. Interestingly, and consistent with a localization to endosomes, knock down of RME-8 also leads to alterations in the trafficking of the cation-independent mannose 6-phosphate receptor and improper sorting of the lysosomal hydrolase cathepsin D. Our data demonstrate that RME-8 functions in intracellular trafficking and provides the first evidence of a functional role for a DnaJ domain-bearing co-chaperone on endosomes.	McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada	McGill University	McPherson, PS (corresponding author), McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.	peter.mcpherson@mcgill.ca						AHLE S, 1990, J CELL BIOL, V111, P19, DOI 10.1083/jcb.111.1.19; Blondeau F, 2004, P NATL ACAD SCI USA, V101, P3833, DOI 10.1073/pnas.0308186101; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Burman JL, 2005, FEBS LETT, V579, P2177, DOI 10.1016/j.febslet.2005.03.008; Chang HC, 2004, J CELL BIOL, V164, P1055, DOI 10.1083/jcb.200311084; Chang HC, 2002, J CELL BIOL, V159, P477, DOI 10.1083/jcb.200205086; DAVIDSON HW, 1995, J CELL BIOL, V130, P797, DOI 10.1083/jcb.130.4.797; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; Doray B, 2001, MOL BIOL CELL, V12, P1925, DOI 10.1091/mbc.12.7.1925; Drake MT, 2001, J BIOL CHEM, V276, P28700, DOI 10.1074/jbc.M104226200; Fotin A, 2004, NATURE, V432, P649, DOI 10.1038/nature03078; Girard M, 2005, MOL CELL PROTEOMICS, V4, P1145, DOI 10.1074/mcp.M500043-MCP200; GIRARD M, 2005, CURRENT PROTOCOLS CE; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; Greener T, 2000, J BIOL CHEM, V275, P1365, DOI 10.1074/jbc.275.2.1365; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; HILLEREHFELD A, 1995, BBA-REV BIOMEMBRANES, V1241, P177, DOI 10.1016/0304-4157(95)00004-B; Hinners I, 2003, J CELL SCI, V116, P763, DOI 10.1242/jcs.00270; Kelley WL, 1999, CURR BIOL, V9, pR305, DOI 10.1016/S0960-9822(99)80185-7; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LEMMON SK, 2001, CURR BIOL, V23, P49; Newmyer SL, 2001, J CELL BIOL, V152, P607, DOI 10.1083/jcb.152.3.607; PILCH PF, 1983, J CELL BIOL, V96, P133, DOI 10.1083/jcb.96.1.133; Puri V, 2001, J CELL BIOL, V154, P535, DOI 10.1083/jcb.200102084; Ramjaun AR, 1998, J NEUROCHEM, V70, P2369; Scheele U, 2003, J BIOL CHEM, V278, P25357, DOI 10.1074/jbc.M303738200; Seaman MNJ, 2004, J CELL BIOL, V165, P111, DOI 10.1083/jcb.200312034; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; Silady RA, 2004, PLANT PHYSIOL, V136, P3095, DOI 10.1104/pp.104.050583; Smythe E, 2003, BIOCHEM SOC T, V31, P736, DOI 10.1042/BST0310736; ter Haar E, 2000, P NATL ACAD SCI USA, V97, P1096, DOI 10.1073/pnas.97.3.1096; Umeda A, 2000, EUR J CELL BIOL, V79, P336, DOI 10.1078/S0171-9335(04)70037-0; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; Wasiak S, 2002, J CELL BIOL, V158, P855, DOI 10.1083/jcb.200205078; Wiley HS, 2001, TRAFFIC, V2, P12, DOI 10.1034/j.1600-0854.2001.020103.x; Young JC, 2003, TRENDS BIOCHEM SCI, V28, P541, DOI 10.1016/j.tibs.2003.08.009; Zhang YH, 2001, MOL BIOL CELL, V12, P2011, DOI 10.1091/mbc.12.7.2011	38	86	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40135	40143		10.1074/jbc.M505036200	http://dx.doi.org/10.1074/jbc.M505036200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16179350	hybrid			2022-12-25	WOS:000233461300053
J	Pledgie, A; Huang, Y; Hacker, A; Zhang, Z; Woster, PM; Davidson, NE; Casero, RA				Pledgie, A; Huang, Y; Hacker, A; Zhang, Z; Woster, PM; Davidson, NE; Casero, RA			Spermine oxidase SMO(PAOh1), not N-1-acetylpolyamine oxidase PAO, is the primary source of cytotoxic H2O2 in polyamine analogue-treated human breast cancer cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERMIDINE/SPERMINE N-1-ACETYLTRANSFERASE; DIFFERENTIAL INDUCTION; MOLECULAR-MECHANISMS; LUNG-CANCER; GROWTH; INHIBITION; METABOLISM; DEATH; N1-ACETYLTRANSFERASE; DERIVATIVES	The induction of polyamine catabolism and its production of H2O2 have been implicated in the response to specific antitumor polyamine analogues. The original hypothesis was that analogue induction of the rate-limiting spermidine/spermine N-1-acetyltransferase (SSAT) provided substrate for the peroxisomal acetylpolyamine oxidase (PAO), resulting in a decrease in polyamine pools through catabolism, oxidation, and excretion of acetylated polyamines and the production of toxic aldehydes and H2O2. However, the recent discovery of the inducible spermine oxidase SMO(PAOh1) suggested the possibility that the original hypothesis may be incomplete. To examine the role of the catabolic enzymes in the response of breast cancer cells to the polyamine analogue N-1, N(1-)bis(ethyl) norspermine (BENSpm), a stable knockdown small interfering RNA strategy was used. BENSpm differentially induced SSAT and SMO(PAOh1) mRNA and activity in several breast cancer cell lines, whereas no N-1-acetylpolyamine oxidase PAO mRNA or activity was detected. BENSpm treatment inhibited cell growth, decreased intracellular polyamine levels, and decreased ornithine decarboxylase activity in all cell lines examined. The stable knockdown of either SSAT or SMO(PAOh1) reduced the sensitivity of MDA-MB-231cells to BENSpm, whereas double knockdown MDA-MB-231 cells were almost entirely resistant to the growth inhibitory effects of the analogue. Furthermore, the H2O2 produced through BENSpm-induced polyamine catabolism was found to be derived exclusively from SMO(PAOh1) activity and not through PAO activity on acetylated polyamines. These data suggested that SSAT and SMO(PAOh1) activities are the major mediators of the cellular response of breast tumor cells to BENSpm and that PAO plays little or no role in this response.	Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA; Wayne State Univ, Coll Pharm & Allied Hlth Profess, Dept Pharmaceut Sci, Detroit, MI 48202 USA	Johns Hopkins University; Johns Hopkins Medicine; Wayne State University	Casero, RA (corresponding author), Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, 1650 Orleans St,CRB 409, Baltimore, MD 21231 USA.	davidna@jhmi.edu; rcasero@jhmi.edu	Woster, Patrick M/A-5604-2010; Huang, Yi/AAW-7892-2021	Woster, Patrick M/0000-0002-9471-1916; Huang, Yi/0000-0002-9982-117X; Casero, Robert/0000-0001-5653-3306	NATIONAL CANCER INSTITUTE [R01CA085509] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA085509] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambrosone CB, 2000, ANTIOXID REDOX SIGN, V2, P903, DOI 10.1089/ars.2000.2.4-903; Bacchi CJ, 2002, ANTIMICROB AGENTS CH, V46, P55, DOI 10.1128/AAC.46.1.55-61.2002; Bellelli A, 2004, BIOCHEM BIOPH RES CO, V322, P1, DOI 10.1016/j.bbrc.2004.07.074; Berchtold CM, 1998, J CELL PHYSIOL, V174, P380, DOI 10.1002/(SICI)1097-4652(199803)174:3<380::AID-JCP12>3.0.CO;2-D; BERGERON RJ, 1988, J MED CHEM, V31, P1183, DOI 10.1021/jm00401a019; BEY P, 1985, J MED CHEM, V28, P1, DOI 10.1021/jm00379a001; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Casero RA, 2001, J MED CHEM, V44, P1, DOI 10.1021/jm000084m; Casero RA, 2003, BIOCHEM SOC T, V31, P361, DOI 10.1042/BST0310361; CASERO RA, 1989, CANCER RES, V49, P3829; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; Chen Y, 2003, MOL PHARMACOL, V64, P1153, DOI 10.1124/mol.64.5.1153; Chen Y, 2001, CANCER RES, V61, P6437; DAVIDSON NE, 1993, CANCER RES, V53, P2071; Devereux W, 2003, CANCER CHEMOTH PHARM, V52, P383, DOI 10.1007/s00280-003-0662-4; FogelPetrovic M, 1997, MOL PHARMACOL, V52, P69, DOI 10.1124/mol.52.1.69; Gabrielson EW, 1999, CLIN CANCER RES, V5, P1638; Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557; Hahm HA, 2002, CLIN CANCER RES, V8, P684; Hahm HA, 2001, CLIN CANCER RES, V7, P391; HOCKENBERY DM, 2000, CELL MOL LFE SCI, V75, P241; Huang Y, 2005, ANTI-CANCER DRUG, V16, P229, DOI 10.1097/00001813-200503000-00002; KABRA PM, 1986, J CHROMATOGR, V380, P19, DOI 10.1016/S0378-4347(00)83621-X; KINGSNORTH AN, 1984, BRIT J SURG, V71, P352, DOI 10.1002/bjs.1800710513; LUK GD, 1987, ADV ENZYME REGUL, V26, P91, DOI 10.1016/0065-2571(87)90007-0; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; McCloskey DE, 1996, CLIN CANCER RES, V2, P441; Seiler N, 2004, AMINO ACIDS, V26, P317, DOI 10.1007/s00726-004-0090-8; Seiler Nikolaus, 2002, Prog Drug Res, V59, P1; Thomas T, 2001, CELL MOL LIFE SCI, V58, P244, DOI 10.1007/PL00000852; Thomas T, 1999, J CELL PHYSIOL, V179, P257, DOI 10.1002/(SICI)1097-4652(199906)179:3<257::AID-JCP3>3.0.CO;2-4; Vujcic S, 2002, BIOCHEM J, V367, P665, DOI 10.1042/BJ20020720; Wallace HM, 2000, CLIN CANCER RES, V6, P3657; Wallace HM, 2003, BIOCHEM J, V376, P1, DOI 10.1042/BJ20031327; Wallace HM, 2004, AMINO ACIDS, V26, P353, DOI 10.1007/s00726-004-0092-6; Wang YL, 2001, CANCER RES, V61, P5370; Wang YL, 2003, BIOCHEM BIOPH RES CO, V304, P605, DOI 10.1016/S0006-291X(03)00636-3; Wolff JC, 2003, CLIN CANCER RES, V9, P5922	38	90	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					39843	39851		10.1074/jbc.M508177200	http://dx.doi.org/10.1074/jbc.M508177200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16207710	hybrid			2022-12-25	WOS:000233461300022
J	Shi, YL; Dodson, GE; Rundell, K; Tibbetts, RS				Shi, YL; Dodson, GE; Rundell, K; Tibbetts, RS			Ataxia-telangiectasia-mutated (ATM) is a T-antigen kinase that controls SV40 viral replication in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY EMBRYONIC LETHALITY; DEPENDENT PROTEIN-KINASE; VIRUS-40 DNA-REPLICATION; LARGE TUMOR-ANTIGEN; CHECKPOINT PATHWAY; DAMAGE CHECKPOINT; GENOTOXIC STRESS; DEFICIENT CELLS; ACTIVATION; PHOSPHORYLATION	The structurally related ATM (ataxia-telangiectasia-mutated) and ATR (ATM-Rad3-related) protein kinases fulfill overlapping yet non-redundant functions as key regulators of cellular DNA damage responses. We recently showed that ATM phosphorylates the cyclic AMP response element-binding protein, CREB, following exposure to ionizing radiation (IR) and other DNA-damaging stimuli. Here, we show that a phospho-specific antibody recognizing the major ATM phosphorylation site in CREB cross-reacts with SV40 large tumor antigen (LTag), a multifunctional oncoprotein required for replication of the SV40 minichromosome. The relevant IR-induced phosphorylation site in LTag recognized by phospho-CREB antibody was mapped to Ser-120. IR strongly induced the phosphorylation of Ser-120 in an ATM-dependent manner in mouse embryo fibroblasts. Infection of African green monkey CV1 cells with SV40 resulted in the activation of ATM and phosphorylation of LTag and endogenous ATM substrates. Infection-induced LTag phosphorylation correlated with the onset of DNA replication, was ATM-dependent, and peaked when viral DNA levels reached their maximum. SV40 replication in CV1 cells required an intact LTag Ser-120 phosphorylation site and was inhibited following transfection with ATM small interfering RNA suggesting that ATM is required for optimal SV40 replication in primate cells. Our findings uncover a direct link between ATM and SV40 LTag that may have implications for understanding the replication cycle of oncogenic polyoma viruses.	Univ Wisconsin, Dept Pharmacol, Sch Med, Madison, WI 53706 USA; Northwestern Univ, Dept Immunol Microbiol, Chicago, IL 60611 USA	University of Wisconsin System; University of Wisconsin Madison; Northwestern University	Tibbetts, RS (corresponding author), Univ Wisconsin, Dept Pharmacol, Sch Med, 1300 Univ Ave, Madison, WI 53706 USA.	rstibbetts@wisc.edu		Tibbetts, Randal/0000-0003-2245-2297	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067868] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM067868-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Becker-Catania SG, 2001, ADV EXP MED BIOL, V495, P191; Boyapati A, 2003, VIROLOGY, V315, P148, DOI 10.1016/S0042-6822(03)00524-5; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Brown EJ, 2000, GENE DEV, V14, P397; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Busino L, 2003, NATURE, V426, P87, DOI 10.1038/nature02082; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; CEGIELSKA A, 1994, J VIROL, V68, P269, DOI 10.1128/JVI.68.1.269-275.1994; CHEN YR, 1991, J VIROL, V65, P5131, DOI 10.1128/JVI.65.10.5131-5140.1991; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; Dodson GE, 2004, J BIOL CHEM, V279, P34010, DOI 10.1074/jbc.C400242200; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; GRASSER FA, 1987, J VIROL, V61, P3373; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kitagawa R, 2004, GENE DEV, V18, P1423, DOI 10.1101/gad.1200304; Lau A, 2005, NAT CELL BIOL, V7, P493, DOI 10.1038/ncb1250; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Lilley CE, 2005, P NATL ACAD SCI USA, V102, P5844, DOI 10.1073/pnas.0501916102; Liu JS, 2000, J BIOL CHEM, V275, P1391, DOI 10.1074/jbc.275.2.1391; Liu QH, 2000, GENE DEV, V14, P1448; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; McHugh MM, 1999, BIOCHEMISTRY-US, V38, P11508, DOI 10.1021/bi990598r; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; Nghiem P, 2001, P NATL ACAD SCI USA, V98, P9092, DOI 10.1073/pnas.161281798; O'Driscoll M, 2003, NAT GENET, V33, P497, DOI 10.1038/ng1129; Okubo E, 2003, J VIROL, V77, P1257, DOI 10.1128/JVI.77.2.1257-1267.2003; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; SCHEIDTMANN KH, 1991, J VIROL, V65, P2098, DOI 10.1128/JVI.65.4.2098-2101.1991; SCHEIDTMANN KH, 1991, J VIROL, V65, P1479, DOI 10.1128/JVI.65.3.1479-1490.1991; SCHNEIDER J, 1988, J VIROL, V62, P1598, DOI 10.1128/JVI.62.5.1598-1605.1988; Shechter D, 2004, DNA REPAIR, V3, P901, DOI 10.1016/j.dnarep.2004.03.020; Shechter D, 2004, NAT CELL BIOL, V6, P648, DOI 10.1038/ncb1145; Shi YL, 2004, P NATL ACAD SCI USA, V101, P5898, DOI 10.1073/pnas.0307718101; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shirata N, 2005, J BIOL CHEM, V280, P30336, DOI 10.1074/jbc.M500976200; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; VIRSHUP DM, 1992, MOL CELL BIOL, V12, P4883, DOI 10.1128/MCB.12.11.4883; Wang Y, 1999, J BIOL CHEM, V274, P22060, DOI 10.1074/jbc.274.31.22060; WANG Y, 1995, RADIAT RES, V142, P169, DOI 10.2307/3579025; WANG Y, 1997, CANCER RES, V57, P654; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; Weisshart K, 1999, J VIROL, V73, P2201, DOI 10.1128/JVI.73.3.2201-2211.1999; Wu XH, 2004, GENE DEV, V18, P1305, DOI 10.1101/gad.1182804; Xiao CY, 1997, J BIOL CHEM, V272, P22191, DOI 10.1074/jbc.272.35.22191; You ZS, 2005, MOL CELL BIOL, V25, P5363, DOI 10.1128/MCB.25.13.5363-5379.2005; Yu J, 2001, VIROLOGY, V290, P192, DOI 10.1006/viro.2001.1204; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Ziegler K, 2004, J VIROL METHODS, V122, P123, DOI 10.1016/j.jviromet.2004.08.012; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	59	80	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40195	40200		10.1074/jbc.C500400200	http://dx.doi.org/10.1074/jbc.C500400200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16221684	hybrid			2022-12-25	WOS:000233461300060
J	Skalet, AH; Isler, JA; King, LB; Harding, HP; Ron, D; Monroe, JG				Skalet, AH; Isler, JA; King, LB; Harding, HP; Ron, D; Monroe, JG			Rapid B cell receptor-induced unfolded protein response in nonsecretory B cells correlates with pro- versus antiapoptotic cell fate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; HEAT-STABLE ANTIGEN(HI); TRANSCRIPTION FACTOR; LYMPHOCYTES-B; PLASMA-CELLS; ANTIBODY SECRETION; MURINE LYMPHOCYTES; MESSENGER-RNA; ER STRESS; DIFFERENTIATION	The adaptive unfolded protein response ( UPR) is essential for the development of antibody-secreting plasma cells. B cells induced by lipopolysaccharide ( LPS) to differentiate into plasma cells exhibit a nonclassical UPR reported to anticipate endoplasmic reticulum stress prior to immunoglobulin production. Here we demonstrate that activation of a physiologic UPR is not limited to cells undergoing secretory cell differentiation. We identify B cell receptor ( BCR) signaling as an unexpected physiologic UPR trigger and demonstrate that in mature B cells, BCR stimulation induces a short lived UPR similar to the LPS-triggered nonclassical UPR. However, unlike LPS, BCR stimulation does not induce plasma cell differentiation. Furthermore, the BCR-inducedUPRis not limited to cells in which BCR induces activation, since a UPR is also induced in transitional immature B cells that respond to BCR stimulation with a rapid apoptotic fate. This response involves sustained up-regulation of Chop mRNA indicative of a terminal UPR. Whereas sustained Chop expression correlates with the ultimate fate of the BCR-triggered B cell and not its developmental stage, Chop-/- B cells undergo apoptosis, indicating that CHOP is not required for this process. These studies establish a system whereby a terminal or adaptive UPR can be alternatively triggered by physiologic stimuli.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; NYU, Sch Med, Skirball Inst Biomol Med, Dept Med, New York, NY 10016 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; New York University	Monroe, JG (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 311 Biomed Res Bldg 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	monroej@mail.med.upenn.edu		Ron, David/0000-0002-3014-5636; Harding, Heather P/0000-0002-7359-7974	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI043620, R01AI032592, F32AI062055] Funding Source: NIH RePORTER; NIAID NIH HHS [F32 AI062055-01, AI43620, AI32592] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allman D, 2001, J IMMUNOL, V167, P6834, DOI 10.4049/jimmunol.167.12.6834; ALLMAN DM, 1992, J IMMUNOL, V149, P2533; ALLMAN DM, 1993, J IMMUNOL, V151, P4431; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Brewer JW, 2005, NAT IMMUNOL, V6, P23, DOI 10.1038/ni1149; Calame KL, 2003, ANNU REV IMMUNOL, V21, P205, DOI 10.1146/annurev.immunol.21.120601.141138; Calame KL, 2001, NAT IMMUNOL, V2, P1103, DOI 10.1038/ni1201-1103; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Chung JB, 2002, INT IMMUNOL, V14, P157, DOI 10.1093/intimm/14.2.157; Gass JN, 2004, TRENDS IMMUNOL, V25, P17, DOI 10.1016/j.it.2003.11.004; Gass JN, 2002, J BIOL CHEM, V277, P49047, DOI 10.1074/jbc.M205011200; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; Iwakoshi NN, 2003, NAT IMMUNOL, V4, P321, DOI 10.1038/ni907; Iwakoshi NN, 2003, IMMUNOL REV, V194, P29, DOI 10.1034/j.1600-065X.2003.00057.x; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; LEWIS MJ, 1985, J BIOL CHEM, V260, P3050; Loder F, 1999, J EXP MED, V190, P75, DOI 10.1084/jem.190.1.75; Ma YJ, 2003, NAT IMMUNOL, V4, P310, DOI 10.1038/ni0403-310; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; MURAKAMI M, 1992, NATURE, V357, P77, DOI 10.1038/357077a0; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; NORVELL A, 1995, J IMMUNOL, V154, P4404; O'Connor BP, 2003, IMMUNOL REV, V194, P61, DOI 10.1034/j.1600-065X.2003.00055.x; PARKER DC, 1980, J EXP MED, V152, P138, DOI 10.1084/jem.152.1.138; PARKER DC, 1975, NATURE, V258, P361, DOI 10.1038/258361a0; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Sandel PC, 1999, IMMUNITY, V10, P289, DOI 10.1016/S1074-7613(00)80029-1; SANDERSON RD, 1989, CELL REGUL, V1, P27, DOI 10.1091/mbc.1.1.27; Sater RA, 1998, INT IMMUNOL, V10, P1673, DOI 10.1093/intimm/10.11.1673; SELL S, 1965, J EXP MED, V122, P823, DOI 10.1084/jem.122.4.823; Shaffer AL, 2004, IMMUNITY, V21, P81, DOI 10.1016/j.immuni.2004.06.010; Shapiro-Shelef M, 2004, CURR OPIN IMMUNOL, V16, P226, DOI 10.1016/j.coi.2004.02.001; Shen XH, 2001, CELL, V107, P893, DOI 10.1016/S0092-8674(01)00612-2; SIDMAN CL, 1978, P NATL ACAD SCI USA, V75, P2401, DOI 10.1073/pnas.75.5.2401; Tagliavacca L, 2003, BIOL CHEM, V384, P1273, DOI 10.1515/BC.2003.141; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; van Anken E, 2003, IMMUNITY, V18, P243, DOI 10.1016/S1074-7613(03)00024-4; WIEST DL, 1990, J CELL BIOL, V110, P1501, DOI 10.1083/jcb.110.5.1501; YELLEN AJ, 1991, J IMMUNOL, V146, P1446; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhang KZ, 2005, J CLIN INVEST, V115, P268, DOI 10.1172/JCI200521848; Zhang KZ, 2004, J BIOL CHEM, V279, P25935, DOI 10.1074/jbc.R400008200; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	57	41	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					39762	39771		10.1074/jbc.M502640200	http://dx.doi.org/10.1074/jbc.M502640200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16188879	hybrid			2022-12-25	WOS:000233461300013
J	Sugawara, K; Suzuki, NN; Fujioka, Y; Mizushima, N; Ohsumi, Y; Inagaki, F				Sugawara, K; Suzuki, NN; Fujioka, Y; Mizushima, N; Ohsumi, Y; Inagaki, F			Structural basis for the specificity and catalysis of human Atg4B responsible for mammalian autophagy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; PROTEIN LIGHT-CHAIN-3; TRANSPORT MODULATOR; GATE-16; GABARAP; HOMOLOG; ENZYME; YEAST; UCH-L3; LC3	Reversible modification of Atg8 with phosphatidylethanolamine is crucial for autophagy, the bulk degradation system conserved in eukaryotic cells. Atg4 is a novel cysteine protease that processes and deconjugates Atg8. Herein, we report the crystal structure of human Atg4B ( HsAtg4B) at 1.9-(A) over circle resolution. Despite no obvious sequence homology with known proteases, the structure of HsAtg4B shows a classical papain-like fold. In addition to the papain fold region, HsAtg4B has a small alpha/beta-fold domain. This domain is thought to be the binding site for Atg8 homologs. The active site cleft of HsAtg4B is masked by a loop ( residues 259 - 262), implying a conformational change upon substrate binding. The structure and in vitro mutational analyses provide the basis for the specificity and catalysis of HsAtg4B. This will enable the design of Atg4-specific inhibitors that block autophagy.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biol Struct, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Natl Inst Basic Biol, Div Mol Cell Biol, Okazaki, Aichi 4448585, Japan; Tokyo Metropolitan Inst Med Sci, Dept Bioregulat & Metab, Tokyo 1138613, Japan; Japan Sci & Technol Agcy, Times Arrow & Biosignaling Precur Res Embryon Sci, Kawaguchi 3320012, Japan	Hokkaido University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Tokyo Metropolitan Institute of Medical Science; Japan Science & Technology Agency (JST)	Inagaki, F (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biol Struct, Kita Ku, N-12,W-6, Sapporo, Hokkaido 0600812, Japan.	finagaki@pharm.hokudai.ac.jp	Mizushima, Noboru/C-3635-2009; Ohsumi, Yoshinori/C-6449-2009; Noda, Nobuo/P-1397-2015	Mizushima, Noboru/0000-0002-6258-6444; Ohsumi, Yoshinori/0000-0003-2384-2166; Fujioka, Yuko/0000-0002-6905-0669; Noda, Nobuo/0000-0002-6940-8069				Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; BABA M, 1994, J CELL BIOL, V124, P903, DOI 10.1083/jcb.124.6.903; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Hemelaar J, 2003, J BIOL CHEM, V278, P51841, DOI 10.1074/jbc.M308762200; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Hu M, 2002, CELL, V111, P1041, DOI 10.1016/S0092-8674(02)01199-6; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Johnston SC, 1999, EMBO J, V18, P3877, DOI 10.1093/emboj/18.14.3877; Johnston SC, 1997, EMBO J, V16, P3787, DOI 10.1093/emboj/16.13.3787; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X; Knight D, 2002, J BIOL CHEM, V277, P5556, DOI 10.1074/jbc.M109753200; Kouno T, 2005, J BIOL CHEM, V280, P24610, DOI 10.1074/jbc.M413565200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Legesse-Miller A, 1998, J BIOL CHEM, V273, P3105, DOI 10.1074/jbc.273.5.3105; LEMASTER DM, 1985, BIOCHEMISTRY-US, V24, P7263, DOI 10.1021/bi00346a036; MANN SS, 1994, J BIOL CHEM, V269, P11492; Marino G, 2003, J BIOL CHEM, V278, P3671, DOI 10.1074/jbc.M208247200; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Misaghi S, 2005, J BIOL CHEM, V280, P1512, DOI 10.1074/jbc.M410770200; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paz Y, 2000, J BIOL CHEM, V275, P25445, DOI 10.1074/jbc.C000307200; Reverter D, 2005, J MOL BIOL, V345, P141, DOI 10.1016/j.jmb.2004.10.022; Reverter D, 2004, STRUCTURE, V12, P1519, DOI 10.1016/j.str.2004.05.023; Scherz-Shouval R, 2003, J BIOL CHEM, V278, P14053, DOI 10.1074/jbc.M212108200; Shen LN, 2005, EMBO J, V24, P1341, DOI 10.1038/sj.emboj.7600628; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Sugawara K, 2004, GENES CELLS, V9, P611, DOI 10.1111/j.1356-9597.2004.00750.x; Tanida I, 2004, J BIOL CHEM, V279, P36268, DOI 10.1074/jbc.M401461200; Tanida I, 2003, BIOCHEM BIOPH RES CO, V300, P637, DOI 10.1016/S0006-291X(02)02907-8; Tanida I, 2002, J BIOL CHEM, V277, P13739, DOI 10.1074/jbc.M200385200; Tanida I, 2001, J BIOL CHEM, V276, P1701, DOI 10.1074/jbc.C000752200; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264	39	105	111	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40058	40065		10.1074/jbc.M509158200	http://dx.doi.org/10.1074/jbc.M509158200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16183633	hybrid			2022-12-25	WOS:000233461300044
J	Wahrle, SE; Jiang, H; Parsadanian, M; Hartman, RE; Bales, KR; Paul, SM; Holtzman, DM				Wahrle, SE; Jiang, H; Parsadanian, M; Hartman, RE; Bales, KR; Paul, SM; Holtzman, DM			Deletion of Abca1 increases A beta deposition in the PDAPP transgenic mouse model of Alzheimer disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; CASSETTE TRANSPORTER 1; DENSITY-LIPOPROTEIN DEFICIENCY; ISOFORM-SPECIFIC BINDING; APOLIPOPROTEIN-E; TANGIER-DISEASE; CHOLESTEROL EFFLUX; PLAQUE-FORMATION; TYPE-4 ALLELE; LDL RECEPTOR	Apolipoprotein E ( apoE) genotype has a major influence on the risk for Alzheimer disease (AD). Different apoE isoforms may alter AD pathogenesis via their interactions with the amyloid beta-peptide (A beta). Mice lacking the lipid transporter ABCA1 were found to have markedly decreased levels and lipidation of apoE in the central nervous system. We hypothesized that if Abca1(-/-) mice were bred to the PDAPP mouse model of AD, PDAPP Abca1(-/-) mice would have a phenotype similar to that of PDAPP Apoe(-/-) and PDAPP Apoe(-/-) mice, which develop less amyloid deposition than PDAPP Apoe(+/+) mice. In contrast to this prediction, 12-month-old PDAPP Abca(-/-) mice had significantly higher levels of hippocampal A beta, and cerebral amyloid angiopathy was significantly more common compared with PDAPP Abca1(-/-) mice. Amyloid precursor protein (APP) C-terminal fragments were not different between Abca1 genotypes prior to plaque deposition in 3-month-old PDAPP mice, suggesting that deletion of Abca1 did not affect APP processing or A beta production. As expected, 3-month-old PDAPP Abca1(-/-) mice had decreased apoE levels, but they also had a higher percentage of carbonate-insoluble apoE, suggesting that poorly lipidated apoE is less soluble in vivo. We also found that 12-month-old PDAPP Abca1(-/-) mice had a higher percentage of carbonate-insoluble apoE and that apoE deposits co-localize with amyloid plaques, demonstrating that poorly lipidated apoE co-deposits with insoluble A beta. Together, these data suggest that despite substantially lower apoE levels, poorly lipidated apoE produced in the absence of ABCA1 is strongly amyloidogenic in vivo.	Washington Univ, Dept Neurol, Sch Med, St Louis, MO 63110 USA; Washington Univ, Neurosci Program, Sch Med, St Louis, MO 63110 USA; Washington Univ, Dept Biol Mol, Sch Med, St Louis, MO 63110 USA; Washington Univ, Dept Pharmacol, Sch Med, St Louis, MO 63110 USA; Washington Univ, Hope Ctr Neurol Disorders, Sch Med, St Louis, MO 63110 USA; Eli Lilly & Co, Lilly Res Labs, Neurosci Discovery Res, Indianapolis, IN 46285 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Eli Lilly	Holtzman, DM (corresponding author), Washington Univ, Dept Neurol, Sch Med, 660 S Euclid Ave,Box 8111, St Louis, MO 63110 USA.	holtzman@neuro.wustl.edu	Paul, Steve/ABE-5400-2020; Hartman, Richard/C-5767-2008	Hartman, Richard/0000-0001-9235-3169; Schindler, Suzanne/0000-0002-1680-1465	NATIONAL INSTITUTE ON AGING [R01AG013956, P01AG011355, R37AG013956] Funding Source: NIH RePORTER; NIA NIH HHS [AG13956, AG11355] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bales KR, 1999, P NATL ACAD SCI USA, V96, P15233, DOI 10.1073/pnas.96.26.15233; Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Beffert U, 1999, MOL BRAIN RES, V68, P181, DOI 10.1016/S0169-328X(99)00073-X; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DeMattos RB, 2002, J NEUROCHEM, V81, P229, DOI 10.1046/j.1471-4159.2002.00889.x; DeMattos RB, 2004, NEURON, V41, P193, DOI 10.1016/S0896-6273(03)00850-X; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; Fagan AM, 2002, NEUROBIOL DIS, V9, P305, DOI 10.1006/nbdi.2002.0483; Fryer JD, 2005, J BIOL CHEM, V280, P25754, DOI 10.1074/jbc.M502143200; Fryer JD, 2005, J NEUROSCI, V25, P2803, DOI 10.1523/JNEUROSCI.5170-04.2005; Fryer JD, 2003, J NEUROSCI, V23, P7889; Fukumoto H, 2002, J BIOL CHEM, V277, P48508, DOI 10.1074/jbc.M209085200; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GREENBERG SM, 1995, ANN NEUROL, V38, P254, DOI 10.1002/ana.410380219; Hirsch-Reinshagen V, 2005, J BIOL CHEM, V280, P43243, DOI 10.1074/jbc.M508781200; Hirsch-Reinshagen V, 2004, J BIOL CHEM, V279, P41197, DOI 10.1074/jbc.M407962200; Holtzman DM, 2000, ANN NEUROL, V47, P739, DOI 10.1002/1531-8249(200006)47:6<739::AID-ANA6>3.0.CO;2-8; Holtzman DM, 2004, J MOL NEUROSCI, V23, P247, DOI 10.1385/JMN:23:3:247; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; Holtzman DM, 2001, J MOL NEUROSCI, V17, P147, DOI 10.1385/JMN:17:2:147; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Koistinaho M, 2004, NAT MED, V10, P719, DOI 10.1038/nm1058; Koldamova R, 2005, J BIOL CHEM, V280, P43224, DOI 10.1074/jbc.M504513200; Koldamova RP, 2003, J BIOL CHEM, V278, P13244, DOI 10.1074/jbc.M300044200; Koldamova T, 2005, J BIOL CHEM, V280, P4079, DOI 10.1074/jbc.M411420200; LADU MJ, 1994, J BIOL CHEM, V269, P23403; LADU MJ, 1995, J BIOL CHEM, V270, P9039, DOI 10.1074/jbc.270.16.9039; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; Narita M, 2002, J BIOCHEM, V132, P743, DOI 10.1093/oxfordjournals.jbchem.a003282; Remaley AT, 1999, P NATL ACAD SCI USA, V96, P12685, DOI 10.1073/pnas.96.22.12685; Ruiz J, 2005, J LIPID RES, V46, P1721, DOI 10.1194/jlr.M500114-JLR200; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SCHAEFER EJ, 1981, J LIPID RES, V22, P217; SCHAEFER EJ, 1978, NEW ENGL J MED, V299, P905, DOI 10.1056/NEJM197810262991701; Schmitz G, 2001, CURR OPIN LIPIDOL, V12, P129, DOI 10.1097/00041433-200104000-00006; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Sun Y, 2003, J BIOL CHEM, V278, P27688, DOI 10.1074/jbc.M300760200; Tokuda T, 2000, BIOCHEM J, V348, P359, DOI 10.1042/0264-6021:3480359; Van Eck M, 2005, CURR OPIN LIPIDOL, V16, P307; Wahrle SE, 2004, J BIOL CHEM, V279, P40987, DOI 10.1074/jbc.M407963200; Wang N, 2003, ARTERIOSCL THROM VAS, V23, P1178, DOI 10.1161/01.ATV.0000075912.83860.26; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; Wisniewski T, 1997, NEUROBIOL DIS, V4, P313, DOI 10.1006/nbdi.1997.0147; Wolozin B, 2004, NEURON, V41, P7, DOI 10.1016/S0896-6273(03)00840-7	49	258	262	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					43236	43242		10.1074/jbc.M508780200	http://dx.doi.org/10.1074/jbc.M508780200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16207708	hybrid			2022-12-25	WOS:000234200800090
J	Zhang, LY; Lookene, A; Wu, GS; Olivecrona, G				Zhang, LY; Lookene, A; Wu, GS; Olivecrona, G			Calcium triggers folding of lipoprotein lipase into active dimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORIDE-DENATURED RHODANESE; RAT ADIPOSE-TISSUE; ENDOPLASMIC-RETICULUM; MOLECULAR-BIOLOGY; METAL-ION; KINASE; BINDING; PROTEIN; STABILITY; HEPARIN	The active form of lipoprotein lipase (LPL) is a noncovalent homodimer of 55-kDa subunits. The dimer is unstable and tends to undergo irreversible dissociation into inactive monomers. We noted that a preparation of such monomers slowly regained traces of activity under assay conditions with substrate, heparin, and serum or in cell culture medium containing serum. We therefore studied the refolding pathway of LPL after full denaturation in 6 M guanidinium chloride or after dissociation into monomers in 1 M guanidinium chloride. In crude systems, we identified serum as the factor promoting reactivation. Further investigations demonstrated that Ca2+ was the crucial component in serum for reactivation of LPL and that refolding involved at least two steps. Studies of far-UV circular dichroism, fluorescence, and proteolytic cleavage patterns showed that LPL started to refold from the C-terminal domain, independent of calcium. The first step was rapid and resulted in formation of an inactive monomer with a completely folded C-terminal domain, whereas the N-terminal domain was in the molten globule state. The second step was promoted by Ca2+ and converted LPL monomers from the molten globule state to dimerization-competent and more tightly folded monomers that rapidly formed active LPL dimers. The second step was slow, and it appears that proline isomerization (rather than dimerization as such) is rate-limiting. Inactive monomers isolated from human tissue recovered activity under the influence of Ca2+. We speculate that Ca2+-dependent control of LPL dimerization might be involved in the normal post-translational regulation of LPL activity.	Umea Univ, Dept Med Biosci Physiol Chem, SE-90187 Umea, Sweden; Tallinn Univ Technol, Dept Gene Technol, EE-12618 Tallinn, Estonia	Umea University; Tallinn University of Technology	Olivecrona, G (corresponding author), Umea Univ, Dept Med Biosci Physiol Chem, Bldg 6M,3rd Floor, SE-90187 Umea, Sweden.	Gunilla.Olivecrona@medbio.umu.se						Arnaudeau S, 2002, J BIOL CHEM, V277, P46696, DOI 10.1074/jbc.M202395200; Ben-Zeev O, 2002, J BIOL CHEM, V277, P10727, DOI 10.1074/jbc.M108128200; BENGTSSONOLIVECRONA G, 1991, METHOD ENZYMOL, V197, P345; BENZEEV O, 1994, J LIPID RES, V35, P1511; Bergo M, 2002, J BIOL CHEM, V277, P11927, DOI 10.1074/jbc.M200325200; Bergo M, 1996, BIOCHEM J, V313, P893, DOI 10.1042/bj3130893; Bey L, 2003, J PHYSIOL-LONDON, V551, P673, DOI 10.1113/jphysiol.2003.045591; Briquet-Laugier V, 1999, J LIPID RES, V40, P2044; Cerasoli E, 2003, BBA-PROTEINS PROTEOM, V1648, P43, DOI 10.1016/S1570-9639(03)00110-9; Couthon F, 1996, BIOCHEM BIOPH RES CO, V227, P854, DOI 10.1006/bbrc.1996.1596; Daugherty DL, 1998, J BIOL CHEM, V273, P33961, DOI 10.1074/jbc.273.51.33961; DOOLITTLE MH, 1990, J BIOL CHEM, V265, P4570; FRIEDMAN G, 1980, BIOCHIM BIOPHYS ACTA, V619, P650, DOI 10.1016/0005-2760(80)90114-9; Goldberg IJ, 2001, FRONT BIOSCI-LANDMRK, V6, pD388, DOI 10.2741/Goldberg; GOLDMAN R, 1990, J LEUKOCYTE BIOL, V48, P193, DOI 10.1002/jlb.48.2.193; Hamilton MT, 2004, EXERC SPORT SCI REV, V32, P161; Ishibashi M, 2003, J PROTEIN CHEM, V22, P345, DOI 10.1023/A:1025338106922; IVERIUS PH, 1971, BIOCHEM J, V124, P677, DOI 10.1042/bj1240677; Kamen DE, 2002, BIOCHEMISTRY-US, V41, P4713, DOI 10.1021/bi0115129; Kobayashi Y, 2002, EUR J BIOCHEM, V269, P4701, DOI 10.1046/j.1432-1033.2002.03179.x; Leckner J, 1997, BBA-PROTEIN STRUCT M, V1342, P19, DOI 10.1016/S0167-4838(97)00074-5; Lindegaard MLS, 2005, J LIPID RES, V46, P2339, DOI 10.1194/jlr.M500277-JLR200; LINDGREN FT, 1972, BLOOD LIPIDS LIPOPRO, P181; Lookene A, 2004, J BIOL CHEM, V279, P49964, DOI 10.1074/jbc.M407419200; Lookene A, 1997, BIOCHEMISTRY-US, V36, P5267, DOI 10.1021/bi962699k; Lookene A, 1996, BIOCHEMISTRY-US, V35, P12155, DOI 10.1021/bi960008e; Majumder A, 2001, J BIOL CHEM, V276, P30948, DOI 10.1074/jbc.M011705200; OLIVECRONA G, 1995, ATHEROSCLEROSIS X, P250; Olivecrona T, 1997, P NUTR SOC, V56, P723, DOI 10.1079/PNS19970072; OLIVECRONA T, 1985, J BIOL CHEM, V260, P6888; OSBORNE JC, 1985, BIOCHEMISTRY-US, V24, P5606, DOI 10.1021/bi00341a048; Ou WB, 2002, INT J BIOCHEM CELL B, V34, P136, DOI 10.1016/S1357-2725(01)00113-3; Preiss-Landl K, 2002, CURR OPIN LIPIDOL, V13, P471, DOI 10.1097/00041433-200210000-00002; Ranganathan G, 2002, J BIOL CHEM, V277, P43281, DOI 10.1074/jbc.M202560200; Rozema D, 1996, BIOCHEMISTRY-US, V35, P15760, DOI 10.1021/bi961638j; Schmid F X, 1986, Methods Enzymol, V131, P70; SEMB H, 1986, BIOCHIM BIOPHYS ACTA, V876, P249, DOI 10.1016/0005-2760(86)90281-X; SENDA M, 1987, P NATL ACAD SCI USA, V84, P4369, DOI 10.1073/pnas.84.13.4369; SHI L, 1994, BIOCHEMISTRY-US, V33, P7536, DOI 10.1021/bi00190a006; SOMA MR, 1989, BIOCHIM BIOPHYS ACTA, V1003, P307, DOI 10.1016/0005-2760(89)90237-3; TANDON S, 1986, J BIOL CHEM, V261, P5615; TANDON S, 1987, J BIOL CHEM, V262, P4486; TORNVALL P, 1995, ARTERIOSCL THROM VAS, V15, P1086, DOI 10.1161/01.ATV.15.8.1086; UEKI H, 1993, BIOL PHARM BULL, V16, P6, DOI 10.1248/bpb.16.6; VANTILBEURGH H, 1994, J BIOL CHEM, V269, P4626; Wang XS, 2000, ATHEROSCLEROSIS, V150, P357, DOI 10.1016/S0021-9150(99)00413-X; Wong H, 1997, P NATL ACAD SCI USA, V94, P5594, DOI 10.1073/pnas.94.11.5594; Wu GS, 2003, J BIOL CHEM, V278, P11925, DOI 10.1074/jbc.M212736200; Xu XL, 2002, BIOCHEMISTRY-US, V41, P3546, DOI 10.1021/bi015819j; YANG CY, 1989, J BIOL CHEM, V264, P16822; Zhang LY, 2003, J BIOL CHEM, V278, P29344, DOI 10.1074/jbc.M300455200	51	49	53	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42580	42591		10.1074/jbc.M507252200	http://dx.doi.org/10.1074/jbc.M507252200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16179346	hybrid			2022-12-25	WOS:000234200800015
J	Fletcher, RJ; Shen, JP; Gomez-Llorente, Y; San Martin, C; Carazo, JM; Chen, XJS				Fletcher, RJ; Shen, JP; Gomez-Llorente, Y; San Martin, C; Carazo, JM; Chen, XJS			Double hexamer disruption and biochemical activities of Methanobacterium thermoautotrophicum MCM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINICHROMOSOME MAINTENANCE PROTEIN; IMAGE-PROCESSING PACKAGE; T-ANTIGEN; DNA-REPLICATION; HELICASE; SYMMETRY; XMIPP; FORM	Methanobacterium thermoautotrophicum MCM (mtMCM) is a helicase required for DNA replication. Previous electron microscopy studies have shown mtMCM in several oligomeric forms. However, biochemical studies suggest that mtMCM is a dodecamer, likely a double hexamer (dHex). The crystal structure of the N-terminal fragment of mtMCM reveals a stable dHex architecture. To further confirm that the dHex is not an artifact of crystal packing of two hexamers, we investigated the relevance of the dHex by disrupting the hexamer-hexamer interactions seen in the crystal structure via site-directed mutagenesis and examining various biochemical activities of the mutants in vitro. Using a combination of biochemical and structural assays, we demonstrated that changing arginine to alanine at amino acid position 161 or the insertion of a six-amino-acid peptide at the hexamer-hexamer interface disrupted dHex formation and produced stable single hexamers (sHex). Furthermore, we showed that the sHex mutants retained wild-type level of ATPase and DNA binding activities but had decreased helicase activity when compared with the wild type dHex protein. These biochemical properties of mtMCM are reminiscent of those of SV40 large T antigen, suggesting that the dHex form of mtMCM may be the active helicase for DNA unwinding during the bidirectional DNA replication.	Univ So Calif, Los Angeles, CA 90089 USA; Univ Colorado, Denver, CO 80262 USA; CNB CSIC, Biocomp Unit, Madrid 28049, Spain	University of Southern California; University of Colorado System; University of Colorado Denver; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Chen, XJS (corresponding author), Univ So Calif, Los Angeles, CA 90089 USA.	Xiaojiang.Chen@USC.edu	Gomez-Llorente, Yacob/E-5631-2013; Garcia, Jose Maria Carazo/E-9234-2016; San Martín, Carmen/A-4074-2010	Garcia, Jose Maria Carazo/0000-0003-0788-8447; San Martín, Carmen/0000-0001-9799-175X	NHLBI NIH HHS [1R01HL70472] Funding Source: Medline; NIAID NIH HHS [R01-AI055926] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070472] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI055926] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alexandrov AI, 2002, J BIOL CHEM, V277, P44886, DOI 10.1074/jbc.M207022200; Chen YJ, 2005, J MOL BIOL, V346, P389, DOI 10.1016/j.jmb.2004.11.076; Chong JPJ, 2000, P NATL ACAD SCI USA, V97, P1530, DOI 10.1073/pnas.030539597; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; Fletcher RJ, 2003, NAT STRUCT BIOL, V10, P160, DOI 10.1038/nsb893; Forsburg SL, 2004, MICROBIOL MOL BIOL R, V68, P109, DOI 10.1128/MMBR.68.1.109-131.2004; Gai' DH, 2004, CELL, V119, P47, DOI 10.1016/j.cell.2004.09.017; Kelman Z, 1999, P NATL ACAD SCI USA, V96, P14783, DOI 10.1073/pnas.96.26.14783; Labib K, 2001, CURR OPIN GENET DEV, V11, P64, DOI 10.1016/S0959-437X(00)00158-1; Lei M, 2001, J CELL SCI, V114, P1447; Li DW, 2003, NATURE, V423, P512, DOI 10.1038/nature01691; Marabini R, 1996, J STRUCT BIOL, V116, P237, DOI 10.1006/jsbi.1996.0036; Marco S, 1996, ULTRAMICROSCOPY, V66, P5, DOI 10.1016/S0304-3991(96)00083-6; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; McGeoch AT, 2005, NAT STRUCT MOL BIOL, V12, P756, DOI 10.1038/nsmb974; Pape T, 2003, EMBO REP, V4, P1079, DOI 10.1038/sj.embor.7400010; Pascual-Montano A, 2001, J STRUCT BIOL, V133, P233, DOI 10.1006/jsbi.2001.4369; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Poplawski A, 2001, J BIOL CHEM, V276, P49371, DOI 10.1074/jbc.M108519200; Sclafani RA, 2004, GENE DEV, V18, P2039, DOI 10.1101/gad.1240604; Shechter DF, 2000, J BIOL CHEM, V275, P15049, DOI 10.1074/jbc.M000398200; Shen JP, 2005, P NATL ACAD SCI USA, V102, P11248, DOI 10.1073/pnas.0409646102; Simmons DT, 2000, ADV VIRUS RES, V55, P75, DOI 10.1016/S0065-3527(00)55002-7; Smelkova NV, 1998, J VIROL, V72, P8676, DOI 10.1128/JVI.72.11.8676-8681.1998; Smelkova NV, 1997, J VIROL, V71, P8766, DOI 10.1128/JVI.71.11.8766-8773.1997; Sorzano COS, 2004, J STRUCT BIOL, V148, P194, DOI 10.1016/j.jsb.2004.06.006; Tye BK, 2000, J BIOL CHEM, V275, P34833, DOI 10.1074/jbc.R000018200; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; UNSER M, 1987, ULTRAMICROSCOPY, V23, P39, DOI 10.1016/0304-3991(87)90225-7; Yu X, 2002, EMBO REP, V3, P792, DOI 10.1093/embo-reports/kvf160	30	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42405	42410		10.1074/jbc.M509773200	http://dx.doi.org/10.1074/jbc.M509773200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16221679	hybrid			2022-12-25	WOS:000233992700071
J	Shamloo, M; Soriano, L; Wieloch, T; Nikolich, K; Urfer, R; Oksenberg, D				Shamloo, M; Soriano, L; Wieloch, T; Nikolich, K; Urfer, R; Oksenberg, D			Death-associated protein kinase is activated by dephosphorylation in response to cerebral ischemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBULAR CELL APOPTOSIS; DAP-KINASE; NEURONAL DEATH; CATALYTIC ACTIVITY; NERVOUS-SYSTEM; BRAIN-INJURY; CATHEPSIN-B; RAT; MECHANISMS; EXPRESSION	Death-associated protein kinase (DAPK) is a calcium calmodulin-regulated serine/threonine protein kinase involved in ischemic neuronal death. In situ hybridization experiments show that DAPK mRNA expression is up-regulated in brain following a global ischemic insult and down-regulated in ischemic tissues after focal ischemia. DAPK is inactive in normal brain tissues, where it is found in its phosphorylated state and becomes rapidly and persistently dephosphorylated and activated in response to ischemia in vivo. A similar dephosphorylation pattern is detected in primary cortical neurons subjected to oxygen glucose deprivation or N-methyl-D-aspartate (NMDA)-induced toxicity. Both a calcineurin inhibitor, FK506, and a selective NMDA receptor antagonist, MK-801, inhibit the dephosphorylation of DAPK after in vitro ischemia. This indicates that DAPK could be activated by NMDA receptor-mediated calcium flux, activation of calcineurin, and subsequent DAPK dephosphorylation. Moreover, concomitantly to dephosphorylation, DAPK is proteolytically processed by cathepsin after ischemia. Furthermore, a selective DAPK inhibitor is neuroprotective in both in vitro and in vivo ischemic models. These results indicate that DAPK plays a key role in mediating ischemic neuronal injury.	AGY Therapeut Inc, San Francisco, CA 94080 USA; Lund Univ, Lab Expt Brain Res, Wallenberg Neurosci Ctr, S-22184 Lund, Sweden	Lund University	Shamloo, M (corresponding author), AGY Therapeut Inc, 270 E Grand Ave, San Francisco, CA 94080 USA.	mshamloo@agyinc.com		Wieloch, Tadeusz/0000-0002-7669-2520				Araki T, 2004, HIPPOCAMPUS, V14, P326, DOI 10.1002/hipo.10184; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1993, RES P ARNMD, V71, P23; Cohen O, 2001, CELL DEATH DIFFER, V8, P6, DOI 10.1038/sj.cdd.4400794; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Cohen O, 1999, J CELL BIOL, V146, P141; DIRNAGL U, 1990, BRAIN RES, V527, P62, DOI 10.1016/0006-8993(90)91060-T; Dumont FJ, 2000, CURR MED CHEM, V7, P731, DOI 10.2174/0929867003374723; Fisher Marc, 2003, Adv Neurol, V92, P401; Gan L, 2004, J BIOL CHEM, V279, P5565, DOI 10.1074/jbc.M306183200; Ginsberg MD, 2003, STROKE, V34, P214, DOI 10.1161/01.STR.0000048846.09677.62; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; Henshall DC, 2003, J NEUROCHEM, V86, P1260, DOI 10.1046/j.1471-4159.2003.01934.x; Hou ST, 2002, INT REV CYTOL, V221, P93; Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599; Jin YJ, 2001, J BIOL CHEM, V276, P39667, DOI 10.1074/jbc.M101886200; Kishino M, 2004, J AM SOC NEPHROL, V15, P1826, DOI 10.1097/01.ASN.0000131527.59781.F2; Kuroda S, 1999, J CEREBR BLOOD F MET, V19, P778, DOI 10.1097/00004647-199907000-00008; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; MEMEZAWA H, 1992, STROKE, V23, P552, DOI 10.1161/01.STR.23.4.552; Pelled D, 2002, J BIOL CHEM, V277, P1957, DOI 10.1074/jbc.M104677200; Raveh T, 2001, EXP CELL RES, V264, P185, DOI 10.1006/excr.2000.5134; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; Sakagami H, 1997, MOL BRAIN RES, V52, P249, DOI 10.1016/S0169-328X(97)00268-4; Schumacher AM, 2002, BBA-PROTEINS PROTEOM, V1600, P128, DOI 10.1016/S1570-9639(02)00453-3; Shamloo M, 1999, J CEREBR BLOOD F MET, V19, P173, DOI 10.1097/00004647-199902000-00009; SHARKEY J, 1994, NATURE, V371, P336, DOI 10.1038/371336a0; Shohat G, 2001, J BIOL CHEM, V276, P47460, DOI 10.1074/jbc.M105133200; SIESJO BK, 1995, J NEUROTRAUM, V12, P943, DOI 10.1089/neu.1995.12.943; SMITH ML, 1984, ACTA NEUROPATHOL, V64, P319, DOI 10.1007/BF00690397; Velentza AV, 2003, BIOORG MED CHEM LETT, V13, P3465, DOI 10.1016/S0960-894X(03)00733-9; Wang WJ, 2002, J CELL BIOL, V159, P169, DOI 10.1083/jcb.200204050; WIELOCH T, 1998, CEREBROVASC DIS, P440; WOODRUFF GN, 1987, NEUROPHARMACOLOGY, V26, P903, DOI 10.1016/0028-3908(87)90068-2; Yamamoto M, 1999, J NEUROSCI RES, V58, P674, DOI 10.1002/(SICI)1097-4547(19991201)58:5<674::AID-JNR8>3.0.CO;2-3; Yamashima T, 2004, CELL CALCIUM, V36, P285, DOI 10.1016/j.ceca.2004.03.001; Yamashima T, 1998, EUR J NEUROSCI, V10, P1723, DOI 10.1046/j.1460-9568.1998.00184.x; Yamashima T, 2000, PROG NEUROBIOL, V62, P273, DOI 10.1016/S0301-0082(00)00006-X; Yukawa K, 2004, INT J MOL MED, V13, P515	40	89	98	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42290	42299		10.1074/jbc.M505804200	http://dx.doi.org/10.1074/jbc.M505804200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16204252	hybrid			2022-12-25	WOS:000233992700058
J	Tanaka, M; Kamata, R; Sakai, R				Tanaka, M; Kamata, R; Sakai, R			EphA2 phosphorylates the cytoplasmic tail of claudin-4 and mediates paracellular permeability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; EPHRINS; TIGHT; RECEPTORS; REVERSE; EXPRESSION; DOMAIN; ROLES; OVEREXPRESSION; JUNCTIONS	Eph receptors and ephrin ligands are widely expressed in epithelial cells and mediate cell-cell interaction. EphA2 is expressed in various cancer tissues and cell lines. Although the mechanism of action of EphA2 is unknown, its expression correlates with progression of the malignant phenotype of cancerous tissues. Here, we have shown that EphA2 modulates the localization and function of claudin-4, a constituent of tight junctions. EphA2 associates with claudin-4 via their extracellular domains. This association, in turn, leads to phosphorylation of the cytoplasmic carboxyl terminus of claudin-4 at Tyr-208. The tyrosine phosphorylation of claudin-4 attenuates association of claudin-4 with ZO-1, decreasing integration of claudin-4 into sites of cell-cell contact and enhancing paracellular permeability. These results indicate that EphA2 moderates the function of tight junctions via phosphorylation of claudin-4.	Natl Canc Ctr, Res Inst, Growth Factor Div, Chuo Ku, Tokyo 1040045, Japan	National Cancer Center - Japan	Sakai, R (corresponding author), Natl Canc Ctr, Res Inst, Growth Factor Div, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	rsakai@gan2.res.ncc.go.jp		Sakai, Ryuichi/0000-0001-6833-1103				Aldred MA, 2004, J CLIN ONCOL, V22, P3531, DOI 10.1200/JCO.2004.08.127; Blits-Huizinga CT, 2004, IUBMB LIFE, V56, P257, DOI 10.1080/15216540412331270076; Bolz J, 2004, J NEUROBIOL, V59, P82, DOI 10.1002/neu.10346; Brantley-Sieders D, 2004, CURR PHARM DESIGN, V10, P3431, DOI 10.2174/1381612043383160; Brantley-Sieders Dana M., 2004, Angiogenesis, V7, P17, DOI 10.1023/B:AGEN.0000037340.33788.87; Cheng N, 2002, CYTOKINE GROWTH F R, V13, P75, DOI 10.1016/S1359-6101(01)00031-4; Cowan CA, 2002, TRENDS CELL BIOL, V12, P339, DOI 10.1016/S0962-8924(02)02317-6; Cowan CA, 2001, NATURE, V413, P174, DOI 10.1038/35093123; Hamazaki Y, 2002, J BIOL CHEM, V277, P455, DOI 10.1074/jbc.M109005200; Himanen JP, 2001, NATURE, V414, P933, DOI 10.1038/414933a; Hinck L, 2004, DEV CELL, V7, P783, DOI 10.1016/j.devcel.2004.11.002; Huot J, 2004, PROG NEURO-PSYCHOPH, V28, P813, DOI 10.1016/j.pnpbp.2004.05.025; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Jones TL, 1998, P NATL ACAD SCI USA, V95, P576, DOI 10.1073/pnas.95.2.576; Kale G, 2003, BIOCHEM BIOPH RES CO, V302, P324, DOI 10.1016/S0006-291X(03)00167-0; Kataoka H, 2004, CANCER SCI, V95, P136, DOI 10.1111/j.1349-7006.2004.tb03194.x; Kinch MS, 2003, CLIN EXP METASTAS, V20, P59, DOI 10.1023/A:1022546620495; Klein R, 2004, CURR OPIN CELL BIOL, V16, P580, DOI 10.1016/j.ceb.2004.07.002; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Mann F, 2004, INT J DEV BIOL, V48, P957, DOI 10.1387/ijdb.041899fm; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; Murai KK, 2003, J CELL SCI, V116, P2823, DOI 10.1242/jcs.00625; Nichols LS, 2004, AM J CLIN PATHOL, V121, P226, DOI 10.1309/K144PHVDDUPDD401; Orsulic S, 2000, J CELL SCI, V113, P1793; Palmer A, 2002, MOL CELL, V9, P725, DOI 10.1016/S1097-2765(02)00488-4; Poliakov A, 2004, DEV CELL, V7, P465, DOI 10.1016/j.devcel.2004.09.006; Potla L, 2002, CANCER LETT, V175, P187, DOI 10.1016/S0304-3835(01)00613-9; Rangel LBA, 2003, CLIN CANCER RES, V9, P2567; Roh MH, 2002, J BIOL CHEM, V277, P27501, DOI 10.1074/jbc.M201177200; Rothen-Rutishauser B, 2002, J MEMBRANE BIOL, V188, P151, DOI 10.1007/s00232-001-0182-2; Surawska H, 2004, CYTOKINE GROWTH F R, V15, P419, DOI 10.1016/j.cytogfr.2004.09.002; Tanaka M, 2004, EMBO J, V23, P1075, DOI 10.1038/sj.emboj.7600128; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Wang YJ, 2002, BIOCHEM BIOPH RES CO, V296, P214, DOI 10.1016/S0006-291X(02)00806-9; Winning RS, 1996, DEV BIOL, V179, P309, DOI 10.1006/dbio.1996.0262; Zantek ND, 1999, CELL GROWTH DIFFER, V10, P629	36	142	150	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42375	42382		10.1074/jbc.M503786200	http://dx.doi.org/10.1074/jbc.M503786200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16236711	hybrid			2022-12-25	WOS:000233992700067
J	Beve, J; Hu, GZ; Myers, LC; Balciunas, D; Werngren, O; Hultenby, K; Wibom, R; Ronne, H; Gustafsson, CM				Beve, J; Hu, GZ; Myers, LC; Balciunas, D; Werngren, O; Hultenby, K; Wibom, R; Ronne, H; Gustafsson, CM			The structural and functional role of Med5 in the yeast mediator tail module	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CELL-SURFACE FLOCCULIN; SACCHAROMYCES-CEREVISIAE; DOMAIN; GENES; PROTEIN; TRANSCRIPTION; HOLOENZYME; EXPRESSION; MUTATIONS	Med5 (Nut1) is identified here as a component of the Mediator tail region. Med5 is positioned peripherally to Med16 (Sin4) together with the three members of the putative Gal11 module, Med15 (Gal11), Med2, and Med3 (Pgd1). The biochemical analysis receives support from genetic interactions between med5 Delta and med15 Delta deletions. The med5 Delta and med16 Delta deletion strains share many phenotypes, including effects on mitochondrial function with enhanced growth on nonfermentable carbon sources, increased citrate synthase activity, and increased oxygen consumption. Deletion of the MED5 gene leads to increased transcription of nuclear genes encoding components of the oxidative phosphorylation machinery, whereas mitochondrial genes encoding components of the same machinery are down-regulated. We discuss a possible role for Med5 in coordinating nuclear and mitochondrial gene transcription.	Karolinska Univ Hosp, Div Metab Dis, SE-14186 Stockholm, Sweden; Karolinska Univ Hosp, Clin Res Ctr, Karolinska Inst, SE-14186 Stockholm, Sweden; Uppsala Univ, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden; Swedish Univ Agr Sci, Dept Plant Biol & Foest Genet, Uppsala Genet Ctr, SE-75007 Uppsala, Sweden; Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Uppsala University; Swedish University of Agricultural Sciences; Dartmouth College	Gustafsson, CM (corresponding author), Karolinska Inst, Div Metab Dis, Novum, SE-14186 Stockholm, Sweden.	claes.gustafsson@ki.se	Balciunas, Darius/AAD-1420-2019	Ronne, Hans/0000-0002-1645-6091; Gustafsson, Claes/0000-0003-3531-8468	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062483] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM062483] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramova NE, 2001, GENETICS, V157, P1169; *AFF, 2000, AFF GEN CHIP EXPR AN; Asturias FJ, 1999, SCIENCE, V283, P985, DOI 10.1126/science.283.5404.985; Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522; BROHL S, 1994, YEAST, V10, P719, DOI 10.1002/yea.320100604; Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; Dotson MR, 2000, P NATL ACAD SCI USA, V97, P14307, DOI 10.1073/pnas.260489497; Ekstrand MI, 2004, HUM MOL GENET, V13, P935, DOI 10.1093/hmg/ddh109; Guglielmi B, 2004, NUCLEIC ACIDS RES, V32, P5379, DOI 10.1093/nar/gkh878; Gustafsson CM, 1998, J BIOL CHEM, V273, P30851, DOI 10.1074/jbc.273.47.30851; JIANG YW, 1992, MOL CELL BIOL, V12, P4503, DOI 10.1128/MCB.12.10.4503; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Liu Y, 2001, J BIOL CHEM, V276, P7169, DOI 10.1074/jbc.M009586200; Lo WS, 1996, J BACTERIOL, V178, P7144, DOI 10.1128/jb.178.24.7144-7151.1996; Lo WS, 1998, MOL BIOL CELL, V9, P161, DOI 10.1091/mbc.9.1.161; Lorch Y, 2000, MOL CELL, V6, P197, DOI 10.1016/S1097-2765(00)00021-6; Muller EM, 2001, GENETICS, V159, P1527; Myers LC, 1999, P NATL ACAD SCI USA, V96, P67, DOI 10.1073/pnas.96.1.67; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SAKAI A, 1990, MOL CELL BIOL, V10, P4130, DOI 10.1128/MCB.10.8.4130; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Sertil O, 1997, GENE, V192, P199, DOI 10.1016/S0378-1119(97)00028-0; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Tabtiang RK, 1998, MOL CELL BIOL, V18, P4707, DOI 10.1128/MCB.18.8.4707; Wang X, 2004, GENETICS, V168, P747, DOI 10.1534/genetics.104.029611; Wibom R, 2002, ANAL BIOCHEM, V311, P139, DOI 10.1016/S0003-2697(02)00424-4; Wredenberg A, 2002, P NATL ACAD SCI USA, V99, P15066, DOI 10.1073/pnas.232591499; Zhang F, 2004, MOL CELL BIOL, V24, P6871, DOI 10.1128/mcb.24.15.6871-6886.2004	30	42	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41366	41372		10.1074/jbc.M511181200	http://dx.doi.org/10.1074/jbc.M511181200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16230344	hybrid			2022-12-25	WOS:000233866900032
J	Chen, CS; Sun, XD; Guo, P; Dong, XY; Sethi, P; Cheng, XH; Zhou, J; Ling, JX; Simons, JW; Lingrel, JB; Dong, JT				Chen, CS; Sun, XD; Guo, P; Dong, XY; Sethi, P; Cheng, XH; Zhou, J; Ling, JX; Simons, JW; Lingrel, JB; Dong, JT			Human Kruppel-like factor 5 is a target of the E3 ubiquitin ligase WWP1 for proteolysis in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR KLF5; PROSTATE-CANCER CELLS; GROWTH FACTOR-A; NEGATIVE REGULATION; EXPRESSION; DOMAIN; REGULATOR; GENE; DEGRADATION; ACTIVATION	The transcription factor KLF5 plays an important role in human carcinogenesis. In epithelial cells, the KLF5 protein is tightly regulated by the ubiquitin-proteasome pathway. To better understand the mechanisms for the regulation of KLF5 protein, we identified and characterized an E3 ubiquitin ligase for KLF5, i.e. WWP1. We found that WWP1 formed a protein complex with KLF5 in vivo and in vitro. Furthermore, WWP1 mediated the ubiquitination and degradation of KLF5, and the catalytic cysteine residue of WWP1 is essential for its function. A PY motif in a transactivation domain of KLF5 is necessary for its interaction with WWP1. Finally, WWP1 was amplified and overexpressed in some cancer cell lines from the prostate and breast, which negatively regulated the function of KLF5 in gene regulation. These findings not only established WWP1 as an E3 ubiquitin ligase for KLF5, they also further implicated the KLF5 pathway in human carcinogenesis.	Emory Univ, Sch Med, Winship Canc Ctr, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Hematol & Oncol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Urol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Program Genet & Mol Biol, Atlanta, GA 30322 USA; Nankai Univ, Coll Life Sci, Dept Genet & Cell Biol, Tianjin 300071, Peoples R China; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45221 USA	Emory University; Emory University; Emory University; Emory University; Nankai University; University System of Ohio; University of Cincinnati	Dong, JT (corresponding author), Emory Univ, Sch Med, Winship Canc Ctr, Atlanta, GA 30322 USA.	jin-tang.dong@emory.edu	guo, peng/AAG-4052-2019; Zhou, Jun/D-4654-2017; Hu, Ruogu/B-2203-2008	Zhou, Jun/0000-0001-7858-8260; Dong, Jin-Tang/0000-0003-2349-5782; Guo, Peng/0000-0002-4575-8443	NATIONAL CANCER INSTITUTE [R01CA087921] Funding Source: NIH RePORTER; NCI NIH HHS [CA87921] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abriel H, 2000, FEBS LETT, V466, P377, DOI 10.1016/S0014-5793(00)01098-X; Adam PJ, 2000, J BIOL CHEM, V275, P37798, DOI 10.1074/jbc.M006323200; Aizawa K, 2004, J BIOL CHEM, V279, P70, DOI 10.1074/jbc.M306621200; Bateman NW, 2004, J BIOL CHEM, V279, P12093, DOI 10.1074/jbc.M311532200; Beckers J, 2005, INT J CANCER, V114, P590, DOI 10.1002/ijc.20798; Calhoun ES, 2003, AM J PATHOL, V163, P1255, DOI 10.1016/S0002-9440(10)63485-2; Chanchevalap S, 2004, FEBS LETT, V578, P99, DOI 10.1016/j.febslet.2004.10.079; Chen C, 2002, ONCOGENE, V21, P6567, DOI 10.1038/sj.onc.1205817; Chen C, 2003, PROSTATE, V55, P81, DOI 10.1002/pros.10205; Chen CS, 2005, ONCOGENE, V24, P3319, DOI 10.1038/sj.onc.1208497; Chen CS, 2004, GENE, V330, P133, DOI 10.1016/j.gene.2004.01.014; Conkright MD, 2001, J BIOL CHEM, V276, P29299, DOI 10.1074/jbc.M103670200; Drobnjak M, 2003, CLIN CANCER RES, V9, P2613; Harvey KF, 1999, TRENDS CELL BIOL, V9, P166, DOI 10.1016/S0962-8924(99)01541-X; Ikeda M, 2002, VIROLOGY, V300, P153, DOI 10.1006/viro.2002.1562; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Ingham RJ, 2004, ONCOGENE, V23, P1972, DOI 10.1038/sj.onc.1207436; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kawai-Kowase K, 1999, CIRC RES, V85, P787, DOI 10.1161/01.RES.85.9.787; Knuutila S, 1998, AM J PATHOL, V152, P1107; Komuro A, 2004, ONCOGENE, V23, P6914, DOI 10.1038/sj.onc.1207885; Leite KRM, 2001, MODERN PATHOL, V14, P428, DOI 10.1038/modpathol.3880330; Lu LF, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-22; Matsumura T, 2005, J BIOL CHEM, V280, P12123, DOI 10.1074/jbc.M410578200; Miyamoto S, 2003, MOL CELL BIOL, V23, P8528, DOI 10.1128/MCB.23.23.8528-8541.2003; Moren A, 2005, J BIOL CHEM, V280, P22115, DOI 10.1074/jbc.M414027200; Mosser EA, 1998, BIOCHEMISTRY-US, V37, P13686, DOI 10.1021/bi981310l; Mu ZM, 2004, PROSTATE, V60, P187, DOI 10.1002/pros.20044; Nandan MO, 2004, ONCOGENE, V23, P3404, DOI 10.1038/sj.onc.1207397; Nupponen NN, 2000, GENE CHROMOSOME CANC, V28, P203; Oishi Y, 2005, CELL METAB, V1, P27, DOI 10.1016/j.cmet.2004.11.005; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Rubin MA, 2004, CANCER RES, V64, P3814, DOI 10.1158/0008-5472.CAN-03-3881; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Shi HK, 2002, J BIOL CHEM, V277, P13539, DOI 10.1074/jbc.M111717200; Shindo T, 2002, NAT MED, V8, P856, DOI 10.1038/nm738; Sun RG, 2001, J BIOL CHEM, V276, P6897, DOI 10.1074/jbc.C000870200; Taneyhill Lisa, 2004, BMC Developmental Biology, V4; Usui S, 2004, J BIOL CHEM, V279, P12300, DOI 10.1074/jbc.M305025200; Verdecia MA, 2003, MOL CELL, V11, P249, DOI 10.1016/S1097-2765(02)00774-8; Wang RX, 2004, CANCER RES, V64, P1589, DOI 10.1158/0008-5472.CAN-03-3331; Watanabe N, 1999, CIRC RES, V85, P182, DOI 10.1161/01.RES.85.2.182; Zhang XL, 2004, BIOCHEM BIOPH RES CO, V316, P139, DOI 10.1016/j.bbrc.2004.02.033; Zhang Z, 2003, P NATL ACAD SCI USA, V100, P11636, DOI 10.1073/pnas.1934692100; Zhang ZP, 2003, NUCLEIC ACIDS RES, V31, P2196, DOI 10.1093/nar/gkg310	45	112	114	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41553	41561		10.1074/jbc.M506183200	http://dx.doi.org/10.1074/jbc.M506183200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16223724	hybrid			2022-12-25	WOS:000233866900055
J	Forneris, F; Binda, C; Vanoni, MA; Battaglioli, E; Mattevi, A				Forneris, F; Binda, C; Vanoni, MA; Battaglioli, E; Mattevi, A			Human histone demethylase LSD1 reads the histone code	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOAMINE-OXIDASE; METHYLATION; CHROMATIN; ENZYMES; DOMAIN; MARKS	Human histone demethylase LSD1 is a flavin-dependent amine oxidase that catalyzes the specific removal of methyl groups from mono- and dimethylated Lys(4) of histone H3. The N-terminal tail of H3 is subject to various covalent modifications, and a fundamental question in LSD1 biology is how these epigenetic marks affect the demethylase activity. We show that LSD1 does not have a strong preference for mono- or dimethylated Lys(4) of H3. Substrate recognition is not confined to the residues neighboring Lys(4), but it requires a sufficiently long peptide segment consisting of the N-terminal 20 amino acids of H3. Electrostatic interactions are an important factor in protein-substrate recognition, as indicated by the high sensitivity of Km to ionic strength. We have probed LSD1 for its ability to demethylate Lys4 in presence of a second modification on the same peptide substrate. Methylation of Lys(9) does not affect enzyme catalysis. Conversely, Lys9 acetylation causes an almost 6-fold increase in the Km value, whereas phosphorylation of Ser(10) totally abolishes activity. LSD1 is inhibited by a demethylated peptide with an inhibition constant of 1.8 mu M, suggesting that LSD1 can bind to H3 independently of Lys(4) methylation. LSD1 is a chromatin-modifying enzyme, which is able to read different epigenetic marks on the histone N-terminal tail and can serve as a docking module for the stabilization of the associated corepressor complex(es) on chromatin.	Univ Milan, Dipartimento Biol & Genet Sci Med, I-20133 Milan, Italy; Univ Pavia, Dipartimento Genet & Microbiol, I-27100 Pavia, Italy; Univ Milan, Dipartimento Sci Biomol & Biotecnol, I-20133 Milan, Italy	University of Milan; University of Pavia; University of Milan	Battaglioli, E (corresponding author), Univ Milan, Dipartimento Biol & Genet Sci Med, Via Viotti 3-5, I-20133 Milan, Italy.	elena.battaglioli@unimi.it; mattevi@ipvgen.unipv.it	mattevi, andrea/K-5464-2012; Forneris, Federico/AAL-5361-2020; Forneris, Federico/B-1145-2011; Mattevi, Andrea/R-4469-2019; battaglioli, elena/H-9350-2017; Vanoni, Maria/AAP-2089-2021	mattevi, andrea/0000-0002-9523-7128; Forneris, Federico/0000-0002-7818-1804; Forneris, Federico/0000-0002-7818-1804; Mattevi, Andrea/0000-0002-9523-7128; Vanoni, Maria/0000-0001-7213-732X; Binda, Claudia/0000-0003-2038-9845; Battaglioli, Elena/0000-0001-9168-7212				Aliverti A, 1999, METH MOL B, V131, P9; Ballas N, 2005, CELL, V121, P645, DOI 10.1016/j.cell.2005.03.013; Ballas N, 2001, NEURON, V31, P353, DOI 10.1016/S0896-6273(01)00371-3; Bannister AJ, 2005, NATURE, V436, P1103, DOI 10.1038/nature04048; Bevington P. R., 1969, DATA REDUCTION ERROR, P56; Biel M, 2005, ANGEW CHEM INT EDIT, V44, P3186, DOI 10.1002/anie.200461346; Binda C, 2002, J BIOL CHEM, V277, P23973, DOI 10.1074/jbc.R200005200; Cheng XD, 2005, ANNU REV BIOPH BIOM, V34, P267, DOI 10.1146/annurev.biophys.34.040204.144452; Edmondson DE, 2004, CURR MED CHEM, V11, P1983, DOI 10.2174/0929867043364784; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Fischle W, 2003, GENE DEV, V17, P1870, DOI 10.1101/gad.1110503; Forneris F, 2005, FEBS LETT, V579, P2203, DOI 10.1016/j.febslet.2005.03.015; Humphrey GW, 2001, J BIOL CHEM, V276, P6817, DOI 10.1074/jbc.M007372200; Jacobs SA, 2001, EMBO J, V20, P5232, DOI 10.1093/emboj/20.18.5232; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Segel J.H., 1975, ENZYME KINETICS, VFirst; Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007	22	192	199	3	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41360	41365		10.1074/jbc.M509549200	http://dx.doi.org/10.1074/jbc.M509549200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16223729	hybrid			2022-12-25	WOS:000233866900031
J	Lee, BH; Yegnasubramanian, S; Lin, XH; Nelson, WG				Lee, BH; Yegnasubramanian, S; Lin, XH; Nelson, WG			Procainamide is a specific inhibitor of DNA methyltransferase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CPG-ISLAND HYPERMETHYLATION; HUMAN CANCER-CELLS; DNA CYTOSINE-5 METHYLTRANSFERASE; RECOMBINANT HUMAN DNA; LUPUS-INDUCING DRUGS; ALLOSTERIC ACTIVATION; CYTIDINE ANALOGS; GSTP1 EXPRESSION; MAMMALIAN-CELLS; BINDING DOMAIN	CpG island hypermethylation occurs in most cases of cancer, typically resulting in the transcriptional silencing of critical cancer genes. Procainamide has been shown to inhibit DNA methyltransferase activity and reactivate silenced gene expression in cancer cells by reversing CpG island hypermethylation. We report here that procainamide specifically inhibits the hemimethylase activity of DNA methyltransferase 1 (DNMT1), the mammalian enzyme thought to be responsible for maintaining DNA methylation patterns during replication. At micromolar concentrations, procainamide was found to be a partial competitive inhibitor of DNMT1, reducing the affinity of the enzyme for its two substrates, hemimethylated DNA and S-adenosyl-L-methionine. By doing so, procainamide significantly decreased the processivity of DNMT1 on hemimethylated DNA. Procainamide was not a potent inhibitor of the de novo methyltransferases DNMT3a and DNMT3b2. As further evidence of the specificity of procainamide for DNMT1, procainamide failed to lower genomic 5-methyl-2'-deoxycytidine levels in HCT116 colorectal cancer cells when DNMT1 was genetically deleted but significantly reduced genomic 5-methyl-2'-deoxycytidine content in parental HCT116 cells and in HCT116 cells where DNMT3b was genetically deleted. Because many reports have strongly linked DNMT1 with epigenetic alterations in carcinogenesis, procainamide may be a useful drug in the prevention of cancer.	Johns Hopkins Univ, Sch Med, Dept Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine	Nelson, WG (corresponding author), Johns Hopkins Univ, Sch Med, Dept Oncol, Sidney Kimmel Comprehens Canc Ctr, Canc Res Bldg 151,1650 Orleans St, Baltimore, MD 21231 USA.	bnelson@jhmi.edu		Lee, Byron/0000-0002-8755-9688	NCI NIH HHS [CA070196, R01 CA070196] Funding Source: Medline; NIEHS NIH HHS [ES014287, F30 ES014287, F30 ES014287-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F30ES014287] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AGOSTON AT, 2005, J BIOL CHEM; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; Bacolla A, 1999, J BIOL CHEM, V274, P33011, DOI 10.1074/jbc.274.46.33011; Bacolla A, 2001, J BIOL CHEM, V276, P18605, DOI 10.1074/jbc.M100404200; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Belinsky SA, 2003, CANCER RES, V63, P7089; Brooks JD, 1998, CANCER EPIDEM BIOMAR, V7, P531; CARINE K, 1989, SOMAT CELL MOLEC GEN, V15, P445, DOI 10.1007/BF01534895; CHARACHE S, 1983, P NATL ACAD SCI-BIOL, V80, P4842, DOI 10.1073/pnas.80.15.4842; Cheng JC, 2003, J NATL CANCER I, V95, P399, DOI 10.1093/jnci/95.5.399; Cheng JC, 2004, MOL CELL BIOL, V24, P1270, DOI 10.1128/MCB.24.3.1270-1278.2004; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; CORNACCHIA E, 1988, J IMMUNOL, V140, P2197; DEVILEE P, 1986, CYTOGENET CELL GENET, V41, P193, DOI 10.1159/000132229; Dover G J, 1983, Prog Clin Biol Res, V134, P475; Eads CA, 2002, CANCER RES, V62, P1296; Fatemi M, 2001, J MOL BIOL, V309, P1189, DOI 10.1006/jmbi.2001.4709; Flynn J, 1996, BIOCHEMISTRY-US, V35, P7308, DOI 10.1021/bi9600512; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Gowher H, 2004, CANCER BIOL THER, V3, P1062, DOI 10.4161/cbt.3.11.1308; Hermann A, 2004, J BIOL CHEM, V279, P48350, DOI 10.1074/jbc.M403427200; JacksonGrusby L, 1997, P NATL ACAD SCI USA, V94, P4681, DOI 10.1073/pnas.94.9.4681; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kaminskas E, 2005, CLIN CANCER RES, V11, P3604, DOI 10.1158/1078-0432.CCR-04-2135; Kelecsenyi Z, 2000, MUTAGENESIS, V15, P25, DOI 10.1093/mutage/15.1.25; KELLEY JA, 1986, J MED CHEM, V29, P2351, DOI 10.1021/jm00161a034; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Lee G, 2004, DNA REPAIR, V3, P155, DOI 10.1016/j.dnarep.2003.10.010; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Ley T J, 1983, Prog Clin Biol Res, V134, P457; LEY TJ, 1983, BLOOD, V62, P370; Lin XH, 2003, CANCER RES, V63, P498; Lin XH, 2001, CANCER RES, V61, P8611; Lin XH, 2001, AM J PATHOL, V159, P1815, DOI 10.1016/S0002-9440(10)63028-3; MARTELLI A, 1995, TOXICOL APPL PHARM, V131, P185, DOI 10.1006/taap.1995.1060; MERETO E, 1995, TOXICOL APPL PHARM, V131, P192, DOI 10.1006/taap.1995.1061; Michel SLJ, 2003, BIOCHEMISTRY-US, V42, P4626, DOI 10.1021/bi034073h; Nakayama M, 2003, AM J PATHOL, V163, P923, DOI 10.1016/S0002-9440(10)63452-9; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011; SCHEINBART LS, 1991, J RHEUMATOL, V18, P530; Segel I.H., 1975, ENZYME KINETICS BEHA, P161; Segura-Pacheco B, 2003, CLIN CANCER RES, V9, P1596; Song JZ, 2002, ONCOGENE, V21, P1048, DOI 10.1038/sj.onc.1205153; SORM F, 1964, EXPERIENTIA, V20, P202, DOI 10.1007/BF02135399; Svedruzic ZM, 2005, BIOCHEMISTRY-US, V44, P9472, DOI 10.1021/bi050295z; THOMAS TJ, 1986, ARTHRITIS RHEUM, V29, P638, DOI 10.1002/art.1780290508; Ting AH, 2004, NAT GENET, V36, P582, DOI 10.1038/ng1365; Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555; Vilkaitis G, 2005, J BIOL CHEM, V280, P64, DOI 10.1074/jbc.M411126200; Villar-Garea A, 2003, CANCER RES, V63, P4984; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; ZACHARIAS W, 1990, ARTHRITIS RHEUM, V33, P366, DOI 10.1002/art.1780330309; ZUCKER KE, 1985, J CELL BIOCHEM, V29, P337, DOI 10.1002/jcb.240290407	59	220	239	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40749	40756		10.1074/jbc.M505593200	http://dx.doi.org/10.1074/jbc.M505593200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16230360	hybrid, Green Accepted			2022-12-25	WOS:000233666600044
J	Wu, ZL; Podust, LM; Guengerich, FP				Wu, ZL; Podust, LM; Guengerich, FP			Expansion of substrate specificity of cytochrome P450 2A6 by random and site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; 1A2 MUTANTS; IN-VITRO; EVOLUTION; OXIDATION; PURIFICATION; METABOLISM; INDOLE; ACID; DEHYDROGENASE	The natural product indole is a substrate for cytochrome P450 2A6. Mutagenesis of P450 2A6 was done to expand its capability in the oxidization of bulky substituted indole compounds, which are not substrates for the wild-type enzyme or the double mutant L240C/N297Q, as determined in our previous work (Wu, Z.- L., Aryal, P., Lozach, O., Meijer, L., and Guengerich, F. P. ( 2005) Chem. Biodivers. 2, 51 - 65). Error-prone PCR and site-directed mutagenesis led to the identification of two critical amino acid residue changes (N297Q and I300V) that achieve the purpose. The new mutant (N297Q/I300V) was able to oxidize both 4- and 5-benzyloxy( OBzl) indoles to form colored products. Both changes were required for oxidation of these bulky substrates. The colored product derived from 5-OBzl-indole was mainly 5,5'-di-OBzl-indirubin, whereas the dominant blue dye isolated upon incubations with 4- OBzl- indole was neither an indigo nor an indirubin. Two-dimensional NMR experiments led to assignment of the structure as 4-OBzl-2-(4'-OBzl-1',7'-dihydro-7'-oxo-6' H-indol-6'-ylidene)indolin-3- one, in which a pyrrole ring and a benzene ring are connected with a double bond instead of the pyrrole-pyrrole connection of other indigoids. Monomeric oxidation products were also isolated and characterized; three phenols (4-OBzl-1H-indol-5-ol, 4- OBzl- 1H- indol- 6- ol, and 4- OBzl- 1H- indol- 7- ol) and one quinone (4-OBzl-1H-indole-6,7-dione, the postulated immediate precursor of the final blue dye) were identified. The results are interpreted in the context of a crystal structure of a P450 2A6-coumarin complex. The I300V change opens an additional pocket to accommodate the OBzl bulk. The N2297Q change is postulated to generate a hydrogen bond between Gln and the substrate oxygen. Thus, the substrate specificity of P450 2A6 was expanded, and new products were obtained in this study.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Guengerich, FP (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 638 Robinson Res Bldg,23rd & Pierce Ave, Nashville, TN 37232 USA.	f.guengerich@vanderbilt.edu	Podust, Larissa/ABB-7940-2020; Wu, Zhong-Liu/D-9017-2017	Podust, Larissa/0000-0002-8537-8760; Wu, Zhong-Liu/0000-0002-0189-5892	NCI NIH HHS [R01CA90426] Funding Source: Medline; NIEHS NIH HHS [P30ES00267] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090426] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARNOLD FH, 2003, METHODS MOL BIOL, V230; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cirino Patrick C, 2003, Methods Mol Biol, V231, P3; Datta S, 2001, P NATL ACAD SCI USA, V98, P14268, DOI 10.1073/pnas.241429098; Gillam EMJ, 2000, BIOCHEMISTRY-US, V39, P13817, DOI 10.1021/bi001229u; Gillam EMJ, 1999, BIOCHEM BIOPH RES CO, V265, P469, DOI 10.1006/bbrc.1999.1702; GOTOH O, 1992, J BIOL CHEM, V267, P83; Guengerich F.P., 2005, CYTOCHROME P450 STRU, V3rd ed., P377, DOI [10.1007/0-387-27447-2_10, DOI 10.1007/0-387-27447-2_10]; Guengerich F. P., 2001, PRINCIPLES METHODS T, P1625; Guengerich FP, 2001, CHEM RES TOXICOL, V14, P611, DOI 10.1021/tx0002583; Guengerich FP, 2004, J MED CHEM, V47, P3236, DOI 10.1021/jm030561b; Guengerich FP, 2002, NAT REV DRUG DISCOV, V1, P359, DOI 10.1038/nrd792; Hecht SS, 2000, P NATL ACAD SCI USA, V97, P12493, DOI 10.1073/pnas.220207697; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim D, 2004, BIOCHEMISTRY-US, V43, P981, DOI 10.1021/bi035593f; KING LJ, 1966, BIOCHEM J, V98, P266, DOI 10.1042/bj0980266; Li QS, 2000, CHEM-EUR J, V6, P1531, DOI 10.1002/(SICI)1521-3765(20000502)6:9<1531::AID-CHEM1531>3.3.CO;2-4; McIntire WS, 1992, ESSAYS BIOCHEM, V27, P119; Nakamura K, 2001, ARCH BIOCHEM BIOPHYS, V395, P25, DOI 10.1006/abbi.2001.2569; Ortiz de Montellano P. R., 2005, CYTOCHROME P450 STRU; PALMER G, 1992, J BIOL CHEM, V267, P665; Parikh A, 1998, BIOTECHNIQUES, V24, P428, DOI 10.2144/98243st01; Parikh A, 1997, NAT BIOTECHNOL, V15, P784, DOI 10.1038/nbt0897-784; Parikh A, 1999, BIOCHEMISTRY-US, V38, P5283, DOI 10.1021/bi990142+; Pearson AR, 2004, BIOCHEMISTRY-US, V43, P5494, DOI 10.1021/bi049863l; Peters MW, 2003, J AM CHEM SOC, V125, P13442, DOI 10.1021/ja0303790; Polychronopoulos P, 2004, J MED CHEM, V47, P935, DOI 10.1021/jm031016d; Rarey M, 1996, J MOL BIOL, V261, P470, DOI 10.1006/jmbi.1996.0477; REMERS WA, 1971, CHEM HETEROCYCLIC CO, V25; Sambrook J, 2001, MOL CLONING LAB MANU; SANDHU P, 1993, ARCH BIOCHEM BIOPHYS, V306, P443, DOI 10.1006/abbi.1993.1536; SCHENKMAN JB, 1967, MOL PHARMACOL, V3, P113; Schoch GA, 2004, J BIOL CHEM, V279, P9497, DOI 10.1074/jbc.M312516200; Soucek P, 1999, ARCH BIOCHEM BIOPHYS, V370, P190, DOI 10.1006/abbi.1999.1388; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; TABATABAIE T, 1992, J MED CHEM, V35, P2261, DOI 10.1021/jm00090a018; WEINSTEIN J, 1956, J AM CHEM SOC, V78, P2387, DOI 10.1021/ja01592a012; Wong TS, 2004, BIOTECHNOL BIOENG, V85, P351, DOI 10.1002/bit.10896; Wu ZLL, 2005, CHEM BIODIVERS, V2, P51, DOI 10.1002/cbdv.200490166; Yamazaki H, 1999, ARCH TOXICOL, V73, P65, DOI 10.1007/s002040050588; Yano JK, 2005, NAT STRUCT MOL BIOL, V12, P822, DOI 10.1038/nsmb971; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597; YUN CH, 1991, MOL PHARMACOL, V40, P679; Yun CH, 2000, BIOCHEMISTRY-US, V39, P11319, DOI 10.1021/bi000869u; Zhao HM, 1998, NAT BIOTECHNOL, V16, P258, DOI 10.1038/nbt0398-258	45	53	58	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					41090	41100		10.1074/jbc.M508182200	http://dx.doi.org/10.1074/jbc.M508182200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16215230	hybrid			2022-12-25	WOS:000233666600083
J	Cui, RT; Nguyen, TT; Taube, JH; Stratton, SA; Feuerman, MH; Barton, MC				Cui, RT; Nguyen, TT; Taube, JH; Stratton, SA; Feuerman, MH; Barton, MC			Family members p53 and p73 act together in chromatin modification and direct repression of alpha-fetoprotein transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER-REGENERATION; GENE-EXPRESSION; SPONTANEOUS TUMORS; HUMAN CANCERS; DNA-DAMAGE; HISTONE H3; P63; MICE; APOPTOSIS; MUTANT	Aberrant expression of the alpha-fetoprotein (AFP) gene is a diagnostic tumor marker of hepatocellular carcinoma. We find that AFP gene expression is repressed by the TP53 family member p73 during normal hepatic development and when p73 alpha or p73 beta is introduced into cultured hepatoma cells that express AFP. Transient co-transfection of p53 family members showed that p53 and transactivating (TA)-p73, but not TA-p63, repress endogenous AFP transcription additively or independently. p53-independent functions of p73 are further supported by delayed, p73-associated compensation of AFP repression during development of the p53-null mouse. Chromatin immunoprecipitation assays of normal and p53-null mouse liver tissue showed that TA-p73 binds at a previously identified p53 repressor site (-860/-830) within the distal promoter of AFP at a level equivalent to p53 in wild type liver, with increased binding of TA-p73 to chromatin in the absence of p53. Sequential chromatin immunoprecipitation analyses revealed that TA-p73 and p53 bind simultaneously to their shared regulatory site in wild type liver. Like the founding family member p53, TA-p73 represses AFP expression by chromatin structure alteration, targeting reduction of acetylated histone H3 lysine 9 and increased dimethylated histone H3 lysine 9 levels. However, chromatin-bound TA-p73 is associated with elevated di- and tri-methylated histone H3 lysine 4 levels in p53-null liver and hepatoma cells, concomitant with a reduced ability to repress transcription compared with p53.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Program Genes & Dev,Grad Sch Biol Sci, Houston, TX 77030 USA; Suny Downstate Med Ctr, Dept Biochem, Brooklyn, NY 11203 USA	University of Texas System; UTMD Anderson Cancer Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Barton, MC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Program Genes & Dev,Grad Sch Biol Sci, 1515 Holcombe Blvd,Box 117, Houston, TX 77030 USA.	mbarton@odin.mdacc.tmc.edu		Taube, Joseph/0000-0002-3636-5189; Barton, Michelle/0000-0002-4042-1374; Cui, Rutao/0000-0002-4377-9988	NIGMS NIH HHS [GM53683, R01 GM053683, R01 GM053683-06S1] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053683] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abelev GI, 1999, SEMIN CANCER BIOL, V9, P95, DOI 10.1006/scbi.1998.0084; Apergis GA, 1998, J BIOL CHEM, V273, P2917, DOI 10.1074/jbc.273.5.2917; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Benard J, 2003, HUM MUTAT, V21, P182, DOI 10.1002/humu.10172; CAMPER SA, 1989, PROG NUCLEIC ACID RE, V36, P131; CAMPER SA, 1989, GENE DEV, V3, P537, DOI 10.1101/gad.3.4.537; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Choi J, 1999, CELL MOL LIFE SCI, V55, P38, DOI 10.1007/s000180050268; Courtois S, 2004, ONCOGENE, V23, P631, DOI 10.1038/sj.onc.1206929; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; De Laurenzi V, 2000, ANN NY ACAD SCI, V926, P90; de Rozieres S, 2000, ONCOGENE, V19, P1691, DOI 10.1038/sj.onc.1203468; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dietz S, 2002, FEBS LETT, V525, P93, DOI 10.1016/S0014-5793(02)03093-4; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Francastel C, 1999, CELL, V99, P259, DOI 10.1016/S0092-8674(00)81657-8; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Garcia-Cao I, 2002, EMBO J, V21, P6225, DOI 10.1093/emboj/cdf595; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; Jin DK, 1998, P NATL ACAD SCI USA, V95, P8767, DOI 10.1073/pnas.95.15.8767; Jin DK, 1996, SOMAT CELL MOLEC GEN, V22, P211, DOI 10.1007/BF02369911; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kubicek S, 2004, CELL, V119, P903, DOI 10.1016/j.cell.2004.12.006; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021; Liu G, 2005, J BIOL CHEM, V280, P20111, DOI 10.1074/jbc.M413889200; LUNA RMD, 1995, NATURE, V378, P203; Martin DIK, 1996, CURR OPIN GENET DEV, V6, P488, DOI 10.1016/S0959-437X(96)80072-4; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Moll UM, 2004, MOL CANCER RES, V2, P371; Nguyen TT, 2005, MOL CELL BIOL, V25, P2147, DOI 10.1128/MCB.25.6.2147-2157.2005; NINKINA NN, 1993, NUCLEIC ACIDS RES, V21, P3175, DOI 10.1093/nar/21.14.3175; Petitjean A, 2005, ONCOGENE, V24, P512, DOI 10.1038/sj.onc.1208215; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Tilghman S M, 1985, Oxf Surv Eukaryot Genes, V2, P160; TILGHMAN SM, 1982, P NATL ACAD SCI-BIOL, V79, P5254, DOI 10.1073/pnas.79.17.5254; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Um SH, 2004, J IMMUNOL, V173, P1772, DOI 10.4049/jimmunol.173.3.1772; VACHER J, 1990, SCIENCE, V250, P1732, DOI 10.1126/science.1702902; Wilkinson DS, 2005, MOL CELL BIOL, V25, P1200, DOI 10.1128/MCB.25.3.1200-1212.2005; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0	58	38	42	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39152	39160		10.1074/jbc.M504655200	http://dx.doi.org/10.1074/jbc.M504655200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16203738	hybrid			2022-12-25	WOS:000233362200030
J	Kawai, S; Fukuda, C; Mukai, T; Murata, K				Kawai, S; Fukuda, C; Mukai, T; Murata, K			MJ0917 in Archaeon Methanococcus jannaschii is a novel NADP phosphatase/NAD kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; COMPLETE GENOME SEQUENCE; INOSITOL MONOPHOSPHATASE; ESCHERICHIA-COLI; RAT-BRAIN; ENZYME; GENE; PURIFICATION; CLONING; FRUCTOSE-1,6-BISPHOSPHATASE	NAD kinase phosphorylates NAD(+) to form NADP(+). Conversely, NADP phosphatase, which has not yet been identified, dephosphorylates NADP(+) to produce NAD(+). Among the NAD kinase homologs, the primary structure of MJ0917 of hyperthermophilic archaeal Methanococcus jannaschii is unique. MJ0917 possesses an NAD kinase homologous region in its C-terminal half and an inositol-1-phosphatase homologous region in its N-terminal half. In this study, MJ0917 was biochemically shown to possess both NAD kinase and phosphatase activities toward NADP(+), NADPH, and fructose 1,6-bisphosphate, but not toward inositol 1-phosphate. With regard to the phosphatase activity, kinetic values indicated that NADP(+) is the preferred substrate and that MJ0917 would function as a novel NADP phosphatase/NAD kinase showing conflicting dual activities, viz. synthesis and degradation of an essential NADP(+). Furthermore, in vitro analysis of MJ0917 showed that, although MJ0917 could supply NADP(+), it prevented excess accumulation of NADP(+); thus, it has the ability to maintain a high NAD(+)/NADP(+) ratio, whereas 5'-AMP would decrease this ratio. The evolutionary process during which MJ0917 arose is also discussed.	Kyoto Univ, Grad Sch Agr, Dept Basic & Appl Mol Biotechnol, Uji, Kyoto 6110011, Japan	Kyoto University	Murata, K (corresponding author), Kyoto Univ, Grad Sch Agr, Dept Basic & Appl Mol Biotechnol, Uji, Kyoto 6110011, Japan.	kmurata@kais.kyoto-u.ac.jp						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ATTWOOD PV, 1988, BIOCHEM J, V253, P387, DOI 10.1042/bj2530387; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BRETAUDIERE JP, 1984, METHODS ENZYM ANAL, V4, P76; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Chen LJ, 1999, APPL ENVIRON MICROB, V65, P4559; Chen LJ, 1998, APPL ENVIRON MICROB, V64, P2609; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; CUSICK ME, 1994, NUCLEIC ACIDS RES, V22, P869, DOI 10.1093/nar/22.5.869; Gallais S, 2000, J EXP BOT, V51, P1389, DOI 10.1093/jexbot/51.349.1389; Garavaglia S, 2003, J BACTERIOL, V185, P4844, DOI 10.1128/JB.185.16.4844-4850.2003; Gillaspy GE, 1995, PLANT CELL, V7, P2175, DOI 10.1105/tpc.7.12.2175; Hendrickson EL, 2004, J BACTERIOL, V186, P6956, DOI 10.1128/JB.186.20.6956-6969.2004; JONES WJ, 1983, ARCH MICROBIOL, V135, P91, DOI 10.1007/BF00408015; Kawai S, 2000, BIOCHEM BIOPH RES CO, V276, P57, DOI 10.1006/bbrc.2000.3433; Kawai S, 2004, J BASIC MICROB, V44, P185, DOI 10.1002/jobm.200310362; Kawai S, 2001, EUR J BIOCHEM, V268, P4359, DOI 10.1046/j.1432-1327.2001.02358.x; Kawai S, 2001, FEMS MICROBIOL LETT, V200, P181, DOI 10.1111/j.1574-6968.2001.tb10712.x; KLINGENBERG M, 1985, METHOD ENZYMAT AN, V7, P251; Kobayashi K, 2003, P NATL ACAD SCI USA, V100, P4678, DOI 10.1073/pnas.0730515100; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVALMARTIN DL, 1990, ARCH BIOCHEM BIOPHYS, V276, P433, DOI 10.1016/0003-9861(90)90742-H; Lerner F, 2001, BIOCHEM BIOPH RES CO, V288, P69, DOI 10.1006/bbrc.2001.5735; Lopez F, 1999, MOL MICROBIOL, V31, P1255, DOI 10.1046/j.1365-2958.1999.01267.x; LUNDQUIST R, 1971, J BIOL CHEM, V246, P1107; MATSUHISA A, 1995, J BACTERIOL, V177, P200, DOI 10.1128/jb.177.1.200-205.1995; MCALLISTER G, 1992, BIOCHEM J, V284, P749, DOI 10.1042/bj2840749; Moat AG, 1987, PYRIDINE NUCLEOTID B, P1; Nigou J, 2002, BIOCHEMISTRY-US, V41, P4392, DOI 10.1021/bi0160056; Ochiai A, 2004, PROTEIN EXPRES PURIF, V36, P124, DOI 10.1016/j.pep.2004.03.012; Outten CE, 2003, EMBO J, V22, P2015, DOI 10.1093/emboj/cdg211; PILKIS SJ, 1991, ANNU REV NUTR, V11, P465, DOI 10.1146/annurev.nu.11.070191.002341; Quintero FJ, 1996, PLANT CELL, V8, P529, DOI 10.1105/tpc.8.3.529; Rashid N, 2002, J BIOL CHEM, V277, P30649, DOI 10.1074/jbc.M202868200; Reidl J, 2000, MOL MICROBIOL, V35, P1573, DOI 10.1046/j.1365-2958.2000.01829.x; RICHTER C, 1987, BIOCHEM BIOPH RES CO, V146, P253, DOI 10.1016/0006-291X(87)90718-2; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; Sato T, 2004, J BACTERIOL, V186, P5799, DOI 10.1128/JB.186.17.5799-5807.2004; SHI F, 2005, EUR J BIOCHEM, V272, P3337; Stec B, 2000, NAT STRUCT BIOL, V7, P1046, DOI 10.1038/80968; Stieglitz KA, 2002, J BIOL CHEM, V277, P22863, DOI 10.1074/jbc.M201042200; TAKIMOTO K, 1985, J BIOCHEM-TOKYO, V98, P363, DOI 10.1093/oxfordjournals.jbchem.a135290; Tillmann H, 1998, GENE, V212, P295, DOI 10.1016/S0378-1119(98)00181-4; TING HY, 1977, ARCH BIOCHEM BIOPHYS, V183, P98, DOI 10.1016/0003-9861(77)90423-4; Turner WL, 2004, PLANT PHYSIOL, V135, P1243, DOI 10.1104/pp.104.040428; Zhang HY, 2002, P NATL ACAD SCI USA, V99, P16678, DOI 10.1073/pnas.262655199; Ziegler M, 2000, EUR J BIOCHEM, V267, P1550, DOI 10.1046/j.1432-1327.2000.01187.x	48	23	26	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39200	39207		10.1074/jbc.M506426200	http://dx.doi.org/10.1074/jbc.M506426200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16192277	hybrid			2022-12-25	WOS:000233362200036
J	Klein, F; Feldhahn, N; Herzog, S; Sprangers, M; Mooster, JL; Jumaa, H; Muschen, M				Klein, F; Feldhahn, N; Herzog, S; Sprangers, M; Mooster, JL; Jumaa, H; Muschen, M			BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells	ONCOGENE			English	Article						lineage commitment; lymphopoiesis; RNA; interference; alternative splicing	EXPRESSION; GENE; RECEPTOR; DIFFERENTIATION; LEUKEMOGENESIS; ISOFORM	Pre-B lymphoblastic leukemia cells carrying a BCR-ABL1 gene rearrangement exhibit an undifferentiated phenotype. Comparing the genome-wide gene expression profiles of normal B-cell subsets and BCR-ABL1(+) pre-B lymphoblastic leukemia cells by SAGE, the leukemia cells show loss of B lymphoid identity and aberrant expression of myeloid lineage-specific molecules. Consistent with this, BCR-ABL1(+) pre-B lymphoblastic leukemia cells exhibit defective expression of IKAROS, a transcription factor needed for early lymphoid lineage commitment. As shown by inducible expression of BCR-ABL1 in human and murine B-cell precursor cell lines, BCR-ABL1 induces the expression of a dominant-negative IKAROS splice variant, termed IK6. Comparing matched leukemia sample pairs from patients before and during therapy with the BCR-ABL1 kinase inhibitor STI571 (Imatinib), inhibition of BCR-ABL1 partially corrected aberrant expression of IK6 and lineage infidelity of the leukemia cells. To elucidate the contribution of IK6 to lineage infidelity in BCR-ABL1(+) cell lines, IK6 expression was silenced by RNA interference. Upon inhibition of IK6, BCR-ABL1(+) leukemia cells partially restored B lymphoid lineage commitment. Therefore, we propose that BCR-ABL1 induces aberrant splicing of IKAROS, which interferes with lineage identity and differentiation of pre-B lymphoblastic leukemia cells.	Univ Dusseldorf, Lab Mol Stem Cell Biol, D-40225 Dusseldorf, Germany; Max Planck Inst Immunobiol, Freiburg, Germany	Heinrich Heine University Dusseldorf; Max Planck Society	Muschen, M (corresponding author), Univ Dusseldorf, Lab Mol Stem Cell Biol, Moorenstr 5,Bldg 14-80, D-40225 Dusseldorf, Germany.	markus.mueschen@uni-duesseldorf.de		Herzog, Sebastian/0000-0001-7167-3489				Busslinger M, 2004, ANNU REV IMMUNOL, V22, P55, DOI 10.1146/annurev.immunol.22.012703.104807; Feldhahn N, 2005, J EXP MED, V201, P1837, DOI 10.1084/jem.20042101; Feldhahn N, 2002, J EXP MED, V196, P1291, DOI 10.1084/jem.20020881; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; Jumaa H, 2003, NATURE, V423, P452, DOI 10.1038/nature01608; Kirstetter P, 2002, EUR J IMMUNOL, V32, P720, DOI 10.1002/1521-4141(200203)32:3<720::AID-IMMU720>3.0.CO;2-P; Klein F, 2005, J IMMUNOL, V174, P367, DOI 10.4049/jimmunol.174.1.367; Klein F, 2004, J EXP MED, V199, P673, DOI 10.1084/jem.20031637; Klein F, 2003, P NATL ACAD SCI USA, V100, P6747, DOI 10.1073/pnas.1031503100; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; Laurent E, 2001, CANCER RES, V61, P2343; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Muschen M, 2002, P NATL ACAD SCI USA, V99, P10014, DOI 10.1073/pnas.152327399; Nakase K, 2000, CANCER RES, V60, P4062; Perrotti D, 2002, ONCOGENE, V21, P8577, DOI 10.1038/sj.onc.1206085; Salesse S, 2004, LEUKEMIA, V18, P727, DOI 10.1038/sj.leu.2403310; Sun L, 1999, P NATL ACAD SCI USA, V96, P680, DOI 10.1073/pnas.96.2.680; Tonnelle C, 2001, BLOOD, V98, P2673, DOI 10.1182/blood.V98.9.2673; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484	20	49	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					1118	1124		10.1038/sj.onc.1209133	http://dx.doi.org/10.1038/sj.onc.1209133			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16205638				2022-12-25	WOS:000235361000016
J	Russell, JL; Weaks, RL; Berton, TR; Johnson, DG				Russell, JL; Weaks, RL; Berton, TR; Johnson, DG			E2F1 suppresses skin carcinogenesis via the ARF-p53 pathway	ONCOGENE			English	Article						E2F; p53; p21; p19ARF	TRANSCRIPTION FACTOR E2F-1; S-PHASE ENTRY; TUMOR-SUPPRESSOR; DNA-DAMAGE; MOUSE SKIN; P53-DEPENDENT APOPTOSIS; E2F-1-INDUCED APOPTOSIS; P53-MEDIATED APOPTOSIS; DEREGULATED EXPRESSION; TRANSGENIC MODEL	The E2F1 transcription factor, which is deregulated in most human cancers by mutations in the p16-cyclin D-Rb pathway, has both oncogenic and tumor-suppressive properties. This is dramatically illustrated by the phenotype of an E2F1 transgenic mouse model that spontaneously develops tumors in the skin and other epithelial tissues but is resistant to papilloma formation when subjected to a two-stage carcinogenesis protocol. Here, this E2F1 transgenic model was used to further explore the tumor-suppressive property of E2F1. Transgenic expression of E2F1 was found to inhibit ras-driven skin carcinogenesis at the promotion stage independent of the type of promoting agent used. E2F1 transgenic epidermis displayed increased expression of p19(ARF), p53, and p21(Cip1). Inactivation of either p53 or Arf in E2F1 transgenic mice restored sensitivity to two-stage skin carcinogenesis. While Arf inactivation impaired tumor suppression and p21 induction by E2F1, it did not reduce the level of apoptosis observed in E2F1 transgenic mice. Based on these findings, we propose that E2F1 suppresses ras-driven skin carcinogenesis through a nonapoptotic mechanism involving ARF and p53.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Johnson, DG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, POB 389, Smithville, TX 78957 USA.	djohnson@mdanderson.org		Johnson, David/0000-0002-6223-1790	NCI NIH HHS [CA 09480, CA 79648, CA 16672] Funding Source: Medline; NIEHS NIH HHS [ES 07784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079648, T32CA009480, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Conner EA, 2000, ONCOGENE, V19, P5054, DOI 10.1038/sj.onc.1203885; Conti C. J, 1994, HDB MOUSE MUTATIONS, P39; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Denchi EL, 2005, MOL CELL BIOL, V25, P2660, DOI 10.1128/MCB.25.7.2660-2672.2005; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; FISCHER SM, 1987, CARCINOGENESIS, V8, P421, DOI 10.1093/carcin/8.3.421; Gorgoulis VG, 2002, J PATHOL, V198, P142, DOI 10.1002/path.1121; Greenhalgh DA, 1996, CANCER RES, V56, P4413; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Khan SH, 2000, P NATL ACAD SCI USA, V97, P3266, DOI 10.1073/pnas.050560997; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Lin WC, 2001, GENE DEV, V15, P1833; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Mitchell DL, 1999, CANCER RES, V59, P2875; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; Paramio JM, 2001, J BIOL CHEM, V276, P44203, DOI 10.1074/jbc.M105650200; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; Powers JT, 2004, MOL CANCER RES, V2, P203; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; RAMIREZ A, 1994, DIFFERENTIATION, V58, P53, DOI 10.1007/s002580050065; Rizos H, 2005, CELL CYCLE, V4, P597, DOI 10.4161/cc.4.4.1588; Rogoff HA, 2004, MOL CELL BIOL, V24, P2968, DOI 10.1128/MCB.24.7.2968-2977.2004; Rogoff HA, 2002, MOL CELL BIOL, V22, P5308, DOI 10.1128/MCB.22.15.5308-5318.2002; Rounbehler RJ, 2002, CANCER RES, V62, P3276; Rounbehler RJ, 2001, ONCOGENE, V20, P5341, DOI 10.1038/sj.onc.1204691; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; SAITO M, 1995, GENOMICS, V25, P130, DOI 10.1016/0888-7543(95)80118-6; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2000, CANCER RES, V60, P3689; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; Tolbert D, 2002, MOL CELL BIOL, V22, P370, DOI 10.1128/MCB.22.1.370-377.2002; Tsai KY, 2002, CURR BIOL, V12, P159, DOI 10.1016/S0960-9822(01)00659-5; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Vorburger SA, 2002, ONCOGENE, V21, P6278, DOI 10.1038/sj.onc.1205761; Wang DW, 2000, MOL CELL BIOL, V20, P3417, DOI 10.1128/MCB.20.10.3417-3424.2000; Wang DW, 2001, MOL CARCINOGEN, V31, P90, DOI 10.1002/mc.1044; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yuspa SH, 1998, J DERMATOL SCI, V17, P1, DOI 10.1016/S0923-1811(97)00071-6; Zhu JW, 2001, MOL CELL BIOL, V21, P8547, DOI 10.1128/MCB.21.24.8547-8564.2001; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	67	13	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					867	876		10.1038/sj.onc.1209120	http://dx.doi.org/10.1038/sj.onc.1209120			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16205640				2022-12-25	WOS:000235212700006
J	Xia, G; Kumar, SP; Stein, JP; Singh, J; Krasnoperov, V; Zhu, S; Hassanieh, L; Smith, DL; Buscarini, M; Broek, D; Quinn, DI; Weaver, FA; Gill, PS				Xia, G; Kumar, SP; Stein, JP; Singh, J; Krasnoperov, V; Zhu, S; Hassanieh, L; Smith, DL; Buscarini, M; Broek, D; Quinn, DI; Weaver, FA; Gill, PS			EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival	ONCOGENE			English	Article						receptor tyrosine kinase; bladder cancer; cell growth; EphB4	LIGAND EPHRIN-B2; CARCINOMA; PROTEIN; CISPLATIN; P53; CHEMOTHERAPY; METHOTREXATE; GEMCITABINE; VINBLASTINE; PROGRESSION	We sought to evaluate the biological function of the receptor tyrosine kinase EphB4 in bladder cancer. All of the nine bladder cancer cell lines examined express EphB4 and the receptor could be phosphorylated following stimulation with its cognate ligand, EphrinB2. Out of the 15 fresh bladder cancer specimens examined, 14 expressed EphB4 with a mean sevenfold higher level of expression compared to adjacent normal urothelium. EphB4 expression was regulated by several mechanisms: EPHB4 gene locus was amplified in 27% tumor specimens and 33% cell lines studied; inhibition of EGFR signaling downregulated EphB4 levels; and forced expression of wild-type p53 reduced EphB4 expression. EphB4 knockdown using specific siRNA and antisense oligodeoxynucleotides molecules led to a profound inhibition in cell viability associated with apoptosis via activation of caspase-8 pathway and downregulation of anti apoptotic factor, bcl-xl. Furthermore, EphB4 knockdown significantly inhibited tumor cell migration and invasion. EphB4 knockdown in an in vivo murine tumor xenograft model led to a nearly 80% reduction in tumor volume associated with reduced tumor proliferation, increased apoptosis and reduced tumor microvasculature. EphB4 is thus a potential candidate as a predictor of disease outcome in bladder cancer and as target for novel therapy.	Univ So Calif, Keck Sch Med, Dept Med, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA USA; Univ So Calif, Keck Sch Med, Dept Surg, Los Angeles, CA USA; Univ So Calif, Keck Sch Med, Dept Urol, Los Angeles, CA USA; VasGene Therapeut Inc, Los Angeles, CA USA; Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA USA	University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California	Gill, PS (corresponding author), Univ So Calif, Keck Sch Med, Dept Med, 1441 Eastlake Ave,Norris Canc Res,NOR 6330, Los Angeles, CA 90033 USA.	parkashg@usc.edu	Quinn, David I/F-4343-2015; Singh, J B/ABF-5574-2021; Quinn, David/N-3730-2019; Reever, Larson/H-9685-2019	Quinn, David I/0000-0002-1411-0417; Singh, J B/0000-0001-9029-2462; Quinn, David/0000-0002-1411-0417; Reever, Larson/0000-0002-5692-4793; buscarini, maurizio/0000-0002-9228-3348; Smith, Lynne/0000-0003-2400-659X	NCI NIH HHS [R01CA72918] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; ANDRES AC, 1995, INT J CANCER, V63, P288, DOI 10.1002/ijc.2910630224; Batlle E, 2005, NATURE, V435, P1126, DOI 10.1038/nature03626; Berclaz G, 1996, BIOCHEM BIOPH RES CO, V226, P869, DOI 10.1006/bbrc.1996.1442; Berclaz G, 2003, ANN ONCOL, V14, P220, DOI 10.1093/annonc/mdg072; Buscarini M, 2005, BJU INT, V95, P739, DOI 10.1111/j.1464-410X.2005.05393.x; Chatterjee SJ, 2004, J CLIN ONCOL, V22, P1007, DOI 10.1200/JCO.2004.05.174; Chow NH, 2001, CLIN CANCER RES, V7, P1957; COOPER MJ, 1994, ONCOL RES, V6, P569; CUTLER SJ, 1982, AUA MONOGRAPHS BLADD, V1, P35; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; ESRIG D, 1994, NEW ENGL J MED, V331, P1259, DOI 10.1056/NEJM199411103311903; Gerety SS, 1999, MOL CELL, V4, P403, DOI 10.1016/S1097-2765(00)80342-1; Gontero P, 2004, EUR UROL, V46, P296, DOI 10.1016/j.eururo.2004.04.001; Hara I, 2001, J UROLOGY, V165, P1769, DOI 10.1016/S0022-5347(05)66411-7; Hasson P, 2005, NAT GENET, V37, P101, DOI 10.1038/ng1486; Holder N, 1999, DEVELOPMENT, V126, P2033; KOSS LG, 1979, HUM PATHOL, V10, P533, DOI 10.1016/S0046-8177(79)80097-0; Lawson ND, 2001, DEVELOPMENT, V128, P3675; LOEHRER PJ, 1992, J CLIN ONCOL, V10, P1066, DOI 10.1200/JCO.1992.10.7.1066; LOGOTHETIS CJ, 1990, J CLIN ONCOL, V8, P1050, DOI 10.1200/JCO.1990.8.6.1050; LUTZEYER W, 1982, J UROLOGY, V127, P250, DOI 10.1016/S0022-5347(17)53725-8; Mao WG, 2004, CANCER RES, V64, P781, DOI 10.1158/0008-5472.CAN-03-1047; Masood R, 2005, BLOOD, V105, P1310, DOI 10.1182/blood-2004-03-0933; Masood R, 2003, INT J CANCER, V104, P603, DOI 10.1002/ijc.10996; Munarini N, 2002, J CELL SCI, V115, P25; Noren NK, 2004, P NATL ACAD SCI USA, V101, P5583, DOI 10.1073/pnas.0401381101; O'Leary DDM, 1999, CURR OPIN NEUROBIOL, V9, P65, DOI 10.1016/S0959-4388(99)80008-7; Oates AC, 1999, MECH DEVELOP, V83, P77, DOI 10.1016/S0925-4773(99)00036-2; Pasquale EB, 1997, CURR OPIN CELL BIOL, V9, P608, DOI 10.1016/S0955-0674(97)80113-5; RIEGER KM, 1995, BRIT J CANCER, V72, P683, DOI 10.1038/bjc.1995.394; Stein JP, 2001, J CLIN ONCOL, V19, P666, DOI 10.1200/JCO.2001.19.3.666; Steinle JJ, 2002, J BIOL CHEM, V277, P43830, DOI 10.1074/jbc.M207221200; Stephenson S A, 2001, BMC Mol Biol, V2, P15, DOI 10.1186/1471-2199-2-15; Sternberg CN, 2001, CANCER, V92, P2993, DOI 10.1002/1097-0142(20011215)92:12<2993::AID-CNCR10108>3.0.CO;2-2; Takai N, 2001, ONCOL REP, V8, P567; Tickle C, 1999, CURR OPIN GENET DEV, V9, P455, DOI 10.1016/S0959-437X(99)80069-0; Vasala K, 2003, UROLOGY, V62, P952, DOI 10.1016/S0090-4295(03)00660-5; von der Maase H, 2000, J CLIN ONCOL, V18, P3068, DOI 10.1200/JCO.2000.18.17.3068; Wu WC, 2003, ONCOGENE, V22, P3361, DOI 10.1038/sj.onc.1206285; XIA G, 2005, CLIN CANCER RES, V11, P405; Xia GB, 2005, CANCER RES, V65, P4623, DOI 10.1158/0008-5472.CAN-04-2667	42	78	86	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					769	780		10.1038/sj.onc.1209108	http://dx.doi.org/10.1038/sj.onc.1209108			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16205642				2022-12-25	WOS:000235068800012
J	Sangwan, V; Paliouras, GN; Cheng, A; Dube, N; Tremblay, ML; Park, M				Sangwan, V; Paliouras, GN; Cheng, A; Dube, N; Tremblay, ML; Park, M			Protein-tyrosine phosphatase 1B deficiency protects against Fas-induced hepatic failure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HEPATOCYTE GROWTH-FACTOR; RECEPTOR-MEDIATED APOPTOSIS; LIVER-REGENERATION; IN-VIVO; MICE LACKING; C-FLIP; INSULIN SENSITIVITY; SIGNALING PATHWAYS; KINASE-ACTIVITY	Genetic disruption of protein-tyrosine phosphatase 1B (PTP1B) in mice leads to increased insulin sensitivity and resistance to weight gain. Although PTP1B has been implicated as a regulator of multiple signals, its function in other physiological responses in vivo is poorly understood. Here we demonstrate that PTP1B-null mice are resistant to Fas-induced liver damage and lethality, as evident by reduced hepatic apoptosis in PTP1B-null versus wild type mice and reduced levels of circulating liver enzymes. Activation of pro-apoptotic caspases- 8, -9, -3, and -6 was attenuated in livers from PTP1B-null mice following Fas receptor stimulation, although components of the death-inducing signaling complex were intact. Activation of anti-apoptotic regulators, such as the hepatocyte growth factor/Met receptor tyrosine kinase, as well as Raf, ERK1/2, FLIPL, and the NF-kappa B pathway, was elevated in response to Fas activation in livers from PTP1B-null mice. Using PTP1B-deficient primary hepatocytes, we show that resistance to Fas-mediated apoptosis is cell autonomous and that signals involving the Met, ERK1/2, and NF-kappa B pathways are required for cytoprotection. This study identifies a previously unknown physiological role for PTP1B in Fas-mediated liver damage and points to PTP1B as a potential therapeutic target against hepatotoxic agents.	McGill Univ, Ctr Hlth, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hlth, Dept Biochem, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hlth, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hlth, Dept Oncol, Montreal, PQ H3A 1A1, Canada; McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University; McGill University; McGill University; McGill University	Park, M (corresponding author), McGill Univ, Ctr Hlth, Royal Victoria Hosp, Mol Oncol Grp, 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	morag.park@mcgill.ca	Barrera, Miguel Calvo-Rubio/G-8790-2015; Cheng, Alan/M-9319-2013	Cheng, Alan/0000-0001-7897-4751				AKIYAMA T, 1991, METHOD ENZYMOL, V201, P362; Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; Asante-Appiah E, 2003, AM J PHYSIOL-ENDOC M, V284, pE663, DOI 10.1152/ajpendo.00462.2002; Balsamo J, 1998, J CELL BIOL, V143, P523, DOI 10.1083/jcb.143.2.523; Barnhart BC, 2003, SEMIN IMMUNOL, V15, P185, DOI 10.1016/S1044-5323(03)00031-9; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Borowiak M, 2004, P NATL ACAD SCI USA, V101, P10608, DOI 10.1073/pnas.0403412101; Buckley DA, 2002, MOL CELL BIOL, V22, P1998, DOI 10.1128/MCB.22.7.1998-2010.2002; Cheng A, 2002, DEV CELL, V2, P497, DOI 10.1016/S1534-5807(02)00149-1; Cheng A, 2001, J BIOL CHEM, V276, P25848, DOI 10.1074/jbc.M009734200; Christensen JG, 2003, CANCER RES, V63, P7345; Cohen J, 2004, BIOCHEM J, V377, P517, DOI 10.1042/BJ20031420; Costelli P, 2003, CELL DEATH DIFFER, V10, P997, DOI 10.1038/sj.cdd.4401281; DABEVA MD, 1993, AM J PATHOL, V143, P1606; DESCHENES J, 1980, IN VITRO CELL DEV B, V16, P722; Dube N, 2004, P NATL ACAD SCI USA, V101, P1834, DOI 10.1073/pnas.0304242101; Eichhorst ST, 2004, NAT MED, V10, P602, DOI 10.1038/nm1049; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; Gilbert S, 2004, MOL CELL BIOL, V24, P7072, DOI 10.1128/MCB.24.16.7072-7081.2004; Gu F, 2004, J BIOL CHEM, V279, P49689, DOI 10.1074/jbc.C400261200; Gu F, 2003, MOL CELL BIOL, V23, P3753, DOI 10.1128/MCB.23.11.3753-3762.2003; Haj FG, 2005, J BIOL CHEM, V280, P15038, DOI 10.1074/jbc.M413240200; HIRAMATSU N, 1994, HEPATOLOGY, V19, P1354, DOI 10.1002/hep.1840190606; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; Huh CG, 2004, P NATL ACAD SCI USA, V101, P4477, DOI 10.1073/pnas.0306068101; Kanzler S, 2000, SEMIN CANCER BIOL, V10, P173, DOI 10.1006/scbi.2000.0318; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Kosai K, 1998, BIOCHEM BIOPH RES CO, V244, P683, DOI 10.1006/bbrc.1998.8293; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; LaMontagne KR, 1998, MOL CELL BIOL, V18, P2965, DOI 10.1128/MCB.18.5.2965; LEIST M, 1994, J IMMUNOL, V153, P1778; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Liu F, 1997, BIOCHEM J, V327, P139, DOI 10.1042/bj3270139; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Mochizuki K, 1996, J HEPATOL, V24, P1, DOI 10.1016/S0168-8278(96)80178-4; Musallam L, 2001, AM J PHYSIOL-GASTR L, V280, pG1360, DOI 10.1152/ajpgi.2001.280.6.G1360; Myers MP, 2001, J BIOL CHEM, V276, P47771, DOI 10.1074/jbc.C100583200; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Ozoren N, 2003, SEMIN CANCER BIOL, V13, P135, DOI 10.1016/S1044-579X(02)00131-1; Ruff SJ, 1997, J BIOL CHEM, V272, P1263, DOI 10.1074/jbc.272.2.1263; Rust C, 2000, AM J MED, V108, P567, DOI 10.1016/S0002-9343(00)00370-3; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scharf JG, 2001, J CLIN PATHOL-MOL PA, V54, P138, DOI 10.1136/mp.54.3.138; Schneider P, 2000, Pharm Acta Helv, V74, P281, DOI 10.1016/S0031-6865(99)00038-2; Schulze-Bergkamen H, 2004, HEPATOLOGY, V39, P645, DOI 10.1002/hep.20138; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Sharp DA, 2005, J BIOL CHEM, V280, P19401, DOI 10.1074/jbc.M413962200; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Suzuki A, 2000, HEPATOLOGY, V32, P796, DOI 10.1053/jhep.2000.17738; Tamura S, 1998, SCAND J IMMUNOL, V47, P296; Taub R, 2004, NAT REV MOL CELL BIO, V5, P836, DOI 10.1038/nrm1489; Timmer T, 2002, J PATHOL, V196, P125, DOI 10.1002/path.1028; Tonks NK, 2003, FEBS LETT, V546, P140, DOI 10.1016/S0014-5793(03)00603-3; TONKS NK, 1988, J BIOL CHEM, V263, P6731; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; Tran SEF, 2004, TRENDS BIOCHEM SCI, V29, P601, DOI 10.1016/j.tibs.2004.09.009; VAN AD, 1996, SCIENCE, V274, P787; van Vliet C, 2005, NAT IMMUNOL, V6, P253, DOI 10.1038/ni1169; Wajant H, 2003, CYTOKINE GROWTH F R, V14, P53, DOI 10.1016/S1359-6101(02)00072-2; Zabolotny JM, 2002, DEV CELL, V2, P489, DOI 10.1016/S1534-5807(02)00148-X; Zhang YL, 1998, J BIOL CHEM, V273, P12281, DOI 10.1074/jbc.273.20.12281	70	56	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					221	228		10.1074/jbc.M507858200	http://dx.doi.org/10.1074/jbc.M507858200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16234234	hybrid			2022-12-25	WOS:000234307200030
J	Dong, JB; Shi, N; Berke, I; Chen, LP; Jiang, YX				Dong, JB; Shi, N; Berke, I; Chen, LP; Jiang, YX			Structures of the MthK RCK domain and the effect of Ca2+ on gating ring stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+ CHANNEL; ESCHERICHIA-COLI; POTASSIUM CHANNEL; BINDING PROTEINS; MECHANISM; TRANSPORT	MthK is a Ca2+-gated K+ channel from Methanobacterium autotrophicum. The crystal structure of the MthK channel in a Ca2+-bound open state was previously determined at 3.3 angstrom and revealed an octameric gating ring composed of eight intracellular ligand-binding RCK (regulate the conductance of K+) domains. It was suggested that Ca2+ binding regulates the gating ring conformation, which in turn leads to the opening and closing of the channel. However, at 3.3 A resolution, the molecular details of the structure are not well defined, and many of the conclusions drawn from that structure were hypothetical. Here we have presented high resolution structures of the MthK RCK domain with and without Ca2+ bound from three different crystals. These structures revealed a dimeric architecture of the RCK domain and allowed us to visualize the Ca2+ binding and protein-protein contacts at atomic detail. The dimerization of RCK domains is also conserved in other RCK-regulated K+ channels and transporters, suggesting that the RCK dimer serves as a basic unit in the gating ring assembly. A comparison of these dimer structures confirmed that the dimer interface is indeed flexible as suggested previously. However, the conformational change at the flexible interface is of an extent smaller than the previously hypothesized gating ring movement, and a reconstruction of these dimers into octamers by applying protein-protein contacts at the fixed interface did not generate enclosed gating rings. This indicated that there is a high probability that the previously defined fixed interface may not be fixed during channel gating. In addition to the structural studies, we have also carried out biochemical analyses and have shown that near physiological pH, isolated RCK domains form a stable octamer in solution, supporting the notion that the formation of octameric gating ring is a functionally relevant event in MthK gating. Additionally, our stability studies indicated that Ca2+ binding stabilizes the RCK domains in this octameric state.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Cornell University	Jiang, YX (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	youxing.jiang@utsouthwestern.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071621] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM071621] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; Bellamacina CR, 1996, FASEB J, V10, P1257, DOI 10.1096/fasebj.10.11.8836039; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Derst C, 1998, J EXP BIOL, V201, P2791; Durell SR, 1999, BIOPHYS J, V77, P775, DOI 10.1016/S0006-3495(99)76931-6; Hellmer J, 2003, FEBS LETT, V547, P165, DOI 10.1016/S0014-5793(03)00706-3; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Jiang YX, 2001, NEURON, V29, P593, DOI 10.1016/S0896-6273(01)00236-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kuo MMC, 2003, EMBO J, V22, P4049, DOI 10.1093/emboj/cdg409; Lewit-Bentley A, 2000, CURR OPIN STRUC BIOL, V10, P637, DOI 10.1016/S0959-440X(00)00142-1; Magleby RL, 2003, J GEN PHYSIOL, V121, P81, DOI 10.1085/jgp.20028721; MEYER E, 1988, ACTA CRYSTALLOGR B, V44, P26, DOI 10.1107/S0108768187007559; Niu XW, 2004, NEURON, V42, P745, DOI 10.1016/j.neuron.2004.05.001; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARRALOPEZ C, 1994, EMBO J, V13, P3964, DOI 10.1002/j.1460-2075.1994.tb06712.x; PICO A, 2003, THESIS ROCKEFELLER U; Ptak CP, 2005, BIOCHEMISTRY-US, V44, P62, DOI 10.1021/bi048390f; Roosild TP, 2002, CELL, V109, P781, DOI 10.1016/S0092-8674(02)00768-7; SCHLOSSER A, 1993, MOL MICROBIOL, V9, P533, DOI 10.1111/j.1365-2958.1993.tb01714.x; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; Yifrach O, 2002, CELL, V111, P231, DOI 10.1016/S0092-8674(02)01013-9	23	47	48	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41716	41724		10.1074/jbc.M508144200	http://dx.doi.org/10.1074/jbc.M508144200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16227203	hybrid			2022-12-25	WOS:000233866900073
J	Nakanishi, M; Tanaka, N; Mizutani, Y; Mochizuki, M; Ueno, Y; Nakamura, KT; Kitade, Y				Nakanishi, M; Tanaka, N; Mizutani, Y; Mochizuki, M; Ueno, Y; Nakamura, KT; Kitade, Y			Functional characterization of 2 ',5 '-linked oligoadenylate binding determinant of human RNase L	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANKYRIN-REPEAT DOMAIN; STRUCTURAL BASIS; 2-5A-DEPENDENT RNASE; SWISS-MODEL; PROTEIN; RECOGNITION	RNase L is activated by the binding of unusual 2', 5'-linked oligoadenylates (2 - 5A) and acts as the effector enzyme of the 2 - 5A system, an interferon-induced anti-virus mechanism. Efforts have been made to understand the 2 - 5A binding mechanism, not only for scientific interests but also for the prospects that the understanding of such mechanisms lead to new remedies for viral diseases. We have recently elucidated the crystal structure of the 2 - 5A binding ankyrin repeat domain of human RNase L complexed with 2 - 5A. To determine the contributions of amino acid residues surrounding the 2 - 5A binding site, point mutants and a deletion mutant were designed based on the crystal structure. These mutant proteins were analyzed for their interaction with 2 - 5A using a steady-state fluorescence technique. In addition, full-length RNase L mutants were tested for their activation by 2 - 5A. The results reveal that pi - pi stacking interactions of Trp(60) and Phe(126), electrostatic interactions of Lys(89) and Arg(155), and hydrogen bonding by Glu(131) make crucial contributions to 2 - 5A binding. It was also found that the crystal structure of the ankyrin repeat domain L(.)2 - 5A complex accurately portrays the 2 - 5A binding mode in full-length RNase L.	Gifu Univ, Fac Engn, Dept Biomol Sci, Gifu 5011193, Japan; Showa Univ, Sch Pharmaceut Sci, Shinagawa Ku, Tokyo 1428555, Japan; Gifu Univ, Ctr Emerging Infect Dis, Gifu 5011193, Japan; Gifu Univ, Ctr Adv Drug Res, Gifu 5011193, Japan	Gifu University; Showa University; Gifu University; Gifu University	Kitade, Y (corresponding author), Gifu Univ, Fac Engn, Dept Biomol Sci, Yanagido 1-1, Gifu 5011193, Japan.	kitade@biomol.gifu-u.ac.jp	Mizutani, Yasuhisa/B-3809-2009	Tanaka, Nobutada/0000-0001-5365-4698				Antson AA, 1999, NATURE, V401, P235, DOI 10.1038/45730; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; Bogden CE, 1999, MOL CELL, V3, P487, DOI 10.1016/S1097-2765(00)80476-1; Casey G, 2002, NAT GENET, V32, P582, DOI 10.1038/ng1021; Chandrasekaran K, 2004, BIOCHEM BIOPH RES CO, V325, P18, DOI 10.1016/j.bbrc.2004.10.016; Dong BH, 1997, J BIOL CHEM, V272, P22236, DOI 10.1074/jbc.272.35.22236; DONG BH, 1994, J BIOL CHEM, V269, P14153; Dong BH, 2001, RNA, V7, P361, DOI 10.1017/S1355838201002230; DROCOURT JL, 1982, NUCLEIC ACIDS RES, V10, P2163, DOI 10.1093/nar/10.6.2163; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hartmann R, 2003, MOL CELL, V12, P1173, DOI 10.1016/S1097-2765(03)00433-7; Li GQ, 2004, J BIOL CHEM, V279, P1123, DOI 10.1074/jbc.M305893200; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; Nakanishi M, 2005, PROTEINS, V60, P131, DOI 10.1002/prot.20474; Nakanishi M, 2004, EUR J BIOCHEM, V271, P2737, DOI 10.1111/j.1432-1033.2004.04202.x; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Player MR, 1998, PHARMACOL THERAPEUT, V78, P55, DOI 10.1016/S0163-7258(97)00167-8; Quiocho FA, 2000, CURR OPIN STRUC BIOL, V10, P78, DOI 10.1016/S0959-440X(99)00053-6; Raghunathan S, 2000, NAT STRUCT BIOL, V7, P648, DOI 10.1038/77943; Sanner M.F., 1995, P 11 ACM S COMP GEOM; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; Silverman R., 1997, RIBONUCLEASES STRUCT, P515; Silverman RH, 2003, BIOCHEMISTRY-US, V42, P1805, DOI 10.1021/bi027147i; Tanaka N, 2005, PROTEIN PEPTIDE LETT, V12, P387, DOI 10.2174/0929866053765734; Tanaka N, 2004, EMBO J, V23, P3929, DOI 10.1038/sj.emboj.7600420; Tiev MP, 2003, CLIN DIAGN LAB IMMUN, V10, P315, DOI 10.1128/CDLI.10.2.315-316.2003; Yoshimura A, 2002, J BIOCHEM, V132, P643, DOI 10.1093/oxfordjournals.jbchem.a003268; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355	31	15	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41694	41699		10.1074/jbc.M507424200	http://dx.doi.org/10.1074/jbc.M507424200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16234235	hybrid			2022-12-25	WOS:000233866900070
J	Chen, CP; Vincent, O; Jin, J; Weisz, OA; Montelaro, RC				Chen, CP; Vincent, O; Jin, J; Weisz, OA; Montelaro, RC			Functions of early (AP-2) and late (AIP1/ALIX) Endocytic proteins in equine infectious anemia virus budding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-DOMAIN; GAG P9; TSG101; BINDING; TRAFFICKING; INTERACT; HOMOLOG; NETWORK; PATHWAY; LIGASES	The proline-rich L domains of human immunodeficiency virus 1 (HIV-1) and other retroviruses interact with late endocytic proteins during virion assembly and budding. In contrast, the YPDL L domain of equine infectious anemia virus ( EIAV) is apparently unique in its reported ability to interact both with the mu 2 subunit of the AP-2 adaptor protein complex and with ALG-2-interacting protein 1 (AIP1/Alix) protein factors involved in early and late endosome formation, respectively. To define further the mechanisms by which EIAV adapts vesicle trafficking machinery to facilitate virion production, we have examined the specificity of EIAV p9 binding to endocytic factors and the effects on virion production of alterations in early and late endocytic protein expression. The results of these studies demonstrated that (i) an similar to 300-residue region of AIP1/Alix( (409 - 715) was sufficient for binding to the EIAV YPDL motif; (ii) overexpression of AIP1/Alix or AP-2 mu 2 subunit specifically inhibited YPDL-mediated EIAV budding; (iii) virion budding from a replicationcompetent EIAV variant with its L domain replaced by the HIV PTAP sequence was inhibited by wild type or mutant mu 2 to a level similar to that observed when a dominant-negative mutant of Tsg101 was expressed; and (iv) overexpression or siRNA silencing of AIP1/Alix and AP-2 revealed additive suppression of YPDL-mediated EIAV budding. Taken together, these results indicated that both early and late endocytic proteins facilitate EIAV production mediated by either YPDL or PTAP L domains, suggesting a comprehensive involvement of endocytic factors in retroviral assembly and budding that can be accessed by distinct L domain specificities.	Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15261 USA; CSIC, Ctr Invest Biol, Dept Mol Microbiol, E-28006 Madrid, Spain	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Montelaro, RC (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, W1144 Biomed Sci Tower, Pittsburgh, PA 15261 USA.	rmont@pitt.edu	vincent, Olivier/H-1620-2015	vincent, Olivier/0000-0003-4355-5367; Chen, Chaoping/0000-0001-9387-6252; Jin, Jing/0000-0003-3994-8600	NATIONAL CANCER INSTITUTE [R01CA049296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI049820] Funding Source: NIH RePORTER; NCI NIH HHS [2R01 CA49296] Funding Source: Medline; NIAID NIH HHS [T32 AI49820] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alroy I, 2005, P NATL ACAD SCI USA, V102, P1478, DOI 10.1073/pnas.0408717102; Blot V, 2004, J CELL SCI, V117, P2357, DOI 10.1242/jcs.01095; BRYANT M, 1990, P NATL ACAD SCI USA, V87, P523, DOI 10.1073/pnas.87.2.523; Chen CP, 2001, J VIROL, V75, P9762, DOI 10.1128/JVI.75.20.9762-9770.2001; Demirov DG, 2002, P NATL ACAD SCI USA, V99, P955, DOI 10.1073/pnas.032511899; Demirov DG, 2004, VIRUS RES, V106, P87, DOI 10.1016/j.virusres.2004.08.007; Derdowski A, 2004, J VIROL, V78, P1230, DOI 10.1128/JVI.78.3.1230-1242.2004; Dong XH, 2005, CELL, V120, P663, DOI 10.1016/j.cell.2004.12.023; Fraile-Ramos A, 2003, TRAFFIC, V4, P243, DOI 10.1034/j.1600-0854.2003.00079.x; FRANKE EK, 1994, J VIROL, V68, P5300, DOI 10.1128/JVI.68.8.5300-5305.1994; Gamble TR, 1997, SCIENCE, V278, P849, DOI 10.1126/science.278.5339.849; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Irie T, 2004, J VIROL, V78, P2657, DOI 10.1128/JVI.78.6.2657-2665.2004; Kikonyogo A, 2001, P NATL ACAD SCI USA, V98, P11199, DOI 10.1073/pnas.201268998; Li F, 2002, J VIROL, V76, P1569, DOI 10.1128/JVI.76.4.1569-1577.2002; Li Feng, 2005, Curr Opin Investig Drugs, V6, P148; Martin-Serrano J, 2003, P NATL ACAD SCI USA, V100, P12414, DOI 10.1073/pnas.2133846100; Motley A, 2003, J CELL BIOL, V162, P909, DOI 10.1083/jcb.200305145; Nesterov A, 1999, EMBO J, V18, P2489, DOI 10.1093/emboj/18.9.2489; Ott DE, 2005, J VIROL, V79, P9038, DOI 10.1128/JVI.79.14.9038-9045.2005; Puffer BA, 1998, J VIROL, V72, P10218, DOI 10.1128/JVI.72.12.10218-10221.1998; Puffer BA, 1997, J VIROL, V71, P6541, DOI 10.1128/JVI.71.9.6541-6546.1997; RUDEN DM, 1991, NATURE, V350, P250, DOI 10.1038/350250a0; Segura-Morales C, 2005, J BIOL CHEM, V280, P27004, DOI 10.1074/jbc.M413735200; SPEARMAN P, 1994, J VIROL, V68, P3232, DOI 10.1128/JVI.68.5.3232-3242.1994; Strack B, 2003, CELL, V114, P689, DOI 10.1016/S0092-8674(03)00653-6; VerPlank L, 2001, P NATL ACAD SCI USA, V98, P7724, DOI 10.1073/pnas.131059198; Vincent O, 1999, EMBO J, V18, P6672, DOI 10.1093/emboj/18.23.6672; Vincent O, 2003, MOL CELL BIOL, V23, P1647, DOI 10.1128/MCB.23.5.1647-1655.2003; von Schwedler UK, 2003, CELL, V114, P701, DOI 10.1016/S0092-8674(03)00714-1; Zhang YQ, 1998, J VIROL, V72, P1782, DOI 10.1128/JVI.72.3.1782-1789.1998	31	51	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40474	40480		10.1074/jbc.M509317200	http://dx.doi.org/10.1074/jbc.M509317200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16215227	hybrid, Green Published			2022-12-25	WOS:000233666600012
J	Hassa, PO; Haenni, SS; Buerki, C; Meier, NI; Lane, WS; Owen, H; Gersbach, M; Imhof, R; Hottiger, MO				Hassa, PO; Haenni, SS; Buerki, C; Meier, NI; Lane, WS; Owen, H; Gersbach, M; Imhof, R; Hottiger, MO			Acetylation of poly(ADP-ribose) polymerase-1 by p300/CREB-binding protein regulates coactivation of NF-kappa B-dependent transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; GENE-EXPRESSION; HISTONE ACETYLATION; SIGNALING PATHWAY; DNA-BINDING; ACTIVATION; P300; PROMOTER; MODULATION; COMPLEX	Poly(ADP-ribose) polymerase-1 (PARP-1) and nuclear factor kappa B (NF-kappa B) have both been demonstrated to play a pathophysiological role in a number of inflammatory disorders. We recently presented evidence that PARP-1 can act as a promoter-specific coactivator of NF-kappa B in vivo independent of its enzymatic activity. PARP-1 directly interacts with p300 and both subunits of NF-kappa B (p65 and p50) and synergistically coactivates NF-kappa B-dependent transcription. Here we show that PARP-1 is acetylated in vivo at specific lysine residues by p300/CREB-binding protein upon stimulation. Furthermore, acetylation of PARP-1 at these residues is required for the interaction of PARP-1 with p50 and synergistic coactivation of NF-kappa B by p300 and the Mediator complex in response to inflammatory stimuli. PARP-1 physically interacts with the Mediator. Interestingly, PARP-1 interacts in vivo with histone deacetylases (HDACs) 1-3 but not with HDACs 4-6 and might be deacetylated in vivo by HDACs 1-3. Thus, acetylation of PARP-1 by p300/CREB-binding protein plays an important regulatory role in NF-kappa B-dependent gene activation by enhancing its functional interaction with p300 and the Mediator complex.	Univ Zurich, Inst Vet Biochem & Mol Biol, CH-8057 Zurich, Switzerland; Harvard Univ, Dept Mol & Cellular Biol, Microchem & Proteom Anal Facil, Cambridge, MA 02138 USA	University of Zurich; Harvard University	Hottiger, MO (corresponding author), Univ Zurich, Inst Vet Biochem & Mol Biol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	hottiger@vetbio.unizh.ch	Hottiger, Michael O./J-7747-2013	Hottiger, Michael O./0000-0002-7323-2270				Blanchard F, 2005, DRUG DISCOV TODAY, V10, P197, DOI 10.1016/S1359-6446(04)03309-4; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Chen LF, 2003, J MOL MED, V81, P549, DOI 10.1007/s00109-003-0469-0; Covic M, 2005, EMBO J, V24, P85, DOI 10.1038/sj.emboj.7600500; Deng WG, 2003, J BIOL CHEM, V278, P4770, DOI 10.1074/jbc.M209286200; DiazGuerra MJM, 1996, J BIOL CHEM, V271, P30114, DOI 10.1074/jbc.271.47.30114; Ganster RW, 2001, P NATL ACAD SCI USA, V98, P8638, DOI 10.1073/pnas.151239498; Ge H, 1998, EMBO J, V17, P6723, DOI 10.1093/emboj/17.22.6723; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Goodman RH, 2000, GENE DEV, V14, P1553; Guermah M, 1998, MOL CELL BIOL, V18, P3234, DOI 10.1128/MCB.18.6.3234; Ha HC, 2001, P NATL ACAD SCI USA, V98, P3364, DOI 10.1073/pnas.051633498; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; Hassa PO, 2001, J BIOL CHEM, V276, P45588, DOI 10.1074/jbc.M106528200; Hassa PO, 2003, J BIOL CHEM, V278, P45145, DOI 10.1074/jbc.M307957200; Hassa PO, 2002, CELL MOL LIFE SCI, V59, P1534, DOI 10.1007/s00018-002-8527-2; Hottiger MO, 1998, EMBO J, V17, P3124, DOI 10.1093/emboj/17.11.3124; Hu J, 2005, MOL CANCER RES, V3, P100, DOI 10.1158/1541-7786.MCR-04-0070; KAISER K, 1995, EMBO J, V14, P3520, DOI 10.1002/j.1460-2075.1995.tb07358.x; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KARIN M, 1998, CANC J SCI AM S1, V4, P92; Kiefmann R, 2004, INTENS CARE MED, V30, P1421, DOI 10.1007/s00134-004-2301-x; Kim DS, 2003, MOL IMMUNOL, V40, P633, DOI 10.1016/j.molimm.2003.07.001; Kim YM, 1999, MOL CELLS, V9, P99; Kumar BRP, 2001, J BIOL CHEM, V276, P16804, DOI 10.1074/jbc.M100934200; Kundu TK, 2000, MOL CELL, V6, P551, DOI 10.1016/S1097-2765(00)00054-X; Malik S, 2000, MOL CELL, V5, P753, DOI 10.1016/S1097-2765(00)80254-3; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Oh YK, 2003, VACCINE, V21, P2837, DOI 10.1016/S0264-410X(03)00178-6; Pavri R, 2005, MOL CELL, V18, P83, DOI 10.1016/j.molcel.2005.02.034; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Perkins ND, 1997, INT J BIOCHEM CELL B, V29, P1433, DOI 10.1016/S1357-2725(97)00088-5; Perrella MA, 1999, J BIOL CHEM, V274, P9045, DOI 10.1074/jbc.274.13.9045; Petrilli V, 2004, J CLIN INVEST, V114, P1072, DOI 10.1172/JCI200421854; Pinhero Reena, 2004, Biol Proced Online, V6, P163, DOI 10.1251/bpo86; Ringenbach L, 1998, GENE THER, V5, P1508, DOI 10.1038/sj.gt.3300756; Roeder RG, 1998, COLD SPRING HARB SYM, V63, P201, DOI 10.1101/sqb.1998.63.201; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Schmitz ML, 2004, CHEMBIOCHEM, V5, P1348, DOI 10.1002/cbic.200400144; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Simbulan-Rosenthal CM, 2003, ONCOGENE, V22, P8460, DOI 10.1038/sj.onc.1206897; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Tinsley RB, 2004, J GENE MED, V6, P1023, DOI 10.1002/jgm.584; Tong X, 2005, J BIOL CHEM, V280, P15503, DOI 10.1074/jbc.M411978200; Tulin A, 2003, SCIENCE, V299, P560, DOI 10.1126/science.1078764; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; Wilson AJ, 2002, CANCER RES, V62, P6006; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zingarelli B, 2004, IMMUNOLOGY, V113, P509, DOI 10.1111/j.1365-2567.2004.01991.x	56	244	247	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40450	40464		10.1074/jbc.M507553200	http://dx.doi.org/10.1074/jbc.M507553200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16204234	hybrid			2022-12-25	WOS:000233666600010
J	Hresko, RC; Mueckler, M				Hresko, RC; Mueckler, M			mTOR center dot RICTOR is the Ser(473) kinase for Akt/protein kinase B in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-LINKED KINASE; DEPENDENT PROTEIN-KINASE; PLASMA-MEMBRANE; GLUCOSE-TRANSPORT; FKBP12-RAPAMYCIN-ASSOCIATED PROTEIN; IONIZING-RADIATION; CRYSTAL-STRUCTURE; MAMMALIAN TARGET; SIGNALING SYSTEM; BINDING PARTNER	The insulin-signaling pathway leading to the activation of Akt/ protein kinase B has been well characterized except for a single step, the phosphorylation of Akt at Ser-473. Double-stranded DNA-dependent protein kinase (DNA-PK), ataxia telangiectasia mutated (ATM) gene product, integrin-linked kinase ( ILK), protein kinase C alpha (PKC alpha), and mammalian target of rapamycin ( mTOR), when complexed to rapamycin-insensitive companion of mTOR (RICTOR), have all been identified as playing a critical role in Akt Ser473 phosphorylation. However, the apparently disparate results reported in these studies are difficult to evaluate, given that different stimuli and cell types were examined and that all of the candidate proteins have never been systematically studied in a single system. Additionally, none of these studies were performed in a classical insulin-responsive cell type or tissue such as muscle or fat. We therefore examined each of these candidates in 3T3-L1 adipocytes. In vitro kinase assays, using different subcellular fractions of 3T3-L1 adipocytes, revealed that phosphatidylinositol 3,4,5-trisphosphate- stimulated Ser-473 phosphorylation correlated well with the amount of DNA-PK, mTOR, and RICTOR but did not correlate with levels of ATM, ILK, and PKC alpha. PKC alpha was completely absent from compartments with Ser- 473 phosphorylation activity. Although purified DNA-PK could phosphorylate a peptide derived from Akt that contains amino acid Ser- 473, it could not phosphorylate full-length Akt2. Vesicles immunoprecipitated from low density microsomes using antibodies directed against mTOR or RICTOR had phosphatidylinositol 3,4,5-trisphosphate- stimulated Ser- 473 activity that was sensitive to wortmannin but not staurosporine. In contrast, immunopurified low density microsome vesicles containing ILK could not phosphorylate Akt on Ser- 473 in vitro. Small interference RNA knockdown of RICTOR, but not DNA-PK, ATM, or ILK, suppressed insulin-activated Ser- 473 phosphorylation and, to a lesser extent, Thr-308 phosphorylation in 3T3-L1 adipocytes. Based on our cell-free kinase and small interference RNA results, we conclude that mTOR complexed to RICTOR is the Ser- 473 kinase in 3T3-L1 adipocytes.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Mueckler, M (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	mike@cellbiology.wustl.edu	Mueckler, Mike M/F-6115-2012		NIDDK NIH HHS [R01 DK067229] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067229] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1999, MOL CELL BIOL, V19, P5061; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Bae SS, 2003, J BIOL CHEM, V278, P49530, DOI 10.1074/jbc.M306782200; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chan DW, 1999, BIOCHEMISTRY-US, V38, P1819, DOI 10.1021/bi982584b; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Dong LQ, 2005, AM J PHYSIOL-ENDOC M, V289, pE187, DOI 10.1152/ajpendo.00011.2005; Dragoi AM, 2005, EMBO J, V24, P779, DOI 10.1038/sj.emboj.7600539; Drenan RM, 2004, J BIOL CHEM, V279, P772, DOI 10.1074/jbc.M305912200; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Frodin M, 2002, EMBO J, V21, P5396, DOI 10.1093/emboj/cdf551; Grashoff C, 2003, EMBO REP, V4, P432, DOI 10.1038/sj.embor.embor801; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hill MM, 1999, MOL CELL BIOL, V19, P7771; Hill MM, 2002, CURR BIOL, V12, P1251, DOI 10.1016/S0960-9822(02)00973-9; Hill MM, 2001, J BIOL CHEM, V276, P25643, DOI 10.1074/jbc.C100174200; Hresko RC, 2003, J BIOL CHEM, V278, P21615, DOI 10.1074/jbc.M302937200; Huang X, 2003, STRUCTURE, V11, P21, DOI 10.1016/S0969-2126(02)00937-1; Jiang ZY, 2003, P NATL ACAD SCI USA, V100, P7569, DOI 10.1073/pnas.1332633100; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim JE, 2000, P NATL ACAD SCI USA, V97, P14340, DOI 10.1073/pnas.011511898; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Lawlor MA, 2001, J CELL SCI, V114, P2903; Letiges M, 2002, MOL ENDOCRINOL, V16, P847, DOI 10.1210/me.16.4.847; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Manning BD, 2004, J CELL BIOL, V167, P399, DOI 10.1083/jcb.200408161; MASTICK CC, 1994, J BIOL CHEM, V269, P6089; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Murata H, 2003, J BIOL CHEM, V278, P21607, DOI 10.1074/jbc.M302934200; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Partovian C, 2004, CELL SIGNAL, V16, P951, DOI 10.1016/j.cellsig.2004.01.008; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; Sable CL, 1998, J BIOL CHEM, V273, P29600, DOI 10.1074/jbc.273.45.29600; Sakai T, 2003, GENE DEV, V17, P926, DOI 10.1101/gad.255603; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; TORDJMAN KM, 1989, P NATL ACAD SCI USA, V86, P7761, DOI 10.1073/pnas.86.20.7761; Tremblay F, 2005, ENDOCRINOLOGY, V146, P1328, DOI 10.1210/en.2004-0777; Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Viniegra JG, 2005, J BIOL CHEM, V280, P4029, DOI 10.1074/jbc.M410344200; Welsh GL, 2005, BIOCHEM SOC T, V33, P346, DOI 10.1042/BST0330346; WHITE MF, 1994, J BIOL CHEM, V269, P1; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Wick MJ, 2000, J BIOL CHEM, V275, P40400, DOI 10.1074/jbc.M003937200; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; Zeigerer A, 2004, MOL BIOL CELL, V15, P4406, DOI 10.1091/mbc.e04-04-0333	64	500	526	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40406	40416		10.1074/jbc.M508361200	http://dx.doi.org/10.1074/jbc.M508361200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16221682	hybrid			2022-12-25	WOS:000233666600005
J	Karamyshev, AL; Kelleher, DJ; Gilmore, R; Johnson, AE; von Heijne, G; Nilsson, I				Karamyshev, AL; Kelleher, DJ; Gilmore, R; Johnson, AE; von Heijne, G; Nilsson, I			Mapping the interaction of the STT3 subunit of the oligosaccharyl transferase complex with nascent polypeptide chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; CORE-GLYCOSYLATION EFFICIENCY; YEAST EXTERNAL INVERTASE; PROTEIN TRANSLOCATION; AMINO-ACID; ESCHERICHIA-COLI; IMPORTANT DETERMINANT; PHOTOCROSS-LINKING; SIGNAL SEQUENCE; IN-VIVO	Many secretory and membrane proteins are N-glycosylated by the oligosaccharyl transferase complex during their translocation across the endoplasmic reticulum membrane. Several experimental observations suggest that the highly conserved STT3 subunit contains the active site of the oligosaccharyl transferase. Here, we report a detailed study of the interaction between the active site of the STT3 protein and nascent polypeptide chains using an in vitro photocrosslinking technique. Our results show that the addition of a glycan moiety in a stretch of similar to 15 residues surrounding a QK*T cross-linking site impairs the interaction between the nascent chain and STT3.	Stockholm Univ, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden; Texas A&M Univ, Syst Hlth Sci Ctr, Dept Med Biochem & Genet, College Stn, TX 77843 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Worcester, MA 01655 USA	Stockholm University; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; University of Massachusetts System; University of Massachusetts Worcester	Nilsson, I (corresponding author), Stockholm Univ, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden.	ingmarie@dbb.su.se	von Heijne, Gunnar/F-5576-2011; Johnson, Arthur E/G-3457-2012; von Heijne, Gunnar/AAH-9389-2019; Nilsson, IngMarie/H-2887-2012	von Heijne, Gunnar/0000-0002-4490-8569; 	NIGMS NIH HHS [GM26494, GM43768] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043768, R01GM026494] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alder NN, 2004, J BIOL CHEM, V279, P22787, DOI 10.1074/jbc.R400002200; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; Feldman MF, 2005, P NATL ACAD SCI USA, V102, P3016, DOI 10.1073/pnas.0500044102; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; JOHANSSON M, 1993, MOL GEN GENET, V239, P251, DOI 10.1007/BF00281625; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; Kelleher DJ, 2003, MOL CELL, V12, P101, DOI 10.1016/S1097-2765(03)00243-0; Kim H, 2005, J BIOL CHEM, V280, P20261, DOI 10.1074/jbc.M412213200; Knauer R, 1999, BBA-GEN SUBJECTS, V1426, P259, DOI 10.1016/S0304-4165(98)00128-7; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; KUROSKY A, 1980, P NATL ACAD SCI-BIOL, V77, P3388, DOI 10.1073/pnas.77.6.3388; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; LILJESTROM P, 1991, J VIROL, V65, P147; LOCKRIDGE O, 1987, J BIOL CHEM, V262, P549; Mellquist JL, 1998, BIOCHEMISTRY-US, V37, P6833, DOI 10.1021/bi972217k; Nilsson I, 2003, J CELL BIOL, V161, P715, DOI 10.1083/jcb.200301043; Nilsson IM, 2001, J BIOL CHEM, V276, P41748, DOI 10.1074/jbc.M105823200; Petrescu AJ, 2004, GLYCOBIOLOGY, V14, P103, DOI 10.1093/glycob/cwh008; Reddy A, 1999, GLYCOBIOLOGY, V9, P547, DOI 10.1093/glycob/9.6.547; REDDY VA, 1988, J BIOL CHEM, V263, P6978; ShakinEshleman SH, 1996, J BIOL CHEM, V271, P6363, DOI 10.1074/jbc.271.11.6363; Wacker M, 2002, SCIENCE, V298, P1790, DOI 10.1126/science.298.5599.1790; WALTER P, 1983, METHOD ENZYMOL, V96, P84; Whitley P, 1996, J BIOL CHEM, V271, P6241, DOI 10.1074/jbc.271.11.6241; Yan G, 2002, J BIOL CHEM, V277, P47692, DOI 10.1074/jbc.M208136200; Zhang H, 2003, NAT BIOTECHNOL, V21, P660, DOI 10.1038/nbt827; ZUFFEREY R, 1995, EMBO J, V14, P4949, DOI 10.1002/j.1460-2075.1995.tb00178.x	29	21	22	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40489	40493		10.1074/jbc.M509168200	http://dx.doi.org/10.1074/jbc.M509168200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16216884	hybrid			2022-12-25	WOS:000233666600014
J	Lee, J; Kim, CH; Simon, DK; Aminova, LR; Andreyev, AY; Kushnareva, YE; Murphy, AN; Lonze, BE; Kim, KS; Ginty, DD; Ferrante, RJ; Ryu, H; Ratan, RR				Lee, J; Kim, CH; Simon, DK; Aminova, LR; Andreyev, AY; Kushnareva, YE; Murphy, AN; Lonze, BE; Kim, KS; Ginty, DD; Ferrante, RJ; Ryu, H; Ratan, RR			Mitochondrial cyclic AMP response element-binding protein (CREB) mediates mitochondrial gene expression and neuronal survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUNTINGTONS-DISEASE; DEPENDENT TRANSCRIPTION; 3-NITROPROPIONIC ACID; RNA-SYNTHESIS; P53 PROTEIN; CELL-DEATH; APOPTOSIS; ENERGY; DNA; LOCALIZATION	Cyclic AMP response element-binding protein (CREB) is a widely expressed transcription factor whose role in neuronal protection is now well established. Here we report that CREB is present in the mitochondrial matrix of neurons and that it binds directly to cyclic AMP response elements (CREs) found within the mitochondrial genome. Disruption of CREB activity in the mitochondria decreases the expression of a subset of mitochondrial genes, including the ND5 subunit of complex I, down-regulates complex I-dependent mitochondrial respiration, and increases susceptibility to 3-nitropropionic acid, a mitochondrial toxin that induces a clinical and pathological phenotype similar to Huntington disease. These results demonstrate that regulation of mitochondrial gene expression by mitochondrial CREB, in part, underlies the protective effects of CREB and raise the possibility that decreased mitochondrial CREB activity contributes to the mitochondrial dysfunction and neuronal loss associated with neurodegenerative disorders.	Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; Bedford Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Bedford, MA 01730 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02115 USA; McLean Hosp, Mol Neurobiol Lab, Boston, MA USA; MitoKor, Mitochondrial Biol, San Diego, CA 92121 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Cornell Univ, Weill Coll Med, Dept Neurol, White Plains, NY 10605 USA; Burke Cornell Med Res Inst, White Plains, NY 10605 USA	Boston University; Boston University; Boston University; Geriatric Research Education & Clinical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; McLean Hospital; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Cornell University	Ryu, H (corresponding author), Bedford Vet Affairs Med Ctr, GRECC 18B,200 Springs Rd, Bedford, MA 01730 USA.	hoonryu@bu.edu	; Murphy, Anne N/H-3217-2016	Andreyev, Alexander Y./0000-0002-9246-9943; Lonze, Bonnie/0000-0002-0973-1657; Murphy, Anne N/0000-0002-5222-9902; Ryu, Hoon/0000-0001-6544-3732	NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH048866, R01MH048866] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U01NS045806, R01NS040591, R29NS034943, R01NS052724, R01NS039170, P01NS045242] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG014930, P30AG013846] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG014930-060001, P01 AG014930, P30 AG013846, P30 AG13846] Funding Source: Medline; NIMH NIH HHS [MH48866, R29 MH048866, R01 MH048866] Funding Source: Medline; NINDS NIH HHS [R01 NS052724, NS40591, P01 NS045242, U01 NS045806, R29 NS034943-04, NS39170, R01 NS040591, NS52724-01, NS045806, NS045242] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Bai YD, 2000, MOL CELL BIOL, V20, P805, DOI 10.1128/MCB.20.3.805-815.2000; BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; BEAL MF, 1993, J NEUROSCI, V13, P4181; BENTLAGE HACM, 1995, BBA-BIOMEMBRANES, V1234, P63, DOI 10.1016/0005-2736(94)00288-Z; Bogdanov MB, 1998, J NEUROCHEM, V71, P2642; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Borthwick GM, 1999, ANN NEUROL, V46, P787, DOI 10.1002/1531-8249(199911)46:5<787::AID-ANA17>3.0.CO;2-8; BROUILLET E, 1995, P NATL ACAD SCI USA, V92, P7105, DOI 10.1073/pnas.92.15.7105; Cammarota M, 1999, J NEUROCHEM, V72, P2272, DOI 10.1046/j.1471-4159.1999.0722272.x; Casas F, 1999, MOL CELL BIOL, V19, P7913; CHANDRASEKARAN K, 1994, MOL BRAIN RES, V24, P336, DOI 10.1016/0169-328X(94)90147-3; Enriquez JA, 1999, MOL CELL BIOL, V19, P657; Gines S, 2003, HUM MOL GENET, V12, P497, DOI 10.1093/hmg/ddg046; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; IMPEY S, 2001, SCI STKE, V82, pPE1; Jaworski J, 2003, J NEUROSCI, V23, P4519; Jazayeri M, 2003, J BIOL CHEM, V278, P9823, DOI 10.1074/jbc.M211730200; Kim CH, 2002, J NEUROSCI, V22, P2579, DOI 10.1523/JNEUROSCI.22-07-02579.2002; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; LUDOLPH AC, 1992, ANN NY ACAD SCI, V648, P300, DOI 10.1111/j.1749-6632.1992.tb24562.x; Mantamadiotis T, 2002, NAT GENET, V31, P47, DOI 10.1038/ng882; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Merrick BA, 1996, BBA-PROTEIN STRUCT M, V1297, P57; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Panov AV, 2002, NAT NEUROSCI, V5, P731, DOI 10.1038/nn884; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Ryu H, 2005, P NATL ACAD SCI USA, V102, P13915, DOI 10.1073/pnas.0502878102; Ryu H, 2003, P NATL ACAD SCI USA, V100, P4281, DOI 10.1073/pnas.0737363100; Shimohata T, 2000, NAT GENET, V26, P29, DOI 10.1038/79139; Wissinger B, 1997, BIOCHEM BIOPH RES CO, V234, P511, DOI 10.1006/bbrc.1997.6660; Wyttenbach A, 2001, HUM MOL GENET, V10, P1829, DOI 10.1093/hmg/10.17.1829; Xu FH, 2004, BIOCHEM J, V382, P331, DOI 10.1042/BJ20040469	36	165	167	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40398	40401		10.1074/jbc.C500140200	http://dx.doi.org/10.1074/jbc.C500140200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16207717	hybrid, Green Accepted			2022-12-25	WOS:000233666600003
J	Varfolomeev, E; Maecker, H; Sharp, D; Lawrence, D; Renz, M; Vucic, D; Ashkenazi, A				Varfolomeev, E; Maecker, H; Sharp, D; Lawrence, D; Renz, M; Vucic, D; Ashkenazi, A			Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DEATH-DOMAIN KINASE; TNF RECEPTOR SUPERFAMILY; CELL-DEATH; DECOY RECEPTORS; SIGNALING COMPLEXES; TARGETING DEATH; GENE INDUCTION; PROTEIN-KINASE; IMMUNE-SYSTEM	Apo2 ligand/ tumor necrosis factor (TNF)-related apoptosis-inducing ligand (Apo2L/TRAIL) mainly activates programmed cell death through caspases. By contrast, TNF primarily induces gene transcription through the inhibitor of kappa B kinase (IKK), c-Jun N-terminal kinase (JNK), and p38 mitogen-activated protein kinase pathways. Apo2L/TRAIL also can stimulate these kinases, albeit less strongly; however, the underlying mechanisms of this stimulation and its relation to apoptosis are not well understood. Here we show that Apo2L/ TRAIL activates kinase pathways by promoting the association of a secondary signaling complex, subsequent to assembly of a primary, death- inducing signaling complex (DISC). The secondary complex retained the DISC components FADD and caspase-8, but recruited several factors involved in kinase activation by TNF, namely, RIP1, TRAF2, and NEMO/IKK gamma. Secondary complex formation required Fas-associated death domain (FADD), as well as caspase-8 activity. Apo2L/TRAIL stimulation of JNK and p38 further depended on RIP1 and TRAF2, whereas IKK activation required NEMO. Apo2L/TRAIL induced secretion of interleukin- 8 and monocyte chemoattractant protein-1, augmenting macrophage migration. Thus, Apo2L/TRAIL and TNF organize common molecular determinants in distinct signaling complexes to stimulate similar kinase pathways. One function of kinase stimulation by Apo2L/ TRAIL may be to promote phagocytic engulfment of apoptotic cells.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA	Roche Holding; Genentech	Ashkenazi, A (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way, San Francisco, CA 94080 USA.	aa@gene.com	Ashkenazi, Avi/ABG-2712-2020	Ashkenazi, Avi/0000-0002-6890-4589; Maecker, Heather/0000-0002-5378-1141				Almasan A, 2003, CYTOKINE GROWTH F R, V14, P337, DOI 10.1016/S1359-6101(03)00029-7; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Chaudhary PM, 2000, ONCOGENE, V19, P4451, DOI 10.1038/sj.onc.1203812; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Cowling V, 2002, CELL DEATH DIFFER, V9, P1046, DOI 10.1038/sj.cdd.4401065; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Devin A, 2003, EMBO REP, V4, P623, DOI 10.1038/sj.embor.embor854; Diehl GE, 2004, IMMUNITY, V21, P877, DOI 10.1016/j.immuni.2004.11.008; Greten FR, 2004, CANCER LETT, V206, P193, DOI 10.1016/j.canlet.2003.08.029; Harper N, 2001, J BIOL CHEM, V276, P34743, DOI 10.1074/jbc.M105693200; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hu WH, 1999, J BIOL CHEM, V274, P30603, DOI 10.1074/jbc.274.43.30603; Idriss HT, 2000, MICROSC RES TECHNIQ, V50, P184, DOI 10.1002/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H; Imamura R, 2004, J BIOL CHEM, V279, P46415, DOI 10.1074/jbc.M403226200; Johnston M D, 1981, Methods Enzymol, V78, P394; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kelley SK, 2004, CURR OPIN PHARMACOL, V4, P333, DOI 10.1016/j.coph.2004.02.006; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; Kim IK, 2000, BIOCHEM BIOPH RES CO, V277, P311, DOI 10.1006/bbrc.2000.3673; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kreuz S, 2004, J CELL BIOL, V166, P369, DOI 10.1083/jcb.200401036; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lee TH, 2003, MOL CELL BIOL, V23, P8377, DOI 10.1128/MCB.23.22.8377-8385.2003; Li-Weber M, 2003, SEMIN IMMUNOL, V15, P145, DOI 10.1016/S1044-5323(03)00030-7; Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Maeda S, 2003, IMMUNITY, V19, P725, DOI 10.1016/S1074-7613(03)00301-7; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Ravichandran KS, 2003, CELL, V113, P817, DOI 10.1016/S0092-8674(03)00471-9; Sabapathy K, 2004, MOL CELL, V15, P713, DOI 10.1016/j.molcel.2004.08.028; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Sharp DA, 2005, J BIOL CHEM, V280, P19401, DOI 10.1074/jbc.M413962200; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; Tada K, 2001, J BIOL CHEM, V276, P36530, DOI 10.1074/jbc.M104837200; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Varfolomeev EE, 2004, CELL, V116, P491, DOI 10.1016/S0092-8674(04)00166-7; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200; Wajant H, 2001, ONCOGENE, V20, P4101, DOI 10.1038/sj.onc.1204558; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	57	218	227	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40599	40608		10.1074/jbc.M509560200	http://dx.doi.org/10.1074/jbc.M509560200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16227629	hybrid			2022-12-25	WOS:000233666600028
J	Jang, YP; Matsuda, H; Itagaki, Y; Nakanishi, K; Sparrow, JR				Jang, YP; Matsuda, H; Itagaki, Y; Nakanishi, K; Sparrow, JR			Characterization of peroxy-A2E and furan-A2E photooxidation products and detection in human and mouse retinal pigment epithelial cell lipofuscin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-INDUCED DAMAGE; FUNDUS FLAVIMACULATUS; STARGARDTS-DISEASE; SINGLET OXYGEN; A2E; FLUOROPHORE; RPE; PHENOTYPE; ENDOPEROXIDES; MECHANISMS	The nondegradable pigments that accumulate in retinal pigment epithelial ( RPE) cells as lipofuscin constituents are considered to be responsible for the loss of RPE cells in recessive Stargardt disease, a blindness macular disorder of juvenile onset. This autofluorescent material may also contribute to the etiology of age-related macular degeneration. The best characterized of these fluorophores is A2E, a compound consisting of two retinoid-derived side arms extending from a pyridinium ring. Evidence indicates that photochemical mechanisms initiated by excitation from the blue region of the spectrum may contribute to the adverse effects of A2E accumulation, with the A2E photooxidation products being damaging intermediates. By studying the oxidation products ( oxo-A2E) generated using oxidizing agents that add one or two oxygens at a time, together with structural analysis by heteronuclear single quantum correlation-NMR spectroscopy, we demonstrated that the oxygen-containing moieties generated within photooxidized A2E include a 5,8-monofuranoid and a cyclic 5,8-monoperoxide. We have shown that the oxidation sites can be assigned to the shorter arm of A2E, to the longer arm, or to both arms by analyzing changes in the UV-visible spectrum of A2E, and we have observed a preference for oxidation on the shorter arm. By liquid chromatography-mass spectrometry, we have also detected both monofuran-A2E and monoperoxy-A2E in aged human RPE and in eye cups of Abca4/Abcr(-/-) mice, a model of Stargardt disease. Because the cytotoxicity of endoperoxide moieties is well known, the production of endoperoxide-containing oxo-A2E may account, at least in part, for cellular damage ensuing from A2E photooxidation.	Columbia Univ, Dept Chem, New York, NY 10027 USA; Columbia Univ, Dept Ophthalmol, New York, NY 10032 USA; Columbia Univ, Dept Pathol, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Nakanishi, K (corresponding author), Columbia Univ, Dept Chem, New York, NY 10027 USA.	kn5@columbia.edu; jrs88@columbia.edu	Jang, Young Pyo/AAJ-8782-2020	Jang, Young Pyo/0000-0001-5865-9228	NATIONAL EYE INSTITUTE [R01EY012951] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034509, R37GM034509] Funding Source: NIH RePORTER; NEI NIH HHS [EY 12951] Funding Source: Medline; NIGMS NIH HHS [GM 34509] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Avalle LB, 2004, EXP EYE RES, V78, P895, DOI 10.1016/j.exer.2003.10.023; BALDAS J, 1966, CHEM COMMUN, P852, DOI 10.1039/c19660000852; Ben-Shabat S, 2002, ANGEW CHEM INT EDIT, V41, P814, DOI 10.1002/1521-3773(20020301)41:5<814::AID-ANIE814>3.0.CO;2-2; Ben-Shabat S, 2002, J BIOL CHEM, V277, P7183, DOI 10.1074/jbc.M108981200; Broniec A, 2005, FREE RADICAL BIO MED, V38, P1037, DOI 10.1016/j.freeradbiomed.2004.12.023; Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312; DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P2327; Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855; Dillon J, 2004, EXP EYE RES, V79, P537, DOI 10.1016/j.exer.2004.06.024; EAGLE RC, 1980, OPHTHALMOLOGY, V87, P1189; ELDRED GE, 1993, NATURE, V364, P396; Fishkin N, 2004, CHIRALITY, V16, P637, DOI 10.1002/chir.20084; Fishkin NE, 2005, P NATL ACAD SCI USA, V102, P7091, DOI 10.1073/pnas.0501266102; Gaillard ER, 2004, EXP EYE RES, V79, P313, DOI 10.1016/j.exer.2004.05.005; Jockusch S, 2004, J AM CHEM SOC, V126, P4646, DOI 10.1021/ja039048d; Kim SR, 2004, P NATL ACAD SCI USA, V101, P11668, DOI 10.1073/pnas.0403499101; Lois N, 2004, AM J OPHTHALMOL, V138, P55, DOI 10.1016/j.ajo.2004.02.056; Lois N, 1999, INVEST OPHTH VIS SCI, V40, P2668; LOPEZ PF, 1990, OPHTHALMOLOGY, V97, P798; Maggs JL, 2004, CHEM-BIOL INTERACT, V147, P173, DOI 10.1016/j.cbi.2003.12.005; Oh KT, 2004, RETINA-J RET VIT DIS, V24, P254, DOI 10.1097/00006982-200404000-00011; Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609; Pawlak A, 2003, PHOTOCHEM PHOTOBIOL, V77, P253, DOI 10.1562/0031-8655(2003)077<0253:COTAPO>2.0.CO;2; Radu RA, 2004, P NATL ACAD SCI USA, V101, P5928, DOI 10.1073/pnas.0308302101; RODGERS MAJ, 1982, J AM CHEM SOC, V104, P5541, DOI 10.1021/ja00384a070; Sakai N, 1996, J AM CHEM SOC, V118, P1559, DOI 10.1021/ja953480g; Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303; Sevin F, 2001, J AM CHEM SOC, V123, P4591, DOI 10.1021/ja010138x; Shroyer NF, 1999, VISION RES, V39, P2537, DOI 10.1016/S0042-6989(99)00037-1; Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988; Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007; Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200; Sparrow JR, 2003, INVEST OPHTH VIS SCI, V44, P2245, DOI 10.1167/iovs.02-0746; Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222; Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981; Takada N, 2001, J NAT PROD, V64, P356, DOI 10.1021/np0003490; TURRO NJ, 1981, J AM CHEM SOC, V103, P7218, DOI 10.1021/ja00414a029; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9; Winkler BS, 1999, MOL VIS, V5; Zhou JL, 2005, EXP EYE RES, V80, P567, DOI 10.1016/j.exer.2004.11.009	40	97	104	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					39732	39739		10.1074/jbc.M504933200	http://dx.doi.org/10.1074/jbc.M504933200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16186115	hybrid			2022-12-25	WOS:000233461300010
J	Kim, D; Wu, ZL; Guengerich, FP				Kim, D; Wu, ZL; Guengerich, FP			Analysis of coumarin 7-hydroxylation activity of cytochrome P450 2A6 using random mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERT-BUTYL ETHER; LUNG-CANCER RISK; LABORATORY EVOLUTION; DIRECTED EVOLUTION; ELECTRON-TRANSFER; ESCHERICHIA-COLI; KINETIC-ANALYSIS; AMINO-ACID; P450; METABOLISM	Cytochrome P450 ( P450) 2A6 is an important human enzyme involved in the metabolism of many xenobiotic chemicals including coumarin, indole, nicotine, and carcinogenic nitrosamines. A combination of random mutagenesis and high-throughput screening was used in the analysis of P450 2A6, utilizing a fluorescent coumarin 7-hydroxylation assay. The steady-state kinetic parameters (k(cat) and K-m) for coumarin 7-hydroxylation by wild-type P450 2A6 and 35 selected mutants were measured and indicated that mutants throughout the coding region can have effects on activity. Five mutants showing decreased catalytic efficiency (kcat/Km) were further analyzed for substrate selectivity and binding affinities and showed reduced catalytic activities for 7-methoxycoumarin O-demethylation, tert-butyl methyl ether O-demethylation, and indole 3-hydroxylation. All mutants except one (K476E) showed decreased coumarin binding affinities ( and also higher Km values), indicating that this is a major basis for the decreased enzymatic activities. A recent x-ray crystal structure of P450 2A6 bound to coumarin (Yano, J. K., Hsu, M. H., Griffin, K. J., Stout, C. D., and Johnson, E. F. ( 2005) Nat. Struct. Mol. Biol. 12, 822 - 823) indicates that the recovered A481T and N297S mutations appear to be close to coumarin, suggesting direct perturbation of substrate interaction. The decreased enzymatic activity of the K476E mutant was associated with decreases both in NADPH oxidation and the reduction rate of the ferric P450 2A6-coumarin complex. The attenuation is caused in part to lower binding affinity for NADPH-P450 reductase, but the K476E mutant did not achieve the wild-type coumarin 7-hydroxylation activity even at high reductase concentrations.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Guengerich, FP (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 638 Robinson Res Bldg,23rd & Pierce Ave, Nashville, TN 37232 USA.	f.guengerich@vanderbilt.edu	Wu, Zhong-Liu/D-9017-2017	Wu, Zhong-Liu/0000-0002-0189-5892	NATIONAL CANCER INSTITUTE [R01CA090426] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA90426] Funding Source: Medline; NIEHS NIH HHS [P30 ES00267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ariyoshi N, 2002, CANCER EPIDEM BIOMAR, V11, P890; Arnold F. H., 2003, DIRECTED ENZYME EVOL, V230; BUDAVARI S, 2001, MERCK INDEX, P1078; DALY AK, 1993, PHARMACOL THERAPEUT, V57, P129, DOI 10.1016/0163-7258(93)90053-G; Farinas ET, 2001, CURR OPIN BIOTECH, V12, P545, DOI 10.1016/S0958-1669(01)00261-0; Fujieda M, 2004, CARCINOGENESIS, V25, P2451, DOI 10.1093/carcin/bgh258; Gillam EMJ, 2000, BIOCHEMISTRY-US, V39, P13817, DOI 10.1021/bi001229u; Gillam EMJ, 1999, BIOCHEM BIOPH RES CO, V265, P469, DOI 10.1006/bbrc.1999.1702; GILLAM EMJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P123, DOI 10.1006/abbi.1993.1401; Girvan HM, 2004, J BIOL CHEM, V279, P23274, DOI 10.1074/jbc.M401716200; Glieder A, 2002, NAT BIOTECHNOL, V20, P1135, DOI 10.1038/nbt744; GOTOH O, 1992, J BIOL CHEM, V267, P83; Guengerich F. P., 2001, PRINCIPLES METHODS T, P1625; Guengerich FP, 2001, CHEM RES TOXICOL, V14, P611, DOI 10.1021/tx0002583; Guengerich FP, 2004, J MED CHEM, V47, P3236, DOI 10.1021/jm030561b; Guengerich FP, 2004, BIOCHEMISTRY-US, V43, P10775, DOI 10.1021/bi0491393; Hanna IH, 1998, ARCH BIOCHEM BIOPHYS, V350, P324, DOI 10.1006/abbi.1997.0534; He XY, 2004, ARCH BIOCHEM BIOPHYS, V427, P143, DOI 10.1016/j.abb.2004.03.016; Henne KR, 2001, BIOCHEMISTRY-US, V40, P12925, DOI 10.1021/bi011171z; Hong JY, 1997, ARCH TOXICOL, V71, P266, DOI 10.1007/s002040050386; Hong JY, 1999, TOXICOL APPL PHARM, V160, P43, DOI 10.1006/taap.1999.8750; Joo H, 1999, NATURE, V399, P670, DOI 10.1038/21395; Kim D, 2004, BIOCHEMISTRY-US, V43, P981, DOI 10.1021/bi035593f; Kim D, 2004, ARCH BIOCHEM BIOPHYS, V432, P102, DOI 10.1016/j.abb.2004.09.001; Le Gal A, 2001, TOXICOL LETT, V124, P47, DOI 10.1016/S0378-4274(00)00286-1; Li QS, 2000, CHEM-EUR J, V6, P1531, DOI 10.1002/(SICI)1521-3765(20000502)6:9<1531::AID-CHEM1531>3.3.CO;2-4; Li QS, 2001, BBA-PROTEIN STRUCT M, V1545, P114, DOI 10.1016/S0167-4838(00)00268-5; London SJ, 1999, LANCET, V353, P898, DOI 10.1016/S0140-6736(98)04984-8; MILES JS, 1990, BIOCHEM J, V267, P365, DOI 10.1042/bj2670365; Nakajima M, 1996, DRUG METAB DISPOS, V24, P1212; Nakamura K, 2001, ARCH BIOCHEM BIOPHYS, V395, P25, DOI 10.1006/abbi.2001.2569; NASH T, 1953, BIOCHEM J, V55, P416, DOI 10.1042/bj0550416; Neubauer O, 1907, H-S Z PHYSIOL CHEM, V52, P375, DOI 10.1515/bchm2.1907.52.3-4.375; Ortiz de Montellano P. R., 2005, CYTOCHROME P450 STRU; PALMER G, 1992, J BIOL CHEM, V267, P665; Parikh A, 1998, BIOTECHNIQUES, V24, P428, DOI 10.2144/98243st01; Patten CJ, 1996, ARCH BIOCHEM BIOPHYS, V333, P127, DOI 10.1006/abbi.1996.0373; Pianezza ML, 1998, NATURE, V393, P750, DOI 10.1038/31623; PORTER TD, 1991, J BIOL CHEM, V266, P13469; POULOS TL, 1985, J BIOL CHEM, V260, P6122; RUSSELL GA, 1969, J AM CHEM SOC, V91, P3851, DOI 10.1021/ja01042a028; SCHENKMAN JB, 1967, MOL PHARMACOL, V3, P113; Schmidt-Dannert C, 2001, BIOCHEMISTRY-US, V40, P13125, DOI 10.1021/bi011310c; Schoch GA, 2004, J BIOL CHEM, V279, P9497, DOI 10.1074/jbc.M312516200; Schwaneberg U, 1999, ANAL BIOCHEM, V269, P359, DOI 10.1006/abio.1999.4047; Shimada T, 2005, ARCH BIOCHEM BIOPHYS, V435, P207, DOI 10.1016/j.abb.2004.12.008; Shimanuki T, 1999, J BIOL CHEM, V274, P26956, DOI 10.1074/jbc.274.38.26956; SHIMIZU T, 1991, J BIOL CHEM, V266, P3372; SONO M, 1982, J BIOL CHEM, V257, P8308; SONO M, 1984, J BIOL CHEM, V259, P13209; Soucek P, 1999, ARCH BIOCHEM BIOPHYS, V370, P190, DOI 10.1006/abbi.1999.1388; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; Wu ZL, 2005, J BIOL CHEM, V280, P41090, DOI 10.1074/jbc.M508182200; Wu ZLL, 2005, CHEM BIODIVERS, V2, P51, DOI 10.1002/cbdv.200490166; YAMANO S, 1990, BIOCHEMISTRY-US, V29, P1322, DOI 10.1021/bi00457a031; YAMAZAKI H, 1992, CARCINOGENESIS, V13, P1789, DOI 10.1093/carcin/13.10.1789; Yano JK, 2005, NAT STRUCT MOL BIOL, V12, P822, DOI 10.1038/nsmb971; Yun CH, 2005, J BIOL CHEM, V280, P12279, DOI 10.1074/jbc.M411019200; YUN CH, 1991, MOL PHARMACOL, V40, P679; Yun CH, 2000, BIOCHEMISTRY-US, V39, P11319, DOI 10.1021/bi000869u	60	64	68	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40319	40327		10.1074/jbc.M508171200	http://dx.doi.org/10.1074/jbc.M508171200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16207711	hybrid			2022-12-25	WOS:000233461300074
J	Yin, TF; Getsios, S; Caldelari, R; Godsel, LM; Kowalczyk, AP; Muller, EJ; Green, KJ				Yin, TF; Getsios, S; Caldelari, R; Godsel, LM; Kowalczyk, AP; Muller, EJ; Green, KJ			Mechanisms of plakoglobin-dependent adhesion - Desmosome-specific functions in assembly and regulation by epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-MESENCHYMAL TRANSITIONS; RIGHT-VENTRICULAR CARDIOMYOPATHY; BETA-CATENIN; E-CADHERIN; TYROSINE PHOSPHORYLATION; KERATINOCYTE MOTILITY; ADHERING JUNCTIONS; ADHERENS JUNCTIONS; EMBRYONIC HEART; CELL SCATTERING	Plakoglobin (PG) is a member of the Armadillo family of adhesion/ signaling proteins that can be incorporated into both adherens junctions and desmosomes. Loss of PG results in defects in the mechanical integrity of heart and skin and decreased adhesive strength in keratinocyte cultures established from the skin of PG knock-out ( PG(-/-)) mice, the latter of which cannot be compensated for by overexpressing the closely related beta-catenin. In this study, we examined the mechanisms of PG-regulated adhesion in murine keratinocytes. Biochemical and morphological analyses indicated that junctional incorporation of desmosomal, but not adherens junction, components was impaired in PG(-/-) cells compared with PG(+/-) controls. Re-expression of PG, but not beta-catenin, in PG(-/-) cells largely reversed these effects, indicating a key role for PG in desmosome assembly. Epidermal growth factor (EGF) receptor activation resulted in Tyr phosphorylation of PG, which was accompanied by a loss of desmoplakin from desmosomes and decreased adhesive strength following 18-h EGF treatment. Importantly, introduction of a phosphorylation-deficient PG mutant into PG null cells prevented the EGF receptor-dependent loss of desmoplakin from junctions, attenuating the effects of long term EGF treatment on cell adhesion. Therefore, PG is essential for maintaining and regulating adhesive strength in keratinocytes largely through its contributions to desmosome assembly and structure. As a target for modulation by EGF, regulation of PG-dependent adhesion may play an important role during wound healing and tumor metastasis.	Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL 60611 USA; CELLnTEC Adv Cell Syst AG, CH-3001 Bern, Switzerland; Emory Univ, Sch Med, Dept Dermatol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Cell Biol, Atlanta, GA 30322 USA; Univ Bern, Inst Anim Pathol, CH-3001 Bern, Switzerland	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Emory University; Emory University; University of Bern	Green, KJ (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Pathol, 303 E Chicago Ave, Chicago, IL 60611 USA.	kgreen@northwestern.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043380, R01AR041836, R01AR048266] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012328] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01AR048266, R01AR43380, R01AR41836] Funding Source: Medline; NIDCR NIH HHS [P01 DE12328] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Andl CD, 2001, J INVEST DERMATOL, V117, P1068, DOI 10.1046/j.0022-202x.2001.01528.x; ANGST BD, 1990, J CELL SCI, V97, P247; Bierkamp C, 1999, DEVELOPMENT, V126, P371; Bierkamp C, 1996, DEV BIOL, V180, P780, DOI 10.1006/dbio.1996.0346; Bonne S, 2003, J CELL BIOL, V161, P403, DOI 10.1083/jcb.200303036; Bonvini P, 2001, CANCER RES, V61, P1671; Bornslaeger EA, 2001, J CELL SCI, V114, P727; Boyer B, 1997, EMBO J, V16, P5904, DOI 10.1093/emboj/16.19.5904; Brennan D, 2004, DIFFERENTIATION, V72, P434, DOI 10.1111/j.1432-0436.2004.07208009.x; Caldelari R, 2001, J CELL BIOL, V153, P823, DOI 10.1083/jcb.153.4.823; Cha D, 1996, J INVEST DERMATOL, V106, P590, DOI 10.1111/1523-1747.ep12345083; Chen XY, 2002, J BIOL CHEM, V277, P10512, DOI 10.1074/jbc.M108765200; Chen YT, 1999, J CELL BIOL, V144, P687, DOI 10.1083/jcb.144.4.687; Condeelis J, 2003, NAT REV CANCER, V3, P921, DOI 10.1038/nrc1231; COWIN P, 1986, CELL, V46, P1063, DOI 10.1016/0092-8674(86)90706-3; Fujii K, 1996, EXP CELL RES, V223, P50, DOI 10.1006/excr.1996.0057; Garrod DR, 2002, MOL MEMBR BIOL, V19, P81, DOI 10.1080/09687680210132476; Gaudry CA, 2001, J BIOL CHEM, V276, P24871, DOI 10.1074/jbc.M102731200; Getsios S, 2004, NAT REV MOL CELL BIO, V5, P271, DOI 10.1038/nrm1356; Green KJ, 2000, NAT REV MOL CELL BIO, V1, P208, DOI 10.1038/35043032; Gumbiner BM, 2005, NAT REV MOL CELL BIO, V6, P622, DOI 10.1038/nrm1699; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Huen AC, 2002, J CELL BIOL, V159, P1005, DOI 10.1083/jcb.200206098; Janmaat ML, 2003, DRUG TODAY, V39, P61; Kaplan SR, 2004, HEART RHYTHM, V1, P3, DOI 10.1016/j.hrthm.2004.01.001; Koeser J, 2003, EXP CELL RES, V285, P114, DOI 10.1016/S0014-4827(03)00016-8; Kowalczyk AP, 2004, CURR OPIN CELL BIOL, V16, P522, DOI 10.1016/j.ceb.2004.07.001; Kowalczyk AP, 1997, J CELL BIOL, V139, P773, DOI 10.1083/jcb.139.3.773; Lewis JE, 1997, J CELL BIOL, V136, P919, DOI 10.1083/jcb.136.4.919; Lorch JH, 2004, J BIOL CHEM, V279, P37191, DOI 10.1074/jbc.M405123200; MATTEY DL, 1986, J CELL SCI, V85, P113; McKoy G, 2000, LANCET, V355, P2119, DOI 10.1016/S0140-6736(00)02379-5; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Miravet S, 2003, MOL CELL BIOL, V23, P7391, DOI 10.1128/MCB.23.20.7391-7402.2003; MUELLER H, 1983, J MOL BIOL, V163, P647, DOI 10.1016/0022-2836(83)90116-X; Muller EJ, 2004, J MOL HISTOL, V35, P263; Nagafuchi A, 2001, CURR OPIN CELL BIOL, V13, P600, DOI 10.1016/S0955-0674(00)00257-X; PASDAR M, 1989, J CELL BIOL, V109, P163, DOI 10.1083/jcb.109.1.163; PASDAR M, 1988, J CELL BIOL, V106, P687, DOI 10.1083/jcb.106.3.687; Posthaus H, 2002, J CELL SCI, V115, P4587, DOI 10.1242/jcs.00141; RODIER JM, 1995, J CELL BIOL, V131, P761, DOI 10.1083/jcb.131.3.761; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Ruiz P, 1996, J CELL BIOL, V135, P215, DOI 10.1083/jcb.135.1.215; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; Solanas G, 2004, J BIOL CHEM, V279, P49849, DOI 10.1074/jbc.M408685200; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Troyanovsky RB, 1996, J CELL SCI, V109, P3069; Vasioukhin V, 2001, NAT CELL BIOL, V3, P1076, DOI 10.1038/ncb1201-1076; Xiao KY, 2003, J BIOL CHEM, V278, P19199, DOI 10.1074/jbc.M211746200; Yin TF, 2005, P NATL ACAD SCI USA, V102, P5420, DOI 10.1073/pnas.0501676102	52	78	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40355	40363		10.1074/jbc.M506692200	http://dx.doi.org/10.1074/jbc.M506692200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16183992	hybrid			2022-12-25	WOS:000233461300078
J	Hidvegi, T; Schmidt, BZ; Hale, P; Perlmutter, DH				Hidvegi, T; Schmidt, BZ; Hale, P; Perlmutter, DH			Accumulation of mutant alpha(1)-antitrypsin Z in the endoplasmic reticulum activates caspases-4 and -12, NF kappa B, and BAP31 but not the unfolded protein response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS-INDUCED APOPTOSIS; LIVER-DISEASE; CELL-DEATH; ALPHA-1-ANTITRYPSIN DEFICIENCY; GENE-EXPRESSION; TRANSGENIC MICE; MESSENGER-RNA; RETENTION; DEGRADATION; INVOLVEMENT	In alpha 1-antitrypsin (alpha 1AT) deficiency, a polymerogenic mutant form of the secretory glycoprotein alpha 1AT, alpha 1ATZ, is retained in the endoplasmic reticulum (ER) of liver cells. It is not yet known how this results in liver injury in a subgroup of deficient individuals and how the remainder of deficient individuals escapes liver disease. One possible explanation is that the "susceptible" subgroup is unable to mount the appropriate protective cellular responses. Here we examined the effect of mutant alpha 1ATZ on several potential protective signaling pathways by using cell lines with inducible expression of mutant alpha 1AT as well as liver from transgenic mice with liver-specific inducible expression of mutant alpha 1AT. The results show that ER retention of polymerogenic mutant alpha 1ATZ does not result in an unfolded protein response (UPR). The UPR can be induced in the presence of alpha 1ATZ by tunicamycin excluding the possibility that the pathway has been disabled. In striking contrast, ER retention of nonpolymerogenic alpha 1AT mutants does induce the UPR. These results indicate that the machinery responsible for activation of the UPR can distinguish the physical characteristics of proteins that accumulate in the ER in such a way that it can respond to misfolded but not relatively ordered polymeric structures. Accumulation of mutant alpha 1ATZ does activate specific signaling pathways, including caspase-12 in mouse, caspase-4 in human, NF kappa B, and BAP31, a profile that was distinct from that activated by nonpolymerogenic alpha 1AT mutants.	Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, Dept Pediat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, Dept Cell Biol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, Dept Physiol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Perlmutter, DH (corresponding author), Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, Dept Pediat, 3705 5th Ave, Pittsburgh, PA 15213 USA.	David.Perlmutter@chp.edu	Hidvegi, Tunda/A-8041-2008	Schmidt, Bela Z/0000-0003-1085-9372	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061760, R01DK052526] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL037784] Funding Source: Medline; NIDDK NIH HHS [DK061760, DK052526] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Breckenridge DG, 2003, J CELL BIOL, V160, P1115, DOI 10.1083/jcb.200212059; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; CARLSON JA, 1989, J CLIN INVEST, V83, P1183, DOI 10.1172/JCI113999; GRAHAM KS, 1990, J BIOL CHEM, V265, P20463; Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015; Hu CB, 2002, AM J PHYSIOL-LUNG C, V282, pL757, DOI 10.1152/ajplung.00271.2001; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; Lawless MW, 2004, J IMMUNOL, V172, P5722, DOI 10.4049/jimmunol.172.9.5722; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Lin L, 2001, J BIOL CHEM, V276, P33893, DOI 10.1074/jbc.M105226200; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Obeng EA, 2005, J BIOL CHEM, V280, P29578, DOI 10.1074/jbc.M502685200; Oyadomari S, 2002, J CLIN INVEST, V109, P525, DOI 10.1172/JCI200214550; Pahl HL, 1996, J CELL BIOL, V132, P511, DOI 10.1083/jcb.132.4.511; Perlmutter DH, 2002, J CLIN INVEST, V110, P1579, DOI 10.1172/JCI200216787; PERLMUTTER DH, 1989, J CLIN INVEST, V84, P1555, DOI 10.1172/JCI114332; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Rudnick DA, 2004, HEPATOLOGY, V39, P1048, DOI 10.1002/hep.20118; Rudnick DA, 2005, HEPATOLOGY, V42, P514, DOI 10.1002/hep.20815; Schamel WWA, 2003, P NATL ACAD SCI USA, V100, P9861, DOI 10.1073/pnas.1633363100; Schmidt BZ, 2005, AM J PHYSIOL-GASTR L, V289, pG444, DOI 10.1152/ajpgi.00237.2004; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Southwood CM, 2002, NEURON, V36, P585, DOI 10.1016/S0896-6273(02)01045-0; Takayama S, 2003, ONCOGENE, V22, P9041, DOI 10.1038/sj.onc.1207114; Teckman JH, 2000, AM J PHYSIOL-GASTR L, V279, pG961, DOI 10.1152/ajpgi.2000.279.5.G961; Teckman JH, 2004, AM J PHYSIOL-GASTR L, V286, pG851, DOI 10.1152/ajpgi.00175.2003; Teckman JH, 2002, AM J PHYSIOL-GASTR L, V283, pG1156, DOI 10.1152/ajpgi.00041.2002; Warnakulasuriyarachchi D, 2004, J BIOL CHEM, V279, P17148, DOI 10.1074/jbc.M308737200; WU Y, 1994, P NATL ACAD SCI USA, V91, P9014, DOI 10.1073/pnas.91.19.9014; Xue X, 2005, J BIOL CHEM, V280, P33917, DOI 10.1074/jbc.M505818200; Zhang KZ, 2004, J BIOL CHEM, V279, P25935, DOI 10.1074/jbc.R400008200; Zhang YM, 2001, MOL BIOL CELL, V12, P1303, DOI 10.1091/mbc.12.5.1303; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	36	191	198	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39002	39015		10.1074/jbc.M508652200	http://dx.doi.org/10.1074/jbc.M508652200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16183649	hybrid			2022-12-25	WOS:000233362200014
J	Castelletti, D; Fracasso, G; Alfalah, M; Cingarlini, S; Colombatti, M; Naim, HY				Castelletti, D; Fracasso, G; Alfalah, M; Cingarlini, S; Colombatti, M; Naim, HY			Apical transport and folding of prostate-specific membrane antigen occurs independent of glycan processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTASE-PHLORHIZIN HYDROLASE; INTESTINAL SUCRASE-ISOMALTASE; DIPEPTIDYL PEPTIDASE-IV; POLARIZED EPITHELIAL-CELLS; LINKED ACIDIC DIPEPTIDASE; ENDOPLASMIC-RETICULUM; N-GLYCANS; MONOCLONAL-ANTIBODIES; SORTING SIGNALS; QUALITY-CONTROL	Prostate- specific membrane antigen ( PSMA) is an integral cell-surface membrane glycoprotein that is overexpressed in prostate carcinomas rendering it an appropriate target for antibody- based therapeutic strategies. The biosynthesis of PSMA in transfected COS- 1 cells reveals a slow conversion of mannose- rich to complex glycosylated PSMA compatible with slow transport kinetics from the endoplasmic reticulum to the Golgi. Importantly, mannose- rich PSMA persists as a trypsin- sensitive protein throughout its entire life cycle, and only Golgi- located PSMA glycoforms acquire trypsin resistance. This resistance, used here as a tool to examine correct folding, does not depend on the type of glycosylation, because different PSMA glycoforms generated in the presence of inhibitors of carbohydrate processing in the Golgi are also trypsin resistant. The conformational transition of PSMA to a correctly folded molecule is likely to occur in the Golgi and does not implicate ER molecular chaperones, such as BiP. We show here that PSMA is not only heavily N- but also O- glycosylated. The question arising is whether glycans, which do not play a role in folding of PSMA, are implicated in its transport to the cell surface. Neither the cell- surface expression of PSMA nor its efficient apical sorting in polarized Madin- Darby canine kidney cells are influenced by modulators of N- and O- glycosylation. The acquisition of folding determinants in the Golgi, therefore, is an essential prerequisite for protein trafficking and sorting of PSMA and suggests that altered or aberrant glycosylation often occurring during tumorigenesis	Univ Vet Med Hannover, Dept Physiol Chem, D-30559 Hannover, Germany; Univ Verona, Dept Pathol, I-37100 Verona, Italy	University of Veterinary Medicine Hannover, Foundation; University of Verona	Naim, HY (corresponding author), Univ Vet Med Hannover, Dept Physiol Chem, Bunteweg 17, D-30559 Hannover, Germany.	hassan.naim@tiho-hannover.de	Fracasso, Giulio/E-1271-2013; Al Falah, Dr. Marwan/C-6281-2011; Fracasso, Giulio/O-3955-2019; cingarlini, sara/ABB-5280-2020; Cingarlini, Sara/AAJ-5263-2021	Fracasso, Giulio/0000-0003-3024-0307; Fracasso, Giulio/0000-0003-3024-0307; Cingarlini, Sara/0000-0003-4786-4781				ABEIJON C, 1992, TRENDS BIOCHEM SCI, V17, P32, DOI 10.1016/0968-0004(92)90424-8; Alfalah M, 1999, CURR BIOL, V9, P593, DOI 10.1016/S0960-9822(99)80263-2; Alfalah M, 2002, J BIOL CHEM, V277, P10683, DOI 10.1074/jbc.M109357200; BABAIAN RJ, 1994, J UROLOGY, V152, P1952, DOI 10.1016/S0022-5347(17)32277-2; Barinka C, 2004, PROTEIN SCI, V13, P1627, DOI 10.1110/ps.04622104; Bello V, 2001, MOL BIOL CELL, V12, P3004, DOI 10.1091/mbc.12.10.3004; Brockhausen I, 1999, BBA-GEN SUBJECTS, V1473, P67, DOI 10.1016/S0304-4165(99)00170-1; Chang SS, 1999, CANCER RES, V59, P3192; Christiansen JJ, 2003, PROSTATE, V55, P9, DOI 10.1002/pros.10203; Fracasso G, 2002, PROSTATE, V53, P9, DOI 10.1002/pros.10117; FRANSEN JAM, 1991, J CELL BIOL, V115, P45, DOI 10.1083/jcb.115.1.45; FUHRMANN U, 1984, NATURE, V307, P755, DOI 10.1038/307755a0; Ghosh A, 2003, PROSTATE, V57, P140, DOI 10.1002/pros.10289; Gong MC, 1999, CANCER METAST REV, V18, P483, DOI 10.1023/A:1006308826967; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P10231, DOI 10.1073/pnas.172380699; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; High S, 2000, FEBS LETT, V476, P38, DOI 10.1016/S0014-5793(00)01666-5; Holmes EH, 1996, PROSTATE, P25; HOROSZEWICZ JS, 1987, ANTICANCER RES, V7, P927; Huet G, 2003, BIOCHIMIE, V85, P323, DOI 10.1016/S0300-9084(03)00056-7; ISRAELI RS, 1993, CANCER RES, V53, P227; ISRAELI RS, 1994, CANCER RES, V54, P1807; Ito M, 2002, BIOCHEM J, V361, P473, DOI 10.1042/0264-6021:3610473; Jacob R, 2000, J BIOL CHEM, V275, P6566, DOI 10.1074/jbc.275.9.6566; JACOB R, 1995, J BIOL CHEM, V270, P18678, DOI 10.1074/jbc.270.31.18678; Jacob R, 2000, J BIOL CHEM, V275, P10630, DOI 10.1074/jbc.275.14.10630; Jacob R, 1999, J BIOL CHEM, V274, P8061, DOI 10.1074/jbc.274.12.8061; JANSEN FK, 1982, IMMUNOL REV, V62, P185, DOI 10.1111/j.1600-065X.1982.tb00394.x; KOJIMA N, 1992, BIOCHEM BIOPH RES CO, V182, P1288, DOI 10.1016/0006-291X(92)91872-N; Landers KA, 2005, INT J CANCER, V114, P950, DOI 10.1002/ijc.20760; Lee MCS, 2004, ANNU REV CELL DEV BI, V20, P87, DOI 10.1146/annurev.cellbio.20.010403.105307; Liu H, 1998, CANCER RES, V58, P4055; Luthi-Carter R, 1998, J PHARMACOL EXP THER, V286, P1020; Marchal I, 1999, GLYCOBIOLOGY, V9, P645, DOI 10.1093/glycob/9.7.645; Miranda KC, 2001, J BIOL CHEM, V276, P22565, DOI 10.1074/jbc.M101907200; Moolenaar CEC, 1997, J CELL SCI, V110, P557; Murphy GP, 1998, UROLOGY, V51, P89, DOI 10.1016/S0090-4295(98)00082-X; Muto S, 2001, BBA-GEN SUBJECTS, V1527, P39, DOI 10.1016/S0304-4165(01)00136-2; NAIM HY, 1992, BIOCHEM J, V286, P451, DOI 10.1042/bj2860451; Naim HY, 1999, J BIOL CHEM, V274, P17961, DOI 10.1074/jbc.274.25.17961; NAIM HY, 1987, BIOCHEM J, V241, P427, DOI 10.1042/bj2410427; NAIM HY, 1991, J BIOL CHEM, V266, P12313; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; Ouwendijk J, 1996, J CLIN INVEST, V97, P633, DOI 10.1172/JCI118459; Pang S, 2004, J CELL SCI, V117, P5079, DOI 10.1242/jcs.01386; Pangalos MN, 1999, J BIOL CHEM, V274, P8470, DOI 10.1074/jbc.274.13.8470; Propsting MJ, 2005, J CELL SCI, V118, P2775, DOI 10.1242/jcs.02364; Propsting MJ, 2003, J BIOL CHEM, V278, P16310, DOI 10.1074/jbc.C300093200; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; Schulke N, 2003, P NATL ACAD SCI USA, V100, P12590, DOI 10.1073/pnas.1735443100; Spodsberg N, 2001, J BIOL CHEM, V276, P46597, DOI 10.1074/jbc.M108187200; Stefani M, 2004, BBA-MOL BASIS DIS, V1739, P5, DOI 10.1016/j.bbadis.2004.08.004; Taylor SC, 2003, EMBO REP, V4, P405, DOI 10.1038/sj.embor.embor797; TKACZ JS, 1975, BIOCHEM BIOPH RES CO, V65, P248, DOI 10.1016/S0006-291X(75)80086-6; TROYER JK, 1995, INT J CANCER, V62, P552, DOI 10.1002/ijc.2910620511; Vogel LK, 2002, J BIOL CHEM, V277, P13883, DOI 10.1074/jbc.M107997200; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929	57	9	11	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3505	3512		10.1074/jbc.M509460200	http://dx.doi.org/10.1074/jbc.M509460200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16221666	hybrid			2022-12-25	WOS:000235128200060
J	Sandrin, V; Cosset, FL				Sandrin, V; Cosset, FL			Intracellular versus cell surface assembly of retroviral pseudotypes is determined by the cellular localization of the viral glycoprotein, its capacity to interact with Gag, and the expression of the Nef protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; VESICULAR STOMATITIS-VIRUS; HIV-1 ENVELOPE GLYCOPROTEIN; PLASMA-MEMBRANE; GENE-TRANSFER; LIPID RAFTS; PARTICLES; REPLICATION; VECTORS; SIGNAL	Retroviral Gag and Env glycoproteins (GPs) are expressed from distinct cellular areas and need to encounter to interact and assemble infectious particles. Retroviral particles may also incorporate GPs derived from other enveloped viruses via active or passive mechanisms, a process known as "pseudotyping." To further understand the mechanisms of pseudotyping, we have investigated the capacity of murine leukemia virus (MLV) or lentivirus core particles to recruit GPs derived from different virus families: the G protein of vesicular stomatitis virus (VSV-G), the hemagglutinin from an influenza virus, the E1E2 glycoproteins of hepatitis C virus (HCVE1E2), and the retroviral Env glycoproteins of MLV and RD114 cat endogenous virus. The parameters that influenced the incorporation of viral GPs onto retroviral core particles were (i) the intrinsic cell localization properties of both viral GP and retroviral core proteins, (ii) the ability of the viral GP to interact with the retroviral core, and (iii) the expression of the lentiviral Nef protein. Whereas the hemagglutinin and VSV-G glycoproteins were recruited by MLV and lentivirus core proteins at the cell surface, the HCV and MLV GPs were most likely recruited in late endosomes. In addition, whereas these glycoproteins could be passively incorporated on either retrovirus type, the MLV GP was also actively recruited by MLV core proteins, which, through interactions with the cytoplasmic tail of the latter GP, induced its localization to late endosomal vesicles. Finally, the expression of Nef proteins specifically enhanced the incorporation of the retroviral GPs by increasing their localization in late endosomes.	Ecole Normale Super Lyon, LVRTG, INSERM, U412, F-69364 Lyon 07, France; BioSci Lyon Gerland, IFR128, F-69007 Lyon, France	Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm)	Cosset, FL (corresponding author), Ecole Normale Super Lyon, LVRTG, INSERM, U412, 46 Allee Italie, F-69364 Lyon 07, France.	flcosset@ens-lyon.fr	Cosset, François-Loïc/M-5862-2019	Cosset, François-Loïc/0000-0001-8842-3726				Aiken C, 1997, J VIROL, V71, P5871, DOI 10.1128/JVI.71.8.5871-5877.1997; Alberts P, 2003, BIOL CELL, V95, P419, DOI 10.1016/S0248-4900(03)00074-1; Arora VK, 2002, MICROBES INFECT, V4, P189, DOI 10.1016/S1286-4579(01)01527-1; Bachrach E, 2000, J VIROL, V74, P8480, DOI 10.1128/JVI.74.18.8480-8486.2000; Bartosch B, 2003, J BIOL CHEM, V278, P41624, DOI 10.1074/jbc.M305289200; Bartosch B, 2003, J EXP MED, V197, P633, DOI 10.1084/jem.20021756; Basyuk E, 2003, DEV CELL, V5, P161, DOI 10.1016/S1534-5807(03)00188-6; Berlioz-Torrent C, 1999, J VIROL, V73, P1350, DOI 10.1128/JVI.73.2.1350-1361.1999; Blot G, 2003, J VIROL, V77, P6931, DOI 10.1128/JVI.77.12.6931-6945.2003; Boge M, 1998, J BIOL CHEM, V273, P15773, DOI 10.1074/jbc.273.25.15773; Briggs JAG, 2003, J GEN VIROL, V84, P757, DOI 10.1099/vir.0.18779-0; Brown EL, 2003, J VIROL, V77, P3985, DOI 10.1128/JVI.77.7.3985-3992.2003; Chazal N, 2001, J VIROL, V75, P4014, DOI 10.1128/JVI.75.8.4014-4018.2001; Christodoulopoulos I, 2001, J VIROL, V75, P4129, DOI 10.1128/JVI.75.9.4129-4138.2001; COSSET FL, 1995, J VIROL, V69, P7430, DOI 10.1128/JVI.69.12.7430-7436.1995; Cosson P, 1996, EMBO J, V15, P5783, DOI 10.1002/j.1460-2075.1996.tb00964.x; Costa LJ, 2004, J VIROL, V78, P5311, DOI 10.1128/JVI.78.10.5311-5323.2004; DUBOVI EJ, 1977, J VIROL, V22, P500, DOI 10.1128/JVI.22.2.500-509.1977; Dubuisson J, 2000, CURR TOP MICROBIOL, V242, P135; Dumonceaux J, 2003, J VIROL, V77, P13418, DOI 10.1128/JVI.77.24.13418-13424.2003; Egan MA, 1996, J VIROL, V70, P6547, DOI 10.1128/JVI.70.10.6547-6556.1996; Egger D, 2002, J VIROL, V76, P5974, DOI 10.1128/JVI.76.12.5974-5984.2002; Flint M, 1999, J VIROL, V73, P6235, DOI 10.1128/JVI.73.8.6235-6244.1999; Freed EO, 1998, VIROLOGY, V251, P1, DOI 10.1006/viro.1998.9398; GALLI T, 1994, J CELL BIOL, V125, P1015, DOI 10.1083/jcb.125.5.1015; Garoff H, 1998, MICROBIOL MOL BIOL R, V62, P1171, DOI 10.1128/MMBR.62.4.1171-1190.1998; GELDERBLOM HR, 1989, ARCH VIROL, V106, P1, DOI 10.1007/BF01311033; GELDERBLOM HR, 1991, AIDS, V5, P617, DOI 10.1097/00002030-199106000-00001; Gould SJ, 2003, P NATL ACAD SCI USA, V100, P10592, DOI 10.1073/pnas.1831413100; Greive SJ, 2002, J VIRAL HEPATITIS, V9, P9, DOI 10.1046/j.1365-2893.2002.00313.x; Hammarstedt M, 2004, J VIROL, V78, P5686, DOI 10.1128/JVI.78.11.5686-5697.2004; Keck ZY, 2004, J VIROL, V78, P9224, DOI 10.1128/JVI.78.17.9224-9232.2004; Lindemann D, 1997, J VIROL, V71, P4815, DOI 10.1128/JVI.71.6.4815-4820.1997; Lindwasser OW, 2004, J VIROL, V78, P6013, DOI 10.1128/JVI.78.11.6013-6023.2004; Lodge R, 1997, J VIROL, V71, P5696, DOI 10.1128/JVI.71.7.5696-5702.1997; LODGE R, 1994, J VIROL, V68, P4857, DOI 10.1128/JVI.68.8.4857-4861.1994; LYLES DS, 1992, J VIROL, V66, P349, DOI 10.1128/JVI.66.1.349-358.1992; Madrid R, 2005, J BIOL CHEM, V280, P5032, DOI 10.1074/jbc.M401202200; Mammano F, 1997, J VIROL, V71, P3341, DOI 10.1128/JVI.71.4.3341-3345.1997; Mangeot PE, 2000, J VIROL, V74, P8307, DOI 10.1128/JVI.74.18.8307-8315.2000; Murakami T, 2000, J VIROL, V74, P3548, DOI 10.1128/JVI.74.8.3548-3554.2000; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; Negre D, 2000, GENE THER, V7, P1613, DOI 10.1038/sj.gt.3301292; Nguyen DG, 2003, J BIOL CHEM, V278, P52347, DOI 10.1074/jbc.M309009200; Nguyen DH, 2000, J VIROL, V74, P3264, DOI 10.1128/JVI.74.7.3264-3272.2000; Nishimura N, 1999, J BIOL CHEM, V274, P15937, DOI 10.1074/jbc.274.22.15937; Nydegger S, 2003, TRAFFIC, V4, P902, DOI 10.1046/j.1600-0854.2003.00145.x; Ohno H, 1997, VIROLOGY, V238, P305, DOI 10.1006/viro.1997.8839; Ono A, 2004, P NATL ACAD SCI USA, V101, P14889, DOI 10.1073/pnas.0405596101; Ono A, 2004, J VIROL, V78, P1552, DOI 10.1128/JVI.78.3.1552-1563.2004; Ono A, 2001, P NATL ACAD SCI USA, V98, P13925, DOI 10.1073/pnas.241320298; ORENSTEIN JM, 1988, J VIROL, V62, P2578, DOI 10.1128/JVI.62.8.2578-2586.1988; OTT D, 1990, J VIROL, V64, P757, DOI 10.1128/JVI.64.2.757-766.1990; Pelchen-Matthews A, 2003, J CELL BIOL, V162, P443, DOI 10.1083/jcb.200304008; Pickl WF, 2001, J VIROL, V75, P7175, DOI 10.1128/JVI.75.15.7175-7183.2001; Piguet V, 1999, IMMUNOL REV, V168, P51, DOI 10.1111/j.1600-065X.1999.tb01282.x; Raposo G, 2002, TRAFFIC, V3, P718, DOI 10.1034/j.1600-0854.2002.31004.x; Resh MD, 2004, SUB CELL BIOCHEM, V37, P217; Sandrin V, 2004, J VIROL, V78, P7153, DOI 10.1128/JVI.78.13.7153-7164.2004; Sandrin V, 2002, BLOOD, V100, P823, DOI 10.1182/blood-2001-11-0042; SANDRIN V, 2003, CURR TOP MICROBIOL I, V100, P137; Sherer NM, 2003, TRAFFIC, V4, P785, DOI 10.1034/j.1600-0854.2003.00135.x; Shimizu YK, 1996, HEPATOLOGY, V23, P205; Sidorenko Y, 2004, BIOTECHNOL BIOENG, V88, P1, DOI 10.1002/bit.20096; SMITH MJ, 1989, EMBO J, V8, P3581, DOI 10.1002/j.1460-2075.1989.tb08530.x; Stumptner-Cuvelette P, 2003, MOL BIOL CELL, V14, P4857, DOI 10.1091/mbc.E03-04-0211; Swanstrom R., 1997, P263; TAKEUCHI Y, 1992, VIROLOGY, V186, P792, DOI 10.1016/0042-6822(92)90049-U; Vincent MJ, 1999, J VIROL, V73, P8138, DOI 10.1128/JVI.73.10.8138-8144.1999; Weclewicz K, 1998, J VIROL, V72, P2832, DOI 10.1128/JVI.72.4.2832-2845.1998; Wyma DJ, 2000, J VIROL, V74, P9381, DOI 10.1128/JVI.74.20.9381-9387.2000; Wyss S, 2001, J VIROL, V75, P2982, DOI 10.1128/JVI.75.6.2982-2992.2001; YEE JK, 1994, METHOD CELL BIOL, V43, P99; Zhang J, 2000, J VIROL, V74, P4634, DOI 10.1128/JVI.74.10.4634-4644.2000; Zheng YH, 2003, P NATL ACAD SCI USA, V100, P8460, DOI 10.1073/pnas.1437453100	75	51	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					528	542		10.1074/jbc.M506070200	http://dx.doi.org/10.1074/jbc.M506070200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16195228	hybrid			2022-12-25	WOS:000234307200065
J	Cruz-Munoz, W; Kim, I; Khokha, R				Cruz-Munoz, W; Kim, I; Khokha, R			TIMP-3 deficiency in the host, but not in the tumor, enhances tumor growth and angiogenesis	ONCOGENE			English	Article						TIMP-3; host stroma; B16F10; teratoma; angiogenesis	TISSUE INHIBITOR; MATRIX METALLOPROTEINASES; CELL-DEATH; GENE; EXPRESSION; SUPPRESSION; CANCER; COMBINATION; MEMBRANE; PROMOTER	Tumor cells, stromal cell compartment and the extracellular matrix (ECM) together generate a multifaceted tumor microenvironment. Matrix metalloproteinases and their tissue inhibitors (TIMPs) provide a means for tumor-stromal interaction during tumorigenesis. Among TIMPs, TIMP-3 is uniquely localized to the ECM and is frequently silenced in human cancers. Here, we asked whether the absence of TIMP-3 in the tumor cell or the host affects the process of tumorigenesis. Timp-3(-/-) ES-cell clones were generated and used to develop teratomas in nude mice. Timp-3(-/-) teratomas showed similar tumor take, growth, and angiogenesis compared to timp-3(-/-) teratomas. To study the effect of TIMP-3 ablation in the host stroma, we measured the growth kinetics of subcutaneous B16F10 melanomas in timp-3(-/-) and wildtype littermates. Tumors grew significantly faster in timp3(-/-) than in wild-type mice and their CD31 content was significantly higher indicating increased angiogenesis. Augmented angiogenesis in timp-3(-/-) mice was directly tested using Matrigel plug and Gelfoam assays. In response to FGF-2, timp-3(-/-) endothelial cells invaded more efficiently, leading to enhanced formation of functional blood vessels. Thus, TIMP-3 deficiency in the host, but not in the tumor per se, leads to enhanced tumor growth and angiogenesis. TIMP-3 located within the tumor microenvironment inhibits tumorigenesis.	Dept Lab Med & Pathobiol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Ontario Canc Inst, Dept Med Biophys, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto	Khokha, R (corresponding author), Dept Lab Med & Pathobiol, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	rkhokha@uhnres.utoronto.ca						AnandApte B, 1997, INVEST OPHTH VIS SCI, V38, P817; AnandApte B, 1996, BIOCHEM CELL BIOL, V74, P853, DOI 10.1139/o96-090; Andreu T, 1998, J BIOL CHEM, V273, P13848, DOI 10.1074/jbc.273.22.13848; Bachman KE, 1999, CANCER RES, V59, P798; Bian JH, 1996, CARCINOGENESIS, V17, P1805, DOI 10.1093/carcin/17.9.1805; BOOKS PC, 1996, CELL, V85, P683; Boulay A, 2001, CANCER RES, V61, P2189; Chan VT, 1998, J INVEST DERMATOL, V111, P1153, DOI 10.1046/j.1523-1747.1998.00416.x; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; DeClerck YA, 2000, EUR J CANCER, V36, P1258, DOI 10.1016/S0959-8049(00)00094-0; Dulaimi E, 2004, CLIN CANCER RES, V10, P3972, DOI 10.1158/1078-0432.CCR-04-0175; Fata JE, 2001, J CLIN INVEST, V108, P831, DOI 10.1172/JCI13171; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Itoh T, 1998, CANCER RES, V58, P1048; Kassiri Z, 2005, CIRC RES, V97, P380, DOI 10.1161/01.RES.0000178789.16929.cf; Kato T, 2001, FEBS LETT, V508, P187, DOI 10.1016/S0014-5793(01)02897-6; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; Kruger A, 1997, BLOOD, V90, P1993, DOI 10.1182/blood.V90.5.1993; Leco KJ, 2001, J CLIN INVEST, V108, P817, DOI 10.1172/JCI12067; Leighl NB, 2005, J CLIN ONCOL, V23, P2831, DOI 10.1200/JCO.2005.04.044; Loging WT, 1999, ONCOGENE, V18, P7608, DOI 10.1038/sj.onc.1203135; Lynch CC, 2002, DIFFERENTIATION, V70, P561, DOI 10.1046/j.1432-0436.2002.700909.x; Martin DC, 1996, ONCOGENE, V13, P569; Masson V, 2004, FASEB J, V18, P234, DOI 10.1096/fj.04-2140fje; McCarty MF, 2002, INT J ONCOL, V21, P5; Michael M, 1999, J CLIN ONCOL, V17, P1802, DOI 10.1200/JCO.1999.17.6.1802; Mori M, 2000, INT J CANCER, V88, P575, DOI 10.1002/1097-0215(20001115)88:4<575::AID-IJC9>3.0.CO;2-C; Murphy G, 2003, BIOCHEM SOC SYMP, V70, P65, DOI 10.1042/bss0700065; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PASSANITI A, 1992, LAB INVEST, V67, P519; Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846; Remacle A, 2000, INT J CANCER, V89, P118, DOI 10.1002/(SICI)1097-0215(20000320)89:2<118::AID-IJC3>3.0.CO;2-8; Sang Q X, 1998, Cell Res, V8, P171; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sogawa K, 2003, CANCER, V98, P1822, DOI 10.1002/cncr.11725; Soloway PD, 1996, ONCOGENE, V13, P2307; Spurbeck WW, 2003, CANCER GENE THER, V10, P161, DOI 10.1038/sj.cgt.7700577; Spurbeck WW, 2002, BLOOD, V100, P3361, DOI 10.1182/blood.V100.9.3361; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; SUN Y, 1995, J BIOL CHEM, V270, P19312, DOI 10.1074/jbc.270.33.19312; Sun Y, 1996, ANTICANCER RES, V16, P1; Thurston G, 1996, AM J PHYSIOL-HEART C, V271, pH2547, DOI 10.1152/ajpheart.1996.271.6.H2547; Wild A, 2003, J CLIN ENDOCR METAB, V88, P1367, DOI 10.1210/jc.2002-021027; Yu WH, 2000, J BIOL CHEM, V275, P31226, DOI 10.1074/jbc.M000907200	44	41	45	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					650	655		10.1038/sj.onc.1209104	http://dx.doi.org/10.1038/sj.onc.1209104			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16186800				2022-12-25	WOS:000234897400016
J	Fischer, U; Stroh, C; Schulze-Osthoff, K				Fischer, U; Stroh, C; Schulze-Osthoff, K			Unique and overlapping substrate specificities of caspase-8 and caspase-10	ONCOGENE			English	Article						apoptosis; caspase-10; caspase-8; Bid; RIP	FACTOR-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; DEATH DOMAIN PROTEIN; SIGNALING COMPLEXES; MEDIATED APOPTOSIS; ACTIVATION; CLEAVAGE; RECEPTORS; LYMPHOCYTE; RIP	Although caspase-8 has an established role as an initiator of death receptor-mediated apoptosis, the function of its closest homolog, caspase-10, is almost completely unknown. To gain a closer insight into the physiological function of caspase-10, we compared the cleavage of known caspase-8 substrates by both initiator caspases. We demonstrate that caspase-10 and -8 have overlapping cleavage preferences for several substrates such as the kinases RIP and PAK2. Interestingly, in other substrates, such as the Bcl-2 protein Bid, we found additional and distinct cleavage sites for both caspases, which might have important consequences for mitochondrial targeting and propagation of the death signal. Caspase-8 and -10 also caused different interchain cleavage patterns of their enzyme precursors. Together, these results suggest that caspase-8 and -10, despite having overlapping functions, also have selective substrate cleavage specificities and might thereby exert nonredundant roles in apoptosis signaling.	Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Fischer, U (corresponding author), Univ Dusseldorf, Inst Mol Med, Bldg 23-12,Univ Str 1, D-40225 Dusseldorf, Germany.	ute.fischer@uni-duesseldorf.de	Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720				Barry M, 2000, MOL CELL BIOL, V20, P3781, DOI 10.1128/MCB.20.11.3781-3794.2000; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Cartron PF, 2003, MOL CELL BIOL, V23, P4701, DOI 10.1128/MCB.23.13.4701-4712.2003; Chang DW, 2003, EMBO J, V22, P4132, DOI 10.1093/emboj/cdg414; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; DEGLIESPOSTI M, 2003, J BIOL CHEM, V278, P15479; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Donepudi M, 2003, MOL CELL, V11, P543, DOI 10.1016/S1097-2765(03)00059-5; Engels IH, 2005, MOL CELL BIOL, V25, P2808, DOI 10.1128/MCB.25.7.2808-2818.2005; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Grimm S, 1996, P NATL ACAD SCI USA, V93, P10923, DOI 10.1073/pnas.93.20.10923; Harper N, 2003, J BIOL CHEM, V278, P25534, DOI 10.1074/jbc.M303399200; Jakobi R, 2003, J BIOL CHEM, V278, P38675, DOI 10.1074/jbc.M306494200; Jakobi R, 2001, J BIOL CHEM, V276, P16624, DOI 10.1074/jbc.M007753200; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Koeplinger KA, 2000, PROTEIN EXPRES PURIF, V18, P378, DOI 10.1006/prep.2000.1205; Kruidering M, 2001, J BIOL CHEM, V276, P38417, DOI 10.1074/jbc.M103471200; Lauber K, 2001, J BIOL CHEM, V276, P29772, DOI 10.1074/jbc.M101524200; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Martinon F, 2000, FEBS LETT, V468, P134, DOI 10.1016/S0014-5793(00)01212-6; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Milhas D, 2005, J BIOL CHEM, V280, P19836, DOI 10.1074/jbc.M414358200; Murphy BM, 2004, J BIOL CHEM, V279, P36916, DOI 10.1074/jbc.M402039200; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Nguyen M, 2000, MOL CELL BIOL, V20, P6731, DOI 10.1128/MCB.20.18.6731-6740.2000; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Schwerk C, 2003, BIOCHEM PHARMACOL, V66, P1453, DOI 10.1016/S0006-2952(03)00497-0; Sohn D, 2005, J BIOL CHEM, V280, P5267, DOI 10.1074/jbc.M408585200; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Wang GQ, 2001, J EXP MED, V194, P1325, DOI 10.1084/jem.194.9.1325; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761	45	73	77	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					152	159		10.1038/sj.onc.1209015	http://dx.doi.org/10.1038/sj.onc.1209015			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16186808				2022-12-25	WOS:000234406400017
J	Isachenko, N; Dyakova, N; Aushev, V; Chepurnych, T; Gurova, K; Tatosyan, A				Isachenko, N; Dyakova, N; Aushev, V; Chepurnych, T; Gurova, K; Tatosyan, A			High expression of shMDG1 gene is associated with low metastatic potential of tumor cells	ONCOGENE			English	Article						shMDG1; metastasis; v-src transformation; chaperones; glycosylation	ROUS-SARCOMA VIRUS; IN-VITRO; CHROMOSOME; CANCER; OLIGOSACCHARIDES; DIFFERENTIATION; IDENTIFICATION; GLYCOPEPTIDES; STRESS; MDG1	Metastasis is the primary cause of mortality associated with cancer. Molecular mechanisms leading to metastatic spread are poorly studied. To get a better understanding of this process, we compared the gene expression pattern of two isogenic cell lines, HET-SR and HET-SR1 (Rous Sarcoma Virus-transformed embryo hamster fibroblasts) with different metastatic activity using the differential display technique. A novel cDNA of hamster gene shMDG1 (Syrian hamster homologue of microvascular differentiation gene 1), which had 94% homology with rat MDG1 gene, was identified. Expression of shMDG1 was increased in low metastatic HET-SR cell line in comparison to high metastatic HET-SR1. Sequence analysis of the ORF of shMDG1 gene showed that it belongs to the DnaJ/heat-shock proteins of 40 kDa (HSP40) chaperones family, considered to function as a cochaperone of HSP70 family. In order to confirm involvement of shMDG1 in metastasis, we injected parental and shMDG1 overexpressed cells into animals. We showed that overexpression of the shMDG1 gene significantly diminished the metastatic activity of both HET-SR and HET-SR1 cells. The shMDG1-induced repression of metastasis was not connected with alterations in cell proliferation and motility in vitro, but correlated well with a decrease in content of the Asn-linked beta 1-6 branched oligosaccharides on cell surface.	Canc Res Ctr, Inst Carcinogenesis, Viral & Cellular Oncogenes Lab, Moscow 115478, Russia; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Genet, Cleveland, OH USA	Cleveland Clinic Foundation	Isachenko, N (corresponding author), Canc Res Ctr, Inst Carcinogenesis, Viral & Cellular Oncogenes Lab, Kashirskoye Sh 24, Moscow 115478, Russia.	isachenko@crc.umos.ru	Aushev, Vasily N./A-7209-2008	Aushev, Vasily N./0000-0001-8003-358X				Blomer U, 1997, J VIROL, V71, P6641; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; CHEPURNYKH TV, 2000, CELL MOL BIOL, V34, P907; DEICHMAN GI, 1989, INT J CANCER, V44, P908, DOI 10.1002/ijc.2910440527; DEMETRIOU M, 1995, J CELL BIOL, V130, P383, DOI 10.1083/jcb.130.2.383; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; Dichamp C, 2004, J NEURO-ONCOL, V67, P281, DOI 10.1023/B:NEON.0000024218.68120.8d; GU JG, 1993, J BIOCHEM, V113, P614, DOI 10.1093/oxfordjournals.jbchem.a124091; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MORIMOTO RI, 1991, CANCER CELL-MON REV, V3, P295; NICOLSON G L, 1991, Current Opinion in Oncology, V3, P75, DOI 10.1097/00001622-199102000-00012; Ohtsuka K, 2000, INT J HYPERTHER, V16, P231, DOI 10.1080/026567300285259; OSAWA T, 1987, ANNU REV BIOCHEM, V56, P21, DOI 10.1146/annurev.biochem.56.1.21; PIERCE M, 1986, J BIOL CHEM, V261, P772; Prols F, 2001, EXP CELL RES, V269, P42, DOI 10.1006/excr.2001.5294; Prols F, 1997, CYTOGENET CELL GENET, V79, P149, DOI 10.1159/000134706; Shen Y, 2002, J BIOL CHEM, V277, P15947, DOI 10.1074/jbc.M112214200; Tatosyan A, 1996, VIROLOGY, V216, P347, DOI 10.1006/viro.1996.0070; Thorstensen L, 2001, SCAND J GASTROENTERO, V36, P1327; Welch WJ, 1990, STRESS PROTEINS BIOL, P223; YOCHEM J, 1978, MOL GEN GENET, V4, P9	22	5	5	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2006	25	2					317	322		10.1038/sj.onc.1209022	http://dx.doi.org/10.1038/sj.onc.1209022			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16205647				2022-12-25	WOS:000234583600017
J	Banerjee, Y; Mizuguchi, J; Iwanaga, S; Kini, RM				Banerjee, Y; Mizuguchi, J; Iwanaga, S; Kini, RM			Hemextin AB complex, a unique anticoagulant protein complex from Hemachatus haemachatus (African Ringhals cobra) venom that inhibits clot initiation and factor VIIa activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE FACTOR PATHWAY; PEPTIDE EXOSITE INHIBITORS; PSEUDONAJA-TEXTILIS VENOM; BLOOD-COAGULATION FACTOR; FACTOR-XA; PROTHROMBIN ACTIVATOR; SNAKE-VENOM; PSEUTARIN-C; STRUCTURAL SIMILARITY; NAFAMOSTAT MESILATE	During injury or trauma, blood coagulation is initiated by the interaction of factor VIIa (FVIIa) in the blood with freshly exposed tissue factor (TF) to form the TF center dot FVIIa complex. However, unwanted clot formation can lead to death and debilitation due to vascular occlusion, and hence, anticoagulants are important for the treatment of thromboembolic disorders. Here, we report the isolation and characterization of two synergistically acting anticoagulant proteins, hemextins A and B, from the venom of Hemachatus haemachatus (African Ringhals cobra). N-terminal sequences and CD spectra of the native proteins indicate that these proteins belong to the three-finger toxin family. Hemextin A (but not hemextin B) exhibits mild anticoagulant activity. However, hemextin B forms a complex (hemextin AB complex) with hemextin A and synergistically enhances its anticoagulant potency. Prothrombin time assay showed that these two proteins form a 1: 1 complex. Complex formation was supported by size-exclusion chromatography. Using a "dissection approach," we determined that hemextin A and the hemextin AB complex prolong clotting by inhibiting TF center dot FVIIa activity. The site of anticoagulant effects was supported by their inhibitory effect on the reconstituted TF center dot FVIIa complex. Furthermore, we demonstrated their specificity of inhibition by studying their effects on 12 serine proteases; the hemextin AB complex potently inhibited the amidolytic activity of FVIIa in the presence and absence of soluble TF. Kinetic studies showed that the hemextin AB complex is a noncompetitive inhibitor of soluble TF center dot FVIIa amidolytic activity, with a K-i of 50 nM. Isothermal titration calorimetric studies showed that the hemextin AB complex binds directly to FVIIa with a binding constant of 1.62 X 105 M-1. The hemextin AB complex is the first reported natural inhibitor of FVIIa that does not require a scaffold to mediate its inhibitory activity. Molecular interactions of the hemextin AB complex with FVIIa/TF center dot FVIIa will provide a new paradigm in the search for anticoagulants that inhibit the initiation of blood coagulation.	Natl Univ Singapore, Prot Sci Lab, Dept Biol Sci, Fac Sci, Singapore 117543, Singapore; Chemo Sero Therapeut Res Inst, Blood Prod Res Dept, Kumamoto 8691298, Japan; Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem, Med Ctr, Richmond, VA 23298 USA	National University of Singapore; Virginia Commonwealth University	Kini, RM (corresponding author), Natl Univ Singapore, Prot Sci Lab, Dept Biol Sci, Fac Sci, Singapore 117543, Singapore.	dbskinim@nus.edu.sg	Kini, Manjunatha/H-8029-2012; Banerjee, Yajnavalka/J-5890-2019	Banerjee, Yajnavalka/0000-0002-7546-8893; Kini, Manjunatha/0000-0002-6100-3251				Barry J, 1976, Curr Top Mol Endocrinol, V3, P451; Baugh RJ, 1998, J BIOL CHEM, V273, P4378, DOI 10.1074/jbc.273.8.4378; BROZE GJ, 1987, BLOOD, V69, P150; Buckman BO, 2005, BIOORG MED CHEM LETT, V15, P2249, DOI 10.1016/j.bmcl.2005.03.019; Chen CP, 2001, J BIOL CHEM, V276, P45079, DOI 10.1074/jbc.M106182200; CONDREA E, 1981, TOXICON, V19, P61, DOI 10.1016/0041-0101(81)90118-5; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DAVIE EW, 1995, THROMB HAEMOSTASIS, V74, P1; Debarbieux L, 1999, CELL, V99, P117, DOI 10.1016/S0092-8674(00)81642-6; Dennis MS, 2000, NATURE, V404, P465, DOI 10.1038/35006574; Dennis MS, 2001, BIOCHEMISTRY-US, V40, P9513, DOI 10.1021/bi010591l; Doorty KB, 1997, J BIOL CHEM, V272, P19925, DOI 10.1074/jbc.272.32.19925; Goolsby Mary Jo, 2002, J Am Acad Nurse Pract, V14, P16, DOI 10.1111/j.1745-7599.2002.tb00065.x; Gustafsson D, 2004, NAT REV DRUG DISCOV, V3, P649, DOI 10.1038/nrd1466; HABERMANN E, 1978, Toxicon, V16, P19, DOI 10.1016/0041-0101(78)90056-9; Higuchi S, 1999, IMMUNOPHARMACOLOGY, V44, P129, DOI 10.1016/S0162-3109(99)00119-8; Hirsh J, 2005, BLOOD, V105, P453, DOI 10.1182/blood-2003-12-4195; HIRSH J, 1991, NEW ENGL J MED, V324, P1565; Hirsh J, 1999, LANCET, V353, P1431, DOI 10.1016/S0140-6736(98)09233-2; HIRSH J, 1991, NEW ENGL J MED, V324, P1865; Hirsh J, 2001, AM HEART J, V142, pS3, DOI 10.1067/mhj.2001.117031; HOKAMA Y, 1976, J BIOCHEM, V79, P559, DOI 10.1093/oxfordjournals.jbchem.a131100; HOUGIE C, 1956, P SOC EXP BIOL MED, V93, P570; Huang Fengyang, 2004, Current Medicinal Chemistry - Cardiovascular & Hematological Agents, V2, P187, DOI 10.2174/1568016043356309; JIM RTS, 1957, J LAB CLIN MED, V50, P45; Johnson K, 1998, CORONARY ARTERY DIS, V9, P83, DOI 10.1097/00019501-199809020-00004; Joseph JS, 1999, BLOOD, V94, P621, DOI 10.1182/blood.V94.2.621.414k25_621_631; Kaetsu H, 1998, THROMB RES, V90, P101, DOI 10.1016/S0049-3848(98)00026-7; Kato H, 2002, ARTERIOSCL THROM VAS, V22, P539, DOI 10.1161/01.ATV.0000013904.40673.CC; Kerns RT, 1999, ARCH BIOCHEM BIOPHYS, V369, P107, DOI 10.1006/abbi.1999.1345; Kini RM, 2005, J THROMB HAEMOST, V3, P170, DOI 10.1111/j.1538-7836.2004.01056.x; Kini RM, 2002, CLIN EXP PHARMACOL P, V29, P815, DOI 10.1046/j.1440-1681.2002.03725.x; Kini RM, 1995, TOXICON, V33, P1585, DOI 10.1016/0041-0101(95)00103-4; Kondo K, 2002, CLIN PHARMACOKINET, V41, P187, DOI 10.2165/00003088-200241030-00003; LANGDELL RD, 1953, J LAB CLIN MED, V41, P637; Lazarus RA, 2004, CURR MED CHEM, V11, P2275, DOI 10.2174/0929867043364568; Lee AYY, 2003, J INTERN MED, V254, P313, DOI 10.1046/j.1365-2796.2003.01224.x; LINDHOUT T, 1995, THROMB HAEMOSTASIS, V74, P910; Mann KG, 2003, ARTERIOSCL THROM VAS, V23, P17, DOI 10.1161/01.ATV.0000046238.23903.FC; Marcinkiewicz C, 2005, CURR PHARM DESIGN, V11, P815, DOI 10.2174/1381612053381765; Maun HR, 2005, PROTEIN SCI, V14, P1171, DOI 10.1110/ps.041097505; Maun HR, 2003, J BIOL CHEM, V278, P21823, DOI 10.1074/jbc.M300951200; McClellan KJ, 1998, DRUGS, V56, P1067, DOI 10.2165/00003495-199856060-00017; Moll S, 2002, SEMIN HEMATOL, V39, P145, DOI 10.1053/shem.2002.34087; MORRISSEY JH, 1993, BLOOD, V81, P734; Morrissey JH, 2001, THROMB HAEMOSTASIS, V86, P66; NAKAGAKI T, 1991, BIOCHEMISTRY-US, V30, P10819, DOI 10.1021/bi00109a001; NEMERSON Y, 1988, BLOOD, V71, P1; O'Shea J Conor, 2002, Expert Opin Pharmacother, V3, P1199; OKAJIMA K, 1990, THROMB HAEMOSTASIS, V63, P48; Olivero AG, 2005, J BIOL CHEM, V280, P9160, DOI 10.1074/jbc.M409068200; Plosker GL, 2003, PHARMACOECONOMICS, V21, P885, DOI 10.2165/00019053-200321120-00005; POSSANI LD, 1992, TOXICON, V30, P1343, DOI 10.1016/0041-0101(92)90511-3; Quick AJ, 1935, J BIOL CHEM, V110, P107; Rao VS, 2003, BLOOD, V102, P1347, DOI 10.1182/blood-2002-12-3839; Rao VS, 2004, THROMB HAEMOSTASIS, V92, P509, DOI 10.1160/TH04-03-0144; Rao VS, 2002, THROMB HAEMOSTASIS, V88, P611, DOI 10.1055/s-0037-1613264; RAPAPORT SI, 1995, THROMB HAEMOSTASIS, V74, P7; Roberge M, 2002, BIOCHEM J, V363, P387, DOI 10.1042/0264-6021:3630387; Roberge M, 2001, BIOCHEMISTRY-US, V40, P9522, DOI 10.1021/bi010592d; SANDERS NL, 1985, BLOOD, V66, P204; Sherman David G, 2002, Curr Med Res Opin, V18 Suppl 2, ps48; Sorensen BB, 1997, J BIOL CHEM, V272, P11863, DOI 10.1074/jbc.272.18.11863; STEFANSSON S, 1990, BIOCHEMISTRY-US, V29, P7742, DOI 10.1021/bi00485a024; STEFANSSON S, 1989, THROMB RES, V55, P481, DOI 10.1016/0049-3848(89)90056-X; STONE MJ, 1995, BIOCHEM J, V310, P605, DOI 10.1042/bj3100605; SU MJ, 1983, TOXICON, V21, P143, DOI 10.1016/0041-0101(83)90057-0; UCHIBA M, 1995, THROMB RES, V77, P381, DOI 10.1016/0049-3848(95)93843-O; UCHIBA M, 1994, THROMB RES, V74, P155, DOI 10.1016/0049-3848(94)90008-6; Wang RH, 1999, BIOCHEMISTRY-US, V38, P7584, DOI 10.1021/bi982132z; WILDGOOSE P, 1989, BLOOD, V73, P1888	71	56	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42601	42611		10.1074/jbc.M508987200	http://dx.doi.org/10.1074/jbc.M508987200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16204244	hybrid			2022-12-25	WOS:000234200800017
J	Shi, YH; Vaden, DL; Ju, SL; Ding, DB; Geiger, JH; Greenberg, ML				Shi, YH; Vaden, DL; Ju, SL; Ding, DB; Geiger, JH; Greenberg, ML			Genetic perturbation of glycolysis results in inhibition of de novo inositol biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIOSEPHOSPHATE ISOMERASE DEFICIENCY; MYOINOSITOL 1-PHOSPHATE SYNTHASE; SACCHAROMYCES-CEREVISIAE; MYO-INOSITOL-1-PHOSPHATE SYNTHASE; GLUCOSE REPRESSION; SUBUNIT INTERFACE; CRYSTAL-STRUCTURE; YEAST; ENZYME; IDENTIFICATION	In a genetic screen for Saccharomyces cerevisiae mutants hypersensitive to the inositol-depleting drugs lithium and valproate, a loss of function allele of TPI1 was identified. The TPI1 gene encodes triose phosphate isomerase, which catalyzes the interconversion of dihydroxyacetone phosphate (DHAP) and glyceraldehyde 3-phosphate. A single mutation (N65K) in tpi1 completely abolished Tpi1p enzyme activity and led to a 30-fold increase in the intracellular DHAP concentration. The tpi1 mutant was unable to grow in the absence of inositol and exhibited the "inositol-less death" phenotype. Similarly, the pgk1 mutant, which accumulates DHAP as a result of defective conversion of 3-phosphoglyceroyl phosphate to 3-phosphoglycerate, exhibited inositol auxotrophy. DHAP as well as glyceraldehyde 3-phosphate and oxaloacetate inhibited activity of both yeast and human myo-inositol-3 phosphate synthase, the rate-limiting enzyme in de novo inositol biosynthesis. Implications for the pathology associated with TPI deficiency and responsiveness to inositol-depleting anti-bipolar drugs are discussed. This study is the first to establish a connection between perturbation of glycolysis and inhibition of de novo inositol biosynthesis.	Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA; Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA	Wayne State University; Michigan State University	Greenberg, ML (corresponding author), Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA.	MLGREEN@sun.science.wayne.edu		Geiger, James/0000-0002-9443-4488	NIMH NIH HHS [MH56220] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH056220] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Arya R, 1997, HUM MUTAT, V10, P290; Ationu A, 1999, BLOOD, V94, P3193, DOI 10.1182/blood.V94.9.3193.421k26_3193_3198; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Bachhawat N, 1999, J MOL BIOL, V291, P531, DOI 10.1006/jmbi.1999.2980; BARNETT JEG, 1970, BIOCHEM J, V119, P183, DOI 10.1042/bj1190183; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carlson M, 1999, CURR OPIN MICROBIOL, V2, P202, DOI 10.1016/S1369-5274(99)80035-6; CASAL JI, 1987, BIOCHEMISTRY-US, V26, P1258, DOI 10.1021/bi00379a009; CHEN IW, 1966, J BIOL CHEM, V241, P2194; Chun JA, 2003, PLANTA, V216, P874, DOI 10.1007/s00425-002-0940-0; CIRIACY M, 1979, J BACTERIOL, V139, P152, DOI 10.1128/JB.139.1.152-160.1979; Colodny L, 1998, Altern Med Rev, V3, P432; Compagno C, 1996, BIOTECHNOL PROGR, V12, P591, DOI 10.1021/bp960043c; CULBERTSON MR, 1975, GENETICS, V80, P23; DELBONI LF, 1995, PROTEIN SCI, V4, P2594, DOI 10.1002/pro.5560041217; DONAHUE TF, 1981, J BIOL CHEM, V256, P7077; Fisher SK, 2002, J NEUROCHEM, V82, P736, DOI 10.1046/j.1471-4159.2002.01041.x; Guan GM, 2003, ARCH BIOCHEM BIOPHYS, V417, P251, DOI 10.1016/S0003-9861(03)00388-6; HENRY SA, 1975, MOL GEN GENET, V143, P5, DOI 10.1007/BF00269415; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; HOLLAN S, 1995, P NATL ACAD SCI USA, V92, P268, DOI 10.1073/pnas.92.1.268; JOHNSON MD, 1995, PLANT PHYSIOL, V107, P613, DOI 10.1104/pp.107.2.613; Ju SL, 2004, J BIOL CHEM, V279, P21759, DOI 10.1074/jbc.M312078200; LINDEGRE.G, 1965, CAN J GENET CYTOL, V7, P491, DOI 10.1139/g65-064; LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6609, DOI 10.1021/bi00480a009; MAITRA PK, 1971, J BIOL CHEM, V246, P475; Majumder AL, 1997, BBA-LIPID LIPID MET, V1348, P245, DOI 10.1016/S0005-2760(97)00122-7; MANDE SC, 1994, PROTEIN SCI, V3, P810, DOI 10.1002/pro.5560030510; Migaud ME, 1996, J AM CHEM SOC, V118, P495, DOI 10.1021/ja952570i; MIGAUD ME, 1995, J AM CHEM SOC, V117, P5154, DOI 10.1021/ja00123a019; O'Donnell T, 2000, BRAIN RES, V880, P84, DOI 10.1016/S0006-8993(00)02797-9; Obrosova I, 1998, DIABETOLOGIA, V41, P1442, DOI 10.1007/s001250051090; Olah J, 2002, BIOCHEM SOC T, V30, P30, DOI 10.1042/bst0300030; Qian OY, 1999, GENETICS, V152, P89; RONNE H, 1995, TRENDS GENET, V11, P12, DOI 10.1016/S0168-9525(00)88980-5; SCHNEIDER A, 1995, AM J HEMATOL, V50, P263, DOI 10.1002/ajh.2830500407; SCHNEIDER AS, 1965, NEW ENGL J MED, V272, P229, DOI 10.1056/NEJM196502042720503; Shaltiel G, 2004, BIOL PSYCHIAT, V56, P868, DOI 10.1016/j.biopsych.2004.08.027; SHERMAN WR, 1981, BIOCHIM BIOPHYS ACTA, V660, P299, DOI 10.1016/0005-2744(81)90174-1; Shirra MK, 1999, GENETICS, V152, P73; Stein AJ, 2000, ACTA CRYSTALLOGR D, V56, P348, DOI 10.1107/S0907444999016777; STEVENS VJ, 1977, J BIOL CHEM, V252, P2998; SUN AQ, 1992, J BIOL CHEM, V267, P20168; TRUEBLOOD N, 1998, AM J PHYSIOL, V375, pH75; Vaden DL, 2001, J BIOL CHEM, V276, P15466, DOI 10.1074/jbc.M004179200; WEISSMAN MM, 1988, PSYCHOL MED, V18, P141, DOI 10.1017/S0033291700001975; WIERENGA RK, 1987, J MOL BIOL, V198, P109, DOI 10.1016/0022-2836(87)90461-X; Williams RSB, 2002, NATURE, V417, P292, DOI 10.1038/417292a	49	25	26	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					41805	41810		10.1074/jbc.M505181200	http://dx.doi.org/10.1074/jbc.M505181200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16221686	hybrid			2022-12-25	WOS:000233992700005
J	Hikita, A; Kadono, Y; Chikuda, H; Fukuda, A; Wakeyama, H; Yasuda, H; Nakamura, K; Oda, H; Miyazaki, T; Tanaka, S				Hikita, A; Kadono, Y; Chikuda, H; Fukuda, A; Wakeyama, H; Yasuda, H; Nakamura, K; Oda, H; Miyazaki, T; Tanaka, S			Identification of an alternatively spliced variant of Ca2+-promoted Ras inactivator as a possible regulator of RANKL shedding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; OSTEOCLAST DIFFERENTIATION FACTOR; KAPPA-B LIGAND; T-CELLS; OSTEOPROTEGERIN LIGAND; RECEPTOR ACTIVATOR; PROTEIN; ARTHRITIS; TRANCE; FAMILY	The receptor activator of NF-kappa B ligand (RANKL), a critical regulator of osteoclastogenesis, is synthesized as a membrane-anchored protein and cleaved into a soluble form by ectodomain shedding. We developed an assay system to identify molecules regulating the RANKL shedding. Using this system, we found that a splice variant of Ca2+-promoted Ras inactivator ( CAPRI), Delta CAPRI, which is expressed in primary osteoblasts, promoted the RANKL shedding. The wild type CAPRI is a member of the Ras GTPase-activating protein ( GAP) family and suppresses Ca2+- dependent Ras activation, whereas Delta CAPRI, which lacks one exon in the GAP-related domain, activated the Ras pathway. Overexpression of Delta CAPRI or a constitutive active form of Ras up-regulated the expression level of matrix-metalloproteinase 14 (MMP14), which directly cleaves the ectodomain of RANKL, whereas Erk activation by expressing the constitutive active Mek1 did not affect the MMP14 expression or RANKL shedding. These results suggest that Delta CAPRI is a possible regulator of RANKL shedding by modulating MMP14 expression through Ras signaling cascades other than the Erk pathway.	Univ Tokyo, Fac Med, Dept Orthopaed Surg, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Inst Med Sci, Ctr Med Expt, Minato Ku, Tokyo 1088639, Japan; Saitama Med Sch, Dept Orthopaed Surg, Iruma, Saitama 3500495, Japan	University of Tokyo; University of Tokyo; Saitama Medical University	Tanaka, S (corresponding author), Univ Tokyo, Fac Med, Dept Orthopaed Surg, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	TANAKAS-ORT@h.u-tokyo.ac.jp	Tanaka, Sakae/Y-3061-2019; Kadono, Yuho/AAO-2405-2020	Tanaka, Sakae/0000-0001-9210-9414; Miyazaki, Tsuyoshi/0000-0003-0715-9017; Yasuda, Hisataka/0000-0003-3511-609X				Ahmadian MR, 1997, NAT STRUCT BIOL, V4, P686, DOI 10.1038/nsb0997-686; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Bivona TG, 2003, NATURE, V424, P694, DOI 10.1038/nature01806; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260; Chesneau V, 2003, J BIOL CHEM, V278, P22331, DOI 10.1074/jbc.M302781200; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Fan HZ, 1999, EMBO J, V18, P6962, DOI 10.1093/emboj/18.24.6962; Harris RC, 2003, EXP CELL RES, V284, P2, DOI 10.1016/S0014-4827(02)00105-2; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Inada M, 2004, P NATL ACAD SCI USA, V101, P17192, DOI 10.1073/pnas.0407788101; Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kotake S, 2001, ARTHRITIS RHEUM, V44, P1003, DOI 10.1002/1529-0131(200105)44:5<1003::AID-ANR179>3.0.CO;2-#; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lockyer PJ, 2001, CURR BIOL, V11, P981, DOI 10.1016/S0960-9822(01)00261-5; Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613; Mizuno A, 2002, J BONE MINER METAB, V20, P337, DOI 10.1007/s007740200049; Nakamura M, 2003, ENDOCRINOLOGY, V144, P5441, DOI 10.1210/en.2003-0717; Nakashima T, 2000, BIOCHEM BIOPH RES CO, V275, P768, DOI 10.1006/bbrc.2000.3379; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Schlondorff J, 2001, J BIOL CHEM, V276, P14665, DOI 10.1074/jbc.M010741200; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Suda T, 1997, METHOD ENZYMOL, V282, P223; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Yamamoto A, 2002, J BONE MINER RES, V17, P612, DOI 10.1359/jbmr.2002.17.4.612; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Zheng YF, 2002, J BIOL CHEM, V277, P42463, DOI 10.1074/jbc.M207459200	32	25	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41700	41706		10.1074/jbc.M507000200	http://dx.doi.org/10.1074/jbc.M507000200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16234249	hybrid			2022-12-25	WOS:000233866900071
J	Shin, KD; Lee, MY; Shin, DS; Lee, S; Son, KH; Koh, S; Paik, YK; Kwon, BM; Han, DC				Shin, KD; Lee, MY; Shin, DS; Lee, S; Son, KH; Koh, S; Paik, YK; Kwon, BM; Han, DC			Blocking tumor cell migration and invasion with biphenyl isoxazole derivative KRIBB3, a synthetic molecule that inhibits Hsp27 phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; TYROSINE PHOSPHORYLATION; CHEMICAL GENETICS; MASS-SPECTROMETRY; BREAST-CANCER; KINASE-C; METASTASIS; EXPRESSION; GROWTH; ADHESION	Cell migration is a prerequisite for cancer invasion and metastasis, suggesting cell motility as a potential therapeutic target for cancer treatment. A synthetic library was screened to identify inhibitors of tumor cell migration. From this, we discovered that CAC-1098 (aurintricarboxylic acid) and CBI-0997 (5-(2,4-dimethoxy-5ethylphenyl)- 4-(4-bromophenyl) isoxazole) inhibited migration of MDA-MB-231 cells with IC50 = 5 and 50 nM, respectively. We synthesized KRIBB3 (5-(5-ethyl-2-hydroxy-4-methoxyphenyl)-4-(4-methoxyphenyl) isoxazole) by replacing the bromide group of CBI-0997 with a methoxyl group. Like CBI-0997, KRIBB3 has anti-migratory and anti-invasive activities in MDA-MB-231 cells. Because KRIBB3 has a better drug-like structure, we focused our effort on further understanding its anti-migratory mechanism. Biotinyl-KRIBB3 was synthesized as an affinity probe for identification of KRIBB3-binding proteins. Using affinity chromatography, we identified Hsp27 as a target protein of KRIBB3 in vitro. Treatment of MDA-MB-231 cells with phorbol 12-myristate 13-acetate induced protein kinase C-dependent phosphorylation of Hsp27 and tumor cell migration. In contrast, treatment of MDA-MB-231 cells with KRIBB3 blocked phorbol 12-myristate 13-acetate-induced phosphorylation of Hsp27 and tumor cell migration. Furthermore, overexpression of Hsp27 antagonized the inhibitory effect of KRIBB3 on tumor cell invasion, and knockdown of Hsp27 using small interfering RNA inhibited tumor cell migration. Overall, our results demonstrate that KRIBB3 inhibits tumor cell migration and invasion by blocking protein kinase C-dependent phosphorylation of Hsp27 through its direct binding to Hsp27.	Korea Res Inst Biosci & Biotechnol, Taejon 305600, South Korea; Yonsei Univ, Dept Biochem, Seoul 120749, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Yonsei University	Kwon, BM (corresponding author), Korea Res Inst Biosci & Biotechnol, 52 Uendong Yoosunggu, Taejon 305600, South Korea.	kwonbm@kribb.re.kr; dchan@kribb.re.kr						Alahari SK, 2002, INT REV CYTOL, V220, P145; BENEZRA M, 1994, ARTERIOSCLER THROMB, V14, P1992, DOI 10.1161/01.ATV.14.12.1992; Blackburn RV, 1997, INT J CANCER, V72, P871, DOI 10.1002/(SICI)1097-0215(19970904)72:5<871::AID-IJC26>3.0.CO;2-A; Butt E, 2001, J BIOL CHEM, V276, P7108, DOI 10.1074/jbc.M009234200; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chen J, 2004, J PROTEOME RES, V3, P1009, DOI 10.1021/pr049916l; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Concannon CG, 2003, APOPTOSIS, V8, P61, DOI 10.1023/A:1021601103096; Cornford PA, 2000, CANCER RES, V60, P7099; Doppler H, 2005, J BIOL CHEM, V280, P15013, DOI 10.1074/jbc.C400575200; EHRENFRIED JA, 1995, SURG ONCOL, V4, P197, DOI 10.1016/S0960-7404(10)80036-2; Firtel RA, 2000, BIOESSAYS, V22, P603, DOI 10.1002/1521-1878(200007)22:7<603::AID-BIES3>3.0.CO;2-#; Franz CM, 2002, DEV CELL, V2, P153, DOI 10.1016/S1534-5807(02)00120-X; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Funamoto S, 2002, CELL, V109, P611, DOI 10.1016/S0092-8674(02)00755-9; GAGLIARDI A, 1993, CANCER RES, V53, P533; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Guay J, 1997, J CELL SCI, V110, P357; Han DC, 2004, J BIOL CHEM, V279, P6911, DOI 10.1074/jbc.M309708200; Hino M, 2000, BIOCHEM BIOPH RES CO, V271, P164, DOI 10.1006/bbrc.2000.2553; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; HUOT J, 1995, EUR J BIOCHEM, V227, P416, DOI 10.1111/j.1432-1033.1995.tb20404.x; Katoh M, 2000, CANCER LETT, V161, P113, DOI 10.1016/S0304-3835(00)00601-7; LANDRY J, 1992, J BIOL CHEM, V267, P794; LANDRY J, 1991, J CELL PHYSIOL, V147, P93, DOI 10.1002/jcp.1041470113; Langdon SP, 1995, CLIN CANCER RES, V1, P1603; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; Liang P, 1997, J CELL SCI, V110, P1431; LOVE S, 1994, BRIT J CANCER, V69, P743, DOI 10.1038/bjc.1994.140; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; Maizels ET, 1998, BIOCHEM J, V332, P703, DOI 10.1042/bj3320703; Mayer TU, 2003, TRENDS CELL BIOL, V13, P270, DOI 10.1016/S0962-8924(03)00077-1; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Nakae K, 2000, J ANTIBIOT, V53, P1130, DOI 10.7164/antibiotics.53.1130; Nam MH, 2003, PROTEOMICS, V3, P2351, DOI 10.1002/pmic.200300509; Njardarson JT, 2004, J AM CHEM SOC, V126, P1038, DOI 10.1021/ja039714a; OESTERREICH S, 1993, CANCER RES, V53, P4443; Pantel K, 2004, NAT REV CANCER, V4, P448, DOI 10.1038/nrc1370; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schreiber SL, 1998, BIOORGAN MED CHEM, V6, P1127, DOI 10.1016/S0968-0896(98)00126-6; Shan DD, 2005, P NATL ACAD SCI USA, V102, P3772, DOI 10.1073/pnas.0500658102; Stockwell BR, 2004, NATURE, V432, P846, DOI 10.1038/nature03196; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; Strassheim D, 2000, J BIOL CHEM, V275, P39767, DOI 10.1074/jbc.M007775200; vanderValk P, 1997, ANN ONCOL, V8, P1023, DOI 10.1023/A:1008265905505; VOLK T, 1984, CANCER RES, V44, P811; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Yarrow JC, 2005, CHEM BIOL, V12, P385, DOI 10.1016/j.chembiol.2005.01.015; ZANTEMA A, 1992, J BIOL CHEM, V267, P12936	54	161	179	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41439	41448		10.1074/jbc.M507209200	http://dx.doi.org/10.1074/jbc.M507209200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16234246	hybrid			2022-12-25	WOS:000233866900041
J	Neculai, D; Neculai, AM; Verrier, S; Straub, K; Klumpp, K; Pfitzner, E; Becker, S				Neculai, D; Neculai, AM; Verrier, S; Straub, K; Klumpp, K; Pfitzner, E; Becker, S			Structure of the unphosphorylated STAT5a dimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; DNA-BINDING; TRANSACTIVATION DOMAIN; LIVING CELLS; ACTIVATION; PHOSPHORYLATION; TRANSCRIPTION; NCOA-1/SRC-1; DIMERIZATION; EXPRESSION	STAT proteins have the function of signaling from the cell membrane into the nucleus, where they regulate gene transcription. Latent mammalian STAT proteins can form dimers in the cytoplasm even before receptor-mediated activation by specific tyrosine phosphorylation. Here we describe the 3.21-angstrom crystal structure of an unphosphorylated STAT5a homodimer lacking the N-terminal domain as well as the C-terminal transactivation domain. The overall structure of this fragment is very similar to phosphorylated STATs. However, important differences exist in the dimerization mode. Although the interface between phosphorylated STATs is mediated by their Src-homology 2 domains, the unphosphorylated STAT5a fragment dimerizes in a completely different manner via interactions between their beta-barrel and four-helix bundle domains. The STAT4 N-terminal domain dimer can be docked onto this STAT5a core fragment dimer based on shape and charge complementarities. The separation of the dimeric arrangement, taking place upon activation and nuclear translocation of STAT5a, is demonstrated by fluorescence resonance energy transfer experiments in living cells.	Univ Gottingen, Dept NMR Based Struct Biol, D-37077 Gottingen, Germany; Univ Gottingen, Dept Neurobiol, Max Planck Inst Biophys Chem, D-37077 Gottingen, Germany; Roche Palo Alto LLC, Palo Alto, CA 94304 USA; Georg Speyer Haus Inst Biomed Res, D-60596 Frankfurt, Germany	University of Gottingen; Max Planck Society; University of Gottingen; Roche Holding	Becker, S (corresponding author), Univ Gottingen, Dept NMR Based Struct Biol, Fassberg 11, D-37077 Gottingen, Germany.	sabe@nmr.mpibpc.mpg.de	Neculai, Dante/A-9923-2011; Pfitzner, Edith/AAU-7927-2021	Neculai, Dante/0000-0001-8887-9168; Pfitzner, Edith/0000-0002-3484-9649				Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Becker S, 1998, FEBS LETT, V441, P141, DOI 10.1016/S0014-5793(98)01543-9; Braunstein J, 2003, J BIOL CHEM, V278, P34133, DOI 10.1074/jbc.M304531200; Chatterjee-Kishore M, 2000, EMBO J, V19, P4111, DOI 10.1093/emboj/19.15.4111; Chen XM, 2003, PROTEIN SCI, V12, P361, DOI 10.1110/ps.0218903; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Haan S, 2000, BIOCHEM J, V345, P417, DOI 10.1042/0264-6021:3450417; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kretzschmar AK, 2004, BIOCHEM J, V377, P289, DOI 10.1042/BJ20030708; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Litterst CM, 2003, J BIOL CHEM, V278, P45340, DOI 10.1074/jbc.M303644200; Mao X, 2005, MOL CELL, V17, P761, DOI 10.1016/j.molcel.2005.02.021; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Moriggl R, 1997, MOL CELL BIOL, V17, P3663, DOI 10.1128/MCB.17.7.3663; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Ndubuisi MI, 1999, J BIOL CHEM, V274, P25499, DOI 10.1074/jbc.274.36.25499; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; Novak U, 1998, BIOCHEM BIOPH RES CO, V247, P558, DOI 10.1006/bbrc.1998.8829; Pfitzner E, 1998, P NATL ACAD SCI USA, V95, P5539, DOI 10.1073/pnas.95.10.5539; Ponstingl H, 2000, PROTEINS, V41, P47; Razeto A, 2004, J MOL BIOL, V336, P319, DOI 10.1016/j.jmb.2003.12.057; Ritchie DW, 2003, PROTEINS, V52, P98, DOI 10.1002/prot.10379; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; Schroder M, 2004, J LEUKOCYTE BIOL, V75, P792, DOI 10.1189/jlb.1003496; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; Zhong MH, 2005, P NATL ACAD SCI USA, V102, P3966, DOI 10.1073/pnas.0501063102	33	90	98	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40782	40787		10.1074/jbc.M507682200	http://dx.doi.org/10.1074/jbc.M507682200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16192273	hybrid, Green Published			2022-12-25	WOS:000233666600048
J	Talukdar, I; Szeszel-Fedorowicz, W; Salati, LM				Talukdar, I; Szeszel-Fedorowicz, W; Salati, LM			Arachidonic acid inhibits the insulin induction of glucose-6-phosphate dehydrogenase via p38 MAP kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; POLYUNSATURATED FATTY-ACIDS; NUCLEAR POSTTRANSCRIPTIONAL MECHANISM; RICH SPLICING FACTOR; C-BETA-II; PHOSPHATIDYLINOSITOL 3-KINASE; RECEPTOR SUBSTRATE-1; MUSCLE-CELLS; SKELETAL-MUSCLE; GENE-EXPRESSION	Polyunsaturated fatty acids are potent inhibitors of lipogenic gene expression in liver. The lipogenic enzyme glucose-6-phosphate dehydrogenase (G6PD) is unique in this gene family, in that fatty acids inhibit at a post-transcriptional step. In this study, we have provided evidence for a signaling pathway for the arachidonic acid inhibition of G6PD mRNA abundance. Arachidonic acid decreases the insulin induction of G6PD expression; by itself, arachidonic acid does not inhibit basal G6PD mRNA accumulation. The insulin stimulation of G6PD involves the phosphoinositide 3-kinase (PI 3-kinase) pathway (Wagle, A., Jivraj, S., Garlock, G. L., and Stapleton, S. R. (1998) J. Biol. Chem. 273, 14968 - 14974). Incubation of hepatocytes with arachidonic acid blocks the activation of PI 3-kinase by insulin as observed by a decrease in Ser(473) phosphorylation of Akt, the downstream effector of PI 3-kinase. The decrease in PI 3-kinase activity was associated with an increase in Ser(307) phosphorylation of IRS-1. Western analysis demonstrated increased phosphorylation of p38 mitogen-activated protein kinase ( MAPK) in arachidonic acid-treated cells, whereas extracellular signal-regulated kinase and c-Jun NH2-terminal kinase activity was not changed. Incubating the hepatocytes with the p38 MAPK inhibitor, SB203580, blocked the arachidonic acid inhibition of G6PD mRNA accumulation. Furthermore, SB203580 decreased the arachidonic acid-mediated Ser(307) phosphorylation of IRS-1 and rescued Akt activation that was otherwise decreased by arachidonic acid. Thus, arachidonic acid inhibits the insulin stimulation of G6PD mRNA accumulation by stimulating the p38 MAPK pathway, thereby inhibiting insulin signal transduction.	W Virginia Univ, Hlth Sci Ctr, Dept Biochem & Mol Pharmacol, Morgantown, WV 26506 USA	West Virginia University	Salati, LM (corresponding author), W Virginia Univ, Hlth Sci Ctr, Dept Biochem & Mol Pharmacol, POB 9142, Morgantown, WV 26506 USA.	Lsalati@hsc.wvu.edu			NIDDK NIH HHS [DK46897, R01 DK046897] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046897, R29DK046897, R56DK046897] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; Amir-Ahmady B, 2001, J BIOL CHEM, V276, P10514, DOI 10.1074/jbc.M010535200; Blaustein M, 2004, J BIOL CHEM, V279, P21029, DOI 10.1074/jbc.M314260200; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Clarke SD, 2004, CURR OPIN LIPIDOL, V15, P13, DOI 10.1097/00041433-200402000-00004; de Alvaro C, 2004, J BIOL CHEM, V279, P17070, DOI 10.1074/jbc.M312021200; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; Fujishiro M, 2003, MOL ENDOCRINOL, V17, P487, DOI 10.1210/me.2002-0131; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; HII CST, 1995, J BIOL CHEM, V270, P4201, DOI 10.1074/jbc.270.9.4201; Hii CST, 1998, J BIOL CHEM, V273, P19277, DOI 10.1074/jbc.273.30.19277; HILLGARTNER F, 1995, PHYSIOL REV, V75, P47, DOI 10.1152/physrev.1995.75.1.47; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Hodge DL, 1997, ARCH BIOCHEM BIOPHYS, V348, P303, DOI 10.1006/abbi.1997.0373; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jump DB, 2004, CRIT REV CL LAB SCI, V41, P41, DOI 10.1080/10408360490278341; Kawaguchi T, 2002, J BIOL CHEM, V277, P3829, DOI 10.1074/jbc.M107895200; KOSUGI H, 1989, FREE RADICAL BIO MED, V7, P205, DOI 10.1016/0891-5849(89)90016-6; Le Marchand-Brustel Y, 2003, BIOCHEM SOC T, V31, P1152; Lemieux K, 2003, FASEB J, V17, P1658, DOI 10.1096/fj.02-1125com; Manning BD, 2003, BIOCHEM SOC T, V31, P573, DOI 10.1042/BST0310573; MOONEY RA, 1981, J BIOL CHEM, V256, P1724; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; Nadeau KJ, 2004, J BIOL CHEM, V279, P34380, DOI 10.1074/jbc.M403596200; Ogura M, 1998, J IMMUNOL, V161, P3569; Patel NA, 2005, J BIOL CHEM, V280, P14302, DOI 10.1074/jbc.M411485200; Patel NA, 2001, J BIOL CHEM, V276, P22648, DOI 10.1074/jbc.M101260200; Pelletier A, 2005, ENDOCRINOLOGY, V146, P2285, DOI 10.1210/en.2004-1565; Pirola L, 2003, J BIOL CHEM, V278, P15641, DOI 10.1074/jbc.M208984200; Prada PO, 2005, ENDOCRINOLOGY, V146, P1576, DOI 10.1210/en.2004-0767; Preville X, 1999, EXP CELL RES, V247, P61, DOI 10.1006/excr.1998.4347; RAO GN, 1994, J BIOL CHEM, V269, P32586; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SALATI LM, 1988, LIPIDS, V23, P36, DOI 10.1007/BF02535302; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; SEGLEN PO, 1973, EXP CELL RES, V82, P391, DOI 10.1016/0014-4827(73)90357-1; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Stabile LP, 1998, J LIPID RES, V39, P1951; Stabile LP, 1996, ARCH BIOCHEM BIOPHYS, V332, P269, DOI 10.1006/abbi.1996.0342; Suchankova G, 2005, BIOCHEM BIOPH RES CO, V326, P851, DOI 10.1016/j.bbrc.2004.11.114; Tao HM, 2002, J BIOL CHEM, V277, P31270, DOI 10.1074/jbc.M203196200; Taouis M, 2002, AM J PHYSIOL-ENDOC M, V282, pE664, DOI 10.1152/ajpendo.00320.2001; Towle HC, 2001, P NATL ACAD SCI USA, V98, P13476, DOI 10.1073/pnas.251530798; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; van Oordt WV, 2000, J CELL BIOL, V149, P307, DOI 10.1083/jcb.149.2.307; Wagle A, 1998, J BIOL CHEM, V273, P14968, DOI 10.1074/jbc.273.24.14968; Wang D, 1998, J BIOL CHEM, V273, P25420, DOI 10.1074/jbc.273.39.25420; Weg-Remers S, 2001, EMBO J, V20, P4194, DOI 10.1093/emboj/20.15.4194; Wu DF, 2003, J BIOL CHEM, V278, P1115, DOI 10.1074/jbc.M207856200; Xu J, 2003, J BIOCHEM MOL TOXIC, V17, P67, DOI 10.1002/jbt.10062; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200; Zierath JB, 1997, DIABETES, V46, P215, DOI 10.2337/diabetes.46.2.215	54	37	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40660	40667		10.1074/jbc.M505531200	http://dx.doi.org/10.1074/jbc.M505531200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16210322	Green Published, hybrid			2022-12-25	WOS:000233666600035
J	Wennerhold, J; Krug, A; Bott, M				Wennerhold, J; Krug, A; Bott, M			The AraC-type regulator RipA represses aconitase and other iron proteins from Corynebacterium under iron limitation and is itself repressed by DtxR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; ESCHERICHIA-COLI; TRANSCRIPTIONAL REGULATORS; NUCLEOTIDE-SEQUENCE; EXPRESSION ANALYSIS; MOLECULAR ANALYSIS; RESPIRATORY-CHAIN; DNA MICROARRAYS; GLUTAMICUM; IDENTIFICATION	The mRNA level of the aconitase gene acn of Corynebacterium glutamicum is reduced under iron limitation. Here we show that an AraC-type regulator, termed RipA for "regulator of iron proteins A," is involved in this type of regulation. A C. glutamicum Delta ripA mutant has a 2-fold higher aconitase activity than the wild type under iron limitation, but not under iron excess. Comparison of the mRNA profiles of the Delta ripA mutant and the wild type revealed that the acn mRNA level was increased in the Delta ripA mutant under iron limitation, but not under iron excess, indicating a repressor function of RipA. Besides acn, some other genes showed increased mRNA levels in the Delta ripA mutant under iron starvation ( i. e. those encoding succinate dehydrogenase (sdhCAB), nitrate/nitrite transporter and nitrate reductase (narKGHJI), isopropylmalate dehydratase (leuCD), catechol 1,2-dioxygenase (catA), and phosphotransacetylase (pta)). Most of these proteins contain iron. Purified RipA binds to the upstream regions of all operons mentioned above and in addition to that of the catalase gene ( katA). From 13 identified binding sites, the RipA consensus binding motif RRGCGN(4)RYGAC was deduced. Expression of ripA itself is repressed under iron excess by DtxR, since purified DtxR binds to a well conserved binding site upstream of ripA. Thus, repression of acn and the other target genes indicated above under iron limitation involves a regulatory cascade of two repressors, DtxR and its target RipA. The modulation of the intracellular iron usage by RipA supplements mechanisms for iron acquisition that are directly regulated by DtxR.	Forschungszentrum Julich, Inst Biotechnol 1, D-52425 Julich, Germany	Helmholtz Association; Research Center Julich	Bott, M (corresponding author), Forschungszentrum Julich, Inst Biotechnol 1, Postfach 1913, D-52425 Julich, Germany.	m.bott@fz-juelich.de	Bott, Michael/E-8004-2011; Frunzke, Julia/A-9918-2012	Bott, Michael/0000-0002-4701-8254; Frunzke, Julia/0000-0001-6209-7950				Andrews SC, 2003, FEMS MICROBIOL REV, V27, P215, DOI 10.1016/S0168-6445(03)00055-X; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Bott M, 2003, J BIOTECHNOL, V104, P129, DOI 10.1016/S0168-1656(03)00144-5; Cerdeno-Tarraga AM, 2003, NUCLEIC ACIDS RES, V31, P6516, DOI 10.1093/nar/gkg874; Costa-Riu N, 2003, MOL MICROBIOL, V50, P1295, DOI 10.1046/j.1365-2958.2003.03754.x; CREMER J, 1990, MOL GEN GENET, V220, P478, DOI 10.1007/BF00391757; Eggeling L., 2005, HDB CORYNEBACTERIUM, DOI 10.1201/9781420039696; EIKMANNS BJ, 1994, MICROBIOL-SGM, V140, P1817, DOI 10.1099/13500872-140-8-1817; Engels S, 2004, MOL MICROBIOL, V52, P285, DOI 10.1111/j.1365-2958.2003.03979.x; Escolar L, 1999, J BACTERIOL, V181, P6223, DOI 10.1128/JB.181.20.6223-6229.1999; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; Gallegos MT, 1997, MICROBIOL MOL BIOL R, V61, P393, DOI 10.1128/.61.4.393-410.1997; Gerstmeir R, 2003, J BIOTECHNOL, V104, P99, DOI 10.1016/S0168-1656(03)00167-6; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; Hantke K, 2001, CURR OPIN MICROBIOL, V4, P172, DOI 10.1016/S1369-5274(00)00184-3; HENSON CP, 1967, J BIOL CHEM, V242, P3833; Ishige T, 2003, J BACTERIOL, V185, P4519, DOI 10.1128/JB.185.15.4519-4529.2003; KEILHAUER C, 1993, J BACTERIOL, V175, P5595, DOI 10.1128/JB.175.17.5595-5603.1993; Kinoshita S., 1957, J GEN APPL MICROBIOL, V3, P193, DOI [10.2323/jgam.3.193, DOI 10.2323/JGAM.3.193]; Krug A, 2005, J BIOL CHEM, V280, P585, DOI 10.1074/jbc.M408271200; Lange C, 2003, APPL ENVIRON MICROB, V69, P2521, DOI 10.1128/AEM.69.5.2521-2532.2003; Lee JH, 1997, INFECT IMMUN, V65, P4273, DOI 10.1128/IAI.65.10.4273-4280.1997; LOBELL RB, 1990, SCIENCE, V250, P528, DOI 10.1126/science.2237403; Martin RG, 2001, CURR OPIN MICROBIOL, V4, P132, DOI 10.1016/S1369-5274(00)00178-8; Masse E, 2002, P NATL ACAD SCI USA, V99, P4620, DOI 10.1073/pnas.032066599; Moker N, 2004, MOL MICROBIOL, V54, P420, DOI 10.1111/j.1365-2958.2004.04249.x; Niebisch A, 2001, ARCH MICROBIOL, V175, P282, DOI 10.1007/s002030100262; Nishio Y, 2003, GENOME RES, V13, P1572, DOI 10.1101/gr.1285603; OGUIZA JA, 1995, J BACTERIOL, V177, P465, DOI 10.1128/jb.177.2.465-467.1995; Pierre JL, 1999, BIOMETALS, V12, P195, DOI 10.1023/A:1009252919854; Polen T, 2004, APPL BIOCHEM BIOTECH, V118, P215, DOI 10.1385/ABAB:118:1-3:215; Reinscheid DJ, 1999, MICROBIOL-SGM, V145, P503, DOI 10.1099/13500872-145-2-503; Rhee S, 1998, P NATL ACAD SCI USA, V95, P10413, DOI 10.1073/pnas.95.18.10413; ROBINSON JR, 1972, J BACTERIOL, V112, P465, DOI 10.1128/JB.112.1.465-473.1972; Rodriguez GM, 2003, MOL MICROBIOL, V47, P1485, DOI 10.1046/j.1365-2958.2003.03384.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAFER A, 1994, GENE, V145, P69, DOI 10.1016/0378-1119(94)90324-7; Shen XH, 2004, BIOTECHNOL LETT, V26, P575; Skerra A, 2000, METHOD ENZYMOL, V326, P271; Smith JL, 2004, CRIT REV MICROBIOL, V30, P173, DOI 10.1080/10408410490435151; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAO X, 1994, MOL MICROBIOL, V14, P191, DOI 10.1111/j.1365-2958.1994.tb01280.x; TAO X, 1994, P NATL ACAD SCI USA, V91, P9646, DOI 10.1073/pnas.91.20.9646; Tauch A, 2005, J BACTERIOL, V187, P4671, DOI 10.1128/JB.187.13.4671-4682.2005; van der Rest ME, 1999, APPL MICROBIOL BIOT, V52, P541, DOI 10.1007/s002530051557; Wade JT, 2000, MOL MICROBIOL, V36, P223, DOI 10.1046/j.1365-2958.2000.01850.x; Wendisch VF, 2003, J BIOTECHNOL, V104, P273, DOI 10.1016/S0168-1656(03)00147-0; Wendisch VF, 2000, J BACTERIOL, V182, P3088, DOI 10.1128/JB.182.11.3088-3096.2000	48	90	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40500	40508		10.1074/jbc.M508693200	http://dx.doi.org/10.1074/jbc.M508693200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16179344	hybrid, Green Published			2022-12-25	WOS:000233666600016
J	Dai, YM; Yang, Y; MacLeod, V; Yue, XP; Rapraeger, AC; Shriver, Z; Venkataraman, G; Sasisekharan, R; Sanderson, RD				Dai, YM; Yang, Y; MacLeod, V; Yue, XP; Rapraeger, AC; Shriver, Z; Venkataraman, G; Sasisekharan, R; Sanderson, RD			HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; SPARC-NULL MICE; MULTIPLE-MYELOMA; EXTRACELLULAR-MATRIX; ENHANCED GROWTH; BINDING; CELLS; PROMOTES; CANCER; ANGIOGENESIS	To participate as co-receptor in growth factor signaling, heparan sulfate must have specific structural features. Recent studies show that when the levels of 6-O-sulfation of heparan sulfate are diminished by the activity of extracellular heparan sulfate 6-O-endosulfatases ( Sulfs), fibroblast growth factor 2-, heparin binding epidermal growth factor-, and hepatocyte growth factor- mediated signaling are attenuated. This represents a novel mechanism for regulating cell growth, particularly within the tumor microenvironment where the Sulfs are known to be misregulated. To directly test the role of Sulfs in tumor growth control in vivo, a human myeloma cell line was transfected with cDNAs encoding either of the two known human endosulfatases, HSulf-1 or HSulf-2. When implanted into severe combined immunodeficient ( SCID) mice, the growth of these tumors was dramatically reduced on the order of 5- to 10-fold as compared with controls. In addition to an inhibition of tumor growth, these studies revealed the following. ( i) HSulf-1 and HSulf-2 have similar functions in vivo. ( ii) The extracellular activity of Sulfs is restricted to the local tumor cell surface. ( iii) The Sulfs promote a marked increase in extracellular matrix deposition within tumors that may, along with attenuated growth factor signaling, contribute to the reduction in tumor growth. These findings demonstrate that dynamic regulation of heparan sulfate structure by Sulfs present within the tumor microenvironment can have a dramatic impact on the growth and progression of malignant cells in vivo.	Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Canc Res Ctr, Little Rock, AR 72205 USA; Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; Momenta Pharmaceut Inc, Cambridge, MA 02142 USA; MIT, Biol Engn Div, Cambridge, MA 02139 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Wisconsin System; University of Wisconsin Madison; Massachusetts Institute of Technology (MIT)	Sanderson, RD (corresponding author), Univ Arkansas Med Sci, Dept Pathol, 4301 W Markham St, Little Rock, AR 72205 USA.	RDSanderson@uams.edu			NCI NIH HHS [CA55819, CA68494] Funding Source: Medline; NIGMS NIH HHS [R01 GM048850] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA055819, R01CA068494] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ai XB, 2003, J CELL BIOL, V162, P341, DOI 10.1083/jcb.200212083; Allen BL, 2001, J CELL BIOL, V155, P845, DOI 10.1083/jcb.200106075; Borset M, 2000, BLOOD, V96, P2528; Brekken RA, 2003, J CLIN INVEST, V111, P487, DOI 10.1172/JCI200316804; Chang Z, 2000, FASEB J, V14, P137, DOI 10.1096/fasebj.14.1.137; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; Derksen PWB, 2002, BLOOD, V99, P1405, DOI 10.1182/blood.V99.4.1405; Dhoot GK, 2001, SCIENCE, V293, P1663, DOI 10.1126/science.293.5535.1663; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; Flanagan JG, 2000, METHOD ENZYMOL, V327, P19, DOI 10.1016/S0076-6879(00)27264-9; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Lai JP, 2004, ONCOGENE, V23, P1439, DOI 10.1038/sj.onc.1207258; Lai JP, 2004, GASTROENTEROLOGY, V126, P231, DOI 10.1053/j.gastro.2003.09.043; Lai JP, 2003, J BIOL CHEM, V278, P23107, DOI 10.1074/jbc.M302203200; LI J, 2005, MOL CANC; Monsky WL, 2002, CLIN CANCER RES, V8, P1008; Morimoto-Tomita M, 2002, J BIOL CHEM, V277, P49175, DOI 10.1074/jbc.M205131200; Netti PA, 2000, CANCER RES, V60, P2497; Ohto T, 2002, GENES CELLS, V7, P173, DOI 10.1046/j.1356-9597.2001.00502.x; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; Puolakkainen PA, 2004, MOL CANCER RES, V2, P215; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; Rhomberg AJ, 1998, P NATL ACAD SCI USA, V95, P4176, DOI 10.1073/pnas.95.8.4176; RUSNATI M, 1994, BIOCHEM BIOPH RES CO, V203, P450, DOI 10.1006/bbrc.1994.2203; SANDERSON RD, 2005, IN PRESS J CELL BIOC; Selva EM, 2001, ADV CANCER RES, V83, P67, DOI 10.1016/S0065-230X(01)83003-7; Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847; Viviano BL, 2004, J BIOL CHEM, V279, P5604, DOI 10.1074/jbc.M310691200; Vlodavsky I, 2002, SEMIN CANCER BIOL, V12, P121, DOI 10.1006/scbi.2001.0420; Wang SW, 2004, P NATL ACAD SCI USA, V101, P4833, DOI 10.1073/pnas.0401028101; Yang Y, 2005, BLOOD, V105, P1303, DOI 10.1182/blood-200406-2141; Yang Y, 2002, BLOOD, V100, P610, DOI 10.1182/blood.V100.2.610; Zhan FH, 2002, BLOOD, V99, P1745, DOI 10.1182/blood.V99.5.1745	34	111	113	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40066	40073		10.1074/jbc.M508136200	http://dx.doi.org/10.1074/jbc.M508136200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16192265	hybrid			2022-12-25	WOS:000233461300045
J	Kumar, M; Mitra, D				Kumar, M; Mitra, D			Heat shock protein 40 is necessary for human immunodeficiency virus-1 Nef-mediated enhancement of viral gene expression and replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; HEAT-SHOCK PROTEINS; HIV-INFECTION; GEL-ELECTROPHORESIS; MAMMALIAN-CELLS; PLASMA-MEMBRANE; HELA-CELLS; T-CELLS; IN-VIVO; HSP 40	The human immunodeficiency virus-1 ( HIV-1) Nef protein, originally identified as a negative factor, has now emerged as one of the most important viral proteins necessary for viral pathogenesis and disease progression. Nef has been also implicated in viral infectivity and replication, however, the molecular mechanism of Nef-induced viral gene expression and replication is not clearly understood. Although involvement of heat shock proteins in viral pathogenesis has been reported earlier, a clear understanding of their role remains to be elucidated. Here we report for the first time that Nef not only interacts with heat shock protein 40 ( Hsp40) but it also induces the expression of Hsp40 in HIV-1-infected cells. The interaction between Nef and Hsp40 is important for increased Hsp40 translocation into the nucleus of infected cells, which seems to facilitate viral gene expression by becoming part of the cyclin-dependent kinase 9-associated transcription complex regulating long terminal repeat-mediated gene expression. The finding is consistent with the failure of the nef-deleted virus to induce Hsp40, resulting in reduced virus production. Our data further shows that, whereas, Hsp40 overexpression induces viral gene expression, silencing of Hsp40 reduces the gene expression in a Nef-dependent manner. Thus our results clearly indicate that Hsp40 is crucial for Nef-mediated enhancement of viral gene expression and replication.	Natl Ctr Cell Sci, Pune 411007, Maharashtra, India	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS)	Mitra, D (corresponding author), Natl Ctr Cell Sci, Pune 411007, Maharashtra, India.	dmitra@nccs.res.in						ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Agnew LL, 2003, AIDS, V17, P1985, DOI 10.1097/00002030-200309050-00019; AHMAD N, 1988, SCIENCE, V241, P1481, DOI 10.1126/science.3262235; Arora VK, 2002, MICROBES INFECT, V4, P189, DOI 10.1016/S1286-4579(01)01527-1; BONNER WM, 1983, METHOD ENZYMOL, V96, P215; Brenner BG, 2001, EXPERT OPIN BIOL TH, V1, P67, DOI 10.1517/14712598.1.1.67; Collette Y, 1999, VIROLOGY, V265, P173, DOI 10.1006/viro.1999.0053; Creagh EM, 2000, LEUKEMIA, V14, P1161, DOI 10.1038/sj.leu.2401841; Dandekar DH, 2005, ANAL BIOCHEM, V342, P341, DOI 10.1016/j.ab.2005.02.006; Doms RW, 2000, GENE DEV, V14, P2677, DOI 10.1101/gad.833300; Fackler OT, 2002, IMMUNITY, V16, P493, DOI 10.1016/S1074-7613(02)00307-2; Fackler OT, 2001, J VIROL, V75, P6601, DOI 10.1128/JVI.75.14.6601-6608.2001; Fan CY, 2003, CELL STRESS CHAPERON, V8, P309, DOI 10.1379/1466-1268(2003)008<0309:MFROHF>2.0.CO;2; Farinha CM, 2002, BIOCHEM J, V366, P797, DOI 10.1042/BJ20011717; Gervaix A, 1997, P NATL ACAD SCI USA, V94, P4653, DOI 10.1073/pnas.94.9.4653; Geyer M, 2001, EMBO REP, V2, P580, DOI 10.1093/embo-reports/kve141; Glotzer JB, 2000, NATURE, V407, P207, DOI 10.1038/35025102; Glushakova S, 1999, J VIROL, V73, P3968, DOI 10.1128/JVI.73.5.3968-3974.1999; Greene WC, 2002, NAT MED, V8, P673, DOI 10.1038/nm0702-673; Gurer C, 2002, J VIROL, V76, P4666, DOI 10.1128/JVI.76.9.4666-4670.2002; HAMMES SR, 1989, P NATL ACAD SCI USA, V86, P9549, DOI 10.1073/pnas.86.23.9549; HATTORI H, 1993, J CELL SCI, V104, P629; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; Iordanskiy S, 2004, J VIROL, V78, P9697, DOI 10.1128/JVI.78.18.9697-9704.2004; Joseph AM, 2005, CURR HIV RES, V3, P87, DOI 10.2174/1570162052773013; Joseph AM, 2003, FEBS LETT, V548, P37, DOI 10.1016/S0014-5793(03)00725-7; Jubier-Maurin V, 1999, AIDS RES HUM RETROV, V15, P23, DOI 10.1089/088922299311673; KIENZLE N, 1992, ARCH VIROL, V124, P123, DOI 10.1007/BF01314630; KIM SY, 1989, P NATL ACAD SCI USA, V86, P9544, DOI 10.1073/pnas.86.23.9544; Kocsis J, 2003, J MED VIROL, V71, P480, DOI 10.1002/jmv.10507; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; LIBEREK K, 1995, P NATL ACAD SCI USA, V92, P6224, DOI 10.1073/pnas.92.14.6224; Liu DK, 1997, J VIROL, V71, P4079, DOI 10.1128/JVI.71.5.4079-4085.1997; Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999; Lundquist CA, 2004, J VIROL, V78, P6287, DOI 10.1128/JVI.78.12.6287-6296.2004; Michels AA, 1997, J BIOL CHEM, V272, P33283, DOI 10.1074/jbc.272.52.33283; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; MURPHY KM, 1993, J VIROL, V67, P6956, DOI 10.1128/JVI.67.12.6956-6964.1993; MURTI KG, 1993, P NATL ACAD SCI USA, V90, P11895, DOI 10.1073/pnas.90.24.11895; NIEDERMAN TMJ, 1989, P NATL ACAD SCI USA, V86, P1128, DOI 10.1073/pnas.86.4.1128; O'Keeffe B, 2000, J BIOL CHEM, V275, P279, DOI 10.1074/jbc.275.1.279; OHTSUKA K, 1993, EXP CELL RES, V209, P357, DOI 10.1006/excr.1993.1321; Omoto S, 2005, J GEN VIROL, V86, P751, DOI 10.1099/vir.0.80449-0; Otake K, 2004, AIDS, V18, P189, DOI 10.1097/00002030-200401230-00007; OVOD V, 1992, AIDS, V6, P25, DOI 10.1097/00002030-199201000-00003; Papkalla A, 2002, J VIROL, V76, P8455, DOI 10.1128/JVI.76.16.8455-8459.2002; Ryu J, 2004, MOL CELLS, V17, P353; Saksela Kalle, 1997, Frontiers in Bioscience, V2, pD606; SHUGARS DC, 1993, J VIROL, V67, P4639, DOI 10.1128/JVI.67.8.4639-4650.1993; Simmons A, 2001, IMMUNITY, V14, P763, DOI 10.1016/S1074-7613(01)00158-3; Stauber RH, 1998, VIROLOGY, V252, P126, DOI 10.1006/viro.1998.9400; Takayama S, 2003, ONCOGENE, V22, P9041, DOI 10.1038/sj.onc.1207114; van Eden W, 2005, NAT REV IMMUNOL, V5, P318, DOI 10.1038/nri1593; Welch WJ, 1991, CURR OPIN CELL BIOL, V3, P1033, DOI 10.1016/0955-0674(91)90125-I; Witte V, 2004, MOL CELL, V13, P179, DOI 10.1016/S1097-2765(04)00004-8; YAMANE M, 1995, CELL STRUCT FUNCT, V20, P157, DOI 10.1247/csf.20.157; Yang YH, 2002, FEBS LETT, V532, P36, DOI 10.1016/S0014-5793(02)03624-4; Yokota S, 2000, CANCER RES, V60, P2942	58	63	68	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40041	40050		10.1074/jbc.M508904200	http://dx.doi.org/10.1074/jbc.M508904200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16179353	hybrid			2022-12-25	WOS:000233461300042
J	Soundararajan, R; Zhang, TT; Wang, J; Vandewalle, A; Pearce, D				Soundararajan, R; Zhang, TT; Wang, J; Vandewalle, A; Pearce, D			A novel role for glucocorticoid-induced leucine zipper protein in epithelial sodium channel-mediated sodium transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORTICAL COLLECTING DUCT; CELL-SURFACE EXPRESSION; NA+ CHANNEL; PRINCIPAL CELL; KINASE PATHWAY; INDUCED GENE; ALDOSTERONE; ACTIVATION; KIDNEY; PHOSPHORYLATION	The steroid hormone aldosterone stimulates sodium ( Na+) transport in tight epithelia by altering the expression of target genes that regulate the activity and trafficking of the epithelial sodium channel ( ENaC). We performed microarray analysis to identify aldosterone-regulated transcripts in mammalian kidney epithelial cells ( mpkC-CDc14). One target, glucocorticoid-induced leucine zipper protein ( GILZ), was previously identified by serial analysis of gene expression ( SAGE); however, its function in epithelial ion transport was unknown. Here we show that GILZ expression is rapidly stimulated by aldosterone in mpkCCD(c14) and that GILZ, in turn, strongly stimulates ENaC-mediated Na+ transport by inhibiting extracellular signal-regulated kinase ( ERK) signaling. In Xenopus oocytes with activated ERK, heterologous GILZ expression consistently inhibited phospho-ERK expression and markedly stimulated ENaC-mediated Na+ current, in a manner similar to that of U0126 ( a pharmacologic inhibitor of ERK signaling). In mpkCCD(c14) cells, GILZ transfection similarly consistently inhibited phospho-ERK expression and stimulated transepithelial Na+ transport. Furthermore, aldosterone treatment of mpkCCD(c14) cells suppressed phospho-ERK levels with a time course that paralleled their increase of Na+ transport. Finally, GILZ expression markedly increased cell surface ENaC expression in epidermal growth factor-treated mammalian kidney epithelial cells, HEK293. These observations suggest a novel link between GILZ and regulation of epithelial sodium transport through modulation of ERK signaling and could represent an important pathway for mediating aldosterone actions in health and disease.	Univ Calif San Francisco, Dept Med, Div Nephrol, San Francisco, CA 94143 USA; Univ Paris 07, INSERM, Unite 478, F-75870 Paris, France; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of California System; University of California San Francisco	Pearce, D (corresponding author), Univ Calif San Francisco, 600 16th St,Rm N274H,Genentech Hall,Miss Bay Camp, San Francisco, CA 94107 USA.	pearced@medicine.ucsf.edu			NIDDK NIH HHS [R01-DK51151] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051151] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andreucci M, 2003, KIDNEY INT, V64, P1189, DOI 10.1046/j.1523-1755.2003.00204.x; Asher C, 1996, AM J PHYSIOL-CELL PH, V271, pC605, DOI 10.1152/ajpcell.1996.271.2.C605; ATTALI B, 1995, P NATL ACAD SCI USA, V92, P6092, DOI 10.1073/pnas.92.13.6092; Ayroldi E, 2002, MOL CELL BIOL, V22, P7929, DOI 10.1128/MCB.22.22.7929-7941.2002; Ayroldi E, 2001, BLOOD, V98, P743, DOI 10.1182/blood.V98.3.743; Bens M, 1999, J AM SOC NEPHROL, V10, P923; BHALLA V, 2005, IN PRESS MOL ENDOCRI; Bhargava A, 2001, ENDOCRINOLOGY, V142, P1587, DOI 10.1210/en.142.4.1587; Booth RE, 2003, AM J PHYSIOL-RENAL, V284, pF938, DOI 10.1152/ajprenal.00373.2002; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; D'Adamio F, 1997, IMMUNITY, V7, P803, DOI 10.1016/S1074-7613(00)80398-2; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Debonneville C, 2004, MOL CELL BIOL, V24, P2397, DOI 10.1128/MCB.24.6.2397-2409.2004; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Esposito L, 2004, J NEUROCHEM, V91, P1260, DOI 10.1111/j.1471-4159.2004.02816.x; Falin R, 2005, AM J PHYSIOL-CELL PH, V288, pC1003, DOI 10.1152/ajpcell.00213.2004; Farsshori PQ, 2003, J STEROID BIOCHEM, V85, P337, DOI 10.1016/S0960-0760(03)00226-7; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Fouladkou F, 2004, AM J PHYSIOL-RENAL, V287, pF550, DOI 10.1152/ajprenal.00353.2003; Fujita H, 2004, AM J PHYSIOL-RENAL, V286, pF120, DOI 10.1152/ajprenal.00351.2002; Grossmann C, 2004, AM J PHYSIOL-RENAL, V286, pF1226, DOI 10.1152/ajprenal.00378.2003; Gumz ML, 2003, AM J PHYSIOL-RENAL, V285, pF664, DOI 10.1152/ajprenal.00353.2002; Harvey, 2005, NEPHRON PHYSIOL, V99, P1, DOI DOI 10.1159/000081796); Hendron E, 2002, MOL BIOL CELL, V13, P3042, DOI 10.1091/mbc.E02-05-0260; Hoffmann R, 1999, EMBO J, V18, P893, DOI 10.1093/emboj/18.4.893; Howard EL, 1999, MOL CELL BIOL, V19, P1990; Ichimura T, 2005, J BIOL CHEM, V280, P13187, DOI 10.1074/jbc.M412884200; Kellner M, 2003, KIDNEY INT, V64, P1199, DOI 10.1046/j.1523-1755.2003.00216.x; King-Jones K, 2005, NAT REV GENET, V6, P311, DOI 10.1038/nrg1581; Loffing J, 2001, AM J PHYSIOL-RENAL, V280, pF675, DOI 10.1152/ajprenal.2001.280.4.F675; Masaki T, 2004, J AM SOC NEPHROL, V15, P1835, DOI 10.1097/01.ASN.0000130623.66271.67; McCormick JA, 2005, PHYSIOLOGY, V20, P134, DOI 10.1152/physiol.00053.2004; Michlig S, 2004, J BIOL CHEM, V279, P51002, DOI 10.1074/jbc.M405674200; MICHLIG S, 2005, J BIOL CHEM; Mittelstadt PR, 2001, J BIOL CHEM, V276, P29603, DOI 10.1074/jbc.M101522200; Muller OG, 2003, J AM SOC NEPHROL, V14, P1107, DOI 10.1097/01.ASN.0000061777.67332.77; Naray-Fejes-Toth A, 2004, P NATL ACAD SCI USA, V101, P17434, DOI 10.1073/pnas.0408146101; Nicod M, 2002, EMBO J, V21, P5109, DOI 10.1093/emboj/cdf509; Pearce D, 2003, VITAM HORM, V66, P29, DOI 10.1016/S0083-6729(03)01002-1; Pearce D, 2001, TRENDS ENDOCRIN MET, V12, P341, DOI 10.1016/S1043-2760(01)00439-8; Prince LS, 1998, BIOCHEM J, V336, P705, DOI 10.1042/bj3360705; Rama S, 2004, MOL CELL ENDOCRINOL, V218, P79, DOI 10.1016/j.mce.2003.12.016; Robert-Nicoud M, 2001, P NATL ACAD SCI USA, V98, P2712, DOI 10.1073/pnas.051603198; Rossier BC, 2003, J CLIN INVEST, V111, P947, DOI 10.1172/JCI200318232; Shen J-P, 2003, AM J PHYSIOL-RENAL, V284, P57; Shi HK, 2002, J BIOL CHEM, V277, P13539, DOI 10.1074/jbc.M111717200; Snyder PM, 2002, J BIOL CHEM, V277, P5, DOI 10.1074/jbc.C100623200; Staruschenko A, 2004, J BIOL CHEM, V279, P37771, DOI 10.1074/jbc.M402176200; Vandewalle A, 1999, CURR OPIN NEPHROL HY, V8, P581, DOI 10.1097/00041552-199909000-00009; VERREY F, 1987, J CELL BIOL, V104, P1231, DOI 10.1083/jcb.104.5.1231; Verrey F, 1999, AM J PHYSIOL-RENAL, V277, pF319, DOI 10.1152/ajprenal.1999.277.3.F319; Wang J, 2001, AM J PHYSIOL-RENAL, V280, pF303, DOI 10.1152/ajprenal.2001.280.2.F303; Wulff P, 2002, J CLIN INVEST, V110, P1263, DOI 10.1172/JCI200215696; Xia HH, 2002, J BIOL CHEM, V277, P47765, DOI 10.1074/jbc.M207122200	55	141	144	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					39970	39981		10.1074/jbc.M508658200	http://dx.doi.org/10.1074/jbc.M508658200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16216878	hybrid			2022-12-25	WOS:000233461300036
J	Diaz-Hernandez, JI; Almeida, A; Delgado-Esteban, M; Fernandez, E; Bolanos, JP				Diaz-Hernandez, JI; Almeida, A; Delgado-Esteban, M; Fernandez, E; Bolanos, JP			Knockdown of glutamate-cysteine ligase by small hairpin RNA reveals that both catalytic and modulatory subunits are essential for the survival of primary neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; AMINO-ACID-SEQUENCE; NITRIC-OXIDE; OXIDATIVE STRESS; RAT-KIDNEY; GLUTATHIONE METABOLISM; PARKINSONS-DISEASE; INTRACELLULAR GLUTATHIONE; MITOCHONDRIAL-FUNCTION; CORTICAL-NEURONS	Glutathione deficiency is an early biochemical feature that occurs during apoptotic neuronal death associated with certain neurological disorders such as Parkinson disease. However, whether specific targeting of glutathione biosynthesis in neurons is sufficient to trigger neurodegeneration remains undetermined. To address this issue, we used a vector-based small hairpin RNA (shRNA) strategy to knock down each subunit of glutamate-cysteine ligase (GCL; gamma-glutamylcysteine synthetase), the heterodimeric enzyme that catalyzes the rate-limiting step of glutathione biosynthesis. Independent targeting of the catalytic and modulatory subunits by shRNA caused disruption of GCL as assessed by Northern and Western blotting, enzyme activity, and glutathione concentrations. Silencing each subunit in primary cortical neurons spontaneously elicited time-dependent apoptotic death, an effect that was synergistic with glutamate or nitric oxide treatment. Moreover, neuronal apoptosis by GCL knockdown was rescued by expressing the corresponding subunit full-length cDNA carrying silent mutations within the shRNA target cDNA sequence and by incubating neurons with gamma-glutamylcysteine or glutathione ethyl ester. In contrast, supplying glutathione precursors to neurons from co-cultured astrocytes did not prevent the apoptotic death triggered by GCL knockdown. Finally, overexpressing the catalytic (but not modulatory) GCL subunit full-length cDNA increased enzyme activity and glutathione concentrations, yielding neurons more resistant to glutamate- or nitric oxide-mediated apoptosis. Thus, specific and independent disruption of each subunit of GCL in neurons can be said to cause a primary decrease in glutathione that is sufficient to promote neurodegeneration.	Hosp Univ Salamanca, Unidad Invest, Salamanca 37007, Spain; Univ Salamanca, Dept Bioquim & Biol Mol, Salamanca 37007, Spain; Univ Salamanca, Ctr Nacl Invest Cardiovasc, Salamanca 37007, Spain	University of Salamanca; University of Salamanca; Centro Nacional de Investigaciones Cardiovasculares (CNIC); University of Salamanca	Almeida, A (corresponding author), Hosp Univ Salamanca, Unidad Invest, Paseo San Vicente 58-182, Salamanca 37007, Spain.	aaparra@usal.es	Delgado-Esteban, María/G-6025-2017; ALMEIDA, ANGELES/B-4727-2017; Bolaños, Juan Pedro/M-9518-2019; Diaz-Hernandez, Juan/B-6268-2011; Díaz-Hernandez, Juan Ignacio/L-6973-2014	Delgado-Esteban, María/0000-0002-6205-6611; ALMEIDA, ANGELES/0000-0003-0485-8904; Bolaños, Juan Pedro/0000-0002-3949-6862; Díaz-Hernandez, Juan Ignacio/0000-0003-2507-5888				Almeida A, 2001, P NATL ACAD SCI USA, V98, P15294, DOI 10.1073/pnas.261560998; Almeida A, 2001, J NEUROCHEM, V77, P676, DOI 10.1046/j.1471-4159.2001.00276.x; Almeida A, 2004, NAT CELL BIOL, V6, P45, DOI 10.1038/ncb1080; Andersen JK, 2004, NAT MED, V10, pS18, DOI 10.1038/nrn1434; Barja G, 2004, TRENDS NEUROSCI, V27, P595, DOI 10.1016/j.tins.2004.07.005; BOLANOS JP, 1995, J NEUROCHEM, V64, P1965; Bolanos JP, 1996, FREE RADICAL BIO MED, V21, P995, DOI 10.1016/S0891-5849(96)00240-7; Boyd-Kimball D, 2005, J NEUROSCI RES, V79, P700, DOI 10.1002/jnr.20394; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Dalton TP, 2000, BIOCHEM BIOPH RES CO, V279, P324, DOI 10.1006/bbrc.2000.3930; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; Dringen R, 2000, PROG NEUROBIOL, V62, P649, DOI 10.1016/S0301-0082(99)00060-X; Dringen R, 1996, J NEUROCHEM, V67, P1375, DOI 10.1046/j.1471-4159.1996.67041375.x; Dringen R, 1999, J NEUROSCI, V19, P562, DOI 10.1523/jneurosci.19-02-00562.1999; Garcia-Nogales P, 2003, J BIOL CHEM, V278, P864, DOI 10.1074/jbc.M206835200; Gegg ME, 2005, BRAIN RES, V1036, P1, DOI 10.1016/j.brainres.2004.11.064; Gegg ME, 2003, J NEUROCHEM, V86, P228, DOI 10.1046/j.1471-4159.2003.01821.x; Gegg ME, 2002, ANAL BIOCHEM, V304, P26, DOI 10.1006/abio.2001.5607; GRIFFITH OW, 1982, J BIOL CHEM, V257, P13704; GRIFFITH OW, 1979, P NATL ACAD SCI USA, V76, P6319, DOI 10.1073/pnas.76.12.6319; HEALES SJR, 1995, NEUROCHEM RES, V20, P31; Hirrlinger J, 2002, J NEUROCHEM, V82, P635, DOI 10.1046/j.1471-4159.2002.00999.x; Hsu M, 2005, J NEUROCHEM, V92, P1091, DOI 10.1111/j.1471-4159.2004.02929.x; HUANG CS, 1995, P NATL ACAD SCI USA, V92, P1232, DOI 10.1073/pnas.92.4.1232; HUANG CS, 1993, J BIOL CHEM, V268, P19675; HUANG CS, 1993, J BIOL CHEM, V268, P20578; Iwata-Ichikawa E, 1999, J NEUROCHEM, V72, P2334, DOI 10.1046/j.1471-4159.1999.0722334.x; Jha N, 2000, J BIOL CHEM, V275, P26096, DOI 10.1074/jbc.M000120200; Kijima H, 1998, BIOCHEM BIOPH RES CO, V247, P697, DOI 10.1006/bbrc.1998.8878; Liu HL, 2004, ANN NY ACAD SCI, V1019, P346, DOI 10.1196/annals.1297.059; Lu T, 2004, NATURE, V429, P883, DOI 10.1038/nature02661; MAKAR TK, 1994, J NEUROCHEM, V62, P45; Meister G, 2004, NATURE, V431, P343, DOI 10.1038/nature02873; MULCAHY RT, 1995, CANCER RES, V55, P4771; Ohtsuka T, 2004, NAT CELL BIOL, V6, P121, DOI 10.1038/ncb1087; ORLOWSKI M, 1971, BIOCHEMISTRY-US, V10, P372, DOI 10.1021/bi00779a003; PERRY TL, 1982, NEUROSCI LETT, V33, P305, DOI 10.1016/0304-3940(82)90390-1; RAFF MC, 1983, J NEUROSCI, V3, P1289; RATAN RR, 1994, J NEUROCHEM, V62, P376; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shi ZZ, 2000, P NATL ACAD SCI USA, V97, P5101, DOI 10.1073/pnas.97.10.5101; Soltaninassab SR, 2000, J CELL PHYSIOL, V182, P163, DOI 10.1002/(SICI)1097-4652(200002)182:2<163::AID-JCP4>3.0.CO;2-1; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Tipnis SR, 1999, BIOCHEM J, V337, P559, DOI 10.1042/0264-6021:3370559; Wang XF, 2000, J NEUROCHEM, V74, P1434, DOI 10.1046/j.1471-4159.2000.0741434.x; Yang Y, 2002, J BIOL CHEM, V277, P49446, DOI 10.1074/jbc.M209372200; YAO KS, 1995, CANCER RES, V55, P4367	48	67	68	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					38992	39001		10.1074/jbc.M507065200	http://dx.doi.org/10.1074/jbc.M507065200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16183645	hybrid			2022-12-25	WOS:000233362200013
J	Panizzi, P; Friedrich, R; Prior, PF; Richter, K; Bock, PE; Bode, W				Panizzi, P; Friedrich, R; Prior, PF; Richter, K; Bock, PE; Bode, W			Fibrinogen substrate recognition by Staphylocoagulase center dot(pro) thrombin complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCUS-AUREUS; CRYSTAL-STRUCTURE; ACTIVE-SITE; MACROMOLECULAR SUBSTRATE; PLASMINOGEN ACTIVATION; NUCLEOTIDE-SEQUENCE; BOVINE TRYPSINOGEN; KINETIC MECHANISM; STRUCTURAL BASIS; BINDING PROTEIN	Thrombin generation and fibrinogen (Fbg) clotting are the ultimate proteolytic reactions in the blood coagulation pathway. Staphylocoagulase (SC), a protein secreted by the human pathogen Staphylococcus aureus, activates prothrombin (ProT) without proteolysis. The SC.(pro) thrombin complex recognizes Fbg as a specific substrate, converting it directly into fibrin. The crystal structure of a fully active SC fragment containing residues 1-325 (SC-(1-325)) bound to human prethrombin 2 showed previously that SC inserts its Ile(1)-Val(2) N terminus into the Ile(16) pocket of prethrombin 2, inducing a functional active site in the cognate zymogen conformationally. Exosite I of alpha-thrombin, the Fbg recognition site, and pro-exosite I on ProT are blocked by domain 2 of SC-(1-325). In the present studies, active site-labeled fluorescent ProT analogs were used to quantitate Fbg binding to the SC-(1-325)(.)ProT complex. Fbg binding and cleavage are mediated by expression of a new Fbg-binding exosite on the SC-(1-325)(.)ProT complex, resulting in formation of an (SC-(1-325)(.)ProT)(2)(.)Fbg pentameric complex with a dissociation constant of 8-34 nM. In both crystal structures, the SC-(1-325)(.)(pre) thrombin complexes form dimers, with both proteinases/zymogens facing each other over a large U-shaped cleft, through which the Fbg substrate could thread. On this basis, a molecular model of the pentameric (SC-(1-325)(.)thrombin)(2)(.)Fbg encounter complex was generated, which explains the coagulant properties and efficient Fbg conversion. The results provide new insight into the mechanism that mediates high affinity Fbg binding and cleavage as a substrate of SC.(pro) thrombin complexes, a process that is central to the molecular pathology of S. aureus endocarditis.	Vanderbilt Univ, Dept Pathol, Sch Med, Med Ctr N, Nashville, TN 37232 USA; Max Planck Inst Biochem, Proteinase Res Grp, D-82152 Martinsried, Germany; Hosp Santa Creu & Sant Pau, CSIC, Inst Catala Ciencies Cardiovasc, Cardiovasc Res Ctr, E-08025 Barcelona, Spain; Tech Univ Munich, Dept Biotechnol, D-85747 Garching, Germany	Vanderbilt University; Max Planck Society; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Institut Catala de Ciencies Cardiovasculars (ICCC); Hospital of Santa Creu i Sant Pau; Technical University of Munich	Bode, W (corresponding author), Vanderbilt Univ, Dept Pathol, Sch Med, Med Ctr N, C3321A, Nashville, TN 37232 USA.	paul.bock@vanderbilt.edu	Richter, Klaus/A-2673-2010; Panizzi, Peter/A-6072-2019	Richter, Klaus/0000-0002-8952-9642; Panizzi, Peter/0000-0003-0141-8807; Fuentes-Prior, Pablo/0000-0002-6618-3204	NHLBI NIH HHS [R37 HL071544-03, R37 HL071544, R01 HL071544, R01 HL038779, HL038779, R01 HL038779-19, HL07751, R00 HL094533, HL071544] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007751, R00HL094533, R37HL071544, R01HL071544, R01HL038779, R29HL038779] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baba T, 2002, LANCET, V359, P1819, DOI 10.1016/S0140-6736(02)08713-5; Belkin AM, 2005, BLOOD, V105, P3561, DOI 10.1182/blood-2004-10-4089; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BINNIE CG, 1993, BLOOD, V81, P3186; BOCK PE, 1992, J BIOL CHEM, V267, P14963; BODE W, 1976, FEBS LETT, V68, P231, DOI 10.1016/0014-5793(76)80443-7; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1978, J MOL BIOL, V118, P99, DOI 10.1016/0022-2836(78)90246-2; Boxrud PD, 2000, J BIOL CHEM, V275, P14579, DOI 10.1074/jbc.275.19.14579; Boxrud PD, 2004, J BIOL CHEM, V279, P36633, DOI 10.1074/jbc.M405264200; Boxrud PD, 2004, J BIOL CHEM, V279, P36642, DOI 10.1074/jbc.M405265200; Brown JH, 2000, P NATL ACAD SCI USA, V97, P85, DOI 10.1073/pnas.97.1.85; Carter PE, 2003, EPIDEMIOL INFECT, V130, P207, DOI 10.1017/S0950268802008038; CHEUNG AI, 1995, INFECT IMMUN, V63, P1914, DOI 10.1128/IAI.63.5.1914-1920.1995; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Dhar J, 2002, J BIOL CHEM, V277, P13257, DOI 10.1074/jbc.M108422200; ESMON CT, 1982, J BIOL CHEM, V257, P7944; FENTON JW, 1977, J BIOL CHEM, V252, P3587; Friedrich R, 2006, J BIOL CHEM, V281, P1188, DOI 10.1074/jbc.M507957200; Friedrich R, 2003, NATURE, V425, P535, DOI 10.1038/nature01962; Fuentes-Prior P, 2000, NATURE, V404, P518, DOI 10.1038/35006683; FuentesPrior P, 1997, P NATL ACAD SCI USA, V94, P11845, DOI 10.1073/pnas.94.22.11845; HENDRIX H, 1983, J BIOL CHEM, V258, P3637; HIGGINS DL, 1983, J BIOL CHEM, V258, P9276; Holden MTG, 2004, P NATL ACAD SCI USA, V101, P9786, DOI 10.1073/pnas.0402521101; KAIDA S, 1987, J BIOCHEM, V102, P1177, DOI 10.1093/oxfordjournals.jbchem.a122156; KAWABATA S, 1985, J BIOCHEM, V98, P1603, DOI 10.1093/oxfordjournals.jbchem.a135430; KAWABATA S, 1986, J BIOL CHEM, V261, P527; Khan AR, 1998, PROTEIN SCI, V7, P815; Korzeniowski O., 1992, BRAUNWALD HEART DIS, V4, P1078; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; Madrazo J, 2001, P NATL ACAD SCI USA, V98, P11967, DOI 10.1073/pnas.211439798; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MARTIN PD, 1992, J BIOL CHEM, V267, P7911; Palma M, 1998, J BIOL CHEM, V273, P13177, DOI 10.1074/jbc.273.21.13177; Palma M, 2001, J BIOL CHEM, V276, P31691, DOI 10.1074/jbc.M104554200; Panizzi P, 2006, J BIOL CHEM, V281, P1169, DOI 10.1074/jbc.M507955200; Parry MAA, 1998, NAT STRUCT BIOL, V5, P917, DOI 10.1038/2359; Pechik I, 2004, P NATL ACAD SCI USA, V101, P2718, DOI 10.1073/pnas.0303440101; PHONIMDAENG P, 1990, MOL MICROBIOL, V4, P393, DOI 10.1111/j.1365-2958.1990.tb00606.x; Sazonova IY, 2004, J BIOL CHEM, V279, P24994, DOI 10.1074/jbc.M400253200; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Schlott B, 1997, J BIOL CHEM, V272, P6067, DOI 10.1074/jbc.272.9.6067; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; Sundram V, 2003, J BIOL CHEM, V278, P30569, DOI 10.1074/jbc.M303799200; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TSIANG M, 1995, J BIOL CHEM, V270, P16854, DOI 10.1074/jbc.270.28.16854; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; Yang Z, 2000, P NATL ACAD SCI USA, V97, P14156, DOI 10.1073/pnas.97.26.14156; Yang Z, 2001, BIOCHEMISTRY-US, V40, P12515, DOI 10.1021/bi011394p	50	48	53	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					1179	1187		10.1074/jbc.M507956200	http://dx.doi.org/10.1074/jbc.M507956200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16230339	Green Accepted, hybrid			2022-12-25	WOS:000234447200060
J	Dang, L; Fan, X; Chaudhry, A; Wang, M; Gaiano, N; Eberhart, CG				Dang, L; Fan, X; Chaudhry, A; Wang, M; Gaiano, N; Eberhart, CG			Notch3 signaling initiates choroid plexus tumor formation	ONCOGENE			English	Article						choroid plexus papilloma; Notch3	MULTIPLE FUNCTIONAL ROLES; RADIAL GLIAL IDENTITY; BRAIN-DEVELOPMENT; TRANSGENIC MICE; GROWTH; EXPRESSION; CANCER; DIFFERENTIATION; TUMORIGENESIS; DELTA-LIKE-1	Notch3 has been studied in the context of brain development, but whether it plays a role in the formation of brain tumors is unclear. We demonstrate that the introduction of constitutively active Notch3 into periventricular cells of embryonic day 9.5 mice causes the formation of choroid plexus tumors (CPTs). Tumors arose in the fourth ventricles in 83% of animals and were associated with hydrocephalus. They were microscopically highly similar to choroid plexus papillomas in humans, with an ongoing proliferation rate of 4-6%. Signs of Notch pathway activity were also present in human choroid plexus lesions, and receptor mRNA levels in papillomas were elevated over those in non-neoplastic choroid plexus. Notch2 was overexpressed approximately 500-fold in one case, suggesting that the role of this pathway in CPTs may not be specific to Notch3. Our findings indicate that activated Notch3 can function as an oncogene in the developing brain, and link the Notch pathway to human CPT pathogenesis.	Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Inst Cell Engn, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Johns Hopkins University; Johns Hopkins University	Eberhart, CG (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, 720 Rutland Ave,Ross Bldg 558, Baltimore, MD 21205 USA.	gaiano@jhmi.edu; ceberha@jhmi.edu		Dang, Louis/0000-0003-4853-4952	NINDS NIH HHS [K08NS43279, K08NS041342] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS041342, K08NS043279] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; Dang TP, 2000, J NATL CANCER I, V92, P1355, DOI 10.1093/jnci/92.16.1355; Fan X, 2004, CANCER RES, V64, P7787, DOI 10.1158/0008-5472.CAN-04-1446; Gaiano N, 2002, ANNU REV NEUROSCI, V25, P471, DOI 10.1146/annurev.neuro.25.030702.130823; Gaiano N, 2000, NEURON, V26, P395, DOI 10.1016/S0896-6273(00)81172-1; Hallahan AR, 2004, CANCER RES, V64, P7794, DOI 10.1158/0008-5472.CAN-04-1813; Irvin DK, 2001, J COMP NEUROL, V436, P167, DOI 10.1002/cne.1059.abs; Irvin DK, 2004, J NEUROSCI RES, V75, P330, DOI 10.1002/jnr.10843; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; KLEIHUES P, 2000, TUMORS NERVOUS SYSTE; Miyamoto Y, 2003, CANCER CELL, V3, P565, DOI 10.1016/S1535-6108(03)00140-5; Nickoloff BJ, 2003, ONCOGENE, V22, P6598, DOI 10.1038/sj.onc.1206758; Purow BW, 2005, CANCER RES, V65, P2353, DOI 10.1158/0008-5472.CAN-04-1890; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; Rae FK, 2000, INT J CANCER, V88, P726, DOI 10.1002/1097-0215(20001201)88:5<726::AID-IJC7>3.0.CO;2-H; Rickert CH, 2002, AM J PATHOL, V160, P1105, DOI 10.1016/S0002-9440(10)64931-0; Solecki DJ, 2001, NEURON, V31, P557, DOI 10.1016/S0896-6273(01)00395-6; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Weng AP, 2004, CURR OPIN GENET DEV, V14, P48, DOI 10.1016/j.gde.2003.11.004; Yoon KJ, 2004, J NEUROSCI, V24, P9497, DOI 10.1523/JNEUROSCI.0993-04.2004	21	58	59	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					487	491		10.1038/sj.onc.1209074	http://dx.doi.org/10.1038/sj.onc.1209074			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16186803				2022-12-25	WOS:000234714100017
J	Barros, MH; Johnson, A; Gin, P; Marbois, BN; Clarke, CF; Tzagoloff, A				Barros, MH; Johnson, A; Gin, P; Marbois, BN; Clarke, CF; Tzagoloff, A			The Saccharomyces cerevisiae COQ10 gene encodes a START domain protein required for function of coenzyme Q in respiration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; Q BIOSYNTHESIS; UBIQUINONE BIOSYNTHESIS; MULTISUBUNIT COMPLEX; C-METHYLTRANSFERASE; YEAST; COQ3; MITOCHONDRIA; EXPRESSION; TRANSPORT	Deletion of the Saccharomyces cerevisiae gene YOL008W, here referred to as COQ10, elicits a respiratory defect as a result of the inability of the mutant to oxidize NADH and succinate. Both activities are restored by exogenous coenzyme Q(2). Respiration is also partially rescued by COQ2, COQ7, or COQ8/ABC1, when these genes are present in high copy. Unlike other coq mutants, all of which lack Q(6), the coq10 mutant has near normal amounts of Q(6) in mitochondria. Coq10p is widely distributed in bacteria and eukaryotes and is homologous to proteins of the "aromatic-rich protein family" Pfam03654 and to members of the START domain superfamily that have a hydrophobic tunnel implicated in binding lipophilic molecules such as cholesterol and polyketides. Analysis of coenzyme Q in polyhistidine-tagged Coq10p purified from mitochondria indicates the presence 0.032-0.034 mol of Q(6)/mol of protein. We propose that Coq10p is a Q(6)-binding protein and that in the coq10 mutant Q(6) it is not able to act as an electron carrier, possibly because of improper localization.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Estadual Paulista, Dept Genet, Inst Biociencias, BR-18607741 Botucatu, SP, Brazil	Columbia University; University of California System; University of California Los Angeles; Universidade Estadual Paulista	Tzagoloff, A (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	spud@cubpet2.bio.columbia.edu	Barros, Mario H/B-8118-2012; Barros, Mario/Q-6358-2019	Barros, Mario/0000-0003-2977-9815	NHLBI NIH HHS [HL2274, R01 HL022174] Funding Source: Medline; NIGMS NIH HHS [GM45952] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022174] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045952] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akiyama N, 1997, CANCER RES, V57, P3548; Baba SW, 2004, J BIOL CHEM, V279, P10052, DOI 10.1074/jbc.M313712200; Barkovich RJ, 1997, J BIOL CHEM, V272, P9182; Barrientos A, 2002, EMBO J, V21, P43, DOI 10.1093/emboj/21.1.43; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Belogrudov GI, 2001, ARCH BIOCHEM BIOPHYS, V392, P48, DOI 10.1006/abbi.2001.2448; CLARKE CF, 1991, J BIOL CHEM, V266, P16636; Do TQ, 2001, J BIOL CHEM, V276, P18161, DOI 10.1074/jbc.M100952200; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; GIBSON F, 1973, Biochemical Society Transactions, V1, P317; Gin P, 2005, J BIOL CHEM, V280, P2676, DOI 10.1074/jbc.M411527200; Gin P, 2003, J BIOL CHEM, V278, P25308, DOI 10.1074/jbc.M303234200; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Glick BS, 1995, METHOD ENZYMOL, V260, P224, DOI 10.1016/0076-6879(95)60140-6; GLOOR U, 1958, HELV CHIM ACTA, V41, P2357, DOI 10.1002/hlca.19580410746; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; Herrmann J. M., 1994, CELL BIOL LAB HDB, VI, P538; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Hsu AY, 2000, BBA-MOL CELL BIOL L, V1484, P287, DOI 10.1016/S1388-1981(00)00019-6; Johnson A, 2005, J BIOL CHEM, V280, P31397, DOI 10.1074/jbc.M503277200; Jonassen T, 2000, J BIOL CHEM, V275, P12381, DOI 10.1074/jbc.275.17.12381; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lo Conte L, 2000, NUCLEIC ACIDS RES, V28, P257, DOI 10.1093/nar/28.1.257; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING LAB MANU; Marbois B, 2005, J BIOL CHEM, V280, P20231, DOI 10.1074/jbc.M501315200; Marbois BN, 1996, J BIOL CHEM, V271, P2995, DOI 10.1074/jbc.271.6.2995; MURACA RF, 1967, J AM CHEM SOC, V89, P1505, DOI 10.1021/ja00982a038; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; OLSON RE, 1983, VITAM HORM, V40, P1, DOI 10.1016/S0083-6729(08)60431-8; Padilla S, 2004, J BIOL CHEM, V279, P25995, DOI 10.1074/jbc.M400001200; Ponting CP, 1999, TRENDS BIOCHEM SCI, V24, P130, DOI 10.1016/S0968-0004(99)01362-6; Poon WW, 1997, MOL ASPECTS MED, V18, pS121; Romanowski MJ, 2002, P NATL ACAD SCI USA, V99, P6949, DOI 10.1073/pnas.052140699; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Shen Y, 2005, PROTEINS, V58, P747, DOI 10.1002/prot.20365; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; VANLOON D, 1986, EUR J BIOCHEM, V157, P347; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	41	70	73	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42627	42635		10.1074/jbc.M510768200	http://dx.doi.org/10.1074/jbc.M510768200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16230336	hybrid			2022-12-25	WOS:000234200800020
J	Lodige, I; Marg, A; Wiesner, B; Malecova, B; Oelgeschlager, T; Vinkemeier, U				Lodige, I; Marg, A; Wiesner, B; Malecova, B; Oelgeschlager, T; Vinkemeier, U			Nuclear export determines the cytokine sensitivity of STAT transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PHOSPHORYLATION; IFN-GAMMA; TYROSINE DEPHOSPHORYLATION; EXTRACELLULAR SIGNALS; INTERFERON-ALPHA; MAP KINASE; ACTIVATION; DOMAIN; BETA; GENE	Cytokine-dependent gene activation critically depends upon the tyrosine phosphorylation ( activation) of STAT transcription factors at membrane-bound cytokine receptors. The extent of STAT activation and hence the specificity of signaling is primarily determined by structural complementarity between the SH2 domain of the STATs and the tyrosine-phosphorylated receptor chains. Here, we identified constitutive nucleocytoplasmic shuttling as another mechanism that controls the differential activation of STAT transcription factors. Our analysis of nucleocytoplasmic cycling of STAT1 revealed that the expression of the alternatively spliced transactivation domain and its signal-dependent serine phosphorylation maximized the rate of nuclear export. Export modulation occurred independently of retention factors or the export receptor CRM1, and was observed both before and during stimulation of cells with cytokines. Our data indicated a dual role for the transactivation domain. It enhanced the nuclear retention of activated STAT1, but had the opposite effect on inactivated molecules. Accordingly, and despite their identical receptor recognition, the STAT1 splice variants differed strongly in the amplitude of tyrosine phosphorylation and in the duration of the cytokine signal. Thus, regulated nuclear export determined the cytokine sensitivity of the shuttling STAT1 transcription factors by controlling their availability at the receptor kinase complex.	Free Univ Berlin, Abt Zellulare Signalverarbeitung, Leibniz Forsch Inst Mol Pharmakol, D-13125 Berlin, Germany; Leibniz Forsch Inst Mol Pharmakol, Abt Mol Med, D-13125 Berlin, Germany; Marie Curie Res Inst, Transcript Lab, Surrey RH8 0TL, England	Free University of Berlin	Vinkemeier, U (corresponding author), Free Univ Berlin, Abt Zellulare Signalverarbeitung, Leibniz Forsch Inst Mol Pharmakol, Robert Rossle Str 10, D-13125 Berlin, Germany.	vinkemeier@fmp-berlin.de	Loedige, Inga/AAF-6015-2019	Malecova, Barbora/0000-0001-5334-3195; Loedige, Inga/0000-0002-2596-4063; Oelgeschlager, Thomas/0000-0002-4086-719X; Vinkemeier, Uwe/0000-0001-6924-1783				Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Bednenko J, 2003, J CELL BIOL, V162, P391, DOI 10.1083/jcb.200303085; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Castano E, 2000, P NATL ACAD SCI USA, V97, P7184, DOI 10.1073/pnas.140202297; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Fagerlund R, 2002, J BIOL CHEM, V277, P30072, DOI 10.1074/jbc.M202943200; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; Ginger RS, 2000, EMBO J, V19, P5483, DOI 10.1093/emboj/19.20.5483; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; Hendry L, 2004, EUR J BIOCHEM, V271, P4613, DOI 10.1111/j.1432-1033.2004.04424.x; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hoey T, 2003, EMBO J, V22, P4237, DOI 10.1093/emboj/cdg393; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Kovarik P, 2001, EMBO J, V20, P91, DOI 10.1093/emboj/20.1.91; Lerner L, 2003, GENE DEV, V17, P2564, DOI 10.1101/gad.1135003; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Marg A, 2004, J CELL BIOL, V165, P823, DOI 10.1083/jcb.200403057; McBride KM, 2000, EMBO J, V19, P6196, DOI 10.1093/emboj/19.22.6196; Meissner T, 2004, CELL, V119, P587, DOI 10.1016/S0092-8674(04)01090-6; Meissner T, 2004, FEBS LETT, V576, P27, DOI 10.1016/j.febslet.2004.08.056; Meyer T, 2004, J BIOL CHEM, V279, P18998, DOI 10.1074/jbc.M400766200; Meyer T, 2002, EMBO J, V21, P344, DOI 10.1093/emboj/21.3.344; Meyer T, 2003, GENE DEV, V17, P1992, DOI 10.1101/gad.268003; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; Palmer A, 1998, EMBO J, V17, P5037, DOI 10.1093/emboj/17.17.5037; Park OK, 2000, J BIOL CHEM, V275, P32244, DOI 10.1074/jbc.M005082200; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; Poon IKH, 2005, TRAFFIC, V6, P173, DOI 10.1111/j.1600-0854.2005.00268.x; Schaefer TS, 1997, MOL CELL BIOL, V17, P5307, DOI 10.1128/MCB.17.9.5307; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; Shuai K, 1996, MOL CELL BIOL, V16, P4932; Smith CL, 1997, J BIOL CHEM, V272, P27493, DOI 10.1074/jbc.272.44.27493; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Strehlow I, 1998, J BIOL CHEM, V273, P28049, DOI 10.1074/jbc.273.43.28049; Swameye I, 2003, P NATL ACAD SCI USA, V100, P1028, DOI 10.1073/pnas.0237333100; Varinou L, 2003, IMMUNITY, V19, P793, DOI 10.1016/S1074-7613(03)00322-4; Vinkemeier U, 2004, J CELL BIOL, V167, P197, DOI 10.1083/jcb.200407163; Wang DM, 1996, MOL CELL BIOL, V16, P6141; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Zakharova N, 2003, J BIOL CHEM, V278, P43067, DOI 10.1074/jbc.M308166200; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618	48	46	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					43087	43099		10.1074/jbc.M509180200	http://dx.doi.org/10.1074/jbc.M509180200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16195225	hybrid			2022-12-25	WOS:000234200800075
J	Meadow, ND; Savtchenko, RS; Nezami, A; Roseman, S				Meadow, ND; Savtchenko, RS; Nezami, A; Roseman, S			Transient state kinetics of Enzyme IICBGlc, a glucose transporter of the phosphoenolpyruvate phosphotransferase system of Escherichia coli - Equilibrium and second order rate constants for the glucose binding and phosphotransfer reactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCING PROTEIN; SUGAR-TRANSPORT; BACTERIAL PHOSPHOENOLPYRUVATE; CARBOHYDRATE TRANSPORTERS; PHOSPHORYLATION; PURIFICATION; PERMEASE; IIIGLC; PHOSPHATE; CATALYSIS	During translocation across the cytoplasmic membrane of Escherichia coli, glucose is phosphorylated by phospho-IIA(Glc) and Enzyme IICBGlc, the last two proteins in the phosphotransfer sequence of the phosphoenolpyruvate: glucose phosphotransferase system. Transient state (rapid quench) methods were used to determine the second order rate constants that describe the phosphotransfer reactions (phospho-IIA(Glc) to IICBGlc to Glc) and also the second order rate constants for the transfer from phospho-IIA(Glc) to molecularly cloned IIBGlc, the soluble, cytoplasmic domain of IICBGlc. The rate constants for the forward and reverse phosphotransfer reactions between IIA(Glc) and IICBGlc were 3.9 X 10(6) and 0.31 x 10(6) M-1 s(-1), respectively, and the rate constant for the physiologically irreversible reaction between [P]IICBGlc and Glc was 3.2 x 10(6) M-1 s(-1). From the rate constants, the equilibrium constants for the transfer of the phospho-group from His(90) of [P]IIA(Glc) to the phosphorylation site Cys of IIBGlc or IICBGlc were found to be 3.5 and 12, respectively. These equilibrium constants signify that the thiophospho-group in these proteins has a high phosphotransfer potential, similar to that of the phosphohistidinyl phosphotransferase system proteins. In these studies, preparations of IICBGlc were invariably found to contain endogenous, firmly bound Glc (estimated K'(D) similar to 10(-7) M). The bound Glc was kinetically competent and was rapidly phosphorylated, indicating that IICBGlc has a random order, Bi Bi, substituted enzyme mechanism. The equilibrium constant for the binding of Glc was deduced from differences in the statistical goodness of fit of the phosphotransfer data to the kinetic model.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	Johns Hopkins University	Roseman, S (corresponding author), Johns Hopkins Univ, Dept Biol, 3400 N Charles St, Baltimore, MD 21218 USA.	roseman@jhu.edu						AKERFELDT S, 1960, ACTA CHEM SCAND, V14, P1980, DOI 10.3891/acta.chem.scand.14-1980; ANDERSON KS, 1988, BIOCHEMISTRY-US, V27, P7395, DOI 10.1021/bi00419a034; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BLACK S, 1955, J BIOL CHEM, V213, P27; BOUMA CL, 1987, P NATL ACAD SCI USA, V84, P930, DOI 10.1073/pnas.84.4.930; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUHR A, 1994, J BIOL CHEM, V269, P23437; Cleland W W, 1979, Methods Enzymol, V63, P103; CORNISHBOWDEN, 1995, FUNDAMENTALS ENZYME; ERNI B, 1986, BIOCHEMISTRY-US, V25, P305, DOI 10.1021/bi00350a004; Garcia-Alles LF, 2002, BIOCHEMISTRY-US, V41, P10077, DOI 10.1021/bi025928d; Garcia-Alles LF, 2002, EUR J BIOCHEM, V269, P4969, DOI 10.1046/j.1432-1033.2002.03197.x; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HERR EB, 1957, BIOCHIM BIOPHYS ACTA, V25, P219, DOI 10.1016/0006-3002(57)90456-0; Hu KY, 2002, RES MICROBIOL, V153, P405, DOI 10.1016/S0923-2508(02)01339-6; JAENICKE L, 1974, ANAL BIOCHEM, V61, P623, DOI 10.1016/0003-2697(74)90429-1; LOLKEMA JS, 1993, J BIOL CHEM, V268, P17850; LOLKEMA JS, 1993, J BIOL CHEM, V268, P17844; LOLKEMA JS, 1991, BIOCHEMISTRY-US, V30, P6716, DOI 10.1021/bi00241a012; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MEADOW ND, 1982, J BIOL CHEM, V257, P4526; Meadow ND, 1996, J BIOL CHEM, V271, P33440, DOI 10.1074/jbc.271.52.33440; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MEINS M, 1988, J BIOL CHEM, V263, P12986; MEINS M, 1993, J BIOL CHEM, V268, P11604; PAS HH, 1988, BIOCHEMISTRY-US, V27, P5835, DOI 10.1021/bi00416a002; PELTON JG, 1991, BIOCHEMISTRY-US, V30, P10043, DOI 10.1021/bi00105a032; ROBILLARD GT, 1988, BIOCHIM BIOPHYS ACTA, V947, P493, DOI 10.1016/0304-4157(88)90005-6; Robillard GT, 1999, BBA-REV BIOMEMBRANES, V1422, P73, DOI 10.1016/S0304-4157(99)00002-7; Rohwer JM, 2000, J BIOL CHEM, V275, P34909, DOI 10.1074/jbc.M002461200; ROOSSIEN FF, 1983, BIOCHIM BIOPHYS ACTA, V760, P185, DOI 10.1016/0304-4165(83)90141-1; Siebold C, 2001, FEBS LETT, V504, P104, DOI 10.1016/S0014-5793(01)02705-3; STOCK JB, 1982, J BIOL CHEM, V257, P4543; WAEBER U, 1993, FEBS LETT, V324, P109, DOI 10.1016/0014-5793(93)81542-8; WAYGOOD EB, 1982, METHOD ENZYMOL, V90, P423; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381	36	8	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					41872	41880		10.1074/jbc.M501440200	http://dx.doi.org/10.1074/jbc.M501440200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16204242	hybrid			2022-12-25	WOS:000233992700013
J	Rossi, V; Teillet, F; Thielens, NM; Bally, I; Arlaud, GJ				Rossi, V; Teillet, F; Thielens, NM; Bally, I; Arlaud, GJ			Functional characterization of complement proteases C1s/mannan-binding lectin-associated serine protease-2 (MASP-2) chimeras reveals the higher C4 recognition efficacy of the MASP-2 complement control protein modules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNAN-BINDING LECTIN; X-RAY-STRUCTURE; SUBSTRATE SPECIFICITIES; CATALYTIC DOMAIN; C1 COMPLEX; ACTIVATION; MBL; PATHWAY; CLR; C(1)OVER-BAR-S	C1s and mannan-binding lectin-associated serine protease-2 (MASP-2) are the proteases that trigger the classical and lectin pathways of complement, respectively. They have identical modular architectures and cleave the same substrates, C2 and C4, but show markedly different efficiencies toward C4. Multisite-directed mutagenesis was used to engineer hybrid C1s/MASP-2 molecules where either the complement control protein (CCP) modules or the serine protease (SP) domain of C1s were swapped for their MASP-2 counterparts. The resulting chimeras (C1s((MASP-2 CCP1/2)) and C1s((MASP-2) (SP)), respectively) were expressed and characterized chemically and functionally. Whereas C1s((MASP-2) (SP)) was recovered as an active enzyme, C1s((MASP-2) (CCP1/2)) was produced in a proenzyme form and was susceptible to activation by C1r, indicating that the activation properties of the chimeras were dictated by the nature of their SP domain. Similarly, each activated chimera had an esterolytic activity characteristic of its own SP domain and cleaved C2 with an efficiency comparable with that of their parent C1s and MASP-2 proteases. Both chimeras cleaved C4, but whereas C1s((MASP-2) (SP)) and C1s had Km values in the micromolar range, C1s((MASP-2) (CCP1/2)) and MASP- 2 had K-m values in the nanomolar range, resulting in 21-27- fold higher k(cat)/K-m ratios. Thus, the higher C4 cleavage efficiency of MASP-2 arises from a higher substrate recognition efficacy of its CCP modules. Remarkably, C1s((MASP-2) (CCP1/2)) retained C1s ability to associate with C1r and C1q to form a pseudo-C1 complex and to undergo activation within this complex, indicating that the C1s-CCP modules have no direct implication in either function.	Inst Biol Struct Jean Pierre Ebel, Lab Enzymol Mol, F-38027 Grenoble, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Arlaud, GJ (corresponding author), Inst Biol Struct Jean Pierre Ebel, Lab Enzymol Mol, F-38027 Grenoble, France.	arlaud@ibs.fr	Thielens, Nicole M/F-2512-2013	Thielens, Nicole M/0000-0002-7354-0302				Ambrus G, 2003, J IMMUNOL, V170, P1374, DOI 10.4049/jimmunol.170.3.1374; ARLAUD GJ, 1993, METHOD ENZYMOL, V223, P61; ARLAUD GJ, 1980, BIOCHIM BIOPHYS ACTA, V616, P116, DOI 10.1016/0005-2744(80)90269-7; ARLAUD GJ, 1979, MOL IMMUNOL, V16, P445, DOI 10.1016/0161-5890(79)90069-5; Bally I, 2005, J IMMUNOL, V175, P4536, DOI 10.4049/jimmunol.175.7.4536; BOCK SC, 1986, BIOCHEMISTRY-US, V25, P4292, DOI 10.1021/bi00363a018; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; COOPER NR, 1985, ADV IMMUNOL, V37, P151, DOI 10.1016/S0065-2776(08)60340-5; DODDS AW, 1993, METHOD ENZYMOL, V223, P46; Duret L, 1999, P NATL ACAD SCI USA, V96, P4482, DOI 10.1073/pnas.96.8.4482; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Gaboriaud C, 2004, TRENDS IMMUNOL, V25, P368, DOI 10.1016/j.it.2004.04.008; Gaboriaud C, 2000, EMBO J, V19, P1755, DOI 10.1093/emboj/19.8.1755; Gregory LA, 2004, J BIOL CHEM, V279, P29391, DOI 10.1074/jbc.M402687200; Gregory LA, 2003, J BIOL CHEM, V278, P32157, DOI 10.1074/jbc.M305175200; Harmat V, 2004, J MOL BIOL, V342, P1533, DOI 10.1016/j.jmb.2004.07.014; Harpel P C, 1976, Methods Enzymol, V45, P751; KING LA, 1992, BACULOVIRUS EXPRESSI, P111; Lacroix M, 2001, J BIOL CHEM, V276, P36233, DOI 10.1074/jbc.M105688200; LUO C, 1992, BIOCHEMISTRY-US, V31, P4254, DOI 10.1021/bi00132a015; MARCH SC, 1974, ANAL BIOCHEM, V60, P149, DOI 10.1016/0003-2697(74)90139-0; Matsushita M, 2000, J IMMUNOL, V164, P2281, DOI 10.4049/jimmunol.164.5.2281; MATSUSHITA M, 1992, J EXP MED, V176, P1497, DOI 10.1084/jem.176.6.1497; Matsushita M, 2002, J IMMUNOL, V168, P3502, DOI 10.4049/jimmunol.168.7.3502; REID KBM, 1986, IMMUNOL TODAY, V7, P230, DOI 10.1016/0167-5699(86)90110-6; ROSSI V, 1995, BIOCHEMISTRY-US, V34, P7311, DOI 10.1021/bi00022a004; Rossi V, 1998, J BIOL CHEM, V273, P1232, DOI 10.1074/jbc.273.2.1232; Rossi V, 2001, J BIOL CHEM, V276, P40880, DOI 10.1074/jbc.M105934200; SCHUMAKER VN, 1987, ANNU REV IMMUNOL, V5, P21, DOI 10.1146/annurev.iy.05.040187.000321; Tacnet-Delorme P, 2001, J IMMUNOL, V167, P6374, DOI 10.4049/jimmunol.167.11.6374; Teillet F, 2005, J IMMUNOL, V174, P2870, DOI 10.4049/jimmunol.174.5.2870; Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0; Thielens NM, 2001, J IMMUNOL, V166, P5068, DOI 10.4049/jimmunol.166.8.5068; THIELENS NM, 1982, FEBS LETT, V141, P19, DOI 10.1016/0014-5793(82)80006-9; THIELENS NM, 1990, J BIOL CHEM, V265, P14469; Vorup-Jensen T, 2000, J IMMUNOL, V165, P2093, DOI 10.4049/jimmunol.165.4.2093; Zundel S, 2004, J IMMUNOL, V172, P4342, DOI 10.4049/jimmunol.172.7.4342	37	28	30	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					41811	41818		10.1074/jbc.M503813200	http://dx.doi.org/10.1074/jbc.M503813200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16227207	hybrid			2022-12-25	WOS:000233992700006
J	Sumioka, A; Nagaishi, S; Yoshida, T; Lin, AN; Miura, M; Suzuki, T				Sumioka, A; Nagaishi, S; Yoshida, T; Lin, AN; Miura, M; Suzuki, T			Role of 14-3-3 gamma in FE65-dependent gene transactivation mediated by the amyloid beta-protein precursor cytoplasmic fragment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED INTRAMEMBRANE PROTEOLYSIS; GAMMA-SECRETASE CLEAVAGE; C-TERMINAL FRAGMENT; INTRACELLULAR DOMAIN; ALZHEIMERS-DISEASE; NEURONAL DIFFERENTIATION; TRANSCRIPTION REGULATION; DEPENDENT REGULATION; SCAFFOLD PROTEINS; ADAPTER PROTEIN	The amyloid beta-protein precursor intracellular domain fragment ( AICD) is generated from amyloid beta-protein precursor by consecutive cleavages. AICD is thought to activate FE65-dependent gene expression, but the molecular mechanism remains under consideration. We found that dimeric 14-3-3 gamma bound both AICD and FE65 simultaneously, and this binding facilitated FE65-dependent gene transactivation by enhancing the association of AICD with FE65. 14-3-3 gamma bound to the (VTPEER672)-V-667 motif of AICD and, most interestingly, the phosphorylation of AICD at Thr-668 in this motif inhibited the interaction with 14-3-3 gamma and blocked gene transactivation. 14-3-3 gamma required a sequence between the WW domain and the first phosphotyrosine interaction domain of FE65 for association with FE65. Deletion of this region blocked 14-3-3 gamma binding to FE65 and suppressed AICD-mediated FE65-dependent gene transactivation, although the deletion mutant FE65 was still able to bind Tip60, a histone acetyltransferase that forms a complex with FE65 in the nucleus. Taken together, these data demonstrate that 14-3-3 gamma facilitates FE65-dependent gene transactivation by forming a complex containing AICD and FE65, and phosphorylation of AICD down-regulates FE65-dependent gene transactivation through the dissociation of 14-3-3 gamma and/or FE65 from AICD. Our findings suggest that multiple interactions of AICD with FE65 and 14-3-3 gamma modulate FE65-dependent gene transactivation.	Hokkaido Univ, Neurosci Lab, Grad Sch Pharmaceut Sci, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Univ Tokyo, Genet Lab, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA	Hokkaido University; University of Tokyo; University of Chicago	Suzuki, T (corresponding author), Hokkaido Univ, Neurosci Lab, Grad Sch Pharmaceut Sci, Kita Ku, Kita 12 Nishi 6, Sapporo, Hokkaido 0600812, Japan.	tsuzuki@pharm.hokudai.ac.jp	Suzuki, Toshiharu/B-5342-2013					AIKEN A, 2002, BIOCHEM SOC T, V30, P351; Ando K, 2001, J BIOL CHEM, V276, P40353, DOI 10.1074/jbc.M104059200; Ando K, 1999, J NEUROSCI, V19, P4421; Aplin AE, 1996, J NEUROCHEM, V67, P699; Araki Y, 2004, J BIOL CHEM, V279, P24343, DOI 10.1074/jbc.M401925200; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Bao JX, 2004, NAT NEUROSCI, V7, P1250, DOI 10.1038/nn1342; Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Cao XW, 2004, J BIOL CHEM, V279, P24601, DOI 10.1074/jbc.M402248200; Engelman JA, 1999, J BIOL CHEM, V274, P35630, DOI 10.1074/jbc.274.50.35630; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Fountoulakis M, 1999, J NEURAL TRANSM-SUPP, P323; Gao YH, 2001, P NATL ACAD SCI USA, V98, P14979, DOI 10.1073/pnas.261463298; Ghersi E, 2004, J BIOL CHEM, V279, P49105, DOI 10.1074/jbc.M405329200; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; Hass MR, 2005, J BIOL CHEM, V280, P36895, DOI 10.1074/jbc.M502861200; Horie M, 1999, GENOMICS, V60, P241, DOI 10.1006/geno.1999.5887; Iijima K, 2000, J NEUROCHEM, V75, P1085, DOI 10.1046/j.1471-4159.2000.0751085.x; Kamal A, 2000, NEURON, V28, P449, DOI 10.1016/S0896-6273(00)00124-0; Kimberly WT, 2005, J NEUROSCI, V25, P5533, DOI 10.1523/JNEUROSCI.4883-04.2005; Lai A, 1998, J BIOL CHEM, V273, P3732, DOI 10.1074/jbc.273.6.3732; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Oishi M, 1997, MOL MED, V3, P111, DOI 10.1007/BF03401803; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; Pardossi-Piquard R, 2005, NEURON, V46, P541, DOI 10.1016/j.neuron.2005.04.008; PATEL Y, 1994, BBA-MOL CELL RES, V1222, P405, DOI 10.1016/0167-4889(94)90048-5; Perkinton MS, 2004, J BIOL CHEM, V279, P22084, DOI 10.1074/jbc.M311479200; Ramelot TA, 2001, J MOL BIOL, V307, P871, DOI 10.1006/jmbi.2001.4535; Ramelot TA, 2000, BIOCHEMISTRY-US, V39, P2714, DOI 10.1021/bi992580m; Sato T, 2003, J BIOL CHEM, V278, P24294, DOI 10.1074/jbc.M211161200; Scheinfeld MH, 2003, P NATL ACAD SCI USA, V100, P1729, DOI 10.1073/pnas.0437908100; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; Selkoe DJ, 2003, NATURE, V426, P900, DOI 10.1038/nature02264; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Standen CL, 2001, J NEUROCHEM, V76, P316, DOI 10.1046/j.1471-4159.2001.00102.x; Sumioka A, 2003, BIOCHEM J, V374, P261, DOI 10.1042/BJ20030489; SUZUKI T, 1994, EMBO J, V13, P1114, DOI 10.1002/j.1460-2075.1994.tb06360.x; Taru H, 2004, J BIOL CHEM, V279, P21628, DOI 10.1074/jbc.M312007200; Taru H, 2002, J BIOL CHEM, V277, P20070, DOI 10.1074/jbc.M108372200; Taru H, 2002, J BIOL CHEM, V277, P27567, DOI 10.1074/jbc.M203713200; Telese F, 2005, EMBO REP, V6, P77, DOI 10.1038/sj.embor.7400309; Tomita S, 1999, J BIOL CHEM, V274, P2243, DOI 10.1074/jbc.274.4.2243; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; von Rotz RC, 2004, J CELL SCI, V117, P4435, DOI 10.1242/jcs.01323; Walsh DM, 2003, BIOCHEMISTRY-US, V42, P6664, DOI 10.1021/bi027375c	50	55	57	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42364	42374		10.1074/jbc.M504278200	http://dx.doi.org/10.1074/jbc.M504278200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16223726	hybrid			2022-12-25	WOS:000233992700066
J	McDonough, MA; Kavanagh, KL; Butler, D; Searls, T; Oppermann, U; Schofield, CJ				McDonough, MA; Kavanagh, KL; Butler, D; Searls, T; Oppermann, U; Schofield, CJ			Structure of human phytanoyl-CoA 2-hydroxylase identifies molecular mechanisms of Refsum disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-METHYL-BRANCHED FATTY-ACIDS; STEROL CARRIER PROTEIN-2; HYPOXIA-INDUCIBLE FACTOR; DEACETOXYCEPHALOSPORIN-C-SYNTHASE; PEROXISOMAL ALPHA-OXIDATION; RAT-LIVER; 2-HYDROXYPHYTANOYL-COA LYASE; CRYSTAL-STRUCTURE; HYDROXYLASE; GENE	Refsum disease (RD), a neurological syndrome characterized by adult onset retinitis pigmentosa, anosmia, sensory neuropathy, and phytanic acidaemia, is caused by elevated levels of phytanic acid. Many cases of RD are associated with mutations in phytanoyl-CoA2-hydroxylase (PAHX), an Fe(II) and 2- oxoglutarate (2OG)dependent oxygenase that catalyzes the initial alpha- oxidation step in the degradation of phytenic acid in peroxisomes. We describe the x- ray crystallographic structure of PAHX to 2.5 angstrom resolution complexed with Fe(II) and 2OG and predict the molecular consequences of mutations causing RD. Like other 2OG oxygenases, PAHX possesses a double-stranded beta-helix core, which supports three iron binding ligands (His(175), Asp(177), and His(264))(;) the 2-oxoacid group of 2OG binds to the Fe( II) in a bidentate manner. The manner in which PAHX binds to Fe( II) and 2OG together with the presence of a cysteine residue (Cys(191)) 6.7 angstrom from the Fe(II) and two further histidine residues (His(155) and His(281)) at its active site distinguishes it from that of the other human 2OG oxygenase for which structures are available, factor inhibiting hypoxia-inducible factor. Of the 15 PAHX residues observed to be mutated in RD patients, 11 cluster in two distinct groups around the Fe(II) (Pro(173), His(175), Gln(176), Asp(177), and His(220)) and 2OG binding sites (Trp(193), Glu(197), Ile(199), Gly(204), Asn(269), and Arg(275)). PAHX may be the first of a new subfamily of coenzyme A- binding 2OG oxygenases.	Univ Oxford, Oxford Ctr Mol Sci, Oxford OX1 3TA, England; Univ Oxford, Dept Chem, Oxford OX1 3TA, England; Univ Oxford, Oxford Struct Genom Consortium, Botnar Res Ctr, Oxford OX3 7LD, England	University of Oxford; University of Oxford; University of Oxford	Schofield, CJ (corresponding author), Univ Oxford, Oxford Ctr Mol Sci, Mansfield Rd, Oxford OX1 3TA, England.	christopher.schofield@chemistry.oxford.ac.uk	McDonough, Michael/N-8913-2019; McDonough, Michael A/G-2744-2013	McDonough, Michael/0000-0003-4664-6942; McDonough, Michael A/0000-0003-4664-6942; Schofield, Christopher/0000-0002-0290-6565	Biotechnology and Biological Sciences Research Council [B18672] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUKER A, 2003, XPREP DATA PREPARATI; Chambraud B, 1999, P NATL ACAD SCI USA, V96, P2104, DOI 10.1073/pnas.96.5.2104; Chance MR, 2002, PROTEIN SCI, V11, P723, DOI 10.1110/ps.4570102; Chen C, 2001, J BIOL CHEM, V276, P46340, DOI 10.1074/jbc.M106124200; Cianci M, 2005, J SYNCHROTRON RADIAT, V12, P455, DOI 10.1107/S0909049505009131; Clifton IJ, 2001, EUR J BIOCHEM, V268, P6625, DOI 10.1046/j.0014-2956.2001.02617.x; Croes K, 1999, J LIPID RES, V40, P601; Croes K, 1997, FEBS LETT, V407, P197, DOI 10.1016/S0014-5793(97)00343-8; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Elkins JM, 2003, J BIOL CHEM, V278, P1802, DOI 10.1074/jbc.C200644200; Elkins JM, 2002, BIOCHEMISTRY-US, V41, P5185, DOI 10.1021/bi016014e; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Foulon V, 1999, P NATL ACAD SCI USA, V96, P10039, DOI 10.1073/pnas.96.18.10039; GIBBERD FB, 2000, HDB ATAXIA DISORDERS, P235; Hewitson KS, 2004, DRUG DISCOV TODAY, V9, P704, DOI 10.1016/S1359-6446(04)03202-7; Jansen GA, 2000, HUM MOL GENET, V9, P1195, DOI 10.1093/hmg/9.8.1195; Jansen GA, 1999, BBA-MOL CELL BIOL L, V1440, P176, DOI 10.1016/S1388-1981(99)00126-2; Jansen GA, 2004, HUM MUTAT, V23, P209, DOI 10.1002/humu.10315; Jansen GA, 1998, CLIN CHIM ACTA, V271, P203, DOI 10.1016/S0009-8981(97)00259-3; Jansen GA, 1997, NAT GENET, V17, P190, DOI 10.1038/ng1097-190; Kershaw NJ, 2001, BIOORG MED CHEM LETT, V11, P2545, DOI 10.1016/S0960-894X(01)00494-2; Koh JT, 2001, MOL BRAIN RES, V87, P223, DOI 10.1016/S0169-328X(01)00004-3; Lancaster DE, 2004, BIOCHEM J, V383, P429, DOI 10.1042/BJ20040735; Lee HJ, 2000, BIOCHEM BIOPH RES CO, V267, P445, DOI 10.1006/bbrc.1999.1957; Lee HJ, 2001, J MOL BIOL, V308, P937, DOI 10.1006/jmbi.2001.4649; Lee ZH, 2000, MOL BRAIN RES, V75, P237, DOI 10.1016/S0169-328X(99)00304-6; Leslie AGW, 1992, JOINT CCP4 ESF EAMCB, V26; McDonough MA, 2005, J AM CHEM SOC, V127, P7680, DOI 10.1021/ja050841b; Mihalik SJ, 1997, NAT GENET, V17, P185, DOI 10.1038/ng1097-185; MIHALIK SJ, 1995, EUR J BIOCHEM, V232, P545, DOI 10.1111/j.1432-1033.1995.tb20842.x; Mole DR, 2003, BIOORG MED CHEM LETT, V13, P2677, DOI 10.1016/S0960-894X(03)00539-0; Mukherji M, 2003, PROG LIPID RES, V42, P359, DOI 10.1016/S0163-7827(03)00016-X; Mukherji M, 2002, CHEM BIOL, V9, P597, DOI 10.1016/S1074-5521(02)00139-4; Mukherji M, 2001, CHEM COMMUN, P972, DOI 10.1039/b101039p; Mukherji M, 2001, HUM MOL GENET, V10, P1971, DOI 10.1093/hmg/10.18.1971; MURALIDHARAN FN, 1985, BIOCHIM BIOPHYS ACTA, V835, P36; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nunez LE, 2003, CHEM BIOL, V10, P301, DOI 10.1016/S1074-5521(03)00069-3; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PLANT GR, 1990, BRIT J RADIOL, V63, P537, DOI 10.1259/0007-1285-63-751-537; Prescott AG, 2000, NAT PROD REP, V17, P367, DOI 10.1039/a902197c; Purdue PE, 2001, ANNU REV CELL DEV BI, V17, P701, DOI 10.1146/annurev.cellbio.17.1.701; Sanders RJ, 2005, J LIPID RES, V46, P1001, DOI 10.1194/jlr.M400510-JLR200; SCHMITZ W, 1994, EUR J BIOCHEM, V222, P313, DOI 10.1111/j.1432-1033.1994.tb18870.x; SCHMITZ W, 1995, EUR J BIOCHEM, V231, P815, DOI 10.1111/j.1432-1033.1995.0815d.x; Searls T, 2005, J LIPID RES, V46, P1660, DOI 10.1194/jlr.M500034-JLR200; Seedorf U, 2000, BBA-MOL CELL BIOL L, V1486, P45, DOI 10.1016/S1388-1981(00)00047-0; Seedorf U, 1998, GENE DEV, V12, P1189, DOI 10.1101/gad.12.8.1189; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Sleeman MC, 2004, J BIOL CHEM, V279, P6730, DOI 10.1074/jbc.M311824200; Steinberg D., 1995, METABOLIC MOL BASES, P2351; Steinberg SJ, 1999, BIOCHEM BIOPH RES CO, V257, P615, DOI 10.1006/bbrc.1999.0510; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Valegard K, 1998, NATURE, V394, P805, DOI 10.1038/29575; van den Brink DM, 2005, J BIOL CHEM, V280, P26838, DOI 10.1074/jbc.M501861200; van den Brink DM, 2003, AM J HUM GENET, V72, P471, DOI 10.1086/346093; VANVELDHOVEN PP, 1997, BIOCHEM BIOPH RES CO, V327, P33; Walter TS, 2003, J APPL CRYSTALLOGR, V36, P308, DOI 10.1107/S0021889803001997; Wanders RJA, 2003, BBA-MOL CELL BIOL L, V1631, P119, DOI 10.1016/S1388-1981(03)00003-9; WANDERS RJA, 2001, METABOLIC MOL BASES, V2, P3303; Wierzbicki AS, 2002, J NEUROCHEM, V80, P727, DOI 10.1046/j.0022-3042.2002.00766.x; Wilmouth RC, 2002, STRUCTURE, V10, P93, DOI 10.1016/S0969-2126(01)00695-5; Wouters FS, 1998, EMBO J, V17, P7179, DOI 10.1093/emboj/17.24.7179; Zhang ZH, 2002, FEBS LETT, V517, P7, DOI 10.1016/S0014-5793(02)02520-6; Zhang ZH, 2000, NAT STRUCT BIOL, V7, P127; Zhou J, 2001, J AM CHEM SOC, V123, P7388, DOI 10.1021/ja004025+	68	67	71	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					41101	41110		10.1074/jbc.M507528200	http://dx.doi.org/10.1074/jbc.M507528200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16186124	hybrid			2022-12-25	WOS:000233666600084
J	Storez, H; Scott, MGH; Issafras, H; Burtey, A; Benmerah, A; Muntaner, O; Piolot, T; Coppey-Moisan, M; Bouvier, M; Labbe-Jullie, C; Marullo, S				Storez, H; Scott, MGH; Issafras, H; Burtey, A; Benmerah, A; Muntaner, O; Piolot, T; Coppey-Moisan, M; Bouvier, M; Labbe-Jullie, C; Marullo, S			Homo- and hetero-oligomerization of beta-arrestins in living cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; PROTEIN-COUPLED RECEPTORS; NUCLEAR EXPORT SIGNAL; CLATHRIN-COATED PITS; ROD OUTER SEGMENTS; BETA(2)-ADRENERGIC RECEPTOR; CRYSTAL-STRUCTURE; VISUAL ARRESTIN; ACTIVATION; BETA-ARRESTIN2	Arrestins are important proteins, which regulate the function of serpentine heptahelical receptors and contribute to multiple signaling pathways downstream of receptors. The ubiquitous beta-arrestins are believed to function exclusively as monomers, although self-association is assumed to control the activity of visual arrestin in the retina, where this isoform is particularly abundant. Here the oligomerization status of beta-arrestins was investigated using different approaches, including co-immunoprecipitation of epitope-tagged beta-arrestins and resonance energy transfer (BRET and FRET) in living cells. At steady state and at physiological concentrations, beta-arrestins constitutively form both homo- and hetero-oligomers. Co-expression of beta-arrestin2 and beta-arrestin1 prevented beta-arrestin1 accumulation into the nucleus, suggesting that hetero- oligomerization may have functional consequences. Our data clearly indicate that beta-arrestins can exist as homo- and hetero-oligomers in living cells and raise the hypothesis that the oligomeric state may regulate their subcellular distribution and functions.	Inst Cochin, Dept Cell Biol, F-75014 Paris, France; Inst Cochin, Dept Infect Dis, F-75014 Paris, France; INSERM, U567, F-75014 Paris, France; CNRS, UMR 8104, F-75014 Paris, France; Univ Paris 05, Fac Med Rene Descartes, UMR S 8104, F-75014 Paris, France; Univ Paris 06, Inst Jacques Monod, UMR 7592, CNRS, Paris, France; Univ Paris 07, Inst Jacques Monod, UMR 7592, CNRS, Paris, France; Univ Montreal, Dept Biochem, Montreal, PQ H3C 3J7, Canada	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; Universite de Montreal	Marullo, S (corresponding author), Inst Cochin, Dept Biol Cellulaire, 27 rue Fg St Jacques, F-75014 Paris, France.	marullo@cochin.inserm.fr	Scott, Mark/R-3521-2019; benmerah, alexandre/H-3742-2017; Bouvier, Michel/H-2758-2014; Marullo, Stefano/C-6142-2008	benmerah, alexandre/0000-0003-0188-8016; Bouvier, Michel/0000-0003-1128-0100; Marullo, Stefano/0000-0001-9604-9973; Scott, Mark G.H./0000-0002-1557-1856; Labbe-Jullie, Catherine/0000-0001-6398-3807; Coppey-Moisan, Maite/0000-0002-6246-4973; Tramier, Marc/0000-0001-8200-6446; Burtey, Anne/0000-0003-4548-8807				Alloway PG, 2000, NEURON, V28, P129, DOI 10.1016/S0896-6273(00)00091-X; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Breitwieser GE, 2004, CIRC RES, V94, P17, DOI 10.1161/01.RES.0000110420.68526.19; Charest PG, 2005, EMBO REP, V6, P334, DOI 10.1038/sj.embor.7400373; Cheng JK, 2005, J BIOL CHEM, V280, P13477, DOI 10.1074/jbc.M414258200; Eidne KA, 2002, TRENDS ENDOCRIN MET, V13, P415, DOI 10.1016/S1043-2760(02)00669-0; Emiliani V, 2003, APPL PHYS LETT, V83, P2471, DOI 10.1063/1.1604938; Gao H, 2004, MOL CELL, V14, P303, DOI 10.1016/S1097-2765(04)00216-3; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; Gurevich VV, 2004, TRENDS PHARMACOL SCI, V25, P105, DOI 10.1016/j.tips.2003.12.008; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Milano SK, 2002, BIOCHEMISTRY-US, V41, P3321, DOI 10.1021/bi015905j; Santini F, 2000, J CELL SCI, V113, P2463; Schubert C, 1999, J BIOL CHEM, V274, P21186, DOI 10.1074/jbc.274.30.21186; Scott MGH, 2002, J BIOL CHEM, V277, P3552, DOI 10.1074/jbc.M106586200; Scott MGH, 2002, J BIOL CHEM, V277, P37693, DOI 10.1074/jbc.M207552200; Shilton BH, 2002, EUR J BIOCHEM, V269, P3801, DOI 10.1046/j.1432-1033.2002.03071.x; Tramier M, 2003, METHOD ENZYMOL, V360, P580; Tramier M, 2002, BIOPHYS J, V83, P3570, DOI 10.1016/S0006-3495(02)75357-5; Vishnivetskiy SA, 2004, J BIOL CHEM, V279, P1262, DOI 10.1074/jbc.M308834200; Wang P, 2003, J BIOL CHEM, V278, P11648, DOI 10.1074/jbc.M208109200; Wang P, 2003, J BIOL CHEM, V278, P6363, DOI 10.1074/jbc.M210350200; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174	32	74	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40210	40215		10.1074/jbc.M508001200	http://dx.doi.org/10.1074/jbc.M508001200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16199535	Green Published, hybrid			2022-12-25	WOS:000233461300062
J	Tseng, SF; Chang, CY; Wu, KJ; Teng, SC				Tseng, SF; Chang, CY; Wu, KJ; Teng, SC			Importin KPNA2 is required for proper nuclear localization and multiple functions of NBS1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIJMEGEN-BREAKAGE-SYNDROME; DOUBLE-STRAND BREAKS; ATM-DEPENDENT PHOSPHORYLATION; DNA-DAMAGE RESPONSE; ATAXIA-TELANGIECTASIA; POSITIONAL CLONING; GENOME STABILITY; TERMINAL DOMAIN; FOCUS FORMATION; SYNDROME GENE	Nijmegen breakage syndrome (NBS) is a chromosomal-instability syndrome associated with cancer predisposition, radiosensitivity, microcephaly, and growth retardation. The NBS gene product, NBS1, is a component of the MRE11-RAD50-NBS1 (MRN) complex, a central player associated with double strand break (DSB) repair. In response to radiation, NBS1 is phosphorylated by ATM, and the MRN complex relocalizes to form punctate nuclear foci for DNA repair. NBS1 controls both the nuclear localization of the MRN complexes and radiation-induced focus formation. We report here that the KPNA2 ( importin alpha 1) is important for the normal nuclear localization of the MRN complex and its proper formation of the nuclear foci. KPNA2 is the only member of the importin alpha family that physically interacts with NBS1, and the KPNA2-mediated nucleus localization sequence (NLS) is mapped to amino acid residues 461-467 of NBS1 that is sufficient for both the interaction with KPNA2 and the proper nuclear localization. Inhibition of KPNA2 or blockage of the KPNA2 interaction with NBS1 results in a reduction of radiation-induced nuclear focus accumulation, DSB repair, and cell cycle checkpoint signaling of NBS1. Collectively, our results strongly suggest that an interaction with KPNA2 contributes to nuclear localization and multiple tumor suppression functions of the NBS1 complex.	Natl Taiwan Univ, Coll Med, Dept Microbiol, Taipei 10018, Taiwan; Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan; Natl Taiwan Univ Hosp, Inst Internal Med, Taipei, Taiwan	National Taiwan University; National Yang Ming Chiao Tung University; National Taiwan University; National Taiwan University Hospital	Teng, SC (corresponding author), Natl Taiwan Univ, Coll Med, Dept Microbiol, 1,Sect 1,Jen Ai Rd, Taipei 10018, Taiwan.	scteng@ha.mc.ntu.edu.tw	Wu, Kou-Juey/P-4654-2015	TENG, SHU-CHUN/0000-0002-6492-2560				[Anonymous], 2005, MOL BIOL CELL, V16, P597, DOI 10.1097/mbc.E04-09-0782; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Cerosaletti KM, 2003, J BIOL CHEM, V278, P21944, DOI 10.1074/jbc.M211689200; Chiang YC, 2003, J BIOL CHEM, V278, P19286, DOI 10.1074/jbc.M212043200; Chook YM, 2001, CURR OPIN STRUC BIOL, V11, P703, DOI 10.1016/S0959-440X(01)00264-0; Desai-Mehta A, 2001, MOL CELL BIOL, V21, P2184, DOI 10.1128/MCB.21.6.2184-2191.2001; Digweed M, 2004, DNA REPAIR, V3, P1207, DOI 10.1016/j.dnarep.2004.03.004; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Girard PM, 2002, ONCOGENE, V21, P4191, DOI 10.1038/sj.onc.1205596; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Harel A, 2004, MOL CELL, V16, P319, DOI 10.1016/S1097-2765(04)00647-1; Hiel JA, 2000, ARCH DIS CHILD, V82, P400; Iijima K, 2004, CHROMOSOMA, V113, P53, DOI 10.1007/s00412-004-0298-0; James P, 1996, GENETICS, V144, P1425; Kotera I, 2005, EMBO J, V24, P942, DOI 10.1038/sj.emboj.7600587; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Lee JH, 2003, MOL CANCER RES, V1, P674; Lukas C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/ncb945; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Matsuura S, 1998, NAT GENET, V19, P179, DOI 10.1038/549; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P6572, DOI 10.1073/pnas.93.13.6572; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; Nishinaka Y, 2004, J BIOL CHEM, V279, P37559, DOI 10.1074/jbc.M405473200; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Ranganathan V, 2001, CURR BIOL, V11, P962, DOI 10.1016/S0960-9822(01)00267-6; Saar K, 1997, AM J HUM GENET, V60, P605; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; SPEE JH, 1993, NUCLEIC ACIDS RES, V21, P777, DOI 10.1093/nar/21.3.777; Stracker TH, 2004, DNA REPAIR, V3, P845, DOI 10.1016/j.dnarep.2004.03.014; Tauchi H, 2002, NATURE, V420, P93, DOI 10.1038/nature01125; Tauchi H, 2002, ONCOGENE, V21, P8967, DOI 10.1038/sj.onc.1206136; Tauchi H, 2000, J RADIAT RES, V41, P9, DOI 10.1269/jrr.41.9; Teng SC, 2000, MOL CELL, V6, P947, DOI 10.1016/S1097-2765(05)00094-8; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; vanderBurgt I, 1996, J MED GENET, V33, P153, DOI 10.1136/jmg.33.2.153; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; Wu GK, 2000, J BIOL CHEM, V275, P30618, DOI 10.1074/jbc.C000390200; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Yoneda Y, 2000, GENES CELLS, V5, P777, DOI 10.1046/j.1365-2443.2000.00366.x; Zannini L, 2003, J BIOL CHEM, V278, P42346, DOI 10.1074/jbc.M303304200; Zhong HY, 2000, MOL PHARMACOL, V57, P961; Zhong Q, 2002, J BIOL CHEM, V277, P28641, DOI 10.1074/jbc.M200748200; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139	48	83	88	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39594	39600		10.1074/jbc.M508425200	http://dx.doi.org/10.1074/jbc.M508425200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16188882	hybrid			2022-12-25	WOS:000233362200082
J	Mottola, A; Antoniotti, S; Lovisolo, D; Munaron, L				Mottola, A; Antoniotti, S; Lovisolo, D; Munaron, L			Regulation of noncapacitative calcium entry by arachidonic acid and nitric oxide in endothelial cells	FASEB JOURNAL			English	Article						calcium channels; proliferation; signal transduction; angiogenesis; inflammation	ACTIVATED PROTEIN-KINASE; FIBROBLAST-GROWTH-FACTOR; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE A(2); UP-REGULATION; CA2+ ENTRY; IN-VITRO; SYNTHASE; PROLIFERATION; ANGIOGENESIS	Several peptides, including vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), activate the release of arachidonic acid (AA) and nitric oxide ( NO) in endothelial cells (ECs). Both messengers are involved in EC proliferation and vascular permeability and control calcium homeostasis in different ways. Interestingly, it has been recently suggested that NO acts as a downstream mediator of AA-induced calcium entry in smooth muscle cells and isolated mouse parotid cells. In this paper, we have investigated the complex relationships that link intracellular calcium, AA, and NO in cultured endothelial cells. Using different experimental approaches, mainly simultaneous Ca2+ and NO fluorimetric confocal imaging, we provide evidence for a complex pathway leading to noncapacitative calcium entry (NCCE) in bovine aortic endothelial cells (BAECs). In particular, AA is able to induce NCCE through two different pathways: one dependent on eNOS recruitment and NO release, the other NO-independent. Finally, we show that NO increase is involved in the control of BAEC proliferation.	Univ Turin, Dept Anim & Human Biol, I-10123 Turin, Italy; Nanostruct Interfaces & Surfaces Ctr Excellence, Turin, Italy	University of Turin	Munaron, L (corresponding author), Univ Turin, Dept Anim & Human Biol, Via Accademia Albertina 13, I-10123 Turin, Italy.	luca.munaron@unito.it		munaron, luca/0000-0001-9247-4446				Ahern GP, 2002, TRENDS NEUROSCI, V25, P510, DOI 10.1016/S0166-2236(02)02254-3; Antoniotti S, 2003, J CELL PHYSIOL, V197, P370, DOI 10.1002/jcp.10359; Babaei S, 1998, CIRC RES, V82, P1007, DOI 10.1161/01.RES.82.9.1007; BARRETT KE, 1995, NEWS PHYSIOL SCI, V10, P153; Berkels R, 2000, MICROVASC RES, V59, P38, DOI 10.1006/mvre.1999.2191; Boonstra Johannes, 2003, Prog Cell Cycle Res, V5, P181; Bussolati B, 2001, AM J PATHOL, V159, P993, DOI 10.1016/S0002-9440(10)61775-0; Cirino G, 2003, TRENDS PHARMACOL SCI, V24, P91, DOI 10.1016/S0165-6147(02)00049-4; Cooke JP, 2003, ATHEROSCLEROSIS SUPP, V4, P53, DOI 10.1016/S1567-5688(03)00034-5; DETHLEFSEN SM, 1994, EXP CELL RES, V212, P262, DOI 10.1006/excr.1994.1142; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dormond O, 2001, NAT MED, V7, P1041, DOI 10.1038/nm0901-1041; FAFEUR V, 1991, J CELL PHYSIOL, V149, P277, DOI 10.1002/jcp.1041490214; Fleming I, 1999, CARDIOVASC RES, V43, P532, DOI 10.1016/S0008-6363(99)00094-2; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Goligorsky MS, 2002, AM J PHYSIOL-RENAL, V283, pF1, DOI 10.1152/ajprenal.00377.2001; Griffioen AW, 2000, PHARMACOL REV, V52, P237; Hood JD, 1998, AM J PHYSIOL-HEART C, V274, pH1054; Isshiki M, 1999, CELL CALCIUM, V26, P201, DOI 10.1054/ceca.1999.0073; Koyama T, 2002, LIFE SCI, V72, P511, DOI 10.1016/S0024-3205(02)02246-4; Kudo I, 2002, PROSTAG OTH LIPID M, V68-9, P3, DOI 10.1016/S0090-6980(02)00020-5; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; Lin S, 2000, J BIOL CHEM, V275, P17979, DOI 10.1074/jbc.275.24.17979; Matalon S, 2003, AM J PHYSIOL-LUNG C, V285, pL1184, DOI 10.1152/ajplung.00281.2003; Meissner G, 2004, CELL CALCIUM, V35, P621, DOI 10.1016/j.ceca.2004.01.015; Moneer Z, 2003, BIOCHEM J, V370, P439, DOI 10.1042/BJ20021104; Morbidelli L, 1996, AM J PHYSIOL-HEART C, V270, pH411, DOI 10.1152/ajpheart.1996.270.1.H411; Munaron L, 2000, J CELL PHYSIOL, V185, P454, DOI 10.1002/1097-4652(200012)185:3<454::AID-JCP17>3.0.CO;2-A; Munaron L, 2004, J CELL MOL MED, V8, P161, DOI 10.1111/j.1582-4934.2004.tb00271.x; Munaron L, 2002, INT J MOL MED, V10, P671; Murohara T, 1999, ARTERIOSCL THROM VAS, V19, P1156, DOI 10.1161/01.ATV.19.5.1156; Nie DT, 2004, SEMIN THROMB HEMOST, V30, P119; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; Pilane CM, 2004, J CELL PHYSIOL, V198, P48, DOI 10.1002/jcp.10382; Pla AF, 2001, CELL CALCIUM, V30, P235, DOI 10.1054/ceca.2001.0234; Rossig L, 1999, J BIOL CHEM, V274, P6823, DOI 10.1074/jbc.274.11.6823; SA G, 1995, J BIOL CHEM, V270, P2360, DOI 10.1074/jbc.270.5.2360; Takeuchi K, 2004, CARDIOVASC RES, V62, P194, DOI 10.1016/j.cardiores.2003.12.028; vanderZee R, 1997, CIRCULATION, V95, P1030; Wang H, 2003, J PHARMACOL EXP THER, V307, P753, DOI 10.1124/jpet.103.052787; Wang Y, 2005, J PHARMACOL EXP THER, V314, P522, DOI 10.1124/jpet.105.083477; Watson EL, 2004, CELL SIGNAL, V16, P157, DOI 10.1016/S0898-6568(03)00102-5; Wicher D, 2004, J BIOL CHEM, V279, P50410, DOI 10.1074/jbc.M405800200; Yao X, 2000, FASEB J, V14, P932, DOI 10.1096/fasebj.14.7.932; Yao XQ, 2003, TRENDS PHARMACOL SCI, V24, P263, DOI 10.1016/S0165-6147(03)00122-6; Zhang JL, 2002, AM J PHYSIOL-CELL PH, V283, pC1080, DOI 10.1152/ajpcell.00048.2002; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451; Ziche M, 1997, CIRC RES, V80, P845, DOI 10.1161/01.res.80.6.845; ZICHE M, 1994, J CLIN INVEST, V94, P2036, DOI 10.1172/JCI117557	49	32	32	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2075	+		10.1096/fj.05-4110fje	http://dx.doi.org/10.1096/fj.05-4110fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16204355				2022-12-25	WOS:000232991100030
J	Zhao, Z; Ho, L; Wang, J; Qin, WP; Festa, ED; Mobbs, C; Hof, P; Rocher, A; Masur, S; Haroutunian, V; Pasinetti, GM				Zhao, Z; Ho, L; Wang, J; Qin, WP; Festa, ED; Mobbs, C; Hof, P; Rocher, A; Masur, S; Haroutunian, V; Pasinetti, GM			Connective tissue growth factor (CTGF) expression in the brain is a downstream effector of insulin resistance-associated promotion of Alzheimer's disease beta-amyloid neuropathology	FASEB JOURNAL			English	Article						diabetes; IDE; secretase; IDE; AKT; MAPK	GAMMA-SECRETASE ACTIVITY; HUMAN MESANGIAL CELLS; DEGRADING ENZYME; NEUROFIBRILLARY TANGLES; EXTRACELLULAR-MATRIX; STEREOLOGIC ANALYSIS; POTENTIAL MECHANISM; DIABETES-MELLITUS; PRECURSOR PROTEIN; NEURITIC PLAQUES	The goal of this study was to further explore potential mechanisms through which diabetogenic dietary conditions that result in promotion of insulin resistance (IR), a feature of non-insulin dependant diabetes mellitus (type-2 diabetes), may influence Alzheimer's disease ( AD). Using genome-wide array technology, we found that connective tissue growth factor ( CTGF), a gene product described previously for its involvement in diabetic fibrosis, is elevated in brain tissue in an established mouse model of diet-induced IR. With this evidence we continued to explore the regulation of CTGF in postmortem AD brain tissue and found that CTGF expression correlated with the progression of AD clinical dementia and amyloid neuritic plaque (NP) neuropathology, but not neurofibrillary tangle (NFT) deposition. Consistent with this evidence, we also found that exposure of Tg2576 mice ( a model AD-type amyloid neuropathology) to a diabetogenic diet that promotes IR results in a similar to 2-fold elevation in CTGF steady-state levels in the brain, coincident with a commensurate promotion of AD-type amyloid plaque burden. Finally, using in vitro cellular models of amyloid precursor protein (APP)-processing and A beta generation/clearance, we confirmed that human recombinant (hr) CTGF may increase A beta(1-40) and A beta(1-42) peptide steady-state levels, possibly through a mechanism that involves gamma-secretase activation and decreased insulin-degrading enzyme (IDE) steady-state levels in a MAP kinase ( MAPK)/ phosphatidylinositol 3-kinase (PI-3K)/protein kinase-B (AKT) 1-dependent manner. The findings in this study tentatively suggest that increased CTGF expression in the brain might be a novel biological predicative factor of AD clinical progression and neuropathology in response to dietary regimens promoting IR conditions.	Mt Sinai Sch Med, Dept Psychiat, Neuroinflammat Res Labs, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Ophthalmol, New York, NY 10029 USA; Bronx Vet Affairs Med Ctr, GRECC, Translat Neurosci Labs, Bronx, NY USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); James J. Peters VA Medical Center	Pasinetti, GM (corresponding author), Mt Sinai Sch Med, Dept Psychiat, Neuroinflammat Res Labs, Box 1230,1 Gustave L Levy Pl, New York, NY 10029 USA.	giulio.pasinetti@mssm.edu		Pasinetti, Giulio/0000-0002-1524-5196; Mobbs, Charles/0000-0002-5815-8711	NATIONAL INSTITUTE ON AGING [R01AG013799, P01AG002219] Funding Source: NIH RePORTER; NIA NIH HHS [AG13799, AG02219] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adler SG, 2002, AM J KIDNEY DIS, V40, P184, DOI 10.1053/ajkd.2002.33928; Bergen HT, 1999, BRAIN RES, V851, P198, DOI 10.1016/S0006-8993(99)02186-1; BRIGSTOCK DR, 1991, BAILLIERE CLIN ENDOC, V5, P791, DOI 10.1016/S0950-351X(10)80015-1; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Bussiere T, 2003, NEUROSCIENCE, V117, P577, DOI 10.1016/S0306-4522(02)00942-9; Bussiere T, 2002, NEUROSCIENCE, V112, P75, DOI 10.1016/S0306-4522(02)00056-8; Candido R, 2003, CIRC RES, V92, P785, DOI 10.1161/01.RES.0000065620.39919.20; Craft S, 2003, PSYCHONEUROENDOCRINO, V28, P809, DOI 10.1016/S0306-4530(02)00087-2; Craft S, 2004, LANCET NEUROL, V3, P169, DOI 10.1016/S1474-4422(04)00681-7; Crean JKG, 2002, J BIOL CHEM, V277, P44187, DOI 10.1074/jbc.M203715200; Dorris DR, 2002, GENOME RES, V12, P976, DOI 10.1101/gr.227402; Eberlein M, 2001, BRIT J PHARMACOL, V133, P1172, DOI 10.1038/sj.bjp.0704173; Edland SD, 2004, J MOL NEUROSCI, V23, P213, DOI 10.1385/JMN:23:3:213; Evin G, 2002, PEPTIDES, V23, P1285, DOI 10.1016/S0196-9781(02)00063-3; Folger PA, 2001, INVEST OPHTH VIS SCI, V42, P2534; Forette F, 1998, LANCET, V352, P1347, DOI 10.1016/S0140-6736(98)03086-4; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; FUJISAWA Y, 1991, BIOL PSYCHIAT, V30, P1219, DOI 10.1016/0006-3223(91)90158-I; Gasparini L, 2001, J NEUROSCI, V21, P2561, DOI 10.1523/JNEUROSCI.21-08-02561.2001; Haroutunian V, 1998, ARCH NEUROL-CHICAGO, V55, P1185, DOI 10.1001/archneur.55.9.1185; Haroutunian V, 1999, ARCH NEUROL-CHICAGO, V56, P713, DOI 10.1001/archneur.56.6.713; Herreman A, 2003, J CELL SCI, V116, P1127, DOI 10.1242/jcs.00292; Hertel M, 2000, EUR J NEUROSCI, V12, P376, DOI 10.1046/j.1460-9568.2000.00930.x; Ho L, 2004, FASEB J, V18, P902, DOI 10.1096/fj.03-0978fje; Hof PR, 2000, J COMP NEUROL, V420, P113, DOI 10.1002/(SICI)1096-9861(20000424)420:1<113::AID-CNE8>3.0.CO;2-N; Kurochkin IV, 2001, TRENDS BIOCHEM SCI, V26, P421, DOI 10.1016/S0968-0004(01)01876-X; Kuusisto J, 1997, BRIT MED J, V315, P1045, DOI 10.1136/bmj.315.7115.1045; Levin-Allerhand J A, 2002, J Nutr Health Aging, V6, P315; Luchsinger JA, 2004, NEUROLOGY, V63, P1187, DOI 10.1212/01.WNL.0000140292.04932.87; Makimura Hideo, 2003, BMC Physiol, V3, P4, DOI 10.1186/1472-6793-3-4; MENEILLY GS, 1993, J AM GERIATR SOC, V41, P710, DOI 10.1111/j.1532-5415.1993.tb07458.x; Meyer JS, 2000, ANN NY ACAD SCI, V903, P411, DOI 10.1111/j.1749-6632.2000.tb06393.x; Mirjany M, 2002, J PHARMACOL EXP THER, V301, P494, DOI 10.1124/jpet.301.2.494; Mirra SS, 1997, NEUROBIOL AGING, V18, pS91, DOI 10.1016/S0197-4580(97)00058-4; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Mizuno TM, 1999, ENDOCRINOLOGY, V140, P4551, DOI 10.1210/en.140.10.4551; Mobbs CV, 2004, NEUROCHEM RES, V29, P1093, DOI 10.1023/B:NERE.0000023596.49140.e0; Murphy M, 1999, J BIOL CHEM, V274, P5830, DOI 10.1074/jbc.274.9.5830; Nimchinsky EA, 2000, J COMP NEUROL, V416, P112, DOI 10.1002/(SICI)1096-9861(20000103)416:1<112::AID-CNE9>3.0.CO;2-K; Ott A, 1999, NEUROLOGY, V53, P1937, DOI 10.1212/WNL.53.9.1937; Paradis V, 2001, HEPATOLOGY, V34, P738, DOI 10.1053/jhep.2001.28055; Peila R, 2004, NEUROLOGY, V63, P228, DOI 10.1212/01.WNL.0000129989.28404.9B; Perez A, 2000, NEUROCHEM RES, V25, P247, DOI 10.1023/A:1007527721160; Petrovitch H, 2000, NEUROBIOL AGING, V21, P57, DOI 10.1016/S0197-4580(00)82479-3; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Qin WP, 2003, J BIOL CHEM, V278, P50970, DOI 10.1074/jbc.M307699200; Ramakrishnan R, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.7.e30; Segarini PR, 2001, J BIOL CHEM, V276, P40659, DOI 10.1074/jbc.M105180200; Skoog I, 1996, LANCET, V347, P1141, DOI 10.1016/S0140-6736(96)90608-X; Spliet WGM, 2003, ACTA NEUROPATHOL, V106, P449, DOI 10.1007/s00401-003-0741-y; Stamer K, 2002, J CELL BIOL, V156, P1051, DOI 10.1083/jcb.200108057; Tandrup T, 1997, J MICROSC-OXFORD, V186, P108, DOI 10.1046/j.1365-2818.1997.2070765.x; Twigg SM, 2002, ENDOCRINOLOGY, V143, P4907, DOI 10.1210/en.2002-220619; Twigg SM, 2001, ENDOCRINOLOGY, V142, P1760, DOI 10.1210/endo.142.5.8141; Ueberham U, 2003, NEUROSCIENCE, V116, P1, DOI 10.1016/S0306-4522(02)00670-X; Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200; Xiang ZM, 2002, GENE EXPRESSION, V10, P271, DOI 10.3727/000000002783992352; Yang M, 2004, FASEB J, V18, P1920, DOI 10.1096/fj.04-2357fje; Zhao LX, 2004, J NEUROSCI, V24, P11120, DOI 10.1523/JNEUROSCI.2860-04.2004	59	34	35	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2005	19	11					2081	+		10.1096/fj.05-4359fje	http://dx.doi.org/10.1096/fj.05-4359fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16186174				2022-12-25	WOS:000232315700005
J	Heckman, CA; Duan, H; Garcia, PB; Boxer, LM				Heckman, CA; Duan, H; Garcia, PB; Boxer, LM			Oct transcription factors mediate t(14;18) lymphoma cell survival by directly regulating bcl-2 expression	ONCOGENE			English	Article						bcl-2; lymphoma; transcription; Oct; Bob-1	NF-KAPPA-B; IMMUNOGLOBULIN GENE-TRANSCRIPTION; T-CELLS; SOMATIC MUTATION; CREB PROTEINS; BINDING-SITE; MYB; ACTIVATION; INDUCTION; APOPTOSIS	Oct-1 and Oct-2 are members of the POU homeodomain family of transcriptional regulators and are critical for normal embryonic development. Gene-targeting studies showed that Oct-1 and Oct-2 are largely dispensable for B-cell development and immunoglobulin production, although both Oct-2 and Bob-1 are required for a proper immune response and germinal center formation. In these studies, we investigated the role of Oct factors in B-cell lymphomas. Recent investigations have shown increased expression of Oct-2 and Bob-1 in lymphomas, and we observed greatly increased levels of Oct-2 in lymphoma cells with the t(14; 18) translocation. Decreased expression of Oct-1, Oct-2, or Bob-1 by RNA interference resulted in apoptosis and down-regulation of bcl-2 expression. Furthermore, Oct-2 induced bcl-2 promoter activity and mediated this effect through three regions in the bcl-2 P2 promoter. Although these regions did not contain canonical octamer motifs, we observed the direct interaction of Oct-2 with all three sites both in vitro by EMSA and in vivo by chromatin immunoprecipitation assay. Moreover, by mutation analysis we found that the ability of Oct-2 to activate bcl-2 required C/EBP, Cdx, and TATA-binding sites. Oct-2, therefore, acts as a cell survival factor in t(14; 18) lymphoma cells by directly activating the antiapoptotic gene bcl-2.	VAHCS, Ctr Mol Biol Med, Palo Alto, CA USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA USA	Stanford University	Boxer, LM (corresponding author), Stanford Univ, Dept Hematol, Sch Med, 269 Campus Dr,CCSR 1155, Stanford, CA 94305 USA.	lboxer@stanford.edu		Heckman, Caroline/0000-0002-4324-8706	NCI NIH HHS [CA 56764] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R56CA056764, R01CA056764] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANNWEILER A, 1994, NUCLEIC ACIDS RES, V22, P4250, DOI 10.1093/nar/22.20.4250; Bendall HH, 1997, J BIOL CHEM, V272, P28826, DOI 10.1074/jbc.272.46.28826; Bertolino E, 2002, MOL CELL, V10, P397, DOI 10.1016/S1097-2765(02)00597-X; Brunner C, 2003, J EXP MED, V197, P1205, DOI 10.1084/jem.20022014; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; Dunn TL, 1996, BLOOD, V88, P4072, DOI 10.1182/blood.V88.10.4072a.bloodjournal88104072a; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; Grassilli E, 1999, CANCER RES, V59, P2451; Greiner A, 2000, AM J PATHOL, V156, P501, DOI 10.1016/S0002-9440(10)64754-2; Grenfell SJ, 1996, BIOCHEM J, V315, P889, DOI 10.1042/bj3150889; Hatada EN, 2000, EUR J IMMUNOL, V30, P174, DOI 10.1002/1521-4141(200001)30:1<174::AID-IMMU174>3.0.CO;2-T; Heckman C, 1997, J BIOL CHEM, V272, P19609, DOI 10.1074/jbc.272.31.19609; Heckman CA, 2000, J BIOL CHEM, V275, P6499, DOI 10.1074/jbc.275.9.6499; Heckman CA, 2003, CANCER RES, V63, P6666; Heckman CA, 2003, ONCOGENE, V22, P7891, DOI 10.1038/sj.onc.1206639; Heckman CA, 2002, ONCOGENE, V21, P3898, DOI 10.1038/sj.onc.1205483; Hoefnagel JJ, 2005, BLOOD, V105, P3671, DOI 10.1182/blood-2004-04-1594; Husson H, 2002, BLOOD, V99, P282, DOI 10.1182/blood.V99.1.282; Inamoto S, 1997, J BIOL CHEM, V272, P29852, DOI 10.1074/jbc.272.47.29852; Ji L, 1996, J BIOL CHEM, V271, P22687, DOI 10.1074/jbc.271.37.22687; Jin TR, 2001, J BIOL CHEM, V276, P14752, DOI 10.1074/jbc.M008277200; KANG SM, 1992, MOL CELL BIOL, V12, P3149, DOI 10.1128/MCB.12.7.3149; Kim U, 2003, P NATL ACAD SCI USA, V100, P8868, DOI 10.1073/pnas.1033108100; Kim U, 1996, NATURE, V383, P542, DOI 10.1038/383542a0; LEBOWITZ JH, 1989, GENE DEV, V3, P1625, DOI 10.1101/gad.3.10.1625; Lossos IS, 2000, BLOOD, V96, P635; Marafioti T, 2003, AM J PATHOL, V162, P861, DOI 10.1016/S0002-9440(10)63882-5; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MEEKER TC, 1985, BLOOD, V65, P1349, DOI 10.1182/blood.V65.6.1349.bloodjournal6561349; MILLER CL, 1991, MOL CELL BIOL, V11, P4885, DOI 10.1128/MCB.11.10.4885; Nagy M, 2002, BRIT J HAEMATOL, V116, P429, DOI 10.1046/j.1365-2141.2002.03271.x; Nielsen PJ, 1996, EUR J IMMUNOL, V26, P3214, DOI 10.1002/eji.1830261255; Pileri SA, 2003, LEUKEMIA LYMPHOMA, V44, pS21, DOI 10.1080/10428190310001623810; Pileri SA, 2003, AM J PATHOL, V162, P243, DOI 10.1016/S0002-9440(10)63815-1; POELLINGER L, 1989, MOL CELL BIOL, V9, P747, DOI 10.1128/MCB.9.2.747; Robetorye RS, 2002, J MOL DIAGN, V4, P123, DOI 10.1016/S1525-1578(10)60693-9; Romero F, 1999, EMBO J, V18, P3419, DOI 10.1093/emboj/18.12.3419; Sauter P, 1997, IMMUNOBIOLOGY, V198, P207, DOI 10.1016/S0171-2985(97)80041-1; Schubart DB, 1996, NATURE, V383, P538, DOI 10.1038/383538a0; Schubart K, 2001, NAT IMMUNOL, V2, P69, DOI 10.1038/83190; Sepulveda MA, 2004, J IMMUNOL, V172, P1054, DOI 10.4049/jimmunol.172.2.1054; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; STAUDT LM, 1988, SCIENCE, V241, P577, DOI 10.1126/science.3399892; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; Wang VEH, 2004, MOL CELL BIOL, V24, P1022, DOI 10.1128/MCB.24.3.1022-1032.2004; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; WIRTH T, 1991, NUCLEIC ACIDS RES, V19, P43, DOI 10.1093/nar/19.1.43; Wong MW, 1998, MOL CELL BIOL, V18, P368, DOI 10.1128/MCB.18.1.368; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; Zwilling S, 1997, SCIENCE, V277, P221, DOI 10.1126/science.277.5323.221	53	29	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					888	898		10.1038/sj.onc.1209127	http://dx.doi.org/10.1038/sj.onc.1209127			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16186795				2022-12-25	WOS:000235212700008
J	Li, H; Zhang, Y; Su, T; Santella, RM; Weinstein, IB				Li, H; Zhang, Y; Su, T; Santella, RM; Weinstein, IB			Hint1 is a haplo-insufficient tumor suppressor in mice	ONCOGENE			English	Article						Hint1; PKCI-1; Fhit; tumorigenesis; tumor-suppressor gene	NUCLEOTIDE-BINDING PROTEIN; HISTIDINE TRIAD PROTEINS; C-INTERACTING PROTEIN-1; FHIT-DEFICIENT MICE; TRANSGENIC MICE; MAMMARY-TUMORS; MAST-CELLS; CANCER; FAMILY; GENE	The HINT1 protein, a member of the histidine triad ( HIT) family, is highly conserved in diverse species and ubiquitously expressed in mammalian tissues. However, its precise function in mammalian cells is not known. As a result of its structural similarity to the tumor-suppressor protein FHIT, we used homozygous-deleted Hint1 mice to study its role in tumorigenesis. We discovered that after 2 to 3 years of age the spontaneous tumor incidence in Hint1 -/- mice was significantly greater than that in wildtype Hint1 +/+ mice (P < 0.05). Using a well-established mouse model of 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary carcinogenesis we found a marked and significant (P < 0.05) increase in the incidence of mammary and ovarian tumors in both, Hint1 -/- and +/- mice versus +/+ mice. The Hint1 -/- and +/- mice had similar tumor incidence and similar tumor histologies. Therefore, deletion of Hint1 in mice enhances both spontaneous tumor development and susceptibility to tumor induction by DMBA. In addition, since the Hint1 +/- tumors retained expression of the unmutated wild type allele, Hint1 is haplo-insufficient with respect to tumor suppression in this model system.	Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ, Inst Human Nutr, New York, NY 10032 USA; Columbia Univ, Dept Environm Hlth Sci, New York, NY 10032 USA; Columbia Univ, Dept Med, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University	Weinstein, IB (corresponding author), Columbia Univ, Herbert Irving Comprehens Canc Ctr, 701 W 168th St,HHSC 1509, New York, NY 10032 USA.	ibw1@columbia.edu			NATIONAL CANCER INSTITUTE [R37CA026056, R01CA026056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005116, P30ES009089] Funding Source: NIH RePORTER; NCI NIH HHS [CA26056-24] Funding Source: Medline; NIEHS NIH HHS [P30 ES009089, P30ES09089, ES05116, R01 ES005116] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aldaz CM, 1996, CARCINOGENESIS, V17, P2069, DOI 10.1093/carcin/17.9.2069; ARCHULETA MM, 1992, TOXICOL APPL PHARM, V113, P133, DOI 10.1016/0041-008X(92)90017-M; Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; Bieganowski P, 2002, J BIOL CHEM, V277, P10852, DOI 10.1074/jbc.M111480200; Brenner C, 2002, BIOCHEMISTRY-US, V41, P9003, DOI 10.1021/bi025942q; Brenner C, 1997, NAT STRUCT BIOL, V4, P231, DOI 10.1038/nsb0397-231; Brzoska PM, 1996, GENOMICS, V36, P151, DOI 10.1006/geno.1996.0435; BRZOSKA PM, 1995, P NATL ACAD SCI USA, V92, P7824, DOI 10.1073/pnas.92.17.7824; Buters J, 2003, CARCINOGENESIS, V24, P327, DOI 10.1093/carcin/24.2.327; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Fong LYY, 2000, P NATL ACAD SCI USA, V97, P4742, DOI 10.1073/pnas.080063497; Gilmour J, 1997, BIOCHEM J, V326, P471, DOI 10.1042/bj3260471; GOERLICH O, 1982, EUR J BIOCHEM, V126, P135, DOI 10.1111/j.1432-1033.1982.tb06757.x; Guranowski A, 2004, FRONT BIOSCI-LANDMRK, V9, P1398, DOI 10.2741/1338; GURANOWSKI A, 1989, BIOCHEM J, V262, P241, DOI 10.1042/bj2620241; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; Ingvarsson S, 2001, SEMIN CANCER BIOL, V11, P361, DOI 10.1006/scbi.2001.0391; Inoue K, 2001, GENE DEV, V15, P2934, DOI 10.1101/gad.929901; Jackson RJ, 2003, CANCER RES, V63, P3021; Kisselev LL, 1998, FEBS LETT, V427, P157, DOI 10.1016/S0014-5793(98)00420-7; Klein MG, 1998, EXP CELL RES, V244, P26, DOI 10.1006/excr.1998.4153; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Korsisaari N, 2000, J BIOL CHEM, V275, P34837, DOI 10.1074/jbc.C000505200; Korsisaari N, 2003, MOL CELL BIOL, V23, P3929, DOI 10.1128/MCB.23.11.3929-3935.2003; Lee YN, 2004, IMMUNITY, V20, P145, DOI 10.1016/S1074-7613(04)00020-2; Lima CD, 1996, P NATL ACAD SCI USA, V93, P5357, DOI 10.1073/pnas.93.11.5357; Lima CD, 1997, SCIENCE, V278, P286, DOI 10.1126/science.278.5336.286; MALKINSON AM, 1986, CANCER RES, V46, P1694; MEDINA D, 1980, CANCER RES, V40, P368; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; Qing WG, 1997, CARCINOGENESIS, V18, P553, DOI 10.1093/carcin/18.3.553; Quon KC, 2001, GENE DEV, V15, P2917, DOI 10.1101/gad.949001; Razin E, 1999, J BIOL CHEM, V274, P34272, DOI 10.1074/jbc.274.48.34272; Seraphin B., 1992, DNA Sequence, V3, P177, DOI 10.3109/10425179209034013; Su T, 2003, P NATL ACAD SCI USA, V100, P7824, DOI 10.1073/pnas.1332160100; Threadgill DW, 1997, MAMM GENOME, V8, P390, DOI 10.1007/s003359900453; Vartanian A, 1999, FEBS LETT, V456, P175, DOI 10.1016/S0014-5793(99)00956-4; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; WITTY JP, 1995, CANCER RES, V55, P1401; Yao Y, 1999, ONCOGENE, V18, P5159, DOI 10.1038/sj.onc.1202908; Yuan BZ, 2004, NEOPLASIA, V6, P412, DOI 10.1593/neo.03490; Zanesi N, 2001, P NATL ACAD SCI USA, V98, P10250, DOI 10.1073/pnas.191345898	44	91	101	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					713	721		10.1038/sj.onc.1209111	http://dx.doi.org/10.1038/sj.onc.1209111			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16186798				2022-12-25	WOS:000235068800007
J	Nishida, S; Kurokawa, K; Matsuo, M; Sakamoto, K; Ueno, K; Kita, K; Sekimizu, K				Nishida, S; Kurokawa, K; Matsuo, M; Sakamoto, K; Ueno, K; Kita, K; Sekimizu, K			Identification and characterization of amino acid residues essential for the active site of UDP-N-acetylenolpyruvylglucosamine reductase (MurB) from Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA DEHYDROGENASE; ESCHERICHIA-COLI; WILD-TYPE; NADP(+) BINDING; S229A MUTANT; INHIBITORS; ENZYME; BIOSYNTHESIS; PURIFICATION; PROTEINS	The enzymes essential for bacterial peptidoglycan biosynthesis are attractive targets for antimicrobial drug development. One of these is MurB, which contains FAD as a cofactor and catalyzes the NADPH-dependent reduction of UDP-N-acetylenolpyruvylglucosamine (UDP-GlcNAcEP) to UDP-N-acetylmuramic acid. This study examined the roles of the conserved amino acid residues of Staphylococcus aureus MurB, which are located near the active site in x-ray crystal structures. Seven of 11 site-directed mutated murB genes lost the ability to complement a temperature-sensitive S. aureus murB mutant. Biochemical characterization of the seven mutated MurB proteins revealed that they cannot carry out the reduction of UDP-GlcNAcEP, although they can all catalyze the intramolecular reduction of FAD via NADPH. Spectrometric analyses of the oxidized form of the mutated proteins in the presence and absence of NADP(+) or UDP-GlcNAcEP revealed that these essential amino acid residues play four distinct roles in substrate interactions: Arg(213) is essential for maintenance of the electronic state of FAD; Arg(176) is required for interaction with UDP-GlcNAcEP; His(259) is required for interaction with both UDP-GlcNAcEP and NADP(+); and Asn(71), Tyr(175), Ser(226), and Glu(296) are not apparently required for interaction with either ligand. The results presented here identify for the first time the amino acid residues of MurB that are required for the interaction with UDP-GlcNAcEP and NADP(+).	Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Dev Biochem, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Med, Dept Biomed Chem, Bunkyo Ku, Tokyo 1130033, Japan; Musashino Univ, Pharmaceut Sci Res Inst, Microbiol Lab, Tokyo 2028585, Japan	University of Tokyo; University of Tokyo	Kurokawa, K (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Dev Biochem, Bunkyo Ku, 7-3-1,Hongo, Tokyo 1130033, Japan.	kurokawa@mol.f.u-tokyo.ac.jp	Sakamoto, Kimitoshi/G-4539-2014; Nishida, Satoshi/J-6680-2014	Nishida, Satoshi/0000-0003-0653-7522; Kita, Kiyoshi/0000-0002-0426-4308				Andres CJ, 2000, BIOORG MED CHEM LETT, V10, P715, DOI 10.1016/S0960-894X(00)00073-1; ANWAR RA, 1979, CAN J BIOCHEM CELL B, V57, P188, DOI 10.1139/o79-023; Axley MJ, 1997, BIOCHEMISTRY-US, V36, P812, DOI 10.1021/bi962260s; BECKER DF, 1993, BIOCHEMISTRY-US, V32, P10736, DOI 10.1021/bi00091a026; BENSON TE, 1995, NAT STRUCT BIOL, V2, P644, DOI 10.1038/nsb0895-644; Benson TE, 1997, BIOCHEMISTRY-US, V36, P806, DOI 10.1021/bi962221g; BENSON TE, 1993, BIOCHEMISTRY-US, V32, P2024, DOI 10.1021/bi00059a019; Benson TE, 2001, BIOCHEMISTRY-US, V40, P2340, DOI 10.1021/bi002162d; Benson TE, 1997, BIOCHEMISTRY-US, V36, P796, DOI 10.1021/bi962220o; Bronson JJ, 2003, BIOORG MED CHEM LETT, V13, P873, DOI 10.1016/S0960-894X(02)01076-4; BROSS P, 1990, J BIOL CHEM, V265, P7116; Constantine KL, 1997, J MOL BIOL, V267, P1223, DOI 10.1006/jmbi.1997.0915; DHALLA AM, 1995, BIOCHEMISTRY-US, V34, P5390, DOI 10.1021/bi00016a010; Dwyer TM, 2000, BIOCHEMISTRY-US, V39, P11488, DOI 10.1021/bi000700g; El Zoeiby A, 2003, MOL MICROBIOL, V47, P1, DOI 10.1046/j.1365-2958.2003.03289.x; ENGLANDER SW, 1987, ANAL BIOCHEM, V161, P300, DOI 10.1016/0003-2697(87)90454-4; Farmer BT, 1996, NAT STRUCT BIOL, V3, P995, DOI 10.1038/nsb1296-995; Fraaije MW, 1998, TRENDS BIOCHEM SCI, V23, P206, DOI 10.1016/S0968-0004(98)01210-9; Gotz F, 2004, CURR OPIN MICROBIOL, V7, P477, DOI 10.1016/j.mib.2004.08.014; Holtje JV, 1998, MICROBIOL MOL BIOL R, V62, P181; Matsuo M, 2003, FEMS MICROBIOL LETT, V222, P107, DOI 10.1016/S0378-1097(03)00260-X; MIYAKAWA T, 1972, J BACTERIOL, V112, P950, DOI 10.1128/JB.112.2.950-958.1972; Murzin AG, 1996, CURR OPIN STRUC BIOL, V6, P386, DOI 10.1016/S0959-440X(96)80059-5; Navarre WW, 1999, MICROBIOL MOL BIOL R, V63, P174, DOI 10.1128/MMBR.63.1.174-229.1999; ROWLAND SL, 1995, GENE, V164, P113, DOI 10.1016/0378-1119(95)00467-K; Sambrook J, 2001, MOL CLONING LAB MANU; TAKU S, 1970, J BIOL CHEM, V245, P5012; van den Heuvel RHH, 2000, J BIOL CHEM, V275, P14799, DOI 10.1074/jbc.275.20.14799; VANHEIJENOORT J, 1996, ESCHERICHIA COLI SAL, P1025	29	19	19	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1714	1724		10.1074/jbc.M509277200	http://dx.doi.org/10.1074/jbc.M509277200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16236703	hybrid			2022-12-25	WOS:000234652000051
J	Zanardelli, S; Crawley, JTB; Chion, CKNCK; Lam, JK; Preston, RJS; Lane, DA				Zanardelli, S; Crawley, JTB; Chion, CKNCK; Lam, JK; Preston, RJS; Lane, DA			ADAMTS13 substrate recognition of von Willebrand factor A2 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE MUTATIONS; CLEAVAGE; BINDING; PROTEASE	ADAMTS13 controls the multimeric size of circulating von Willebrand factor (VWF) by cleaving the Tyr(1605)-Met(1606) bond in the A2 domain. To examine substrate recognition, we expressed in bacteria and purified three A2 (VWF76-(1593-1668), VWF115(1554-1668), VWFA2-(1473-1668)) and one A2-A3 (VWF115-A3-(1554-1874)) domain fragments. Using high pressure liquid chromatography analysis, the initial rates of VWF115 cleavage by ADAMTS13 at different substrate concentrations were determined, and from this the kinetic constants were derived (K-m 1.61 mu M; k(cat') 0.14 s(-1)), from which the specificity constant k(cat)/K-m was calculated, 8.70 x 10(4) M-1 s(-1). Similar values of the specificity constant were obtained for VWF76 and VWF115-A3. To identify residues important for recognition and proteolysis of VWF115, we introduced certain type 2A von Willebrand disease mutations by site-directed mutagenesis. Although most were cleaved normally, one (D1614G) was cleaved similar to 8-fold slower. Mutagenesis of additional charged residues predicted to be in close proximity to Asp(1614) on the surface of the A2 domain (R1583A, D1587A, D1614A, E1615A, K1617A, E1638A, E1640A) revealed up to 13-fold reduction in k(cat)/ Km for D1587A, D1614A, E1615A, and K1617A mutants. When introduced into the intact VWFA2 domain, proteolysis of the D1587A, D1614A, and E1615A mutants was also slowed, particularly in the presence of urea. Surface plasmon resonance demonstrated appreciable reduction in binding affinity between ADAMTS13 and VWF115 mutants (K-D up to similar to 1.3 mu M), compared with VWF115 (K-D 20 nM). These results demonstrate an important role for Asp(1614) and surrounding charged residues in the binding and cleavage of the VWFA2 domain by ADAMTS13.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Haematol, London W12 0NN, England	Imperial College London	Crawley, JTB (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Haematol, 5th Floor,Commonwlth Bldg,Hammersmith Hosp Campus, London W12 0NN, England.	j.crawley@imperial.ac.uk	Crawley, James TB/A-9290-2008	Crawley, James TB/0000-0002-6723-7841; Preston, Roger/0000-0003-0108-4077				Ai JH, 2005, J BIOL CHEM, V280, P29428, DOI 10.1074/jbc.M505513200; Bajaj MS, 1999, THROMB HAEMOSTASIS, V82, P1047; Crawley JTB, 2005, BLOOD, V105, P1085, DOI 10.1182/blood-2004-03-1101; Cruz MA, 2003, THROMB HAEMOSTASIS, V90, P1204, DOI 10.1160/TH03-06-0398; De Cristofaro R, 2005, J BIOL CHEM, V280, P23295, DOI 10.1074/jbc.M501143200; de Wit TR, 2001, BEST PRACT RES CL HA, V14, P241; Dong JF, 2003, J BIOL CHEM, V278, P29633, DOI 10.1074/jbc.M301385200; Dong JF, 2002, BLOOD, V100, P4033, DOI 10.1182/blood-2002-05-1401; Furlan M, 1996, BLOOD, V87, P4223, DOI 10.1182/blood.V87.10.4223.bloodjournal87104223; Haberichter SL, 2000, BLOOD, V96, P1808, DOI 10.1182/blood.V96.5.1808.h8001808_1808_1815; Kokame K, 2005, BRIT J HAEMATOL, V129, P93, DOI 10.1111/j.1365-2141.2005.05420.x; Kokame K, 2004, BLOOD, V103, P607, DOI 10.1182/blood-2003-08-2861; Majerus EM, 2005, J BIOL CHEM, V280, P21773, DOI 10.1074/jbc.M502529200; Nishio K, 2004, P NATL ACAD SCI USA, V101, P10578, DOI 10.1073/pnas.0402041101; ROTH GJ, 1986, BIOCHEMISTRY-US, V25, P8357, DOI 10.1021/bi00374a004; RUGGERI ZM, 1983, J CLIN INVEST, V72, P1, DOI 10.1172/JCI110946; Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395; Siedlecki CA, 1996, BLOOD, V88, P2939, DOI 10.1182/blood.V88.8.2939.bloodjournal8882939; Sutherland JJ, 2004, J MOL MODEL, V10, P259, DOI 10.1007/s00894-004-0194-9; Tsai HM, 1997, BLOOD, V89, P1954, DOI 10.1182/blood.V89.6.1954; Tsai HM, 2004, J THROMB HAEMOST, V2, P2057, DOI 10.1111/j.1538-7836.2004.00985.x; Tsai HM, 1996, BLOOD, V87, P4235, DOI 10.1182/blood.V87.10.4235.bloodjournal87104235; Zwaal RFA, 1998, BBA-REV BIOMEMBRANES, V1376, P433, DOI 10.1016/S0304-4157(98)00018-5	23	66	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1555	1563		10.1074/jbc.M508316200	http://dx.doi.org/10.1074/jbc.M508316200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16221672	hybrid			2022-12-25	WOS:000234652000033
J	Dagon, Y; Avraham, Y; Magen, I; Gertler, A; Ben-Hur, T; Berry, EM				Dagon, Y; Avraham, Y; Magen, I; Gertler, A; Ben-Hur, T; Berry, EM			Nutritional status, cognition, and survival - A new role for leptin and AMP kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PARKINSONS-DISEASE; DOPAMINERGIC-NEURONS; DIETARY RESTRICTION; CALORIE RESTRICTION; FOOD-INTAKE; STEM-CELLS; MICE; APOPTOSIS; MEMORY	Although adequate nutrition is essential for optimal neural activity and survival, mild energy restriction may improve cognition and prolong longevity. Energy status is monitored by the cellular AMP-activated protein kinase ( AMPK) system, whereas leptin regulates total energy balance. We investigated the roles of AMPK and leptin in cognition and survival under diet restriction ( DR). Hippocampal AMPK activity increases with energy restriction. Modest activation ( DR to 60%) induces neurogenesis and improves cognition. However, DR to 40% augmented AMPK activity, reduced cognition and catecholamines, and increased neural apoptosis and mortality. Leptin signaling is preserved only in DR to 60%, countering the effects of AMPK "overactivation" by preventing neuroapoptosis, restoring noradrenergic activity and behavioral performance, and increasing longevity. The balance between leptin and AMPK is crucial in determining neuronal fate, cognitive ability, and survival. Should these findings extend to Man, then controlled activation of AMPK may improve neurodegenerative diseases, and leptin may have a new role in treating stress-associated malnutrition.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Human Nutr & Metab, Braun Sch Publ Hlth,Fac Med, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Dept Neurol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Agr, IL-76100 Rehovot, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem	Berry, EM (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Human Nutr & Metab, Braun Sch Publ Hlth,Fac Med, IL-91120 Jerusalem, Israel.	Berry@md.huji.ac.il	Dagon, Yossi/AAI-5882-2020	Magen, Iddo/0000-0002-3011-3175				Andersson U, 2004, J BIOL CHEM, V279, P12005, DOI 10.1074/jbc.C300557200; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Campas C, 2003, BLOOD, V101, P3674, DOI 10.1182/blood-2002-07-2339; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; Dridi S, 2000, DOMEST ANIM ENDOCRIN, V18, P325, DOI 10.1016/S0739-7240(00)00053-9; Duan WZ, 1999, J NEUROSCI RES, V57, P195, DOI 10.1002/(SICI)1097-4547(19990715)57:2&lt;195::AID-JNR5&gt;3.0.CO;2-P; During MJ, 2003, NAT MED, V9, P1173, DOI 10.1038/nm919; FERNANDES G, 1976, P NATL ACAD SCI USA, V73, P1279, DOI 10.1073/pnas.73.4.1279; Fernandez-Galaz C, 2002, DIABETOLOGIA, V45, P997, DOI 10.1007/s00125-002-0851-4; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Hartmann A, 2000, P NATL ACAD SCI USA, V97, P2875, DOI 10.1073/pnas.040556597; Ido Y, 2002, DIABETES, V51, P159, DOI 10.2337/diabetes.51.1.159; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Lee J, 2002, J NEUROCHEM, V80, P539, DOI 10.1046/j.0022-3042.2001.00747.x; Love R, 2005, LANCET NEUROL, V4, P84, DOI 10.1016/S1474-4422(05)00985-3; Maruyama W, 2003, NEUROSCI LETT, V341, P233, DOI 10.1016/S0304-3940(03)00211-8; McCay CM, 1935, J NUTR, V10, P63, DOI 10.1093/jn/10.1.63; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Meisse D, 2002, FEBS LETT, V526, P38, DOI 10.1016/S0014-5793(02)03110-1; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; OLTON DS, 1976, J EXP PSYCHOL-ANIM B, V2, P97, DOI 10.1037/0097-7403.2.2.97; PETIT TL, 1988, NEUROTOXICOLOGY, V9, P413; PICK CG, 1983, INT J NEUROSCI, V21, P63, DOI 10.3109/00207458308986121; PITSIKAS N, 1992, NEUROBIOL AGING, V13, P369, DOI 10.1016/0197-4580(92)90110-J; RANDT CT, 1971, SCIENCE, V172, P498, DOI 10.1126/science.172.3982.498; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Tschape JA, 2002, EMBO J, V21, P6367, DOI 10.1093/emboj/cdf636; TURNER E, 1969, LANCET, V2, P1123; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; Wilsey J, 2004, J ENDOCRINOL, V181, P297, DOI 10.1677/joe.0.1810297; ZIV I, 1994, NEUROSCI LETT, V170, P136, DOI 10.1016/0304-3940(94)90258-5	38	93	103	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42142	42148		10.1074/jbc.M507607200	http://dx.doi.org/10.1074/jbc.M507607200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16203737	hybrid			2022-12-25	WOS:000233992700041
J	Doucleff, M; Malak, LT; Pelton, JG; Wemmer, DE				Doucleff, M; Malak, LT; Pelton, JG; Wemmer, DE			The C-terminal RpoN domain of sigma(54) forms an unpredicted helix-turn-helix motif similar to domains of sigma(70)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SEQUENCE ALIGNMENT; RNA-POLYMERASE HOLOENZYME; CRYSTAL-STRUCTURE; TRANSCRIPTIONAL REGULATION; ESCHERICHIA-COLI; STRUCTURAL BASIS; INITIATION; SIGMA-54; COMPLEX; ARCHITECTURE	The "sigma" subunit of prokaryotic RNA polymerase allows gene-specific transcription initiation. Two sigma families have been identified, sigma(70) and sigma(54), which use distinct mechanisms to initiate transcription and share no detectable sequence homology. Although the sigma(70)-type factors have been well characterized structurally by x-ray crystallography, no high resolution structural information is available for the sigma(54)-type factors. Here we present the NMR-derived structure of the C- terminal domain of sigma(54) from Aquifex aeolicus. This domain (Thr-323 to Gly-389), which contains the highly conserved RpoN box sequence, consists of a poorly structured N-terminal tail followed by a three-helix bundle, which is surprisingly similar to domains of the sigma(70)-type proteins. Residues of the RpoN box, which have previously been shown to be critical for DNA binding, form the second helix of an unpredicted helix-turn-helix motif. The homology of this structure with other DNA-binding proteins, combined with previous biochemical data, suggests how the C- terminal domain of sigma(54) binds to DNA.	Lawrence Livermore Natl Lab, Phys Biosci Div, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Wemmer, DE (corresponding author), Lawrence Livermore Natl Lab, Phys Biosci Div, Berkeley, CA 94720 USA.	DEWemmer@lbl.gov			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062163] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62163] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beitz E, 2000, BIOINFORMATICS, V16, P135, DOI 10.1093/bioinformatics/16.2.135; Bordes P, 2003, P NATL ACAD SCI USA, V100, P2278, DOI 10.1073/pnas.0537525100; Buck M, 2000, J BACTERIOL, V182, P4129, DOI 10.1128/JB.182.15.4129-4136.2000; BURGESS RR, 1969, NATURE, V221, P43, DOI 10.1038/221043a0; Burrows PC, 2003, J BIOL CHEM, V278, P29728, DOI 10.1074/jbc.M303596200; Campbell EA, 2002, MOL CELL, V9, P527, DOI 10.1016/S1097-2765(02)00470-7; Campbell EA, 2003, MOL CELL, V11, P1067, DOI 10.1016/S1097-2765(03)00148-5; CANNON W, 1995, J MOL BIOL, V248, P781, DOI 10.1006/jmbi.1995.0260; CANNON W, 1994, MOL MICROBIOL, V11, P227, DOI 10.1111/j.1365-2958.1994.tb00303.x; Cannon WV, 1997, P NATL ACAD SCI USA, V94, P5006, DOI 10.1073/pnas.94.10.5006; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Chilcott GS, 2000, MICROBIOL MOL BIOL R, V64, P694, DOI 10.1128/MMBR.64.4.694-708.2000; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Cuff JA, 2000, PROTEINS, V40, P502, DOI 10.1002/1097-0134(20000815)40:3<502::AID-PROT170>3.0.CO;2-Q; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Fisher MA, 2005, P NATL ACAD SCI USA, V102, P5162, DOI 10.1073/pnas.0408536102; Garcia-Castellanos R, 2004, J BIOL CHEM, V279, P17888, DOI 10.1074/jbc.M313123200; Garcia-Castellanos R, 2003, J BIOL CHEM, V278, P39897, DOI 10.1074/jbc.M307199200; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; HIRSCHMAN J, 1985, P NATL ACAD SCI USA, V82, P7525, DOI 10.1073/pnas.82.22.7525; Jain D, 2004, MOL CELL, V13, P45, DOI 10.1016/S1097-2765(03)00483-0; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leonard PM, 2001, EMBO J, V20, P990, DOI 10.1093/emboj/20.5.990; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; Malhotra A, 1996, CELL, V87, P127, DOI 10.1016/S0092-8674(00)81329-X; Marley J, 2001, J BIOMOL NMR, V20, P71, DOI 10.1023/A:1011254402785; Mer G, 2000, CELL, V103, P449, DOI 10.1016/S0092-8674(00)00136-7; Missailidis S, 1997, MOL MICROBIOL, V24, P653, DOI 10.1046/j.1365-2958.1997.3691738.x; Murakami KS, 2002, SCIENCE, V296, P1280, DOI 10.1126/science.1069594; Murakami KS, 2003, CURR OPIN STRUC BIOL, V13, P31, DOI 10.1016/S0959-440X(02)00005-2; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; Nichols MD, 1999, EMBO J, V18, P6177, DOI 10.1093/emboj/18.21.6177; Paget MSB, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-1-203; Pohl E, 2003, MOL MICROBIOL, V47, P903, DOI 10.1046/j.1365-2958.2003.03337.x; Rappas M, 2005, SCIENCE, V307, P1972, DOI 10.1126/science.1105932; SASSEDWIGHT S, 1990, CELL, V62, P945, DOI 10.1016/0092-8674(90)90269-K; Sorenson MK, 2004, MOL CELL, V14, P127, DOI 10.1016/S1097-2765(04)00150-9; SPERA S, 1991, J AM CHEM SOC, V113, P5490, DOI 10.1021/ja00014a071; Svergun DI, 2000, J BIOL CHEM, V275, P4210, DOI 10.1074/jbc.275.6.4210; Taylor M, 1996, MOL MICROBIOL, V22, P1045, DOI 10.1046/j.1365-2958.1996.01547.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Voskuil MI, 2002, J MOL BIOL, V322, P521, DOI 10.1016/S0022-2836(02)00802-1; Wang L, 2001, J BIOL CHEM, V276, P8979, DOI 10.1074/jbc.M009587200; WEDEL A, 1990, SCIENCE, V248, P486, DOI 10.1126/science.1970441; Wintjens R, 1996, J MOL BIOL, V262, P294, DOI 10.1006/jmbi.1996.0514; WONG CN, 1994, J MOL BIOL, V236, P81, DOI 10.1006/jmbi.1994.1120; Wosten MMSM, 1998, FEMS MICROBIOL REV, V22, P127, DOI 10.1016/S0168-6445(98)00011-4; Xu H, 2001, CURR OPIN MICROBIOL, V4, P138, DOI 10.1016/S1369-5274(00)00179-X; Xu HE, 1999, GENE DEV, V13, P1263, DOI 10.1101/gad.13.10.1263	54	32	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41530	41536		10.1074/jbc.M509010200	http://dx.doi.org/10.1074/jbc.M509010200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16210314	hybrid, Green Submitted			2022-12-25	WOS:000233866900052
J	Velazquez-Dones, A; Hagopian, JC; Ma, CT; Zhong, XY; Zhou, HL; Ghosh, G; Fu, XD; Adams, JA				Velazquez-Dones, A; Hagopian, JC; Ma, CT; Zhong, XY; Zhou, HL; Ghosh, G; Fu, XD; Adams, JA			Mass spectrometric and kinetic analysis of ASF/SF2 phosphorylation by SRPK1 and Clk/Sty	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA SPLICING FACTORS; PROTEIN-KINASE CLK/STY; MESSENGER-RNA; SERINE-RICH; SR PROTEINS; PROCESSIVE PHOSPHORYLATION; INTRANUCLEAR DISTRIBUTION; RS DOMAIN; LOCALIZATION; SPECIFICITY	Assembly of the spliceosome requires the participation of SR proteins, a family of splicing factors rich in arginine-serine dipeptide repeats. The repeat regions (RS domains) are polyphosphorylated by the SRPK and Clk/Sty families of kinases. The two families of kinases have distinct enzymatic properties, raising the question of how they may work to regulate the function of SR proteins in RNA metabolism in mammalian cells. Here we report the first mass spectral analysis of the RS domain of ASF/SF2, a prototypical SR protein. We found that SRPK1 was responsible for efficient phosphorylation of a short stretch of amino acids in the N-terminal portion of the RS domain of ASF/SF2 while Clk/Sty was able to transfer phosphate to all available serine residues in the RS domain, indicating that SR proteins may be phosphorylated by different kinases in a stepwise manner. Both kinases bind with high affinity and use fully processive catalytic mechanisms to achieve either restrictive or complete RS domain phosphorylation. These findings have important implications on the regulation of SR proteins in vivo by the SRPK and Clk/Sty families of kinases.	Univ Calif San Diego, Dept Cellular & Mol Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Fu, XD (corresponding author), Univ Calif San Diego, Dept Cellular & Mol Biol, La Jolla, CA 92093 USA.	xdfu@ucsd.edu; joeadams@chem.ucsd.edu		Zhou, Huilin/0000-0002-1350-4430	NIGMS NIH HHS [GM52872, GM07752, GM67969] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067969, R01GM052872] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akker SA, 2001, J MOL ENDOCRINOL, V27, P123, DOI 10.1677/jme.0.0270123; Allemand E, 2001, MOL CELL BIOL, V21, P1345, DOI 10.1128/MCB.21.4.1345-1359.2001; Aubol BE, 2003, P NATL ACAD SCI USA, V100, P12601, DOI 10.1073/pnas.1635129100; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; CACERES JF, 1993, EMBO J, V12, P4715, DOI 10.1002/j.1460-2075.1993.tb06160.x; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; Colwill K, 1996, J BIOL CHEM, V271, P24569, DOI 10.1074/jbc.271.40.24569; Duncan PI, 1998, EXP CELL RES, V241, P300, DOI 10.1006/excr.1998.4083; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; GUI JF, 1994, P NATL ACAD SCI USA, V91, P10824, DOI 10.1073/pnas.91.23.10824; GUTFREUND H, 1995, KINETICS LIFE SCI RE, P111; Huang YQ, 2003, MOL CELL, V11, P837, DOI 10.1016/S1097-2765(03)00089-3; Huang YQ, 2001, MOL CELL, V7, P899, DOI 10.1016/S1097-2765(01)00233-7; JAMISON SF, 1995, NUCLEIC ACIDS RES, V23, P3260, DOI 10.1093/nar/23.16.3260; Koizumi J, 1999, J BIOL CHEM, V274, P11125, DOI 10.1074/jbc.274.16.11125; Lai MC, 2004, J BIOL CHEM, V279, P31745, DOI 10.1074/jbc.C400173200; Lai MC, 2001, P NATL ACAD SCI USA, V98, P10154, DOI 10.1073/pnas.181354098; Modrek B, 2002, NAT GENET, V30, P13, DOI 10.1038/ng0102-13; Ngo JCK, 2005, MOL CELL, V20, P77, DOI 10.1016/j.molcel.2005.08.025; Pellicena P, 2001, J BIOL CHEM, V276, P28190, DOI 10.1074/jbc.M100055200; Prasad J, 1999, MOL CELL BIOL, V19, P6991; Prasad J, 2003, MOL CELL BIOL, V23, P4139, DOI 10.1128/MCB.23.12.4139-4149.2003; Resing KA, 1997, METHOD ENZYMOL, V283, P29; Sacco-Bubulya P, 2002, J CELL BIOL, V156, P425, DOI 10.1083/jcb.200107017; Sanford JR, 2004, GENE DEV, V18, P755, DOI 10.1101/gad.286404; Shen HH, 2004, MOL CELL, V13, P367, DOI 10.1016/S1097-2765(04)00025-5; Shen HH, 2004, MOL CELL, V16, P363, DOI 10.1016/j.molcel.2004.10.021; Stojdl DF, 1999, BIOCHEM CELL BIOL, V77, P293, DOI 10.1139/bcb-77-4-293; Wang HY, 1998, J CELL BIOL, V140, P737, DOI 10.1083/jcb.140.4.737; Xiao SH, 1998, EMBO J, V17, P6359, DOI 10.1093/emboj/17.21.6359; Xiao SH, 1997, GENE DEV, V11, P334, DOI 10.1101/gad.11.3.334; Yeakley JM, 1999, J CELL BIOL, V145, P447, DOI 10.1083/jcb.145.3.447	33	69	72	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41761	41768		10.1074/jbc.M504156200	http://dx.doi.org/10.1074/jbc.M504156200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16223727	hybrid			2022-12-25	WOS:000233866900078
J	Santos, MJ; Quintanilla, RA; Toro, AS; Grandy, R; Dinamarca, MC; Godoy, JA; Inestrosa, NC				Santos, MJ; Quintanilla, RA; Toro, AS; Grandy, R; Dinamarca, MC; Godoy, JA; Inestrosa, NC			Peroxisomal proliferation protects from beta-amyloid neurodegeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED-RECEPTOR-ALPHA; INTEGRAL MEMBRANE-PROTEINS; VITAMIN-E PROTECTS; ALZHEIMERS-DISEASE; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; CELL-DEATH; HIPPOCAMPAL-NEURONS; ZELLWEGER SYNDROME; PEPTIDE NEUROTOXICITY	Alzheimer disease is a neurodegenerative process that leads to severe cognitive impairment as a consequence of selective death of neuronal populations. The molecular pathogenesis of Alzheimer disease involves the participation of the beta-amyloid peptide (A beta) and oxidative stress. We report here that peroxisomal proliferation attenuated A beta-dependent toxicity in hippocampal neurons. Pretreatment with Wy-14.463 (Wy), a peroxisome proliferator, prevent the neuronal cell death and neuritic network loss induced by the A beta peptide. Moreover, the hippocampal neurons treated with this compound, showed an increase in the number of peroxisomes, with a concomitant increase in catalase activity. Additionally, we evaluate the Wy protective effect on beta-catenin levels, production of intracellular reactive oxygen species, cytoplasmic calcium uptake, and mitochondrial potential in hippocampal neurons exposed to H2O2 and A beta peptide. Results show that the peroxisomal proliferation prevents beta-catenin degradation, reactive oxygen species production, cytoplasmic calcium increase, and changes in mitochondrial viability. Our data suggest, for the first time, a direct link between peroxisomal proliferation and neuroprotection from A beta-induced degenerative changes.	Ctr Regulac Celular & Patol Joaquin V Luco, Inst Milenio, Santiago, Chile; Pontificia Univ Catolica Chile, Unidad Bioquim Celular & Genet, Fac Ciencias Biol, Santiago, Chile	Pontificia Universidad Catolica de Chile	Inestrosa, NC (corresponding author), Pontificia Univ Catolica Chile, CRCP, Biomed Ctr, Alameda 340, Santiago, Chile.	ninestr@genes.bio.puc.cl	QUINTANILLA, RODRIGO/ABG-8829-2021; Godoy, Juan A/F-5398-2018	Godoy, Juan A/0000-0001-9920-6698				Abramov AY, 2004, J NEUROSCI, V24, P565, DOI 10.1523/JNEUROSCI.4042-03.2004; Alvarez A, 1998, J NEUROSCI, V18, P3213; ARNOLD G, 1979, J HISTOCHEM CYTOCHEM, V27, P735, DOI 10.1177/27.3.39097; BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; BEHL C, 1992, BIOCHEM BIOPH RES CO, V186, P944, DOI 10.1016/0006-291X(92)90837-B; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Bonnefort AB, 1998, FEBS LETT, V441, P220, DOI 10.1016/S0014-5793(98)01552-X; Bush AI, 2003, TRENDS NEUROSCI, V26, P207, DOI 10.1016/S0166-2236(03)00067-5; Calderon FH, 1999, J NEUROSCI RES, V56, P620; CITKOWITZ E, 1973, J HISTOCHEM CYTOCHEM, V21, P34, DOI 10.1177/21.1.34; Corton JC, 2000, ANNU REV PHARMACOL, V40, P491, DOI 10.1146/annurev.pharmtox.40.1.491; De Ferrari GV, 2003, MOL PSYCHIATR, V8, P195, DOI 10.1038/sj.mp.4001208; DEDUVE C, 1969, PROC R SOC SER B-BIO, V173, P71, DOI 10.1098/rspb.1969.0039; DEDUVE C, 1966, PHYSIOL REV, V46, P323, DOI 10.1152/physrev.1966.46.2.323; Deplanque D, 2003, J NEUROSCI, V23, P6264; Dringen R, 1999, J NEUROCHEM, V72, P2523, DOI 10.1046/j.1471-4159.1999.0722523.x; Faust PL, 2003, J COMP NEUROL, V461, P394, DOI 10.1002/cne.10699; Faust PL, 2001, J MOL NEUROSCI, V16, P289, DOI 10.1385/JMN:16:2-3:289; Fuentealba RA, 2004, BRAIN RES REV, V47, P275, DOI 10.1016/j.brainresrev.2004.07.018; Garrido JL, 2002, FASEB J, V16, P1982, DOI 10.1096/fj.02-0327fje; GOLDFISCHER S, 1985, SCIENCE, V227, P67, DOI 10.1126/science.3964959; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Hashimoto T, 1999, J BIOL CHEM, V274, P19228, DOI 10.1074/jbc.274.27.19228; Heppner TJ, 2005, PHARMACOLOGY, V73, P15, DOI 10.1159/000081070; Howroyd P, 2004, TOXICOL PATHOL, V32, P591, DOI 10.1080/01926230490515283; INESTROSA NC, 1979, BIOCHEM J, V182, P779, DOI 10.1042/bj1820779; Inestrosa NC, 2005, EXP CELL RES, V304, P91, DOI 10.1016/j.yexcr.2004.09.032; Inestrosa NC, 1996, NEURON, V16, P881, DOI 10.1016/S0896-6273(00)80108-7; Ischiropoulos H, 2003, J CLIN INVEST, V111, P163, DOI 10.1172/JCI200317638; Ishikawa T, 2001, EXP CELL RES, V266, P260, DOI 10.1006/excr.2001.5226; Jang JH, 2004, BIOCHEM BIOPH RES CO, V320, P880, DOI 10.1016/j.bbrc.2004.06.035; Janssen A, 2003, J NEUROSCI, V23, P9732; Kamsler A, 2004, MOL NEUROBIOL, V29, P167, DOI 10.1385/MN:29:2:167; Kevil CG, 1998, FREE RADICAL BIO MED, V24, P1015, DOI 10.1016/S0891-5849(97)00433-4; Kevil CG, 2001, AM J PHYSIOL-CELL PH, V281, pC1940, DOI 10.1152/ajpcell.2001.281.6.C1940; Koppal T, 1998, BRAIN RES, V786, P270, DOI 10.1016/S0006-8993(97)01466-2; Kukar T, 2005, NAT MED, V11, P545, DOI 10.1038/nm1235; Lacor PN, 2004, J NEUROSCI, V24, P10191, DOI 10.1523/JNEUROSCI.3432-04.2004; LaFerla FM, 2002, NAT REV NEUROSCI, V3, P862, DOI 10.1038/nrn960; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; Lazarow PB, 2003, CURR OPIN CELL BIOL, V15, P489, DOI 10.1016/S0955-0674(03)00082-6; LEIGHTON F, 1975, J CELL BIOL, V67, P281, DOI 10.1083/jcb.67.2.281; Liu N, 2002, J NEUROVIROL, V8, P318, DOI 10.1080/13550280290100699; LOVELL MA, 1995, NEUROLOGY, V45, P1594, DOI 10.1212/WNL.45.8.1594; Mandard S, 2004, CELL MOL LIFE SCI, V61, P393, DOI 10.1007/s00018-003-3216-3; MCKENNA O, 1976, BRAIN RES, V117, P181, DOI 10.1016/0006-8993(76)90729-0; Miranda S, 2000, PROG NEUROBIOL, V62, P633, DOI 10.1016/S0301-0082(00)00015-0; Miranda S, 1999, BIOCHEM BIOPH RES CO, V258, P44, DOI 10.1006/bbrc.1999.0580; Morgan C, 2004, PROG NEUROBIOL, V74, P323, DOI 10.1016/j.pneurobio.2004.10.004; Munoz FJ, 1999, FEBS LETT, V450, P205, DOI 10.1016/S0014-5793(99)00468-8; NAIKI H, 1991, LAB INVEST, V65, P104; Newman EA, 1997, SCIENCE, V275, P844, DOI 10.1126/science.275.5301.844; Opazo C, 2002, J BIOL CHEM, V277, P40302, DOI 10.1074/jbc.M206428200; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Poynter ME, 1998, J BIOL CHEM, V273, P32833, DOI 10.1074/jbc.273.49.32833; Qi X, 2004, MOL PHARMACOL, V66, P899, DOI 10.1124/mol.104.001339; Quintanilla RA, 2000, CELL CALCIUM, V28, P97, DOI 10.1054/ceca.2000.0135; Quintanilla RA, 2005, J BIOL CHEM, V280, P11615, DOI 10.1074/jbc.M411936200; Rhee SG, 1999, EXP MOL MED, V31, P53, DOI 10.1038/emm.1999.9; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; SANTOS MJ, 1988, J BIOL CHEM, V263, P10502; SANTOS MJ, 1988, SCIENCE, V239, P1536, DOI 10.1126/science.3281254; SANTOS MJ, 1985, P NATL ACAD SCI USA, V82, P6556, DOI 10.1073/pnas.82.19.6556; SANTOS MJ, 1994, J BIOL CHEM, V269, P24890; Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; SHACKLETON GL, 1995, TOXICOL APPL PHARM, V130, P294, DOI 10.1006/taap.1995.1034; Shin SY, 2004, CANCER LETT, V212, P225, DOI 10.1016/j.canlet.2004.03.003; SHIN SY, 2005, IN PRESS CELL SIGNAL; SMALL GM, 1988, J INHERIT METAB DIS, V11, P358, DOI 10.1007/BF01800425; Smith MA, 1996, NATURE, V382, P120, DOI 10.1038/382120b0; Smith SA, 2001, J NEUROSCI RES, V66, P236, DOI 10.1002/jnr.1216; Stamer K, 2002, J CELL BIOL, V156, P1051, DOI 10.1083/jcb.200108057; Stokin GB, 2005, SCIENCE, V307, P1282, DOI 10.1126/science.1105681; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Svoboda K, 1997, NATURE, V385, P161, DOI 10.1038/385161a0; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Wei HM, 2000, ANN NEUROL, V47, P286, DOI 10.1002/1531-8249(200003)47:3<286::AID-ANA3>3.3.CO;2-2; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Zerby SE, 1996, BRAIN RES, V712, P1, DOI 10.1016/0006-8993(95)01383-0	83	131	137	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					41057	41068		10.1074/jbc.M505160200	http://dx.doi.org/10.1074/jbc.M505160200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16204253	hybrid			2022-12-25	WOS:000233666600080
J	Weaver, JR; Kugel, JF; Goodrich, JA				Weaver, JR; Kugel, JF; Goodrich, JA			The sequence at specific positions in the early transcribed region sets the rate of transcript synthesis by RNA polymerase II in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTER ESCAPE; STRUCTURAL BASIS; HYBRID DUPLEXES; DNA HYBRID; INITIATION; COMPLEX; ELONGATION; STABILITY; TRANSITION; PARAMETERS	To further understand the mechanism of promoter escape by RNA polymerase II, we have systematically investigated the effect of core promoter sequence on the rate of transcript synthesis in vitro. Chimeric and mutant promoters were made by swapping sequences between the human interleukin-2 promoter and the adenovirus major late promoter, which exhibit different rates of transcript synthesis. Kinetic studies at these promoters revealed that sequences downstream of the start sites set the rate of transcript synthesis. Specifically, the sequences at +2 and +7/ +8 are critical for determining the rate; when either +2 is a C (nontemplate strand) or +7/ +8 is a TT (nontemplate strand), transcript synthesis is slow. At +7/ +8, the thermodynamic stability of the RNA: DNA hybrid controls the overall rate of transcript synthesis. Our data support a model in which the rate-limiting step during transcript synthesis by RNA polymerase II in vitro occurs at the point in the reaction at which early ternary complexes transform into elongation complexes.	Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Kugel, JF (corresponding author), Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA.	jennifer.kugel@colorado.edu; james.goodrich@colorado.edu			NIGMS NIH HHS [GM55235, T32 GM07135] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007135] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bushnell DA, 2004, SCIENCE, V303, P983, DOI 10.1126/science.1090838; CAI H, 1987, J BIOL CHEM, V262, P298; Dvir A, 1997, J BIOL CHEM, V272, P28175, DOI 10.1074/jbc.272.45.28175; Dvir A, 2002, BBA-GENE STRUCT EXPR, V1577, P208, DOI 10.1016/S0167-4781(02)00453-0; FELSENFE.G, 1967, ANNU REV BIOCHEM, V36, P407, DOI 10.1146/annurev.bi.36.070167.002203; Ferguson HA, 2001, J MOL BIOL, V314, P993, DOI 10.1006/jmbi.2000.5215; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; Holstege FCP, 1997, EMBO J, V16, P7468, DOI 10.1093/emboj/16.24.7468; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; Kaufmann J, 1996, GENE DEV, V10, P873, DOI 10.1101/gad.10.7.873; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; Keene RG, 1999, J BIOL CHEM, V274, P11526, DOI 10.1074/jbc.274.17.11526; Kireeva ML, 2000, J BIOL CHEM, V275, P6530, DOI 10.1074/jbc.275.9.6530; Kugel JF, 1998, P NATL ACAD SCI USA, V95, P9232, DOI 10.1073/pnas.95.16.9232; Kugel JF, 2002, MOL CELL BIOL, V22, P762, DOI 10.1128/MCB.22.3.762-773.2002; Kugel JF, 2000, J BIOL CHEM, V275, P40483, DOI 10.1074/jbc.M006401200; Lo K, 1996, GENE, V182, P13, DOI 10.1016/S0378-1119(96)00438-6; LUSE DS, 1987, J BIOL CHEM, V262, P289; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; MARTIN FH, 1980, NUCLEIC ACIDS RES, V8, P2295, DOI 10.1093/nar/8.10.2295; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Pal M, 2005, MOL CELL, V19, P101, DOI 10.1016/j.molcel.2005.05.024; Pal M, 2003, P NATL ACAD SCI USA, V100, P5700, DOI 10.1073/pnas.1037057100; Pal M, 2002, MOL CELL BIOL, V22, P30, DOI 10.1128/MCB.22.1.30-40.2002; Samkurashvili I, 1998, MOL CELL BIOL, V18, P5343, DOI 10.1128/MCB.18.9.5343; SantaLucia J, 1996, BIOCHEMISTRY-US, V35, P3555, DOI 10.1021/bi951907q; Smale ST, 1998, COLD SPRING HARB SYM, V63, P21, DOI 10.1101/sqb.1998.63.21; SUGIMOTO N, 1995, BIOCHEMISTRY-US, V34, P11211, DOI 10.1021/bi00035a029; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; Westover KD, 2004, SCIENCE, V303, P1014, DOI 10.1126/science.1090839; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479	34	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					39860	39869		10.1074/jbc.M509376200	http://dx.doi.org/10.1074/jbc.M509376200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16210313	hybrid			2022-12-25	WOS:000233461300024
J	Fonseca, SG; Fukuma, M; Lipson, KL; Nguyen, LX; Allen, JR; Oka, Y; Urano, F				Fonseca, SG; Fukuma, M; Lipson, KL; Nguyen, LX; Allen, JR; Oka, Y; Urano, F			WFS1 is a novel component of the unfolded protein response and maintains homeostasis of the endoplasmic reticulum in pancreatic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIABETES-MELLITUS; TRANSMEMBRANE PROTEIN; TRANSLATIONAL CONTROL; WOLFRAM-SYNDROME; OPTIC ATROPHY; STRESS; GENE; KINASE; ACTIVATION; EXPRESSION	In Wolfram syndrome, a rare form of juvenile diabetes, pancreatic beta-cell death is not accompanied by an autoimmune response. Although it has been reported that mutations in the WFS1 gene are responsible for the development of this syndrome, the precise molecular mechanisms underlying beta-cell death caused by the WFS1 mutations remain unknown. Here we report that WFS1 is a novel component of the unfolded protein response and has an important function in maintaining homeostasis of the endoplasmic reticulum ( ER) in pancreatic beta-cells. WFS1 encodes a transmembrane glycoprotein in the ER. WFS1 mRNA and protein are induced by ER stress. The expression of WFS1 is regulated by inositol requiring 1 and PKR-like ER kinase, central regulators of the unfolded protein response. WFS1 is normally up-regulated during insulin secretion, whereas inactivation of WFS1 in beta-cells causes ER stress and beta-cell dysfunction. These results indicate that the pathogenesis of Wolfram syndrome involves chronic ER stress in pancreatic beta-cells caused by the loss of function of WFS1.	Univ Massachusetts, Sch Med, Program Gene Funct & Express, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Tohoku Univ, Grad Sch Med, Div Mol Metab & Diabet, Sendai, Miyagi 9808575, Japan	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Tohoku University	Urano, F (corresponding author), Univ Massachusetts, Sch Med, Program Gene Funct & Express, Worcester, MA 01605 USA.	Fumihiko.Urano@umassmed.edu	Urano, Fumihiko/AAF-4492-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067493] Funding Source: NIH RePORTER; NIDDK NIH HHS [1R01DK067493-01, R01 DK067493] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barrett TG, 1997, J MED GENET, V34, P838, DOI 10.1136/jmg.34.10.838; Bertolotti A, 2001, J CLIN INVEST, V107, P585, DOI 10.1172/JCI11476; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Delepine M, 2000, NAT GENET, V25, P406, DOI 10.1038/78085; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2002, DIABETES, V51, pS455, DOI 10.2337/diabetes.51.2007.S455; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Hoeflich KP, 1999, ONCOGENE, V18, P5814, DOI 10.1038/sj.onc.1202975; Hofmann S, 2003, HUM MOL GENET, V12, P2003, DOI 10.1093/hmg/ddg214; Inoue H, 1998, NAT GENET, V20, P143, DOI 10.1038/2441; Ishihara H, 2004, HUM MOL GENET, V13, P1159, DOI 10.1093/hmg/ddh125; Iwawaki T, 2004, NAT MED, V10, P98, DOI 10.1038/nm970; KARASIK A, 1989, DIABETES CARE, V12, P135, DOI 10.2337/diacare.12.2.135; Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Osman AA, 2003, J BIOL CHEM, V278, P52755, DOI 10.1074/jbc.M310331200; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; RANDO TA, 1992, NEUROLOGY, V42, P1220, DOI 10.1212/WNL.42.6.1220; Scheuner D, 2003, VIROLOGY, V317, P263, DOI 10.1016/j.virol.2003.08.010; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Strom TM, 1998, HUM MOL GENET, V7, P2021, DOI 10.1093/hmg/7.13.2021; Takeda K, 2001, HUM MOL GENET, V10, P477, DOI 10.1093/hmg/10.5.477; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Wolfram D.J., 1938, MAYO CLIN PROC, V13, P715; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zhang PC, 2002, MOL CELL BIOL, V22, P3864, DOI 10.1128/MCB.22.11.3864-3874.2002	38	233	242	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39609	39615		10.1074/jbc.M507426200	http://dx.doi.org/10.1074/jbc.M507426200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16195229	hybrid			2022-12-25	WOS:000233362200084
J	Fujii, N; Hirshman, MF; Kane, EM; Ho, RC; Peter, LE; Seifert, MM; Goodyear, LJ				Fujii, N; Hirshman, MF; Kane, EM; Ho, RC; Peter, LE; Seifert, MM; Goodyear, LJ			AMP-activated protein kinase alpha 2 activity is not essential for contraction- and hyperosmolarity-induced glucose transport in skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; GAMMA-SUBUNIT ISOFORMS; ACETYL-COA CARBOXYLASE; CATALYTIC SUBUNIT; INSULIN; RAT; EXPRESSION; EXERCISE; STIMULATION; METABOLISM	To examine the role of AMP-activated protein kinase ( AMPK) in muscle glucose transport, we generated muscle-specific transgenic mice (TG) carrying cDNAs of inactive alpha 2 (alpha 2i TG) and alpha 1 (alpha 1i TG) catalytic subunits. Extensor digitorum longus (EDL) muscles from wild type and TG mice were isolated and subjected to a series of in vitro incubation experiments. In alpha 2i TG mice basal alpha 2 activity was barely detectable, whereas basal alpha 1 activity was only partially reduced. Known AMPK stimuli including 5-aminoimidazole-4-carboxamide-1- beta-4-ribofuranoside (AICAR), rotenone ( a Complex I inhibitor), dinitrophenol ( a mitochondrial uncoupler), muscle contraction, and sorbitol ( producing hyperosmolar shock) did not increase AMPK alpha 2 activity in alpha 2i TG mice, whereas alpha 1 activation was attenuated by only 30 - 50%. Glucose transport was measured in vitro using isolated EDL muscles from alpha 2i TG mice. AICAR- and rotenone-stimulated glucose transport was fully inhibited in alpha 2iTG mice; however, the lack of AMPK alpha 2 activity had no effect on contraction or sorbitol-induced glucose transport. Similar to these observations in vitro, contraction-stimulated glucose transport, assessed in vivo by 2-deoxy-D-[H-3] glucose incorporation into EDL, tibialis anterior, and gastrocnemius muscles, was normal in alpha 2i TG mice. Thus, AMPK alpha 2 activation is essential for some, but not all, insulin-independent glucose transport. Muscle contraction- and hyperosmolarity-induced glucose transport may be regulated by a redundant mechanism in which AMPK alpha 2 is one of multiple signaling pathways.	Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Goodyear, LJ (corresponding author), Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA.	Laurie.Goodyear@joslin.harvard.edu	Fujii, Nobuharu/J-2724-2014	Fujii, Nobuharu/0000-0002-0974-3033; Peter, Lauren/0000-0002-2105-7503	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045670, R29AR042238, R01AR042238, F32AR049662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836] Funding Source: NIH RePORTER; NIAMS NIH HHS [F32 AR049662, R01 AR45670, AR42238] Funding Source: Medline; NIDDK NIH HHS [DK36836] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bergeron R, 1999, AM J PHYSIOL-ENDOC M, V276, pE938, DOI 10.1152/ajpendo.1999.276.5.E938; Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005; Chen HC, 2002, J BIOL CHEM, V277, P23554, DOI 10.1074/jbc.M201152200; Chen ZP, 1999, FEBS LETT, V460, P343, DOI 10.1016/S0014-5793(99)01371-X; Cheung PCF, 2000, BIOCHEM J, V346, P659, DOI 10.1042/0264-6021:3460659; Crute BE, 1998, J BIOL CHEM, V273, P35347, DOI 10.1074/jbc.273.52.35347; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; Dyck JRB, 1996, J BIOL CHEM, V271, P17798, DOI 10.1074/jbc.271.30.17798; FERRE P, 1985, BIOCHEM J, V228, P103, DOI 10.1042/bj2280103; Fisher JS, 2002, AM J PHYSIOL-ENDOC M, V282, pE18, DOI 10.1152/ajpendo.2002.282.1.E18; FORSAYETH J, 1981, AM J PHYSIOL, V240, pE263, DOI 10.1152/ajpendo.1981.240.3.E263; Fryer LGD, 2000, DIABETES, V49, P1978, DOI 10.2337/diabetes.49.12.1978; Fryer LGD, 2002, BIOCHEM J, V363, P167, DOI 10.1042/0264-6021:3630167; Fujii N, 2004, AM J PHYSIOL-CELL PH, V287, pC200, DOI 10.1152/ajpcell.00415.2003; Fujii N, 2000, BIOCHEM BIOPH RES CO, V273, P1150, DOI 10.1006/bbrc.2000.3073; Gadalla AE, 2004, J NEUROCHEM, V88, P1272, DOI 10.1046/j.1471-4159.2003.02253.x; GOODYEAR LJ, 1995, AM J PHYSIOL-ENDOC M, V268, pE987, DOI 10.1152/ajpendo.1995.268.5.E987; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hayashi T, 2000, DIABETES, V49, P527, DOI 10.2337/diabetes.49.4.527; Hayashi T, 1998, DIABETES, V47, P1369, DOI 10.2337/diabetes.47.8.1369; Ho RC, 2004, AM J PHYSIOL-REG I, V286, pR342, DOI 10.1152/ajpregu.00563.2003; Jorgensen SB, 2004, J BIOL CHEM, V279, P1070, DOI 10.1074/jbc.M306205200; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; Mahlapuu M, 2004, AM J PHYSIOL-ENDOC M, V286, pE194, DOI 10.1152/ajpendo.00147.2003; Merrill GF, 1997, AM J PHYSIOL-ENDOC M, V273, pE1107, DOI 10.1152/ajpendo.1997.273.6.E1107; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Musi N, 2001, DIABETES, V50, P921, DOI 10.2337/diabetes.50.5.921; Musi N, 2001, AM J PHYSIOL-ENDOC M, V280, pE677, DOI 10.1152/ajpendo.2001.280.5.E677; Musi Nicolas, 2002, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V2, P119; Patel N, 2001, BIOCHEM BIOPH RES CO, V285, P1066, DOI 10.1006/bbrc.2001.5275; Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1; RUDERMAN NB, 1971, BIOCHEM J, V124, P639, DOI 10.1042/bj1240639; Rutter GA, 2003, BIOCHEM J, V375, P1, DOI 10.1042/BJ20030048; SHULMAN GI, 1990, NEW ENGL J MED, V322, P223, DOI 10.1056/NEJM199001253220403; Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437; Thornton C, 1998, J BIOL CHEM, V273, P12443, DOI 10.1074/jbc.273.20.12443; Vavvas D, 1997, J BIOL CHEM, V272, P13255, DOI 10.1074/jbc.272.20.13255; VINCENT MF, 1991, ADV EXP MED BIOL, V309, P359; Viollet B, 2003, J CLIN INVEST, V111, P91, DOI 10.1172/JCI200316567; Winder WW, 1996, AM J PHYSIOL-ENDOC M, V270, pE299, DOI 10.1152/ajpendo.1996.270.2.E299; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1; Woods A, 2000, MOL CELL BIOL, V20, P6704, DOI 10.1128/MCB.20.18.6704-6711.2000; Xing YQ, 2003, J BIOL CHEM, V278, P28372, DOI 10.1074/jbc.M303521200; Young ME, 1996, FEBS LETT, V382, P43, DOI 10.1016/0014-5793(96)00129-9; Zierath JR, 1996, DIABETOLOGIA, V39, P1180, DOI 10.1007/BF02658504	47	140	143	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39033	39041		10.1074/jbc.M504208200	http://dx.doi.org/10.1074/jbc.M504208200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16186119	hybrid			2022-12-25	WOS:000233362200017
J	Gao, JX; Gusa, AA; Scott, JR; Churchward, G				Gao, JX; Gusa, AA; Scott, JR; Churchward, G			Binding of the global response regulator protein CovR to the sag promoter of Streptococcus pyogenes reveals a new mode of CovR-DNA interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCUS; 2-COMPONENT SIGNAL-TRANSDUCTION; HYALURONIC-ACID CAPSULE; SYSTEM; IDENTIFICATION; RECOGNITION; EXPRESSION; CSRR/CSRS; GENE; CSRR	CovR (CsrR) is a response regulator of gene expression in Streptococcus pyogenes. It regulates similar to 15% of the genome, including the genes encoding several streptococcal virulence factors, and acts primarily as a repressor rather than an activator of transcription. We showed that in vitro, CovR is sufficient to repress transcription from the sag promoter, which directs the expression of streptolysin S, a hemolysin that can damage the membranes of eukaryotic cells and subcellular organelles. Repression was stimulated 10-fold by phosphorylation of CovR with acetyl phosphate. In contrast to binding at the has and cov promoters, which direct the expression of genes involved in capsule biosynthesis and of CovR itself, binding of CovR to Psag was highly cooperative. CovR bound to two extended regions of Psag, an upstream region overlapping the -35 and -10 promoter elements and a downstream region overlapping the translation initiation signals of the sagA gene. Each of these regions contains only a single consensus CovR binding sequence, ATTARA, which at the has promoter defines individual sites to which CovR binds non-cooperatively. At Phas and Pcov the T residues in the sequence ATTARA are important for CovR binding. However, using uracil interference experiments we find that although the ATTARA sequence in the Psag upstream region contains thymine residues important for CovR binding, important thymine residues in the Psag downstream region are located outside this sequence. Furthermore, again in contrast to its behavior at the has and cov promoters where phosphorylation of CovR leads to a 2-3-fold increase in DNA binding affinity, binding of CovR to the sag promoter was stimulated 8-32-fold by phosphorylation. We suggest that these differences in CovR binding mean that individual promoters will be repressed at different intracellular levels of phosphorylated CovR, permitting differences in the response of members of the CovR regulon to environmental and internal metabolic signals.	Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA	Emory University	Churchward, G (corresponding author), Emory Univ, Sch Med, Dept Microbiol & Immunol, 1510 Clifton Rd, Atlanta, GA 30322 USA.	ggchurc@microbio.emory.edu	GUSA, ASIYA/HGD-5776-2022	GUSA, ASIYA/0000-0001-9915-1834	NIAID NIH HHS [AI20723, T32-AI07470] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI020723, R37AI020723, R01AI020723, R56AI020723, T32AI007470] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alves R, 2003, MOL MICROBIOL, V48, P25, DOI 10.1046/j.1365-2958.2003.03344.x; Bernish B, 1999, J BIOL CHEM, V274, P4786, DOI 10.1074/jbc.274.8.4786; Blanco AG, 2002, STRUCTURE, V10, P701, DOI 10.1016/S0969-2126(02)00761-X; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; Dalton TL, 2004, J BACTERIOL, V186, P3928, DOI 10.1128/JB.186.12.3928-3937.2004; Federle MJ, 2002, MOL MICROBIOL, V43, P1161, DOI 10.1046/j.1365-2958.2002.02810.x; Graham MR, 2002, P NATL ACAD SCI USA, V99, P13855, DOI 10.1073/pnas.202353699; Gryllos I, 2003, P NATL ACAD SCI USA, V100, P4227, DOI 10.1073/pnas.0636231100; Gusa AA, 2005, MOL MICROBIOL, V56, P1195, DOI 10.1111/j.1365-2958.2005.04623.x; Heath A, 1999, INFECT IMMUN, V67, P5298, DOI 10.1128/IAI.67.10.5298-5305.1999; Hoch JA, 2001, J BACTERIOL, V183, P4941, DOI 10.1128/JB.183.17.4941-4949.2001; Kenney LJ, 2002, CURR OPIN MICROBIOL, V5, P135, DOI 10.1016/S1369-5274(02)00310-7; Levin JC, 1998, MOL MICROBIOL, V30, P209, DOI 10.1046/j.1365-2958.1998.01057.x; Miller AA, 2001, MOL MICROBIOL, V40, P976, DOI 10.1046/j.1365-2958.2001.02441.x; Munson GP, 1999, J BACTERIOL, V181, P2110, DOI 10.1128/JB.181.7.2110-2117.1999; PU WT, 1992, NUCLEIC ACIDS RES, V20, P771, DOI 10.1093/nar/20.4.771; Russo F D, 1993, Trends Microbiol, V1, P306, DOI 10.1016/0966-842X(93)90007-E; SCOTT JR, 1986, J EXP MED, V164, P1641, DOI 10.1084/jem.164.5.1641; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183	19	50	52	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					38948	38956		10.1074/jbc.M506121200	http://dx.doi.org/10.1074/jbc.M506121200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16174772	hybrid			2022-12-25	WOS:000233362200008
J	Jacob, RF; Mason, RP				Jacob, RF; Mason, RP			Lipid peroxidation induces cholesterol domain formation in model membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; X-RAY-DIFFRACTION; ATP HYDROLYZING ACTIVITY; CELL PLASMA-MEMBRANES; SMOOTH-MUSCLE CELLS; ALZHEIMERS-DISEASE; ATHEROSCLEROTIC LESIONS; NEURONAL DEGENERATION; LIPOSOMAL MEMBRANES; OXIDATIVE STRESS	Numerous reports have established that lipid peroxidation contributes to cell injury by altering the basic physical properties and structural organization of membrane components. Oxidative modification of polyunsaturated phospholipids has been shown, in particular, to alter the intermolecular packing, thermodynamic, and phase parameters of the membrane bilayer. In this study, the effects of oxidative stress on membrane phospholipid and sterol organization were measured using small angle x-ray diffraction approaches. Model membranes enriched in dilinoleoylphosphatidylcholine were prepared at various concentrations of cholesterol and subjected to lipid peroxidation at physiologic conditions. At cholesterol-to-phospholipid mole ratios ( C/P) as low as 0.4, lipid peroxidation induced the formation of discrete, membrane-restricted cholesterol domains having a unit cell periodicity or d-space value of 34 angstrom. The formation of cholesterol domains correlated directly with lipid hydroperoxide levels and was inhibited by treatment with vitamin E. In the absence of oxidative stress, similar cholesterol domains were observed only at C/P ratios of 1.0 or higher. In addition to changes in sterol organization, lipid peroxidation also caused reproducible changes in overall membrane structure, including a 10 angstrom reduction in the width of the surrounding, sterol-poor membrane bilayer. These data provided direct evidence that lipid peroxidation alters the essential organization and structure of membrane lipids in a manner that may contribute to changes in membrane function during aging and oxidative stress-related disorders.	Elucida Res, Beverly, MA 01915 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Cardiovasc Div, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Jacob, RF (corresponding author), Elucida Res, 100 Cummings Ctr,Ste 135L,POB 7100, Beverly, MA 01915 USA.	rjacob@elucidaresearch.com						Ahuja RP, 1999, FREE RADICAL BIO MED, V27, P177, DOI 10.1016/S0891-5849(99)00068-4; BANGHAM AD, 1965, J MOL BIOL, V13, P238, DOI 10.1016/S0022-2836(65)80093-6; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; BHUYAN KC, 1986, LIFE SCI, V38, P1463, DOI 10.1016/0024-3205(86)90559-X; BIALECKI RA, 1989, AM J PHYSIOL, V257, P306; BOLOTINA V, 1991, P ROY SOC B-BIOL SCI, V244, P51, DOI 10.1098/rspb.1991.0050; BORCHMAN D, 1992, LIPIDS, V27, P261, DOI 10.1007/BF02536472; Borchman D, 1998, INVEST OPHTH VIS SCI, V39, P1053; Buege J A, 1978, Methods Enzymol, V52, P302; CERVATO G, 1988, CHEM PHYS LIPIDS, V49, P135, DOI 10.1016/0009-3084(88)90075-8; CHANG HM, 1995, J MEMBRANE BIOL, V143, P51; CHATTERJEE SN, 1988, FREE RADICAL BIO MED, V4, P51, DOI 10.1016/0891-5849(88)90011-1; CHEN M, 1995, BBA-MOL BASIS DIS, V1272, P101, DOI 10.1016/0925-4439(95)00073-D; CHIA LS, 1984, BIOCHIM BIOPHYS ACTA, V775, P308, DOI 10.1016/0005-2736(84)90185-8; DEKRUIJFF B, 1976, BIOCHIM BIOPHYS ACTA, V436, P726; Diaz MN, 1997, NEW ENGL J MED, V337, P408, DOI 10.1056/NEJM199708073370607; DINIS TCP, 1993, ARCH BIOCHEM BIOPHYS, V301, P256, DOI 10.1006/abbi.1993.1142; ELSAADANI M, 1989, J LIPID RES, V30, P627; ELYANDOUZI EH, 1993, BIOCHEMISTRY-US, V32, P2047, DOI 10.1021/bi00059a023; ENGELMAN DM, 1972, J BIOL CHEM, V247, P3694; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; FRANKS NP, 1976, J MOL BIOL, V100, P345, DOI 10.1016/S0022-2836(76)80067-8; GARDNER HW, 1975, J AGR FOOD CHEM, V23, P129, DOI 10.1021/jf60198a012; GARNER MH, 1986, EXP EYE RES, V42, P339, DOI 10.1016/0014-4835(86)90027-8; GARNER WH, 1983, P NATL ACAD SCI-BIOL, V80, P2044, DOI 10.1073/pnas.80.7.2044; GIRAUD F, 1981, BIOCHIM BIOPHYS ACTA, V647, P249, DOI 10.1016/0005-2736(81)90253-4; Girotti AW, 1998, J LIPID RES, V39, P1529; GLEASON MM, 1991, CIRC RES, V69, P216, DOI 10.1161/01.RES.69.1.216; GOEL R, 1993, NEUROSCI LETT, V151, P219, DOI 10.1016/0304-3940(93)90024-F; GOLDSTEIN IM, 1977, BIOCHEM BIOPH RES CO, V75, P604, DOI 10.1016/0006-291X(77)91515-7; Heinecke JW, 1998, ATHEROSCLEROSIS, V141, P1, DOI 10.1016/S0021-9150(98)00173-7; HERBETTE LG, 1985, BIOPHYS J, V20, P245; HORIKAWA Y, 1990, J EYE, V7, P561; Jacob RF, 2001, J BIOL CHEM, V276, P13573, DOI 10.1074/jbc.M010077200; Jacob RF, 1999, J BIOL CHEM, V274, P31613, DOI 10.1074/jbc.274.44.31613; Kellner-Weibel G, 1999, ARTERIOSCL THROM VAS, V19, P1891, DOI 10.1161/01.ATV.19.8.1891; Kourie JI, 1998, AM J PHYSIOL-CELL PH, V275, pC1, DOI 10.1152/ajpcell.1998.275.1.C1; KUNIMOTO M, 1981, BIOCHIM BIOPHYS ACTA, V646, P169, DOI 10.1016/0005-2736(81)90284-4; KUTRYK MJB, 1991, CIRC RES, V68, P18, DOI 10.1161/01.RES.68.1.18; LAU YT, 1994, ATHEROSCLEROSIS, V110, P251, DOI 10.1016/0021-9150(94)90209-7; LEIBOWITZ ME, 1971, J LIPID RES, V12, P662; LEONARD A, 1991, BIOCHIMIE, V73, P1295, DOI 10.1016/0300-9084(91)90092-F; MANDAL TK, 1980, RADIAT RES, V83, P290, DOI 10.2307/3575280; Mason R Preston, 2002, Methods Mol Biol, V196, P69; MASON RP, 1995, NEUROBIOL AGING, V16, P531, DOI 10.1016/0197-4580(95)00057-L; Mason RP, 1996, ANN NY ACAD SCI, V777, P368, DOI 10.1111/j.1749-6632.1996.tb34447.x; Mason RP, 1997, FREE RADICAL BIO MED, V23, P419, DOI 10.1016/S0891-5849(97)00101-9; Mason RP, 2003, CIRCULATION, V107, P2270, DOI 10.1161/01.CIR.0000062607.02451.B6; Mason RP, 2003, BBA-BIOMEMBRANES, V1610, P198, DOI 10.1016/S0005-2736(03)00018-X; MASON RP, 1992, MOL PHARMACOL, V41, P315; Mattson MP, 1999, ANN NY ACAD SCI, V893, P154, DOI 10.1111/j.1749-6632.1999.tb07824.x; Mattson MP, 1998, TRENDS NEUROSCI, V21, P53, DOI 10.1016/S0166-2236(97)01188-0; MCINTOSH TJ, 1978, BIOCHIM BIOPHYS ACTA, V513, P43, DOI 10.1016/0005-2736(78)90110-4; MCLEAN LR, 1992, FREE RADICAL BIO MED, V12, P113, DOI 10.1016/0891-5849(92)90004-Z; MOWRI H, 1984, J BIOCHEM-TOKYO, V95, P551, DOI 10.1093/oxfordjournals.jbchem.a134638; NAKAZAWA T, 1986, DRUG EXP CLIN RES, V12, P831; Petrescu AD, 2001, J BIOL CHEM, V276, P36970, DOI 10.1074/jbc.M101939200; PORTER NA, 1995, LIPIDS, V30, P277, DOI 10.1007/BF02536034; RUOCCO MJ, 1984, BIOPHYS J, V46, P695, DOI 10.1016/S0006-3495(84)84068-0; SCHROEDER F, 1991, P SOC EXP BIOL MED, V196, P235; SEVANIAN A, 1987, LIPIDS, V22, P627, DOI 10.1007/BF02533940; Sevanian A, 2000, FREE RADICAL BIO MED, V29, P306, DOI 10.1016/S0891-5849(00)00342-7; SHATOS MA, 1991, ARTERIOSCLER THROMB, V11, P594, DOI 10.1161/01.ATV.11.3.594; SMALL DM, 1988, ARTERIOSCLEROSIS, V8, P103, DOI 10.1161/01.ATV.8.2.103; SPECTOR A, 1995, FASEB J, V9, P1173, DOI 10.1096/fasebj.9.12.7672510; STEINBERG D, 1991, CIRCULATION, V84, P1420, DOI 10.1161/01.CIR.84.3.1420; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1989, J BIOL CHEM, V264, P15216; Tulenko TN, 1998, J LIPID RES, V39, P947; VANDUIJN G, 1984, BIOCHEMISTRY-US, V23, P4969, DOI 10.1021/bi00316a022; Verhagen JCD, 1996, J LIPID RES, V37, P1488; VERMA SP, 1986, RADIAT RES, V107, P183, DOI 10.2307/3576806; VIANI P, 1990, CHEM PHYS LIPIDS, V52, P49, DOI 10.1016/0009-3084(90)90006-D; VIANI P, 1991, J NEUROCHEM, V56, P253, DOI 10.1111/j.1471-4159.1991.tb02589.x; WOOD WG, 1995, BRAIN RES, V683, P36; YEAGLE PL, 1983, BIOCHIM BIOPHYS ACTA, V727, P39, DOI 10.1016/0005-2736(83)90366-8; YEAGLE PL, 1988, BIOCHEMISTRY-US, V27, P6449, DOI 10.1021/bi00417a037; YEAGLE PL, 1985, BIOCHIM BIOPHYS ACTA, V822, P267, DOI 10.1016/0304-4157(85)90011-5; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; YUKAWA O, 1983, INT J RADIAT BIOL, V43, P391, DOI 10.1080/09553008314550451; ZIGLER JS, 1983, ARCH BIOCHEM BIOPHYS, V225, P149, DOI 10.1016/0003-9861(83)90018-8	81	112	151	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39380	39387		10.1074/jbc.M507587200	http://dx.doi.org/10.1074/jbc.M507587200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16195227	hybrid			2022-12-25	WOS:000233362200059
J	Kukreja, R; Singh, B				Kukreja, R; Singh, B			Biologically active novel conformational state of botulinum, the most poisonous poison	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLTEN-GLOBULE STATE; STRUCTURAL-ANALYSIS; TRYPTOPHANYL RESIDUES; CRYSTAL-STRUCTURE; NEUROTOXIN; PROTEINS; LIGHT; EXPOSURE; INTERMEDIATE; FEATURES	Botulinum neurotoxins (serotypes A-G), the most toxic substances known to humankind, cause flaccid muscle paralysis by blocking acetylcholine release at nerve-muscle junctions through a very specific and exclusive endopeptidase activity against SNARE proteins of presynaptic exocytosis machinery. We have examined polypeptide folding of the endopeptidase moiety of botulinum neurotoxin/A ( the light chain) under conditions of its optimal enzymatic activity and have found that one of its stable conformational states is a molten-globule, which retains over 60% of its optimal enzyme activity. More importantly, we have discovered that the light chain acquires a novel pre-imminent molten-globule enzyme conformation at the physiologically relevant temperature, 37 degrees C. The pre-imminent molten-globule enzyme form also exhibited the maximum endopeptidase activity against its intracellular substrate, SNAP-25 ( synaptosomal associated protein of 25 kDa). These findings will not only open new avenues to design effective diagnostics and antidotes against botulism but also provide new information on enzymatically active molten-globule or molten-globule like structures.	Univ Massachusetts, Dept Chem & Biochem, Dartmouth, MA 02747 USA	University of Massachusetts System; University Massachusetts Dartmouth	Singh, B (corresponding author), Univ Massachusetts, Dept Chem & Biochem, 285 Old Westport Rd, Dartmouth, MA 02747 USA.	bsingh@umassd.edu			NIAID NIH HHS [AI057159-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI057159] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agarwal R, 2004, BIOCHEMISTRY-US, V43, P6637, DOI 10.1021/bi036278w; Arai M, 2000, ADV PROTEIN CHEM, V53, P209; Arnon SS, 2001, JAMA-J AM MED ASSOC, V285, P1059, DOI 10.1001/jama.285.8.1059; BETZ SF, 1999, CURR OPIN STRUC BIOL, V3, P601; Breidenbach MA, 2004, NATURE, V432, P925, DOI 10.1038/nature03123; BRYSON JW, 1995, SCIENCE, V270, P935, DOI 10.1126/science.270.5238.935; Bychkova V. E., 1993, CHEMTRACTS BIOCH MOL, V4, P133; BYCHKOVA VE, 1988, FEBS LETT, V238, P231, DOI 10.1016/0014-5793(88)80485-X; Cai SW, 2001, BIOCHEMISTRY-US, V40, P4693, DOI 10.1021/bi0025363; Cai SW, 2001, BIOCHEMISTRY-US, V40, P15327, DOI 10.1021/bi011350g; Cordivari C, 2004, MOVEMENT DISORD, V19, pS157, DOI 10.1002/mds.20071; DEMCHENKO AP, 1986, ESSAYS BIOCHEM, V22, P120; DESHPANDE SS, 1989, BIOCHIM BIOPHYS ACTA, V998, P179, DOI 10.1016/0167-4838(89)90271-9; Dubey VK, 2003, BIOCHEMISTRY-US, V42, P12287, DOI 10.1021/bi035047m; EFTINK MR, 1977, BIOCHEMISTRY-US, V16, P5546, DOI 10.1021/bi00644a024; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; EFTINK MR, 1975, P NATL ACAD SCI USA, V72, P3290, DOI 10.1073/pnas.72.9.3290; ERGBUTH FJ, 2004, MOVEMENT DISORD, V19, pS2; Eswaramoorthy S, 2002, BIOCHEMISTRY-US, V41, P9795, DOI 10.1021/bi020060c; France RM, 2000, BIOCHEM BIOPH RES CO, V269, P709, DOI 10.1006/bbrc.2000.2346; HOOPER NM, 1994, FEBS LETT, V354, P1, DOI 10.1016/0014-5793(94)01079-X; Klein AW, 2004, DERMATOL SURG, V30, P452, DOI 10.1111/j.1524-4725.2004.30118.x; Lacy DB, 1999, J MOL BIOL, V291, P1091, DOI 10.1006/jmbi.1999.2945; Lacy DB, 1998, NAT STRUCT BIOL, V5, P898, DOI 10.1038/2338; Li L, 2000, BIOCHEMISTRY-US, V39, P6466, DOI 10.1021/bi992729u; Li L, 1999, PROTEIN EXPRES PURIF, V17, P339, DOI 10.1006/prep.1999.1138; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; NAKAGAWA SH, 1993, BIOCHEMISTRY-US, V32, P7237, DOI 10.1021/bi00079a021; OHGUSHI M, 1983, FEBS LETT, V164, P21, DOI 10.1016/0014-5793(83)80010-6; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; RAGONE R, 1984, BIOCHEMISTRY-US, V23, P1871, DOI 10.1021/bi00303a044; SCHIAVO G, 1995, J BIOL CHEM, V270, P10566, DOI 10.1074/jbc.270.18.10566; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; Schiavo G, 2000, PHYSIOL REV, V80, P717, DOI 10.1152/physrev.2000.80.2.717; SCHIAVO G, 1993, FEBS LETT, V335, P99, DOI 10.1016/0014-5793(93)80448-4; Segelke B, 2004, P NATL ACAD SCI USA, V101, P6888, DOI 10.1073/pnas.0400584101; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SINGH BR, 1989, BIOPHYS CHEM, V34, P259, DOI 10.1016/0301-4622(89)80063-8; Singh BR, 2000, NAT STRUCT BIOL, V7, P617, DOI 10.1038/77900; SINGH BR, 1990, J PROTEIN CHEM, V9, P705, DOI 10.1007/BF01024765; SINGH BR, 1989, MOL CELL BIOCHEM, V85, P67; SINGH BR, 2002, SCI THERAPEUTIC ASPE, P75; Swaminathan S, 2000, NAT STRUCT BIOL, V7, P693, DOI 10.1038/78005; Vaidyanathan VV, 1999, J NEUROCHEM, V72, P327, DOI 10.1046/j.1471-4159.1999.0720327.x; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; Vamvaca K, 2004, P NATL ACAD SCI USA, V101, P12860, DOI 10.1073/pnas.0404109101; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; Washbourne P, 1997, FEBS LETT, V418, P1, DOI 10.1016/S0014-5793(97)01328-8; Wheeler AH, 1997, AM FAM PHYSICIAN, V55, P541	49	37	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39346	39352		10.1074/jbc.M508463200	http://dx.doi.org/10.1074/jbc.M508463200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16179354	hybrid			2022-12-25	WOS:000233362200055
J	De, A; Gambhir, SS				De, A; Gambhir, SS			Noninvasive imaging of protein-protein interactions from live cells and living subjects using bioluminescence resonance energy transfer	FASEB JOURNAL			English	Article						Renilla luciferase; green fluorescent protein; rapamycin and optical CCD imaging	FLUORESCENT INDICATORS; FIREFLY LUCIFERASE; GENE-EXPRESSION; RECEPTOR; COMPLEMENTATION; PHOSPHORYLATION; OLIGOMERIZATION; DISCOVERY; DYNAMICS; GROWTH	This study demonstrates a significant advancement of imaging of a distance-dependent physical process, known as the bioluminescent resonance energy transfer (BRET2) signal in living subjects, by using a cooled charge-coupled device (CCD) camera. A CCD camera-based spectral imaging strategy enables simultaneous visualization and quantitation of BRET signal from live cells and cells implanted in living mice. We used the BRET2 system, which utilizes Renilla luciferase (hRluc) protein and its substrate DeepBlueC (DBC) as an energy donor and a mutant green fluorescent protein (GFP(2)) as the acceptor. To accomplish this objective in this proof-of-principle study, the donor and acceptor proteins were fused to FKBP12 and FRB, respectively, which are known to interact only in the presence of the small molecule mediator rapamycin. Mammalian cells expressing these fusion constructs were imaged using a cooled-CCD camera either directly from culture dishes or by implanting them into mice. By comparing the emission photon yields in the presence and absence of rapamycin, the specific BRET signal was determined. The CCD imaging approach of BRET signal is particularly appealing due to its capacity to seamlessly bridge the gap between in vitro and in vivo studies. This work validates BRET as a powerful tool for interrogating and observing protein-protein interactions directly at limited depths in living mice.	Stanford Univ, Dept Radiol Bioengn, Sch Med, MIPS, Stanford, CA 94305 USA; Stanford Univ, Dept Radiol, Sch Med, BioX Program, Stanford, CA 94305 USA; Stanford Univ, Dept Bioengn, Sch Med, BioX Program, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University	Gambhir, SS (corresponding author), Stanford Univ, Dept Radiol Bioengn, Sch Med, MIPS, 318 Campus Dr,E150, Stanford, CA 94305 USA.	Sgambhir@stanford.edu			NCI NIH HHS [P50 CA114747, U54 CA119367, 5R01 CA82214] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U54CA119367, P50CA114747, R01CA082214] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arai R, 2002, J BIOSCI BIOENG, V94, P362, DOI 10.1263/jbb.94.362; Bertrand L, 2002, J RECEPT SIGNAL TR R, V22, P533, DOI 10.1081/RRS-120014619; Burack WR, 2005, J BIOL CHEM, V280, P3832, DOI 10.1074/jbc.M410031200; Clemons PA, 1999, CURR OPIN CHEM BIOL, V3, P112, DOI 10.1016/S1367-5931(99)80020-9; Colland F, 2004, BIOCHIMIE, V86, P625, DOI 10.1016/j.biochi.2004.09.014; Contag CH, 1997, PHOTOCHEM PHOTOBIOL, V66, P523, DOI 10.1111/j.1751-1097.1997.tb03184.x; Cotrin SS, 2004, ANAL BIOCHEM, V335, P244, DOI 10.1016/j.ab.2004.09.012; DIONNE P, 2002, LUMINESCENCE BIOTECH, P539; Dues G, 2001, FEBS LETT, V505, P75, DOI 10.1016/S0014-5793(01)02782-X; Eidne KA, 2002, TRENDS ENDOCRIN MET, V13, P415, DOI 10.1016/S1043-2760(02)00669-0; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; Fujita H, 2005, J BIOL CHEM, V280, P5022, DOI 10.1074/jbc.M409701200; GADELLA TWJ, 1995, J CELL BIOL, V129, P1543, DOI 10.1083/jcb.129.6.1543; Germain-Desprez D, 2003, J BIOL CHEM, V278, P22367, DOI 10.1074/jbc.M302234200; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Jensen AA, 2002, EUR J BIOCHEM, V269, P5076, DOI 10.1046/j.1432-1033.2002.03218.x; Kaihara A, 2003, ANAL CHEM, V75, P4176, DOI 10.1021/ac0300800; Keppler A, 2003, NAT BIOTECHNOL, V21, P86, DOI 10.1038/nbt765; Klammt J, 2004, BIOCHEM BIOPH RES CO, V325, P183, DOI 10.1016/j.bbrc.2004.10.018; LEHMING N, 2002, GENOMIC PROTEOMIC, V1, P230; Luker GD, 2002, P NATL ACAD SCI USA, V99, P6961, DOI 10.1073/pnas.092022399; Luker KE, 2004, P NATL ACAD SCI USA, V101, P12288, DOI 10.1073/pnas.0404041101; Luker KE, 2004, METHOD ENZYMOL, V385, P349; Nagai T, 2001, P NATL ACAD SCI USA, V98, P3197, DOI 10.1073/pnas.051636098; Ozawa T, 2001, ANAL CHEM, V73, P2516, DOI 10.1021/ac0013296; Paulmurugan R, 2004, CANCER RES, V64, P2113, DOI 10.1158/0008-5472.CAN-03-2972; Paulmurugan R, 2003, ANAL CHEM, V75, P1584, DOI 10.1021/ac020731c; Paulmurugan R, 2002, P NATL ACAD SCI USA, V99, P15608, DOI 10.1073/pnas.242594299; Perroy J, 2004, NAT METHODS, V1, P203, DOI 10.1038/NMETH722; Rossi F, 1997, P NATL ACAD SCI USA, V94, P8405, DOI 10.1073/pnas.94.16.8405; Sasaki K, 2003, J BIOL CHEM, V278, P30945, DOI 10.1074/jbc.M212167200; Sato M, 2002, NAT BIOTECHNOL, V20, P287, DOI 10.1038/nbt0302-287; Sato M, 1999, ANAL CHEM, V71, P3948, DOI 10.1021/ac990318d; Schaaf CP, 2004, FASEB J, V18, P267, DOI 10.1096/fj.04-1558fje; Sorkin A, 2000, CURR BIOL, V10, P1395, DOI 10.1016/S0960-9822(00)00785-5; Vrecl M, 2004, J BIOMOL SCREEN, V9, P322, DOI 10.1177/1087057104263212; Wouters FS, 1999, CURR BIOL, V9, P1127, DOI 10.1016/S0960-9822(99)80484-9; Wu JC, 2002, CIRCULATION, V105, P1631, DOI 10.1161/01.CIR.0000014984.95520.AD; Xu XH, 2005, MOL BIOL CELL, V16, P676, DOI 10.1091/mbc.E04-07-0544; Xu Y, 1999, P NATL ACAD SCI USA, V96, P151, DOI 10.1073/pnas.96.1.151	40	77	84	1	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2017	+		10.1096/fj.05-4628fje	http://dx.doi.org/10.1096/fj.05-4628fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16204354				2022-12-25	WOS:000232991100029
J	Meex, SJR; van der Kallen, CJH; van Greevenbroek, MMJ; Eurlings, PMH; El Hasnaoui, M; Evelo, CTA; Lindsey, PJ; Luiken, JJFP; Glatz, JFC; de Bruin, TWA				Meex, SJR; van der Kallen, CJH; van Greevenbroek, MMJ; Eurlings, PMH; El Hasnaoui, M; Evelo, CTA; Lindsey, PJ; Luiken, JJFP; Glatz, JFC; de Bruin, TWA			Up-regulation of CD36/FAT in preadipocytes in familial combined hyperlipidemia	FASEB JOURNAL			English	Article						lipid metabolism; fatty acids; metabolic syndrome; gene expression	CHAIN FATTY-ACIDS; CORONARY-HEART-DISEASE; DENSITY-LIPOPROTEIN; ADIPOSE-TISSUE; GLUCOSE; MUSCLE; LOCUS; IDENTIFICATION; METABOLISM; OXIDATION	Familial combined hyperlipidemia (FCHL) shows many features of the metabolic syndrome. The strong genetic component makes it an excellent model to study the genetic background of metabolic syndrome and insulin resistance. Adipose tissue is believed to contribute to, or even underlie, the FCHL phenotype and is an interesting target tissue for gene expression studies. However, interpretation of adipose tissue gene expression experiments is complex since expression differences cannot only arise as a direct consequence of a genetic trait, but may also reflect an adaptation to metabolic influences at the cellular level. In the present study, we measured gene expression levels in cultured primary human preadipocytes from FCHL and control subjects. Since isolated preadipocytes were allowed to replicate for weeks under standardized conditions, the contribution of previous metabolic influences is rather small whereas genetic defects are preserved and expressed in vitro. The main finding was upregulation of CD36/FAT in FCHL preadipocytes, confirmed in two independent groups of subjects, and a concomitant increase in CD36/FAT-mediated fatty acid uptake. CD36/FAT overexpression has previously been shown to be associated with other insulin-resistant states. The present data suggest that CD36/FAT overexpression in FCHL occurs very early in adipocyte differentiation and may be of genetic origin.	Maastricht Univ, Dept Internal Med, Lab Mol Metab & Endocrinol, POB 616, NL-6200 MD Maastricht, Netherlands; Maastricht Univ, BiGCaT Bioinformat, NL-6200 MD Maastricht, Netherlands; Maastricht Univ, Dept Human Genet, NL-6200 MD Maastricht, Netherlands; Maastricht Univ, Dept Mol Genet, CARIM, NL-6200 MD Maastricht, Netherlands	Maastricht University; Maastricht University; Maastricht University; Maastricht University; Maastricht University Medical Centre (MUMC)	Meex, SJR (corresponding author), Maastricht Univ, Dept Internal Med, Lab Mol Metab & Endocrinol, POB 616, NL-6200 MD Maastricht, Netherlands.	steven.meex@intmed.unimaas.nl	Evelo, Chris TA/D-2914-2009; Lindsey, Patrick/AAD-8100-2021	Evelo, Chris TA/0000-0002-5301-3142; van der Kallen, Carla/0000-0003-1468-8793; van Greevenbroek, Marleen/0000-0002-2989-1631; Meex, Steven/0000-0001-8147-9006				ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Aitman TJ, 1999, NAT GENET, V21, P76, DOI 10.1038/5013; Akaike H., 1973, P 2 INT S INF THEOR, VI, P610, DOI DOI 10.1007/978-1-4612-1694-0_15; Allayee H, 2002, CIRC RES, V90, P926, DOI 10.1161/01.RES.0000015885.27134.F0; Aouizerat BE, 1999, AM J HUM GENET, V65, P397, DOI 10.1086/302490; Bonen A, 2004, FASEB J, V18, P1144, DOI 10.1096/fj.03-1065fje; BROWN MS, 1974, P NATL ACAD SCI USA, V71, P788, DOI 10.1073/pnas.71.3.788; Coburn CT, 2000, J BIOL CHEM, V275, P32523, DOI 10.1074/jbc.M003826200; Coort SLM, 2004, DIABETES, V53, P1655, DOI 10.2337/diabetes.53.7.1655; Coort SLM, 2002, MOL CELL BIOCHEM, V239, P213, DOI 10.1023/A:1020539932353; Eurlings PMH, 2002, J LIPID RES, V43, P930; Gaster M, 2004, DIABETES, V53, P542, DOI 10.2337/diabetes.53.3.542; Georgieva AM, 2004, ARTERIOSCL THROM VAS, V24, P744, DOI 10.1161/01.ATV.0000119681.47218.a4; GOLDSTEIN JL, 1973, J CLIN INVEST, V52, P1544, DOI 10.1172/JCI107332; Griffin E, 2001, NAT MED, V7, P840, DOI 10.1038/89969; Hirano K, 2003, TRENDS CARDIOVAS MED, V13, P136, DOI 10.1016/S1050-1738(03)00026-4; Ibrahimi A, 1999, J BIOL CHEM, V274, P26761, DOI 10.1074/jbc.274.38.26761; Keulen ETP, 2001, AM J HYPERTENS, V14, P357, DOI 10.1016/S0895-7061(00)01280-2; Liang CP, 2004, J CLIN INVEST, V113, P764, DOI [10.1172/JCI200419528, 10.1172/JCI19528]; Lindsey JK, 1998, STAT MED, V17, P59, DOI 10.1002/(SICI)1097-0258(19980115)17:1<59::AID-SIM733>3.3.CO;2-Z; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; NIKKILA EA, 1973, LANCET, V1, P954; Pajukanta P, 2004, NAT GENET, V36, P371, DOI 10.1038/ng1320; Pajukanta P, 1998, NAT GENET, V18, P369, DOI 10.1038/ng0498-369; Pajukanta P, 2003, AM J HUM GENET, V72, P903, DOI 10.1086/374177; ROSE HG, 1973, AM J MED, V54, P148, DOI 10.1016/0002-9343(73)90218-0; van der Kallen CJH, 2002, ATHEROSCLEROSIS, V164, P337, DOI 10.1016/S0021-9150(02)00109-0; Voors-Pette C, 2001, ATHEROSCLEROSIS, V157, P481, DOI 10.1016/S0021-9150(00)00752-8	28	14	16	1	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12								10.1096/fj.04-2403fje	http://dx.doi.org/10.1096/fj.04-2403fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16219805	Bronze, Green Published			2022-12-25	WOS:000232991100023
J	Ohki, Y; Heissig, B; Sato, Y; Akiyama, H; Zhu, ZP; Hicklin, DJ; Shimada, K; Ogawa, H; Daida, H; Hattori, K; Ohsaka, A				Ohki, Y; Heissig, B; Sato, Y; Akiyama, H; Zhu, ZP; Hicklin, DJ; Shimada, K; Ogawa, H; Daida, H; Hattori, K; Ohsaka, A			Granulocyte colony-stimulating factor promotes neovascularization by releasing vascular endothelial growth factor from neutrophils	FASEB JOURNAL			English	Article						angiogenesis; hematopoietic cells; angiogenic factors; VEGF receptors	HEMATOPOIETIC STEM-CELLS; MARROW-DERIVED CELLS; VEGF RECEPTOR FLT-1; FACTOR G-CSF; PROGENITOR CELLS; TUMOR ANGIOGENESIS; IN-VIVO; POSTNATAL NEOVASCULARIZATION; MYOCARDIAL-INFARCTION; HUMAN MONOCYTES	The granulocyte colony-stimulating factor (G-CSF) promotes angiogenesis. However, the exact mechanism is not known. We demonstrate that vascular endothelial growth factor ( VEGF) was released by Gr-1(+) CD11b(-) neutrophils but not Gr-1(-)CD11b(+) monocytes prestimulated with GCSF in vitro and in vivo. Similarly, in vivo, concomitant with an increase in neutrophil numbers in circulation, G-CSF augmented plasma VEGF level in vivo. Local G-CSF administration into ischemic tissue increased capillary density and provided a functional vasculature and contributed to neovascularization of ischemic tissue. Blockade of the VEGF pathway abrogated G-CSF-induced angiogenesis. On the other hand, as we had shown previously, VEGF can induce endothelial progenitor cell ( EPC) mobilization. Here, we show that G-CSF also augmented the number of circulating VEGF receptor-2 (VEGFR2) EPCs as compared with untreated controls. Blocking the VEGF/VEGFR1, but to a much lesser extent, the VEGF/VEGFR2 pathway in GCSF-treated animals delayed tissue revascularization in a hindlimb model. These data clearly show that G-CSF modulates angiogenesis by increasing myelomonocytic cells (VEGFR1(+) neutrophils) and their release of VEGF. Our results indicated that administration of G-CSF into ischemic tissue provides a novel and safe therapeutic strategy to improve neovascularization.	Univ Tokyo, Ctr Med Expt, Inst Med Sci, Minato Ku, Tokyo 1088639, Japan; ImClone Syst Inc, New York, NY USA; Juntendo Univ, Sch Med, Dept Cardiol, Tokyo 113, Japan; Juntendo Univ, Sch Med, Atopy Allergy Res Ctr, Bunkyo Ku, Tokyo 113, Japan; Juntendo Univ, Sch Med, Dept Transfus Med & Stem Cell Regulat, Bunkyo Ku, Tokyo 113, Japan	University of Tokyo; Eli Lilly; Juntendo University; Juntendo University; Juntendo University	Hattori, K (corresponding author), Univ Tokyo, Ctr Med Expt, Inst Med Sci, Minato Ku, 4-6-1,Shirokanedai, Tokyo 1088639, Japan.	khattori@ims.u-tokyo.ac.jp	Heissig, Beate/AAF-6771-2021	Heissig, Beate/0000-0002-0348-5934				Ancelin M, 2004, LAB INVEST, V84, P502, DOI 10.1038/labinvest.3700053; Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Bautz F, 2000, EXP HEMATOL, V28, P700, DOI 10.1016/S0301-472X(00)00168-5; BOCCHIETTO E, 1993, J CELL PHYSIOL, V155, P89, DOI 10.1002/jcp.1041550112; BUSSOLINO F, 1991, J CLIN INVEST, V87, P986, DOI 10.1172/JCI115107; BUSSOLINO F, 1989, NATURE, V337, P471, DOI 10.1038/337471a0; Crivellato E, 2004, LEUKEMIA, V18, P331, DOI 10.1038/sj.leu.2403246; Crosby JR, 2000, CIRC RES, V87, P728, DOI 10.1161/01.RES.87.9.728; Cursiefen C, 2004, J CLIN INVEST, V113, P1040, DOI 10.1172/JCI200420465; DEHAAS M, 1994, BLOOD, V84, P3885, DOI 10.1182/blood.V84.11.3885.bloodjournal84113885; Eubank TD, 2003, J IMMUNOL, V171, P2637, DOI 10.4049/jimmunol.171.5.2637; Falanga A, 1999, BLOOD, V93, P2506, DOI 10.1182/blood.V93.8.2506.408k31_2506_2514; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Gothert JR, 2004, BLOOD, V104, P1769, DOI 10.1182/blood-2003-11-3952; Gunningham SP, 2001, CANCER RES, V61, P3206; Harada M, 2005, NAT MED, V11, P305, DOI 10.1038/nm1199; Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740; Hattori K, 2001, J EXP MED, V193, P1005, DOI 10.1084/jem.193.9.1005; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Iba O, 2002, CIRCULATION, V106, P2019, DOI 10.1161/01.CIR.0000031332.45480.79; Kang HJ, 2004, LANCET, V363, P751, DOI 10.1016/S0140-6736(04)15689-4; Kearney JB, 2004, BLOOD, V103, P4527, DOI 10.1182/blood-2003-07-2315; Kitayama Y, 2000, LAB INVEST, V80, P779, DOI 10.1038/labinvest.3780081; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Lagasse E, 1996, J IMMUNOL METHODS, V197, P139, DOI 10.1016/0022-1759(96)00138-X; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Nakayama T, 2004, J CLIN INVEST, V114, P1317, DOI 10.1172/JCI200422089; Natori T, 2002, BIOCHEM BIOPH RES CO, V297, P1058, DOI 10.1016/S0006-291X(02)02335-5; Ohtsuka M, 2004, FASEB J, V18, P851, DOI 10.1096/fj.03-0637fje; Orlic D, 1998, BLOOD, V91, P3247, DOI 10.1182/blood.V91.9.3247.3247_3247_3254; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Ozawa CR, 2004, J CLIN INVEST, V113, P516, DOI 10.1172/JCI200418420; Rafii S, 2002, NAT REV CANCER, V2, P826, DOI 10.1038/nrc925; Rafii S, 2002, SEMIN CELL DEV BIOL, V13, P61, DOI 10.1006/scdb.2001.0285; Rafii S, 2003, NAT MED, V9, P702, DOI 10.1038/nm0603-702; Rehman J, 2003, CIRCULATION, V107, P1164, DOI 10.1161/01.CIR.0000058702.69484.A0; Shintani S, 2001, CIRCULATION, V103, P897, DOI 10.1161/01.CIR.103.6.897; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Takakura N, 2000, CELL, V102, P199, DOI 10.1016/S0092-8674(00)00025-8; TAMURA M, 1987, BIOCHEM BIOPH RES CO, V142, P454, DOI 10.1016/0006-291X(87)90296-8; Tateishi-Yuyama E, 2002, LANCET, V360, P427, DOI 10.1016/S0140-6736(02)09670-8; Yamada T, 1996, LAB INVEST, V74, P384; Yamaguchi J, 2003, CIRCULATION, V107, P1322, DOI 10.1161/01.CIR.0000055313.77510.22; Yong KL, 1996, BRIT J HAEMATOL, V94, P40, DOI 10.1046/j.1365-2141.1996.d01-1752.x; YUO A, 1989, BLOOD, V74, P2144; Zhang W, 2000, CANCER RES, V60, P6757; Ziegelhoeffer T, 2004, CIRC RES, V94, P230, DOI 10.1161/01.RES.0000110419.50982.1C	51	197	217	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2005	+		10.1096/fj.04-3496fje	http://dx.doi.org/10.1096/fj.04-3496fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16223785				2022-12-25	WOS:000232991100019
J	Takeda, T; Asahi, M; Yamaguchi, O; Hikoso, S; Nakayama, H; Kusakari, Y; Kawai, M; Hongo, K; Higuchi, Y; Kashiwase, K; Watanabe, T; Taniike, M; Nakai, A; Nishida, K; Kurihara, S; Donoviel, DB; Bernstein, A; Tomita, T; Iwatsubo, T; Hori, M; Otsu, K				Takeda, T; Asahi, M; Yamaguchi, O; Hikoso, S; Nakayama, H; Kusakari, Y; Kawai, M; Hongo, K; Higuchi, Y; Kashiwase, K; Watanabe, T; Taniike, M; Nakai, A; Nishida, K; Kurihara, S; Donoviel, DB; Bernstein, A; Tomita, T; Iwatsubo, T; Hori, M; Otsu, K			Presenilin 2 regulates the systolic function of heart by modulating Ca2+ signaling	FASEB JOURNAL			English	Article						ryanodine receptor; sorcin; calcium; excitation-contraction coupling	MULTIDRUG-RESISTANT CELLS; SARCOPLASMIC-RETICULUM; RYANODINE RECEPTOR; RELEASE CHANNELS; PROTEIN; EXPRESSION; SORCIN; LOCALIZATION; STIMULATION	Genetic studies of families with familial Alzheimer's disease have implicated presenilin 2 (PS2) in the pathogenesis of this disease. PS2 is ubiquitously expressed in various tissues including hearts. In this study, we examined cardiac phenotypes of PS2 knockout (PS2KO) mice to elucidate a role of PS2 in hearts. PS2KO mice developed normally with no evidence of cardiac hypertrophy and fibrosis. Invasive hemodynamic analysis revealed that cardiac contractility in PS2KO mice increased compared with that in their littermate controls. A study of isolated papillary muscle showed that peak amplitudes of Ca2+ transients and peak tension were significantly higher in PS2KO mice than those in their littermate controls. PS2KO mouse hearts exhibited no change in expression of calcium regulatory proteins. Since it has been demonstrated that PS2 in brain interacts with sorcin, which serves as a modulator of cardiac ryanodine receptor (RyR2), we tested whether PS2 also interacts with RyR2. Immmunoprecipitation analysis showed that PS2, sorcin, and RyR2 interact with each other in HEK-293 cells overexpressing these proteins or in mouse hearts. Immunohistochemistry of heart muscle indicated that PS2 colocalizes with RyR2 and sorcin at the Z-lines. Elevated Ca2+ attenuated the association of RyR2 with PS2, whereas the association of sorcin with PS2 was enhanced. The enhanced Ca2+ transients and contractility in PS2KO mice were observed at low extracellular [Ca2+] but not at high levels of [Ca2+]. Taken together, our results suggest that PS2 plays an important role in cardiac excitation-contraction coupling by interacting with RyR2.	Osaka Univ, Dept Cardiovasc Med, Grad Sch Med, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Biochem, Grad Sch Med, Suita, Osaka 5650871, Japan; Jikei Univ, Sch Med, Dept Physiol 2, Tokyo 1058461, Japan; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Tokyo, Dept Neuropathol & Neurosci, Grad Sch Pharmaceut Sci, Tokyo 1130033, Japan	Osaka University; Osaka University; Jikei University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Tokyo	Otsu, K (corresponding author), Osaka Univ, Dept Cardiovasc Med, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	kotsu@medone.med.osaka-u.ac.jp	Tomita, Taisuke/L-5427-2015; Hikoso, Shungo/R-4281-2018	Tomita, Taisuke/0000-0002-0075-5943; Hikoso, Shungo/0000-0003-2284-1970; Yamaguchi, Osamu/0000-0002-7461-369X				Asahi M, 2004, P NATL ACAD SCI USA, V101, P9199, DOI 10.1073/pnas.0402596101; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Endo M, 1972, Nihon Seirigaku Zasshi, V34, P88; Guo W, 1996, J BIOL CHEM, V271, P458, DOI 10.1074/jbc.271.1.458; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; HONGO K, 1993, J PHYSIOL-LONDON, V461, P167, DOI 10.1113/jphysiol.1993.sp019507; IMAGAWA T, 1989, J BIOCHEM-TOKYO, V106, P342, DOI 10.1093/oxfordjournals.jbchem.a122855; Iwamoto T, 1998, BIOCHEMISTRY-US, V37, P17230, DOI 10.1021/bi981521q; Ji Y, 1999, ANAL BIOCHEM, V269, P236, DOI 10.1006/abio.1999.4059; KAWAI M, 1994, CELL CALCIUM, V16, P123, DOI 10.1016/0143-4160(94)90007-8; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee MK, 1996, J NEUROSCI, V16, P7513, DOI 10.1523/jneurosci.16-23-07513.1996; Leissring MA, 1999, J BIOL CHEM, V274, P32535, DOI 10.1074/jbc.274.46.32535; Lokuta AJ, 1997, J BIOL CHEM, V272, P25333, DOI 10.1074/jbc.272.40.25333; Mattson MP, 2001, BIOCHEM SOC SYMP, V67, P151, DOI 10.1042/bss0670151; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MEYERS MB, 1987, BIOCHEM PHARMACOL, V36, P2373, DOI 10.1016/0006-2952(87)90606-X; MEYERS MB, 1995, J BIOL CHEM, V270, P26411, DOI 10.1074/jbc.270.44.26411; Nakayama H, 2002, FASEB J, V16, P61, DOI 10.1096/fj.02-0474fje; OGAWA Y, 1994, CRIT REV BIOCHEM MOL, V29, P229, DOI 10.3109/10409239409083482; Pack-Chung E, 2000, J BIOL CHEM, V275, P14440, DOI 10.1074/jbc.M909882199; Sorrentino V, 1995, Adv Pharmacol, V33, P67, DOI 10.1016/S1054-3589(08)60666-3; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; SUZUKI T, 1986, J BIOL CHEM, V261, P7018; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; TIMERMAN AP, 1994, BIOCHEM BIOPH RES CO, V198, P701, DOI 10.1006/bbrc.1994.1101; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; VANDERBLIEK AM, 1986, EMBO J, V5, P3201, DOI 10.1002/j.1460-2075.1986.tb04630.x; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; Yamaguchi O, 2003, P NATL ACAD SCI USA, V100, P15883, DOI 10.1073/pnas.2136717100; Zhang L, 1997, J BIOL CHEM, V272, P23389, DOI 10.1074/jbc.272.37.23389; Zucchi R, 1997, PHARMACOL REV, V49, P1	36	41	44	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2069	+		10.1096/fj.05-3744fje	http://dx.doi.org/10.1096/fj.05-3744fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16204356				2022-12-25	WOS:000232991100031
J	Jacquel, A; Herrant, M; Defamie, V; Belhacene, N; Colosetti, P; Marchetti, S; Legros, L; Deckert, M; Mari, B; Cassuto, JP; Hofman, P; Auberger, P				Jacquel, A; Herrant, M; Defamie, V; Belhacene, N; Colosetti, P; Marchetti, S; Legros, L; Deckert, M; Mari, B; Cassuto, JP; Hofman, P; Auberger, P			A survey of the signaling pathways involved in megakaryocytic differentiation of the human K562 leukemia cell line by molecular and c-DNA array analysis	ONCOGENE			English	Article						megakaryocyte differentiation; PKC; MAPK; c-DNA array; leukemia	PROTEIN-KINASE-C; CHRONIC MYELOID-LEUKEMIA; ERYTHROID-DIFFERENTIATION; PHORBOL ESTER; EPH RECEPTORS; T-CELLS; ACTIVATION; INHIBITION; EXPRESSION; SURVIVAL	The K562 cell line serves as a model to study the molecular mechanisms associated with leukemia differentiation. We show here that cotreatment of K562 cells with PMA and low doses of SB202190 (SB), an inhibitor of the p38 MAPK pathway, induced a majority of cells to differentiate towards the megakaryocytic lineage. Electronic microscopy analysis showed that K562 cells treated with PMA+SB exhibited characteristic features of physiological megakaryocytic differentiation including the presence of vacuoles and demarcation membranes. Differentiation was also accompanied by a net increase in megakaryocytic markers and a reduction of erythroid markers, especially when both effectors were present. PMA effect was selectively mediated by new PKC isoforms. Differentiation of K562 cells by the combination of PMA and SB required Erk1/2 activation, a threshold of JNK activation and p38 MAPK inhibit ion. Interestingly, higher concentrations of SB, which drastically activated JNK, blocked megakaryocytic differentiation, and considerably increased cell death in the presence of PMA. c-DNA microarray membranes and PCR analysis allow us to identify a set of genes modulated during PMA-induced K562 cell differentiation. Several gene families identified in our screening, including ephrins receptors and some angiogenic factors, had never been reported so far to be regulated during megakaryocytic differentiation.	Univ Nice Sophia Antipolis, U526, Fac Med Pasteur, INSERM,Equipe Labellisee Ligue Natl Canc,IFR50, F-06107 Nice 2, France; CNRS, Inst Pharmacol Mol & Cellulaire, UMR 6097, F-06560 Valbonne, France; Hop Archet, Hematol Serv, F-06202 Nice 2, France; Hop Archet, INSERM, U576, F-06202 Nice, France; Univ Nice Sophia Antipolis, INSERM, U721, IFR50,Fac Med, F-06107 Nice 2, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Auberger, P (corresponding author), Univ Nice Sophia Antipolis, U526, Fac Med Pasteur, INSERM,Equipe Labellisee Ligue Natl Canc,IFR50, Ave Valombrose, F-06107 Nice 2, France.	auberger@unice.fr	Mari, Bernard/Q-5832-2019; Mari, Bernard P/D-7445-2015; Jacquel, Arnaud/AAJ-4760-2021; Deckert, Marcel/T-3566-2019; Mari, Bernard P/GVS-3100-2022; Marchetti, Sandrine/P-6479-2016; AUBERGER, Patrick/G-1491-2013; Jacquel, Arnaud/O-1928-2017; Mari, Bernard P/F-8960-2013; Colosetti, Pascal/ABH-4585-2020; Deckert, Marcel/M-4998-2016; Hofman, Paul/P-7654-2018	Mari, Bernard/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; Jacquel, Arnaud/0000-0001-5062-8048; Deckert, Marcel/0000-0003-2094-559X; Mari, Bernard P/0000-0002-0422-9182; Marchetti, Sandrine/0000-0001-8326-5730; AUBERGER, Patrick/0000-0002-2481-8275; Jacquel, Arnaud/0000-0001-5062-8048; Mari, Bernard P/0000-0002-0422-9182; Hofman, Paul/0000-0003-0431-9353; Defamie, Virginie/0000-0002-6405-0539				ALITALO R, 1990, LEUKEMIA RES, V14, P501, DOI 10.1016/0145-2126(90)90002-Q; Belhacene N, 1998, FASEB J, V12, P531; Bertolotto C, 2000, J BIOL CHEM, V275, P37246, DOI 10.1074/jbc.M007732200; Brantley-Sieders D, 2004, CURR PHARM DESIGN, V10, P3431, DOI 10.2174/1381612043383160; Busuttil V, 2002, ONCOGENE, V21, P3213, DOI 10.1038/sj.onc.1205433; Chen G, 2000, J BIOL CHEM, V275, P38973, DOI 10.1074/jbc.M002856200; CHENG T, 1994, J BIOL CHEM, V269, P30848; Cramer EM, 1997, BLOOD, V89, P2336, DOI 10.1182/blood.V89.7.2336; Dorsey JF, 2002, BLOOD, V99, P1388, DOI 10.1182/blood.V99.4.1388; Garcia J, 2002, EMBO J, V21, P5151, DOI 10.1093/emboj/cdf488; Goldfarb AN, 2001, J BIOL CHEM, V276, P29526, DOI 10.1074/jbc.M103825200; Herrant M, 2002, ONCOGENE, V21, P4957, DOI 10.1038/sj.onc.1205689; Herrera R, 1998, EXP CELL RES, V238, P407, DOI 10.1006/excr.1997.3847; Hong Y, 1996, BLOOD, V87, P123, DOI 10.1182/blood.V87.1.123.bloodjournal871123; Huang M, 2004, LEUKEMIA, V18, P1857, DOI 10.1038/sj.leu.2403490; Jacquel A, 2003, FASEB J, V17, P2160, DOI 10.1096/fj.03-0322fje; Kawano T, 2004, LEUKEMIA RES, V28, P623, DOI 10.1016/j.leukres.2003.10.022; Kawano T, 2004, MOL CELL BIOCHEM, V258, P25, DOI 10.1023/B:MCBI.0000012830.96393.b9; Kim KW, 2001, J BIOL CHEM, V276, P13186, DOI 10.1074/jbc.M008092200; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Lam LT, 2000, J BIOL CHEM, V275, P19676, DOI 10.1074/jbc.M002866200; Legros L, 2004, BLOOD, V104, P495, DOI 10.1182/blood-2003-08-2695; LONG MW, 1990, J CLIN INVEST, V85, P1072, DOI 10.1172/JCI114538; Matsumura I, 2000, BLOOD, V96, P2440; Melemed AS, 1997, BLOOD, V90, P3462, DOI 10.1182/blood.V90.9.3462; MOORE DC, 1991, BLOOD, V77, P1452; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; Nalefski EA, 2001, BIOCHEMISTRY-US, V40, P13216, DOI 10.1021/bi010761u; NAMCIU S, 1994, ONCOGENE, V9, P1407; NEUBAUER A, 1994, BLOOD, V84, P1931; Park JI, 2001, CELL GROWTH DIFFER, V12, P481; Parker PJ, 2004, J CELL SCI, V117, P131, DOI 10.1242/jcs.00982; Pettiford SM, 2003, LEUKEMIA, V17, P366, DOI 10.1038/sj.leu.2402767; Poliakov A, 2004, DEV CELL, V7, P465, DOI 10.1016/j.devcel.2004.09.006; Racke FK, 1997, J BIOL CHEM, V272, P23366, DOI 10.1074/jbc.272.37.23366; Racke FK, 2001, J BIOL CHEM, V276, P522, DOI 10.1074/jbc.M005236200; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Rouyez MC, 1997, MOL CELL BIOL, V17, P4991, DOI 10.1128/MCB.17.9.4991; Ruan GR, 2004, LEUKEMIA RES, V28, P763, DOI 10.1016/j.leukres.2003.11.017; Schaefer M, 2001, FASEB J, V15, P1634, DOI 10.1096/fj.00-0824fje; Shelly C, 1998, LEUKEMIA, V12, P1951, DOI 10.1038/sj.leu.2401221; Surawska H, 2004, CYTOKINE GROWTH F R, V15, P419, DOI 10.1016/j.cytogfr.2004.09.002; Tanimura A, 2002, J BIOL CHEM, V277, P29054, DOI 10.1074/jbc.M201130200; Uddin S, 2004, P NATL ACAD SCI USA, V101, P147, DOI 10.1073/pnas.0307075101; Villalba M, 2001, J IMMUNOL, V166, P5955, DOI 10.4049/jimmunol.166.10.5955; Wang XN, 2001, J CELL BIOCHEM, V82, P68, DOI 10.1002/jcb.1141; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947	47	67	68	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					781	794		10.1038/sj.onc.1209119	http://dx.doi.org/10.1038/sj.onc.1209119			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16186797				2022-12-25	WOS:000235068800013
J	Xie, Y; Xu, K; Dai, B; Guo, Z; Jiang, T; Chen, H; Qiu, Y				Xie, Y; Xu, K; Dai, B; Guo, Z; Jiang, T; Chen, H; Qiu, Y			The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs	ONCOGENE			English	Article						kinase; cancer; phosphorylation; signal transduction; apoptosis	HETEROCHROMATIN PROTEIN-1 HP1; PLECKSTRIN-HOMOLOGY DOMAIN; PIM-1 TRANSGENIC MICE; C-MYC; PHOSPHORYLATION; ACTIVATION; ANDROGEN; LEUKEMIA; LYMPHOMAGENESIS; EXPRESSION	Protein kinase Pim-1 has been implicated in the development of hematopoietic and prostatic malignancies. Here, we present the evidence that two isoforms, the 44 and 33 kDa Pim-1, are expressed in all human prostate cancer cell lines examined. The subcellular localization of human 44 kDa Pim-1 is primarily on the plasma membrane, while the 33 kDa isoform is present in both the cytosol and nucleus in PCA cells. The 44 kDa Pim-1 contains the proline-rich motif at the N-terminus and directly binds to the SH3 domain of tyrosine kinase Etk. Such interaction leads to the activation of Etk kinase activity possibly by competing with the tumor suppressor p53. This is corroborated by the fact that overexpression of the 44 kDa Pim-1 in prostate cancer cells confers the resistance to chemotherapeutic drugs. Our results suggest that these two isoforms of Pim-1 kinase may regulate distinct substrates and the 44 kDa Pim-1 may play a more prominent role in drug resistance in prostate cancer cells.	Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Qiu, Y (corresponding author), Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, 655 W Baltimore St, Baltimore, MD 21201 USA.	yqiu@som.umaryland.edu			NATIONAL CANCER INSTITUTE [R01CA085380] Funding Source: NIH RePORTER; NCI NIH HHS [CA85380] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aho TLT, 2004, FEBS LETT, V571, P43, DOI 10.1016/j.febslet.2004.06.050; AMSON R, 1989, P NATL ACAD SCI USA, V86, P8857, DOI 10.1073/pnas.86.22.8857; BREUER M, 1989, NATURE, V340, P61, DOI 10.1038/340061a0; Chen RY, 2001, NAT CELL BIOL, V3, P439, DOI 10.1038/35074500; CUYPERS HT, 1984, CELL, V37, P141; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Gregory CW, 2001, CANCER RES, V61, P2892; Imasato Y, 2000, J UROLOGY, V164, P1819, DOI 10.1016/S0022-5347(05)67113-3; Ishibashi Y, 2001, FEBS LETT, V506, P33, DOI 10.1016/S0014-5793(01)02881-2; Jiang TY, 2004, J BIOL CHEM, V279, P50181, DOI 10.1074/jbc.M409108200; Kim O, 2004, ONCOGENE, V23, P1838, DOI 10.1038/sj.onc.1207304; Kim O, 2002, J BIOL CHEM, V277, P30066, DOI 10.1074/jbc.M201713200; Koike N, 2000, FEBS LETT, V467, P17, DOI 10.1016/S0014-5793(00)01105-4; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; Mochizuki T, 1999, J BIOL CHEM, V274, P18659, DOI 10.1074/jbc.274.26.18659; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; Valdman A, 2004, PROSTATE, V60, P367, DOI 10.1002/pros.20064; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VONLINDERN M, 1989, ONCOGENE, V4, P75; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wang ZP, 2002, BBA-MOL CELL RES, V1593, P45, DOI 10.1016/S0167-4889(02)00347-6; Yan B, 2003, J BIOL CHEM, V278, P45358, DOI 10.1074/jbc.M307933200; Zhao T, 2001, J BIOL CHEM, V276, P9512, DOI 10.1074/jbc.M010098200	26	90	99	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					70	78		10.1038/sj.onc.1209058	http://dx.doi.org/10.1038/sj.onc.1209058			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16186805				2022-12-25	WOS:000234406400008
J	Ariel, A; Li, PL; Wang, W; Tang, WX; Fredman, G; Hong, S; Gotlinger, KH; Serhan, CN				Ariel, A; Li, PL; Wang, W; Tang, WX; Fredman, G; Hong, S; Gotlinger, KH; Serhan, CN			The docosatriene Protectin D1 is produced by T(H)2 skewing and promotes human T cell apoptosis via lipid raft clustering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; DOCOSAHEXAENOIC ACID; RHEUMATOID-ARTHRITIS; HUMAN-NEUTROPHILS; IMMUNE-RESPONSES; DENDRITIC CELLS; LIPOXIN A(4); HUMAN BLOOD; INFLAMMATION	Docosahexaenoic acid, a major omega-3 fatty acid in human brain, synapses, retina, and other neural tissues, displays beneficial actions in neuronal development, cancer, and inflammatory diseases by mechanisms that remain to be elucidated. In this study we found, using lipid mediator informatics employing liquid chromatography-tandem mass spectrometry, that (10, 17S)-docosatriene/neuroprotectin D1, now termed protectin D1 (PD1), is generated from docosahexaenoic acid by T helper type 2-skewed peripheral blood mononuclear cells in a lipoxygenase-dependent manner. PD1 blocked T cell migration in vivo, inhibited tumor necrosis factor alpha and interferon-gamma secretion, and promoted apoptosis mediated by raft clustering. These results demonstrated novel anti-inflammatory roles for PD1 in regulating events associated with inflammation and resolution.	Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Medical College of Wisconsin	Serhan, CN (corresponding author), Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Dept Anesthesiol Perioperat & Pain Med, 75 Francis St, Boston, MA 02115 USA.	cnserhan@zeus.bwh.harvard.edu			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE013499, P50DE016191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038765, R01GM038765, R29GM038765] Funding Source: NIH RePORTER; NIDCR NIH HHS [P01-DE13499, P50-DE016191] Funding Source: Medline; NIGMS NIH HHS [GM38765] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson HA, 2000, NAT IMMUNOL, V1, P156, DOI 10.1038/77842; ANEL A, 1990, BIOCHIM BIOPHYS ACTA, V1044, P323, DOI 10.1016/0005-2760(90)90076-A; Ariel A, 2003, J IMMUNOL, V170, P6266, DOI 10.4049/jimmunol.170.12.6266; Arrington JL, 2001, CLIN EXP IMMUNOL, V125, P499, DOI 10.1046/j.1365-2249.2001.01627.x; Billman GE, 1999, CIRCULATION, V99, P2452, DOI 10.1161/01.CIR.99.18.2452; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; Calder PC, 2001, CURR OPIN CLIN NUTR, V4, P115, DOI 10.1097/00075197-200103000-00006; D'Ambrosio D, 2003, J IMMUNOL METHODS, V273, P3, DOI 10.1016/S0022-1759(02)00414-3; Feldmann M, 2002, NAT REV IMMUNOL, V2, P364, DOI 10.1038/nri802; Field CJ, 2001, LIPIDS, V36, P1025, DOI 10.1007/s11745-001-0813-6; Gallin J.I., 1999, INFLAMMATION BASIC P; Geng JG, 2001, CELL RES, V11, P85, DOI 10.1038/sj.cr.7290071; Goodarzi K, 2003, NAT IMMUNOL, V4, P965, DOI 10.1038/ni972; Greaves DR, 2002, TRENDS IMMUNOL, V23, P535, DOI 10.1016/S1471-4906(02)02331-1; Green DR, 2003, IMMUNOL REV, V193, P5, DOI 10.1034/j.1600-065X.2003.00045.x; Gronert K, 2005, J BIOL CHEM, V280, P15267, DOI 10.1074/jbc.M410638200; Hanada T, 2002, CYTOKINE GROWTH F R, V13, P413, DOI 10.1016/S1359-6101(02)00026-6; Hibbeln JR, 2002, J AFFECT DISORDERS, V69, P15, DOI 10.1016/S0165-0327(01)00374-3; Hong S, 2003, J BIOL CHEM, V278, P14677, DOI 10.1074/jbc.M300218200; Kollias George, 2002, Curr Dir Autoimmun, V5, P30; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; Lawrence T, 2002, NAT REV IMMUNOL, V2, P787, DOI 10.1038/nri915; LEE TH, 1984, J CLIN INVEST, V74, P1922, DOI 10.1172/JCI111612; LEVY BD, 1993, J CLIN INVEST, V92, P1572, DOI 10.1172/JCI116738; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; Lu B, 2002, AM J PHYSIOL-CELL PH, V283, pC831, DOI 10.1152/ajpcell.00045.2002; Lukiw WJ, 2005, J CLIN INVEST, V115, P2774, DOI 10.1172/JCI25420; Marcheselli VL, 2003, J BIOL CHEM, V278, P43807, DOI 10.1074/jbc.M305841200; Moriguchi T, 2003, J NEUROCHEM, V87, P297, DOI 10.1046/j.1471-4159.2003.01966.x; Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101; NASSAR GM, 1994, J BIOL CHEM, V269, P27631; O'Shea JJ, 2002, NAT REV IMMUNOL, V2, P37, DOI 10.1038/nri702; Orteu CH, 1998, J IMMUNOL, V161, P1619; Radi ZA, 2001, J VET INTERN MED, V15, P516, DOI 10.1892/0891-6640(2001)015&lt;0516:CAMLTA&gt;2.3.CO;2; Riffo-Vasquez Y, 2000, INT J BIOCHEM CELL B, V32, P833, DOI 10.1016/S1357-2725(00)00029-7; ROBINSON DR, 1993, J LIPID RES, V34, P1435; Salem N, 2001, LIPIDS, V36, P945, DOI 10.1007/s11745-001-0805-6; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; Scheel-Toellner D, 2002, BIOCHEM BIOPH RES CO, V297, P876, DOI 10.1016/S0006-291X(02)02311-2; SERHAN CN, 1995, BIOCHEMISTRY-US, V34, P14609, DOI 10.1021/bi00044a041; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Serhan CN, 2000, J EXP MED, V192, P1197, DOI 10.1084/jem.192.8.1197; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Spanbroek R, 2001, P NATL ACAD SCI USA, V98, P5152, DOI 10.1073/pnas.091076998; Suvannavejh GC, 2000, J CLIN INVEST, V105, P223, DOI 10.1172/JCI8561; Switzer KC, 2004, J LIPID RES, V45, P1482, DOI 10.1194/jlr.M400028-JLR200; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; Zhang GX, 2002, MULT SCLER, V8, P463, DOI 10.1191/1352458502ms857oa	49	181	190	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					43079	43086		10.1074/jbc.M509796200	http://dx.doi.org/10.1074/jbc.M509796200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16216871	Green Published, hybrid			2022-12-25	WOS:000234200800074
J	O'Reilly, PG; Wagner, S; Franks, DJ; Cailliau, K; Browaeys, E; Dissous, C; Sabourin, LA				O'Reilly, PG; Wagner, S; Franks, DJ; Cailliau, K; Browaeys, E; Dissous, C; Sabourin, LA			The Ste20-like kinase SLK is required for cell cycle progression through G(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOSIS-SPECIFIC PHOSPHORYLATION; SPINDLE ASSEMBLY CHECKPOINT; CHROMOSOME CONDENSATION; STE20-RELATED KINASE; G2/M TRANSITION; MESSENGER-RNA; HUMAN MYT1; M-PHASE; PHOSPHATASE; ANAPHASE	We have previously shown that the Ste20-like kinase SLK is a microtubule-associated protein that can regulate actin reorganization during cell adhesion and spreading (Wagner, S., Flood, T. A., O'Reilly, P., Hume, K., and Sabourin, L. A. ( 2002) J. Biol. Chem. 277, 37685-37692). Because of its association with the microtubule network, we investigated whether SLK plays a role in cell cycle progression, a process that requires microtubule dynamics during mitosis. Consistent with microtubule association in exponentially growing cells, our results showed that SLK co-localizes with the mitotic spindle in cells undergoing mitosis. Expression of a kinase-inactive mutant or SLK small interfering RNAs inhibited cell proliferation and resulted in an accumulation of quiescent cells stimulated to re-enter the cell cycle in the G(2) phase. Cultures expressing the mutant SLK displayed a normal pattern of cyclin D, E, and B expression but failed to down-regulate cyclin A levels, suggesting that they cannot proceed through M phase. In addition, these cultures displayed low levels of both phospho-H3 and active p34/cdc2 kinase. Overexpression of active SLK resulted in ectopic spindle assembly and the induction of cell cycle re-entry of Xenopus oocytes, suggesting that SLK is required for progression through G(2) upstream of H1 kinase activation.	Neurosci Res Inst, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Dept Bioichem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada; Neurosci Program, Ottawa Hlth Res Inst, Ottawa, ON K1H 8M5, Canada; Inst Pasteur, INSERM, U547, F-59019 Lille, France; Univ Sci & Technol Lille, F-59655 Villeneuve Dascq, France	University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Universite de Lille - ISITE; Universite de Lille	Sabourin, LA (corresponding author), Neurosci Res Inst, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	Lsab@uottawa.ca		cailliau, katia/0000-0003-1772-1034; Cailliau, Katia/0000-0001-7993-8437; Dissous, Colette/0000-0002-5003-8205				ALLIS CD, 1981, BIOCHEMISTRY-US, V20, P3828, DOI 10.1021/bi00516a025; Bahassi ELM, 2004, ONCOGENE, V23, P2658, DOI 10.1038/sj.onc.1207425; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Booher RN, 1997, J BIOL CHEM, V272, P22300, DOI 10.1074/jbc.272.35.22300; BRADBURY EM, 1973, EUR J BIOCHEM, V33, P131, DOI 10.1111/j.1432-1033.1973.tb02664.x; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; Ellinger-Ziegelbauer H, 2000, GENES CELLS, V5, P491, DOI 10.1046/j.1365-2443.2000.00337.x; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; Geley S, 2001, J CELL BIOL, V153, P137, DOI 10.1083/jcb.153.1.137; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; PIAGGIO G, 1995, EXP CELL RES, V216, P396, DOI 10.1006/excr.1995.1050; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; Pines J, 2001, NAT CELL BIOL, V3, pE3, DOI 10.1038/35050676; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; Qian YW, 1998, SCIENCE, V282, P1701, DOI 10.1126/science.282.5394.1701; ROTH SY, 1991, EMBO J, V10, P2069, DOI 10.1002/j.1460-2075.1991.tb07738.x; Rusan NM, 2001, MOL BIOL CELL, V12, P971, DOI 10.1091/mbc.12.4.971; Sabourin LA, 2000, MOL CELL BIOL, V20, P684, DOI 10.1128/MCB.20.2.684-696.2000; Sabourin LA, 1999, ONCOGENE, V18, P7566, DOI 10.1038/sj.onc.1203119; Schmitt A, 2002, J CELL SCI, V115, P2457; Scholey JM, 2003, NATURE, V422, P746, DOI 10.1038/nature01599; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4; Vicogne J, 2004, J BIOL CHEM, V279, P37407, DOI 10.1074/jbc.M313738200; Wagner S, 2002, J BIOL CHEM, V277, P37685, DOI 10.1074/jbc.M205899200; Walter SA, 2003, J BIOL CHEM, V278, P18221, DOI 10.1074/jbc.M212556200; YAMASHIRO S, 1990, NATURE, V344, P675, DOI 10.1038/344675a0; Zhang YH, 2002, DEV BRAIN RES, V139, P205, DOI 10.1016/S0165-3806(02)00551-5	41	42	43	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42383	42390		10.1074/jbc.M510763200	http://dx.doi.org/10.1074/jbc.M510763200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16236704	hybrid			2022-12-25	WOS:000233992700068
J	McCormick, MM; Rahimi, F; Bobryshev, YV; Gaus, K; Zreiqat, H; Cai, H; Lord, RSA; Geczy, CL				McCormick, MM; Rahimi, F; Bobryshev, YV; Gaus, K; Zreiqat, H; Cai, H; Lord, RSA; Geczy, CL			S100A8 and S100A9 in human arterial wall - Implications for atherogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MICROVASCULAR ENDOTHELIAL-CELLS; HUMAN ATHEROSCLEROTIC LESIONS; OXIDATIVE CROSS-LINKING; TRANSENDOTHELIAL MIGRATION; VASCULAR CALCIFICATION; CHEMOTACTIC PROTEIN; HUMAN KERATINOCYTES; MATRIX VESICLES; BINDING PROTEIN	Atherogenesis is a complex process involving inflammation. S100A8 and S100A9, the Ca2+-binding neutrophil cytosolic proteins, are associated with innate immunity and regulate processes leading to leukocyte adhesion and transmigration. In neutrophils and monocytes the S100A8-S100A9 complex regulates phosphorylation, NADPH-oxidase activity, and fatty acid transport. The proteins have anti-microbial properties, and S100A8 may play a role in oxidant defense in inflammation. Murine S100A8 is regulated by inflammatory mediators and recruits macrophages with a proatherogenic phenotype. S100A9 but not S100A8 was found in macrophages in ApoE(-/-) murine atherosclerotic lesions, whereas both proteins are expressed in human giant cell arteritis. Here we demonstrate S100A8 and S100A9 protein and mRNA in macrophages, foam cells, and neovessels in human atheroma. Monomeric and complexed forms were detected in plaque extracts. S100A9 was strongly expressed in calcifying areas and the surrounding extracellular matrix. Vascular matrix vesicles contain high levels of Ca2+-binding proteins and phospholipids that regulate calcification. Matrix vesicles characterized by electron microscopy, x-ray microanalysis, nucleoside triphosphate pyrophosphohydrolase assay and cholesterol/phospholipid analysis contained predominantly S100A9. We propose that S100A9 associated with lipid structures in matrix vesicles may influence phospholipid-Ca2+ binding properties to promote dystrophic calcification. S100A8 and S100A9 were more sensitive to hypochlorite oxidation than albumin or low density lipoprotein and immunoaffinity confirmed S100A8-S100A9 complexes; some were resistant to reduction, suggesting that hypochlorite may contribute to protein cross-linking. S100A8 and S100A9 in atherosclerotic plaque and calcifying matrix vesicles may significantly influence redox- and Ca2+-dependent processes during atherogenesis and its chronic complications, particularly dystrophic calcification.	Univ New S Wales, Sch Med Sci, Inflammatory Dis Res Unit, Sydney, NSW 2052, Australia; Univ New S Wales, Professorial Surg Unit, St Vincent Hosp, Sydney, NSW 2052, Australia	University of New South Wales Sydney; St Vincents Hospital Sydney; University of New South Wales Sydney	Geczy, CL (corresponding author), Univ New S Wales, Sch Med Sci, Inflammatory Dis Res Unit, Sydney, NSW 2052, Australia.	c.geczy@unsw.edu.au	Rahimi, Farid/E-6522-2018; Bobryshev, Yuri/J-2838-2013	Rahimi, Farid/0000-0002-0920-8188; Gaus, Katharina/0000-0002-8009-9658; Zreiqat, Hala/0000-0003-0521-7711; Chwilkowska, Agnieszka/0000-0002-3499-4627; Maksymowicz, Krzysztof/0000-0003-4876-1733				Ahmad A, 2003, AM J RESP CELL MOL, V29, P523, DOI 10.1165/rcmb.2002-0286OC; ANDERSON HC, 1989, LAB INVEST, V60, P320; ANDERSON HC, 1983, ARCH PATHOL LAB MED, V107, P341; Balcerzak M, 2003, ACTA BIOCHIM POL, V50, P1019; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bobryshev YV, 1999, ATHEROSCLEROSIS, V143, P451; BOBRYSHEV YV, 1995, ATHEROSCLEROSIS, V118, P9, DOI 10.1016/0021-9150(95)05588-N; Bobryshev YV, 1998, CARDIOVASC RES, V37, P799, DOI 10.1016/S0008-6363(97)00229-0; BONUCCI E, 1967, J ULTRA MOL STRUCT R, V20, P33, DOI 10.1016/S0022-5320(67)80034-0; BOSTROM K, 1993, J CLIN INVEST, V91, P1800, DOI 10.1172/JCI116391; Brown AJ, 1996, J LIPID RES, V37, P320; Canfield AE, 2002, J PATHOL, V196, P228, DOI 10.1002/path.1020; Daphna EM, 1998, MOL CELL BIOCHEM, V183, P55, DOI 10.1023/A:1006848730927; Deshpande R, 2000, J INVEST DERMATOL, V115, P477, DOI 10.1046/j.1523-1747.2000.00078.x; Dhore CR, 2001, ARTERIOSCL THROM VAS, V21, P1998, DOI 10.1161/hq1201.100229; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; Drueke TB, 2002, BLOOD PURIFICAT, V20, P494, DOI 10.1159/000065203; Duarte WR, 2003, J BONE MINER RES, V18, P493, DOI 10.1359/jbmr.2003.18.3.493; EDGEWORTH J, 1989, NATURE, V342, P189, DOI 10.1038/342189a0; Eue I, 2000, ATHEROSCLEROSIS, V151, P593, DOI 10.1016/S0021-9150(00)00476-7; FITZPATRICK LA, 1994, J CLIN INVEST, V94, P1597, DOI 10.1172/JCI117501; Foell D, 2004, CLIN CHIM ACTA, V344, P37, DOI 10.1016/j.cccn.2004.02.023; Foell D, 2004, J PATHOL, V204, P311, DOI 10.1002/path.1660; Fu XY, 2002, BIOCHEMISTRY-US, V41, P1293, DOI 10.1021/bi015777z; Gelissen IC, 1996, J BIOL CHEM, V271, P17852, DOI 10.1074/jbc.271.30.17852; Gillette JM, 2004, J CELL SCI, V117, P441, DOI 10.1242/jcs.00909; Goch G, 2005, FEBS J, V272, P2557, DOI 10.1111/j.1742-4658.2005.04680.x; Grimbaldeston MA, 2003, J INVEST DERMATOL, V121, P1168, DOI 10.1046/j.1523-1747.2003.12561.x; Guignard F, 1996, EUR J BIOCHEM, V241, P265, DOI 10.1111/j.1432-1033.1996.0265t.x; Harrison CA, 1999, J BIOL CHEM, V274, P8561, DOI 10.1074/jbc.274.13.8561; Hawkins CL, 1999, BIOCHEM J, V340, P539, DOI 10.1042/0264-6021:3400539; HAZELL LJ, 1994, BIOCHEM J, V302, P297, DOI 10.1042/bj3020297; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; Heinecke JW, 2003, AM J CARDIOL, V91, p12A; Hsu HHT, 1999, ATHEROSCLEROSIS, V143, P353, DOI 10.1016/S0021-9150(98)00322-0; HSU HHT, 1983, J BIOL CHEM, V258, P3463; Hwang R, 2004, J BIOL CHEM, V279, P21239, DOI 10.1074/jbc.M312771200; IISMAA SE, 1994, DNA CELL BIOL, V13, P183, DOI 10.1089/dna.1994.13.183; Jono S, 2000, J BIOL CHEM, V275, P20197, DOI 10.1074/jbc.M909174199; Kerkhoff C, 1999, PATHOBIOLOGY, V67, P230, DOI 10.1159/000028098; Kislinger T, 2001, ARTERIOSCL THROM VAS, V21, P905, DOI 10.1161/01.ATV.21.6.905; Kocher M, 1996, INFECT IMMUN, V64, P1342, DOI 10.1128/IAI.64.4.1342-1350.1996; LACKMANN M, 1993, J IMMUNOL, V150, P2981; LAU W, 1995, J CLIN INVEST, V95, P1957, DOI 10.1172/JCI117879; MARKOVIC B, 1992, J PATHOL, V167, P369, DOI 10.1002/path.1711670404; Murshed M, 2004, J CELL BIOL, V165, P625, DOI 10.1083/jcb.200402046; Nacken W, 2004, FEBS LETT, V572, P289, DOI 10.1016/j.febslet.2004.07.024; Nacken W, 2003, MICROSC RES TECHNIQ, V60, P569, DOI 10.1002/jemt.10299; Pampena DA, 2004, BIOCHEM J, V378, P1083, DOI 10.1042/BJ20031150; Panasenko OM, 2003, FREE RADICAL BIO MED, V34, P553, DOI 10.1016/S0891-5849(02)01358-8; RACHOW JW, 1988, ARTHRITIS RHEUM, V31, P408, DOI 10.1002/art.1780310313; Raftery MJ, 2001, J BIOL CHEM, V276, P33393, DOI 10.1074/jbc.M101566200; Ravasi T, 2004, GENOMICS, V84, P10, DOI 10.1016/j.ygeno.2004.02.002; Robinson MJ, 2002, J BIOL CHEM, V277, P3658, DOI 10.1074/jbc.M102950200; SIEGEL SA, 1983, J BIOL CHEM, V258, P8601; SOKOLOFF L, 1974, P SOC EXP BIOL MED, V146, P1166; Sugiyama S, 2001, AM J PATHOL, V158, P879, DOI 10.1016/S0002-9440(10)64036-9; Tugizov S, 2005, J VIROL, V79, P1099, DOI 10.1128/JVI.79.2.1099-1112.2005; vandenBos C, 1996, J IMMUNOL, V156, P1247; Viemann D, 2005, BLOOD, V105, P2955, DOI 10.1182/blood-2004-07-2520; Vogl T, 2004, BLOOD, V104, P4260, DOI 10.1182/blood-2004-02-0446; Wada T, 1999, CIRC RES, V84, P166, DOI 10.1161/01.RES.84.2.166; Wu LNY, 2002, J BIOL CHEM, V277, P5126, DOI 10.1074/jbc.M107899200; Wu LNY, 1997, J BIOL CHEM, V272, P4404, DOI 10.1074/jbc.272.7.4404; Xu K, 2000, J IMMUNOL, V164, P4916, DOI 10.4049/jimmunol.164.9.4916; Yen T, 1997, BLOOD, V90, P4812, DOI 10.1182/blood.V90.12.4812.4812_4812_4821; Zhang T, 2002, J INVEST DERMATOL, V119, P1196, DOI 10.1046/j.1523-1747.2002.19520.x; Zhukova L, 2004, BBA-MOL CELL RES, V1742, P191, DOI 10.1016/j.bbamcr.2004.10.002	69	145	154	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41521	41529		10.1074/jbc.M509442200	http://dx.doi.org/10.1074/jbc.M509442200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16216873	hybrid			2022-12-25	WOS:000233866900051
J	Gomez-Llorente, Y; Fletcher, RJ; Chen, XJS; Carazo, JM; Martin, CS				Gomez-Llorente, Y; Fletcher, RJ; Chen, XJS; Carazo, JM; Martin, CS			Polymorphism and double hexamer structure in the archaeal minichromosome maintenance (MCM) helicase from Methanobacterium thermoautotrophicum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE T-ANTIGEN; IMAGE-PROCESSING PACKAGE; DNA-REPLICATION; SIMIAN-VIRUS-40 ORIGIN; ELECTRON-MICROSCOPY; PROTEIN; RESOLUTION; RECONSTRUCTION; MECHANISM; XMIPP	Methanobacterium thermoautotrophicum minichromosome maintenance complex (mtMCM), a cellular replicative helicase, is a useful model for the more complex eukaryotic MCMs. Biochemical and crystallographic evidence indicates that mtMCM assembles as a double hexamer (dHex), but previous electron microscopy studies reported only the presence of single heptamers or single hexamers (Pape, T., Meka, H., Chen, S., Vicentini, G., Van Heel, M., and Onesti, S. (2003) EMBO Rep. 4, 1079-1083; Yu, X., VanLoock, M. S., Poplawski, A., Kelman, Z., Xiang, T., Tye, B. K., and Egelman, E. H. (2002) EMBO Rep. 3, 792-797). Here we present the first three-dimensional electron microscopy reconstruction of the full-length mtMCM dHex in which two hexamers contact each other via the structurally well defined N-terminal domains. The dHex has obvious side openings that resemble the side channels of LTag (large T antigen). 6-fold and 7-fold rings were observed in the same mtMCM preparation, but we determined that assembly as a double ring favors 6-fold structures. Additionally, open rings were also detected, which suggests a direct mtMCM loading mechanism onto DNA.	CSIC, Ctr Nacl Biotecnol, Biocomp Unit, E-28049 Madrid, Spain; Univ So Calif, Los Angeles, CA 90078 USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); University of Southern California	Carazo, JM (corresponding author), CSIC, Ctr Nacl Biotecnol, Biocomp Unit, Darwin 3, E-28049 Madrid, Spain.	carazo@cnb.uam.es	San Martín, Carmen/A-4074-2010; Gomez-Llorente, Yacob/E-5631-2013; Garcia, Jose Maria Carazo/E-9234-2016	San Martín, Carmen/0000-0001-9799-175X; Garcia, Jose Maria Carazo/0000-0003-0788-8447	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070472] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048747] Funding Source: NIH RePORTER; NHLBI NIH HHS [1R01-HL70472-01] Funding Source: Medline; NIAID NIH HHS [R01-AI048747] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahnert P, 2000, EMBO J, V19, P3418, DOI 10.1093/emboj/19.13.3418; Alexandrov AI, 2002, J BIOL CHEM, V277, P44886, DOI 10.1074/jbc.M207022200; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Chen YJ, 2005, J MOL BIOL, V346, P389, DOI 10.1016/j.jmb.2004.11.076; Chong JPJ, 2000, P NATL ACAD SCI USA, V97, P1530, DOI 10.1073/pnas.030539597; DEAN FB, 1992, J BIOL CHEM, V267, P14129; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Fletcher RJ, 2005, J BIOL CHEM, V280, P42405, DOI 10.1074/jbc.M509773200; Fletcher RJ, 2003, NAT STRUCT BIOL, V10, P160, DOI 10.1038/nsb893; Forsburg SL, 2004, MICROBIOL MOL BIOL R, V68, P109, DOI 10.1128/MMBR.68.1.109-131.2004; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Gomez-Lorenzo MG, 2003, EMBO J, V22, P6205, DOI 10.1093/emboj/cdg612; Kearsey SE, 1998, BBA-GENE STRUCT EXPR, V1398, P113, DOI 10.1016/S0167-4781(98)00033-5; Kelman LM, 2003, MOL MICROBIOL, V48, P605, DOI 10.1046/j.1365-2958.2003.03369.x; Kelman Z, 1999, P NATL ACAD SCI USA, V96, P14783, DOI 10.1073/pnas.96.26.14783; Kleywegt G. J., 2001, INT TABLES CRYSTALLO, VF, P353, DOI DOI 10.1107/97809553602060000111; Li DW, 2003, NATURE, V423, P512, DOI 10.1038/nature01691; Marabini R, 1998, ULTRAMICROSCOPY, V72, P53, DOI 10.1016/S0304-3991(97)00127-7; Marabini R, 1996, J STRUCT BIOL, V116, P237, DOI 10.1006/jsbi.1996.0036; Marco S, 1996, ULTRAMICROSCOPY, V66, P5, DOI 10.1016/S0304-3991(96)00083-6; Pape T, 2003, EMBO REP, V4, P1079, DOI 10.1038/sj.embor.7400010; Pascual-Montano A, 2001, J STRUCT BIOL, V133, P233, DOI 10.1006/jsbi.2001.4369; PENCZEK P, 1992, ULTRAMICROSCOPY, V40, P33, DOI 10.1016/0304-3991(92)90233-A; PENCZEK PA, 1994, ULTRAMICROSCOPY, V53, P251, DOI 10.1016/0304-3991(94)90038-8; PIPAS JM, 1985, J VIROL, V54, P569, DOI 10.1128/JVI.54.2.569-575.1985; Sclafani RA, 2004, GENE DEV, V18, P2039, DOI 10.1101/gad.1240604; Shechter DF, 2000, J BIOL CHEM, V275, P15049, DOI 10.1074/jbc.M000398200; Simmons DT, 2000, ADV VIRUS RES, V55, P75, DOI 10.1016/S0065-3527(00)55002-7; Skordalakes E, 2003, CELL, V114, P135, DOI 10.1016/S0092-8674(03)00512-9; Smelkova NV, 1997, J VIROL, V71, P8766, DOI 10.1128/JVI.71.11.8766-8773.1997; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Sorzano COS, 2004, J STRUCT BIOL, V148, P194, DOI 10.1016/j.jsb.2004.06.006; Toth EA, 2003, MOL CELL, V12, P1113, DOI 10.1016/S1097-2765(03)00442-8; Trus BL, 2004, J VIROL, V78, P12668, DOI 10.1128/JVI.78.22.12668-12671.2004; Tye BK, 2000, J BIOL CHEM, V275, P34833, DOI 10.1074/jbc.R000018200; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Unser M, 2005, J STRUCT BIOL, V149, P243, DOI 10.1016/j.jsb.2004.10.011; UNSER M, 1987, ULTRAMICROSCOPY, V23, P39, DOI 10.1016/0304-3991(87)90225-7; Valle M, 2000, MOL CELL BIOL, V20, P34, DOI 10.1128/MCB.20.1.34-41.2000; Yu X, 2002, EMBO REP, V3, P792, DOI 10.1093/embo-reports/kvf160	40	67	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40909	40915		10.1074/jbc.M509760200	http://dx.doi.org/10.1074/jbc.M509760200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16221680	hybrid			2022-12-25	WOS:000233666600063
J	Helms, MN; Liu, L; Liang, YY; Vandewalle, A; Saxena, S; Eaton, DC; Ma, HP				Helms, MN; Liu, L; Liang, YY; Vandewalle, A; Saxena, S; Eaton, DC; Ma, HP			Phosphatidylinositol 3,4,5-trisphosphate mediates aldosterone stimulation of epithelial sodium channel (ENaC) and interacts with gamma-ENaC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; SENSITIVE NA+ CHANNEL; K-ATP CHANNELS; ANIONIC PHOSPHOLIPIDS; PLASMA-MEMBRANE; PROTEIN-KINASE; BINDING-SITE; CELL-LINE; SGK; TRANSPORT	Whole cell voltage clamp experiments were performed in a mouse cortical collecting duct principal cell line using patch pipettes back-filled with a solution containing phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 significantly increased amiloride-sensitive current in control cells but not in the cells prestimulated by aldosterone. Additionally, aldosterone stimulated amiloride-sensitive current in control cells, but not in the cells that expressed a PIP3-binding protein (Grp1-PH), which sequestered intracellular PIP3. 12 amino acids from the N-terminal tail (APGEKIKAKIKK) of gamma-epithelial sodium channel (gamma-ENaC) were truncated by PCR-based mutagenesis (gamma(T)-ENaC). Whole cell and confocal microscopy experiments were conducted in Madin-Darby canine kidney cells co-expressing alpha- and beta-ENaC only or with either gamma-ENaC or gamma(T)-ENaC. The data demonstrated that the N-terminal tail truncation significantly decreased amiloride-sensitive current and that both the N-terminal tail truncation and LY-294002 (a PI3K inhibitor) prevented ENaC translocation to the plasma membrane. These data suggest that PIP3 mediates aldosterone-induced ENaC activity and trafficking and that the N-terminal tail of gamma-ENaC is necessary for channel trafficking, probably channel gating as well. Additionally, we demonstrated a novel interaction between gamma-ENaC and PIP3.	Univ Alabama Birmingham, Dept Med, Div Nephrol, Birmingham, AL 35294 USA; Emory Univ, Sch Med, Dept Physiol, Atlanta, GA 30322 USA; Univ Paris 07, INSERM, U478, F-75870 Paris, France; Stevens Inst Technol, Dept Chem & Biol Chem, Hoboken, NJ 07030 USA	University of Alabama System; University of Alabama Birmingham; Emory University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Stevens Institute of Technology	Ma, HP (corresponding author), Univ Alabama Birmingham, Dept Med, Div Nephrol, 1530 3rd Ave S,Sparks Ctr 865, Birmingham, AL 35294 USA.	hepingma@uab.edu		Eaton, Douglas/0000-0002-2686-6692	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067110, R37DK037963, R01DK057717] Funding Source: NIH RePORTER; NIDDK NIH HHS [1R01-DK57717, 1R01-DK067110, 1R37-DK37963] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; Bens M, 1999, J AM SOC NEPHROL, V10, P923; Blazer-Yost BL, 1999, AM J PHYSIOL-CELL PH, V277, pC531, DOI 10.1152/ajpcell.1999.277.3.C531; Blazer-Yost BL, 2005, PFLUG ARCH EUR J PHY, V450, P75, DOI 10.1007/s00424-004-1371-5; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Chalfant ML, 1999, J BIOL CHEM, V274, P32889, DOI 10.1074/jbc.274.46.32889; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; De la Rosa DA, 2003, AM J PHYSIOL-CELL PH, V284, pC404, DOI 10.1152/ajpcell.00398.2002; de la Rosa DA, 2000, ANNU REV PHYSIOL, V62, P573, DOI 10.1146/annurev.physiol.62.1.573; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Fyfe GK, 1998, SEMIN NEPHROL, V18, P138; Fyfe GK, 1998, J GEN PHYSIOL, V112, P423, DOI 10.1085/jgp.112.4.423; Gray A, 1999, BIOCHEM J, V344, P929, DOI 10.1042/0264-6021:3440929; Helms MN, 2003, AM J PHYSIOL-RENAL, V284, pF480, DOI 10.1152/ajprenal.00299.2002; Hilgemann D W, 2001, Sci STKE, V2001, pre19, DOI 10.1126/stke.2001.111.re19; Horisberger JD, 1998, CURR OPIN CELL BIOL, V10, P443, DOI 10.1016/S0955-0674(98)80056-2; Hummler E, 1996, NAT GENET, V12, P325, DOI 10.1038/ng0396-325; Ishii M, 2002, P NATL ACAD SCI USA, V99, P4325, DOI 10.1073/pnas.072073399; Klarlund JK, 2000, J BIOL CHEM, V275, P32816, DOI 10.1074/jbc.M002435200; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Konig J, 2001, EMBO REP, V2, P1047, DOI 10.1093/embo-reports/kve232; Krauter T, 2001, MOL PHARMACOL, V59, P1086, DOI 10.1124/mol.59.5.1086; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; Ma HP, 2005, J AM SOC NEPHROL, V16, P3182, DOI 10.1681/ASN.2005040434; Ma HP, 1996, AM J PHYSIOL-RENAL, V270, pF798, DOI 10.1152/ajprenal.1996.270.5.F798; Ma HP, 2002, J BIOL CHEM, V277, P7641, DOI 10.1074/jbc.C100737200; MCDONALD FJ, 1994, AM J PHYSIOL, V266, pL728, DOI 10.1152/ajplung.1994.266.6.L728; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; Naray-Fejes-Toth A, 2004, MOL CELL ENDOCRINOL, V217, P197, DOI 10.1016/j.mce.2003.10.043; Naray-Fejes-Toth A, 2000, KIDNEY INT, V57, P1290, DOI 10.1046/j.1523-1755.2000.00964.x; Oatey PB, 1999, BIOCHEM J, V344, P511, DOI 10.1042/0264-6021:3440511; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Pearce D, 2000, KIDNEY INT, V57, P1283, DOI 10.1046/j.1523-1755.2000.00963.x; Pochynyuk O, 2005, J BIOL CHEM, V280, P37565, DOI 10.1074/jbc.M509071200; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Schulze D, 2003, J BIOL CHEM, V278, P10500, DOI 10.1074/jbc.M208413200; Shigaev A, 2000, AM J PHYSIOL-RENAL, V278, pF613, DOI 10.1152/ajprenal.2000.278.4.F613; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; Tong QS, 2004, J BIOL CHEM, V279, P22654, DOI 10.1074/jbc.M401004200; Venkateswarlu K, 1998, BIOCHEM J, V335, P139, DOI 10.1042/bj3350139; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; Vuagniaux G, 2000, J AM SOC NEPHROL, V11, P828, DOI 10.1681/ASN.V115828; Wang J, 2001, AM J PHYSIOL-RENAL, V280, pF303, DOI 10.1152/ajprenal.2001.280.2.F303; Yue G, 2002, J BIOL CHEM, V277, P11965, DOI 10.1074/jbc.M108951200; Zheng J, 1996, J MOL BIOL, V255, P14, DOI 10.1006/jmbi.1996.0002	45	53	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40885	40891		10.1074/jbc.M509646200	http://dx.doi.org/10.1074/jbc.M509646200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16204229	hybrid			2022-12-25	WOS:000233666600060
J	Constantin, N; Dzantiev, L; Kadyrov, FA; Modrich, P				Constantin, N; Dzantiev, L; Kadyrov, FA; Modrich, P			Human mismatch repair - Reconstitution of a nick-directed bidirectional reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-DELTA; ESCHERICHIA-COLI MUTS; SACCHAROMYCES-CEREVISIAE; PROVOKED EXCISION; NUCLEAR EXTRACTS; EXONUCLEASE 1; ATP; REQUIREMENT; PROTEIN; SYSTEM	Bidirectional mismatch repair directed by a strand break located 3' or 5' to the mispair has been reconstituted using seven purified human activities: MutS alpha, MutL alpha, EXOI, replication protein A ( RPA), proliferating cell nuclear antigen ( PCNA), replication factor C ( RFC) and DNA polymerase delta. In addition to DNA polymerase delta, PCNA, RFC, and RPA, 5'-directed repair depends on MutS alpha and EXOI, whereas 3'-directed mismatch correction also requires MutL alpha. The repair reaction displays specificity for DNA polymerase delta, an effect that presumably reflects interactions with other repair activities. Because previous studies have suggested potential involvement of the editing function of a replicative polymerase in mismatch-provoked excision, we have evaluated possible participation of DNA polymerase delta in the excision step of repair. RFC and PCNA dramatically activate polymerase delta-mediated hydrolysis of a primer-template. Nevertheless, the contribution of the polymerase to mismatch-provoked excision is very limited, both in the purified system and in HeLa extracts, as judged by in vitro assay using nicked circular heteroplex DNAs. Thus, excision and repair in the purified system containing polymerase delta are reduced 10-fold upon omission of EXOI or by substitution of a catalytically dead form of the exonuclease. Furthermore, aphidicolin inhibits both 3'- and 5'-directed excision in HeLa nuclear extracts by only 20-30%. Although this modest inhibition could be because of nonspecific effects, it may indicate limited dependence of bidirectional excision on an aphidicolinsensitive DNA polymerase.	Duke Univ, Ctr Med, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Ctr Med, Howard Hughes Med Inst, Durham, NC 27710 USA	Duke University; Duke University; Howard Hughes Medical Institute	Modrich, P (corresponding author), Duke Univ, Ctr Med, Dept Biochem, Durham, NC 27710 USA.	modrich@biochem.duke.edu		Modrich, Paul/0000-0001-8708-9885	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045190] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM045190, GM45190] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya S, 2003, MOL CELL, V12, P233, DOI 10.1016/S1097-2765(03)00219-3; Amin NS, 2001, MOL CELL BIOL, V21, P5142, DOI 10.1128/MCB.21.15.5142-5155.2001; AU KG, 1992, J BIOL CHEM, V267, P12142; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; Burdett V, 2001, P NATL ACAD SCI USA, V98, P6765, DOI 10.1073/pnas.121183298; CHENG CH, 1993, BIOCHEMISTRY-US, V32, P8568, DOI 10.1021/bi00084a025; COOPER DL, 1993, J BIOL CHEM, V268, P11823; Dao V, 1998, J BIOL CHEM, V273, P9202, DOI 10.1074/jbc.273.15.9202; Datta A, 2000, MOL CELL, V6, P593, DOI 10.1016/S1097-2765(00)00058-7; Dzantiev L, 2004, MOL CELL, V15, P31, DOI 10.1016/j.molcel.2004.06.016; FANG WH, 1993, J BIOL CHEM, V268, P11838; FANG WH, 1993, THESIS DUKE U; Galio L, 1999, NUCLEIC ACIDS RES, V27, P2325, DOI 10.1093/nar/27.11.2325; Genschel J, 2002, J BIOL CHEM, V277, P13302, DOI 10.1074/jbc.M111854200; GOSCIN LP, 1982, BIOCHEMISTRY-US, V21, P2513, DOI 10.1021/bi00539a034; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Guo SL, 2004, J BIOL CHEM, V279, P16912, DOI 10.1074/jbc.M313213200; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; Jin YH, 2005, MOL CELL BIOL, V25, P461, DOI 10.1128/MCB.25.1.461-471.2005; Jiricny J, 1998, MUTAT RES-DNA REPAIR, V409, P107, DOI 10.1016/S0921-8777(98)00056-1; Kunkel TA, 2005, ANNU REV BIOCHEM, V74, P681, DOI 10.1146/annurev.biochem.74.082803.133243; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; Lee B, 2002, NUCLEIC ACIDS RES, V30, P942, DOI 10.1093/nar/30.4.942; Lee BI, 1999, J BIOL CHEM, V274, P37763, DOI 10.1074/jbc.274.53.37763; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; Longley MJ, 1997, J BIOL CHEM, V272, P10917; Mo JY, 2000, BIOCHEMISTRY-US, V39, P7245, DOI 10.1021/bi0000871; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; Podust VN, 2002, J BIOL CHEM, V277, P3894, DOI 10.1074/jbc.M109684200; SABATINO RD, 1988, BIOCHEMISTRY-US, V27, P2266, DOI 10.1021/bi00407a003; Schofield MJ, 2001, J BIOL CHEM, V276, P28291, DOI 10.1074/jbc.M103148200; Selmane T, 2003, J MOL BIOL, V334, P949, DOI 10.1016/j.jmb.2003.10.010; Spampinato C, 2000, J BIOL CHEM, V275, P9863, DOI 10.1074/jbc.275.13.9863; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; SU SS, 1988, J BIOL CHEM, V263, P6829; Tran HT, 1999, MOL CELL BIOL, V19, P2000; Tran PT, 2004, DNA REPAIR, V3, P1549, DOI 10.1016/j.dnarep.2004.05.015; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Viswanathan M, 2001, J BIOL CHEM, V276, P31053, DOI 10.1074/jbc.M105481200; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Wang HX, 2002, J BIOL CHEM, V277, P26143, DOI 10.1074/jbc.M200358200; Wei KC, 2003, GENE DEV, V17, P603, DOI 10.1101/gad.1060603; Wilson DM, 1998, NUCLEIC ACIDS RES, V26, P3762, DOI 10.1093/nar/26.16.3762; Xie B, 2002, BIOCHEMISTRY-US, V41, P13133, DOI 10.1021/bi0262707; Yuan FH, 2004, J BIOL CHEM, V279, P20935, DOI 10.1074/jbc.M401931200	49	173	176	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					39752	39761		10.1074/jbc.M509701200	http://dx.doi.org/10.1074/jbc.M509701200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16188885	hybrid, Green Accepted			2022-12-25	WOS:000233461300012
J	Satoh, S; Noaki, T; Ishigure, T; Osada, S; Imagawa, M; Miura, N; Yamada, K; Noguchi, T				Satoh, S; Noaki, T; Ishigure, T; Osada, S; Imagawa, M; Miura, N; Yamada, K; Noguchi, T			Nuclear factor 1 family members interact with hepatocyte nuclear factor 1 alpha to synergistically activate L-type pyruvate kinase gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE RESPONSE ELEMENT; NUCLEAR FACTOR-1 FAMILY; GLUCOSE RESPONSE; BINDING PROTEIN; DIETARY FRUCTOSE; TRANSGENIC MICE; RAT HEPATOCYTES; PROMOTER; EXPRESSION; LIVER	Transcription of hepatic L-type pyruvate kinase ( L-PK) gene is cell type-specific and is under the control of various nutritional conditions. The L-PK gene contains multiple cis-regulatory elements located within a 170-bp upstream region necessary for these regulations. These elements can synergistically stimulate L-PK gene transcription, although their mechanisms are largely unknown. Because nuclear factor ( NF) 1 family members bind to specific cis-regulatory elements known as L-IIA and L-IIB and hepatocyte nuclear factor ( HNF) 1 alpha binds to the adjacent element L-I, we examined the functional and physical interactions between these two transcription factors. Reporter gene assay showed that these two factors synergistically activated the L-PK promoter containing the 5'- flanking region up to -189. Although two NF1-binding sites are required for the maximum synergistic effect of NF1 family members with HNF1 alpha, significant functional interaction between the two factors was observed in the L-PK promoter containing two mutated NF1-binding sites and also in the promoter containing only the HNF1 alpha-binding site, raising the possibility that NF1 proteins function as HNF1 alpha co-activators. Chromatin immunoprecipitation assay revealed that both NF1 proteins and HNF1 alpha bound to the promoter region of the L-PK gene in vivo. In vitro binding assay confirmed that NF1 proteins directly interacted mainly with the homeodomain of HNF1 alpha via their DNA- binding domains. This interaction enhanced HNF1 alpha binding to the L-I element and was also observed in rat liver by co-immunoprecipitation assay. Thus, we conclude that cooperative interaction between NF1 family members and HNF1 alpha plays an important role in hepatic L-PK transcription.	Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Chikusa Ku, Nagoya, Aichi 4648601, Japan; Nagoya City Univ, Grad Sch Pharmaceut Sci, Dept Mol Biol, Mizuho Ku, Nagoya, Aichi 4678603, Japan; Hamamatsu Univ Sch Med, Dept Biochem, Hamamatsu, Shizuoka 4313192, Japan; Univ Fukui, Fac Med Sci, Dept Biochem, Matsuoka, Fukui 9101193, Japan	Nagoya University; Nagoya City University; Hamamatsu University School of Medicine; University of Fukui	Noguchi, T (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Chikusa Ku, Nagoya, Aichi 4648601, Japan.	tnoguchi@agr.nagoya-u.ac.jp						Ban N, 2002, DIABETES, V51, P1409, DOI 10.2337/diabetes.51.5.1409; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; Chaudhry AZ, 1997, DEV DYNAM, V208, P313; CUIF MH, 1993, J BIOL CHEM, V268, P13769; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; Eeckhoute J, 2004, NUCLEIC ACIDS RES, V32, P2586, DOI 10.1093/nar/gkh581; Gronostajski RM, 2000, GENE, V249, P31, DOI 10.1016/S0378-1119(00)00140-2; GUERRA MJMD, 1993, MOL CELL BIOL, V13, P7725, DOI 10.1128/MCB.13.12.7725; Iizuka K, 2004, P NATL ACAD SCI USA, V101, P7281, DOI 10.1073/pnas.0401516101; Ishii S, 2004, P NATL ACAD SCI USA, V101, P15597, DOI 10.1073/pnas.0405238101; Krones A, 2001, ENDOCRINOLOGY, V142, P2707, DOI 10.1210/en.142.6.2707; LIIMATTA M, 1994, MOL ENDOCRINOL, V8, P1147, DOI 10.1210/me.8.9.1147; LIU ZR, 1993, J BIOL CHEM, V268, P12787; Lou DQ, 1999, J BIOL CHEM, V274, P28385, DOI 10.1074/jbc.274.40.28385; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Ma L, 2005, J BIOL CHEM, V280, P12019, DOI 10.1074/jbc.M413063200; MATSUDA T, 1990, J BIOCHEM-TOKYO, V108, P778, DOI 10.1093/oxfordjournals.jbchem.a123280; MIURA N, 1993, EUR J CELL BIOL, V60, P376; NOGUCHI T, 1982, J BIOL CHEM, V257, P1110; NOGUCHI T, 1987, J BIOL CHEM, V262, P14366; NOGUCHI T, 1993, FEBS LETT, V318, P269, DOI 10.1016/0014-5793(93)80526-Z; NOGUCHI T, 1985, J BIOL CHEM, V260, P4393; NOGUCHI T, 1986, J BIOL CHEM, V261, P3807; Osada S, 1999, BIOCHEM J, V342, P189, DOI 10.1042/0264-6021:3420189; Oyadomari S, 2000, FEBS LETT, V478, P141, DOI 10.1016/S0014-5793(00)01840-8; Schrem H, 2002, PHARMACOL REV, V54, P129, DOI 10.1124/pr.54.1.129; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SHIH HM, 1992, J BIOL CHEM, V267, P13222; Soutoglou E, 2000, J BIOL CHEM, V275, P12515, DOI 10.1074/jbc.275.17.12515; TAKENAKA M, 1989, J BIOL CHEM, V264, P2363; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; Yamada K, 1999, BIOCHEM BIOPH RES CO, V257, P44, DOI 10.1006/bbrc.1999.0410; Yamada K, 1997, BIOCHEM J, V324, P917, DOI 10.1042/bj3240917; YAMADA K, 1990, J BIOL CHEM, V265, P19885; Yamada K, 1999, BIOCHEM J, V337, P1, DOI 10.1042/0264-6021:3370001; Yamada K, 2000, J BIOL CHEM, V275, P18129, DOI 10.1074/jbc.M001543200; Yamashita H, 2001, P NATL ACAD SCI USA, V98, P9116, DOI 10.1073/pnas.161284298; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050	39	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					39827	39834		10.1074/jbc.M507303200	http://dx.doi.org/10.1074/jbc.M507303200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16204235	hybrid			2022-12-25	WOS:000233461300020
J	Vietor, I; Kurzbauer, R; Brosch, G; Huber, LA				Vietor, I; Kurzbauer, R; Brosch, G; Huber, LA			TIS7 regulation of the beta-catenin/Tcf-4 target gene osteopontin (OPN) is histone deacetylase-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIM PROTEIN FHL2; BETA-CATENIN; TRANSCRIPTIONAL REGULATION; EXPRESSION; MUSCLE; CELLS; GROWTH; IDENTIFICATION; ACETYLATION; INDUCTION	12-O-Tetradecanoylphorbol-13-acetate-induced sequence 7 ( TIS7) acts as a transcriptional co-repressor interacting with SIN3, the histone deacetylase-containing complex. The overexpression of TIS7 down-regulates expression of a specific set of genes. Homozygous deletion of this gene in mice delays injury-induced muscle regeneration and inhibits muscle satellite cell differentiation and fusion of myoblasts in vitro. Osteopontin ( OPN), a known beta-catenin/T cell factor-4 ( Tcf-4) downstream target gene, is up-regulated in tumors and in cells with increased motility such as muscle cells. OPN promoter sequence contains binding sites for Sp1, glucocorticoid receptor, E-box-binding factors, octamer motif-binding protein, c-Myc, and other transcription factors. Previously we have shown that TIS7 regulates the OPN expression through the inhibition of the Sp1-activating effects. Here we show that TIS7 has the capacity to inhibit OPN expression also through Lef-1, the second identified OPN regulatory element. TIS7 has the capacity to down-regulate beta-catenin/Tcf-4 transcriptional activity. TIS7 homologous deletion in mouse embryonic fibroblasts increased not only the TOPflash reporter gene transcriptional activity but also the expression of c-Myc and OPN. Furthermore, we show that TIS7 overexpression leads to the beta-catenin interaction with enzymatically active histone deacetylases. We propose that TIS7 down-regulates the beta-catenin/Tcf-4 transcriptional activity via its interaction with histone deacetylase-containing complex thereby inhibiting the expression of beta-catenin downstream target genes such as c-Myc and OPN. We hypothesize that TIS7 as a negative regulator of transcriptional activity represses expression of OPN and beta-catenin/Tcf-4 target genes, which are involved in myogenesis, muscle maintenance, and regeneration in a histone deacetylase dependent manner.	Med Univ Innsbruck, Div Cell Biol, Bioctr, A-6020 Innsbruck, Austria; Inst Mol Pathol, A-1030 Vienna, Austria; Med Univ Innsbruck, Div Mol Biol, Bioctr, A-6020 Innsbruck, Austria	Medical University of Innsbruck; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Medical University of Innsbruck	Huber, LA (corresponding author), Med Univ Innsbruck, Div Cell Biol, Bioctr, Fritz Pregl Str 3, A-6020 Innsbruck, Austria.	Lukas.A.Huber@uibk.ac.at	Huber, Lukas Alfons/AAM-3499-2021	Huber, Lukas Alfons/0000-0003-1116-2120				ARENANDER AT, 1989, J NEUROSCI RES, V24, P107, DOI 10.1002/jnr.490240115; Bartl S, 1997, MOL CELL BIOL, V17, P5033, DOI 10.1128/MCB.17.9.5033; Bidder M, 2002, J BIOL CHEM, V277, P44485, DOI 10.1074/jbc.M206235200; Billin AN, 2000, MOL CELL BIOL, V20, P6882, DOI 10.1128/MCB.20.18.6882-6890.2000; BTAJBAKHSH S, 1998, DEVELOPMENT, V125, P4155; Charge SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; El-Tanani M, 2001, J BIOL CHEM, V276, P41675, DOI 10.1074/jbc.M103966200; El-Tanani M, 2004, J BIOL CHEM, V279, P20794, DOI 10.1074/jbc.M311131200; ELTANANI M, 2001, CANCER RES, V61, P6519; ELTANANI MK, 2001, ONCOOGENE, V20, P1973; HASHIMOTO Y, 1990, MOL CARCINOGEN, V3, P302, DOI 10.1002/mc.2940030511; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hirata A, 2003, AM J PATHOL, V163, P203, DOI 10.1016/S0002-9440(10)63644-9; Kim HJ, 2002, J CELL BIOCHEM, V87, P93, DOI 10.1002/jcb.10280; Labalette C, 2004, MOL CELL BIOL, V24, P10689, DOI 10.1128/MCB.24.24.10689-10702.2004; Lechner T, 1996, BBA-PROTEIN STRUCT M, V1296, P181, DOI 10.1016/0167-4838(96)00069-6; Levy L, 2004, MOL CELL BIOL, V24, P3404, DOI 10.1128/MCB.24.8.3404-3414.2004; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Medico E, 2001, CANCER RES, V61, P5861; Mi ZY, 2004, J BIOL CHEM, V279, P46659, DOI 10.1074/jbc.M407952200; Miyagishi M, 2000, J BIOL CHEM, V275, P35170, DOI 10.1074/jbc.C000258200; Muller T, 2002, EXP CELL RES, V280, P119, DOI 10.1006/excr.2002.5630; Nagai S, 2001, INT IMMUNOL, V13, P367, DOI 10.1093/intimm/13.3.367; Polesskaya A, 2003, CELL, V113, P841, DOI 10.1016/S0092-8674(03)00437-9; Renault MA, 2003, CIRC RES, V93, P674, DOI 10.1161/01.RES.0000094747.05021.62; Rittling SR, 1997, CELL GROWTH DIFFER, V8, P1061; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; Standal T, 2004, EXP ONCOL, V26, P179; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Vadivelu SK, 2004, MOL CELL BIOL, V24, P3514, DOI 10.1128/MCB.24.8.3514-3525.2004; VARNUM BC, 1989, ONCOGENE, V4, P1263; Vietor I, 2002, EMBO J, V21, P4621, DOI 10.1093/emboj/cdf461; Vietor I, 2001, EMBO REP, V2, P306, DOI 10.1093/embo-reports/kve066; Wai PY, 2004, J SURG RES, V121, P228, DOI 10.1016/j.jss.2004.03.028; Wang DY, 2000, ONCOGENE, V19, P5801, DOI 10.1038/sj.onc.1203917; Wei Y, 2003, J BIOL CHEM, V278, P5188, DOI 10.1074/jbc.M207216200; Wick N, 2004, J MOL BIOL, V336, P589, DOI 10.1016/j.jmb.2003.11.060; Wolf D, 2002, J BIOL CHEM, V277, P25562, DOI 10.1074/jbc.M201196200; Yin JL, 2001, IMMUNOL CELL BIOL, V79, P213, DOI 10.1046/j.1440-1711.2001.01002.x; Zammit PS, 2004, J CELL BIOL, V166, P347, DOI 10.1083/jcb.200312007	44	22	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					39795	39801		10.1074/jbc.M509836200	http://dx.doi.org/10.1074/jbc.M509836200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16204248	hybrid			2022-12-25	WOS:000233461300016
J	Habibian, R; Dzioba, J; Barrett, J; Galperin, MY; Loewen, PC; Dibrov, P				Habibian, R; Dzioba, J; Barrett, J; Galperin, MY; Loewen, PC; Dibrov, P			Functional analysis of conserved polar residues in Vc-NhaD, Na+/H+ antiporter of Vibrio cholerae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BACILLUS-SUBTILIS; PH; MEMBRANE; PROTEINS; MECHANISM; SODIUM; HISTIDINE-226; EXPRESSION; EXCHANGE	Vc-NhaD is a Na+/H+ antiporter from Vibrio cholerae with a sharp maximum of activity at pH similar to 8.0. NhaD homologues are present in many bacteria as well as in higher plants. However, very little is known about structure-function relations in NhaD-type antiporters. In this work 14 conserved polar residues associated with putative transmembrane segments of Vc-NhaD have been screened for their possible role in the ion translocation and pH regulation of Vc-NhaD. Substitutions S150A, D154G, N155A, N189A, D199A, T201A, T202A, S389A, N394G, S428A, and S431A completely abolished the Vc-NhaD-mediated Na+-dependent H+ transfer in inside-out membrane vesicles. Substitutions T157A and S428A caused a significant increase of apparent Km values for alkali cations, with the K-m for Li+ elevated more than that for Na+, indicating that Thr-157 and Ser-428 are involved in alkali cation binding/translocation. Of six conserved His residues, mutation of only His-93 and His-210 affected the Na+(Li+)/H+ antiport, resulting in an acidic shift of its pH profile, whereas H93A also caused a 7-fold increase of apparent K-m for Na+ without affecting the Km for Li+. These data suggest that side chains of His-93 and His-210 are involved in proton binding and that His-93 also contributes to the binding of Na+ ions during the catalytic cycle. These 15 residues are clustered in three distinct groups, two located at opposite sides of the membrane, presumably facilitating the access of substrate ions to the third group, a putative catalytic site in the middle of lipid bilayer. The distribution of these key residues in Vc-NhaD molecule also suggests that transmembrane segments IV, V, VI, X, XI, and XII are situated close to one another, creating a transmembrane relay of charged/polar residues involved in the attraction, coordination, and translocation of transported cations.	Univ Manitoba, Dept Microbiol, Winnipeg, MB R3T 2N2, Canada; NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA	University of Manitoba; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Dibrov, P (corresponding author), Univ Manitoba, Dept Microbiol, Ft Garry Campus,Rm 425 Buller Bldg, Winnipeg, MB R3T 2N2, Canada.	dibrovp@ms.umanitoba.ca	Galperin, Michael Y./B-5859-2013	Galperin, Michael Y./0000-0002-2265-5572	Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Busch W, 2002, CRIT REV BIOCHEM MOL, V37, P287, DOI 10.1080/10409230290771528; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; DE la Vieja A, 2000, PHYSIOL REV, V80, P1083, DOI 10.1152/physrev.2000.80.3.1083; Dibrov P, 2004, J MOL MICROB BIOTECH, V8, P1, DOI 10.1159/000082075; DIBROV PA, 1993, FEBS LETT, V336, P525, DOI 10.1016/0014-5793(93)80869-V; DIBROV PA, 1993, FEBS LETT, V336, P530, DOI 10.1016/0014-5793(93)80870-Z; Dzioba J, 2002, MOL CELL BIOCHEM, V229, P119, DOI 10.1023/A:1017932829927; Galili L, 2002, BIOCHEMISTRY-US, V41, P609, DOI 10.1021/bi011655v; GERCHMAN Y, 1993, P NATL ACAD SCI USA, V90, P1212, DOI 10.1073/pnas.90.4.1212; Gerchman Y, 2001, BIOCHEMISTRY-US, V40, P3403, DOI 10.1021/bi002669o; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; Harding MM, 2004, ACTA CRYSTALLOGR D, V60, P849, DOI 10.1107/S0907444904004081; Hase CC, 2001, MICROBIOL MOL BIOL R, V65, P353, DOI 10.1128/MMBR.65.3.353-370.2001; Heidelberg JF, 2000, NATURE, V406, P477, DOI 10.1038/35020000; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Hunte C, 2005, NATURE, V435, P1197, DOI 10.1038/nature03692; INOUE H, 1995, FEBS LETT, V363, P264, DOI 10.1016/0014-5793(95)00331-3; Jockel P, 2000, BIOCHEMISTRY-US, V39, P2307, DOI 10.1021/bi992261v; Kaim G, 1997, BIOCHEMISTRY-US, V36, P9185, DOI 10.1021/bi970831q; Kosono S, 2000, J BACTERIOL, V182, P898, DOI 10.1128/JB.182.4.898-904.2000; Krulwich TA, 2001, J MOL MICROB BIOTECH, V3, P237; Noumi T, 1997, J BIOCHEM-TOKYO, V121, P661; Nozaki K, 1998, BBA-BIOMEMBRANES, V1369, P213, DOI 10.1016/S0005-2736(97)00223-X; Olami Y, 1997, J BIOL CHEM, V272, P1761, DOI 10.1074/jbc.272.3.1761; Ostroumov E, 2002, BBA-BIOMEMBRANES, V1564, P99, DOI 10.1016/S0005-2736(02)00407-8; Padan E, 2004, BBA-BIOENERGETICS, V1658, P2, DOI 10.1016/j.bbabio.2004.04.018; PADAN E, 1989, J BIOL CHEM, V264, P20297; PADAN E, 1994, BBA-BIOENERGETICS, V1185, P129, DOI 10.1016/0005-2728(94)90204-6; Padan E, 2001, BBA-BIOENERGETICS, V1505, P144, DOI 10.1016/S0005-2728(00)00284-X; PADAN E, 1992, ALKALI CATION TRANSP, P3; PINNER E, 1992, J BIOL CHEM, V267, P11064; PINNER E, 1993, J BIOL CHEM, V268, P1729; PINNER E, 1994, J BIOL CHEM, V269, P26274; Pragai Z, 2001, J BACTERIOL, V183, P2505, DOI 10.1128/JB.183.8.2505-2515.2001; Quick M, 1996, EUR J BIOCHEM, V239, P732, DOI 10.1111/j.1432-1033.1996.0732u.x; Rahlfs S, 1997, FEBS LETT, V404, P269, DOI 10.1016/S0014-5793(97)00088-4; Rimon A, 2002, BIOCHEMISTRY-US, V41, P14897, DOI 10.1021/bi0261342; Rimon A, 1998, J BIOL CHEM, V273, P26470, DOI 10.1074/jbc.273.41.26470; RIMON A, 1995, J BIOL CHEM, V270, P26813, DOI 10.1074/jbc.270.45.26813; Southworth TW, 2001, J BACTERIOL, V183, P5896, DOI 10.1128/JB.183.20.5896-5903.2001; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289; TAGLICHT D, 1993, J BIOL CHEM, V268, P5382; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; Tzubery T, 2004, J BIOL CHEM, V279, P3265, DOI 10.1074/jbc.M309021200; Zhang YM, 1999, P NATL ACAD SCI USA, V96, P1710, DOI 10.1073/pnas.96.4.1710	47	21	25	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39637	39643		10.1074/jbc.M509328200	http://dx.doi.org/10.1074/jbc.M509328200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16186100	hybrid			2022-12-25	WOS:000233362200087
J	Staruschenko, A; Pochynyuk, O; Stockand, JD				Staruschenko, A; Pochynyuk, O; Stockand, JD			Regulation of epithelial Na+ channel activity by conserved serine/threonine switches within sorting signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOHYPOALDOSTERONISM TYPE-I; PHOSPHOINOSITIDE 3-OH KINASE; SODIUM-CHANNEL; GAMMA-ENAC; ENDOCYTIC PATHWAY; LIDDLES SYNDROME; CYSTIC-FIBROSIS; NEDD4; CLATHRIN; ACTIVATION	The PY and YXX phi motifs are canonical sorting signals involved in trafficking. Nedd4-2 and the mu 2-subunit of the AP-2 complex target these motifs to facilitate internalization. Epithelial Na+ channel (ENaC) subunits contain both motifs in their cytosolic COOH termini where they overlap ((S/T) PPPXYX(S/T)phi). Just preceding the PY and embedded within the YXX phi motifs are conserved serine/threonine. We test here whether these conserved Ser/Thr modulate ENaC activity by influencing the function of the internalization domains. We find that co-expression of dominant-negative dynamin (K44A) with ENaC increases channel activity. Conversely, coexpression of Nedd4-2 and epsin with ENaC decrease activity. Alanine substitution of the conserved Thr(628) preceding the PY motif in gamma-mENaC had no effect on basal activity. Channels with this mutation, however, responded to K44A and epsin but not Nedd4-2. Similarly, mutation of the proline repeat in the PY motif of gamma-mENaC disrupted only Nedd4-2 regulation having no effect on regulation by K44A and epsin. Alanine substitution of the conserved Thr within the YXX phi motif of gamma-mENaC (T635A) increased basal activity. Channels containing this mutation responded to Nedd4-2 but not K44A and epsin. Channels containing the T635(D/E) substitution in gamma-mENaC did not have increased basal activity and responded to Nedd4-2 but not K44A. The double mutant T628A, T635A did not respond to Nedd4-2 or K44A. Mutation of Thr(628) and Thr(635) also disrupted ENaC precipitation with the mu(2)-subunit of the AP-2 complex. Moreover, the YXX phi motif, independent of the PY motif, was sufficient to target degradation with T635A disrupting this effect. These results demonstrate that the overlapping PY and YXX phi motifs in ENaC are, in some instances, capable of independent function and that the Ser/Thr just preceding and within these domains impact this function.	Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Stockand, JD (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Physiol, 7703 Floyd Curl Dr,7756, San Antonio, TX 78229 USA.	stockand@uthscsa.edu		Staruschenko, Alexander/0000-0002-5190-8356; Stockand, James/0000-0002-3817-4319	NIDDK NIH HHS [R01-DK59594] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059594] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barker PM, 1998, J CLIN INVEST, V102, P1634, DOI 10.1172/JCI3971; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; Bonny O, 2000, KIDNEY INT, V57, P1313, DOI 10.1046/j.1523-1755.2000.00968.x; Bonny O, 1999, J CLIN INVEST, V104, P967, DOI 10.1172/JCI6821; Booth RE, 2003, J BIOL CHEM, V278, P41367, DOI 10.1074/jbc.M305400200; Booth RE, 2003, AM J PHYSIOL-RENAL, V284, pF938, DOI 10.1152/ajprenal.00373.2002; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Chen H, 2005, P NATL ACAD SCI USA, V102, P2766, DOI 10.1073/pnas.0409719102; Chigaev A, 2001, AM J PHYSIOL-RENAL, V280, pF1030, DOI 10.1152/ajprenal.2001.280.6.F1030; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Estevez R, 2001, NATURE, V414, P558, DOI 10.1038/35107099; Fotia AB, 2004, J BIOL CHEM, V279, P28930, DOI 10.1074/jbc.M402820200; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Geller DS, 1998, NAT GENET, V19, P279, DOI 10.1038/966; Hendron E, 2002, MOL BIOL CELL, V13, P3042, DOI 10.1091/mbc.E02-05-0260; Hendron E, 2002, J BIOL CHEM, V277, P34480, DOI 10.1074/jbc.M204615200; Henry PC, 2003, J BIOL CHEM, V278, P20019, DOI 10.1074/jbc.M211153200; Kanelis V, 2001, NAT STRUCT BIOL, V8, P407, DOI 10.1038/87562; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kosolapov A, 2004, NEURON, V44, P295, DOI 10.1016/j.neuron.2004.09.011; Lifton RP, 2001, CELL, V104, P545, DOI 10.1016/S0092-8674(01)00241-0; Mall M, 1999, AM J PHYSIOL-GASTR L, V277, pG709, DOI 10.1152/ajpgi.1999.277.3.G709; Mall M, 2004, NAT MED, V10, P487, DOI 10.1038/nm1028; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; Rossier BC, 2002, ANNU REV PHYSIOL, V64, P877, DOI 10.1146/annurev.physiol.64.082101.143243; Rotin D, 1998, CURR TOP MICROBIOL, V228, P115; Rotin D, 2001, AM J PHYSIOL-RENAL, V281, pF391, DOI 10.1152/ajprenal.2001.281.3.F391; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; Shi HK, 2002, J BIOL CHEM, V277, P13539, DOI 10.1074/jbc.M111717200; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; Snyder PM, 2002, ENDOCR REV, V23, P258, DOI 10.1210/er.23.2.258; Snyder PM, 2002, J BIOL CHEM, V277, P5, DOI 10.1074/jbc.C100623200; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Staruschenko A, 2004, J BIOL CHEM, V279, P49989, DOI 10.1074/jbc.M409812200; Staruschenko A, 2004, J BIOL CHEM, V279, P37771, DOI 10.1074/jbc.M402176200; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Staub O, 2000, KIDNEY INT, V57, P809, DOI 10.1046/j.1523-1755.2000.00919.x; Thomas MA, 2003, J CELL SCI, V116, P2213, DOI 10.1242/jcs.00440; Tong QS, 2004, J BIOL CHEM, V279, P22654, DOI 10.1074/jbc.M401004200; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; Wendland B, 2002, NAT REV MOL CELL BIO, V3, P971, DOI 10.1038/nrm970; White S, 1998, J BIOL CHEM, V273, P14355, DOI 10.1074/jbc.273.23.14355	46	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39161	39167		10.1074/jbc.M509608200	http://dx.doi.org/10.1074/jbc.M509608200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16203727	hybrid			2022-12-25	WOS:000233362200031
J	Chen, CS; Weng, SC; Tseng, PH; Lin, HP; Chen, CS				Chen, CS; Weng, SC; Tseng, PH; Lin, HP; Chen, CS			Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LEUKEMIA-CELLS; BREAST-CANCER CELLS; PROTEIN PHOSPHATASE-1; IN-VIVO; REVERSIBLE ACETYLATION; KINASE; ACTIVATION; PP1; PHOSPHORYLATION; APOPTOSIS	Despite advances in understanding the role of histone deacetylases (HDACs) in tumorigenesis, the mechanism by which HDAC inhibitors mediate antineoplastic effects remains elusive. Modifications of the histone code alone are not sufficient to account for the antitumor effect of HDAC inhibitors. The present study demonstrates a novel histone acetylation-independent mechanism by which HDAC inhibitors cause Akt dephosphorylation in U87MG glioblastoma and PC-3 prostate cancer cells by disrupting HDAC-protein phosphatase 1 (PP1) complexes. Of four HDAC inhibitors examined, trichostatin A (TSA) and HDAC42 exhibit the highest activity in down-regulating phospho-Akt, followed by suberoylanilide hydroxamic acid, whereas MS-275 shows only a marginal effect at 5 mu M. This differential potency parallels the respective activities in inducing tubulin acetylation, a non-histone substrate for HDAC6. Evidence indicates that this Akt dephosphorylation is not mediated through deactivation of upstream kinases or activation of downstream phosphatases. However, the effect of TSA on phospho-Akt can be rescued by PP1 inhibition but not that of protein phosphatase 2A. Immunochemical analyses reveal that TSA blocks specific interactions of PP1 with HDACs 1 and 6, resulting in increased PP1-Akt association. Moreover, we used isozyme-specific small interfering RNAs to confirm the role of HDACs 1 and 6 as key mediators in facilitating Akt dephosphorylation. The selective action of HDAC inhibitors on HDAC-PP1 complexes represents the first example of modulating specific PP1 interactions by small molecule agents. From a clinical perspective, identification of this PP1-facilitated dephosphorylation mechanism underscores the potential use of HDAC inhibitors in lowering the apoptosis threshold for other therapeutic agents through Akt down-regulation.	Ohio State Univ, Coll Pharm, Div Med Chem, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Chen, CS (corresponding author), Ohio State Univ, Coll Pharm, Div Med Chem, 336 Parks Hall,500 12th Ave, Columbus, OH 43210 USA.	chen.844@osu.edu			NCI NIH HHS [CA-94829, CA-112250] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094829, R01CA112250] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bali P, 2004, CLIN CANCER RES, V10, P4991, DOI 10.1158/1078-0432.CCR-04-0210; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Brinkmann H, 2001, J BIOL CHEM, V276, P22491, DOI 10.1074/jbc.M100206200; Brush MH, 2004, J BIOL CHEM, V279, P7685, DOI 10.1074/jbc.M310997200; Canettieri G, 2003, NAT STRUCT BIOL, V10, P175, DOI 10.1038/nsb895; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Ching TT, 2001, J BIOL CHEM, V276, P43932, DOI 10.1074/jbc.M105159200; Cohen PTW, 2002, J CELL SCI, V115, P241; Connor JH, 1999, J BIOL CHEM, V274, P22366, DOI 10.1074/jbc.274.32.22366; Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Fuino L, 2003, MOL CANCER THER, V2, P971; GEORGE P, 2004, BLOOD, V105, P1768; Gupta V, 1997, J MED CHEM, V40, P3199, DOI 10.1021/jm960873x; Haggarty SJ, 2003, P NATL ACAD SCI USA, V100, P4389, DOI 10.1073/pnas.0430973100; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Johnstone RW, 2003, CANCER CELL, V4, P13, DOI 10.1016/S1535-6108(03)00165-X; Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5; Kovacs JJ, 2005, MOL CELL, V18, P601, DOI 10.1016/j.molcel.2005.04.021; Kulp SK, 2004, CANCER RES, V64, P1444, DOI 10.1158/0008-5472.CAN-03-2396; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lim YM, 2002, J BIOL CHEM, V277, P12735, DOI 10.1074/jbc.M111011200; Liu W, 2003, CELL DEATH DIFFER, V10, P772, DOI 10.1038/sj.cdd.4401238; Lu Q, 2005, J MED CHEM, V48, P5530, DOI 10.1021/jm0503749; Lu Q, 2004, J MED CHEM, V47, P467, DOI 10.1021/jm0303655; Maggio SC, 2004, CANCER RES, V64, P2590, DOI 10.1158/0008-5472.CAN-03-2631; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; Manfroid I, 2001, MOL ENDOCRINOL, V15, P625, DOI 10.1210/me.15.4.625; Marks PA, 2003, CURR OPIN PHARMACOL, V3, P344, DOI 10.1016/S1471-4892(03)00084-5; Matsuoka Y, 2003, BRIT J PHARMACOL, V138, P1303, DOI 10.1038/sj.bjp.0705182; Matsuyama A, 2002, EMBO J, V21, P6820, DOI 10.1093/emboj/cdf682; Miller TA, 2003, J MED CHEM, V46, P5097, DOI 10.1021/jm0303094; Mitsuhashi S, 2003, J BIOL CHEM, V278, P82, DOI 10.1074/jbc.M208888200; Nimmanapalli R, 2003, BLOOD, V101, P3236, DOI 10.1182/blood-2002-08-2675; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; Rahmani M, 2003, CANCER RES, V63, P8420; Salinas M, 2000, MOL CELL NEUROSCI, V15, P156, DOI 10.1006/mcne.1999.0813; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Schubert KM, 2000, J BIOL CHEM, V275, P13330, DOI 10.1074/jbc.275.18.13330; Solit DB, 2003, CANCER RES, V63, P2139; Thiagalingam S, 2003, ANN NY ACAD SCI, V983, P84, DOI 10.1111/j.1749-6632.2003.tb05964.x; Xu WP, 2003, CANCER RES, V63, P7777; Yellaturu CR, 2002, J BIOL CHEM, V277, P40148, DOI 10.1074/jbc.M206376200; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; Zhang Y, 2003, EMBO J, V22, P1168, DOI 10.1093/emboj/cdg115	45	205	211	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38879	38887		10.1074/jbc.M505733200	http://dx.doi.org/10.1074/jbc.M505733200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16186112	hybrid			2022-12-25	WOS:000233239800090
J	Hoffmann, J; Feng, Y; vom Hagen, F; Hillenbrand, A; Lin, J; Erber, R; Vajkoczy, P; Gourzoulidou, E; Waldmann, H; Giannis, A; Wolburg, H; Shani, M; Jaeger, V; Weich, HA; Preissner, KT; Hoffmann, S; Deutsch, U; Hammes, HP				Hoffmann, J; Feng, Y; vom Hagen, F; Hillenbrand, A; Lin, J; Erber, R; Vajkoczy, P; Gourzoulidou, E; Waldmann, H; Giannis, A; Wolburg, H; Shani, M; Jaeger, V; Weich, HA; Preissner, KT; Hoffmann, S; Deutsch, U; Hammes, HP			Endothelial survival factors and spatial completion, but not pericyte coverage of retinal capillaries, determine vessel plasticity	FASEB JOURNAL			English	Article						angiogenesis; vessel maturation; retinopathy	EXPERIMENTAL DIABETIC-RETINOPATHY; RECEPTOR TYROSINE KINASES; GROWTH-FACTOR; BLOOD-VESSELS; PDGF-B; MICROVASCULAR PERICYTES; VASCULAR PATTERNS; MESSENGER-RNA; TIE2 RECEPTOR; IN-VITRO	Pericyte loss and capillary regression are characteristic for incipient diabetic retinopathy. Pericyte recruitment is involved in vessel maturation, and ligand-receptor systems contributing to pericyte recruitment are survival factors for endothelial cells in pericyte-free in vitro systems. We studied pericyte recruitment in relation to the susceptibility toward hyperoxia-induced vascular remodeling using the pericyte reporter X-LacZ mouse and the mouse model of retinopathy of prematurity(ROP). Pericytes were found in close proximity to vessels, both during formation of the superficial and the deep capillary layers. When exposure of mice to the ROP was delayed by 24 h, i.e., after the deep retinal layer had formed [at postnatal (p) day 8], preretinal neovascularizations were substantially diminished at p18. Mice with a delayed ROP exposure had 50% reduced avascular zones. Formation of the deep capillary layers at p8 was associated with a combined up-regulation of angiopoietin-1 and PDGF-B, while VEGF was almost unchanged during the transition from a susceptible to a resistant capillary network. Inhibition of Tie-2 function either by soluble Tie-2 or by a sulindac analog, an inhibitor of Tie-2 phosphorylation, resensitized retinal vessels to neovascularizations due to a reduction of the deep capillary network. Inhibition of Tie-2 function had no effect on pericyte recruitment. Our data indicate that the final maturation of the retinal vasculature and its resistance to regressive signals such as hyperoxia depend on the completion of the multilayer structure, in particular the deep capillary layers, and are independent of the coverage by pericytes.	Univ Giessen, Med Clin & Policlin 3, D-35392 Giessen, Germany; Heidelberg Univ, Med Clin 5, Fac Clin Med, D-68167 Mannheim, Germany; Heidelberg Univ, Dept Neurosurg, Fac Med, D-68167 Mannheim, Germany; Univ Dortmund, Fachbereich Organ Chem 3, D-44227 Dortmund, Germany; Max Planck Inst Mol Physiol, Dept Biol Chem, D-44227 Dortmund, Germany; Univ Leipzig, Inst Organ Chem, D-04103 Leipzig, Germany; Univ Tubingen, Inst Pathol, D-72076 Tubingen, Germany; Volcani Ctr, Inst Anim Sci, Bet Dagan, Israel; Gesell Biotechnol Forsch mbH, Dept Cell Culture Technol, D-38124 Braunschweig, Germany; Gesell Biotechnol Forsch mbH, Dept Gene Regulat & Differentiat, D-38124 Braunschweig, Germany; Univ Giessen, Inst Biochem, Fac Med, D-35392 Giessen, Germany; Heidelberg Univ, Med Res Ctr, Univ Clin Mannheim, Fac Med, D-68167 Mannheim, Germany; Univ Munster, Max Planck Inst Vasc Biol, Inst Cell Biol, ZMBE, Munster, Germany; Univ Bern, Theodor Kocher Inst, CH-3012 Bern, Switzerland	Justus Liebig University Giessen; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Dortmund University of Technology; Max Planck Society; Leipzig University; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH; Gesellschaft fur Biotechnologische Forschung mbH; Gesellschaft fur Biotechnologische Forschung mbH; Justus Liebig University Giessen; Ruprecht Karls University Heidelberg; Max Planck Society; University of Munster; University of Bern	Hammes, HP (corresponding author), Heidelberg Univ, Klinikum Mannheim, Dept 5, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.	hans-peter.hammes@med5.ma.uni-heidelberg.de	Hammes, Hans-Peter/S-3719-2019; Erber, Ralf/B-6790-2008; Erber, Ralf/AAF-3002-2020	Deutsch, Urban/0000-0003-4265-6262				BATTEGAY EJ, 1994, J CELL BIOL, V125, P917, DOI 10.1083/jcb.125.4.917; Beitz J G, 1992, EXS, V61, P85; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Benjamin LE, 1998, DEVELOPMENT, V125, P1591; BOADO RJ, 1994, J NEUROSCI RES, V39, P430, DOI 10.1002/jnr.490390410; Bondjers C, 2003, AM J PATHOL, V162, P721, DOI 10.1016/S0002-9440(10)63868-0; Castellon R, 2002, EXP EYE RES, V74, P523, DOI 10.1006/exer.2001.1161; COGAN DG, 1961, ARCH OPHTHALMOL-CHIC, V66, P366, DOI 10.1001/archopht.1961.00960010368014; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DENOFRIO D, 1989, J CELL BIOL, V109, P191, DOI 10.1083/jcb.109.1.191; Enge M, 2002, EMBO J, V21, P4307, DOI 10.1093/emboj/cdf418; ENGERMAN RL, 1976, T AM ACAD OPHTHALMOL, V81, pO710; ENGERMAN RL, 1987, DIABETES, V36, P808, DOI 10.2337/diabetes.36.7.808; ENGERMAN RL, 1989, DIABETES, V38, P1203, DOI 10.2337/diabetes.38.10.1203; Erber R, 2003, FASEB J, V17, P338, DOI 10.1096/fj.03-0271fje; ERBER WN, 1993, PATHOLOGY, V25, P63, DOI 10.3109/00313029309068904; Faude F, 2001, J NEUROCYTOL, V30, P379; Fiedler U, 2003, J BIOL CHEM, V278, P1721, DOI 10.1074/jbc.M208550200; Fruttiger M, 2002, INVEST OPHTH VIS SCI, V43, P522; Gao GQ, 2002, DIABETES, V51, P1218, DOI 10.2337/diabetes.51.4.1218; Gee MS, 2003, AM J PATHOL, V162, P183, DOI 10.1016/S0002-9440(10)63809-6; Gerber HP, 1999, DEVELOPMENT, V126, P1149; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; Gerhardt H, 2003, CELL TISSUE RES, V314, P15, DOI 10.1007/s00441-003-0745-x; Gourzoulidou E, 2005, CHEMBIOCHEM, V6, P527, DOI 10.1002/cbic.200400192; Hackett SF, 2000, J CELL PHYSIOL, V184, P275, DOI 10.1002/1097-4652(200009)184:3<275::AID-JCP1>3.3.CO;2-Z; HAMMES HP, 1995, DIABETOLOGIA, V38, P269, DOI 10.1007/s001250050280; Hammes HP, 2004, DIABETES, V53, P1104, DOI 10.2337/diabetes.53.4.1104; Hammes HP, 2002, DIABETES, V51, P3107, DOI 10.2337/diabetes.51.10.3107; Hammes HP, 1996, DIABETOLOGIA, V39, P251; HAMMES HP, 1991, P NATL ACAD SCI USA, V88, P11555, DOI 10.1073/pnas.88.24.11555; Hellstrom M, 2001, J CELL BIOL, V153, P543, DOI 10.1083/jcb.153.3.543; Hirschi KK, 1999, CIRC RES, V84, P298, DOI 10.1161/01.RES.84.3.298; Kim I, 2000, CIRC RES, V86, P952, DOI 10.1161/01.RES.86.9.952; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; KOYAMA N, 1994, J CELL PHYSIOL, V158, P1, DOI 10.1002/jcp.1041580102; KUWABARA T, 1960, ARCH OPHTHALMOL-CHIC, V64, P904, DOI 10.1001/archopht.1960.01840010906012; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; MARX M, 1994, J CLIN INVEST, V93, P131, DOI 10.1172/JCI116936; NEHLS V, 1992, CELL TISSUE RES, V270, P469, DOI 10.1007/BF00645048; NEHLS V, 1991, J CELL BIOL, V113, P147, DOI 10.1083/jcb.113.1.147; ORLIDGE A, 1987, J CELL BIOL, V105, P1455, DOI 10.1083/jcb.105.3.1455; Ozerdem U, 2001, DEV DYNAM, V222, P218, DOI 10.1002/dvdy.1200; Papapetropoulos A, 1999, LAB INVEST, V79, P213; Reynolds JD, 2001, PEDIATR DRUGS, V3, P263, DOI 10.2165/00128072-200103040-00003; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Seo MS, 2000, AM J PATHOL, V157, P995, DOI 10.1016/S0002-9440(10)64612-3; Shih SC, 2003, P NATL ACAD SCI USA, V100, P15859, DOI 10.1073/pnas.2136855100; Smith A, 2002, NAT REV DRUG DISCOV, V1, P8, DOI 10.1038/nrd716; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; Stalmans I, 2002, J CLIN INVEST, V109, P327, DOI 10.1172/jci0214362; Sundberg C, 2002, LAB INVEST, V82, P387, DOI 10.1038/labinvest.3780433; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; Thommen R, 1997, J CELL BIOCHEM, V64, P403; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Tidhar A, 2001, DEV DYNAM, V220, P60, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1089>3.0.CO;2-X; Uemura A, 2002, J CLIN INVEST, V110, P1619, DOI 10.1172/JCI200215621	61	32	34	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2035	+		10.1096/fj.04-2109fje	http://dx.doi.org/10.1096/fj.04-2109fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16215210				2022-12-25	WOS:000232991100024
J	Wasilewska-Sampaio, AP; Silveira, MS; Holub, O; Goecking, R; Gomes, FCA; Neto, VM; Linden, R; Ferreira, ST; De Felice, FG				Wasilewska-Sampaio, AP; Silveira, MS; Holub, O; Goecking, R; Gomes, FCA; Neto, VM; Linden, R; Ferreira, ST; De Felice, FG			Neuritogenesis and neuronal differentiation promoted by 2,4-dinitrophenol, a novel anti-amyloidogenic compound	FASEB JOURNAL			English	Article						DNP; central neurons; cAMP; neuritogenesis; tau; differentiation	MICROTUBULE-ASSOCIATED PROTEIN; NERVE GROWTH-FACTOR; TAU-ANTISENSE OLIGONUCLEOTIDES; SPINAL-CORD-INJURY; ALZHEIMERS-DISEASE; CYCLIC-AMP; PC12 CELLS; HIPPOCAMPAL-NEURONS; AXONAL REGENERATION; FUNCTIONAL RECOVERY	Neurite outgrowth is a critical event in neuronal development, formation, and remodeling of synapses, response to injury, and regeneration. We examined the effects of 2,4-dinitrophenol (DNP), a recently described blocker of the aggregation and neurotoxicity of the beta-amyloid peptide, on neurite elongation of central neurons. Morphometric analysis of rat embryo hippocampal and cortical neuronal cultures showed that neurite outgrowth was stimulated by DNP. This effect was accompanied by increases in the neuronal levels of the microtubule-associated protein tau and of cyclic adenosine 3',5' monophosphate (cAMP). DNP also promoted cAMP accumulation, increased tau level, neurite outgrowth, and neuronal differentiation in the mouse neuroblastoma cell line N2A. We show that DNP-induced differentiation requires activation of the extracellular signal-regulated kinase (ERK). The finding that DNP promotes neuritogenesis and neuronal differentiation suggests that, in addition to its anti-amyloidogenic actions, it may be a useful lead compound in the development of novel therapeutic approaches targeting neurite dystrophy and synaptic dysfunction in neurodegenerative pathologies such as Alzheimer's disease.	Univ Fed Rio de Janeiro, Inst Bioquim Med, Programa Bioquim & Biofis Celular, Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Dept Anat, Inst Ciencias Biomed, Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro	Ferreira, ST (corresponding author), Univ Fed Rio de Janeiro, Inst Bioquim Med, Programa Bioquim & Biofis Celular, Rio De Janeiro, Brazil.	ferreira@bioqmed.ufrj.br	Linden, Rafael/F-2275-2011; Ferreira, Sergio/AAZ-1576-2020; Moura-Neto, VIVALDO/V-9913-2019; Gomes, Flavia/AAX-6354-2021; De Felice, Fernanda G/M-1074-2017; Silveira, Mariana/M-4865-2013; Gomes, Flavia/C-5383-2013	Linden, Rafael/0000-0003-3287-336X; Ferreira, Sergio/0000-0001-7160-9866; Moura-Neto, VIVALDO/0000-0002-6266-043X; Silveira, Mariana/0000-0002-0496-1517; Gomes, Flavia/0000-0003-2966-0638				Ambrosini A, 2000, MOL BRAIN RES, V75, P54, DOI 10.1016/S0169-328X(99)00294-6; Ammer H, 1997, NEUROSCI LETT, V230, P143, DOI 10.1016/S0304-3940(97)00495-3; Avila J, 2004, PHYSIOL REV, V84, P361, DOI 10.1152/physrev.00024.2003; AVILA J, 1994, INT J DEV BIOL, V38, P13; Bhatt DH, 2004, SCIENCE, V305, P254, DOI 10.1126/science.1098439; BLACK MM, 1994, PROG BRAIN RES, V102, P61; BOTELHO LHP, 1988, J BIOL CHEM, V263, P5301; BRE MH, 1990, CELL MOTIL CYTOSKEL, V15, P88, DOI 10.1002/cm.970150205; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; CACERES A, 1991, J NEUROSCI, V11, P1515; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; Cai D, 2001, J NEUROSCI, V21, P4731, DOI 10.1523/JNEUROSCI.21-13-04731.2001; Chalasani SH, 2003, J NEUROSCI, V23, P4601; Christensen AE, 2003, J BIOL CHEM, V278, P35394, DOI 10.1074/jbc.M302179200; CONRAD MJ, 1979, P NATL ACAD SCI USA, V76, P5202, DOI 10.1073/pnas.76.10.5202; De Felice FG, 2004, FASEB J, V18, P1366, DOI 10.1096/fj.04-1764com; De Felice FG, 2001, FASEB J, V15, P1297, DOI 10.1096/fj.00-0676fje; Dehmelt L, 2003, J NEUROSCI, V23, P9479; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; DRUBIN DG, 1986, J CELL BIOL, V103, P2739, DOI 10.1083/jcb.103.6.2739; FERREIRA A, 1992, J NEUROSCI RES, V32, P516, DOI 10.1002/jnr.490320407; FERREIRA A, 1989, DEV BRAIN RES, V49, P215, DOI 10.1016/0165-3806(89)90023-0; Gong YS, 2003, P NATL ACAD SCI USA, V100, P10417, DOI 10.1073/pnas.1834302100; GREENE LA, 1983, J CELL BIOL, V96, P76, DOI 10.1083/jcb.96.1.76; HEIDEMANN SR, 1985, J CELL BIOL, V100, P916, DOI 10.1083/jcb.100.3.916; Heidemann SR, 1996, INT REV CYTOL, V165, P235, DOI 10.1016/S0074-7696(08)62224-X; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; HO PL, 1992, J CELL PHYSIOL, V150, P647, DOI 10.1002/jcp.1041500326; Iida N, 2001, J NEUROSCI, V21, P6459, DOI 10.1523/JNEUROSCI.21-17-06459.2001; Ivins JK, 2004, J NEUROSCI, V24, P1212, DOI 10.1523/JNEUROSCI.4689-03.2004; KAHN JS, 1964, ANAL BIOCHEM, V9, P389, DOI 10.1016/0003-2697(64)90198-8; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; Lin SL, 2003, J NEUROCHEM, V87, P1076, DOI 10.1046/j.1471-4159.2003.02076.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu P, 2004, J NEUROSCI, V24, P6402, DOI 10.1523/JNEUROSCI.1492-04.2004; MACCIONI RB, 1989, ARCH BIOCHEM BIOPHYS, V275, P568, DOI 10.1016/0003-9861(89)90403-7; MATUS A, 1991, J CELL SCI, P61; Mei FC, 2002, J BIOL CHEM, V277, P11497, DOI 10.1074/jbc.M110856200; Ming GI, 1999, NEURON, V23, P139, DOI 10.1016/S0896-6273(00)80760-6; Moreno-Flores MT, 2003, J NEUROCHEM, V87, P879, DOI 10.1046/j.1471-4159.2003.02051.x; Nakagawa S, 2002, J NEUROSCI, V22, P3673; Nikulina E, 2004, P NATL ACAD SCI USA, V101, P8786, DOI 10.1073/pnas.0402595101; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Pearse DD, 2004, NAT MED, V10, P610, DOI 10.1038/nm1056; Pham N, 2000, CURR BIOL, V10, P555, DOI 10.1016/S0960-9822(00)00473-5; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; Sanchez S, 2004, NEUROCHEM INT, V44, P231, DOI 10.1016/S0197-0186(03)00150-5; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Selkoe DJ, 2002, SCIENCE, V298, P963; SILVEIRA MS, 2004, IN PRESS BRAIN REPAR; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; Spencer T, 2004, J ANAT, V204, P49, DOI 10.1111/j.1469-7580.2004.00259.x; Takahashi N, 2002, J BIOL CHEM, V277, P16906, DOI 10.1074/jbc.M200585200; TANAKA E, 1995, CELL, V83, P171, DOI 10.1016/0092-8674(95)90158-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUCKER RP, 1990, BRAIN RES REV, V15, P101, DOI 10.1016/0165-0173(90)90013-E; Tuszynski MH, 2002, LANCET NEUROL, V1, P51, DOI 10.1016/S1474-4422(02)00006-6; Tuszynski MH, 2004, PROG BRAIN RES, V146, P441; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WU DK, 1983, J CYCLIC NUCL PROT, V9, P59	65	35	38	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					1627	1636		10.1096/fj.05-3812com	http://dx.doi.org/10.1096/fj.05-3812com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16195371				2022-12-25	WOS:000232991100040
J	Brunori, M; Mathieu, N; Ricoul, M; Bauwens, S; Koering, CE; de Climens, AR; Belleville, A; Wang, Q; Puisieux, I; Decimo, D; Puisieux, A; Sabatier, L; Gilson, E				Brunori, M; Mathieu, N; Ricoul, M; Bauwens, S; Koering, CE; de Climens, AR; Belleville, A; Wang, Q; Puisieux, I; Decimo, D; Puisieux, A; Sabatier, L; Gilson, E			TRF2 inhibition promotes anchorage-independent growth of telomerase-positive human fibroblasts	ONCOGENE			English	Article						telomere; TRF2; malignant transformation	REPEAT BINDING-FACTORS; NORMAL HUMAN-CELLS; HUMAN TUMOR-CELLS; TO-END FUSIONS; CHROMOSOMAL INSTABILITY; GENOMIC INSTABILITY; EPITHELIAL-CELLS; CANCER-CELLS; MOUSE CELLS; DNA-DAMAGE	Although telomere instability is observed in human tumors and is associated with the development of cancers in mice, it has yet to be established that it can contribute to the malignant transformation of human cells. We show here that in checkpoint-compromised telomerase-positive human. fibroblasts an episode of TRF2 inhibition promotes heritable changes that increase the ability to grow in soft agar, but not tumor growth in nude mice. This transforming activity is associated to a burst of telomere instability but is independent of an altered control of telomere length. Moreover, it cannot be recapitulated by an increase in chromosome breaks induced by an exposure to gamma-radiations. Since it can be revealed in the context of telomerase-proficient human cells, telomere dysfunction might contribute to cancer progression even at late stages of the oncogenesis process, after the telomerase reactivation step.	Ecole Normale Super Lyon, Lab Biol Mol Cellule, CNRS, UMR,INRA,ENS, F-69364 Lyon 07, France; CEA, Commissariat Energ Atom, Lab Radiobiol & Oncol, Fontenay Aux Roses, France; Ctr Leon Berard, INSERM, Unite Oncol Mol, Unite 590, F-69373 Lyon, France; Ctr Hosp Lyon Sud, Tumor Biol Unit, F-69310 Pierre Benite, France; Ecole Normale Super Lyon, Lab Human Virol, INSERM, ENS, F-69364 Lyon, France	INRAE; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet; CEA; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; CHU Lyon; Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm)	Gilson, E (corresponding author), Ecole Normale Super Lyon, Lab Biol Mol Cellule, CNRS, UMR,INRA,ENS, 46 Allee Italie, F-69364 Lyon 07, France.	Eric.Gilson@ens-lyon.fr		PUISIEUX, Alain/0000-0002-9938-3798; Sabatier, Laure/0000-0003-0552-6549; Decimo, Didier/0000-0002-0390-1205				Ancelin K, 2002, MOL CELL BIOL, V22, P3474, DOI 10.1128/MCB.22.10.3474-3487.2002; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Artandi SE, 2002, P NATL ACAD SCI USA, V99, P8191, DOI 10.1073/pnas.112515399; Artandi SE, 2000, CURR OPIN GENET DEV, V10, P39, DOI 10.1016/S0959-437X(99)00047-7; Barcellos-Hoff MH, 2000, CANCER RES, V60, P1254; Baur JA, 2001, SCIENCE, V292, P2075, DOI 10.1126/science.1062329; Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bradshaw PS, 2005, NAT GENET, V37, P193, DOI 10.1038/ng1506; Callen E, 2004, MUTAT RES-REV MUTAT, V567, P85, DOI 10.1016/j.mrrev.2004.06.003; Chin K, 2004, NAT GENET, V36, P984, DOI 10.1038/ng1409; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Colgin L, 2004, CURR BIOL, V14, pR901, DOI 10.1016/j.cub.2004.09.075; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Ferreira MG, 2001, MOL CELL, V7, P55, DOI 10.1016/S1097-2765(01)00154-X; FEUER G, 1995, J VIROL, V69, P1328, DOI 10.1128/JVI.69.2.1328-1333.1995; Gisselsson D, 2001, P NATL ACAD SCI USA, V98, P12683, DOI 10.1073/pnas.211357798; Gonzalez-Suarez E, 2000, NAT GENET, V26, P114, DOI 10.1038/79089; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Karlseder J, 2004, PLOS BIOL, V2, P1150, DOI 10.1371/journal.pbio.0020240; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Klapper W, 2003, LEUKEMIA, V17, P2007, DOI 10.1038/sj.leu.2403086; Koering CE, 2002, EMBO REP, V3, P1055, DOI 10.1093/embo-reports/kvf215; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; Lechel A, 2005, EMBO REP, V6, P275, DOI 10.1038/sj.embor.7400352; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Lin SY, 2003, CELL, V113, P881, DOI 10.1016/S0092-8674(03)00430-6; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; Marcand S, 1999, EMBO J, V18, P3509, DOI 10.1093/emboj/18.12.3509; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; Miyachi K, 2002, J EXP CLIN CANC RES, V21, P269; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nakanishi K, 2003, CLIN CANCER RES, V9, P1105; O'Sullivan JN, 2002, NAT GENET, V32, P280, DOI 10.1038/ng989; Oh BK, 2005, AM J PATHOL, V166, P73, DOI 10.1016/S0002-9440(10)62233-X; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; Shay JW, 1997, J CELL PHYSIOL, V173, P266, DOI 10.1002/(SICI)1097-4652(199711)173:2<266::AID-JCP33>3.0.CO;2-B; Smogorzewska A, 2002, CURR BIOL, V12, P1635, DOI 10.1016/S0960-9822(02)01179-X; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Smogorzewska A, 2002, EMBO J, V21, P4338, DOI 10.1093/emboj/cdf433; Teixeira MT, 2004, CELL, V117, P323, DOI 10.1016/S0092-8674(04)00334-4; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Wang RC, 2004, CELL, V119, P355, DOI 10.1016/j.cell.2004.10.011; Woo RA, 2004, GENE DEV, V18, P1317, DOI 10.1101/gad.1165204; Yamada K, 2002, ANTICANCER RES, V22, P1315; Yamada M, 2002, ANTICANCER RES, V22, P3303; Zhang AJ, 2004, ONCOGENE, V23, P7441, DOI 10.1038/sj.onc.1207527; Zimonjic D, 2001, CANCER RES, V61, P8838	59	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2006	25	7					990	997		10.1038/sj.onc.1209135	http://dx.doi.org/10.1038/sj.onc.1209135			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16205637				2022-12-25	WOS:000235361000004
J	Fifre, A; Sponne, I; Koziel, V; Kriem, B; Potin, FTY; Bihain, BE; Olivier, JL; Oster, T; Pillot, T				Fifre, A; Sponne, I; Koziel, V; Kriem, B; Potin, FTY; Bihain, BE; Olivier, JL; Oster, T; Pillot, T			Microtubule-associated protein MAP1A, MAP1B, and MAP2 proteolysis during soluble amyloid beta-peptide-induced neuronal apoptosis - Synergistic involvement of calpain and caspase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE PATIENTS; PAIRED HELICAL FILAMENTS; NEUROFIBRILLARY TANGLES; CORTICAL-NEURONS; NERVOUS-SYSTEM; CELL-DEATH; A-BETA; NEUROBLASTOMA-CELLS; HUNTINGTONS-DISEASE; MOLECULAR-BASIS	A growing body of evidence supports the notion that soluble oligomeric forms of the amyloid beta-peptide (A beta) may be the proximate effectors of neuronal injuries and death in the early stages of Alzheimer disease. However, the molecular mechanisms associated with neuronal apoptosis induced by soluble A beta remain to be elucidated. We recently demonstrated the involvement of an early reactive oxygen species-dependent perturbation of the microtubule network (Sponne, I., Fifre, A., Drouet, B., Klein, C., Koziel, V., Pincon-Raymond, M., Olivier, J.-L., Chambaz, J., and Pillot, T. ( 2003) J. Biol. Chem. 278, 3437-3445). Because microtubule-associated proteins (MAPs) are responsible for the polymerization, stabilization, and dynamics of the microtubule network, we investigated whether MAPs might represent the intracellular targets that would enable us to explain the microtubule perturbation involved in soluble A beta-mediated neuronal apoptosis. The data presented here show that soluble A beta oligomers induce a time-dependent degradation of MAP1A, MAP1B, and MAP2 involving a perturbation of Ca2+ homeostasis with subsequent calpain activation that, on its own, is sufficient to induce the proteolysis of isoforms MAP2a, MAP2b, and MAP2c. In contrast, MAP1A and MAP1B sequential proteolysis results from the A beta-mediated activation of caspase-3 and calpain. The prevention of MAP1A, MAP1B, and MAP2 proteolysis by antioxidants highlights the early reactive oxygen species generation in the perturbation of the microtubule network induced by soluble A beta. These data clearly demonstrate the impact of cytoskeletal perturbations on soluble A beta-mediated cell death and support the notion of microtubule-stabilizing agents as effective Alzheimer disease drugs.	Inst Natl Polytech Lorraine, Lab Med & Therapeut Mol, Lipidomix, Jeune Equipe 2482, F-54500 Vandoeuvre Les Nancy, France	Universite de Lorraine	Pillot, T (corresponding author), Inst Natl Polytech Lorraine, Lab Med & Therapeut Mol, Lipidomix, Jeune Equipe 2482, 15 Rue Bois Champelle, F-54500 Vandoeuvre Les Nancy, France.	Thierry.Pillot@mtm.nancy.inserm.fr	Yen, Frances T/G-9175-2014; Olivier, Jean luc/AAQ-2721-2021	Yen, Frances T/0000-0001-8740-4304; 				Adlard PA, 2002, ACTA NEUROPATHOL, V103, P377, DOI 10.1007/s00401-001-0476-6; Alexa A, 2002, BIOCHEMISTRY-US, V41, P12427, DOI 10.1021/bi025916s; ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; BALLOUGH GPH, 1995, J NEUROSCI METH, V61, P23, DOI 10.1016/0165-0270(95)00019-Q; BILLGER M, 1988, CELL CALCIUM, V9, P33, DOI 10.1016/0143-4160(88)90036-X; Bizat N, 2003, J BIOL CHEM, V278, P43245, DOI 10.1074/jbc.M305057200; Blomgren K, 2001, J BIOL CHEM, V276, P10191, DOI 10.1074/jbc.M007807200; Bouras C, 2001, ACTA NEUROPATHOL, V102, P373; Carragher NO, 2001, J BIOL CHEM, V276, P4270, DOI 10.1074/jbc.M008972200; Cash AD, 2003, AM J PATHOL, V162, P1623, DOI 10.1016/S0002-9440(10)64296-4; Chan SL, 1999, J NEUROSCI RES, V58, P167, DOI 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.3.CO;2-B; Chua BT, 2000, J BIOL CHEM, V275, P5131, DOI 10.1074/jbc.275.7.5131; Chui DH, 1999, NAT MED, V5, P560, DOI 10.1038/8438; Chung CW, 2001, NEUROBIOL DIS, V8, P162, DOI 10.1006/nbdi.2000.0335; Cribbs DH, 2004, AM J PATHOL, V165, P353, DOI 10.1016/S0002-9440(10)63302-0; DeTure MA, 1996, J BIOL CHEM, V271, P32702, DOI 10.1074/jbc.271.51.32702; Dewar D, 1997, ACTA NEUROPATHOL, V93, P71, DOI 10.1007/s004010050584; Dickson DW, 2004, J CLIN INVEST, V114, P23, DOI 10.1172/JC1200422317; Dickson DW, 1997, J NEUROPATH EXP NEUR, V56, P321, DOI 10.1097/00005072-199704000-00001; Drouet B, 2000, CELL MOL LIFE SCI, V57, P705, DOI 10.1007/s000180050035; Ebneth A, 1998, J CELL BIOL, V143, P777, DOI 10.1083/jcb.143.3.777; Farah CA, 2003, J NEUROCHEM, V84, P77, DOI 10.1046/j.1471-4159.2003.01505.x; Fasulo L, 2000, J NEUROCHEM, V75, P624, DOI 10.1046/j.1471-4159.2000.0750624.x; FERREIRA A, 1989, DEV BRAIN RES, V49, P215, DOI 10.1016/0165-3806(89)90023-0; Fink JK, 1996, GENOMICS, V35, P577, DOI 10.1006/geno.1996.0400; FISCHER I, 1991, NEUROCHEM RES, V16, P891, DOI 10.1007/BF00965538; FRIEDRICH P, 1991, FEBS LETT, V295, P5, DOI 10.1016/0014-5793(91)81371-E; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Gonzalez-Billault C, 2004, J NEUROBIOL, V58, P48, DOI 10.1002/neu.10283; Grynspan F, 1997, BRAIN RES, V763, P145, DOI 10.1016/S0006-8993(97)00384-3; Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6; HASEGAWA M, 1990, NEURON, V4, P909, DOI 10.1016/0896-6273(90)90144-5; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Hutter-Paier B, 2000, CELL TISSUE RES, V302, P39, DOI 10.1007/s004410000258; IQBAL K, 1986, LANCET, V2, P421; Irving EA, 1996, ACTA NEUROPATHOL, V92, P186, DOI 10.1007/s004010050507; JOHNSON GVW, 1991, J NEUROCHEM, V56, P1630, DOI 10.1111/j.1471-4159.1991.tb02061.x; Kim HJ, 2002, FASEB J, V16, P118, DOI 10.1096/fj.01-0987fje; Kim YJ, 2001, P NATL ACAD SCI USA, V98, P12784, DOI 10.1073/pnas.221451398; Kirkitadze MD, 2002, J NEUROSCI RES, V69, P567, DOI 10.1002/jnr.10328; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; Kook S, 2003, BIOCHEM BIOPH RES CO, V303, P37, DOI 10.1016/S0006-291X(03)00280-8; KOSIK KS, 1984, P NATL ACAD SCI-BIOL, V81, P7941, DOI 10.1073/pnas.81.24.7941; KOSIK KS, 1986, P NATL ACAD SCI USA, V83, P4044, DOI 10.1073/pnas.83.11.4044; Kriem B, 2004, FASEB J, V18, P85, DOI 10.1096/fj.04-1807fje; LaFerla FM, 2002, NAT REV NEUROSCI, V3, P862, DOI 10.1038/nrn960; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lankiewicz S, 2000, J BIOL CHEM, V275, P17064, DOI 10.1074/jbc.275.22.17064; Larson J, 1999, BRAIN RES, V840, P23, DOI 10.1016/S0006-8993(99)01698-4; Liu W, 2000, NUCLEIC ACIDS RES, V28, P4180, DOI 10.1093/nar/28.21.4180; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; Lue LF, 1999, AM J PATHOL, V155, P853, DOI 10.1016/S0002-9440(10)65184-X; MATESIC DF, 1994, J NEUROCHEM, V63, P1012; MATTSON MP, 1991, MOL CHEM NEUROPATHOL, V15, P117, DOI 10.1007/BF03159951; Mattson MP, 2003, CELL CALCIUM, V34, P385, DOI 10.1016/S0143-4160(03)00128-3; McGinnis KM, 1998, J BIOL CHEM, V273, P19993, DOI 10.1074/jbc.273.32.19993; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; Michaelis ML, 2003, J PHARMACOL EXP THER, V304, P897, DOI 10.1124/jpet.102.035840; NASSOGNE MC, 1995, P NATL ACAD SCI USA, V92, P11029, DOI 10.1073/pnas.92.24.11029; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Neumar RW, 2003, J BIOL CHEM, V278, P14162, DOI 10.1074/jbc.M212255200; NIETO A, 1989, ACTA NEUROPATHOL, V78, P47, DOI 10.1007/BF00687401; NIXON RA, 1994, ANN NY ACAD SCI, V747, P77; Nixon RA, 2003, AGEING RES REV, V2, P407, DOI 10.1016/S1568-1637(03)00029-1; Noraberg J, 1998, NEUROREPORT, V9, P3177, DOI 10.1097/00001756-199810050-00010; Pillot T, 1999, J NEUROCHEM, V73, P1626, DOI 10.1046/j.1471-4159.1999.0731626.x; Pillot T, 1996, J BIOL CHEM, V271, P28757, DOI 10.1074/jbc.271.46.28757; Rami A, 2003, NEUROBIOL DIS, V13, P75, DOI 10.1016/S0969-9961(03)00018-4; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Reimertz C, 2001, J NEUROCHEM, V78, P1256, DOI 10.1046/j.1471-4159.2001.00503.x; Rohn TT, 2001, AM J PATHOL, V158, P189, DOI 10.1016/S0002-9440(10)63957-0; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; Sanchez C, 2000, PROG NEUROBIOL, V61, P133, DOI 10.1016/S0301-0082(99)00046-5; Schwab B, 2001, J PHYSIOL-LONDON, V530, P497, DOI 10.1111/j.1469-7793.2001.0497k.x; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shah RD, 2003, MOL CELL NEUROSCI, V24, P503, DOI 10.1016/S1044-7431(03)00166-0; Shim SR, 2001, BIOCHEM BIOPH RES CO, V286, P601, DOI 10.1006/bbrc.2001.5441; Sponne I, 2004, FASEB J, V18, P836, DOI 10.1096/fj.03-0372fje; Sponne I, 2003, J BIOL CHEM, V278, P3437, DOI 10.1074/jbc.M206745200; Springer JE, 1997, J NEUROCHEM, V69, P1592, DOI 10.1046/j.1471-4159.1997.69041592.x; Su JH, 2001, BRAIN RES, V898, P350, DOI 10.1016/S0006-8993(01)02018-2; TAKAHASHI H, 1991, ACTA NEUROPATHOL, V81, P626, DOI 10.1007/BF00296372; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Terry RD, 1996, J NEUROPATH EXP NEUR, V55, P1023, DOI 10.1097/00005072-199655100-00001; Trushina E, 2003, P NATL ACAD SCI USA, V100, P12171, DOI 10.1073/pnas.2034961100; Uchida Y, 2003, J BIOL CHEM, V278, P366, DOI 10.1074/jbc.M210091200; ULLOA L, 1994, MOL BRAIN RES, V26, P113, DOI 10.1016/0169-328X(94)90081-7; Vanderklish PW, 2000, INT J EXP PATHOL, V81, P323, DOI 10.1046/j.1365-2613.2000.00169.x; Walsh DM, 2002, BIOCHEM SOC T, V30, P552, DOI 10.1042/BST0300552; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Westerman MA, 2002, J NEUROSCI, V22, P1858, DOI 10.1523/JNEUROSCI.22-05-01858.2002; Wilquet V, 2004, CURR OPIN NEUROBIOL, V14, P582, DOI 10.1016/j.conb.2004.08.001	93	96	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					229	240		10.1074/jbc.M507378200	http://dx.doi.org/10.1074/jbc.M507378200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16234245	hybrid			2022-12-25	WOS:000234307200031
J	Wang, JM; Hoshijima, M; Lam, J; Zhou, ZJ; Jokiel, A; Dalton, ND; Hultenby, K; Ruiz-Lozano, P; Ross, J; Tryggvason, K; Chien, KR				Wang, JM; Hoshijima, M; Lam, J; Zhou, ZJ; Jokiel, A; Dalton, ND; Hultenby, K; Ruiz-Lozano, P; Ross, J; Tryggvason, K; Chien, KR			Cardiomyopathy associated with microcirculation dysfunction in laminin alpha 4 chain-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCULAR-DYSTROPHY; SMOOTH-MUSCLE; EXPRESSION; PURIFICATION; DISRUPTION; APOPTOSIS; ISCHEMIA; DELETION; LACKING; MODELS	Laminin alpha 4 chain is a component of extracellular matrix (ECM) laminin-8 and -9 and serves dual roles as a structure protein and as a signaling molecule. The abundance of laminin alpha 4 chain transcripts in the heart suggests an important role of this protein in cardiovascular development and function. In this study, we demonstrate that laminin alpha 4 deficient mice gradually develop cardiac hypertrophy with impaired function. We show that depletion of laminin alpha 4 chain did not alter the levels of dystrophin-glycoprotein complex (DGC) components or affect cell membrane integrity. No alteration in integrin beta 1D protein was observed in terms of expression level or distribution pattern, indicating that the postnatal development of cardiac hypertrophy and cardiomyopathy in these mice is unlikely associated with the stability of sarcolemmal DGC and integrin complexes. Moreover, cardiomyocytes isolated from Lama4-/- mutant hearts maintained their contractility in vitro. In contrast, elevated levels of hypoxia-inducible factor 1 alpha (Hif1 alpha) and vascular endothelial growth factor A (Vegfa) transcripts, along with multiple foci of cardiomyocyte degeneration and fibrosis suggested sustained cardiac ischemia. Electron microscopy confirmed malformed blood vessels and wide pericapillary ECM spaces, suggesting the presence of microcirculation abnormalities in Lama4-/- mutant hearts. We thus conclude that mutation in the laminin alpha 4 chain leads to abnormal cardiovascular ECM structure that cause insufficient oxygen supply to the heart and the subsequent ischemic cardiac phenotype observed. Our study links the genetic deficiency of an ECM protein to cardiomyopathy and implies a novel pathway of idiopathic cardiomyopathy in human.	Univ Calif San Diego, Inst Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA; Univ Hong Kong, Fac Med, Dept Biochem, Hong Kong, Hong Kong, Peoples R China; Huddinge Univ Hosp, Karolinska Inst, Dept Pathol, SE-14183 Huddinge, Sweden; Karolinska Inst, Div Matrix Biol, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden; Burnham Inst, La Jolla, CA 92037 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Hong Kong; Karolinska Institutet; Karolinska Institutet; Sanford Burnham Prebys Medical Discovery Institute	Chien, KR (corresponding author), Univ Calif San Diego, Inst Mol Med, La Jolla, CA 92093 USA.	kchien@partners.org	zhou, zhongjun/D-4818-2012; Zhou, Zhongjun/C-4476-2009	Zhou, Zhongjun/0000-0001-7092-8128	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077181] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL077181-01 A1] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aumailley M, 1996, J INVEST DERMATOL, V106, P209, DOI 10.1111/1523-1747.ep12340471; Coral-Vazquez R, 1999, CELL, V98, P465, DOI 10.1016/S0092-8674(00)81975-3; Delbridge LMD, 1997, J MOL CELL CARDIOL, V29, P11, DOI 10.1006/jmcc.1996.0247; Ferrara N, 1997, EXS, V79, P209; Forster C, 2004, P NATL ACAD SCI USA, V101, P14234, DOI 10.1073/pnas.0405571101; Fujiwara H, 2001, J BIOL CHEM, V276, P17550, DOI 10.1074/jbc.M010155200; Girgenrath M, 2004, J CLIN INVEST, V114, P1635, DOI 10.1172/JCI200422928; HJALLMANN R, 2005, PHYSIOL REV, V85, P979; Huang Y, 2004, FASEB J, V18, P1138, DOI 10.1096/fj.04-1510fje; Iivanainen A, 1997, J BIOL CHEM, V272, P27862, DOI 10.1074/jbc.272.44.27862; Kortesmaa J, 2000, J BIOL CHEM, V275, P14853, DOI 10.1074/jbc.275.20.14853; Lee GH, 2000, CIRC RES, V87, P489; Lee SH, 2000, NEW ENGL J MED, V342, P626, DOI 10.1056/NEJM200003023420904; Miner JH, 1998, J CELL BIOL, V143, P1713, DOI 10.1083/jcb.143.6.1713; Miyagoe Y, 1997, FEBS LETT, V415, P33, DOI 10.1016/S0014-5793(97)01007-7; Patton BL, 2001, NAT NEUROSCI, V4, P597, DOI 10.1038/88414; Patton BL, 1997, J CELL BIOL, V139, P1507, DOI 10.1083/jcb.139.6.1507; Pham CG, 2000, AM J PHYSIOL-HEART C, V279, pH2916, DOI 10.1152/ajpheart.2000.279.6.H2916; Ross RS, 1998, CIRC RES, V82, P1160, DOI 10.1161/01.RES.82.11.1160; Semenza GL, 2000, ADV EXP MED BIOL, V475, P123; Shai SY, 2002, CIRC RES, V90, P458, DOI 10.1161/hh0402.105790; Simkhovich BZ, 2003, CARDIOVASC RES, V59, P450, DOI 10.1016/S0008-6363(03)00399-7; Simkhovich BZ, 2003, CARDIOVASC PATHOL, V12, P180, DOI 10.1016/S1054-8807(03)00038-3; Straub V, 1997, J CELL BIOL, V139, P375, DOI 10.1083/jcb.139.2.375; Talts JF, 2000, J BIOL CHEM, V275, P35192, DOI 10.1074/jbc.M003261200; Tanaka N, 1996, CIRCULATION, V94, P1109, DOI 10.1161/01.CIR.94.5.1109; Thyboll J, 2002, MOL CELL BIOL, V22, P1194, DOI 10.1128/MCB.22.4.1194-1202.2002; Tiemann K, 2003, AM J PHYSIOL-HEART C, V284, pH464, DOI 10.1152/ajpheart.00540.2002; TOME FMS, 1994, CR ACAD SCI III-VIE, V317, P351; Wang JM, 2001, P NATL ACAD SCI USA, V98, P4038, DOI 10.1073/pnas.061038798; Wheeler MT, 2004, J CLIN INVEST, V113, P668, DOI 10.1172/JCI200420410; XU H, 1994, NAT GENET, V8, P297, DOI 10.1038/ng1194-297; Zhao W, 2003, CARDIOVASC RES, V57, P71, DOI 10.1016/S0008-6363(02)00609-0	33	60	69	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					213	220		10.1074/jbc.M505061200	http://dx.doi.org/10.1074/jbc.M505061200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16204254	hybrid			2022-12-25	WOS:000234307200029
J	Kenjale, R; Wilson, J; Zenk, SF; Saurya, S; Picking, WL; Picking, WD; Blocker, A				Kenjale, R; Wilson, J; Zenk, SF; Saurya, S; Picking, WL; Picking, WD; Blocker, A			The needle component of the type III secreton of Shigella regulates the activity of the secretion apparatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECRETION; FLAGELLAR HOOK; SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; YERSINIA-PESTIS; HRP PILUS; SUPRAMOLECULAR STRUCTURE; BACTERIAL INJECTISOMES; SUBSTRATE-SPECIFICITY; ANGSTROM RESOLUTION	Gram-negative bacteria commonly interact with eukaryotic host cells by using type III secretion systems (TTSSs or secretons). TTSSs serve to transfer bacterial proteins into host cells. Two translocators, IpaB and IpaC, are first inserted with the aid of IpaD by Shigella into the host cell membrane. Then at least two supplementary effectors of cell invasion, IpaA and IpgD, are transferred into the host cytoplasm. How TTSSs are induced to secrete is unknown, but their activation appears to require direct contact of the external distal tip of the apparatus with the host cell. The extracellular domain of the TTSS is a hollow needle protruding 60 nm beyond the bacterial surface. The monomeric unit of the Shigella flexneri needle, MxiH, forms a superhelical assembly. To probe the role of the needle in the activation of the TTSS for secretion, we examined the structure-function relationship of MxiH by mutagenesis. Most point mutations led to normal needle assembly, but some led to polymerization or possible length control defects. In other mutants, secretion was constitutively turned "on." In a further set, it was "constitutively on" but experimentally "uninducible." Finally, upon induction of secretion, some mutants released only the translocators and not the effectors. Most types of mutants were defective in interactions with host cells. Together, these data indicate that the needle directly controls the activity of the TTSS and suggest that it may be used to "sense" host cells.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA	University of Oxford; University of Kansas	Blocker, A (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	ariel.blocker@path.ox.ac.uk	Blocker, Ariel/Q-6617-2016		NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034428, R29AI034428] Funding Source: NIH RePORTER; Medical Research Council [G0401595] Funding Source: Medline; NCRR NIH HHS [RR017708] Funding Source: Medline; NIAID NIH HHS [AI034428] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G0401595] Funding Source: UKRI	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Aizawa SI, 1996, MOL MICROBIOL, V19, P1, DOI 10.1046/j.1365-2958.1996.344874.x; Anderson DM, 1999, MOL MICROBIOL, V31, P1139, DOI 10.1046/j.1365-2958.1999.01254.x; Bahrani FK, 1997, INFECT IMMUN, V65, P4005, DOI 10.1128/IAI.65.10.4005-4010.1997; Blocker A, 1999, J CELL BIOL, V147, P683, DOI 10.1083/jcb.147.3.683; Blocker A, 2003, P NATL ACAD SCI USA, V100, P3027, DOI 10.1073/pnas.0535335100; Blocker A, 2001, MOL MICROBIOL, V39, P652, DOI 10.1046/j.1365-2958.2001.02200.x; CALLADINE CR, 1982, SYM SOC EXP BIOL, P33; Coombes BK, 2004, J BIOL CHEM, V279, P49804, DOI 10.1074/jbc.M404299200; Cordes FS, 2005, J MOL BIOL, V354, P206, DOI 10.1016/j.jmb.2005.09.062; Cordes FS, 2003, J BIOL CHEM, V278, P17103, DOI 10.1074/jbc.M300091200; Creasey EA, 2003, MICROBIOL-SGM, V149, P3639, DOI 10.1099/mic.0.26735-0; Crepin VF, 2005, J BACTERIOL, V187, P2881, DOI 10.1128/JB.187.8.2881-2889.2005; Daniell SJ, 2003, MOL MICROBIOL, V49, P301, DOI 10.1046/j.1365-2958.2003.03555.x; Deng WY, 2005, INFECT IMMUN, V73, P2135, DOI 10.1128/IAI.73.4.2135-2146.2005; Edqvist PJ, 2003, J BACTERIOL, V185, P2259, DOI 10.1128/JB.185.7.2259-2266.2003; EMERSON SU, 1970, SCIENCE, V169, P190, DOI 10.1126/science.169.3941.190; Ferracci F, 2005, MOL MICROBIOL, V57, P970, DOI 10.1111/j.1365-2958.2005.04738.x; GALAN JE, 1992, J BACTERIOL, V174, P4338; Hasegawa K, 1998, BIOPHYS J, V74, P569, DOI 10.1016/S0006-3495(98)77815-4; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Jin QL, 2001, SCIENCE, V294, P2556, DOI 10.1126/science.1066397; Journet L, 2003, SCIENCE, V302, P1757, DOI 10.1126/science.1091422; Kane CD, 2002, J BACTERIOL, V184, P4409, DOI 10.1128/JB.184.16.4409-4419.2002; KANTO S, 1991, J MOL BIOL, V219, P471, DOI 10.1016/0022-2836(91)90187-B; KATO S, 1984, J MOL BIOL, V173, P463, DOI 10.1016/0022-2836(84)90391-7; Kimbrough TG, 2000, P NATL ACAD SCI USA, V97, P11008, DOI 10.1073/pnas.200209497; Komoriya K, 1999, MOL MICROBIOL, V34, P767, DOI 10.1046/j.1365-2958.1999.01639.x; Koroyasu S, 1998, BIOPHYS J, V74, P436, DOI 10.1016/S0006-3495(98)77801-4; Kubori T, 1998, SCIENCE, V280, P602, DOI 10.1126/science.280.5363.602; Kubori T, 2002, J BACTERIOL, V184, P4699, DOI 10.1128/JB.184.17.4699-4708.2002; Kubori T, 2000, P NATL ACAD SCI USA, V97, P10225, DOI 10.1073/pnas.170128997; Lee YH, 2005, J BIOL CHEM, V280, P21409, DOI 10.1074/jbc.M500972200; Li CM, 2002, EMBO J, V21, P1909, DOI 10.1093/emboj/21.8.1909; Macnab RM, 2003, ANNU REV MICROBIOL, V57, P77, DOI 10.1146/annurev.micro.57.030502.090832; Magdalena J, 2002, J BACTERIOL, V184, P3433, DOI 10.1128/JB.184.13.3433-3441.2002; Marlovits TC, 2004, SCIENCE, V306, P1040, DOI 10.1126/science.1102610; MIMORI Y, 1995, J MOL BIOL, V249, P69, DOI 10.1006/jmbi.1995.0281; MORGAN DG, 1995, J MOL BIOL, V249, P88, DOI 10.1006/jmbi.1995.0282; Mota LJ, 2005, SCIENCE, V307, P1278, DOI 10.1126/science.1107679; Muramoto K, 1998, J MOL BIOL, V277, P871, DOI 10.1006/jmbi.1998.1659; Muramoto K, 1999, J BACTERIOL, V181, P5808, DOI 10.1128/JB.181.18.5808-5813.1999; NAMBA K, 1989, NATURE, V342, P648, DOI 10.1038/342648a0; Niebuhr K, 2000, MOL MICROBIOL, V38, P8, DOI 10.1046/j.1365-2958.2000.02041.x; Niebuhr Kirsten, 2003, Methods Mol Med, V73, P125; O'Connell CB, 2004, MOL MICROBIOL, V52, P1613, DOI 10.1111/j.1365-2958.2004.04101.x; Ozin AJ, 2003, FEMS MICROBIOL LETT, V219, P219, DOI 10.1016/S0378-1097(02)01208-9; Page AL, 2002, MOL MICROBIOL, V43, P1533, DOI 10.1046/j.1365-2958.2002.02835.x; Pallen MJ, 2005, BMC MICROBIOL, V5, DOI 10.1186/1471-2180-5-9; Parsot C, 1994, Curr Top Microbiol Immunol, V192, P217; PARSOT C, 1995, MOL MICROBIOL, V16, P291, DOI 10.1111/j.1365-2958.1995.tb02301.x; Pettersson J, 1996, SCIENCE, V273, P1231, DOI 10.1126/science.273.5279.1231; Picking WL, 2005, INFECT IMMUN, V73, P1432, DOI 10.1128/IAI.73.3.1432-1440.2005; Picking WL, 2001, MOL MICROBIOL, V39, P100, DOI 10.1046/j.1365-2958.2001.02210.x; Quinaud M, 2005, J BIOL CHEM, V280, P36293, DOI 10.1074/jbc.M508089200; Ramamurthi KS, 2003, MOL MICROBIOL, V50, P1189, DOI 10.1046/j.1365-2958.2003.03772.x; Ramamurthi KS, 2002, J BACTERIOL, V184, P3321, DOI 10.1128/JB.184.12.3321-3328.2002; Samatey FA, 2004, NATURE, V431, P1062, DOI 10.1038/nature02997; Samatey FA, 2001, NATURE, V410, P331, DOI 10.1038/35066504; Sansonetti PJ, 1998, ANTON LEEUW INT J G, V74, P191, DOI 10.1023/A:1001519806727; Tamano K, 2002, J BACTERIOL, V184, P1244, DOI 10.1128/JB.184.5.1244-1252.2002; Tamano K, 2000, EMBO J, V19, P3876, DOI 10.1093/emboj/19.15.3876; Thomas D, 2001, J BACTERIOL, V183, P6404, DOI 10.1128/JB.183.21.6404-6412.2001; Torruellas J, 2005, MOL MICROBIOL, V57, P1719, DOI 10.1111/j.1365-2958.2005.04790.x; West NP, 2005, SCIENCE, V307, P1313, DOI 10.1126/science.1108472; Williams AW, 1996, J BACTERIOL, V178, P2960, DOI 10.1128/jb.178.10.2960-2970.1996; Wulff-Strobel CR, 2002, MOL MICROBIOL, V43, P411, DOI 10.1046/j.1365-2958.2002.02752.x; Yip CK, 2005, NAT STRUCT MOL BIOL, V12, P75, DOI 10.1038/nsmb879; Yu XJ, 2004, MOL MICROBIOL, V54, P604, DOI 10.1111/j.1365-2958.2004.04297.x	68	122	127	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42929	42937		10.1074/jbc.M508377200	http://dx.doi.org/10.1074/jbc.M508377200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16227202	Green Published, hybrid			2022-12-25	WOS:000234200800055
J	Valls, E; Sanchez-Molina, S; Martinez-Balbas, MA				Valls, E; Sanchez-Molina, S; Martinez-Balbas, MA			Role of histone modifications in marking and activating genes through mitosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE GENES; CHROMATIN; ACETYLATION; TRANSCRIPTION; METHYLATION; MEMORY; H3; ASSOCIATION; ANTIBODIES	The global inhibition of transcription at the mitotic phase of the cell cycle occurs together with the general displacement of transcription factors from the mitotic chromatin. Nevertheless, the DNase- and potassium permanganate-hypersensitive sites are maintained on potentially active promoters during mitosis, helping to mark active genes at this stage of the cell cycle. Our study focuses on the role of histone acetylation and H3 (Lys-4) methylation in the maintenance of the competency of these active genes during mitosis. To this end we have analyzed histone modifications across the promoters and coding regions of constitutively active, inducible, and inactive genes in mitotic arrested cells. Our results show that basal histone modifications are maintained during mitosis at promoters and coding regions of the active and inducible RNA polymerase II-transcribed genes. In addition we have demonstrated that, together with H3 acetylation and H3 (Lys-4) methylation, H4 (Lys-12) acetylation at the coding regions contributes to the formation of a stable mark on active genes at this stage of the cell cycle. Finally, analysis of cyclin B1 gene activation during mitosis revealed that the former occurs with a strong increase of H3 (Lys-4) trimethylation but not H3 or H4 acetylation, suggesting that histone methyltransferases are active during this stage. These data demonstrate a critical role of histone acetylation and H3 (Lys-4) methylation during mitosis in marking and activating genes during the mitotic stage of the cell cycle.	CSIC, Inst Biol Mol Barcelona, E-08028 Barcelona, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB)	Martinez-Balbas, MA (corresponding author), CSIC, Inst Biol Mol Barcelona, Parc Cient Barcelona,Josep Samitier 1-5, E-08028 Barcelona, Spain.	mmbbmc@ibmb.csic.es	Sánchez-Molina, Sara/B-2148-2017	Sánchez-Molina, Sara/0000-0002-1430-131X; Martinez-Balbas, Marian/0000-0003-0173-0964				Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Breiling A, 2001, NATURE, V412, P651, DOI 10.1038/35088090; Christova R, 2002, NAT CELL BIOL, V4, P79, DOI 10.1038/ncb733; Cimini D, 2003, MOL BIOL CELL, V14, P3821, DOI 10.1091/mbc.E03-01-0860; de la Cruz X, 2005, BIOESSAYS, V27, P164, DOI 10.1002/bies.20176; Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; GARCIARAMIREZ M, 1995, J BIOL CHEM, V270, P17923, DOI 10.1074/jbc.270.30.17923; Herrera JE, 2000, MOL CELL BIOL, V20, P523, DOI 10.1128/MCB.20.2.523-529.2000; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jeppesen P, 1997, BIOESSAYS, V19, P67, DOI 10.1002/bies.950190111; JEPPESEN P, 1992, CHROMOSOMA, V101, P322, DOI 10.1007/BF00346011; Kanno T, 2004, MOL CELL, V13, P33, DOI 10.1016/S1097-2765(03)00482-9; Kim JM, 2003, J CELL BIOL, V162, P37, DOI 10.1083/jcb.200303047; KONBERG RD, 1999, CURR OPIN GENE DEV, V9, P148; Kouskouti A, 2005, EMBO J, V24, P347, DOI 10.1038/sj.emboj.7600516; Kruhlak MJ, 2001, J BIOL CHEM, V276, P38307; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Martens JA, 2003, CURR OPIN GENET DEV, V13, P136, DOI 10.1016/S0959-437X(03)00022-4; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; Nowak SJ, 2004, TRENDS GENET, V20, P214, DOI 10.1016/j.tig.2004.02.007; Santos-Rosa H, 2003, MOL CELL, V12, P1325, DOI 10.1016/S1097-2765(03)00438-6; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076; SCHWARZ PM, 1994, J BIOL CHEM, V269, P16284; Sciortino S, 2001, EMBO REP, V2, P1018, DOI 10.1093/embo-reports/kve223; Smith CM, 2002, P NATL ACAD SCI USA, V99, P16454, DOI 10.1073/pnas.182424999; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Th'ng JPH, 2001, BIOCHEM CELL BIOL, V79, P305, DOI 10.1139/bcb-79-3-305; Thomson S, 2004, MOL CELL, V15, P585, DOI 10.1016/j.molcel.2004.08.002; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; TURNER BM, 1989, EUR J BIOCHEM, V179, P131, DOI 10.1111/j.1432-1033.1989.tb14530.x; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; Zeng L, 2002, FEBS LETT, V513, P124, DOI 10.1016/S0014-5793(01)03309-9	36	80	84	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42592	42600		10.1074/jbc.M507407200	http://dx.doi.org/10.1074/jbc.M507407200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16199528	Green Submitted, hybrid			2022-12-25	WOS:000234200800016
J	Zhang, H; Xie, XY; Zhu, XD; Zhu, JH; Hao, CF; Lu, QJ; Ding, LH; Liu, YF; Zhou, L; Liu, YL; Huang, CF; Wen, CG; Ye, QN				Zhang, H; Xie, XY; Zhu, XD; Zhu, JH; Hao, CF; Lu, QJ; Ding, LH; Liu, YF; Zhou, L; Liu, YL; Huang, CF; Wen, CG; Ye, QN			Stimulatory cross-talk between NFAT3 and estrogen receptor in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT TRANSCRIPTIONAL ACTIVITY; LIGAND-INDEPENDENT ACTIVATION; ER-ALPHA; SIGNALING PATHWAYS; HORMONE RECEPTORS; NUCLEAR RECEPTORS; GENE-EXPRESSION; COACTIVATOR; BETA; PROTEIN	Estrogen receptors (ER alpha and ER alpha) are ligand-regulated transcription factors that play critical roles in the development and progression of breast cancer by regulating target genes involved in cellular proliferation. The transcriptional activity of ER alpha and ER alpha is known to be modulated by cofactor proteins. We used a yeast two-hybrid system and identified NFAT3 as a novel ER beta-binding protein. NFAT3 interacted with ER alpha and ER beta both in vitro and in mammalian cells in a ligand-independent fashion. NFAT3 bound specifically to the ER beta region containing the activation function-1 domain, a ligand-independent transactivation domain. Overexpression of NFAT3 enhanced both ER alpha and ER beta transcriptional activities in a ligand-independent manner and up-regulated downstream estrogen-responsive genes including pS2 and cathepsin D. Reduction of endogenous NFAT3 with NFAT3 small interfering RNA or overexpression of NFAT3 deletion mutants that lack the ER-binding sites reduced the NFAT3 coactivation of ER alpha and ER beta. NFAT3 increased binding of ER alpha to the estrogen-responsive element and was recruited to endogenous estrogen-responsive promoters. NFAT3 was expressed differentially in many breast cancer cell lines and overexpressed in a subset of breast cancer patients. Knockdown of endogenous NFAT3 reduced the growth of human breast cancer ZR75-1 cells in a ligand-independent manner. Taken together, these results suggest that NFAT3 may play important roles in ER signaling and represent a novel target for breast cancer therapy.	Beijing Inst Biotechnol, Dept Mol Oncol, Beijing 100850, Peoples R China; Beijing Inst Biotechnol, Dept Pharmacol & Toxicol, Beijing 100850, Peoples R China; Univ Nanchang, Dept Biol Sci, Nanchang 330047, Peoples R China	Nanchang University	Ye, QN (corresponding author), Beijing Inst Biotechnol, Dept Mol Oncol, 27 tai Ping Lu Rd, Beijing 100850, Peoples R China.	yeqn@nic.bmi.ac.cn						Aiyar SE, 2004, GENE DEV, V18, P2134, DOI 10.1101/gad.1214104; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Belandia B, 2002, EMBO J, V21, P4094, DOI 10.1093/emboj/cdf412; Brunnberg S, 2003, P NATL ACAD SCI USA, V100, P6517, DOI 10.1073/pnas.1136688100; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Bushdid PB, 2003, CIRC RES, V92, P1305, DOI 10.1161/01.RES.0000077045.84609.9F; Cowley SM, 1999, J STEROID BIOCHEM, V69, P165, DOI 10.1016/S0960-0760(99)00055-2; deMedeiros SRB, 1997, J BIOL CHEM, V272, P18250, DOI 10.1074/jbc.272.29.18250; Ding LH, 2003, NUCLEIC ACIDS RES, V31, P5266, DOI 10.1093/nar/gkg731; Dobrzycka KM, 2003, ENDOCR-RELAT CANCER, V10, P517, DOI 10.1677/erc.0.0100517; Endoh H, 1999, MOL CELL BIOL, V19, P5363; Fang Y, 2004, BIOCHEM BIOPH RES CO, V323, P269, DOI 10.1016/j.bbrc.2004.08.100; Ferguson AT, 1997, CRIT REV ONCOGENESIS, V8, P29, DOI 10.1615/CritRevOncog.v8.i1.20; Fuqua SAW, 2003, CANCER RES, V63, P2434; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; Groth RD, 2003, J NEUROSCI, V23, P8125; Gustafsson JA, 2000, SEMIN PERINATOL, V24, P66, DOI 10.1016/S0146-0005(00)80059-2; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Ichida M, 2001, J BIOL CHEM, V276, P3524, DOI 10.1074/jbc.M004275200; Johansson L, 1999, J BIOL CHEM, V274, P345, DOI 10.1074/jbc.274.1.345; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Katzenellenbogen BS, 1996, BIOL REPROD, V54, P287, DOI 10.1095/biolreprod54.2.287; Klinge CM, 2000, STEROIDS, V65, P227, DOI 10.1016/S0039-128X(99)00107-5; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120; Lazennec G, 1999, MOL CELL ENDOCRINOL, V149, P93, DOI 10.1016/S0303-7207(98)00254-8; Lopez-Rodriguez C, 1999, P NATL ACAD SCI USA, V96, P7214, DOI 10.1073/pnas.96.13.7214; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; Metivier R, 2002, EMBO J, V21, P3443, DOI 10.1093/emboj/cdf344; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Qi C, 2002, J BIOL CHEM, V277, P28624, DOI 10.1074/jbc.M201053200; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Saji S, 2000, P NATL ACAD SCI USA, V97, P337, DOI 10.1073/pnas.97.1.337; Serfling E, 2000, BBA-MOL CELL RES, V1498, P1, DOI 10.1016/S0167-4889(00)00082-3; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Thenot S, 1997, J BIOL CHEM, V272, P12062, DOI 10.1074/jbc.272.18.12062; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Weigel NL, 1998, J MOL MED, V76, P469, DOI 10.1007/s001090050241; Wu LY, 2003, J BIOL CHEM, V278, P15192, DOI 10.1074/jbc.M212332200; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Ye QN, 2000, BBA-GENE STRUCT EXPR, V1493, P373, DOI 10.1016/S0167-4781(00)00202-5; ZHAU HY, 1996, P NATL ACAD SCI USA, V24, P15152; Zhu YJ, 1999, P NATL ACAD SCI USA, V96, P10848, DOI 10.1073/pnas.96.19.10848; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	48	49	54	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					43188	43197		10.1074/jbc.M506598200	http://dx.doi.org/10.1074/jbc.M506598200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16219765	hybrid			2022-12-25	WOS:000234200800085
J	Baker, PRS; Lin, YM; Schopfer, FJ; Woodcock, SR; Groeger, AL; Batthyany, C; Sweeney, S; Long, MH; Iles, KE; Baker, LMS; Branchaud, BP; Chen, YQE; Freeman, BA				Baker, PRS; Lin, YM; Schopfer, FJ; Woodcock, SR; Groeger, AL; Batthyany, C; Sweeney, S; Long, MH; Iles, KE; Baker, LMS; Branchaud, BP; Chen, YQE; Freeman, BA			Fatty acid transduction of nitric oxide signaling - Multiple nitrated unsaturated fatty acid derivatives exist in human blood and urine and serve as endogenous peroxisome proliferator-activated receptor ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN OXIDATION; DEPENDENT PROTEIN NITRATION; OXIDIZED LIPID DERIVATIVES; NITROGEN-DIOXIDE; STRUCTURAL-CHARACTERIZATION; NITROLINOLEIC ACID; METHYL LINOLEATE; ALPHA-TOCOPHEROL; PEROXYL RADICALS; ETHYL LINOLEATE	Mass spectrometric analysis of human plasma and urine revealed abundant nitrated derivatives of all principal unsaturated fatty acids. Nitrated palmitoleic, oleic, linoleic, linolenic, arachidonic and eicosapentaenoic acids were detected in concert with their nitrohydroxy derivatives. Two nitroalkene derivatives of the most prevalent fatty acid, oleic acid, were synthesized (9- and 10-nitro-9cis-octadecenoic acid; OA-NO2), structurally characterized and determined to be identical to OA-NO2 found in plasma, red cells, and urine of healthy humans. These regioisomers of OA-NO2 were quantified in clinical samples using C-13 isotope dilution. Plasma free and esterified OA-NO2 concentrations were 619 +/- 52 and 302 +/- 369 nM, respectively, and packed red blood cell free and esterified OA-NO2 was 59 +/- 11 and 155 +/- 65 nM. The OA-NO2 concentration of blood is similar to 50% greater than that of nitrated linoleic acid, with the combined free and esterified blood levels of these two fatty acid derivatives exceeding 1 mu M. OA-NO2 is a potent ligand for peroxisome proliferator activated receptors at physiological concentrations. CV-1 cells co-transfected with the luciferase gene under peroxisome proliferator-activated receptor (PPAR) response element regulation, in concert with PPAR gamma, PPAR alpha, or PPAR delta expression plasmids, showed dose-dependent activation of all PPARs by OA-NO2. PPAR gamma showed the greatest response, with significant activation at 100 nM, while PPAR alpha and PPAR delta were activated at similar to 300 nM OA-NO2. OA-NO2 also induced PPAR gamma-dependent adipogenesis and deoxyglucose uptake in 3T3-L1 preadipocytes at a potency exceeding nitrolinoleic acid and rivaling synthetic thiazolidinediones. These data reveal that nitrated fatty acids comprise a class of nitric oxide-derived, receptor-dependent, cell signaling mediators that act within physiological concentration ranges.	Univ Alabama Birmingham, Dept Anesthesiol, Birmingham, AL 35233 USA; Univ Alabama Birmingham, Ctr Free Rad Biol, Birmingham, AL 35233 USA; Univ Alabama Birmingham, Dept Environm Hlth Sci, Birmingham, AL 35233 USA; Morehouse Sch Med, Cardiovasc Res Inst, Atlanta, GA 30310 USA; Univ Oregon, Dept Chem, Eugene, OR 97403 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Morehouse School of Medicine; University of Oregon	Freeman, BA (corresponding author), Univ Alabama Birmingham, Dept Anesthesiol, 304-8 Biomed Res Bldg 11,901 19th St, Birmingham, AL 35233 USA.	freerad@uab.edu	Freeman, Bruce A/H-9342-2012; Batthyany, Carlos I./A-6478-2009; Schopfer, Francisco Jose/AAE-8125-2020; Schopfer, Francisco/AAW-6505-2021; Woodcock, Steven/AAE-9199-2020	Schopfer, Francisco Jose/0000-0001-9526-695X; Batthyany, Carlos/0000-0002-0627-1982	NHLBI NIH HHS [R37 HL058115, R01 HL068878, R01 HL058115, T32HL07457, R01 HL058115-09, HL068878, HL58115, R01 HL075397, R25 HL003676, HL075397, HL64937, R01 HL064937, UH1 HL003676, R01 HL064937-05A1, HL03676] Funding Source: Medline; NIGMS NIH HHS [S06 GM008248, S06GM08248] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068878, R01HL058115, T32HL007457, R37HL058115, R01HL064937, R25HL003676, R01HL075397, UH1HL003676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM008248] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker PRS, 2004, P NATL ACAD SCI USA, V101, P11577, DOI 10.1073/pnas.0402587101; Balazy M, 2001, J PHARMACOL EXP THER, V299, P611; Baldus S, 2001, AM J RESP CRIT CARE, V163, P308, DOI 10.1164/ajrccm.163.2.ed2000c; Bannenberg GL, 2005, J IMMUNOL, V174, P4345, DOI 10.4049/jimmunol.174.7.4345; BATEMAN L, 1953, T FARADAY SOC, V49, P1026, DOI 10.1039/tf9534901026; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Castro L, 2004, ARCH BIOCHEM BIOPHYS, V421, P99, DOI 10.1016/j.abb.2003.08.033; Coles B, 2002, CIRC RES, V91, P375, DOI 10.1161/01.RES.0000032114.68919.EF; Coles B, 2002, J BIOL CHEM, V277, P5832, DOI 10.1074/jbc.M105209200; Cosby K, 2003, NAT MED, V9, P1498, DOI 10.1038/nm954; d'Ischia M, 1999, TETRAHEDRON, V55, P9297, DOI 10.1016/S0040-4020(99)00491-3; Deng YZ, 2004, RAPID COMMUN MASS SP, V18, P1681, DOI 10.1002/rcm.1540; Denmark SE, 2003, J ORG CHEM, V68, P8015, DOI 10.1021/jo034853w; dIschia M, 1996, TETRAHEDRON LETT, V37, P5773, DOI 10.1016/0040-4039(96)01182-3; DODGE JT, 1967, J LIPID RES, V8, P667; Eiserich JP, 2002, SCIENCE, V296, P2391, DOI 10.1126/science.1106830; Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025; FINLAYSONPITTS BJ, 1987, TOXICOL APPL PHARM, V89, P438, DOI 10.1016/0041-008X(87)90163-3; GALLON AA, 1993, LIPIDS, V28, P125, DOI 10.1007/BF02535776; GALLON AA, 1994, LIPIDS, V29, P171, DOI 10.1007/BF02536725; Gladwin MT, 2000, P NATL ACAD SCI USA, V97, P11482, DOI 10.1073/pnas.97.21.11482; HOGG N, 1993, FEBS LETT, V334, P170, DOI 10.1016/0014-5793(93)81706-6; IGNARRO LJ, 1988, J PHARMACOL EXP THER, V244, P181; Koppenol WH, 1996, METHOD ENZYMOL, V269, P296; Larfars G, 1999, BLOOD, V93, P1399, DOI 10.1182/blood.V93.4.1399.404k07_1399_1405; Lee CH, 2002, TRENDS ENDOCRIN MET, V13, P331, DOI 10.1016/S1043-2760(02)00668-9; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; Li AC, 2004, J CLIN INVEST, V114, P1564, DOI 10.1172/JCI200418730; Lim DG, 2002, P NATL ACAD SCI USA, V99, P15941, DOI 10.1073/pnas.232409599; Lima ES, 2002, BIOCHEMISTRY-US, V41, P10717, DOI 10.1021/bi025504j; Lucet D, 2000, EUR J ORG CHEM, V2000, P3575; Marshall HE, 2000, FASEB J, V14, P1889, DOI 10.1096/fj.00.011rev; Marx N, 2004, CIRC RES, V94, P1168, DOI 10.1161/01.RES.0000127122.22685.0A; MIRANDA K, 2000, NITRIC OXIDE BIOL PA; Montuschi P, 2004, FASEB J, V18, P1791, DOI 10.1096/fj.04-2330rev; Mukherjee R, 2000, MOL ENDOCRINOL, V14, P1425, DOI 10.1210/me.14.9.1425; Napolitano A, 2002, TETRAHEDRON, V58, P5061, DOI 10.1016/S0040-4020(02)00460-X; Napolitano A, 2000, J ORG CHEM, V65, P4853, DOI 10.1021/jo000090q; O'Donnell VB, 1999, CHEM RES TOXICOL, V12, P83, DOI 10.1021/tx980207u; ODonnell VB, 1997, BIOCHEMISTRY-US, V36, P15216, DOI 10.1021/bi971891z; ONO N, 1988, B CHEM SOC JPN, V61, P4470, DOI 10.1246/bcsj.61.4470; PAI TG, 1987, ANAL BIOCHEM, V166, P150, DOI 10.1016/0003-2697(87)90557-4; Rassaf T, 2003, NAT MED, V9, P481, DOI 10.1038/nm0503-481; Rassaf T, 2002, FREE RADICAL BIO MED, V33, P1590, DOI 10.1016/S0891-5849(02)01183-8; RUBBO H, 1994, J BIOL CHEM, V269, P26066; Rubbo H, 2000, J BIOL CHEM, V275, P10812, DOI 10.1074/jbc.275.15.10812; Rubbo H, 1995, ARCH BIOCHEM BIOPHYS, V324, P15, DOI 10.1006/abbi.1995.9935; Schopfer FJ, 2003, TRENDS BIOCHEM SCI, V28, P646, DOI 10.1016/j.tibs.2003.10.006; Schopfer FJ, 2005, J BIOL CHEM, V280, P19289, DOI 10.1074/jbc.M414689200; Schopfer FJ, 2005, P NATL ACAD SCI USA, V102, P2340, DOI 10.1073/pnas.0408384102; SMITH WL, 1992, AM J PHYSIOL, V263, P181; Vidwans AS, 2001, BIOCHEMISTRY-US, V40, P11533, DOI 10.1021/bi0108960; Wang NP, 2002, J BIOL CHEM, V277, P34176, DOI 10.1074/jbc.M203436200; Zelinsky N, 1912, Z PHYS CHEM-STOCH VE, V78, P629; Zhang JF, 2004, P NATL ACAD SCI USA, V101, P10703, DOI 10.1073/pnas.0403652101	56	298	314	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42464	42475		10.1074/jbc.M504212200	http://dx.doi.org/10.1074/jbc.M504212200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16227625	Green Accepted, hybrid			2022-12-25	WOS:000233992700077
J	Karasawa, A; Tsuboi, Y; Inoue, H; Kinoshita, R; Nakamura, N; Kanazawa, H				Karasawa, A; Tsuboi, Y; Inoue, H; Kinoshita, R; Nakamura, N; Kanazawa, H			Detection of oligomerization and conformational changes in the Na+/H+ antiporter from Helicobacter pylori by fluorescence resonance energy transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NHAA; GENE; MECHANISM; PROTEIN; DOMAINS; CLONING; OVERPRODUCTION; TRANSPORTER; EXPRESSION	Oligomerization and conformational changes in the Na+/H+ antiporter from Helicobacter pylori (HPNhaA) were studied by means of fluorescence resonance energy transfer (FRET) analysis. Na+/H+ antiporter-deficient Escherichia coli cells expressing C-terminal fusions of HPNhaA to green fluorescent protein (GFP) variants exhibited wild-type levels of antiporter activity in their everted membrane vesicles. Vesicles containing both HPNhaA-CFP and HPNhaA-YFP or HPNhaA-Venus exhibited FRET from CFP (donor) to YFP or Venus (acceptor), suggesting that HPNhaA forms an oligomer. Co-precipitation of HPNhaA tagged by Venus and FLAG sequences confirmed oligomerization. FRET decreased extensively after treatment of the vesicles with proteinase K, which released GFP variants from the fusion proteins. FRET was not observed by merely mixing vesicles expressing the donor or acceptor fusion alone. Fluorescence of Venus is less sensitive to anions and stronger than that of anion-sensitive YFP. Using HPNhaA-Venus as the acceptor, Li+ was found to cause a significant decrease in FRET regardless of the presence or absence of Delta pH across the membranes, whereas Na+ caused a much weaker effect. This Li+ effect was minimal in vesicles prepared from cells expressing HPNhaA containing an Asp(141) to Asn mutation, which results in defective Li+/H+ antiporter activity, possibly Li+ binding. These results demonstrate that monomer interactions within the HPNhaA oligomer are weakened possibly by Li+ binding. Dynamic interactions between HPNhaA monomers were detectable in membranes by FRET analysis, thus providing a new approach to study dynamic conformational changes in NhaA during antiport activity.	Osaka Univ, Grad Sch Sci, Dept Biol Sci, Osaka 5600043, Japan	Osaka University	Kanazawa, H (corresponding author), Osaka Univ, Grad Sch Sci, Dept Biol Sci, Machikaneyama Cho 1-1, Osaka 5600043, Japan.	kanazawa@bio.sci.osaka-u.ac.jp						Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; Galili L, 2004, J BIOL CHEM, V279, P23104, DOI 10.1074/jbc.M400288200; Gerchman Y, 2001, BIOCHEMISTRY-US, V40, P3403, DOI 10.1021/bi002669o; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Hunte C, 2005, NATURE, V435, P1197, DOI 10.1038/nature03692; INOUE H, 1995, FEBS LETT, V363, P264, DOI 10.1016/0014-5793(95)00331-3; Inoue H, 1998, BIOL PHARM BULL, V21, P1128; Inoue H, 1999, FEBS LETT, V443, P11, DOI 10.1016/S0014-5793(98)01652-4; Inoue S, 2001, J BIOCHEM, V129, P569, DOI 10.1093/oxfordjournals.jbchem.a002892; IVEY DM, 1993, J BIOL CHEM, V268, P11296; KANAZAWA H, 1979, P NATL ACAD SCI USA, V76, P1126, DOI 10.1073/pnas.76.3.1126; KARPEL R, 1988, J BIOL CHEM, V263, P10408; Kuwabara N, 2004, J BIOL CHEM, V279, P40567, DOI 10.1074/jbc.M401132200; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Maniatis T., 1982, MOL CLONING LAB MANU; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Nakamura T, 2001, J BACTERIOL, V183, P5762, DOI 10.1128/JB.183.19.5762-5767.2001; Nozaki K, 1996, BIOCHEM BIOPH RES CO, V222, P774, DOI 10.1006/bbrc.1996.0820; Overton MC, 2002, METHODS, V27, P324, DOI 10.1016/S1046-2023(02)00090-7; PADAN E, 1994, BBA-BIOENERGETICS, V1185, P129, DOI 10.1016/0005-2728(94)90204-6; Padan E, 1998, MICR EXTREM UNUSUAL, P163; PADAN E, 1992, ALKALI CATION TRANSP, P3; PINNER E, 1992, J BIOL CHEM, V267, P11064; PINNER E, 1994, J BIOL CHEM, V269, P26274; Rothman A, 1996, J BIOL CHEM, V271, P32288, DOI 10.1074/jbc.271.50.32288; Rothman A, 1997, BIOCHEMISTRY-US, V36, P14572, DOI 10.1021/bi971800y; Schuldiner S., 1992, ALKALI CATION TRANSP, P25; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289; THELEN P, 1991, J BACTERIOL, V173, P6553, DOI 10.1128/jb.173.20.6553-6557.1991; Tsien Roger Y., 1993, Trends in Cell Biology, V3, P242, DOI 10.1016/0962-8924(93)90124-J; Tsuboi Y, 2003, J BIOL CHEM, V278, P21467, DOI 10.1074/jbc.M301932200; Williams KA, 1999, EMBO J, V18, P3558, DOI 10.1093/emboj/18.13.3558; Williams KA, 2000, NATURE, V403, P112, DOI 10.1038/47534	35	21	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					41900	41911		10.1074/jbc.M510795200	http://dx.doi.org/10.1074/jbc.M510795200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16216867	hybrid			2022-12-25	WOS:000233992700016
J	Kim, SH; Sisodia, SS				Kim, SH; Sisodia, SS			Evidence that the "NF" motif in transmembrane domain 4 of presenilin 1 is critical for binding with PEN-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SECRETASE COMPLEX; AMYLOID PRECURSOR PROTEIN; COORDINATED EXPRESSION; ALZHEIMERS-DISEASE; APH-1; NICASTRIN; NOTCH; ENDOPROTEOLYSIS; TOPOLOGY; BETA	Macromolecular complexes containing presenilins (PS1 and PS2), nicastrin, anterior pharynx defective phenotype 1 (APH-1), and PS enhancer 2 (PEN-2) mediate the intramembranous, gamma-secretase cleavage of beta-amyloid precursor protein (APP), Notch, and a variety of type 1 membrane proteins. We previously demonstrated that PEN-2 is critical for promoting endoproteolysis of PS1 and that the proximal two-thirds of transmembrane domain (TMD) 1 of PEN-2 is required for binding with PS1. In this study, we sought to identify the structural domains of PS1 that are necessary for binding with PEN-2. To address this issue, we generated a series of constructs encoding PS1 mutants harboring deletions or replacements of specific TMDs of PS1-NTF, and examined the effects of encoded molecules on interactions with PEN-2, stabilization and endoproteolysis of PS1, and gamma-secretase activity. We now show that PS1 TMDs 1 and 2 and the intervening hydrophilic loop are dispensable for binding to PEN-2. Furthermore, analysis of chimeric PS1 molecules that harbor replacements of each TMD with corresponding transmembrane segments from the sterol regulatory element-binding protein cleavage activating protein (SCAP) revealed that the PS1-SCAP TMD4 mutant failed to coimmunoprecipitate endogenous PEN-2, strongly suggesting that the fourth TMD of PS1 is required for interaction with PEN-2. Further mutational analyses revealed that the "NF" sequence within the TMD4 of PS1 is the minimal motif that is required for binding with PEN-2, promoting PS1 endoproteolysis and gamma-secretase activity.	Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA	University of Chicago	Sisodia, SS (corresponding author), 947 E 58th St,MC0926, Chicago, IL USA.	ssisodia@drugs.bsd.uchicago.edu			NATIONAL INSTITUTE ON AGING [R01AG021494] Funding Source: NIH RePORTER; NIA NIH HHS [AG021494] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; Capell A, 2003, J BIOL CHEM, V278, P52519, DOI 10.1074/jbc.C300435200; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Crystal AS, 2003, J BIOL CHEM, V278, P20117, DOI 10.1074/jbc.M213107200; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Fraering PC, 2004, BIOCHEMISTRY-US, V43, P323, DOI 10.1021/bi035748j; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Hu Y, 2003, J CELL BIOL, V161, P685, DOI 10.1083/jcb.200304014; Kaether C, 2004, EMBO J, V23, P4738, DOI 10.1038/sj.emboj.7600478; Kim SH, 2005, J BIOL CHEM, V280, P1992, DOI 10.1074/jbc.M412404200; Kim SH, 2004, J BIOL CHEM, V279, P48615, DOI 10.1074/jbc.C400396200; Kim SH, 2003, J BIOL CHEM, V278, P33992, DOI 10.1074/jbc.M305834200; Kim SH, 2001, J BIOL CHEM, V276, P43343, DOI 10.1074/jbc.M108245200; Laudon H, 2005, J BIOL CHEM, V280, P35352, DOI 10.1074/jbc.M507217200; LaVoie MJ, 2003, J BIOL CHEM, V278, P37213, DOI 10.1074/jbc.M303941200; Lee SF, 2004, J BIOL CHEM, V279, P4144, DOI 10.1074/jbc.M309745200; Leem JY, 2002, NEUROBIOL DIS, V11, P64, DOI 10.1006/nbdi.2002.0546; Li XJ, 1998, P NATL ACAD SCI USA, V95, P7109, DOI 10.1073/pnas.95.12.7109; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Martys-Zage JL, 2000, J MOL NEUROSCI, V15, P189, DOI 10.1385/JMN:15:3:189; Morais VA, 2003, J BIOL CHEM, V278, P43284, DOI 10.1074/jbc.M305685200; Murphy MP, 2000, J BIOL CHEM, V275, P26277, DOI 10.1074/jbc.M002812200; Periz G, 2004, J NEUROSCI RES, V77, P309, DOI 10.1002/jnr.20203; Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479; Prokop S, 2004, J BIOL CHEM, V279, P23255, DOI 10.1074/jbc.M401789200; Ratovitski T, 1997, J BIOL CHEM, V272, P24536, DOI 10.1074/jbc.272.39.24536; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; Watanabe N, 2005, J BIOL CHEM, V280, P41967, DOI 10.1074/jbc.M509066200; Yu CJ, 2001, J BIOL CHEM, V276, P43756, DOI 10.1074/jbc.C100410200	37	68	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					41953	41966		10.1074/jbc.M509070200	http://dx.doi.org/10.1074/jbc.M509070200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16234243	hybrid			2022-12-25	WOS:000233992700021
J	Cervinski, MA; Foster, JD; Vaughan, RA				Cervinski, MA; Foster, JD; Vaughan, RA			Psychoactive substrates stimulate dopamine transporter phosphorylation and down-regulation by cocaine-sensitive and protein kinase C-dependent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; STRIATAL SYNAPTOSOMES; SURFACE EXPRESSION; XENOPUS OOCYTES; PHORBOL ESTERS; SYNTAXIN 1A; AMPHETAMINE; TRAFFICKING; EFFLUX; INTERNALIZATION	Dopamine transporters (DATs) undergo intracellular sequestration and functional down-regulation upon exposure to psychostimulant substrates. To investigate the potential mechanism underlying these responses, we examined the acute in vitro and in vivo effects of amphetamine and methamphetamine ( METH) on phosphorylation and down-regulation of rat DAT using wild type and N-terminal truncation mutants. Phosphorylation of DAT assessed by (PO4)-P-32 metabolic labeling was increased up to 2-fold by in vitro treatment of rDAT LLC-PK1 cells with amphetamine or METH and was similarly increased in rat striatal tissue by in vitro application or in vivo injection of METH. The dopamine transport blocker (-)-cocaine did not affect DAT phosphorylation but prevented the phosphorylation increase induced by METH. Phosphorylation of DAT induced by METH was also prevented by the protein kinase C blocker bisindoylmaleimide I and was absent in an N-terminally truncated protein that lacks the first 21 residues including 6 serines that also represent the site of phorbol ester induced phosphorylation. Down-regulation of transport induced by METH was also cocaine- and protein kinase C-dependent but was retained in the N-terminal truncation mutant. These results demonstrate that transport or binding of METH stimulates DAT phosphorylation and down-regulation by a mechanism that requires protein kinase C but that METH-induced down-regulation can occur independently of direct transporter phosphorylation. The finding that DAT phosphorylation is stimulated by amphetamines reveals a previously unknown effect of these drugs that is not produced by cocaine and may be related to reinforcement.	Univ N Dakota, Sch Med & Hlth Sci, Dept Biochem & Mol Biol, Grand Forks, ND 58202 USA	University of North Dakota Grand Forks	Vaughan, RA (corresponding author), Univ N Dakota, Sch Med & Hlth Sci, Dept Biochem & Mol Biol, Grand Forks, ND 58202 USA.	rvaughan@medicine.nodak.edu	Cervinski, Mark/ABC-6456-2020	Cervinski, Mark/0000-0001-5116-3780	NATIONAL INSTITUTE ON DRUG ABUSE [F31DA017520, R01DA013147] Funding Source: NIH RePORTER; NIDA NIH HHS [F31 DA17520, R01 DA13147] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Beckman ML, 1998, J NEUROSCI, V18, P6103; Chi LM, 2003, J PHARMACOL EXP THER, V307, P729, DOI 10.1124/jpet.103.055095; Cowell RM, 2000, EUR J PHARMACOL, V389, P59, DOI 10.1016/S0014-2999(99)00828-6; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; Daws LC, 2002, BIOCHEM BIOPH RES CO, V290, P1545, DOI 10.1006/bbrc.2002.6384; Doolen S, 2002, FEBS LETT, V516, P187, DOI 10.1016/S0014-5793(02)02554-1; ESHLEMAN AJ, 1994, MOL PHARMACOL, V45, P312; Falkenburger BH, 2001, SCIENCE, V293, P2465, DOI 10.1126/science.1060645; Fleckenstein AE, 1997, J PHARMACOL EXP THER, V282, P834; Fleckenstein AE, 1999, EUR J PHARMACOL, V382, P45, DOI 10.1016/S0014-2999(99)00588-9; Foster JD, 2003, MOL BRAIN RES, V110, P100, DOI 10.1016/S0169-328X(02)00645-9; Foster JD, 2002, J BIOL CHEM, V277, P25178, DOI 10.1074/jbc.M200294200; Gaffaney JD, 2004, MOL PHARMACOL, V65, P692, DOI 10.1124/mol.65.3.692; Giambalvo CCT, 2004, SYNAPSE, V51, P128, DOI 10.1002/syn.10289; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; Gnegy ME, 2004, MOL PHARMACOL, V66, P137, DOI 10.1124/mol.66.1.137; Gorentla BK, 2005, NEUROPHARMACOLOGY, V49, P759, DOI 10.1016/j.neuropharm.2005.08.011; Granas C, 2003, J BIOL CHEM, V278, P4990, DOI 10.1074/jbc.M205058200; GRENADER A, 1991, AM J PHYSIOL, V260, pF906, DOI 10.1152/ajprenal.1991.260.6.F906; GU H, 1994, J BIOL CHEM, V269, P7124; Gulley JM, 2002, J NEUROCHEM, V83, P400, DOI 10.1046/j.1471-4159.2002.01133.x; Huff RA, 1997, J NEUROCHEM, V68, P225; Johnson LA, 2005, J BIOL CHEM, V280, P10914, DOI 10.1074/jbc.M413887200; Kahlig KM, 2004, J BIOL CHEM, V279, P8966, DOI 10.1074/jbc.M303976200; Kantor L, 1998, J PHARMACOL EXP THER, V284, P592; Khoshbouei H, 2004, PLOS BIOL, V2, P387, DOI 10.1371/journal.pbio.0020078; Khoshbouei H, 2003, J BIOL CHEM, V278, P12070, DOI 10.1074/jbc.M212815200; Kramer HK, 1997, NEUROPSYCHOPHARMACOL, V17, P117; Loder MK, 2003, J BIOL CHEM, V278, P22168, DOI 10.1074/jbc.M301845200; Melikian HE, 1999, J NEUROSCI, V19, P7699; Miller GW, 1999, TRENDS PHARMACOL SCI, V20, P424, DOI 10.1016/S0165-6147(99)01379-6; Quick MW, 2004, J BIOL CHEM, V279, P15961, DOI 10.1074/jbc.M306924200; Quick MW, 2002, P NATL ACAD SCI USA, V99, P5686, DOI 10.1073/pnas.082712899; Ramamoorthy S, 1999, SCIENCE, V285, P763, DOI 10.1126/science.285.5428.763; Samuvel DJ, 2005, J NEUROSCI, V25, P29, DOI 10.1523/JNEUROSCI.3754-04.2005; Sandoval V, 2001, J NEUROSCI, V21, P1413; Saunders C, 2000, P NATL ACAD SCI USA, V97, P6850, DOI 10.1073/pnas.110035297; Seidel S, 2005, MOL PHARMACOL, V67, P140, DOI 10.1124/mol.67.1.140; SULZER D, 1995, J NEUROSCI, V15, P4102; Sung U, 2003, J NEUROSCI, V23, P1697; Torres GE, 2003, J BIOL CHEM, V278, P2731, DOI 10.1074/jbc.M201926200; Vaughan RA, 2004, J PHARMACOL EXP THER, V310, P1, DOI 10.1124/jpet.103.052423; Vaughan RA, 1997, J BIOL CHEM, V272, P15541, DOI 10.1074/jbc.272.24.15541	43	101	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40442	40449		10.1074/jbc.M501969200	http://dx.doi.org/10.1074/jbc.M501969200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16204245	hybrid			2022-12-25	WOS:000233666600009
J	Mason, JM; Cliff, MJ; Sessions, RB; Clarke, AR				Mason, JM; Cliff, MJ; Sessions, RB; Clarke, AR			Low energy pathways and non-native interactions - The influence of artificial disulfide bridges on the mechanism of folding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIPARALLEL BETA-SHEETS; TRANSITION-STATE; STABILITY; PROTEINS; INTERMEDIATE; BACKBONE; DYNAMICS; BONDS	Four versions of a beta-sheet protein (CD2.d1) have been made, each with a single artificial disulfide bond inserted into hairpin structures. Folding kinetics of reduced and oxidized forms shows bridge position strongly influences its effect on the folding reaction. Bridging residues 58 and 62 does not affect the rapidly formed intermediate (I) or rate-limiting transition (t) state, whereas bridging 33 and 38, or 31 and 41, lowers the t-state energy, with the latter having the stronger influence. Bridging residues 79 and 90 stabilizes both I-and t-states. To assess additivity in the energetic effects of these bridges, four double-bridge variants have also been made. All show precise additivity of overall stability, with two showing additivity when ground states and the rate-limiting t-state are assessed, i.e. no measurable change in the folding mechanism occurs. However, combining 31-41 and 79-90 bridges produces a molecule that folds through a different pathway, with a much more stable intermediate than expected and a much higher t-state barrier. This is explained by the artificial introduction of stabilizing, non-native contacts in the I-state. More surprisingly, for another double-bridge version (58-62 and 79-90) both I- and t-states are less stable than expected, showing that conformational constraints introduced by the two bridges prevent formation of non-native contacts that would otherwise stabilize the I- and t-states, thereby lowering the energy of the folding landscape in the wild-type ( unbridged) molecule. We conclude that the lowest energy path for folding has I- and t-state structures that are stabilized by non-native interactions.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Bristol	Mason, JM (corresponding author), Univ Freiburg, Inst Biol 3, Schaenzlestr 1, D-79104 Freiburg, Germany.	Jody@biologie.uni-freiburg.de	Mason, Jody/W-8204-2019; Mason, Jody/A-9329-2011	Mason, Jody/0000-0002-4118-1958; Mason, Jody/0000-0002-4118-1958; Sessions, Richard/0000-0003-0320-0895; Cliff, Matthew/0000-0002-7482-0234				CLARKE J, 1993, BIOCHEMISTRY-US, V32, P4322, DOI 10.1021/bi00067a022; Clarke J, 1999, STRUCT FOLD DES, V7, P1145, DOI 10.1016/S0969-2126(99)80181-6; CREIGHTON T, 1990, PROTEIN STRUCTURE PR, P101; DRISCOLL PC, 1991, NATURE, V353, P762, DOI 10.1038/353762a0; Fowler SB, 2001, STRUCTURE, V9, P355, DOI 10.1016/S0969-2126(01)00596-2; Grantcharova VP, 2000, P NATL ACAD SCI USA, V97, P7084, DOI 10.1073/pnas.97.13.7084; Hosszu LLP, 1997, NAT STRUCT BIOL, V4, P801, DOI 10.1038/nsb1097-801; Hutchinson EG, 1998, PROTEIN SCI, V7, P2287, DOI 10.1002/pro.5560071106; Lorch M, 2000, BIOCHEMISTRY-US, V39, P3480, DOI 10.1021/bi9923510; Mason JM, 2002, BIOCHEMISTRY-US, V41, P12093, DOI 10.1021/bi026398o; PACE CN, 1988, J BIOL CHEM, V263, P11820; Parker MJ, 1997, BIOCHEMISTRY-US, V36, P13396, DOI 10.1021/bi971294c; PARKER MJ, 1995, J MOL BIOL, V253, P771, DOI 10.1006/jmbi.1995.0590; Parker MJ, 1997, BIOCHEMISTRY-US, V36, P5786, DOI 10.1021/bi9629283; WOUTERS MA, 1995, PROTEINS, V22, P119, DOI 10.1002/prot.340220205; Yokota A, 2000, J MOL BIOL, V295, P1275, DOI 10.1006/jmbi.1999.3442; Zavodszky M, 2001, PROTEIN SCI, V10, P149, DOI 10.1110/ps.26801	17	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40494	40499		10.1074/jbc.M509281200	http://dx.doi.org/10.1074/jbc.M509281200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16216876	hybrid			2022-12-25	WOS:000233666600015
J	Tehei, M; Madern, D; Franzetti, B; Zaccai, G				Tehei, M; Madern, D; Franzetti, B; Zaccai, G			Neutron scattering reveals the dynamic basis of protein adaptation to extreme temperature	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HALOPHILIC MALATE-DEHYDROGENASE; L-LACTATE DEHYDROGENASE; CRYSTAL-STRUCTURE; CONFORMATIONAL FLEXIBILITY; METHANOCOCCUS-JANNASCHII; SOLVENT CONDITIONS; ALPHA-AMYLASE; STABILITY; MECHANISMS; ENZYMES	To explore protein adaptation to extremely high temperatures, two parameters related to macromolecular dynamics, the mean square atomic fluctuation and structural resilience, expressed as a mean force constant, were measured by neutron scattering for hyperthermophilic malate dehydrogenase from Methanococcus jannaschii and a mesophilic homologue, lactate dehydrogenase from Oryctolagus cunniculus ( rabbit) muscle. The root mean square fluctuations, defining flexibility, were found to be similar for both enzymes ( 1.5 angstrom) at their optimal activity temperature. Resilience values, defining structural rigidity, are higher by an order of magnitude for the high temperature- adapted protein ( 0.15 Newtons/ meter for O. cunniculus lactate dehydrogenase and 1.5 Newtons/ meter for M. jannaschii malate dehydrogenase). Thermoadaptation appears to have been achieved by evolution through selection of appropriate structural rigidity in order to preserve specific protein structure while allowing the conformational flexibility required for activity.	Inst Max Von Laue Paul Langevin, F-38042 Grenoble, France; Univ Grenoble 1, CNRS, CEA, Inst Biol Struct, F-38027 Grenoble, France	Institut Laue-Langevin (ILL); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Zaccai, G (corresponding author), Inst Max Von Laue Paul Langevin, 6 Rue Jules Horowitz,BP 156, F-38042 Grenoble, France.	zaccai@ill.fr	Tehei, Moeava/W-6965-2019	Tehei, Moeava/0000-0003-3654-6833				ADAMS MWW, 1995, BIO-TECHNOL, V13, P662, DOI 10.1038/nbt0795-662; Adams MWW, 1998, TRENDS BIOTECHNOL, V16, P329, DOI 10.1016/S0167-7799(98)01193-7; ALBER T, 1987, BIOCHEMISTRY-US, V26, P3754, DOI 10.1021/bi00387a002; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BARLOW DJ, 1983, J MOL BIOL, V168, P867, DOI 10.1016/S0022-2836(83)80079-5; Bertini I, 2000, PROTEINS, V41, P75, DOI 10.1002/1097-0134(20001001)41:1<75::AID-PROT100>3.0.CO;2-2; Bicout DJ, 2001, BIOPHYS J, V80, P1115, DOI 10.1016/S0006-3495(01)76089-4; BONNETE F, 1994, J MOL BIOL, V244, P436, DOI 10.1006/jmbi.1994.1741; Cambillau C, 2000, J BIOL CHEM, V275, P32383, DOI 10.1074/jbc.C000497200; CHOTHIA C, 1974, NATURE, V248, P338, DOI 10.1038/248338a0; Dalhus B, 2002, J MOL BIOL, V318, P707, DOI 10.1016/S0022-2836(02)00050-5; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; Fitter J, 2004, BIOCHEMISTRY-US, V43, P9589, DOI 10.1021/bi0493362; Fitter J, 2001, BIOCHEMISTRY-US, V40, P10723, DOI 10.1021/bi010808b; Fitter J, 2000, BIOPHYS J, V79, P1629, DOI 10.1016/S0006-3495(00)76413-7; Gabel F, 2005, EUR BIOPHYS J BIOPHY, V34, P1, DOI 10.1007/s00249-004-0433-0; Gabel F, 2002, Q REV BIOPHYS, V35, P327, DOI 10.1017/S0033583502003840; Gibrat JF, 1996, CURR OPIN STRUC BIOL, V6, P377, DOI 10.1016/S0959-440X(96)80058-3; Grottesi A, 2002, PROTEINS, V46, P287, DOI 10.1002/prot.10045; Guinier A., 1955, SMALL ANGLE SCATTERI; Hennig M, 1995, STRUCTURE, V3, P1295, DOI 10.1016/S0969-2126(01)00267-2; Hernandez G, 2000, P NATL ACAD SCI USA, V97, P3166, DOI 10.1073/pnas.040569697; Irimia A, 2004, J MOL BIOL, V335, P343, DOI 10.1016/j.jmb.2003.10.054; JAENICKE R, 1991, EUR J BIOCHEM, V202, P715, DOI 10.1111/j.1432-1033.1991.tb16426.x; Jaenicke R, 1996, NATURWISSENSCHAFTEN, V83, P544; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Lee BI, 2001, J MOL BIOL, V307, P1351, DOI 10.1006/jmbi.2001.4532; Madern D, 2002, J MOL EVOL, V54, P825, DOI 10.1007/s00239-001-0088-8; Madern D, 2000, EXTREMOPHILES, V4, P91, DOI 10.1007/s007920050142; Madern D, 2000, MOL MICROBIOL, V37, P1515, DOI 10.1046/j.1365-2958.2000.02113.x; MATSUMURA M, 1988, NATURE, V334, P406, DOI 10.1038/334406a0; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; PAKULA AA, 1989, ANNU REV GENET, V23, P289, DOI 10.1146/annurev.ge.23.120189.001445; Reat V, 1997, BIOLOGICAL MACROMOLECULAR DYNAMICS, P117; RUSSELL RJM, 1994, STRUCTURE, V2, P1157, DOI 10.1016/S0969-2126(94)00118-9; SMITH JC, 1991, Q REV BIOPHYS, V24, P227, DOI 10.1017/S0033583500003723; Tehei M, 2004, EMBO REP, V5, P66, DOI 10.1038/sj.embor.7400049; Tehei M, 2001, P NATL ACAD SCI USA, V98, P14356, DOI 10.1073/pnas.251537298; Wang YL, 2000, TRENDS BIOCHEM SCI, V25, P300, DOI 10.1016/S0968-0004(00)01561-9; WRBA A, 1990, BIOCHEMISTRY-US, V29, P7584, DOI 10.1021/bi00485a007; Zaccai G, 2000, SCIENCE, V288, P1604, DOI 10.1126/science.288.5471.1604; Zaccai G, 2000, J PHYS IV, V10, P283, DOI 10.1051/jp4:2000757; Zavodszky P, 1998, P NATL ACAD SCI USA, V95, P7406, DOI 10.1073/pnas.95.13.7406	44	63	63	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40974	40979		10.1074/jbc.M508417200	http://dx.doi.org/10.1074/jbc.M508417200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16203729	hybrid			2022-12-25	WOS:000233666600071
J	Stokes, NR; Sievers, J; Barker, S; Bennett, JM; Brown, DR; Collins, I; Errington, VM; Foulger, D; Hall, M; Halsey, R; Johnson, H; Rose, V; Thomaides, HB; Haydon, DJ; Czaplewski, LG; Errington, J				Stokes, NR; Sievers, J; Barker, S; Bennett, JM; Brown, DR; Collins, I; Errington, VM; Foulger, D; Hall, M; Halsey, R; Johnson, H; Rose, V; Thomaides, HB; Haydon, DJ; Czaplewski, LG; Errington, J			Novel inhibitors of bacterial cytokinesis identified by a cell-based antibiotic screening assay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZIPA-FTSZ INTERACTION; BACILLUS-SUBTILIS; SMALL-MOLECULE; PROTEIN FTSZ; DIVISION; GENE; SPORULATION; SEPTATION; MUTANTS; RING	The continuous emergence of antibiotic resistance demands that novel classes of antibiotics continue to be developed. The division machinery of bacteria is an attractive target because it comprises seven or more essential proteins that are conserved almost throughout the bacteria but are absent from humans. We describe the development of a cell-based assay for inhibitors of cell division and its use to isolate a new inhibitor of FtsZ protein, a key player in the division machinery. Biochemical, cytological, and genetic data are presented that demonstrate that FtsZ is the specific target for the compound. We also describe the effects of more potent analogues of the original hit compound that act on important pathogens, again at the level of cell division. The assay and the compounds have the potential to provide novel antibiotics with no pool of pre-existing resistance. They have provided new insight into cytokinesis in bacteria and offer important reagents for further studies of the cell division machinery.	Univ Oxford, Prolysis Ltd, Yarnton OX5 1PF, Oxon, England; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford; University of Oxford	Czaplewski, LG (corresponding author), Univ Oxford, Prolysis Ltd, Begbroke Sci Pk,Sandy Lane, Yarnton OX5 1PF, Oxon, England.	lloyd.czaplewski@prolysis.com	Errington, Jeff/G-1832-2011; Stokes, Neil/ABA-4660-2020	Errington, Jeff/0000-0002-6977-9388; Thomaides-Brears, Helena/0000-0003-0774-6983; Bennett, James/0000-0003-1396-8400	MRC [G9826944] Funding Source: UKRI; Medical Research Council [G9826944] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Addinall SG, 1997, J BACTERIOL, V179, P4277, DOI 10.1128/jb.179.13.4277-4284.1997; ANAGNOSTOPOULOS C, 1961, J BACTERIOL, V81, P741, DOI 10.1128/JB.81.5.741-746.1961; Arends SJR, 2004, J BACTERIOL, V186, P880, DOI 10.1128/JB.186.3.880-884.2004; Eberhardt C, 2003, J BACTERIOL, V185, P3726, DOI 10.1128/JB.185.13.3726-3734.2003; Errington J, 2003, MICROBIOL MOL BIOL R, V67, P52, DOI 10.1128/MMBR.67.1.52-65.2003; ERRINGTON J, 1986, J GEN MICROBIOL, V132, P2967; Errington J, 2001, CURR OPIN MICROBIOL, V4, P660, DOI 10.1016/S1369-5274(01)00266-1; Haeusser DP, 2004, MOL MICROBIOL, V52, P801, DOI 10.1111/j.1365-2958.2004.04016.x; JENKINSON HF, 1983, J GEN MICROBIOL, V129, P1945; Jennings LD, 2004, BIOORGAN MED CHEM, V12, P5115, DOI 10.1016/j.bmc.2004.07.031; KARAMATA D, 1970, MOL GEN GENET, V108, P277, DOI 10.1007/BF00283358; KUNST F, 1995, J BACTERIOL, V177, P2403, DOI 10.1128/jb.177.9.2403-2407.1995; Lowe J, 1998, NATURE, V391, P203, DOI 10.1038/34472; Margalit DN, 2004, P NATL ACAD SCI USA, V101, P11821, DOI 10.1073/pnas.0404439101; Ohashi Y, 1999, J BACTERIOL, V181, P1348, DOI 10.1128/JB.181.4.1348-1351.1999; Pinho MG, 2003, MOL MICROBIOL, V50, P871, DOI 10.1046/j.1365-2958.2003.03719.x; REYNOLDS PE, 1989, EUR J CLIN MICROBIOL, V8, P943, DOI 10.1007/BF01967563; Reynolds RC, 2004, BIOORG MED CHEM LETT, V14, P3161, DOI 10.1016/j.bmcl.2004.04.012; SAMBROOK J, 1989, MOL CLONIGN LAB MANU; Sutherland AG, 2003, ORG BIOMOL CHEM, V1, P4138, DOI 10.1039/b312016c; Wang J, 2003, J BIOL CHEM, V278, P44424, DOI 10.1074/jbc.M307625200; White EL, 2002, J ANTIMICROB CHEMOTH, V50, P111, DOI 10.1093/jac/dkf075; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206	23	98	113	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					39709	39715		10.1074/jbc.M506741200	http://dx.doi.org/10.1074/jbc.M506741200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16174771	hybrid			2022-12-25	WOS:000233461300007
J	Pham, JW; Sontheimer, EJ				Pham, JW; Sontheimer, EJ			Molecular requirements for RNA-induced silencing complex assembly in the Drosophila RNA interference pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; MESSENGER-RNA; FUNCTIONAL-ANATOMY; CRYSTAL-STRUCTURE; SLICER ACTIVITY; ENZYME COMPLEX; PIWI PROTEIN; SIRNA; RECOGNITION; CLEAVAGE	Complexes in the Drosophila RNA-induced silencing complex (RISC) assembly pathway can be resolved using native gel electrophoresis, revealing an initiator called R1, an intermediate called R2, and an effector called R3 (now referred to as holo-RISC). Here we show that R1 forms when the Dicer-2/R2D2 heterodimer binds short interfering RNA (siRNA) duplexes. The heterodimer alone can initiate RISC assembly, indicating that other factors are dispensable for initiation. During assembly, R2 requires Argonaute 2 to convert into holo-RISC. This requirement is reminiscent of the RISC-loading complex, which also requires Argonaute 2 for assembly into RISC. We have compared R2 to the RISC-loading complex and show that the two complexes are similar in their sensitivities to ATP and to chemical modifications on siRNA duplexes, indicating that they are likely to be identical. We have examined the requirements for RISC formation and show that the siRNA 5'-termini are repeatedly monitored during RISC assembly, first by the Dcr-2/R2D2 heterodimer and again after R2 formation, before siRNA unwinding. The 2'-position of the 5'-terminal nucleotide also affects RISC assembly, because an siRNA strand bearing a 2'-deoxyribose at this position can inhibit the cognate strand from entering holo-RISC; in contrast, the 2'-deoxyribose-modified strand has enhanced activity in the RNA interference pathway.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University	Sontheimer, EJ (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2205 Tech Dr, Evanston, IL 60208 USA.	erik@northwestern.edu		Sontheimer, Erik/0000-0002-0881-0310	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM072830] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM072830] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amarzguioui M, 2003, NUCLEIC ACIDS RES, V31, P589, DOI 10.1093/nar/gkg147; Chiu YL, 2003, RNA, V9, P1034, DOI 10.1261/rna.5103703; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gazzani S, 2004, SCIENCE, V306, P1046, DOI 10.1126/science.1101092; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8; Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513; Liu QH, 2003, SCIENCE, V301, P1921, DOI 10.1126/science.1088710; Ma JB, 2005, NATURE, V434, P666, DOI 10.1038/nature03514; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; Okamura K, 2004, GENE DEV, V18, P1655, DOI 10.1101/gad.1210204; Orban TI, 2005, RNA, V11, P459, DOI 10.1261/rna.7231505; Parker JS, 2005, NATURE, V434, P663, DOI 10.1038/nature03462; Parker JS, 2004, EMBO J, V23, P4727, DOI 10.1038/sj.emboj.7600488; Parrish S, 2000, MOL CELL, V6, P1077, DOI 10.1016/S1097-2765(00)00106-4; Pham JW, 2004, CELL, V117, P83, DOI 10.1016/S0092-8674(04)00258-2; Rand TA, 2004, P NATL ACAD SCI USA, V101, P14385, DOI 10.1073/pnas.0405913101; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Song JJ, 2004, SCIENCE, V305, P1434, DOI 10.1126/science.1102514; Souret FF, 2004, MOL CELL, V15, P173, DOI 10.1016/j.molcel.2004.06.006; Tomari Y, 2004, SCIENCE, V306, P1377, DOI 10.1126/science.1102755; Tomari Y, 2004, CELL, V116, P831, DOI 10.1016/S0092-8674(04)00218-1; Tuschl T, 1999, GENE DEV, V13, P3191, DOI 10.1101/gad.13.24.3191; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0	31	59	62	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39278	39283		10.1074/jbc.M509202200	http://dx.doi.org/10.1074/jbc.M509202200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16179342	hybrid			2022-12-25	WOS:000233362200046
J	Qi, HY; Shelhamer, JH				Qi, HY; Shelhamer, JH			Toll-like receptor 4 signaling regulates cytosolic phospholipase A(2) activation and lipid generation in lipopolysaccharide-stimulated macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR; CYTOSOLIC PHOSPHOLIPASE A(2); NF-KAPPA-B; ARACHIDONIC-ACID; HUMAN NEUTROPHILS; CUTTING EDGE; KEY ROLE; EXPRESSION; MICE; PHOSPHORYLATION	Inflammatory lipid mediators such as prostaglandins and leukotrienes play crucial roles in the pathogenesis of bacterial lipopolysaccharide (LPS)-induced inflammation. Cytosolic phospholipase A(2) (cPLA(2)) is a key enzyme in the generation of pro-inflammatory lipid mediators. Here, we found that Toll-like receptor 4 (TLR4) is essential for LPS-induced cPLA2 activation and lipid release. Inhibition of TLR4 protein expression by TLR4 small interfering RNA or neutralization of TLR4 by the specific antibody against TLR4/MD2 blocked cPLA(2) phosphorylation and cPLA(2)-hydrolyzed arachidonic acid release. Furthermore, activation of the TLR4 signaling pathway by LPS regulated cPLA(2) activation and lipid release. cPLA(2) phosphorylation and cPLA(2)-hydrolyzed lipid release were significantly impaired when TLR4 adaptor protein, either MyD88 or TRIF, was knocked down in LPS-stimulated macrophages. Similarly, LPS-induced arachidonate release was inhibited in cells transfected with a dominant-negative MyD88 or TRIF construct. Subsequently, cPLA(2) activation could be suppressed by inhibition of the TLR4 adaptor protein-directed p38 and ERK MAPK pathways. These findings suggest that, in LPS-induced inflammation, the TLR4-mediated MyD88-and TRIF-dependent MAPK pathways result in cPLA(2) activation and production of pro-inflammatory lipid mediators.	NIH, Dept Crit Care Med, Ctr Clin, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Shelhamer, JH (corresponding author), NIH, Dept Crit Care Med, Ctr Clin, Bldg 10,Rm 7-D-43, Bethesda, MD 20892 USA.	jshelhamer@nih.gov			CLINICAL CENTER [ZIACL000182, Z01CL000182] Funding Source: NIH RePORTER	CLINICAL CENTER		Akashi S, 2000, J IMMUNOL, V164, P3471, DOI 10.4049/jimmunol.164.7.3471; Ardeshna KM, 2000, BLOOD, V96, P1039, DOI 10.1182/blood.V96.3.1039.015k04_1039_1046; Ashkar AA, 2004, J INFECT DIS, V190, P1841, DOI 10.1086/425079; Barton GM, 2003, SCIENCE, V300, P1524, DOI 10.1126/science.1085536; Beutler B, 2003, NAT REV IMMUNOL, V3, P169, DOI 10.1038/nri1004; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Bulger EM, 2000, CRIT CARE MED, V28, pN27, DOI 10.1097/00003246-200004001-00004; CHAO W, 1993, BIOCHEM J, V292, P617, DOI 10.1042/bj2920617; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326; Deane JA, 2004, ANNU REV IMMUNOL, V22, P563, DOI 10.1146/annurev.immunol.22.012703.104721; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Dieter P, 2002, CELL SIGNAL, V14, P199, DOI 10.1016/S0898-6568(01)00243-1; DOERFLER ME, 1994, J CLIN INVEST, V93, P1583, DOI 10.1172/JCI117138; DUNNE A, 2003, SCI STKE, pRE3, DOI DOI 10.1126/STKE.2003.171.RE3; Fujishima H, 1999, P NATL ACAD SCI USA, V96, P4803, DOI 10.1073/pnas.96.9.4803; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Geijsen N, 2000, FEBS LETT, V471, P83, DOI 10.1016/S0014-5793(00)01373-9; Guha M, 2002, J BIOL CHEM, V277, P32124, DOI 10.1074/jbc.M203298200; HANEL AM, 1993, BIOCHEMISTRY-US, V32, P5949, DOI 10.1021/bi00074a005; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; HENDERSON WR, 1994, ANN INTERN MED, V121, P684, DOI 10.7326/0003-4819-121-9-199411010-00010; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Hoshino K, 1999, J IMMUNOL, V162, P3749; Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Kalyvas A, 2004, NEURON, V41, P323, DOI 10.1016/S0896-6273(04)00003-0; Kramer RM, 1997, FEBS LETT, V410, P49, DOI 10.1016/S0014-5793(97)00322-0; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Lakhani SA, 2003, CURR OPIN PEDIATR, V15, P278, DOI 10.1097/00008480-200306000-00009; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Li XW, 2003, INFECT IMMUN, V71, P4414, DOI 10.1128/IAI.71.8.4414-4420.2003; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MacKichan ML, 1999, J BIOL CHEM, V274, P1767, DOI 10.1074/jbc.274.3.1767; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; Mathiak G, 1997, SHOCK, V7, P391, DOI 10.1097/00024382-199706000-00001; Mosior M, 1998, J BIOL CHEM, V273, P2184, DOI 10.1074/jbc.273.4.2184; MURAKAMI M, 1995, J EXP MED, V182, P197, DOI 10.1084/jem.182.1.197; Myou S, 2001, NAT IMMUNOL, V2, P145, DOI 10.1038/84244; Nagase T, 2000, NAT IMMUNOL, V1, P42, DOI 10.1038/76897; Nagase T, 2002, NAT MED, V8, P480, DOI 10.1038/nm0502-480; OByrne PM, 1997, CHEST, V111, pS27, DOI 10.1378/chest.111.2_Supplement.27S; Ojaniemi M, 2003, EUR J IMMUNOL, V33, P597, DOI 10.1002/eji.200323376; Pettus BJ, 2004, J BIOL CHEM, V279, P11320, DOI 10.1074/jbc.M309262200; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Sapirstein A, 2000, BBA-MOL CELL BIOL L, V1488, P139, DOI 10.1016/S1388-1981(00)00116-5; Schoenberger SP, 2003, NAT IMMUNOL, V4, P937, DOI 10.1038/ni1003-937; Serhan CN, 2000, NAT IMMUNOL, V1, P13, DOI 10.1038/76865; SHARP JD, 1991, J BIOL CHEM, V266, P14850; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Takami M, 2002, J IMMUNOL, V169, P1516, DOI 10.4049/jimmunol.169.3.1516; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; Van Amersfoort ES, 2003, CLIN MICROBIOL REV, V16, P379, DOI 10.1128/CMR.16.3.379-414.2003; VENABLE ME, 1993, J BIOL CHEM, V268, P7965; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yeh WC, 2003, NATURE, V424, P736, DOI 10.1038/424736a; Yum HK, 2001, J IMMUNOL, V167, P6601, DOI 10.4049/jimmunol.167.11.6601; Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351	65	95	100	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					38969	38975		10.1074/jbc.M509352200	http://dx.doi.org/10.1074/jbc.M509352200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16176925	hybrid			2022-12-25	WOS:000233362200010
J	Sung, JS; DeMott, MS; Demple, B				Sung, JS; DeMott, MS; Demple, B			Long-patch base excision DNA repair of 2-deoxyribonolactone prevents the formation of DNA-protein cross-links with DNA polymerase beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN APURINIC ENDONUCLEASE; CELL NUCLEAR ANTIGEN; FLAP ENDONUCLEASE-1; ESCHERICHIA-COLI; MAMMALIAN-CELLS; 2'-DEOXYRIBONOLACTONE LESION; EXONUCLEASE-III; ABASIC SITES; MECHANISM; DAMAGE	Oxidized abasic sites are a major form of DNA damage induced by free radical attack and deoxyribose oxidation. 2-Deoxyribonolactone (dL) is a C1'-oxidized abasic site implicated in DNA strand breakage, mutagenesis, and formation of covalent DNA-protein cross-links (DPCs) with repair enzymes such as DNA polymerase beta (pol beta). We show here that mammalian cell-free extracts incubated with Ape1-incised dL substrates under non-repair conditions give rise to DPCs, with a major species dependent on the presence of pol beta. DPC formation was much less under repair than non-repair conditions, with extracts of either pol beta-proficient or -deficient cells. Partial base excision DNA repair (BER) reconstituted with purified enzymes demonstrated that Flap endonuclease 1 ( FEN1) efficiently excises a displaced oligonucleotide containing a 5'-terminal dL residue, as would be produced during long-patch (multinucleotide) BER. Simultaneous monitoring of dL repair and dL-mediated DPC formation demonstrated that removal of the dL residue through the combined action of strand-displacement DNA synthesis by pol beta and excision by FEN1 markedly diminished DPC formation with the polymerase. Analysis of the patch size distribution associated with DNA repair synthesis in cell-free extracts showed that the processing of dL residues is associated with the synthesis of >= 2 nucleotides, compared with predominantly single nucleotide replacement for regular abasic sites. Our observations reveal a cellular repair process for dL lesions that avoids formation of DPCs that would threaten the integrity of DNA and perhaps cell viability.	Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Demple, B (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, 665 Huntington Ave, Boston, MA 02115 USA.	bdemple@hsph.harvard.edu			NCI NIH HHS [CA71993] Funding Source: Medline; NIGMS NIH HHS [GM40000] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071993] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atamna H, 2000, P NATL ACAD SCI USA, V97, P686, DOI 10.1073/pnas.97.2.686; Bebenek K, 2001, SCIENCE, V291, P2156, DOI 10.1126/science.1058386; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Bennett SE, 2001, J BIOL CHEM, V276, P42588, DOI 10.1074/jbc.M106212200; Bornarth CJ, 1999, BIOCHEMISTRY-US, V38, P13347, DOI 10.1021/bi991321u; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; Cappelli E, 2001, CARCINOGENESIS, V22, P387, DOI 10.1093/carcin/22.3.387; CHEN DS, 1991, NUCLEIC ACIDS RES, V19, P5907, DOI 10.1093/nar/19.21.5907; Chen KH, 1998, NUCLEIC ACIDS RES, V26, P2001, DOI 10.1093/nar/26.8.2001; DeMott MS, 2002, J BIOL CHEM, V277, P7637, DOI 10.1074/jbc.C100577200; Demple B, 2002, ONCOGENE, V21, P8926, DOI 10.1038/sj.onc.1206178; Dianov GL, 1999, J BIOL CHEM, V274, P13741, DOI 10.1074/jbc.274.20.13741; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; Dogliotti E, 2001, PROG NUCLEIC ACID RE, V68, P3; Donny W, 2004, J BIOL CHEM, V279, P25268, DOI 10.1074/jbc.M400804200; Faure V, 2004, NUCLEIC ACIDS RES, V32, P2937, DOI 10.1093/nar/gkh622; Feng JA, 1998, BIOCHEMISTRY-US, V37, P9605, DOI 10.1021/bi9808619; Fortini P, 1999, J BIOL CHEM, V274, P15230, DOI 10.1074/jbc.274.21.15230; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; Friedberg EC, 2003, NATURE, V421, P436, DOI 10.1038/nature01408; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; Greenberg MM, 2004, BIOCHEMISTRY-US, V43, P8178, DOI 10.1021/bi0496236; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Haracska L, 2003, GENE DEV, V17, P2777, DOI 10.1101/gad.1146103; Hashimoto M, 2001, J AM CHEM SOC, V123, P3161, DOI 10.1021/ja003354z; Horton JK, 2000, J BIOL CHEM, V275, P2211, DOI 10.1074/jbc.275.3.2211; Huggins CF, 2002, MOL CELL, V10, P1201, DOI 10.1016/S1097-2765(02)00736-0; Hwang JT, 1999, NUCLEIC ACIDS RES, V27, P3805, DOI 10.1093/nar/27.19.3805; Jourdan M, 1999, BIOCHEMISTRY-US, V38, P3985, DOI 10.1021/bi982743r; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kotera M, 2000, CHEM-EUR J, V6, P4163, DOI 10.1002/1521-3765(20001117)6:22<4163::AID-CHEM4163>3.0.CO;2-K; Kroeger KM, 2003, BIOCHEMISTRY-US, V42, P2449, DOI 10.1021/bi027168c; Krokan HE, 1997, BIOCHEM J, V325, P1; Lenox HJ, 2001, ORG LETT, V3, P2415, DOI 10.1021/ol016255e; LEVIN JD, 1988, J BIOL CHEM, V263, P8066; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Masuda Y, 1998, J BIOL CHEM, V273, P30352, DOI 10.1074/jbc.273.46.30352; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Nakamura J, 1999, CANCER RES, V59, P2522; Nakano T, 2003, J BIOL CHEM, V278, P25264, DOI 10.1074/jbc.M212847200; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; Podlutsky AJ, 2001, BIOCHEMISTRY-US, V40, P809, DOI 10.1021/bi002064s; PRATVIEL G, 1991, NUCLEIC ACIDS RES, V19, P6283, DOI 10.1093/nar/19.22.6283; PUTNEY SD, 1981, P NATL ACAD SCI-BIOL, V78, P7350, DOI 10.1073/pnas.78.12.7350; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; Sattler U, 2003, EMBO REP, V4, P363, DOI 10.1038/sj.embor.embor796; SIGMAN DS, 1993, CHEM REV, V93, P2295, DOI 10.1021/cr00022a011; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001; Sung JS, 2003, BIOCHEMISTRY-US, V42, P4613, DOI 10.1021/bi027115v; Tissier A, 2000, GENE DEV, V14, P1642; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; von Sonntag C, 1991, Basic Life Sci, V58, P287; Von Sonntag C, 1987, CHEM BASIS RAD BIOL; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; Wiederhold L, 2004, MOL CELL, V15, P209, DOI 10.1016/j.molcel.2004.06.003; Xu YJ, 2003, DNA REPAIR, V2, P175, DOI 10.1016/S1568-7864(02)00194-5	59	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39095	39103		10.1074/jbc.M506480200	http://dx.doi.org/10.1074/jbc.M506480200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16188889	hybrid			2022-12-25	WOS:000233362200024
J	Tsuboi, T; Fukuda, M				Tsuboi, T; Fukuda, M			The C2B domain of rabphilin directly interacts with SNAP-25 and regulates the docking step of dense core vesicle exocytosis in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EVANESCENT-WAVE MICROSCOPY; SLP HOMOLOGY DOMAIN; PHOSPHOLIPID-BINDING; SECRETORY GRANULES; SYNAPTOTAGMIN-I; SYNTAXIN 1A; PROTEIN; MEMBRANE; IDENTIFICATION; RAB27A	Rabphilin is a membrane trafficking protein on secretory vesicles that consists of an N-terminal Rab-binding domain and C-terminal tandem C2 domains. The N-terminal part of rabphilin has recently been shown to function as an effector domain for both Rab27A and Rab3A in PC12 cells (Fukuda, M., Kanno, E., and Yamamoto, A. (2004) J. Biol. Chem. 279, 13065-13075), but the function of the C2 domains of rabphilin during secretory vesicle exocytosis is largely unknown. In this study we investigated the interaction between rabphilin and SNAREs (soluble N-ethylmaleimide-sensitive factor attachment protein receptors, VAMP-2/synaptobrevin-2, syntaxin IA, and SNAP-25) and SNARE-associated proteins (Munc18-1 and Munc13-1) and found that the C2B domain of rabphilin, but not of other Rab27A-binding proteins with tandem C2 domains (i.e. Slp1-5), directly interacts with a plasma membrane protein, SNAP-25. The interaction between rabphilin and SNAP-25 occurs even in the absence of Ca2+ (EC50 =0.817 mu M SNAP-25), but 0.5 mM Ca2+ increases the affinity for SNAP-25 2-fold (EC50 = 0.405 mu M SNAP25) without changing the B-max value (1.06 mol of SNAP-25/mol of rabphilin). Furthermore, vesicle dynamics were imaged by total internal reflection fluorescence microscopy in a single PC12 cell expressing a lumen-targeted pH-insensitive yellow fluorescent protein ( Venus), neuropeptide Y-Venus. Expression of the wild-type rabphilin in PC12 cells significantly increased the number of docked vesicles to the plasma membrane without altering the kinetics of individual secretory events, whereas expression of the mutant rabphilin lacking the C2B domain, rabphilin-Delta C2B, decreased the number of docked vesicle or fusing at the plasma membrane. These findings suggest that rabphilin is involved in the docking step of regulated exocytosis in PC12 cells, possibly through interaction between the C2B domain and SNAP-25.	RIKEN, Inst Phys & Chem Res, Fukuda Initiat Res Unit, Wako, Saitama 3510198, Japan	RIKEN	Fukuda, M (corresponding author), RIKEN, Inst Phys & Chem Res, Fukuda Initiat Res Unit, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	mnfukuda@brain.riken.go.jp	Fukuda, MItsunori/I-1511-2015; TSUBOI, Takashi/AAD-7976-2019	Fukuda, MItsunori/0000-0002-8620-5853; TSUBOI, Takashi/0000-0001-8290-2021				AXELROD D, 1981, J CELL BIOL, V89, P141, DOI 10.1083/jcb.89.1.141; Burns ME, 1998, J GEN PHYSIOL, V111, P243, DOI 10.1085/jgp.111.2.243; Catz SD, 2002, P NATL ACAD SCI USA, V99, P11652, DOI 10.1073/pnas.172382799; Chen D, 1997, BIOCHEM MOL MED, V60, P27, DOI 10.1006/bmme.1996.2559; Cheviet S, 2004, MOL ENDOCRINOL, V18, P117, DOI 10.1210/me.2003-0300; Chung SH, 1998, J BIOL CHEM, V273, P10240, DOI 10.1074/jbc.273.17.10240; Chung SH, 1999, J BIOL CHEM, V274, P18113, DOI 10.1074/jbc.274.25.18113; CHUNG SH, 1995, J BIOL CHEM, V270, P16714, DOI 10.1074/jbc.270.28.16714; Coppola T, 2002, MOL BIOL CELL, V13, P1906, DOI 10.1091/mbc.02-02-0025; Fukuda M, 2004, J BIOL CHEM, V279, P13065, DOI 10.1074/jbc.M306812200; Fukuda M, 2003, J BIOL CHEM, V278, P15373, DOI 10.1074/jbc.M212341200; Fukuda M, 2002, J BIOL CHEM, V277, P30351, DOI 10.1074/jbc.M204056200; Fukuda M, 2005, METHOD ENZYMOL, V403, P445, DOI 10.1016/S0076-6879(05)03039-9; Fukuda M, 2005, METHOD ENZYMOL, V403, P457, DOI 10.1016/S0076-6879(05)03040-5; Fukuda M, 2005, J BIOCHEM, V137, P9, DOI 10.1093/jb/mvi002; Fukuda M, 1999, J BIOL CHEM, V274, P31421, DOI 10.1074/jbc.274.44.31421; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; Fukuda M, 2002, J BIOL CHEM, V277, P39673, DOI 10.1074/jbc.M205349200; Fukuda M, 2002, BIOCHEM J, V366, P681, DOI 10.1042/BJ20020484; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V283, P513, DOI 10.1006/bbrc.2001.4803; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V281, P1226, DOI 10.1006/bbrc.2001.4512; Fukuda M, 2003, J BIOL CHEM, V278, P15390, DOI 10.1074/jbc.M213090200; Imai A, 2004, J CELL SCI, V117, P1945, DOI 10.1242/jcs.01048; IMAZUMI K, 1994, BIOCHEM BIOPH RES CO, V205, P1409, DOI 10.1006/bbrc.1994.2822; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Joberty G, 1999, J CELL SCI, V112, P3579; Kato M, 1996, J BIOL CHEM, V271, P31775, DOI 10.1074/jbc.271.50.31775; Komuro R, 1996, BIOCHEM BIOPH RES CO, V219, P435, DOI 10.1006/bbrc.1996.0251; Kuroda TS, 2005, METHOD ENZYMOL, V403, P431, DOI 10.1016/S0076-6879(05)03038-7; Kuroda TS, 2004, NAT CELL BIOL, V6, P1195, DOI 10.1038/ncb1197; Kuroda TS, 2002, BIOCHEM BIOPH RES CO, V293, P899, DOI 10.1016/S0006-291X(02)00320-0; Kuroda TS, 2002, J BIOL CHEM, V277, P9212, DOI 10.1074/jbc.M112414200; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; Masumoto N, 1996, J CELL BIOL, V135, P1741, DOI 10.1083/jcb.135.6.1741; MIYAZAKI M, 1994, BIOCHEM BIOPH RES CO, V205, P460, DOI 10.1006/bbrc.1994.2688; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Ohya T, 1998, J BIOL CHEM, V273, P613, DOI 10.1074/jbc.273.1.613; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Perin MS, 1996, BIOCHEMISTRY-US, V35, P13808, DOI 10.1021/bi960853x; Schluter OM, 1999, J NEUROSCI, V19, P5834, DOI 10.1523/JNEUROSCI.19-14-05834.1999; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; Staunton J, 2001, J NEUROSCI, V21, P9255, DOI 10.1523/JNEUROSCI.21-23-09255.2001; Torii S, 2004, J BIOL CHEM, V279, P22532, DOI 10.1074/jbc.M400600200; Torii S, 2002, MOL CELL BIOL, V22, P5518, DOI 10.1128/MCB.22.15.5518-5526.2002; Tsuboi T, 2000, CURR BIOL, V10, P1307, DOI 10.1016/S0960-9822(00)00756-9; Tsuboi T, 2004, J BIOL CHEM, V279, P47115, DOI 10.1074/jbc.M408179200; Tsuboi T, 2003, CURR BIOL, V13, P563, DOI 10.1016/S0960-9822(03)00176-3; Tsuboi T, 2002, BIOPHYS J, V83, P172, DOI 10.1016/S0006-3495(02)75159-X; Wang XL, 2001, J BIOL CHEM, V276, P32480, DOI 10.1074/jbc.M103337200; Willshaw A, 2004, FEBS LETT, V559, P13, DOI 10.1016/S0014-5793(03)01513-8; YAMAGUCHI T, 1993, J BIOL CHEM, V268, P27164; Yi Z, 2002, MOL CELL BIOL, V22, P1858, DOI 10.1128/MCB.22.6.1858-1867.2002	53	78	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39253	39259		10.1074/jbc.M507173200	http://dx.doi.org/10.1074/jbc.M507173200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16203731	hybrid			2022-12-25	WOS:000233362200042
J	Han, GS; Sreenivas, A; Choi, MG; Chang, YF; Martin, SS; Baldwin, EP; Carman, GM				Han, GS; Sreenivas, A; Choi, MG; Chang, YF; Martin, SS; Baldwin, EP; Carman, GM			Expression of human CTP synthetase in Saccharomyces cerevisiae reveals phosphorylation by protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTIDINE-TRIPHOSPHATE-SYNTHETASE; CYTOSINE INDUCES APOPTOSIS; ESCHERICHIA-COLI; 5'-TRIPHOSPHATE SYNTHETASE; PHOSPHOLIPID BIOSYNTHESIS; LYMPHOBLASTIC-LEUKEMIA; MUTATOR GENE; YEAST GENES; URA7 GENE; RAT-LIVER	CTP synthetase (EC 6.3.4.2, UTP: ammonia ligase (ADP-forming)) is an essential enzyme in all organisms; it generates the CTP required for the synthesis of nucleic acids and membrane phospholipids. In this work we showed that the human CTP synthetase genes, CTPS1 and CTPS2, were functional in Saccharomyces cerevisiae and complemented the lethal phenotype of the ura7 Delta ura8 Delta mutant lacking CTP synthetase activity. The expression of the CTPS1- and CTPS2-encoded human CTP synthetase enzymes in the ura7 Delta ura8 Delta mutant was shown by immunoblot analysis of CTP synthetase proteins, the measurement of CTP synthetase activity, and the synthesis of CTP in vivo. Phosphoamino acid and phosphopeptide mapping analyses of human CTP synthetase 1 isolated from P-32(i)-labeled cells revealed that the enzyme was phosphorylated on multiple serine residues in vivo. Activation of protein kinase A activity in yeast resulted in transient increases (2-fold) in the phosphorylation of human CTP synthetase 1 and the cellular level of CTP. Human CTP synthetase 1 was also phosphorylated by mammalian protein kinase A in vitro. Using human CTP synthetase 1 purified from Escherichia coli as a substrate, protein kinase A activity was dose- and time-dependent, and dependent on the concentrations of CTP synthetase 1 and ATP. These studies showed that S. cerevisiae was useful for the analysis of human CTP synthetase phosphorylation.	Rutgers State Univ, New Jersey Agr Expt Stn, Cook Coll, Dept Food Sci, New Brunswick, NJ 08901 USA; Univ Calif Davis, Dept Mol & Cellular Biol, Davis, CA 95616 USA; Univ Calif Davis, Dept Chem, Davis, CA 95616 USA	Rutgers State University New Brunswick; University of California System; University of California Davis; University of California System; University of California Davis	Carman, GM (corresponding author), Rutgers State Univ, New Jersey Agr Expt Stn, Cook Coll, Dept Food Sci, 65 Dudley Rd, New Brunswick, NJ 08901 USA.	carman@aesop.rutgers.edu		Baldwin, Enoch/0000-0002-1472-0944	NIGMS NIH HHS [GM-63109, R01 GM063109, GM-50679, R01 GM050679] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050679, R01GM063109] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON PM, 1983, BIOCHEMISTRY-US, V22, P3285, DOI 10.1021/bi00282a038; ARONOW B, 1984, J BIOL CHEM, V259, P9035; ARONOW B, 1987, J BIOL CHEM, V262, P5106; Blom N, 2004, PROTEOMICS, V4, P1633, DOI 10.1002/pmic.200300771; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; CHOCK PB, 1980, ANNU REV BIOCHEM, V49, P813, DOI 10.1146/annurev.bi.49.070180.004121; Choi MG, 2003, J BIOL CHEM, V278, P23610, DOI 10.1074/jbc.M303337200; CHU EHY, 1984, BIOCHEM GENET, V22, P701, DOI 10.1007/BF00485854; Endrizzi JA, 2004, BIOCHEMISTRY-US, V43, P6447, DOI 10.1021/bi0496945; Evans DR, 2004, J BIOL CHEM, V279, P33035, DOI 10.1074/jbc.R400007200; FRIDOVICHKEIL JL, 1993, P NATL ACAD SCI USA, V90, P398, DOI 10.1073/pnas.90.2.398; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Goto M, 2004, STRUCTURE, V12, P1413, DOI 10.1016/j.str.2004.05.013; HAID A, 1983, METHOD ENZYMOL, V96, P192; Harlow E., 1988, ANTIBODIES LAB MANUA; Hatch GM, 1996, J BIOL CHEM, V271, P25810, DOI 10.1074/jbc.271.42.25810; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KAUFMAN ER, 1986, MUTAT RES, V161, P19, DOI 10.1016/0027-5107(86)90096-5; Kim JH, 1997, BIOCHEM MOL BIOL INT, V43, P925; Kim KH, 1999, J BIOL CHEM, V274, P9531, DOI 10.1074/jbc.274.14.9531; KIZAKI H, 1980, CANCER RES, V40, P3921; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; Kokkola T, 1998, BIOCHEM BIOPH RES CO, V249, P531, DOI 10.1006/bbrc.1998.9182; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; KRUGER WD, 1994, P NATL ACAD SCI USA, V91, P6614, DOI 10.1073/pnas.91.14.6614; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RT, 1992, P NATL ACAD SCI USA, V89, P10887, DOI 10.1073/pnas.89.22.10887; LEVITZKI A, 1969, P NATL ACAD SCI USA, V62, P1121, DOI 10.1073/pnas.62.4.1121; LEVITZKI A, 1971, BIOCHEMISTRY-US, V10, P3365, DOI 10.1021/bi00794a008; LEVITZKI A, 1972, BIOCHEMISTRY-US, V11, P247, DOI 10.1021/bi00752a016; LEVITZKI A, 1972, BIOCHEMISTRY-US, V11, P241, DOI 10.1021/bi00752a015; LEWIS DA, 1989, BIOCHEMISTRY-US, V28, P8454, DOI 10.1021/bi00447a027; LIEBERMAN I, 1956, J BIOL CHEM, V222, P765; LONG CW, 1967, J BIOL CHEM, V242, P4715; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; MCDONOUGH VM, 1995, J BIOL CHEM, V270, P18774, DOI 10.1074/jbc.270.32.18774; MEUTH M, 1979, P NATL ACAD SCI USA, V76, P6505, DOI 10.1073/pnas.76.12.6505; MEUTH M, 1982, SOMAT CELL GENET, V8, P423, DOI 10.1007/BF01538705; NADKARNI AK, 1995, J BIOL CHEM, V270, P24982, DOI 10.1074/jbc.270.42.24982; Ostrander DB, 1998, J BIOL CHEM, V273, P18992, DOI 10.1074/jbc.273.30.18992; Outeiro TF, 2003, SCIENCE, V302, P1772, DOI 10.1126/science.1090439; OZIERKALOGEROPOULOS O, 1991, MOL GEN GENET, V231, P7, DOI 10.1007/BF00293815; OZIERKALOGEROPOULOS O, 1994, MOL GEN GENET, V242, P431, DOI 10.1007/BF00281793; Pappas A, 1998, J BIOL CHEM, V273, P15954, DOI 10.1074/jbc.273.26.15954; Pappas A, 1999, BIOCHEMISTRY-US, V38, P16671, DOI 10.1021/bi9920127; Park TS, 1999, BIOCHEMISTRY-US, V38, P8839, DOI 10.1021/bi990784x; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Shan XY, 1999, J BIOL CHEM, V274, P32613, DOI 10.1074/jbc.274.46.32613; Shan XY, 1998, NAT GENET, V19, P91, DOI 10.1038/ng0598-91; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; Steinmetz LM, 2002, NAT GENET, V31, P400, DOI 10.1038/ng929; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; THEVELEIN JM, 1994, YEAST, V10, P1753, DOI 10.1002/yea.320101308; THEVELEIN JM, 1985, J GEN MICROBIOL, V131, P3199; THOMAS PE, 1988, BIOCHIM BIOPHYS ACTA, V953, P334, DOI 10.1016/0167-4838(88)90042-8; TIPPLES G, 1995, J BIOL CHEM, V270, P7908, DOI 10.1074/jbc.270.14.7908; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; TRACH K, 1988, J BACTERIOL, V170, P4194, DOI 10.1128/jb.170.9.4194-4208.1988; TRAUT TW, 1988, CRC CR REV BIOCH MOL, V23, P121, DOI 10.3109/10409238809088318; TRUDEL M, 1984, J BIOL CHEM, V259, P2355; van Kuilenburg ABP, 2000, BBA-GENE STRUCT EXPR, V1492, P548, DOI 10.1016/S0167-4781(00)00141-X; VANDENBERG AA, 1995, EUR J CANCER, V31A, P108, DOI 10.1016/0959-8049(94)00442-8; VANDENBERG AA, 1993, EUR J BIOCHEM, V216, P161; Verschuur AC, 1998, ADV EXP MED BIOL, V431, P667; Verschuur AC, 2000, ADV EXP MED BIOL, V486, P319; Verschuur AC, 2001, LEUKEMIA RES, V25, P891, DOI 10.1016/S0145-2126(01)00047-9; VINCENT BRD, 1980, BIOCHIM BIOPHYS ACTA, V610, P352; VONDERSAAL W, 1985, J BIOL CHEM, V260, P4993; Wadskov-Hansen SLL, 2001, J BIOL CHEM, V276, P38002; WARNER JR, 1991, METHOD ENZYMOL, V194, P423; WEBER G, 1980, LIFE SCI, V27, P793, DOI 10.1016/0024-3205(80)90333-1; Weber G, 1978, Adv Enzyme Regul, V17, P1; WENG M, 1986, J BIOL CHEM, V261, P5568; WILLIAMS JC, 1978, NATURE, V271, P71, DOI 10.1038/271071a0; YAMAUCHI M, 1990, EMBO J, V9, P2095, DOI 10.1002/j.1460-2075.1990.tb07377.x; Yang WL, 1996, J BIOL CHEM, V271, P28777, DOI 10.1074/jbc.271.46.28777; Yang WL, 1996, J BIOL CHEM, V271, P11113, DOI 10.1074/jbc.271.19.11113; YANG WL, 1994, BIOCHEMISTRY-US, V33, P10785, DOI 10.1021/bi00201a028; YANG WL, 1995, J BIOL CHEM, V270, P14983, DOI 10.1074/jbc.270.25.14983	84	31	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38328	38336		10.1074/jbc.M509622200	http://dx.doi.org/10.1074/jbc.M509622200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16179339	Green Published, Green Accepted, hybrid			2022-12-25	WOS:000233239800028
J	Iribarren, P; Chen, KQ; Hu, JY; Gong, WH; Cho, EH; Lockett, S; Uranchimeg, B; Wang, JM				Iribarren, P; Chen, KQ; Hu, JY; Gong, WH; Cho, EH; Lockett, S; Uranchimeg, B; Wang, JM			CpG-containing oligodeoxynucleotide promotes microglial cell uptake of amyloid beta 1-42 peptide by up-regulating the expression of the G-protein-coupled receptor mFPR2	FASEB JOURNAL			English	Article						Alzheimer's disease; chemotaxis; inflammation; phagocytosis; TLR9	AMYLOID-BETA-PROTEIN; TOLL-LIKE RECEPTOR-9; ANTI-DNA ANTIBODIES; ALZHEIMERS-DISEASE; BACTERIAL-DNA; GENE-THERAPY; MOUSE MODEL; B-CELLS; INFLAMMATION; ACTIVATION	Human G protein-coupled formyl peptide receptor like 1 (FPRL1) and its mouse homologue murine formyl peptide receptor 2 (mFPR2) mediate the chemotactic activity of amyloid beta 1-42 (A beta(42)), a key pathogenic peptide in Alzheimer's disease ( AD). Since mFPR2 is up-regulated in mouse microglia by lipopolysaccharide (LPS), a Toll-like receptor 4 ligand, we investigated the capacity of CpG-containing oligodeoxynucleotide (ODN), a Toll-like receptor (TLR) 9 ligand, to regulate the expression of mFPR2 in mouse microglia. CpG ODN markedly enhanced the expression and function of mFPR2 in microglial cells, which exhibited increased chemotactic responses to mFPR2 agonists, including A beta(42). The effect of CpG ODN is dependent on activation of p38 MAPK. Further studies showed that CpG ODN-treated microglia increased their capacity to endocytose A beta(42) through mFPR2, as this process was abrogated by pertussis toxin, a Gi protein inhibitor, and W peptide, another potent mFPR2 agonist. Our results suggest that TLR9 may play an important role in promoting microglial recognition of A beta(42), thus affecting the pathogenic process of AD.	NCI, Mol Immunoregulat Lab, Canc Res Ctr, Frederick, MD 21702 USA; SAIC Frederick, Basic Res Program, Frederick, MD 21702 USA; SAIC Frederick, Image Anal Lab, Frederick, MD 21702 USA; SAIC Frederick, Dev Therapeut Program, Tumor Hypoxia Program, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Science Applications International Corporation (SAIC); SAIC-Frederick; Science Applications International Corporation (SAIC); SAIC-Frederick	Wang, JM (corresponding author), NCI, Mol Immunoregulat Lab, Canc Res Ctr, Bldg 560,Room 31-40, Frederick, MD 21702 USA.	wangji@mail.ncifcrf.gov	Cho, Edward/B-3727-2012	Cho, Edward/0000-0002-0278-334X	Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [N01-CO-12400] Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Ard MD, 1996, J NEUROSCI RES, V43, P190, DOI 10.1002/(SICI)1097-4547(19960115)43:2<190::AID-JNR7>3.0.CO;2-B; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Bessis N, 2004, GENE THER, V11, pS10, DOI 10.1038/sj.gt.3302364; Blesch A, 2004, YONSEI MED J, V45, P28; Boehme KW, 2004, J VIROL, V78, P7867, DOI 10.1128/JVI.78.15.7867-7873.2004; Citron M, 1996, P NATL ACAD SCI USA, V93, P13170, DOI 10.1073/pnas.93.23.13170; Cotter RL, 1999, J LEUKOCYTE BIOL, V65, P416, DOI 10.1002/jlb.65.4.416; Cui YH, 2002, J LEUKOCYTE BIOL, V72, P628; Cui YH, 2002, NEUROBIOL DIS, V10, P366, DOI 10.1006/nbdi.2002.0517; Cui YH, 2002, J IMMUNOL, V168, P434, DOI 10.4049/jimmunol.168.1.434; Dalpke AH, 2002, J IMMUNOL, V168, P4854, DOI 10.4049/jimmunol.168.10.4854; DeWitt DA, 1998, EXP NEUROL, V149, P329, DOI 10.1006/exnr.1997.6738; Dickson DW, 1997, J NEUROPATH EXP NEUR, V56, P321, DOI 10.1097/00005072-199704000-00001; DURAND ML, 1993, NEW ENGL J MED, V328, P21, DOI 10.1056/NEJM199301073280104; Eikelenboom P, 1998, EXP NEUROL, V154, P89, DOI 10.1006/exnr.1998.6920; ElKhoury J, 1996, NATURE, V382, P716; Giulian D, 1999, AM J HUM GENET, V65, P13, DOI 10.1086/302477; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; Hartt JK, 1999, J EXP MED, V190, P741, DOI 10.1084/jem.190.5.741; Hirsch EC, 2003, ANN NY ACAD SCI, V991, P214; Iribarren P, 2003, J IMMUNOL, V171, P5482, DOI 10.4049/jimmunol.171.10.5482; Iribarren P, 2005, IMMUNOL RES, V31, P165, DOI 10.1385/IR:31:3:165; Kalaria R N, 1999, Curr Opin Hematol, V6, P15, DOI 10.1097/00062752-199901000-00004; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Krug A, 2004, BLOOD, V103, P1433, DOI 10.1182/blood-2003-08-2674; Le YY, 1999, J IMMUNOL, V163, P6777; Leadbetter EA, 2002, NATURE, V416, P603, DOI 10.1038/416603a; Lee Sung Joong, 2002, Current Drug Targets - Inflammation and Allergy, V1, P181; Liu L, 2003, IMMUNOLOGY, V110, P341, DOI 10.1046/j.1365-2567.2003.01739.x; Lombardo JA, 2003, J NEUROSCI, V23, P10879, DOI 10.1523/jneurosci.23-34-10879.2003; Lund J, 2003, J EXP MED, V198, P513, DOI 10.1084/jem.20030162; Macfarlane DE, 1998, J IMMUNOL, V160, P1122; Marshak-Rothstein A, 2004, RHEUM DIS CLIN N AM, V30, P559, DOI 10.1016/j.rdc.2004.04.005; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; McGeer PL, 1999, J LEUKOCYTE BIOL, V65, P409, DOI 10.1002/jlb.65.4.409; Minagar A, 2002, J NEUROL SCI, V202, P13, DOI 10.1016/S0022-510X(02)00207-1; Monsonego A, 2003, SCIENCE, V302, P834, DOI 10.1126/science.1088469; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; PISETSKY DS, 1992, RHEUM DIS CLIN N AM, V18, P437; Pocock JM, 2002, E SCHERING RES FDN W, V39, P105; Rogers J, 2001, NEUROCHEM INT, V39, P333, DOI 10.1016/S0197-0186(01)00040-7; SADIK K, 2003, ALZ DIS ASSOC DIS, V3, pS75; SANO H, 1989, SCAND J IMMUNOL, V30, P51, DOI 10.1111/j.1365-3083.1989.tb01188.x; Scheff SW, 1998, J NEUROPATH EXP NEUR, V57, P1146, DOI 10.1097/00005072-199812000-00006; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; SHLOMCHIK MJ, 1993, INT IMMUNOL, V5, P1329, DOI 10.1093/intimm/5.10.1329; Stalder M, 2001, NEUROBIOL AGING, V22, P427, DOI 10.1016/S0197-4580(01)00209-3; Tabeta K, 2004, P NATL ACAD SCI USA, V101, P3516, DOI 10.1073/pnas.0400525101; Tiffany HL, 2001, J BIOL CHEM, V276, P23645, DOI 10.1074/jbc.M101031200; Uchihara T, 1997, STROKE, V28, P1948, DOI 10.1161/01.STR.28.10.1948; Viglianti GA, 2003, IMMUNITY, V19, P837, DOI 10.1016/S1074-7613(03)00323-6; Wegiel J, 1995, BRAIN RES, V705, P225, DOI 10.1016/0006-8993(95)01156-0; WHITLEY RJ, 1990, NEW ENGL J MED, V323, P242, DOI 10.1056/NEJM199007263230406; Wilcock DM, 2003, J NEUROSCI, V23, P3745, DOI 10.1523/jneurosci.23-09-03745.2003; WISNIEWSKI KE, 1985, ANN NEUROL, V17, P278, DOI 10.1002/ana.410170310; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Yazawa H, 2001, FASEB J, V15, P2454, DOI 10.1096/fj.01-0251com; Yi AK, 1998, J IMMUNOL, V160, P4755; Ying GG, 2004, J IMMUNOL, V172, P7078, DOI 10.4049/jimmunol.172.11.7078	61	68	70	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2032	+		10.1096/fj.05-4578fje	http://dx.doi.org/10.1096/fj.05-4578fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16219804	Bronze			2022-12-25	WOS:000232991100022
J	Goncalves, A; Esterni, B; Bertucci, F; Sauvan, R; Chabannon, C; Cubizolles, M; Bardou, VJ; Houvenaegel, G; Jacquemier, J; Granjeaud, S; Meng, XY; Fung, ET; Birnbaum, D; Maraninchi, D; Viens, P; Borg, JP				Goncalves, A; Esterni, B; Bertucci, F; Sauvan, R; Chabannon, C; Cubizolles, M; Bardou, VJ; Houvenaegel, G; Jacquemier, J; Granjeaud, S; Meng, XY; Fung, ET; Birnbaum, D; Maraninchi, D; Viens, P; Borg, JP			Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy	ONCOGENE			English	Article						proteomics; breast cancer; prognosis; chemotherapy; SELDI-TOF MS; serum profiling	PARTIAL LEAST-SQUARES; TUMOR CLASSIFICATION; CELL-MIGRATION; BIOMARKERS; GROWTH; IDENTIFICATION; HAPTOGLOBIN; DISCOVERY; DIAGNOSIS; VARIANTS	A total of 30 - 50% of early breast cancer ( EBC) patients considered as high risk using standard prognostic factors develop metastatic recurrence despite standard adjuvant systemic treatment. A means to better predict clinical outcome is needed to optimize and individualize therapeutic decisions. To identify a protein signature correlating with metastatic relapse, we performed surface-enhanced laser desorption/ionization-time of flight mass spectrometry profiling of early postoperative serum from 81 high-risk EBC patients. Denatured and fractionated serum samples were incubated with IMAC30 and CM10 ProteinChip arrays. Several protein peaks were differentially expressed according to clinical outcome. By combining partial least squares and logistic regression methods, we built a multiprotein model that correctly predicted outcome in 83% of patients. The 5-year metastasis-free survival in 'good prognosis' and 'poor prognosis' patients as defined using the multiprotein index were strikingly different ( 83 and 22%, respectively; P < 0.0001, log-rank test). In a multivariate Cox regression including conventional pathological factors and multiprotein index, the latter retained the strongest independent prognostic significance for metastatic relapse. Major components of the multiprotein index included haptoglobin, C3a complement fraction, transferrin, apolipoprotein C1 and apolipoprotein A1. Therefore, postoperative serum protein pattern may have an important prognostic value in high-risk EBC.	Inst J Paoli I Calmettes, Dept Med Oncol, INSERM, UMR599, F-13273 Marseille 9, France; Inst J Paoli I Calmettes, Dept Mol Pharmacol, UMR599, INSERM, F-13009 Marseille, France; Univ Mediterranee, UFR Med, Marseille, France; Inst J Paoli I Calmettes, Dept Biostat, UMR599, INSERM, F-13009 Marseille, France; Inst J Paoli I Calmettes, Dept Mol Oncol, UMR599, INSERM, F-13009 Marseille, France; Inst J Paoli I Calmettes, Biol Resource Ctr, UMR599, INSERM, F-13009 Marseille, France; Ciphergen Biosyst, Fremont, CA USA; Inst J Paoli I Calmettes, Dept Pathol, UMR599, INSERM, F-13009 Marseille, France; INSERM, ERM 206, TAGC, Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Goncalves, A (corresponding author), Inst J Paoli I Calmettes, Dept Med Oncol, INSERM, UMR599, 273 Blvd St Marguerite, F-13273 Marseille 9, France.	goncalvesa@marseille.fnclcc.fr	Cubizolles, Myriam/AAZ-7719-2021; Borg, Jean-Paul/AAX-8096-2020; Granjeaud, Samuel/AAE-6488-2022	Borg, Jean-Paul/0000-0001-8418-3382; Granjeaud, Samuel/0000-0001-9245-1535				Abe O, 1998, LANCET, V352, P930; Adam BL, 2002, CANCER RES, V62, P3609; Ahmed N, 2004, BRIT J CANCER, V91, P129, DOI 10.1038/sj.bjc.6601882; Antoniadis A, 2003, BIOINFORMATICS, V19, P563, DOI 10.1093/bioinformatics/btg062; Bertucci F, 2005, CANCER RES, V65, P2170, DOI 10.1158/0008-5472.CAN-04-4115; Bertucci F, 2002, HUM MOL GENET, V11, P863, DOI 10.1093/hmg/11.8.863; Bharti A, 2004, ANTICANCER RES, V24, P1031; BONADONNA G, 1995, JAMA-J AM MED ASSOC, V273, P542; Carlevaro MF, 1997, J CELL BIOL, V136, P1375, DOI 10.1083/jcb.136.6.1375; Cavanaugh PG, 1998, J CELL PHYSIOL, V174, P48, DOI 10.1002/(SICI)1097-4652(199801)174:1<48::AID-JCP6>3.0.CO;2-G; Cavanaugh PG, 1999, BREAST CANCER RES TR, V56, P203; CID MC, 1993, J CLIN INVEST, V91, P977, DOI 10.1172/JCI116319; Citron ML, 2003, J CLIN ONCOL, V21, P1431, DOI 10.1200/JCO.2003.09.081; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; COX DR, 1972, J R STAT SOC B, V34, P187; de Kleijn DPV, 2002, FASEB J, V16, P1123, DOI 10.1096/fj.02-0019fje; Demicheli R, 1997, ANN ONCOL, V8, P1075, DOI 10.1023/A:1008263116022; Diamandis EP, 2004, J NATL CANCER I, V96, P353, DOI 10.1093/jnci/djh056; Eifel P, 2001, JNCI-J NATL CANCER I, V93, P979; FISHER B, 1989, CANCER RES, V49, P1996; Fung ET, 2005, INT J CANCER, V115, P783, DOI 10.1002/ijc.20928; Fung ET, 2001, CURR OPIN BIOTECH, V12, P65, DOI 10.1016/S0958-1669(00)00167-1; Goldhirsch A, 2003, J CLIN ONCOL, V21, P3357, DOI 10.1200/JCO.2003.04.576; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Heimann R, 2000, EUR J CANCER, V36, P1631, DOI 10.1016/S0959-8049(00)00151-9; Henderson IC, 2003, J CLIN ONCOL, V21, P976, DOI 10.1200/JCO.2003.02.063; INOUE T, 1993, J CELL PHYSIOL, V156, P212, DOI 10.1002/jcp.1041560128; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Koopmann J, 2004, CLIN CANCER RES, V10, P860, DOI 10.1158/1078-0432.CCR-1167-3; Kozak KR, 2003, P NATL ACAD SCI USA, V100, P12343, DOI 10.1073/pnas.2033602100; Kwak JY, 2004, EXP HEMATOL, V32, P836, DOI 10.1016/j.exphem.2004.06.006; NABHOLTZ JM, 2002, P ASCO, V21, P141; Nguyen DV, 2002, BIOINFORMATICS, V18, P1216, DOI 10.1093/bioinformatics/18.9.1216; Nguyen DV, 2002, BIOINFORMATICS, V18, P39, DOI 10.1093/bioinformatics/18.1.39; NICOLSON GL, 1992, J NATL CANCER I MONO, V13, P153; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Paradis V, 2005, HEPATOLOGY, V41, P40, DOI 10.1002/hep.20505; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Petricoin EF, 2002, J NATL CANCER I, V94, P1576; Petricoin EF, 2002, LANCET, V359, P572, DOI 10.1016/S0140-6736(02)07746-2; Pupa SM, 2002, J CELL PHYSIOL, V192, P259, DOI 10.1002/jcp.10142; Rozanov DV, 2004, J BIOL CHEM, V279, P46551, DOI 10.1074/jbc.M405284200; Steel LF, 2003, PROTEOMICS, V3, P601, DOI 10.1002/pmic.200300399; Tagliabue E, 2003, LANCET, V362, P527, DOI 10.1016/S0140-6736(03)14112-8; Tolson J, 2004, LAB INVEST, V84, P845, DOI 10.1038/labinvest.3700097; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van 't Veer LJ, 2003, BREAST CANCER RES, V5, P57, DOI 10.1186/bcr562; Vlahou Antonia, 2003, Clin Breast Cancer, V4, P203, DOI 10.3816/CBC.2003.n.026; Wadsworth JT, 2004, CLIN CANCER RES, V10, P1625, DOI 10.1158/1078-0432.CCR-0297-3; Zhang Z, 2004, CANCER RES, V64, P5882, DOI 10.1158/0008-5472.CAN-04-0746	50	95	112	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					981	989		10.1038/sj.onc.1209131	http://dx.doi.org/10.1038/sj.onc.1209131			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16186794				2022-12-25	WOS:000235361000003
J	Friedrich, R; Panizzi, P; Kawabata, SI; Bode, W; Bock, PE; Fuentes-Prior, P				Friedrich, R; Panizzi, P; Kawabata, SI; Bode, W; Bock, PE; Fuentes-Prior, P			Structural basis for reduced staphylocoagulase-mediated bovine prothrombin activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-ARG CHLOROMETHYLKETONE; RAY CRYSTAL-STRUCTURE; HUMAN ALPHA-THROMBIN; PLASMINOGEN ACTIVATION; KINETIC MECHANISM; STREPTOKINASE; STAPHYLOKINASE; PROTEASE; COMPLEX	Staphylocoagulase (SC) is a protein secreted by the human pathogen, Staphylococcus aureus, that activates human prothrombin (ProT) by inducing a conformational change. SC-bound ProT efficiently clots fibrinogen, thus bypassing the physiological blood coagulation pathway. The crystal structure of a fully active SC fragment, SC-(1-325), bound to human prethrombin 2 showed that the SC-(1-325) N terminus inserts into the Ile(16) pocket of prethrombin 2, thereby inducing expression of a functional catalytic site in the cognate zymogen without peptide bond cleavage. As shown here, SC-(1-325) binds to bovine and human ProT with similar affinity but activates the bovine zymogen only very poorly. By contrast to the similar to 2-fold difference in chromogenic substrate kinetic constants between human thrombin and the SC-(1-325)center dot human (pro) thrombin complexes, SC-(1-325)center dot bovine ProT shows a 3,500-fold lower k(cat)/K-m compared with free bovine thrombin, because of a 47-fold increase in K-m and a 67-fold decrease in k(cat). The SC-(1-325)center dot bovine ProT complex is similar to 5,800-fold less active compared with its human counterpart. Comparison of human and bovine fibrinogen as substrates of human and bovine thrombin and the SC-( 1 325)center dot(pro)thrombin complexes indicates that the species specificity of SC-(1-325) cofactor activity is determined primarily by differences in conformational activation of bound ProT. These results suggest that the catalytic site in the SC-(1-325)center dot bovine ProT complex is incompletely formed. The current crystal structure of SC-( 1 325)center dot bovine thrombin reveals that SC would dock similarly to the bovine proenzyme, whereas the bovine (pro)thrombin-characteristic residues Arg(144) and Arg(145) would likely interfere with insertion of the SCN terminus, thus explaining the greatly reduced activation of bovine ProT.	Vanderbilt Univ, Sch Med, Dept Pathol, Med Ctr N, Nashville, TN 37232 USA; Max Planck Inst Biochem, Proteinase Res Grp, D-82152 Martinsried, Germany; Kyushu Univ, Dept Biol, Fukuoka 8128581, Japan; Hosp Santa Cruz & San Pablo, CSIC, Inst Catala Ciencies Cardiovasc, Cardiovasc Res Ctr, E-08025 Barcelona, Spain	Vanderbilt University; Max Planck Society; Kyushu University; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Institut Catala de Ciencies Cardiovasculars (ICCC)	Bock, PE (corresponding author), Vanderbilt Univ, Sch Med, Dept Pathol, Med Ctr N, C3321A, Nashville, TN 37232 USA.	paul.bock@vanderbilt.edu	Panizzi, Peter/A-6072-2019	Panizzi, Peter/0000-0003-0141-8807; Fuentes-Prior, Pablo/0000-0002-6618-3204	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071544, R00HL094533, R37HL071544] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL071544, R37 HL071544-03, R37 HL071544, HL071544, R00 HL094533] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson PJ, 2000, J BIOL CHEM, V275, P16428, DOI 10.1074/jbc.M001254200; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1992, PROTEIN SCI, V1, P426; BODE W, 1992, THROMBIN STRUCTURE F; Boxrud PD, 2004, J BIOL CHEM, V279, P36633, DOI 10.1074/jbc.M405264200; Boxrud PD, 2004, J BIOL CHEM, V279, P36642, DOI 10.1074/jbc.M405265200; Boyle MDP, 1997, THROMB HAEMOSTASIS, V77, P1; BRANDSTETTER H, 1992, J MOL BIOL, V226, P1085, DOI 10.1016/0022-2836(92)91054-S; Castellino F J, 1976, Methods Enzymol, V45, P244; COLLEN D, 1993, J BIOL CHEM, V268, P8284; FENTON JW, 1974, THROMB RES, V4, P809, DOI 10.1016/0049-3848(74)90024-3; FENTON JW, 1977, J BIOL CHEM, V252, P3587; Finlay BB, 1997, MICROBIOL MOL BIOL R, V61, P136, DOI 10.1128/.61.2.136-169.1997; Friedrich R, 2003, NATURE, V425, P535, DOI 10.1038/nature01962; Gladysheva IP, 2003, P NATL ACAD SCI USA, V100, P9168, DOI 10.1073/pnas.1631716100; Grella DK, 1997, BLOOD, V89, P1585, DOI 10.1182/blood.V89.5.1585.1585_1585_1589; HEMKER HC, 1975, BIOCHIM BIOPHYS ACTA, V379, P180, DOI 10.1016/0005-2795(75)90020-3; HENDRIX H, 1983, J BIOL CHEM, V258, P3637; KAWABATA S, 1985, J BIOCHEM, V98, P1603, DOI 10.1093/oxfordjournals.jbchem.a135430; Khan AR, 1998, PROTEIN SCI, V7, P815; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MCCOY HE, 1991, J INFECT DIS, V164, P515, DOI 10.1093/infdis/164.3.515; Panizzi P, 2006, J BIOL CHEM, V281, P1179, DOI 10.1074/jbc.M507956200; Panizzi P, 2006, J BIOL CHEM, V281, P1169, DOI 10.1074/jbc.M507955200; Parry MAA, 1998, NAT STRUCT BIOL, V5, P917, DOI 10.1038/2359; Rabijns A, 1997, NAT STRUCT BIOL, V4, P357, DOI 10.1038/nsb0597-357; RAUS J, 1991, J CLIN MICROBIOL, V29, P570, DOI 10.1128/JCM.29.3.570-572.1991; SODEINDE OA, 1992, SCIENCE, V258, P1004, DOI 10.1126/science.1439793; Sun HM, 2004, SCIENCE, V305, P1283, DOI 10.1126/science.1101245; Vandeputte-Rutten L, 2001, EMBO J, V20, P5033, DOI 10.1093/emboj/20.18.5033; Wang SG, 1999, BIOCHEMISTRY-US, V38, P5232, DOI 10.1021/bi981915h; Wang XQ, 1998, SCIENCE, V281, P1662, DOI 10.1126/science.281.5383.1662; Zajdel M, 1973, Contrib Microbiol Immunol, V1, P364	33	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					1188	1195		10.1074/jbc.M507957200	http://dx.doi.org/10.1074/jbc.M507957200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16230338	Green Accepted, hybrid			2022-12-25	WOS:000234447200061
J	Schneider-Merck, T; Pohnke, Y; Kempf, R; Christian, M; Brosens, JJ; Gellersen, B				Schneider-Merck, T; Pohnke, Y; Kempf, R; Christian, M; Brosens, JJ; Gellersen, B			Physical interaction and mutual transrepression between CCAAT/enhancer-binding protein beta and the p53 tumor suppressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ENDOMETRIAL STROMAL CELLS; C/EBP-BETA; DNA-BINDING; TRANSCRIPTION FACTORS; INTERLEUKIN-6 PROMOTER; INHIBITORY PROTEIN; ESTROGEN-RECEPTOR; GENE-EXPRESSION; LEUCINE-ZIPPER	The tumor suppressor protein p53 is not only involved in defending cells against genotoxic insults but is also implicated in differentiation processes, a function that it shares with the CCAAT/enhancer-binding protein beta (C/EBP beta). We previously reported an up-regulation of both factors in the cycle-dependent differentiation process of human endometrial stromal cells, termed decidualization. C/EBP beta-mediated activation of a decidualization marker, the decidual prolactin promoter, was antagonized by p53. Here we report that C/EBP beta in turn represses the transcriptional activity of p53. Competition for limiting amounts of coactivator CREB-binding protein/p300 was ruled out as the underlying mechanism of transrepression. Physical interaction between p53 and C/EBP beta was demonstrated in vitro and in vivo and shown to depend on the C-terminal domains of both proteins. In gel shift experiments, C/EBP beta reduced complex formation between p53 and its response element. Conversely, p53 strongly inhibited binding of endogenous C/EBP beta from endometrial stromal cells to the C/EBP-responsive region in the decidual prolactin promoter. The observed negative cross-talk between p53 and C/EBP beta is likely to impact expression of their respective target genes.	Endokrinologiku Hamburg, D-20251 Hamburg, Germany; Univ Hamburg, Inst Hormone & Fertil Res, D-20251 Hamburg, Germany; Hammersmith Hosp, Imperial Coll London, Inst Reprod & Dev Biol, London W12 0NN, England	University of Hamburg; Imperial College London	Gellersen, B (corresponding author), Endokrinologiku Hamburg, Falkenried 88, D-20251 Hamburg, Germany.	gellersen@endokrinologikum.com		Brosens, Jan/0000-0003-0116-9329; Christian, Mark/0000-0002-1616-4179	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Baer M, 2000, J BIOL CHEM, V275, P26582, DOI 10.1074/jbc.M004268200; Bauknecht T, 1996, J VIROL, V70, P7695, DOI 10.1128/JVI.70.11.7695-7705.1996; Bundy LM, 2003, ONCOGENE, V22, P869, DOI 10.1038/sj.onc.1206216; Calkhoven CF, 2000, GENE DEV, V14, P1920; Christian M, 2002, J BIOL CHEM, V277, P20825, DOI 10.1074/jbc.M201018200; Christian M, 2002, MOL ENDOCRINOL, V16, P141, DOI 10.1210/me.16.1.141; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gellersen B, 1997, MOL ENDOCRINOL, V11, P97, DOI 10.1210/me.11.1.97; Gellersen B, 2003, J ENDOCRINOL, V178, P357, DOI 10.1677/joe.0.1780357; Goodman RH, 2000, GENE DEV, V14, P1553; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Hattori T, 2003, ONCOGENE, V22, P1273, DOI 10.1038/sj.onc.1206204; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; Ikeda A, 2000, BIOCHEM BIOPH RES CO, V272, P375, DOI 10.1006/bbrc.2000.2786; Kim E, 2003, ONCOGENE, V22, P7716, DOI 10.1038/sj.onc.1207155; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubicka S, 1999, J BIOL CHEM, V274, P32137, DOI 10.1074/jbc.274.45.32137; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Lee YH, 1997, MOL CELL BIOL, V17, P2038, DOI 10.1128/MCB.17.4.2038; Lee YM, 1996, MOL CELL BIOL, V16, P4257; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Liu G, 2003, J BIOL CHEM, V278, P17557, DOI 10.1074/jbc.M210696200; Liu G, 1999, BIOCHEM BIOPH RES CO, V264, P359, DOI 10.1006/bbrc.1999.1525; MARGULIES L, 1993, J BIOL CHEM, V268, P15096; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; McNagny KM, 1998, EMBO J, V17, P3669, DOI 10.1093/emboj/17.13.3669; Milde-Langosch K, 2003, BREAST CANCER RES TR, V79, P175, DOI 10.1023/A:1023929504884; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Oya M, 2003, CLIN CANCER RES, V9, P1021; Pohnke Y, 2004, J CLIN ENDOCR METAB, V89, P5233, DOI 10.1210/jc.2004-0012; Pohnke Y, 1999, J BIOL CHEM, V274, P24808, DOI 10.1074/jbc.274.35.24808; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Rask K, 2000, INT J CANCER, V86, P337, DOI 10.1002/(SICI)1097-0215(20000501)86:3<337::AID-IJC6>3.3.CO;2-V; Ravi R, 1998, CANCER RES, V58, P4531; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Scolnick DM, 1997, CANCER RES, V57, P3693; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; Sengupta S, 2004, ANN NY ACAD SCI, V1024, P54, DOI 10.1196/annals.1321.005; Sivaraman L, 2001, P NATL ACAD SCI USA, V98, P12379, DOI 10.1073/pnas.221459098; STEIN B, 1995, MOL CELL BIOL, V15, P4971; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; Sundfeldt K, 1999, BRIT J CANCER, V79, P1240, DOI 10.1038/sj.bjc.6690199; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Uesugi M, 1999, P NATL ACAD SCI USA, V96, P14801, DOI 10.1073/pnas.96.26.14801; Vinson C, 2002, MOL CELL BIOL, V22, P6321, DOI 10.1128/MCB.22.18.6321-6335.2002; Wadgaonkar R, 1999, J BIOL CHEM, V274, P13760, DOI 10.1074/jbc.274.20.13760; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; WANG L, 1995, J BIOL CHEM, V270, P23159, DOI 10.1074/jbc.270.39.23159; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Webster NJG, 1996, CANCER RES, V56, P2781; Yap N, 1996, P NATL ACAD SCI USA, V93, P4273, DOI 10.1073/pnas.93.9.4273; Yu CL, 1997, BIOCHEM BIOPH RES CO, V239, P617, DOI 10.1006/bbrc.1997.7522; Yu CL, 1997, CANCER LETT, V116, P191, DOI 10.1016/S0304-3835(97)00186-9; Zhu SY, 2002, P NATL ACAD SCI USA, V99, P207, DOI 10.1073/pnas.012437299; Zotchev SB, 2000, NUCLEIC ACIDS RES, V28, P4005, DOI 10.1093/nar/28.20.4005	64	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					269	278		10.1074/jbc.M503459200	http://dx.doi.org/10.1074/jbc.M503459200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16227626	hybrid			2022-12-25	WOS:000234307200035
J	Defossez, PA; Kelly, KF; Filion, GJP; Perez-Torrado, R; Magdinier, F; Menoni, H; Nordgaard, CL; Daniel, JM; Gilson, E				Defossez, PA; Kelly, KF; Filion, GJP; Perez-Torrado, R; Magdinier, F; Menoni, H; Nordgaard, CL; Daniel, JM; Gilson, E			The human enhancer blocker CTC-binding factor interacts with the transcription factor Kaiso	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; ZINC-FINGER; PARTNER KAISO; POZ DOMAIN; PROTEIN; INSULATOR; METHYLATION; GENE; P120(CTN); SEQUENCE	CTC-binding factor (CTCF) is a DNA-binding protein of vertebrates that plays essential roles in regulating genome activity through its capacity to act as an enhancer blocker. We performed a yeast two-hybrid screen to identify protein partners of CTCF that could regulate its activity. Using full-length CTCF as bait we recovered Kaiso, a POZ-zinc finger transcription factor, as a specific binding partner. The interaction occurs through a C-terminal region of CTCF and the POZ domain of Kaiso. CTCF and Kaiso are co-expressed in many tissues, and CTCF was specifically co-immunoprecipitated by several Kaiso monoclonal antibodies from nuclear lysates. Kaiso is a bimodal transcription factor that recognizes methylated CpG dinucleotides or a conserved unmethylated sequence (TNGCAGGA, the Kaiso binding site). We identified one consensus unmethylated Kaiso binding site in close proximity to the CTCF binding site in the human 5' beta-globin insulator. We found, in an insulation assay, that the presence of this Kaiso binding site reduced the enhancer-blocking activity of CTCF. These data suggest that the Kaiso-CTCF interaction negatively regulates CTCF insulator activity.	Ecole Normale Super Lyon, CNRS, UMR5161, F-69364 Lyon 07, France; Inst Curie, CNRS, UMR218, Sect Rech, F-75248 Paris 05, France; McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); McMaster University	Defossez, PA (corresponding author), Ecole Normale Super Lyon, CNRS, UMR5161, 46 Allee Italie, F-69364 Lyon 07, France.	Defossez@Curie.fr	Magdinier, Frederique/I-4735-2016; Filion, Guillaume/G-9619-2015; Perez Torrado, Roberto/E-7613-2012	Magdinier, Frederique/0000-0002-0159-9559; Filion, Guillaume/0000-0002-3473-1632; Perez Torrado, Roberto/0000-0002-3118-6755; Menoni, Herve/0000-0002-5302-4933; Defossez, Pierre-Antoine/0000-0002-6463-9263				BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Burgess-Beusse B, 2002, P NATL ACAD SCI USA, V99, P16433, DOI 10.1073/pnas.162342499; Chernukhin IV, 2000, J BIOL CHEM, V275, P29915, DOI 10.1074/jbc.M001538200; Collins T, 2001, MOL CELL BIOL, V21, P3609, DOI 10.1128/MCB.21.11.3609-3615.2001; Daniel JM, 2002, NUCLEIC ACIDS RES, V30, P2911, DOI 10.1093/nar/gkf398; Daniel JM, 1999, MOL CELL BIOL, V19, P3614; Daniel JM, 2001, HYBRIDOMA, V20, P159, DOI 10.1089/027245701750293484; Defossez PA, 2002, NUCLEIC ACIDS RES, V30, P5136, DOI 10.1093/nar/gkf629; El-Kady A, 2005, FEBS LETT, V579, P1424, DOI 10.1016/j.febslet.2005.01.044; Farrell CM, 2002, MOL CELL BIOL, V22, P3820, DOI 10.1128/MCB.22.11.3820-3831.2002; Filippova GN, 1996, MOL CELL BIOL, V16, P2802; Filippova GN, 1998, GENE CHROMOSOME CANC, V22, P26, DOI 10.1002/(SICI)1098-2264(199805)22:1<26::AID-GCC4>3.0.CO;2-9; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; James P, 1996, GENETICS, V144, P1425; Kanduri C, 2000, CURR BIOL, V10, P853, DOI 10.1016/S0960-9822(00)00597-2; Kelly KF, 2004, J CELL SCI, V117, P2675, DOI 10.1242/jcs.01101; Kim J, 2003, HUM MOL GENET, V12, P233, DOI 10.1093/hmg/ddg028; Kim SW, 2004, NAT CELL BIOL, V6, P1212, DOI 10.1038/ncb1191; Klenova E, 2002, METHODS, V26, P254, DOI 10.1016/S1046-2023(02)00029-4; Klenova EA, 2002, SEMIN CANCER BIOL, V12, P399, DOI 10.1016/S1044-579X(02)00060-3; KLENOVA EM, 1993, MOL CELL BIOL, V13, P7612, DOI 10.1128/MCB.13.12.7612; Klenova EM, 2001, MOL CELL BIOL, V21, P2221, DOI 10.1128/MCB.21.6.2221-2234.2001; Labrador M, 2002, CELL, V111, P151, DOI 10.1016/S0092-8674(02)01004-8; LEDOUARIN B, 1995, NUCLEIC ACIDS RES, V23, P876, DOI 10.1093/nar/23.5.876; Lee DK, 2002, J BIOL CHEM, V277, P26761, DOI 10.1074/jbc.M202078200; Li QL, 2002, NUCLEIC ACIDS RES, V30, P2484, DOI 10.1093/nar/30.11.2484; Li QL, 2002, BLOOD, V100, P3077, DOI 10.1182/blood-2002-04-1104; Loukinov DI, 2002, P NATL ACAD SCI USA, V99, P6806, DOI 10.1073/pnas.092123699; Lutz M, 2003, EMBO J, V22, P1579, DOI 10.1093/emboj/cdg147; Melnick A, 2000, MOL CELL BIOL, V20, P6550, DOI 10.1128/MCB.20.17.6550-6567.2000; Melnick A, 2002, MOL CELL BIOL, V22, P1804, DOI 10.1128/MCB.22.6.1804-1818.2002; Ohlsson R, 2001, TRENDS GENET, V17, P520, DOI 10.1016/S0168-9525(01)02366-6; Prokhortchouk A, 2001, GENE DEV, V15, P1613, DOI 10.1101/gad.198501; Rodova M, 2004, MOL CELL BIOL, V24, P7188, DOI 10.1128/MCB.24.16.7188-7196.2004; Spring CM, 2005, EXP CELL RES, V305, P253, DOI 10.1016/j.yexcr.2005.01.007; Tanimoto K, 2003, MOL CELL BIOL, V23, P8946, DOI 10.1128/MCB.23.24.8946-8952.2003; Wai AWK, 2003, EMBO J, V22, P4489, DOI 10.1093/emboj/cdg437; West AG, 2002, GENE DEV, V16, P271, DOI 10.1101/gad.954702; Yoon HG, 2003, MOL CELL, V12, P723, DOI 10.1016/j.molcel.2003.08.008; Yu WQ, 2004, NAT GENET, V36, P1105, DOI 10.1038/ng1426; Yusufzai TM, 2004, P NATL ACAD SCI USA, V101, P8620, DOI 10.1073/pnas.0402938101; Yusufzai TM, 2004, MOL CELL, V13, P291, DOI 10.1016/S1097-2765(04)00029-2	45	66	69	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					43017	43023		10.1074/jbc.M510802200	http://dx.doi.org/10.1074/jbc.M510802200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16230345	Green Published, hybrid			2022-12-25	WOS:000234200800066
J	Perani, M; Antonson, P; Hamoudi, R; Ingram, CJE; Cooper, CS; Garrett, MD; Goodwin, GH				Perani, M; Antonson, P; Hamoudi, R; Ingram, CJE; Cooper, CS; Garrett, MD; Goodwin, GH			The proto-oncoprotein SYT interacts with SYT-interacting protein/co-activator activator (SIP/CoAA), a human nuclear receptor co-activator with similarity to EWS and TLS/FUS family of proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN-REMODELING COMPLEX; RNA-POLYMERASE-II; SYNOVIAL SARCOMA TRANSLOCATION; IN-VIVO FUNCTIONS; GLUCOCORTICOID-RECEPTOR; TRANSCRIPTIONAL ACTIVATION; BINDING PROTEIN; NUCLEOSOME DISRUPTION; SPLICING FACTORS; SWI/SNF COMPLEX	The proto-oncoprotein SYT is involved in the unique translocation t(X; 18) found in synovial sarcoma SYT-SSX fusions. SYT has a conserved N-terminal domain (SNH domain) that interacts with the human paralog of Drosophila Brahma (hBRM) and Brahma-related gene 1 (BRG1) chromatin remodeling proteins and a C-terminal transactivating sequence rich in glutamine, proline, glycine, and tyrosine (QPGY domain). Here we reported the isolation of the ribonucleoprotein SYT-interacting protein/co-activator activator (SIP/CoAA), which specifically binds the QPGY domain of SYT and also the SYT-SSX2 translocation fusion. SIP/CoAA is a general nuclear co-activator and an RNA splicing modulator that contains two RNA recognition motifs and multiple hexapeptide repeats. We showed that the region consisting of the hexapeptide motif (YQ domain) is similar to the hexapeptide repeat domain found in EWS and in TLS/FUS family proteins. The YQ domain also resembles the QPGY region of SYT itself and like all these other domains acts as a transcriptional activator in reporter assays. Most interestingly, the last 84 amino acids adjacent to YQ down-modulate by 25-fold the YQ transactivation of the reporter gene, and both domains are important for SIP/CoAA binding to SYT. In addition, SYT acts together with SIP/CoAA in stimulating estrogen and glucocorticoid receptor-dependent transcriptional activation. Activation is hormone-dependent and requires functional hBRM and/or BRG1. The stimulation is strongly reduced if the N-terminal region of hBRM/BRG1 (amino acids 1-211) is deleted. This region encompasses the SNF11 binding domain (amino acids 156-211), which interacts specifically with SYT in vivo and in vitro.	Inst Canc Res, Sect Mol Carcinogenesis, Sutton SM2 5NG, Surrey, England; Inst Canc Res, Canc Res UK, Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England	University of London; Institute of Cancer Research - UK; Cancer Research UK; University of London; Institute of Cancer Research - UK	Perani, M (corresponding author), Inst Canc Res, Sect Mol Carcinogenesis, Brookes Lawley Bldg,15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.	michela.perani@icr.ac.uk		Hamoudi, Rifat/0000-0002-1402-0868; Antonson, Per/0000-0001-9335-9941; Ingram, Catherine/0000-0003-2863-8930	Worldwide Cancer Research [99-0108] Funding Source: Medline	Worldwide Cancer Research		Aman P, 1999, SEMIN CANCER BIOL, V9, P303, DOI 10.1006/scbi.1999.0130; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Araya N, 2003, J BIOL CHEM, V278, P5427, DOI 10.1074/jbc.M210234200; Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; Auboeuf D, 2004, MOL CELL BIOL, V24, P442, DOI 10.1128/MCB.24.1.442-453.2004; Auboeuf D, 2002, SCIENCE, V298, P416, DOI 10.1126/science.1073734; Belandia B, 2000, J BIOL CHEM, V275, P30801, DOI 10.1074/jbc.C000484200; Belandia B, 2002, EMBO J, V21, P4094, DOI 10.1093/emboj/cdf412; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; de Bruijn DRH, 2001, ONCOGENE, V20, P3281, DOI 10.1038/sj.onc.1204419; deBruijn DRH, 1996, ONCOGENE, V13, P643; DeCristofaro MF, 2001, J CELL PHYSIOL, V186, P136; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DELEEUW B, 1995, HUM MOL GENET, V4, P1097, DOI 10.1093/hmg/4.6.1097; Dilworth FJ, 2001, ONCOGENE, V20, P3047, DOI 10.1038/sj.onc.1204329; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; Du J, 1998, GENETICS, V150, P987; Eid JE, 2000, CELL, V102, P839, DOI 10.1016/S0092-8674(00)00072-6; Farrants AKO, 1997, MOL CELL BIOL, V17, P895, DOI 10.1128/MCB.17.2.895; Fletcher TM, 2002, MOL CELL BIOL, V22, P3255, DOI 10.1128/MCB.22.10.3255-3263.2002; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Glass CK, 2000, GENE DEV, V14, P121; Gregory SG, 1997, GENOME RES, V7, P1162, DOI 10.1101/gr.7.12.1162; Helman LJ, 2003, NAT REV CANCER, V3, P685, DOI 10.1038/nrc1168; Hsiao PW, 2003, MOL CELL BIOL, V23, P6210, DOI 10.1128/MCB.23.17.6210-6220.2003; Huang ZQ, 2003, EMBO J, V22, P2146, DOI 10.1093/emboj/cdg219; Ichinose H, 1997, GENE, V188, P95, DOI 10.1016/S0378-1119(96)00785-8; Inoue H, 2002, J BIOL CHEM, V277, P41674, DOI 10.1074/jbc.M205961200; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Iwasaki T, 2005, ENDOCRINOLOGY, V146, P3892, DOI 10.1210/en.2004-1513; Iwasaki T, 2001, J BIOL CHEM, V276, P33375, DOI 10.1074/jbc.M101517200; Kato H, 2002, J BIOL CHEM, V277, P5498, DOI 10.1074/jbc.M108702200; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Li KKC, 2000, J BIOL CHEM, V275, P23053, DOI 10.1074/jbc.M002961200; Marshall TW, 2003, J BIOL CHEM, V278, P30605, DOI 10.1074/jbc.M304582200; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Meissner M, 2003, EXP CELL RES, V283, P184, DOI 10.1016/S0014-4827(02)00046-0; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Nagai M, 2001, P NATL ACAD SCI USA, V98, P3843, DOI 10.1073/pnas.061036798; Nie ZQ, 2000, MOL CELL BIOL, V20, P8879, DOI 10.1128/MCB.20.23.8879-8888.2000; Perani M, 2003, ONCOGENE, V22, P8156, DOI 10.1038/sj.onc.1207031; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; Rachez C, 2001, CURR OPIN CELL BIOL, V13, P274, DOI 10.1016/S0955-0674(00)00209-X; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Sheldon LA, 1999, MOL CELL BIOL, V19, P8146; Skalsky YM, 2001, ONCOGENE, V20, P178, DOI 10.1038/sj.onc.1204056; Skytting B, 1999, J NATL CANCER I, V91, P974, DOI 10.1093/jnci/91.11.974; Soderlund C, 1997, COMPUT APPL BIOSCI, V13, P523; Soulez M, 1999, ONCOGENE, V18, P2739, DOI 10.1038/sj.onc.1202613; Thaete C, 1999, HUM MOL GENET, V8, P585, DOI 10.1093/hmg/8.4.585; TREICH I, 1995, MOL CELL BIOL, V15, P4240; Tsukiyama T, 2002, NAT REV MOL CELL BIO, V3, P422, DOI 10.1038/nrm828; VIVANCO MD, 1995, EMBO J, V14, P2217, DOI 10.1002/j.1460-2075.1995.tb07216.x; Wallberg AE, 2000, MOL CELL BIOL, V20, P2004, DOI 10.1128/MCB.20.6.2004-2013.2000; Wallberg AE, 2000, BIOCHEM SOC T, V28, P410, DOI 10.1042/0300-5127:0280410; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; West DC, 2000, CURR OPIN ONCOL, V12, P323, DOI 10.1097/00001622-200007000-00008; Woychik NA, 2002, CELL, V108, P453, DOI 10.1016/S0092-8674(02)00646-3; Xu JM, 2003, MOL ENDOCRINOL, V17, P1681, DOI 10.1210/me.2003-0116; Yang L, 2000, J BIOL CHEM, V275, P37612, DOI 10.1074/jbc.M005739200; Yang L, 1998, J BIOL CHEM, V273, P27761, DOI 10.1074/jbc.273.43.27761; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	72	32	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42863	42876		10.1074/jbc.M502963200	http://dx.doi.org/10.1074/jbc.M502963200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16227627	hybrid			2022-12-25	WOS:000234200800049
J	Pillai, JB; Isbatan, A; Imai, S; Gupta, MP				Pillai, JB; Isbatan, A; Imai, S; Gupta, MP			Poly(ADP-ribose) polymerase-1-dependent cardiac myocyte cell death during heart failure is mediated by NAD(+) depletion and reduced Sir2 alpha deacetylase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSE; POLYMERASE; SIR2; APOPTOSIS; HYPERTROPHY; BIOSYNTHESIS; REGULATOR; LONGEVITY; COMPLEX; STRESS	Robust activation of poly(ADP-ribose) polymerase-1 (PARP) by oxidative stress has been implicated as a major cause of caspase-independent-myocyte cell death contributing to heart failure. Here, we show that depletion of myocyte NAD levels and the subsequent reduction of Sir2 alpha deacetylase activity are the sequential steps contributing to PARP-mediated myocyte cell death. In both failing hearts and cultured cardiac myocytes, the increased activity of PARP was associated with depletion of cellular NAD levels and reduced Sir2 alpha deacetylase activity. Myocyte cell death induced by PARP activation was prevented by repletion of cellular NAD levels either by adding NAD directly to the culture medium or by overexpressing NAD biosynthetic enzymes. The beneficial effect of NAD repletion was seen, however, only when Sir2 alpha was intact. Knocking down Sir2 alpha levels by small interfering RNA eliminated this benefit, indicating that Sir2 alpha is a downstream target of NAD replenishment leading to cell protection. NAD repletional so prevented loss of the transcriptional regulatory activity of the Sir2 alpha catalytic core domain resulting from PARP activation. We also show that PARP activation and the concomitant reduction of Sir2 alpha activity in failing hearts regulate the post-translational acetylation of p53. These data demonstrate that, in stressed cardiac myocytes, depletion of cellular NAD levels forms a link between PARP activation and reduced Sir2 alpha deacetylase activity, contributing to myocyte cell death during heart failure.	Univ Chicago, Dept Cardiothorac Surg, Chicago, IL 60637 USA; Univ Chicago, Committee Mol Med & Pathol, Chicago, IL 60637 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	University of Chicago; University of Chicago; Washington University (WUSTL)	Gupta, MP (corresponding author), Univ Chicago, Dept Surg, 5841 S Maryland Ave,MC 5040, Chicago, IL 60637 USA.	mgupta@surgery.bsd.uchicago.edu			NHLBI NIH HHS [R01 HL-77788, R01 HL-68083] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068083, R01HL077788] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alano CC, 2004, J BIOL CHEM, V279, P18895, DOI 10.1074/jbc.M313329200; Alcendor RR, 2004, CIRC RES, V95, P971, DOI 10.1161/01.RES.0000147557.75257.ff; Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Bai N, 2005, PHARMACOL THERAPEUT, V105, P189, DOI 10.1016/j.pharmthera.2004.10.005; Bartunek J, 2002, J AM COLL CARDIOL, V40, P1097, DOI 10.1016/S0735-1097(02)02122-8; Borra MT, 2002, J BIOL CHEM, V277, P12632, DOI 10.1074/jbc.M111830200; Bruzzone S, 2001, FASEB J, V15, P10; Burkle A, 2001, BIOESSAYS, V23, P795, DOI 10.1002/bies.1115; Butler AJ, 1999, MOL CELL BIOL, V19, P296; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Chiarugi A, 2002, TRENDS PHARMACOL SCI, V23, P122, DOI 10.1016/S0165-6147(00)01902-7; Clerk A, 2003, PHARMACOL THERAPEUT, V97, P223, DOI 10.1016/S0163-7258(02)00339-X; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Di Lisa F, 2001, FEBS LETT, V492, P4, DOI 10.1016/S0014-5793(01)02198-6; EMMANUEL T, 1996, J CLIN INVEST, V97, P2891; Fulco M, 2003, MOL CELL, V12, P51, DOI 10.1016/S1097-2765(03)00226-0; Galande S, 1999, J BIOL CHEM, V274, P20521, DOI 10.1074/jbc.274.29.20521; Hassa PO, 2002, CELL MOL LIFE SCI, V59, P1534, DOI 10.1007/s00018-002-8527-2; Hein S, 2003, CIRCULATION, V107, P984, DOI 10.1161/01.CIR.0000051865.66123.B7; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; JACOBSON EL, 1976, ARCH BIOCHEM BIOPHYS, V175, P627, DOI 10.1016/0003-9861(76)90553-1; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kang PM, 2000, CIRC RES, V86, P1107; Kang PM, 2004, AM J PHYSIOL-HEART C, V287, pH72, DOI 10.1152/ajpheart.00556.2003; KATZ AM, 1990, NEW ENGL J MED, V322, P100; Knaapen MWM, 2001, CARDIOVASC RES, V51, P304, DOI 10.1016/S0008-6363(01)00290-5; KOBAYASHI K, 1979, CIRC RES, V44, P166, DOI 10.1161/01.RES.44.2.166; Kun E, 2004, BIOCHEMISTRY-US, V43, P210, DOI 10.1021/bi0301791; North BJ, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-224; Pillai JB, 2005, AM J PHYSIOL-HEART C, V288, pH486, DOI 10.1152/ajpheart.00437.2004; Revollo JR, 2004, J BIOL CHEM, V279, P50754, DOI 10.1074/jbc.M408388200; Sawyer DB, 2002, J MOL CELL CARDIOL, V34, P379, DOI 10.1006/jmcc.2002.1526; Smith JS, 2002, TRENDS CELL BIOL, V12, P404, DOI 10.1016/S0962-8924(02)02342-5; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Wieler S, 2003, J BIOL CHEM, V278, P18914, DOI 10.1074/jbc.M211641200; Xiao CY, 2005, J PHARMACOL EXP THER, V312, P891, DOI 10.1124/jpet.104.077164; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Ying WH, 2005, J NEUROSCI RES, V79, P216, DOI 10.1002/jnr.20289; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Yun SJ, 2003, NEUROREPORT, V14, P935, DOI 10.1097/01.wnr.0000074340.81633.fl	41	324	346	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					43121	43130		10.1074/jbc.M506162200	http://dx.doi.org/10.1074/jbc.M506162200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16207712	hybrid			2022-12-25	WOS:000234200800078
J	Saito, Y; Yokota, T; Mitani, T; Ito, K; Anzai, M; Miyagishi, M; Taira, K; Mizusawa, H				Saito, Y; Yokota, T; Mitani, T; Ito, K; Anzai, M; Miyagishi, M; Taira, K; Mizusawa, H			Transgenic small interfering RNA halts amyotrophic lateral sclerosis in a mouse model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CU/ZN SUPEROXIDE-DISMUTASE; ALS-LINKED SOD1; MUTANT SOD1; SURVIVAL; NEURODEGENERATION; EXPRESSION; MUTATIONS; DISEASE; DEATH; CELLS	Many autosomal dominant diseases such as familial amyotrophic lateral sclerosis (ALS) with copper/zinc superoxide dismutase (SOD1) mutation may be induced by missense point mutations that result in the production of proteins with toxic properties. Reduction in the encoding of proteins from such mutated genes can therefore be expected to improve the disease phenotype. The duplex of 21-nucleotide RNA, known as small interfering RNA (siRNA), has recently emerged as a powerful gene silencing tool. We made transgenic (Tg) mice with modified siRNA, which had multiple mismatch alternations within the sense strand, to prevent the "shutdown phenomenon" of transgenic siRNA. Consequently, the in vivo knockdown effect of siRNA on SOD1 expression did not diminish over four generations. When we crossed these anti-SOD1 siRNA Tg mice with SOD1(G93A) Tg mice, a model for ALS, siRNA prevented the development of disease by inhibiting mutant G93A SOD1 production in the central nervous system. Our findings clearly proved the principle that siRNA-mediated gene silencing can stop the development of familial ALS with SOD1 mutation.	Tokyo Med & Dent Univ, Grad Sch, Dept Neurol & Neurol Sci, Bunkyo Ku, Tokyo 1138519, Japan; Kinki Univ, Inst Adv Technol, Wakayama 6420017, Japan; Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1130013, Japan; Tokyo Med & Dent Univ, Cent COE Program Brain Integrat & Disorders 21, Bunkyo Ku, Tokyo 1138519, Japan	Tokyo Medical & Dental University (TMDU); Kindai University (Kinki University); University of Tokyo; Tokyo Medical & Dental University (TMDU)	Yokota, T (corresponding author), Tokyo Med & Dent Univ, Grad Sch, Dept Neurol & Neurol Sci, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.	tak-yokota.nuro@tmd.ac.jp	Miyagishi, Makoto/L-8174-2016	Miyagishi, Makoto/0000-0001-7654-3616; Yokota, Takanori/0000-0002-6490-3263				Alexander GM, 2004, MOL BRAIN RES, V130, P7, DOI 10.1016/j.molbrainres.2004.07.002; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Clement AM, 2003, SCIENCE, V302, P113, DOI 10.1126/science.1086071; Cleveland DW, 1999, NEURON, V24, P515, DOI 10.1016/S0896-6273(00)81108-3; Gong YH, 2000, J NEUROSCI, V20, P660, DOI 10.1523/JNEUROSCI.20-02-00660.2000; HASUWA H, 2003, GENE MED TOKYO, V7, P59; Lino MM, 2002, J NEUROSCI, V22, P4825, DOI 10.1523/JNEUROSCI.22-12-04825.2002; Matzuk MM, 1998, ENDOCRINOLOGY, V139, P4008, DOI 10.1210/en.139.9.4008; Miller TM, 2005, ANN NEUROL, V57, P773, DOI 10.1002/ana.20453; Miyagishi M, 2004, J GENE MED, V6, P715, DOI 10.1002/jgm.556; Ralph GS, 2005, NAT MED, V11, P429, DOI 10.1038/nm1205; Raoul C, 2002, NEURON, V35, P1067, DOI 10.1016/S0896-6273(02)00905-4; Raoul C, 2005, NAT MED, V11, P423, DOI 10.1038/nm1207; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Xia HB, 2004, NAT MED, V10, P816, DOI 10.1038/nm1076; Yokota T, 2004, BIOCHEM BIOPH RES CO, V314, P283, DOI 10.1016/j.bbrc.2003.12.098	16	45	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42826	42830		10.1074/jbc.M507685200	http://dx.doi.org/10.1074/jbc.M507685200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16221675	hybrid			2022-12-25	WOS:000234200800044
J	Martin, S; Driessen, K; Nixon, SJ; Zerial, M; Parton, RG				Martin, S; Driessen, K; Nixon, SJ; Zerial, M; Parton, RG			Regulated localization of rab18 to lipid droplets - Effects of lipolytic stimulation and inhibition of lipid droplet catabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORTER GLUT4; DOMINANT-NEGATIVE MUTANT; MEMBRANE DOMAINS; TARGETING DOMAIN; BINDING PROTEIN; H-RAS; BODIES; CAVEOLIN; IDENTIFICATION; CHOLESTEROL	Rab GTPases are crucial regulators of membrane traffic. Here we have examined a possible association of Rab proteins with lipid droplets (LDs), neutral lipid-containing organelles surrounded by a phospholipid monolayer, also known as lipid bodies, which have been traditionally considered relatively inert storage organelles. Although we found close apposition between LDs and endosomal compartments labeled by expressed Rab5, Rab7, or Rab11 constructs, there was no detectable labeling of the LD surface itself by these Rab proteins. In contrast, GFP-Rab18 localized to LDs and immunoelectron microscopy showed direct association with the monolayer surface. Green fluorescent protein (GFP)-Rab18-labeled LDs underwent oscillatory movements in a localized area as well as sporadic, rapid, saltatory movements both in the periphery of the cell and toward the perinuclear region. In both adipocytes and non-adipocyte cell lines Rab18 localized to a subset of LDs. To gain insights into this specific localization, Rab18 was co-expressed with Cav3(DGV), a truncation mutant of caveolin-3 shown to inhibit the catabolism and motility of lipid droplets. GFP-Rab18 and mRFP-Cav3(DGV) labeled mutually exclusive subpopulations of LDs. Moreover, in 3T3-L1 adipocytes, stimulation of lipolysis increased the localization of Rab18 to LDs, an effect reversed by beta-adrenergic antagonists. These results show that a Rab protein localizes directly to the monolayer surface of LDs. In addition, association with the LD surface was increased following stimulation of lipolysis and inhibited by a caveolin mutant suggesting that recruitment of Rab18 is regulated by the metabolic state of individual LDs.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Ctr Microscopy & Microanal, Brisbane, Qld 4072, Australia; Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany	University of Queensland; University of Queensland; Max Planck Society	Martin, S (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	s.martin@imb.uq.edu.au	Parton, Robert G/C-5673-2009; Martin, Sally/A-7150-2010; Nixon, Susan/D-4588-2017	Parton, Robert G/0000-0002-7494-5248; Martin, Sally/0000-0001-9294-5404; Nixon, Susan/0000-0003-0346-9683				BLANCHETTEMACKIE EJ, 1995, J LIPID RES, V36, P1211; Brasaemle DL, 2004, J BIOL CHEM, V279, P46835, DOI 10.1074/jbc.M409340200; Bucci C, 2000, MOL BIOL CELL, V11, P467, DOI 10.1091/mbc.11.2.467; Calero M, 2003, MOL BIOL CELL, V14, P1852, DOI 10.1091/mbc.E02-11-0707; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Fujimoto Y, 2004, BBA-MOL CELL RES, V1644, P47, DOI 10.1016/j.bbamcr.2003.10.018; Gomes AQ, 2003, MOL BIOL CELL, V14, P1882, DOI 10.1091/mbc.E02-10-0639; Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201; Liu PS, 2004, J BIOL CHEM, V279, P3787, DOI 10.1074/jbc.M311945200; Londos C, 1999, ANN NY ACAD SCI, V892, P155, DOI 10.1111/j.1749-6632.1999.tb07794.x; Luetterforst R, 1999, J CELL BIOL, V145, P1443, DOI 10.1083/jcb.145.7.1443; LUTCKE A, 1994, J CELL SCI, V107, P3437; Martin S, 1997, J CELL SCI, V110, P2281; Martin S, 2005, SEMIN CELL DEV BIOL, V16, P163, DOI 10.1016/j.semcdb.2005.01.007; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; Martin S, 2000, TRAFFIC, V1, P652, DOI 10.1034/j.1600-0854.2000.010809.x; Morrow IC, 2002, J BIOL CHEM, V277, P48834, DOI 10.1074/jbc.M209082200; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Murphy DJ, 2001, PROG LIPID RES, V40, P325, DOI 10.1016/S0163-7827(01)00013-3; Overmeyer JH, 2001, J BIOL CHEM, V276, P20379, DOI 10.1074/jbc.M101511200; Ozeki S, 2005, J CELL SCI, V118, P2601, DOI 10.1242/jcs.02401; Pereira-Leal JB, 2000, J MOL BIOL, V301, P1077, DOI 10.1006/jmbi.2000.4010; Pol A, 2001, J CELL BIOL, V152, P1057, DOI 10.1083/jcb.152.5.1057; Pol A, 2004, MOL BIOL CELL, V15, P99, DOI 10.1091/mbc.E03-06-0368; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Roberts RL, 1999, J CELL SCI, V112, P3667; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Seabra MC, 2004, CURR OPIN CELL BIOL, V16, P451, DOI 10.1016/j.ceb.2004.06.014; Shewan AM, 2000, BIOCHEM J, V350, P99, DOI 10.1042/0264-6021:3500099; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; Tansey JT, 2004, IUBMB LIFE, V56, P379, DOI 10.1080/15216540400009968; Targett-Adams P, 2003, J BIOL CHEM, V278, P15998, DOI 10.1074/jbc.M211289200; TOKUYASU KT, 1980, HISTOCHEM J, V12, P381, DOI 10.1007/BF01011956; Trigatti BL, 1999, BIOCHEM BIOPH RES CO, V255, P34, DOI 10.1006/bbrc.1998.0123; Umlauf E, 2004, J BIOL CHEM, V279, P23699, DOI 10.1074/jbc.M310546200; Valetti C, 1999, MOL BIOL CELL, V10, P4107, DOI 10.1091/mbc.10.12.4107; Vock R, 1996, J EXP BIOL, V199, P1689; Yu WG, 2000, BLOOD, V95, P1078, DOI 10.1182/blood.V95.3.1078.003k16_1078_1085; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	40	223	228	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42325	42335		10.1074/jbc.M506651200	http://dx.doi.org/10.1074/jbc.M506651200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16207721	hybrid			2022-12-25	WOS:000233992700062
J	Jordanova, R; Radoslavov, G; Fischer, P; Torda, A; Lottspeich, F; Boteva, R; Walter, RD; Bankov, I; Liebau, E				Jordanova, R; Radoslavov, G; Fischer, P; Torda, A; Lottspeich, F; Boteva, R; Walter, RD; Bankov, I; Liebau, E			The highly abundant protein Ag-Ibp55 from Ascaridia galli represents a novel type of lipid-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SEQUENCE ALIGNMENT; AMINO-ACID-SEQUENCE; FATTY-ACID; STRUCTURAL-CHARACTERIZATION; STRUCTURE PREDICTION; SECONDARY STRUCTURE; GAP PENALTIES; NEMATODES; DATABASE; RECOGNITION	Lipid-binding proteins exhibit important functions in lipid transport, cellular signaling, gene transcription, and cytoprotection. Their functional analogues in nematodes are nematode polyprotein allergens/antigens and fatty acid and retinoid-binding proteins. This work describes a novel 55-kDa protein, Ag-lbp55, purified from the parasitic nematode Ascaridia galli. By direct N-terminal sequencing, a partial amino acid sequence was obtained that allowed the design of oligonucleotide primers to obtain the full-length cDNA sequence. Sequence analysis revealed the presence of an N-terminal signal peptide of 25 amino acid residues and a FAR domain at the C terminus. Data base searches showed almost no significant homologies to other described proteins. The secondary structure of Ag-lbp55 was predominantly alpha-helical (65%) as shown by CD spectroscopy. It was found to bind with high affinity fatty acids ( caprylic, oleic, and palmitic acid) and their fluorescent analogue dansylaminoundecanic acid. Immunolocalization showed that Ag-lbp55 is a highly abundant protein, mainly distributed in the inner hypodermis and extracellularly in the pseudocoelomatic fluid. A similar staining pattern was observed in other pathogenic nematodes, indicating the existence of similar proteins in these species.	Inst Expt Pathol & Parasitol, Sofia 1113, Bulgaria; Bernhard Nocht Inst Trop Med, D-20359 Hamburg, Germany; Univ Hamburg, Ctr Bioinformat, D-20146 Hamburg, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Natl Ctr Radiobiol & Radiat Protect, Sofia 1756, Bulgaria	Bulgarian Academy of Sciences; Bernhard Nocht Institut fur Tropenmedizin; University of Hamburg; Max Planck Society	Liebau, E (corresponding author), Univ Munster, Inst Anim Physiol, Hindenburgpl 55, D-48143 Munster, Germany.	liebaue@uni-muenster.de	Fischer, Peter/A-2746-2008; Radoslavov, Georgi/AAO-5374-2021	Radoslavov, Georgi/0000-0003-0550-3291; Fischer, Peter/0000-0003-4558-3417				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Barrett J, 2001, PERSPECTIVES ON HELMINTHOLOGY, P309; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; Cuff JA, 2000, PROTEINS, V40, P502, DOI 10.1002/1097-0134(20000815)40:3<502::AID-PROT170>3.0.CO;2-Q; ECKERSKORN C, 1993, ELECTROPHORESIS, V14, P831, DOI 10.1002/elps.11501401133; Fischer P, 2002, EXP PARASITOL, V102, P201, DOI 10.1016/S0014-4894(03)00058-4; Garnier J, 1996, METHOD ENZYMOL, V266, P540; Garofalo A, 2003, J BIOL CHEM, V278, P8065, DOI 10.1074/jbc.M206278200; Garofalo A, 2002, MOL BIOCHEM PARASIT, V122, P161, DOI 10.1016/S0166-6851(02)00097-X; Hadley C, 1999, STRUCT FOLD DES, V7, P1099, DOI 10.1016/S0969-2126(99)80177-4; Jaroszewski L, 2005, NUCLEIC ACIDS RES, V33, pW284, DOI 10.1093/nar/gki418; Jordanova R, 2005, FEBS J, V272, P180, DOI 10.1111/j.1432-1033.2004.04398.x; Karplus K, 1998, BIOINFORMATICS, V14, P846, DOI 10.1093/bioinformatics/14.10.846; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kennedy Malcolm W., 2001, P309, DOI 10.1079/9780851994239.0309; Kennedy MW, 2000, BBA-PROTEIN STRUCT M, V1476, P149, DOI 10.1016/S0167-4838(99)00249-6; Kennedy MW, 1997, J BIOL CHEM, V272, P29442, DOI 10.1074/jbc.272.47.29442; KENNEDY MW, 1995, BIOCHEMISTRY-US, V34, P6700, DOI 10.1021/bi00020a015; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; Levine T, 2004, TRENDS CELL BIOL, V14, P483, DOI 10.1016/j.tcb.2004.07.017; Loewen CJR, 2003, EMBO J, V22, P2025, DOI 10.1093/emboj/cdg201; Marchler-Bauer A, 2005, NUCLEIC ACIDS RES, V33, pD192, DOI 10.1093/nar/gki069; McDermott L, 2002, BIOCHEMISTRY-US, V41, P6706, DOI 10.1021/bi0159635; McDermott L, 1999, MOL CELL BIOCHEM, V192, P69, DOI 10.1023/A:1006822321081; McGuffin LJ, 2003, BIOINFORMATICS, V19, P874, DOI 10.1093/bioinformatics/btg097; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Noy N, 2000, BIOCHEM J, V348, P481, DOI 10.1042/0264-6021:3480481; Park J, 1998, J MOL BIOL, V284, P1201, DOI 10.1006/jmbi.1998.2221; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P229, DOI 10.1016/0010-4655(82)90174-6; Rost B, 1996, METHOD ENZYMOL, V266, P525; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; STONE KL, 1986, J CHROMATOGR, V359, P203, DOI 10.1016/0021-9673(86)80074-7; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TIELENS AGM, 1994, PARASITOL TODAY, V10, P346, DOI 10.1016/0169-4758(94)90245-3; Timanova A, 1999, EUR J BIOCHEM, V261, P569, DOI 10.1046/j.1432-1327.1999.00328.x; Timanova AM, 1997, PARASITOL RES, V83, P518, DOI 10.1007/s004360050291; Torda AE, 2004, NUCLEIC ACIDS RES, V32, pW532, DOI 10.1093/nar/gkh357; TWEEDIE S, 1993, EXP PARASITOL, V76, P156, DOI 10.1006/expr.1993.1018; WILTON DC, 1990, BIOCHEM J, V270, P163, DOI 10.1042/bj2700163; Zimmerman AW, 2002, CELL MOL LIFE SCI, V59, P1096, DOI 10.1007/s00018-002-8490-y	47	11	11	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41429	41438		10.1074/jbc.M504474200	http://dx.doi.org/10.1074/jbc.M504474200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16210327	hybrid			2022-12-25	WOS:000233866900040
J	Li, Y; Wright, JM; Qian, F; Germino, GG; Guggino, WB				Li, Y; Wright, JM; Qian, F; Germino, GG; Guggino, WB			Polycystin 2 interacts with type I inositol 1,4,5-trisphosphate receptor to modulate intracellular Ca2+ signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; SMOOTH-MUSCLE-CELLS; KIDNEY-DISEASE; CATION CHANNEL; CALCIUM WAVES; PKD1; PROTEIN; GENE; TRISPHOSPHATE	Autosomal dominant polycystic kidney disease, a common cause of renal failure, arises from mutations in either the PKD1 or the PKD2 gene. The precise function of both PKD gene products polycystins (PCs) 1 and 2 remain controversial. PC2 has been localized to numerous cellular compartments, including the endoplasmic reticulum, plasma membrane, and cilia. It is unclear what pools are the most relevant to its physiological function as a putative Ca2+ channel. We employed a Xenopus oocyte Ca2+ imaging system to directly investigate the role of PC2 in inositol 1,4,5-trisphosphate (IP3)-dependent Ca2+ signaling. Cytosolic Ca2+ signals were recorded following UV photolysis of caged IP3 in the absence of extracellular Ca2+. We demonstrated that overexpression of PC2, as well as type I IP3 receptor (IP3R), significantly prolonged the half-decay time (t(1/2)) of IP3-induced Ca2+ transients. However, over-expressing the disease-associated PC2 mutants, the point mutation D511V, and the C-terminally truncated mutation R742X did not alter the t(1/2). In addition, we found that D511V overexpression significantly reduced the amplitude of IP3-induced Ca2+ transients. Interestingly, overexpression of the C terminus of PC2 not only significantly reduced the amplitude but also prolonged the t(1/2). Co-immunoprecipitation assays indicated that PC2 physically interacts with IP3R through its C terminus. Taken together, our data suggest that PC2 and IP3R functionally interact and modulate intracellular Ca2+ signaling. Therefore, mutations in either PC1 or PC2 could result in the misregulation of intracellular Ca2+ signaling, which in turn could contribute to the pathology of autosomal dominant polycystic kidney disease.	Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Div Nephrol, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Guggino, WB (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, 725 N Wolfe St, Baltimore, MD 21205 USA.	wguggino@jhmi.edu		Germino, Gregory/0000-0002-3609-5588	NIDDK NIH HHS [5 R01 DK32753, R01 DK062199, DK48006] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062199, R01DK032753, R37DK048006, R01DK048006] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguiari G, 2004, FASEB J, V18, P884, DOI 10.1096/fj.03-0687fje; Anyatonwu GI, 2004, BIOCHEM BIOPH RES CO, V322, P1364, DOI 10.1016/j.bbrc.2004.08.043; Bultynck G, 2003, PFLUG ARCH EUR J PHY, V445, P629, DOI 10.1007/s00424-002-0971-1; Cai YQ, 2004, J BIOL CHEM, V279, P19987, DOI 10.1074/jbc.M312031200; Cai ZQ, 1999, J BIOL CHEM, V274, P28557, DOI 10.1074/jbc.274.40.28557; Callamaras N, 1998, Methods Enzymol, V291, P380; CAMACHO P, 1995, CIBA F SYMP, V188, P66; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; CAMACHO P, 1993, SCIENCE, V260, P226, DOI 10.1126/science.8385800; Cantiello HF, 2004, AM J PHYSIOL-RENAL, V286, pF1012, DOI 10.1152/ajprenal.00181.2003; Chen J, 2005, J BIOL CHEM, V280, P29912, DOI 10.1074/jbc.M504516200; Chen XZ, 2001, BIOCHEM BIOPH RES CO, V282, P1251, DOI 10.1006/bbrc.2001.4720; Gallagher AR, 2002, CELL MOL LIFE SCI, V59, P682, DOI 10.1007/s00018-002-8457-z; Gonzalez-Perrett S, 2001, P NATL ACAD SCI USA, V98, P1182, DOI 10.1073/pnas.021456598; Grayson TH, 2004, CELL CALCIUM, V36, P447, DOI 10.1016/j.ceca.2004.04.005; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; Hill CE, 2001, MED RES REV, V21, P1; Hooper KM, 2005, AM J PHYSIOL-RENAL, V289, pF521, DOI 10.1152/ajprenal.00355.2004; Ikeda M, 2002, CURR OPIN NEPHROL HY, V11, P539, DOI 10.1097/00041552-200209000-00010; John LM, 2001, J PHYSIOL-LONDON, V535, P3, DOI 10.1111/j.1469-7793.2001.t01-2-00003.x; John LM, 1998, J CELL BIOL, V142, P963, DOI 10.1083/jcb.142.4.963; Kip SN, 2005, CIRC RES, V96, P873, DOI 10.1161/01.RES.0000163278.68142.8a; Koulen P, 2002, NAT CELL BIOL, V4, P191, DOI 10.1038/ncb754; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; Lechleiter JD, 1998, BIOPHYS CHEM, V72, P123, DOI 10.1016/S0301-4622(98)00128-8; Li Y, 2004, J CELL BIOL, V164, P35, DOI 10.1083/jcb.200307010; Lu WN, 1997, NAT GENET, V17, P179, DOI 10.1038/ng1097-179; Luo Y, 2003, MOL CELL BIOL, V23, P2600, DOI 10.1128/MCB.23.7.2600-2607.2003; Markovska RP, 1999, ADSORPT SCI TECHNOL, V17, P25, DOI 10.1177/026361749901700103; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Newby LJ, 2002, J BIOL CHEM, V277, P20763, DOI 10.1074/jbc.M107788200; Parker I, 1996, BIOPHYS J, V70, P222, DOI 10.1016/S0006-3495(96)79565-6; Parker I, 1996, CELL CALCIUM, V20, P105, DOI 10.1016/S0143-4160(96)90100-1; Parker I, 1996, J PHYSIOL-LONDON, V491, P663, DOI 10.1113/jphysiol.1996.sp021247; PARYS JB, 1994, DEV BIOL, V161, P466, DOI 10.1006/dbio.1994.1045; Peters DJM, 2001, LANCET, V358, P1439, DOI 10.1016/S0140-6736(01)06531-X; Piontek KB, 2004, J AM SOC NEPHROL, V15, P3035, DOI 10.1097/01.ASN.0000144204.01352.86; Pritchard L, 2000, HUM MOL GENET, V9, P2617, DOI 10.1093/hmg/9.18.2617; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; Qian Q, 2003, HUM MOL GENET, V12, P1875, DOI 10.1093/hmg/ddg190; Rizk D, 2003, AM J KIDNEY DIS, V42, P1305, DOI 10.1053/j.ajkd.2003.10.002; Roderick HL, 2000, J CELL BIOL, V149, P1235, DOI 10.1083/jcb.149.6.1235; Sandford R, 1997, HUM MOL GENET, V6, P1483, DOI 10.1093/hmg/6.9.1483; Schwiebert EM, 2002, AM J PHYSIOL-RENAL, V282, pF763, DOI 10.1152/ajprenal.0337.2000; Sutters M, 2003, J LAB CLIN MED, V141, P91, DOI 10.1067/mlc.2003.13; TATE SS, 1990, FASEB J, V4, P227, DOI 10.1096/fasebj.4.2.2298343; Triggle Chris R., 2003, Journal of Smooth Muscle Research, V39, P249, DOI 10.1540/jsmr.39.249; Tsiokas L, 1999, P NATL ACAD SCI USA, V96, P3934, DOI 10.1073/pnas.96.7.3934; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; Vassilev PM, 2001, BIOCHEM BIOPH RES CO, V282, P341, DOI 10.1006/bbrc.2001.4554; Weston BS, 2003, FEBS LETT, V538, P8, DOI 10.1016/S0014-5793(03)00130-3	52	132	137	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41298	41306		10.1074/jbc.M510082200	http://dx.doi.org/10.1074/jbc.M510082200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16223735	hybrid			2022-12-25	WOS:000233866900024
J	Rabu, C; Quemener, A; Jacques, Y; Echasserieau, K; Vusio, P; Lang, F				Rabu, C; Quemener, A; Jacques, Y; Echasserieau, K; Vusio, P; Lang, F			Production of recombinant human trimeric CD137L (4-1BBL) - Cross-linking is essential to its T cell co-stimulation activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SOLUBLE FAS LIGAND; EFFECTOR FUNCTION; FACTOR-ALPHA; IN-VIVO; PROTEIN; ACTIVATION; COSTIMULATION; LYMPHOCYTES; FORM	The interaction between 4-1BB ligand (CD137L), a member of the tumor necrosis factor superfamily, and its receptor 4-1BB provides a co-stimulatory signal for T lymphocyte proliferation and survival. However, the structure of 4-1BBL has not been thoroughly investigated, and none of the human recombinant 4-1BBL molecules available have been described as capable of co-stimulating T cells. The present work provides a model of the three-dimensional structure of the tumor necrosis factor homology domain of 4-1BBL and describes the production of a recombinant human soluble 4-1BBL whose originality lies in that it contains the whole extracellular tail preceding the tumor necrosis factor homology domain and an AviTag peptide (AviTag-4-1BBL) allowing enzymatic biotinylation and multimerization via streptavidin. We provide evidence that this chimeric protein exists as a homotrimer, whereas commercial FLAG-tagged 4-1BBL does not. This resulted in a much higher affinity for 4-1BB (1.2 nM) as compared with FLAG-4-1BBL (55.2 nM). We demonstrate that the single extracellular cysteine residue in the tail (Cys-51) could form a disulfide bond, both in our recombinant protein and in physiologically expressed 4-1BBL. The mutation of this cysteine residue exerted no effect on trimerization but increased the dissociation rate of AviTag-4-1BBL from 4-1BB. In its soluble form, AviTag-4-1BBL did not stimulate purified T cells but dramatically inhibited proliferation of peripheral blood mononuclear cells stimulated with anti-CD3 mAb. In contrast, a very significant co-stimulatory effect was observed on purified T cells once AviTag-4-1BBL was immobilized onto streptavidin beads. In addition, we show that the cross-linking of two trimeric AviTag-4-1BBL molecules was the minimum step required to elicit significant costimulatory activity.	INSERM, Inst Biol, U601, F-44035 Nantes, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Lang, F (corresponding author), INSERM, Inst Biol, U601, 9 Quai Moncousu, F-44035 Nantes, France.	francois.lang@univ-nantes.fr	QUEMENER, Agnès/R-9489-2019; Rabu, Catherine/K-7369-2015; LANG, François/K-7403-2015	QUEMENER, Agnès/0000-0002-4026-8496; Rabu, Catherine/0000-0001-8405-2809; LANG, François/0000-0002-0762-4647				ALDERSON MR, 1994, EUR J IMMUNOL, V24, P2219, DOI 10.1002/eji.1830240943; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Bertram EM, 2004, J IMMUNOL, V172, P981, DOI 10.4049/jimmunol.172.2.981; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Bodmer JL, 2002, TRENDS BIOCHEM SCI, V27, P19, DOI 10.1016/S0968-0004(01)01995-8; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Bucher MH, 2002, ACTA CRYSTALLOGR D, V58, P392, DOI 10.1107/S0907444901021187; Cannons JL, 2001, J IMMUNOL, V167, P1313, DOI 10.4049/jimmunol.167.3.1313; Carbonnelle D, 2005, EUR J IMMUNOL, V35, P546, DOI 10.1002/eji.200425007; Chen YW, 2001, P NATL ACAD SCI USA, V98, P7218, DOI 10.1073/pnas.131076098; Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; GILSON MK, 1988, PROTEINS, V4, P7, DOI 10.1002/prot.340040104; GOODWIN RG, 1993, EUR J IMMUNOL, V23, P2631, DOI 10.1002/eji.1830231037; Gramaglia I, 2000, EUR J IMMUNOL, V30, P392, DOI 10.1002/1521-4141(200002)30:2<392::AID-IMMU392>3.0.CO;2-H; Holler N, 2003, MOL CELL BIOL, V23, P1428, DOI 10.1128/MCB.23.4.1428-1440.2003; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Hurtado JC, 1997, J IMMUNOL, V158, P2600; KWON BS, 1989, P NATL ACAD SCI USA, V86, P1963, DOI 10.1073/pnas.86.6.1963; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lee HW, 2002, J IMMUNOL, V169, P4882, DOI 10.4049/jimmunol.169.9.4882; Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613; MartinezLorenzo MJ, 1996, IMMUNOLOGY, V89, P511, DOI 10.1046/j.1365-2567.1996.d01-782.x; Maus MV, 2002, NAT BIOTECHNOL, V20, P143, DOI 10.1038/nbt0202-143; Melero I, 1997, NAT MED, V3, P682, DOI 10.1038/nm0697-682; Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Salih HR, 2001, J IMMUNOL, V167, P4059, DOI 10.4049/jimmunol.167.7.4059; Saoulli K, 1998, J EXP MED, V187, P1849, DOI 10.1084/jem.187.11.1849; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Schneider P, 1999, J EXP MED, V189, P1747, DOI 10.1084/jem.189.11.1747; Shindyalov IN, 1998, PROTEIN ENG, V11, P739, DOI 10.1093/protein/11.9.739; Shuford WW, 1997, J EXP MED, V186, P47, DOI 10.1084/jem.186.1.47; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; SMITH RA, 1987, J BIOL CHEM, V262, P6951; Starck L, 2005, EUR J IMMUNOL, V35, P1257, DOI 10.1002/eji.200425686; Suda T, 1997, J EXP MED, V186, P2045, DOI 10.1084/jem.186.12.2045; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; Vinay DS, 1998, SEMIN IMMUNOL, V10, P481, DOI 10.1006/smim.1998.0157; WARZOCHA K, 1995, EUR CYTOKINE NETW, V6, P83; Wen T, 2002, J IMMUNOL, V168, P4897, DOI 10.4049/jimmunol.168.10.4897	44	43	59	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41472	41481		10.1074/jbc.M506881200	http://dx.doi.org/10.1074/jbc.M506881200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16204238	hybrid			2022-12-25	WOS:000233866900045
J	Smirnov, SP; Barzaghi, P; McKee, KK; Ruegg, MA; Yurchenco, PD				Smirnov, SP; Barzaghi, P; McKee, KK; Ruegg, MA; Yurchenco, PD			Conjugation of LG domains of agrins and perlecan to polymerizing laminin-2 promotes acetylcholine receptor clustering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE; NEUROMUSCULAR-JUNCTION; ALPHA-DYSTROGLYCAN; POSTSYNAPTIC DIFFERENTIATION; TYROSINE PHOSPHORYLATION; ALPHA-7-BETA-1 INTEGRIN; BINDING-SITES; SCHWANN-CELLS; MUSCLE; HEPARIN	Neuromuscular junction (NMJ) assembly is characterized by the clustering and neuronal alignment of acetylcholine receptors (AChRs). In this study we have addressed post-synaptic contributions to assembly that may arise from the NMJ basement membrane with cultured myotubes. We show that the cell surface-binding LG domains of non-neural (muscle) agrin and perlecan promote AChR clustering in the presence of laminin-2. This type of AChR clustering occurs with a several hour lag, requires muscle-specific kinase (MuSK), and is accompanied by tyrosine phosphorylation of MuSK and beta AChR. It also requires conjugation of the agrin or perlecan to laminin together with laminin polymerization. Furthermore, AChR clustering can be mimicked with antibody binding to non-neural agrin, supporting a mechanism of ligand aggregation. Neural agrin, in addition to its unique ability to cluster AChRs through its B/z sequence insert, also exhibits laminin-dependent AChR clustering, the latter enhancing and stabilizing its activity. Finally, we show that type IV collagen, which lacks clustering activity on its own, stabilizes laminin-dependent AChR clusters. These findings provide evidence for cooperative and partially redundant MuSK-dependent functions of basement membrane in AChR assembly that can enhance neural agrin activity yet operate in its absence. Such interactions may contribute to the assembly of aneural AChR clusters that precede neural agrin release as well as affect later NMJ development.	Robert Wood Johnson Med Sch, Dept Pathol & Lab Med, Piscataway, NJ 08854 USA; Univ Basel, Biozentrum, CH-4056 Basel, Switzerland	Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Basel	Yurchenco, PD (corresponding author), 675 Hoes Lane, Piscataway, NJ 08854 USA.	yurchenc@umdnj.edu	Ruegg, Markus/X-7256-2019	Ruegg, Markus/0000-0002-4974-9384; Yurchenco, Peter/0000-0003-0387-2317	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038469] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS038469, R01-NS38469] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arikawa-Hirasawa E, 2002, NAT NEUROSCI, V5, P119, DOI 10.1038/nn801; Aumailley M, 2005, MATRIX BIOL, V24, P326, DOI 10.1016/j.matbio.2005.05.006; Banks GB, 2003, J NEUROCYTOL, V32, P709, DOI 10.1023/B:NEUR.0000020619.24681.2b; Bezakova G, 2003, NAT REV MOL CELL BIO, V4, P295, DOI 10.1038/nrm1074; Bix G, 2004, J CELL BIOL, V166, P97, DOI 10.1083/jcb.200401150; Brown JC, 1997, EUR J BIOCHEM, V250, P39, DOI 10.1111/j.1432-1033.1997.t01-1-00039.x; Burgess RW, 2000, J CELL BIOL, V151, P41, DOI 10.1083/jcb.151.1.41; Burgess RW, 1999, NEURON, V23, P33, DOI 10.1016/S0896-6273(00)80751-5; Burkin DJ, 1998, J CELL BIOL, V143, P1067, DOI 10.1083/jcb.143.4.1067; Burkin DJ, 2000, J CELL SCI, V113, P2877; Cheng YS, 1997, J BIOL CHEM, V272, P31525, DOI 10.1074/jbc.272.50.31525; Colognato H, 1999, J CELL BIOL, V145, P619, DOI 10.1083/jcb.145.3.619; Denzer AJ, 1997, J CELL BIOL, V137, P671, DOI 10.1083/jcb.137.3.671; Engler A, 2004, BIOPHYS J, V86, P617, DOI 10.1016/S0006-3495(04)74140-5; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; Gesemann M, 1996, NEURON, V16, P755, DOI 10.1016/S0896-6273(00)80096-3; GESEMANN M, 1995, J CELL BIOL, V128, P625, DOI 10.1083/jcb.128.4.625; Hoch W, 2003, TRENDS NEUROSCI, V26, P335, DOI 10.1016/S0166-2236(03)00131-0; Hohenester E, 1999, MOL CELL, V4, P783, DOI 10.1016/S1097-2765(00)80388-3; Hopf C, 1998, J BIOL CHEM, V273, P6467, DOI 10.1074/jbc.273.11.6467; Hopf M, 2001, J MOL BIOL, V311, P529, DOI 10.1006/jmbi.2001.4878; Irvine DJ, 2002, BIOPHYS J, V82, P120, DOI 10.1016/S0006-3495(02)75379-4; Jacobson C, 2001, J CELL BIOL, V152, P435, DOI 10.1083/jcb.152.3.435; Jacobson C, 1998, J NEUROSCI, V18, P6340; Kammerer RA, 1999, EMBO J, V18, P6762, DOI 10.1093/emboj/18.23.6762; Kummer TT, 2004, J CELL BIOL, V164, P1077, DOI 10.1083/jcb.200401115; Li S, 2002, J CELL BIOL, V157, P1279, DOI 10.1083/jcb.200203073; Li SH, 2005, J CELL BIOL, V169, P179, DOI 10.1083/jcb.200501098; Lin WC, 2001, NATURE, V410, P1057, DOI 10.1038/35074025; Marangi PA, 2002, J CELL BIOL, V157, P883, DOI 10.1083/jcb.200202110; Mascarenhas JB, 2003, EMBO J, V22, P529, DOI 10.1093/emboj/cdg041; Meier T, 1998, EUR J NEUROSCI, V10, P3141, DOI 10.1046/j.1460-9568.1998.00320.x; Moll J, 2001, NATURE, V413, P302, DOI 10.1038/35095054; Neumann FR, 2001, MOL CELL NEUROSCI, V17, P208, DOI 10.1006/mcne.2000.0932; Poschl E, 2004, DEVELOPMENT, V131, P1619, DOI 10.1242/dev.01037; Sanes JR, 2003, J BIOL CHEM, V278, P12601, DOI 10.1074/jbc.R200027200; Sanes JR, 2001, NAT REV NEUROSCI, V2, P791, DOI 10.1038/35097557; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; Smirnov SP, 2002, J BIOL CHEM, V277, P18928, DOI 10.1074/jbc.M201880200; Smyth N, 1999, J CELL BIOL, V144, P151, DOI 10.1083/jcb.144.1.151; Sugiyama JE, 1997, J CELL BIOL, V139, P181, DOI 10.1083/jcb.139.1.181; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; Tisi D, 2000, EMBO J, V19, P1432, DOI 10.1093/emboj/19.7.1432; Tsiper MV, 2002, J CELL SCI, V115, P1005; YURCHENCO PD, 1984, BIOCHEMISTRY-US, V23, P1839, DOI 10.1021/bi00303a040; Yurchenco PD, 2004, MATRIX BIOL, V22, P521, DOI 10.1016/j.matbio.2003.10.006; YURCHENCO PD, 1987, J BIOL CHEM, V262, P17668	47	22	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41449	41457		10.1074/jbc.M508939200	http://dx.doi.org/10.1074/jbc.M508939200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16219760	hybrid			2022-12-25	WOS:000233866900042
J	Tsatskis, Y; Khambati, J; Dobson, M; Bogdanov, M; Dowhan, W; Wood, JM				Tsatskis, Y; Khambati, J; Dobson, M; Bogdanov, M; Dowhan, W; Wood, JM			The osmotic activation of transporter ProP is tuned by both its C-terminal coiled-coil and osmotically induced changes in phospholipid composition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; CORYNEBACTERIUM-GLUTAMICUM; GLYCINE BETAINE; GENE-EXPRESSION; SIGMA(S)-DEPENDENT GENES; CARDIOLIPIN SYNTHASE; STRUCTURAL MODEL; MEMBRANE-LIPIDS; OSMOSENSOR PROP; PROTEIN	Transporter ProP of Escherichia coli (ProPEc) senses extracellular osmolality and mediates osmoprotectant uptake when it is rising or high. A replica of the ProPEc C terminus (Asp(468)-Arg(497)) forms an intermolecular alpha-helical coiled-coil. This structure is implicated in the osmoregulation of intact ProPEc, in vivo. Like that from Corynebacterium glutamicum (ProPCg), the ProP orthologue from Agrobacterium tumefaciens (ProPAt) sensed and responded to extracellular osmolality after expression in E. coli. The osmotic activation profiles of all three orthologues depended on the osmolality of the bacterial growth medium, the osmolality required for activation rising as the growth osmolality approached 0.7 mol/kg. Thus, each could undergo osmotic adaptation. The proportion of cardiolipin in a polar lipid extract from E. coli increased with extracellular osmolality so that the osmolality activating ProPEc was a direct function of membrane cardiolipin content. Group A ProP orthologues ( ProPEc, ProPAt) share the C-terminal coiled-coil domain and were activated at low osmolalities. Like variant ProPEc-R488I, in which the C-terminal coiled-coil is disrupted, ProPEc derivatives that lack the coiled-coil and Group B orthologue ProPCg required a higher osmolality to activate. The amplitude of ProPEc activation was reduced 10-fold in its deletion derivatives. The coiled-coil structure is not essential for osmotic activation of ProP per se. However, it tunes Group A orthologues to osmoregulate over a low osmolality range. Coiled-coil lesions may impair both coiled-coil formation and interaction of ProPEc with amplifier protein ProQ. Cardiolipin may contribute to ProP adaptation by altering bulk membrane properties or by acting as a ProP ligand.	Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON N1G 2W1, Canada; Univ Texas, Houston Med Sch, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Guelph; University of Texas System; University of Texas Health Science Center Houston	Wood, JM (corresponding author), Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON N1G 2W1, Canada.	jwood@uoguelph.ca	Bogdanov, Mikhail/J-3695-2017	Tsatskis, Yonit/0000-0003-2580-0728	NIGMS NIH HHS [R37 GM20487] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAYLISS C, 1993, CAN J MICROBIOL, V39, P1111, DOI 10.1139/m93-168; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Blount P, 2003, NEURON, V37, P731, DOI 10.1016/S0896-6273(03)00122-3; BROWN ED, 1992, J BIOL CHEM, V267, P13086; Cronan JE, 2003, ANNU REV MICROBIOL, V57, P203, DOI 10.1146/annurev.micro.57.030502.090851; Culham DE, 2000, J MOL RECOGNIT, V13, P309, DOI 10.1002/1099-1352(200009/10)13:5<309::AID-JMR505>3.3.CO;2-I; CULHAM DE, 1993, J MOL BIOL, V229, P268, DOI 10.1006/jmbi.1993.1030; Culham DE, 2003, BIOCHEMISTRY-US, V42, P11815, DOI 10.1021/bi034939j; Culham DE, 2003, BIOCHEMISTRY-US, V42, P410, DOI 10.1021/bi0264364; Danevcic T, 2005, BBA-BIOMEMBRANES, V1712, P1, DOI 10.1016/j.bbamem.2005.03.013; Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199; Fyfe PK, 2001, TRENDS BIOCHEM SCI, V26, P106, DOI 10.1016/S0968-0004(00)01746-1; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HEBER S, 1991, BIOCHIM BIOPHYS ACTA, V1129, P1, DOI 10.1016/0167-4781(91)90206-2; Hillar A, 2005, BIOCHEMISTRY-US, V44, P10170, DOI 10.1021/bi050774y; Hillar A, 2003, BIOCHEMISTRY-US, V42, P15170, DOI 10.1021/bi035122t; Hirai T, 2003, J BACTERIOL, V185, P1712, DOI 10.1128/JB.185.5.1712-1718.2003; HOISCHEN C, 1990, J BACTERIOL, V172, P3409, DOI 10.1128/jb.172.6.3409-3416.1990; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; IVANISEVIC R, 1995, J BACTERIOL, V177, P1766, DOI 10.1128/jb.177.7.1766-1771.1995; Karnezis T, 2002, J BACTERIOL, V184, P4114, DOI 10.1128/JB.184.15.4114-4123.2002; KHAMBATI J, 2003, DOES COILED DOMAIN P; Kramer R, 2004, BBA-BIOENERGETICS, V1658, P31, DOI 10.1016/j.bbabio.2004.05.006; Kunte HJ, 1999, J BACTERIOL, V181, P1537, DOI 10.1128/JB.181.5.1537-1543.1999; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lacour S, 2004, J BACTERIOL, V186, P7186, DOI 10.1128/JB.186.21.7186-7195.2004; Lopez CS, 1998, CURR MICROBIOL, V36, P55; Machado MC, 2004, ARCH BIOCHEM BIOPHYS, V422, P61, DOI 10.1016/j.abb.2003.11.001; McLeod SM, 2002, J MOL BIOL, V316, P517, DOI 10.1006/jmbi.2001.5391; Mileykovskaya E, 2005, CURR OPIN MICROBIOL, V8, P135, DOI 10.1016/j.mib.2005.02.012; MILNER JL, 1989, J BACTERIOL, V171, P947, DOI 10.1128/jb.171.2.947-951.1989; Morbach S, 2002, CHEMBIOCHEM, V3, P385, DOI 10.1002/1439-7633(20020503)3:5<384::AID-CBIC384>3.0.CO;2-H; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; OPERAKOVA M, 2005, BIOCHIM BIOPHYS ACTA, V1610, P11; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; Patten CL, 2004, MOL GENET GENOMICS, V272, P580, DOI 10.1007/s00438-004-1089-2; Peter H, 1998, J BACTERIOL, V180, P6005, DOI 10.1128/JB.180.22.6005-6012.1998; Peter H, 1996, J BACTERIOL, V178, P5229, DOI 10.1128/jb.178.17.5229-5234.1996; Pinkart HC, 1997, J BACTERIOL, V179, P4219, DOI 10.1128/jb.179.13.4219-4226.1997; Poolman B, 2004, BBA-BIOMEMBRANES, V1666, P88, DOI 10.1016/j.bbamem.2004.06.013; PRASAD R, 1996, MANUAL MEMBRANE LIPI, P2; Racher KI, 1999, BIOCHEMISTRY-US, V38, P1676, DOI 10.1021/bi981279n; Racher KI, 2001, BIOCHEMISTRY-US, V40, P7324, DOI 10.1021/bi002331u; Rubenhagen R, 2000, J BIOL CHEM, V275, P735, DOI 10.1074/jbc.275.2.735; SALAMITOU S, 1994, J BACTERIOL, V176, P2828, DOI 10.1128/JB.176.10.2828-2834.1994; SAMBROOKS J, 2001, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Smith MN, 2004, BIOCHEMISTRY-US, V43, P12979, DOI 10.1021/bi048561g; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TROPP BE, 1995, J BACTERIOL, V177, P5155, DOI 10.1128/jb.177.17.5155-5157.1995; Tropp BE, 1997, BBA-LIPID LIPID MET, V1348, P192, DOI 10.1016/S0005-2760(97)00100-8; TSATSKIS Y, 2005, ROLE C TERMINAL COIL; van der Heide T, 2000, P NATL ACAD SCI USA, V97, P7102, DOI 10.1073/pnas.97.13.7102; van der Heide T, 2001, EMBO J, V20, P7022, DOI 10.1093/emboj/20.24.7022; Vijayakumar SRV, 2004, J BACTERIOL, V186, P8499, DOI 10.1128/JB.186.24.8499-8507.2004; Weber A, 2002, J BACTERIOL, V184, P5502, DOI 10.1128/JB.184.19.5502-5507.2002; Weber H, 2005, J BACTERIOL, V187, P1591, DOI 10.1128/JB.187.5.1591-1603.2005; Wikstrom M, 2004, J BIOL CHEM, V279, P10484, DOI 10.1074/jbc.M310183200; Wood JM, 2005, BIOCHEMISTRY-US, V44, P5634, DOI 10.1021/bi047383o; Wood JM, 2001, COMP BIOCHEM PHYS A, V130, P437, DOI 10.1016/S1095-6433(01)00442-1; Zhang M, 2005, J BIOL CHEM, V280, P29403, DOI 10.1074/jbc.M504955200; Zhang M, 2002, J BIOL CHEM, V277, P43553, DOI 10.1074/jbc.C200551200; Zoetewey DL, 2003, J MOL BIOL, V334, P1063, DOI 10.1016/j.jmb.2003.10.020	65	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41387	41394		10.1074/jbc.M508362200	http://dx.doi.org/10.1074/jbc.M508362200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16239220	hybrid			2022-12-25	WOS:000233866900035
J	Choi, MS; Kim, MC; Yoo, JH; Moon, BC; Koo, SC; Park, BO; Lee, JH; Koo, YD; Han, HJ; Lee, SY; Chung, WS; Lim, CO; Cho, MJ				Choi, MS; Kim, MC; Yoo, JH; Moon, BC; Koo, SC; Park, BO; Lee, JH; Koo, YD; Han, HJ; Lee, SY; Chung, WS; Lim, CO; Cho, MJ			Isolation of a calmodulin-binding transcription factor from rice (Oryza sativa L.)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; DIFFERENTIAL DISPLAY; SIGNAL-TRANSDUCTION; OXIDATIVE BURST; FUNGAL ELICITOR; CELL-DEATH; PROTEIN; GENE; CALCIUM; IDENTIFICATION	Calmodulin (CaM) regulates diverse cellular functions by modulating the activities of a variety of enzymes and proteins. However, direct modulation of transcription factors by CaM has been poorly understood. In this study, we isolated a putative transcription factor by screening a rice cDNA expression library by using CaM: horseradish peroxidase as a probe. This factor, which we have designated OsCBT (Oryza sativa CaM- binding transcription factor), has structural features similar to Arabidopsis AtSRs/AtCAMTAs and encodes a 103-kDa protein because it contains a CG-1 homology DNA-binding domain, three ankyrin repeats, a putative transcriptional activation domain, and five putative CaM- binding motifs. By using a gel overlay assay, gel mobility shift assays, and site- directed mutagenesis, we showed that OsCBT has two different types of functional CaM- binding domains, an IQ motif, and a Ca2+-dependent motif. To determine the DNA binding specificity of OsCBT, we employed a random binding site selection method. This analysis showed that OsCBT preferentially binds to the sequence 5'-TWCG(C/T) GTKKKKTKCG-3' (W and K represent A or C and T or G, respectively). OsCBT was able to bind this sequence and activate beta-glucuronidase reporter gene expression driven by a minimal promoter containing tandem repeats of these sequences in Arabidopsis leaf protoplasts. Green fluorescent protein fusions of two putative nuclear localization signals of OsCBT, a bipartite and a SV40 type, were predominantly localized in the nucleus. Most interestingly, the transcriptional activation mediated by OsCBT was inhibited by co-transfection with a CaM gene. Taken together, our results suggest that OsCBT is a transcription activator modulated by CaM.	Gyeongsang Natl Univ, Plant Mol Biol & Biotechnol Res Ctr, Div Appl Life Sci, BK21 Program, Jinju 660701, South Korea; Gyeongsang Natl Univ, Environm Biotechnol Natl Core Res Ctr, Jinju 660701, South Korea; Gyeongsang Natl Univ, Div Plant Resources & Environm, Jinju 660701, South Korea	Gyeongsang National University; Gyeongsang National University; Gyeongsang National University	Lim, CO (corresponding author), Gyeongsang Natl Univ, Plant Mol Biol & Biotechnol Res Ctr, Div Appl Life Sci, BK21 Program, Jinju 660701, South Korea.	colim@gsnu.ac.kr; choslab@gsnu.ac.kr	Cho, Moo Je/F-1649-2010					Aharon GS, 1998, FEBS LETT, V424, P17, DOI 10.1016/S0014-5793(98)00129-X; Baum G, 1996, EMBO J, V15, P2988, DOI 10.1002/j.1460-2075.1996.tb00662.x; Blume B, 2000, PLANT CELL, V12, P1425, DOI 10.1105/tpc.12.8.1425; Bouche N, 2002, J BIOL CHEM, V277, P21851, DOI 10.1074/jbc.M200268200; Brault M, 2004, PLANT PHYSIOL, V135, P231, DOI 10.1104/pp.104.039255; CAREY J, 1991, METHOD ENZYMOL, V208, P103; Choi JY, 2002, J BIOL CHEM, V277, P21630, DOI 10.1074/jbc.M110803200; Chung WS, 2000, PLANT CELL, V12, P1393, DOI 10.1105/tpc.12.8.1393; CORNELIUSSEN B, 1994, NATURE, V368, P760, DOI 10.1038/368760a0; Grant M, 2000, PLANT J, V23, P441, DOI 10.1046/j.1365-313x.2000.00804.x; Hetherington AM, 2004, ANNU REV PLANT BIOL, V55, P401, DOI 10.1146/annurev.arplant.55.031903.141624; Hsieh HL, 1996, PLANT MOL BIOL, V30, P135, DOI 10.1007/BF00017808; Ikura M, 2002, BIOESSAYS, V24, P625, DOI 10.1002/bies.10105; Jabs T, 1997, P NATL ACAD SCI USA, V94, P4800, DOI 10.1073/pnas.94.9.4800; Jin JB, 2001, PLANT CELL, V13, P1511, DOI 10.1105/tpc.13.7.1511; Katoh M, 2003, INT J ONCOL, V23, P1219; Kim CY, 2000, MOL PLANT MICROBE IN, V13, P470, DOI 10.1094/MPMI.2000.13.4.470; Kim CY, 1998, PLANT MOL BIOL, V37, P523, DOI 10.1023/A:1005960313459; Kim MC, 2002, NATURE, V416, P447, DOI 10.1038/416447a; Kim MC, 2002, J BIOL CHEM, V277, P19304, DOI 10.1074/jbc.M108478200; Klymchuk DO, 2003, ADV SPACE RES-SERIES, V31, P2283, DOI 10.1016/S0273-1177(03)00256-4; Lee SH, 1999, BBA-PROTEIN STRUCT M, V1433, P56, DOI 10.1016/S0167-4838(99)00149-1; Lee YJ, 2001, PLANT CELL, V13, P2175, DOI 10.1105/tpc.13.10.2175; Liu Z, 1993, Chin J Biotechnol, V9, P241; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Nunomura W, 2000, J BIOL CHEM, V275, P6360, DOI 10.1074/jbc.275.9.6360; OLIPHANT AR, 1989, MOL CELL BIOL, V9, P2944, DOI 10.1128/MCB.9.7.2944; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Onions J, 1997, J BIOL CHEM, V272, P23930, DOI 10.1074/jbc.272.38.23930; Onions J, 2000, BIOCHEMISTRY-US, V39, P4366, DOI 10.1021/bi992533u; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; Raghothama KG, 1997, PLANT MOL BIOL, V34, P393, DOI 10.1023/A:1005812217945; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Samso M, 2002, J BIOL CHEM, V277, P1349, DOI 10.1074/jbc.M109196200; Sanchez-Barrena MJ, 2005, J MOL BIOL, V345, P1253, DOI 10.1016/j.jmb.2004.11.025; Schwechheimer C, 1998, ANNU REV PLANT PHYS, V49, P127, DOI 10.1146/annurev.arplant.49.1.127; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; Sheen J, 1996, SCIENCE, V274, P1900, DOI 10.1126/science.274.5294.1900; SILVA ODE, 1994, PLANT MOL BIOL, V25, P921, DOI 10.1007/BF00028887; SUNDARESAN V, 1995, GENE DEV, V9, P1797, DOI 10.1101/gad.9.14.1797; Szymanski DB, 1996, PLANT CELL, V8, P1069, DOI 10.1105/tpc.8.6.1069; Xu HX, 1998, PLANT CELL, V10, P585, DOI 10.1105/tpc.10.4.585; Yang TB, 2002, J BIOL CHEM, V277, P45049, DOI 10.1074/jbc.M207941200; Yang TB, 2000, J BIOL CHEM, V275, P38467, DOI 10.1074/jbc.M003566200; Yoo JH, 2005, J BIOL CHEM, V280, P3697, DOI 10.1074/jbc.M408237200; Zegzouti H, 1999, PLANT J, V18, P589, DOI 10.1046/j.1365-313x.1999.00483.x; Zhu Q, 1995, PLANT MOL BIOL, V29, P535, DOI 10.1007/BF00020983; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	48	89	99	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40820	40831		10.1074/jbc.M504616200	http://dx.doi.org/10.1074/jbc.M504616200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16192280	hybrid			2022-12-25	WOS:000233666600053
J	Shintaku, M; Matsuura, K; Yoshioka, S; Takahashi, S; Ishimori, K; Morishima, I				Shintaku, M; Matsuura, K; Yoshioka, S; Takahashi, S; Ishimori, K; Morishima, I			Absence of a detectable intermediate in the compound I formation of horseradish peroxidase at ambient temperature	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; HYDROGEN-BOND NETWORK; HEME DISTAL SITE; SUBSTRATE-BINDING; ELEMENTARY STEPS; HISTIDINE; RESIDUE; MECHANISM; CATALYSIS; ROLES	A microsecond-resolved absorption spectrometer was developed to investigate the elementary steps in hydrogen peroxide (H2O2) activation reaction of horseradish peroxidase (HRP) at ambient temperature. The kinetic absorption spectra of HRP upon the mixing with various concentrations of H2O2 (0.5-3 mM) were monitored in the time range from 50 to 300 mu s. The time-resolved spectra in the Soret region possessed isosbestic points that were close to those between the resting state and compound I. The kinetic changes in the Soret absorbance could be well fitted by a single exponential function. Accordingly, no distinct spectrum of the putative intermediate between the resting state and compound I was identified. These results were consistent with the proposal that the O-O bond activation in heme peroxidases is promoted by the imidazolium form of the distal histidine that exists only transiently. It was estimated that the rate constant for the breakage of the O-O bond in H2O2 by HRP is significantly faster than 1 x 10(4) s(-1).	Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6158510, Japan	Kyoto University	Takahashi, S (corresponding author), Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6158510, Japan.	st@protein.osaka-u.ac.jp; morisima@mds.moleng.kyoto-u.ac.jp	Ishimori, Koichiro/S-1247-2016; Ishimori, Koichiro/AAQ-4434-2021; MATSUURA, Koji/B-2419-2011; Matsuura, Koji/AAU-9111-2021	Ishimori, Koichiro/0000-0002-5868-0462; Ishimori, Koichiro/0000-0002-5868-0462; 				Akiyama S, 2002, P NATL ACAD SCI USA, V99, P1329, DOI 10.1073/pnas.012458999; BAEK HK, 1989, BIOCHEMISTRY-US, V28, P5714, DOI 10.1021/bi00440a003; BAEK HK, 1992, J AM CHEM SOC, V114, P718, DOI 10.1021/ja00028a046; BANLY C, 1987, EUR BIOPHYS J, V14, P375; Berglund GI, 2002, NATURE, V417, P463, DOI 10.1038/417463a; Brittain T, 1997, BIOCHEM J, V326, P109, DOI 10.1042/bj3260109; BRUICE TC, 1986, P NATL ACAD SCI USA, V83, P4646, DOI 10.1073/pnas.83.13.4646; Denisov IG, 2002, J BIOL CHEM, V277, P42706, DOI 10.1074/jbc.M207949200; Dunford H. B., 1999, HEME PEROXIDASES; DUNFORD HB, 1977, BIOCHEMISTRY-US, V16, P2949, DOI 10.1021/bi00632a023; Egawa T, 2000, J BIOL CHEM, V275, P34858, DOI 10.1074/jbc.M004026200; Egawa T, 2003, J BIOL CHEM, V278, P41597, DOI 10.1074/jbc.M210383200; ERMAN JE, 1993, BIOCHEMISTRY-US, V32, P9798, DOI 10.1021/bi00088a035; Folkes LK, 1997, FEBS LETT, V412, P305, DOI 10.1016/S0014-5793(97)00792-8; GAZYNA Z, 1979, FEBS LETT, V106, P213; Harris DL, 2001, CURR OPIN CHEM BIOL, V5, P724, DOI 10.1016/S1367-5931(01)00272-1; Harris DL, 1996, J AM CHEM SOC, V118, P10588, DOI 10.1021/ja9617247; HINTER ANP, 2002, J INORG BIOCHEM, V91, P27; Isaac IS, 1999, ESSAYS BIOCHEM, V34, P51, DOI 10.1042/bse0340051; JACOBS SA, 1984, ANAL CHEM, V56, P1058, DOI 10.1021/ac00271a004; Kimura T, 2002, J AM CHEM SOC, V124, P11596, DOI 10.1021/ja026639f; NAGANO S, 1995, BIOCHEM BIOPH RES CO, V207, P417, DOI 10.1006/bbrc.1995.1204; Nagano S, 1996, BIOCHEMISTRY-US, V35, P14251, DOI 10.1021/bi961740g; NEWMYER SL, 1995, J BIOL CHEM, V270, P19430, DOI 10.1074/jbc.270.33.19430; Ozaki S, 1998, J AM CHEM SOC, V120, P8020, DOI 10.1021/ja9714696; Ozaki SI, 2001, ACCOUNTS CHEM RES, V34, P818, DOI 10.1021/ar9502590; PENNERHAHN JE, 1986, J AM CHEM SOC, V108, P7819, DOI 10.1021/ja00284a054; POULOS TL, 1980, J BIOL CHEM, V255, P8199; POULOS TL, 1980, J BIOL CHEM, V255, P575; Roder H, 2004, METHODS, V34, P15, DOI 10.1016/j.ymeth.2004.03.003; Rodriguez-Lopez JN, 2000, BIOCHEMISTRY-US, V39, P13201, DOI 10.1021/bi001150p; Rodriguez-Lopez JN, 2001, J AM CHEM SOC, V123, P11838, DOI 10.1021/ja011853+; RodriguezLopez JN, 1996, J BIOL INORG CHEM, V1, P136, DOI 10.1007/s007750050032; RodriguezLopez JN, 1996, J BIOL CHEM, V271, P4023; Savenkova MI, 1998, BIOCHEMISTRY-US, V37, P10828, DOI 10.1021/bi9725780; SCHONBAUM GR, 1972, J BIOL CHEM, V247, P3353; SHANNON LM, 1966, J BIOL CHEM, V241, P2166; Tanaka M, 1998, BIOCHEMISTRY-US, V37, P2629, DOI 10.1021/bi9725273; Tanaka M, 1997, BIOCHEMISTRY-US, V36, P9791, DOI 10.1021/bi9706172; Tanaka M, 1996, BIOCHEM BIOPH RES CO, V227, P393, DOI 10.1006/bbrc.1996.1518; Tanaka M, 2003, BIOPHYS J, V84, P1998, DOI 10.1016/S0006-3495(03)75008-5; Tanaka M, 1997, BIOCHEMISTRY-US, V36, P9889, DOI 10.1021/bi970906q; Veitch NC, 2001, ADV INORG CHEM, V51, P107; VITELLO LB, 1993, BIOCHEMISTRY-US, V32, P9807, DOI 10.1021/bi00088a036	44	20	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40934	40938		10.1074/jbc.M503472200	http://dx.doi.org/10.1074/jbc.M503472200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16221678	hybrid			2022-12-25	WOS:000233666600066
J	McDonald, C; Chen, FF; Ollendorff, V; Ogura, Y; Marchetto, S; Lecine, P; Borg, JP; Nunez, G				McDonald, C; Chen, FF; Ollendorff, V; Ogura, Y; Marchetto, S; Lecine, P; Borg, JP; Nunez, G			A role for Erbin in the regulation of Nod2-dependent NF-kappa B signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURAMYL DIPEPTIDE RECOGNITION; INTESTINAL EPITHELIAL-CELLS; CROHNS-DISEASE; OLIGOMERIZATION DOMAIN-2; CARD15 MUTATIONS; BREAST-CANCER; NOD2; PROTEIN; ACTIVATION; EXPRESSION	Nod2 is an intracellular sensor of a specific bacterial cell wall component, muramyl dipeptide, and activation of Nod2 stimulates an inflammatory response. Specific mutations of Nod2 have been associated with two inflammatory diseases, Crohn disease and Blau syndrome, and are thought to contribute to disease susceptibility through altering Nod2 signaling. Association of disease with inappropriate activation of Nod2 highlights the importance of proper regulation of Nod2 activity. However, little is known about specific regulation of the Nod2 pathway. We performed a biochemical screen to discover potential regulators of Nod2 and identified Erbin, a protein involved in cell polarity, receptor localization, and regulation of the mitogen-activated protein kinase pathway, as a novel Nod2-interacting protein. In our studies, we demonstrate specific interaction of Erbin and Nod2 both in vitro and in vivo and characterize the regions required for interaction in both proteins. We found that Nod2-dependent activation of NF-kappa B and cytokine secretion is inhibited by Erbin overexpression, whereas Erbin(-/-) mouse embryo fibroblasts show an increased sensitivity to muramyl dipeptide. These studies identify Erbin as a regulator of Nod2 signaling and demonstrate a novel role for Erbin in inflammatory responses.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Univ Paul Cezanne St Jerome, INRA, IMRN, UMR, F-13397 Marseille, France; Inst J Paoli I Calmettes, F-13009 Marseille, France; INSERM, Inst Rech Canc Marseille, Dept Mol Pharmacol, F-13009 Marseille, France	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; INRAE; UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm)	Nunez, G (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 4215 CCGC,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	bclx@umich.edu	Borg, Jean-Paul/AAX-8096-2020; Lecine, Patrick/H-9338-2016; Nuñez, Gabriel/A-7160-2014	Borg, Jean-Paul/0000-0001-8418-3382; McDonald, Christine/0000-0002-6745-9487; Ollendorff, Vincent/0000-0001-9751-2202; Lecine, Patrick/0000-0002-8091-7286	NIAID NIH HHS [5F32AI054053, F32 AI054053] Funding Source: Medline; NIDDK NIH HHS [DK61707, DK067628] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI054053] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061707, R01DK067628] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abbott DW, 2004, CURR BIOL, V14, P2217, DOI 10.1016/j.cub.2004.12.032; Atalay A, 2002, BIOCHEM BIOPH RES CO, V299, P839, DOI 10.1016/S0006-291X(02)02751-1; Barnich N, 2005, J CELL BIOL, V170, P21, DOI 10.1083/jcb.200502153; Barnich N, 2005, J BIOL CHEM, V280, P19021, DOI 10.1074/jbc.M413776200; Benedict MA, 2000, J BIOL CHEM, V275, P8461, DOI 10.1074/jbc.275.12.8461; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; Brint EK, 2004, NAT IMMUNOL, V5, P373, DOI 10.1038/ni1050; Chamaillard M, 2003, P NATL ACAD SCI USA, V100, P3455, DOI 10.1073/pnas.0530276100; Chen CM, 2004, J BIOL CHEM, V279, P25876, DOI 10.1074/jbc.M400682200; Damiano JS, 2004, BIOCHEM J, V381, P213, DOI 10.1042/BJ20031506; Dowds TA, 2003, BIOCHEM BIOPH RES CO, V302, P575, DOI 10.1016/S0006-291X(03)00221-3; Favre B, 2001, J BIOL CHEM, V276, P32427, DOI 10.1074/jbc.M011005200; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Hampe J, 2002, P NATL ACAD SCI USA, V99, P321, DOI 10.1073/pnas.261567999; HARVEY M, 1993, ONCOGENE, V8, P2457; Huang YZ, 2003, J BIOL CHEM, V278, P1108, DOI 10.1074/jbc.M205413200; Huang YZ, 2001, J BIOL CHEM, V276, P19318, DOI 10.1074/jbc.M100494200; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Inohara N, 2000, J BIOL CHEM, V275, P27823; Inohara N, 2005, ANNU REV BIOCHEM, V74, P355, DOI 10.1146/annurev.biochem.74.082803.133347; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Izawa I, 2002, GENES CELLS, V7, P475, DOI 10.1046/j.1365-2443.2002.00533.x; Jaulin-Bastard F, 2002, J BIOL CHEM, V277, P2869, DOI 10.1074/jbc.M109652200; Kanazawa N, 2005, BLOOD, V105, P1195, DOI 10.1182/blood-2004-07-2972; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Kobayashi KS, 2005, SCIENCE, V307, P731, DOI 10.1126/science.1104911; Kolch Walter, 2003, Sci STKE, V2003, ppe37; Laura RP, 2002, J BIOL CHEM, V277, P12906, DOI 10.1074/jbc.M200818200; Legouis R, 2003, EMBO REP, V4, P1096, DOI 10.1038/sj.embor.7400006; Li J, 2004, HUM MOL GENET, V13, P1715, DOI 10.1093/hmg/ddh182; Maeda S, 2005, SCIENCE, V307, P734, DOI 10.1126/science.1103685; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Miceli-Richard C, 2001, NAT GENET, V29, P19, DOI 10.1038/ng720; Mockli N, 2004, BIOTECHNIQUES, V36, P872; Netea MG, 2005, J IMMUNOL, V174, P6518, DOI 10.4049/jimmunol.174.10.6518; Ogura Y, 2003, GUT, V52, P1591, DOI 10.1136/gut.52.11.1591; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Opitz B, 2004, J BIOL CHEM, V279, P36426, DOI 10.1074/jbc.M403861200; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rangwala R, 2005, J BIOL CHEM, V280, P11790, DOI 10.1074/jbc.M414154200; SCHRECK R, 1992, CLIN EXP IMMUNOL, V90, P188; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tanabe T, 2004, EMBO J, V23, P1587, DOI 10.1038/sj.emboj.7600175; van Heel DA, 2005, LANCET, V365, P1794, DOI 10.1016/S0140-6736(05)66582-8; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a	48	143	158	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40301	40309		10.1074/jbc.M508538200	http://dx.doi.org/10.1074/jbc.M508538200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16203728	hybrid, Green Published			2022-12-25	WOS:000233461300072
J	Bagchi, S; Liao, ZJ; Gonzalez, FA; Chorna, NE; Seye, CI; Weisman, GA; Erb, L				Bagchi, S; Liao, ZJ; Gonzalez, FA; Chorna, NE; Seye, CI; Weisman, GA; Erb, L			The P2Y(2) nucleotide receptor interacts with alpha(v) integrins to activate G(o) and induce cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P2Y(2) NUCLEOTIDE RECEPTOR; SMOOTH-MUSCLE-CELLS; GROWTH-FACTOR-I; RHO-GTPASES; EXTRACELLULAR NUCLEOTIDES; SIGNALING PATHWAYS; G-PROTEINS; ADHESION; CHEMOTAXIS; RAC	Extracellular ATP and UTP induce chemotaxis, or directed cell migration, by stimulating the G protein-coupled P2Y(2) nucleotide receptor (P2Y(2)R). Previously, we found that an arginine-glycineaspartic acid (RGD) integrin binding domain in the P2Y(2)R enables this receptor to interact selectively with alpha(v)beta(3) and alpha(V)beta(5) integrins, an interaction that is prevented by mutation of the RGD sequence to arginine-glycine- glutamic acid (RGE) (Erb, L., Liu, J., Ockerhausen, J., Kong, Q., Garrad, R. C., Griffin, K., Neal, C., Krugh, B., Santiago-Perez, L. I., Gonzalez, F. A., Gresham, H. D., Turner, J. T., and Weisman, G. A. ( 2001) J. Cell Biol. 153, 491 - 501). This RGD domain also was found to be necessary for coupling the P2Y(2)R to G(o)- but not G(q)- mediated intracellular calcium mobilization, leading us to investigate the role of P2Y(2)R interaction with integrins in nucleotide-induced chemotaxis. Here we show that mutation of the RGD sequence to RGE in the human P2Y(2)R expressed in 1321N1 astrocytoma cells completely prevented UTP-induced chemotaxis as well as activation of G(o), Rac, and Vav2, a guanine nucleotide exchange factor for Rac. UTP also increased expression of vitronectin, an extracellular matrix protein that is a ligand for alpha(v)beta(3)/alpha(V)beta(5) integrins, in cells expressing the wild-type but not the RGE mutant P2Y(2)R. P2Y(2)R-mediated chemotaxis, Rac and Vav2 activation, and vitronectin up-regulation were inhibited by pretreatment of the cells with anti-alpha(v)beta(5) integrin antibodies, alpha(v) integrin antisense oligo-nucleotides, or the G(i/o) inhibitor, pertussis toxin. Thus, the RGD-dependent interaction between the P2Y(2)R and alpha(v) integrins is necessary for the P2Y(2)R to activate Go and to initiate Go- mediated signaling events leading to chemotaxis.	Univ Missouri, Life Sci Ctr 540F, Dept Biochem, Columbia, MO 65211 USA; Univ Puerto Rico, Dept Chem, Rio Piedras, PR 00931 USA	University of Missouri System; University of Missouri Columbia; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus; University of Puerto Rico Rio Piedras	Erb, L (corresponding author), Univ Missouri, Life Sci Ctr 540F, Dept Biochem, 1201 Rollins Rd, Columbia, MO 65211 USA.	erbl@missouri.edu	Chorna, Nataliya/AHC-2895-2022	Chorna, Nataliya/0000-0002-7761-6802; Erb, Laurie/0000-0001-6372-3378	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015565] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE007389] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R23DE007389] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG018357] Funding Source: NIH RePORTER; NCRR NIH HHS [RR15565] Funding Source: Medline; NIA NIH HHS [AG18357] Funding Source: Medline; NIDCR NIH HHS [DE07389] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Allen WE, 1997, J CELL SCI, V110, P707; BROWN SL, 1994, CARDIOVASC RES, V28, P1815, DOI 10.1093/cvr/28.12.1815; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Chaulet H, 2001, CIRC RES, V89, P772, DOI 10.1161/hh2101.098617; Chernyavsky AI, 2004, J CELL BIOL, V166, P261, DOI 10.1083/jcb.200401034; Clemmons DR, 2005, MOL ENDOCRINOL, V19, P1, DOI 10.1210/me.2004-0376; Cox EA, 1998, MICROSC RES TECHNIQ, V43, P412, DOI 10.1002/(SICI)1097-0029(19981201)43:5<412::AID-JEMT7>3.0.CO;2-F; Cronshaw DG, 2004, J IMMUNOL, V172, P7761, DOI 10.4049/jimmunol.172.12.7761; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; ERB L, 1995, J BIOL CHEM, V270, P4185, DOI 10.1074/jbc.270.9.4185; Erb L, 2001, J CELL BIOL, V153, P491, DOI 10.1083/jcb.153.3.491; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Firtel RA, 2000, BIOESSAYS, V22, P603, DOI 10.1002/1521-1878(200007)22:7<603::AID-BIES3>3.0.CO;2-#; Garrad RC, 1998, J BIOL CHEM, V273, P29437, DOI 10.1074/jbc.273.45.29437; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Haque NS, 2004, BLOOD, V103, P1296, DOI 10.1182/blood-2002-05-1480; Idzko M, 2004, J IMMUNOL, V172, P4480, DOI 10.4049/jimmunol.172.7.4480; Jin JG, 1998, BRIT J PHARMACOL, V123, P789, DOI 10.1038/sj.bjp.0701665; Jones JI, 1996, P NATL ACAD SCI USA, V93, P2482, DOI 10.1073/pnas.93.6.2482; Kaczmarek E, 2005, THROMB HAEMOSTASIS, V93, P735, DOI 10.1160/TH04-09-0576; Kaido T, 2004, J BIOL CHEM, V279, P17731, DOI 10.1074/jbc.M308425200; Kindzelskii AL, 1996, J IMMUNOL, V156, P297; Kiosses WB, 2001, NAT CELL BIOL, V3, P316, DOI 10.1038/35060120; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Marignani PA, 2001, J CELL BIOL, V154, P177, DOI 10.1083/jcb.200103134; Martin KH, 2002, SCIENCE, V296, P1652, DOI 10.1126/science.296.5573.1652; Meyer A, 2004, NEOPLASIA, V6, P332, DOI 10.1593/neo.03445; Neptune ER, 1997, P NATL ACAD SCI USA, V94, P14489, DOI 10.1073/pnas.94.26.14489; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Qi AD, 2005, J BIOL CHEM, V280, P29169, DOI 10.1074/jbc.M501301200; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; Satterwhite CM, 1999, AM J PHYSIOL-HEART C, V276, pH1091, DOI 10.1152/ajpheart.1999.276.3.H1091; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Seye CI, 2004, J BIOL CHEM, V279, P35679, DOI 10.1074/jbc.M401799200; Seye CI, 2002, CIRCULATION, V106, P2720, DOI 10.1161/01.CIR.0000038111.00518.35; Seye CI, 1997, ARTERIOSCL THROM VAS, V17, P3602, DOI 10.1161/01.ATV.17.12.3602; Stawowy P, 2004, CIRCULATION, V109, P770, DOI 10.1161/01.CIR.0000112583.50762.DE; TIAN WN, 1994, MOL PHARMACOL, V45, P524; Van Haastert PJM, 2004, NAT REV MOL CELL BIO, V5, P626, DOI 10.1038/nrm1435; Xu JS, 2003, CELL, V114, P201, DOI 10.1016/S0092-8674(03)00555-5; Zhelev DV, 2002, ANN BIOMED ENG, V30, P356, DOI 10.1114/1.1477446; Ziche M, 2004, CURR DRUG TARGETS, V5, P485, DOI 10.2174/1389450043345371	45	89	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39050	39057		10.1074/jbc.M504819200	http://dx.doi.org/10.1074/jbc.M504819200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16186116	hybrid			2022-12-25	WOS:000233362200019
J	Hanfrey, C; Elliott, KA; Franceschetti, M; Mayer, MJ; Illingworth, C; Michael, AJ				Hanfrey, C; Elliott, KA; Franceschetti, M; Mayer, MJ; Illingworth, C; Michael, AJ			A dual upstream open reading frame-based autoregulatory circuit controlling polyamine-responsive translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE DECARBOXYLASE; MESSENGER-RNA; GENE-EXPRESSION; INITIATION; LEADER; PLANT; SEQUENCE; ARGININE; PEPTIDE; TRANSFORMATION	A novel form of translational regulation is described for the key polyamine biosynthetic enzyme S-adenosylmethionine decarboxylase (AdoMetDC). Plant AdoMetDC mRNA 5' leaders contain two highly conserved overlapping upstream open reading frames (uORFs): the 5' tiny and 3' small uORFs. We demonstrate that the small uORF-encoded peptide is responsible for constitutively repressing downstream translation of the AdoMetDC proenzyme ORF in the absence of increased polyamine levels. This first example of a sequence-dependent uORF to be described in plants is also functional in Saccharomyces cerevisiae. The tiny uORF is required for normal polyamine-responsive AdoMetDC mRNA translation, and we propose that this is achieved by control of ribosomal recognition of the occluded small uORF, either by ribosomal leaky scanning or by programmed -1 frameshifting. In vitro expression demonstrated that both the tiny and the small uORFs are translated. This tiny/small uORF configuration is highly conserved from moss to Arabidopsis thaliana, and a more diverged tiny/small uORF arrangement is found in the AdoMetDC mRNA 5' leader of the single-celled green alga Chlamydomonas reinhardtii, indicating an ancient origin for the uORFs.	Inst Food Res, Norwich NR4 7UA, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia	Michael, AJ (corresponding author), Inst Food Res, Norwich Res Pk, Norwich NR4 7UA, Norfolk, England.	tony.michael@bbsrc.ac.uk						Alderete JP, 1999, J VIROL, V73, P8330, DOI 10.1128/JVI.73.10.8330-8337.1999; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burtin D, 1997, BIOCHEM J, V325, P331, DOI 10.1042/bj3250331; Cao JH, 1996, MOL CELL BIOL, V16, P603; CIGAN AM, 1989, P NATL ACAD SCI USA, V86, P2784, DOI 10.1073/pnas.86.8.2784; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Coffino P, 2001, NAT REV MOL CELL BIO, V2, P188, DOI 10.1038/35056508; Cohen S A, 1998, Guttmacher Rep Public Policy, V1, P1; DELBECQ P, 1994, MOL CELL BIOL, V14, P2378, DOI 10.1128/MCB.14.4.2378; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Fang P, 2000, J BIOL CHEM, V275, P26710; Fang P, 2004, P NATL ACAD SCI USA, V101, P4059, DOI 10.1073/pnas.0400554101; Franceschetti M, 2004, FEBS LETT, V576, P477, DOI 10.1016/j.febslet.2004.08.085; Franceschetti M, 2001, BIOCHEM J, V353, P403, DOI 10.1042/0264-6021:3530403; Gaba A, 2001, EMBO J, V20, P6453, DOI 10.1093/emboj/20.22.6453; Geballe AP, 2000, COLD SPRING HARBOR M, V39, P595; GIANNAKOUROS T, 1990, MOL CELL BIOCHEM, V99, P9, DOI 10.1007/BF01261388; Grundy FJ, 2003, P NATL ACAD SCI USA, V100, P12057, DOI 10.1073/pnas.2133705100; Hanfrey C, 2002, J BIOL CHEM, V277, P44131, DOI 10.1074/jbc.M206161200; Hedges SB, 2002, NAT REV GENET, V3, P838, DOI 10.1038/nrg929; HILL JR, 1992, J BIOL CHEM, V267, P21886; Hu WW, 2005, PLANT PHYSIOL, V138, P276, DOI 10.1104/pp.104.056770; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; Ivanov IP, 2000, NUCLEIC ACIDS RES, V28, P3185, DOI 10.1093/nar/28.17.3185; Jansen R, 2003, NUCLEIC ACIDS RES, V31, P2242, DOI 10.1093/nar/gkg306; Jones Jonathan D. G., 1992, Transgenic Research, V1, P285, DOI 10.1007/BF02525170; Kozak M, 2002, GENE, V299, P1, DOI 10.1016/S0378-1119(02)01056-9; KURODA Y, 1982, SCIENCE, V215, P415, DOI 10.1126/science.7058326; Law GL, 2001, J BIOL CHEM, V276, P38036; Mathews MB, 2000, COLD SPRING HARBOR M, V39, P1; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; MELLOR J, 1985, NATURE, V313, P243, DOI 10.1038/313243a0; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; Nahvi A, 2002, CHEM BIOL, V9, P1043, DOI 10.1016/S1074-5521(02)00224-7; Nakatogawa H, 2002, CELL, V108, P629, DOI 10.1016/S0092-8674(02)00649-9; PIPER PW, 1994, MOL GENETICS YEAST P, P135; Raney A, 2000, J BIOL CHEM, V275, P24444, DOI 10.1074/jbc.M003364200; Ruan HJ, 1996, J BIOL CHEM, V271, P29576, DOI 10.1074/jbc.271.47.29576; Ryabova LA, 2000, GENE DEV, V14, P817; SHANTZ LM, 1994, BIOCHEM J, V302, P765, DOI 10.1042/bj3020765; Vilela C, 1999, EMBO J, V18, P3139, DOI 10.1093/emboj/18.11.3139; WATANABE S, 1991, J BIOL CHEM, V266, P20803; Winkler W, 2002, NATURE, V419, P952, DOI 10.1038/nature01145	43	111	116	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39229	39237		10.1074/jbc.M509340200	http://dx.doi.org/10.1074/jbc.M509340200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16176926	hybrid			2022-12-25	WOS:000233362200039
J	Muciaccia, B; Padula, F; Vicini, E; Gandini, L; Lenzi, A; Stefanini, M				Muciaccia, B; Padula, F; Vicini, E; Gandini, L; Lenzi, A; Stefanini, M			Beta-chemokine receptors 5 and 3 are expressed on the head region of human spermatozoon	FASEB JOURNAL			English	Article						CCR5; CCR3; sperm chemotaxis; Delta 32 mutation; HIV-1 carrier	CHEMOKINE RECEPTORS CCR3; HIV-1 INFECTION; MESSENGER-RNA; SPERM; TRANSMISSION; INDIVIDUALS; CHEMOTAXIS; RESISTANCE; ALLELES; VIRUSES	Induction of human sperm chemotaxis is an established phenomenon, though signaling systems physiologically involved have not been identified. Recently, it has been demonstrated that RANTES is present in the follicular fluid and that this molecule is a chemoactractant for human spermatozoa. However, the presence of beta-chemokine receptors on human spermatozoa has never been reported. By cytometric, Western blotting and immunofluorescence analysis, we demonstrate the presence of CCR5 and CCR3 on ejaculated spermatozoa from healthy subjects. CCR5 was detected in the periacrosomal region of the sperm surface, whereas CCR3 was also present in the postacrosomal cap. Individual variability was observed on CCR5 and CCR3 positive sperm percentages. Presence of Delta 32(+/-) mutation was demonstrated in two subjects expressing CCR5 in half of the ejaculated spermatozoa. Our findings represent the missing information in favor of the possibility that beta-chemokines and their receptors are involved in sperm chemotaxis. Identification of molecular mechanisms of sperm chemotaxis may allow us to identify predictive parameters of sperm fertilizing ability in hypofertile or infertile subjects. Finally, both CCR5 and CCR3 expressed on the sperm cell surface may be involved in HIV-1 adhesion to spermatozoa, thus allowing these cells to perform as virion cellular carriers during sexual transmission of HIV-1 infection.	Univ Roma La Sapienza, Dept Histol & Med Embryol, I-00161 Rome, Italy; Univ Roma La Sapienza, Dept Med Physiopathol, I-00161 Rome, Italy; Univ Roma La Sapienza, Ctr Eccellenza Biol & Med Mol, I-00161 Rome, Italy	Sapienza University Rome; Sapienza University Rome; Sapienza University Rome	Stefanini, M (corresponding author), Univ Roma La Sapienza, Dept Histol & Med Embryol, Via Antonio Scarpa 14, I-00161 Rome, Italy.	mario.stefanini@uniroma1.it	Lenzi, Andrea/I-7711-2015; GANDINI, Loredana/K-3315-2015	Lenzi, Andrea/0000-0002-7711-0465; Vicini, Elena/0000-0003-0399-0145; GANDINI, Loredana/0000-0002-4274-0491				BAUER HM, 1991, JAMA-J AM MED ASSOC, V265, P472, DOI 10.1001/jama.265.4.472; Beaulieu S, 2002, J IMMUNOL, V169, P2925, DOI 10.4049/jimmunol.169.6.2925; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Berger EA, 1997, AIDS, V11, pS3; Blanpain C, 2000, BLOOD, V96, P1638, DOI 10.1182/blood.V96.5.1638.h8001638_1638_1645; BORZY MS, 1988, J ACQ IMMUN DEF SYND, V1, P419; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Dejucq N, 2001, MICROBIOL MOL BIOL R, V65, P208, DOI 10.1128/MMBR.65.2.208-231.2001; Dejucq-Rainsford N, 2004, CURR PHARM DESIGN, V10, P557, DOI 10.2174/1381612043453225; Dragic T, 2001, J GEN VIROL, V82, P1807, DOI 10.1099/0022-1317-82-8-1807; Dulkys Y, 2001, J IMMUNOL, V167, P3443, DOI 10.4049/jimmunol.167.6.3443; DUSSAIX E, 1993, RES VIROLOGY, V144, P487, DOI 10.1016/S0923-2516(06)80064-6; Eisenbach M, 1999, REV REPROD, V4, P56, DOI 10.1530/revreprod/4.1.56; Eisenbach M, 1999, DEV GENET, V25, P87, DOI 10.1002/(SICI)1520-6408(1999)25:2&lt;87::AID-DVG2&gt;3.0.CO;2-4; ERICKSON RP, 1981, J REPROD IMMUNOL, V3, P195, DOI 10.1016/0165-0378(81)90042-5; Fabro G, 2002, BIOL REPROD, V67, P1565, DOI 10.1095/biolreprod.102.006395; Forsythe P, 2003, AM J RESP CELL MOL, V28, P405, DOI 10.1165/rcmb.F265; Garcia-Velasco JA, 1999, FERTIL STERIL, V71, P983, DOI 10.1016/S0015-0282(99)00120-X; Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; Hendriksen PJM, 1999, THERIOGENOLOGY, V52, P1295, DOI 10.1016/S0093-691X(99)00218-6; Hornung D, 2001, MOL HUM REPROD, V7, P163, DOI 10.1093/molehr/7.2.163; HUANG RD, 1996, FINANCIAL MARKETS I, V5, P1; Isobe T, 2002, HUM REPROD, V17, P1441, DOI 10.1093/humrep/17.6.1441; Januchowski R, 2004, J ANDROL, V25, P757; Kato H, 1999, GENES IMMUN, V1, P97, DOI 10.1038/sj.gene.6363638; Kawano Y, 2001, AM J REPROD IMMUNOL, V45, P1, DOI 10.1111/j.8755-8920.2001.450101.x; Kim LU, 1999, AIDS, V13, P645, DOI 10.1097/00002030-199904160-00004; Larson JL, 1997, BIOL REPROD, V57, P442, DOI 10.1095/biolreprod57.2.442; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; McDermott DH, 1998, LANCET, V352, P866, DOI 10.1016/S0140-6736(98)04158-0; Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219; Muciaccia B, 2005, AIDS, V19, P1424, DOI 10.1097/01.aids.0000180809.04427.04; Oliveira RG, 1999, J REPROD FERTIL, V115, P23, DOI 10.1530/jrf.0.1150023; Oppermann M, 2004, CELL SIGNAL, V16, P1201, DOI 10.1016/j.cellsig.2004.04.007; Quillent C, 1998, LANCET, V351, P14, DOI 10.1016/S0140-6736(97)09185-X; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Rottman JB, 1997, AM J PATHOL, V151, P1341; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Suter L, 1997, CYTOMETRY, V27, P161, DOI 10.1002/(SICI)1097-0320(19970201)27:2<161::AID-CYTO8>3.0.CO;2-J; Tamasauskas D, 2001, BLOOD, V97, P3651, DOI 10.1182/blood.V97.11.3651; World Health Organization, 1999, WHO LAB MAN EX HUM S; Zaitseva M, 1997, NAT MED, V3, P1369, DOI 10.1038/nm1297-1369; Zhang Q, 2004, HUM REPROD, V19, P409, DOI 10.1093/humrep/deh085; Zheng Y, 2001, BIOL REPROD, V64, P1730, DOI 10.1095/biolreprod64.6.1730	45	26	29	1	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					2048	+		10.1096/fj.05-3962fje	http://dx.doi.org/10.1096/fj.05-3962fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16174786				2022-12-25	WOS:000232315700007
J	Masselli, A; Wang, JYJ				Masselli, A; Wang, JYJ			Phosphorylation site mutated RB exerts contrasting effects on apoptotic response to different stimuli	ONCOGENE			English	Article						tetracycline-regulated gene expression; p53	RETINOBLASTOMA PROTEIN; CELL-DEATH; G(1) ARREST; INHIBITION; NECROSIS; STAUROSPORINE; ACTIVATION; CLEAVAGE; PRB; DEGRADATION	The retinoblastoma tumor-suppressor protein (RB) is an important regulator of cell cycle and apoptosis. RB is phosphorylated by cyclin-dependent protein kinase during cell cycle progression. A phosphorylation site mutated (PSM)-RB has previously been shown to cause G1 arrest and to interfere with S phase progression. In this study, we examined the effect of inducible PSM-RB expression on the apoptotic response to three different death stimuli: doxorubicin (DOXO), staurosporine (STS) and tumor necrosis factor (TNF) in Rat-16 cells. Induced expression of PSM-RB attenuated caspase activation by DOXO as a result of cell cycle arrest. STS has been shown to cause RB-dependent G1 arrest or apoptosis; however, expression of PSM-RB did not prevent caspase activation by STS. Surprisingly, induced expression of PSM-RB stimulated the apoptotic response to TNF in Rat-16 cells, which mostly undergo necrosis in the absence of PSM-RB. These results show that PSM-RB exerts disparate effects on apoptotic response to different stimuli, and that cell cycle arrest does not always associate with resistance to apoptosis.	Univ Calif San Diego, Sch Med, Div Hematol Oncol & Moores Canc Ctr, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Wang, JYJ (corresponding author), Univ Calif San Diego, Sch Med, Div Hematol Oncol & Moores Canc Ctr, Dept Med, 3855 Hlth Sci Dr, La Jolla, CA 92093 USA.	jywang@ucsd.edu			NATIONAL CANCER INSTITUTE [R01CA058320] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA058320, CA 58320] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bosco EE, 2004, NUCLEIC ACIDS RES, V32, P25, DOI 10.1093/nar/gkg919; Boutillier AL, 2000, ONCOGENE, V19, P2171, DOI 10.1038/sj.onc.1203532; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Cauwels A, 2003, NAT IMMUNOL, V4, P387, DOI 10.1038/ni914; Chau BN, 2002, NAT CELL BIOL, V4, P757, DOI 10.1038/ncb853; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; Chen XM, 2000, JNCI-J NATL CANCER I, V92, P1999, DOI 10.1093/jnci/92.24.1999; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Darnell GA, 2003, MOL CELL BIOL, V23, P6520, DOI 10.1128/MCB.23.18.6520-6532.2003; Denecker G, 2001, CELL DEATH DIFFER, V8, P829, DOI 10.1038/sj.cdd.4400883; Fattman CL, 2001, ONCOGENE, V20, P2918, DOI 10.1038/sj.onc.1204414; Fattman CL, 1997, J CELL BIOCHEM, V67, P399; Ferguson KL, 2001, NEUROREPORT, V12, pA55, DOI 10.1097/00001756-200107030-00001; GERA JF, 1993, J IMMUNOL, V151, P3746; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Humphreys DT, 1999, CYTOKINE, V11, P773, DOI 10.1006/cyto.1998.0492; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Lin Y, 2004, J BIOL CHEM, V279, P10822, DOI 10.1074/jbc.M313141200; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Los M, 2002, MOL BIOL CELL, V13, P978, DOI 10.1091/mbc.01-05-0272; Mayhew CN, 2004, ONCOGENE, V23, P4107, DOI 10.1038/sj.onc.1207503; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; MORGAN DO, 1998, CANC J SCI AM S1, V4, P77; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Orr MS, 1998, J BIOL CHEM, V273, P3803, DOI 10.1074/jbc.273.7.3803; Panaretakis T, 2002, J BIOL CHEM, V277, P44317, DOI 10.1074/jbc.M205273200; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Schneider-Brachert W, 2004, IMMUNITY, V21, P415, DOI 10.1016/j.immuni.2004.08.017; Schnier JB, 1996, P NATL ACAD SCI USA, V93, P5941, DOI 10.1073/pnas.93.12.5941; Sever-Chroneos Z, 2001, MOL CELL BIOL, V21, P4032, DOI 10.1128/MCB.21.12.4032-4045.2001; Siu WY, 1999, FEBS LETT, V461, P299, DOI 10.1016/S0014-5793(99)01481-7; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Tan XQ, 1997, J BIOL CHEM, V272, P9613; Wagner S, 2005, BIOCHEM PHARMACOL, V69, P1059, DOI 10.1016/j.bcp.2004.12.017; Xiao B, 2003, P NATL ACAD SCI USA, V100, P2363, DOI 10.1073/pnas.0436813100	48	12	13	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1290	1298		10.1038/sj.onc.1209161	http://dx.doi.org/10.1038/sj.onc.1209161			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16205627				2022-12-25	WOS:000235708200002
J	Shkryl, VM; Shirokova, N				Shkryl, VM; Shirokova, N			Transfer and tunneling of Ca2+ from sarcoplasmic reticulum to mitochondria in skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-UPTAKE; FIBERS; MYOTUBES; RELEASE; MYOCYTES; CHANNEL; SPARKS	The role of mitochondrial Ca2+ transport in regulating intracellular Ca2+ signaling and mitochondrial enzymes involved in energy metabolism is widely recognized in many tissues. However, the ability of skeletal muscle mitochondria to sequester Ca2+ released from the sarcoplasmic reticulum (SR) during the muscle contraction-relaxation cycle is still disputed. To assess the functional cross-talk of Ca2+ between SR and mitochondria, we examined the mutual relationship connecting cytosolic and mitochondrial Ca2+ dynamics in permeabilized skeletal muscle fibers. Cytosolic and mitochondrial Ca2+ transients were recorded with digital photometry and confocal microscopy using fura-2 and mag-rhod-2, respectively. In the presence of 0.5 mM slow Ca2+ buffer (EGTA (ethylene glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid)), application of caffeine induced a synchronized increase in both cytosolic and mitochondrial [Ca2+]. 5 mM fast Ca2+ buffer (BAPTA (1,2-bis(2-aminophenoxy) ethane-N,N,N',N'-tetraacetic acid)) nearly eliminated caffeine-induced increases in [Ca2+](c) but only partially decreased the amplitude of mitochondrial Ca2+ transients. Confocal imaging revealed that in EGTA, almost all mitochondria picked up Ca2+ released from the SR by caffeine, whereas only about 70% of mitochondria did so in BAPTA. Taken together, these results indicated that a subpopulation of mitochondria is in close functional and presumably structural proximity to the SR, giving rise to subcellular microdomains in which Ca2+ has preferential access to the juxtaposed organelles.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pharmacol & Physiol, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Shirokova, N (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pharmacol & Physiol, 185 S Orange Ave, Newark, NJ 07103 USA.	nshiroko@umdnj.edu		Shirokova, Natalia/0000-0003-4648-4592	NIAMS NIH HHS [R01 AR45690] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045690] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Brini M, 2003, CELL CALCIUM, V34, P399, DOI 10.1016/S0143-4160(03)00145-3; Brini M, 1997, MOL BIOL CELL, V8, P129, DOI 10.1091/mbc.8.1.129; Bruton J, 2003, J PHYSIOL-LONDON, V551, P179, DOI 10.1113/jphysiol.2003.043927; Challet C, 2001, J BIOL CHEM, V276, P3791, DOI 10.1074/jbc.M006209200; Chen GP, 2001, AM J PHYSIOL-CELL PH, V281, pC114, DOI 10.1152/ajpcell.2001.281.1.C114; Cheng H, 1999, BIOPHYS J, V76, P606, DOI 10.1016/S0006-3495(99)77229-2; Csordas G, 2001, TRENDS CARDIOVAS MED, V11, P269, DOI 10.1016/S1050-1738(01)00123-2; Duchen MR, 2000, J PHYSIOL-LONDON, V529, P57, DOI 10.1111/j.1469-7793.2000.00057.x; Duke AM, 1998, PFLUG ARCH EUR J PHY, V436, P104, DOI 10.1007/s004240050610; GARCIA J, 1993, J PHYSIOL-LONDON, V463, P709, DOI 10.1113/jphysiol.1993.sp019618; Gillis JM, 1997, J MUSCLE RES CELL M, V18, P473, DOI 10.1023/A:1018603032590; Gurney AM, 2000, CELL CALCIUM, V27, P339, DOI 10.1054/ceca.2000.0124; Isaeva EV, 2005, J PHYSIOL-LONDON, V565, P855, DOI 10.1113/jphysiol.2005.086280; Isaeva EV, 2003, J PHYSIOL-LONDON, V547, P453, DOI 10.1113/jphysiol.2002.036129; Jouaville LS, 1999, P NATL ACAD SCI USA, V96, P13807, DOI 10.1073/pnas.96.24.13807; Lannergren J, 2001, J MUSCLE RES CELL M, V22, P265, DOI 10.1023/A:1012227009544; Madsen K, 1996, AM J PHYSIOL-ENDOC M, V271, pE1044, DOI 10.1152/ajpendo.1996.271.6.E1044; Naraghi M, 1997, J NEUROSCI, V17, P6961; OGATA T, 1985, CELL TISSUE RES, V241, P251, DOI 10.1007/BF00217168; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Rizzuto Rosario, 2004, Sci STKE, V2004, pre1, DOI 10.1126/stke.2152004re1; Robert V, 2001, J BIOL CHEM, V276, P4647, DOI 10.1074/jbc.M006337200; Rudolf R, 2004, J CELL BIOL, V166, P527, DOI 10.1083/jcb.200403102; SEMBROWICH WL, 1985, J APPL PHYSIOL, V59, P137, DOI 10.1152/jappl.1985.59.1.137; Sharma VK, 2000, J BIOENERG BIOMEMBR, V32, P97, DOI 10.1023/A:1005520714221; Shirokova N, 1996, J GEN PHYSIOL, V107, P1, DOI 10.1085/jgp.107.1.1; Simpson PB, 1998, BRAIN RES REV, V26, P72, DOI 10.1016/S0165-0173(97)00056-8; Smith GD, 1996, BIOPHYS J, V70, P2527, DOI 10.1016/S0006-3495(96)79824-7; STERN MD, 1992, CELL CALCIUM, V13, P183, DOI 10.1016/0143-4160(92)90046-U	29	76	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1547	1554		10.1074/jbc.M505024200	http://dx.doi.org/10.1074/jbc.M505024200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16216882	hybrid			2022-12-25	WOS:000234652000032
J	McCormick, KL; Wang, XD; Mick, GJ				McCormick, KL; Wang, XD; Mick, GJ			Evidence that the 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD1) is regulated by pentose pathway flux - Studies in rat adipocytes and microsomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ADIPOSE-TISSUE; 11-BETA-HYDROXYSTEROID DEHYDROGENASE; HEXOSE-6-PHOSPHATE DEHYDROGENASE; LIVER-MICROSOMES; GLUCOCORTICOID ACTION; PHOSPHATE PATHWAY; 6-PHOSPHOGLUCONATE DEHYDROGENASES; ENDOPLASMIC-RETICULUM; GLUCOSE-DEHYDROGENASE; CORTISOL METABOLISM	11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1) catalyzes the interconversion of biologically inactive 11 keto derivatives (cortisone, 11-dehydrocorticosterone) to active glucocorticoids (cortisol, corticosterone) in fat, liver, and other tissues. It is located in the intraluminal compartment of the endoplasmic reticulum. Inasmuch as an oxo-reductase requires NADPH, we reasoned that 11 beta-HSD1 would be metabolically interconnected with the cytosolic pentose pathway because this pathway is the primary producer of reduced cellular pyridine nucleotides. To test this theory, 11 beta-HSD1 activity and pentose pathway were simultaneously measured in isolated intact rodent adipocytes. Established inhibitors of NAPDH production via the pentose pathway (dehydroandrostenedione or norepinephrine) inhibited 11 beta-HSD1 oxo-reductase while decreasing cellular NADPH content. Conversely these compounds slightly augmented the reverse, or dehydrogenase, reaction of 11 beta-HSD1. Importantly, using isolated intact microsomes, the inhibitors did not directly alter the tandem microsomal 11 beta-HSD1 and hexose-6-phosphate dehydrogenase enzyme unit. Metabolites of 11 beta-HSD1 (corticosterone or 11-dehydrocorticosterone) inhibited or increased pentose flux, respectively, demonstrating metabolic interconnectivity. Using isolated intact liver or fat microsomes, glucose-6 phosphate stimulated 11 beta-HSD1 oxo-reductase, and this effect was blocked by selective inhibitors of glucose-6-phosphate transport. In summary, we have demonstrated a metabolic interconnection between pentose pathway and 11 beta-HSD1 oxo-reductase activities that is dependent on cytosolic NADPH production. These observations link cytosolic carbohydrate flux with paracrine glucocorticoid formation. The clinical relevance of these findings may be germane to the regulation of paracrine glucocorticoid formation in disturbed nutritional states such as obesity.	Univ Alabama Birmingham, Dept Pediat, Div Endocrinol, Birmingham, AL 35233 USA	University of Alabama System; University of Alabama Birmingham	McCormick, KL (corresponding author), Univ Alabama Birmingham, Dept Pediat, Div Endocrinol, ACC 608,1600 7th Ave S, Birmingham, AL 35233 USA.	kmccormick@peds.uab.edu						AGARWAL AK, 1990, MOL ENDOCRINOL, V4, P1827, DOI 10.1210/mend-4-12-1827; Apostolova G, 2005, AM J PHYSIOL-ENDOC M, V288, pE957, DOI 10.1152/ajpendo.00442.2004; Arion WJ, 1997, ARCH BIOCHEM BIOPHYS, V339, P315, DOI 10.1006/abbi.1996.9874; Atanasov AG, 2004, FEBS LETT, V571, P129, DOI 10.1016/j.febslet.2004.06.065; AYALA A, 1990, MOL CELL BIOCHEM, V95, P107; AYALA A, 1991, MOL CELL BIOCHEM, V105, P1; Bader T, 2002, HORM METAB RES, V34, P752, DOI 10.1055/s-2002-38255; BUBLITZ C, 1988, J BIOL CHEM, V263, P12849; BUBLITZ C, 1988, BIOCHIM BIOPHYS ACTA, V965, P90, DOI 10.1016/0304-4165(88)90155-9; Bujalska IJ, 1999, ENDOCRINOLOGY, V140, P3188, DOI 10.1210/en.140.7.3188; Bujalska IJ, 2002, J CLIN ENDOCR METAB, V87, P1205, DOI 10.1210/jc.87.3.1205; Bujalska IJ, 1997, LANCET, V349, P1210, DOI 10.1016/S0140-6736(96)11222-8; Clarke JL, 2003, ARCH BIOCHEM BIOPHYS, V415, P229, DOI 10.1016/S0003-9861(03)00229-7; Draper N, 2003, NAT GENET, V34, P434, DOI 10.1038/ng1214; Engeli S, 2004, OBES RES, V12, P9, DOI 10.1038/oby.2004.3; FABREGAT I, 1985, ARCH BIOCHEM BIOPHYS, V236, P110, DOI 10.1016/0003-9861(85)90610-1; FABREGAT I, 1987, MOL CELL BIOCHEM, V74, P77; FABREGAT I, 1987, BIOCHEM BIOPH RES CO, V146, P920, DOI 10.1016/0006-291X(87)90618-8; Gerin I, 2002, FEBS LETT, V517, P257, DOI 10.1016/S0014-5793(02)02640-6; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; GUMAA KA, 1969, BIOCHEM J, V114, P253, DOI 10.1042/bj1140253; HAMMAMI MM, 1991, J CLIN ENDOCR METAB, V73, P326, DOI 10.1210/jcem-73-2-326; Hamman BD, 1997, CELL, V89, P535, DOI 10.1016/S0092-8674(00)80235-4; HINO Y, 1982, J BIOCHEM, V92, P547, DOI 10.1093/oxfordjournals.jbchem.a133963; JAMIESON PM, 1995, ENDOCRINOLOGY, V136, P4754, DOI 10.1210/en.136.11.4754; KATZ J, 1966, J BIOL CHEM, V241, P727; Katz JR, 1999, CLIN ENDOCRINOL, V50, P63, DOI 10.1046/j.1365-2265.1999.00598.x; Kotelevtsev Y, 1997, P NATL ACAD SCI USA, V94, P14924, DOI 10.1073/pnas.94.26.14924; LARRABEE MG, 1989, J BIOL CHEM, V264, P15875; LARRABEE MG, 1990, BIOCHEM J, V272, P127, DOI 10.1042/bj2720127; Le Gall S, 2004, MOL BIOL CELL, V15, P447, DOI 10.1091/mbc.E03-05-0325; Lindsay RS, 2003, J CLIN ENDOCR METAB, V88, P2738, DOI 10.1210/jc.2002-030017; Livingstone DEW, 2000, ENDOCRINOLOGY, V141, P560, DOI 10.1210/en.141.2.560; MANDULA B, 1970, ARCH BIOCHEM BIOPHYS, V141, P155, DOI 10.1016/0003-9861(70)90118-9; MASER E, 1994, J STEROID BIOCHEM, V48, P257, DOI 10.1016/0960-0760(94)90153-8; Masuzaki H, 2001, SCIENCE, V294, P2166, DOI 10.1126/science.1066285; Masuzaki Hiroaki, 2003, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V3, P255; MCCORMICK KL, 1992, BIOCHIM BIOPHYS ACTA, V1135, P1, DOI 10.1016/0167-4889(92)90158-8; MCCORMICK KL, 1991, AM J PHYSIOL, V261, pC476, DOI 10.1152/ajpcell.1991.261.3.C476; Mick GJ, 2002, ENDOCRINOLOGY, V143, P948, DOI 10.1210/en.143.3.948; MICK GJ, 1988, J BIOL CHEM, V263, P10667; Napolitano A, 1998, J STEROID BIOCHEM, V64, P251, DOI 10.1016/S0960-0760(97)00200-8; OKA KI, 1981, BIOCHIM BIOPHYS ACTA, V662, P318, DOI 10.1016/0005-2744(81)90045-0; OTTOSSON M, 1994, J CLIN ENDOCR METAB, V79, P820, DOI 10.1210/jc.79.3.820; OZOLS J, 1995, J BIOL CHEM, V270, P10360; Rask E, 2001, J CLIN ENDOCR METAB, V86, P1418, DOI 10.1210/jc.86.3.1418; RAUCY JL, 1991, METHOD ENZYMOL, V206, P577; RICHARDSON DK, 1978, AM J PHYSIOL, V234, pE182, DOI 10.1152/ajpendo.1978.234.2.E182; Ricketts ML, 1998, J CLIN ENDOCR METAB, V83, P1325, DOI 10.1210/jc.83.4.1325; ROMANELLI A, 1994, BIOCHEM BIOPH RES CO, V200, P1491, DOI 10.1006/bbrc.1994.1619; Seckl JR, 2001, ENDOCRINOLOGY, V142, P1371, DOI 10.1210/en.142.4.1371; Sekar N, 1999, ENDOCRINOLOGY, V140, P1125, DOI 10.1210/en.140.3.1125; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SLAVIN BG, 1994, J LIPID RES, V35, P1535; STDENIS JF, 1995, J BIOL CHEM, V270, P21092, DOI 10.1074/jbc.270.36.21092; Stewart PM, 1999, J CLIN ENDOCR METAB, V84, P1022, DOI 10.1210/jc.84.3.1022; Stulnig TM, 2004, DIABETOLOGIA, V47, P1, DOI 10.1007/s00125-003-1284-4; TAKAHASHI T, 1978, BIOCHIM BIOPHYS ACTA, V524, P262, DOI 10.1016/0005-2744(78)90163-8; Tomlinson JW, 2002, HORM METAB RES, V34, P746, DOI 10.1055/s-2002-38242; VANVELDHOVEN P, 1983, BIOCHEM J, V210, P685, DOI 10.1042/bj2100685; Whorwood CB, 2001, J CLIN ENDOCR METAB, V86, P2296, DOI 10.1210/jc.86.5.2296	61	64	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	2006	281	1					341	347		10.1074/jbc.M506026200	http://dx.doi.org/10.1074/jbc.M506026200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	998GS	16234247	hybrid			2022-12-25	WOS:000234307200043
J	Hasina, R; Pontier, AL; Fekete, MJ; Martin, LE; Qi, XM; Brigaudeau, C; Pramanik, R; Cline, EI; Coignet, LJ; Lingen, MW				Hasina, R; Pontier, AL; Fekete, MJ; Martin, LE; Qi, XM; Brigaudeau, C; Pramanik, R; Cline, EI; Coignet, LJ; Lingen, MW			NOL7 is a nucleolar candidate tumor suppressor gene in cervical cancer that modulates the angiogenic phenotype	ONCOGENE			English	Article						cervical cancer; nucleolus; tumor suppressor gene; angiogenesis; VEGF; TSP-1	THROMBOSPONDIN-1 EXPRESSION; P53 GENE; IN-VIVO; CARCINOMA; RNA; IDENTIFICATION; PROGRESSION; REPRESSION; INDUCTION; LEUKEMIA	Cervical cancer is associated with human papilloma virus infection. However, this infection is insufficient to induce transformation and progression. Loss of heterozygosity analyses suggest the presence of a tumor suppressor gene (TSG) on chromosome 6p21.3-p25. Here we report the cloning NOL7, its mapping to chromosome band 6p23, and localization of the protein to the nucleolus. Fluorescence in situ hybridization analysis demonstrated an allelic loss of an NOL7 in cultured tumor cells and human tumor samples. Transfection of NOL7 into cervical carcinoma cells inhibited their growth in mouse xenografts, confirming its in vivo tumor suppressor activity. The induction of tumor dormancy correlated with an angiogenic switch caused by a decreased production of vascular endothelial growth factor and an increase in the production of the angiogenesis inhibitor thrombospondin-1. These data suggest that NOL7 may function as a TSG in part by modulating the expression of the angiogenic phenotype.	Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA; Vet Affairs Edward Hines Jr Hosp, Maywood, IL USA; Loyola Univ, Med Ctr, Maywood, IL 60153 USA; Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	University of Chicago; University of Chicago; University of Chicago; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Loyola University Chicago; Roswell Park Cancer Institute	Lingen, MW (corresponding author), Univ Chicago, Dept Pathol, MC 6101,5841 S Maryland Ave, Chicago, IL 60637 USA.	mark.lingen@uchospitals.edu			NIDCR NIH HHS [DE12322, DE00470] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012322] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Cannistra SA, 1996, NEW ENGL J MED, V334, P1030, DOI 10.1056/NEJM199604183341606; CHEN TM, 1993, CANCER RES, V53, P1167; Chen Z, 2000, CANCER GENET CYTOGEN, V121, P22, DOI 10.1016/S0165-4608(00)00222-3; Claudio PP, 2001, CANCER RES, V61, P462; Coignet LJA, 1999, GENE CHROMOSOME CANC, V25, P222, DOI 10.1002/(SICI)1098-2264(199907)25:3<222::AID-GCC4>3.0.CO;2-C; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Dejong V, 1999, ONCOGENE, V18, P3143, DOI 10.1038/sj.onc.1202654; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Huettner PC, 1998, HUM PATHOL, V29, P364, DOI 10.1016/S0046-8177(98)90117-4; Jinawath N, 2004, CANCER SCI, V95, P430, DOI 10.1111/j.1349-7006.2004.tb03227.x; Kersemaekers AMF, 1998, INT J CANCER, V79, P411, DOI 10.1002/(SICI)1097-0215(19980821)79:4<411::AID-IJC17>3.0.CO;2-7; Kraemer M, 1999, CELL GROWTH DIFFER, V10, P193; Lazo PA, 1999, BRIT J CANCER, V80, P2008, DOI 10.1038/sj.bjc.6690635; Lingen MW, 1998, CANCER RES, V58, P5551; Lingen MW, 1997, CARCINOGENESIS, V18, P329, DOI 10.1093/carcin/18.2.329; LINGEN MW, 2002, WOUND HEALING METHOD, P337; Marconcini L, 1999, P NATL ACAD SCI USA, V96, P9671, DOI 10.1073/pnas.96.17.9671; MITRA AB, 1994, CANCER RES, V54, P4481; MONTGOMERY KD, 1995, GENE CHROMOSOME CANC, V14, P97, DOI 10.1002/gcc.2870140203; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; Muliokandov MR, 1996, CANCER RES, V56, P197; Nagai H, 1999, GENE CHROMOSOME CANC, V25, P277, DOI 10.1002/(SICI)1098-2264(199907)25:3<277::AID-GCC10>3.0.CO;2-L; Nakase K, 2000, LEUKEMIA RES, V24, P79, DOI 10.1016/S0145-2126(99)00139-3; Olson MOJ, 2000, TRENDS CELL BIOL, V10, P189, DOI 10.1016/S0962-8924(00)01738-4; Rader JS, 2000, GENE CHROMOSOME CANC, V27, P373, DOI 10.1002/(SICI)1098-2264(200004)27:4<373::AID-GCC6>3.3.CO;2-M; RAK J, 1995, CANCER RES, V55, P4575; Sheibani N, 1996, CANCER LETT, V107, P45, DOI 10.1016/0304-3835(96)04341-8; SLACK JL, 1994, CELL GROWTH DIFFER, V5, P1373; SRIVASTAVA S, 1992, CARCINOGENESIS, V13, P1273, DOI 10.1093/carcin/13.7.1273; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Takeshita A, 2004, CANCER GENET CYTOGEN, V152, P56, DOI 10.1016/j.cancergencyto.2003.10.002; Tikhonenko AT, 1996, J BIOL CHEM, V271, P30741, DOI 10.1074/jbc.271.48.30741; UEJIMA H, 1995, GENE CHROMOSOME CANC, V14, P120, DOI 10.1002/gcc.2870140206; Visintin R, 2000, CURR OPIN CELL BIOL, V12, P372, DOI 10.1016/S0955-0674(00)00102-2; Volpert OV, 1997, ONCOGENE, V14, P1495, DOI 10.1038/sj.onc.1200977; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wen SH, 2001, P NATL ACAD SCI USA, V98, P4622, DOI 10.1073/pnas.081063798; Wolf JK, 2001, CANCER INVEST, V19, P621, DOI 10.1081/CNV-100104290; YAGINUMA Y, 1991, CANCER RES, V51, P6506; ZABRENETZKY V, 1994, INT J CANCER, V59, P191, DOI 10.1002/ijc.2910590209; Zhang YW, 2003, P NATL ACAD SCI USA, V100, P12718, DOI 10.1073/pnas.2135113100	45	26	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					588	598		10.1038/sj.onc.1209070	http://dx.doi.org/10.1038/sj.onc.1209070			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16205646	Bronze			2022-12-25	WOS:000234897400010
J	Avraham, E; Szargel, R; Eyal, A; Rott, R; Engelender, S				Avraham, E; Szargel, R; Eyal, A; Rott, R; Engelender, S			Glycogen synthase kinase 3 beta modulates synphilin-1 ubiquitylation and cellular inclusion formation by SIAH - Implications for proteasomal function and Lewy body formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; ENDOPLASMIC-RETICULUM STRESS; ALPHA-SYNUCLEIN; PROTEIN; MUTATION; GENE; PHOSPHORYLATION; BODIES; NEURODEGENERATION; ASSOCIATION	alpha-Synuclein is known to play a major role in the pathogenesis of Parkinson disease. We previously identified synphilin-1 as an alpha-synuclein-interacting protein and more recently found that synphilin-1 also interacts with the E3 ubiquitin ligases SIAH-1 and SIAH-2. SIAH proteins ubiquitylate synphilin-1 and promote its degradation through the ubiquitin proteasome system. Inability of the proteasome to degrade synphilin-1 promotes the formation of ubiquitylated inclusion bodies. We now show that synphilin-1 is phosphorylated by GSK3 beta within amino acids 550-659 and that this phosphorylation is significantly decreased by pharmacological inhibition of GSK3 beta and suppression of GSK3 beta expression by small interfering RNA duplex. Mutation analysis showed that Ser(556) is a major GSK3 beta phosphorylation site in synphilin-1. GSK3 beta co-immunoprecipitated with synphilin-1, and protein 14-3-3, an activator of GSK3 beta activity, increased synphilin-1 phosphorylation. GSK3 beta decreased the in vitro and in vivo ubiquitylation of synphilin-1 as well as its degradation promoted by SIAH. Pharmacological inhibition and small interfering RNA suppression of GSK3 beta greatly increased ubiquitylation and inclusion body formation by SIAH. Additionally, synphilin-1 S556A mutant, which is less phosphorylated by GSK3 beta, formed more inclusion bodies than wild type synphilin-1. Inhibition of GSK3 beta in primary neuronal cultures decreased the levels of endogenous synphilin-1, indicating that synphilin-1 is a physiologic substrate of GSK3 beta. Using GFPu as a reporter to measure proteasome function in vivo, we found that synphilin-1 S556A is more efficient in inhibiting the proteasome than wild type synphilin-1, raising the possibility that the degree of synphilin-1 phosphorylation may regulate the proteasome function. Activation of GSK3 beta during endoplasmic reticulum stress and the specific phosphorylation of synphilin-1 by GSK3 beta place synphilin-1 as a possible mediator of endoplasmic reticulum stress and proteasomal dysfunction observed in Parkinson disease.	Technion Israel Inst Technol, B Rappaport Inst Med Med, Dept Pharmacol, IL-31096 Haifa, Israel	Technion Israel Institute of Technology	Engelender, S (corresponding author), Technion Israel Inst Technol, B Rappaport Inst Med Med, Dept Pharmacol, Efron St,Bat Galim, IL-31096 Haifa, Israel.	simone@tx.technion.ac.il		Engelender, Simone/0000-0001-7401-6855				Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Chen G, 2004, FASEB J, V18, P1162, DOI 10.1096/fj.04-1551fje; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Dunnett SB, 1999, NATURE, V399, pA32, DOI 10.1038/399a032; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; Geschwind DH, 2003, NEURON, V40, P457, DOI 10.1016/S0896-6273(03)00681-0; Hyun DH, 2003, J NEUROCHEM, V86, P363, DOI 10.1046/j.1471-4159.2003.01841.x; Ihara M, 2003, J BIOL CHEM, V278, P24095, DOI 10.1074/jbc.M301352200; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Kalia SK, 2004, NEURON, V44, P931, DOI 10.1016/j.neuron.2004.11.026; Kawamoto Y, 2002, J NEUROPATH EXP NEUR, V61, P245, DOI 10.1093/jnen/61.3.245; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lee G, 2004, J BIOL CHEM, V279, P6834, DOI 10.1074/jbc.M312760200; Lee G, 2002, J NEUROCHEM, V83, P346, DOI 10.1046/j.1471-4159.2002.01136.x; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Liani E, 2004, P NATL ACAD SCI USA, V101, P5500, DOI 10.1073/pnas.0401081101; Lindersson E, 2004, J BIOL CHEM, V279, P12924, DOI 10.1074/jbc.M306390200; Marx FP, 2003, HUM MOL GENET, V12, P1223, DOI 10.1093/hmg/ddg134; McNaught KSP, 2001, NEUROSCI LETT, V297, P191, DOI 10.1016/S0304-3940(00)01701-8; Meijer L, 2004, TRENDS PHARMACOL SCI, V25, P471, DOI 10.1016/j.tips.2004.07.006; Nagano Y, 2003, J BIOL CHEM, V278, P51504, DOI 10.1074/jbc.M306347200; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Ribeiro CS, 2002, J BIOL CHEM, V277, P23927, DOI 10.1074/jbc.M201115200; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Ryu EJ, 2002, J NEUROSCI, V22, P10690; Snyder H, 2003, J BIOL CHEM, V278, P11753, DOI 10.1074/jbc.M208641200; Song L, 2002, J BIOL CHEM, V277, P44701, DOI 10.1074/jbc.M206047200; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Tanaka M, 2004, J BIOL CHEM, V279, P4625, DOI 10.1074/jbc.M310994200; Tanaka Y, 2001, HUM MOL GENET, V10, P919, DOI 10.1093/hmg/10.9.919; Tanji K, 2003, NEUROPATHOLOGY, V23, P199, DOI 10.1046/j.1440-1789.2003.00503.x; Wakabayashi K, 2000, ANN NEUROL, V47, P521, DOI 10.1002/1531-8249(200004)47:4<521::AID-ANA18>3.3.CO;2-2; Yuan ZF, 2004, J BIOL CHEM, V279, P26105, DOI 10.1074/jbc.M308298200; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795	38	41	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42877	42886		10.1074/jbc.M505608200	http://dx.doi.org/10.1074/jbc.M505608200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16174773	hybrid			2022-12-25	WOS:000234200800050
J	Subramanian, D; Griffith, JD				Subramanian, D; Griffith, JD			p53 Monitors replication fork regression by binding to "chickenfoot" intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACHROMOSOMAL HOMOLOGOUS RECOMBINATION; MUTANT P53; HOLLIDAY JUNCTIONS; WILD-TYPE; TRANSACTIVATION ACTIVITY; SYNDROME PROTEIN; TERMINAL DOMAIN; DNA STRUCTURES; BULGED BASES; HUMAN RAD51	The tumor suppressor protein, p53, utilizes multiple mechanisms to ensure faithful transmission of the genome including regulation of DNA replication, repair, and recombination. Monitoring these pathways may involve direct binding of p53 to the DNA intermediates of these processes. In this study, we generated templates resembling stalled replication forks and utilized electron microscopy to examine p53 interactions with these substrates. Our results show that p53 bound with high affinity to the junction of stalled forks, whereas two cancer-derived p53 mutants showed weak binding. Additionally, some of the templates were rearranged to form "chickenfoot" structures in the presence of p53. These were mostly formed due to p53 trapping intermediates of spontaneous fork regression; however, in a small population, the protein appeared to be promoting their formation. Collectively, these results demonstrate the importance of sequence-independent binding in p53-mediated maintenance of genomic integrity.	Univ N Carolina, Lineberger Comprehens Canc Ctr 119, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Griffith, JD (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr 119, CB 7295,Mason Farm Rd, Chapel Hill, NC 27599 USA.	jdg@med.unc.edu			NCI NIH HHS [CA19014] Funding Source: Medline; NIGMS NIH HHS [GM31819] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA019014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; Bishop AJR, 2003, CANCER RES, V63, P5335; Blander G, 1999, J BIOL CHEM, V274, P29463, DOI 10.1074/jbc.274.41.29463; Boehden GS, 2003, ONCOGENE, V22, P4111, DOI 10.1038/sj.onc.1206632; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; Degtyareva N, 2001, J BIOL CHEM, V276, P8778, DOI 10.1074/jbc.M006795200; Di Como CJ, 1998, ONCOGENE, V16, P2527; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; Garkavtsev IV, 2001, ONCOGENE, V20, P8276, DOI 10.1038/sj.onc.1205120; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Janz C, 2002, ONCOGENE, V21, P5929, DOI 10.1038/sj.onc.1205757; Kawamura M, 1996, ONCOGENE, V12, P2361; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; Linke SP, 2003, CANCER RES, V63, P2596; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; Mirza A, 2003, ONCOGENE, V22, P3645, DOI 10.1038/sj.onc.1206477; Notterman D, 1998, ONCOGENE, V17, P2743, DOI 10.1038/sj.onc.1202210; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Saintigny Y, 2002, ONCOGENE, V21, P488, DOI 10.1038/sj.onc.1205040; Sar F, 2004, J BIOL CHEM, V279, P39289, DOI 10.1074/jbc.M405793200; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Subramanian D, 2002, NUCLEIC ACIDS RES, V30, P2427, DOI 10.1093/nar/30.11.2427; Sugikawa E, 1999, ANTICANCER RES, V19, P3099; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang Y, 2000, GENE DEV, V14, P927; Willers H, 2000, INT J RADIAT BIOL, V76, P1055; Willers H, 2000, ONCOGENE, V19, P632, DOI 10.1038/sj.onc.1203142; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; Yang Q, 2002, J BIOL CHEM, V277, P31980, DOI 10.1074/jbc.M204111200; Yoon D, 2004, J MOL BIOL, V336, P639, DOI 10.1016/j.jmb.2003.12.050; Zhao RB, 2000, GENE DEV, V14, P981; Zhou JM, 2003, NUCLEIC ACIDS RES, V31, P3881, DOI 10.1093/nar/gkg468	37	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42568	42572		10.1074/jbc.M506348200	http://dx.doi.org/10.1074/jbc.M506348200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16204246	Green Published, hybrid			2022-12-25	WOS:000234200800013
J	Sakurai, H; Bush, KT; Nigam, SK				Sakurai, H; Bush, KT; Nigam, SK			Heregulin induces glial cell line-derived neurotrophic growth factor-independent, non-branching growth and differentiation of ureteric bud epithelia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-GLAND; DEVELOPING KIDNEY; IN-VITRO; MORPHOGENESIS; IDENTIFICATION; PROLIFERATION; NEUREGULINS; REQUIREMENT; LIGAND; ERBB3	We have purified a protein present in a conditioned medium derived from the metanephric mesenchyme that supports non-branching growth and epithelial differentiation of the isolated ureteric bud ( UB) independent of glial cell line-derived neurotrophic growth factor ( GDNF). By sequential liquid chromatography, together with protein microsequencing, the protein was identified as heregulin( HRG)alpha. The addition of recombinant HRG to the isolated UB grown in three-dimensional culture confirmed the proliferative activity of HRG. In branching UBs induced by whole metanephric mesenchyme cell-conditioned medium, proliferating cells were localized at ampullae, where a binding receptor for GDNF, GFR alpha 1, was found. In HRG-induced UBs, however, the expression of GFR alpha 1 was down-regulated, and proliferating cells were distributed throughout the structure. Electron microscopic examination of the HRG-induced UB revealed the presence of structurally mature and polarized epithelial cells reminiscent of the epithelial cells found in the stalk portion of the branching UB. cDNA array analysis further revealed that genes ontologically classified as developmental were down-regulated by HRG, whereas those involved in transport were up-regulated. For example, the mRNA for the GDNF receptors, GFR alpha 1 and ret9, was down-regulated, whereas the mRNA for collecting duct transporters, such as urea transporter2, aquaporin3, and sodium-hydrogen exchanger2 was up-regulated in HRG-treated UBs compared with UBs grown in the presence of branch-promoting factors. Moreover, HRG promoted growth of UBs cultured in the absence of GDNF. Taken together, the data suggest that HRG supports UB epithelial cell differentiation and non-GDNF- dependent growth, raising the possibility that this kind of activity plays a role in the growth and differentiation of the stalk portion of the branching epithelial UB.	Univ Calif San Diego, Dept Med, Div Nephrol Hypertens, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Cellular & Mol Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Nigam, SK (corresponding author), Univ Calif San Diego, Dept Med, Div Nephrol Hypertens, 9500 Gilman Dr,0693, La Jolla, CA 92093 USA.	snigam@ucsd.edu			NIDDK NIH HHS [DK57286] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057286] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Britsch S, 1998, GENE DEV, V12, P1825, DOI 10.1101/gad.12.12.1825; Bush KT, 2004, DEV BIOL, V266, P285, DOI 10.1016/j.ydbio.2003.10.023; Doniger SW, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-1-r7; Erickson SL, 1997, DEVELOPMENT, V124, P4999; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Kramer R, 1996, P NATL ACAD SCI USA, V93, P4833, DOI 10.1073/pnas.93.10.4833; Lemke G, 1996, MOL CELL NEUROSCI, V7, P247, DOI 10.1006/mcne.1996.0019; Li L, 2002, ONCOGENE, V21, P4900, DOI 10.1038/sj.onc.1205634; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; Meyer TN, 2004, DEV BIOL, V275, P44, DOI 10.1016/j.ydbio.2004.07.022; Michael L, 2004, J ANAT, V204, P241, DOI 10.1111/j.0021-8782.2004.00285.x; Miyazaki Y, 2000, J CLIN INVEST, V105, P863, DOI 10.1172/JCI8256; Niemann C, 1998, J CELL BIOL, V143, P533, DOI 10.1083/jcb.143.2.533; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; Qiao J, 2001, MECH DEVELOP, V109, P123, DOI 10.1016/S0925-4773(01)00592-5; Qiao JZ, 1999, P NATL ACAD SCI USA, V96, P7330, DOI 10.1073/pnas.96.13.7330; Sakural H, 2001, DEVELOPMENT, V128, P3283; Shakya R, 2005, DEV CELL, V8, P65, DOI 10.1016/j.devcel.2004.11.008; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	20	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42181	42187		10.1074/jbc.M507962200	http://dx.doi.org/10.1074/jbc.M507962200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16183643	hybrid			2022-12-25	WOS:000233992700046
J	Bullock, AN; Debreczeni, J; Amos, AL; Knapp, S; Turk, BE				Bullock, AN; Debreczeni, J; Amos, AL; Knapp, S; Turk, BE			Structure and substrate specificity of the Pim-1 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; RECOGNITION MOTIFS; CRYSTAL-STRUCTURE; PEPTIDE; PHOSPHORYLATION; EXPRESSION; INHIBITOR; LEUKEMIA; MYC; IDENTIFICATION	The Pim kinases are a family of three vertebrate protein serine/threonine kinases (Pim-1, -2, and -3) belonging to the CAMK (calmodulin-dependent protein kinase-related) group. Pim kinases are emerging as important mediators of cytokine signaling pathways in hematopoietic cells, and they contribute to the progression of certain leukemias and solid tumors. A number of cytoplasmic and nuclear proteins are phosphorylated by Pim kinases and may act as their effectors in normal physiology and in disease. Recent crystallographic studies of Pim-1 have identified unique structural features but have not provided insight into how the kinase recognizes its target substrates. Here, we have conducted peptide library screens to exhaustively determine the sequence specificity of active site-mediated phosphorylation by Pim-1 and Pim-3. We have identified the major site of Pim-1 autophosphorylation and find surprisingly that it maps to a novel site that diverges from its consensus phosphorylation motif. We have solved the crystal structure of Pim-1 bound to a high affinity peptide substrate in complexes with either the ATP analog AMP-PNP or the bisindolylmaleimide kinase inhibitor 2-[1-(3-dimethylaminopropyl)-1H-indol-3- yl]-3-(1H-indol3-yl) maleimide HCl. These structures reveal an unanticipated mode of recognition for basic residues upstream of the phosphorylation site, distinct from that of other kinases with similar substrate specificity. The structures provide a rationale for the unusually high affinity of Pim kinases for peptide substrates and suggest a general mode for substrate binding to members of the CAMK group.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Univ Oxford, Ctr Struct Genom, Botnar Res Ctr, Oxford OX3 7LD, England	Yale University; University of Oxford	Turk, BE (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, POB 208066,333 Cedar St, New Haven, CT 06520 USA.	ben.turk@yale.edu	Knapp, Stefan/AAG-2347-2019	Knapp, Stefan/0000-0001-5995-6494	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503; Aho TLT, 2004, FEBS LETT, V571, P43, DOI 10.1016/j.febslet.2004.06.050; Akasaka H, 2000, CANCER RES, V60, P2335; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Allen JD, 1997, ONCOGENE, V15, P1133, DOI 10.1038/sj.onc.1201288; AMSON R, 1989, P NATL ACAD SCI USA, V86, P8857, DOI 10.1073/pnas.86.22.8857; Bachmann M, 2005, INT J BIOCHEM CELL B, V37, P726, DOI 10.1016/j.biocel.2004.11.005; Bachmann M, 2004, J BIOL CHEM, V279, P48319, DOI 10.1074/jbc.M404440200; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BREUER ML, 1989, EMBO J, V8, P743, DOI 10.1002/j.1460-2075.1989.tb03434.x; Brown NR, 1999, NAT CELL BIOL, V1, P438, DOI 10.1038/15674; BULLOCK AN, 2005, IN PRESS J MED CHEM; Chen XP, 2002, P NATL ACAD SCI USA, V99, P2175, DOI 10.1073/pnas.042035699; Cohen AM, 2004, LEUKEMIA LYMPHOMA, V45, P951, DOI 10.1080/10428190310001641251; CUYPERS HT, 1984, CELL, V37, P141; DALE S, 1995, FEBS LETT, V361, P191, DOI 10.1016/0014-5793(95)00172-6; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; DOMEN J, 1993, BLOOD, V82, P1445; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Evans P. R., 1993, P CCP4 STUD WEEK DAT, P114; Fox CJ, 2005, J EXP MED, V201, P259, DOI 10.1084/jem.20042020; Fox CJ, 2003, GENE DEV, V17, P1841, DOI 10.1101/gad.1105003; FRIEDMANN M, 1992, ARCH BIOCHEM BIOPHYS, V298, P594, DOI 10.1016/0003-9861(92)90454-5; Fujii C, 2005, INT J CANCER, V114, P209, DOI 10.1002/ijc.20719; Fujii K, 2004, P NATL ACAD SCI USA, V101, P13744, DOI 10.1073/pnas.0401881101; Giles F, 2005, BLOOD, V105, P4158, DOI 10.1182/blood-2005-03-1150; Hammerman PS, 2005, BLOOD, V105, P4477, DOI 10.1182/blood-2004-09-3706; Hammerman PS, 2004, CANCER RES, V64, P8341, DOI 10.1158/0008-5472.CAN-04-2284; Hutti JE, 2004, NAT METHODS, V1, P27, DOI 10.1038/NMETH708; Jacobs MD, 2005, J BIOL CHEM, V280, P13728, DOI 10.1074/jbc.M413155200; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Koike N, 2000, FEBS LETT, V467, P17, DOI 10.1016/S0014-5793(00)01105-4; Kumar A, 2005, J MOL BIOL, V348, P183, DOI 10.1016/j.jmb.2005.02.039; Leslie AGW, 1992, JOINT CCP4 ESF EAMCB, V26; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; Lowe ED, 1997, EMBO J, V16, P6646, DOI 10.1093/emboj/16.22.6646; MADHUSUDAN, 1994, PROTEIN SCI, V3, P176; Manke IA, 2005, MOL CELL, V17, P37, DOI 10.1016/j.molcel.2004.11.021; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Mikkers H, 2004, MOL CELL BIOL, V24, P6104, DOI 10.1128/MCB.24.13.6104-6115.2004; Mikkers H, 2002, NAT GENET, V32, P459, DOI 10.1038/ng1102-459b; Mochizuki T, 1999, J BIOL CHEM, V274, P18659, DOI 10.1074/jbc.274.26.18659; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Palaty CK, 1997, J BIOL CHEM, V272, P10514; Palaty CK, 1997, BIOCHEM CELL BIOL, V75, P153, DOI 10.1139/bcb-75-2-153; Parang K, 2002, PHARMACOL THERAPEUT, V93, P145, DOI 10.1016/S0163-7258(02)00184-5; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Qian KC, 2005, J BIOL CHEM, V280, P6130, DOI 10.1074/jbc.M409123200; Rainio EM, 2002, J IMMUNOL, V168, P1524, DOI 10.4049/jimmunol.168.4.1524; Ross H, 2002, BIOCHEM J, V366, P977, DOI 10.1042/BJ20020786; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; TESSMER GW, 1977, J BIOL CHEM, V252, P5666; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; Wang Z, 2001, J Vet Sci, V2, P167; Wang ZP, 2002, BBA-MOL CELL RES, V1593, P45, DOI 10.1016/S0167-4889(02)00347-6; White RR, 1998, J BIOL CHEM, V273, P3166, DOI 10.1074/jbc.273.6.3166; Winn LM, 2003, CELL CYCLE, V2, P258, DOI 10.4161/cc.2.3.383; Yan B, 2003, J BIOL CHEM, V278, P45358, DOI 10.1074/jbc.M307933200; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; Zhu GZ, 2005, J BIOL CHEM, V280, P10743, DOI 10.1074/jbc.M413159200; Zhu N, 2002, J IMMUNOL, V168, P744, DOI 10.4049/jimmunol.168.2.744	65	153	160	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41675	41682		10.1074/jbc.M510711200	http://dx.doi.org/10.1074/jbc.M510711200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16227208	hybrid, Green Published			2022-12-25	WOS:000233866900068
J	Rocha, HAO; Moraes, FA; Trindade, ES; Franco, CRC; Torquato, RJS; Veiga, SS; Valente, AP; Mourao, PAS; Leite, EL; Nader, HB; Dietrich, CP				Rocha, HAO; Moraes, FA; Trindade, ES; Franco, CRC; Torquato, RJS; Veiga, SS; Valente, AP; Mourao, PAS; Leite, EL; Nader, HB; Dietrich, CP			Structural and hemostatic activities of a sulfated galactofucan from the brown alga Spatoglossum schroederi - An ideal antithrombotic agent?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE; ACIDIC MUCOPOLYSACCHARIDES; ANTICOAGULANT ACTIVITY; CELL-ADHESION; FUCANS; POLYSACCHARIDES; FUCOIDAN; IDENTIFICATION; PROTEOGLYCAN; FEATURES	The brown alga Spatoglossum schroederi contains three fractions of sulfated polysaccharides. One of them was purified by acetone fractionation, ion exchange, and molecular sieving chromatography. It has a molecular size of 21.5 kDa and contains fucose, xylose, galactose, and sulfate in a molar ratio of 1.0:0.5:2.0:2.0 and contains trace amounts of glucuronic acid. Chemical analyses, methylation studies, and NMR spectroscopy showed that the polysaccharide has a unique structure, composed of a central core formed mainly by 4-linked beta-galactose units, partially sulfated at the 3-O position. Approximately 25% of these units contain branches of oligosaccharides (mostly tetrasaccharides) composed of 3-sulfated, 4-linked alpha-fucose and one or two nonsulfated, 4-linked beta-xylose units at the reducing and nonreducing end, respectively. This sulfated galacto-fucan showed no anticoagulant activity on several "in vitro" assays. Nevertheless, it had a potent antithrombotic activity on an animal model of experimental venous thrombosis. This effect is time-dependent, reaching the maximum 8 h after its administration compared with the more transient action of heparin. The effect was not observed with the desulfated molecule. Furthermore, the sulfated galactofucan was 2-fold more potent than heparin in stimulating the synthesis of an antithrombotic heparan sulfate by endothelial cells. Again, this action was also abolished by desulfation of the polysaccharide. Because this sulfated galactofucan has no anticoagulant activity but strongly stimulates the synthesis of heparan sulfate by endothelial cells, we suggested that this last effect may be related to the "in vivo" antithrombotic activity of this polysaccharide. In this case the highly sulfated heparan sulfate produced by the endothelial cells is in fact the antithrombotic agent. Our results suggested that this sulfated galactofucan may have a potential application as an antithrombotic drug.	Univ Fed Sao Paulo, Escola Paulista Med, Dept Bioquim, BR-04044020 Sao Paulo, Brazil; Univ Fed Rio Grande do Norte, Dept Bioquim, Lab Biotecnol Polimeros Nat BIOPOL, BR-59072970 Natal, RN, Brazil; Univ Fed Parana, Dept Biol Celular, BR-83531990 Curitiba, Parana, Brazil; Univ Fed Rio de Janeiro, Inst Bioquim Med, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Univ Hosp, BR-21941590 Rio De Janeiro, Brazil	Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal do Rio Grande do Norte; Universidade Federal do Parana; Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro	Nader, HB (corresponding author), Univ Fed Sao Paulo, Escola Paulista Med, Dept Bioquim, Rua 3 Maio 100, BR-04044020 Sao Paulo, Brazil.	hbnader.bioq@epm.br	Trindade, Edvaldo S/AAL-6275-2020; Rocha, Hugo Alexandre Oliveira/X-6410-2019; Mourao, Paulo/AAA-5386-2020; Nader, Helena Bonciani/D-9253-2012; Veiga, Silvio Sanches/C-2194-2013; Valente, Ana Paula/J-3010-2017; de Oliveira Rocha, Hugo Alexandre/I-5130-2019; Rocha, Hugo Alexandre Oliveira/X-6411-2019	Trindade, Edvaldo S/0000-0002-8051-6298; Rocha, Hugo Alexandre Oliveira/0000-0003-2252-1221; Veiga, Silvio Sanches/0000-0002-9691-1225; Valente, Ana Paula/0000-0001-7219-1123; NADER, HELENA/0000-0002-7569-2166				Albuquerque IRL, 2004, BRAZ J MED BIOL RES, V37, P167, DOI 10.1590/S0100-879X2004000200002; Berteau O, 2003, GLYCOBIOLOGY, V13, p29R, DOI 10.1093/glycob/cwg058; BIANCHINI P, 1980, J CHROMATOGR, V196, P455, DOI 10.1016/S0021-9673(00)84747-0; Boisson-Vidal C., 1995, Drugs of the Future, V20, P1237; BUONASSISI V, 1976, P NATL ACAD SCI USA, V73, P1612, DOI 10.1073/pnas.73.5.1612; Campos ITN, 2004, ARCH BIOCHEM BIOPHYS, V425, P87, DOI 10.1016/j.abb.2004.03.004; Chevolot L, 1999, CARBOHYD RES, V319, P154, DOI 10.1016/S0008-6215(99)00127-5; Chizhov AO, 1999, CARBOHYD RES, V320, P108, DOI 10.1016/S0008-6215(99)00148-2; COLBURN P, 1982, BIOCHEM BIOPH RES CO, V104, P220, DOI 10.1016/0006-291X(82)91962-3; COLLIEC S, 1991, THROMB RES, V64, P143, DOI 10.1016/0049-3848(91)90114-C; Dietrich CP, 1998, CELL MOL BIOL, V44, P417; DIETRICH CP, 1977, J CHROMATOGR, V130, P299, DOI 10.1016/S0021-9673(00)89809-X; Dietrich CP, 1999, SEMIN THROMB HEMOST, V25, P43; DIETRICH CP, 1995, PLANT SCI, V108, P143, DOI 10.1016/0168-9452(95)04142-H; Dietrich CP, 1999, BBA-GEN SUBJECTS, V1428, P273, DOI 10.1016/S0304-4165(99)00087-2; Dische Z., 1962, METHODS CARBOHYDRATE, V1, P501; Dische Z, 1962, METHODS CARBOHYDRATE, V1, P484; Dische Z., 1962, METHODS CARBOHYDRATE, V1, P497; Duarte MER, 2001, CARBOHYD RES, V333, P281, DOI 10.1016/S0008-6215(01)00149-5; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Farias WRL, 2000, J BIOL CHEM, V275, P29299, DOI 10.1074/jbc.M002422200; Haroun-Bouhedja F, 2002, ANTICANCER RES, V22, P2285; HOFFMAN DL, 1989, AM J MED, V87, pS23, DOI 10.1016/0002-9343(89)80527-3; HUSSEIN MMD, 1980, PHYTOCHEMISTRY, V19, P2133; KIRCHER HW, 1960, ANAL CHEM, V32, P1103, DOI 10.1021/ac60165a016; KLOAREG B, 1988, OCEANOGR MAR BIOL, V26, P259; KOZAKAI M, 1975, ANAL BIOCHEM, V78, P425; Leite EL, 1998, PLANT SCI, V132, P215, DOI 10.1016/S0168-9452(98)00012-0; Logeart D, 1997, EUR J CELL BIOL, V74, P385; Maes E, 1997, GLYCOCONJUGATE J, V14, P127, DOI 10.1023/A:1018577302255; Marais MF, 2001, CARBOHYD RES, V336, P155, DOI 10.1016/S0008-6215(01)00257-9; MEDCALF DG, 1977, CARBOHYD RES, V59, P531, DOI 10.1016/S0008-6215(00)83190-0; Moll S, 2002, SEMIN HEMATOL, V39, P145, DOI 10.1053/shem.2002.34087; Mourao PAS, 2004, CURR PHARM DESIGN, V10, P967, DOI 10.2174/1381612043452730; Mulloy B, 2000, J BIOTECHNOL, V77, P123, DOI 10.1016/S0168-1656(99)00211-4; Nader HB, 2004, CURR PHARM DESIGN, V10, P951, DOI 10.2174/1381612043452758; NADER HB, 1990, J BIOL CHEM, V265, P16807; NADER HB, 1977, ANAL BIOCHEM, V78, P112, DOI 10.1016/0003-2697(77)90014-8; NADER HB, 1989, J CELL PHYSIOL, V140, P305, DOI 10.1002/jcp.1041400216; Nagaoka M, 1999, GLYCOCONJUGATE J, V16, P19, DOI 10.1023/A:1006945618657; PATANKAR MS, 1993, J BIOL CHEM, V268, P21770; Pereira MS, 1999, J BIOL CHEM, V274, P7656, DOI 10.1074/jbc.274.12.7656; Pinhal MAS, 2001, THROMB RES, V103, P35, DOI 10.1016/S0049-3848(01)00274-2; PINHAL MAS, 1994, THROMB RES, V74, P143, DOI 10.1016/0049-3848(94)90007-8; Ponce NMA, 2003, CARBOHYD RES, V338, P153, DOI 10.1016/S0008-6215(02)00403-2; Porcionatto MA, 1998, J CELL BIOCHEM, V70, P563, DOI 10.1002/(SICI)1097-4644(19980915)70:4<563::AID-JCB12>3.0.CO;2-I; Preeprame S, 2001, CHEM PHARM BULL, V49, P484, DOI 10.1248/cpb.49.484; REYERS I, 1980, THROMB RES, V18, P669, DOI 10.1016/0049-3848(80)90221-2; Rocha HAO, 2001, BRAZ J MED BIOL RES, V34, P621, DOI 10.1590/S0100-879X2001000500009; SANTOS J, 1991, EUR J BIOCHEM, V91, P669; Schaeffer DJ, 2000, ECOTOX ENVIRON SAFE, V45, P208, DOI 10.1006/eesa.1999.1862; Shanmugam M, 2000, CURR SCI INDIA, V79, P1672; SPECTOR T, 1978, ANAL BIOCHEM, V86, P142, DOI 10.1016/0003-2697(78)90327-5; Teleman A, 2000, CARBOHYD RES, V329, P807, DOI 10.1016/S0008-6215(00)00249-4; Vilela-Silva ACES, 2002, J BIOL CHEM, V277, P379, DOI 10.1074/jbc.M108496200; 2003, NATL VITAL STAT REPO, V51, P4	56	119	130	1	17	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41278	41288		10.1074/jbc.M501124200	http://dx.doi.org/10.1074/jbc.M501124200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16174777	hybrid			2022-12-25	WOS:000233866900022
J	Shaner, L; Wegele, H; Buchner, J; Morano, KA				Shaner, L; Wegele, H; Buchner, J; Morano, KA			The yeast Hsp110 Sse1 functionally interacts with the Hsp70 chaperones Ssa and Ssb	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; MOLECULAR CHAPERONES; SACCHAROMYCES-CEREVISIAE; HSP105-ALPHA SUPPRESSES; ENDOPLASMIC-RETICULUM; NASCENT CHAIN; IN-VIVO; EXPRESSION; SSE1; TRANSLOCATION	There is growing evidence that members of the extended Hsp70 family of molecular chaperones, including the Hsp110 and Grp170 subgroups, collaborate in vivo to carry out essential cellular processes. However, relatively little is known regarding the interactions and cellular functions of Sse1, the yeast Hsp110 homolog. Through co-immunoprecipitation analysis, we found that Sse1 forms heterodimeric complexes with the abundant cytosolic Hsp70s Ssa and Ssb in vivo. Furthermore, these complexes can be efficiently reconstituted in vitro using purified proteins. Binding of Ssa or Ssb to Sse1 was mutually exclusive. The ATPase domain of Sse1 was found to be critical for interaction as inactivating point mutations severely reduced interaction with Ssa and Ssb. Sse1 stimulated Ssa1 ATPase activity synergistically with the co-chaperone Ydj1, and stimulation required complex formation. Ssa1 is required for post-translational translocation of the yeast mating pheromone alpha-factor into the endoplasmic reticulum. Like ssa mutants, we demonstrate that sse1 Delta cells accumulate prepro-alpha-factor, but not the co-translationally imported protein Kar2, indicating that interaction between Sse1 and Ssa is functionally significant in vivo. These data suggest that the Hsp110 chaperone operates in concert with Hsp70 in yeast and that this collaboration is required for cellular Hsp70 functions.	Univ Texas, Sch Med, Dept Microbiol & Mol Genet, Houston, TX 77030 USA; Roche Diagnost GmbH, Pharma Dev, D-82377 Penzberg, Germany; Tech Univ Munich, Inst Organ Chem & Biochem, D-85757 Garching, Germany	University of Texas System; Roche Holding; Technical University of Munich	Morano, KA (corresponding author), Univ Texas, Sch Med, Dept Microbiol & Mol Genet, 6431 Fannin St, Houston, TX 77030 USA.	kevin.a.morano@uth.tmc.edu	Gimenez, Luis E Diaz/D-9291-2011; Buchner, Johannes/A-2651-2010	Morano, Kevin/0000-0002-5992-0253; Buchner, Johannes/0000-0003-1282-7737				Becker J, 1996, MOL CELL BIOL, V16, P4378; Brodsky JL, 1999, J BIOL CHEM, V274, P3453, DOI 10.1074/jbc.274.6.3453; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; CYR DM, 1992, J BIOL CHEM, V267, P20927; Easton DP, 2000, CELL STRESS CHAPERON, V5, P276, DOI 10.1379/1466-1268(2000)005<0276:THAGSP>2.0.CO;2; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Gautschi M, 2002, P NATL ACAD SCI USA, V99, P4209, DOI 10.1073/pnas.062048599; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Goeckeler JL, 2002, MOL BIOL CELL, V13, P2760, DOI 10.1091/mbc.02-04-0051; Hainzl O, 2004, J BIOL CHEM, V279, P23267, DOI 10.1074/jbc.M402189200; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; HERSKOWITZ I, 1991, P132; Huang P, 2005, NAT STRUCT MOL BIOL, V12, P497, DOI 10.1038/nsmb942; Hundley H, 2002, P NATL ACAD SCI USA, V99, P4203, DOI 10.1073/pnas.062048399; Ishihara K, 2003, J BIOL CHEM, V278, P25143, DOI 10.1074/jbc.M302975200; Ishihara K, 1999, BBA-GENE STRUCT EXPR, V1444, P138, DOI 10.1016/S0167-4781(98)00254-1; James P, 1997, SCIENCE, V275, P387, DOI 10.1126/science.275.5298.387; Kabani M, 2002, MOL CELL BIOL, V22, P4677, DOI 10.1128/MCB.22.13.4677-4689.2002; Liu XD, 1999, J BIOL CHEM, V274, P26654, DOI 10.1074/jbc.274.38.26654; Mayer MP, 2002, ADV PROTEIN CHEM, V59, P1; McClellan AJ, 2000, GENETICS, V156, P501; MUKAI H, 1993, GENE, V132, P57; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; Oh HJ, 1999, J BIOL CHEM, V274, P15712, DOI 10.1074/jbc.274.22.15712; Oh HJ, 1997, J BIOL CHEM, V272, P31636, DOI 10.1074/jbc.272.50.31636; Oka M, 1998, J BIOL CHEM, V273, P29727, DOI 10.1074/jbc.273.45.29727; Pfund C, 1998, EMBO J, V17, P3981, DOI 10.1093/emboj/17.14.3981; Pfund C, 2001, MOL BIOL CELL, V12, P3773, DOI 10.1091/mbc.12.12.3773; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Shaner L, 2004, J BIOL CHEM, V279, P21992, DOI 10.1074/jbc.M313739200; SHIRAYAMA M, 1993, MOL GEN GENET, V240, P323, DOI 10.1007/BF00280382; Slepenkov SV, 2002, MOL MICROBIOL, V45, P1197, DOI 10.1046/j.1365-2958.2002.03093.x; Steel GJ, 2004, SCIENCE, V303, P98, DOI 10.1126/science.1092287; Tomashek JJ, 1996, J BIOL CHEM, V271, P10397, DOI 10.1074/jbc.271.17.10397; Trott A, 2005, GENETICS, V170, P1009, DOI 10.1534/genetics.105.043109; Wang XY, 2000, FEBS LETT, V465, P98, DOI 10.1016/S0014-5793(99)01733-0; Wegele H, 2003, J CHROMATOGR B, V786, P109, DOI 10.1016/S1570-0232(02)00724-9; Wegele H, 2003, J BIOL CHEM, V278, P25970, DOI 10.1074/jbc.M301548200; WERNERWASHBURNE M, 1987, MOL CELL BIOL, V7, P2568, DOI 10.1128/MCB.7.7.2568; Yam AYW, 2005, J BIOL CHEM, V280, P41252, DOI 10.1074/jbc.M503615200; Yamagishi N, 2004, J BIOL CHEM, V279, P41727, DOI 10.1074/jbc.M407947200	43	78	80	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41262	41269		10.1074/jbc.M503614200	http://dx.doi.org/10.1074/jbc.M503614200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16221677	hybrid			2022-12-25	WOS:000233866900020
J	Sivaraja, V; Kumar, TKS; Leena, PST; Chang, AN; Vidya, C; Goforth, RL; Rajalingam, D; Arvind, K; Ye, JL; Chou, J; Henry, R; Yu, C				Sivaraja, V; Kumar, TKS; Leena, PST; Chang, AN; Vidya, C; Goforth, RL; Rajalingam, D; Arvind, K; Ye, JL; Chou, J; Henry, R; Yu, C			Three-dimensional solution structures of the chromodomains of cpSRP43	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; ISOTHERMAL TITRATION CALORIMETRY; CHROMO DOMAIN; PROTEIN-IMPORT; NMR; BINDING; CHLOROPLASTS; REPEATS; YEAST	Chloroplasts contain a unique signal recognition particle (cpSRP). Unlike the cytoplasmic forms, the cpSRP lacks RNA but contains a conserved 54-kDa GTPase and a novel 43-kDa subunit (cpSRP43). Recently, three functionally distinct chromodomains (CDs) have been identified in cpSRP43. In the present study, we report the three-dimensional solution structures of the three CDs (CD1, CD2, and CD3) using a variety of triple resonance NMR experiments. The structure of CD1 consists of a triple-stranded beta-sheet segment. The C-terminal helical segment typically found in the nuclear chromodomains is absent in CD1. The secondary structural elements in CD2 and CD3 include a triple-stranded antiparallel beta-sheet and a C-terminal helix. Interestingly, the orientation of the C-terminal helix is significantly different in the structures of CD2 and CD3. Critical comparison of the structures of the chromodomains of cpSRP43 with those found in nuclear chromodomain proteins revealed that the diverse protein-protein interactions mediated by the CDs appear to stem from the differences that exist in the surface charge potentials of each CD. Results of isothermal titration calorimetry experiments confirmed that only CD2 is involved in binding to cpSRP54. The negatively charged C-terminal helix in CD2 possibly plays a crucial role in the cpSRP54-cpSRP43 interaction.	Univ Arkansas, Dept Chem & Biochem, Fayetteville, AR 72701 USA; Natl Tsing Hua Univ, Dept Chem, Hsinchu 30043, Taiwan; Univ Arkansas, Dept Biol Sci, Fayetteville, AR 72701 USA; Xiamen Univ, Dept Chem, Coll Chem & Chem Engn, Fujian, Peoples R China; Gentara Corp, Malvern, PA 19355 USA	University of Arkansas System; University of Arkansas Fayetteville; National Tsing Hua University; University of Arkansas System; University of Arkansas Fayetteville; Xiamen University	Yu, C (corresponding author), Univ Arkansas, Dept Chem & Biochem, Chem 101, Fayetteville, AR 72701 USA.	cyu@uark.edu	Kumar, Dr Suresh/HHZ-2615-2022; Ye, JL/G-4597-2010; KUMAR, P. SURESH/AAT-8951-2020; Kumar, Suresh Thallapuranam/R-5606-2016	Kumar, Dr Suresh/0000-0002-2539-6553; KUMAR, P. SURESH/0000-0003-3222-2604; Kumar, Suresh Thallapuranam/0000-0001-7262-1373	PHS HHS [1 P20] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Ball LJ, 1997, EMBO J, V16, P2473, DOI 10.1093/emboj/16.9.2473; BAUMANN H, 1995, J MOL BIOL, V247, P840, DOI 10.1006/jmbi.1995.0184; BAX A, 1991, Journal of Biomolecular NMR, V1, P99, DOI 10.1007/BF01874573; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cline K., 2003, LIGHT HARVESTING ANT, P353; Eichacker LA, 2001, BBA-MOL CELL RES, V1541, P120, DOI 10.1016/S0167-4889(01)00151-3; Eissenberg JC, 2001, GENE, V275, P19, DOI 10.1016/S0378-1119(01)00628-X; Elcock AH, 2001, J PHYS CHEM B, V105, P1504, DOI 10.1021/jp003602d; Funke S, 2005, J BIOL CHEM, V280, P8912, DOI 10.1074/jbc.M409992200; GLORE GM, 1994, METHOD ENZYMOL, V239, P349; GODDERD TD, SPARKY3; Goforth RL, 2004, J BIOL CHEM, V279, P43077, DOI 10.1074/jbc.M401600200; Groves MR, 2001, J BIOL CHEM, V276, P27778, DOI 10.1074/jbc.M103470200; Heringa J, 1998, CURR OPIN STRUC BIOL, V8, P338, DOI 10.1016/S0959-440X(98)80068-7; Horita DA, 2001, J MOL BIOL, V307, P861, DOI 10.1006/jmbi.2001.4515; Jonas-Straube E, 2001, J BIOL CHEM, V276, P24654, DOI 10.1074/jbc.M100153200; KAY LE, 1994, J MAGN RESON SER A, V109, P129, DOI 10.1006/jmra.1994.1145; KEELER J, 1994, METHOD ENZYMOL, V239, P145; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Mosavi LK, 2004, PROTEIN SCI, V13, P1435, DOI 10.1110/ps.03554604; Nielsen PR, 2005, J BIOL CHEM, V280, P32326, DOI 10.1074/jbc.M501347200; Nielsen PR, 2002, NATURE, V416, P103, DOI 10.1038/nature722; Pool MR, 2005, MOL MEMBR BIOL, V22, P3, DOI 10.1080/09687860400026348; Schnell DJ, 2000, ESSAYS BIOCHEM, V36, P47, DOI 10.1042/bse0360047; Schunemann D, 2004, CURR GENET, V44, P295, DOI 10.1007/s00294-003-0450-z; Soll J, 2004, NAT REV MOL CELL BIO, V5, P198, DOI 10.1038/nrm1333; Sreerama N, 2004, METHOD ENZYMOL, V383, P318; Turnbull WB, 2003, J AM CHEM SOC, V125, P14859, DOI 10.1021/ja036166s; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; Zhang T, 2003, BIOPHYS J, V85, P3279, DOI 10.1016/S0006-3495(03)74746-8	35	22	24	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41465	41471		10.1074/jbc.M507077200	http://dx.doi.org/10.1074/jbc.M507077200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16183644	hybrid			2022-12-25	WOS:000233866900044
J	Yagi, T; Minoura, I; Fujiwara, A; Saito, R; Yasunaga, T; Hirono, M; Kamiya, R				Yagi, T; Minoura, I; Fujiwara, A; Saito, R; Yasunaga, T; Hirono, M; Kamiya, R			An axonemal dynein particularly important for flagellar movement at high viscosity - Implications from a new Chlamydomonas mutant deficient in the dynein heavy chain gene DHC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNER-ARM DYNEIN; MICROTUBULE-BINDING; REGULATORY-COMPLEX; BENDING PATTERNS; RADIAL SPOKES; ORGANIZATION; MOTOR; CILIA; TRANSLOCATION; REINHARDTII	Ciliary and flagellar axonemes contain multiple inner arm dyneins of which the functional difference is largely unknown. In this study, a Chlamydomonas mutant, ida9, lacking inner arm dynein c was isolated and shown to carry a mutation in the DHC9 dynein heavy chain gene. The cDNA sequence of DHC9 was determined, and its information was used to show that > 80% of it is lost in the mutant. Electron microscopy and image analysis showed that the ida9 axoneme lacked electron density near the base of the S2 radial spoke, indicating that dynein c localizes to this site. The mutant ida9 swam only slightly slower than the wild type in normal media. However, swimming velocity was greatly reduced when medium viscosity was modestly increased. Thus, dynein c in wild type axonemes must produce a significant force when flagella are beating in viscous media. Because motility analyses in vitro have shown that dynein c is the fastest among all the inner arm dyneins, we can regard this dynein as a fast yet powerful motor.	Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Tokyo 1130033, Japan; Natl Inst Basic Biol, Okazaki, Aichi 4448585, Japan; Kyushu Inst Technol, Dept Biochem Engn & Sci, Iizuka, Fukuoka 8208502, Japan; Japan Sci & Technol Corp, Kawaguchi 3320012, Japan	University of Tokyo; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Kyushu Institute of Technology; Japan Science & Technology Agency (JST)	Kamiya, R (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biol Sci, 7-3-1 Hongo, Tokyo 1130033, Japan.	kamiyar@biol.s.u-tokyo.ac.jp	Minoura, Itsushi/GNH-5436-2022; Hirono, Masafumi/G-5140-2013; HIRONO, MASAFUMI/G-4948-2014; Yasunaga, Takuo/C-8316-2009	Hirono, Masafumi/0000-0002-2497-4227; HIRONO, MASAFUMI/0000-0002-2497-4227; Yasunaga, Takuo/0000-0002-2494-9603				AFZELIUS BA, 1985, CRC CR REV BIOCH MOL, V19, P63, DOI 10.3109/10409238509086788; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BROKAW CJ, 1983, J SUBMICR CYTOL PATH, V15, P5; Brokaw CJ, 1999, CELL MOTIL CYTOSKEL, V42, P134, DOI 10.1002/(SICI)1097-0169(1999)42:2<134::AID-CM5>3.0.CO;2-B; BROKAW CJ, 1985, CELL MOTIL CYTOSKEL, V5, P195, DOI 10.1002/cm.970050303; BROKAW CJ, 1987, CELL MOTIL CYTOSKEL, V8, P68, DOI 10.1002/cm.970080110; BROKAW CJ, 1994, CELL MOTIL CYTOSKEL, V28, P199, DOI 10.1002/cm.970280303; Brokaw CJ, 2001, BIOPHYS J, V81, P1333, DOI 10.1016/S0006-3495(01)75790-6; Burgess SA, 2003, NATURE, V421, P715, DOI 10.1038/nature01377; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DiBella LM, 2001, INT REV CYTOL, V210, P227; FERNANDEZ E, 1989, P NATL ACAD SCI USA, V86, P6449, DOI 10.1073/pnas.86.17.6449; GARDNER LC, 1994, J CELL BIOL, V127, P1311, DOI 10.1083/jcb.127.5.1311; Gee MA, 1997, NATURE, V390, P636, DOI 10.1038/37663; Gibbons IR, 2005, J BIOL CHEM, V280, P23960, DOI 10.1074/jbc.M501636200; GOODENOUGH UW, 1985, J CELL BIOL, V100, P2008, DOI 10.1083/jcb.100.6.2008; GOODENOUGH UW, 1987, J MOL BIOL, V194, P481, DOI 10.1016/0022-2836(87)90676-0; Harris E.H., 1989, CHLAMYDOMONAS SOURCE, P1; HUANG B, 1979, J BIOL CHEM, V254, P3091; KAGAMI O, 1992, J CELL SCI, V103, P653; KAMIYA R, 1988, J CELL BIOL, V107, P2253, DOI 10.1083/jcb.107.6.2253; KAMIYA R, 1991, J CELL BIOL, V112, P441, DOI 10.1083/jcb.112.3.441; Kamiya R, 2002, INT REV CYTOL, V219, P115; KAMIYA R, 1995, CELL MOTIL CYTOSKEL, V32, P98, DOI 10.1002/cm.970320205; Kamiya R, 2000, METHODS, V22, P383, DOI 10.1006/meth.2000.1090; KATO T, 1993, CELL STRUCT FUNCT, V18, P371, DOI 10.1247/csf.18.371; KatoMinoura T, 1997, J CELL BIOL, V137, P649, DOI 10.1083/jcb.137.3.649; KING SJ, 1994, J CELL BIOL, V126, P1255, DOI 10.1083/jcb.126.5.1255; King SM, 2000, J CELL SCI, V113, P2521; Kon T, 2004, BIOCHEMISTRY-US, V43, P11266, DOI 10.1021/bi048985a; Koonce MP, 1997, J BIOL CHEM, V272, P19714, DOI 10.1074/jbc.272.32.19714; KURIMOTO E, 1991, CELL MOTIL CYTOSKEL, V19, P275, DOI 10.1002/cm.970190406; LEDIZET M, 1995, MOL BIOL CELL, V6, P697, DOI 10.1091/mbc.6.6.697; MASTRONARDE DN, 1992, J CELL BIOL, V118, P1145, DOI 10.1083/jcb.118.5.1145; MINOURA I, 1995, CELL MOTIL CYTOSKEL, V31, P130, DOI 10.1002/cm.970310205; Mitchell DR, 2000, J PHYCOL, V36, P261, DOI 10.1046/j.1529-8817.2000.99218.x; MUTO E, 1991, J CELL SCI, V99, P57; Myster SH, 1997, MOL BIOL CELL, V8, P607, DOI 10.1091/mbc.8.4.607; Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; Okada Y, 1999, SCIENCE, V283, P1152, DOI 10.1126/science.283.5405.1152; Pazour GJ, 2005, J CELL BIOL, V170, P103, DOI 10.1083/jcb.200504008; Perrone CA, 2000, MOL BIOL CELL, V11, P2297, DOI 10.1091/mbc.11.7.2297; Perrone CA, 1998, MOL BIOL CELL, V9, P3351, DOI 10.1091/mbc.9.12.3351; PIPERNO G, 1990, J CELL BIOL, V110, P379, DOI 10.1083/jcb.110.2.379; PIPERNO G, 1994, J CELL BIOL, V125, P1109, DOI 10.1083/jcb.125.5.1109; Porter ME, 1996, GENETICS, V144, P569; Porter ME, 1996, CURR OPIN CELL BIOL, V8, P10, DOI 10.1016/S0955-0674(96)80042-1; Porter ME, 2000, J CELL BIOL, V151, pF37, DOI 10.1083/jcb.151.5.F37; Sakakibara H, 1998, J CELL SCI, V111, P1155; Sakakibara H, 1999, NATURE, V400, P586, DOI 10.1038/23066; Sambrook J., 2001, MOL CLONING LAB MANU; SMITH EF, 1991, CELL MOTIL CYTOSKEL, V18, P258, DOI 10.1002/cm.970180403; TAM LW, 1993, GENETICS, V135, P375; WEEKS DP, 1986, ANAL BIOCHEM, V152, P376, DOI 10.1016/0003-2697(86)90423-9; Witman George B., 1994, V13, P229; Yanagisawa H, 2001, BIOCHEM BIOPH RES CO, V288, P443, DOI 10.1006/bbrc.2001.5776; Yasunaga T, 1996, J STRUCT BIOL, V116, P155, DOI 10.1006/jsbi.1996.0025; Yoshida T, 2002, J MOL BIOL, V315, P73, DOI 10.1006/jmbi.2001.5220; Zhang YJ, 2002, J BIOL CHEM, V277, P17906, DOI 10.1074/jbc.M200348200	59	85	85	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41412	41420		10.1074/jbc.M509072200	http://dx.doi.org/10.1074/jbc.M509072200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16236707	hybrid			2022-12-25	WOS:000233866900038
J	Gaidarov, I; Zhao, YQ; Keen, JH				Gaidarov, I; Zhao, YQ; Keen, JH			Individual phosphoinositide 3-kinase C2 alpha domain activities independently regulate clathrin function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II PHOSPHOINOSITIDE 3-KINASE; ASSEMBLY PROTEIN AP-2; PHOSPHATIDYLINOSITOL 3-KINASE; ADAPTER COMPLEX; COATED VESICLES; CELL-MIGRATION; C2 DOMAIN; ENDOCYTOSIS; RECEPTORS; C2-ALPHA	Phosphoinositide 3-kinase C2 alpha (PI3K-C2 alpha) is a member of the class II PI-3 kinases, defined by the presence of a second C2 domain at their C termini. The cellular functions of the class II enzymes are incompletely understood, though they have been implicated in receptor activation pathways initiated by epidermal growth factor, insulin, and chemokines. PI3K-C2 alpha was recently found to be localized to clathrin-coated membranes in the trans-Golgi network and at endocytic sites on the plasmamembrane. Further, a specific binding site was identified for clathrin on the N terminus of PI3K-C2 alpha, whose occupancy resulted in lipid kinase activation. Expression of PI3K-C2 alpha in cells dramatically affected clathrin distribution and function in cells, leading to accumulation of intracellular clathrin-coated structures, which are visualized here at the ultrastructural level, and inhibition of clathrin-mediated transport from both the plasma membrane and the trans-Golgi network. In this study we have demonstrated that the isolated clathrin binding domain of PI3K-C2 alpha can drive clathrin lattice assembly and that both it and the lipid kinase activity of the protein can independently modulate clathrin distribution and function when expressed in cells. Together, these results suggest that PI3K-C2 alpha employs both protein-protein interaction and localized production of 3-phosphoinositides to affect clathrin dynamics at sites of membrane budding and targeting.	Thomas Jefferson Univ, Dept Biochem & Mol Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Keen, JH (corresponding author), Thomas Jefferson Univ, Dept Biochem & Mol Biol, Philadelphia, PA 19107 USA.	jim.keen@mail.jci.tju.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049217] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-49217] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arcaro A, 2000, MOL CELL BIOL, V20, P3817, DOI 10.1128/MCB.20.11.3817-3830.2000; BECK KA, 1991, J BIOL CHEM, V266, P4442; BECK KA, 1991, J BIOL CHEM, V266, P4437; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Brown RA, 1999, J BIOL CHEM, V274, P14529, DOI 10.1074/jbc.274.21.14529; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; Didichenko SA, 2001, J BIOL CHEM, V276, P48135, DOI 10.1074/jbc.M104610200; Domin J, 1997, BIOCHEM J, V326, P139, DOI 10.1042/bj3260139; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; Domin J, 2000, J BIOL CHEM, V275, P11943, DOI 10.1074/jbc.275.16.11943; Engqvist-Goldstein AEY, 2003, ANNU REV CELL DEV BI, V19, P287, DOI 10.1146/annurev.cellbio.19.111401.093127; Gaidarov I, 2001, MOL CELL, V7, P443, DOI 10.1016/S1097-2765(01)00191-5; Gaidarov L, 2005, DEV CELL, V8, P801, DOI 10.1016/j.devcel.2005.05.013; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; Guilherme A, 2004, J BIOL CHEM, V279, P10593, DOI 10.1074/jbc.M307702200; Honing S, 2005, MOL CELL, V18, P519, DOI 10.1016/j.molcel.2005.04.019; Janmey PA, 2004, NAT REV MOL CELL BIO, V5, P658, DOI 10.1038/nrm1434; KEEN JH, 1987, J CELL BIOL, V105, P1989, DOI 10.1083/jcb.105.5.1989; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; Lemmon MA, 2003, TRAFFIC, V4, P201, DOI 10.1034/j.1600-0854.2004.00071.x; MacDougall LK, 2004, MOL CELL BIOL, V24, P796, DOI 10.1128/MCB.24.2.796-808.2004; Maffucci T, 2005, J CELL BIOL, V169, P789, DOI 10.1083/jcb.200408005; Merrifield CJ, 2004, TRENDS CELL BIOL, V14, P352, DOI 10.1016/j.tcb.2004.05.008; Owen DJ, 2004, ANNU REV CELL DEV BI, V20, P153, DOI 10.1146/annurev.cellbio.20.010403.104543; Paulhe F, 2002, BIOCHEM BIOPH RES CO, V297, P261, DOI 10.1016/S0006-291X(02)02065-X; Robinson MS, 2004, TRENDS CELL BIOL, V14, P167, DOI 10.1016/j.tcb.2004.02.002; Roth MG, 2004, PHYSIOL REV, V84, P699, DOI 10.1152/physrev.00033.2003; Santini F, 1996, J CELL BIOL, V132, P1025, DOI 10.1083/jcb.132.6.1025; SMITH RM, 1985, J CELL PHYSIOL, V123, P167, DOI 10.1002/jcp.1041230204; Song X, 2001, BIOCHEMISTRY-US, V40, P8940, DOI 10.1021/bi0155100; Turner SJ, 1998, J BIOL CHEM, V273, P25987, DOI 10.1074/jbc.273.40.25987; Virbasius JV, 1996, J BIOL CHEM, V271, P13304, DOI 10.1074/jbc.271.23.13304; Wenk MR, 2004, P NATL ACAD SCI USA, V101, P8262, DOI 10.1073/pnas.0401874101; Zhao XH, 2001, J CELL SCI, V114, P353	36	37	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40766	40772		10.1074/jbc.M507731200	http://dx.doi.org/10.1074/jbc.M507731200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16215232	hybrid			2022-12-25	WOS:000233666600046
J	Costachel, C; Coddeville, B; Latge, JP; Fontaine, T				Costachel, C; Coddeville, B; Latge, JP; Fontaine, T			Glycosylphosphatidylinositol-anchored fungal polysaccharide in Aspergillus fumigatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAS-LIQUID-CHROMATOGRAPHY; MASS-SPECTROMETRY; CELL-WALL; GLYCOSYLINOSITOL PHOSPHORYLCERAMIDE; INVASIVE ASPERGILLOSIS; PENICILLIUM-CHARLESII; CANDIDA-ALBICANS; YEAST FORMS; SPHINGOLIPIDS; GLYCOSPHINGOLIPIDS	Galactomannan is a characteristic polysaccharide of the human filamentous fungal pathogen Aspergillus fumigatus that can be used to diagnose invasive aspergillosis. In this study, we report the isolation of a galactomannan fraction associated to membrane preparations from A. fumigatus mycelium by a lipid anchor. Specific chemical and enzymatic degradations and mass spectrometry analysis showed that the lipid anchor is a glycosylphosphatidylinositol ( GPI). The lipid part is an inositol phosphoceramide containing mainly C-18-phytosphingosine and monohydroxylated lignoceric acid ( 20H-C-24:0 fatty acid). GPI glycan is a tetramannose structure linked to a glucosamine residue: Man alpha 1-2Man alpha 1-2Man alpha 1-6Man alpha 1-4GlcN. The galactomannan polymer is linked to the GPI structure throught the mannan chain. The GPI structure is a type 1, closely related to the one previously described for the GPI-anchored proteins of A. fumigatus. This is the first time that a fungal polysaccharide is shown to be GPI-anchored.	Inst Pasteur, Unite Aspergillus, F-75724 Paris, France; Univ Sci & Technol Lille, Chim Biol Lab, F-59655 Villeneuve Dascq, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universite de Lille - ISITE; Universite de Lille	Fontaine, T (corresponding author), Inst Pasteur, Unite Aspergillus, 25 Rue Dr Roux, F-75724 Paris, France.	tfontain@pasteur.fr	Latge, Jean Paul/C-9846-2014; Fontaine, thierry/Q-2201-2018; Fontaine, Thierry/F-8227-2011	Fontaine, thierry/0000-0002-8184-789X; 				AARONSON LR, 1983, BIOCHIM BIOPHYS ACTA, V735, P252, DOI 10.1016/0005-2736(83)90300-0; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; Aoki K, 2004, BIOCHEM J, V378, P461, DOI 10.1042/BJ20031307; BAR K, 1984, BIOCHEMISTRY-US, V23, P5581; Bennion B, 2003, J LIPID RES, V44, P2073, DOI 10.1194/jlr.M300184-JLR200; BJORNDAL H, 1970, ANGEW CHEM INT EDIT, V9, P610, DOI 10.1002/anie.197006101; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DEREPENTIGNY L, 1987, J CLIN MICROBIOL, V25, P863, DOI 10.1128/JCM.25.5.863-867.1987; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Ferguson M. A. J., 1993, GLYCOBIOLOGY, P349; Fontaine T, 2004, BIOCHEMISTRY-US, V43, P15267, DOI 10.1021/bi0486029; Fontaine T, 2003, GLYCOBIOLOGY, V13, P169, DOI 10.1093/glycob/cwg004; FONTAINE T, 1991, ANAL BIOCHEM, V199, P154, DOI 10.1016/0003-2697(91)90083-6; Fontaine T, 2000, J BIOL CHEM, V275, P27594; FOURNET B, 1981, ANAL BIOCHEM, V116, P489, DOI 10.1016/0003-2697(81)90393-6; Frankhauser C., 1993, J BIOL CHEM, V268, P26365; GANDER JE, 1974, J BIOL CHEM, V249, P2063; Hartland RP, 1996, J BIOL CHEM, V271, P26843, DOI 10.1074/jbc.271.43.26843; Heise N, 2002, GLYCOBIOLOGY, V12, P409, DOI 10.1093/glycob/cwf053; Ikuta K, 1997, BIOCHEM J, V323, P297, DOI 10.1042/bj3230297; Jennemann R, 2001, EUR J BIOCHEM, V268, P1190, DOI 10.1046/j.1432-1327.2001.01963.x; KLIS FM, 1994, YEAST, V10, P851, DOI 10.1002/yea.320100702; LATGE JP, 1994, INFECT IMMUN, V62, P5424; Latge JP, 1999, CLIN MICROBIOL REV, V12, P310, DOI 10.1128/CMR.12.2.310; Levery SB, 1998, BIOCHEMISTRY-US, V37, P8764, DOI 10.1021/bi9730083; Levery SB, 2001, RAPID COMMUN MASS SP, V15, P2240, DOI 10.1002/rcm.505; LEWIS KA, 1993, BIOCHEMISTRY-US, V32, P8836, DOI 10.1021/bi00085a014; Penhal CVLY, 2001, EUR J BIOCHEM, V268, P4243, DOI 10.1046/j.1432-1327.2001.02339.x; SAWARDEKAR JS, 1967, ANAL CHEM, V37, P1602; SCHNEIDER P, 1995, METHOD ENZYMOL, V250, P614; Schneider P, 1996, BIOCHEM J, V313, P963, DOI 10.1042/bj3130963; STYNEN D, 1995, J CLIN MICROBIOL, V33, P497, DOI 10.1128/JCM.33.2.497-500.1995; Toledo MS, 2001, FEBS LETT, V493, P50, DOI 10.1016/S0014-5793(01)02275-X; Treumann A, 1998, METH MOL B, V76, P213; Trinel PA, 2002, J BIOL CHEM, V277, P37260, DOI 10.1074/jbc.M202295200; TURCO SJ, 1989, J BIOL CHEM, V264, P6711; UNKEFER CJ, 1990, J BIOL CHEM, V265, P685; Wells GB, 1996, J BACTERIOL, V178, P6223, DOI 10.1128/jb.178.21.6223-6226.1996	38	71	73	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					39835	39842		10.1074/jbc.M510163200	http://dx.doi.org/10.1074/jbc.M510163200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16204227	hybrid			2022-12-25	WOS:000233461300021
J	Shen, HY; He, JC; Wang, YM; Huang, QY; Chen, JF				Shen, HY; He, JC; Wang, YM; Huang, QY; Chen, JF			Geldanamycin induces heat shock protein 70 and protects against MPTP-induced dopaminergic neurotoxicity in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SYNUCLEIN AGGREGATION; HEAT-SHOCK PROTEINS; PARKINSONS-DISEASE; IN-VIVO; MOLECULAR CHAPERONES; STRESS-RESPONSE; HUNTINGTONS-DISEASE; CEREBRAL-ISCHEMIA; INDUCIBLE HSP70; MOUSE MODEL	As key molecular chaperone proteins, heat shock proteins (HSPs) represent an important cellular protective mechanism against neuronal cell death in various models of neurological disorders. In this study, we investigated the effect as well as the molecular mechanism of geldanamycin (GA), an inhibitor of Hsp90, on 1-methyl-4-pheny1,2,3,6-tetrahydropyridine (MPTP)- induced dopaminergic neurotoxicity, amouse model of Parkinson disease. Neurochemical analysis showed that pretreatment with GA (via intracerebral ventricular injection 24 h prior to MPTP treatment) increased residual dopamine content and tyrosine hydroxylase immunoreactivity in the striatum 24 h after MPTP treatment. To dissect out the molecular mechanism underlying this neuroprotection, we showed that the GA-mediated protection against MPTP was associated with a reduction of cytosolic Hsp90 and an increase in Hsp70, with no significant changes in Hsp40 and Hsp25 levels. Furthermore, in parallel with the induction of Hsp70, striatal nuclear HSF1 levels and HSF1 binding to heat shock element sites in the Hsp70 promoter were significantly enhanced by the GA pretreatment. Together these results suggested that the molecular cascade leading to the induction of Hsp70 is critical to the neuroprotection afforded by GA against MPTP-induced neurotoxicity in the brain and that pharmacological inhibition of Hsp90 may represent a potential therapeutic strategy for Parkinson disease.	Boston Univ, Sch Med, Dept Neurol, Mol Neuropharmacol Lab, Boston, MA 02118 USA; Affiliated First Teaching Hosp, Dept Neurol, Wenzhou 325000, Peoples R China; Wenzhou Med Coll, Expt Neurobiol Res Inst, Wenzhou 325000, Peoples R China	Boston University; Wenzhou Medical University	Chen, JF (corresponding author), Boston Univ, Sch Med, Dept Neurol, Mol Neuropharmacol Lab, 715 Albany St,E301, Boston, MA 02118 USA.	chenjf@bu.edu		Chen, Jiang-Fan/0000-0002-0446-3956; Shen, Hai-Ying/0000-0001-8430-2978; Chen, Jiang-Fan/0000-0003-3582-3448	NINDS NIH HHS [NS41083, NS37403] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041083, R01NS037403] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		An WG, 2000, CELL GROWTH DIFFER, V11, P355; Auluck PK, 2005, J BIOL CHEM, V280, P2873, DOI 10.1074/jbc.M412106200; Auluck PK, 2002, NAT MED, V8, P1185, DOI 10.1038/nm1102-1185; Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Batulan Z, 2003, J NEUROSCI, V23, P5789; Bonini NM, 2002, P NATL ACAD SCI USA, V99, P16407, DOI 10.1073/pnas.152330499; Chen JF, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-10-j0001.2001; Chiosis G, 2004, DRUG DISCOV TODAY, V9, P881, DOI 10.1016/S1359-6446(04)03245-3; Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163-7258(98)00013-8; Cullen KE, 1997, J BIOL CHEM, V272, P1742, DOI 10.1074/jbc.272.3.1742; Cummings CJ, 2001, HUM MOL GENET, V10, P1511, DOI 10.1093/hmg/10.14.1511; Dabir DV, 2004, AM J PATHOL, V164, P155, DOI 10.1016/S0002-9440(10)63106-9; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Dedeoglu A, 2002, EXP NEUROL, V176, P262, DOI 10.1006/exnr.2002.7933; Dong ZZ, 2005, MOL THER, V11, P80, DOI 10.1016/j.ymthe.2004.09.007; Eiseman JL, 2005, CANCER CHEMOTH PHARM, V55, P21, DOI 10.1007/s00280-004-0865-3; Forman MS, 2004, NAT MED, V10, P1055, DOI 10.1038/nm1113; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Giffard RG, 2004, J EXP BIOL, V207, P3213, DOI 10.1242/jeb.01034; GORZOWSKI JJ, 1995, J BIOL CHEM, V270, P26940, DOI 10.1074/jbc.270.45.26940; Hansson O, 2003, BRAIN RES, V970, P47, DOI 10.1016/S0006-8993(02)04275-0; Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; KABAKOV AE, 1995, EXP CELL RES, V217, P15, DOI 10.1006/excr.1995.1058; Kalia SK, 2004, NEURON, V44, P931, DOI 10.1016/j.neuron.2004.11.026; Katsuno M, 2003, CYTOGENET GENOME RES, V100, P243, DOI 10.1159/000072860; Kiang JG, 2004, J APPL PHYSIOL, V97, P564, DOI 10.1152/japplphysiol.00194.2004; Klucken J, 2004, J BIOL CHEM, V279, P25497, DOI 10.1074/jbc.M400255200; Korczyn AD, 2002, DRUGS, V62, P775, DOI 10.2165/00003495-200262050-00005; Lang AE, 1998, NEW ENGL J MED, V339, P1130, DOI 10.1056/NEJM199810153391607; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; Lee JE, 2001, EXP NEUROL, V170, P129, DOI 10.1006/exnr.2000.7614; Lu AG, 2002, J NEUROCHEM, V81, P355, DOI 10.1046/j.1471-4159.2002.00835.x; McLean PJ, 2004, BIOCHEM BIOPH RES CO, V321, P665, DOI 10.1016/j.bbrc.2004.07.021; McLean PJ, 2002, J NEUROCHEM, V83, P846, DOI 10.1046/j.1471-4159.2002.01190.x; Millar DG, 2003, NAT MED, V9, P1469, DOI 10.1038/nm962; Moratalla R, 1996, NEURON, V17, P147, DOI 10.1016/S0896-6273(00)80288-3; Morimoto RI, 1998, NAT BIOTECHNOL, V16, P833, DOI 10.1038/nbt0998-833; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Neckers L, 1999, DRUG RESIST UPDATE, V2, P165, DOI 10.1054/drup.1999.0082; Olanow CW, 2004, ANNU REV MED, V55, P41, DOI 10.1146/annurev.med.55.091902.104422; Olsson T, 2004, EXP BRAIN RES, V154, P442, DOI 10.1007/s00221-003-1683-2; Planas AM, 1997, PROG NEUROBIOL, V51, P607, DOI 10.1016/S0301-0082(97)00004-X; Quigney DJ, 2003, BRAIN RES, V993, P133, DOI 10.1016/j.brainres.2003.09.004; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sittler A, 2001, HUM MOL GENET, V10, P1307, DOI 10.1093/hmg/10.12.1307; Wegele H, 2004, REV PHYSIOL BIOCH P, V151, P1, DOI 10.1007/s10254-003-0021-1; Winklhofer KF, 2001, J BIOL CHEM, V276, P45160, DOI 10.1074/jbc.M104873200; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Wu YR, 2004, HUM GENET, V114, P236, DOI 10.1007/s00439-003-1050-1; Wyttenbach A, 2002, HUM MOL GENET, V11, P1137, DOI 10.1093/hmg/11.9.1137; Xiao NQ, 1999, J NEUROCHEM, V72, P95, DOI 10.1046/j.1471-4159.1999.0720095.x; Yan LJ, 2002, EMBO J, V21, P5164, DOI 10.1093/emboj/cdf528; Yasmineh W G, 1974, Methods Cell Biol, V8, P151, DOI 10.1016/S0091-679X(08)60450-1; Zhou H, 2001, J BIOL CHEM, V276, P48417, DOI 10.1074/jbc.M104140200; Zourlidou A, 2004, J NEUROCHEM, V88, P1439, DOI 10.1046/j.1471-4159.2003.02273.x	56	145	157	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					39962	39969		10.1074/jbc.M505524200	http://dx.doi.org/10.1074/jbc.M505524200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16210323	hybrid			2022-12-25	WOS:000233461300035
J	Boonyaratanakornkit, JB; Cogoli, A; Li, CF; Schopper, T; Pippia, P; Galleri, G; Meloni, MA; Hughes-Fulford, M				Boonyaratanakornkit, JB; Cogoli, A; Li, CF; Schopper, T; Pippia, P; Galleri, G; Meloni, MA; Hughes-Fulford, M			Key gravity-sensitive signaling pathways drive T-cell activation	FASEB JOURNAL			English	Article						immune response; gene expression; signal transduction; microarray; microgravity	NF-KAPPA-B; PROTEIN-KINASE-C; GENE-EXPRESSION; RECEPTOR; MICROGRAVITY; LYMPHOCYTES; SPACEFLIGHT; TRANSLOCATION; TRANSCRIPTION; CYTOSKELETON	Returning astronauts have experienced altered immune function and increased vulnerability to infection during spaceflights dating back to Apollo and Skylab. Lack of immune response in microgravity occurs at the cellular level. We analyzed differential gene expression to find gravity-dependent genes and pathways. We found inhibited induction of 91 genes in the simulated freefall environment of the random positioning machine. Altered induction of 10 genes regulated by key signaling pathways was verified using real-time RT-PCR. We discovered that impaired induction of early genes regulated primarily by transcription factors NF-kappa B, CREB, ELK, AP-1, and STAT after crosslinking the T-cell receptor contributes to T-cell dysfunction in altered gravity environments. We have previously shown that PKA and PKC are key early regulators in T-cell activation. Since the majority of the genes were regulated by NF-kappa B, CREB, and AP-1, we studied the pathways that regulated these transcription factors. We found that the PKA pathway was down-regulated in vg. In contrast, PI3-K, PKC, and its upstream regulator pLAT were not significantly down-regulated by vectorless gravity. Since NF-kappa B, AP-1, and CREB are all regulated by PKA and are transcription factors predicted by microarray analysis to be involved in the altered gene expression in vectorless gravity, the data suggest that PKA is a key player in the loss of T-cell activation in altered gravity.	Univ Calif San Francisco, Lab Cell Growth, Dept Med, Vet Affairs Med Ctr, San Francisco, CA 94121 USA; Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA; Swiss Fed Inst Technol, CH-8005 Zurich, Switzerland; No Calif Inst Res & Educ, Lab Cell Growth, San Francisco, CA 94121 USA; Univ Sassari, Dept Physiol Biochem & Cellular Sci, I-07100 Sassari, Italy; Univ Calif San Francisco, Lab Cell Growth, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; Swiss Federal Institutes of Technology Domain; ETH Zurich; Northern California Institute for Research & Education; University of Sassari; University of California System; University of California San Francisco	Hughes-Fulford, M (corresponding author), Univ Calif San Francisco, Lab Cell Growth, Dept Med, Vet Affairs Med Ctr, 4150 Clement St,MC151F, San Francisco, CA 94121 USA.	millie.hughes-fulford@med.va.gov	Galleri, Grazia/AAD-3278-2021	Galleri, Grazia/0000-0001-5379-9387; Hughes-Fulford, Millie/0000-0002-0756-068X	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000083] Funding Source: NIH RePORTER; NCRR NIH HHS [M01RR00083-42] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Berry C., 1975, BIOMEDICAL RESULTS A, P43; CERDAN C, 1995, RES IMMUNOL, V146, P164, DOI 10.1016/0923-2494(96)80251-3; CHANDRASEKAR A, 1999, PAP METEOROL GEOPHYS, V50, P65, DOI DOI 10.2467/MRIPAPERS.50.65; COGOLI A, 1993, J LEUKOCYTE BIOL, V53, P569, DOI 10.1002/jlb.53.5.569; Cogoli A, 1997, Gravit Space Biol Bull, V10, P5; COGOLI A, 1984, SCIENCE, V225, P228, DOI 10.1126/science.6729481; Cristillo AD, 2003, BLOOD, V101, P216, DOI 10.1182/blood-2002-03-0697; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Frost LL, 2001, TOXICOL APPL PHARM, V172, P186, DOI 10.1006/taap.2001.9153; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Hamalainen HK, 2001, ANAL BIOCHEM, V299, P63, DOI 10.1006/abio.2001.5369; Hammond TG, 1999, NAT MED, V5, P359, DOI 10.1038/7331; Harrop JA, 1998, J BIOL CHEM, V273, P27548, DOI 10.1074/jbc.273.42.27548; Hatton JP, 1999, FASEB J, V13, pS23, DOI 10.1096/fasebj.13.9001.s23; Hoson T, 1997, PLANTA, V203, pS187, DOI 10.1007/PL00008108; Hughes-Fulford M, 2005, CELL SIGNAL, V17, P1111, DOI 10.1016/j.cellsig.2004.12.016; Hughes-Fulford M, 2003, ADV SPACE RES-SERIES, V32, P1585, DOI 10.1016/S0273-1177(03)90399-1; HUGHESFULFORD M, 2004, SCI STKE, V249, pRE12; HUIJSER RH, 2000, DESKTOP RPM NEW SMAL, P1; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Kim JO, 2003, FEBS LETT, V541, P163, DOI 10.1016/S0014-5793(03)00326-0; Kimzey SL, 1977, BIOMEDICAL RESULTS S, P248; Leach CS, 1977, BIOMEDICAL RESULTS S, P204; Lewis ML, 1998, FASEB J, V12, P1007, DOI 10.1096/fasebj.12.11.1007; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; MESSER G, 1990, Cytokine, V2, P389, DOI 10.1016/1043-4666(90)90046-V; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Pavlidis P, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2001-2-10-research0042; Pippia P, 1996, J BIOTECHNOL, V47, P215, DOI 10.1016/0168-1656(96)01387-9; Quackenbush J, 2001, NAT REV GENET, V2, P418, DOI 10.1038/35076576; Raychaudhuri S, 2000, Pac Symp Biocomput, P455; Schraven B, 1999, IMMUNOL TODAY, V20, P431, DOI 10.1016/S0167-5699(99)01519-4; Sciola L, 1999, ADV SPACE RES, V24, P801, DOI 10.1016/S0273-1177(99)00078-2; SHADDUCK RK, 1971, BLOOD-J HEMATOL, V38, P559, DOI 10.1182/blood.V38.5.559.559; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; TIXADOR R, 1985, ACTA ASTRONAUT, V12, P131, DOI 10.1016/0094-5765(85)90082-7; Tjandrawinata RR, 1997, FASEB J, V11, P493, DOI 10.1096/fasebj.11.6.9194530; Unsworth BR, 1998, NAT MED, V4, P901, DOI 10.1038/nm0898-901; WALTENBERGER J, 1998, ANGIOGENESIS, V2, P115; Wingender E, 2001, NUCLEIC ACIDS RES, V29, P281, DOI 10.1093/nar/29.1.281; Zhang WG, 2000, SEMIN IMMUNOL, V12, P35, DOI 10.1006/smim.2000.0205; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	45	108	118	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2020	+		10.1096/fj.05-3778fje	http://dx.doi.org/10.1096/fj.05-3778fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16210397	Bronze			2022-12-25	WOS:000232991100025
J	Hong, KM; Burdick, MD; Phillips, RJ; Heber, D; Strieter, RM				Hong, KM; Burdick, MD; Phillips, RJ; Heber, D; Strieter, RM			Characterization of human fibrocytes as circulating adipocyte progenitors and the formation of human adipose tissue in SCID mice	FASEB JOURNAL			English	Article						adipogenesis; chemokine	MESENCHYMAL STEM-CELLS; EXTRACELLULAR-MATRIX SUBSTRATA; PERIPHERAL-BLOOD FIBROCYTES; STROMAL-VASCULAR CELLS; BONE-MARROW STROMA; TGF-BETA; DIFFERENTIATION; ADIPOGENESIS; POPULATION; MODULATION	An increase in fat mass associated with obesity results from recruitment and differentiation of adipocyte progenitor cells. The precise origin of these cells is unknown, although accumulating evidence suggests that circulating stem cells can differentiate into cells of mesenchymal lineage. It is currently unclear whether a progenitor adipocyte population exists in circulation. One potential candidate is the fibrocyte, which may represent a common progenitor cell for several mesenchymal lineages. We demonstrate that these circulating progenitors become adipocytes when cultured under adipogenic conditions, with intracellular lipids accumulation and upregulation of proteins specific for adipocyte differentiation, including leptin, PPAR gamma, and FABP4. cDNA microarray analysis revealed gene clusters that were differentially regulated during adipogenesis of fibrocytes, which were similar to visceral and subcutaneous adipose tissue preadipocyte-to-adipocyte differentiation. Moreover, these progenitors engrafted and formed human adipose tissue following injection into SCID mice. Although fibrocytes express an array of chemokine receptors, we observed an up-regulation of CCR2 expression following fibrocytes differentiation into adipocytes, which was associated with increased chemotactic response to CCL2. This paradigm supports the notion that elevated CCL2 levels in visceral adipose tissue associated with Metabolic Syndrome is a chemotactic niche, whereby fibrocytes can home to and differentiate into adipocytes to perpetuate its tissue formation.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Ctr Human Nutr, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Strieter, RM (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Pulm & Crit Care Med, 900 Vet Ave,14-154 Warren Hall, Los Angeles, CA 90095 USA.	rstrieter@mednet.ucla.edu						Abe R, 2001, J IMMUNOL, V166, P7556, DOI 10.4049/jimmunol.166.12.7556; Bruun JM, 2005, J CLIN ENDOCR METAB, V90, P2282, DOI 10.1210/jc.2004-1696; BUCALA R, 1994, MOL MED, V1, P71, DOI 10.1007/bf03403533; Chesney J, 2000, Curr Rheumatol Rep, V2, P501, DOI 10.1007/s11926-000-0027-5; Chesney J, 1997, P NATL ACAD SCI USA, V94, P6307, DOI 10.1073/pnas.94.12.6307; Chesney J, 1998, J IMMUNOL, V160, P419; Choy L, 2000, J CELL BIOL, V149, P667, DOI 10.1083/jcb.149.3.667; D'Ippolito G, 2004, J CELL SCI, V117, P2971, DOI 10.1242/jcs.01103; Fukumura D, 2003, CIRC RES, V93, pE88, DOI 10.1161/01.RES.0000099243.20096.FA; Gaustad KG, 2004, BIOCHEM BIOPH RES CO, V314, P420, DOI 10.1016/j.bbrc.2003.12.109; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; Hausman GJ, 1996, J ANIM SCI, V74, P2117; Janderova L, 2003, OBES RES, V11, P65, DOI 10.1038/oby.2003.11; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534-5807(04)00075-9; Metz CN, 2003, CELL MOL LIFE SCI, V60, P1342, DOI 10.1007/s00018-003-2328-0; Mizuno Hiroshi, 2003, Journal of Nippon Medical School, V70, P300; O'Connor KC, 2003, BIOTECHNOL LETT, V25, P1967, DOI 10.1023/B:BILE.0000004386.08923.ab; PETRUSCHKE T, 1994, INT J OBESITY, V18, P532; Phillips RJ, 2004, J CLIN INVEST, V114, P438, DOI 10.1172/jci200420997; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; RAMIREZZACARIAS JL, 1992, HISTOCHEMISTRY, V97, P493, DOI 10.1007/BF00316069; SBARBATI R, 1991, BLOOD, V77, P764; Sekiya I, 2004, J BONE MINER RES, V19, P256, DOI 10.1359/JBMR.0301220; Sekiya I, 2002, STEM CELLS, V20, P530, DOI 10.1634/stemcells.20-6-530; SILVERMAN KJ, 1988, BIOCHEM BIOPH RES CO, V153, P347, DOI 10.1016/S0006-291X(88)81229-4; Simper D, 2002, CIRCULATION, V106, P1199, DOI 10.1161/01.CIR.0000031525.61826.A8; Sordella R, 2003, CELL, V113, P147, DOI 10.1016/S0092-8674(03)00271-X; SPIEGELMAN BM, 1983, CELL, V35, P657, DOI 10.1016/0092-8674(83)90098-3; Takahashi K, 2003, J BIOL CHEM, V278, P46654, DOI 10.1074/jbc.M309895200; Theise ND, 2000, HEPATOLOGY, V32, P11, DOI 10.1053/jhep.2000.9124; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Zhou SH, 2004, J BONE MINER RES, V19, P463, DOI 10.1359/JBMR.0301239; Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02-02-0105	36	99	106	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2005	19	11					2029	+		10.1096/fj.05-4295fje	http://dx.doi.org/10.1096/fj.05-4295fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16188961				2022-12-25	WOS:000232315700002
J	Ichimura, K; Mungall, AJ; Fiegler, H; Pearson, DM; Dunham, I; Carter, NP; Collins, VP				Ichimura, K; Mungall, AJ; Fiegler, H; Pearson, DM; Dunham, I; Carter, NP; Collins, VP			Small regions of overlapping deletions on 6q26 in human astrocytic tumours identified using chromosome 6 tile path array-CGH	ONCOGENE			English	Article						brain tumour; molecular cytogenetics; array-CGH; glioblastoma; astrocytoma	COMPARATIVE GENOMIC HYBRIDIZATION; RECESSIVE JUVENILE PARKINSONISM; SUPPRESSOR GENE; WAF1/CIP1 GENE; OVARIAN-CANCER; EXPRESSION; MUTATIONS; GLIOMAS; ABNORMALITIES; MICROARRAY	Deletions of chromosome 6 are a common abnormality in diverse human malignancies including astrocytic tumours, suggesting the presence of tumour suppressor genes (TSG). In order to help identify candidate TSGs, we have constructed a chromosome 6 tile path microarray. The array contains 1780 clones (778 P1-derived artificial chromosome and 1002 bacterial artificial chromosome) that cover 98.3% of the published chromosome 6 sequences. A total of 104 adult astrocytic tumours (10 diffuse astrocytomas, 30 anaplastic astrocytomas (AA), 64 glioblastomas (GB)) were analysed using this array. Single copy number change was successfully detected and the result was in general concordant with a microsatellite analysis. The pattern of copy number change was complex with multiple interstitial deletions/ gains. However, a predominance of telomeric 6q deletions was seen. Two small common and overlapping regions of deletion at 6q26 were identified. One was 1002 kb in size and contained PACRG and QKI, while the second was 199 kb and harbours a single gene, AR1D1B. The data show that the chromosome 6 tile path array is useful in mapping copy number changes with high resolution and accuracy. We confirmed the high frequency of chromosome 6 deletions in AA and GB, and identified two novel commonly deleted regions that may harbour TSGs.	Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Div Mol Histopathol, Cambridge CB2 2QQ, England; Wellcome Trust Sanger Inst, Cambridge, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Wellcome Trust Sanger Institute	Ichimura, K (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Div Mol Histopathol, Level 3,Lab Block,Box 231, Cambridge CB2 2QQ, England.	ki212@cam.ac.uk	Mungall, Andrew J./U-7067-2018	Mungall, Andrew J./0000-0002-0905-2742; Dunham, Ian/0000-0003-2525-5598	Cancer Research UK [A6618] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Cancer Research UK(Cancer Research UK); Wellcome Trust(Wellcome TrustEuropean Commission)		Acquati F, 2001, ONCOGENE, V20, P980, DOI 10.1038/sj.onc.1204178; Bentley DR, 2001, NATURE, V409, P942, DOI 10.1038/35057165; BHATIA K, 1995, CANCER RES, V55, P1431; BIGNER SH, 1988, CANCER RES, V48, P405; Buschges R, 1999, BRAIN PATHOL, V9, P435; Cesari R, 2003, P NATL ACAD SCI USA, V100, P5956, DOI 10.1073/pnas.0931262100; Chibon F, 2004, GENE CHROMOSOME CANC, V40, P32, DOI 10.1002/gcc.20012; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Cowell JK, 2004, CANCER GENET CYTOGEN, V151, P36, DOI 10.1016/j.cancergencyto.2003.09.012; Denison SR, 2003, GENE CHROMOSOME CANC, V38, P40, DOI 10.1002/gcc.10236; Ekong R, 2004, HUM MUTAT, V24, P76, DOI 10.1002/humu.20059; Fiegler H, 2003, GENE CHROMOSOME CANC, V36, P361, DOI 10.1002/gcc.10155; GAO X, 1995, ONCOGENE, V11, P1395; Hardy RJ, 1996, J NEUROSCI, V16, P7941; Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416; Ichimura K, 2000, CANCER RES, V60, P417; Ichimura K, 1996, ONCOGENE, V13, P1065; Ichimura K, 2004, J NEURO-ONCOL, V70, P137, DOI 10.1007/s11060-004-2747-2; Imai Y, 2003, J BIOL CHEM, V278, P51901, DOI 10.1074/jbc.M309655200; Ishkanian AS, 2004, NAT GENET, V36, P299, DOI 10.1038/ng1307; Kleihues P, 2000, PATHOLOGY GENETICS T; KOOPMANN J, 1995, BRIT J CANCER, V72, P1230, DOI 10.1038/bjc.1995.491; Li ZZ, 2002, JPN J CANCER RES, V93, P167, DOI 10.1111/j.1349-7006.2002.tb01255.x; Liu L, 2000, J NEUROPATH EXP NEUR, V59, P1087, DOI 10.1093/jnen/59.12.1087; Liu Y, 2002, BMC GENET, V3, DOI 10.1186/1471-2156-3-20; Miyakawa A, 2000, BRIT J CANCER, V82, P543; Mungall AJ, 2003, NATURE, V425, P805, DOI 10.1038/nature02055; Richards RI, 2001, TRENDS GENET, V17, P339, DOI 10.1016/S0168-9525(01)02303-4; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918; Seng TJ, 2005, GENE CHROMOSOME CANC, V43, P181, DOI 10.1002/gcc.20181; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Sonoki T, 2001, BLOOD, V98, P2837, DOI 10.1182/blood.V98.9.2837; Steinemann D, 2003, GENE CHROMOSOME CANC, V37, P421, DOI 10.1002/gcc.10231; Stewart CA, 2004, GENOME RES, V14, P1176, DOI 10.1101/gr.2188104; Tagawa H, 2004, CANCER RES, V64, P5948, DOI 10.1158/0008-5472.CAN-03-4056; Tchinda J, 2004, BRIT J HAEMATOL, V126, P495, DOI 10.1111/j.1365-2141.2004.05082.x; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Vissers LELM, 2003, AM J HUM GENET, V73, P1261, DOI 10.1086/379977; Wang XM, 2004, BIOCHEM J, V383, P319, DOI 10.1042/BJ20040524; West AB, 2003, J MOL BIOL, V326, P11, DOI 10.1016/S0022-2836(02)01376-1; Wu JI, 2002, P NATL ACAD SCI USA, V99, P4233, DOI 10.1073/pnas.072090399	43	53	54	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2006	25	8					1261	1271		10.1038/sj.onc.1209156	http://dx.doi.org/10.1038/sj.onc.1209156			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	015FO	16205629	Green Accepted			2022-12-25	WOS:000235537500013
J	Cancellotti, E; Wiseman, F; Tuzi, NL; Baybutt, H; Monaghan, P; Aitchison, L; Simpson, J; Manson, JC				Cancellotti, E; Wiseman, F; Tuzi, NL; Baybutt, H; Monaghan, P; Aitchison, L; Simpson, J; Manson, JC			Altered glycosylated PrP proteins can have different neuronal trafficking in brain but do not acquire scrapie-like properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NORMAL PRION PROTEIN; SINGLE AMINO-ACID; SPONGIFORM ENCEPHALOPATHY; INCUBATION-TIME; EXPRESSION; RESISTANT; MUTATION; RODENT; MICE; LOCALIZATION	N-Linked glycans have been shown to have an important role in the cell biology of a variety of cell surface glycoproteins, including PrP protein. It has been suggested that glycosylation of PrP can influence the susceptibility to transmissible spongiform encephalopathy and determine the characteristics of the many different strains observed in this particular type of disease. To understand the role of carbohydrates in influencing the PrP maturation, stability, and cell biology, we have produced and analyzed gene-targeted murine models expressing differentially glycosylated PrP. Transgenic mice carrying the PrP substitution threonine for asparagine 180 (G1) or threonine for asparagine 196 (G2) or both mutations combined (G3), which eliminate the first, second, and both glycosylation sites, respectively, have been generated by double replacement gene targeting. An in vivo analysis of altered PrP has been carried out in transgenic mouse brains, and our data show that the lack of glycans does not influence PrP maturation and stability. The presence of one chain of sugar is sufficient for the trafficking to the cell membrane, whereas the unglycosylated PrP localization is mainly intracellular. However, this altered cellular localization of PrP does not lead to any overt phenotype in the G3 transgenic mice. Most importantly, we found that, in vivo, unglycosylated PrP does not acquire the characteristics of the aberrant pathogenic form (PrPSc), as was previously reported using in vitro models.	Inst Anim Hlth, Neuropathogenesis Unit, Edinburgh EH9 3JF, Midlothian, Scotland; Univ Padua, Dept Histol Microbiol & Med Biotechnol, I-35100 Padua, Italy; Inst Anim Hlth, Woking GU24 0NF, Surrey, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; University of Edinburgh; University of Padua; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute	Cancellotti, E (corresponding author), Inst Anim Hlth, Neuropathogenesis Unit, Ogston Bldg,W Mains Rd, Edinburgh EH9 3JF, Midlothian, Scotland.	enrico.cancellotti@bbsrc.ac.uk	Wiseman, Frances K/M-4701-2014; Monaghan, Paul/H-1973-2013	Wiseman, Frances/0000-0001-9323-3548; manson, jean/0000-0002-0175-9890	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Barmada S, 2004, NEUROBIOL DIS, V16, P527, DOI 10.1016/j.nbd.2004.05.005; Barnard G, 2000, LUMINESCENCE, V15, P357, DOI 10.1002/1522-7243(200011/12)15:6<357::AID-BIO621>3.0.CO;2-V; Barron RM, 2003, J GEN VIROL, V84, P3165, DOI 10.1099/vir.0.19147-0; Barron RM, 2001, EMBO J, V20, P5070, DOI 10.1093/emboj/20.18.5070; BOLTON DC, 1985, J VIROL, V53, P596, DOI 10.1128/JVI.53.2.596-606.1985; Bruce ME, 2003, BRIT MED BULL, V66, P99, DOI 10.1093/bmb/66.1.99; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; Capellari Sabina, 2000, Journal of Alzheimer's Disease, V2, P27; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DeArmond SJ, 1999, J NEUROPATH EXP NEUR, V58, P1000, DOI 10.1097/00005072-199909000-00010; DeArmond SJ, 1997, NEURON, V19, P1337, DOI 10.1016/S0896-6273(00)80424-9; Ford MJ, 2002, NEUROSCIENCE, V111, P533, DOI 10.1016/S0306-4522(01)00603-0; Foster JD, 1996, VET REC, V139, P512, DOI 10.1136/vr.139.21.512; FRASER H, 1967, NATURE, V216, P1310, DOI 10.1038/2161310a0; Gambetti P, 2003, BRIT MED BULL, V66, P213, DOI 10.1093/bmb/66.1.213; Grasbon-Frodl E, 2004, ACTA NEUROPATHOL, V108, P476, DOI 10.1007/s00401-004-0913-4; Haeberle AM, 2000, MICROSC RES TECHNIQ, V50, P66, DOI 10.1002/1097-0029(20000701)50:1<66::AID-JEMT10>3.0.CO;2-3; Harris B, 2003, CLIO MED, V71, P85; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Korth C, 2000, J GEN VIROL, V81, P2555, DOI 10.1099/0022-1317-81-10-2555; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Laine J, 2001, EUR J NEUROSCI, V14, P47, DOI 10.1046/j.0953-816x.2001.01621.x; Lehmann S, 1997, J BIOL CHEM, V272, P21479, DOI 10.1074/jbc.272.34.21479; Li RL, 2000, J MOL BIOL, V301, P567, DOI 10.1006/jmbi.2000.3986; Lowe JB, 2003, ANNU REV BIOCHEM, V72, P643, DOI 10.1146/annurev.biochem.72.121801.161809; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; Manson JC, 1999, EMBO J, V18, P6855, DOI 10.1093/emboj/18.23.6855; MANSON JC, 1994, MOL NEUROBIOL, V8, P121, DOI 10.1007/BF02780662; MANSON JC, 2001, EXP REV MOL MED; Mironov A, 2003, J NEUROSCI, V23, P7183, DOI 10.1523/JNEUROSCI.23-18-07183.2003; Monaghan P, 2001, J MICROSC-OXFORD, V203, P223, DOI 10.1046/j.1365-2818.2001.00888.x; Moore RC, 1998, NAT GENET, V18, P118, DOI 10.1038/ng0298-118; Neuendorf E, 2004, J BIOL CHEM, V279, P53306, DOI 10.1074/jbc.M410796200; Nitrini R, 1997, ANN NEUROL, V42, P138, DOI 10.1002/ana.410420203; Peters PJ, 2003, J CELL BIOL, V162, P703, DOI 10.1083/jcb.200304140; Petersen RB, 1996, J BIOL CHEM, V271, P12661, DOI 10.1074/jbc.271.21.12661; Priola SA, 2001, EMBO J, V20, P6692, DOI 10.1093/emboj/20.23.6692; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; ROGERS M, 1990, Glycobiology, V1, P101, DOI 10.1093/glycob/1.1.101; Rouiller I, 1998, J VIROL, V72, P2373, DOI 10.1128/JVI.72.3.2373-2387.1998; Rudd PM, 1999, P NATL ACAD SCI USA, V96, P13044, DOI 10.1073/pnas.96.23.13044; Sales N, 1998, EUR J NEUROSCI, V10, P2464, DOI 10.1046/j.1460-9568.1998.00258.x; SELFRIDGE J, 1992, SOMAT CELL MOLEC GEN, V18, P325, DOI 10.1007/BF01235756; Sigurdson CJ, 2003, BRIT MED BULL, V66, P199, DOI 10.1093/bmb/66.1.199; STAHL N, 1990, BIOCHEMISTRY-US, V29, P5405, DOI 10.1021/bi00474a028; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; Stimson E, 1999, BIOCHEMISTRY-US, V38, P4885, DOI 10.1021/bi982330q; TARABOULOS A, 1992, MOL BIOL CELL, V3, P851, DOI 10.1091/mbc.3.8.851; Tuzi NL, 2004, GENESIS, V40, P1, DOI 10.1002/gene.20046; van Rheede T, 2003, MOL BIOL EVOL, V20, P111, DOI 10.1093/molbev/msg014; Vetrugno V, 1999, NEUROSCI LETT, V270, P41, DOI 10.1016/S0304-3940(99)00460-7; Wang XH, 2005, J BIOL CHEM, V280, P317, DOI 10.1074/jbc.M410649200; Will RG, 2003, BRIT MED BULL, V66, P255, DOI 10.1093/bmb/66.1.255; WILLISON K, 1989, CELL, V57, P621, DOI 10.1016/0092-8674(89)90131-1; Winklhofer KF, 2003, TRAFFIC, V4, P313, DOI 10.1034/j.1600-0854.2003.00088.x; Zanusso G, 1998, P NATL ACAD SCI USA, V95, P8812, DOI 10.1073/pnas.95.15.8812	58	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42909	42918		10.1074/jbc.M509557200	http://dx.doi.org/10.1074/jbc.M509557200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16219759	hybrid			2022-12-25	WOS:000234200800053
J	Berthold, CL; Moussatche, P; Richards, NGJ; Lindqvist, Y				Berthold, CL; Moussatche, P; Richards, NGJ; Lindqvist, Y			Structural basis for activation of the thiamin diphosphate-dependent enzyme oxalyl-CoA decarboxylase by adenosine diphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A DECARBOXYLASE; YEAST PYRUVATE DECARBOXYLASE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; OXALOBACTER-FORMIGENES; ACETOHYDROXYACID SYNTHASE; 3-DIMENSIONAL STRUCTURE; ACETOLACTATE SYNTHASE; BENZOYLFORMATE DECARBOXYLASE; MECHANISTIC IMPLICATIONS	Oxalyl-coenzyme A decarboxylase is a thiamin diphosphate-dependent enzyme that plays an important role in the catabolism of the highly toxic compound oxalate. We have determined the crystal structure of the enzyme from Oxalobacter formigenes from a hemi-hedrally twinned crystal to 1.73 angstrom resolution and characterized the steady-state kinetic behavior of the decarboxylase. The monomer of the tetrameric enzyme consists of three alpha/beta-type domains, commonly seen in this class of enzymes, and the thiamin diphosphate-binding site is located at the expected subunit-subunit interface between two of the domains with the cofactor bound in the conserved V-conformation. Although oxalyl-CoA decarboxylase is structurally homologous to acetohydroxyacid synthase, a molecule of ADP is bound in a region that is cognate to the FAD-binding site observed in acetohydroxyacid synthase and presumably fulfils a similar role in stabilizing the protein structure. This difference between the two enzymes may have physiological importance since oxalyl-CoA decarboxylation is an essential step in ATP generation in O. formigenes, and the decarboxylase activity is stimulated by exogenous ADP. Despite the significant degree of structural conservation between the two homologous enzymes and the similarity in catalytic mechanism to other thiamin diphosphate-dependent enzymes, the active site residues of oxalyl-CoA decarboxylase are unique. A suggestion for the reaction mechanism of the enzyme is presented.	Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Univ Florida, Dept Chem, Gainesville, FL 32611 USA	Karolinska Institutet; State University System of Florida; University of Florida	Lindqvist, Y (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.	ylva.lindqvist@ki.se	Lindqvist, Ylva/F-9009-2010	Moussatche, Patricia/0000-0003-4540-0609; Lindqvist, Ylva/0000-0003-3162-8661	NIDDK NIH HHS [DK61666] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK061666, R01DK061666] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AEvarsson A, 2000, STRUCTURE, V8, P277, DOI 10.1016/S0969-2126(00)00105-2; ALLISON MJ, 1985, ARCH MICROBIOL, V141, P1, DOI 10.1007/BF00446731; ALLISON MJ, 1986, J NUTR, V116, P455, DOI 10.1093/jn/116.3.455; ANANTHARAM V, 1989, J BIOL CHEM, V264, P7244; Arjunan P, 2002, BIOCHEMISTRY-US, V41, P5213, DOI 10.1021/bi0118557; Arjunan P, 1996, J MOL BIOL, V256, P590, DOI 10.1006/jmbi.1996.0111; BAETZ AL, 1990, J BACTERIOL, V172, P3537, DOI 10.1128/jb.172.7.3537-3540.1990; BAETZ AL, 1992, SYST APPL MICROBIOL, V15, P167, DOI 10.1016/S0723-2020(11)80087-1; BAETZ AL, 1989, J BACTERIOL, V171, P2605, DOI 10.1128/jb.171.5.2605-2608.1989; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bartlett GJ, 2003, J MOL BIOL, V331, P829, DOI 10.1016/S0022-2836(03)00734-4; Benner SA, 2000, RES MICROBIOL, V151, P97, DOI 10.1016/S0923-2508(00)00123-6; Berthold CL, 2006, BBA-PROTEINS PROTEOM, V1764, P122, DOI 10.1016/j.bbapap.2005.08.016; Bornemann S, 2002, NAT PROD REP, V19, P761, DOI 10.1039/b108916c; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHANG YY, 1988, J BACTERIOL, V170, P3937, DOI 10.1128/jb.170.9.3937-3945.1988; CHANG YY, 1993, J BIOL CHEM, V268, P3911; CROMARTIE TH, 1976, J BIOL CHEM, V251, P329; Dobritzsch D, 1998, J BIOL CHEM, V273, P20196, DOI 10.1074/jbc.273.32.20196; Duggleby RG, 2000, J BIOCHEM MOL BIOL, V33, P1; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Frank RAW, 2004, SCIENCE, V306, P872, DOI 10.1126/science.1101030; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; Gerlt JA, 2005, ARCH BIOCHEM BIOPHYS, V433, P59, DOI 10.1016/j.abb.2004.07.034; Gerlt JA, 2001, ANNU REV BIOCHEM, V70, P209, DOI 10.1146/annurev.biochem.70.1.209; Hasson MS, 1998, BIOCHEMISTRY-US, V37, P9918, DOI 10.1021/bi973047e; Hatch M, 2005, UROL RES, V33, P1, DOI 10.1007/s00240-004-0445-3; HATCH M, 1994, PFLUG ARCH EUR J PHY, V426, P101, DOI 10.1007/BF00374677; HAWKINS CF, 1989, FEBS LETT, V255, P77, DOI 10.1016/0014-5793(89)81064-6; Hirai T, 2002, NAT STRUCT BIOL, V9, P597, DOI 10.1038/nsb821; Hodgkinson A., 1977, OXALIC ACID BIOL MED; HORN F, 1983, J BIOL CHEM, V258, P6912; Hu QY, 2004, J AM CHEM SOC, V126, P68, DOI 10.1021/ja0390505; JAMES LF, 1972, CLIN TOXICOL, V5, P231, DOI 10.3109/15563657208991002; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jonsson S, 2004, J BIOL CHEM, V279, P36003, DOI 10.1074/jbc.M404873200; Jordan F, 2005, BIOORG CHEM, V33, P190, DOI 10.1016/j.bioorg.2005.02.001; Jordan F, 2003, NAT PROD REP, V20, P184, DOI 10.1039/b111348h; JORDAN F, 2004, THIAMINE CATALYTIC M, P173; Kern D, 1997, SCIENCE, V275, P67, DOI 10.1126/science.275.5296.67; Kim J, 2004, BIOCHEM J, V384, P59, DOI 10.1042/BJ20040427; LAROSSA RA, 1984, J BIOL CHEM, V259, P8753; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, JOINT CCP4 PLUS ESF, V26; LINDQVIST Y, 1992, EMBO J, V11, P2373, DOI 10.1002/j.1460-2075.1992.tb05301.x; LINDQVIST Y, 1993, CURR OPIN STRUC BIOL, V3, P896, DOI 10.1016/0959-440X(93)90153-C; Lu GG, 2000, EUR J BIOCHEM, V267, P861, DOI 10.1046/j.1432-1327.2000.01070.x; LUNG HY, 1994, J BACTERIOL, V176, P2468, DOI 10.1128/JB.176.8.2468-2472.1994; McCourt JA, 2005, BIOCHEMISTRY-US, V44, P2330, DOI 10.1021/bi047980a; MULLER YA, 1993, STRUCTURE, V1, P95, DOI 10.1016/0969-2126(93)90025-C; MULLER YA, 1993, SCIENCE, V259, P965, DOI 10.1126/science.8438155; Nakai T, 2004, J MOL BIOL, V337, P1011, DOI 10.1016/j.jmb.2004.02.011; Nemeria N, 2005, J BIOL CHEM, V280, P21473, DOI 10.1074/jbc.M502691200; NILSSON U, 1993, FEBS LETT, V326, P145, DOI 10.1016/0014-5793(93)81779-Y; Pang SS, 2002, J MOL BIOL, V317, P249, DOI 10.1006/jmbi.2001.5419; Pang SS, 2004, J BIOL CHEM, V279, P2242, DOI 10.1074/jbc.M304038200; Pang SS, 2004, ACTA CRYSTALLOGR D, V60, P153, DOI 10.1107/S0907444903025423; Pang SS, 2003, J BIOL CHEM, V278, P7639, DOI 10.1074/jbc.M211648200; Polovnikova ES, 2003, BIOCHEMISTRY-US, V42, P1820, DOI 10.1021/bi026490k; QUAYLE JR, 1963, BIOCHEM J, V87, P368, DOI 10.1042/bj0870368; REES DC, 1980, ACTA CRYSTALLOGR A, V36, P578, DOI 10.1107/S0567739480001234; Ricagno S, 2003, EMBO J, V22, P3210, DOI 10.1093/emboj/cdg333; RODBY RA, 1991, AM J MED, V90, P498; RUAN ZS, 1992, J BIOL CHEM, V267, P10537; Schellenberger A, 1998, BBA-PROTEIN STRUCT M, V1385, P177, DOI 10.1016/S0167-4838(98)00067-3; SCHNEIDER G, 1993, BIOORG CHEM, V21, P109, DOI 10.1006/bioo.1993.1012; Schneider G, 1998, BBA-PROTEIN STRUCT M, V1385, P387, DOI 10.1016/S0167-4838(98)00082-X; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Segel IH., 1993, ENZYME KINETICS BEHA; Sergienko EA, 2000, BIOCHEMISTRY-US, V39, P13862, DOI 10.1021/bi001214w; Sergienko EA, 2001, BIOCHEMISTRY-US, V40, P7382, DOI 10.1021/bi002857e; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Sidhu H, 1998, LANCET, V352, P1026, DOI 10.1016/S0140-6736(98)03038-4; Sidhu H, 1999, J AM SOC NEPHROL, V10, pS334; SINGH BK, 1995, PLANT CELL, V7, P935; Stewart CS, 2004, FEMS MICROBIOL LETT, V230, P1, DOI 10.1016/S0378-1097(03)00864-4; STORMER FC, 1967, J BIOL CHEM, V242, P1756; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; WILLIAMS HE, 1968, AM J MED, V45, P715, DOI 10.1016/0002-9343(68)90207-6; Yeates TO, 1997, METHOD ENZYMOL, V276, P344, DOI 10.1016/S0076-6879(97)76068-3	81	45	49	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41645	41654		10.1074/jbc.M509921200	http://dx.doi.org/10.1074/jbc.M509921200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16216870	hybrid			2022-12-25	WOS:000233866900065
J	Maric, J; Kiss, RS; Franklin, V; Marcel, YL				Maric, J; Kiss, RS; Franklin, V; Marcel, YL			Intracellular lipidation of newly synthesized apolipoprotein A-1 in primary murine hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; CASSETTE TRANSPORTER A1; CHICKEN LIVER; CELL-LINE; APOA-I; SECRETION; BIOSYNTHESIS; CHOLESTEROL; LIPIDS; PHOSPHORYLATION	Hepatocytes, which are the main site of apolipoprotein (apo) A-I and ATP-binding cassette transporter A1 (ABCA1) expression, are also the main source of circulating high density lipoprotein. Here we have characterized the intracellular lipidation of newly synthesized apoA-I, in primary hepatocytes cultured with [H-3] choline to label choline-phospholipids, low density lipoprotein-[H-3] cholesterol to label the cell surface, or [H-3] mevalonate to label de novo synthesized cholesterol. Phospholipidation of apoA-I is significant and most evident in endoplasmic reticulum (ER) and medial Golgi, both in the lumen and on the membrane fractions of the ER and medial Golgi. In the presence of cycloheximide, endogenous apoA-I is substantially phospholipidated intracellularly but acquires some additional lipid after export out of the cell. In cells labeled with low density lipoprotein-[H-3] cholesterol, intracellular cholesterol lipidation of apoA-I is entirely absent, but the secreted apoA-I rapidly accumulates cholesterol after secretion from the cell in the media. On the other hand, de novo synthesized cholesterol can lipidate apoA-I intracellularly. We also showed the interaction between apoA-I and ABCA1 in ER and Golgi fractions. In hepatocytes lacking ABCA1, lipidation by low density lipoprotein- cholesterol was significantly reduced at the plasma membrane, phospholipidation and lipidation by de novo synthesized sterols were both reduced in Golgi compartments, whereas ER lipidation remained mostly unchanged. Therefore, the early lipidation in ER is ABCA1 independent, but in contrast, the lipidation of apoA-I in Golgi and at the plasma membrane requires ABCA1. Thus, we demonstrated that apoA-I phospholipidation starts early in the ER and is partially dependent on ABCA1, with the bulk of lipidation by phospholipids and cholesterol occurring in the Golgi and at the plasmamembrane, respectively. Finally, we showed that the previously reported association of newly synthesized apoA-I and apoB (Zheng, H., Kiss, R. S., Franklin, V., Wang, M. D., Haidar, B., and Marcel, Y. L. (2005) J. Biol. Chem. 280, 21612 - 21621) occurs after secretion at the cell surface.	Univ Ottawa, Lipoprot & Atherosclerosis Res Grp, Inst Heart, Dept Biochem, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Dept Microbiol & Immunol, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Dept Pathol & Lab Med, Ottawa, ON K1Y 4W7, Canada	University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa	Marcel, YL (corresponding author), 40 Ruskin St, Ottawa, ON K1Y 4W7, Canada.	ylmarcel@ottawaheart.ca						Alaupovic P, 1987, Adv Exp Med Biol, V210, P7; ALAUPOVIC P, 1991, PROG LIPID RES, V30, P105, DOI 10.1016/0163-7827(91)90008-S; BANERJEE D, 1984, J CELL BIOL, V99, P1917, DOI 10.1083/jcb.99.6.1917; BANERJEE D, 1983, J CELL BIOL, V96, P651, DOI 10.1083/jcb.96.3.651; BELL RM, 1981, J LIPID RES, V22, P391; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRESLOW JL, 1985, ANNU REV BIOCHEM, V54, P699, DOI 10.1146/annurev.biochem.54.1.699; BRESLOW JL, 1987, AM HEART J, V113, P422, DOI 10.1016/0002-8703(87)90608-9; Cavelier LB, 2001, J BIOL CHEM, V276, P18046, DOI 10.1074/jbc.M100565200; Chisholm JW, 2002, J LIPID RES, V43, P36; COLEMAN R, 1978, J CELL BIOL, V76, P245, DOI 10.1083/jcb.76.1.245; DASHTI N, 1987, J LIPID RES, V28, P423; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; Fitzgerald ML, 2001, J BIOL CHEM, V276, P15137, DOI 10.1074/jbc.M100474200; Haidar B, 2002, J LIPID RES, V43, P2087, DOI 10.1194/jlr.M200235-JLR200; KENNEDY EP, 1961, FED PROC, V20, P934; Kiss RS, 2003, J BIOL CHEM, V278, P10119, DOI 10.1074/jbc.M300137200; Langmann T, 2003, CLIN CHEM, V49, P230, DOI 10.1373/49.2.230; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; MARCEL YL, 1987, J LIPID RES, V28, P768; MARCEL YL, 1991, J BIOL CHEM, V266, P3644; Martinez LO, 2003, J BIOL CHEM, V278, P37368, DOI 10.1074/jbc.M307161200; McManus DC, 2000, J BIOL CHEM, V275, P5043, DOI 10.1074/jbc.275.7.5043; MELIN B, 1984, BIOCHIM BIOPHYS ACTA, V795, P574, DOI 10.1016/0005-2760(84)90188-7; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Shelness GS, 2005, CURR OPIN LIPIDOL, V16, P325, DOI 10.1097/01.mol.0000169353.12772.eb; Singaraja RR, 2001, J BIOL CHEM, V276, P33969, DOI 10.1074/jbc.M102503200; Swift LL, 2001, J LIPID RES, V42, P218; Tang CR, 2004, J BIOL CHEM, V279, P7622, DOI 10.1074/jbc.M312571200; THRIFT RN, 1986, J LIPID RES, V27, P236; Timmins JM, 2005, J CLIN INVEST, V115, P1333, DOI 10.1172/JCI200523915; Tran K, 2002, J BIOL CHEM, V277, P31187, DOI 10.1074/jbc.M200249200; Tsujita M, 2005, J LIPID RES, V46, P154, DOI 10.1194/jlr.M400402-JLR200; Wellington CL, 2002, LAB INVEST, V82, P273, DOI 10.1038/labinvest.3780421; Yamauchi Y, 2003, J BIOL CHEM, V278, P47890, DOI 10.1074/jbc.M306258200; YAO ZM, 1994, BBA-LIPID LIPID MET, V1212, P152, DOI 10.1016/0005-2760(94)90249-6; Zheng H, 2005, J BIOL CHEM, V280, P21612, DOI 10.1074/jbc.m502200200	39	43	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					39942	39949		10.1074/jbc.M507733200	http://dx.doi.org/10.1074/jbc.M507733200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16204232	hybrid			2022-12-25	WOS:000233461300033
J	Kukolj, G; McGibbon, GA; McKercher, G; Marquis, M; Lefebvre, S; Thauvette, L; Gauthier, J; Goulet, S; Poupart, MA; Beaulieu, PL				Kukolj, G; McGibbon, GA; McKercher, G; Marquis, M; Lefebvre, S; Thauvette, L; Gauthier, J; Goulet, S; Poupart, MA; Beaulieu, PL			Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT RNA-POLYMERASE; CRYSTAL-STRUCTURE; SERINE-PROTEASE; ALLOSTERIC INHIBITORS; STRUCTURAL-ANALYSIS; REPLICATION; MECHANISM; CONFORMATIONS; RHINOVIRUS; DISCOVERY	The virally encoded NS5B RNA-dependent RNA polymerase has emerged as a prime target in the search for specific HCV antivirals. A series of benzimidazole 5-carboxamide compounds inhibit the cellular RNA replication of a HCV subgenomic replicon and we have advanced our understanding of this class of inhibitors through a combination of complementary approaches that include biochemical cross-linking experiments with a photoreactive analogue followed by mass spectrometry analysis of the enzyme. A novel binding site has been localized for these inhibitors at the junction of the thumb domain and the N-terminal finger loop. Furthermore, the isolation and characterization of resistant replicon mutants that co-localize to this region distinguished this class of compounds from other non-nucleoside NS5B inhibitors that bind to distinct allosteric sites. Resistant mutations that emerged with the benzimidazole 5-carboxamide and related compounds were found at three amino acid positions in the thumb domain: Pro(495) with substitutions to Ser, Leu, Ala, or Thr; Pro(496) substitutions to Ser or Ala; and a V499A substitution. Mutations at each of these positions conferred different levels of resistance to this drug class: the Pro(495) changes provided the greatest shifts in compound potency, followed by moderate changes in potency with the Pro(496) substitutions, and finally only minor shifts in potency with V499A. Combinations that include the benzimidazole 5-carboxamide polymerase inhibitors and compounds that bind other sites or other HCV targets, including HCV protease inhibitors, are complementary in cell culture models of HCV RNA replication at suppressing the emergence of resistant variants. This novel class of compounds and unique binding site expand the diversity of HCV antivirals currently under development and offer the potential to improve the treatment of chronic HCV infection.	Boehringer Ingelheim Canada Ltd, Res & Dev, Dept Biol Sci, Laval, PQ H7S 2G5, Canada; Boehringer Ingelheim Canada Ltd, Res & Dev, Dept Chem, Laval, PQ H7S 2G5, Canada	Boehringer Ingelheim; Boehringer Ingelheim	Kukolj, G (corresponding author), 2100 Rue Cunard, Laval, PQ H7S 2G5, Canada.	gkukolj@lav.boehringer-ingelheim.com						Ago H, 1999, STRUCTURE, V7, P1417, DOI 10.1016/S0969-2126(00)80031-3; Appleby TC, 2005, J VIROL, V79, P277, DOI 10.1128/JVI.79.1.277-288.2005; Beaulieu P. L., 2002, US Patent, Patent No. 06448281; Beaulieu Pierre L, 2004, Curr Opin Investig Drugs, V5, P838; Beaulieu PL, 2004, J MED CHEM, V47, P6884, DOI 10.1021/jm040134d; Beaulieu PL, 2004, BIOORG MED CHEM LETT, V14, P967, DOI 10.1016/j.bmcl.2003.12.032; Beaulieu PL, 2004, BIOORG MED CHEM LETT, V14, P119, DOI 10.1016/j.bmcl.2003.10.023; Beaulieu PL, 2003, SYNTHESIS-STUTTGART, P1683; Biswal BK, 2005, J BIOL CHEM, V280, P18202, DOI 10.1074/jbc.M413410200; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; Bressanelli S, 2002, J VIROL, V76, P3482, DOI 10.1128/JVI.76.7.3482-3492.2002; Butcher SJ, 2000, ACTA CRYSTALLOGR D, V56, P1473, DOI 10.1107/S0907444900010702; Butcher SJ, 2001, NATURE, V410, P235, DOI 10.1038/35065653; Carroll SS, 2003, J BIOL CHEM, V278, P11979, DOI 10.1074/jbc.M210914200; Choi KH, 2004, P NATL ACAD SCI USA, V101, P4425, DOI 10.1073/pnas.0400660101; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Davidson W, 2004, ANAL CHEM, V76, P2095, DOI 10.1021/ac035335o; De Francesco R, 2003, ANTIVIR RES, V58, P1, DOI 10.1016/S0166-3542(03)00028-7; Di Bisceglie AM, 1998, LANCET, V351, P351, DOI 10.1016/S0140-6736(97)07361-3; Di Marco S, 2005, J BIOL CHEM, V280, P29765, DOI 10.1074/jbc.M505423200; Faucher AM, 2004, ORG LETT, V6, P2901, DOI 10.1021/ol0489907; Ferrari E, 1999, J VIROL, V73, P1649, DOI 10.1128/JVI.73.2.1649-1654.1999; Ferrer-Orta C, 2004, J BIOL CHEM, V279, P47212, DOI 10.1074/jbc.M405465200; Hong Z, 2001, VIROLOGY, V285, P6, DOI 10.1006/viro.2001.0948; KUKOLJ G, 2002, Patent No. 67006874; Labonte P, 2002, J BIOL CHEM, V277, P38838, DOI 10.1074/jbc.M204657200; Lamarre D, 2003, NATURE, V426, P186, DOI 10.1038/nature02099; LaPlante SR, 2004, ANGEW CHEM INT EDIT, V43, P4306, DOI 10.1002/anie.200460326; Laurila MRL, 2002, J BIOL CHEM, V277, P17117, DOI 10.1074/jbc.M111220200; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; Lin C, 2004, J BIOL CHEM, V279, P17508, DOI 10.1074/jbc.M313020200; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Love RA, 2004, STRUCTURE, V12, P1533, DOI 10.1016/j.str.2004.05.024; Love RA, 2003, J VIROL, V77, P7575, DOI 10.1128/JVI.77.13.7575-7581.2003; Lu LJ, 2004, ANTIMICROB AGENTS CH, V48, P2260, DOI 10.1128/AAC.48.6.2260-2266.2004; McKercher G, 2004, NUCLEIC ACIDS RES, V32, P422, DOI 10.1093/nar/gkh160; Migliaccio G, 2003, J BIOL CHEM, V278, P49164, DOI 10.1074/jbc.M305041200; Neumann AU, 1998, SCIENCE, V282, P103, DOI 10.1126/science.282.5386.103; Ng KKS, 2004, J BIOL CHEM, V279, P16638, DOI 10.1074/jbc.M400584200; Ng KKS, 2002, J BIOL CHEM, V277, P1381, DOI 10.1074/jbc.M109261200; Nguyen TT, 2003, ANTIMICROB AGENTS CH, V47, P3525, DOI 10.1128/AAC.47.11.3525-3530.2003; Pause A, 2003, J BIOL CHEM, V278, P20374, DOI 10.1074/jbc.M210785200; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; Summa V, 2004, J MED CHEM, V47, P5336, DOI 10.1021/jm0494669; Thompson AA, 2004, EMBO J, V23, P3462, DOI 10.1038/sj.emboj.7600357; Tomei L, 2004, J VIROL, V78, P938, DOI 10.1128/JVI.78.2.938-946.2004; Tomei L, 2003, J VIROL, V77, P13225, DOI 10.1128/JVI.77.24.13225-13231.2003; Tomei L, 2000, J GEN VIROL, V81, P759, DOI 10.1099/0022-1317-81-3-759; Trozzi C, 2003, J VIROL, V77, P3669, DOI 10.1128/JVI.77.6.3669-3679.2003; Wang MT, 2003, J BIOL CHEM, V278, P9489, DOI 10.1074/jbc.M209397200; Yamashita T, 1998, J BIOL CHEM, V273, P15479, DOI 10.1074/jbc.273.25.15479	51	118	130	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39260	39267		10.1074/jbc.M506407200	http://dx.doi.org/10.1074/jbc.M506407200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16188890	hybrid			2022-12-25	WOS:000233362200043
J	Shimono, K; Shimono, Y; Shimokata, K; Ishiguro, N; Takahashi, M				Shimono, K; Shimono, Y; Shimokata, K; Ishiguro, N; Takahashi, M			Microspherule protein 1, Mi-2 beta, and RET finger protein associate in the nucleolus and up-regulate ribosomal gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-I; CHROMATIN REMODELING COMPLEX; CELL-CYCLE; HISTONE DEACETYLASE; TUMOR-SUPPRESSOR; NUCLEAR-BODIES; DNA; INTERACTS; EXPRESSION; SUBUNIT	The nucleolus is the site of ribosomal DNA ( rDNA) transcription and ribosome production. In exploring the role of nucleolar protein MCRS1 ( microspherule protein1)/MSP58 ( 58-kDa microspherule protein), we found that Mi-2 beta, a component of a nucleosome remodeling and deacetylase ( NuRD) complex, RET finger protein ( RFP), and upstream binding factor ( UBF) were associated with MCRS1. Yeast two-hybrid assays revealed that MCRS1 bound to the ATPase/helicase region of Mi-2 beta and the coiled-coil region of RFP. Interestingly, confocal microscopic analyses revealed the co-localization of MCRS1, Mi-2 beta, RFP, and the rRNA transcription factor UBF in the nucleoli. We also found that MCRS1, Mi-2 beta, and RFP were associated with rDNA using a chromatin immunoprecipitation assay. Finally, we showed that MCRS1, Mi-2 beta, and RFP up-regulated transcriptional activity of the rDNA promoter and that ribosomal RNA transcription was repressed when MCRS1, Mi-2 beta, and RFP expression was reduced using siRNA. These results indicated that Mi-2 beta and RFP, known to be involved in transcriptional repression in the nucleus, co-localize with MCRS1 in the nucleolus and appear to activate the rRNA transcription.	Nagoya Univ, Grad Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Dept Orthoped Surg, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Dept Internal Med, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Dept Mol Pathol, Ctr Neurol Dis & Canc, Showa Ku, Nagoya, Aichi 4668550, Japan	Nagoya University; Nagoya University; Nagoya University; Nagoya University	Takahashi, M (corresponding author), Nagoya Univ, Grad Sch Med, Dept Pathol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	mtakaha@med.nagoya-u.ac.jp	Ishiguro, Naoki/I-1563-2012; Takahashi, Masahide/AAN-4770-2020; TAKAHASHI, Masahide/I-7244-2014	Takahashi, Masahide/0000-0002-2803-2683; Shimono, Yohei/0000-0002-6256-4704				Arabi A, 2005, NAT CELL BIOL, V7, P303, DOI 10.1038/ncb1225; Bader AG, 2001, ONCOGENE, V20, P7524, DOI 10.1038/sj.onc.1204938; Bruni R, 1998, J VIROL, V72, P8525, DOI 10.1128/JVI.72.11.8525-8531.1998; Cao TY, 1998, J CELL SCI, V111, P1319; Chen DY, 2004, P NATL ACAD SCI USA, V101, P15106, DOI 10.1073/pnas.0404767101; CONCONI A, 1989, CELL, V57, P753, DOI 10.1016/0092-8674(89)90790-3; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Ghoshal K, 2004, J BIOL CHEM, V279, P6783, DOI 10.1074/jbc.M309393200; Grandori C, 2005, NAT CELL BIOL, V7, P311, DOI 10.1038/ncb1224; Grewal SS, 2005, NAT CELL BIOL, V7, P295, DOI 10.1038/ncb1223; Grummt I, 2003, GENE DEV, V17, P1691, DOI 10.1101/gad.1098503R; Halkidou K, 2004, NUCLEIC ACIDS RES, V32, P1654, DOI 10.1093/nar/gkh296; HEIX J, 1995, CURR OPIN GENET DEV, V5, P652, DOI 10.1016/0959-437X(95)80035-2; HENDERSON AS, 1972, P NATL ACAD SCI USA, V69, P3394, DOI 10.1073/pnas.69.11.3394; Hirose F, 2002, MOL CELL BIOL, V22, P5182, DOI 10.1128/MCB.22.14.5182-5193.2002; Hirschler-Laszkiewicz I, 2001, NUCLEIC ACIDS RES, V29, P4114, DOI 10.1093/nar/29.20.4114; Ivanova AV, 2005, CELL MOL LIFE SCI, V62, P471, DOI 10.1007/s00018-004-4423-2; JIMENEZGARCIA LF, 1989, BIOL CELL, V65, P239, DOI 10.1016/0248-4900(89)90034-8; Johnson DR, 2004, BIOCHEM BIOPH RES CO, V318, P714, DOI 10.1016/j.bbrc.2004.04.087; Lawrence RJ, 2004, MOL CELL, V13, P599, DOI 10.1016/S1097-2765(04)00064-4; Lin DY, 2002, J BIOL CHEM, V277, P25446, DOI 10.1074/jbc.M200633200; Matsuura T, 2005, EXP CELL RES, V308, P65, DOI 10.1016/j.yexcr.2005.04.022; MIESFELD R, 1982, NUCLEIC ACIDS RES, V10, P3933, DOI 10.1093/nar/10.13.3933; Morris-Desbois C, 1999, J CELL SCI, V112, P3331; Moss T, 2002, CELL, V109, P545, DOI 10.1016/S0092-8674(02)00761-4; Murawsky CM, 2001, EMBO REP, V2, P1089, DOI 10.1093/embo-reports/kve252; O'Sullivan AC, 2002, MOL CELL BIOL, V22, P657, DOI 10.1128/MCB.22.2.657-668.2002; OCHS RL, 1985, BIOL CELL, V54, P123, DOI 10.1111/j.1768-322X.1985.tb00387.x; Okumura K, 2005, P NATL ACAD SCI USA, V102, P2703, DOI 10.1073/pnas.0409370102; PAI CY, 1995, J CELL SCI, V108, P1911; PALMER TD, 1993, NUCLEIC ACIDS RES, V21, P3451, DOI 10.1093/nar/21.15.3451; Pelletier G, 2000, MOL CELL, V6, P1059, DOI 10.1016/S1097-2765(00)00104-0; Raska I, 2004, BIOL CELL, V96, P579, DOI 10.1016/j.biolcel.2004.04.015; Ren Y, 1998, EUR J BIOCHEM, V253, P734, DOI 10.1046/j.1432-1327.1998.2530734.x; RENDON MC, 1994, CELL STRUCT FUNCT, V19, P153, DOI 10.1247/csf.19.153; ROUSSEL P, 1993, J CELL SCI, V104, P327; Sandmeier JJ, 2002, EMBO J, V21, P4959, DOI 10.1093/emboj/cdf498; Santoro R, 2002, NAT GENET, V32, P393, DOI 10.1038/ng1010; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; Shimono Y, 2003, J BIOL CHEM, V278, P51638, DOI 10.1074/jbc.M309198200; Shimono Y, 2000, J BIOL CHEM, V275, P39411, DOI 10.1074/jbc.M006585200; Song H, 2004, BIOCHEM BIOPH RES CO, V316, P1116, DOI 10.1016/j.bbrc.2004.02.166; Staub E, 2004, BIOESSAYS, V26, P567, DOI 10.1002/bies.20032; Strohner R, 2001, EMBO J, V20, P4892, DOI 10.1093/emboj/20.17.4892; Strohner R, 2004, MOL CELL BIOL, V24, P1791, DOI 10.1128/MCB.24.4.1791-1798.2004; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; Tezel G, 1999, PATHOL INT, V49, P881, DOI 10.1046/j.1440-1827.1999.00957.x; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Williams CJ, 2004, IMMUNITY, V20, P719, DOI 10.1016/j.immuni.2004.05.005; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Zhai WG, 2000, MOL CELL BIOL, V20, P5930, DOI 10.1128/MCB.20.16.5930-5938.2000; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4; Zhou YG, 2002, EMBO J, V21, P4632, DOI 10.1093/emboj/cdf460	55	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39436	39447		10.1074/jbc.M507356200	http://dx.doi.org/10.1074/jbc.M507356200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16186106	hybrid			2022-12-25	WOS:000233362200065
J	Wolfe, JT; Krantz, BA; Rainey, GJA; Young, JAT; Collier, RJ				Wolfe, JT; Krantz, BA; Rainey, GJA; Young, JAT; Collier, RJ			Whole-cell voltage clamp measurements of anthrax toxin pore current	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID-BILAYER MEMBRANES; PLANAR LIPID-BILAYERS; PROTECTIVE ANTIGEN; DIPHTHERIA-TOXIN; LETHAL FACTOR; PROTEIN TRANSLOCATION; ADENYLATE-CYCLASE; CRYSTAL-STRUCTURE; MAMMALIAN-CELLS; RECEPTOR	Protective antigen ( PA) of anthrax toxin binds cellular receptors and forms pores in target cell membranes, through which catalytic lethal factor ( LF) and edema factor ( EF) are believed to translocate to the cytoplasm. Using patch clamp electrophysiological techniques, we assayed pore formation by PA in real time on the surface of cultured cells. The membranes of CHO-K1 cells treated with activated PA had little to no electrical conductivity at neutral pH ( 7.3) but exhibited robust mixed ionic currents in response to voltage stimuli at pH 5.3. Pore formation depended on specific cellular receptors and exhibited voltage-dependent inactivation at large potentials (> 60mV). The pH requirement for pore formation was receptor-specific as membrane insertion occurs at significantly different pH values when measured in cells specifically expressing tumor endothelial marker 8 ( TEM8) or capillary morphogenesis protein 2 ( CMG2),the two known cellular receptors for anthrax toxin. Pores were inhibited by an N-terminal fragment of LF and by micromolar concentrations of tetrabutylammonium ions. These studies demonstrated basic biophysical properties of PA pores in cell membranes and served as a foundation for the study of LF and EF translocation in vivo.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA; Salk Inst Biol Studies, Infect Dis Lab, La Jolla, CA 92037 USA	Harvard University; Harvard Medical School; Salk Institute	Collier, RJ (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, 200 Longwood Ave, Boston, MA 02115 USA.	john_collier@hms.harvard.edu	Wolfe, Joshua/H-3821-2013	Young, John/0000-0003-1824-2561; Krantz, Bryan/0000-0002-4911-5824; Collier, R John/0000-0002-2427-4239	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI062204] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL007572] Funding Source: Medline; NIAID NIH HHS [F32 AI062204-02, F32 AI062204] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beauregard KE, 2000, CELL MICROBIOL, V2, P251, DOI 10.1046/j.1462-5822.2000.00052.x; BEISE J, 1994, N-S ARCH PHARMACOL, V349, P66; BLAUSTEIN RO, 1989, P NATL ACAD SCI USA, V86, P2209, DOI 10.1073/pnas.86.7.2209; BLAUSTEIN RO, 1990, J GEN PHYSIOL, V96, P905, DOI 10.1085/jgp.96.5.905; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Christensen KA, 2005, BIOCHEMISTRY-US, V44, P1047, DOI 10.1021/bi047791s; Collier RJ, 2003, ANNU REV CELL DEV BI, V19, P45, DOI 10.1146/annurev.cellbio.19.111301.140655; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; ERIKSEN S, 1994, EMBO J, V13, P4433, DOI 10.1002/j.1460-2075.1994.tb06765.x; GORDON VM, 1988, INFECT IMMUN, V56, P1066, DOI 10.1128/IAI.56.5.1066-1069.1988; Haug G, 2003, J BIOL CHEM, V278, P32266, DOI 10.1074/jbc.M303980200; HOCH DH, 1985, P NATL ACAD SCI USA, V82, P1692, DOI 10.1073/pnas.82.6.1692; KAGAN BL, 1981, P NATL ACAD SCI-BIOL, V78, P4950, DOI 10.1073/pnas.78.8.4950; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; Krantz BA, 2005, SCIENCE, V309, P777, DOI 10.1126/science.1113380; Lacy DB, 2004, P NATL ACAD SCI USA, V101, P13147, DOI 10.1073/pnas.0405405101; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; Miller CJ, 1999, BIOCHEMISTRY-US, V38, P10432, DOI 10.1021/bi990792d; MILNE JC, 1993, MOL MICROBIOL, V10, P647, DOI 10.1111/j.1365-2958.1993.tb00936.x; MILNE JC, 1994, J BIOL CHEM, V269, P20607; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; Rainey GJA, 2005, P NATL ACAD SCI USA, V102, P13278, DOI 10.1073/pnas.0505865102; Ratts R, 2003, J CELL BIOL, V160, P1139, DOI 10.1083/jcb.200210028; SANDVIG K, 1982, J BIOL CHEM, V257, P7504; Santelli E, 2004, NATURE, V430, P905, DOI 10.1038/nature02763; Scobie HM, 2005, J INFECT DIS, V192, P1047, DOI 10.1086/432731; Scobie HM, 2003, P NATL ACAD SCI USA, V100, P5170, DOI 10.1073/pnas.0431098100; Sellman BR, 2001, J BIOL CHEM, V276, P8371, DOI 10.1074/jbc.M008309200; Taupiac MP, 1996, J BIOL CHEM, V271, P26170, DOI 10.1074/jbc.271.42.26170; Wigelsworth DJ, 2004, J BIOL CHEM, V279, P23349, DOI 10.1074/jbc.M401292200; Xu HX, 2004, PLOS BIOL, V2, P378, DOI 10.1371/journal.pbio.0020050; Zhang S, 2004, P NATL ACAD SCI USA, V101, P16756, DOI 10.1073/pnas.0405754101; Zhang S, 2004, BIOPHYS J, V87, P3842, DOI 10.1529/biophysj.104.050864; ZHAO JM, 1995, J BIOL CHEM, V270, P18626, DOI 10.1074/jbc.270.31.18626	34	31	32	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39417	39422		10.1074/jbc.M509049200	http://dx.doi.org/10.1074/jbc.M509049200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16183642	hybrid			2022-12-25	WOS:000233362200063
J	Lenz, G; Avruch, J				Lenz, G; Avruch, J			Glutamatergic regulation of the p70S6 kinase in primary mouse neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; LOCAL PROTEIN-SYNTHESIS; METHYL-D-ASPARTATE; NMDA RECEPTOR; ACTIVATION; TRANSLATION; ELONGATION; EXPRESSION; INDUCTION; PATHWAY	Brief glutamatergic stimulation of neurons from fetal mice, cultured in vitro for 6 days, activates the mTOR-S6 kinase, ERK1/2 and Akt pathways, to an extent approaching that elicited by brain-derived neurotrophic factor. In contrast, sustained glutamatergic stimulation inhibits ERK, Akt, and S6K. Glutamatergic activation of S6K is calcium/calmodulin-dependent and is prevented by inhibitors of calcium/calmodulin-dependent protein kinase 2, phosphatidylinositol 3-OH-kinase and by rapamycin. 2-Amino-5- phosphonovaleric acid, an inhibitor of N'-methyl-D-aspartate receptors, abolishes glutamatergic activation of ERK1/2 but not the activation of mTOR-S6K; the latter is completely abolished by inhibitors of voltage-dependent calcium channels. Added singly, dopamine gives slight, and norepinephrine a more significant, activation of ERK and S6K; both catecholeamines, however, enhance glutamatergic activation of S6K but not ERK. After 12 days in culture, the response to direct glutamatergic activation is attenuated but can be uncovered by suppression of gamma-aminobutyric acid interneurons with bicuculline in the presence of the weak K+ channel blocker 4-aminopyridine (4-AP). This selective synaptic activation of mTOR-S6K is also resistant to APV and inhibited by Ca2+ channel blockers and higher concentrations of glutamate. Elongation factor 2 (EF2) is phosphorylated and inhibited by the eEF2 kinase (CaM kinase III); the latter is inhibited by the S6K or Rsk. Bicuculline/4-AP or KCl-induced depolarization reduces, whereas higher concentrations of glutamate increases, EF2 phosphorylation. Thus the mTOR-S6K pathway in neurons, a critical component of the late phase of LTP, is activated by glutamatergic stimulation in a calcium/calmodulin-dependent fashion through a calcium pool controlled by postsynaptic voltage-dependent calcium channels, whereas sustained stimulation of extrasynaptic glutamate receptors is inhibitory.	Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Med Serv, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA; Univ Fed Rio Grande do Sul, Dept Biophys, IB, BR-91501970 Porto Alegre, RS, Brazil	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Universidade Federal do Rio Grande do Sul	Avruch, J (corresponding author), Dept Mol Biol, Richard B Simches Res Bldg,6th Floor,185 Cambridg, Boston, MA 02114 USA.	avruch@molbio.mgh.harvard.edu	Lenz, Guido/A-7618-2008		NCI NIH HHS [CA73818] Funding Source: Medline; NIDDK NIH HHS [R37 DK017776, DK17776] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017776, R37DK017776] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aakalu G, 2001, NEURON, V30, P489, DOI 10.1016/S0896-6273(01)00295-1; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; Browne GJ, 2002, EUR J BIOCHEM, V269, P5360, DOI 10.1046/j.1432-1033.2002.03290.x; Cammalleri M, 2003, P NATL ACAD SCI USA, V100, P14368, DOI 10.1073/pnas.2336098100; Cavus I, 1996, J NEUROPHYSIOL, V76, P3038, DOI 10.1152/jn.1996.76.5.3038; Chandler LJ, 2001, J BIOL CHEM, V276, P2627, DOI 10.1074/jbc.M003390200; English JD, 1996, J BIOL CHEM, V271, P24329, DOI 10.1074/jbc.271.40.24329; Goridis C, 2002, NAT REV NEUROSCI, V3, P531, DOI 10.1038/nrn871; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Hardingham GE, 2003, TRENDS NEUROSCI, V26, P81, DOI 10.1016/S0166-2236(02)00040-1; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; HUANG YY, 1995, P NATL ACAD SCI USA, V92, P2446, DOI 10.1073/pnas.92.7.2446; Izumi Y, 1999, SYNAPSE, V31, P196, DOI 10.1002/(SICI)1098-2396(19990301)31:3<196::AID-SYN4>3.0.CO;2-K; Kato-Negishi M, 2004, DEV BRAIN RES, V152, P99, DOI 10.1016/j.devbrainres.2004.05.013; Lee FJS, 2002, CELL, V111, P219, DOI 10.1016/S0092-8674(02)00962-5; Lesuisse C, 2002, J NEUROBIOL, V51, P9, DOI 10.1002/neu.10037; Lisman J, 2002, NAT REV NEUROSCI, V3, P175, DOI 10.1038/nrn753; Lynch MA, 2004, PHYSIOL REV, V84, P87, DOI 10.1152/physrev.00014.2003; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Marin P, 1997, J NEUROSCI, V17, P3445; MCDONALD JW, 1988, BRAIN RES, V459, P200, DOI 10.1016/0006-8993(88)90306-X; McGaugh JL, 2002, TRENDS NEUROSCI, V25, P456, DOI 10.1016/S0166-2236(02)02211-7; Morgan SL, 2001, NEUROBIOL LEARN MEM, V76, P229, DOI 10.1006/nlme.2001.4016; Sanna PP, 2002, J NEUROSCI, V22, P3359; Scheetz AJ, 2000, NAT NEUROSCI, V3, P211, DOI 10.1038/72915; Smith WB, 2005, NEURON, V45, P765, DOI 10.1016/j.neuron.2005.01.015; Sutton G, 2002, J NEUROCHEM, V82, P1097, DOI 10.1046/j.1471-4159.2002.01031.x; Takei N, 2001, J BIOL CHEM, V276, P42818, DOI 10.1074/jbc.M103237200; Takei N, 2004, J NEUROSCI, V24, P9760, DOI 10.1523/JNEUROSCI.1427-04.2004; Tang SJ, 2002, P NATL ACAD SCI USA, V99, P467, DOI 10.1073/pnas.012605299; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; Woodside BL, 2004, NEUROBIOL LEARN MEM, V81, P105, DOI 10.1016/j.nlm.2003.10.003	32	113	116	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38121	38124		10.1074/jbc.C500363200	http://dx.doi.org/10.1074/jbc.C500363200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16183639	hybrid, Green Published			2022-12-25	WOS:000233239800003
J	Wu, D; Chen, B; Parihar, K; He, L; Fan, C; Zhang, J; Liu, L; Gillis, A; Bruce, A; Kapoor, A; Tang, D				Wu, D; Chen, B; Parihar, K; He, L; Fan, C; Zhang, J; Liu, L; Gillis, A; Bruce, A; Kapoor, A; Tang, D			ERK activity facilitates activation of the S-phase DNA damage checkpoint by modulating ATR function	ONCOGENE			English	Article						hydroxyurea; MEK1; Erk; ATR; S-phase checkpoint	ATAXIA TELANGIECTASIA CELLS; PROTEIN-KINASE KINASE; HISTONE H2AX; SUSTAINED ACTIVATION; CYCLIN D1; P53; INHIBITORS; REPAIR; TRANSFORMATION; INSTABILITY	Although Erk kinase has been recently reported to function in the DNA damage response, the mechanism governing this process is unknown. We report here that hydroxyurea (HU) activates Erk via MEK1, a process that is sensitized by a constitutively active MEK1 (MEK1Q56P) and attenuated by a dominant-negative MEK1 (MEK1K97M). While ectopic MEK1Q56P sensitized HU-induced S-phase arrest, inhibition of Erk activation via U0126, PD98059, and MEK1K97M attenuated the arrest, and thereby enhanced cells to HU-induced toxicity. Taken together, we demonstrate an important contribution of Erk to the activation of the S-phase DNA damage checkpoint. This can be attributed to Erk's regulatory role in modulating ATR function. Inhibition of Erk activation with U0126/PD98059 and MEK1K97M substantially reduced HU-induced ATR nuclear foci, leading to a dramatic reduction of gamma H2AX and its nuclear foci. Reduction of MEK1 function by a small interference RNA ( siRNA) MEK1 and ectopic MEK1K97M significantly decreased HU-induced gamma H2AX. Conversely, ectopic MEK1Q56P enhanced gamma H2AX foci. Furthermore, immunofluorescent and cell fractioning experiments revealed cytosolic and nuclear localization of ATR. HU treatment caused the redistribution of ATR from the cytosol to the nucleus, a process that is inhibited by U0126. Collectively, we show that Erk kinase modulates HU-initiated DNA damage response by regulating ATR function.	St Joseph Hosp, Father Sean Sullivan Res Inst, Hamilton, ON L8N 4A6, Canada; McMaster Univ, Dept Med, Div Nephrol, Hamilton, ON, Canada; McMaster Univ, Dept Surg, Hamilton, ON L8S 4L8, Canada	McMaster University; McMaster University	Tang, D (corresponding author), St Joseph Hosp, Father Sean Sullivan Res Inst, T3310,50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.	damut@mcmaster.ca	Tang, Damu/AAQ-1786-2021; Kapoor, Anil/AAQ-7184-2021	Tang, Damu/0000-0002-3282-9521; Kapoor, Anil/0000-0001-9180-8029				Ahn NG, 2001, METHOD ENZYMOL, V332, P417; ATKIN CL, 1973, J BIOL CHEM, V248, P7464; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Chen HT, 2000, SCIENCE, V290, P1962, DOI 10.1126/science.290.5498.1962; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fernandez-Capetillo O, 2003, DEV CELL, V4, P497, DOI 10.1016/S1534-5807(03)00093-5; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Johns DG, 1998, BIOCHEM PHARMACOL, V55, P1551, DOI 10.1016/S0006-2952(97)00664-3; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Krepinsky J, 2002, EXPERT OPIN THER PAT, V12, P1795, DOI 10.1517/13543776.12.12.1795; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lee SW, 2000, P NATL ACAD SCI USA, V97, P8302, DOI 10.1073/pnas.150024397; LEHMANN AR, 1979, NUCLEIC ACIDS RES, V6, P1953, DOI 10.1093/nar/6.5.1953; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li YX, 2004, ONCOGENE, V23, P7355, DOI 10.1038/sj.onc.1207957; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Mahadevaiah SK, 2001, NAT GENET, V27, P271, DOI 10.1038/85830; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Pippin JW, 2003, J CLIN INVEST, V111, P877, DOI 10.1172/JCI200315645; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Sarkaria JN, 1999, CANCER RES, V59, P4375; Schar P, 2001, CELL, V104, P329, DOI 10.1016/S0092-8674(01)00220-3; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; SHILOH Y, 1982, CARCINOGENESIS, V3, P815, DOI 10.1093/carcin/3.7.815; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Tang D, 2001, J BIOL CHEM, V276, P30461, DOI 10.1074/jbc.M102045200; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; TAYLOR AMR, 1979, CANCER RES, V39, P1046; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Yang DQ, 2000, NAT CELL BIOL, V2, P893, DOI 10.1038/35046542; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	49	44	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2006	25	8					1153	1164		10.1038/sj.onc.1209148	http://dx.doi.org/10.1038/sj.onc.1209148			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	015FO	16186792				2022-12-25	WOS:000235537500003
J	Ruckert, C; Fiorillo, MT; Loll, B; Moretti, R; Biesiadka, J; Saenger, W; Ziegler, A; Sorrentino, R; Uchanska-Ziegler, B				Ruckert, C; Fiorillo, MT; Loll, B; Moretti, R; Biesiadka, J; Saenger, W; Ziegler, A; Sorrentino, R; Uchanska-Ziegler, B			Conformational dimorphism of self-peptides and molecular mimicry in a disease-associated HLA-B27 subtype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-RECEPTOR; ANKYLOSING-SPONDYLITIS; KLEBSIELLA-PNEUMONIAE; CRYSTAL-STRUCTURES; STRUCTURAL BASIS; TCR; COMPLEX; RECOGNITION; MECHANISM; SURFACE	An interesting property of certain peptides presented by major histocompatibility complex (MHC) molecules is their acquisition of a dual binding mode within the peptide binding groove. Using x-ray crystallography at 1.4 angstrom resolution, we show here that the glucagon receptor-derived self-peptide pGR ((RRRWHRWRL420)-R-412) is presented by the disease-associated human MHC class I subtype HLA-B*2705 in a dual conformation as well, with the middle of the peptide bent toward the floor of the peptide binding groove of the molecule in both binding modes. The conformations of pGR are compared here with those of another self-peptide (pVIPR, RRK-WRRWHL) that is also displayed in two binding modes by HLA-B*2705 antigens and with that of the viral peptide pLMP2 (RRRWRRLTV). Conserved structural features suggest that the N-terminal halves of the peptides are crucial in allowing cytotoxic T lymphocyte (CTL) cross-reactivity. In addition, an analysis of T cell receptors (TCRs) from pGR-or pVIPR-directed, HLA-B27-restricted CTL clones demonstrates that TCR from distinct clones but with comparable reactivity may share CDR3 alpha but not CDR3 alpha regions. Therefore, the cross-reactivity of these CTLs depends on TCR-CDR3 alpha, is modulated by TCR-CDR3 alpha sequences, and is ultimately a consequence of the conformational dimorphism that characterizes binding of the self-peptides to HLA-B*2705. These results lend support to the concept that conformational dimorphisms of MHC class I-bound peptides might be connected with the occurrence of self-reactive CTL.	Univ Roma La Sapienza, Dipartimento Biol Cellulare & Sviluppo, I-00185 Rome, Italy; Humboldt Univ, Univ Med Berlin, Charite, Inst Immungenet, D-14050 Berlin, Germany; Free Univ Berlin, Inst Chem & Biochem Kristallog, D-14195 Berlin, Germany	Sapienza University Rome; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin	Sorrentino, R (corresponding author), Univ Roma La Sapienza, Dipartimento Biol Cellulare & Sviluppo, Via Sardi 70, I-00185 Rome, Italy.	rosa.sorrentino@uniroma1.it; barbara.uchanska-ziegler@charite.de	Sorrentino, Rosa/G-5472-2012; Loll, Bernhard/J-4815-2019	Sorrentino, Rosa/0000-0002-9632-2383; Loll, Bernhard/0000-0001-7928-4488; FIORILLO, Maria Teresa/0000-0002-6859-5851				Allen RL, 1999, IMMUNOGENETICS, V50, P220, DOI 10.1007/s002510050596; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BENJAMIN R, 1990, IMMUNOL TODAY, V11, P137, DOI 10.1016/0167-5699(90)90051-A; BROOKS JM, 1993, J EXP MED, V178, P879, DOI 10.1084/jem.178.3.879; Colbert RA, 2000, MOL MED TODAY, V6, P224, DOI 10.1016/S1357-4310(00)01699-3; de Castro JAL, 2004, TISSUE ANTIGENS, V63, P424, DOI 10.1111/j.0001-2815.2004.00220.x; DELPORTO P, 1994, J IMMUNOL, V153, P3093; Duchmann R, 1996, SCAND J IMMUNOL, V43, P101, DOI 10.1046/j.1365-3083.1996.d01-16.x; Duchmann R, 2001, CLIN EXP IMMUNOL, V123, P315, DOI 10.1046/j.1365-2249.2001.01440.x; Fiorillo MT, 2000, J CLIN INVEST, V106, P47, DOI 10.1172/JCI9295; Fiorillo MT, 2005, J BIOL CHEM, V280, P2962, DOI 10.1074/jbc.M410807200; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; GECZY AF, 1982, J RHEUMATOL, V9, P97; Hahn M, 2005, NAT IMMUNOL, V6, P490, DOI 10.1038/ni1187; Han BY, 2005, J CLIN INVEST, V115, P1879, DOI 10.1172/JCI24219; Hillig RC, 2004, J BIOL CHEM, V279, P652, DOI 10.1074/jbc.M307457200; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Horton R, 2004, NAT REV GENET, V5, P889, DOI 10.1038/nrg1489; Housset D, 2003, TRENDS IMMUNOL, V24, P429, DOI 10.1016/S1471-4906(03)00180-7; Hulsmeyer M, 2005, J MOL BIOL, V346, P1367, DOI 10.1016/j.jmb.2004.12.047; Hulsmeyer M, 2004, J EXP MED, V199, P271, DOI 10.1084/jem.20031690; Hulsmeyer M, 2002, J BIOL CHEM, V277, P47844, DOI 10.1074/jbc.M206392200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KALAMS SA, 1994, J EXP MED, V179, P1261, DOI 10.1084/jem.179.4.1261; Khan MA, 2002, BEST PRACT RES CL RH, V16, P675, DOI 10.1053/BERH.2002.0243; Kim YR, 2004, BIOMACROMOLECULES, V5, P889, DOI 10.1021/bm0344147; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; Kjer-Nielsen L, 2003, IMMUNITY, V18, P53, DOI 10.1016/S1074-7613(02)00513-7; Lang HLE, 2002, NAT IMMUNOL, V3, P940, DOI 10.1038/ni835; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lombardi G, 2001, J IMMUNOL, V166, P3549, DOI 10.4049/jimmunol.166.5.3549; Luthra-Guptasarma M, 2004, FEBS LETT, V575, P1, DOI 10.1016/j.febslet.2004.08.037; MADDEN DR, 1995, ANNU REV IMMUNOL, V13, P587, DOI 10.1146/annurev.iy.13.040195.003103; Mayo KE, 2003, PHARMACOL REV, V55, P167, DOI 10.1124/pr.55.1.6; Menssen R, 1999, J MOL BIOL, V285, P645, DOI 10.1006/jmbi.1998.2363; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; OLDSTONE MBA, 1987, CELL, V50, P819, DOI 10.1016/0092-8674(87)90507-1; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paladini F, 2005, ARTHRITIS RHEUM-US, V52, P3319, DOI 10.1002/art.21308; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Pohlmann T, 2004, J BIOL CHEM, V279, P28197, DOI 10.1074/jbc.C400128200; Probst-Kepper M, 2004, J IMMUNOL, V173, P5610, DOI 10.4049/jimmunol.173.9.5610; Ramos M, 2002, TISSUE ANTIGENS, V60, P191, DOI 10.1034/j.1399-0039.2002.600301.x; Reiser JB, 2000, NAT IMMUNOL, V1, P291, DOI 10.1038/79728; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; SCHWIMMBECK PL, 1987, J EXP MED, V166, P173, DOI 10.1084/jem.166.1.173; Serra P, 2002, P NATL ACAD SCI USA, V99, P15566, DOI 10.1073/pnas.242321099; Shiina T, 2004, TISSUE ANTIGENS, V64, P631, DOI 10.1111/j.1399-0039.2004.00327.x; SIEPER J, 1995, ARTHRITIS RHEUM, V38, P1547, DOI 10.1002/art.1780381105; Stewart-Jones GBE, 2005, EUR J IMMUNOL, V35, P341, DOI 10.1002/eji.200425724; Tiwana H, 1998, BRIT J RHEUMATOL, V37, P525; Uchanska-Ziegler B, 2003, TRENDS IMMUNOL, V24, P73, DOI 10.1016/S1471-4906(02)00028-5; UCHANSKAZIEGLER B, 2004, IN PRESS HLA 2004 IM; Vigneron N, 2004, SCIENCE, V304, P587, DOI 10.1126/science.1095522; Wan SZ, 2005, J IMMUNOL, V175, P1715, DOI 10.4049/jimmunol.175.3.1715; WILLIAMS WV, 1993, DNA CELL BIOL, V12, P425, DOI 10.1089/dna.1993.12.425; Wu LC, 2002, NATURE, V418, P552, DOI 10.1038/nature00920	60	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2306	2316		10.1074/jbc.M508528200	http://dx.doi.org/10.1074/jbc.M508528200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16221670	hybrid			2022-12-25	WOS:000234760400056
J	Zhou, WB; Freed, CR				Zhou, WB; Freed, CR			DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T alpha-synuclein toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONSET PARKINSONS-DISEASE; CELL-DEATH; DROSOPHILA DJ-1; CYSTEINE MODIFICATION; CRYSTAL-STRUCTURE; FIBRIL FORMATION; IN-VITRO; PROTEIN; AGGREGATION; MUTATIONS	DJ-1 is the third gene that has been linked to Parkinson disease. Mutations in the DJ-1 gene cause early onset PD with autosomal recessive inheritance. To clarify the mechanism of DJ-1 protection, we have overexpressed the gene in cultured dopaminergic cells that were then subjected to chemical stress. In the rat dopaminergic cell line, N27, and in primary dopamine neurons, overexpression of wild type DJ-1 protected cells from death induced by hydrogen peroxide and 6-hydroxydopamine. Overexpressing the L166P mutant DJ-1 had no protective effect. By contrast, knocking down endogenous DJ-1 with antisense DJ-1 rendered cells more susceptible to oxidative damage. We have found that DJ-1 improves survival by increasing cellular glutathione levels through an increase in the rate-limiting enzyme glutamate cysteine ligase. Blocking glutathione synthesis eliminated the beneficial effect of DJ-1. Protection could be restored by adding exogenous glutathione. Wild type DJ-1 reduced cellular reactive oxygen species and reduced the levels of protein oxidation caused by oxidative stress. By a separate mechanism, overexpressing wild type DJ-1 inhibited the protein aggregation and cytotoxicity usually caused by A53T human alpha-synuclein. Under these circumstances, DJ-1 increased the level of heat shock protein 70 but did not change the glutathione level. Our data indicate that DJ-1 protects dopaminergic neurons from oxidative stress through up-regulation of glutathione synthesis and from the toxic consequences of mutant human alpha-synuclein through increased expression of heat shock protein 70. We conclude that DJ-1 has multiple specific mechanisms for protecting dopamine neurons from cell death.	Univ Colorado, Hlth Sci Ctr, Dept Med, Div Clin Pharmacol & Toxicol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Freed, CR (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, Div Clin Pharmacol & Toxicol, 4200 E 9th Ave, Denver, CO 80262 USA.	Curt.Freed@UCHSC.edu						Auluck PK, 2005, J BIOL CHEM, V280, P2873, DOI 10.1074/jbc.M412106200; Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Bonifati V, 2004, J MOL MED, V82, P163, DOI 10.1007/s00109-003-0512-1; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Canet-Aviles RM, 2004, P NATL ACAD SCI USA, V101, P9103, DOI 10.1073/pnas.0402959101; Chen LN, 2005, J BIOL CHEM, V280, P21418, DOI 10.1074/jbc.M413955200; Clark LN, 2004, MOVEMENT DISORD, V19, P796, DOI 10.1002/mds.20131; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; da Costa CA, 2002, J BIOL CHEM, V277, P50980, DOI 10.1074/jbc.M207825200; Dalton TP, 2004, FREE RADICAL BIO MED, V37, P1511, DOI 10.1016/j.freeradbiomed.2004.06.040; Dawson TM, 2002, NEURON, V35, P219, DOI 10.1016/S0896-6273(02)00780-8; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Dedmon MM, 2005, J BIOL CHEM, V280, P14733, DOI 10.1074/jbc.m413024200; Dickinson DA, 2004, FREE RADICAL BIO MED, V37, P1152, DOI 10.1016/j.freeradbiomed.2004.06.011; Dong ZZ, 2005, MOL THER, V11, P80, DOI 10.1016/j.ymthe.2004.09.007; Goldberg MS, 2005, NEURON, V45, P489, DOI 10.1016/j.neuron.2005.01.041; Hague S, 2003, ANN NEUROL, V54, P271, DOI 10.1002/ana.10663; Hod Y, 1999, J CELL BIOCHEM, V72, P435, DOI 10.1002/(SICI)1097-4644(19990301)72:3<435::AID-JCB12>3.3.CO;2-8; Junn E, 2005, P NATL ACAD SCI USA, V102, P9691, DOI 10.1073/pnas.0409635102; Kaul S, 2005, MOL BRAIN RES, V139, P137, DOI 10.1016/j.molbrainres.2005.05.022; Kim RH, 2005, CANCER CELL, V7, P263, DOI 10.1016/j.ccr.2005.02.010; Kim RH, 2005, P NATL ACAD SCI USA, V102, P5215, DOI 10.1073/pnas.0501282102; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Klucken J, 2004, BIOCHEM BIOPH RES CO, V325, P367, DOI 10.1016/j.bbrc.2004.10.037; Klucken J, 2004, J BIOL CHEM, V279, P25497, DOI 10.1074/jbc.M400255200; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; Levonen AL, 2004, BIOCHEM J, V378, P373, DOI 10.1042/BJ20031049; Lewy F., 1914, DEUT Z NERVENHEILKD, V50, P50; Li WX, 2005, J NEUROCHEM, V93, P1542, DOI 10.1111/j.1471-4159.2005.03146.x; Lim SY, 2004, J BIOL CHEM, V279, P46263, DOI 10.1074/jbc.M406555200; McLean PJ, 2004, BIOCHEM BIOPH RES CO, V321, P665, DOI 10.1016/j.bbrc.2004.07.021; Menzies FM, 2005, CURR BIOL, V15, P1578, DOI 10.1016/j.cub.2005.07.036; Meulener M, 2005, CURR BIOL, V15, P1572, DOI 10.1016/j.cub.2005.07.064; Miller DW, 2003, J BIOL CHEM, V278, P36588, DOI 10.1074/jbc.M304272200; Mitsumoto A, 2001, FREE RADICAL RES, V35, P885, DOI 10.1080/10715760100301381; Mitsumoto A, 2001, FREE RADICAL RES, V35, P301, DOI 10.1080/10715760100300831; Nagakubo D, 1997, BIOCHEM BIOPH RES CO, V231, P509, DOI 10.1006/bbrc.1997.6132; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; SHENDELMAN S, 2004, PLOS BIOL, V2, pE352; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Taira T, 2004, EMBO REP, V5, P213, DOI 10.1038/sj.embor.7400074; Takahashi K, 2001, J BIOL CHEM, V276, P37556, DOI 10.1074/jbc.M101730200; Tao X, 2003, J BIOL CHEM, V278, P31372, DOI 10.1074/jbc.M304221200; Wilson MA, 2003, P NATL ACAD SCI USA, V100, P9256, DOI 10.1073/pnas.1133288100; Woods JS, 1999, TOXICOL APPL PHARM, V160, P207, DOI 10.1006/taap.1999.8774; Xu J, 2005, HUM MOL GENET, V14, P1231, DOI 10.1093/hmg/ddi134; Yang YF, 2005, P NATL ACAD SCI USA, V102, P13670, DOI 10.1073/pnas.0504610102; Yokota T, 2003, BIOCHEM BIOPH RES CO, V312, P1342, DOI 10.1016/j.bbrc.2003.11.056; Zhou WB, 2000, BRAIN RES, V866, P33, DOI 10.1016/S0006-8993(00)02215-0; Zhou WB, 2004, J BIOL CHEM, V279, P10128, DOI 10.1074/jbc.M307563200	52	287	305	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					43150	43158		10.1074/jbc.M507124200	http://dx.doi.org/10.1074/jbc.M507124200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16227205	hybrid			2022-12-25	WOS:000234200800081
J	Zhang, F; Marcus, WD; Goyal, NH; Selvaraj, P; Springer, TA; Zhu, C				Zhang, F; Marcus, WD; Goyal, NH; Selvaraj, P; Springer, TA; Zhu, C			Two-dimensional kinetics regulation of alpha(L)beta(2)-ICAM-1 interaction by conformational changes of the alpha(L)-inserted domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE-1 ICAM-1; I-DOMAIN; EXTRACELLULAR SEGMENT; CRYSTAL-STRUCTURE; SELECTIN BINDING; STRUCTURAL BASIS; A DOMAIN; LIGAND; AFFINITY; DIMERIZATION	The leukocyte integrin alpha(L)beta(2) mediates cell adhesion and migration during inflammatory and immune responses. Ligand binding of alpha(L)beta(2) is regulated by or induces conformational changes in the inserted ( I) domain. By using a micropipette, we measured the conformational regulation of two-dimensional ( 2D) binding affinity and the kinetics of cell-bound intercellular adhesion molecule-1 interacting with alpha(L)beta(2) or isolated I domain expressed on K562 cells. Locking the I domain into open and intermediate conformations with a disulfide bond increased the affinities by similar to 8000- and similar to 30-fold, respectively, from the locked closed conformation, which has similar affinity as the wild-type I domain. Most surprisingly, the 2D affinity increases were due mostly to the 2D on-rate increases, as the 2D off-rates only decreased by severalfold. The wild-type alpha(L)beta(2), but not its I domain in isolation, could be up-regulated by Mn2+ or Mg2+ to have high affinities and on-rates. Locking the I domain in any of the three conformations abolished the ability of divalent cations to regulate 2D affinity. These results indicate that a downward displacement of the I domain C-terminal helix, induced by conformational changes of other domains of the alpha(L)beta(2), is required for affinity and on-rate up-regulation.	Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30332 USA; Georgia Inst Technol, George W Woodruff Sch Mech Engn, Atlanta, GA 30332 USA; Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	University System of Georgia; Georgia Institute of Technology; University System of Georgia; Georgia Institute of Technology; Emory University; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School	Zhu, C (corresponding author), Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30332 USA.	cheng.zhu@me.gatech.edu	Zhu, Cheng/A-5724-2011		NCI NIH HHS [R01 CA031798, CA31798, R37 CA031798] Funding Source: Medline; NIAID NIH HHS [R01 AI049400, AI38282, R29 AI038282, AI049400, R01 AI044902, R56 AI038282, R01 AI038282, R21 AI044902, AI44902] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA031798, R37CA031798] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049400, R01AI038282, R21AI044902, R29AI038282, R01AI044902] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alonso JL, 2002, CURR BIOL, V12, pR340, DOI 10.1016/S0960-9822(02)00852-7; CARPEN O, 1992, J CELL BIOL, V118, P1223, DOI 10.1083/jcb.118.5.1223; Chesla SE, 2000, J BIOL CHEM, V275, P10235, DOI 10.1074/jbc.275.14.10235; Chesla SE, 1998, BIOPHYS J, V75, P1553, DOI 10.1016/S0006-3495(98)74074-3; CHILKOTI A, 1995, J AM CHEM SOC, V117, P10622, DOI 10.1021/ja00148a003; COLOMBATTI A, 1991, BLOOD, V77, P2305; Doggett TA, 2002, BIOPHYS J, V83, P194, DOI 10.1016/S0006-3495(02)75161-8; Dumaswala UJ, 1996, BLOOD, V88, P697, DOI 10.1182/blood.V88.2.697.bloodjournal882697; Dustin ML, 2001, ANNU REV CELL DEV BI, V17, P133, DOI 10.1146/annurev.cellbio.17.1.133; Evans E, 2000, J PHYS-CONDENS MAT, V12, pA315, DOI 10.1088/0953-8984/12/8A/341; Evans E, 2001, ANNU REV BIOPH BIOM, V30, P105, DOI 10.1146/annurev.biophys.30.1.105; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Huang J, 2004, J BIOL CHEM, V279, P44915, DOI 10.1074/jbc.M407039200; Huth JR, 2000, P NATL ACAD SCI USA, V97, P5231, DOI 10.1073/pnas.97.10.5231; Jin M, 2004, STRUCTURE, V12, P2137, DOI 10.1016/j.str.2004.10.005; JOHNSTON SC, 1990, J IMMUNOL, V145, P1181; Jun CD, 2001, P NATL ACAD SCI USA, V98, P6830, DOI 10.1073/pnas.121186998; Kumar RA, 2003, BIOPHYS J, V85, P4099, DOI 10.1016/S0006-3495(03)74822-X; Labadia ME, 1998, J IMMUNOL, V161, P836; Legge GB, 2000, J MOL BIOL, V295, P1251, DOI 10.1006/jmbi.1999.3409; Lomakina EB, 2004, BIOPHYS J, V86, P1223, DOI 10.1016/S0006-3495(04)74196-X; Long M, 2001, ANN BIOMED ENG, V29, P935, DOI 10.1114/1.1415529; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2387, DOI 10.1073/pnas.041606398; Luo BH, 2004, J BIOL CHEM, V279, P27466, DOI 10.1074/jbc.M404354200; Mehta P, 1998, J BIOL CHEM, V273, P32506, DOI 10.1074/jbc.273.49.32506; Merkel R, 1999, NATURE, V397, P50, DOI 10.1038/16219; MILLER J, 1995, J EXP MED, V182, P1231, DOI 10.1084/jem.182.5.1231; Miura S, 2000, J BIOL CHEM, V275, P7539, DOI 10.1074/jbc.275.11.7539; Mould AP, 2003, J BIOL CHEM, V278, P17028, DOI 10.1074/jbc.M213139200; Nicholson MW, 1998, J BIOL CHEM, V273, P763, DOI 10.1074/jbc.273.2.763; PETRUZZELLI L, 1995, J IMMUNOL, V155, P854; REILLY PL, 1995, J IMMUNOL, V155, P529; Salas A, 2002, J BIOL CHEM, V277, P50255, DOI 10.1074/jbc.M209822200; Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541; Shimaoka M, 2001, P NATL ACAD SCI USA, V98, P6009, DOI 10.1073/pnas.101130498; Shimaoka M, 2003, IMMUNITY, V19, P391, DOI 10.1016/S1074-7613(03)00238-3; Shimaoka M, 2003, CELL, V112, P99, DOI 10.1016/S0092-8674(02)01257-6; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; SILVIUS JR, 1993, BIOCHEMISTRY-US, V32, P3153, DOI 10.1021/bi00063a030; SMITH JW, 1994, J BIOL CHEM, V269, P960; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2002, IMMUNOL REV, V186, P141, DOI 10.1034/j.1600-065X.2002.18613.x; Thoumine O, 2000, EUR BIOPHYS J BIOPHY, V29, P398, DOI 10.1007/s002490000087; Vitte J, 2004, BIOPHYS J, V86, P4059, DOI 10.1529/biophysj.103.038778; Wild MK, 2001, J BIOL CHEM, V276, P31602, DOI 10.1074/jbc.M104844200; Williams TE, 2000, BIOPHYS J, V79, P1858, DOI 10.1016/S0006-3495(00)76435-6; Williams TE, 2001, J BIOL CHEM, V276, P13283, DOI 10.1074/jbc.M010427200; Xiao T, 2004, NATURE, V432, P59, DOI 10.1038/nature02976; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Yang YT, 2004, MOL CELL, V14, P269, DOI 10.1016/S1097-2765(04)00204-7; Zhang XH, 2002, BIOPHYS J, V83, P2270, DOI 10.1016/S0006-3495(02)73987-8	55	63	63	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42207	42218		10.1074/jbc.M510407200	http://dx.doi.org/10.1074/jbc.M510407200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16234238	Green Accepted, hybrid			2022-12-25	WOS:000233992700049
J	Listman, JA; Wara-Aswapati, N; Race, JE; Blystone, LW; Walker-Kopp, N; Yang, ZY; Auron, PE				Listman, JA; Wara-Aswapati, N; Race, JE; Blystone, LW; Walker-Kopp, N; Yang, ZY; Auron, PE			Conserved ETS domain arginines mediate DNA binding, nuclear localization, and a novel mode of bZIP interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR PU.1; CRYSTAL-STRUCTURE; TERNARY COMPLEX; IL-1-BETA GENE; C/EBP FAMILY; IN-VITRO; C-JUN; PROTEIN; RECOGNITION; EXPRESSION	The DNA-binding ETS transcription factor Spi-1/PU.1 is of central importance in determining the myeloid-erythroid developmental switch and is required for monocyte and osteoclast differentiation. Many monocyte genes are dependent upon this factor, including the gene that codes for interleukin-1 beta. It has long been known that the conserved ETS DNA-binding domain of Spi-1/PU.1 functionally cooperates via direct association with a diverse collection of DNA-binding proteins, including members of the basic leucine zipper domain ( bZIP) family. However, the molecular basis for this interaction has long been elusive. Using a combination of approaches, we have mapped a single residue on the surface of the ETS domain critical for protein tethering by the C/EBP beta carboxyl-terminal bZIP domain. This residue is also important for nuclear localization and DNA binding. In addition, dependence upon the leucine zipper suggests a novel mode for both protein-DNA interaction and functional cooperativity.	Univ Pittsburgh, Sch Med, Pittsburgh, PA 15261 USA; SUNY Syracuse, Syracuse, NY 13210 USA; Khon Kaen Univ, Khon Kaen 40002, Thailand; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; State University of New York (SUNY) System; Khon Kaen University; Harvard University; Harvard Medical School	Auron, PE (corresponding author), Univ Pittsburgh, Sch Med, BSTWR-W1142,200 Lothrop St, Pittsburgh, PA 15261 USA.	auron@pitt.edu			NCI NIH HHS [CA068544] Funding Source: Medline; NIDDK NIH HHS [K08DK002788] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068544] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002788] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Auron PE, 2005, MEASURING IMMUNITY: BASIC BIOLOGY AND CLINICAL ASSESSMENT, P91, DOI 10.1016/B978-012455900-4/50269-5; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; Brass AL, 1999, EMBO J, V18, P977, DOI 10.1093/emboj/18.4.977; Escalante CR, 2002, MOL CELL, V10, P1097, DOI 10.1016/S1097-2765(02)00703-7; Fisher RC, 1998, STEM CELLS, V16, P25, DOI 10.1002/stem.160025; Forwood JK, 2001, BIOCHEMISTRY-US, V40, P5208, DOI 10.1021/bi002732+; Friedman AD, 2002, ONCOGENE, V21, P3377, DOI 10.1038/sj.onc.1205324; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Jamieson AC, 2003, NAT REV DRUG DISCOV, V2, P361, DOI 10.1038/nrd1087; KELLER W, 1995, J MOL BIOL, V254, P657, DOI 10.1006/jmbi.1995.0645; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; KOMINATO Y, 1995, MOL CELL BIOL, V15, P59; LACASSE EC, 1995, NUCLEIC ACIDS RES, V23, P1647, DOI 10.1093/nar/23.10.1647; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; Marecki S, 2001, J IMMUNOL, V166, P6829, DOI 10.4049/jimmunol.166.11.6829; Oikawa T, 1999, CELL DEATH DIFFER, V6, P599, DOI 10.1038/sj.cdd.4400534; Pio F, 1996, J BIOL CHEM, V271, P23329, DOI 10.1074/jbc.271.38.23329; SCHULZ GE, 1984, PRINCIPALS PROTEIN S, P27; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; SHIRAKAWA F, 1993, MOL CELL BIOL, V13, P1332, DOI 10.1128/MCB.13.3.1332; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Tahirov TH, 2002, CELL, V108, P57, DOI 10.1016/S0092-8674(01)00636-5; Tsukada J, 1997, BLOOD, V90, P3142, DOI 10.1182/blood.V90.8.3142; TSUKADA J, 1994, MOL CELL BIOL, V14, P7285, DOI 10.1128/MCB.14.11.7285; Verger A, 2002, BIOESSAYS, V24, P362, DOI 10.1002/bies.10068; Verger A, 2001, J BIOL CHEM, V276, P17181, DOI 10.1074/jbc.M010208200; WAEBER G, 1991, MOL ENDOCRINOL, V5, P1431, DOI 10.1210/mend-5-10-1431; Wara-Aswapati N, 1999, MOL CELL BIOL, V19, P6803; Williams SC, 1997, GENE EXPRESSION, V6, P371; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Xie Y, 2002, J BIOL CHEM, V277, P11802, DOI 10.1074/jbc.M109296200; Yamamoto H, 1999, ONCOGENE, V18, P1495, DOI 10.1038/sj.onc.1202427; Yang ZY, 2000, J BIOL CHEM, V275, P21272, DOI 10.1074/jbc.M000145200	39	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41421	41428		10.1074/jbc.M509143200	http://dx.doi.org/10.1074/jbc.M509143200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16223730	hybrid			2022-12-25	WOS:000233866900039
J	Storre, J; Schafer, A; Reichert, N; Barbero, JL; Hauser, S; Eilers, M; Gaubatz, S				Storre, J; Schafer, A; Reichert, N; Barbero, JL; Hauser, S; Eilers, M; Gaubatz, S			Silencing of the meiotic genes SMC1 beta and STAG3 in somatic cells by E2F6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAINS; FAMILY-MEMBER; TRANSCRIPTION; METHYLATION; COMPLEX; PROLIFERATION; REPRESSOR; CHROMATIN; PROTEIN; IDENTIFICATION	E2F6, a member of the E2F-family of transcription factors, is a retinoblastoma protein-independent transcriptional repressor. E2F6 associates with polycomb group (Pc-G) multiprotein complexes that contain histone H3 methyltransferases, suggesting that E2F6 represses genes by covalent histone modification. However, genes that are repressed by E2F6 via a mechanism that involves histone H3 methylation have not been identified. Using cDNA microarray experiments comparing wild-type and E2f6-/- mouse embryonic fibroblasts, we now found that E2F6 is required to silence the meiosis-specific genes SMC1 beta and STAG3 in somatic cells. Re-expression of E2F6 in E2f6-/- cells was sufficient to restore their repression. E2F6 binds in vivo to the promoters of these genes through a conserved binding site. Transcriptional repression of SMC1 beta and STAG3 by E2F6-/- involves multiple mechanisms, including methylation of histone H3 on lysine 9 and lysine 27. Our findings suggest a molecular mechanism for the stable transcriptional silencing of meiotic genes in somatic cells by E2F6.	Univ Marburg, Inst Mol Biol & Tumor res, D-35037 Marburg, Germany; Ctr Nacl Biotecnol, Consejo Super Invest, Dept Immunol & Oncol, Madrid 28049, Spain	Philipps University Marburg; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Gaubatz, S (corresponding author), Univ Marburg, Inst Mol Biol & Tumor res, Emil Mannkoffstr 2, D-35037 Marburg, Germany.	gaubatz@imt.uni-marburg.de	Barbero, Jose Luis/J-9833-2014	Eilers, Martin/0000-0002-0376-6533; BARBERO, JOSE LUIS/0000-0002-1226-0323; Gaubatz, Stefan/0000-0001-8751-4191				Attwooll C, 2005, J BIOL CHEM, V280, P1199, DOI 10.1074/jbc.M412509200; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; Christensen J, 2005, NUCLEIC ACIDS RES, V33, P5458, DOI 10.1093/nar/gki855; de Bruin A, 2003, J BIOL CHEM, V278, P42041, DOI 10.1074/jbc.M308105200; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Dimova DK, 2003, GENE DEV, V17, P2308, DOI 10.1101/gad.1116703; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; Gaubatz S, 2000, MOL CELL, V6, P729, DOI 10.1016/S1097-2765(00)00071-X; Giangrande PH, 2004, GENE DEV, V18, P2941, DOI 10.1101/gad.1239304; Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493; Logan N, 2005, ONCOGENE, V24, P5000, DOI 10.1038/sj.onc.1208703; Logan N, 2004, ONCOGENE, V23, P5138, DOI 10.1038/sj.onc.1207649; Morkel M, 1997, NATURE, V390, P567, DOI 10.1038/37507; Oberley MJ, 2003, J BIOL CHEM, V278, P42466, DOI 10.1074/jbc.M307733200; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Pezzi N, 2000, FASEB J, V14, P581, DOI 10.1096/fasebj.14.3.581; Pohlers M, 2005, CURR BIOL, V15, P1051, DOI 10.1016/j.cub.2005.04.060; Prieto I, 2001, NAT CELL BIOL, V3, P761, DOI 10.1038/35087082; Revenkova E, 2001, MOL CELL BIOL, V21, P6984, DOI 10.1128/MCB.21.20.6984-6998.2001; Storre J, 2002, EMBO REP, V3, P695, DOI 10.1093/embo-reports/kvf141; Takahashi Y, 2000, GENE DEV, V14, P804; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Trimarchi JM, 2001, P NATL ACAD SCI USA, V98, P1519, DOI 10.1073/pnas.041597698; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Wells J, 2002, P NATL ACAD SCI USA, V99, P3890, DOI 10.1073/pnas.062047499; Wells JM, 1997, J BIOL CHEM, V272, P4483, DOI 10.1074/jbc.272.7.4483	29	26	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41380	41386		10.1074/jbc.M506797200	http://dx.doi.org/10.1074/jbc.M506797200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16236716	hybrid			2022-12-25	WOS:000233866900034
J	Lee, MH; Chang, YC; Hong, EL; Grubb, J; Chang, CS; Bishop, DK; Wang, TF				Lee, MH; Chang, YC; Hong, EL; Grubb, J; Chang, CS; Bishop, DK; Wang, TF			Calcium ion promotes yeast Dmc1 activity via formation of long and fine helical filaments with single-stranded DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEIOTIC CHROMOSOME SYNAPSIS; SACCHAROMYCES-CEREVISIAE; RECA PROTEIN; ELECTRON-MICROSCOPY; RECOMBINASE DMC1; OCTAMERIC RING; RAD51 PROTEIN; DUPLEX DNA; COMPLEXES; ATP	Dmc1 is specifically required for homologous recombination during meiosis. Here we report that the calcium ion enabled Dmc1 from budding yeast to form regular helical filaments on single-stranded-DNA (ssDNA) and activate its strand assimilation activity. Relative to magnesium, calcium increased the affinity of Dmc1 for ATP and but reduces its DNA-dependent ATPase activity. These effects, together with previous studies of other RecA-like recombinases, support the view that ATP binding to Dmc1 protomers is required for functional filament structure. The helical pitch of the Saccharomyces cerevisiae Dmc1- ssDNA helical filament was estimated to be 13.4 +/- 2.5 nm. Analysis of apparently "complete" Dmc1-ssDNA filaments indicated a stoichiometry of 24 +/- 2 nucleotides per turn of the Dmc1 helix. This finding suggests that the number or protomers per helical turn and/ or the number of nucleotides bound per Dmc1 protomer differs from that reported previously for Rad51 and RecA filaments. Our data support the view that the active form of Dmc1 protein is a helical filament rather than a ring. We speculate that Ca2+ plays a significant role in regulating meiotic recombination.	Acad Sinica, Inst Biol Chem, Taipei 11529, Taiwan; Acad Sinica, Inst Phys, Taipei 11529, Taiwan; Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA	Academia Sinica - Taiwan; Academia Sinica - Taiwan; University of Chicago	Wang, TF (corresponding author), Acad Sinica, Inst Biol Chem, Taipei 11529, Taiwan.	tfwang@gate.sinica.edu.tw	Chang, Chia-Seng/AAP-8155-2021; CHANG, Yuan-Chih/J-2609-2016; Wang, Ting-Fang/ABI-3818-2020	CHANG, Yuan-Chih/0000-0002-0289-3768; Wang, Ting-Fang/0000-0001-6306-9505	NIGMS NIH HHS [GM50936] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beeler T, 1997, BBA-BIOMEMBRANES, V1323, P310, DOI 10.1016/S0005-2736(96)00199-X; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; Bugreev DV, 2005, J BIOL CHEM, V280, P26886, DOI 10.1074/jbc.M502248200; Bugreev DV, 2004, P NATL ACAD SCI USA, V101, P9988, DOI 10.1073/pnas.0402105101; Chang YC, 2005, BIOCHEMISTRY-US, V44, P6052, DOI 10.1021/bi048897q; DICAPUA E, 1982, J MOL BIOL, V157, P87, DOI 10.1016/0022-2836(82)90514-9; EGELMAN EH, 1986, J MOL BIOL, V191, P677, DOI 10.1016/0022-2836(86)90453-5; Gupta RC, 2001, P NATL ACAD SCI USA, V98, P8433, DOI 10.1073/pnas.121005298; HALACHMI D, 1989, FEBS LETT, V256, P55, DOI 10.1016/0014-5793(89)81717-X; HEUSER J, 1989, J MOL BIOL, V210, P473, DOI 10.1016/0022-2836(89)90124-1; Hong E. L., 2002, THESIS U CHICAGO CHI, P84; Hong ERL, 2001, J BIOL CHEM, V276, P41906, DOI 10.1074/jbc.M105563200; Kinebuchi T, 2004, MOL CELL, V14, P363, DOI 10.1016/S1097-2765(04)00218-7; Lee MH, 2004, BIOCHEM BIOPH RES CO, V323, P845, DOI 10.1016/j.bbrc.2004.08.163; Li ZF, 1997, P NATL ACAD SCI USA, V94, P11221, DOI 10.1073/pnas.94.21.11221; Masson JY, 1999, EMBO J, V18, P6552, DOI 10.1093/emboj/18.22.6552; Mazina OM, 2004, J BIOL CHEM, V279, P52042, DOI 10.1074/jbc.M410244200; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; Passy SI, 1999, P NATL ACAD SCI USA, V96, P10684, DOI 10.1073/pnas.96.19.10684; ROCKMILL B, 1995, GENE DEV, V9, P2684, DOI 10.1101/gad.9.21.2684; Sehorn MG, 2004, NATURE, V429, P433, DOI 10.1038/nature02563; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SUIZU T, 1995, CAN J MICROBIOL, V41, P1035, DOI 10.1139/m95-143; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Yu X, 1997, NAT STRUCT BIOL, V4, P101, DOI 10.1038/nsb0297-101	26	38	39	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40980	40984		10.1074/jbc.M505896200	http://dx.doi.org/10.1074/jbc.M505896200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16204247	hybrid			2022-12-25	WOS:000233666600072
J	Zhang, H; Xu, YK; Joseph, J; Kalyanaraman, B				Zhang, H; Xu, YK; Joseph, J; Kalyanaraman, B			Intramolecular electron transfer between tyrosyl radical and cysteine residue inhibits tyrosine nitration and induces thiyl radical formation in model peptides treated with myeloperoxidase, H2O2, and NO2- - EPR spin trapping studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXYNITRITE-MEDIATED OXIDATION; LOW-DENSITY-LIPOPROTEIN; NITRIC-OXIDE; IN-VIVO; S-NITROSYLATION; PHOSPHOLIPID-MEMBRANES; EOSINOPHIL PEROXIDASE; PROTEIN NITRATION; SUPEROXIDE; NITROGEN	We investigated the effects of a cysteine residue on tyrosine nitration in several model peptides treated with myeloperoxidase (MPO), H2O2, and nitrite anion (NO2-) and with horseradish peroxidase and H2O2. Sequences of model peptides were acetyl-Tyr-Cys-amide(YC), acetyl-Tyr- Ala-Cys-amide(YAC), acetyl-Tyr-Ala-Ala-Cys-amide(YAAC), and acetyl-Tyr-Ala-Ala-Ala-Ala-Cys-amide(YAAAAC). Results indicate that nitration and oxidation products of tyrosyl residue in YC and other model peptides were barely detectable. Amajorproductdetected was the corresponding disulfide ( e. g. YCysCysY). Spin trapping experiments with 5,5'-dimethyl-1-pyrrolineN-oxide(DMPO) revealed thiyl adduct ( e. g. DMPO-SCys-Tyr) formation from peptides ( e. g. YC) treated withMPO/H2O2 and MPO/H2O2/NO2-. The steady-state concentrations of DMPO-thiyl adducts decreased with increasing chain length of model peptides. Blocking the sulfydryl group in YC with methylmethanethiosulfonate(that formed YCSSCH3) totally inhibited thiyl radical formation as did substitution of Tyr with Phe (i.e. FC) in the presence of MPO/H2O2/NO2-. However, increased tyrosine nitration, tyrosine dimerization, and tyrosyl radical formation were detected in theMPO/H2O2/NO2-/YCSSCH3 system. Increased formation of S-nitrosated YC(YCysNO) was detected in the MPO/H2O2/(NO)-N-center dot system. We conclude that a rapid intramolecular electron transfer reaction between the tyrosyl radical and the Cys residue impedes tyrosine nitration and induces corresponding thiyl radical and nitrosocysteine product. Implications of this novel intramolecular electron transfer mechanism in protein nitration and nitrosation are discussed.	Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Free Rad Res Ctr, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin	Kalyanaraman, B (corresponding author), Med Coll Wisconsin, Dept Biophys, 8701 Watertown Plank Rd,POB 26509, Milwaukee, WI 53226 USA.	balarama@mcw.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063119] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL63119] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arstall MA, 1998, J MOL CELL CARDIOL, V30, P979, DOI 10.1006/jmcc.1998.0662; Baldus S, 2002, FREE RADICAL BIO MED, V33, P1010, DOI 10.1016/S0891-5849(02)00993-0; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; Brennan ML, 2002, J BIOL CHEM, V277, P17415, DOI 10.1074/jbc.M112400200; Bryan NS, 2004, P NATL ACAD SCI USA, V101, P4308, DOI 10.1073/pnas.0306706101; Candeias LP, 1997, BIOCHEMISTRY-US, V36, P7081, DOI 10.1021/bi970384e; Denicola A, 1998, P NATL ACAD SCI USA, V95, P3566, DOI 10.1073/pnas.95.7.3566; Denicola A, 2002, J BIOL CHEM, V277, P932, DOI 10.1074/jbc.M106589200; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Espey MG, 2002, P NATL ACAD SCI USA, V99, P11127, DOI 10.1073/pnas.152157599; Foster MW, 2004, J BIOL CHEM, V279, P25891, DOI 10.1074/jbc.M313853200; Gao CJ, 2005, NITRIC OXIDE-BIOL CH, V12, P121, DOI 10.1016/j.niox.2004.11.006; Goss SPA, 1999, ARCH BIOCHEM BIOPHYS, V363, P333, DOI 10.1006/abbi.1998.1094; Gow A, 1996, ARCH BIOCHEM BIOPHYS, V333, P42, DOI 10.1006/abbi.1996.0362; Gow AJ, 2004, AM J PHYSIOL-LUNG C, V287, pL262, DOI 10.1152/ajplung.00295.2003; Greenacre SAB, 2001, FREE RADICAL RES, V34, P541, DOI 10.1080/10715760100300471; Gunther MR, 2003, CHEM RES TOXICOL, V16, P652, DOI 10.1021/tx0256580; HADDAD IY, 1994, J CLIN INVEST, V94, P2407, DOI 10.1172/JCI117607; Hao G, 2004, J BIOL CHEM, V279, P36192, DOI 10.1074/jbc.M404866200; HARMAN LS, 1984, J BIOL CHEM, V259, P5606; Ischiropoulos H, 2003, BIOCHEM BIOPH RES CO, V305, P776, DOI 10.1016/S0006-291X(03)00814-3; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; Jourd'heuil D, 2001, J BIOL CHEM, V276, P28799, DOI 10.1074/jbc.M102341200; Kalyanaraman B, 1996, ANAL BIOCHEM, V241, P75, DOI 10.1006/abio.1996.0380; Karoui H, 1996, J BIOL CHEM, V271, P6000, DOI 10.1074/jbc.271.11.6000; Khairutdinov RF, 2000, BIOCHEMISTRY-US, V39, P14238, DOI 10.1021/bi001270x; Kooy NW, 1997, CRIT CARE MED, V25, P812, DOI 10.1097/00003246-199705000-00017; Lakshmi VM, 2005, J BIOL CHEM, V280, P1746, DOI 10.1074/jbc.M411263200; Lanone S, 2002, BIOCHEM J, V366, P399, DOI 10.1042/BJ20020339; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P1433, DOI 10.1074/jbc.272.3.1433; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; MacPherson JC, 2001, J IMMUNOL, V166, P5763, DOI 10.4049/jimmunol.166.9.5763; Marla SS, 1997, P NATL ACAD SCI USA, V94, P14243, DOI 10.1073/pnas.94.26.14243; Marshall HE, 2002, J BIOL CHEM, V277, P34223, DOI 10.1074/jbc.M201638200; McVey M, 1999, J BIOL CHEM, V274, P18887, DOI 10.1074/jbc.274.27.18887; Newman DK, 2002, BIOCHEM BIOPH RES CO, V296, P1171, DOI 10.1016/S0006-291X(02)02060-0; Pavlick KP, 2002, FREE RADICAL BIO MED, V33, P311, DOI 10.1016/S0891-5849(02)00853-5; Paxinou E, 2001, J NEUROSCI, V21, P8053, DOI 10.1523/JNEUROSCI.21-20-08053.2001; Pfeiffer S, 2001, FASEB J, V15, P2355, DOI 10.1096/fj.01-0295com; PRUETZ W A, 1985, Archives of Biochemistry and Biophysics, V243, P125; PRUETZ W A, 1982, Biochimica et Biophysica Acta, V705, P139; PRUETZ W A, 1981, Journal of the Chemical Society Faraday Transactions I, V77, P281; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; Radi R, 1999, METHOD ENZYMOL, V301, P353; Rassaf T, 2002, FREE RADICAL BIO MED, V33, P1590, DOI 10.1016/S0891-5849(02)01183-8; RUBBO H, 1994, J BIOL CHEM, V269, P26066; SAEZ G, 1982, BIOCHIM BIOPHYS ACTA, V719, P24, DOI 10.1016/0304-4165(82)90302-6; Schopfer FJ, 2003, TRENDS BIOCHEM SCI, V28, P646, DOI 10.1016/j.tibs.2003.10.006; Shao BH, 2005, J BIOL CHEM, V280, P5983, DOI 10.1074/jbc.M411484200; Souza JM, 1999, ARCH BIOCHEM BIOPHYS, V371, P169, DOI 10.1006/abbi.1999.1480; Tanner C, 1998, FREE RADICAL BIO MED, V24, P671, DOI 10.1016/S0891-5849(97)00340-7; Turko IV, 2002, PHARMACOL REV, V54, P619, DOI 10.1124/pr.54.4.619; van Dalen CJ, 2000, J BIOL CHEM, V275, P11638, DOI 10.1074/jbc.275.16.11638; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; VONFREYBERG B, 1991, J COMPUT CHEM, V12, P1065, DOI 10.1002/jcc.540120904; WHITE CR, 1994, P NATL ACAD SCI USA, V91, P1044, DOI 10.1073/pnas.91.3.1044; Wu WJ, 1999, J BIOL CHEM, V274, P25933, DOI 10.1074/jbc.274.36.25933; Yang Y, 2005, P NATL ACAD SCI USA, V102, P117, DOI 10.1073/pnas.0405989102; Yao DD, 2004, P NATL ACAD SCI USA, V101, P10810, DOI 10.1073/pnas.0404161101; Yasinska IM, 2003, FEBS LETT, V549, P105, DOI 10.1016/S0014-5793(03)00807-X; Zhang H, 2003, J BIOL CHEM, V278, P8969, DOI 10.1074/jbc.M211561200; Zhang H, 2001, BIOCHEMISTRY-US, V40, P7675, DOI 10.1021/bi002958c; Zhang YY, 1996, J BIOL CHEM, V271, P14271, DOI 10.1074/jbc.271.24.14271	65	60	63	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40684	40698		10.1074/jbc.M504503200	http://dx.doi.org/10.1074/jbc.M504503200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16176930	hybrid			2022-12-25	WOS:000233666600038
J	Zhang, NX; Kaur, R; Lu, XY; Shen, X; Li, L; Legerski, RJ				Zhang, NX; Kaur, R; Lu, XY; Shen, X; Li, L; Legerski, RJ			The Pso4 mRNA splicing and DNA repair complex interacts with WRN for processing of DNA interstrand cross-links	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WERNER-SYNDROME PROTEIN; NUCLEOTIDE EXCISION-REPAIR; SACCHAROMYCES-CEREVISIAE; NUCLEAR-MATRIX; U-BOX; PRP19P-ASSOCIATED COMPLEX; HOMOLOGOUS RECOMBINATION; FUNCTIONAL-ANALYSIS; MASS-SPECTROMETRY; HELICASE ACTIVITY	DNA interstrand cross-links ( ICLs) are perhaps the most formidable lesion encountered by the cellular DNA repair machinery, and the elucidation of the process by which they are removed in eukaryotic cells has proved a daunting task. In particular, the early stages of adduct recognition and uncoupling of the cross-link have remained elusive principally because genetic studies have not been highly revealing. We have developed a biochemical assay in which processing of a DNA substrate containing a site-specific psoralen ICL can be monitored in vitro. Using this assay we have shown previously that the mismatch repair factor MutS beta, the nucleotide excision repair heterodimer Ercc1-Xpf, and the replication proteins RPA and PCNA are involved in an early stage of psoralen ICL processing. Here, we report the identification of two additional factors required in the ICL repair process, a previously characterized pre-mRNA splicing complex composed of Pso4/Prp19, Cdc5L, Plrg1, and Spf27 (Pso4 complex), and WRN the protein deficient in Werner syndrome. Analysis of the WRN protein indicates that its DNA helicase function, but not its exonuclease activity, is required for ICL processing in vitro. In addition, we show that WRN and the Pso4 complex interact through a direct physical association between WRN and Cdc5L. A putative model for uncoupling of ICLs in mammalian cells is presented.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Legerski, RJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rlegersk@mdanderson.org			NCI NIH HHS [CA075160, CA09102, CA097175, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA097175, P30CA016672, R01CA075160] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ajuh P, 2000, EMBO J, V19, P6569, DOI 10.1093/emboj/19.23.6569; Ajuh P, 2003, NUCLEIC ACIDS RES, V31, P6104, DOI 10.1093/nar/gkg817; Akkari YMN, 2000, MOL CELL BIOL, V20, P8283, DOI 10.1128/MCB.20.21.8283-8289.2000; Barber LJ, 2005, MOL CELL BIOL, V25, P2297, DOI 10.1128/MCB.25.6.2297-2309.2005; Berardini M, 1999, J BACTERIOL, V181, P2878, DOI 10.1128/JB.181.9.2878-2882.1999; Berardini M, 1997, BIOCHEMISTRY-US, V36, P3506, DOI 10.1021/bi962778w; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Bode J, 2000, J CELL BIOCHEM, P3; Burns CG, 1999, P NATL ACAD SCI USA, V96, P13789, DOI 10.1073/pnas.96.24.13789; Chan SP, 2003, SCIENCE, V302, P279, DOI 10.1126/science.1086602; CHENG SC, 1993, MOL CELL BIOL, V13, P1876, DOI 10.1128/MCB.13.3.1876; COLE RS, 1976, J MOL BIOL, V103, P39, DOI 10.1016/0022-2836(76)90051-6; COLE RS, 1973, YALE J BIOL MED, V46, P492; Comai L, 2004, MECH AGEING DEV, V125, P521, DOI 10.1016/j.mad.2004.06.004; Cremer T, 2000, CRIT REV EUKAR GENE, V10, P179; DARDALHON M, 1995, MUTAT RES-DNA REPAIR, V336, P49, DOI 10.1016/0921-8777(94)00037-7; De Silva IU, 2000, MOL CELL BIOL, V20, P7980, DOI 10.1128/MCB.20.21.7980-7990.2000; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Erdemir T, 2002, MOL MICROBIOL, V46, P947, DOI 10.1046/j.1365-2958.2002.03224.x; Erdemir T, 2002, J CELL SCI, V115, P207; Godthelp BC, 2002, NUCLEIC ACIDS RES, V30, P2172, DOI 10.1093/nar/30.10.2172; Gotzmann J, 2000, EXP CELL RES, V261, P166, DOI 10.1006/excr.2000.5025; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Greenberg RB, 2001, J BIOL CHEM, V276, P31551, DOI 10.1074/jbc.M103588200; Grey M, 1996, NUCLEIC ACIDS RES, V24, P4009, DOI 10.1093/nar/24.20.4009; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; HENRIQUES JAP, 1989, MUTAT RES, V218, P111, DOI 10.1016/0921-8777(89)90017-7; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; JACHYMCZYK WJ, 1981, MOL GEN GENET, V182, P196, DOI 10.1007/BF00269658; Jin SH, 2003, CANCER RES, V63, P4204; Jurica MS, 2003, MOL CELL, V12, P5, DOI 10.1016/S1097-2765(03)00270-3; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Kamiuchi S, 2002, P NATL ACAD SCI USA, V99, P201, DOI 10.1073/pnas.012473199; Koehler DR, 1996, NUCLEIC ACIDS RES, V24, P2877, DOI 10.1093/nar/24.15.2877; Kuraoka I, 2000, J BIOL CHEM, V275, P26632, DOI 10.1074/jbc.C000337200; Lan L, 2004, DNA REPAIR, V3, P135, DOI 10.1016/j.dnarep.2003.10.005; Lee JW, 2005, MECH AGEING DEV, V126, P79, DOI 10.1016/j.mad.2004.09.011; Li JL, 2001, BIOCHEMISTRY-US, V40, P15194, DOI 10.1021/bi011067h; Li L, 1999, MOL CELL BIOL, V19, P5619; Li L, 2000, NUCLEIC ACIDS RES, V28, P1424, DOI 10.1093/nar/28.6.1424; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; Loscher M, 2005, BIOCHEM J, V388, P593, DOI 10.1042/BJ20041517; Mahajan KN, 2003, P NATL ACAD SCI USA, V100, P10746, DOI 10.1073/pnas.1631060100; Makarov EM, 2002, SCIENCE, V298, P2205, DOI 10.1126/science.1077783; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; Mauldin SK, 2002, NUCLEIC ACIDS RES, V30, P4075, DOI 10.1093/nar/gkf529; McDonald WH, 1999, MOL CELL BIOL, V19, P5352; McHugh PJ, 2000, MOL CELL BIOL, V20, P3425, DOI 10.1128/MCB.20.10.3425-3433.2000; McHugh PJ, 1999, NUCLEIC ACIDS RES, V27, P3259, DOI 10.1093/nar/27.16.3259; MILLER RD, 1982, MOL CELL BIOL, V2, P939, DOI 10.1128/MCB.2.8.939; MULLENDERS LHF, 1990, PROG CLIN BIOL RES, V340, P223; Neubauer G, 1998, NAT GENET, V20, P46, DOI 10.1038/1700; Ohi MD, 2005, MOL CELL BIOL, V25, P451, DOI 10.1128/MCB.25.1.451-460.2005; Ohi MD, 2003, NAT STRUCT BIOL, V10, P250, DOI 10.1038/nsb906; Ohi MD, 2002, RNA, V8, P798, DOI 10.1017/S1355838202025050; Opresko PL, 2003, CARCINOGENESIS, V24, P791, DOI 10.1093/carcin/bgg034; Opresko PL, 2001, J BIOL CHEM, V276, P44677, DOI 10.1074/jbc.M107548200; Poot M, 2002, FASEB J, V16, P757, DOI 10.1096/fj.01-0906fje; Poot M, 2001, FASEB J, V15, P1224, DOI 10.1096/fj.00-0611fje; Prince PR, 2001, GENE DEV, V15, P933, DOI 10.1101/gad.877001; Saintigny Y, 2002, MOL CELL BIOL, V22, P6971, DOI 10.1128/MCB.22.20.6971-6978.2002; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; SLADEK FM, 1989, J BIOL CHEM, V264, P6755; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; Swanson C, 2004, DNA REPAIR, V3, P475, DOI 10.1016/j.dnarep.2004.01.002; TARN WY, 1993, MOL CELL BIOL, V13, P1883, DOI 10.1128/MCB.13.3.1883; Tsai WY, 1999, J BIOL CHEM, V274, P9455, DOI 10.1074/jbc.274.14.9455; von Kobbe C, 2002, J BIOL CHEM, V277, P22035, DOI 10.1074/jbc.M200914200; Wang X, 2001, MOL CELL BIOL, V21, P713, DOI 10.1128/MCB.21.3.713-720.2001; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; XU J, 1994, CARCINOGENESIS, V15, P1443, DOI 10.1093/carcin/15.7.1443; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; Zhang NX, 2000, NUCLEIC ACIDS RES, V28, P4800, DOI 10.1093/nar/28.23.4800; Zhang NX, 2003, BIOCHEM BIOPH RES CO, V309, P71, DOI 10.1016/S0006-291X(03)01535-3; Zhang NX, 2002, MOL CELL BIOL, V22, P2388, DOI 10.1128/MCB.22.7.2388-2397.2002; Zhang XS, 2004, MOL CELL BIOL, V24, P9207, DOI 10.1128/MCB.24.20.9207-9220.2004; Zheng HY, 2003, MOL CELL BIOL, V23, P754, DOI 10.1128/MCB.23.2.754-761.2003	77	104	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40559	40567		10.1074/jbc.M508453200	http://dx.doi.org/10.1074/jbc.M508453200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16223718	hybrid			2022-12-25	WOS:000233666600023
J	Becker, HM; Hirnet, D; Fecher-Trost, C; Sultemeyer, D; Deitmer, JW				Becker, HM; Hirnet, D; Fecher-Trost, C; Sultemeyer, D; Deitmer, JW			Transport activity of MCT1 expressed in Xenopus oocytes is increased by interaction with carbonic anhydrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM/BICARBONATE COTRANSPORTER; LACTATE TRANSPORT; O-18 EXCHANGE; II BINDS; BICARBONATE; ASTROCYTES; METABOLON; SUBSTRATE; CELLS; PH	Injection of carbonic anhydrase isoform II (CA) into Xenopus frog oocytes increased the rate of H+ flux via the rat monocarboxylate transporter isoform 1 (MCT1) expressed in the oocytes. MCT1 activity was assessed by changes of intracellular H+ concentration measured by pH-selective microelectrodes during application of lactate. CA-induced augmentation of the rate of H+ flux mediated by MCT1 was not inhibited by ethoxyzolamide (10 mu M) and did not depend on the presence of added CO2/HCO3- but was suppressed by injection of an antibody against CA. Deleting the C terminus of the MCT1 greatly reduced its transport rate and removed transport facilitation by CA. Injected CA accelerated the CO2/HCO3--induced acidification severalfold, which was blocked by ethoxyzolamide and was independent of MCT1 expression. Mass spectrometry confirmed activity of CA as injected into the frog oocytes. With pulldown assays we demonstrated a specific binding of CA to MCT1 that was not attributed to the C terminus of MCT1. Our results suggest that CA enhances MCT1 transport activity, independent of its enzymatic reaction center, presumably by binding to MCT1.	Tech Univ Kaiserlautern, Fachbereich Biol, Abt Allgemeine Zool, D-67653 Kaiserslautern, Germany; Tech Univ Kaiserlautern, Fachbereich Biol, Abt Prot Funkt Proteom, D-67653 Kaiserslautern, Germany; Tech Univ Kaiserlautern, Fachbereich Biol, Abt Pflanzenokol & Systemat, D-67653 Kaiserslautern, Germany	University of Kaiserslautern; University of Kaiserslautern; University of Kaiserslautern	Deitmer, JW (corresponding author), Tech Univ Kaiserlautern, Fachbereich Biol, Abt Allgemeine Zool, POB 3049, D-67653 Kaiserslautern, Germany.	deitmer@rhrk.uni-kl.de	Becker, Holger/AAB-4322-2020					Alvarez BV, 2003, BIOCHEMISTRY-US, V42, P12321, DOI 10.1021/bi0353124; Becker HM, 2004, J BIOL CHEM, V279, P28057, DOI 10.1074/jbc.M402401200; Becker HM, 2004, BIOPHYS J, V86, P235, DOI 10.1016/S0006-3495(04)74099-0; BECKER HM, 2005, PFLUG ARCH EUR J PHY, V449, pS33; Broer S, 1998, BIOCHEM J, V333, P167, DOI 10.1042/bj3330167; BROER S, 1997, J BIOL CHEM, V272, P3096; Cater HL, 2001, J PHYSIOL-LONDON, V531, P459, DOI 10.1111/j.1469-7793.2001.0459i.x; Cordat E, 2003, TRAFFIC, V4, P642, DOI 10.1034/j.1600-0854.2003.00123.x; Deitmer JW, 2000, BIOESSAYS, V22, P747, DOI 10.1002/1521-1878(200008)22:8<747::AID-BIES8>3.3.CO;2-S; DEITMER JW, 1991, J GEN PHYSIOL, V98, P637, DOI 10.1085/jgp.98.3.637; Galic S, 2003, BIOCHEM J, V376, P413, DOI 10.1042/BJ20030799; Gross E, 2002, J PHYSIOL-LONDON, V544, P679, DOI 10.1113/jphysiol.2002.029777; Halestrap AP, 2004, PFLUG ARCH EUR J PHY, V447, P619, DOI 10.1007/s00424-003-1067-2; JEFFREY M, 1991, J COMP PATHOL, V104, P337, DOI 10.1016/S0021-9975(08)80144-2; Li XJ, 2002, J BIOL CHEM, V277, P36085, DOI 10.1074/jbc.M111952200; Loiselle FB, 2003, MOL MEMBR BIOL, V20, P307, DOI 10.1080/0968768031000122520; Magistretti P J, 2000, Rev Med Suisse Romande, V120, P739; McMurtrie HL, 2004, J ENZYM INHIB MED CH, V19, P231, DOI 10.1080/14756360410001704443; PUSHKIN A, J PHYSL, V559, P55; Ro HA, 2004, J BIOL CHEM, V279, P37115, DOI 10.1074/jbc.M403099200; Schurr A, 1997, J NEUROCHEM, V69, P423; SCHURR A, 1988, SCIENCE, V240, P1326, DOI 10.1126/science.3375817; SILVERMAN DN, 1982, METHOD ENZYMOL, V87, P732; Sterling D, 2001, J BIOL CHEM, V276, P47886, DOI 10.1074/jbc.M105959200; SULTEMEYER DF, 1990, PLANT PHYSIOL, V94, P1250, DOI 10.1104/pp.94.3.1250; Svichar N, 2003, GLIA, V41, P415, DOI 10.1002/glia.10187; Vaughan-Jones RD, 2002, J PHYSIOL-LONDON, V541, P139, DOI 10.1113/jphysiol.2001.013267; Vince JW, 1998, J BIOL CHEM, V273, P28430, DOI 10.1074/jbc.273.43.28430; WEINER MP, 1994, GENE, V151, P119, DOI 10.1016/0378-1119(94)90641-6	29	71	72	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					39882	39889		10.1074/jbc.M503081200	http://dx.doi.org/10.1074/jbc.M503081200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16174776	hybrid			2022-12-25	WOS:000233461300026
J	Iwaki, S; Tkaczyk, C; Satterthwaite, AB; Halcomb, K; Beaven, MA; Metcalfe, DD; Gilfillan, AM				Iwaki, S; Tkaczyk, C; Satterthwaite, AB; Halcomb, K; Beaven, MA; Metcalfe, DD; Gilfillan, AM			Btk plays a crucial role in the amplification of Fc epsilon RI-mediated mast cell activation by Kit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; BRUTONS TYROSINE KINASE; ALPHA GENE-EXPRESSION; PROTEIN-KINASE; NUCLEAR-FACTOR; C-KIT; TERMINAL KINASE; T-CELLS; CYTOKINE PRODUCTION; ARACHIDONIC-ACID	Stem cell factor (SCF) acts in synergy with antigen to enhance the calcium signal, degranulation, activation of transcription factors, and cytokine production in human mast cells. However, the underlying mechanisms for this synergy remain unclear. Here we show, utilizing bone marrow-derived mast cells (BMMCs) from Btk and Lyn knock-out mice, that activation of Btk via Lyn plays a key role in promoting synergy. As in human mast cells, SCF enhanced degranulation and cytokine production in BMMCs. In Btk(-/-) BMMCs, in which there was a partial reduction in the capacity to degranulate in response to antigen, SCF was unable to enhance the residual antigen-mediated degranulation. Furthermore, as with antigen, the ability of SCF to promote cytokine production was abrogated in the Btk(-/-) BMMCs. The impairment of responses in Btk(-/-) cells correlated with an inability of SCF to augment phospholipase C gamma(1) activation and calcium mobilization, and to phosphorylate NF kappa B and NFAT for cytokine gene transcription in these cells. Similar studies with Lyn(-/-) and Btk(-/-)/ Lyn(-/-) BMMCs indicated that Lyn was a regulator of Btk for these responses. These data demonstrate, for the first time, that Btk is a key regulator of a Kit-mediated amplification pathway that augments Fc epsilon RI-mediated mast cell activation.	NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Ctr Immunol, Dallas, TX 75390 USA; NHLBI, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Gilfillan, AM (corresponding author), NIAID, Lab Allerg Dis, NIH, Bldg 10,Rm 11C206,10 Ctr Dr,MSC 1881, Bethesda, MD 20892 USA.	agilfillan@niaid.nih.gov			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000993, Z01HL000993] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000850] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Ali K, 2004, NATURE, V431, P1007, DOI 10.1038/nature02991; Antony P, 2004, BIOCHEM SOC T, V32, P113, DOI 10.1042/BST0320113; Antony P, 2003, EXP CELL RES, V291, P11, DOI 10.1016/S0014-4827(03)00338-0; BARKER SA, 1995, MOL BIOL CELL, V6, P1145, DOI 10.1091/mbc.6.9.1145; Brdicka T, 2002, J EXP MED, V196, P1617, DOI 10.1084/jem.20021405; Chaves-Dias C, 2001, J IMMUNOL, V166, P6647, DOI 10.4049/jimmunol.166.11.6647; Chayama K, 2001, P NATL ACAD SCI USA, V98, P4599, DOI 10.1073/pnas.081021898; Coward WR, 2002, J IMMUNOL, V169, P5287, DOI 10.4049/jimmunol.169.9.5287; ElHillal O, 1997, P NATL ACAD SCI USA, V94, P1919, DOI 10.1073/pnas.94.5.1919; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; GALLI SJ, 1993, AM J PATHOL, V142, P965; HAIG DM, 1994, BLOOD, V83, P72; Hao SL, 2003, EMBO J, V22, P4166, DOI 10.1093/emboj/cdg401; Hata D, 1998, J BIOL CHEM, V273, P10979, DOI 10.1074/jbc.273.18.10979; Hata D, 1998, J EXP MED, V187, P1235, DOI 10.1084/jem.187.8.1235; Hernandez-Hansen V, 2004, J IMMUNOL, V173, P100, DOI 10.4049/jimmunol.173.1.100; Hirasawa N, 2000, BBA-BIOENERGETICS, V1456, P45, DOI 10.1016/S0005-2728(99)00104-8; HIRASAWA N, 1995, J IMMUNOL, V154, P5391; Holmberg CI, 2002, TRENDS BIOCHEM SCI, V27, P619, DOI 10.1016/S0968-0004(02)02207-7; Humphries LA, 2004, J BIOL CHEM, V279, P37651, DOI 10.1074/jbc.M311985200; Hundley TR, 2004, BLOOD, V104, P2410, DOI 10.1182/blood-2004-02-0631; IEMURA A, 1994, AM J PATHOL, V144, P321; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; Kawakami Y, 2000, J IMMUNOL, V165, P1210, DOI 10.4049/jimmunol.165.3.1210; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; Kimura T, 1997, J IMMUNOL, V159, P4426; Kitaura J, 2000, J EXP MED, V192, P729, DOI 10.1084/jem.192.5.729; Li HL, 1999, P NATL ACAD SCI USA, V96, P6890, DOI 10.1073/pnas.96.12.6890; LIN PY, 1994, BIOCHEM J, V299, P109, DOI 10.1042/bj2990109; Linnekin D, 1999, INT J BIOCHEM CELL B, V31, P1053, DOI 10.1016/S1357-2725(99)00078-3; Lorentz A, 2003, J ALLERGY CLIN IMMUN, V111, P1062, DOI 10.1067/mai.2003.1342; Marquardt DL, 2000, J ALLERGY CLIN IMMUN, V105, P500, DOI 10.1067/mai.2000.104942; MEININGER CJ, 1992, BLOOD, V79, P958; NAKANO T, 1985, J EXP MED, V162, P1025, DOI 10.1084/jem.162.3.1025; Nishizumi H, 1997, J IMMUNOL, V158, P2350; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; OZAWA K, 1993, J BIOL CHEM, V268, P1749; Parravicini V, 2002, NAT IMMUNOL, V3, P741, DOI 10.1038/ni817; Pelletier C, 1998, J IMMUNOL, V161, P4768; PRIBLUDA VS, 1994, P NATL ACAD SCI USA, V91, P11246, DOI 10.1073/pnas.91.23.11246; Rivera J, 2002, CURR OPIN IMMUNOL, V14, P688, DOI 10.1016/S0952-7915(02)00396-5; Saitoh S, 2000, IMMUNITY, V12, P525, DOI 10.1016/S1074-7613(00)80204-6; Satterthwaite AB, 1998, J EXP MED, V188, P833, DOI 10.1084/jem.188.5.833; Tkaczyk C, 2004, BLOOD, V104, P207, DOI 10.1182/blood-2003-08-2769; Tkaczyk C, 2003, J BIOL CHEM, V278, P48474, DOI 10.1074/jbc.M301350200; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021; Wu CC, 2003, MOL CELL BIOL, V23, P6442, DOI 10.1128/MCB.23.18.6442-6454.2003; Yi AK, 2003, INT IMMUNOL, V15, P577, DOI 10.1093/intimm/dxg058; Zhang C, 1997, J BIOL CHEM, V272, P13397, DOI 10.1074/jbc.272.20.13397	49	86	135	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40261	40270		10.1074/jbc.M506063200	http://dx.doi.org/10.1074/jbc.M506063200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16176929	hybrid			2022-12-25	WOS:000233461300068
J	Lechardeur, D; Dougaparsad, S; Nemes, C; Lukacs, GL				Lechardeur, D; Dougaparsad, S; Nemes, C; Lukacs, GL			Oligomerization state of the DNA fragmentation factor in normal and apoptotic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE-ACTIVATED DNASE; CHROMATIN CONDENSATION; NUCLEASE; INHIBITOR; IDENTIFICATION; DFF40; CAD; MECHANISM; CLEAVAGE; DOMAINS	The caspase-activated DNase (CAD) is the primary nuclease responsible for oligonucleosomal DNA fragmentation during apoptosis. The DNA fragmentation factor (DFF) is composed of the 40-kDa CAD (DFF40) in complex with its cognate 45-kDa inhibitor ( inhibitor of CAD: ICAD or DFF45). The association of ICAD with CAD not only inhibits the DNase activity but is also essential for the co-translational folding of CAD. Activation of CAD requires caspase-3-dependent proteolysis of ICAD. The tertiary structures of neither the inactive nor the activated DFF have been conclusively established. Whereas the inactive DFF is thought to consist of the CAD/ICAD heterodimer, activated CAD has been isolated as a large (>MDa) multimer, as well as a monomer. To establish the subunit stoichiometry of DFF and some of its structural determinants in normal and apoptotic cells, we utilized size-exclusion chromatography in combination with co-immunoprecipitation and mutagenesis techniques. Both endogenous and heterologously expressed DFF have an apparent molecular mass of 160-190 kDa and contain 2 CAD and 2 ICAD molecules (CAD/ICAD) 2 in HeLa cells. Although the N-terminal (CIDE-N) domain of CAD is not required for ICAD binding, it is necessary but not sufficient for ICAD homodimerization in the DFF. In contrast, the CIDE-N domain of ICAD is required for CAD/ICAD association. Using bioluminescence resonance energy transfer (BRET), dimerization of ICAD in DFF was confirmed in live cells. In apoptotic cells, endogenous and exogenous CAD forms limited oligomers, representing the active nuclease. A model is proposed for the rearrangement of the DFF subunit stoichiometry in cells undergoing programmed cell death.	Hosp Sick Children, Program Cell & Lung Biol, Res Inst, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Lukacs, GL (corresponding author), Hosp Sick Children, Program Cell & Lung Biol, Res Inst, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	glukacs@sickkids.ca		Lechardeur, Delphine/0000-0002-5331-4607; Lukacs, Gergely/0000-0003-0900-0675				Durrieu F, 2000, CURR BIOL, V10, P923, DOI 10.1016/S0960-9822(00)00620-5; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a; Herrmann M, 1998, ARTHRITIS RHEUM-US, V41, P1241, DOI 10.1002/1529-0131(199807)41:7<1241::AID-ART15>3.0.CO;2-H; Inohara N, 1999, J BIOL CHEM, V274, P270, DOI 10.1074/jbc.274.1.270; Kampinga HH, 2003, MOL CELL BIOL, V23, P4948, DOI 10.1128/MCB.23.14.4948-4958.2003; Kimura H, 2001, J CELL BIOL, V153, P1341, DOI 10.1083/jcb.153.7.1341; Korn C, 2005, J BIOL CHEM, V280, P6005, DOI 10.1074/jbc.M413035200; Lechardeur D, 2004, J CELL BIOL, V167, P851, DOI 10.1083/jcb.200404105; Lechardeur D, 2000, J CELL BIOL, V150, P321, DOI 10.1083/jcb.150.2.321; Liu QL, 2003, BLOOD, V102, P1788, DOI 10.1182/blood-2002-11-3499; Liu XS, 1999, J BIOL CHEM, V274, P13836, DOI 10.1074/jbc.274.20.13836; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Lugovskoy AA, 1999, CELL, V99, P747, DOI 10.1016/S0092-8674(00)81672-4; McCarty JS, 1999, BIOCHEM BIOPH RES CO, V264, P181, DOI 10.1006/bbrc.1999.1498; Meiss G, 2001, NUCLEIC ACIDS RES, V29, P3901, DOI 10.1093/nar/29.19.3901; Misteli T, 2000, NATURE, V408, P877, DOI 10.1038/35048610; Mukae N, 2000, J BIOL CHEM, V275, P21402, DOI 10.1074/jbc.M909611199; Mukae N, 1998, P NATL ACAD SCI USA, V95, P9123, DOI 10.1073/pnas.95.16.9123; Nagata S, 2005, ANNU REV IMMUNOL, V23, P853, DOI 10.1146/annurev.immunol.23.021704.115811; Nagata S, 2000, EXP CELL RES, V256, P12, DOI 10.1006/excr.2000.4834; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Otomo T, 2000, NAT STRUCT BIOL, V7, P658, DOI 10.1038/77957; Perroy J, 2004, NAT METHODS, V1, P203, DOI 10.1038/NMETH722; Renatus M, 2001, P NATL ACAD SCI USA, V98, P14250, DOI 10.1073/pnas.231465798; Sakahira H, 2000, J BIOL CHEM, V275, P8091, DOI 10.1074/jbc.275.11.8091; Sakahira H, 2002, J BIOL CHEM, V277, P3364, DOI 10.1074/jbc.M110071200; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Samejima K, 1998, EXP CELL RES, V243, P453, DOI 10.1006/excr.1998.4212; Samuelsson MKR, 2002, BIOCHEM BIOPH RES CO, V296, P702, DOI 10.1016/S0006-291X(02)00912-9; Scholz SR, 2002, NUCLEIC ACIDS RES, V30, P3045, DOI 10.1093/nar/gkf431; Scovassi AI, 2003, EUR J HISTOCHEM, V47, P185; Toh SY, 1998, BIOCHEM BIOPH RES CO, V250, P598, DOI 10.1006/bbrc.1998.9369; Widlak P, 2005, J CELL BIOCHEM, V94, P1078, DOI 10.1002/jcb.20409; Widlak P, 2000, J BIOL CHEM, V275, P8226, DOI 10.1074/jbc.275.11.8226; Widlak P, 2003, J BIOL CHEM, V278, P26915, DOI 10.1074/jbc.M303807200; Widlak P, 2001, MOL CELL BIOCHEM, V218, P125, DOI 10.1023/A:1007231822086; Woo EJ, 2004, MOL CELL, V14, P531, DOI 10.1016/S1097-2765(04)00258-8; Yokoyama H, 2000, J BIOL CHEM, V275, P12978, DOI 10.1074/jbc.275.17.12978; Zhang JH, 2002, TRENDS CELL BIOL, V12, P84, DOI 10.1016/S0962-8924(01)02206-1; Zhou P, 2001, P NATL ACAD SCI USA, V98, P6051, DOI 10.1073/pnas.111145098	43	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40216	40225		10.1074/jbc.M502220200	http://dx.doi.org/10.1074/jbc.M502220200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16204257	Green Published, hybrid			2022-12-25	WOS:000233461300063
J	Sanders, PR; Gilson, PR; Cantin, GT; Greenbaum, DC; Nebl, T; Carucci, DJ; McConville, MJ; Schofield, L; Hodder, AN; Yates, JR; Crabb, BS				Sanders, PR; Gilson, PR; Cantin, GT; Greenbaum, DC; Nebl, T; Carucci, DJ; McConville, MJ; Schofield, L; Hodder, AN; Yates, JR; Crabb, BS			Distinct protein classes including novel merozoite surface antigens in raft-like membranes of Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALARIA PARASITES; LIFE-CYCLE; PARASITOPHOROUS VACUOLE; INHIBITORY ANTIBODIES; SHOTGUN PROTEOMICS; HUMAN ERYTHROCYTES; TOXOPLASMA-GONDII; IDENTIFICATION; INVASION; DOMAIN	Glycosylphosphatidylinositol (GPI)-anchored proteins coat the surface of extracellular Plasmodium falciparum merozoites, of which several are highly validated candidates for inclusion in a blood-stage malaria vaccine. Here we determined the proteome of gradient-purified detergent-resistant membranes of mature blood-stage parasites and found that these membranes are greatly enriched in GPI-anchored proteins and their putative interacting partners. Also prominent in detergent-resistant membranes are apical organelle (rhoptry), multimembrane-spanning, and proteins destined for export into the host erythrocyte cytosol. Four new GPI-anchored proteins were identified, and a number of other novel proteins that are predicted to localize to the merozoite surface and/or apical organelles were detected. Three of the putative surface proteins possessed six-cysteine (Cys6) motifs, a distinct fold found in adhesive surface proteins expressed in other life stages. All three Cys6 proteins, termed Pf12, Pf38, and Pf41, were validated as merozoite surface antigens recognized strongly by antibodies present in naturally infected individuals. In addition to the merozoite surface, Pf38 was particularly prominent in the secretory apical organelles. A different cysteine-rich putative GPI-anchored protein, Pf92, was also localized to the merozoite surface. This insight into merozoite surfaces provides new opportunities for understanding both erythrocyte invasion and anti-parasite immunity.	Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Univ Melbourne, Dept Med Biol, Parkville, Vic 3010, Australia; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Fdn Nat Inst Hlth, Bethesda, MD 20814 USA; Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3050, Australia	Walter & Eliza Hall Institute; University of Melbourne; Scripps Research Institute; University of Melbourne	Crabb, BS (corresponding author), Walter & Eliza Hall Inst Med Res, 1G Royal Parade, Parkville, Vic 3050, Australia.	crabb@wehi.edu.au	Crabb, Brendan/F-5287-2013; Nebl, Thomas/N-1620-2017	Nebl, Thomas/0000-0003-4003-9340				Baldi DL, 2000, EMBO J, V19, P2435, DOI 10.1093/emboj/19.11.2435; Black CG, 2003, MOL BIOCHEM PARASIT, V127, P59, DOI 10.1016/S0166-6851(02)00308-0; Bozdech Z, 2003, PLOS BIOL, V1, P85, DOI 10.1371/journal.pbio.0000005; Carter R, 2001, VACCINE, V19, P2309, DOI 10.1016/S0264-410X(00)00521-1; COOPER JA, 1992, MOL BIOCHEM PARASIT, V51, P301, DOI 10.1016/0166-6851(92)90080-4; Cowman AF, 2002, SCIENCE, V298, P126, DOI 10.1126/science.1078169; COWMAN AF, 2005, IN PESS MOL APPROACH; Crabb BS, 1996, P NATL ACAD SCI USA, V93, P7289, DOI 10.1073/pnas.93.14.7289; de Koning-Ward TF, 2003, J EXP MED, V198, P869, DOI 10.1084/jem.20030085; Drew DR, 2005, INFECT IMMUN, V73, P3912, DOI 10.1128/IAI.73.7.3912-3922.2005; ELLIOTT JF, 1990, P NATL ACAD SCI USA, V87, P6363, DOI 10.1073/pnas.87.16.6363; Fidock DA, 1997, P NATL ACAD SCI USA, V94, P10931, DOI 10.1073/pnas.94.20.10931; Florens L, 2002, NATURE, V419, P520, DOI 10.1038/nature01107; FOTER LJ, 2003, P NATL ACAD SCI USA, V100, P5813; Fox BA, 1997, EXP PARASITOL, V85, P121, DOI 10.1006/expr.1996.4118; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Gaskins E, 2004, J CELL BIOL, V165, P383, DOI 10.1083/jcb.200311137; Gilberger TW, 2003, J BIOL CHEM, V278, P14480, DOI 10.1074/jbc.M211446200; Hiller NL, 2004, SCIENCE, V306, P1934, DOI 10.1126/science.1102737; Hodder AN, 2003, J BIOL CHEM, V278, P48169, DOI 10.1074/jbc.M306755200; Hodder AN, 2001, INFECT IMMUN, V69, P3286, DOI 10.1128/IAI.69.5.3286-3294.2001; HOLDER AA, 1985, NATURE, V317, P270, DOI 10.1038/317270a0; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Lasonder E, 2002, NATURE, V419, P537, DOI 10.1038/nature01111; Lauer S, 2000, EMBO J, V19, P3556, DOI 10.1093/emboj/19.14.3556; Le Roch KG, 2004, GENOME RES, V14, P2308, DOI 10.1101/gr.2523904; Le Roch KG, 2003, SCIENCE, V301, P1503, DOI 10.1126/science.1087025; Marshall VM, 1997, INFECT IMMUN, V65, P4460, DOI 10.1128/IAI.65.11.4460-4467.1997; Marshall VM, 1998, MOL BIOCHEM PARASIT, V94, P13, DOI 10.1016/S0166-6851(98)00045-0; Marti M, 2004, SCIENCE, V306, P1930, DOI 10.1126/science.1102452; MCCOLL DJ, 1994, MOL BIOCHEM PARASIT, V68, P53, DOI 10.1016/0166-6851(94)00149-9; McDonald WH, 2002, DIS MARKERS, V18, P99, DOI 10.1155/2002/505397; Meissner M, 2005, P NATL ACAD SCI USA, V102, P2980, DOI 10.1073/pnas.0500112102; Miller SK, 2002, J BIOL CHEM, V277, P47524, DOI 10.1074/jbc.M206974200; Mills KE, 2002, MOL MICROBIOL, V43, P1401, DOI 10.1046/j.1365-2958.2002.02834.x; Moskes C, 2004, MOL MICROBIOL, V54, P676, DOI 10.1111/j.1365-2958.2004.04313.x; O'Donnell RA, 2001, J EXP MED, V193, P1403, DOI 10.1084/jem.193.12.1403; Pachebat JA, 2001, MOL BIOCHEM PARASIT, V117, P83, DOI 10.1016/S0166-6851(01)00336-X; Pearce JA, 2005, MOL BIOCHEM PARASIT, V139, P141, DOI 10.1016/j.molbiopara.2004.09.012; Reed MB, 2000, P NATL ACAD SCI USA, V97, P7509, DOI 10.1073/pnas.97.13.7509; Rug M, 2004, INFECT IMMUN, V72, P6095, DOI 10.1128/IAI.72.10.6095-6105.2004; SMYTHE JA, 1988, P NATL ACAD SCI USA, V85, P5195, DOI 10.1073/pnas.85.14.5195; Tabb DL, 2002, J PROTEOME RES, V1, P21, DOI 10.1021/pr015504q; Templeton TJ, 1999, MOL BIOCHEM PARASIT, V101, P223, DOI 10.1016/S0166-6851(99)00066-3; Thompson J, 2001, MOL BIOCHEM PARASIT, V118, P147, DOI 10.1016/S0166-6851(01)00377-2; Thompson JK, 2001, MOL MICROBIOL, V41, P47, DOI 10.1046/j.1365-2958.2001.02484.x; Tonkin CJ, 2004, MOL BIOCHEM PARASIT, V137, P13, DOI 10.1016/j.molbiopara.2004.05.009; Topolska AE, 2004, J BIOL CHEM, V279, P4648, DOI 10.1074/jbc.M307859200; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Trucco C, 2001, MOL BIOCHEM PARASIT, V112, P91, DOI 10.1016/S0166-6851(00)00350-9; van Dijk MR, 2001, CELL, V104, P153, DOI 10.1016/S0092-8674(01)00199-4; Wang L, 2003, MOL BIOCHEM PARASIT, V130, P149, DOI 10.1016/S0166-6851(03)00165-8; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Wickham ME, 2003, MOL BIOCHEM PARASIT, V129, P147, DOI 10.1016/S0166-6851(03)00118-X	54	176	187	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40169	40176		10.1074/jbc.M509631200	http://dx.doi.org/10.1074/jbc.M509631200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16203726	hybrid			2022-12-25	WOS:000233461300057
J	Svedruzic, ZM; Wang, CB; Kosmoski, JV; Smerdon, MJ				Svedruzic, ZM; Wang, CB; Kosmoski, JV; Smerdon, MJ			Accommodation and repair of a UV photoproduct in DNA at different rotational settings on the nucleosome surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; GLUCOCORTICOID RESPONSE ELEMENT; HUMAN CELL-EXTRACTS; PYRIMIDINE DIMERS; CRYSTAL-STRUCTURE; CORE DNA; CHROMATIN; DAMAGE; TRANSCRIPTION; MECHANISMS	Cyclobutane-thymine dimers ( CTDs), the most common DNA lesion induced by UV radiation, cause 30 bending and 9 unwinding of the DNA helix. We prepared site-specific CTDs within a short sequence bracketed by strong nucleosome-positioning sequences. The rotational setting of CTDs over one turn of the helix near the dyad center on the histone surface was analyzed by hydroxyl radical footprinting. Surprisingly, the position of CTDs over one turn of the helix does not affect the rotational setting of DNA on the nucleosome surface. Gel-shift analysis indicates that one CTD destabilizes histone-DNA interactions by 0.6 or 1.1 kJ/ mol when facing away or toward the histone surface, respectively. Thus, 0.5 kJ/ mol energy penalty for a buried CTD is not enough to change the rotational setting of sequences with strong rotational preference. The effect of rotational setting on CTD removal by nucleotide excision repair ( NER) was examined using Xenopus oocyte nuclear extracts. The NER rates are only 2 - 3 times lower in nucleosomes and change by only 1.5-fold when CTDs face away or toward the histone surface. Therefore, in Xenopus nuclear extracts, the rotational orientation of CTDs on nucleosomes has surprisingly little effect on rates of repair. These results indicate that nucleosome dynamics and/or chromatin remodeling may facilitate NER in gaining access to DNA damage in nucleosomes.	Washington State Univ, Dept Biochem & Biophys, Sch Mol Biosci, Pullman, WA 99164 USA	Washington State University	Smerdon, MJ (corresponding author), Washington State Univ, Dept Biochem & Biophys, Sch Mol Biosci, Pullman, WA 99164 USA.	smerdon@wsu.edu	Svedruzic, Zeljko M/R-3281-2018	Svedruzic, Zeljko M/0000-0002-0736-6182	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002614, R01ES004106, R37ES002614] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES04106, ES02614] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ackerman EJ, 2000, METHODS, V22, P188, DOI 10.1006/meth.2000.1060; ASHIKAWA I, 1983, BIOCHEMISTRY-US, V22, P6018, DOI 10.1021/bi00294a050; Beard BC, 2003, P NATL ACAD SCI USA, V100, P7465, DOI 10.1073/pnas.1330328100; BEDOYAN J, 1992, J BIOL CHEM, V267, P5996; Boyer LA, 2000, J BIOL CHEM, V275, P18864, DOI 10.1074/jbc.M002810200; Buttinelli M, 1998, P NATL ACAD SCI USA, V95, P8544, DOI 10.1073/pnas.95.15.8544; Cleaver JE, 2002, FRONT BIOSCI-LANDMRK, V7, pD1024, DOI 10.2741/cleaver; DODSON ML, 1989, MUTAT RES, V218, P49, DOI 10.1016/0921-8777(89)90011-6; GALE JM, 1987, P NATL ACAD SCI USA, V84, P6644, DOI 10.1073/pnas.84.19.6644; GALE JM, 1990, PHOTOCHEM PHOTOBIOL, V51, P411, DOI 10.1111/j.1751-1097.1990.tb01732.x; GALE JM, 1988, J MOL BIOL, V204, P949, DOI 10.1016/0022-2836(88)90054-X; Hanawalt PC, 1998, MUTAT RES-FUND MOL M, V400, P117, DOI 10.1016/S0027-5107(98)00084-0; Hara R, 2000, MOL CELL BIOL, V20, P9173, DOI 10.1128/MCB.20.24.9173-9181.2000; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; HUSAIN I, 1988, P NATL ACAD SCI USA, V85, P2558, DOI 10.1073/pnas.85.8.2558; Kosmoski JV, 2001, P NATL ACAD SCI USA, V98, P10113, DOI 10.1073/pnas.181073398; Kosmoski JV, 1999, BIOCHEMISTRY-US, V38, P9485, DOI 10.1021/bi990297h; Li G, 2004, NAT STRUCT MOL BIOL, V11, P763, DOI 10.1038/nsmb801; LI Q, 1993, GENE DEV, V7, P2471, DOI 10.1101/gad.7.12a.2471; LI Q, 1995, MOL CELL BIOL, V15, P4375; Li Y, 2004, NAT STRUCT MOL BIOL, V11, P784, DOI 10.1038/nsmb792; Liu XQ, 2000, J BIOL CHEM, V275, P23729, DOI 10.1074/jbc.M002206200; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Mann DB, 1997, P NATL ACAD SCI USA, V94, P2215, DOI 10.1073/pnas.94.6.2215; MITCHELL DL, 1990, J BIOL CHEM, V265, P5353; Park H, 2002, P NATL ACAD SCI USA, V99, P15965, DOI 10.1073/pnas.242422699; PEARLMAN DA, 1985, SCIENCE, V227, P1304, DOI 10.1126/science.3975615; RAO SN, 1984, NUCLEIC ACIDS RES, V12, P4789, DOI 10.1093/nar/12.11.4789; RIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; SMERDON MJ, 1990, CELL, V61, P675, DOI 10.1016/0092-8674(90)90479-X; SMERDON MJ, 1978, BIOCHEMISTRY-US, V17, P2377, DOI 10.1021/bi00605a020; SMERDON MJ, 1990, NUCLEIC ACIDS RES, V18, P2045, DOI 10.1093/nar/18.8.2045; SMERDON MJ, 1978, P NATL ACAD SCI USA, V75, P4238, DOI 10.1073/pnas.75.9.4238; SUGASAWA K, 1993, J BIOL CHEM, V268, P9098; SUQUET C, 1993, J BIOL CHEM, V268, P23755; Tommasi S, 1996, BIOCHEMISTRY-US, V35, P15693, DOI 10.1021/bi962117z; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; WANG J, 1982, P NATL ACAD SCI-BIOL, V79, P5896, DOI 10.1073/pnas.79.19.5896; WANG ZG, 1991, J BIOL CHEM, V266, P22472; Wellinger RE, 1997, EMBO J, V16, P5046, DOI 10.1093/emboj/16.16.5046; Widlund HR, 1997, J MOL BIOL, V267, P807, DOI 10.1006/jmbi.1997.0916; WILKINS RJ, 1974, NATURE, V247, P35, DOI 10.1038/247035a0; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711	46	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40051	40057		10.1074/jbc.M509478200	http://dx.doi.org/10.1074/jbc.M509478200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16210312	hybrid			2022-12-25	WOS:000233461300043
J	Ramjeet, M; Deslandes, V; St Michael, F; Cox, AD; Kobisch, MN; Gottschalk, M; Jacques, M				Ramjeet, M; Deslandes, V; St Michael, F; Cox, AD; Kobisch, MN; Gottschalk, M; Jacques, M			Truncation of the lipopolysaccharide outer core affects susceptibility to antimicrobial peptides and virulence of Actinobacillus pleuropneumoniae serotype 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE ALVEOLAR MACROPHAGES; NECROSIS-FACTOR-ALPHA; HAEMOPHILUS-PLEUROPNEUMONIAE; INFLAMMATORY CYTOKINE; RESPIRATORY-TRACT; EXPRESSION; PIGS; MUTANTS; OLIGOSACCHARIDES; PASTEURELLACEAE	We reported previously that the core oligosaccharide region of the lipopolysaccharide (LPS) is essential for optimal adhesion of Actinobacillus pleuropneumoniae, an important swine pathogen, to respiratory tract cells. Rough LPS and core LPS mutants of A. pleuropneumoniae serotype 1 were generated by using a mini-Tn10 transposon mutagenesis system. Here we performed a structural analysis of the oligosaccharide region of three core LPS mutants that still produce the same O-antigen by using methylation analyses and mass spectrometry. We also performed a kinetic study of proinflammatory cytokines production such as interleukin (IL)-6, tumor necrosis factor-alpha, IL1-beta, MCP-1, and IL8 by LPS-stimulated porcine alveolar macrophages, which showed that purified LPS of the parent strain, the rough LPS and core LPS mutants, had the same ability to stimulate the production of cytokines. Most interestingly, an in vitro susceptibility test of these LPS mutants to antimicrobial peptides showed that the three core LPS mutants were more susceptible to cationic peptides than both the rough LPS mutant and the wild type parent strain. Furthermore, experimental pig infections with these mutants revealed that the galactose (Gal I) and D, D-heptose (Hep IV) residues present in the outer core of A. pleuropneumoniae serotype 1 LPS are important for adhesion and overall virulence in the natural host, whereas deletion of the terminal GalNAc-Gal II disaccharide had no effect. Our data suggest that an intact core-lipid A region is required for optimal protection of A. pleuropneumoniae against cationic peptides and that deletion of specific residues in the outer LPS core results in the attenuation of the virulence of A. pleuropneumoniae serotype 1.	Univ Montreal, Fac Med Vet, Grp Rech Malad Infect Porc, St Hyacinthe, PQ J2S 7C6, Canada; Univ Montreal, Fac Med Vet, Dept Pathol & Microbiol, St Hyacinthe, PQ J2S 7C6, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Agence Francaise Secur Sanit Aliments, Unite Rech Mycoplasmol & Bacteriol, F-22440 Ploufragan, France	Universite de Montreal; Universite de Montreal; National Research Council Canada; Agence Nationale de Securite Sanitaire de l'Alimentation, de l'Environnement du Travail (ANSES)	Jacques, M (corresponding author), Univ Montreal, Fac Med Vet, Grp Rech Malad Infect Porc, St Hyacinthe, PQ J2S 7C6, Canada.	mario.jacques@umontreal.ca	Gottschalk, Marcelo/I-8116-2012; Deslandes, Vincent/AIF-4404-2022; Jacques, Mario/D-4901-2015	Deslandes, Vincent/0000-0003-2970-5496; Cox, Andrew/0000-0002-8397-9271				ALTMAN E, 1986, BIOCHEM CELL BIOL, V64, P1317, DOI 10.1139/o86-173; BAARSCH MJ, 1995, INFECT IMMUN, V63, P3587, DOI 10.1128/IAI.63.9.3587-3594.1995; Baarsch MJ, 2000, AM J VET RES, V61, P684, DOI 10.2460/ajvr.2000.61.684; BAARSCH MJ, 1991, J IMMUNOL METHODS, V140, P15, DOI 10.1016/0022-1759(91)90121-U; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; Bals R, 2000, Respir Res, V1, P141, DOI 10.1186/rr25; Bosse JT, 2002, MICROBES INFECT, V4, P225, DOI 10.1016/S1286-4579(01)01534-9; Campbell GRO, 2002, P NATL ACAD SCI USA, V99, P3938, DOI 10.1073/pnas.062425699; Campos MA, 2004, INFECT IMMUN, V72, P7107, DOI 10.1128/IAI.72.12.7107-7114.2004; Chiou MT, 2000, VET MICROBIOL, V71, P9, DOI 10.1016/S0378-1135(99)00159-5; Cho WS, 2004, VET PATHOL, V41, P666, DOI 10.1354/vp.41-6-666; Cho WS, 2002, VET PATHOL, V39, P27, DOI 10.1354/vp.39-1-27; Choi C, 1999, J COMP PATHOL, V121, P349, DOI 10.1053/jcpa.1999.0332; DARVEAU RP, 1983, J BACTERIOL, V155, P831, DOI 10.1128/JB.155.2.831-838.1983; Ding L, 2003, BIOCHEMISTRY-US, V42, P12251, DOI 10.1021/bi035130+; Dubreuil J. Daniel, 2000, Animal Health Research Reviews, V1, P73, DOI 10.1017/S1466252300000074; Dungworth DL, 1993, PATHOLOGY DOMESTIC A, VII, P539; FREY J, 1995, TRENDS MICROBIOL, V3, P257, DOI 10.1016/S0966-842X(00)88939-8; Fry BN, 1998, MICROBIOL-SGM, V144, P2049, DOI 10.1099/00221287-144-8-2049; GALARNEAU C, 2000, PATHOGENESIS, V1, P253; Ganz T, 2004, J LEUKOCYTE BIOL, V75, P34, DOI 10.1189/jlb.0403150; Haesebrouck F, 1997, VET MICROBIOL, V58, P239, DOI 10.1016/S0378-1135(97)00162-4; Hitchen PG, 2002, MOL MICROBIOL, V44, P1637, DOI 10.1046/j.1365-2958.2002.02990.x; Jacques M, 2004, CAN J VET RES, V68, P81; Jacques M, 1996, TRENDS MICROBIOL, V4, P408, DOI 10.1016/0966-842X(96)10054-8; Jacques M, 1998, FEMS MICROBIOL REV, V22, P45, DOI 10.1016/S0168-6445(98)00007-2; Labrie J, 2002, J ENDOTOXIN RES, V8, P27, DOI [10.1179/096805102125000065, 10.1177/09680519020080010301]; Lehrer RI, 1999, CURR OPIN IMMUNOL, V11, P23, DOI 10.1016/S0952-7915(99)80005-3; LIN GF, 1994, J BIOL CHEM, V269, P77; Matsuzaki K, 1999, FEBS LETT, V449, P221, DOI 10.1016/S0014-5793(99)00443-3; MAUDSLEY JR, 1986, INFECT IMMUN, V51, P501, DOI 10.1128/IAI.51.2.501-506.1986; Michael FS, 2004, CARBOHYD RES, V339, P1973, DOI 10.1016/j.carres.2004.04.019; MOLLER K, 1993, VET MICROBIOL, V36, P261, DOI 10.1016/0378-1135(93)90093-M; Muroi M, 2002, INFECT IMMUN, V70, P6043, DOI 10.1128/IAI.70.11.6043-6047.2002; Nesper J, 2001, INFECT IMMUN, V69, P435, DOI 10.1128/IAI.69.1.435-445.2001; Rioux S, 2000, MICROB PATHOGENESIS, V28, P279, DOI 10.1006/mpat.1999.0347; Rioux S, 1999, CAN J MICROBIOL, V45, P1017, DOI 10.1139/cjm-45-12-1017; Savoye C, 2000, VET MICROBIOL, V73, P337, DOI 10.1016/S0378-1135(00)00181-4; Segura M, 1999, INFECT IMMUN, V67, P4646, DOI 10.1128/IAI.67.9.4646-4654.1999; SIDIBE M, 1993, CAN J VET RES, V57, P204; STEPHENS KE, 1988, AM REV RESPIR DIS, V137, P1364, DOI 10.1164/ajrccm/137.6.1364; Stevens MK, 1997, INFECT IMMUN, V65, P651, DOI 10.1128/IAI.65.2.651-660.1997; TAYLOR DJ, 1999, DIS SWINE, P343; Uthaisangsook S, 2002, ANN ALLERG ASTHMA IM, V88, P253, DOI 10.1016/S1081-1206(10)62005-4; WEISSBORN AC, 1994, J BACTERIOL, V176, P2611, DOI 10.1128/JB.176.9.2611-2618.1994; [No title captured]	46	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39104	39114		10.1074/jbc.M502852200	http://dx.doi.org/10.1074/jbc.M502852200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16188878	hybrid			2022-12-25	WOS:000233362200025
J	Barrier, A; Olaya, N; Chiappini, F; Roser, F; Scatton, O; Artus, C; Franc, B; Dudoit, S; Flahault, A; Debuire, B; Azoulay, D; Lemoine, A				Barrier, A; Olaya, N; Chiappini, F; Roser, F; Scatton, O; Artus, C; Franc, B; Dudoit, S; Flahault, A; Debuire, B; Azoulay, D; Lemoine, A			Ischemic preconditioning modulates the expression of several genes, leading to the overproduction of IL-1Ra, iNOS, and Bcl-2 in a human model of liver ischemia-reperfusion	FASEB JOURNAL			English	Article						preconditioning; liver transplantation; gene expression; apoptosis	INFLOW OCCLUSION; ENDOTHELIAL-CELL; NITRIC-OXIDE; MOUSE-LIVER; APOPTOSIS; INJURY; PROTECTS; INHIBITION; ADENOSINE; AUTOPHAGY	Ischemia triggers an inflammatory response that precipitates cell death during reperfusion. Several studies have shown that tissues are protected by ischemic preconditioning (IP) consisting of 10 min of ischemia followed by 10 min of reperfusion just before ischemia. The molecular basis of this protective effect is poorly understood. We used cDNA arrays (20K) to compare global gene expression in liver biopsies from living human liver donors who underwent IP (n = 7) or not (n = 7) just before liver devascularization. Microarray data were analyzed using paired t test with a type I error rate fixed at alpha = 2.5 10(6) (Bonferroni correction). We found that 60 genes were differentially expressed (36 over- and 24 underexpressed in preconditioning group). After IP, the most significantly overexpressed gene was IL-1R alpha. This was confirmed by immunoblotting. Differentially expressed were genes involved in apoptosis (NOD2, ephrin-A1, and calpain) and in the carbohydrate metabolism. A significant increase in the amount of the anti-apoptotic protein Bcl-2 in preconditioned livers but no change in the cleavage of procaspase-3, -8, and -9 was observed. We also observed an increase in the amount in the inducible nitric oxide synthase. Therefore, the benefits of IP may be associated with the overproduction of IL-1Ra, Bcl-2, and NO countering the proinflammatory and proapoptotic effects generated during ischemia-reperfusion.	Hop Univ Paul Brousse, F-94800 Villejuif, France; INSERM, Serv Biochim & Biol, F-75654 Paris, France; Univ Paris 11, Villejuif, France; Assistance Publ Hop Paris, Paris, France; Univ Calif Berkeley, Div Biostat, Berkeley, CA 94720 USA; Univ Paris 06, INSERM, U444, Hop Tenon, Paris, France; Hop Paul Brousse, Ctr Hepato Biliaire, Villejuif, France; Hop Ambroise Pare, Serv Anat Pathol, Boulogne, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; University of California System; University of California Berkeley; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP	Lemoine, A (corresponding author), Hop Univ Paul Brousse, F-94800 Villejuif, France.	antoinette.lemoine@pbr.ap-hop-paris.fr	Chiappini, Franck/AAB-9894-2021	Chiappini, Franck/0000-0002-2684-1241				ADAM R, 1992, LANCET, V340, P1373, DOI 10.1016/0140-6736(92)92559-X; Arai M, 2000, HEPATOLOGY, V32, P297, DOI 10.1053/jhep.2000.8896; BELGHITI J, 1992, SURG GYNECOL OBSTET, V175, P271; Bolli R, 1998, CIRCULATION, V98, P824; Bonventre JV, 2002, CURR OPIN NEPHROL HY, V11, P43, DOI 10.1097/00041552-200201000-00007; BORGHISCOARZC G, 1997, LIVER TRANSPLANT SUR, V4, P407; CALNE RY, 1968, BMJ-BRIT MED J, V4, P535, DOI 10.1136/bmj.4.5630.535; Carini R, 2003, GASTROENTEROLOGY, V125, P1480, DOI 10.1016/j.gastro.2003.05.005; Carini R, 2001, HEPATOLOGY, V33, P131, DOI 10.1053/jhep.2001.21050; CHARLOTTE F, 1994, AM J PATHOL, V144, P460; Clavien PA, 2003, ANN SURG, V238, P843, DOI 10.1097/01.sla.0000098620.27623.7d; Clavien PA, 2000, ANN SURG, V232, P155, DOI 10.1097/00000658-200008000-00001; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; Cursio R, 1999, FASEB J, V13, P253, DOI 10.1096/fasebj.13.2.253; CYWES R, 1992, ANN SURG, V216, P235, DOI 10.1097/00000658-199209000-00003; Du ZY, 1996, J HEART LUNG TRANSPL, V15, P1258; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Gabay C, 1997, J CLIN INVEST, V99, P2930, DOI 10.1172/JCI119488; GAO WS, 1995, TRANSPLANTATION, V59, P674, DOI 10.1097/00007890-199503150-00005; Gao WS, 1998, HEPATOLOGY, V27, P1652, DOI 10.1002/hep.510270626; Garland JM, 1997, J BIOL CHEM, V272, P4680, DOI 10.1074/jbc.272.8.4680; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; Haendeler J, 1996, SHOCK, V6, P405, DOI 10.1097/00024382-199612000-00004; Harada H, 2002, TRANSPLANTATION, V74, P1434, DOI 10.1097/00007890-200211270-00016; HEURTEAUX C, 1995, P NATL ACAD SCI USA, V92, P4666, DOI 10.1073/pnas.92.10.4666; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hotter G, 1996, BIOCHEM BIOPH RES CO, V222, P27, DOI 10.1006/bbrc.1996.0692; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Jaeschke H, 2003, GASTROENTEROLOGY, V125, P1246, DOI 10.1016/S0016-5085(03)01209-5; Kim JS, 2003, GASTROENTEROLOGY, V124, P494, DOI 10.1053/gast.2003.50059; Klionsky DJ, 2005, J CELL SCI, V118, P7, DOI 10.1242/jcs.01620; Kohli V, 1999, GASTROENTEROLOGY, V116, P168, DOI 10.1016/S0016-5085(99)70241-6; Kohli V, 1997, P NATL ACAD SCI USA, V94, P9354, DOI 10.1073/pnas.94.17.9354; Kohli V, 1999, TRANSPLANTATION, V67, P1099, DOI 10.1097/00007890-199904270-00003; Koti RS, 2002, FASEB J, V16, P1654, DOI 10.1096/fj.01-1034fje; Kume M, 2000, BRIT J SURG, V87, P1168, DOI 10.1046/j.1365-2168.2000.01509.x; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; Li J, 2004, HUM MOL GENET, V13, P1715, DOI 10.1093/hmg/ddh182; Li SQ, 2004, WORLD J GASTROENTERO, V10, P2580, DOI 10.3748/wjg.v10.i17.2580; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Maedler K, 2004, P NATL ACAD SCI USA, V101, P8138, DOI 10.1073/pnas.0305683101; Mazel S, 1996, J EXP MED, V183, P2219, DOI 10.1084/jem.183.5.2219; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; PANG CY, 1995, BIOCHEM PHARMACOL, V49, P1023, DOI 10.1016/0006-2952(94)00467-Z; Peralta C, 1999, HEPATOLOGY, V29, P126, DOI 10.1002/hep.510290104; Peralta C, 2002, AM J PATHOL, V160, P2111, DOI 10.1016/S0002-9440(10)61160-1; Peralta C, 1997, HEPATOLOGY, V25, P934, DOI 10.1002/hep.510250424; Qian T, 1997, AM J PHYSIOL-CELL PH, V273, pC1783, DOI 10.1152/ajpcell.1997.273.6.C1783; RAZ R, 1994, J BIOL CHEM, V269, P24391; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SCHUMER M, 1992, AM J PATHOL, V140, P831; Selzner N, 2003, J HEPATOL, V39, P55, DOI 10.1016/S0168-8278(03)00147-8; Serafin A, 2004, HEPATOLOGY, V39, P688, DOI 10.1002/hep.20089; Serafin A, 2002, AM J PATHOL, V161, P587, DOI 10.1016/S0002-9440(10)64214-9; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Sindram D, 1999, TRANSPLANTATION, V68, P136, DOI 10.1097/00007890-199907150-00025; SUZUKI K, 2001, CIRCULATION S1, V104, P308; TRUMP BF, 1965, LAB INVEST, V14, P2000; Watanabe Y, 2003, HEPATOL RES, V25, P343, DOI 10.1016/S1386-6346(02)00305-4; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; Yadav SS, 1999, HEPATOLOGY, V30, P1223, DOI 10.1002/hep.510300513; Yamazoe N, 1998, J ELECTROCERAM, V2, P243, DOI 10.1023/A:1009974506712; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zhang Shui-Jun, 2003, Hepatobiliary Pancreat Dis Int, V2, P509	68	53	59	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					1617	1626		10.1096/fj.04-3445com	http://dx.doi.org/10.1096/fj.04-3445com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16195370				2022-12-25	WOS:000232991100039
J	Huang, DM; Hung, Y; Ko, BS; Hsu, SC; Chen, WH; Chien, CL; Tsai, CP; Kuo, CT; Kang, JC; Yang, CS; Mou, CY; Chen, YC				Huang, DM; Hung, Y; Ko, BS; Hsu, SC; Chen, WH; Chien, CL; Tsai, CP; Kuo, CT; Kang, JC; Yang, CS; Mou, CY; Chen, YC			Highly efficient cellular labeling of mesoporous nanoparticles in human mesenchymal stem cells: implication for stem cell tracking	FASEB JOURNAL			English	Article						intracellular internalization; endocytosis; bone marrow; differentiation	IN-VIVO TRACKING; BONE-MARROW; SILICA; DRUG; DELIVERY; RELEASE; TRANSFECTION; IBUPROFEN; PROTEINS; CARRIER	Tracking the distribution of stem cells is crucial to their therapeutic use. However, the usage of current vectors in cellular labeling is restricted by their low internalizing efficiency. Here, we reported a cellular labeling approach with a novel vector composed of mesoporous silica nanoparticles (MSNs) conjugated with fluorescein isothiocyanate in human bone marrow mesenchymal stem cells and 3T3-L1 cells, and the mechanism about fluorescein isothiocyanate-conjugated MSNs (FITC-MSNs) internalization was studied. FITC-MSNs were efficiently internalized into mesenchymal stem cells and 3T3-L1 cells even in short-term incubation. The process displayed a time-and concentration-dependent manner and was dependent on clathrin-mediated endocytosis. In addition, clathrin-dependent endocytosis seemed to play a decisive role on more internalization and longer stay of FITC-MSNs in mesenchymal stem cells than in 3T3-L1 cells. The internalization of FITC-MSNs did not affect the cell viability, proliferation, immunophenotype,and differentiation potential of mesenchymal stem cells, and 3T3-L1 cells. Finally, FITC-MSNs could escape from endolysosomal vesicles and were retained the architectonic integrity after internalization. We conclude that the advantages of biocompatibility, durability, and higher efficiency in internalization suit MSNs to be a better vector for stem cell tracking than others currently used.	Natl Taiwan Univ Hosp, Dept Lab Med, Taipei 100, Taiwan; Natl Hlth Res Inst, Stem Cell Res Ctr, Miaoli, Taiwan; Natl Taiwan Univ, Dept Chem, Taipei 10764, Taiwan; Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; Natl Taiwan Univ, Coll Med, Dept Anat & Cell Biol, Taipei 10764, Taiwan; Natl Hlth Res Inst, Ctr Nanomed Res, Miaoli, Taiwan	National Taiwan University; National Taiwan University Hospital; National Health Research Institutes - Taiwan; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Health Research Institutes - Taiwan	Chen, YC (corresponding author), Natl Taiwan Univ Hosp, Dept Lab Med, 7,Chung Shan S Rd, Taipei 100, Taiwan.	ycchenmd@ha.mc.ntu.edu.tw	Huang, Dong-Ming/E-3663-2010; Yang, Chung-Shi/E-3999-2010	Huang, Dong-Ming/0000-0002-9284-3448; KO, BOR-SHENG/0000-0002-7965-7579; MOU, CHUNG-YUAN/0000-0001-7060-9899; CHIEN, CHUNG-LIANG/0000-0001-9806-486X				Andersson J, 2004, CHEM MATER, V16, P4160, DOI 10.1021/cm0401490; Bulte JWM, 2001, NAT BIOTECHNOL, V19, P1141, DOI 10.1038/nbt1201-1141; BULTE JWM, 1993, MAGNET RESON MED, V29, P32, DOI 10.1002/mrm.1910290108; Charnay C, 2004, EUR J PHARM BIOPHARM, V57, P533, DOI 10.1016/j.ejpb.2003.12.007; Clark PR, 1999, CURR OPIN MOL THER, V1, P158; Dodd SJ, 1999, BIOPHYS J, V76, P103, DOI 10.1016/S0006-3495(99)77182-1; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; Handgretinger R, 1998, BONE MARROW TRANSPL, V21, P987, DOI 10.1038/sj.bmt.1701228; He XX, 2002, J NANOSCI NANOTECHNO, V2, P317, DOI 10.1166/jnn.2002.105; He XX, 2004, J NANOSCI NANOTECHNO, V4, P585, DOI 10.1166/jnn.2004.011; Hill JM, 2003, CIRCULATION, V108, P1009, DOI 10.1161/01.CIR.0000084537.66419.7A; Jendelova P, 2003, MAGNET RESON MED, V50, P767, DOI 10.1002/mrm.10585; Jendelova P, 2004, J NEUROSCI RES, V76, P232, DOI 10.1002/jnr.20041; Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h; Lai CY, 2003, J AM CHEM SOC, V125, P4451, DOI 10.1021/ja028650l; Larson DR, 2003, SCIENCE, V300, P1434, DOI 10.1126/science.1083780; Lewin M, 2000, NAT BIOTECHNOL, V18, P410, DOI 10.1038/74464; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Luo D, 2000, NAT BIOTECHNOL, V18, P893, DOI 10.1038/78523; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; Moore A, 1998, BBA-MOL CELL RES, V1402, P239, DOI 10.1016/S0167-4889(98)00002-0; Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Panyam J, 2002, FASEB J, V16, DOI 10.1096/fj.02-0088com; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Radu DR, 2004, J AM CHEM SOC, V126, P13216, DOI 10.1021/ja046275m; Roco MC, 2003, CURR OPIN BIOTECH, V14, P337, DOI 10.1016/S0958-1669(03)00068-5; Rudelius M, 2003, EUR J NUCL MED MOL I, V30, P1038, DOI 10.1007/s00259-002-1110-0; Sahoo SK, 2003, DRUG DISCOV TODAY, V8, P1112, DOI 10.1016/S1359-6446(03)02903-9; Santra S, 2004, CHEM COMMUN, P2810, DOI 10.1039/b411916a; Schoepf U, 1998, BIOTECHNIQUES, V24, P642, DOI 10.2144/98244rr01; Vallet-Regi M, 2001, CHEM MATER, V13, P308, DOI 10.1021/cm0011559; Weissleder R, 1997, J MAGN RESON IMAGING, V7, P258, DOI 10.1002/jmri.1880070140; Wilkinson J M, 2003, Med Device Technol, V14, P29; YEH TC, 1993, MAGN RESON MED, V30, P617, DOI 10.1002/mrm.1910300513	35	268	274	4	83	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2014	+		10.1096/fj.05-4288fje	http://dx.doi.org/10.1096/fj.05-4288fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16230334	Green Submitted			2022-12-25	WOS:000232991100015
J	Wilson, LA; Gemin, A; Espiritu, R; Singh, G				Wilson, LA; Gemin, A; Espiritu, R; Singh, G			ets-1 is transcriptionally up-regulated by H2O2 via an antioxidant response element	FASEB JOURNAL			English	Article						tumor-derived factor; reactive oxygen species; gel shift analysis	LYMPH-NODE METASTASIS; GROWTH-FACTOR; PLASMINOGEN-ACTIVATOR; ENDOTHELIAL-CELLS; NITRIC-OXIDE; OXIDATIVE STRESS; EXPRESSION; GENE; INDUCTION; UROKINASE	Expression of the transcription factor Ets-1 is increasingly associated with the progression of several human cancers. A tumor-derived factor is expected to be involved in the inappropriate up-regulation of ets-1 in tumor and surrounding cells. A link between hydrogen peroxide (H2O2) and increased Ets-1 expression has also been suggested, leading to the proposal that this reactive oxygen species (ROS) may be an important factor in directly regulating the expression of ets-1 in tumor cells. Ets-1 expression in response to H2O2 was examined in an ovarian carcinoma cell model, and the genes promoter region was analyzed in order to identify putative elements involved in redox responsiveness. The up-regulation of Ets-1 by H2O2 was confirmed in the cells tested. Luciferase assays using constructs generated to test the contribution of specific promoter elements indicated that an antioxidant response element (ARE) is primarily involved in the H2O2-mediated induction. Gel shift analysis confirmed the increased binding of an Nrf(2) containing protein complex to the ets-1 ARE after H2O2 treatment. This study has delineated a key element involved in the transcriptional regulation of ets-1 under basal and induced conditions. Ets-1 has obvious deleterious effects in many cancer cells, and thus, the identification of this regulatory pathway has provided possible targets for manipulating its expression.	McMaster Univ, Juravinski Canc Ctr, Hamilton, ON, Canada; McMaster Univ, Dept Pathol & Mol Med, Fac Hlth Sci, Hamilton, ON, Canada	McMaster University; McMaster University	Singh, G (corresponding author), Ctr Canc, 699 Concess St, Hamilton, ON L8V 5C2, Canada.	gurmit.singh@hrcc.on.ca	Singh, Gurmit/C-6744-2014					ANDREWS PA, 1992, CANCER RES, V52, P1895; Behrens P, 2001, J PATHOL, V194, P43, DOI 10.1002/path.844; Behrens P, 2003, INT J CANCER, V107, P183, DOI 10.1002/ijc.11336; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; CHEN JH, 1993, ONCOGENE, V8, P3375; Coulet F, 2003, J BIOL CHEM, V278, P46230, DOI 10.1074/jbc.M305420200; Davidson B, 2001, CLIN CANCER RES, V7, P551; DEVRIES N, 1993, J CELL BIOCHEM, P270; Dhakshinamoorthy S, 2004, J BIOL CHEM, V279, P20096, DOI 10.1074/jbc.M312492200; Dhakshinamoorthy S, 2002, ONCOGENE, V21, P5301, DOI 10.1038/sj.onc.1205642; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; Dittmer Jurgen, 2003, Mol Cancer, V2, P29, DOI 10.1186/1476-4598-2-29; Elvert G, 2003, J BIOL CHEM, V278, P7520, DOI 10.1074/jbc.M211298200; Foulds CE, 2004, MOL CELL BIOL, V24, P10954, DOI 10.1128/MCB.24.24.10954-10964.2004; Guyton KZ, 1996, BIOCHEM J, V314, P547, DOI 10.1042/bj3140547; Hegen A, 2004, ARTERIOSCL THROM VAS, V24, P1803, DOI 10.1161/01.ATV.0000140819.81839.0e; Jaiswal AK, 2004, FREE RADICAL BIO MED, V36, P1199, DOI 10.1016/j.freeradbiomed.2004.02.074; Jiang Y, 2001, BIOCHEM BIOPH RES CO, V286, P1123, DOI 10.1006/bbrc.2001.5521; Keehn CA, 2003, MODERN PATHOL, V16, P772, DOI 10.1097/01.MP.0000082395.59356.4F; KESTON AS, 1965, ANAL BIOCHEM, V11, P1, DOI 10.1016/0003-2697(65)90034-5; Kita D, 2001, CANCER RES, V61, P7985; Kitange G, 1999, LAB INVEST, V79, P407; Kitange G, 2000, CANCER, V89, P2292, DOI 10.1002/1097-0142(20001201)89:11<2292::AID-CNCR18>3.0.CO;2-0; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; Lindemann RK, 2001, J BIOL CHEM, V276, P46661, DOI 10.1074/jbc.M105816200; Martin D, 2004, J BIOL CHEM, V279, P8919, DOI 10.1074/jbc.M309660200; Mukherjee T, 2003, J CANCER RES CLIN, V129, P430, DOI 10.1007/s00432-003-0457-3; Nakada M, 1999, J NEUROPATH EXP NEUR, V58, P329, DOI 10.1097/00005072-199904000-00003; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; NGUYEN T, 1994, J BIOL CHEM, V269, P13656; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; Oikawa M, 2001, BIOCHEM BIOPH RES CO, V289, P39, DOI 10.1006/bbrc.2001.5927; OKA T, 1991, ONCOGENE, V6, P2077; Ordway JM, 2003, MOL CELL BIOL, V23, P4257, DOI 10.1128/MCB.23.12.4257-4266.2003; Pande P, 1999, J PATHOL, V189, P40, DOI 10.1002/(SICI)1096-9896(199909)189:1<40::AID-PATH405>3.0.CO;2-#; Policastro L, 2004, MOL CARCINOGEN, V39, P103, DOI 10.1002/mc.20001; Preston TJ, 2003, EXP CELL RES, V285, P146, DOI 10.1016/S0014-4827(03)00015-6; Radjendirane V, 1999, BIOCHEM PHARMACOL, V58, P597, DOI 10.1016/S0006-2952(99)00143-4; Reichard JF, 2004, BIOCHEM BIOPH RES CO, V322, P842, DOI 10.1016/j.bbrc.2004.07.180; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; SETH A, 1990, ONCOGENE, V5, P1761; Shimizu S, 2004, INT J BIOCHEM CELL B, V36, P114, DOI 10.1016/S1357-2725(03)00170-5; Span PN, 2002, ONCOGENE, V21, P8506, DOI 10.1038/sj.onc.1206040; Suzuki H, 1998, BIOCHEM BIOPH RES CO, V249, P542, DOI 10.1006/bbrc.1998.9181; Tokuhara K, 2003, INT SURG, V88, P25; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9; Watanabe D, 2004, AM J PATHOL, V164, P1827, DOI 10.1016/S0002-9440(10)63741-8; Wilson LA, 2004, MOL CANCER THER, V3, P823; Yamamoto H, 2000, CANCER RES, V60, P134; Yasuda M, 1998, LIFE SCI, V64, P249, DOI 10.1016/S0024-3205(98)00560-8; Zhang YS, 2004, MOL CANCER THER, V3, P885	52	72	72	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2085	+		10.1096/fj.05-4401fje	http://dx.doi.org/10.1096/fj.05-4401fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16234432				2022-12-25	WOS:000232991100014
J	Keiper, T; Al-Fakhri, N; Chavakis, E; Athanasopoulos, AN; Isermann, B; Herzog, S; Saffrich, R; Hersemeyer, K; Bohle, RM; Haendeler, J; Preissner, KT; Santoso, S; Chavakis, T				Keiper, T; Al-Fakhri, N; Chavakis, E; Athanasopoulos, AN; Isermann, B; Herzog, S; Saffrich, R; Hersemeyer, K; Bohle, RM; Haendeler, J; Preissner, KT; Santoso, S; Chavakis, T			The role of junctional adhesion molecule-C (JAM-C) in oxidized LDL-mediated leukocyte recruitment	FASEB JOURNAL			English	Article						atherosclerosis; endothelial cells; inflammation; vascular smooth muscle cells	MIGRATION IN-VITRO; ATHEROSCLEROTIC LESIONS; TRANSENDOTHELIAL MIGRATION; IMMUNOGLOBULIN SUPERFAMILY; LIPID HYDROPEROXIDE; XYLENOL ORANGE; MICE REVEALS; DEFICIENT; INTERACTS; CELLS	The junctional adhesion molecule-C (JAM-C) was recently shown to be a counter receptor for the leukocyte beta 2-integrin Mac-1 (CD11b/CD18), thereby mediating interactions between vascular cells, particularly in inflammatory cell recruitment. Here, we investigated the role of JAM-C in oxidized low-density lipoprotein (LDL)-mediated leukocyte recruitment. As compared with normal arteries, immunostaining of atherosclerotic vessels revealed a high expression of JAM-C in association with neointimal smooth muscle cells and the endothelium. Moreover, JAM-C was strongly up-regulated in the spontaneous early lesions in ApoE -/- mice. In vitro, cultured human arterial smooth muscle cells (HASMC) were found to express JAM-C, and oxLDL, as well as enzymatically modified LDL (eLDL) significantly up-regulated JAM-C on both HASMC and endothelial cells in a time-and dose-dependent manner. Although under quiescent conditions, JAM-C predominantly localized to interendothelial cell-cell contacts in close proximity to zonula occludens-1 (ZO-1), oxLDL treatment induced a disorganization of JAM-C localization that was no more restricted to the interendothelial junctions. JAM-C thereby mediated both leukocyte adhesion and leukocyte transendothelial migration upon oxLDL treatment of endothelial cells, whereas JAM-C on quiescent endothelial cells only mediates leukocyte transmigration. Thus, upon oxLDL stimulation endothelial JAM-C functions as both an adhesion, as well as a transmigration receptor for leukocytes. Taken together, JAM-C is upregulated by oxLDL and may thereby contribute to increased inflammatory cell recruitment during atherosclerosis. JAM-C may therefore provide a novel molecular target for antagonizing interactions between vascular cells in atherosclerosis.	NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA; Heidelberg Univ, Dept Internal Med 1, Heidelberg, Germany; Univ Giessen, Inst Clin Chem & Pathobiochem, Giessen, Germany; Goethe Univ Frankfurt, Dept Internal Med 3, D-6000 Frankfurt, Germany; Heidelberg Univ, Dept Internal Med 5, Heidelberg, Germany; Univ Giessen, Inst Biochem, Giessen, Germany; Univ Giessen, Inst Pathol, Giessen, Germany; Univ Giessen, Inst Clin Immunol & Transfus Med, Giessen, Germany	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Ruprecht Karls University Heidelberg; Justus Liebig University Giessen; Goethe University Frankfurt; Ruprecht Karls University Heidelberg; Justus Liebig University Giessen; Justus Liebig University Giessen; Justus Liebig University Giessen	Chavakis, T (corresponding author), NCI, Expt Immunol Branch, NIH, 10 Ctr Dr,Rm 4B17, Bethesda, MD 20892 USA.	chavakist@mail.nih.gov	Chavakis, Triantafyllos/ABE-8845-2020	Saffrich, Rainer/0000-0002-0547-4550; Haendeler, Judith/0000-0001-8507-4540	NATIONAL CANCER INSTITUTE [Z01BC010663, ZIABC010663] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Ancuta P, 2003, J EXP MED, V197, P1701, DOI 10.1084/jem.20022156; Aurrand-Lions M, 2001, BLOOD, V98, P3699, DOI 10.1182/blood.V98.13.3699; Bazzoni G, 2000, J BIOL CHEM, V275, P20520, DOI 10.1074/jbc.M905251199; BOGEN S, 1994, J EXP MED, V179, P1059, DOI 10.1084/jem.179.3.1059; Boisvert WA, 1998, J CLIN INVEST, V101, P353, DOI 10.1172/JCI1195; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; CARLOS TM, 1994, BLOOD, V84, P2068; Chavakis E, 2001, CIRCULATION, V103, P2102; Chavakis T, 2005, BLOOD, V105, P1036, DOI 10.1182/blood-2004-01-0166; Chavakis T, 2004, J BIOL CHEM, V279, P55602, DOI 10.1074/jbc.M404676200; Chavakis T, 2003, J EXP MED, V198, P1507, DOI 10.1084/jem.20030800; Chavakis T, 2003, THROMB HAEMOSTASIS, V89, P13; Cunningham SA, 2002, J BIOL CHEM, V277, P27589, DOI 10.1074/jbc.C200331200; Ebnet K, 2000, J BIOL CHEM, V275, P27979; Ebnet K, 2004, J CELL SCI, V117, P19, DOI 10.1242/jcs.00930; GERRITY RG, 1981, AM J PATHOL, V103, P181; JIANG ZY, 1991, LIPIDS, V26, P853, DOI 10.1007/BF02536169; JIANG ZY, 1992, ANAL BIOCHEM, V202, P384, DOI 10.1016/0003-2697(92)90122-N; Johnson-Leger CA, 2002, BLOOD, V100, P2479, DOI 10.1182/blood-2001-11-0098; Kita T, 2001, ANN NY ACAD SCI, V947, P199; Liang TW, 2002, J IMMUNOL, V168, P1618, DOI 10.4049/jimmunol.168.4.1618; Liao F, 1997, J EXP MED, V185, P1349, DOI 10.1084/jem.185.7.1349; LIBBY P, 1991, LAB INVEST, V64, P5; Mamdouh Z, 2003, NATURE, V421, P748, DOI 10.1038/nature01300; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Muller WA, 2002, LAB INVEST, V82, P521, DOI 10.1038/labinvest.3780446; NAGEH MF, 1997, ARTERIOSCLER THROMB, V80, P810; Naik MU, 2003, BLOOD, V102, P2108, DOI 10.1182/blood-2003-04-1114; Naik MU, 2003, ARTERIOSCL THROM VAS, V23, P2165, DOI 10.1161/01.ATV.0000093982.84451.87; Nakashima Y, 1998, ARTERIOSCL THROM VAS, V18, P842, DOI 10.1161/01.ATV.18.5.842; OBRIEN KD, 1993, J CLIN INVEST, V92, P945, DOI 10.1172/JCI116670; Ostermann G, 2002, NAT IMMUNOL, V3, P151, DOI 10.1038/ni755; Ozaki H, 1999, J IMMUNOL, V163, P553; Palmeri D, 2000, J BIOL CHEM, V275, P19139, DOI 10.1074/jbc.M003189200; Peterson JA, 1998, BLOOD, V92, P2053, DOI 10.1182/blood.V92.6.2053.418k14_2053_2063; Ramos CL, 1999, CIRC RES, V84, P1237, DOI 10.1161/01.RES.84.11.1237; RICHARDSON M, 1994, ARTERIOSCLER THROMB, V14, P760, DOI 10.1161/01.ATV.14.5.760; Rosenfeld ME, 2002, ARTERIOSCL THROM VAS, V22, P361, DOI 10.1161/hq0302.104847; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Santoso S, 2002, J EXP MED, V196, P679, DOI 10.1084/jem.20020267; Schenkel AR, 2002, NAT IMMUNOL, V3, P143, DOI 10.1038/ni749; Simon DI, 2000, J CLIN INVEST, V105, P293, DOI 10.1172/JCI7811; SMITH JD, 1995, P NATL ACAD SCI USA, V92, P8264, DOI 10.1073/pnas.92.18.8264; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STARY HC, 1992, VIRCHOWS ARCH A, V421, P277, DOI 10.1007/BF01660974; STARY HC, 1995, ARTERIOSCL THROM VAS, V15, P1512, DOI 10.1161/01.ATV.15.9.1512; STEWART M, 1995, CURR OPIN CELL BIOL, V7, P690, DOI 10.1016/0955-0674(95)80111-1; SUNDERKOTTER C, 1991, PHARMACOL THERAPEUT, V51, P195, DOI 10.1016/0163-7258(91)90077-Y; Suriyaphol P, 2002, CIRCULATION, V106, P2581, DOI 10.1161/01.CIR.0000038366.11851.D0	49	70	72	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					2078	+		10.1096/fj.05-4196fje	http://dx.doi.org/10.1096/fj.05-4196fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16195363				2022-12-25	WOS:000232315700001
J	Panizzi, P; Friedrich, R; Prior, PF; Kroh, HK; Briggs, J; Tans, G; Bode, W; Bock, PE				Panizzi, P; Friedrich, R; Prior, PF; Kroh, HK; Briggs, J; Tans, G; Bode, W; Bock, PE			Novel fluorescent prothrombin analogs as probes of staphylocoagulase-prothrombin interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE CHLOROMETHYL KETONES; BLOOD-COAGULATION PROTEINASES; HUMAN ALPHA-THROMBIN; ACTIVE-SITE; CRYSTAL-STRUCTURE; FACTOR-V; ARG CHLOROMETHYLKETONE; PROCOAGULANT-BINDING; ENZYMATIC-PROPERTIES; CATALYTIC SITE	Staphylocoagulase (SC) is a potent nonproteolytic prothrombin (ProT) activator and the prototype of a newly established zymogen activator and adhesion protein family. The staphylocoagulase fragment containing residues 1-325 (SC-(1-325)) represents a new type of nonproteolytic activator with a unique fold consisting of two three-helix bundle domains. The N-terminal, domain 1 of SC (D1, residues 1-146) interacts with the 148 loop of thrombin and prethrombin 2 and the south rim of the catalytic site, whereas domain 2 of SC(D2, residues 147-325) occupies (pro) exosite I, the fibrinogen (Fbg) recognition exosite. Reversible conformational activation of ProT by SC-(1-325) was used to create novel analogs of ProT covalently labeled at the catalytic site with fluorescence probes. Analogs selected from screening 10 such derivatives were used to characterize quantitatively equilibrium binding of SC-(1-325) to ProT, competitive binding with native ProT, and SC domain interactions. The results support the conclusion that SC-(1-325) binds to a single site on fluorescein-labeled and native ProT with indistinguishable dissociation constants of 17-72 pM. The results obtained for isolated SC domains indicate that D2 binds ProT with similar to 130-fold greater affinity than D1, yet D1 binding accounts for the majority of the fluorescence enhancement that accompanies SC-(1-325) binding. The SC-(1-325)(.)(pro) thrombin complexes and free thrombin showed little difference in substrate specificity for tripeptide substrates or with their natural substrate, Fbg. Lack of a significant effect of blockage of (pro) exosite I of (pro) thrombin by SC-(1-325) on Fbg cleavage indicates that a new Fbg substrate recognition exosite is expressed on the SC-(1-325)(.)(pro) thrombin complexes. Our results provide new insight into the mechanism that mediates zymogen activation by this prototypical bacterial activator.	Vanderbilt Univ, Dept Pathol, Sch Med, Med Ctr N, Nashville, TN 37232 USA; Max Planck Inst Biochem, Proteinase Res Grp, D-82152 Martinsried, Germany; Hosp Santa Creu & Sant Pau, CSIC, Inst Catala Ciencies Cardiovasc, Cardiovasc Res Ctr, E-08025 Barcelona, Spain; Univ Maastricht, Cardiovasc Res Inst Maastricht, Dept Biochem, NL-6200 MD Maastricht, Netherlands	Vanderbilt University; Max Planck Society; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Institut Catala de Ciencies Cardiovasculars (ICCC); Hospital of Santa Creu i Sant Pau; Maastricht University	Bock, PE (corresponding author), Vanderbilt Univ, Dept Pathol, Sch Med, Med Ctr N, C3321A, Nashville, TN 37232 USA.	paul.bock@vanderbilt.edu	Panizzi, Peter/A-6072-2019	Panizzi, Peter/0000-0003-0141-8807; Fuentes-Prior, Pablo/0000-0002-6618-3204	NHLBI NIH HHS [R37 HL071544, R01 HL038779, R01 HL071544, R01 HL038779-19, HL071544, R00 HL094533, HL07751, HL038779, R37 HL071544-03] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007751, R01HL071544, R37HL071544, R00HL094533, R29HL038779, R01HL038779] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson PJ, 2000, J BIOL CHEM, V275, P16428, DOI 10.1074/jbc.M001254200; Anderson PJ, 2000, J BIOL CHEM, V275, P16435, DOI 10.1074/jbc.M001255200; BOCK PE, 1993, METHOD ENZYMOL, V222, P478; Bock PE, 1996, J BIOL CHEM, V271, P1072, DOI 10.1074/jbc.271.2.1072; Bock PE, 1997, J BIOL CHEM, V272, P19837, DOI 10.1074/jbc.272.32.19837; BOCK PE, 1992, J BIOL CHEM, V267, P14963; BOCK PE, 1992, J BIOL CHEM, V267, P14974; BODE W, 1976, FEBS LETT, V68, P231, DOI 10.1016/0014-5793(76)80443-7; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1992, PROTEIN SCI, V1, P426; BODE W, 1992, THROMBIN STRUCTURE F; Boxrud PD, 2000, J BIOL CHEM, V275, P14579, DOI 10.1074/jbc.275.19.14579; BUTKOWSKI RJ, 1977, J BIOL CHEM, V252, P4942; Dharmawardana KR, 1998, BIOCHEMISTRY-US, V37, P13143, DOI 10.1021/bi9812165; Esmon CT, 1996, J BIOL CHEM, V271, P13882, DOI 10.1074/jbc.271.23.13882; FENTON JW, 1974, THROMB RES, V4, P809, DOI 10.1016/0049-3848(74)90024-3; FENTON JW, 1977, J BIOL CHEM, V252, P3587; Friedrich R, 2003, NATURE, V425, P535, DOI 10.1038/nature01962; Heilmann C, 2002, J INFECT DIS, V186, P32, DOI 10.1086/341081; HEMKER HC, 1975, BIOCHIM BIOPHYS ACTA, V379, P180, DOI 10.1016/0005-2795(75)90020-3; HENDRIX H, 1983, J BIOL CHEM, V258, P3637; Hogg PJ, 1996, J BIOL CHEM, V271, P26088, DOI 10.1074/jbc.271.42.26088; Jacques SL, 2000, J BIOL CHEM, V275, P40671, DOI 10.1074/jbc.M004544200; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; KAWABATA S, 1985, J BIOCHEM, V98, P1603, DOI 10.1093/oxfordjournals.jbchem.a135430; KAWABATA S, 1985, J BIOCHEM, V97, P1073, DOI 10.1093/oxfordjournals.jbchem.a135150; KAWABATA S, 1986, J BIOL CHEM, V261, P1427; KAWABATA S, 1986, J BIOL CHEM, V261, P527; KAWABATA SI, 1987, J PROTEIN CHEM, V6, P17; Korzeniowski O., 1992, BRAUNWALD HEART DIS, V4, P1078; LINDAHL P, 1991, BIOCHEM J, V276, P387, DOI 10.1042/bj2760387; LIU LW, 1991, J BIOL CHEM, V266, P16977; MANN KG, 1981, METHOD ENZYMOL, V80, P286; Myles T, 2001, J BIOL CHEM, V276, P25143, DOI 10.1074/jbc.M011324200; NASKI MC, 1991, J BIOL CHEM, V266, P13003; NASKI MC, 1990, J BIOL CHEM, V265, P13484; OLSON ST, 1991, ARCH BIOCHEM BIOPHYS, V286, P533, DOI 10.1016/0003-9861(91)90076-U; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Panizzi P, 2006, J BIOL CHEM, V281, P1179, DOI 10.1074/jbc.M507956200; PHONIMDAENG P, 1990, MOL MICROBIOL, V4, P393, DOI 10.1111/j.1365-2958.1990.tb00606.x; PHONIMDAENG P, 1988, J GEN MICROBIOL, V134, P75; Pineda AO, 2004, J BIOL CHEM, V279, P39824, DOI 10.1074/jbc.M407272200; ROGERS SJ, 1992, J BIOL CHEM, V267, P3613; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; Sawai T, 1997, INFECT IMMUN, V65, P466, DOI 10.1128/IAI.65.2.466-471.1997; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SOULIER JP, 1967, THROMB DIATH HAEMOST, V17, P321, DOI 10.1055/s-0038-1654156; TAGER M, 1965, ANN NY ACAD SCI, V128, P92, DOI 10.1111/j.1749-6632.1965.tb11632.x; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; Wang XQ, 1998, SCIENCE, V281, P1662, DOI 10.1126/science.281.5383.1662; YE J, 1992, J BIOL CHEM, V267, P11023	51	29	30	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					1169	1178		10.1074/jbc.M507955200	http://dx.doi.org/10.1074/jbc.M507955200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16230340	Green Accepted, hybrid			2022-12-25	WOS:000234447200059
J	Baez, MV; Boccaccio, GL				Baez, MV; Boccaccio, GL			Mammalian smaug is a translational repressor that forms cytoplasmic foci similar to stress granules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUGH ENDOPLASMIC-RETICULUM; MENTAL-RETARDATION PROTEIN; MESSENGER-RNA TRANSPORT; MOTOR-NEURON PROTEIN; BINDING PROTEIN; DROSOPHILA EMBRYO; PROCESSING BODIES; SAM DOMAIN; GW BODIES; STAUFEN	Cytoplasmic events depending on RNA-binding proteins contribute to the fine-tuning of gene expression. Sterile alpha motif-containing RNA-binding proteins constitute a novel family of post-transcriptional regulators that recognize a specific RNA sequence motif known as Smaug recognition element (SRE). The Drosophila member of this family, dSmaug, triggers the translational repression and deadenylation of maternal mRNAs by independent mechanisms, and the yeast homologue Vts1 stimulates degradation of SRE-containing messengers. Two homologous genes are present in the mammalian genome. Here we showed that hSmaug 1, encoded in human chromosome 14, represses the translation of reporter transcripts carrying SRE motifs. When expressed in fibroblasts, hSmaug 1 forms cytoplasmic granules that contain polyadenylated mRNA and the RNA-binding proteins Staufen, TIAR, TIA-1, and HuR. Smaug 1 foci are distinct from degradation foci. The murine protein mSmaug 1 is expressed in the central nervous system and is abundant in post-synaptic densities, a subcellular region where translation is tightly regulated by synaptic stimulation. Biochemical analysis indicated that mSmaug 1 is present in synaptoneurosomal 20 S particles. These results suggest a role for mammalian Smaug 1 in RNA granule formation and translation regulation in neurons.	Consejo Nacl Invest Cient & Tecn, Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)		gboccaccio@leloir.org.ar	Baez, Veronica/ABF-9940-2021	Baez, Maria Veronica/0000-0001-5105-2888	FOGARTY INTERNATIONAL CENTER [R03TW006037] Funding Source: NIH RePORTER; FIC NIH HHS [1 R03 TW 006037-01A1] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Anderson P, 2002, J CELL SCI, V115, P3227; Andrei MA, 2005, RNA, V11, P717, DOI 10.1261/rna.2340405; Antar LN, 2004, J NEUROSCI, V24, P2648, DOI 10.1523/JNEUROSCI.0099-04.2004; Antic D, 1998, J CELL SCI, V111, P183; Aviv T, 2003, NAT STRUCT BIOL, V10, P614, DOI 10.1038/nsb956; Bailey CH, 2004, NEURON, V44, P49, DOI 10.1016/j.neuron.2004.09.017; Cougot N, 2004, J CELL BIOL, V165, P31, DOI 10.1083/jcb.200309008; Dahanukar A, 1999, MOL CELL, V4, P209, DOI 10.1016/S1097-2765(00)80368-8; Dostie J, 2000, EMBO J, V19, P3142, DOI 10.1093/emboj/19.12.3142; Eystathioy T, 2003, RNA, V9, P1171, DOI 10.1261/rna.5810203; Gallouzi IE, 2000, P NATL ACAD SCI USA, V97, P3073, DOI 10.1073/pnas.97.7.3073; Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488; Gilks N, 2004, MOL BIOL CELL, V15, P5383, DOI 10.1091/mbc.E04-08-0715; Green JB, 2003, MOL CELL, V11, P1537, DOI 10.1016/S1097-2765(03)00178-3; Green JB, 2002, BIOCHEM BIOPH RES CO, V297, P1085, DOI 10.1016/S0006-291X(02)02327-6; Hua YM, 2004, FEBS LETT, V572, P69, DOI 10.1016/j.febslet.2004.07.010; Kedersha N, 2000, J CELL BIOL, V151, P1257, DOI 10.1083/jcb.151.6.1257; Kedersha N, 2005, J CELL BIOL, V169, P871, DOI 10.1083/jcb.200502088; Kedersha NL, 1999, J CELL BIOL, V147, P1431, DOI 10.1083/jcb.147.7.1431; Keene JD, 2001, P NATL ACAD SCI USA, V98, P7018, DOI 10.1073/pnas.111145598; Kiebler MA, 1999, J NEUROSCI, V19, P288, DOI 10.1523/JNEUROSCI.19-01-00288.1999; Kimball SR, 2003, AM J PHYSIOL-CELL PH, V284, pC273, DOI 10.1152/ajpcell.00314.2002; Krichevsky AM, 2001, NEURON, V32, P683, DOI 10.1016/S0896-6273(01)00508-6; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo M, 2002, BIOCHEM J, V365, P817, DOI 10.1042/BJ20020263; Ma L, 2003, J NEUROSCI, V23, P3164; Mallardo M, 2003, P NATL ACAD SCI USA, V100, P2100, DOI 10.1073/pnas.0334355100; Marion RM, 1999, MOL CELL BIOL, V19, P2212; Mazroui R, 2002, HUM MOL GENET, V11, P3007, DOI 10.1093/hmg/11.24.3007; Menon KP, 2004, NEURON, V44, P663, DOI 10.1016/j.neuron.2004.10.028; Nelson MR, 2004, EMBO J, V23, P150, DOI 10.1038/sj.emboj.7600026; Ostroff LE, 2002, NEURON, V35, P535, DOI 10.1016/S0896-6273(02)00785-7; Pinkstaff JK, 2001, P NATL ACAD SCI USA, V98, P2770, DOI 10.1073/pnas.051623398; Semotok JL, 2005, CURR BIOL, V15, P284, DOI 10.1016/j.cub.2005.01.048; Si K, 2003, CELL, V115, P893, DOI 10.1016/S0092-8674(03)01021-3; Smibert CA, 1999, RNA, V5, P1535, DOI 10.1017/S1355838299991392; Smibert CA, 1996, GENE DEV, V10, P2600, DOI 10.1101/gad.10.20.2600; Steward O, 2001, ANNU REV NEUROSCI, V24, P299, DOI 10.1146/annurev.neuro.24.1.299; Stoecklin G, 2004, EMBO J, V23, P1313, DOI 10.1038/sj.emboj.7600163; Takei N, 2004, J NEUROSCI, V24, P9760, DOI 10.1523/JNEUROSCI.1427-04.2004; Tang SJ, 2001, NEURON, V32, P463, DOI 10.1016/S0896-6273(01)00493-7; Thomas MG, 2005, MOL BIOL CELL, V16, P405, DOI 10.1091/mbc.E04-06-0516; Tourriere H, 2003, J CELL BIOL, V160, P823, DOI 10.1083/jcb.200212128; Wayne NL, 2004, BIOL REPROD, V70, P277, DOI 10.1095/biolreprod.103.022491; Wickham L, 1999, MOL CELL BIOL, V19, P2220; Wilczynska A, 2005, J CELL SCI, V118, P981, DOI 10.1242/jcs.01692; Yang Z, 2004, J CELL SCI, V117, P5567, DOI 10.1242/jcs.01477; Ye B, 2004, CURR BIOL, V14, P314, DOI 10.1016/j.cub.2004.01.052; Zalfa F, 2003, CELL, V112, P317, DOI 10.1016/S0092-8674(03)00079-5; Zhang HLL, 2003, J NEUROSCI, V23, P6627	50	63	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					43131	43140		10.1074/jbc.M508374200	http://dx.doi.org/10.1074/jbc.M508374200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16221671	Green Published, hybrid			2022-12-25	WOS:000234200800079
J	Gokhale, NA; Abraham, A; Digman, MA; Gratton, E; Cho, W				Gokhale, NA; Abraham, A; Digman, MA; Gratton, E; Cho, W			Phosphoinositide specificity of and mechanism of lipid domain formation by annexin A2-p11 heterotetramer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN INTERACTIONS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; SUBCELLULAR-LOCALIZATION; PHOSPHOLIPID-BINDING; ACTIN CYTOSKELETON; ENDOTHELIAL-CELLS; COMPLEX; CHOLESTEROL; VESICLES; DYNAMICS	Annexin A2 is a phospholipid-binding protein that forms a heterotetramer (annexin II-p11 heterotetramer; A2t) with p11 (S100A10). It has been reported that annexin A2 is involved in binding to phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P-2) and in inducing membrane microdomain formation. To understand the mechanisms underlying these findings, we determined the membrane binding properties of annexin A2 wild type and mutants both as monomer and as A2t. Our results from surface plasmon resonance analysis showed that A2t and annexin A2 has modest selectivity for PtdIns(4,5)P-2 over other phosphoinositides, which is conferred by conserved basic residues, including Lys(279) and Lys(281), on the convex surface of annexin A2. Fluorescence microscopy measurements using giant unilamellar vesicles showed that A2t of wild type, but not (K279A)(2)-(p11)(2) or (K281A)(2)-(p11)(2), specifically induced the formation of 1-mu m-sized PtdIns(4,5)P-2 clusters, which were stabilized by cholesterol. Collectively, these studies elucidate the structural determinant of the PtdIns(4,5)P-2 selectivity of A2t and suggest that A2t may be involved in the regulation of PtdIns(4,5)P-2 clustering in the cell.	Univ Illinois, Dept Chem, Chicago, IL 60607 USA; Univ Illinois, Dept Phys, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Urbana-Champaign	Cho, W (corresponding author), Univ Illinois, Dept Chem, M-C 111,845 W Taylor St, Chicago, IL 60607 USA.	wcho@uic.edu		, Michelle/0000-0003-4611-7100	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR003155] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052598, R01GM068849] Funding Source: NIH RePORTER; NCRR NIH HHS [P41-RRO3155] Funding Source: Medline; NIGMS NIH HHS [GM52598, GM68849] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ananthanarayanan B, 2003, J BIOL CHEM, V278, P46886, DOI 10.1074/jbc.M307853200; Ayala-Sanmartin J, 2001, BIOCHEM BIOPH RES CO, V283, P72, DOI 10.1006/bbrc.2001.4748; Ayala-Sanmartin J, 2001, BBA-BIOMEMBRANES, V1510, P18, DOI 10.1016/S0005-2736(00)00262-5; Babiychuk EB, 2000, J CELL BIOL, V150, P1113, DOI 10.1083/jcb.150.5.1113; Bagatolli LA, 1999, BIOPHYS J, V77, P2090, DOI 10.1016/S0006-3495(99)77050-5; Benaud C, 2004, J CELL BIOL, V164, P133, DOI 10.1083/jcb.200307098; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; Botelho RJ, 2000, J CELL BIOL, V151, P1353, DOI 10.1083/jcb.151.7.1353; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Caroni P, 2001, EMBO J, V20, P4332, DOI 10.1093/emboj/20.16.4332; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Cho WH, 2005, ANNU REV BIOPH BIOM, V34, P119, DOI 10.1146/annurev.biophys.33.110502.133337; Cho WW, 2001, ANAL BIOCHEM, V296, P153, DOI 10.1006/abio.2001.5225; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; Dietrich C, 2001, BIOPHYS J, V80, P1417, DOI 10.1016/S0006-3495(01)76114-0; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; Filipenko NR, 2001, J BIOL CHEM, V276, P5310, DOI 10.1074/jbc.M009710200; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Gerke V, 2005, NAT REV MOL CELL BIO, V6, P449, DOI 10.1038/nrm1661; Gerke V, 1997, BBA-MOL CELL RES, V1357, P129, DOI 10.1016/S0167-4889(97)00038-4; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; HARDER T, 1994, BBA-MOL CELL RES, V1223, P375, DOI 10.1016/0167-4889(94)90098-1; Harder T, 1997, MOL BIOL CELL, V8, P533, DOI 10.1091/mbc.8.3.533; Hayes MJ, 2004, J BIOL CHEM, V279, P14157, DOI 10.1074/jbc.M313025200; Huang SH, 2004, MOL CELL BIOL, V24, P9102, DOI 10.1128/MCB.24.20.9102-9123.2004; Janmey PA, 2004, NAT REV MOL CELL BIO, V5, P658, DOI 10.1038/nrm1434; JANMEY PA, 1992, J BIOL CHEM, V267, P11818; JOHNSSON N, 1988, EMBO J, V7, P2435, DOI 10.1002/j.1460-2075.1988.tb03089.x; Kates M., 1986, TECHNIQUES LIPIDOLOG; Klein DE, 1998, J BIOL CHEM, V273, P27725, DOI 10.1074/jbc.273.42.27725; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Konig J, 1998, J BIOL CHEM, V273, P19679, DOI 10.1074/jbc.273.31.19679; Laux T, 2000, J CELL BIOL, V149, P1455, DOI 10.1083/jcb.149.7.1455; Martin TFJ, 2001, CURR OPIN CELL BIOL, V13, P493, DOI 10.1016/S0955-0674(00)00241-6; Mayran N, 2003, EMBO J, V22, P3242, DOI 10.1093/emboj/cdg321; McLaughlin S, 2002, ANNU REV BIOPH BIOM, V31, P151, DOI 10.1146/annurev.biophys.31.082901.134259; McMurray W. C., 1973, FORM FUNCTION PHOSPH, P205; Menger FM, 1998, CURR OPIN CHEM BIOL, V2, P726, DOI 10.1016/S1367-5931(98)80110-5; Menke M, 2004, CHEMBIOCHEM, V5, P1003, DOI 10.1002/cbic.200400004; Merrifield CJ, 2001, CURR BIOL, V11, P1136, DOI 10.1016/S0960-9822(01)00321-9; Nilius B, 1996, J BIOL CHEM, V271, P30631, DOI 10.1074/jbc.271.48.30631; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; Rescher U, 2004, J CELL SCI, V117, P3473, DOI 10.1242/jcs.01208; Rescher U, 2004, J CELL SCI, V117, P2631, DOI 10.1242/jcs.01245; Rety S, 1999, NAT STRUCT BIOL, V6, P89; Ross M, 2003, BIOCHEMISTRY-US, V42, P3131, DOI 10.1021/bi027069z; Roth MG, 2004, PHYSIOL REV, V84, P699, DOI 10.1152/physrev.00033.2003; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Stahelin RV, 2004, J BIOL CHEM, V279, P29501, DOI 10.1074/jbc.M403191200; Stahelin RV, 2003, J BIOL CHEM, V278, P12452, DOI 10.1074/jbc.M212864200; Stahelin RV, 2003, J BIOL CHEM, V278, P28993, DOI 10.1074/jbc.M302865200; Stahelin RV, 2002, J BIOL CHEM, V277, P26379, DOI 10.1074/jbc.M201106200; Stahelin RV, 2001, BIOCHEMISTRY-US, V40, P4672, DOI 10.1021/bi0020325; Stock A, 1999, EMBO J, V18, P5274, DOI 10.1093/emboj/18.19.5274; SWAIRJO MA, 1994, ANNU REV BIOPH BIOM, V23, P193, DOI 10.1146/annurev.bb.23.060194.001205; Terebiznik MR, 2002, NAT CELL BIOL, V4, P766, DOI 10.1038/ncb854; van Rheenen J, 2005, EMBO J, V24, P1664, DOI 10.1038/sj.emboj.7600655; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592; Watt SA, 2002, BIOCHEM J, V363, P657, DOI 10.1042/0264-6021:3630657; Waugh MG, 1998, J BIOL CHEM, V273, P17115, DOI 10.1074/jbc.273.27.17115; Waugh MG, 2001, BIOCHEM SOC T, V29, P509, DOI 10.1042/BST0290509; Zobiack N, 2002, J CELL SCI, V115, P91	67	80	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42831	42840		10.1074/jbc.M508129200	http://dx.doi.org/10.1074/jbc.M508129200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16230353	hybrid, Green Published			2022-12-25	WOS:000234200800045
J	Komuro, I; Yasuda, T; Iwamoto, A; Akagawa, KS				Komuro, I; Yasuda, T; Iwamoto, A; Akagawa, KS			Catalase plays a critical role in the CSF-independent survival of human macrophages via regulation of the expression of BCL-2 family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; MONOCYTE-DERIVED MACROPHAGES; HUMAN ALVEOLAR MACROPHAGES; MEDIATED REDOX REGULATION; PREVENTS APOPTOSIS; CELL APOPTOSIS; CANCER CELLS; GLUTATHIONE; INHIBITION; PROTEIN	M-colony-stimulating factor (M-CSF)-induced monocyte-derived macrophages (M-M Phi) required continuous presence of M-CSF for their survival, and depletion of M-CSF from the culture induced apoptosis, whereas human alveolar macrophages (A-M Phi) and granulocyte-macrophage (GM)-CSF-induced monocyte-derived macrophages (GM-M Phi) survived even in the absence of CSF. The expression of BCL-2 was higher in M-M Phi, and M-CSF withdrawal down-regulated the expression. The expression of BCL-X-L was higher in A-M Phi and GM-M Phi, and the expression was CSF-independent. The expression of MCL-1 and BAX were not different between M-M Phi and GM-M Phi and were CSF-independent. Down-regulation of the expression of BCL- 2 and BCL- XL by RNA interference showed the important role of BCL- 2 and BCL- XL in the survival of M-M Phi and GM-M Phi, respectively. Human erythrocyte catalase (HEC) and conditioned medium obtained from GM-M Phi or A-M Phi cultured in the absence of GM-CSF prevented the M-M Phi from apoptosis and restored the expression of BCL-2. The activity of the conditioned medium was abrogated by pretreatment with anti-HEC antibody. Anti-HEC antibody also induced the apoptosis of M-M Phi cultured in the presence of M-CSF and GM-M Phi and A-M Phi cultured in the presence or absence of GM-CSFand down-regulated the expression of BCL-2 and BCL-X-L in these M Phi s. GM-M Phi and A-M Phi, but not M-M Phi, can produce both extracellular catalase and cell-associated catalase in a CSF-independent manner. Intracellular glutathione levels were kept equivalent in these M Phi s, both in the presence or absence of CSF. These results indicate a critical role of extracellular catalase in the survival of human macrophages via regulation of the expression of BCL-2 family genes.	Natl Inst Infect Dis, Dept Immunol, Shinjuku Ku, Tokyo 1628640, Japan; Natl Inst Infect Dis, Dept Parasitol, Shinjuku Ku, Tokyo 1628640, Japan; Univ Tokyo, Inst Med Sci, Div Infect Dis, Adv Clin Res Ctr,Minato Ku, Tokyo 1088639, Japan	National Institute of Infectious Diseases (NIID); National Institute of Infectious Diseases (NIID); University of Tokyo	Akagawa, KS (corresponding author), Natl Inst Infect Dis, Dept Immunol, Shinjuku Ku, Toyama 1-23-1, Tokyo 1628640, Japan.	akagawak@nih.go.jp						Akagawa KS, 2002, INT J HEMATOL, V76, P27, DOI 10.1007/BF02982715; ANDERSON ME, 1989, GLUTATHIONE CHEM BIO, VA, P339; Borutaite V, 2001, FEBS LETT, V500, P114, DOI 10.1016/S0014-5793(01)02593-5; BROOME HE, 1995, J IMMUNOL, V155, P2311; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; DRANOFF G, 1994, SCIENCE, V264, P713, DOI 10.1126/science.8171324; EISCHEN A, 1994, BRIT J HAEMATOL, V88, P712, DOI 10.1111/j.1365-2141.1994.tb05109.x; Garland JM, 1998, BLOOD, V92, P1235, DOI 10.1182/blood.V92.4.1235.416k18_1235_1246; Goyal A, 2002, AM J RESP CELL MOL, V26, P224, DOI 10.1165/ajrcmb.26.2.4640; Hashimoto S, 2001, J IMMUNOL, V167, P3619, DOI 10.4049/jimmunol.167.7.3619; HAUGHN L, 2003, J BIOL CHEM, V28, P28; Iwai K, 2003, J BIOL CHEM, V278, P9813, DOI 10.1074/jbc.M201867200; Iwata S, 1997, J IMMUNOL, V158, P3108; Kirkland RA, 2001, J NEUROSCI, V21, P1949, DOI 10.1523/JNEUROSCI.21-06-01949.2001; Komuro I, 2001, J BIOL CHEM, V276, P24360, DOI 10.1074/jbc.M102081200; Komuro I, 2003, J EXP MED, V198, P443, DOI 10.1084/jem.20022018; LIU H, 2003, BLOOD, V13, P13; Mercatante DR, 2001, J BIOL CHEM, V276, P16411, DOI 10.1074/jbc.M009256200; PIETARINEN P, 1995, AM J RESP CELL MOL, V13, P434, DOI 10.1165/ajrcmb.13.4.7546773; Raffo A, 2004, CLIN CANCER RES, V10, P3195, DOI 10.1158/1078-0432.CCR-03-0287; SANDSTROM PA, 1993, P NATL ACAD SCI USA, V90, P4708, DOI 10.1073/pnas.90.10.4708; SATO N, 1995, J IMMUNOL, V154, P3194; Shankaranarayanan P, 2003, J IMMUNOL, V170, P887, DOI 10.4049/jimmunol.170.2.887; Tomita K, 2002, AM J RESP CRIT CARE, V166, P724, DOI 10.1164/rccm.2104010; Valks DM, 2003, J BIOL CHEM, V278, P25542, DOI 10.1074/jbc.M303760200; XIAO D, 2004, ONCOGENE, V7, P7; Yamada Y, 2001, BBA-MOL CELL BIOL L, V1532, P115, DOI 10.1016/S1388-1981(01)00123-8; Yamaguchi H, 2001, ONCOGENE, V20, P7779, DOI 10.1038/sj.onc.1204984	28	10	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41137	41145		10.1074/jbc.M509793200	http://dx.doi.org/10.1074/jbc.M509793200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16204228	hybrid			2022-12-25	WOS:000233866900004
J	Katoh, S; Tsunoda, Y; Murata, K; Minami, E; Katoh, E				Katoh, S; Tsunoda, Y; Murata, K; Minami, E; Katoh, E			Active site residues and amino acid specificity of the ubiquitin carrier protein-binding RING-H2 finger domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGASE; ARABIDOPSIS; EL5; IDENTIFICATION; RECOGNITION; MECHANISMS; EXPRESSION; FAMILY; GENE	EL5 is a rice ubiquitin- protein isopeptide ligase (E3) containing a RING-H2 finger domain that interacts with Oryza sativa (Os) UBC5b, a rice ubiquitin carrier protein. We introduced point mutations into the EL5 RING-H2 finger so that residues that functionally interact with OsUBC5b could be identified when assayed for ubiquitination activity in vitro. The residue positions were selected based on the results of an EL5 RING-H2 finger/OsUBC5b NMR titration experiment. These RING-H2 finger residues form or are adjacent to a shallow groove that is recognized by OsUBC5b. The E3 activity of EL5 is shown to be dependent on a Trp located at the center of the groove. We classified rice RING fingers according to the type of metal- chelating motif, i. e. RING-H2 or RING- HC, and according to the presence or absence of a conserved EL5-like Trp. We discuss the probable relationship between E3 activity and the conserved Trp.	Natl Inst Agrobiol Sci, Dept Biochem, Tsukuba, Ibaraki 3058602, Japan	National Institute of Agrobiological Sciences - Japan	Katoh, E (corresponding author), Natl Inst Agrobiol Sci, Dept Biochem, 2-1-2 Kannondai, Tsukuba, Ibaraki 3058602, Japan.	ekatoh@nias.affrc.go.jp						Albert TK, 2002, EMBO J, V21, P355, DOI 10.1093/emboj/21.3.355; BAX A, 1986, J MAGN RESON, V67, P565, DOI 10.1016/0022-2364(86)90395-1; Bellon SF, 1997, NAT STRUCT BIOL, V4, P586, DOI 10.1038/nsb0797-586; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; Borden KLB, 1998, BIOCHEM CELL BIOL, V76, P351, DOI 10.1139/bcb-76-2-3-351; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; Brzovic PS, 2003, P NATL ACAD SCI USA, V100, P5646, DOI 10.1073/pnas.0836054100; Brzovic PS, 2001, J BIOL CHEM, V276, P41399, DOI 10.1074/jbc.M106551200; Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Hanzawa H, 2001, J BIOL CHEM, V276, P10185, DOI 10.1074/jbc.M009298200; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Katoh S, 2003, J BIOL CHEM, V278, P15341, DOI 10.1074/jbc.M210531200; Kikkert M, 2004, J BIOL CHEM, V279, P3525, DOI 10.1074/jbc.M307453200; Kikuchi S, 2003, SCIENCE, V301, P376, DOI 10.1126/science.1081288; Kosarev P, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-4-research0016; LIVE DH, 1984, J AM CHEM SOC, V106, P1939, DOI 10.1021/ja00319a006; MartinezGarcia M, 1996, MOL GEN GENET, V252, P587, DOI 10.1007/s004380050266; Matsuda N, 2001, J CELL SCI, V114, P1949; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Salinas-Mondragon RE, 1999, PLANT MOL BIOL, V40, P579, DOI 10.1023/A:1006267201855; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Takai R, 2002, PLANT J, V30, P447, DOI 10.1046/j.1365-313X.2002.01299.x; Takai R, 2001, PLANT SCI, V160, P577, DOI 10.1016/S0168-9452(00)00390-3; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	29	34	38	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					41015	41024		10.1074/jbc.M411127200	http://dx.doi.org/10.1074/jbc.M411127200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16186120	hybrid			2022-12-25	WOS:000233666600076
J	Polytarchou, C; Hatziapostolou, M; Papadimitriou, E				Polytarchou, C; Hatziapostolou, M; Papadimitriou, E			Hydrogen peroxide stimulates proliferation and migration of human prostate cancer cells through activation of activator protein-1 and up-regulation of the heparin affin regulatory peptide gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOGENESIS IN-VIVO; TRANSCRIPTIONAL ACTIVITY; DOWN-REGULATION; C-FOS; EXPRESSION; GROWTH; INDUCTION; KINASE; PROGRESSION; ADHESION	It is becoming increasingly recognized that hydrogen peroxide (HP) plays a role in cell proliferation and migration. In the present study we found that exogenous HP significantly induced human prostate cancer LNCaP cell proliferation and migration. Heparin affin regulatory peptide (HARP) seems to be involved in the stimulatory effect of HP, because the latter had no effect on stably transfected LNCaP cells that did not express HARP. Moreover, HP significantly increased HARP mRNA and protein amounts in a concentration- and time-dependent manner. Curcumin and activator protein-1 (AP-1) decoy oligonucleotides abrogated both HP-induced HARP expression and LNCaP cell proliferation and migration. HP increased luciferase activity of the 5'-flanking region of the HARP gene introduced in a reporter gene vector, an effect that was abolished when even one of the two putative AP-1 binding sites of the HARP promoter was mutated. The effect of HP seems to be due to the binding of Fra-1, JunD, and phospho-c-Jun to the HARP promoter. These results support the notion that HARP is important for human prostate cancer cell proliferation and migration, establish the role of AP-1 in the up- regulation of HARP expression by low concentrations of HP, and characterize the AP-1 dimers involved.	Univ Patras, Dept Pharm, Mol Pharmacol Lab, GR-26504 Patras, Greece	University of Patras	Papadimitriou, E (corresponding author), Univ Patras, Dept Pharm, Mol Pharmacol Lab, GR-26504 Patras, Greece.	epapad@upatras.gr	Papadimitriou, Evangelia/ABG-1356-2020; Papadimitriou, Evangelia/F-3396-2010; Hatziapostolou, Maria/N-1820-2015	Papadimitriou, Evangelia/0000-0001-6429-4325; Hatziapostolou, Maria/0000-0003-2493-7028				Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094; Bianchi L, 2002, ARCH BIOCHEM BIOPHYS, V401, P115, DOI 10.1016/S0003-9861(02)00019-X; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Chen HX, 2005, J BIOL CHEM, V280, P19373, DOI 10.1074/jbc.M413528200; Daubeuf S, 2004, BIOCHEM BIOPH RES CO, V313, P300, DOI 10.1016/j.bbrc.2003.11.121; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Florin L, 2005, J CELL SCI, V118, P1981, DOI 10.1242/jcs.02303; HAN TH, 1995, MOL CELL BIOL, V15, P2907; Hatziapostolou M, 2005, PROSTATE, V65, P151, DOI 10.1002/pros.20270; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hong S, 2005, J BIOL CHEM, V280, P25202, DOI 10.1074/jbc.M413985200; Kumar A, 2005, FASEB J, V19, P443, DOI 10.1096/fj.03-1364fje; Laurent A, 2005, CANCER RES, V65, P948; LI YS, 1992, J BIOL CHEM, V267, P26011; Lim SD, 2005, PROSTATE, V62, P200, DOI 10.1002/pros.20137; Lu KV, 2005, J BIOL CHEM, V280, P26953, DOI 10.1074/jbc.M502614200; Marks-Konczalik J, 1998, J BIOL CHEM, V273, P22201, DOI 10.1074/jbc.273.35.22201; Milde-Langosch K, 2004, BREAST CANCER RES TR, V86, P139, DOI 10.1023/B:BREA.0000032982.49024.71; Morishita R, 2004, CURR OPIN PHARMACOL, V4, P139, DOI 10.1016/j.coph.2003.10.008; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; OHNO Y, 1985, J BIOL CHEM, V260, P8438; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Papadimitriou E, 2004, CURR CANCER DRUG TAR, V4, P471, DOI 10.2174/1568009043332835; Papadimitriou E, 2001, BIOCHEM BIOPH RES CO, V282, P306, DOI 10.1006/bbrc.2001.4574; Pognonec P, 1997, ONCOGENE, V14, P2091, DOI 10.1038/sj.onc.1201046; Polykratis A, 2005, J BIOL CHEM, V280, P22454, DOI 10.1074/jbc.M414407200; Polytarchou C, 2005, EUR J PHARMACOL, V510, P31, DOI 10.1016/j.ejphar.2005.01.004; Polytarchou C, 2004, FREE RADICAL RES, V38, P501, DOI 10.1080/10715760410001684621; Potapova O, 2000, J BIOL CHEM, V275, P24767, DOI 10.1074/jbc.M904591199; Stone JR, 2002, ENDOTHELIUM-J ENDOTH, V9, P231, DOI 10.1080/10623320214733; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Wu H, 2005, J CUTAN PATHOL, V32, P125, DOI 10.1111/j.0303-6987.2005.00282.x	36	107	108	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40428	40435		10.1074/jbc.M505120200	http://dx.doi.org/10.1074/jbc.M505120200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16199533	hybrid			2022-12-25	WOS:000233666600007
J	Chiapperino, D; Cai, MM; Sayer, JM; Yagi, H; Kroth, H; Masutani, C; Hanaoka, F; Jerina, DM; Cheh, AM				Chiapperino, D; Cai, MM; Sayer, JM; Yagi, H; Kroth, H; Masutani, C; Hanaoka, F; Jerina, DM; Cheh, AM			Error-prone translesion synthesis by human DNA polymerase eta on DNA-containing deoxyadenosine adducts of 7,8-dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE PHOSPHORIBOSYLTRANSFERASE GENE; DOSE-DEPENDENT DIFFERENCES; TEMPLATE-PRIMER JUNCTION; NMR SOLUTION STRUCTURE; THYMINE DIMER BYPASS; DG MISMATCH OPPOSITE; CODON 61 SEQUENCE; XERODERMA-PIGMENTOSUM; CRYSTAL-STRUCTURE; Y-FAMILY	When human DNA polymerase eta(pol eta) encounters N-6-deoxyadenosine adducts formed by trans epoxide ring opening of the 7,8-dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene ( BaP DE) isomer with ( +)-7R,8S,9S,10R configuration (( +)-BaP DE-2), misincorporation of A or G and incorporation of the correct T are equally likely to occur. On the other hand, the enzyme exhibits a 3-fold preference for correct T incorporation opposite adducts formed by trans ring opening of the ( -)-(7S,8R,9R,10S)- DE-2 enantiomer. Adducts at dA formed by cis ring opening of these two BaP DE-2 isomers exhibit a 3-fold preference for A over T incorporation, with G intermediate between the two. Extension one nucleotide beyond these adducts is generally weaker than incorporation across from them, but among mismatches the ( adducted A*)(.)A mispair is the most favored for extension. Because mutations can only occur if mispairs are extended, this observation is consistent with the occurrence of A(.)T to T(.)A transversions as common mutations in animal cells treated with BaP DE-2 isomers. Adducts with S absolute configuration at the point of attachment of the hydrocarbon to the base inhibit incorporation and extension by pol eta to a lesser extent than their R counterparts. Template-primers containing each of the four isomeric dA adducts derived from BaP DE-2 and two adducts derived from 9,10-epoxy-7,8,9,10-tetrahydrobenzo[ a] pyrene in which the 7- and 8-hydroxyl groups of the DEs are replaced with hydrogens exhibit reduced electrophoretic mobilities relative to the unadducted oligonucleotides. This effect is largely independent of DNA sequence. Decreased mobility correlates with an increased rate of incorporation by pol eta, suggesting a systematic relationship between the overall DNA structure and efficiency of the enzyme.	NIDDK, Bioorgan Chem Lab, NIH, DHHS, Bethesda, MD 20892 USA; American Univ, Dept Chem, Washington, DC 20016 USA; Japan Sci & Technol Corp, RIKEN, Wako, Saitama 3510198, Japan; Japan Sci & Technol Corp, Solut Oriented Res Sci & Technol, Wako, Saitama 3510198, Japan; Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); American University; Japan Science & Technology Agency (JST); RIKEN; Japan Science & Technology Agency (JST); Osaka University	Cheh, AM (corresponding author), NIDDK, Bioorgan Chem Lab, NIH, DHHS, Bethesda, MD 20892 USA.	acheh@american.edu	Masutani, Chikahide/I-6160-2014	Masutani, Chikahide/0000-0002-8600-8227; Kroth, Heiko/0000-0002-6936-3921	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK031104] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		[Anonymous], 1985, BIOACTIVATION FOREIG; Baynton K, 2000, TRENDS BIOCHEM SCI, V25, P74, DOI 10.1016/S0968-0004(99)01524-8; Beard WA, 2002, J BIOL CHEM, V277, P47393, DOI 10.1074/jbc.M210036200; BUENING MK, 1978, P NATL ACAD SCI USA, V75, P5358, DOI 10.1073/pnas.75.11.5358; Chiapperino D, 2002, J BIOL CHEM, V277, P11765, DOI 10.1074/jbc.M112139200; CHRISTNER DF, 1994, BIOCHEMISTRY-US, V33, P14297, DOI 10.1021/bi00251a043; COSMAN M, 1995, BIOCHEMISTRY-US, V34, P15334, DOI 10.1021/bi00046a043; Creighton S, 1995, METHOD ENZYMOL, V262, P232; Dipple A., 1984, ACS MONOGR SER, V182, P41, DOI DOI 10.1074/JBC.M409155200; Feng BB, 1997, BIOCHEMISTRY-US, V36, P13769, DOI 10.1021/bi970069s; Friedberg EC, 1999, CELL, V98, P413, DOI 10.1016/S0092-8674(00)81970-4; Goodman MF, 2000, NAT REV MOL CELL BIO, V1, P101, DOI 10.1038/35040051; Huang XW, 2003, BIOCHEMISTRY-US, V42, P2456, DOI 10.1021/bi026912q; Hwang HS, 2005, BIOCHEMISTRY-US, V44, P4850, DOI 10.1021/bi048244+; JERINA DM, 1984, FOREIGN COMPOUND MET, P257; Jerina DM, 1990, BIOL REACT INTERMED, P533; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 2000, J BIOL CHEM, V275, P7447, DOI 10.1074/jbc.275.11.7447; Johnson RE, 2001, MOL CELL BIOL, V21, P3558, DOI 10.1128/MCB.21.10.3558-3563.2001; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Ling H, 2004, P NATL ACAD SCI USA, V101, P2265, DOI 10.1073/pnas.0308332100; Liu TM, 1996, CHEM RES TOXICOL, V9, P255, DOI 10.1021/tx9501086; Mao B, 1999, BIOCHEMISTRY-US, V38, P10831, DOI 10.1021/bi991212f; Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; McCulloch SD, 2004, NATURE, V428, P97, DOI 10.1038/nature02352; Nair DT, 2004, NATURE, V430, P377, DOI 10.1038/nature02692; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Page JE, 1999, CHEM RES TOXICOL, V12, P258, DOI 10.1021/tx980244l; Park H, 2002, P NATL ACAD SCI USA, V99, P15965, DOI 10.1073/pnas.242422699; Pradhan P, 2001, BIOCHEMISTRY-US, V40, P5870, DOI 10.1021/bi002896q; Ramos LA, 2001, CHEM RES TOXICOL, V14, P1082, DOI 10.1021/tx010076o; Rechkoblit O, 1999, BIOCHEMISTRY-US, V38, P11834, DOI 10.1021/bi990614k; Rechkoblit O, 2002, J BIOL CHEM, V277, P30488, DOI 10.1074/jbc.M201167200; Ruan Q, 2001, BIOCHEMISTRY-US, V40, P10458, DOI 10.1021/bi002643x; SAYER JM, 1991, J ORG CHEM, V56, P20, DOI 10.1021/jo00001a007; Schiltz M, 1999, CARCINOGENESIS, V20, P2279, DOI 10.1093/carcin/20.12.2279; SCHURTER EJ, 1995, BIOCHEMISTRY-US, V34, P1364, DOI 10.1021/bi00004a031; Silvian LF, 2001, NAT STRUCT BIOL, V8, P984, DOI 10.1038/nsb1101-984; Strauss BS, 2002, DNA REPAIR, V1, P125, DOI 10.1016/S1568-7864(01)00014-3; Suzuki N, 2002, BIOCHEMISTRY-US, V41, P6100, DOI 10.1021/bi020049c; TOPAL MD, 1976, NATURE, V263, P285, DOI 10.1038/263285a0; Trincao J, 2001, MOL CELL, V8, P417, DOI 10.1016/S1097-2765(01)00306-9; Uijon SN, 2004, STRUCTURE, V12, P1395, DOI 10.1016/j.str.2004.05.011; Vaisman A, 2005, EMBO J, V24, P2957, DOI 10.1038/sj.emboj.7600786; Vaisman A, 2000, BIOCHEMISTRY-US, V39, P4575, DOI 10.1021/bi000130k; Volk DE, 2000, BIOCHEMISTRY-US, V39, P14040, DOI 10.1021/bi001669l; Volk DE, 2003, BIOCHEMISTRY-US, V42, P1410, DOI 10.1021/bi026745u; Washington MT, 2003, MOL CELL BIOL, V23, P8316, DOI 10.1128/MCB.23.22.8316-8322.2003; Washington MT, 2003, MOL CELL BIOL, V23, P5107, DOI 10.1128/MCB.23.14.5107-5112.2003; WEI SJC, 1993, CANCER RES, V53, P3294; WEI SJC, 1994, CARCINOGENESIS, V15, P1729, DOI 10.1093/carcin/15.8.1729; WEI SJC, 1991, P NATL ACAD SCI USA, V88, P11227, DOI 10.1073/pnas.88.24.11227; Wood RD, 1999, NATURE, V399, P639, DOI 10.1038/21323; Woodgate R, 1999, GENE DEV, V13, P2191, DOI 10.1101/gad.13.17.2191; Yang W, 2005, FEBS LETT, V579, P868, DOI 10.1016/j.febslet.2004.11.047; YEH HJC, 1995, BIOCHEMISTRY-US, V34, P13570, DOI 10.1021/bi00041a037; Zegar IS, 1998, BIOCHEMISTRY-US, V37, P16516, DOI 10.1021/bi9817616; Zegar IS, 1996, BIOCHEMISTRY-US, V35, P6212, DOI 10.1021/bi9524732	61	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					39684	39692		10.1074/jbc.M508008200	http://dx.doi.org/10.1074/jbc.M508008200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16188888	hybrid			2022-12-25	WOS:000233461300004
J	Di Noto, L; Whitson, LJ; Cao, XH; Hart, PJ; Levine, RL				Di Noto, L; Whitson, LJ; Cao, XH; Hart, PJ; Levine, RL			Proteasomal degradation of mutant superoxide dismutases linked to amyotrophic lateral sclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; MOLECULAR-WEIGHT COMPLEXES; MOTOR-NEURON DEGENERATION; CU,ZN-SUPEROXIDE DISMUTASE; SELECTIVE DEGRADATION; GLUTAMINE-SYNTHETASE; MODIFIED HEMOGLOBIN; 20S PROTEASOME; STABILITY; SOD1	Mutations in copper-zinc superoxide dismutase cause the neurodegenerative disease amyotrophic lateral sclerosis. Many of the mutant proteins have increased turnover in vivo and decreased thermal stability. Here we show that purified, metal-free superoxide dismutases are degraded in vitro by purified 20 S proteasome in the absence of ATP and without ubiquitinylation, whereas their metal-bound counterparts are not. The rate of degradation by the proteasome varied among the mutants studied, and the rate correlated with the in vivo half-life. The monomeric forms of both mutant and wild-type superoxide dismutase are particularly susceptible to degradation by the proteasome. Exposure of hydrophobic regions as a consequence of decreased thermal stability may allow the proteasome to recognize these molecules as non-native.	NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Xray Crystallog Core Lab, San Antonio, TX 78229 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Levine, RL (corresponding author), Bldg 50 Rm 2351, Bethesda, MD 20892 USA.	rlevine@nih.gov	Levine, Rodney L/D-9885-2011		Intramural NIH HHS Funding Source: Medline; NINDS NIH HHS [NS39112, R01 NS039112] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000225] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039112] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bartnikas TB, 2003, J BIOL CHEM, V278, P33602, DOI 10.1074/jbc.M305435200; BORCHELT DR, 1995, J BIOL CHEM, V270, P3234, DOI 10.1074/jbc.270.7.3234; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; CERVERA J, 1988, FASEB J, V2, P2591, DOI 10.1096/fasebj.2.10.2898411; Conconi M, 1996, ARCH BIOCHEM BIOPHYS, V331, P232, DOI 10.1006/abbi.1996.0303; Doucette PA, 2004, J BIOL CHEM, V279, P54558, DOI 10.1074/jbc.M409744200; Elam JS, 2003, J BIOL CHEM, V278, P21032, DOI 10.1074/jbc.M300484200; Elam JS, 2003, NAT STRUCT BIOL, V10, P461, DOI 10.1038/nsb935; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Forster A, 2003, EMBO J, V22, P4356, DOI 10.1093/emboj/cdg436; FRIGUET B, 1994, ARCH BIOCHEM BIOPHYS, V311, P168, DOI 10.1006/abbi.1994.1222; FRIGUET B, 1994, J BIOL CHEM, V269, P21639; GHADGE GS, 2005, IN PRESS NEUROBIOL D; GIULIVI C, 1994, ARCH BIOCHEM BIOPHYS, V311, P329, DOI 10.1006/abbi.1994.1245; Groll M, 2003, INT J BIOCHEM CELL B, V35, P606, DOI 10.1016/S1357-2725(02)00390-4; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hart P.J., 2005, MED INORGANIC CHEM, P348; Hayward LJ, 2002, J BIOL CHEM, V277, P15923, DOI 10.1074/jbc.M112087200; Hoffman EK, 1996, J NEUROL SCI, V139, P15, DOI 10.1016/S0022-510X(96)00031-7; HOFFMAN L, 1994, J BIOL CHEM, V269, P16890; Hoffman L, 1996, CURR TOP CELL REGUL, V34, P1, DOI 10.1016/S0070-2137(96)80001-X; Hong YK, 2002, BIOCHEMISTRY-MOSCOW+, V67, P1289, DOI 10.1023/A:1021313724450; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Kang DK, 2003, J BIOL CHEM, V278, P14857, DOI 10.1074/jbc.M300616200; Kisselev AF, 2002, J BIOL CHEM, V277, P22260, DOI 10.1074/jbc.M112360200; LEPOCK JR, 1990, J BIOL CHEM, V265, P21612; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; Lindberg MJ, 2002, P NATL ACAD SCI USA, V99, P16607, DOI 10.1073/pnas.262527099; MALINOWSKI DP, 1979, BIOCHEMISTRY-US, V18, P5055, DOI 10.1021/bi00590a005; Miyazaki K, 2004, J BIOL CHEM, V279, P11327, DOI 10.1074/jbc.M312389200; Niwa J, 2002, J BIOL CHEM, V277, P36793, DOI 10.1074/jbc.M206559200; Oeda T, 2001, HUM MOL GENET, V10, P2013, DOI 10.1093/hmg/10.19.2013; Ortega J, 2005, J MOL BIOL, V346, P1221, DOI 10.1016/j.jmb.2004.12.049; PACIFICI RE, 1993, J BIOL CHEM, V268, P15405; PACIFICI RE, 1989, FREE RADICAL BIO MED, V7, P521, DOI 10.1016/0891-5849(89)90028-2; Petrovic N, 1996, J BIOL CHEM, V271, P28331, DOI 10.1074/jbc.271.45.28331; Ratovitski T, 1999, HUM MOL GENET, V8, P1451, DOI 10.1093/hmg/8.8.1451; RIVETT AJ, 1987, ARCH BIOCHEM BIOPHYS, V259, P423, DOI 10.1016/0003-9861(87)90508-X; Rodriguez JA, 2002, J BIOL CHEM, V277, P15932, DOI 10.1074/jbc.M112088200; Rodriguez JA, 2005, P NATL ACAD SCI USA, V102, P10516, DOI 10.1073/pnas.0502515102; Rowland LP, 2001, NEW ENGL J MED, V344, P1688, DOI 10.1056/NEJM200105313442207; Schonbrunn E, 2000, P NATL ACAD SCI USA, V97, P6345, DOI 10.1073/pnas.120120397; Shringarpure R, 2003, J BIOL CHEM, V278, P311, DOI 10.1074/jbc.M206279200; SLAVIK J, 1982, BIOCHIM BIOPHYS ACTA, V694, P1, DOI 10.1016/0304-4157(82)90012-0; Taggart C, 2000, J BIOL CHEM, V275, P27258; Tiwari A, 2003, J BIOL CHEM, V278, P5984, DOI 10.1074/jbc.M210419200; Valentine JS, 2003, P NATL ACAD SCI USA, V100, P3617, DOI 10.1073/pnas.0730423100; Valentine JS, 2005, ANNU REV BIOCHEM, V74, P563, DOI 10.1146/annurev.biochem.72.121801.161647; Wang J, 2002, NEUROBIOL DIS, V9, P139, DOI 10.1006/nbdi.2001.0471; Watanabe Y, 1997, FEBS LETT, V400, P108, DOI 10.1016/S0014-5793(96)01362-2; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515	55	41	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					39907	39913		10.1074/jbc.M506247200	http://dx.doi.org/10.1074/jbc.M506247200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16195234	hybrid			2022-12-25	WOS:000233461300029
J	Zhou, WH; Dong, LL; Ginsburg, D; Bouhassira, EE; Tsai, HM				Zhou, WH; Dong, LL; Ginsburg, D; Bouhassira, EE; Tsai, HM			Enzymatically active ADAMTS13 variants are not inhibited by anti-ADAMTS13 autoantibodies - A novel therapeutic strategy?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBOTIC THROMBOCYTOPENIC PURPURA; VON-WILLEBRAND-FACTOR; FACTOR-CLEAVING PROTEASE; HEMOLYTIC-UREMIC SYNDROME; SPACER DOMAIN; MUTATIONS; CLEAVAGE; FAMILY; DEFICIENCY; ANTIBODIES	ADAMTS13 (a disintegrin and metalloprotease with thrombospondin motifs), a circulating multidomain zinc metalloprotease of the reprolysin subfamily, is critical for preventing von Willebrand factor-platelet interaction under high shear stress conditions. A deficiency of the protease, due to mutations in the ADAMTS13 gene or the presence of antibodies that inhibit the activity of the protease, causes thrombotic thrombocytopenic purpura (TTP). Plasma therapy, the conventional therapy for TTP, may cause serious adverse reactions and is ineffective in some patients. In order to develop new strategies for improving the diagnosis and treatment of TTP, we produced a series of truncated ADAMTS13 proteins in mammalian cells and analyzed their binding with and suppression by the IgG derived from the TTP patients. The results revealed that truncation of the ADAMTS13 protein at its cysteine-rich region eliminated its recognition by the antibodies without abolishing its von Willebrand factor-cleaving activity. This raises the possibility that resistant ADAMTS13 variants may be exploited to circumvent inhibitory antibodies that cause TTP.	Montefiore Med Ctr, Div Hematol, Bronx, NY 10467 USA; Albert Einstein Coll Med, Div Hematol, Bronx, NY 10467 USA; Univ Michigan, Howard Hughes Med Inst, Dept Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Howard Hughes Med Inst, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA; Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Yeshiva University; Albert Einstein College of Medicine	Tsai, HM (corresponding author), Montefiore Med Ctr, Div Hematol, 111 E 210th St, Bronx, NY 10467 USA.	htsai@montefiore.org	Bouhassira, Eric/AAZ-4184-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062136, R01HL072876] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL62136, R01 HL062136, R01 HL062136-04, R01 HL062136-06A2, R01HL72876, R01 HL072876] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antoine G, 2003, BRIT J HAEMATOL, V120, P821, DOI 10.1046/j.1365-2141.2003.04183.x; Apte SS, 2004, INT J BIOCHEM CELL B, V36, P981, DOI 10.1016/j.biocel.2004.01.014; Assink K, 2003, KIDNEY INT, V63, P1995, DOI 10.1046/j.1523-1755.63.6s.1.x; Bestetti G, 2003, THROMB HAEMOSTASIS, V90, P955; Bianchi V, 2002, BLOOD, V100, P710, DOI 10.1182/blood-2002-02-0344; BUKOWSKI RM, 1982, PROG HEMOST THROMB, V6, P287; Dong JF, 2003, J BIOL CHEM, V278, P29633, DOI 10.1074/jbc.M301385200; Furlan M, 1998, BLOOD, V91, P2839, DOI 10.1182/blood.V91.8.2839.2839_2839_2846; Furlan M, 1998, NEW ENGL J MED, V339, P1578, DOI 10.1056/NEJM199811263392202; HANDIN RI, 1989, PROG HEMOST THROMB, V9, P233; Kashiwagi M, 2004, J BIOL CHEM, V279, P10109, DOI 10.1074/jbc.M312123200; Klaus C, 2004, BLOOD, V103, P4514, DOI 10.1182/blood-2003-12-4165; Kokame K, 2002, P NATL ACAD SCI USA, V99, P11902, DOI 10.1073/pnas.172277399; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; Luken BM, 2005, THROMB HAEMOSTASIS, V93, P267, DOI 10.1160/TH04-05-0301; Matsumoto M, 2004, BLOOD, V103, P1305, DOI 10.1182/blood-2003-06-1796; Pimanda JE, 2004, BLOOD, V103, P627, DOI 10.1182/blood-2003-04-1346; ROCK GA, 1991, NEW ENGL J MED, V325, P393, DOI 10.1056/NEJM199108083250604; Savasan S, 2003, BLOOD, V101, P4449, DOI 10.1182/blood-2002-12-3796; Schneppenheim R, 2003, BLOOD, V101, P1845, DOI 10.1182/blood-2002-08-2399; Soejima K, 2003, BLOOD, V102, P3232, DOI 10.1182/blood-2003-03-0908; Tsai H M, 2001, Clin Lab, V47, P387; Tsai HM, 2004, SEMIN THROMB HEMOST, V30, P549, DOI 10.1055/s-2004-835675; Tsai HM, 2003, SEMIN THROMB HEMOST, V29, P479; Tsai HM, 1998, NEW ENGL J MED, V339, P1585, DOI 10.1056/NEJM199811263392203; Tsai HM, 1996, BLOOD, V87, P4235, DOI 10.1182/blood.V87.10.4235.bloodjournal87104235; Tsai HM, 2001, PEDIATR RES, V49, P653, DOI 10.1203/00006450-200105000-00008; Uchida T, 2004, BLOOD, V104, P2081, DOI 10.1182/blood-2004-02-0715; Veyradier A, 2001, BLOOD, V98, P1765, DOI 10.1182/blood.V98.6.1765; Zheng XL, 2003, J BIOL CHEM, V278, P30136, DOI 10.1074/jbc.M305331200; Zhou WH, 2004, THROMB HAEMOSTASIS, V91, P806, DOI 10.1160/TH03-11-0675	31	40	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					39934	39941		10.1074/jbc.M504919200	http://dx.doi.org/10.1074/jbc.M504919200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16203734	Green Accepted, hybrid			2022-12-25	WOS:000233461300032
J	Fukuda, M; Imai, A; Nashida, T; Shimomura, H				Fukuda, M; Imai, A; Nashida, T; Shimomura, H			Slp4-a/granuphilin-a interacts with syntaxin-2/3 in a Munc18-2-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROTID ACINAR-CELLS; CORE VESICLE EXOCYTOSIS; SLP HOMOLOGY DOMAIN; MYOSIN-VA; MELANOSOME TRANSPORT; SECRETORY GRANULES; PLASMA-MEMBRANE; BINDING DOMAIN; PC12 CELLS; C2 DOMAINS	Slp4-a/granuphilin-a was originally described as a protein specifically associated with insulin-containing granules in pancreatic beta-cells, but it was subsequently found to be present on amylase-containing granules in parotid acinar cells. Although Slp4-a has been suggested to control insulin secretion through interaction with syntaxin-1a and/or Munc18-1, nothing is known about the binding partner(s) of Slp4-a during amylase release from parotid acinar cells, which do not endogenously express either syntaxin-1a or Munc18-1. In this study we systematically investigated the interaction between syntaxin-1-5 and Munc18-1-3 by co-immunoprecipitation assay using COS-7 cells and discovered that Slp4-a interacts with a closed conformation of syntaxin-2/3 in a Munc18-2-dependent manner, whereasMunc18-2itself hardly interacts with Slp4-a at all. By contrast, Slp4-a was found to strongly interact with Munc18-1 regardless of the presence of syntaxin-2/3, and syntaxin-2/3 co-immunoprecipitated with Slp4-a only in the presence of Munc18-1/2. Deletion analysis showed that the syntaxin-2/3 (or Munc18-1/2)-binding site is a linker domain of Slp4a (amino acid residues 144-354), a previously uncharacterized region located between the N-terminal Rab27A binding domain and the C2A domain. We also found that the Slp4-a(.)syntaxin-2 complex is actually present in rat parotid glands and that introduction of the antibody against Slp4-a linker domain into streptolysin O-permeabilized parotid acinar cells severely attenuates isoproterenol-stimulated amylase release, possibly by disrupting the interaction between Slp4-a and syntaxin-2/3 (or Munc18-2). These results suggest that Slp4-a modulates amylase release from parotid acinar cells through interaction with syntaxin-2/3 on the apical plasma membrane.	RIKEN, Fukuda Initiat Res Unit, Wako, Saitama 3510198, Japan; Nippon Dent Univ, Sch Dent Niigata, Dept Biochem, Niigata 9518580, Japan	RIKEN; Nippon Dental University	Fukuda, M (corresponding author), RIKEN, Fukuda Initiat Res Unit, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	mnfukuda@brain.riken.go.jp	Fukuda, MItsunori/I-1511-2015	Fukuda, MItsunori/0000-0002-8620-5853				BERNFELD P, 1955, METHOD ENZYMOL, V1, P149, DOI 10.1016/0076-6879(55)01021-5; Catz SD, 2002, P NATL ACAD SCI USA, V99, P11652, DOI 10.1073/pnas.172382799; Cheviet S, 2004, MOL ENDOCRINOL, V18, P117, DOI 10.1210/me.2003-0300; Coppola T, 2002, MOL BIOL CELL, V13, P1906, DOI 10.1091/mbc.02-02-0025; Desnos C, 2003, J CELL BIOL, V163, P559, DOI 10.1083/jcb.200302157; Dulubova I, 2003, P NATL ACAD SCI USA, V100, P32, DOI 10.1073/pnas.232701299; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; El-Amraoui A, 2002, EMBO REP, V3, P463, DOI 10.1093/embo-reports/kvf090; Feldmann J, 2003, CELL, V115, P461, DOI 10.1016/S0092-8674(03)00855-9; Fukuda M, 2004, J BIOL CHEM, V279, P13065, DOI 10.1074/jbc.M306812200; Fukuda M, 2003, J BIOL CHEM, V278, P15373, DOI 10.1074/jbc.M212341200; Fukuda M, 2002, J BIOL CHEM, V277, P30351, DOI 10.1074/jbc.M204056200; Fukuda M, 2000, J BIOL CHEM, V275, P28180; Fukuda M, 2005, METHOD ENZYMOL, V403, P445, DOI 10.1016/S0076-6879(05)03039-9; Fukuda M, 2005, J BIOCHEM, V137, P9, DOI 10.1093/jb/mvi002; Fukuda M, 1999, J BIOL CHEM, V274, P31421, DOI 10.1074/jbc.274.44.31421; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; Fukuda M, 2002, J BIOL CHEM, V277, P39673, DOI 10.1074/jbc.M205349200; Fukuda M, 2002, J BIOL CHEM, V277, P43096, DOI 10.1074/jbc.M203862200; Fukuda M, 2002, BIOCHEM J, V366, P681, DOI 10.1042/BJ20020484; Fukuda M, 2002, J BIOL CHEM, V277, P12432, DOI 10.1074/jbc.C200005200; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V283, P513, DOI 10.1006/bbrc.2001.4803; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V281, P1226, DOI 10.1006/bbrc.2001.4512; Fukuda M, 2003, J BIOL CHEM, V278, P15390, DOI 10.1074/jbc.M213090200; FUKUDA M, 2003, RECENT RES DEV CHEM, V1, P15; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; Imai A, 2004, J CELL SCI, V117, P1945, DOI 10.1242/jcs.01048; Imai A, 2004, ARCH BIOCHEM BIOPHYS, V422, P175, DOI 10.1016/j.abb.2003.12.021; Imai A, 2003, ARCH ORAL BIOL, V48, P597, DOI 10.1016/S0003-9969(03)00116-X; Imai A, 2001, ARCH ORAL BIOL, V46, P955, DOI 10.1016/S0003-9969(01)00048-6; Izumi T, 2003, CELL STRUCT FUNCT, V28, P465, DOI 10.1247/csf.28.465; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Koch H, 2000, BIOCHEM J, V349, P247, DOI 10.1042/0264-6021:3490247; Kuroda TS, 2005, J BIOL CHEM, V280, P28015, DOI 10.1074/jbc.M501465200; Kuroda TS, 2004, NAT CELL BIOL, V6, P1195, DOI 10.1038/ncb1197; Kuroda TS, 2003, MOL CELL BIOL, V23, P5245, DOI 10.1128/MCB.23.15.5245-5255.2003; Kuroda TS, 2002, BIOCHEM BIOPH RES CO, V293, P899, DOI 10.1016/S0006-291X(02)00320-0; Kuroda TS, 2002, J BIOL CHEM, V277, P9212, DOI 10.1074/jbc.M112414200; Matesic LE, 2001, P NATL ACAD SCI USA, V98, P10238, DOI 10.1073/pnas.181336698; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nagashima K, 2002, FEBS LETT, V517, P233, DOI 10.1016/S0014-5793(02)02634-0; Neeft M, 2005, MOL BIOL CELL, V16, P731, DOI 10.1091/mbc.E04-10-0923; Richmond JE, 2001, NATURE, V412, P338, DOI 10.1038/35085583; Shirakawa R, 2004, J BIOL CHEM, V279, P10730, DOI 10.1074/jbc.M309426200; Strom M, 2002, J BIOL CHEM, V277, P25423, DOI 10.1074/jbc.M202574200; Takuma T, 2000, ARCH ORAL BIOL, V45, P369, DOI 10.1016/S0003-9969(00)00004-2; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; Tolmachova T, 2004, MOL BIOL CELL, V15, P332, DOI 10.1091/mbc.e03-07-0452; Torii S, 2004, J BIOL CHEM, V279, P22532, DOI 10.1074/jbc.M400600200; Torii S, 2002, MOL CELL BIOL, V22, P5518, DOI 10.1128/MCB.22.15.5518-5526.2002; Wang J, 1999, J BIOL CHEM, V274, P28542, DOI 10.1074/jbc.274.40.28542; Waselle L, 2003, MOL BIOL CELL, V14, P4103, DOI 10.1091/mbc.E03-01-0022; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247; Yi Z, 2002, MOL CELL BIOL, V22, P1858, DOI 10.1128/MCB.22.6.1858-1867.2002	56	43	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39175	39184		10.1074/jbc.M505759200	http://dx.doi.org/10.1074/jbc.M505759200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16186111	hybrid			2022-12-25	WOS:000233362200033
J	McClendon, AK; Rodriguez, AC; Osheroff, N				McClendon, AK; Rodriguez, AC; Osheroff, N			Human topoisomerase II alpha rapidly relaxes positively supercoiled DNA - Implications for enzyme action ahead of replication forks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; REVERSE GYRASE; ANTICANCER DRUGS; CLINICAL-APPLICATIONS; SINGLE-MOLECULE; IN-VITRO; CLEAVAGE; BETA; YEAST; IV	Movement of the DNA replication machinery through the double helix induces acute positive supercoiling ahead of the fork and precatenanes behind it. Because topoisomerase I and II create transient single- and double-stranded DNA breaks, respectively, it has been assumed that type I enzymes relax the positive supercoils that precede the replication fork. Conversely, type II enzymes primarily resolve the precatenanes and untangle catenated daughter chromosomes. However, studies on yeast and bacteria suggest that type II topoisomerases may also function ahead of the replication machinery. If this is the case, then positive DNA supercoils should be the preferred relaxation substrate for topoisomerase II alpha, the enzyme isoform involved in replicative processes in humans. Results indicate that human topoisomerase II alpha relaxes positively supercoiled plasmids > 10-fold faster than negatively supercoiled molecules. In contrast, topoisomerase II beta, which is not required for DNA replication, displays no such preference. In addition to its high rates of relaxation, topoisomerase II alpha maintains lower levels of DNA cleavage complexes with positively supercoiled molecules. These properties suggest that human topoisomerase II alpha has the potential to alleviate torsional stress ahead of replication forks in an efficient and safe manner.	Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med Hematol Oncol, Sch Med, Nashville, TN 37232 USA; Bard High Sch Early Coll, New York, NY 10002 USA	Vanderbilt University; Vanderbilt University	Osheroff, N (corresponding author), Vanderbilt Univ, Dept Biochem, Sch Med, 654 Robinson Res Bldg, Nashville, TN 37232 USA.	neil.osheroff@vanderbilt.edu			NCI NIH HHS [T32 CA009582, 5T32 CA09582] Funding Source: Medline; NIGMS NIH HHS [GM33944] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Austin CA, 1998, BIOESSAYS, V20, P215, DOI 10.1002/(SICI)1521-1878(199803)20:3<215::AID-BIES5>3.0.CO;2-Q; Baguley BC, 1998, BBA-GENE STRUCT EXPR, V1400, P213, DOI 10.1016/S0167-4781(98)00137-7; Baldwin EL, 2004, BIOCHEMISTRY-US, V43, P728, DOI 10.1021/bi035472f; Bauman ME, 1997, MODERN PATHOL, V10, P168; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; BRILL SJ, 1987, NATURE, V326, P414, DOI 10.1038/326414a0; Bromberg KD, 2002, J BIOL CHEM, V277, P31201, DOI 10.1074/jbc.M204741200; Caron P R, 1994, Adv Pharmacol, V29B, P271; CHAMPOUX JJ, 1972, P NATL ACAD SCI USA, V69, P143, DOI 10.1073/pnas.69.1.143; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Champoux JJ, 2002, P NATL ACAD SCI USA, V99, P11998, DOI 10.1073/pnas.202483499; Charvin G, 2003, P NATL ACAD SCI USA, V100, P9820, DOI 10.1073/pnas.1631550100; Corbett KD, 2005, J MOL BIOL, V351, P545, DOI 10.1016/j.jmb.2005.06.029; Corbett KD, 2004, P NATL ACAD SCI USA, V101, P7293, DOI 10.1073/pnas.0401595101; Cozzarelli N.R., 1990, DNA TOPOLOGY ITS BIO; Crisona NJ, 2000, GENE DEV, V14, P2881, DOI 10.1101/gad.838900; DARPA P, 1990, CANCER RES, V50, P6919; DELATOUR CB, 1990, J BACTERIOL, V172, P6803, DOI 10.1128/jb.172.12.6803-6808.1990; Dereuddre S, 1997, CANCER RES, V57, P4301; DRAKE FH, 1987, J BIOL CHEM, V262, P16739; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; Forterre P, 2002, TRENDS GENET, V18, P236, DOI 10.1016/S0168-9525(02)02650-1; Fortune JM, 1999, BIOCHEMISTRY-US, V38, P15580, DOI 10.1021/bi991792g; Fortune JM, 2000, PROG NUCLEIC ACID RE, V64, P221, DOI 10.1016/S0079-6603(00)64006-0; Fortune JM, 1998, J BIOL CHEM, V273, P17643, DOI 10.1074/jbc.273.28.17643; Gootz TD, 1996, MED RES REV, V16, P433, DOI 10.1002/(SICI)1098-1128(199609)16:5<433::AID-MED3>3.0.CO;2-W; GOTO T, 1984, CELL, V36, P1073, DOI 10.1016/0092-8674(84)90057-6; Grue P, 1998, J BIOL CHEM, V273, P33660, DOI 10.1074/jbc.273.50.33660; HALLIGAN BD, 1985, J BIOL CHEM, V260, P2475; Hande KR, 1998, BBA-GENE STRUCT EXPR, V1400, P173, DOI 10.1016/S0167-4781(98)00134-1; Hande KR, 1998, EUR J CANCER, V34, P1514, DOI 10.1016/S0959-8049(98)00228-7; HECK MMS, 1986, J CELL BIOL, V103, P2569, DOI 10.1083/jcb.103.6.2569; HIASA H, 1994, J BIOL CHEM, V269, P16371; Hiasa H, 1996, J BIOL CHEM, V271, P26424, DOI 10.1074/jbc.271.42.26424; HOLM C, 1989, CANCER RES, V49, P6365; Hong G, 2003, P NATL ACAD SCI USA, V100, P5046, DOI 10.1073/pnas.0835166100; Hooper DC, 1998, CLIN INFECT DIS, V27, pS54, DOI 10.1086/514923; HOWARD MT, 1994, P NATL ACAD SCI USA, V91, P12031, DOI 10.1073/pnas.91.25.12031; HSIANG YH, 1988, CANCER RES, V48, P3230; Hsieh TJ, 2004, J BIOL CHEM, V279, P55587, DOI 10.1074/jbc.M408934200; Hsieh TJ, 2004, ACTA CRYSTALLOGR D, V60, P564, DOI 10.1107/S0907444903029779; Isaacs RJ, 1998, BBA-GENE STRUCT EXPR, V1400, P121, DOI 10.1016/S0167-4781(98)00131-6; Jensen S, 1996, MOL GEN GENET, V252, P79, DOI 10.1007/BF02173207; KANAAR R, 1992, CURR OPIN STRUC BIOL, V2, P369, DOI DOI 10.1016/0959-440X(92)90227-X; Kaufmann SH, 1998, BBA-GENE STRUCT EXPR, V1400, P195, DOI 10.1016/S0167-4781(98)00136-5; Khodursky AB, 2000, P NATL ACAD SCI USA, V97, P9419, DOI 10.1073/pnas.97.17.9419; KHODURSKY AB, 1995, P NATL ACAD SCI USA, V92, P11801, DOI 10.1073/pnas.92.25.11801; KIKUCHI A, 1984, NATURE, V309, P677, DOI 10.1038/309677a0; KIM RA, 1989, J MOL BIOL, V208, P257, DOI 10.1016/0022-2836(89)90387-2; Kingma PS, 1997, BIOCHEMISTRY-US, V36, P5934, DOI 10.1021/bi970507v; Kingma PS, 1997, J BIOL CHEM, V272, P1148, DOI 10.1074/jbc.272.2.1148; Leontiou C, 2003, FEBS LETT, V554, P206, DOI 10.1016/S0014-5793(03)01172-4; Levine C, 1998, BBA-GENE STRUCT EXPR, V1400, P29, DOI 10.1016/S0167-4781(98)00126-2; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; MADDEN KR, 1995, EMBO J, V14, P5399, DOI 10.1002/j.1460-2075.1995.tb00224.x; Maxwell A, 1997, TRENDS MICROBIOL, V5, P102, DOI 10.1016/S0966-842X(96)10085-8; Meczes EL, 1997, CANCER CHEMOTH PHARM, V39, P367, DOI 10.1007/s002800050585; Mielke SP, 2004, J CHEM PHYS, V121, P8104, DOI 10.1063/1.1799613; MILLER KG, 1981, J BIOL CHEM, V256, P9334; Nitiss JL, 1998, BBA-GENE STRUCT EXPR, V1400, P63, DOI 10.1016/S0167-4781(98)00128-6; O'Reilly EK, 2002, BIOCHEMISTRY-US, V41, P7989, DOI 10.1021/bi025897m; Oestergaard VH, 2004, J BIOL CHEM, V279, P28093, DOI 10.1074/jbc.M402120200; Osheroff N, 1998, BBA-GENE STRUCT EXPR, V1400, P1, DOI 10.1016/S0167-4781(98)00123-7; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P4303, DOI 10.1021/bi00388a018; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; OSHEROFF N, 1983, MECH DNA REPLICATION, V10, P55; Peter BJ, 1998, CELL, V94, P819, DOI 10.1016/S0092-8674(00)81740-7; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; ROCA J, 1993, J BIOL CHEM, V268, P14250; Roca J, 2001, J MOL BIOL, V305, P441, DOI 10.1006/jmbi.2000.4307; Rodriguez AC, 2002, J BIOL CHEM, V277, P29865, DOI 10.1074/jbc.M202853200; Rodriguez AC, 2002, EMBO J, V21, P418, DOI 10.1093/emboj/21.3.418; Schvartzman JB, 2004, EMBO REP, V5, P256, DOI 10.1038/sj.embor.7400101; Stone MD, 2003, P NATL ACAD SCI USA, V100, P8654, DOI 10.1073/pnas.1133178100; Takimoto CH, 1998, BBA-GENE STRUCT EXPR, V1400, P107, DOI 10.1016/S0167-4781(98)00130-4; Ullsperger C, 1996, J BIOL CHEM, V271, P31549, DOI 10.1074/jbc.271.49.31549; Vaughn J, 2005, J BIOL CHEM, V280, P11920, DOI 10.1074/jbc.M411841200; Velez-Cruz R, 2005, BIOCHEMISTRY-US, V44, P3972, DOI 10.1021/bi0478289; VELEZCRUZ R, 2004, ENCY BIOL CHEM, V1, P806; Wang J. C., 1990, DNA TOPOLOGY ITS BIO, P321; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; WASSERMAN RA, 1993, CANCER RES, V53, P3591; WATSON JD, 1953, NATURE, V171, P964, DOI 10.1038/171964b0; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0; Wilstermann AM, 2003, CURR TOP MED CHEM, V3, P321, DOI 10.2174/1568026033452519; WOESSNER RD, 1991, CELL GROWTH DIFFER, V2, P209; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; WYCKOFF E, 1988, P NATL ACAD SCI USA, V85, P6272, DOI 10.1073/pnas.85.17.6272; ZECHIEDRICH EL, 1990, EMBO J, V9, P4555, DOI 10.1002/j.1460-2075.1990.tb07908.x	91	111	111	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39337	39345		10.1074/jbc.M503320200	http://dx.doi.org/10.1074/jbc.M503320200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16188892	hybrid			2022-12-25	WOS:000233362200054
J	Nalavadi, V; Nyitrai, M; Bertolini, C; Adamek, N; Geeves, MA; Bahler, M				Nalavadi, V; Nyitrai, M; Bertolini, C; Adamek, N; Geeves, MA; Bahler, M			Kinetic mechanism of myosin IXB and the contributions of two class IX-specific regions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							END-DIRECTED MOTOR; MUSCLE-CONTRACTION; PROCESSIVE MOTOR; ATPASE ACTIVITY; LIGHT-CHAIN; ADP RELEASE; ACTIN; BINDING; DOMAIN; TROPOMYOSIN	Myosin IXb (Myo9b) was reported to be a single-headed, processive myosin. In its head domain it contains an N-terminal extension and a large loop 2 insertion that are specific for class IX myosins. We characterized the kinetic properties of purified, recombinant rat Myo9b, and we compared them with those of Myo9b mutants that had either the N-terminal extension or the loop 2 insertion deleted. Unlike other processive myosins, Myo9b exhibited a low affinity for ADP, and ADP release was not rate-limiting in the ATPase cycle. Myo9b is the first myosin for which ATP hydrolysis or an isomerization step after ATP binding is rate-limiting. Myo9b-ATP appeared to be in a conformation with a weak affinity for actin as determined by pyrene-actin fluorescence. However, in actin cosedimentation experiments, a subpopulation of Myo9b-ATP bound F-actin with a remarkably high affinity. Deletion of the N-terminal extension reduced actin affinity and increased the rate of nucleotide binding. Deletion of the loop 2 insertion reduced the actin affinity and altered the communication between actin and nucleotide-binding sites.	Univ Kent, Dept Biosci, Canterbury CT7 NJ, Kent, England; Univ Munster, Inst Gen Zool & Genet, D-48149 Munster, Germany	University of Kent; University of Munster	Geeves, MA (corresponding author), Univ Kent, Dept Biosci, Canterbury CT7 NJ, Kent, England.	m.a.geeves@kent.ac.uk; baehler@nwz.uni-muenster.de	Geeves, Michael/F-7583-2011	Geeves, Michael/0000-0002-9364-8898; Nyitrai, Miklos/0000-0002-6229-4337	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Clark RJ, 2003, J MUSCLE RES CELL M, V24, P315; Coluccio LR, 1999, J BIOL CHEM, V274, P21575, DOI 10.1074/jbc.274.31.21575; Cremo CR, 1998, BIOCHEMISTRY-US, V37, P1969, DOI 10.1021/bi9722406; CRIDDLE AH, 1985, BIOCHEM J, V232, P343, DOI 10.1042/bj2320343; De la Cruz EM, 2000, BIOPHYS J, V79, P1524, DOI 10.1016/S0006-3495(00)76403-4; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; De la Cruz EM, 2001, J BIOL CHEM, V276, P32373, DOI 10.1074/jbc.M104136200; Forkey JN, 2003, NATURE, V422, P399, DOI 10.1038/nature01529; Furch M, 1998, BIOCHEMISTRY-US, V37, P6317, DOI 10.1021/bi972851y; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; Graf B, 2000, CELL MICROBIOL, V2, P601, DOI 10.1046/j.1462-5822.2000.00084.x; Herm-Gotz A, 2002, EMBO J, V21, P2149, DOI 10.1093/emboj/21.9.2149; Hodge T, 2000, J CELL SCI, V113, P3353; Holmes KC, 2003, NATURE, V425, P423, DOI 10.1038/nature02005; Inoue A, 2002, NAT CELL BIOL, V4, P302, DOI 10.1038/ncb774; Joel PB, 2001, J BIOL CHEM, V276, P2998, DOI 10.1074/jbc.M006930200; Kovacs M, 2005, J BIOL CHEM, V280, P15071, DOI 10.1074/jbc.M500616200; Muller RT, 1997, MOL BIOL CELL, V8, P2039, DOI 10.1091/mbc.8.10.2039; Nitta R, 2004, SCIENCE, V305, P678, DOI 10.1126/science.1096621; NORBY JG, 1971, ACTA CHEM SCAND, V25, P2717, DOI 10.3891/acta.chem.scand.25-2717; O'Connell CB, 2003, NAT CELL BIOL, V5, P171, DOI 10.1038/ncb924; Okada Y, 2000, P NATL ACAD SCI USA, V97, P640, DOI 10.1073/pnas.97.2.640; Okada Y, 2003, NATURE, V424, P574, DOI 10.1038/nature01804; Post PL, 2002, J BIOL CHEM, V277, P11679, DOI 10.1074/jbc.M111173200; PUTKEY JA, 1985, J BIOL CHEM, V260, P4704; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; REINHARD J, 1995, EMBO J, V14, P697, DOI 10.1002/j.1460-2075.1995.tb07048.x; REYNARD AM, 1961, J BIOL CHEM, V236, P2277; Silva R, 2003, J MUSCLE RES CELL M, V24, P489, DOI 10.1023/B:JURE.0000009809.69829.74; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Stoffler HE, 1998, J BIOL CHEM, V273, P14605, DOI 10.1074/jbc.273.23.14605; Webb MR, 2001, BIOPHYS J, V81, P1562, DOI 10.1016/S0006-3495(01)75810-9; Yengo CM, 2004, BIOCHEMISTRY-US, V43, P2605, DOI 10.1021/bi035510v	33	34	34	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					38957	38968		10.1074/jbc.M507161200	http://dx.doi.org/10.1074/jbc.M507161200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16179355	hybrid			2022-12-25	WOS:000233362200009
J	Okuhira, K; Fitzgerald, ML; Sarracino, DA; Manning, JJ; Bell, SA; Goss, JL; Freeman, MW				Okuhira, K; Fitzgerald, ML; Sarracino, DA; Manning, JJ; Bell, SA; Goss, JL; Freeman, MW			Purification of ATP-binding cassette transporter A1 and associated binding proteins reveals the importance of beta 1-syntrophin in cholesterol efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; TANGIER-DISEASE; PEST SEQUENCE; ABCA1; MUTATIONS; ATHEROSCLEROSIS; PHOSPHORYLATION; STABILIZATION; INACTIVATION; FIBROBLASTS	ATP-binding cassette transporter A1 ( ABCA1) plays a critical role in HDL cholesterol metabolism, but the mechanism by which it transports lipid across membranes is poorly understood. Because growing evidence implicates accessory proteins in this process, we developed a method by which proteins interacting with the intact transporter could be identified. cDNAs encoding wild-type ABCA1 and a mutant lacking the C-terminal PDZ binding motif of ABCA1 were transfected into 293 cells, and the expressed proteins were solubilized using detergent conditions ( 0.75% CHAPS, 1 mg/ml phosphatidylcholine) predicted to retain high affinity protein-protein interactions. Proteins that co-purified with ABCA1 on an antibody affinity column were identified by liquid chromatographymass spectrometric analysis. A novel interaction with the PDZ protein beta 1-syntrophin was identified using this approach, and this interaction was confirmed in human THP-1 macrophages and in mouse liver. Small interference RNA inhibition of beta 1-syntrophin expression reduced cholesterol efflux from primary skin fibroblasts by 50% while decreasing efflux 30% in bone marrow-derived macrophages. Inhibition of beta 1-syntrophin decreased ABCA1 protein levels, whereas overexpression of beta 1-syntrophin increased ABCA1 cell-surface expression and stimulated efflux to apolipoprotein A-I. These findings indicate that beta 1-syntrophin acts through a class-I PDZ interaction with the C terminus of ABCA1 to regulate the cellular distribution and activity of the transporter. The approach used to identify beta 1-syntrophin as an ABCA1-binding protein should prove useful in elucidating other protein interactions upon which ABCA1 function depends.	Harvard Univ, Lipid Metab Unit, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA; Harvard Univ, Partners Ctr Genet & Genom, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Partners Healthcare System	Fitzgerald, ML (corresponding author), Harvard Univ, Lipid Metab Unit, Sch Med, Massachusetts Gen Hosp, Jackson 1321, Boston, MA 02114 USA.	mfitzger@molbio.mgh.harvard.edu; freeman@molbio.mgh.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074136, R01HL045098, R01HL068988, R01HL072358] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL72358, HL68988, HL45098, HL074136] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aiello RJ, 2002, ARTERIOSCL THROM VAS, V22, P630, DOI 10.1161/01.ATV.0000014804.35824.DA; Arakawa R, 2004, J BIOL CHEM, V279, P6217, DOI 10.1074/jbc.C300553200; Arakawa R, 2002, J BIOL CHEM, V277, P22426, DOI 10.1074/jbc.M202996200; Basso F, 2003, J LIPID RES, V44, P296, DOI 10.1194/jlr.M200414-JLR200; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Brousseau ME, 2000, J LIPID RES, V41, P433; Buechler C, 2002, J BIOL CHEM, V277, P41307, DOI 10.1074/jbc.C200436200; Buechler C, 2002, BIOCHEM BIOPH RES CO, V293, P759, DOI 10.1016/S0006-291X(02)00303-0; Chauhan NB, 2003, J LIPID RES, V44, P2019, DOI 10.1194/jlr.R300010-JLR200; Cohen JC, 2004, SCIENCE, V305, P869, DOI 10.1126/science.1099870; Costet P, 2000, J BIOL CHEM, V275, P28240; Fitzgerald ML, 2004, J BIOL CHEM, V279, P48477, DOI 10.1074/jbc.M409848200; Fitzgerald ML, 2002, J BIOL CHEM, V277, P33178, DOI 10.1074/jbc.M204996200; Fitzgerald ML, 2001, J BIOL CHEM, V276, P15137, DOI 10.1074/jbc.M100474200; Haidar B, 2004, J BIOL CHEM, V279, P9963, DOI 10.1074/jbc.M313487200; Joyce CW, 2002, P NATL ACAD SCI USA, V99, P407, DOI 10.1073/pnas.012587699; Kim WS, 2005, J BIOL CHEM, V280, P3989, DOI 10.1074/jbc.M412602200; Kyriakou T, 2005, ARTERIOSCL THROM VAS, V25, P418, DOI 10.1161/01.ATV.0000149379.72018.20; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Martinez LO, 2003, J BIOL CHEM, V278, P37368, DOI 10.1074/jbc.M307161200; MILLER NE, 1977, LANCET, V1, P965, DOI 10.1016/S0140-6736(77)92274-7; Munehira Y, 2004, J BIOL CHEM, V279, P15091, DOI 10.1074/jbc.M313436200; Oram JF, 2002, TRENDS MOL MED, V8, P168, DOI 10.1016/S1471-4914(02)02289-X; Peters MF, 1997, J CELL BIOL, V138, P81, DOI 10.1083/jcb.138.1.81; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; ROGLER G, 1995, ARTERIOSCL THROM VAS, V15, P683, DOI 10.1161/01.ATV.15.5.683; Roosbeek S, 2004, J BIOL CHEM, V279, P37779, DOI 10.1074/jbc.M401821200; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; See RH, 2002, J BIOL CHEM, V277, P41835, DOI 10.1074/jbc.M204923200; Singaraja RR, 2002, J CLIN INVEST, V110, P35, DOI 10.1172/JCI200215748; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269; Tang CR, 2004, J BIOL CHEM, V279, P7622, DOI 10.1074/jbc.M312571200; Timmins JM, 2005, J CLIN INVEST, V115, P1333, DOI 10.1172/JCI200523915; Van Eck M, 2002, P NATL ACAD SCI USA, V99, P6298, DOI 10.1073/pnas.092327399; Wang N, 2003, J CLIN INVEST, V111, P99, DOI 10.1172/JCI200316808; Wellington CL, 2002, LAB INVEST, V82, P273, DOI 10.1038/labinvest.3780421; Yamauchi Y, 2003, J BIOL CHEM, V278, P47890, DOI 10.1074/jbc.M306258200	40	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39653	39664		10.1074/jbc.M510187200	http://dx.doi.org/10.1074/jbc.M510187200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16192269	hybrid			2022-12-25	WOS:000233362200089
J	Al-Lamki, RS; Wang, J; Vandenabeele, P; Bradley, JA; Thiru, S; Luo, DH; Min, W; Pober, JS; Bradley, JR				Al-Lamki, RS; Wang, J; Vandenabeele, P; Bradley, JA; Thiru, S; Luo, DH; Min, W; Pober, JS; Bradley, JR			TNFR1-and TNFR2-mediated signaling pathways in human kidney are cell type-specific and differentially contribute to renal injury	FASEB JOURNAL			English	Article						TNF; ASK1; Etk; apoptosis; proliferation	NECROSIS-FACTOR-RECEPTOR; KINASE; ACTIVATION; TNF; APOPTOSIS; FAMILY; DEATH; ASK1; ETK/BMX	In normal kidney, TNFR1 is expressed in glomerular and peritubular capillary EC, and some tubular cells, and colocalizes with inactive apoptosis signal-regulating kinase-1 (ASK1) phosphorylated at serine 967. Biopsies of rejecting or ischemic renal allografts, which show both tubular cell injury and proliferation, display down-regulation of TNFR1 and activation of ASK1 as well as up-regulation of TNFR2 on tubular cells, where it colocalizes with phosphorylated endothelial/epithelial tyrosine kinase (Etk). We have exploited receptor-selective muteins and evaluated phosphorylation of receptor-specific kinases to study TNF responses in situ. In organ culture, a TNFR1-specific mutein changes phosphorylation of ASK1 to threonine 845, indicative of kinase activation. A TNFR2-specific mutein down-regulates TNFR1 in glomerular EC, up-regulates TNFR2 and Etk in tubular cells, and induces phosphorylation of Etk. Wild-type TNF induces TNFR2 and Etk and activates both ASK1 and Etk but does not down-regulate TNFR1. Wild-type TNF and TNFR1-specific mutein trigger tubular cell apoptosis whereas wild-type TNF and TNFR2-specific mutein induce tubular cells to express proliferating cell nuclear antigen. Differential activation of ASK1 and Etk by regulated TNFRs in patient-derived materials provides an explanation for diverse and opposing responses to TNF at distinct sites, and an in situ bioassay of TNFR signaling.	Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Dept Surg, Cambridge CB2 2QQ, England; State Univ Ghent VIB, Interdept Program Vasc Biol & Transportat, Dept Mol Biomed Res, B-9000 Ghent, Belgium; Yale Univ, Sch Med, Dept Pathol, Boyer Ctr Mol Med, New Haven, CT 06510 USA	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Flanders Institute for Biotechnology (VIB); Ghent University; Yale University	Bradley, JR (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Med, Hills Rd, Cambridge CB2 2QQ, England.	john.bradley@addenbrookes.nhs.uk	Vandenabeele, Peter/C-8597-2009; Vandenabeele, Peter/AAD-5793-2022	Vandenabeele, Peter/0000-0002-6669-8822; Wang, Jun/0000-0003-3667-3760; Bradley, John/0000-0002-7774-8805				Abassi YA, 2003, J BIOL CHEM, V278, P35636, DOI 10.1074/jbc.M306438200; Al-Lamki RS, 2001, LAB INVEST, V81, P1503, DOI 10.1038/labinvest.3780364; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Hamm-Alvarez SF, 2001, AM J PHYSIOL-CELL PH, V280, pC1657, DOI 10.1152/ajpcell.2001.280.6.C1657; Jones SJ, 1999, J IMMUNOL, V162, P1042; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Liu YM, 2002, CIRC RES, V90, P1259, DOI 10.1161/01.RES.0000022160.64355.62; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Lu F, 2001, CELL RES, V11, P217, DOI 10.1038/sj.cr.7290089; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Pan S, 2002, MOL CELL BIOL, V22, P7512, DOI 10.1128/MCB.22.21.7512-7523.2002; Pimentel-Muinos FX, 1999, IMMUNITY, V11, P783, DOI 10.1016/S1074-7613(00)80152-1; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SLOWIK MR, 1993, AM J PATHOL, V143, P1724; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080; VAN OX, 1994, EUR J BIOCHEM, V220, P771; VAN OX, 1993, NATURE, V361, P266; Zhang HF, 2004, J BIOL CHEM, V279, P44955, DOI 10.1074/jbc.M407617200; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zhang R, 2003, J CLIN INVEST, V111, P1933, DOI 10.1172/JCI200317790; Zheng LX, 1998, J IMMUNOL, V160, P763	23	119	120	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					1637	1645		10.1096/fj.05-3841com	http://dx.doi.org/10.1096/fj.05-3841com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16195372				2022-12-25	WOS:000232991100041
J	Kumarapeli, ARK; Horak, KM; Glasford, JW; Li, J; Chen, QH; Liu, JB; Zheng, HQ; Wang, XJ				Kumarapeli, ARK; Horak, KM; Glasford, JW; Li, J; Chen, QH; Liu, JB; Zheng, HQ; Wang, XJ			A novel transgenic mouse model reveals deregulation of the ubiquitin-proteasome system in the heart by doxorubicin	FASEB JOURNAL			English	Article						proteolysis; peptidase; cardiac function; green fluorescence protein	CARDIOVASCULAR RESEARCH; DILATED CARDIOMYOPATHY; GENETIC-MODIFICATION; DEGRADATION SIGNALS; PROTEIN AGGREGATION; CARDIAC MYOCYTES; CANCER CACHEXIA; QUALITY-CONTROL; 26S PROTEASOME; MICE	Ubiquitin-proteasome system ( UPS) mediated proteolysis is responsible for the degradation of majority of cellular proteins, thereby playing essential roles in maintaining cellular homeostasis and regulating a number of cellular functions. UPS dysfunction was implicated in the pathogenesis of numerous disorders, including neurodegenerative disease, muscular dystrophy, and a subset of cardiomyopathies. However, monitoring in vivo functional changes of the UPS remains a challenge, which hinders the elucidation of UPS pathophysiology. We have recently created a novel transgenic mouse model that ubiquitously expresses a surrogate protein substrate for the UPS. The present study validates its suitability to monitor in vivo changes of UPS proteolytic function in virtually all major organs. Primary culture of cells derived from the adult transgenic mice was also developed and tested for their applications in probing UPS involvement in pathogenesis. Applying these newly established in vivo and in vitro approaches, we have proven in the present study that doxorubicin enhances UPS function in the heart and in cultured cardiomyocytes, suggesting that UPS hyper-function may play an important role in the acute cardiotoxicity of doxorubicin therapy.	S Dakota Res Fdn, Cardiovasc Res Inst, Sioux Falls, SD USA; Univ S Dakota, Sch Med, Div Basic Biomed Sci, Sioux Falls, SD 57105 USA; Guangzhou Med Coll, Dept Pathophysiol, Guangzhou, Guangdong, Peoples R China; Wuhan Univ, Sch Med, Dept Physiol & Pathophysiol, Wuhan 430072, Peoples R China	University of South Dakota; Guangzhou Medical University; Wuhan University	Wang, XJ (corresponding author), Univ S Dakota, Sch Med, Cardiovasc Res Inst, 1100 E 21st St,Suite 700, Sioux Falls, SD 57105 USA.	xwang@usd.edu	Wang, Xuejun/AAT-9490-2021; Wang, Xuejun/K-8874-2013	Wang, Xuejun/0000-0001-9267-1343; Wang, Xuejun/0000-0001-9267-1343; LI, JIE/0000-0003-3902-642X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072166] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL72166, R01 HL072166] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acharyya S, 2004, J CLIN INVEST, V114, P370, DOI 10.1172/jci200420174; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bossy-Wetzel E, 2004, NAT MED, V10, pS2, DOI 10.1038/nm1067; Bulteau AL, 2001, J BIOL CHEM, V276, P30057, DOI 10.1074/jbc.M100142200; Ciftci O, 2001, BLOOD, V97, P2830, DOI 10.1182/blood.V97.9.2830; Dantuma NP, 2000, NAT BIOTECHNOL, V18, P538, DOI 10.1038/75406; de Vrij FMS, 2004, PROG NEUROBIOL, V74, P249, DOI 10.1016/j.pneurobio.2004.10.001; Dong X, 2004, AM J PHYSIOL-HEART C, V287, pH1417, DOI 10.1152/ajpheart.01233.2003; Dorn GW, 2003, CIRC RES, V92, P1171, DOI 10.1161/01.RES.0000077012.11088.BC; FIELD LJ, 1993, ANNU REV PHYSIOL, V55, P97; Forman MS, 2004, NAT MED, V10, P1055, DOI 10.1038/nm1113; Gilon T, 2000, MOL CELL BIOL, V20, P7214, DOI 10.1128/MCB.20.19.7214-7219.2000; Gilon T, 1998, EMBO J, V17, P2759, DOI 10.1093/emboj/17.10.2759; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Huang WY, 2000, NAT MED, V6, P482, DOI 10.1038/74914; Huber AH, 2001, J BIOL CHEM, V276, P12301, DOI 10.1074/jbc.M010377200; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; Kiyomiya K, 1998, LIFE SCI, V62, P1853, DOI 10.1016/S0024-3205(98)00151-9; Kiyomiya KI, 2002, INT J ONCOL, V20, P1205; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Kostin S, 2003, CIRC RES, V92, P715, DOI 10.1161/01.RES.0000067471.95890.5C; Kumarapeli ARK, 2004, J MOL CELL CARDIOL, V37, P1097, DOI 10.1016/j.yjmcc.2004.07.004; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Lindsten K, 2003, NAT BIOTECHNOL, V21, P897, DOI 10.1038/nbt851; Liu XW, 2002, AM J PHYSIOL-HEART C, V283, pH254, DOI 10.1152/ajpheart.01023.2001; Liu XW, 2004, AM J PHYSIOL-HEART C, V286, pH933, DOI 10.1152/ajpheart.00759.2003; Luker GD, 2003, NAT MED, V9, P969, DOI 10.1038/nm894; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; Meiners S, 2002, CIRCULATION, V105, P483, DOI 10.1161/hc0402.102951; Minotti G, 2004, PHARMACOL REV, V56, P185, DOI 10.1124/pr.56.2.6; Pasumarthi KBS, 2005, CIRC RES, V96, P110, DOI 10.1161/01.RES.0000152326.91223.4F; Reverte CG, 2001, DEV BIOL, V231, P447, DOI 10.1006/dbio.2001.0153; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Robbins J, 2004, J MOL CELL CARDIOL, V36, P643, DOI 10.1016/j.yjmcc.2004.02.012; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Sarikas A, 2005, CARDIOVASC RES, V66, P33, DOI 10.1016/j.cardiores.2005.01.004; Tisdale MJ, 2000, SCIENCE, V289, P2293, DOI 10.1126/science.289.5488.2293; VARSHAVSKY A, 1991, CELL, V64, P13, DOI 10.1016/0092-8674(91)90202-A; Vikstrom KL, 1998, CIRC RES, V82, P773, DOI 10.1161/01.RES.82.7.773; Vosberg HP, 2005, CARDIOVASC RES, V66, P1, DOI 10.1016/j.cardiores.2005.02.002; Wang XJ, 2003, CIRC RES, V93, P998, DOI 10.1161/01.RES.0000102401.77712.ED; Wang XJ, 2001, CIRC RES, V89, P84, DOI 10.1161/hh1301.092688; Wang XJ, 2001, CIRCULATION, V103, P2402, DOI 10.1161/01.cir.103.19.2402; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Weekes J, 2003, PROTEOMICS, V3, P208, DOI 10.1002/pmic.200390029; Yeh ETH, 2002, CIRCULATION, V105, P408, DOI 10.1161/circ.105.4.408; Zhou YY, 2000, AM J PHYSIOL-HEART C, V279, pH429	49	93	96	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2005	19	11					2051	+		10.1096/fj.05-3973fje	http://dx.doi.org/10.1096/fj.05-3973fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16188962				2022-12-25	WOS:000232315700003
J	Kilic, E; Kilic, U; Soliz, J; Bassetti, CL; Gassmann, M; Hermann, DM				Kilic, E; Kilic, U; Soliz, J; Bassetti, CL; Gassmann, M; Hermann, DM			Brain-derived erythropoietin protects from focal cerebral ischemia by dual activation of ERK-1/-2 and Akt pathways	FASEB JOURNAL			English	Article						neuroprotection; mitogen-activated protein kinase; phosphatidyl inositol-3 kinase; NO synthase	MICE OVEREXPRESSING ERYTHROPOIETIN; ARTERY-OCCLUSION; RETINAL DEGENERATION; NEURONAL APOPTOSIS; NITRIC-OXIDE; CELL-DEATH; INJURY; KINASE; NEUROPROTECTION; EXPRESSION	Apart from its hematopoietic function, erythropoietin (Epo) exerts neuroprotective functions in brain hypoxia and ischemia. To examine the mechanisms mediating Epo's neuroprotective activity in vivo, we made use of our transgenic mouse line tg21 that constitutively expresses human Epo in brain without inducing excessive erythrocytosis. We show that human Epo is expressed in tg21 brains and that cortical and striatal neurons carry the Epo receptor. After middle cerebral artery occlusion, human Epo potently protected brains of tg21 mice against ischemic injury, both when severe (90 min) and mild (30 min) ischemia was imposed. Histochemical studies revealed that Epo induced an activation of JAK-2, ERK-1/-2, and Akt pathways in the ischemic brain. This activation was associated with elevated Bcl-X-L and decreased NO synthase-1 and -2 levels in neurons. Intracerebroventricular injections of selective inhibitors of ERK-1/-2 (PD98059) or Akt (wortmannin) pathways revealed that both ERK-1/-2 and Akt were required for Epo's neuroprotective function, antagonization of either pathway completely abolishing tissue protection. On the other hand, ERK-1/-2 and Akt blockade did not reverse the neuronal NO synthase-1/-2 inhibition, indicating that Epo down-regulates these NO synthases in an ERK-1/-2 and Akt independent manner. On the basis of our data, the dual activation of ERK-1/-2 and Akt is crucial for Epo's neuroprotective activity.	Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland; Univ Zurich, Inst Vet Physiol, Vetsuisse Fac, Zurich, Switzerland	University of Zurich; University Zurich Hospital; University of Zurich	Kilic, E (corresponding author), Univ Zurich Hosp, Dept Neurol, Frauenklin Str 26, CH-8091 Zurich, Switzerland.	ertugrul.kilic@usz.ch	Hermann, Dirk/GZB-9350-2022; Hermann, Dirk M/AAP-5538-2020; Hermann, Dirk M./AAT-3652-2021; Soliz, Jorge/AAA-9752-2022; Kilic, Ertugrul/W-4563-2018	Hermann, Dirk M./0000-0003-0198-3152; Kilic, Ertugrul/0000-0001-6494-8923; Soliz, Jorge/0000-0002-2335-5862; Bassetti, Claudio/0000-0002-4535-0245; Gassmann, Max/0000-0003-2750-8878				Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; Brines M, 2004, P NATL ACAD SCI USA, V101, P14907, DOI 10.1073/pnas.0406491101; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Chong ZZ, 2003, J NEUROSCI RES, V71, P659, DOI 10.1002/jnr.10528; Chong ZZ, 2003, J CEREBR BLOOD F MET, V23, P320, DOI 10.1097/01.WCB.0000050061.57184.AE; DALKARA T, 1994, BRAIN PATHOL, V4, P49; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Gassmann M, 2003, ADV EXP MED BIOL, V543, P323; Grimm C, 2002, NAT MED, V8, P718, DOI 10.1038/nm723; Grimm C, 2005, SEMIN CELL DEV BIOL, V16, P531, DOI 10.1016/j.semcdb.2005.03.004; Grimm C, 2004, J NEUROSCI, V24, P5651, DOI 10.1523/JNEUROSCI.1288-04.2004; Han BH, 2000, J NEUROSCI, V20, P5775, DOI 10.1523/jneurosci.20-15-05775.2000; Hermann DM, 2001, NEUROBIOL DIS, V8, P655, DOI 10.1006/nbdi.2001.0399; Hermann DM, 2001, NEUROSCIENCE, V104, P947, DOI 10.1016/S0306-4522(01)00125-7; Hirt L, 2004, STROKE, V35, P1738, DOI 10.1161/01.STR.0000131480.03994.b1; Hopfl G, 2004, AM J PHYSIOL-REG I, V286, pR608, DOI 10.1152/ajpregu.00538.2003; Hudson JQ, 2002, PHARMACOTHERAPY, V22, p141S, DOI 10.1592/phco.22.14.141S.33397; Irving EA, 2002, J CEREBR BLOOD F MET, V22, P631, DOI 10.1097/00004647-200206000-00001; Jacobs-Helber SM, 2000, BLOOD, V96, P933, DOI 10.1182/blood.V96.3.933.015k52_933_940; Kilic E, 2005, FASEB J, V19, P2026, DOI 10.1096/fj.05-3941fje; Kilic E, 2002, ANN NEUROL, V52, P617, DOI 10.1002/ana.10356; Kilic U, 2005, J PINEAL RES, V38, P67, DOI 10.1111/j.1600-079X.2004.00178.x; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Macdougall Iain C, 2003, Curr Hematol Rep, V2, P459; Maeda K, 1999, NEUROBIOL DIS, V6, P101, DOI 10.1006/nbdi.1998.0235; Marti HH, 1996, EUR J NEUROSCI, V8, P666, DOI 10.1111/j.1460-9568.1996.tb01252.x; Nagata Y, 1998, BLOOD, V92, P1859, DOI 10.1182/blood.V92.6.1859.418k37_1859_1869; Okuno S, 2004, J NEUROSCI, V24, P7879, DOI 10.1523/JNEUROSCI.1745-04.2004; Ruscher K, 2002, J NEUROSCI, V22, P10291, DOI 10.1523/jneurosci.22-23-10291.2002; Ruschitzka FT, 2000, P NATL ACAD SCI USA, V97, P11609, DOI 10.1073/pnas.97.21.11609; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Squadrito F, 1999, BRIT J PHARMACOL, V127, P482, DOI 10.1038/sj.bjp.0702521; Wang YM, 2005, BRAIN, V128, P52, DOI 10.1093/brain/awh325; Wenger RH, 1998, INT J MOL MED, V2, P317; Wiessner C, 2001, J CEREBR BLOOD F MET, V21, P857, DOI 10.1097/00004647-200107000-00011	37	239	269	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2026	+		10.1096/fj.05-3941fje	http://dx.doi.org/10.1096/fj.05-3941fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	15556972				2022-12-25	WOS:000232991100027
